PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Benov, L; Fridovich, I				Benov, L; Fridovich, I			Superoxide dependence of the toxicity of short chain sugars	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; PHYSIOLOGICAL CONDITIONS; AMINOGUANIDINE; PREVENTION; PROTEINS; AUTOXIDATION; MECHANISM; ENZYMES; STRESS; ACID	Erythrose inhibited the growth of a sodA sodB strain of Escherichia coli under aerobiosis; but did not inhibit anaerobic growth of the sodA sodB strain, or the aerobic growth of the superoxide dismutase (SOD)-competent parental strain. A SOD mimic protected the sodA sodB strain against the toxicity of erythrose as did the carbonyl-blocking reagents hydrazine and aminoguanidine. Three carbon sugars, such as glyceraldehyde and dihydroxy acetone, and the two carbon sugar glycolaldehyde, were similarly toxic in an O-2(radical anion)-dependent manner. An unidentified dialyzable component in E. coli extract augmented the oxidation of short chain sugars, and this was partially inhibitable by SOD. The toxicity of the short chain sugars appears to be because of an O-2(radical anion)-dependent oxidation to alpha,beta-dicarbonyl compounds. In keeping with this view was the O-2(radical anion)-independent toxicity of methylglyoxal.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.		Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL056025] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56025-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ansari NH, 1996, BIOCHEM MOL MED, V59, P68, DOI 10.1006/bmme.1996.0067; Batinic-Haberle I, 1998, J BIOL CHEM, V273, P24521, DOI 10.1074/jbc.273.38.24521; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; Ceriello A, 1996, DIABETES, V45, P471, DOI 10.2337/diabetes.45.4.471; Corman B, 1998, P NATL ACAD SCI USA, V95, P1301, DOI 10.1073/pnas.95.3.1301; Demasi R, 1996, FREE RADICAL BIO MED, V20, P291, DOI 10.1016/0891-5849(95)02035-7; ERICKSON JG, 1952, J AM CHEM SOC, V74, P4706, DOI 10.1021/ja01138a506; ERIKSSON UJ, 1991, DIABETOLOGIA, V34, P325, DOI 10.1007/BF00405004; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GARST J, 1982, OXY RADICALS THEIR S, P125; HAGAY ZJ, 1995, AM J OBSTET GYNECOL, V173, P1036, DOI 10.1016/0002-9378(95)91323-8; HE RQ, 1995, BIOCHEM J, V309, P133, DOI 10.1042/bj3090133; HERMESLIMA M, 1995, FREE RADICAL BIO MED, V19, P381, DOI 10.1016/0891-5849(95)00015-P; Hiraku Y, 1996, CANCER RES, V56, P1786; HIRSCH J, 1992, CARBOHYD RES, V232, P125, DOI 10.1016/S0008-6215(00)90999-6; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KHATAMI M, 1988, LIFE SCI, V43, P1725, DOI 10.1016/0024-3205(88)90484-5; Li YM, 1996, P NATL ACAD SCI USA, V93, P3902, DOI 10.1073/pnas.93.9.3902; LO TWC, 1994, BIOCHEM PHARMACOL, V48, P1865, DOI 10.1016/0006-2952(94)90584-3; Lovry O.H., 1951, J BIOL CHEM, V193, P265; Maniatis T, 1982, MOL CLONING LABORATO, P68; MASHINO T, 1987, ARCH BIOCHEM BIOPHYS, V254, P547, DOI 10.1016/0003-9861(87)90136-6; Meyerhof O, 1925, BIOCHEM Z, V159, P432; ROBERTSON P, 1981, ARCH BIOCHEM BIOPHYS, V207, P282, DOI 10.1016/0003-9861(81)90035-7; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x; Smythe CV, 1932, BER DTSCH CHEM GES, V65, P819, DOI 10.1002/cber.19320650527; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4	29	17	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25741	25744		10.1074/jbc.273.40.25741	http://dx.doi.org/10.1074/jbc.273.40.25741			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748243	hybrid			2022-12-25	WOS:000076263100034
J	Mould, AP; Burrows, L; Humphries, MJ				Mould, AP; Burrows, L; Humphries, MJ			Identification of amino acid residues that form part of the ligand-binding pocket of integrin alpha 5 beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CELL-ADHESION; A-DOMAIN; FIBRONECTIN; SUBUNIT; SITE; REGION; ALPHA(IIB)BETA(3); OCCUPANCY; FRAGMENTS	Arg-Arg-Glu-Thr-Ala-Trp-Ala (RRETAWA) is a novel ligand peptide for integrin alpha(5)beta(1), which blocks alpha(5)beta(1)-mediated cell adhesion to fibronectin (Koivunen, E., Wang, B., and Ruoslahti, E. (1994) J. Cell Biol. 124, 373-380), Here we ha ve localized the binding site for RRETAWA on alpha(5)beta(1) using inhibitory monoclonal antibodies (mAbs) and site-directed mutagenesis. A cyclic peptide containing this sequence (*CRRETAWAC*) had little effect on the binding of most anti-alpha(5) and anti-beta(1) mAbs to alpha(5)beta(1) but completely blocked binding of the anti-alpha(5) mAb 16 in a directly competitive manner. Hence, the binding site of RRETAWA appears to closely overlap with the epitope of mAb 16, *CRRETAWAC* also acted as a direct competitive inhibitor of the binding of Arg-Gly-Asp (RGD)-containing fibronectin fragments to alpha(5)beta(1), suggesting that the binding site for RRETAWA is also closely overlapping with that for RGD. However, differences between the binding sites of RRETAWA and RGD were apparent in that (i) RGD peptides allosterically inhibited the binding of mAb 16 to alpha(5)beta(1), and (ii) several mAbs that perturbed binding of alpha(5)beta(1) to RGD had little effect on binding of alpha(5)beta(1) to RRETAWA. A double mutation in alpha(5) (S156G/W157S) blocked the interaction of both RRETAWA and mAb 16 with alpha(5)beta(1) but had no effect on fibronectin binding or on the binding of other anti-alpha(5) mAbs. Ser(156)-Trp(157) is located near the apex of a putative loop region on the upper surface of a predicted beta-propeller structure formed by the NH2-terminal repeats of alpha(5). Our findings suggest that this sequence forms part of the ligand-binding pocket of alpha(5)beta(1). Furthermore, as Ser(156)-Trp(157) is unique to the alpha(5) subunit, it may be responsible for the specific recognition of RRETAWA by alpha(5)beta(1).	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	pmould@fs1.scg.man.ac.uk		Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AOTA S, 1994, J BIOL CHEM, V269, P24756; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; Kunicki TJ, 1996, J BIOL CHEM, V271, P20315, DOI 10.1074/jbc.271.34.20315; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Mould AP, 1996, J CELL SCI, V109, P2613; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; Newham P, 1998, J IMMUNOL, V160, P4508; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Pujades C, 1997, MOL BIOL CELL, V8, P2647, DOI 10.1091/mbc.8.12.2647; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Takada Y, 1997, MATRIX BIOL, V16, P143, DOI 10.1016/S0945-053X(97)90002-0; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	32	48	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25664	25672		10.1074/jbc.273.40.25664	http://dx.doi.org/10.1074/jbc.273.40.25664			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748233	hybrid			2022-12-25	WOS:000076263100024
J	Vu-Dac, N; Chopin-Delannoy, S; Gervois, P; Bonnelye, E; Martin, G; Fruchart, JC; Laudet, V; Staels, B				Vu-Dac, N; Chopin-Delannoy, S; Gervois, P; Bonnelye, E; Martin, G; Fruchart, JC; Laudet, V; Staels, B			The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erb alpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-RECEPTOR; TISSUE-SELECTIVE MANNER; OB GENE-EXPRESSION; C-III EXPRESSION; ORPHAN RECEPTOR; LIPOPROTEIN METABOLISM; SIGNALING PATHWAYS; RESPONSE ELEMENT; OPPOSITE STRAND; FATTY-ACIDS	Fibrates are widely used hypolipidemic drugs which activate the nuclear peroxisome proliferator-activated receptor (PPAR) alpha and thereby alter the transcription of genes controlling lipoprotein metabolism. Fibrates influence plasma high density lipoprotein and its major protein, apolipoprotein (apo) A-I, in an opposite manner in man (increase) versus rodents (decrease), In the present study we studied the molecular mechanisms of this species-specific regulation of apoA-I expression by fibrates, In primary rat and human hepatocytes fenofibric acid, respectively, decreased and increased apoA-I mRNA levels. The absence of induction of rat apoA-I gene expression by fibrates is due to 3 nucleotide differences between the rat and the human apoA-I promoter A site, rendering a positive PPAR-response element in the human apoA-I promoter nonfunctional in rats. In contrast, rat, but not human, apoA-I transcription is repressed by the nuclear receptor Rev-erb alpha, which binds to a negative response element adjacent to the TATA box of the rat apoA-I promoter. In rats fibrates increase liver Rev-erb alpha mRNA levels >10-fold. In conclusion, the opposite regulation of rat and human apoA-I gene expression by fibrates is linked to differences in cis-elements in their respective promoters leading to repression by Rev-erb alpha of rat apoA-I and activation by PPAR alpha of human apoA-I, Finally, Rev-erb alpha is identified as a novel fibrate target gene, suggesting a role for this nuclear receptor in lipid and lipoprotein metabolism.	Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, Lille, France; Inst Biol Lille, CNRS, UMR 319, Endocrinos Grp, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS)	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, INSERM, U325, 1 Rue Calmette, F-59019 Lille, France.		Bonnelye, Edith/AAT-9134-2021; Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503				Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BERTHOU L, 1995, EUR J BIOCHEM, V232, P179, DOI 10.1111/j.1432-1033.1995.tb20797.x; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; BONNELYE E, 1994, CELL GROWTH DIFFER, V5, P1357; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666; Downes M, 1996, NUCLEIC ACIDS RES, V24, P4379, DOI 10.1093/nar/24.22.4379; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAHN SE, 1992, BIOCHEM PHARMACOL, V43, P625, DOI 10.1016/0006-2952(92)90586-8; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; Haubenwallner S, 1995, J LIPID RES, V36, P2541; HERTZ R, 1993, BIOCHIMIE, V75, P257, DOI 10.1016/0300-9084(93)90085-7; Hertz R, 1996, J BIOL CHEM, V271, P218, DOI 10.1074/jbc.271.1.218; Hertz R, 1996, BIOCHEM J, V319, P241, DOI 10.1042/bj3190241; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; Jin FY, 1996, ARTERIOSCL THROM VAS, V16, P1052, DOI 10.1161/01.ATV.16.8.1052; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAUDET V, 1995, CURR BIOL, V5, P124, DOI 10.1016/S0960-9822(95)00031-5; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1990, DNA CELL BIOL, V9, P77, DOI 10.1089/dna.1990.9.77; LI AP, 1992, J TISSUE CULT METHOD, V14, P139; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSSIERCACAN S, 1989, ATHEROSCLEROSIS, V78, P167, DOI 10.1016/0021-9150(89)90221-9; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; Miyamoto T, 1997, J BIOL CHEM, V272, P7752, DOI 10.1074/jbc.272.12.7752; MUNROE SH, 1991, J BIOL CHEM, V266, P22083; Murao K, 1997, BIOCHEMISTRY-US, V36, P301, DOI 10.1021/bi9613943; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; QUEVA C, 1992, DEVELOPMENT, V114, P125; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SAKU K, 1985, J CLIN INVEST, V75, P1702, DOI 10.1172/JCI111879; Saladin R, 1996, EUR J BIOCHEM, V239, P451, DOI 10.1111/j.1432-1033.1996.0451u.x; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SPANJAARD RA, 1994, MOL ENDOCRINOL, V8, P286, DOI 10.1210/me.8.3.286; STAELS B, 1990, ENDOCRINOLOGY, V126, P2153; Staels B, 1997, CURR PHARM DESIGN, V3, P1; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STAELS B, 1992, BIOCHIM BIOPHYS ACTA, V1123, P227, DOI 10.1016/0005-2760(92)90115-C; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; STAELS B, 1992, J LIPID RES, V33, P727; TAM SP, 1991, ATHEROSCLEROSIS, V91, P51, DOI 10.1016/0021-9150(91)90186-7; TIKKANEN MJ, 1992, CURR OPIN LIPIDOL, V3, P29; VANACKER JM, 1993, J VIROL, V67, P7668, DOI 10.1128/JVI.67.12.7668-7672.1993; VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401; VUDAC N, 1994, J BIOL CHEM, V269, P31012; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	76	257	260	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25713	25720		10.1074/jbc.273.40.25713	http://dx.doi.org/10.1074/jbc.273.40.25713			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748239	hybrid			2022-12-25	WOS:000076263100030
J	Yun, CHC; Lamprecht, G; Forster, DV; Sider, A				Yun, CHC; Lamprecht, G; Forster, DV; Sider, A			NHE3 kinase A regulatory protein E3KARP binds the epithelial brush border Na+/H+ exchanger NHE3 and the cytoskeletal protein ezrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; NITRIC-OXIDE SYNTHASE; H+ EXCHANGER; PDZ PROTEIN; DOMAIN; IDENTIFICATION; PHOSPHOPROTEIN; COFACTOR; REQUIRES; PSD-95	Cyclic AMP is a major second messenger that inhibits the brush border Na+/H+ exchanger NHE3. We have previously shown that either of two related regulatory proteins, E3KARP or NHERF, is necessary for the cAMP-dependent inhibition of NHE3. in the present study, we characterized the interaction between NHE3 and E3KARP using in vitro binding assays. We found that NHE3 directly binds to E3KARP and that the entirety of the second PSD-95/Dlg/ZO-1 (PDZ) domain plus the carboxyl-terminal domain of E3KARP are required to bind NHE3. E3KARP binds an internal region within the NHE3 C-terminal cytoplasmic tail, defining a new mode of PDZ domain interaction. Analyses of cellular distribution of NHE3 and E3KARP expressed in PS120 fibroblasts show that NHE3 and E3KARP are co-localized on the plasma membrane, but not in a distinct juxtanuclear compartment in which NHE3 is predominantly expressed. The distributions of NHE3 and E3KARP were not affected by treatment with 8-bromo-cAMP. As shown earlier for the human homolog of NHERF, we also found that the cytoskeletal protein ezrin binds to the carboxyl-terminal domain of E3KARP. These results are consistent with the possibility that E3KARP and NHERF may function as scaffold proteins that bind to both NHE3 and ezrin, Since ezrin is a protein kinase A anchoring protein, we suggest that the scaffolding function of E3KARP binding to both ezrin and NHE3 localizes cAMP-dependent protein kinase in the vicinity of the cytoplasmic domain of NHE3, which is phosphorylated by elevated cAMP.	Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA	Johns Hopkins University	Yun, CHC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 918 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	cyun@welchlink.welch.jhu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44484] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1986, CURR TOP MEMBR TRANS, V26, P57; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cabado AG, 1996, J BIOL CHEM, V271, P3590; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; DOUSZA S, 1998, J BIOL CHEM, V273, P2035; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Lamprecht G, 1998, GASTROENTEROLOGY, V114, pA390, DOI 10.1016/S0016-5085(98)81582-5; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	27	247	247	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25856	25863		10.1074/jbc.273.40.25856	http://dx.doi.org/10.1074/jbc.273.40.25856			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748260	hybrid			2022-12-25	WOS:000076263100051
J	He, HL; Qi, XM; Grossmann, J; Distelhorst, CW				He, HL; Qi, XM; Grossmann, J; Distelhorst, CW			c-Fos degradation by the proteasome - An early, Bcl-2-regulated step in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; MOUSE LYMPHOMA-CELLS; GLUCOCORTICOID RECEPTOR; INTERSEGMENTAL MUSCLES; ENDOPLASMIC-RETICULUM; TRANSFORMING ACTIVITY; THYMOCYTE APOPTOSIS; GENE-EXPRESSION; MANDUCA-SEXTA; CA2+ FLUXES	c-Fos is a transcription factor that promotes cell growth, differentiation, and transformation. We found that c-Fos was degraded when WEHI7.2 mouse lymphoma cells were induced to undergo apoptosis with the calcium ATPase inhibitor, thapsigargin, or the glucocorticoid hormone, dexamethasone. The degradation of c-Fos preceded caspase-3 activation and apoptotic nuclear chromatin condensation and was inhibited by the proteasome inhibitors MG132, N-acetyl-leucyl-leucyl-norleucinal, and lactacystin, Stable transfection of WEHI7.2 cells with a mutant form of c-Fos that was not degraded by the proteasome inhibited apoptosis. Also, overexpression of Bcl-2 in WEHI7.2 cells blocked c-Fos degradation and inhibited apoptosis. The results indicate that proteasome-mediated degradation of c-Fos is an early, Bcl-2-regulated step in apoptosis induction by thapsigargin and dexamethasone. These findings suggest that c-Fos may have a protective action that is eliminated by proteasome-mediated degradation and preserved by Bcl-2.	Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Dept Med, BRB 329,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA042755] Funding Source: NIH RePORTER; NCI NIH HHS [CA42755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aizawa H, 1996, BIOCHEM BIOPH RES CO, V218, P224, DOI 10.1006/bbrc.1996.0039; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CARILLO S, 1989, ONCOGENE, V9, P1079; Chen RH, 1996, ONCOGENE, V12, P1493; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Cui HL, 1997, P NATL ACAD SCI USA, V94, P7515, DOI 10.1073/pnas.94.14.7515; CURRAN T, 1992, TRANSCRIPTIONAL REGU, P797; DAWSON SP, 1995, J BIOL CHEM, V270, P1850, DOI 10.1074/jbc.270.4.1850; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; Distelhorst CW, 1996, CELL CALCIUM, V19, P473, DOI 10.1016/S0143-4160(96)90056-1; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLOMERFELT FA, 1994, J CELL BIOL, V127, P1729, DOI 10.1083/jcb.127.6.1729; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JarielEncontre I, 1997, MOL BIOL REP, V24, P51, DOI 10.1023/A:1006804723722; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES MEE, 1995, DEV BIOL, V169, P436, DOI 10.1006/dbio.1995.1159; Kaina B, 1997, CANCER RES, V57, P2721; KAWAHARA H, 1994, DEV BIOL, V166, P623, DOI 10.1006/dbio.1994.1342; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1984, CELL, V36, P51; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Preston GA, 1996, MOL CELL BIOL, V16, P211; Qi XM, 1997, ONCOGENE, V15, P2849, DOI 10.1038/sj.onc.1201463; REALINI C, 1995, J BIOL CHEM, V270, P29664; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; Shimizu S, 1996, ONCOGENE, V12, P2251; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	64	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25015	25019		10.1074/jbc.273.39.25015	http://dx.doi.org/10.1074/jbc.273.39.25015			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737957	hybrid			2022-12-25	WOS:000076085400007
J	Taoka, S; Ohja, S; Shan, XY; Kruger, WD; Banerjee, R				Taoka, S; Ohja, S; Shan, XY; Kruger, WD; Banerjee, R			Evidence for heme-mediated redox regulation of human cystathionine beta-synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT METHIONINE SYNTHASE; ESCHERICHIA-COLI; CULTURED-CELLS; HUMAN-LIVER; RAT-LIVER; EXPRESSION; PURIFICATION; HOMOCYSTEINE; HEMOPROTEIN-H-450; CYTOCHROME-P-450	Human cystathionine beta-synthase catalyzes the first step in the catabolic removal of the toxic metabolite, homocysteine. It is unique in being dependent on both pyridoxal phosphate (PLP) and heme for activity. The reaction involves condensation of serine and homocysteine to give cystathionine. Although the role of PLP can be rationalized in analogy with other PLP dependent enzymes that catalyze beta-replacement reactions, the role of the heme is unknown. In this study, we have purified and characterized the recombinant human enzyme and have examined the effect of heme oxidation state on enzyme activity. We find that under reducing conditions, generated by addition of titanium citrate, the enzyme exhibits a 1.7-fold lower activity than under oxidizing conditions. Reoxidation of the ferrous enzyme with ferricyanide results in alleviation of inhibition. This redox-linked change in enzyme activity correlates with changes in heme oxidation state monitored by UV-visible spectroscopy. Dithiothreitol, which does not reduce the enzyme-bound heme, does not perturb enzyme activity. These studies provide the first evidence for redox-linked regulation of cystathionine beta-synthase which is heme-dependent.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19046 USA	University of Nebraska System; University of Nebraska Lincoln; Fox Chase Cancer Center	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.		kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 	NHLBI NIH HHS [HL58984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; BUKOVSKA G, 1994, PROTEIN EXPRES PURIF, V5, P442, DOI 10.1006/prep.1994.1063; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; DRUMMOND JT, 1995, ANAL BIOCHEM, V228, P323, DOI 10.1006/abio.1995.1358; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Gonzalez JC, 1996, BIOCHEMISTRY-US, V35, P12228, DOI 10.1021/bi9615452; Goulding CW, 1997, BIOCHEMISTRY-US, V36, P15749, DOI 10.1021/bi971988l; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES JB, 1977, COMMUN SOIL SCI PLAN, V8, P349, DOI 10.1080/00103627709366727; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KASHIWAMATA S, 1970, BIOCHIM BIOPHYS ACTA, V212, P488, DOI 10.1016/0005-2744(70)90255-X; KERY V, 1995, ARCH BIOCHEM BIOPHYS, V316, P24, DOI 10.1006/abbi.1995.1005; KERY V, 1994, J BIOL CHEM, V269, P25283; KIMURA H, 1971, J BIOCHEM-TOKYO, V69, P711, DOI 10.1093/oxfordjournals.jbchem.a129520; KRAUS J, 1978, J BIOL CHEM, V253, P6523; KRAUS JP, 1993, HUM MOL GENET, V2, P1633, DOI 10.1093/hmg/2.10.1633; KRAUS JP, 1983, ARCH BIOCHEM BIOPHYS, V222, P44, DOI 10.1016/0003-9861(83)90500-3; KRUGER WD, 1994, P NATL ACAD SCI USA, V91, P6614, DOI 10.1073/pnas.91.14.6614; Lentz SR, 1997, LIFE SCI, V61, P1205, DOI 10.1016/S0024-3205(97)00392-5; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MCCULLY KS, 1983, ATHER REV, V11, P157; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; ROPER MD, 1992, ARCH BIOCHEM BIOPHYS, V298, P514, DOI 10.1016/0003-9861(92)90443-Z; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; SKOVBY F, 1984, J BIOL CHEM, V259, P588; SKOVBY F, 1984, J BIOL CHEM, V259, P583; SUDA M, 1973, METHOD ENZYMOL, V17, P454; SVASTITS EW, 1989, BIOCHEM BIOPH RES CO, V165, P1170, DOI 10.1016/0006-291X(89)92725-3	31	214	217	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25179	25184		10.1074/jbc.273.39.25179	http://dx.doi.org/10.1074/jbc.273.39.25179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737978	hybrid			2022-12-25	WOS:000076085400028
J	Hingorani, MM; O'Donnell, M				Hingorani, MM; O'Donnell, M			ATP binding to the Escherichia coli clamp loader powers opening of the ring-shaped clamp of DNA polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; LAGGING-STRAND REPLICATION; CELL NUCLEAR ANTIGEN; SLIDING CLAMPS; ACCESSORY PROTEINS; PRIMER-TEMPLATE; COMPLEX; SUBUNIT; MECHANISM; PARTICLE	The Escherichia coli gamma complex serves as a clamp loader, catalyzing ATP-dependent assembly of beta protein clamps onto primed DNA templates during DNA replication. These ring-shaped clamps tether DNA polymerase III holoenzyme to the template, facilitating rapid and processive DNA synthesis. This report focuses on the role of ATP binding and hydrolysis catalyzed by the gamma complex during clamp loading. We show that the energy from ATP binding to gamma complex powers several initial events in the clamp loading pathway. The gamma complex ((gamma 2)delta delta'(chi)psi) binds two ATP molecules (one per gamma subunit in the complex) with high affinity (K-d = 1-2.5 x 10(-6) M) or two adenosine 5'-O-(3-thiotriphosphate) (ATP gamma S) molecules with slightly lower affinity (K-d = 5-6.5 x 10(-6) nr). Experiments performed prior to the first ATP turnover (k(cat) = 4 x 10(-3) s(-1) at 4 degrees C), or in the presence of ATP gamma S (k(cat) = 1 x 10(-4) s(-1) at 37 degrees C), demonstrate that upon interaction with ATP the gamma complex undergoes a change in conformation. This ATP-bound gamma complex binds beta and opens the ring at the dimer interface. Still prior to ATP hydrolysis, the composite of gamma complex and the open beta ring binds with high affinity to primer-template DNA. Thus ATP binding powers all the steps in the clamp loading pathway leading up to the assembly of a gamma complex open beta ring.DNA intermediate, setting the stage for ring closing and turnover of the clamp loader, steps that may be linked to subsequent hydrolysis of ATP.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	manju@mod.rockefeller.edu; odonnel@rockvax.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berdis AJ, 1997, BIOCHEMISTRY-US, V36, P2733, DOI 10.1021/bi962139l; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BISWAS SB, 1984, J BIOL CHEM, V259, P7990; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MUNN MM, 1991, J BIOL CHEM, V266, P20034; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; ONRUST R, 1993, THESIS CORNELL U MED, P198; Pietroni P, 1997, J BIOL CHEM, V272, P31666, DOI 10.1074/jbc.272.50.31666; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; Turner J, 1995, METHOD ENZYMOL, V262, P442; WU CA, 1992, J BIOL CHEM, V267, P4064; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773; XIAO H, 1996, THESIS CORNELL U MED; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	59	117	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24550	24563		10.1074/jbc.273.38.24550	http://dx.doi.org/10.1074/jbc.273.38.24550			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733750	hybrid			2022-12-25	WOS:000076007300042
J	Pasheva, EA; Pashev, IG; Favre, A				Pasheva, EA; Pashev, IG; Favre, A			Preferential binding of high mobility group 1 protein to UV-damaged - DNA role of the COOH-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); NUCLEOPROTEIN STRUCTURES; TRANSCRIPTION FACTOR; THERMAL-DENATURATION; DEFINED-SEQUENCE; NUCLEAR-PROTEIN; HUMAN-CELLS; HMG DOMAIN; CISPLATIN; COMPLEX	Binding of chromosomal high mobility group 1 protein (HMG1) to UV-damaged DNA has been studied with oligonucleotides containing a single dipyrimidine site for formation of UV photolesions, Irradiation of an oligonucleotide with unique TT dinucleotide resulted in generation of cyclobutane pyrimidine dimer with no evidence for induction of (6-4) photoproducts, whereas the analysis of irradiated TC-containing oligonucleotide detected (6-4) photoproducts but not cyclobutane pyrimidine dimers, Mobility shift assays have revealed that HMG1 protein binds preferentially to irradiated TT and TC oligonucleotides. Photoreversal of cyclobutane pyrimidine dimers with DNA photolyase and hydrolysis of the (6-4) photoproducts with hot alkali substantially reduced but did not eliminate binding of HMG1. The protein, therefore, appears to bind the two main types of UV damages in DNA, but some other photolesion(s) contributes to the preferential binding of HMG1 to irradiated DNA, By quantifying gel shift assays and considering the efficiencies of lesion formation, we determined dissociation constants of 1.2 +/- 0.5 and 4.0 +/- 1.5 mu M for irradiated TT and TC oligonucleotides, respectively, and 70 +/- 20 mu M for the control non-irradiated probes. Tryptic removal of the acidic COOH-terminal domain of HMG1 significantly affected binding of the protein to both irradiated and intact oligonucleotides, The potential role of HMG1 in recognition of the UV lesions in DNA is discussed.	Bulgarian Acad Sci, Inst Mol Biol, BU-1113 Sofia, Bulgaria; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris, France	Bulgarian Academy of Sciences; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Pasheva, EA (corresponding author), Bulgarian Acad Sci, Inst Mol Biol, BU-1113 Sofia, Bulgaria.	eva@obzor.bio2l.bas.bg						BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BOURRE F, 1985, BIOCHIMIE, V67, P293, DOI 10.1016/S0300-9084(85)80071-7; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CADET J, 1990, BIOORGANIC PHOTOCHEM, V1, P1; CARBALLO M, 1984, EMBO J, V2, P17559; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; DYSON M, 1984, INT J PEPT PROT RES, V24, P201; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FRANKLIN WA, 1982, J BIOL CHEM, V257, P13533; FRIEDBERG EC, 1972, MUTAT RES, V15, P113, DOI 10.1016/0027-5107(72)90024-3; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; ISACKSON PJ, 1979, J BIOL CHEM, V254, P5569; JACKSON JB, 1981, BIOCHEMISTRY-US, V20, P1042, DOI 10.1021/bi00507a060; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JAVAHERIAN K, 1979, NUCLEIC ACIDS RES, V6, P3569, DOI 10.1093/nar/6.11.3569; Johns EW, 1982, HMG CHROMOSOMAL PROT; KIM JK, 1995, EUR J BIOCHEM, V228, P849, DOI 10.1111/j.1432-1033.1995.0849m.x; KOHLSTAEDT LA, 1987, J BIOL CHEM, V262, P524; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; MAREKOV LN, 1984, BIOCHIM BIOPHYS ACTA, V789, P63, DOI 10.1016/0167-4838(84)90061-X; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; NER SS, 1994, TRENDS BIOCHEM SCI, V19, P185, DOI 10.1016/0968-0004(94)90017-5; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Schultz TF, 1996, J BIOL CHEM, V271, P25742, DOI 10.1074/jbc.271.42.25742; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; Smerdon MJ, 1991, CURR OPIN CELL BIOL, V3, P422, DOI 10.1016/0955-0674(91)90069-B; SPIVAK G, 1988, MUTAT RES, V193, P97, DOI 10.1016/0167-8817(88)90040-5; STROS M, 1990, INT J BIOL MACROMOL, V12, P282, DOI 10.1016/0141-8130(90)90014-2; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; Turchi JJ, 1996, BIOCHEMISTRY-US, V35, P2992, DOI 10.1021/bi951843j; UMLAS ME, 1985, PHOTOCHEM PHOTOBIOL, V42, P265, DOI 10.1111/j.1751-1097.1985.tb08941.x; VANASSENDELFT GB, 1993, NUCLEIC ACIDS RES, V21, P3399, DOI 10.1093/nar/21.15.3399; VARGAWEISZ P, 1994, BIOCHEM BIOPH RES CO, V203, P1904, DOI 10.1006/bbrc.1994.2410; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	56	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24730	24736		10.1074/jbc.273.38.24730	http://dx.doi.org/10.1074/jbc.273.38.24730			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733773	hybrid			2022-12-25	WOS:000076007300065
J	Wang, TF; Ou, Y; Guidotti, G				Wang, TF; Ou, Y; Guidotti, G			The transmembrane domains of ectoapyrase (CD39) affect its enzymatic activity and quaternary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ACTIVATION ANTIGEN; ECTO-ATPASE; MEMBRANE-PROTEINS; DIPHOSPHOHYDROLASE; PURIFICATION; CLONING; IDENTIFICATION; APYRASE; GENE; HOMOLOGY	Mammalian ectoapyrase (CD39) is an integral membrane protein with two transmembrane domains and a large extracellular region. The enzymatic activity of ectoapyrase is inhibited by most detergents used for membrane protein solubilization. In contrast, the enzymatic activities of soluble E-type ATPases, including potato tuber (Solanum tuberosum) apyrase and parasite ecto-ATPase, are not affected by detergents. Here we show that ectoapyrase is a tetramer and that detergents that reduce the activity of the enzyme promote dissociation of the tetramer to monomers. We expressed a secreted form of the ectoapyrase in COS-7 cells by fusing the signal peptide of murine CD4 with the extracellular domain of the ectoapyrase. The soluble ectoapyrase is catalytically active and its activity is not affected by detergents. Mutants of the ectoapyrase with only the NH2- or the COOH-terminal transmembrane domain are membrane-bound, and their activity is no longer affected by detergents. The enzymatic activity of all of the mutant proteins is less than that of the native enzyme. These results suggest that the proper contacts between the transmembrane domains of the monomers in the tetramer are necessary for full enzymatic activity.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Guidotti, G (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	guidotti@ifas.harvard.edu	Wang, Ting-Fang/ABI-3818-2020	Wang, Ting-Fang/0000-0001-6306-9505	NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; AIYER RA, 1983, J BIOL CHEM, V258, P4992; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Chadwick BP, 1997, MAMM GENOME, V8, P668, DOI 10.1007/s003359900534; CLARKE S, 1975, J BIOL CHEM, V250, P5459; Coppi MV, 1997, ARCH BIOCHEM BIOPHYS, V346, P312, DOI 10.1006/abbi.1997.0332; EDSALL JT, 1970, CRC HDB BIOCH SELECT, pC10; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; HARLOW E, 1988, ANTIBODIES LABORATOR, P494; Hsieh HL, 1996, PLANT MOL BIOL, V30, P135, DOI 10.1007/BF00017808; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Kim M, 1997, BIOCHEM BIOPH RES CO, V240, P618, DOI 10.1006/bbrc.1997.7713; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KYTE J, 1995, STRUCTURE PROTEIN CH, P520; LewisCarl S, 1997, J BIOL CHEM, V272, P23645, DOI 10.1074/jbc.272.38.23645; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; Liu JY, 1997, BBA-GEN SUBJECTS, V1336, P370, DOI 10.1016/S0304-4165(96)00153-5; Lu KH, 1996, MOL BIOL CELL, V7, P679, DOI 10.1091/mbc.7.5.679; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; NEER EJ, 1974, J BIOL CHEM, V249, P6527; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLESNER L, 1995, INT REV CYTOL, V158, P141; SABBADINI RA, 1989, J BIOENERG BIOMEMBR, V21, P163, DOI 10.1007/BF00812068; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; Smith TM, 1997, ARCH BIOCHEM BIOPHYS, V337, P351, DOI 10.1006/abbi.1996.9779; Stout JG, 1996, BIOCHEMISTRY-US, V35, P8289, DOI 10.1021/bi960563g; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Tanford C., 1961, PHYS CHEM MACROMOLEC, P356; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; Wang TF, 1997, MOL BRAIN RES, V47, P295, DOI 10.1016/S0169-328X(97)00066-1; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; YOON KL, 1994, J BIOL CHEM, V269, P28249; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	46	119	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24814	24821		10.1074/jbc.273.38.24814	http://dx.doi.org/10.1074/jbc.273.38.24814			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733785	Green Published, hybrid			2022-12-25	WOS:000076007300077
J	Beglova, N; LeSauteur, L; Ekiel, I; Saragovi, HU; Gehring, K				Beglova, N; LeSauteur, L; Ekiel, I; Saragovi, HU; Gehring, K			Solution structure and internal motion of a bioactive peptide derived from nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; HETERONUCLEAR NMR-SPECTROSCOPY; TRK PROTOONCOGENE PRODUCT; RECEPTOR-BINDING; NATURAL-ABUNDANCE; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; BIOLOGICAL-ACTIVITY; CARBOXYL-TERMINUS; AFFINITY RECEPTOR	The conformation and internal dynamics of a bioactive cyclic peptide, N-acetyl-YCTDEKQCY, derived from the C-D loop of beta-nerve growth factor (beta-NGF) were analyzed by solution NMR spectroscopy. NMR experimental data were used to calculate an ensemble of peptide structures. All of the structures had a beta-turn at residues Asp(4)-Gln(7) but could be divided into two families according the presence or absence of a hydrogen bond at Gln(7). Comparison of the calculated structures with the corresponding C-D loops from the x-ray structures of the NGF revealed striking similarity. The orientation of Glu(5), Lys(6), and Gln7 side chains in the NGF mimetic was very similar to the C-D loop of NGF. These residues are known to participate in interactions with the TrkA receptor. Relaxation measurements of the peptidomimetic alpha-carbons at C-13 natural abundance and calculated dynamic parameters suggest that the loop region of peptide is well structured but that residues Thr(3), Asp(4), Glu(5), and Lys(6) undergo slow conformational exchange. These results suggest that conformational similarity and possibly peptide dynamics are responsible for the bioactivity of the peptide.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Joint Ctr Struct Biol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Natl Res Council Canada, Pharmaceut Biotechnol Sector, Biomol NMR Grp, Montreal, PQ H4P 2R2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada	McGill University; McGill University; McGill University; McGill University; National Research Council Canada; National Research Council Canada	Gehring, K (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St,McIntyre Med Sci Bldg, Montreal, PQ H3G 1Y6, Canada.	kalle.gehring@bri.nrc.ca	Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				Alattia T, 1996, EUR J BIOCHEM, V237, P561, DOI 10.1111/j.1432-1033.1996.0561p.x; ALLERHAN.A, 1972, J CHEM PHYS, V56, P3718, DOI 10.1063/1.1677754; ALLERHAN.A, 1971, J AM CHEM SOC, V93, P544, DOI 10.1021/ja00731a053; ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bax B, 1997, STRUCTURE, V5, P1275, DOI 10.1016/S0969-2126(97)00280-3; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; Cuello AC, 1996, PROG BRAIN RES, V109, P347; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; Ekiel I, 1997, J MOL BIOL, V271, P266, DOI 10.1006/jmbi.1997.1150; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; ILAG LL, 1994, J BIOL CHEM, V269, P19941; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kramer K, 1996, CLIN CANCER RES, V2, P1361; Kruttgen A, 1997, J BIOL CHEM, V272, P29222, DOI 10.1074/jbc.272.46.29222; KULLANDER K, 1994, J NEUROSCI RES, V39, P195, DOI 10.1002/jnr.490390210; Kullander K, 1997, J BIOL CHEM, V272, P9300; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LeSauteur L, 1996, NAT BIOTECHNOL, V14, P1120, DOI 10.1038/nbt0996-1120; LESAUTEUR L, 1995, J BIOL CHEM, V270, P6564, DOI 10.1074/jbc.270.12.6564; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Longsworth LG, 1960, J PHYS CHEM-US, V64, P1914, DOI 10.1021/j100841a027; LUO Y, 1992, J BIOL CHEM, V267, P12275; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Marchetti D, 1996, CANCER RES, V56, P2856; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MILLS R, 1973, J PHYS CHEM-US, V77, P685, DOI 10.1021/j100624a025; Mufson EJ, 1997, EXP NEUROL, V146, P91, DOI 10.1006/exnr.1997.6504; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROBINSON RC, 1995, BIOCHEMISTRY-US, V34, P4139, DOI 10.1021/bi00013a001; Ryden M, 1997, J BIOL CHEM, V272, P33085, DOI 10.1074/jbc.272.52.33085; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHIH A, 1994, J BIOL CHEM, V269, P27679; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; TORCHIA DA, 1975, BIOCHEMISTRY-US, V14, P887, DOI 10.1021/bi00676a004; TORCHIA DA, 1974, BIOPOLYMERS, V13, P97, DOI 10.1002/bip.1974.360130106; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Woo SB, 1996, J BIOL CHEM, V271, P24433, DOI 10.1074/jbc.271.40.24433; [No title captured]; [No title captured]	66	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23652	23658		10.1074/jbc.273.37.23652	http://dx.doi.org/10.1074/jbc.273.37.23652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726969	hybrid			2022-12-25	WOS:000075893100010
J	Garcia-Cozar, FJ; Okamura, H; Aramburu, JF; Shaw, KTY; Pelletier, L; Showalter, R; Villafranca, E; Rao, A				Garcia-Cozar, FJ; Okamura, H; Aramburu, JF; Shaw, KTY; Pelletier, L; Showalter, R; Villafranca, E; Rao, A			Two-site interaction of nuclear factor of activated T cells with activated calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFAT1; CYCLOSPORINE-A; NF-AT; LIMITED PROTEOLYSIS; FAMILY; DOMAIN; EXPRESSION; BINDING; COMPLEX; FK506	Transcription factors belonging to the nuclear factor of activated T cells (NFAT) family regulate the expression of cytokine genes and other inducible genes during the immune response. The functions of NFAT proteins are directly controlled by the calcium- and calmodulin-dependent phosphatase calcineurin, Here we show that the binding of calcineurin to NFAT is substantially increased when calcineurin is activated with calmodulin and calcium. FK506-FKBP12 drug-immunophilin complexes inhibited the interaction of NFAT with activated calcineurin much more effectively than they inhibited the interaction with inactive calcineurin, suggesting that part of the interaction with activated calcineurin involved the enzyme active site. We have previously shown that NFAT is targeted to inactive calcineurin at a region distinct from the calcineurin active site (Aramburu, J,, Garcia-Cozar, F, J,, Raghavan, A, Okamura, H,, Rao, A., and Hogan, P, G, (1998) Mel. Cell 1, 627-637); this region is also involved in NFAT binding to activated calcineurin, since binding is inhibited by an NFAT peptide spanning the calcineurin docking site on NFAT, The interacting surfaces are located on the catalytic domain of the calcineurin A chain and on an 86-amino acid fragment of the NFAT regulatory domain. NFAT binding to the calcineurin catalytic domain was inhibited by the calcineurin autoinhibitory domain and the RII substrate peptide, which bind in the calcineurin active site, as well as by the NFAT docking site peptide, which binds to a region of calcineurin distinct from the active site.; We propose that, in resting cells, NFAT is targeted to a region of the calcineurin catalytic domain that does not overlap the calcineurin active site, Upon cell activation, displacement of the autoinhibitory domain by calmodulin binding allows NFAT to bind additionally to the calcineurin active site, thus positioning NFAT for immediate dephosphorylation at functional phosphoserine residues.	Harvard Univ, Sch Med, Dept Pathol, Ctr Blood Res, Boston, MA 02115 USA; Agouron Pharmaceut Inc, San Diego, CA 92121 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Pfizer	Rao, A (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.		Aramburu, J/G-8991-2014; Garcia-Cozar, Francisco/A-6212-2013	Aramburu, J/0000-0001-9279-9523; Garcia-Cozar, Francisco/0000-0003-3720-259X	NIAID NIH HHS [AI 40127] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040127] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; COCKERILL GW, 1995, BLOOD, V86, P2689; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HO AM, 1994, J BIOL CHEM, V269, P28181; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Loh C, 1996, MOL CELL BIOL, V16, P3945; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Luo C, 1996, MOL CELL BIOL, V16, P3955; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; NALEFSKI EA, 1995, J BIOL CHEM, V270, P22351, DOI 10.1074/jbc.270.38.22351; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274	40	85	88	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23877	23883		10.1074/jbc.273.37.23877	http://dx.doi.org/10.1074/jbc.273.37.23877			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727000	hybrid			2022-12-25	WOS:000075893100041
J	Kato, A; Ozawa, F; Saitoh, Y; Fukazawa, Y; Sugiyama, H; Inokuchi, K				Kato, A; Ozawa, F; Saitoh, Y; Fukazawa, Y; Sugiyama, H; Inokuchi, K			Novel members of the Vesl/Homer family of PDZ proteins that bind metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; MESSENGER-RNA; LATE-PHASE; PSD-95; LTP; HIPPOCAMPUS; MAINTENANCE; INDUCTION; DOMAIN; CAMP	Vesl-1S (186 amino acids, also called Homer) is a protein containing EVH1- and PDZ-like domains whose expression in the hippocampus is regulated during long term potentiation (LTP), one form of synaptic plasticity thought to underlie memory formation (Kato, A., Ozawa, F., Saitoh, Y., Hirai, K., and Inokuchi, K. (1997) FEBS Lett. 412, 183-189; Brakeman, P. R., Lanahan, A. A., O'Brien, R., Roche, K., Barnes, C. A., Huganir, R. L., and Worley, P. F. (1997) Nature 386, 284-288). Here we report additional members of the Veal/Homer family of proteins, Vesl-1L and Vesl-2. Vesl-1L (366 amino acids), a splicing variant of Vesl-1S, shares N-terminal 175 amino acids with Vesl-1S and contains additional amino acids at the C terminus. Vesl-2 (354 amino acids) was highly related to Vesl-1L in that both contain EVH1- and PDZ-like domains at the N terminus (86% conservation) and an MCC (mutated in colorectal cancer)-like domain and a leucine zipper at the C terminus. In contrast to vesl-1S, we observed no changes in the levels of vesl-1L and vesl-2 mRNAs during dentate gyrus LTP. All these proteins interacted with metabotropic glutamate receptors (mGluR1 and mGluR5) as well as several hippocampal proteins in vitro. Vesl-1L and Vesl-2, but not Vesl-1S, interacted with each other through the C-terminal portion that was absent in Vesl-1S. Vesl-1L and Vesl-2 may mediate clustering of mGluRs at synaptic junctions. We propose that Vesl-1S may be involved in the structural changes that occur at metabotropic glutamatergic synapses during the maintenance phase of LTP by modulating the redistribution of synaptic components.	Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Kyushu Univ, Fac Sci, Dept Biol, Higashi Ku, Fukuoka 81281, Japan	Kyushu University	Inokuchi, K (corresponding author), Mitsubishi Kasei Inst Life Sci, 11 Minamiooya, Machida, Tokyo 1948511, Japan.		Inokuchi, Kaoru/AAI-9693-2020; Fukazawa, Yugo/H-9899-2012	Inokuchi, Kaoru/0000-0002-5393-3133; Fukazawa, Yugo/0000-0001-7436-8797				ABRAHAM WC, 1993, NEUROSCIENCE, V56, P717, DOI 10.1016/0306-4522(93)90369-Q; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Geinisman Y, 1996, J COMP NEUROL, V368, P413; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Inokuchi K, 1996, FEBS LETT, V382, P48, DOI 10.1016/0014-5793(96)00135-4; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Nguyen PV, 1996, J NEUROSCI, V16, P3189; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; Sambrook J., 2002, MOL CLONING LAB MANU; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	24	250	257	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23969	23975		10.1074/jbc.273.37.23969	http://dx.doi.org/10.1074/jbc.273.37.23969			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727012	hybrid			2022-12-25	WOS:000075893100053
J	Kinoshita, N; Ghaedi, K; Shimozawa, N; Wanders, RJA; Matsuzono, Y; Imanaka, T; Okumoto, K; Suzuki, Y; Kondo, N; Fujiki, Y				Kinoshita, N; Ghaedi, K; Shimozawa, N; Wanders, RJA; Matsuzono, Y; Imanaka, T; Okumoto, K; Suzuki, Y; Kondo, N; Fujiki, Y			Newly identified Chinese hamster ovary cell mutants are defective in biogenesis of peroxisomal membrane vesicles (peroxisomal ghosts), representing a novel complementation group in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; TARGETING SIGNAL-1 RECEPTOR; ASSEMBLY FACTOR-II; ZELLWEGER SYNDROME; PROTEIN IMPORT; PTS2 RECEPTOR; PLASMALOGEN BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; HUMAN PEX7	We isolated peroxisome biogenesis-defective mutants from Chinese hamster ovary cells by the 9-(1'-pyrene)nonanol/ultraviolet (P90H/UV) method. Seven cell mutants, ZP116, ZP119, ZP160, ZP161, ZP162, ZP164, and ZP165, of 11 P90H/UV-resistant cell clones showed cytosolic localization of catalase, a peroxisomal matrix enzyme, apparently indicating a defect of peroxisome biogenesis. By transfection of PEX cDNAs and cell fusion analysis, mutants ZP119 and ZP165 were found to belong to a novel complementation group (CG), distinct from earlier mutants. CG analysis by cell fusion with fibroblasts from patients with peroxisome biogenesis disorders such as Zellweger syndrome indicated that ZP119 and ZP165 were in the same CG as the most recently identified human CG-J. The peroxisomal matrix proteins examined, including PTS1 proteins as well as a PTS2 protein, 3-ketoacyl-CoA thiolase, were also found in the cytosol its ZP119 and ZP165. Furthermore, these mutants showed typical percdxisorne assembly-defective phenotype such as severe loss of resistance to 12-(1'-pyrene)dodecanoic acid/UV treatment. Most strikingly, peroxisomal reminiscent vesicular structures, so-called peroxisomal ghosts noted in all CGs of earlier Chinese hamster ovary cell mutants as well as in eight CGs of patients' fibroblasts, were not discernible ire ZP119 and ZP165, despite normal synthesis of peroxisomal membrane proteins. Accordingly, ZP119 and ZP165 are the first cell mutants defective in import of both soluble and membrane proteins, representing the 14th peroxisome-deficient CG in mammals, including humans.	Kyushu Univ, Fac Sci, Dept Biol, Higashi Ku, Fukuoka 8128581, Japan; Gifu Univ, Fac Med, Dept Pediat, Gifu 5008076, Japan; Univ Amsterdam, Acad Med Ctr, Dept Pediat, NL-1100 DE Amsterdam, Netherlands; Teikyo Univ, Fac Pharmaceut Sci, Dept Microbiol & Mol Pathol, Sagamiko, Kanagawa 1990211, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1700013, Japan	Kyushu University; Gifu University; University of Amsterdam; Academic Medical Center Amsterdam; Teikyo University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.		Ghaedi, Kamran/X-9824-2018	Ghaedi, Kamran/0000-0002-9790-5644; Imanaka, Tsuneo/0000-0003-4677-1356; Shimozawa, Nobuyuki/0000-0003-3040-5458				Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BRUL S, 1988, J CLIN INVEST, V81, P1710, DOI 10.1172/JCI113510; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; Fujiki Y, 1997, BBA-MOL BASIS DIS, V1361, P235, DOI 10.1016/S0925-4439(97)00051-3; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; Fukuda S, 1996, AM J HUM GENET, V59, P1210; Imanaka T, 1996, J BIOL CHEM, V271, P3706; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323, DOI 10.1016/0167-4781(92)90510-7; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZAROW PB, 1995, DISORDERS PEROXISOME, P2287; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MORAND OH, 1990, BIOCHIM BIOPHYS ACTA, V1034, P132, DOI 10.1016/0304-4165(90)90066-6; MOSER AB, 1995, J PEDIATR-US, V127, P13, DOI 10.1016/S0022-3476(95)70250-4; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; Okumoto K, 1997, EXP CELL RES, V233, P11, DOI 10.1006/excr.1997.3552; Okumoto K, 1997, NAT GENET, V17, P265, DOI 10.1038/ng1197-265; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Portsteffen H, 1997, NAT GENET, V17, P449, DOI 10.1038/ng1297-449; POULOS A, 1995, J PEDIATR-US, V127, P596, DOI 10.1016/S0022-3476(95)70121-4; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Reuber BE, 1997, NAT GENET, V17, P445, DOI 10.1038/ng1297-445; SANTOS MJ, 1992, J CELL PHYSIOL, V151, P103, DOI 10.1002/jcp.1041510115; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; Shimozawa N, 1998, BIOCHEM BIOPH RES CO, V243, P368, DOI 10.1006/bbrc.1997.8067; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SHIMOZAWA N, 1988, PEDIATR RES, V24, P723, DOI 10.1203/00006450-198812000-00015; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; Subramani S, 1997, NAT GENET, V15, P331, DOI 10.1038/ng0497-331; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Tateishi K, 1997, EUR J CELL BIOL, V73, P352; THIERINGER R, 1993, J BIOL CHEM, V268, P12631; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V230, P402, DOI 10.1006/bbrc.1996.5971; TSUKAMOTO T, 1994, MOL CELL BIOL, V14, P5458, DOI 10.1128/MCB.14.8.5458; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Waterham HR, 1997, BIOESSAYS, V19, P57, DOI 10.1002/bies.950190110; WENDLAND M, 1993, J CLIN INVEST, V92, P2462, DOI 10.1172/JCI116854; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x; YAJIMA S, 1992, HUM GENET, V88, P491, DOI 10.1007/BF00219334; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590; ZOELLER RA, 1992, J BIOL CHEM, V267, P8299	60	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24122	24130		10.1074/jbc.273.37.24122	http://dx.doi.org/10.1074/jbc.273.37.24122			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727033	hybrid			2022-12-25	WOS:000075893100074
J	Wright, MB; Hugo, C; Seifert, R; Disteche, CM; Bowen-Pope, DF				Wright, MB; Hugo, C; Seifert, R; Disteche, CM; Bowen-Pope, DF			Proliferating and migrating mesangial cells responding to injury express a novel receptor protein-tyrosine phosphatase in experimental mesangial proliferative glomerulonephritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SMOOTH MUSCLE ACTIN; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; FOCAL ADHESIONS; RAT; DROSOPHILA; FIBRONECTIN; NEPHRITIS; ALPHA	The mesangial cell provides structural support to the kidney glomerulus, A polymerase chain reaction-based cDNA display approach identified a novel protein-tyrosine phosphatase, rPTP-GMC1, whose transcript expression is transiently and dramatically up-regulated during the period of mesangial cell migration and proliferation that follows mesangial cell injury in the anti-Thy 1 model of mesangial proliferative glomerulonephritis in the rat. In situ hybridization analysis confirmed that rPTP-GMC1 mRNA is up-regulated specifically by mesangial cells responding to the injury and is not detectable in other cells in the kidney or in many normal tissues. In cell culture, rPTP-GMC1 is expressed by mesangial cells but not by glomerular endothelial or epithelial cells (podocytes), The longest transcript (7.5 kilobases) encodes a receptor-like protein-tyrosine phosphatase consisting of a single catalytic domain, a transmembrane segment, and 18 fibronectin type like repeats in the extracellular segment. A splice variant predicts a truncated molecule missing the catalytic domain. rPTP-GMC1 maps to human chromosome 12q15 and to the distal end of mouse chromosome 10, The predicted structure of rPTP-GMC1 and its pattern of expression in vivo and in culture suggest that it prays a role in regulating the adhesion and migration of mesangial cells in response to injury.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Div Nephrol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bowen-Pope, DF (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.			Wright, matthewwright/0000-0002-0532-3381				ADLER S, 1986, J CLIN INVEST, V77, P762, DOI 10.1172/JCI112372; ADLER S, 1993, KIDNEY INT, V44, P278, DOI 10.1038/ki.1993.242; ALPERS CE, 1992, KIDNEY INT, V41, P1134, DOI 10.1038/ki.1992.173; BARNES JL, 1994, AM J PATHOL, V145, P585; BARNES JL, 1990, LAB INVEST, V62, P379; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BOEHM T, 1993, ONCOGENE, V8, P1385; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; Borson N D, 1992, PCR Methods Appl, V2, P144; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHAREST A, 1995, GENOMICS, V28, P501, DOI 10.1006/geno.1995.1181; Desai CJ, 1997, DEVELOPMENT, V124, P1941; EDELHOFF S, 1994, ONCOGENE, V9, P665; FLOEGE J, 1993, J CLIN INVEST, V92, P2952, DOI 10.1172/JCI116918; FLOEGE J, 1992, J CLIN INVEST, V90, P2362, DOI 10.1172/JCI116126; FLOEGE J, 1995, MINER ELECTROL METAB, V21, P271; HUGO C, 1995, KIDNEY INT, V48, P1846, DOI 10.1038/ki.1995.483; Hugo C, 1997, J CLIN INVEST, V100, P786, DOI 10.1172/JCI119592; Hugo C, 1996, J CLIN INVEST, V97, P2499, DOI 10.1172/JCI118697; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; IVANOVA NB, 1995, NUCLEIC ACIDS RES, V23, P2954, DOI 10.1093/nar/23.15.2954; JOHNSON R, 1992, J AM SOC NEPHROL, V2, P1388; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; JOHNSON RJ, 1994, KIDNEY INT, V45, P1769, DOI 10.1038/ki.1994.230; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; MORITA T, 1983, KIDNEY INT, V24, P1, DOI 10.1038/ki.1983.119; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; TARABOLETTI G, 1992, LAB INVEST, V67, P566; Taylor BA, 1997, MAMM GENOME, V7, pS176, DOI 10.1007/s003359900322; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; WIGGINS RC, 1995, GENOMICS, V27, P174, DOI 10.1006/geno.1995.1021; Yang DH, 1996, LAB INVEST, V74, P571; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; Zinn Kai, 1993, Seminars in Cell Biology, V4, P397, DOI 10.1006/scel.1993.1047	49	32	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23929	23937		10.1074/jbc.273.37.23929	http://dx.doi.org/10.1074/jbc.273.37.23929			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727007	hybrid			2022-12-25	WOS:000075893100048
J	Ghedin, E; Charest, H; Zhang, WW; Debrabant, A; Dwyer, D; Matlashewski, G				Ghedin, E; Charest, H; Zhang, WW; Debrabant, A; Dwyer, D; Matlashewski, G			Inducible expression of suicide genes in Leishmania donovani amastigotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-NUCLEOTIDASE NUCLEASE; THYMIDINE KINASE; PROMASTIGOTES; CLONING; DNA; A2; 5'-NUCLEOTIDASE; INFECTION; PROTEINS; REGION	This study tests the feasibility of using the A2 gene regulatory system to create a Leishmania cell line in which attenuation is developmentally regulated when the parasite differentiates from promastigotes to amastigotes. The Leishmania donovani- inducible A2 gene regulatory system was used to differentially express in amastigotes two potential suicide genes: a truncated version of the L. donovani 3'-nucleotidase/nuclease expressed in the cytoplasm and the herpes simplex virus thymidine kinase gene. These genes were inserted between A2 noncoding regulatory sequences for up-regulation of expression in amastigotes. The accumulation of toxic products affected L. donovani cell replication and viability both in vitro and in vivo. The inducible expression of toxic gene products represents a valuable tool for the development of safe and effective vaccines.	McGill Univ, Inst Parasitol, St Anne Bellevue, PQ H9X 3V9, Canada; NIAID, Immunobiol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NIAID, Cell Biol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Matlashewski, G (corresponding author), McGill Univ, Inst Parasitol, 21111 Lakeshore Rd,Macdonald Campus, St Anne Bellevue, PQ H9X 3V9, Canada.		Ghedin, Elodie/Y-5654-2019	Ghedin, Elodie/0000-0002-1515-725X; Zhang, Wenwei/0000-0003-1996-876X				CAMPBELL TA, 1991, MOL BIOCHEM PARASIT, V47, P109, DOI 10.1016/0166-6851(91)90153-W; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; COBURN CM, 1991, MOL BIOCHEM PARASIT, V46, P169, DOI 10.1016/0166-6851(91)90210-W; COLBEREGARAPIN F, 1979, P NATL ACAD SCI USA, V76, P3755, DOI 10.1073/pnas.76.8.3755; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; DWYER DM, 1984, MOL BIOCHEM PARASIT, V10, P139, DOI 10.1016/0166-6851(84)90002-1; DWYER DM, 1977, EXP PARASITOL, V41, P341, DOI 10.1016/0014-4894(77)90107-2; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; GOTTLIEB M, 1983, MOL BIOCHEM PARASIT, V7, P303, DOI 10.1016/0166-6851(83)90013-0; GOTTLIEB M, 1986, COMP BIOCHEM PHYS B, V83, P63, DOI 10.1016/0305-0491(86)90332-9; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1992, MOL BIOCHEM PARASIT, V51, P321, DOI 10.1016/0166-6851(92)90082-U; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Molyneux DH, 1987, LEISHMANIASES BIOL M, V1, P121; MOORE KJ, 1993, J IMMUNOL, V150, P4457; MURRAY HW, 1989, J CLIN INVEST, V83, P1253, DOI 10.1172/JCI114009; Muyombwe A, 1997, EXP PARASITOL, V85, P35, DOI 10.1006/expr.1996.4115; Muyombwe A, 1998, J INFECT DIS, V177, P188, DOI 10.1086/513821; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; SACCI JB, 1990, EXP PARASITOL, V71, P158, DOI 10.1016/0014-4894(90)90018-8; STAUBER LA, 1966, EXP PARASITOL, V18, P1, DOI 10.1016/0014-4894(66)90002-6; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6; Zhang WW, 1997, P NATL ACAD SCI USA, V94, P8807, DOI 10.1073/pnas.94.16.8807; ZHANG WW, 1995, NUCLEIC ACIDS RES, V23, P4073, DOI 10.1093/nar/23.20.4073; ZLOTNICK GW, 1987, COMP BIOCHEM PHYS B, V87, P629, DOI 10.1016/0305-0491(87)90063-0	28	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22997	23003		10.1074/jbc.273.36.22997	http://dx.doi.org/10.1074/jbc.273.36.22997			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722523	hybrid			2022-12-25	WOS:000075778100023
J	Ouyang, L; Chen, XY; Bieker, JJ				Ouyang, L; Chen, XY; Bieker, JJ			Regulation of erythroid Kruppel-like factor (EKLF) transcriptional activity by phosphorylation of a protein kinase casein kinase II site within its interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN GENE-EXPRESSION; HUMAN GAMMA-GLOBIN; DNA-BINDING; BETA-THALASSEMIA; ACTIVATION; CELLS; CHROMATIN; SUBUNIT; RESIDUE; GATA-1	Erythroid Kruppel-like factor (EKLF) is a red cell-specific activator whose presence is crucial for establishing high levels of adult beta-globin expression in definitive cells during erythroid ontogeny, However, its simple presence within the erythroid lineage is not sufficient to activate the beta-globin promoter. One explanation that may account for this is that post-translational modification of EKLF differs within erythroid cell populations and regulates its activity. We have therefore addressed whether phosphorylation plays a role in modulating EKLF action. First, in vivo analyses implicate serine/threonine kinases as important players in the terminal differentiation of MEL cells, and demonstrate that EKLF is phosphorylated at serine and threonine residues within its transactivation region, Second, directed disruption of a protein kinase casein kinase (CK) II site, located within the EKLF interaction domain, abolishes EKLF transactivation and in vivo competition activity, Third, in vitro assays demonstrate that CKII alpha interacts with EKLF, and that the EKLF interaction domain is phosphorylated by CKII only at Thr-41; however, the CKII-site mutant is not phosphorylated. Finally, the transactivation capability of EKLF is augmented by cotransfection of CKII alpha. We conclude that EKLF is a phosphoprotein whose ability to transcriptionally activate an adjacent promoter is critically dependent on the phosphorylation status of a specific site located within the EKLF interaction domain, and that serine/threonine kinases play an important role in this process.	CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Bieker, JJ (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, Box 1126,1 Gustave L Levy Pl, New York, NY 10029 USA.	jbieker@smtplink.mssm.edu			NIDDK NIH HHS [DK46865] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046865] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FENG WC, 1994, J BIOL CHEM, V269, P1493; GONZATTIHACES MI, 1982, J BIOL CHEM, V257, P6642; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; HOEFFLER WK, 1994, NUCLEIC ACIDS RES, V22, P1305, DOI 10.1093/nar/22.7.1305; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Lim SK, 1997, BLOOD, V90, P1291, DOI 10.1182/blood.V90.3.1291.1291_1291_1299; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; Massimi P, 1996, ONCOGENE, V12, P2325; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; OReilly D, 1997, EMBO J, V16, P2420, DOI 10.1093/emboj/16.9.2420; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; Reese TT, 1997, GROWTH FACTORS, V14, P161, DOI 10.3109/08977199709021518; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Southwood CM, 1996, DEV DYNAM, V206, P248, DOI 10.1002/(SICI)1097-0177(199607)206:3<248::AID-AJA3>3.0.CO;2-I; STAMATOYANNOPOU.G, 1994, HEMOGLOBIN SWITCHING, P107; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wood WG, 1996, TRENDS GENET, V12, P204, DOI 10.1016/0168-9525(96)30043-7; YAN ZF, 1994, J BIOL CHEM, V269, P13231; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	57	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23019	23025		10.1074/jbc.273.36.23019	http://dx.doi.org/10.1074/jbc.273.36.23019			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722526	hybrid			2022-12-25	WOS:000075778100026
J	Ruiz-Arguello, MB; Goni, FM; Alonso, A				Ruiz-Arguello, MB; Goni, FM; Alonso, A			Vesicle membrane fusion induced by the concerted activities of sphingomyelinase and phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE DILUTION KINETICS; PHASE-TRANSITIONS; CELLULAR-RESPONSES; LIPOSOME FUSION; CUBIC PHASES; DIACYLGLYCEROL; MECHANISMS; CERAMIDE; LIPIDS; PHOSPHATIDYLETHANOLAMINE	When vesicles composed of an equimolar mixture of sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, and cholesterol are treated with phospholipase C, phospholipid hydrolysis occurs without major changes in vesicle architecture. In the same way, addition of sphingomyelinase leads only to sphingomyelin cleavage. However, when both enzymes are added together, their joint hydrolytic activities give rise to leakage-free vesicle aggregation, lipid mixing, and aqueous contents mixing, i.e. vesicle fusion, The contribution of both enzymes is unequal, the main role of sphingomyelinase being the production of relatively large amounts of ceramide that will facilitate the lamellar-to-nonlamellar transition in the formation of the fusion pore, whereas phospholipase C provides mainly a localized, asymmetric, high concentration of diacylglycerol that constitutes the trigger for the fusion process. The lipidic endproducts of both enzymes cooperate in destabilizing and fusing the membranes in a way that is never achieved through the action of any of the enzymes individually, nor by the products themselves when premixed with the other lipids during liposome preparation. Thus the enzymes appear to be coupled through their reaction products. This is the first observation of membrane fusion induced by the concerted activities of two enzymes. Besides, considering that both diacylglycerol and ceramide are important metabolites involved in cell signaling, it may also provide new ideas in the exploration of "cross-talk" phenomena between different signal transduction pathways.	Univ Basque Country, Dept Bioquim, CSIC, Unidad Asociada,Grp Biomembranas, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country	Alonso, A (corresponding author), Univ Basque Country, Dept Bioquim, CSIC, Unidad Asociada,Grp Biomembranas, Aptdo 644, E-48080 Bilbao, Spain.	gbpaliza@lg.ehu.es	Alonso, Alicia/E-5310-2012; Goni, Felix M/M-5425-2015	Alonso, Alicia/0000-0002-2730-7470; Goni, Felix M/0000-0001-6270-9216				Basanez G, 1997, BIOPHYS J, V72, P2630, DOI 10.1016/S0006-3495(97)78906-9; Basanez G, 1996, BIOPHYS J, V70, P2299, DOI 10.1016/S0006-3495(96)79795-3; Basanez G, 1998, BIOCHEMISTRY-US, V37, P3901, DOI 10.1021/bi9728497; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Bottcher C, 1961, ANAL CHIM ACTA, V1061, P297; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; CHERNOMORDIK L, 1995, BIOPHYS J, V69, P922, DOI 10.1016/S0006-3495(95)79966-0; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; DENNIS EA, 1973, ARCH BIOCHEM BIOPHYS, V158, P485, DOI 10.1016/0003-9861(73)90540-7; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P4141, DOI 10.1021/bi00362a023; Fanani ML, 1997, MOL MEMBR BIOL, V14, P25, DOI 10.3109/09687689709048166; Ghosh S, 1997, FASEB J, V11, P45, DOI 10.1096/fasebj.11.1.9034165; GOMEZMUNOZ A, 1997, SPHINGOLIPID MEDIATE, P103; GUNTHERAUSBORN S, 1995, J BIOL CHEM, V270, P29279; HAMILTON JA, 1991, J BIOL CHEM, V266, P1177; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; IKEZAWA H, 1978, BIOCHIM BIOPHYS ACTA, V528, P247; KOZLOV GV, 1983, PHYS REV B, V28, P255, DOI 10.1103/PhysRevB.28.255; Luzzati V, 1997, CURR OPIN STRUC BIOL, V7, P661, DOI 10.1016/S0959-440X(97)80075-9; MALLABIABARRENA A, 1995, CELL, V83, P667, DOI 10.1016/0092-8674(95)90177-9; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MONCK JR, 1994, NEURON, V12, P707, DOI 10.1016/0896-6273(94)90325-5; NIEVA JL, 1993, BIOCHEMISTRY-US, V32, P1054, DOI 10.1021/bi00055a009; NIEVA JL, 1995, FEBS LETT, V368, P143, DOI 10.1016/0014-5793(95)00631-I; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; SASAKI T, 1995, BIOCHEM J, V311, P829, DOI 10.1042/bj3110829; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Tong SG, 1996, BIOCHEMISTRY-US, V35, P4956, DOI 10.1021/bi9526903; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	35	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22977	22982		10.1074/jbc.273.36.22977	http://dx.doi.org/10.1074/jbc.273.36.22977			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722520	hybrid			2022-12-25	WOS:000075778100020
J	Ikezawa, K; Ohtsubo, M; Norwood, TH; Narayanan, AS				Ikezawa, K; Ohtsubo, M; Norwood, TH; Narayanan, AS			Role of cyclin E and cyclin E-dependent kinase in mitogenic stimulation by cementum-derived growth factor in human fibroblasts	FASEB JOURNAL			English	Article						tooth cementum; CGF; epidermal growth factor; cell cycle phase; gingival fibroblast; mesenchymal cells	DIFFERENTIAL EXPRESSION; MAMMALIAN FIBROBLASTS; SIGNAL TRANSDUCTION; G(1) CYCLINS; FACTOR-I; MECHANISMS; CELLS; PROLIFERATION; OSTEOBLASTS; INHIBITORS	Cementum-derived growth factor (CGF) is a 14 kDa polypeptide sequestered in tooth cementum. It is an IGF-I like molecule that is weakly mitogenic to fibroblasts, but its mitogenic action is synergistically potentiated in the presence of epidermal growth factor (EGF) or serum. We have examined whether the CGF affects cyclin E levels and the activity of cyclin-dependent kinase (Cdk) associated with this cyclin, and whether these changes contribute to the synergism in mitogenic activity between CGF and EGF. Optimal DNA synthesis by serum-starved human gingival fibroblasts required the presence of CGF for 0-12 h and EGF for 0-3 h. Therefore, cells were serum starved for 48 h and then exposed to CGF, EGF, or CGF + EGF. Cells incubated with 10% fetal bovine serum (FBS) served as positive controls. At various time points after the addition of growth factors, cyclin E levels were examined by Western analysis. Cdk associated with cyclin E was immunoprecipitated with anti-cyclin E antibody and kinase activity was measured using H1 histone as substrate. Cyclin E and the HI kinase activity level increased after 8-12 h in cells exposed to CGF and in positive controls exposed to 10% FBS. They returned to basal level 4 h later in cells exposed to CGF alone, whereas in the presence of CGF + EGF and FBS they remained elevated for up to 20 h. The cyclin E levels did not increase in the presence of EGF alone. Cyclin-dependent kinase inhibitors p21(cip1) and p27(kip1) were barely detectable in these cells. Fibroblasts transfected with LXSN-cyclin E, a retroviral vector containing cyclin E cDNA, overexpressed cyclin E and their steady-state cyclin E-Cdk activity was higher than control cells. DNA synthesis by cyclin E overexpressing cells was higher, but optimal DNA synthesis by these cells required the presence of CGF and EGF. These results show that CGF action involves an increase in the level of cyclin E and E-Cdk activity and that the higher levels are maintained in the presence of both CGF and EGF. They also indicate that sustained high cyclin E level and Cdk2 activity during G(1) phase are necessary, but not sufficient, for optimal mitogenic response in human fibroblasts.-Ike-zawa, IC, Ohtsubo, M., Norwood, T. H., Narayanan, A. S. Role of cyclin E and cyclin E-dependent kinase in mitogenic stimulation by cementum-derived growth factor in human fibroblasts.	Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Kurume Univ, Inst Life Sci, Div Mol Genet, Kurume, Fukuoka 830, Japan	University of Washington; University of Washington Seattle; Kurume University	Narayanan, AS (corresponding author), Univ Washington, Sch Med, Dept Pathol, Box 357470, Seattle, WA 98195 USA.			ohtsubo, motoaki/0000-0002-2479-3178	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229, R01DE010491] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-10491, DE-08229] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; DELANY AM, 1994, J CELL BIOCHEM, V55, P328, DOI 10.1002/jcb.240550309; DeLoia JA, 1997, PLACENTA, V18, P9, DOI 10.1016/S0143-4004(97)90066-7; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Ikezawa K, 1997, CONNECT TISSUE RES, V36, P309, DOI 10.3109/03008209709160230; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Li ZR, 1997, BBA-MOL CELL RES, V1356, P149, DOI 10.1016/S0167-4889(96)00172-3; MACNEIL RL, 1993, J PERIODONTAL RES, V28, P550, DOI 10.1111/j.1600-0765.1993.tb02123.x; NAKAE H, 1991, BIOCHEMISTRY-US, V30, P7047, DOI 10.1021/bi00243a002; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PITARU S, 1994, J PERIODONTAL RES, V29, P81, DOI 10.1111/j.1600-0765.1994.tb01095.x; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith E, 1997, J CELL BIOCHEM, V66, P141, DOI 10.1002/(SICI)1097-4644(19970801)66:2<141::AID-JCB2>3.0.CO;2-Q; SMITH E, 1995, CANCER RES, V55, P5019; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; YONEMURA K, 1993, J BIOL CHEM, V268, P26120; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	30	8	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1233	1239		10.1096/fasebj.12.12.1233	http://dx.doi.org/10.1096/fasebj.12.12.1233			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737726				2022-12-25	WOS:000075738500018
J	Wice, BM; Gordon, JI				Wice, BM; Gordon, JI			Forced expression of Id-1 in the adult mouse small intestinal epithelium is associated with development of adenomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; ACID-BINDING-PROTEIN; B-CELL DEVELOPMENT; TRANSGENIC MICE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; DNA-BINDING; STEM-CELL; PANETH CELLS; MUSCLE DIFFERENTIATION	Ids are dominant-negative helix-loop-helix (HLH) proteins that play overlapping yet distinct roles in antagonizing basic HLH transcription factors. Although Ids affect myogenesis, neurogenesis, and B-cell development, little is known about their in vivo functions in epithelia, we have examined the effects of forced expression of Id-1 in the small intestinal epithelium of adult chimeric mice. 129/Sv embryonic stem cells, transfected with DNA containing Id-1 under the control of transcriptional regulatory elements that function in all intestinal epithelial cell lineages, were introduced into C57BI/6 (B6) blastocysts heterozygous for the ROSA26 marker. The B6 ROSA26/+ intestinal epithelium of the resulting adult chimeras produces Escherichia coli P-galactosidase, allowing identification of this internal control cell population. Chimeras produced from nontransfected embryonic stem cells served as additional controls. Immunohistochemical studies of the control chimeras indicated that the small intestinal epithelium supports a complex pattern of endogenous Id expression. Id-1 is restricted to the cytoplasm; levels do not decrease as descendants of multipotent intestinal stem cells differentiate. Id-2 and Id-3 are only detectable in nuclei; levels increase markedly as epithelial cells differentiate. Forced expression of Id-1 in the 129/Sv epithelium results in a decline in Id-2 and Id-3 to below the limits of immunodetection, A subset of chimeric-transgenic mice lacked growth factor- and defensin-producing Paneth cells in their 129/Sv epithelium and also developed intestinal adenomas, These changes were not present in normal control chimeras. Adenomas were composed of proliferating beta-Gal-positive and -negative epithelial cells, suggesting that they arose through cooperative interactions between 129/Sv(Id-1) and B6 ROSA26/+ cells. These chimeras provide a model for studying how perturbations in Id expression affect tumorigenesis.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@pharmdec.wustl.edu			NIDDK NIH HHS [DK 37960] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037960] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BJERKNES M, 1981, AM J ANAT, V160, P65, DOI 10.1002/aja.1001600106; Bjerknes M, 1997, CANCER RES, V57, P355; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; COHN SM, 1984, J BIOL CHEM, V259, P2456; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; CROSS JC, 1995, DEVELOPMENT, V121, P2513; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gould KA, 1996, GENETICS, V144, P1769; Gould KA, 1996, GENETICS, V144, P1777; Gould KA, 1996, CELL GROWTH DIFFER, V7, P1361; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUNDERSEN K, 1994, P NATL ACAD SCI USA, V91, P3647, DOI 10.1073/pnas.91.9.3647; HAGEMANN RF, 1971, AM J ANAT, V129, P41; HALL PA, 1994, J CELL SCI, V107, P3569; HARA E, 1994, J BIOL CHEM, V269, P2139; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LI YQ, 1994, J CELL SCI, V107, P3271; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Merritt AJ, 1997, P NATL ACAD SCI USA, V94, P13927, DOI 10.1073/pnas.94.25.13927; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; Novelli MR, 1996, SCIENCE, V272, P1187, DOI 10.1126/science.272.5265.1187; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROBINSON GLWG, 1994, MOL CELL BIOL, V14, P6704, DOI 10.1128/MCB.14.10.6704; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; SIMON TC, 1993, J BIOL CHEM, V268, P18345; Simon TC, 1997, J BIOL CHEM, V272, P10652; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TOTAFURNO J, 1987, BIOPHYS J, V52, P279, DOI 10.1016/S0006-3495(87)83215-0; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; WANG YQ, 1992, DEV DYNAM, V194, P222, DOI 10.1002/aja.1001940307; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	83	70	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25310	25319		10.1074/jbc.273.39.25310	http://dx.doi.org/10.1074/jbc.273.39.25310			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737997	hybrid			2022-12-25	WOS:000076085400047
J	Ju, H; Venema, VJ; Marrero, MB; Venema, RC				Ju, H; Venema, VJ; Marrero, MB; Venema, RC			Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; BINDING DOMAIN; CAVEOLIN; EXPRESSION; CALMODULIN; IDENTIFICATION; CLONING; MUSCLE; CELLS	It has been shown previously that the endothelial nitric-oxide synthase (eNOS) interacts reversibly with the plasmalemmal caveolae structural protein, caveolin-1. The eNOS-caveolin-1 interaction inhibits eNOS catalytic activity. In the present study, we show that eNOS also participates in reversible inhibitory interactions with the G protein-coupled bradykinin B2 receptor, eNOS and the B2 receptor are coimmunoprecipitated from endothelial cell lysates by antibodies directed against either of the two proteins. A glutathione S-transferase fusion protein containing intracellular domain 4 of the receptor is bound by purified recombinant eNOS in in vitro binding assays. The fusion protein selectively inhibits the activity of purified eNOS. A synthetic peptide corresponding to membrane-proximal residues 310-334 in intracellular domain 4 also potently inhibits eNOS activity (IC50 < 1 mu M). Treatment of cultured endothelial cells with bradykinin or Ca2+ ionophore promotes a rapid dissociation of the eNOS B2 receptor complex. These data demonstrate that the bradykinin B2 receptor physically associates with eNOS in a ligand- and Ca2+ dependent manner. Reversible and inhibitory membrane-docking interactions of eNOS, therefore, are not restricted to those with caveolin-1 but also occur with the bradykinin B2 receptor.	Med Coll Georgia, Dept Pediat, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Venema, RC (corresponding author), Med Coll Georgia, Dept Pediat, Vasc Biol Ctr, Augusta, GA 30912 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057201, R01HL057201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDALLA S, 1993, J BIOL CHEM, V268, P17277; Busse R, 1996, DIABETES, V45, pS8, DOI 10.2337/diab.45.1.S8; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEENER EP, 1995, J CLIN INVEST, V95, P1353, DOI 10.1172/JCI117786; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MONCADA S, 1991, PHARMACOL REV, V43, P109; Pueyo ME, 1998, AM J PHYSIOL-CELL PH, V274, pC214, DOI 10.1152/ajpcell.1998.274.1.C214; VAUGHAN DE, 1995, J CLIN INVEST, V95, P995, DOI 10.1172/JCI117809; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Venema VJ, 1998, BIOCHEM BIOPH RES CO, V246, P70, DOI 10.1006/bbrc.1998.8574; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187	19	132	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24025	24029		10.1074/jbc.273.37.24025	http://dx.doi.org/10.1074/jbc.273.37.24025			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727019	hybrid			2022-12-25	WOS:000075893100060
J	Kudoh, S; Komuro, I; Hiroi, Y; Zou, YZ; Harada, K; Sugaya, T; Takekoshi, N; Murakami, K; Kadowaki, T; Yazaki, Y				Kudoh, S; Komuro, I; Hiroi, Y; Zou, YZ; Harada, K; Sugaya, T; Takekoshi, N; Murakami, K; Kadowaki, T; Yazaki, Y			Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; COUPLED RECEPTORS; CELL HYPERTROPHY; TYROSINE KINASE; EGF RECEPTOR; MUSCLE-CELLS; STRESS; INHIBITION; PHOSPHORYLATION	Many lines of evidence have suggested that angiotensin II (AngII) plays an important role in the development of cardiac hypertrophy through AngII type 1 receptor (AT1). To determine whether AngII is indispensable for the development of mechanical stress-induced cardiac hypertrophy, we examined the activity of mitogen-activated protein kinase (MAPK) family and the expression of the c-fos gene as hypertrophic responses after stretching cultured cardiac myocytes of AT1a knockout (KO) mice. When cardiac myocytes were stretched by 20% for 10 min, extracellular signal-regulated protein kinases (ERKs) were strongly activated in KO cardiomyocytes as well as wild type (WT) myocytes. Both basal and stimulated levels of ERKs were higher in cardiomyocytes of KO mice than in those of WT mice. Activation of another member of the MAPK family, p38(MAPK), and expression of the c-fos gene were also induced by stretching cardiac myocytes of both types of mice. An AT1 antagonist attenuated stretch-induced activation of ERKs in WT cardiomyocytes but not in KO cardiomyocytes, Down-regulation of protein kinase C inhibited stretch-induced ERK activation in WT cardiomyocytes, whereas a broad spectrum tyrosine kinase inhibitor (genistein) and selective inhibitors of epidermal growth factor receptor (tyrphostin, AG1478, and B42) suppressed stretch-induced activation of ERKs in KO cardiac myocytes. Epidermal growth factor receptor was phosphorylated at tyrosine residues by stretching cardiac myocytes of KO mice. These results suggest that mechanical stretch could evoke hypertrophic responses in cardiac myocytes that lack the AT1 signaling pathway possibly through tyrosine kinase activation.	Univ Tokyo, Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3050005, Japan; Kanazawa Med Univ, Dept Cardiol, Kanazawa, Ishikawa 9200265, Japan	University of Tokyo; University of Tsukuba; Kanazawa Medical University	Komuro, I (corresponding author), Univ Tokyo, Sch Med, Dept Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harada K, 1998, CIRCULATION, V97, P1952, DOI 10.1161/01.CIR.97.19.1952; Harada K, 1998, CIRC RES, V82, P779, DOI 10.1161/01.RES.82.7.779; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; Kent RL, 1996, CIRC RES, V78, P829, DOI 10.1161/01.RES.78.5.829; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1995, CIRC RES, V76, P1; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	45	109	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24037	24043		10.1074/jbc.273.37.24037	http://dx.doi.org/10.1074/jbc.273.37.24037			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727021	hybrid			2022-12-25	WOS:000075893100062
J	Martins, LJ; Jensen, LT; Simons, JR; Keller, GL; Winge, DR				Martins, LJ; Jensen, LT; Simons, JR; Keller, GL; Winge, DR			Metalloregulation of FRE1 and FRE2 homologs in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER TRANSPORT PROTEIN; IRON UPTAKE; NADPH OXIDASE; FERRIC REDUCTASE; MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL CONTROL; FET3 GENE; YEAST; BINDING; REPRESSION	The high affinity uptake systems for iron and copper ions in Saccharomyces cerevisiae involve metal-specific permeases and two known cell surface Cu(II) and Fe(III) metalloreductases, Fre1 and Fre2, Five novel genes found in the S. cerevisiae genome exhibit marked sequence similarity to Fre1 and Fre2, suggesting that the homologs are part of a family of proteins related to Fre1 and Fre2, The homologs are expressed genes in S. cerevisiae, and their expression is metalloregulated as is true with FRE1 and FRE2. Four of the homologs (FRE3-FRE6) are specifically hen-regulated through the Aft1 transcription factor. These genes are expressed either in cells limited for iron ion uptake by treatment with a chelator or in cells lacking the high affinity iron uptake system. Expression of FRE3-FRE6 is elevated in AFT1-1(up) cells and attenuated in aft1 null cells, showing that iron modulation occurs through the Aft1 transcriptional activator. The fifth homolog FRE7 is specifically copper-metalloregulated, FRE7 is expressed in cells limited in copper ion uptake by a Cu(I)-specific chelator or in cells lacking the high affinity Cu(I) permeases, The constitutive expression of FRE7 in MAC1(up1) cells and the lack of expression in mac1-1 cells are consistent with Mad being the critical transcriptional activator of FRE7 expression, The 5' promoter sequence of FRE7 contains three copper-responsive promoter elements. Two elements are critical for Mad-dependent FRE7 expression. Combinations of either the distal and central elements or the central and proximal elements result in copper-regulated FRE7 expression. Spacing between Mac1-responsive sites is important as shown by the attenuated expression of FRE7 and CTR1 when two elements are separated by over 100 base pairs. From the three Mac1-responsive elements in FRE7, a new consensus sequence for Mad binding can be established as TTTGC(T/G)C(A/G).	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.		Winge, Dennis/G-3611-2010	Jensen, Laran/0000-0003-3199-1743; Martins, Laura/0000-0001-8535-5350	NATIONAL CANCER INSTITUTE [P30CA042014, R01CA061286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NCI NIH HHS [5P30-CA 42014, CA61286] Funding Source: Medline; NIDDK NIH HHS [T32 DK07115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROSS AR, 1994, J BIOL CHEM, V269, P21448; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LESK AM, 1991, PROTEIN ARCHITECTURE, P68; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; Moore DD, 1995, GLOB MOB SURV; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; VANDERHELM D, 1994, HYDROXAMATES POLYCAB, P39; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	32	156	169	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23716	23721		10.1074/jbc.273.37.23716	http://dx.doi.org/10.1074/jbc.273.37.23716			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726978	hybrid			2022-12-25	WOS:000075893100019
J	Scheller, A; Hughes, E; Golden, KL; Robins, DM				Scheller, A; Hughes, E; Golden, KL; Robins, DM			Multiple receptor domains interact to permit, or restrict, androgen-specific gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; AMINO-TERMINAL DOMAIN; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENT; TRANSACTIVATION DOMAIN; HORMONE RECEPTOR; STEROID-BINDING; PROBASIN GENE; INSECT CELLS; IN-VIVO	A critical problem within transcription factor families is how diverse regulatory programs are directed by highly related members. Androgen and glucocorticoid receptors (AR, GR) recognize a consensus DNA hormone response element (HRE), but they activate target genes with precise specificity, largely dependent on the promoter and cell context. We have assessed the role of different receptor domains in hormone-specific response by testing chimeras of AR and GR for their ability to activate the androgen-specific enhancer of the mouse sex-limited protein (Slp) gene Although all of the mutant receptors activated simple HREs, only a few activated the androgen-specific element. One component shared by receptors functional on the AR-specific target was the AR DNA binding domain. Activation was not due to differential DNA affinity but rather to the AR DNA binding domain escaping suppression directed at the GR DNA binding domain in this enhancer context. A further mechanism increasing specific activation was cooperation of receptors at multiple and weak HREs, which was accentuated in the presence of both the AR N terminus and ligand binding domain, These domains together increased recognition of weak HREs, as demonstrated by in vitro DNase I footprinting and transactivation of mutant enhancers. Further, AR N-terminal subdomains reported to interact directly with the ligand binding domain relieved an inhibitory effect imposed by that domain. Therefore, functions intrinsic to AR augment steroid-specific gene activation, by evading negative regulation operating on the domains of other receptors and by enhancing cooperativity through intra- and inter-receptor domain interactions. These subtle distinctions in AR and GR behavior enforce transcriptional specificity established by the context of nonreceptor factors.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Robins, DM (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.			Robins, Diane M./0000-0001-6727-6309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031546] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31546] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Andersson S, 1996, TRENDS ENDOCRIN MET, V7, P121, DOI 10.1016/1043-2760(96)00034-3; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chandran UR, 1996, J BIOL CHEM, V271, P20412, DOI 10.1074/jbc.271.34.20412; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABRE S, 1994, J BIOL CHEM, V269, P5857; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HE WW, 1990, BIOCHEM BIOPH RES CO, V171, P697, DOI 10.1016/0006-291X(90)91202-4; HO KC, 1993, J BIOL CHEM, V268, P27226; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; KALLIO PJ, 1994, J BIOL CHEM, V269, P11514; KASPER S, 1994, J BIOL CHEM, V269, P31763; KATO S, 1995, MOL CELL BIOL, V15, P5858; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; Nelson SA, 1997, MOL CELL ENDOCRINOL, V133, P89, DOI 10.1016/S0303-7207(97)00150-0; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; TAN JA, 1992, J BIOL CHEM, V267, P4456; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; WONG CI, 1993, J BIOL CHEM, V268, P19004; XIE YB, 1992, J BIOL CHEM, V267, P4939; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	51	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24216	24222		10.1074/jbc.273.37.24216	http://dx.doi.org/10.1074/jbc.273.37.24216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727045	hybrid			2022-12-25	WOS:000075893100086
J	Lemasson, I; Thebault, S; Sardet, C; Devaux, C; Mesnard, JM				Lemasson, I; Thebault, S; Sardet, C; Devaux, C; Mesnard, JM			Activation of E2F-mediated transcription by human T-cell leukemia virus type I tax protein in a p16(INK4A)-negative T-cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; NF-KAPPA-B; E2F FAMILY MEMBERS; S-PHASE ENTRY; HTLV-I; TRANSACTIVATOR TAX; CONSTITUTIVE ACTIVATION; INTERLEUKIN-2 RECEPTOR; RAT FIBROBLASTS; LYMPHOMA VIRUS	The human T-cell leukemia virus type I (HTLV-I) is a causative agent of adult T-cell leukemia. Although the exact mechanism by which HTLV-I contributes to leukemogenesis is still unclear, the Tax protein is thought to play a major role in this process. This 40-kDa polypeptide is able to interact with the tumor suppressor p16(INK4A). Consequently, Tax can activate the signaling pathway that lead to the release of E2F that in turn induces expression of factors required for cell cycle progression. In this paper, we demonstrate that Tax can also activate E2F-mediated transcription independently of p16(INK4A). Indeed, when Tax is coexpressed with the E2F-1 transcription factor in CEM T-cells, which lack expression of p16(INK4A), it strongly potentiates the E2F-dependent activation of a reporter construct driven by a promoter containing E2F binding sites. This stimulation is abrogated by mutations affecting the E2F-binding sites. In addition, Tax also stimulates the transcription of the E2F-1 gene itself. Using Tax mutants that fail to activate either ATF- or NF-kappa B-dependent promoters and different 5' truncation mutants of the E2F-1 promoter, we show that the Tax-dependent transcriptional control of the E2F1 gene involves, at least in part, the ATF binding site located in the E2F-1 promoter.	Inst Biol, Lab Infect Retrovirales & Signalisat Cellulaire, CRBM, CNRS,UPR 1086, F-34060 Montpellier, France; Inst Genet Mol Montpellier, CNRS, UMR 5535, F-34033 Montpellier 1, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Mesnard, JM (corresponding author), Inst Biol, Lab Infect Retrovirales & Signalisat Cellulaire, CRBM, CNRS,UPR 1086, 4 Bd Henri IV, F-34060 Montpellier, France.	mesnard@crbm.cnrs-mop.fr	Lemasson, Isabelle/N-1355-2013	Mesnard, Jean-Michel/0000-0003-3344-5367				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Corbeil J, 1996, J EXP MED, V183, P39, DOI 10.1084/jem.183.1.39; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; Geng Y, 1996, ONCOGENE, V12, P1173; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HISCOTT J, 1995, VIROLOGY, V214, P3, DOI 10.1006/viro.1995.9960; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HOSHINO H, 1983, P NATL ACAD SCI-BIOL, V80, P6061, DOI 10.1073/pnas.80.19.6061; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Langton B., 1988, MED VIROL, V8, P295; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lemasson I, 1996, J IMMUNOL, V156, P859; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; Miyoshi I., 1982, GANN MONOGR, V28, P219; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Mori N, 1997, EUR J HAEMATOL, V58, P114; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NEVINS JR, 1992, SCIENCE, V258, P424; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Pajovic S, 1997, MOL CELL BIOL, V17, P6459, DOI 10.1128/MCB.17.11.6459; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PAUL NL, 1990, J VIROL, V64, P5412, DOI 10.1128/JVI.64.11.5412-5419.1990; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Richardson JH, 1997, VIROLOGY, V237, P209, DOI 10.1006/viro.1997.8779; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yang Xiao-He, 1995, Gene Expression, V4, P195; Yoshida M, 1996, J ACQ IMMUN DEF SYND, V13, pS63, DOI 10.1097/00042560-199600001-00012; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	77	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23598	23604		10.1074/jbc.273.36.23598	http://dx.doi.org/10.1074/jbc.273.36.23598			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722600	hybrid			2022-12-25	WOS:000075778100100
J	Vadiveloo, PK; Vairo, G; Royston, AK; Novak, U; Hamilton, JA				Vadiveloo, PK; Vairo, G; Royston, AK; Novak, U; Hamilton, JA			Proliferation-independent induction of macrophage cyclin D2, and repression of cyclin D1, by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; STIMULATING FACTOR-I; CELL-CYCLE; GENE-EXPRESSION; GROWTH-FACTOR; ANTIPROLIFERATIVE AGENTS; D1-DEPENDENT KINASE; DEPENDENT KINASES; PHASE PROGRESSION; NUCLEAR-PROTEIN	D-type cyclins are induced in response to mitogens and are essential, and rate-limiting for G(1) phase progression in normal mammalian cells. Macrophages proliferating in response to colony-stimulating factor-1 (CSF-1) express cyclin D1 and to a lesser extent cyclin D2 but not cyclin D3, Previously we showed that the macrophage-activating agent lipopolysaccharide (LPS) blocks CSF-1-induced proliferation and cyclin D1 expression in macrophages, Here we report upon the effect of LPS on expression of cyclin D2 in normal mouse bone marrow-derived macrophages (BMM). Unexpectedly me found that this anti-mitogen raised levels of CSF-1-stimulated cyclin D2 mRNA and protein. Furthermore, LPS alone induced cyclin Ha but not cyclin D1. Inhibition of the MEK/ERK (MAPK/ERK kinase/extracellular signal-regulated kinase) mitogen-activated protein kinase pathway repressed LPS-induced cyclin D2 mRNA, whereas inhibition of the p38 mitogen-activated protein kinase enhanced expression. However, in contrast to cyclin D1, cyclin D2 in bone marrow-derived macrophages did not appear to be regulated by protein kinase A pathways. The present data (a) show elevation of a D-type cyclin in the absence of proliferation, (b) demonstrate inverse regulation of two distinct D-type cyclins under identical conditions, and (c) suggest that cyclin D2 plays a role in macrophage activation by LPS.	Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; University of Melbourne; Walter & Eliza Hall Institute	Vadiveloo, PK (corresponding author), St Vincents Hosp, Bernard OBrien Inst Microsurg, Fitzroy, Vic 3065, Australia.			Hamilton, John A/0000-0002-9493-9224				Adachi M, 1997, BLOOD, V90, P126; ADAMS DO, 1992, MACROPHAGE, P76; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKS BG, 1992, J BIOL CHEM, V267, P12307; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HAMILTON JA, 1992, J IMMUNOL, V148, P4028; Jaworowski A, 1996, BIOCHEM J, V320, P1011, DOI 10.1042/bj3201011; JIANG W, 1993, ONCOGENE, V8, P3447; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LUKAS J, 1995, ONCOGENE, V10, P2125; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; OKADA F, 1995, BBA-MOL CELL RES, V1265, P201, DOI 10.1016/0167-4889(94)00228-7; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RADDASSI K, 1993, CELL IMMUNOL, V149, P50, DOI 10.1006/cimm.1993.1135; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1991, J IMMUNOL, V146, P3469; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VAIRO G, 1988, J CELL PHYSIOL, V134, P13, DOI 10.1002/jcp.1041340103; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WILLIAMS JG, 1993, SURGERY, V114, P314; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23104	23109		10.1074/jbc.273.36.23104	http://dx.doi.org/10.1074/jbc.273.36.23104			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722538	hybrid			2022-12-25	WOS:000075778100038
J	McFerran, BW; Graham, ME; Burgoyne, RD				McFerran, BW; Graham, ME; Burgoyne, RD			Neuronal Ca2+ sensor 1, the mammalian homologue of frequenin, is expressed in chromaffin and PC12 cells and regulates neurosecretion from dense-core granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; NERVOUS-SYSTEM; CA2+-DEPENDENT EXOCYTOSIS; TRANSMITTER RELEASE; MOLECULAR-CLONING; DROSOPHILA; NEUROCALCIN; RECOVERIN; HIPPOCALCIN; SECRETION	Neuronal Ca2+ sensor 1 (NCS-1) is the mammalian homologue of the Ca2+-binding protein frequenin previously implicated in regulation of neurotransmission in Drosophila (Pongs, O., Lindemeier, J., Zhu, X. R., Theil, T., Endelkamp, D., Krah-Jentgens, I., Lambrecht, H.-G., Koch, R. W., Schwemer, J., Rivosecchi, R., Mallart, A., Galceran, J., Canal, I., Barbas, J. A., and Ferrus, A. (1993) Neuron 11, 15-28). NCS-1 has been considered to be expressed only in neurons, but we show that NCS-1 expression can be detected in bovine adrenal chromaffin and PC12 cells, two widely studied model neuroendocrine cells. NCS-1 was present in both cytosolic and membrane fractions including purified chromaffin granules, and in immunofluorescence, its distribution overlapped with peripheral punctate staining seen with the synaptic-like microvesicle marker synaptophysin in PC12 cells. The possible functional role of NCS-1 in exocytosis of dense core granules was tested using transient transfection in PC12 cells and assay of co-transfected growth hormone (GH) release. Overexpression of NCS-1 increased evoked GH release in intact cells in response to ATP. No effect of overexpression was seen on GH release because of Ca2+ in permeabilized cells suggesting that NCS-1 may have a regulatory but not direct role in neurosecretion.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Calakos N, 1996, PHYSIOL REV, V76, P1; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; COX JA, 1994, J BIOL CHEM, V269, P32807; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Graham ME, 1997, MOL BIOL CELL, V8, P431, DOI 10.1091/mbc.8.3.431; Graham ME, 1997, J NEUROCHEM, V69, P2369; IINO, 1997, CELL TISSUE RES, V289, P439; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; LADANT D, 1995, J BIOL CHEM, V270, P3179; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Morgan A, 1997, SEMIN CELL DEV BIOL, V8, P141, DOI 10.1006/scdb.1996.0133; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; Olafsson P, 1997, MOL BRAIN RES, V44, P73, DOI 10.1016/S0169-328X(96)00188-X; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; POULAIN C, 1994, PFLUG ARCH EUR J PHY, V427, P71, DOI 10.1007/BF00585944; RIVOSECCHI R, 1994, J PHYSIOL-LONDON, V474, P223, DOI 10.1113/jphysiol.1994.sp020015; ROTH D, 1994, BIOCHEM J, V301, P305, DOI 10.1042/bj3010305; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; WICK PF, 1993, J BIOL CHEM, V268, P10983; YAMAGATA K, 1990, NEURON, V4, P469, DOI 10.1016/0896-6273(90)90059-O	35	135	141	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22768	22772		10.1074/jbc.273.35.22768	http://dx.doi.org/10.1074/jbc.273.35.22768			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712909	hybrid			2022-12-25	WOS:000075616600085
J	Roscher, A; Emsley, L; Raymond, P; Roby, C				Roscher, A; Emsley, L; Raymond, P; Roby, C			Unidirectional steady state rates of central metabolism enzymes measured simultaneously in a living plant tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIZE ROOT-TIPS; NUCLEAR MAGNETIC-RESONANCE; NMR EXCHANGE SPECTROSCOPY; CARBOHYDRATE-METABOLISM; SUCROSE; GROWTH; RESPIRATION; INVIVO; PYROPHOSPHATE; SEEDLINGS	The unidirectional steady state reaction rates of several enzymes and metabolic fluxes of distinct processes were measured simultaneously in hypoxic maize root tips using two-dimensional phosphorus NMR exchange spectroscopy. A single spectrum monitors ATP synthesis and hydrolysis as well as the activities of four enzymes involved in key pathways of central metabolism: UDP-glucose pyrophosphorylase, phosphoglucomutase, hexose-phosphate isomerase, and enolase, The corresponding unidirectional reaction rates and net metabolic fluxes were calculated from spectral intensities. This method provides a unique picture, at enzyme resolution, of how metabolism reacts in a concerted fashion to changes in external parameters such as temperature and oxygen concentration, By increasing hypoxia via an increase in temperature, we measured the expected increase in glycolysis through enolase activity while total ATP synthesis settled. At the same time, we observed a net flux through phosphoglucomutase and UDP-glucose pyrophosphorylase toward carbohydrate synthesis. This result is discussed in relation to the current hypothesis on the turnover of cell walls and sucrose. This reaction also produces a net flux of pyrophosphate, which is needed by pyrophosphate:fructose-6-phosphate 1-phosphotransferase to work as a glycolytic enzyme.	CEA, Lab Resonance Magnet Biol Metab, F-38054 Grenoble 9, France; Univ Grenoble 1, F-38054 Grenoble 9, France; Ecole Normale Super Lyon, Lab Stereochim & Interact Mol, F-69364 Lyon 07, France; INRA, Stn Physiol Vegetale, F-33883 Villenave Dornon, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	Roby, C (corresponding author), CEA, Lab DBMS RMBM, 17 Rue Martyrs, F-38054 Grenoble 9, France.	roby@cea.fr	Emsley, Lyndon/AAS-6384-2020; Roscher, Albrecht/AGZ-4644-2022; Emsley, Lyndon/C-6108-2008	Emsley, Lyndon/0000-0003-1360-2572; Emsley, Lyndon/0000-0003-1360-2572; Roscher, Albrecht/0000-0003-2597-367X				ABEL EW, 1986, J MAGN RESON, V70, P34, DOI 10.1016/0022-2364(86)90361-6; ALGER JR, 1984, Q REV BIOPHYS, V17, P83, DOI 10.1017/S0033583500005266; Ap Rees T., 1994, Plant Cell and Environment, V17, P587, DOI 10.1111/j.1365-3040.1994.tb00151.x; ATWELL BJ, 1985, PLANT CELL ENVIRON, V8, P179, DOI 10.1111/1365-3040.ep11604603; BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; BALABAN RS, 1983, J BIOL CHEM, V258, P2787; Bouny JM, 1996, PLANT PHYSIOL, V111, P187, DOI 10.1104/pp.111.1.187; BRETHARTE MS, 1994, PLANT PHYSIOL, V105, P19, DOI 10.1104/pp.105.1.19; BRINDLE KM, 1988, PROG NUCL MAG RES SP, V20, P257, DOI 10.1016/0079-6565(88)80003-7; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; DANCER JE, 1989, J PLANT PHYSIOL, V135, P197, DOI 10.1016/S0176-1617(89)80177-4; Dennis D.T., 1997, PLANT METABOLISM, P181; DENNIS DT, 1997, PLANT METABOLISM, P105; DENNIS DT, 1987, BIOCH ENERGY UTILIZA; DIEUAIDENOUBHANI M, 1995, J BIOL CHEM, V270, P13147, DOI 10.1074/jbc.270.22.13147; Douce R., 1985, MITOCHONDRIA HIGHER; Drew MC, 1997, ANNU REV PLANT PHYS, V48, P223, DOI 10.1146/annurev.arplant.48.1.223; ERNST RR, 1987, PRINCIPLES NMR ONE 2, P495; FELL DA, 1997, UNDERSTANDING CONTRO, pCH1; GARLICK PB, 1983, J MAGN RESON, V51, P536, DOI 10.1016/0022-2364(83)90306-2; GEIGENBERGER P, 1991, PLANTA, V185, P81, DOI 10.1007/BF00194518; GEIGENBERGER P, 1993, PLANTA, V189, P329, DOI 10.1007/BF00194429; GIBEAUT DM, 1991, PLANT PHYSIOL, V97, P551, DOI 10.1104/pp.97.2.551; Gillies RF, 1994, NMR PHYSL BIOMEDICIN; GUPTA RK, 1987, NMR SPECTROSCOPY CEL; HARGREAVES JA, 1988, PHYTOCHEMISTRY, V27, P1627, DOI 10.1016/0031-9422(88)80416-3; HATFIELD PM, 1997, PLANT METABOLISM, P26; HEINRICH R, 1996, REGULATION CELLULAR, P38; HILL SA, 1994, PLANTA, V192, P52, DOI 10.1007/BF00198692; HOCHACHKA PW, 1984, BIOCH ADAPTATION, P8; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kacser H, 1987, BIOCH PLANTS, P39; KESSLER H, 1984, J MAGN RESON, V57, P331, DOI 10.1016/0022-2364(84)90136-7; KO K, 1997, PLANT METABOLISM, P17; KOCK M, 1994, ANGEW CHEM INT EDIT, V33, P332, DOI 10.1002/anie.199403321; KRUGER NJ, 1997, PLANT METABOLISM, P83; Kuchel P W, 1990, NMR Biomed, V3, P102, DOI 10.1002/nbm.1940030303; Larcher W., 1995, PHYSL PLANT ECOLOGY, P321, DOI [10.1007/978-3-642-87851-0_6, DOI 10.1007/978-3-642-87851-0_6]; LEFEBVRE DD, 1997, PLANT METABOLISM, P3; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; MOHANTY B, 1993, PHYTOCHEMISTRY, V34, P75, DOI 10.1016/S0031-9422(00)90785-4; PFEFFER PE, 1989, NMR AGR; Plaxton W.C., 1997, PLANT METABOLISM, P50; Plaxton WC, 1996, ANNU REV PLANT PHYS, V47, P185, DOI 10.1146/annurev.arplant.47.1.185; RATCLIFFE RG, 1996, NUCL MAGNETIC RESONA, P1; REICH JG, 1981, ENERGY METABOLISM CE, P147; ROBERTS JKM, 1984, PLANT PHYSIOL, V74, P632, DOI 10.1104/pp.74.3.632; ROBERTS JKM, 1990, BIOCHIM BIOPHYS ACTA, V1051, P29, DOI 10.1016/0167-4889(90)90170-I; ROBERTS JKM, 1986, MOD METHOD PLANT, V2, P43; ROBY C, 1987, J BIOL CHEM, V262, P5000; ROSCHER A, 1997, THESIS J FOURIER U G; SAGLIO PH, 1984, PLANT PHYSIOL, V76, P151, DOI 10.1104/pp.76.1.151; SAINTGES V, 1991, EUR J BIOCHEM, V200, P477, DOI 10.1111/j.1432-1033.1991.tb16207.x; SALISBURY FB, 1992, PLANT PHYSIOL, P267; Smirnoff N., 1995, ENV PLANT METABOLISM; STEPHANOPOULOS G, 1991, SCIENCE, V252, P1675, DOI 10.1126/science.1904627; STITT M, 1990, ANNU REV PLANT PHYS, V41, P153, DOI 10.1146/annurev.pp.41.060190.001101; SUNG SJS, 1988, PHYSIOL PLANTARUM, V72, P650, DOI 10.1111/j.1399-3054.1988.tb09177.x; Taiz L., 1991, PLANT PHYSIOL, P265; Tofts P S, 1988, NMR Biomed, V1, P1, DOI 10.1002/nbm.1940010103; Viola R, 1996, PLANTA, V198, P179, DOI 10.1007/BF00206242; WEINER H, 1987, BIOCHIM BIOPHYS ACTA, V893, P13, DOI 10.1016/0005-2728(87)90143-5; WENDLER R, 1991, PLANTA, V183, P31, DOI 10.1007/BF00197564	64	39	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25053	25061		10.1074/jbc.273.39.25053	http://dx.doi.org/10.1074/jbc.273.39.25053			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737962	hybrid, Green Published			2022-12-25	WOS:000076085400012
J	Spicer, AP; Kaback, LA; Smith, TJ; Seldin, MF				Spicer, AP; Kaback, LA; Smith, TJ; Seldin, MF			Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE DIPHOSPHOGLUCOSE DEHYDROGENASE; HUMAN-SKIN FIBROBLASTS; HYALURONAN SYNTHASE; BOVINE LIVER; GLYCOSAMINOGLYCAN SYNTHESIS; CHROMOSOMAL LOCALIZATION; CONNECTIVE-TISSUE; SUGAR METABOLISM; BIOSYNTHESIS; STIMULATION	The enzyme UDP-glucose dehydrogenase (Udpgdh) (EC 1.1.1.22) converts UDP-glucose to UDP-glucuronate, a critical component of the glycosaminoglycans, hyaluronan, chondroitin sulfate, and heparan sulfate. Although Udpgdh is a comparatively well characterized enzyme, no vertebrate genes encoding this enzyme have been reported to date. We report the cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. Mouse and human cDNAs predicted proteins of 493 and 494 amino acids, 24-25 residues longer at their carboxyl termini than the previously reported bovine Udpgdh sequence. The mouse Ugdh gene is composed of 10 exons, spanning 15 kilobases, Northern analyses indicated widespread expression of the gene in embryo and adult, Through interspecific backcross analyses, we localized the Ugdh gene to mouse chromosome 5 at approximately 39 centimorgans, suggesting that the human UGDH gene is localized to chromosome 4p13-15. Results from Southern analyses strongly suggest that Udpgdh is encoded by a single gene in the mouse. Transfection of mouse Ugdh expression vectors led to an increase in detectable Udpgdh activity in mammalian cells. Preliminary expression studies indicated that proinflammatory cytokines, such as interleukin Ip, can substantially increase the expression of human UGDH in cultured human fibroblasts, suggesting that glycosaminoglycan biosynthesis may be partly regulated by the availability of activated UDP-glucuronate, as determined by relative Udpgdh expression levels.	Univ Calif Davis, Sch Med, Dept Biol Chem, Rowe Program Human Genet & Mol Med, Davis, CA 95616 USA; Albany Med Coll, Dept Med, Div Mol & Cellular Med, Albany, NY 12208 USA; Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA; Samuel S Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA	University of California System; University of California Davis; Albany Medical College; Albany Medical College	Spicer, AP (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Rowe Program Human Genet & Mol Med, Tupper Hall, Davis, CA 95616 USA.	apspicer@ucdavis.edu	Smith, Terry/ABG-1360-2020	Smith, Terry/0000-0002-6279-9685	NEI NIH HHS [EY11708, EY08976] Funding Source: Medline; NHGRI NIH HHS [HG00734] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008976, R01EY011708] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Binari RC, 1997, DEVELOPMENT, V124, P2623; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANZEN JS, 1980, BIOCHEMISTRY-US, V19, P6080, DOI 10.1021/bi00567a021; GAINEY PA, 1972, BIOCHEM J, V128, P215, DOI 10.1042/bj1280215; GAINEY PA, 1975, BIOCHEM J, V145, P129, DOI 10.1042/bj1450129; Green EL, 1981, GENETICS PROBABILITY, P77; GRUBB MF, 1993, BIOCHEM MOL BIOL INT, V30, P819; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HANDLEY CJ, 1972, BIOCHEM J, V127, P911, DOI 10.1042/bj1270911; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JAENICKE R, 1986, BIOCHEMISTRY-US, V25, P7283, DOI 10.1021/bi00371a006; JANSEN PLM, 1992, HEPATOLOGY, V15, P532, DOI 10.1002/hep.1840150328; KLEWES L, 1994, J CELL PHYSIOL, V160, P539, DOI 10.1002/jcp.1041600317; KORNFELD R, 1980, BIOCH GLYCOPROTEINS; LAURENT TC, 1998, CHEM BIOL MED APPL H, V72; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; PEROZICH J, 1995, ADV EXP MED BIOL, V372, P79; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SMITH TJ, 1989, ENDOCR REV, V10, P366, DOI 10.1210/edrv-10-3-366; SMITH TJ, 1995, AM J PHYSIOL-CELL PH, V268, pC382, DOI 10.1152/ajpcell.1995.268.2.C382; SMITH TJ, 1984, J CLIN INVEST, V74, P2157, DOI 10.1172/JCI111642; SMITH TJ, 1991, J CLIN ENDOCR METAB, V72, P1169, DOI 10.1210/jcem-72-5-1169; SMITH TJ, 1988, METABOLISM, V37, P179, DOI 10.1016/S0026-0495(98)90015-4; Spicer AP, 1997, GENOMICS, V41, P493, DOI 10.1006/geno.1997.4696; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; SPICER AP, 1995, J IMMUNOL, V155, P3079; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; STROMINGER JL, 1954, J AM CHEM SOC, V76, P6411, DOI 10.1021/ja01653a051; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; SWEENEY C, 1993, BIOCHEM J, V290, P563, DOI 10.1042/bj2900563; Tenhaken R, 1996, PLANT PHYSIOL, V112, P1127, DOI 10.1104/pp.112.3.1127; Wang HS, 1996, J BIOL CHEM, V271, P22718, DOI 10.1074/jbc.271.37.22718; WATSON ML, 1994, METH MOL G, V5, P369; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; YSART GE, 1994, BIOCHEM J, V303, P713, DOI 10.1042/bj3030713; ZALITIS J, 1969, ARCH BIOCHEM BIOPHYS, V132, P457, DOI 10.1016/0003-9861(69)90389-0; ZALITIS J, 1968, BIOCHEM BIOPH RES CO, V31, P693, DOI 10.1016/0006-291X(68)90617-7	46	123	126	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25117	25124		10.1074/jbc.273.39.25117	http://dx.doi.org/10.1074/jbc.273.39.25117			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737970	hybrid			2022-12-25	WOS:000076085400020
J	Colussi, PA; Harvey, NL; Kumar, S				Colussi, PA; Harvey, NL; Kumar, S			Prodomain-dependent nuclear localization of the caspase-2 (Nedd2) precursor - A novel function for a caspase prodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE-LIKE PROTEASES; CELL-DEATH; CYSTEINE PROTEASE; GRANZYME-B; APOPTOSIS; ENZYME; EXPRESSION; FAMILY; CED-3; CPP32	Caspases are cysteine proteases that play an essential role in apoptosis by cleaving several key cellular proteins. Despite their function in apoptosis, little is known about where in the cell they are localized and whether they are translocated to specific cellular compartments upon activation. In the present paper, using Aequorea victoria green fluorescent protein fusion constructs, we have determined the localization of Nedd2 (mouse caspase-2) and show that both precursor and processed caspase-2 localize to the cytoplasmic and the nuclear compartments. We demonstrate that the nuclear localization of caspase-2 is strictly dependent on the presence of the prodomain. A caspase-2 prodomain-green fluorescent protein localized to dot- and fiber-like structures mostly in the nucleus, whereas a protein lacking the prodomain was largely concentrated in the cytoplasm, We also show that an amino-terminal fusion of the prodomain of caspase-2 to caspase-3 mediates nuclear transport of caspase-3, which is normally localized in the cytoplasm. These results suggest that, in addition to roles in dimerization and recruitment through adaptors, the caspase-2 prodomain has a novel function in nuclear transport.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.		Kumar, Sharad/AAX-7787-2020	Kumar, Sharad/0000-0001-7126-9814; Harvey, Natasha/0000-0001-9839-8966				ALLET B, 1996, J CELL BIOL, V135, P480; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COLUSSI PA, 1998, IN PRESS J BIOL CHEM; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; FLAWS JA, 1995, ENDOCRINOLOGY, V136, P5042, DOI 10.1210/en.136.11.5042; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Kinoshita M, 1997, J CEREBR BLOOD F MET, V17, P507, DOI 10.1097/00004647-199705000-00004; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawara A, 1997, CANCER RES, V57, P4578; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Troy CM, 1997, J NEUROSCI, V17, P1911; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	39	133	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24535	24542		10.1074/jbc.273.38.24535	http://dx.doi.org/10.1074/jbc.273.38.24535			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733748	hybrid			2022-12-25	WOS:000076007300040
J	Shukla, D; Zhu, XY; Matsumura, P				Shukla, D; Zhu, XY; Matsumura, P			Flagellar motor-switch finding face of CheY and the biochemical basis of suppression by CheY mutants that compensate for motor-switch defects in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT BINDING; CHEMOTAXIS PROTEIN CHEY; BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; SALMONELLA-TYPHIMURIUM; 3-DIMENSIONAL STRUCTURE; CONSERVED ASPARTATE; RESPONSE REGULATOR; GENES; COMPLEX	CheY is a response regulator protein of Escherichia coli that interacts with the flagellar motor-switch complex to modulate flagellar rotation during chemotaxis. The switch complex is composed of three proteins, FliG, FliM, and FliN, Recent biochemical data suggest a direct interaction of CheY with FliM. In order to determine the FliM binding face of CheY, we isolated dominant suppressors of fliM mutations in cheY with limited allele specificity. The protein products of suppressor cheY alleles were purified and assayed for FliM binding. Six out of nine CheY mutants were defective in FliM binding. Suppressor amino acid substitutions were mapped on the crystal structure of CheY showing clustering of reduced binding mutations on a solvent-accessible face of CheY, thus revealing a FliM binding face of CheY. To examine the basis of genetic suppression, we cloned, purified, and tested FliM mutants for CheY binding. Like the wild-type FliM, the mutants were also defective in binding to various CheY suppressor mutants. This was not expected if CheY suppressors were compensatory conformational suppressors. Furthermore, a comparison of flagellar rotation patterns indicated that the cheY suppressors had readjusted the clockwise bias of the fliM strains. However, a chemotaxis assay revealed that the readjustment of the clockwise bias was not sufficient to make cells chemotactic. Although the suppressors did not restore chemotaxis, they did increase swarming on motility plates by a process called "pseudotaxis." Therefore, our genetic selection scheme generated suppressors of pseudotaxis or switch bias adjustment. The binding results suggest that the mechanism for this adjustment is the reduction in binding affinity of activated CheY, Therefore, these suppressors identified the switch-binding surface of CheY by loss-of-function defects rather than gain-of-function compensatory conformational changes.	Univ Illinois, Dept Microbiol & Immunol MC 790, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Matsumura, P (corresponding author), Univ Illinois, Dept Microbiol & Immunol MC 790, 835 S Wolcott Ave, Chicago, IL 60612 USA.	Philip.Matsumura@uic.edu		Shukla, Deepak/0000-0002-3039-6953	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018985] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18985] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; AMSLER CD, 1993, J BACTERIOL, V175, P6238, DOI 10.1128/JB.175.19.6238-6244.1993; Amsler CD., 1995, 2 COMPONENT SIGNAL T, P89; Bellsolell L, 1996, J MOL BIOL, V257, P116, DOI 10.1006/jmbi.1996.0151; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; KAR L, 1992, BIOCHEM J, V287, P521, DOI 10.1042/bj2870521; KOOP AH, 1987, GENE, V52, P245, DOI 10.1016/0378-1119(87)90051-5; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; MACNAB RM, 1995, 2 COMPONENT SIGNAL T, P181; MAGARIYAMA Y, 1990, J BACTERIOL, V172, P4359, DOI 10.1128/jb.172.8.4359-4369.1990; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; NICHOLS BP, 1983, METHOD ENZYMOL, V101, P155; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PARKINSON JS, 1983, J BACTERIOL, V155, P265, DOI 10.1128/JB.155.1.265-274.1983; PARKINSON JS, 1976, J BACTERIOL, V126, P758, DOI 10.1128/JB.126.2.758-770.1976; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1979, P NATL ACAD SCI USA, V76, P2390, DOI 10.1073/pnas.76.5.2390; PARKINSON JS, 1993, CELL, V337, P745; RAVID S, 1986, P NATL ACAD SCI USA, V83, P7157, DOI 10.1073/pnas.83.19.7157; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SHUKLA D, 1995, J BIOL CHEM, V270, P24414, DOI 10.1074/jbc.270.41.24414; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; SWANSON RV, 1995, NAT STRUCT BIOL, V2, P906, DOI 10.1038/nsb1095-906; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10270; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986; ZHU X, 1996, J BACTERIOL, V176, P4208; ZHULIN IB, 1991, CURR MICROBIOL, V22, P307, DOI 10.1007/BF02091959	47	28	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23993	23999		10.1074/jbc.273.37.23993	http://dx.doi.org/10.1074/jbc.273.37.23993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727015	hybrid			2022-12-25	WOS:000075893100056
J	Swanson, DJ; Zellmer, E; Lewis, EJ				Swanson, DJ; Zellmer, E; Lewis, EJ			AP1 proteins mediate the cAMP response of the dopamine beta-hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NEUROTRANSMITTER BIOSYNTHETIC GENES; C-JUN ACTIVATION; CYCLIC-AMP; SIGNAL-TRANSDUCTION; REGULATORY ELEMENT; FOS TRANSCRIPTION; CHROMAFFIN CELLS; MAMMALIAN-CELLS; TRANSGENIC MICE	Neurotransmitter biosynthesis is regulated by environmental stimuli, which transmit intracellular signals via second messengers and protein kinase pathways, For the catecholamine biosynthetic enzymes, dopamine beta-hydroxylase and tyrosine hydroxylase, regulation of gene expression by cyclic AMP, diacyl glycerol, and Ca2+ leads to increased neurotransmitter biosynthesis, In this report, we demonstrate that the cAMP-mediated regulation of transcription from the dopamine beta-hydroxylase promoter is mediated by the AP1 proteins c-Fos, c-Jun, and JunD, Following treatment of cultured cells with cAMP, protein complexes bound to the dopamine beta-hydroxylase AP1/cAMP response element element change from consisting of c-Jun and JunD to include c-Fos, c-Jun, and JunD. The homeodomain protein Arix is also a component of this DNA-protein complex, binding to the adjacent homeodomain recognition sites. Transfection of a dominant negative JunD expression plasmid inhibits cAMP-mediated expression of the dopamine beta-hydroxylase promoter construct in PC12 and CATH.a cells. In addition to the role of c-Fos in regulating dopamine beta-hydroxylase gene expression in response to cAMP, a second pathway, involving Rap1/BRaf is involved. These experiments illustrate an unusual divergence of cAMP-dependent protein kinase signaling through multiple pathways that then reconverge on a single element in the dopamine beta-hydroxylase promoter to elicit activation of gene expression.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lewis, EJ (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, L224, Portland, OR 97201 USA.				NIGMS NIH HHS [GM38696] Funding Source: Medline; NINDS NIH HHS [NS33159] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038696, R29GM038696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033159] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Afar R, 1996, MOL BRAIN RES, V36, P79, DOI 10.1016/0169-328X(95)00247-P; AGARWAL S, 1995, ONCOGENE, V11, P427; Anderson DJ, 1997, TRENDS GENET, V13, P276, DOI 10.1016/S0168-9525(97)01187-6; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ausbel F.M., 1995, CURRENT PROTOCOLS MO; Bacher B, 1996, J NEUROCHEM, V66, P2264; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BOUTILLIER AL, 1992, J BIOL CHEM, V267, P23520; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; Hahm SH, 1996, J NEUROCHEM, V67, P1872; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; Lo LC, 1998, DEVELOPMENT, V125, P609; MacArthur L, 1996, J NEUROCHEM, V67, P2256; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Messersmith DJ, 1996, MOL BRAIN RES, V40, P15; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; NANKOVA B, 1993, J NEUROCHEM, V61, P776; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Robert JJ, 1997, J NEUROCHEM, V68, P2152; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SEASHOLTZ AF, 1988, MOL ENDOCRINOL, V2, P1311, DOI 10.1210/mend-2-12-1311; Serova LI, 1998, J NEUROCHEM, V70, P1935; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; SURI C, 1993, J NEUROSCI, V13, P1280; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; Youssoufian H, 1998, BIOTECHNIQUES, V24, P198, DOI 10.2144/98242bm05; Zellmer E, 1995, J NEUROSCI, V15, P8109	50	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24065	24074		10.1074/jbc.273.37.24065	http://dx.doi.org/10.1074/jbc.273.37.24065			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727025	hybrid			2022-12-25	WOS:000075893100066
J	Ganju, RK; Brubaker, SA; Meyer, J; Dutt, P; Yang, YM; Qin, SX; Newman, W; Groopman, JE				Ganju, RK; Brubaker, SA; Meyer, J; Dutt, P; Yang, YM; Qin, SX; Newman, W; Groopman, JE			The alpha-chemokine, stromal cell-derived factor-1 alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; NF-KAPPA-B; TYROSINE KINASE; HIV-1 ENTRY; PHOSPHATIDYLINOSITOL 3-KINASE; LYMPHOCYTE CHEMOATTRACTANT; HUMAN NEUTROPHILS; T-LYMPHOCYTES; CLONING; PHOSPHORYLATION	The alpha-chemokine stromal cell-derived factor (SDF)-1 alpha binds to the seven transmembrane G-protein-coupled CXCR-4 receptor and acts to modulate cell migration and proliferation. The signaling pathways that mediate the effects of SDF-1 alpha are not well. characterized. We studied events following SDF-1 alpha binding to CXCR-4 in a model murine pre-B cell line transfected with human CXCR-4. There was enhanced tyrosine phosphorylation and association of components of focal adhesion complexes such as the related adhesion focal tyrosine kinase, paxillin, and Crk. We also observed activation of phosphatidylinositol 3-kinase. Wortmannin, a selective inhibitor of phosphatidylinositol 3-kinase, partially in hibited the SDF-1 alpha-induced migration and tyrosine phosphorylation of paxillin. SDF-1 alpha treatment selectively activated p44/42 mitogen-activated protein kinase (Erk 1 and Erk 2) and its upstream kinase mitogen-activated protein kinase kinase but not p38 mitogen-activated protein kinase, c-Jun amino-terminal kinase or mitogen activated protein kinase kinase. We also observed that SDF-1 alpha treatment increased NF-kappa B activity in nuclear extracts from the CXCR-4 transfectants. Taken together, these studies revealed that SDF-1 alpha activates distinct signaling pathways that may mediate cell growth, migration, and transcriptional activation.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA; LeukoSite Inc, Cambridge, MA 02142 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Groopman, JE (corresponding author), Harvard Univ, Inst Med, BIDMC, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	jgroopma@west.bidmc.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055187, R01HL053745] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 53745, HL 43510, HL 55187] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Derman MP, 1996, J BIOL CHEM, V271, P4251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forster R, 1998, J IMMUNOL, V160, P1522; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Heesen M, 1996, J IMMUNOL, V157, P5455; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Liu ZY, 1997, BLOOD, V90, P2253, DOI 10.1182/blood.V90.6.2253.2253_2253_2259; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sanchez X, 1997, J BIOL CHEM, V272, P27529, DOI 10.1074/jbc.272.44.27529; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Taub D D, 1994, Ther Immunol, V1, P229; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Ueda H, 1997, J BIOL CHEM, V272, P24966, DOI 10.1074/jbc.272.40.24966; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202; YAN MH, 1994, NATURE, V372, P798; YANG YM, 1993, CELL GROWTH DIFFER, V4, P595; Yi YJ, 1998, J VIROL, V72, P772, DOI 10.1128/JVI.72.1.772-777.1998	61	538	555	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23169	23175		10.1074/jbc.273.36.23169	http://dx.doi.org/10.1074/jbc.273.36.23169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722546	hybrid			2022-12-25	WOS:000075778100046
J	Li, QD; Gardner, K; Zhang, LJ; Tsang, B; Bostick-Bruton, F; Reed, E				Li, QD; Gardner, K; Zhang, LJ; Tsang, B; Bostick-Bruton, F; Reed, E			Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA EXCISION-REPAIR; INTERSTRAND CROSS-LINKS; PROTEIN-KINASE PATHWAY; PIGMENTOSUM GROUP-F; C-JUN; HA-RAS; GENE-EXPRESSION; ACTIVATION DOMAIN; ADDUCT FORMATION; TUMOR-CELLS	ERCC-1 is a critical gene within the nucleotide excision repair pathway, and cells without a functional ERCC-1 do not perform cisplatin-DNA adduct repair. We therefore investigated the cisplatin effect on ERCC-1 mRNA expression in vitro. In response to a l-h cisplatin exposure, A2780/CP70 human ovarian cancer cells showed a B-fold increase in steady-state level of ERCC-1 mRNA This rise was attributable to increased transcription as measured by nuclear run-on assays and a 60% increase in ERCC-1 mRNA half-life. The increase in ERCC-1 mRNA was preceded by a 4-5-fold rise in mRNA expressions of c-fos and c-jun, a 14-fold increase in c-Jun protein phosphorylation, and an increase in in vitro nuclear extract binding activity to the AP-1-like site of ERCC-1, These data suggest that the induction of ERCC-1 expression in A2780/CP70 cells exposed to cisplatin results from two major factors: (a) an increase in the expression of transactivating factors that bind the AP-1-like site in the 5'-flanking region of ERCC-1 and (b) an increase in the level of c-Jun phosphorylation that enhances its transactivation property.	NCI, Med Ovarian Canc Sect, Dept Dev Therapeut, Med Branch,NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mol Oncol Sect, Pediat Branch, Div Clin Sci,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reed, E (corresponding author), NCI, Med Ovarian Canc Sect, Dept Dev Therapeut, Med Branch,NIH, Bldg 10,Rm 13N248,9000 Rockville Pike, Bethesda, MD 20892 USA.	reed92@helix.nih.gov						ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Aboussekhra A., 1996, Cellular Pharmacology, V3, P221; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; BEHRENS BC, 1987, CANCER RES, V47, P414; Belasco J. G., 1993, CONTROL MESSENGER RN, P475; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; CALSOU P, 1993, EUR J BIOCHEM, V211, P403, DOI 10.1111/j.1432-1033.1993.tb17563.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN G, 1995, CELL BIOL TOXICOL, V11, P273, DOI 10.1007/BF00757625; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper G.M., 1995, ONCOGENES; Dabholkar M, 1996, Cancer Chemother Biol Response Modif, V16, P88; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; DePooter CM, 1996, BIOCHEM PHARMACOL, V51, P629, DOI 10.1016/S0006-2952(95)02229-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Gosland M, 1996, PHARMACOTHERAPY, V16, P16; GOTTLICHER M, 1997, TRANSCRIPTION FACTOR, P67; HAMAGUCHI K, 1993, CANCER RES, V53, P5225; HILL BT, 1994, EUR J CANCER, V30A, P832, DOI 10.1016/0959-8049(94)90301-8; ISONISHI S, 1991, CANCER RES, V51, P5903; JOHNSON SW, 1994, CANCER RES, V54, P5911; JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5; JONES JC, 1991, J BIOL CHEM, V266, P7101; KASHANISABET M, 1990, EUR J CANCER, V26, P383, DOI 10.1016/0277-5379(90)90238-O; KASHANISABET M, 1990, J BIOL CHEM, V265, P11285; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; LEE KB, 1993, CARCINOGENESIS, V14, P2177, DOI 10.1093/carcin/14.10.2177; LEE KB, 1995, CANCER LETT, V88, P57, DOI 10.1016/0304-3835(94)03626-T; LEPRE CA, 1990, NUCL ACIDS MOL BIOL, V4, P9, DOI [DOI 10.1007/978-3-642-84150-7-2, DOI 10.1007/978-3-642-84150-7]; LEWIN B, 1994, GENES, V5; Li Q., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P241; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MASUDA H, 1988, CANCER RES, V48, P5713; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; PETERS GJ, 1993, INT J CANCER, V54, P450, DOI 10.1002/ijc.2910540316; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rabo YB, 1996, INT J CANCER, V65, P821; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; REED E, 1996, CANC CHEMOTHERAPY BI, P357; REED E, 1993, CANC PRINCIPLES PRAC, P390; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCANLON KJ, 1989, ANTICANCER RES, V9, P1301; SCANLON KJ, 1991, PHARMACOL THERAPEUT, V52, P385, DOI 10.1016/0163-7258(91)90033-I; SKLAR MD, 1988, CANCER RES, V48, P793; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TAVERNA P, 1994, CARCINOGENESIS, V15, P2053, DOI 10.1093/carcin/15.9.2053; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDUIN M, 1987, NUCLEIC ACIDS RES, V15, P9195, DOI 10.1093/nar/15.22.9195; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689; [No title captured]; [No title captured]	64	110	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23419	23425		10.1074/jbc.273.36.23419	http://dx.doi.org/10.1074/jbc.273.36.23419			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722577	hybrid			2022-12-25	WOS:000075778100077
J	Okajima, Y; Matsumura, I; Nishiura, T; Hashimoto, K; Yoshida, H; Ishikawa, J; Wakao, H; Yoshimura, A; Kanakura, Y; Tomiyama, Y; Matsuzawa, Y				Okajima, Y; Matsumura, I; Nishiura, T; Hashimoto, K; Yoshida, H; Ishikawa, J; Wakao, H; Yoshimura, A; Kanakura, Y; Tomiyama, Y; Matsuzawa, Y			Insulin-like growth factor-I augments erythropoietin-induced proliferation through enhanced tyrosine phosphorylation of STAT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECOMBINANT HUMAN THROMBOPOIETIN; MYELOBLASTIC-LEUKEMIA CELLS; ERYTHROID-DIFFERENTIATION; PROGENITOR CELLS; MESSENGER-RNA; RECEPTOR; ACTIVATION; TRANSCRIPTION; INTERLEUKIN-3	Insulin-like growth factor (IGF-I) is known to synergistically stimulate the proliferation of hematopoietic cells in combination with other hematopoietic growth factors. However, the precise mechanism underlying the cooperative effects of IGF-I is unknown. In a human interleukin-3 or erythropoietin (EPO)-dependent cell line, F-36P, IGF-I alone failed to stimulate DNA synthesis but did augment the EPO dependent DNA synthesis of F-36P cells. The treatment of F-36P cells with a combination of EPO and IGF-I (EPO/IGF-I) was found to enhance EPO-induced tyrosine phosphorylation of STATE, whereas IGF-I alone did not. Furthermore, c-CIS mRNA expression, one of the target molecules of STATE, was more effectively induced by EPO/IGF-I than by EPO alone. To examine the mechanisms of the EPO- and EPO/ IGF-I-induced proliferation of F-36P cells, we expressed dominant negative (dn) mutants of STATE and Ras in an inducible system. The EPO-induced DNA synthesis and the cooperative effect of EPO/IGF-I were significantly inhibited by the inducible expression of dn-STAT5 or dn-Ras. In addition, the inducible expression of dn-Ras abolished the IGF-I-enhanced tyrosine phosphorylation of STATE. These results suggest that IGF-I may augment EPO-induced proliferation by enhancing tyrosine phosphorylation of STATE and raise the possibility that Ras may be involved in the augmentation of STATE tyrosyl phosphorylation.	Osaka Univ, Sch Med, Dept Internal Med 2, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Hematol & Oncol, Osaka 5650871, Japan; Helix Res Inst, Kisarazu, Chiba, Japan; Inst Life Sci, Kurume, Fukuoka 839, Japan	Osaka University; Osaka University	Nishiura, T (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yamada Oka, Osaka 5650871, Japan.		Yoshimura, Akihiko/K-5515-2013; WAKAO, Hiroshi/A-4242-2012	Tomiyama, Yoshiaki/0000-0001-7645-0989				AKAHANE K, 1987, EXP HEMATOL, V15, P797; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BASERGA R, 1995, CANCER RES, V55, P249; BOYER SH, 1992, BLOOD, V80, P2503; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; CHIBA S, 1991, BLOOD, V78, P2261; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHIOU ST, 1992, BIOCHEM BIOPH RES CO, V183, P524, DOI 10.1016/0006-291X(92)90513-K; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; CORREA PN, 1991, BLOOD, V78, P2823; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; GIBSON LF, 1993, BLOOD, V82, P3005; GOLDRING M B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P301; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Hoefsloot LH, 1997, BLOOD, V89, P1690, DOI 10.1182/blood.V89.5.1690.1690_1690_1700; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; KRANTZ SB, 1991, BLOOD, V77, P419; LANDRETH KS, 1992, BLOOD, V80, P1207; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1996, BLOOD, V88, P3074, DOI 10.1182/blood.V88.8.3074.bloodjournal8883074; MATSUMURA I, 1995, BLOOD, V86, P703, DOI 10.1182/blood.V86.2.703.bloodjournal862703; MERCHAV S, 1988, J CLIN INVEST, V81, P791, DOI 10.1172/JCI113385; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; MULI AL, 1996, EMBO J, V15, P2425; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; SANDERS M, 1993, EXP HEMATOL, V21, P25; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SUGAHARA H, 1994, J EXP MED, V179, P1757, DOI 10.1084/jem.179.6.1757; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Wakao H, 1997, BIOCHEM BIOPH RES CO, V234, P198, DOI 10.1006/bbrc.1997.6486; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEILAND M, 1991, J CELL PHYSIOL, V149, P428, DOI 10.1002/jcp.1041490311; WHITE MF, 1994, J BIOL CHEM, V269, P1; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZHOU LF, 1997, ONCOGENE, V15, P961	51	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22877	22883		10.1074/jbc.273.36.22877	http://dx.doi.org/10.1074/jbc.273.36.22877			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722506	hybrid			2022-12-25	WOS:000075778100006
J	Aigner, S; Ramos, CL; Hafezi-Moghadam, A; Lawrence, MB; Friederichs, J; Altevogt, P; Ley, K				Aigner, S; Ramos, CL; Hafezi-Moghadam, A; Lawrence, MB; Friederichs, J; Altevogt, P; Ley, K			CD24 mediates rolling of breast carcinoma cells on P-selectin	FASEB JOURNAL			English	Article						adhesion; tumor cells; metastasis	HUMAN TUMOR-CELLS; ENDOTHELIAL-CELLS; GLYCOPROTEIN LIGAND-1; MONOCLONAL-ANTIBODY; ADHESION MOLECULE-1; DEPENDENT ADHESION; TYROSINE SULFATION; EXPRESSION CLONING; CANCER METASTASIS; HUMAN NEUTROPHILS	P-selectin mediates rolling of neutrophils and other leukocytes on activated endothelial cells and platelets through binding to P-selectin glycoprotein ligand-l (PSGL-1). Certain PSGL-1 negative tumor cell lines can bind P-selectin under static conditions through the GPI-linked surface mucin, CD24, but the physiological significance of this interaction and whether it can occur under flow conditions is not known. Here, we show that CD24(+) PSGL-1(-) KS breast carcinoma cells attach to and roll on recombinant P-selectin under a continuous wall shear stress, although at a lower density and higher velocity than CD24(+) PSGL-1(+) cells, such as HL-60. Adding excess soluble CD24 or removing CD24 from the cell surface with phosphatidylinositol-phospholipase C (PI-PLC) significantly reduced KS cell rolling on P-selectin. The ability of KS cells to roll on P-selectin was positively correlated with the CD24 expression level. Comparison with three other CD24(+) cell. Lines established that expression of sialyl-Lewis(x) antigen was also necessary for CD24-mediated rolling on P-selectin. CD24 purified from KS cells supported rolling of P-selectin transfectants, but not L-selectin transfectants. Finally, KS cells rolled on vascular endothelium in vivo in a P-selectin-dependent manner. Together our data show that CD24 serves as a ligand for P-selectin under physiological now conditions. Interaction of tumor cells with P-selectin via CD24 may be an important adhesion pathway in cancer metastasis.-Aigner, S., Ramos, C. L., Hafezi-Moghadam, A., Lawrence, M. B., Friederichs, J., Altevogt, P., and Ley, K. CD24 mediates rolling of breast carcinoma cells on P-selectin.	Univ Virginia, Dept Biomed Engn, Ctr Hlth Sci, Charlottesville, VA 22908 USA; German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany	University of Virginia; Helmholtz Association; German Cancer Research Center (DKFZ)	Ley, K (corresponding author), Univ Virginia, Dept Biomed Engn, Ctr Hlth Sci, Box 377, Charlottesville, VA 22908 USA.	kfl3f@virginia.edu		Hafezi-Moghadam, Ali/0000-0002-5336-0697	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054136, R29HL054614, R01HL054614] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL09578, HL54136, HL54614] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; AIGNER S, 1995, INT IMMUNOL, V7, P1557, DOI 10.1093/intimm/7.10.1557; AKASHI T, 1994, VIRCHOWS ARCH, V425, P399; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BARGATZE RF, 1987, J EXP MED, V166, P1125, DOI 10.1084/jem.166.4.1125; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; CELI A, 1991, P SOC EXP BIOL MED, V198, P703; DROZ D, 1990, HUM PATHOL, V21, P536, DOI 10.1016/0046-8177(90)90011-S; FOGH J, 1986, CANCER INVEST, V4, P157, DOI 10.3109/07357908609038260; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; FRIEDRICHS K, 1995, CANCER RES, V55, P901; GAROFALO A, 1995, CANCER RES, V55, P414; GASIC GJ, 1984, CANCER METAST REV, V3, P99, DOI 10.1007/BF00047657; GAZDAR AF, 1980, CANCER RES, V40, P3502; GIAVAZZI R, 1993, J CLIN INVEST, V92, P3038, DOI 10.1172/JCI116928; Goetz DJ, 1996, ANN BIOMED ENG, V24, P87, DOI 10.1007/BF02770998; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; GRIGNANI G, 1986, HAEMATOLOGICA, V71, P245; GROVES RW, 1993, AM J PATHOL, V143, P1220; GUCKEL B, 1995, CYTOKINES MOL THER, V1, P211; HANSKI C, 1990, J CLIN PATHOL, V43, P379, DOI 10.1136/jcp.43.5.379; HIROSE S, 1995, METHOD ENZYMOL, V250, P582; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; JACKSON D, 1992, CANCER RES, V52, P5264; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KUNZENDORF U, 1994, CANCER RES, V54, P1109; Lafrenie R M, 1993, Cell Biophys, V23, P3; LAURI D, 1991, JNCI-J NATL CANCER I, V83, P1321, DOI 10.1093/jnci/83.18.1321; LAVABREBERTRAND T, 1994, LEUKEMIA, V8, P402; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; MAJURI ML, 1992, BIOCHEM BIOPH RES CO, V182, P1376, DOI 10.1016/0006-291X(92)91885-T; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MOULD AP, 1994, J BIOL CHEM, V269, P27224; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; PERRI RT, 1983, BLOOD, V61, P871; PIRRUCCELLO SJ, 1986, J IMMUNOL, V136, P3779; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; RENEMAN RS, 1992, NATO ADV SCI INST SE, V235, P25; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAMMAR M, 1994, INT IMMUNOL, V6, P1027, DOI 10.1093/intimm/6.7.1027; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SAWADA R, 1994, J BIOL CHEM, V269, P1425; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STONE JP, 1993, J CLIN INVEST, V92, P804, DOI 10.1172/JCI116654; TOZEREN A, 1995, INT J CANCER, V60, P426; VANDENBRENK HA, 1974, BRIT J CANCER, V30, P246, DOI 10.1038/bjc.1974.189; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	62	223	233	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1241	1251		10.1096/fasebj.12.12.1241	http://dx.doi.org/10.1096/fasebj.12.12.1241			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737727				2022-12-25	WOS:000075738500019
J	Lovric, J; Dammeier, S; Kieser, A; Mischak, H; Kolch, W				Lovric, J; Dammeier, S; Kieser, A; Mischak, H; Kolch, W			Activated Raf induces the hyperphosphorylation of stathmin and the reorganization of the microtubule network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MAP KINASE KINASE; CELL-CYCLE ARREST; MAJOR CYTOSOLIC TARGET; PROTEIN-KINASE; DNA-SYNTHESIS; IN-VITRO; REGULATED PHOSPHORYLATION; MULTISITE PHOSPHORYLATION; TUBULIN POLYMERIZATION	Raf kinases are regulators of cellular proliferation, transformation, differentiation, and apoptosis. To identify downstream targets of Raf-1 in vivo, we used NIR 3T3 fibroblasts expressing a Raf-1 kinase domain-estrogen receptor fusion protein (BXB-ER), whose activity can be acutely regulated by estrogen, Proteins differentially phosphorylated 20 min after BXB-ER activation in Living cells were displayed by two-dimensional electrophoresis. The protein with the most prominent newly induced phosphorylation was identified as stathmin, a phosphorylation-sensitive regulator of microtubule dynamics. Stathmin is rapidly phosphorylated on two ERK phosphorylation sites (serines 25 and 38) upon BXB-ER activation. The mitogen-activated protein kinase/extracellular signal-regulated kinase-kinase (MEK) inhibitor PD98059 abolished this phosphorylation, demonstrating that stathmin is targeted by BXB-ER via the MEK/ERK pathway. Prolonged BXB-ER activation resulted in the accumulation of a stathmin phosphoisomer with impaired microtubule-destabilizing activity. The appearance of this phosphoisomer after BXB-ER activation correlated with rearrangements in the microtubule network, resulting in the formation of long bundled microtubules extending toward the rim of the cells. Our results identify stathmin as a main target of the Raf/MEK/ERK kinase cascade in vivo and strongly suggest that ERK-mediated stathmin phosphorylation plays an important role for the microtubule reorganization induced by acute activation of Raf-1.	GSF Munich, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Lovric, J (corresponding author), GSF Munich, Inst Klin Mol Biol & Tumorgenet, Marchioninistr 25, D-81377 Munich, Germany.	Lovric@gsf.de	Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021; Kieser, Arnd/M-4616-2014; Mischak, Harald/E-8685-2011	Kieser, Arnd/0000-0003-0783-1950; Mischak, Harald/0000-0003-0323-0306; Kolch, Walter/0000-0001-5777-5016; Lovric, Josip/0000-0002-0338-6581				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALL RL, 1992, CELL MOTIL CYTOSKEL, V23, P265, DOI 10.1002/cm.970230406; Belmont L, 1996, TRENDS BIOCHEM SCI, V21, P197, DOI 10.1016/S0968-0004(96)80013-2; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1357, DOI 10.1002/elps.11501401209; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNET A, 1994, ONCOGENE, V9, P3379; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CROSSIN KL, 1981, CELL, V23, P61, DOI 10.1016/0092-8674(81)90270-1; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GORG A, 1988, ELECTROPHORESIS, V9, P681, DOI 10.1002/elps.1150091103; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; Lovric J, 1996, ONCOGENE, V12, P1109; LUO XN, 1994, J BIOL CHEM, V269, P10312; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; NGUYEN DN, 1995, J CHROMATOGR A, V705, P21, DOI 10.1016/0021-9673(94)01256-E; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; ROBINSON JM, 1995, J CELL SCI, V108, P645; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAW JP, 1988, J BIOL CHEM, V263, P1459; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; THYBERG J, 1984, EXP CELL RES, V155, P1, DOI 10.1016/0014-4827(84)90761-4; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	62	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22848	22855						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712920				2022-12-25	WOS:000075616600096
J	Decker, H; Rimke, T				Decker, H; Rimke, T			Tarantula hemocyanin shows phenoloxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHROPOD HEMOCYANIN; EURYPELMA-CALIFORNICUM; CRYSTAL-STRUCTURE; PROPHENOLOXIDASE; ACTIVATION; TYROSINASE; RESOLUTION; PROENZYME; SEQUENCE; LIMULUS	An enzyme generally catalyzes one well defined reaction with high specificity and efficiency. We report here in contrast that the copper protein hemocyanin of the tarantula Eurypelma californicum exhibits two different functions. These occur at the same active site. While hemocyanin usually is an oxygen carrier, its function can be transformed totally to monophenoloxidase and o-diphenoloxidase activity after limited proteolysis with trypsin or chymotrypsin, N-acetyldopamine (NADA) is more effectively oxidized than L-dopa or dopamine. This irreversible functional switch of tarantula hemocyanin function is limited to the two subunits b and c of its seven subunit types. A conserved phenylalanine in the hemocyanin molecule acts as a placeholder for other substrates that are phenylalanine derivatives. The proteolytic cleavage removes an N-terminal fragment, including the critical phenylalanine residue, which opens an entrance for substrates. Therefore no new arrangement of the active site, with its two copper atoms and the mu - eta(2):eta(2) bound O-2 molecule, is necessary to develop the catalytic function.	Univ Mainz, Inst Mol Biophys, D-55128 Mainz, Germany	Johannes Gutenberg University of Mainz	Decker, H (corresponding author), Univ Mainz, Inst Mol Biophys, Welder Weg 26, D-55128 Mainz, Germany.	decker@biophysik.biologie.uni-mainz.de						Andersen Svend Olav, 1991, P123; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; BASYONI M, 1990, THESIS U MUNICH; BEINTEMA JJ, 1994, MOL BIOL EVOL, V11, P493; BELTRAMINI M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P365, DOI 10.1016/0167-4838(90)90134-2; Brivio MF, 1996, COMP BIOCHEM PHYS B, V113, P281, DOI 10.1016/0305-0491(95)02025-X; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; DECKER H, 1990, J MOL BIOL, V211, P281, DOI 10.1016/0022-2836(90)90027-J; FUJIMOTO K, 1995, P NATL ACAD SCI USA, V92, P7769, DOI 10.1073/pnas.92.17.7769; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HAZES B, 1993, PROTEIN SCI, V2, P597; HernandezLopez J, 1996, COMP BIOCHEM PHYS C, V113, P61, DOI 10.1016/0742-8413(95)02033-0; Kopacek P, 1995, INSECT BIOCHEM MOLEC, V25, P1081, DOI 10.1016/0965-1748(95)00040-2; LAMY J, 1979, H-S Z PHYSIOL CHEM, V360, P889, DOI 10.1515/bchm2.1979.360.2.889; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MARKL J, 1981, H-S Z PHYSIOL CHEM, V362, P1631, DOI 10.1515/bchm2.1981.362.2.1631; Markl J., 1992, Advances in Comparative and Environmental Physiology, V13, P325; Nellaiappan K, 1996, COMP BIOCHEM PHYS B, V113, P163, DOI 10.1016/0305-0491(95)02047-0; SALVATO B, 1990, LIFE CHEM REPORTS, V8, P1; SALVATO B, 1998, IN PRESS BIOCHEMISTR; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; SAVELNIEMANN A, 1988, J MOL BIOL, V204, P385, DOI 10.1016/0022-2836(88)90583-9; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; SOLOMON EI, 1996, CHEM REV, V96, P25; SUGUMARAN M, 1993, PARASITES PATHOGENS, V1, P317; Sugumaran Manickam, 1991, P141; VanGelder CWG, 1997, PHYTOCHEMISTRY, V45, P1309, DOI 10.1016/S0031-9422(97)00186-6; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; Zlateva T, 1996, FEBS LETT, V384, P251, DOI 10.1016/0014-5793(96)00326-2	31	185	206	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25889	25892		10.1074/jbc.273.40.25889	http://dx.doi.org/10.1074/jbc.273.40.25889			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748264	hybrid			2022-12-25	WOS:000076263100055
J	Lee, CH; Leeds, P; Ross, J				Lee, CH; Leeds, P; Ross, J			Purification and characterization of a polysome-associated endoribonuclease that degrades c-myc mRNA in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; CELL-FREE-EXTRACTS; PROTEIN-SYNTHESIS; POSTTRANSCRIPTIONAL REGULATION; ENDONUCLEOLYTIC CLEAVAGE; CODING REGION; HALF-LIFE; SEQUENCES; RIBONUCLEASE; DEGRADATION	The regulation of mRNA half-lives is determined by multiple factors, including the activity of the messenger RNases (mRNases) responsible for destroying mRNA molecules. Previously, we used cell-free mRNA decay assays to identify a polysome-associated endonuclease that cleaves c-mye mRNA within the coding region. A similar activity has been solubilized and partially purified from a high salt extract of adult rat liver polysomes. Based on a correlation between protein and enzyme activity, the endonuclease is tentatively identified as a similar to 39-kDa protein. It cleaves the coding region stability determinant of c-myc mRNA with considerable specificity. Cleavages occur predominantly in an A-rich segment of the RNA. The endonuclease is resistant to RNase A inhibitors, sensitive to vanadyl ribonucleoside complex, and dependent on magnesium. In these and other respects, the soluble enzyme we have purified resembles the polysome-associated c-mye mRNase.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ross, J (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.							BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BONNIEU A, 1990, ONCOGENE, V5, P1585; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; BROWN BD, 1990, GENE DEV, V4, P1925, DOI 10.1101/gad.4.11.1925; Chernokalskaya E, 1997, NUCLEIC ACIDS RES, V25, P735, DOI 10.1093/nar/25.4.735; ClaverieMartin F, 1997, J BIOL CHEM, V272, P13823, DOI 10.1074/jbc.272.21.13823; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; FUSI P, 1993, EUR J BIOCHEM, V211, P305, DOI 10.1111/j.1432-1033.1993.tb19899.x; Gruppuso PA, 1997, IN VITRO CELL DEV-AN, V33, P562; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; HUA J, 1993, NUCLEIC ACIDS RES, V21, P155, DOI 10.1093/nar/21.1.155; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1990, ONCOGENE, V5, P1511; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; PUSKAS RS, 1982, BIOCHEMISTRY-US, V21, P4602, DOI 10.1021/bi00262a014; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHNEIDER R, 1993, SCIENCE, V261, P1169, DOI 10.1126/science.8356450; SCHOENBERG DR, 1997, MRNA METABOLISM POST, P217; STEER CJ, 1996, FASEB J, V10, P559; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Zaug AJ, 1996, NUCLEIC ACIDS RES, V24, P532, DOI 10.1093/nar/24.3.532	37	53	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25261	25271		10.1074/jbc.273.39.25261	http://dx.doi.org/10.1074/jbc.273.39.25261			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737991	hybrid			2022-12-25	WOS:000076085400041
J	Oehlen, LJWM; Cross, FR				Oehlen, LJWM; Cross, FR			Potential regulation of Ste20 function by the Cln1-Cdc28 and Cln2-Cdc28 cyclin-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; YEAST-CELL CYCLE; MITOGEN-ACTIVATED PROTEIN; BETA-GAMMA COMPLEX; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS-GROWTH; BUDDING YEAST; SIGNAL-TRANSDUCTION; S-CEREVISIAE; MAP KINASES	The activity of the Saccharomyces cerevisiae pheromone signal transduction pathway is regulated by Cln1/2-Cdc28 cyclin-dependent kinase. High level expression of CLN2 can repress activation of the pathway by mating factor or by deletion of the alpha-subunit of the heterotrimeric G-protein. We now show that CLN2 overexpression can also repress FUS1 induction if the signaling pathway is activated at the level of the beta-subunit of the G-protein (STE4) but not when activated at the level of downstream kinases (STE20 and STE11) or at the level of the transcription factor STE12. This epistatic analysis indicates that repression of pheromone signaling pathway by Cln2-Cdc28 kinase takes place at a level around STE20. In agreement with this, a marked reduction in the electrophoretic mobility of the Ste20 protein is observed at the time in the cell cycle of maximal expression of CLN2. This mobility change is constitutive in cells overexpressing CLN2 and absent in cells lacking CLN1 and CLN2. These changes in electrophoretic mobility correlate with repression of pheromone signaling and suggest Ste20 as a target for repression of signaling by G(1) cyclins. Two morphogenic pathways for which Ste20 is essential, pseudohyphal differentiation and haploid-invasive growth, also require CLN1 and CLN2. Together with the previous observation that Cln1 and Cln2 are required for the function of Ste20 in cytokinesis, this suggests that Cln1 and Cln2 regulate the biological activity of Ste20 by promoting morphogenic functions, while inhibiting the mating factor signal transduction function.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Oehlen, LJWM (corresponding author), CADUS Pharmaceut Corp, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049716] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49716] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COMPANY M, 1988, MOL CELL BIOL, V8, P5299, DOI 10.1128/MCB.8.12.5299; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; FIELDS S, 1987, MOL CELL BIOL, V7, P3818, DOI 10.1128/MCB.7.10.3818; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; Leberer E, 1996, MOL GEN GENET, V252, P608, DOI 10.1007/s004380050268; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Levine K, 1996, MOL CELL BIOL, V16, P6794; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Oehlen LJWM, 1998, J BIOL CHEM, V273, P8556, DOI 10.1074/jbc.273.15.8556; OEHLEN LJWM, 1994, GENE DEV, V8, P1058, DOI 10.1101/gad.8.9.1058; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Wassmann K, 1997, J BIOL CHEM, V272, P13180, DOI 10.1074/jbc.272.20.13180; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZANOLARI B, 1991, MOL CELL BIOL, V11, P5251, DOI 10.1128/MCB.11.10.5251; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	50	47	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25089	25097		10.1074/jbc.273.39.25089	http://dx.doi.org/10.1074/jbc.273.39.25089			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737966	hybrid			2022-12-25	WOS:000076085400016
J	Batinic-Haberle, I; Benov, L; Spasojevic, I; Fridovich, I				Batinic-Haberle, I; Benov, L; Spasojevic, I; Fridovich, I			The ortho effect makes Manganese(III) Meso-Tetrakis(N-Methylpyridinium-2-yl) porphyrin a powerful and potentially useful superoxide dismutase mimic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-BINDING HEMOPROTEINS; WATER-SOLUBLE PORPHYRINS; SYNTHETIC MODELS; NUCLEIC-ACIDS; METALLOPORPHYRINS; ELECTROCHEMISTRY; REDUCTION; DERIVATIVES; COMPLEXES; DIANION	The ortho, meta, and para isomers of manganese(III) 5,10,15,20-tetrakis(N-methylpyridyl)porphyrin MnTM-2-PyP5+, MnTM-3-PyP5+, and MnTM-4-PyP5+, respectively, were analyzed in terms of their superoxide dismutase (SOD) activity in vitro and in vivo. The impact of their interaction with DNA and RNA on the SOD activity in vivo and in vitro has also been analyzed. Differences in their behavior are due to the combined steric and electrostatic factors. In vitro catalytic activities are closely related to their redox potentials. The half-wave potentials (E-1/2) are +0.220 mV, +0.052 mV, and +0.060 V versus normal hydrogen electrode, whereas the rates of dismutation (k(cat)) are 6.0 x 10(7), 4.1 x 10(6), and 3.8 x 10(6) M-1 s(-1) for the ortho, meta, and para isomers, respectively. However, the in vitro activity is not a sufficient predictor of in vivo efficacy. The ortho and meta isomers, although of significantly different in vitro SOD activities, have fairly close in vivo SOD efficacy due to their similarly weak interactions with DNA. In contrast, due to a higher degree of interaction with DNA, the para isomer inhibited growth of SOD-deficient Escherichia coli.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Dept Chem, Durham, NC 27708 USA	Duke University; Duke University	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.		Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146				Autret M, 1996, J CHEM SOC DALTON, P2793, DOI 10.1039/dt9960002793; BARRETTE WC, 1983, BIOCHEMISTRY-US, V22, P624, DOI 10.1021/bi00272a015; BatinicHaberle I, 1997, ARCH BIOCHEM BIOPHYS, V343, P225, DOI 10.1006/abbi.1997.0157; BHATTI W, 1973, J PHARM SCI, V62, P1574, DOI 10.1002/jps.2600620951; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BINSTEAD RA, 1991, INORG CHEM, V30, P1259, DOI 10.1021/ic00006a019; BOSCHI T, 1986, INORG CHIM ACTA, V119, P191, DOI 10.1016/S0020-1693(00)84339-X; BUTLER J, 1982, J BIOL CHEM, V257, P747; COLLMAN JP, 1977, ACCOUNTS CHEM RES, V10, P265, DOI 10.1021/ar50115a006; COLLMAN JP, 1975, J AM CHEM SOC, V97, P1427, DOI 10.1021/ja00839a026; DAVILA J, 1987, J CHEM SOC CHEM COMM, P525, DOI 10.1039/c39870000525; EATON SS, 1974, J CHEM SOC CHEM COMM, P576, DOI 10.1039/c39740000576; EATON SS, 1972, J ORGANOMET CHEM, V39, P179, DOI 10.1016/S0022-328X(00)88918-4; EATON SS, 1975, J AM CHEM SOC, V97, P3660, DOI 10.1021/ja00846a016; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; GIRAUDEAU A, 1979, J AM CHEM SOC, V101, P3857, DOI 10.1021/ja00508a024; HAMBRIGHT P, 1976, INORG CHEM, V15, P2314, DOI 10.1021/ic50163a072; HAMBRIGHT P, 1970, INORG CHEM, V9, P1757, DOI 10.1021/ic50089a030; HAMBRIGHT P, 1977, J INORG NUCL CHEM, V39, P1102, DOI 10.1016/0022-1902(77)80282-0; Hariprasad G, 1996, J CHEM SOC DALTON, P3429, DOI 10.1039/dt9960003429; HARRIMAN A, 1979, J CHEM SOC FARAD T 2, V75, P1532, DOI 10.1039/f29797501532; HODGSON EK, 1973, ANAL BIOCHEM, V51, P470, DOI 10.1016/0003-2697(73)90502-2; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KADISH KM, 1990, J AM CHEM SOC, V112, P8364, DOI 10.1021/ja00179a021; KALYANASUNDARAM K, 1984, INORG CHEM, V23, P2453, DOI 10.1021/ic00184a019; KAUFMANN T, 1995, INORG CHEM, V34, P5073, DOI 10.1021/ic00124a025; Koppenol W. H., 1985, ADV FREE RADICALS BI, V1, P91, DOI DOI 10.1016/8755-9668(85)90005-5; KOPPENOL WH, 1987, BIOELECTROCH BIOENER, V18, P3, DOI 10.1016/0302-4598(87)85002-X; LEE WA, 1984, CHEM PHYS LETT, V107, P308, DOI 10.1016/0009-2614(84)85135-0; LONGO FR, 1973, ANN NY ACAD SCI, V206, P420, DOI 10.1111/j.1749-6632.1973.tb43227.x; MCADAM ME, 1977, BIOCHEM J, V161, P697, DOI 10.1042/bj1610697; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEOTNER M, 1975, J AM CHEM SOC, V97, P5107, DOI 10.1021/ja00851a014; MIN L, 1990, BIOCHEMISTRY-US, V29, P1614; MULLER W, 1973, EUR J BIOCHEM, V39, P223, DOI 10.1111/j.1432-1033.1973.tb03120.x; PASTERNACK RF, 1995, SCIENCE, V269, P935, DOI 10.1126/science.7638615; PASTERNACK RF, 1985, J AM CHEM SOC, V107, P8179, DOI 10.1021/ja00312a061; PASTERNACK RF, 1983, BIOCHEMISTRY-US, V22, P2406, DOI 10.1021/bi00279a016; PASTERNACK RF, 1983, BIOCHEMISTRY-US, V22, P5409, DOI 10.1021/bi00292a024; QUIMBY DJ, 1975, J AM CHEM SOC, V97, P5110; Richards RA, 1996, INORG CHEM, V35, P1940, DOI 10.1021/ic941434w; SAWADA Y, 1973, BIOCHIM BIOPHYS ACTA, V327, P257, DOI 10.1016/0005-2744(73)90408-7; Sen A, 1997, J CHEM SOC FARADAY T, V93, P4281, DOI 10.1039/a704663d; STRICKLAND JA, 1988, BIOCHEMISTRY-US, V27, P8870, DOI 10.1021/bi00424a027; Tabata M, 1996, B CHEM SOC JPN, V69, P673, DOI 10.1246/bcsj.69.673; Tagliatesta P, 1996, INORG CHEM, V35, P5570, DOI 10.1021/ic960148c; TAKEUCHI T, 1994, J AM CHEM SOC, V116, P9730, DOI 10.1021/ja00100a043; TROFIMOV BA, 1980, KHIM GETEROTSIKL+, P632; Uno T, 1997, INORG CHEM, V36, P1676, DOI 10.1021/ic960824a; VALIOTTI A, 1981, J INORG NUCL CHEM, V43, P2653, DOI 10.1016/0022-1902(81)80593-3; VERGELDT FJ, 1995, J PHYS CHEM-US, V99, P4397, DOI 10.1021/j100013a007; Warburg O, 1939, BIOCHEM Z, V303, P40; WARD B, 1986, BIOCHEMISTRY-US, V25, P6875, DOI 10.1021/bi00370a021; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3; YU CH, 1994, J ELECTROANAL CHEM, V368, P323, DOI 10.1016/0022-0728(93)03073-X	55	238	248	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24521	24528		10.1074/jbc.273.38.24521	http://dx.doi.org/10.1074/jbc.273.38.24521			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733746	hybrid			2022-12-25	WOS:000076007300038
J	Beschin, A; Bilej, M; Hanssens, F; Raymakers, J; Van Dyck, E; Revets, H; Brys, L; Gomez, J; De Baetselier, P; Timmermans, M				Beschin, A; Bilej, M; Hanssens, F; Raymakers, J; Van Dyck, E; Revets, H; Brys, L; Gomez, J; De Baetselier, P; Timmermans, M			Identification and cloning of a glucan- and liopoplysaccharide-binding protein from Eisenia foetida earthworm involved in the activation of prophenoloxidase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNELID NEREIS-DIVERSICOLOR; CRAYFISH BLOOD-CELLS; CELOMIC FLUID; FETIDA-ANDREI; LUMBRICUS-TERRESTRIS; MOLECULAR-CLONING; CELLULAR-IMMUNITY; SERINE PROTEASES; BOMBYX-MORI; PURIFICATION	Coelomic fluid of Eisenia foetida earthworms contains a 42-kDa protein named coelomic cytolytic factor 1 (CCF-1) that was described previously to be involved in cytolytic, opsonizing, and hemolytic properties of the coelomic fluid. Cloning and sequencing of CCF-1 reveal significant homology with the putative catalytic region of beta-1,3- and beta-1,3-1,4-glucanases. CCF-1 also displays homology with coagulation factor G from Limulus polyphemus and with Gram-negative bacteria-binding protein of Bombyx mori silkworm, two proteins involved in invertebrate defense mechanisms. We show that CCF-1 efficiently binds both beta-1,3-glucan and lipopolysaccharide, Moreover, CCF-1 participates in the activation of prophenoloxidase cascade via recognition of yeast and Gram-negative bacteria cell wall components. These results suggest that the 42-kDa CCF-1 protein of E. foetida coelomic fluid likely plays a role in the protection of earthworms against microbes.	Free Univ Brussels, Flemisch Interuniv Inst Biotechnol, Unit Cellular Immunol, B-1640 Rhode St Genese, Belgium; Acad Sci Czech Republic, Inst Microbiol, Dept Immunol, CR-14220 Prague 4, Czech Republic; NV Innogenet, B-9052 Zwijnaarde, Belgium	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Innogenetics NV	Beschin, A (corresponding author), Free Univ Brussels, Flemisch Interuniv Inst Biotechnol, Unit Cellular Immunol, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	abeschin@vub.ac.be	Bilej, Martin/I-4564-2014; Beschin, Alain/L-2154-2014; De Baetselier, Patrick/D-3866-2014	Beschin, Alain/0000-0001-8478-6941; 				ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; ASPAN A, 1991, INSECT BIOCHEM, V21, P363, DOI 10.1016/0020-1790(91)90002-V; ASPAN A, 1990, INSECT BIOCHEM, V20, P709, DOI 10.1016/0020-1790(90)90085-9; Bachman ES, 1996, P NATL ACAD SCI USA, V93, P6808, DOI 10.1073/pnas.93.13.6808; BIELY P, 1985, ANAL BIOCHEM, V144, P142, DOI 10.1016/0003-2697(85)90095-8; BILEJ M, 1995, IMMUNOL LETT, V45, P123, DOI 10.1016/0165-2478(94)00248-P; Bilej M, 1998, IMMUNOL LETT, V60, P23, DOI 10.1016/S0165-2478(97)00127-2; CERENIUS L, 1994, J BIOL CHEM, V269, P29462; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALES RP, 1983, J INVERTEBR PATHOL, V42, P288, DOI 10.1016/0022-2011(83)90077-0; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FISCHER E, 1978, ACTA HISTOCHEM, V63, P210; GRAHAM DG, 1978, J INVEST DERMATOL, V70, P113, DOI 10.1111/1523-1747.ep12541249; Johansson M.W., 1996, Progress in Molecular and Subcellular Biology, V15, P46; JOHANSSON MW, 1989, PARASITOL TODAY, V5, P171, DOI 10.1016/0169-4758(89)90139-7; LASSALLE F, 1988, COMP BIOCHEM PHYS B, V91, P187, DOI 10.1016/0305-0491(88)90133-2; Lassegues M, 1997, EUR J BIOCHEM, V246, P756, DOI 10.1111/j.1432-1033.1997.00756.x; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LEIPNER C, 1993, COMP BIOCHEM PHYS B, V105, P637, DOI 10.1016/0305-0491(93)90099-Q; MCCLEARY BV, 1988, METHOD ENZYMOL, V160, P74; Milochau A, 1997, BBA-PROTEIN STRUCT M, V1337, P123, DOI 10.1016/S0167-4838(96)00160-4; MOHRIG W, 1989, ZOOL JAHRB ALLG ZOOL, V93, P303; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; NAYAR JK, 1989, J MED ENTOMOL, V26, P159, DOI 10.1093/jmedent/26.3.159; NOVOTNA V, 1996, INT J BIOCHROMATOGR, V2, P37; Olafsen J.A., 1996, Advances in Comparative and Environmental Physiology, V24, P49; PAWELEK JM, 1978, NATURE, V276, P627, DOI 10.1038/276627a0; Poinar G.O. Jr., 1977, Comparative Pathobiol, V3, P69; PORCHETHENNERE E, 1987, J INVERTEBR PATHOL, V50, P58, DOI 10.1016/0022-2011(87)90146-7; PORCHETHENNERE E, 1992, CELL TISSUE RES, V269, P167, DOI 10.1007/BF00384737; ROCH P, 1991, COMP BIOCHEM PHYS B, V98, P597, DOI 10.1016/0305-0491(91)90261-B; Roch Ph., 1996, Advances in Comparative and Environmental Physiology, V23, P115; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SEKI N, 1994, J BIOL CHEM, V269, P1370; SEYMOUR J, 1993, ANIM BIOL, V2, P1; SILVERMAN DHS, 1986, J IMMUNOL, V136, P2195; SINKORA M, 1993, CELL BIOL INT, V17, P935, DOI 10.1006/cbir.1993.1015; Smith V.J., 1996, Advances in Comparative and Environmental Physiology, V23, P75; SMITH VJ, 1991, DEV COMP IMMUNOL, V15, P251, DOI 10.1016/0145-305X(91)90018-T; SODERHALL K, 1982, J INVERTEBR PATHOL, V39, P105, DOI 10.1016/0022-2011(82)90164-1; Soderhall K., 1986, P208; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; Soderhall K., 1986, P251; THORNQVIST PO, 1994, DEV COMP IMMUNOL, V18, P3, DOI 10.1016/0145-305X(94)90247-X; TUCKOVA L, 1986, DEV COMP IMMUNOL, V10, P181, DOI 10.1016/0145-305X(86)90002-9; VALEMBOIS P, 1991, J INVERTEBR PATHOL, V57, P177, DOI 10.1016/0022-2011(91)90114-6; VALEMBOIS P, 1992, DEV COMP IMMUNOL, V16, P95, DOI 10.1016/0145-305X(92)90010-A; VALEMBOIS P, 1982, J INVERTEBR PATHOL, V40, P21, DOI 10.1016/0022-2011(82)90032-5; Vasta G.R., 1996, Progress in Molecular and Subcellular Biology, V17, P158; YAMAMOTO M, 1993, BIOSCI BIOTECH BIOCH, V57, P1518, DOI 10.1271/bbb.57.1518	51	154	163	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24948	24954		10.1074/jbc.273.38.24948	http://dx.doi.org/10.1074/jbc.273.38.24948			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733802	hybrid			2022-12-25	WOS:000076007300094
J	Flores-Diaz, M; Alape-Giron, A; Titball, RW; Moos, M; Guillouard, I; Cole, S; Howells, AM; von Eichel-Streiber, C; Florin, I; Thelestam, M				Flores-Diaz, M; Alape-Giron, A; Titball, RW; Moos, M; Guillouard, I; Cole, S; Howells, AM; von Eichel-Streiber, C; Florin, I; Thelestam, M			UDP-glucose deficiency causes hypersensitivity to the cytotoxic effect of Clostridium perfringens phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DIFFICILE TOXIN-B; ALPHA-TOXIN; GAS-GANGRENE; BACTERIAL PHOSPHOLIPASES; HEMOLYTIC ACTIVITIES; MOLECULAR-CLONING; ARACHIDONIC-ACID; BACILLUS-CEREUS; MAMMALIAN-CELLS	A Chinese hamster cell line with a mutation in the UDP-glucose pyrophosphorylase (UDPG:PP) gene leading to UDP-glucose deficiency as well as a revertant cell were previously isolated. We now show that the mutant cell is 10(5) times more sensitive to the cytotoxic effect of Clostridium perfringens phospholipase C (PLC) than the revertant cell. To clarify whether there is a connection between the UDP-glucose deficiency and the hypersensitivity to C. perfringens PLC, stable transfectant cells were prepared using a wild type UDPG:PP cDNA. Clones of the mutant transfected with a construct having the insert in the sense orientation had increased their UDP-glucose level, whereas those of the revertant transfected with a UDPG:PP antisense had reduced their level of UDP-glucose compared with control clones transfected with the vector. Exposure of these two types of transfectant clones to C. perfringens PLC demonstrated that a cellular UDP-glucose deficiency causes hypersensitivity to the cytotoxic effect of this phospholipase. Further experiments with genetically engineered C. perfringens PLC variants showed that the sphingomyelinase activity and the C-domain are required for its cytotoxic effect in UDP-glucose-deficient cells.	Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Univ Costa Rica, Fac Med, Dept Bioquim, San Jose, Costa Rica; Chem & Biol Def Estab, Def Evaluat & Res Agcy, Salisbury SP4 0JQ, Wilts, England; Inst Med Mikrobiol & Hyg, D-55101 Mainz, Germany; Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France	Karolinska Institutet; Universidad Costa Rica; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Thelestam, M (corresponding author), Karolinska Inst, Microbiol & Tumorbiol Ctr, Box 280, S-17177 Stockholm, Sweden.	monica.thelestam@mtc.ki.se						AW TY, 1984, BIOCHEM J, V219, P707, DOI 10.1042/bj2190707; AWAD MM, 1995, MOL MICROBIOL, V15, P191, DOI 10.1111/j.1365-2958.1995.tb02234.x; BASAK AK, 1994, J MOL BIOL, V244, P648, DOI 10.1006/jmbi.1994.1758; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONADONNA RC, 1993, J CLIN INVEST, V92, P486, DOI 10.1172/JCI116592; Bunting M, 1997, J CLIN INVEST, V100, P565, DOI 10.1172/JCI119566; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; Chapnick EK, 1996, INFECT DIS CLIN N AM, V10, P835, DOI 10.1016/S0891-5520(05)70329-9; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FloresDiaz M, 1997, J BIOL CHEM, V272, P23784, DOI 10.1074/jbc.272.38.23784; FLORIN I, 1991, MICROB PATHOGENESIS, V11, P337, DOI 10.1016/0882-4010(91)90019-7; Franks SE, 1996, ANTICANCER RES, V16, P1365; Guillouard I, 1996, INFECT IMMUN, V64, P2440, DOI 10.1128/IAI.64.7.2440-2444.1996; Guillouard I, 1997, MOL MICROBIOL, V26, P867, DOI 10.1046/j.1365-2958.1997.6161993.x; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KENT C, 1986, ARCH BIOCHEM BIOPHYS, V250, P519, DOI 10.1016/0003-9861(86)90757-5; KONISHI Y, 1993, J BIOCHEM-TOKYO, V114, P61, DOI 10.1093/oxfordjournals.jbchem.a124141; LESLIE D, 1989, MOL MICROBIOL, V3, P383, DOI 10.1111/j.1365-2958.1989.tb00183.x; LOGAN AJ, 1991, INFECT IMMUN, V59, P4338, DOI 10.1128/IAI.59.12.4338-4342.1991; MOLLBY R, 1974, J MEMBRANE BIOL, V16, P313, DOI 10.1007/BF01872421; NAGAHAMA M, 1995, J BACTERIOL, V177, P1179, DOI 10.1128/jb.177.5.1179-1185.1995; Nagahama M, 1997, INFECT IMMUN, V65, P3489, DOI 10.1128/IAI.65.8.3489-3492.1997; NAGAHAMA M, 1994, FEMS MICROBIOL LETT, V120, P297, DOI 10.1016/0378-1097(94)90487-1; NINOMIYA M, 1994, INFECT IMMUN, V62, P5032, DOI 10.1128/IAI.62.11.5032-5039.1994; PELSRIJCKEN WR, 1995, GLYCOBIOLOGY, V5, P495; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROGSTAD B, 1993, INFECTION, V21, P54, DOI 10.1007/BF01739316; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; SAKURAI J, 1993, INFECT IMMUN, V61, P3711, DOI 10.1128/IAI.61.9.3711-3718.1993; SAKURAI J, 1994, INFECT IMMUN, V62, P717, DOI 10.1128/IAI.62.2.717-721.1994; SCHIESS K, 1992, BIOCHIM BIOPHYS ACTA, V1137, P82, DOI 10.1016/0167-4889(92)90104-J; SHEED SF, 1993, NMR BIOMED, V6, P254; SHOSHAN MC, 1990, EUR J CELL BIOL, V53, P357; SLEIGHT R, 1983, J BIOL CHEM, V258, P824; SOCHOR M, 1991, DIABETES, V40, P1467, DOI 10.2337/diabetes.40.11.1467; Songer JG, 1997, TRENDS MICROBIOL, V5, P156, DOI 10.1016/S0966-842X(97)01005-6; SPIRO MJ, 1984, DIABETOLOGIA, V26, P70; Stevens DL, 1997, J INFECT DIS, V176, P189, DOI 10.1086/514022; STEVENS DL, 1997, CLIN INFECT DIS   S2, V25, P160; SUNG SSJ, 1985, BIOCHIM BIOPHYS ACTA, V845, P204, DOI 10.1016/0167-4889(85)90178-8; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TITBALL RW, 1993, FEMS MICROBIOL LETT, V110, P45, DOI 10.1016/0378-1097(93)90240-3; TITBALL RW, 1991, INFECT IMMUN, V59, P1872, DOI 10.1128/IAI.59.5.1872-1874.1991; TITBALL RW, 1989, INFECT IMMUN, V57, P367, DOI 10.1128/IAI.57.2.367-376.1989; TITBALL RW, 1993, MICROBIOL REV, V57, P347, DOI 10.1128/MMBR.57.2.347-366.1993; TSO JY, 1989, INFECT IMMUN, V57, P468, DOI 10.1128/IAI.57.2.468-476.1989; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WICE BM, 1985, J BIOL CHEM, V260, P139; WILLIAMSON ED, 1993, VACCINE, V11, P1253, DOI 10.1016/0264-410X(93)90051-X	52	30	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24433	24438		10.1074/jbc.273.38.24433	http://dx.doi.org/10.1074/jbc.273.38.24433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733734	hybrid			2022-12-25	WOS:000076007300026
J	Granovsky, AE; Natochin, M; McEntaffer, RL; Haik, TL; Francis, SH; Corbin, JD; Artemyev, NO				Granovsky, AE; Natochin, M; McEntaffer, RL; Haik, TL; Francis, SH; Corbin, JD; Artemyev, NO			Probing domain functions of chimeric PDE6 alpha'/PDE5 cGMP-phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; GAMMA-SUBUNIT; CATALYTIC SUBUNITS; BINDING-SITES; PHOTORECEPTOR PHOSPHODIESTERASE; NUCLEOTIDE PHOSPHODIESTERASE; VISUAL TRANSDUCTION; HIGH-AFFINITY; RETINAL RODS	Chimeric cGMP phosphodiesterases (PDEs) have been constructed using components of the cGMP-binding PDE (PDE5) and cone photoreceptor phosphodiesterase (PDE6 alpha') in order to study structure and function of the photoreceptor enzyme. A fully functional chimeric PDE6 alpha'/PDE5 enzyme containing the PDE6 alpha' noncatalytic cGMP-binding sites, and the PDE5 catalytic domain has been efficiently expressed in the baculovirus/High Five cell system. The catalytic properties of this chimera were practically indistinguishable from those of PDE5, whereas the noncatalytic cGMP binding was similar to that of native purified PDE6 alpha'. The inhibitory gamma subunit of PDE6 (P gamma) enhanced the affinity of cGMP binding at noncatalytic sites of native PDE6 alpha' by similar to 6-fold, The polycationic region of P gamma, P gamma-24-45, was mainly responsible for this effect, while the inhibitory domain of P gamma, P gamma-63-87, was ineffective. On the contrary, Py failed to inhibit catalytic activity of the chimeric PDE6 alpha'/PDE5 or to modulate its noncatalytic cGMP binding. Substitutions of Ala residues for the conserved Asn, Asn(193) or Asn(402), in the two N(K/R)XD-like motifs of the chimeric PDE noncatalytic cGMP-binding sites, each led to a loss of the noncatalytic cGMP binding. Our data suggest that both putative noncatalytic sites of PDE6 alpha' are important for binding of cGMP, and that the two binding sites are coupled, Furthermore, mutation Asn402 --> Ala resulted in an approximately 10-fold increase of the K-m value for cGMP, indicating that occupation of the noncatalytic cGMP- binding sites of PDE6 alpha' may regulate catalytic properties of the enzyme.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, Nashville, TN 37232 USA	University of Iowa; Vanderbilt University	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	nikolai-artemyev@uiowa.edu		Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK40029] Funding Source: Medline; NIGMS NIH HHS [GM 41269] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; Lochhead A, 1997, J BIOL CHEM, V272, P18397, DOI 10.1074/jbc.272.29.18397; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; QIN N, 1994, J BIOL CHEM, V269, P3265; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; STROOP SD, 1991, J BIOL CHEM, V266, P23802; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	43	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24485	24490		10.1074/jbc.273.38.24485	http://dx.doi.org/10.1074/jbc.273.38.24485			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733741	hybrid			2022-12-25	WOS:000076007300033
J	Richter, MF; Dumenil, G; Uze, G; Fellous, M; Pellegrini, S				Richter, MF; Dumenil, G; Uze, G; Fellous, M; Pellegrini, S			Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; JAK1; SUBUNIT; PATHWAY; CHAIN; INTERLEUKIN-6; ASSOCIATION; P135(TYK2)	Cytokine signaling involves the activation of the Janus kinase (JAK) family of tyrosine kinases. These enzymes are physically associated with cytokine receptor components. Here, we sought to define the molecular basis of the interaction between Tyk2 and IFNAR1, a component of the interferon alpha/beta receptor, by delimiting a minimal IFNAR1 binding region in the Tyk2 protein. Using an in vitro assay system, we narrowed down the interaction domain to a region comprising the JH7 and part of the JH6 homology boxes (amino acids 22-221). When expressed in Tyk2-negative cells, the JH7-6 region was unable to stabilize IFNAR1 protein levels, a critical function that we previously attributed to the N region (amino acids 1-591) of Tyk2. Moreover, substitution of the JR7-JH6 domain in JAK1 with that of Tyk2 did not restore IFNAR1 level nor interferon Lu signaling in Tyk2-negative cells. Thus, the major interaction surface lies within JH7-6, but additional JH regions (JH5-4-3) contribute in a specific manner to the in vivo assembly of Tyk2 and IFNAR1. Evidence is also provided of the lack of specificity of the Tyk2 kinase-like and tyrosine kinase domains in interferon alpha/beta receptor signaling.	Inst Pasteur, INSERM, U276, F-75724 Paris 15, France; CNRS, UMR 9942, Inst Mol Genet, F-34033 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Pellegrini, S (corresponding author), Inst Pasteur, INSERM, U276, 25 Rue Dr Roux, F-75724 Paris 15, France.		Dumenil, Guillaume/F-7567-2015; Dumenil, Guillaume/N-3377-2019; Pellegrini, Sandra/Y-6351-2019; Richter, Marc François/AAC-6105-2020; Uzé, Gilles/O-6383-2019; Pellegrini, Sandra -/G-5546-2015	Dumenil, Guillaume/0000-0001-9174-9110; Dumenil, Guillaume/0000-0001-9174-9110; Pellegrini, Sandra/0000-0001-5837-7589; Richter, Marc François/0000-0002-0868-9127; Pellegrini, Sandra -/0000-0001-5837-7589; Uze, Gilles/0000-0002-4150-5772				BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; FINBLOOM DS, 1995, J IMMUNOL, V155, P1070; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Yan H, 1998, J BIOL CHEM, V273, P4046, DOI 10.1074/jbc.273.7.4046; Yan H, 1996, MOL CELL BIOL, V16, P2074; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0; Zou J, 1997, J BIOL CHEM, V272, P6073, DOI 10.1074/jbc.272.9.6073	29	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24723	24729		10.1074/jbc.273.38.24723	http://dx.doi.org/10.1074/jbc.273.38.24723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733772	Green Published, hybrid			2022-12-25	WOS:000076007300064
J	Thomas, NSB; Pizzey, AR; Tiwari, SJ; Williams, CD; Yang, JW				Thomas, NSB; Pizzey, AR; Tiwari, SJ; Williams, CD; Yang, JW			p130, p107, and pRb are differentially regulated in proliferating cells and during cell cycle arrest by alpha-interferon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE HEMATOPOIETIC-CELLS; KINASE INHIBITOR P21; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; DAUDI CELLS; GROWTH SUPPRESSION; RB PROTEIN; IN-VIVO; C-MYC; DEREGULATED EXPRESSION	We have determined how the phosphorylation of the retinoblastoma family (pRb, p107, and p130) is governed in individual cell cycle phases of Daudi B-cells during cell cycle exit triggered by alpha-interferon (alpha-IFN). alpha-IFN causes dephosphorylation of pRb and loss of p130 phosphorylated Form 3. However, the change in p130 phosphorylation in response to alpha-IFN occurs before dephosphorylation of pRb is complete because loss of p130 Form 3 occurs throughout the cell cycle prior to complete arrest in G(1), whereas pRb is dephosphorylated only in G(1). In contrast, p107 is dephosphorylated and is then depleted from cells as they exit the cell cycle. p130, predominantly in Form 1, and hypophosphorylated pRb bind an E2F DNA binding site; p130 complexes E2F-4, whereas pRb binds both E2F-4 and E2F-1, The phosphorylated forms of E2F-4 that bind to the E2F DNA site are different from hyperphosphorylated E2F-4, which predominates in primary hemopoietic cells in G(1). We conclude that although cell cycle arrest induced by alpha-IFN may be mediated in part by formation of a complex containing p130 and E2F-4, alpha-IFN does not induce hyperphosphorylation of E2F-4, which characterizes primary hemopoietic cells in G(1).	Univ Coll & Middlesex Sch Med, Dept Haematol, London WC1E 6HX, England	University of London; University College London	Thomas, NSB (corresponding author), Univ Coll & Middlesex Sch Med, Dept Haematol, 98 Chenie Mews, London WC1E 6HX, England.		Tiwari, Sanjay/Q-1853-2016; Pizzey, Arnold/E-6301-2015	Tiwari, Sanjay/0000-0002-3804-3300; Pizzey, Arnold/0000-0003-1850-1121				ARANY I, 1994, ANTIVIR RES, V23, P131, DOI 10.1016/0166-3542(94)90040-X; BARON S, 1991, JAMA-J AM MED ASSOC, V266, P1375, DOI 10.1001/jama.266.10.1375; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BURKE LC, 1992, ONCOGENE, V7, P783; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CLAUDIO PP, 1994, CANCER RES, V54, P5556; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARZYNKIEWICZ Z, 1982, J CELL PHYSIOL, V113, P465, DOI 10.1002/jcp.1041130316; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1796; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DENT CL, 1991, J BIOL CHEM, V266, P20888; DEVALIA V, 1992, BLOOD, V80, P68; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; THOMAS NSB, 1991, ONCOGENE, V6, P317; Thomas NSB, 1999, TEXTBOOK OF MALIGNANT HAEMATOLOGY, P133; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; TIWARI S, 1996, PROTEIN PHOSPHORYLAT, P255; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VARIO G, 1995, GENE DEV, V9, P869; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WHYTE P, 1995, APOPTOSIS CELL CYCLE, P77; Williams CD, 1997, BRIT J HAEMATOL, V96, P688, DOI 10.1046/j.1365-2141.1997.d01-2086.x; Williams CD, 1997, BLOOD, V90, P194; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; Yamada H, 1995, MOL CELL BIOCHEM, V152, P149, DOI 10.1007/BF01076077; Zetterberg A, 1996, APOPTOSIS CELL CYCLE, P17; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	77	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23659	23667		10.1074/jbc.273.37.23659	http://dx.doi.org/10.1074/jbc.273.37.23659			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726970	hybrid			2022-12-25	WOS:000075893100011
J	Lorenzo, P; Neame, P; Sommarin, Y; Heinegard, D				Lorenzo, P; Neame, P; Sommarin, Y; Heinegard, D			Cloning and deduced amino acid sequence of a novel cartilage protein (CILP) identifies a preform including a nucleotide pyrophosphohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTICULAR-CARTILAGE; MESSENGER-RNA; THROMBOSPONDIN; CHONDROCYTE; CLEAVAGE; EXPRESSION; COLLAGEN; BINDING; SIGNAL; SITES	The cDNA cloning and expression in vitro and in eukaryotic cells of a novel protein isolated from human articular cartilage, cartilage intermediate layer protein (CILP) is described. A single 4.2-kilobase mRNA detected in human articular cartilage encodes a polypeptide of 1184 amino acids with a calculated molecular mass of 132.5 kDa, The protein has a putative signal peptide of 21 amino acids, and is a preform of two polypeptides. The amino-terminal half corresponds to CILP (molecular mass of 78.5 kDa, not including post-translational modifications) and the carboxyl-terminal half corresponds to a protein homologous to a porcine nucleotide pyrophosphohydrolase, NTPPHase (molecular mass of 51.8 kDa, not including post-translational modifications). CILP has SO cysteines and six putative N-glycosylation sites. The human homolog of porcine NTPPHase described here contains 10 cysteine residues and two putative N-glycosylation sites. In the precursor protein the NTPPHase region is immediately preceded by a tetrapeptide conforming to a furin proteinase cleavage consensus sequence. Expression of the full-length cDNA in a cell-free translation system and in COS-7 or EBNA cells indicates that the precursor protein is synthesized as a single polypeptide chain that is processed, possibly by a furin-like protease, into two polypeptides upon or preceding secretion.	Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, S-22100 Lund, Sweden; Shriners Hosp Crippled Children, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	Lund University	Heinegard, D (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, POB 94, S-22100 Lund, Sweden.	Dick.Heinegard@medkem.lu.se						ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; GUO NH, 1992, J BIOL CHEM, V267, P19349; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HEDLUND H, 1993, APMIS, V101, P133, DOI 10.1111/j.1699-0463.1993.tb00092.x; Heinegard D, 1998, WENN GR INT, V72, P113; Heinegard D, 1998, OSTEOARTHRITIS, P74; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEE CC, 1992, METHOD ENZYMOL, V216, P69; Lorenzo P, 1998, J BIOL CHEM, V273, P23463, DOI 10.1074/jbc.273.36.23463; Masuda I, 1997, GENE, V197, P277, DOI 10.1016/S0378-1119(97)00272-2; MASUDA I, 1995, J CLIN INVEST, V95, P699, DOI 10.1172/JCI117716; MILLER RR, 1988, BIOCHEM BIOPH RES CO, V153, P708, DOI 10.1016/S0006-291X(88)81152-5; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Sambrook J., 2002, MOL CLONING LAB MANU; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	24	56	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23469	23475		10.1074/jbc.273.36.23469	http://dx.doi.org/10.1074/jbc.273.36.23469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722584	hybrid			2022-12-25	WOS:000075778100084
J	Park, JI; Grant, CM; Davies, MJ; Dawes, IW				Park, JI; Grant, CM; Davies, MJ; Dawes, IW			The cytoplasmic Cu,Zn superoxide dismutase of Saccharomyces cerevisiae is required for resistance to freeze-thaw stress - Generation of free radicals during freezing and thawing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; OXIDATIVE STRESS; IN-VIVO; YEAST; GENE; GLUTATHIONE; PROTECTION; ANTIOXIDANTS; BIOLOGY; GROWTH	The involvement of oxidative stress in freeze-thaw injury to yeast cells was analyzed using mutants defective in a range of antioxidant functions, including Cu,Zn superoxide dismutase (encoded by SOD1), Mn superoxide dismutase (SOD2), catalase A, catalase T, glutathione reductase, gamma-glutamylcysteine synthetase and Yap1 transcription factor. Only those affecting superoxide dismutases showed decreased freeze-thaw tolerance, with the sod1 mutant and the sod1 sod2 double mutant being most affected. This indicated that superoxide anions were formed during freezing and thawing. This was confirmed since the sod1 mutant could be made more resistant by treatment with the superoxide anion scavenger MnCl2, or by freezing in the absence of oxygen, or by the generation of a rho(0) petite. Increased expression of SOD2 conferred freeze-thaw tolerance on the sod1 mutant indicating the ability of the mitochondrial superoxide dismutase to compensate for the lack of the cytoplasmic enzyme. Free radicals generated as a result of freezing and thawing were detected in cells directly using electron paramagnetic resonance spectroscopy with either alpha-phenyl-N-tert-butylnitrone or 5,5-dimethyl-1-pyrroline-N-oxide as spin trap. Highest levels were formed in the sod1 and sod1 sod2 mutant strains, but lower levels were detected in the wild type. The results show that oxidative stress causes major injury to cells during aerobic freezing and thawing and that this is mainly initiated in the cytoplasm by an oxidative burst of superoxide radicals formed from oxygen and electrons leaked from the mitochondrial electron transport chain.	Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Univ New S Wales, Cooperat Res Ctr Food Ind Innovat, Sydney, NSW 2052, Australia; Heart Res Inst, Sydney, NSW 2050, Australia	University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; Heart Research Institute	Dawes, IW (corresponding author), Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia.	I.Dawes@unsw.edu.au	Davies, Michael J/H-4939-2011; Davies, Michael/GWV-2527-2022; Davies, Michael/AGX-9184-2022	Davies, Michael J/0000-0002-5196-6919; Davies, Michael/0000-0002-5196-6919; Park, Jong-In/0000-0001-7248-4735; Grant, Chris/0000-0002-0616-6576				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARCHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V214, P452, DOI 10.1016/0003-9861(82)90049-2; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CHAPUT M, 1983, BIOCHIMIE, V65, P501, DOI 10.1016/S0300-9084(83)80132-1; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLEGG JS, 1982, CRYOBIOLOGY, V19, P306, DOI 10.1016/0011-2240(82)90159-6; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; FlatteryOBrien JA, 1997, MOL MICROBIOL, V23, P303, DOI 10.1046/j.1365-2958.1997.2121581.x; FRANKS F, 1983, CRYOBIOLOGY, V20, P298, DOI 10.1016/0011-2240(83)90018-4; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GEITZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; Gille G, 1995, FOLIA MICROBIOL, V40, P131, DOI 10.1007/BF02815413; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GRALLA EB, 1997, OXIDATIVE STRESS MOL, P495; Grant CM, 1996, REDOX REP, V2, P223, DOI 10.1080/13510002.1996.11747054; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; GUTTERIDGE JMC, 1994, CHEM-BIOL INTERACT, V91, P133, DOI 10.1016/0009-2797(94)90033-7; HALLIWELL B, 1995, FOOD CHEM TOXICOL, V33, P601, DOI 10.1016/0278-6915(95)00024-V; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HALLIWELL B, 1987, FREE RADICAL BIO MED, P20; Jacob RA, 1996, AM J CLIN NUTR, V63, P985; LEVITT J, 1966, CRYOBIOLOGY, P495; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MAZUR P, 1970, SCIENCE, V168, P939, DOI 10.1126/science.168.3934.939; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; Park JI, 1997, APPL ENVIRON MICROB, V63, P3818, DOI 10.1128/AEM.63.10.3818-3824.1997; Rock CL, 1996, J AM DIET ASSOC, V96, P693, DOI 10.1016/S0002-8223(96)00190-3; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; RUIS H, 1997, OXIDATIVE STRESS MOL, P309; Sambrook J., 2002, MOL CLONING LAB MANU; Scandalios JG, 1992, MOL BIOL FREE RADICA, P117; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; Sherman F., 1986, METHODS YEAST GENETI; SPENCER JFT, 1988, YEAST PRACTICAL APPR, P65; STAVELEY BE, 1990, GENOME, V33, P867, DOI 10.1139/g90-130; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; WU AL, 1993, J BIOL CHEM, V268, P18850; [No title captured]	48	109	111	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22921	22928		10.1074/jbc.273.36.22921	http://dx.doi.org/10.1074/jbc.273.36.22921			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722512	hybrid			2022-12-25	WOS:000075778100012
J	Pouponnot, C; Jayaraman, L; Massague, J				Pouponnot, C; Jayaraman, L; Massague, J			Physical and functional interaction of SMADs and p300/CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MAD-RELATED PROTEIN; ADENOVIRUS E1A PROTEINS; FAMILY MEDIATOR SMAD1; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; BINDING; TRANSCRIPTION; RECEPTOR; CBP	SMADs are transforming growth factor beta (TGF-beta) receptor substrates and mediators of TGF-beta transcriptional responses. Here we provide evidence that the coactivators p300 and CBP interact with Smads 1 through 4. The biological relevance of this interaction is shown in vivo by overexpression of the adenovirus E1A protein and mutant forms of E1A that lack p300-binding sites. Wild-type EIA, but not the mutants, inhibits SMAD-dependent transcriptional responses to TGF-beta. E1A also inhibits the intrinsic transactivating function of the Smad4 MH2 domain. In addition, overexpression of p300 enhances SMAD-dependent transactivation. Our results suggest a role for p300/CBP in SMAD-mediated transcriptional activation and provide an explanation for the observed ability of E1A to interfere with TGF-beta action.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, Box 116,1275 York Ave, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; COUSSENS LM, 1994, J CELL PHYSL, V160, P534; Das P, 1998, DEVELOPMENT, V125, P1519; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; DEGROOT RP, 1995, CELL GROWTH DIFFER, V6, P531; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Hudson JB, 1998, DEVELOPMENT, V125, P1407; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kim DH, 1997, J BIOL CHEM, V272, P688; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	51	281	289	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22865	22868		10.1074/jbc.273.36.22865	http://dx.doi.org/10.1074/jbc.273.36.22865			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722503	hybrid			2022-12-25	WOS:000075778100003
J	Worth, L; Bader, T; Yang, J; Clark, S				Worth, L; Bader, T; Yang, J; Clark, S			Role of MutS ATPase activity in MutS,L-dependent block of in vitro strand transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MISMATCH REPAIR; DNA-BASE PAIRS; NEGATIVE MUTATOR MUTATIONS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; SACCHAROMYCES-CEREVISIAE; GENE; RECOMBINATION; PROTEIN; HOMOLOG	In addition to mismatch recognition, Escherichia coli MutS has an associated ATPase activity that is fundamental to repair. Hence, we have characterized two MutS mutant gene products to define the role of ATP hydrolysis in homeologous recombination. These mutants, denoted MutS501 and MutS506, have single point mutations within the Walker A motif, and rate constants for ATP hydrolysis are down 60-100-fold as compared with wild type. Both MutS501 and MutS506 retain mismatch binding and,unlike wild type, fail to relinquish this specificity in the presence of ATP, adenosine 5'-O-(thiotriphosphate), and adenosine 5'-(beta,gamma-imino)triphosphate. Both MutS501 and MutS506 blocked the level of strand transfer between M13 and fd DNAs, The level of inhibition varied between the mutants and corresponded with the relative affinities to a G/T mispair. Neither MutS501 nor MutS506, however, would afford complete block of full-length heteroduplex in the presence of MutL. DNase I footprinting data are consistent with these results, as the region of protection by MutS501 and MutS506 was unchanged in the presence of ATP and MutL. Taken together, these studies suggest that 1) MutS impedes RecA-mediated homeologous exchange as a distinct mismatch-provoked event and 2) the role of MutL is coupled to MutS-dependent ATP hydrolysis, These observations are in good agreement with the present model for E. coli methyl-directed mismatch repair.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Inst Mol Pathol, Res Inst Mol Pathol, A-1030 Vienna, Austria	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Worth, L (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.							Abdulkarim F, 1996, J MOL BIOL, V260, P506, DOI 10.1006/jmbi.1996.0418; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; AU KG, 1992, J BIOL CHEM, V267, P12142; Bawa S, 1997, CANCER RES, V57, P2715; Brosh RM, 1997, J BIOL CHEM, V272, P572; Buning H, 1996, ANAL BIOCHEM, V234, P227, DOI 10.1006/abio.1996.0078; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; FENG G, 1995, BIOTECHNIQUES, V19, P956; FENG WY, 1991, GENETICS, V129, P1007; FISHEL RA, 1986, J MOL BIOL, V188, P147, DOI 10.1016/0022-2836(86)90300-1; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1988, MUTAT RES, V198, P37, DOI 10.1016/0027-5107(88)90037-1; LANGLEROUAULT F, 1987, EMBO J, V6, P1121, DOI 10.1002/j.1460-2075.1987.tb04867.x; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; MATIC I, 1994, GENETICS, V136, P17; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; PETIT MA, 1991, GENETICS, V129, P327; RAYSSIGUIER C, 1991, BIOCHIMIE, V73, P371, DOI 10.1016/0300-9084(91)90103-8; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Schar P, 1997, GENETICS, V146, P1275; SELVA EM, 1995, GENETICS, V139, P1175; Smith J, 1996, P NATL ACAD SCI USA, V93, P4374, DOI 10.1073/pnas.93.9.4374; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; WATERS S, 1994, PROTEIN EXPRES PURIF, V5, P534, DOI 10.1006/prep.1994.1073; WINGFIELD PT, 1995, CURR PROTOCOLS PROTE, V1; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; ZAHRT TC, 1994, J BACTERIOL, V176, P1527, DOI 10.1128/jb.176.5.1527-1529.1994	42	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23176	23182		10.1074/jbc.273.36.23176	http://dx.doi.org/10.1074/jbc.273.36.23176			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722547	hybrid			2022-12-25	WOS:000075778100047
J	Mandal, M; Adam, L; Mendelsohn, J; Kumar, R				Mandal, M; Adam, L; Mendelsohn, J; Kumar, R			Nuclear targeting of Bax during apoptosis in human colorectal cancer cells	ONCOGENE			English	Article						apoptosis; Bax; colorectal cancer; growth; factor receptor	EPIDERMAL GROWTH-FACTOR; RECEPTOR MONOCLONAL-ANTIBODY; BUTYRATE-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; IN-VIVO PATTERNS; WILD-TYPE P53; FACTOR-ALPHA; HUMAN-COLON; ENDOPLASMIC-RETICULUM; CARCINOMA CELLS	Homeostasis in colonic epithelial cells is regulated by the balance between proliferative activity and cell loss by apoptosis. Because epithelial cells at the apex of colonic crypts undergo apoptosis and proliferative activity is usually restricted to the base of the crypts, it has been proposed that the limited availability of growth factor-signals at the upper portions of the crypts may trigger apoptosis. In the present studies, we investigate the mechanism of apoptosis mediated by growth factor deprivation in colorectal carcinoma cells by delineating the possible involvement of Bax and its subcellular localization. We report that inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase activity and downregulation of EGFR by anti-EGFR mAb 225 induces apoptosis in human colorectal carcinoma DiFi and FET cells. Induction of apoptosis was preceded by enhanced expression of newly synthesized Bax protein, and required protein synthesis. In the mAb 225-treated cells, Bax was redistributed from the cytosol to the nucleus and subsequently, to the nuclear membranes. The observed induction of Bax expression by mAb 225 was not associated with p53 induction. However, mAb 225 treatment also triggered relocalization of p53 from the cytosol to a nuclear membrane-bound form. Induction of Bax and its redistribution to the nucleus of DiFi cells during apoptosis was also demonstrated in response to butyrate, a physiological relevant molecule in colonic epithelial cells as it is the principal short-chain fatty acid produced by bacterial fermentation of dietary fiber in colonic epithelium. Using immunofluorescence and confocal microscopy, we observed that Bax is predominantly localized in the cytosol, but during apoptosis it is localized both inside and along the nuclear membrane. Taken together, these findings suggest that apoptosis induced by growth factor-deprivation or butyrate may involve the subcellular redistribution of Bax in human colorectal carcinoma cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323	NCI NIH HHS [CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATLAS I, 1992, CANCER RES, V52, P3335; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BEDI A, 1995, CANCER RES, V55, P1811; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOISE LH, 1993, CELL, V79, P341; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Brattain Michael G., 1994, Current Opinion in Oncology, V6, P77, DOI 10.1097/00001622-199401000-00011; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; COFFEY RJ, 1986, CANCER RES, V46, P1164; COLES HSR, 1993, DEVELOPMENT, V118, P777; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; FAN Z, 1993, J BIOL CHEM, V268, P21073; GarciaLloret MI, 1996, J CELL PHYSIOL, V167, P324, DOI 10.1002/(SICI)1097-4652(199605)167:2<324::AID-JCP17>3.0.CO;2-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; HUANG S, 1992, INT J CANCER, V52, P978, DOI 10.1002/ijc.2910520625; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewski S, 1997, BLOOD, V89, P3817, DOI 10.1182/blood.V89.10.3817.3817_3817_3825; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KUMAR R, 1991, Current Opinion in Oncology, V3, P70, DOI 10.1097/00001622-199102000-00011; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LUCIANO AM, 1994, BIOL REPROD, V51, P646, DOI 10.1095/biolreprod51.4.646; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAJIMA M, 1994, NEUROSCI LETT, V176, P161, DOI 10.1016/0304-3940(94)90072-8; OLIVE M, 1993, IN VITRO CELL DEV-AN, V29A, P239; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; UNTAWALE S, 1993, CANCER RES, V53, P1630; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	63	122	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					999	1007		10.1038/sj.onc.1202020	http://dx.doi.org/10.1038/sj.onc.1202020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747879				2022-12-25	WOS:000075560900008
J	Troppmair, J; Hartkamp, J; Rapp, UR				Troppmair, J; Hartkamp, J; Rapp, UR			Activation of NF-Kappa B by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade	ONCOGENE			English	Article						Raf; stress kinase pathway; NF-Kappa B	TRANSCRIPTION FACTOR; C-JUN; MAMMALIAN-CELLS; TYROSINE KINASE; REQUIRES RAF-1; TRANSFORMATION; EXPRESSION; SITE; PROTEINS; PATHWAY	Raf-l kinase has been implicated in the induction of NF-kappa B activity by serum growth factors, phorbol ester and PTK oncogenes. Here we show that Raf activation of NF-kappa B, as measured in reporter gene assays, occurs indirectly and requires the stress kinase cascade. The stress pathway presumably becomes activated through induction of an autocrine loop by activated Raf (Raf-BXB) as suramin, the tyrphostin AG1478 and a dominant negative mutant of the EGF-R blocked NF-kappa B activation. Raf-BXB synergizes with SAPKs and a dominant negative mutant of SEK significantly reduces activation of NF-kappa B consistent with a role of this signaling pathway in the activation of NF-kappa B.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837; Hartkamp, Joerg/0000-0002-6863-9228				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FLORY E, 1998, IN PRESS J VIROL; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEE S, 1997, CELL, V88, P213; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU ZG, 1996, CELL, V87, P567; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; QUI RG, 1995, NATURE, V374, P457; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCHRECK R, 1997, IN PRESS TRANSCRIPTI; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7070; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					685	690		10.1038/sj.onc.1201981	http://dx.doi.org/10.1038/sj.onc.1201981			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715269				2022-12-25	WOS:000075337200002
J	Barbieri, MA; Hoffenberg, S; Roberts, R; Mukhopadhyay, A; Pomrehn, A; Dickey, BF; Stahl, PD				Barbieri, MA; Hoffenberg, S; Roberts, R; Mukhopadhyay, A; Pomrehn, A; Dickey, BF; Stahl, PD			Evidence for a symmetrical requirement for Rab5-GTP in in vitro endosome-endosome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB5; ENDOCYTIC MEMBRANE-FUSION; XANTHINE NUCLEOTIDES; GDP/GTP EXCHANGE; PROTEIN; VACUOLES; RABAPTIN-5; TRANSPORT; EFFECTOR; VESICLES	Early endosome fusion, which has been extensively characterized using an in vitro reconstitution assay, is Rab5-dependent. To examine the requirement for Rab5 on both fusion partners, we prepared cytosol and endosomes depleted of Rab5, Unlike control cytosol, Rab5-depleted cytosol was only marginally active in the in vitro endosome fusion. However, fusion could be restored by the addition of wild-type Rab5 or Rab5 D136N, a mutant whose nucleotide specificity favors xanthine over guanine. The addition of Rab5 D136N restored fusion only in the presence of XTP. In the absence of XTP or in the presence of XDP, Rab5 D136N failed to restore fusion, When fusion was carried out with endosomal vesicles depleted of Rab GTPases (by preincubation of vesicles with GDP dissociation inhibitor), together with cytosol immunodepleted of Rab5, fusion was virtually absent. We then used immunodepleted cytosol and GDP dissociation inhibitor-treated vesicles to determine whether Rab5 is required by both fusion partners. Using separate sets of endosomal vesicles, we found that priming both sets of Rab5-depleted vesicles with Rab5 Q79L, a GTPase defective mutant, substantially stimulated endosome fusion. Priming one set of vesicles with Rab5 Q79L and a second set of vesicles with Rab5 S34N failed to activate fusion. When both sets of Rab5-depleted vesicles mere primed with Rab5 D136N supplemented with XTP, endosome fusion was stimulated, similar to that observed with Rab5 Q79L. However, when one set of vesicles was preincubated with Rab5 D136N plus XTP and the second set with Rab5 D136N and XDP, no stimulation of fusion was observed. We conclude that Rab5-GTP is required on both fusion partners for docking and fusion of early endosomes. To confirm the fusion of Rab5-GTP-positive vesicles in vivo, we expressed GFP-Rab5 Q79L in fibroblasts and observed fusion of Rab5-positive vesicles. We failed to record fusion of Rab5-positive vesicles with Rab5-negative vesicles. We conclude that Rab5-GTP is required on both sets of endosomes for fusion in vitro and in living cells.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Washington University (WUSTL); Baylor College of Medicine	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	pstahl@cellbio.wustl.edu	Stahl, Philip/D-6315-2012					ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barbieri MA, 1996, ARCH BIOCHEM BIOPHYS, V326, P64, DOI 10.1006/abbi.1996.0047; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DIAZ R, 1988, J BIOL CHEM, V263, P6093; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; HOFFENBERG S, 1995, BIOCHEM BIOPH RES CO, V215, P241, DOI 10.1006/bbrc.1995.2459; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOUFFER C, 1994, ANNU REV BIOCHEM, V63, P949; Ohya T, 1998, J BIOL CHEM, V273, P613, DOI 10.1074/jbc.273.1.613; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schmidt G, 1996, ONCOGENE, V12, P87; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yanachkov I, 1997, MOL PHARMACOL, V51, P47, DOI 10.1124/mol.51.1.47; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015	34	62	63	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25850	25855		10.1074/jbc.273.40.25850	http://dx.doi.org/10.1074/jbc.273.40.25850			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748259	hybrid			2022-12-25	WOS:000076263100050
J	Chinetti, G; Griglio, S; Antonucci, M; Torra, IP; Delerive, P; Majd, Z; Fruchart, JC; Chapman, J; Najib, J; Staels, B				Chinetti, G; Griglio, S; Antonucci, M; Torra, IP; Delerive, P; Majd, Z; Fruchart, JC; Chapman, J; Najib, J; Staels, B			Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PPAR-GAMMA; FATTY-ACIDS; CHOLESTEROL DEPOSITION; GENE-EXPRESSION; ATHEROSCLEROSIS; LIPOPROTEIN; INHIBITION; BINDING; DIFFERENTIATION	Peroxisome proliferator-activated receptors (PPARs) have been implicated in metabolic diseases, such as obesity, diabetes, and atherosclerosis, due to their activity in liver and adipose tissue on genes involved in lipid and glucose homeostasis. Here, we show that the PPAR alpha and PPAR gamma forms are expressed in differentiated human monocyte-derived macrophages, which participate in inflammation control and atherosclerotic plaque formation. Whereas PPAR alpha is already present in undifferentiated monocytes, PPAR gamma expression is induced upon differentiation into macrophages. Immunocytochemistry analysis demonstrates that PPAR alpha resides constitutively in the cytoplasm, whereas PPAR gamma is predominantly nuclear localized. Transient transfection experiments indicate that PPAR alpha and PPAR gamma are transcriptionally active after ligand stimulation. Ligand activation of PPAR gamma, but not of PPAR alpha, results in apoptosis induction of unactivated differentiated macrophages as measured by the TUNEL assay and the appearance of the active proteolytic subunits of the cell death protease caspase-3. However, both PPAR alpha and PPAR gamma ligands induce apoptosis of macrophages activated with tumor necrosis factor alpha/interferon gamma. Finally, PPAR gamma inhibits the transcriptional activity of the NF kappa B p65/RelA subunit, suggesting that PPAR activators induce macrophage apoptosis by negatively interfering with the anti-apoptotic NF kappa B signaling pathway. These data demonstrate a novel function of PPAR in human macrophages with likely consequences in inflammation and atherosclerosis.	Inst Pasteur, INSERM, U325, Dept Atherosclerose, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Hop La Pitie Salpetriere, INSERM, U321, F-75651 Paris 13, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Staels, B (corresponding author), Inst Pasteur, INSERM, U325, Dept Atherosclerose, 1 Rue Calmette, F-59019 Lille, France.	Bart.Staels@pasteur-lille.fr	chinetti, giulia/Q-6901-2016; Staels, Bart/N-9497-2016	chinetti, giulia/0000-0001-8048-8138; Staels, Bart/0000-0002-3784-1503				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; AQEL NM, 1984, ATHEROSCLEROSIS, V53, P265, DOI 10.1016/0021-9150(84)90127-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bjorkerud S, 1996, AM J PATHOL, V149, P367; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508a0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frick MH, 1997, CIRCULATION, V96, P2137; GENG YJ, 1995, AM J PATHOL, V147, P251; GERRITY RG, 1979, AM J PATHOL, V95, P775; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Guyton John R., 1994, Current Opinion in Lipidology, V5, P376, DOI 10.1097/00041433-199410000-00010; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Mallat Z, 1997, CIRCULATION, V96, P424; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MINAMIKAWA J, 1909, J CLIN ENDOCR METAB, V83, P1041; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; MUNRO JM, 1988, LAB INVEST, V58, P249; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P9, DOI 10.1161/01.ATV.7.1.9; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROUIS M, 1990, ARTERIOSCLEROSIS, V10, P246, DOI 10.1161/01.ATV.10.2.246; Saitoh Kiyoshi, 1995, Folia Pharmacologica Japonica, V106, P41, DOI 10.1254/fpj.106.41; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	55	790	820	0	32	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25573	25580		10.1074/jbc.273.40.25573	http://dx.doi.org/10.1074/jbc.273.40.25573			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748221	hybrid			2022-12-25	WOS:000076263100012
J	Dickinson, JR; Harrison, SJ; Hewlins, MJE				Dickinson, JR; Harrison, SJ; Hewlins, MJE			An investigation of the metabolism of valine to isobutyl alcohol in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLE NITROGEN-SOURCE; CHAIN AMINO-ACIDS; DEHYDROGENASE COMPLEX; MITOCHONDRIAL; YEAST; CATABOLISM; HOMOLOGS; ECA39; GENE	The metabolism of valine to isobutyl alcohol in yeast was examined by C-13 nuclear magnetic resonance spectroscopy and combined gas chromatography-mass spectrometry, The product of valine transamination, alpha-ketoisovalerate, had four potential routes to isobutyl alcohol. The first, via branched-chain alpha-ketoacid dehydrogenase to isobutyryl-CoA is not required for the synthesis of isobutyl alcohol because abolition of branched-chain alpha-ketoacid dehydrogenase activity in an lpd1 disruption mutant did not prevent the formation of isobutyl alcohol. The second route, via pyruvate decarboxylase, is the one that is used because elimination of pyruvate decarboxylase activity in a pdc1 pdc5 pdc6 triple mutant virtually abolished isobutyl alcohol production. A third potential route involved alpha-ketoisovalerate reductase, but this had no role in the formation of isobutyl alcohol from alpha-hydroxyisovalerate because cell homogenates could not convert alpha-hydroxyisovalerate to isobutyl alcohol. The final possibility, use of the pyruvate decarboxylase-like enzyme encoded by YDL080c, seemed to be irrelevant, because a strain with a disruption in this gene produced wild-type levels of isobutyl alcohol. Thus there are major differences in the catabolism of leucine and valine to their respective "fusel" alcohols. Whereas in the catabolism of leucine to isoamyl alcohol the major route is via the decarboxylase encoded by YDL080c, any single isozyme of pyruvate decarboxylase is sufficient for the formation of isobutyl alcohol from valine, Finally, analysis of the C-13-labeled products revealed that the pathways of valine catabolism and leucine biosynthesis share a common pool of alpha-ketoisovalerate.	Univ Wales, Sch Pure & Appl Biol, Cardiff CF1 3TL, S Glam, Wales; Finnigan PLC, MassLab Grp, Manchester, Lancs, England; Univ Wales, Dept Chem, Cardiff CF1 3TB, S Glam, Wales	Cardiff University; Cardiff University	Dickinson, JR (corresponding author), Univ Wales, Sch Pure & Appl Biol, POB 915, Cardiff CF1 3TL, S Glam, Wales.							Bender D.A., 1975, AMINO ACID METABOLIS; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; DERRICK S, 1993, J GEN MICROBIOL, V139, P2783, DOI 10.1099/00221287-139-11-2783; DICKINSON JR, 1993, FEBS LETT, V326, P29, DOI 10.1016/0014-5793(93)81754-N; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; Dickinson JR, 1997, J BIOL CHEM, V272, P26871, DOI 10.1074/jbc.272.43.26871; DICKINSON JR, 1992, J GEN MICROBIOL, V138, P2029, DOI 10.1099/00221287-138-10-2029; Eden A, 1996, J BIOL CHEM, V271, P20242, DOI 10.1074/jbc.271.34.20242; Ehrlich F, 1907, BER DTSCH CHEM GES, V40, P1027, DOI 10.1002/cber.190704001156; HOHMANN S, 1991, J BACTERIOL, V173, P7963, DOI 10.1128/jb.173.24.7963-7969.1991; Kispal G, 1996, J BIOL CHEM, V271, P24458, DOI 10.1074/jbc.271.40.24458; Lanterman MM, 1996, HUM MOL GENET, V5, P1643, DOI 10.1093/hmg/5.10.1643; Large P. J., 1986, YEAST, V2, P1; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; Neubauer O, 1911, H-S Z PHYSIOL CHEM, V70, P326; NISHIMURA H, 1992, J BACTERIOL, V174, P4701, DOI 10.1128/JB.174.14.4701-4706.1992; REPETTO B, 1991, MOL CELL BIOL, V11, P3931, DOI 10.1128/MCB.11.8.3931; Sherman F, 1975, Methods Cell Biol, V11, P189, DOI 10.1016/S0091-679X(08)60323-4; SINCLAIR DA, 1995, GENETICS, V140, P1213; SINCLAIR DA, 1993, BIOCHEM MOL BIOL INT, V31, P911; ter Schure EG, 1998, APPL ENVIRON MICROB, V64, P1303; WEBB A. DINSMOOR, 1963, ADVAN APPL MICROBIOL, V5, P317, DOI 10.1016/S0065-2164(08)70014-5	22	134	180	0	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25751	25756		10.1074/jbc.273.40.25751	http://dx.doi.org/10.1074/jbc.273.40.25751			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748245	hybrid			2022-12-25	WOS:000076263100036
J	Didry, D; Carlier, MF; Pantaloni, D				Didry, D; Carlier, MF; Pantaloni, D			Synergy between actin depolymerizing factor cofilin and profilin in increasing actin filament turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ACANTHAMOEBA-CASTELLANII; PROTEIN; DYNAMICS; NUCLEOTIDE; BINDING; THYMOSIN-BETA-4; TROPOMYOSIN; ACTOPHORIN; MYOSIN	The mechanism of control of the steady state of actin assembly by actin depolymerizing factor (ADF)/cofilin and profilin has been investigated. Using TP, as an indicator of the concentration of ATP-G-actin, we show that ADF increases the concentration of ATP-G-actin at steady state. The measured higher concentration of ATP-G-actin is quantitatively consistent with the increase in treadmilling, caused by the large increase in the rate of depolymerization from the pointed ends induced by ADF (Carlier, M.-F., Laurent, V., Santolini, J., Didry, D., Melki, R., Xia, G.-X., Hong, Y., Chua, N.-H., and Pantaloni, D. (1997) J. Cell Biol. 136, 1307-1322). Experiments demonstrate that profilin synergizes with ADF to further enhance the turnover of actin filaments up to a value 125-fold higher than in pure F-actin solutions. Profilin and ADF act at the two ends of filaments in a complementary fashion to increase the processivity of treadmilling. Using the capping protein CapZ, we show that ADF increases the number of filaments at steady state by 1.3-fold, which cannot account for the 25-fold increase in turnover rate. Computer modeling of the combined actions of ADF and profilin on the dynamics of actin filaments using experimentally determined rate constants generates a distribution of the different actin species at steady state, which is in quantitative agreement with the data.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.							Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Bubb MR, 1998, CELL MOTIL CYTOSKEL, V39, P134, DOI 10.1002/(SICI)1097-0169(1998)39:2<134::AID-CM4>3.0.CO;2-6; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOPER JA, 1986, J BIOL CHEM, V261, P477; Doi M., 1989, THEORY POLYM DYNAMIC; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; Isambert H, 1996, MACROMOLECULES, V29, P1036, DOI 10.1021/ma946418x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; Manseau L, 1996, DEVELOPMENT, V122, P2109; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; Oosawa F., 1975, THERMODYNAMICS POLYM; PANTALONI D, 1984, J BIOL CHEM, V259, P6274; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; Perelroizen I., 1995, Molecular Biology of the Cell, V6, p142A; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866	31	164	169	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25602	25611		10.1074/jbc.273.40.25602	http://dx.doi.org/10.1074/jbc.273.40.25602			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748225	hybrid			2022-12-25	WOS:000076263100016
J	Dumortier, C; Holt, JM; Meyer, TE; Cusanovich, MA				Dumortier, C; Holt, JM; Meyer, TE; Cusanovich, MA			Imidazole binding to Rhodobacter capsulatus cytochrome c(2) - Effect of site-directed mutants on ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NETWORK; HORSE	Although ligand binding in c-type cytochromes is not directly related to their physiological function, it has the potential to provide valuable information on protein stability and dynamics, particularly in the region of the methionine sixth heme ligand and the nearby peptide chain that has been implicated in electron transfer. Thus, we have measured the equilibrium and kinetics of binding of imidazole to eight mutants of Rhodobacter capsulatus cytochrome c(2) that differ in overall protein stability. We found that imidazole binding affinity varies 70-fold, but does not correlate with overall protein stability. Instead, each mutant exerts an effect at the local level, with the largest change due to mutant G95E (glycine substituted by glutamate), which shows 30-fold stronger binding as compared with the wild-type protein. The kinetics of imidazole binding are monophasic and reach saturation at high ligand concentrations for all the mutants and wild-type protein, which is attributed to a rate limiting conformational change leading to breakage of the iron-methionine bond and providing a binding site for imidazole, The mutants show as much as an 18-fold variation in the first-order rate constant for the conformational change, with the largest effect found with mutant G95E, The kinetics also show a lack of correlation with overall protein stability, but are consistent with localized effects on the dynamics of hinge region 88-102 of the protein, which changes conformation to permit ligand binding. These results are consistent with R. capsulatus cytochrome c(2) stabilizing the complex through hydrogen bonding to the imidazole, The larger effects of mutant G95E on equilibrium and kinetics are likely to be due to its location within the hinge region adjacent to heme ligand methionine 96, which is displaced by imidazole.	Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	University of Arizona	Cusanovich, MA (corresponding author), Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD HL, 1994, ACTA CRYSTALLOGR D, V50, P596, DOI 10.1107/S0907444994001319; BENNING MM, 1991, J MOL BIOL, V220, P673, DOI 10.1016/0022-2836(91)90109-J; BERGHUIS AM, 1994, J MOL BIOL, V236, P786, DOI 10.1006/jmbi.1994.1189; Caffrey MS, 1997, PROTEIN ENG, V10, P77, DOI 10.1093/protein/10.1.77; CAFFREY MS, 1991, BIOCHEMISTRY-US, V30, P4119, DOI 10.1021/bi00231a002; CAFFREY MS, 1994, BBA-BIOENERGETICS, V1187, P277, DOI 10.1016/0005-2728(94)90001-9; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; FERRER JC, 1993, J AM CHEM SOC, V115, P7507, DOI 10.1021/ja00069a062; GOOLEY PR, 1991, EUR J BIOCHEM, V196, P653, DOI 10.1111/j.1432-1033.1991.tb15862.x; GOOLEY PR, 1992, BIOCHEMISTERY, V31, P433; KNAPP JA, 1974, BIOCHEMISTRY-US, V13, P1289, DOI 10.1021/bi00703a036; SCHEJTER A, 1969, BIOCHEMISTRY-US, V8, P149, DOI 10.1021/bi00829a021; SUTIN N, 1972, J BIOL CHEM, V247, P6932	13	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25647	25653		10.1074/jbc.273.40.25647	http://dx.doi.org/10.1074/jbc.273.40.25647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748230	hybrid			2022-12-25	WOS:000076263100021
J	Huang, C; Liu, JL; Haudenschild, CC; Zhan, X				Huang, C; Liu, JL; Haudenschild, CC; Zhan, X			The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-1; HEMATOPOIETIC-LINEAGE; SH2 DOMAINS; C-SRC; PROTEIN; ACTIN; IDENTIFICATION; ASSOCIATION; SUBSTRATE; KINASES	Cortactin, a filamentous actin cross-linking protein and a substrate of Src protein tyrosine kinase, is phosphorylated at tyrosine residues upon stimulation by extracellular signals. We have previously demonstrated that the filamentous actin cross-linking activity of cortactin is attenuated by Src (Huang, C., Ni, Y., Gao, Y., Haudenschild, C. C,, and Zhan, X. (1997) J. Biol Chem. 272, 13911-13915). In vitro, tyrosine phosphorylation of cortactin occurs specifically within the region between the proline-rich sequence and the Src homology 3 domain. Among the nine tyrosine residues in this region, mutations at Tyr(421), Tyr(466), and Tyr(482) significantly reduced Src-meditated tyrosine phosphorylation both in vitro and in vivo. Ectopic expression of wild-type cortactin in ECV304, a spontaneously transformed human umbilical endothelial cell line, resulted in an enhanced cell migration. In contrast, overexpression of a cortactin mutant deficient in tyrosine phosphorylation impaired the migration of endothelial cells. These findings reveal an intracellular signaling mechanism whereby the motility of endothelial cells is regulated by a Src-mediated tyrosine phosphorylation of cortactin.	Amer Red Cross, Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; George Washington Univ, Dept Anat & Cell Biol, Washington, DC 20037 USA; George Washington Univ, Dept Pathol, Washington, DC 20037 USA	American Red Cross; George Washington University; George Washington University	Zhan, X (corresponding author), Amer Red Cross, Holland Lab, Dept Expt Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	zhanx@usa.redcross.org	Christian, Haudenschild C/D-1602-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052753] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL52753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUNATI AM, 1995, EUR J BIOCHEM, V229, P164, DOI 10.1111/j.1432-1033.1995.0164l.x; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; MAA MC, 1992, ONCOGENE, V7, P2429; MARTINZANCA D, 1986, COLD SPRING HARB SYM, V51, P983, DOI 10.1101/SQB.1986.051.01.112; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang K, 1996, J BIOL CHEM, V271, P4304; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387; ZHAN X, 1993, J BIOL CHEM, V268, P24427; Zhan X, 1997, BLOOD, V89, P457, DOI 10.1182/blood.V89.2.457; ZHAN X, 1994, J BIOL CHEM, V269, P20221	31	234	243	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25770	25776		10.1074/jbc.273.40.25770	http://dx.doi.org/10.1074/jbc.273.40.25770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748248	hybrid			2022-12-25	WOS:000076263100039
J	Knox, C; Sass, E; Neupert, W; Pines, O				Knox, C; Sass, E; Neupert, W; Pines, O			Import into mitochondria, folding and retrograde movement of fumarase in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; ENDOPLASMIC-RETICULUM; TRANSLOCATION; MEMBRANE; BINDING; PRODUCT; FUM1	A single translation product of the FUM1 gene encoding fumarase is distributed between the cytosol and mitochondria of Saccharomyces cerevisiae. All fumarase translation products are targeted and processed in mitochondria before distribution. Here we show that targeting of fumarase is coupled to translation and initially involves insertion of the protein across the mitochondrial membranes and processing by the matrix protease, Rapid folding of fumarase may determine its requirement for coupling of its translocation with translation and unique route of distribution. The amino termini of most fumarase molecules are translocated across the mitochondrial membranes and processed. Unlike the in vivo situation where these molecules are released into the cytosol, in vitro they remain externally attached to the mitochondria, thereby positioned for release from the organelle. Our model suggests that fumarase displays a unique mechanism of targeting and distribution, which occurs cotranslationally and involves folding and retrograde movement of the processed protein back through the translocation pore.	Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel; Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	Hebrew University of Jerusalem; University of Munich	Pines, O (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel.	ophry@md2.huji.ac.il	pines, ophry/C-4086-2011	pines, ophry/0000-0001-7126-2575				ADES IZ, 1980, J BIOL CHEM, V255, P9918; Bandlow W, 1998, BIOCHEM J, V329, P359, DOI 10.1042/bj3290359; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HORNE DW, 1992, J NUTR, V122, P2204, DOI 10.1093/jn/122.11.2204; KANAREK L, 1964, J BIOL CHEM, V239, P2402; NELSON N, 1979, P NATL ACAD SCI USA, V76, P4365, DOI 10.1073/pnas.76.9.4365; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Pines O, 1996, APPL MICROBIOL BIOT, V46, P393, DOI 10.1007/s002530050835; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SHERMAN F, 1984, METHODS YEAST GENETI; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WU M, 1987, J BIOL CHEM, V262, P12275; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	27	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25587	25593		10.1074/jbc.273.40.25587	http://dx.doi.org/10.1074/jbc.273.40.25587			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748223	hybrid			2022-12-25	WOS:000076263100014
J	Lieste, JR; Koopman, WJH; Reynen, VCJ; Scheenen, WJJM; Jenks, BC; Roubos, ER				Lieste, JR; Koopman, WJH; Reynen, VCJ; Scheenen, WJJM; Jenks, BC; Roubos, ER			Action currents generate stepwise intracellular Ca2+ patterns in a neuroendocrine cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS CALCIUM OSCILLATIONS; XENOPUS-LAEVIS; INOSITOL TRISPHOSPHATE; MELANOTROPE CELLS; INTERMEDIATE PITUITARY; PROOPIOMELANOCORTIN BIOSYNTHESIS; BACKGROUND ADAPTATION; ELEMENTARY EVENTS; ACTION-POTENTIALS; EXCITABLE CELLS	It is believed that specific patterns of changes in the cytosolic-free calcium concentration ([Ca2+](i)) are used to control cellular processes such as gene transcription, cell proliferation, differentiation, and secretion. me recently showed that the Ca2+ oscillations in the neuroendocrine melanotrope cells of Xenopus laevis are built up by a number of discrete Ca2+ rises, the Ca2+ steps. The origin of the Ca2+ steps and their role in the generation of long-lasting Ca2+ patterns were unclear. By simultaneous, noninvasive measuring of melanotrope plasma membrane electrical activity and the [Ca2+](i), we show that numbers, amplitude, and frequency of Ca2+ steps are variable among individual oscillations and are determined by the firing pattern and shape of the action currents. The general Na+ channel blocker tetrodotoxin had no effect on either action currents or the [Ca2+](i). Under Na+-free conditions, a depolarizing pulse of 20 mM K+ induced repetitive action currents and stepwise increases in the [Ca2+](i). The Ca2+ channelblocker CoCl2 eliminated action currents and stepwise increases in the [Ca2+](i) in both the absence and presence of high K+. We furthermore demonstrate that the speed of Ca2+ removal from the cytoplasm depends on the [Ca2+](i), also between Ca2+ steps during the rising phase of an oscillation, It is concluded that Ca2+ channels, and not Na+ channels, are essential for the generation of specific step patterns and, furthermore, that the frequency and shape of Ca2+ action currents in combination with the Ca2+ removal rate determine the oscillatory pattern.	Catholic Univ Nijmegen, Inst Cellular Signaling, Dept Cellular Anim Physiol, NL-6525 ED Nijmegen, Netherlands; Catholic Univ Nijmegen, Nijmegen Inst Neurosci, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Jenks, BC (corresponding author), Catholic Univ Nijmegen, Inst Cellular Signaling, Dept Cellular Anim Physiol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.		Koopman, Werner J.H./AAC-9668-2020; Roubos, Eric W/D-1912-2010; Scheenen, Wim/E-3674-2012; Koopman, Werner J.H./D-3592-2009	Koopman, Werner J.H./0000-0002-5340-6747; Koopman, Werner J.H./0000-0002-5340-6747				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRADY KD, 1994, BIOPHYS J, V66, P1697, DOI 10.1016/S0006-3495(94)80961-0; CHAY TR, 1990, BIOL CYBERN, V63, P15, DOI 10.1007/BF00202449; CHAY TR, 1990, J THEOR BIOL, V142, P305, DOI 10.1016/S0022-5193(05)80555-7; Cheek TR, 1991, CURR OPIN CELL BIOL, V3, P199, DOI 10.1016/0955-0674(91)90139-P; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLDINGJORGENSEN M, 1992, J THEOR BIOL, V156, P309, DOI 10.1016/S0022-5193(05)80678-2; CORCUFF JB, 1993, J BIOL CHEM, V268, P22313; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dolphin AC, 1996, TRENDS NEUROSCI, V19, P35, DOI 10.1016/0166-2236(96)81865-0; Dotman CH, 1996, ENDOCRINOLOGY, V137, P4551, DOI 10.1210/en.137.11.4551; Dotman CH, 1997, NEUROENDOCRINOLOGY, V66, P106, DOI 10.1159/000127226; DOUGLAS WW, 1980, J PHYSIOL-LONDON, V309, P623, DOI 10.1113/jphysiol.1980.sp013530; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; GUERINEAU N, 1991, ENDOCRINOLOGY, V129, P40; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Helmchen F, 1997, BIOPHYS J, V72, P1458, DOI 10.1016/S0006-3495(97)78792-7; HILLE B, 1992, IONIC CHANNELS EXCIT, P59; JENKS BG, 1993, ZOOL SCI, V10, P1; Koopman WJH, 1997, CELL CALCIUM, V22, P167, DOI 10.1016/S0143-4160(97)90010-5; LI XY, 1995, BIOPHYS J, V69, P785; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MOLLARD P, 1989, BIOCHEM BIOPH RES CO, V164, P1045, DOI 10.1016/0006-291X(89)91775-0; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; PRESS WH, 1992, NUMEICAL RECIPES PAS; Roubos EW, 1997, COMP BIOCHEM PHYS A, V118, P533, DOI 10.1016/S0300-9629(97)00035-2; Sabatini BL, 1998, BIOPHYS J, V74, P1549, DOI 10.1016/S0006-3495(98)77867-1; SATIN LS, 1989, PFLUG ARCH EUR J PHY, V414, P1, DOI 10.1007/BF00585619; SCHEENEN WJJM, 1994, CELL CALCIUM, V15, P36, DOI 10.1016/0143-4160(94)90102-3; SCHEENEN WJJM, 1994, PFLUG ARCH EUR J PHY, V427, P244, DOI 10.1007/BF00374530; SCHEENEN WJJM, 1994, J NEUROENDOCRINOL, V6, P457, DOI 10.1111/j.1365-2826.1994.tb00607.x; Scheenen WJJM, 1996, CELL CALCIUM, V19, P219, DOI 10.1016/S0143-4160(96)90023-8; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SHIBUYA I, 1993, ENDOCRINOLOGY, V132, P2176, DOI 10.1210/en.132.5.2176; SHIBUYA I, 1993, ENDOCRINOLOGY, V132, P2166, DOI 10.1210/en.132.5.2166; Thorn P, 1996, EMBO J, V15, P999, DOI 10.1002/j.1460-2075.1996.tb00436.x; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; Valentijn JA, 1997, CELL CALCIUM, V21, P241, DOI 10.1016/S0143-4160(97)90048-8; WILLIAMS PJ, 1991, BRAIN RES, V564, P12, DOI 10.1016/0006-8993(91)91345-2; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	50	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25686	25694		10.1074/jbc.273.40.25686	http://dx.doi.org/10.1074/jbc.273.40.25686			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748236	hybrid			2022-12-25	WOS:000076263100027
J	Hammerle, M; Bauer, J; Rose, M; Szallies, A; Thumm, M; Dusterhus, S; Mecke, D; Entian, KD; Wolf, DH				Hammerle, M; Bauer, J; Rose, M; Szallies, A; Thumm, M; Dusterhus, S; Mecke, D; Entian, KD; Wolf, DH			Proteins of newly isolated mutants and the amino-terminal proline are essential for ubiquitin-proteasome-catalyzed catabolite degradation of fructose-1,6-bisphosphatase of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE; YEAST FRUCTOSE-1,6-BISPHOSPHATASE; MULTIFUNCTIONAL PROTEINASE; MALATE-DEHYDROGENASE; ISOCITRATE LYASE; LACZ FUSIONS; INACTIVATION; PHOSPHORYLATION; INVIVO; SITE	Addition of glucose to cells of the yeast Saccharomyces cerevisiae growing on a non-fermentable carbon source leads to selective and rapid degradation of fructose-1,6-bisphosphatase, This so called catabolite inactivation of the enzyme is brought about by the ubiquitin-proteasome system. To identify additional components of the catabolite inactivation machinery, we isolated three mutant strains, gid1, gid2, and gid3, defective in glucose-induced degradation of fructose-1,6-bisphosphatase, All mutant strains show in addition a defect in catabolite inactivation of three other gluconeogenic enzymes: cytosolic malate dehydrogenase, isocitrate lyase, and phosphoenolpyruvate carboxykinase, These findings indicate a common mechanism for the inactivation of all four enzymes. The mutants were also impaired in degradation of short-lived N-end rule substrates, which are degraded via the ubiquitin-proteasome system. Site-directed mutagenesis of the amino-terminal proline residue yielded fructose-1,6-bisphosphatase forms that were no longer degraded via the ubiquitin-proteasome pathway. All amino termini other than proline made fructose-1,6-bisphosphatase inaccessible to degradation. However, the exchange of the amino-terminal proline had no effect on the phosphorylation of the mutated enzyme. Our findings suggest an essential function of the amino-terminal proline residue for the degradation process of fructose-1,6-bisphosphatase. Phosphorylation of the enzyme was not necessary for degradation to occur.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany	University of Stuttgart; Goethe University Frankfurt; Eberhard Karls University of Tubingen	Wolf, DH (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.		Entian, Karl-Dieter/D-3080-2011; Thumm, Michael/A-8033-2015	Thumm, Michael/0000-0003-3238-4857				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; DIXON GH, 1959, BIOCHEM J, V72, P3; DUNTZE W, 1968, EUR J BIOCHEM, V3, P326, DOI 10.1111/j.1432-1033.1968.tb19533.x; ENTIAN KD, 1983, ARCH MICROBIOL, V134, P187, DOI 10.1007/BF00407756; Fink GR., 1970, METHODS ENZYMOL VOL, V17, P59, DOI DOI 10.1016/0076-6879(71)17167-4; FISCHER M, 1994, FEBS LETT, V355, P69, DOI 10.1016/0014-5793(94)01177-X; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; GANCEDO JM, 1971, ARCH MIKROBIOL, V76, P132, DOI 10.1007/BF00411787; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAARASILTA S, 1975, EUR J BIOCHEM, V52, P1, DOI 10.1111/j.1432-1033.1975.tb03966.x; HAGELE E, 1978, EUR J BIOCHEM, V83, P67, DOI 10.1111/j.1432-1033.1978.tb12069.x; HANSEN RJ, 1976, ANAL BIOCHEM, V74, P576, DOI 10.1016/0003-2697(76)90240-2; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOPEZBOADO YS, 1987, ARCH MICROBIOL, V147, P231, DOI 10.1007/BF00463480; MARCUS F, 1988, J BIOL CHEM, V263, P6058; MAZON MJ, 1982, J BIOL CHEM, V257, P1128; MULLER D, 1981, BIOCHEM BIOPH RES CO, V103, P926, DOI 10.1016/0006-291X(81)90899-8; MULLER M, 1981, J BIOL CHEM, V256, P723; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; ORDIZ I, 1995, FEBS LETT, V367, P219, DOI 10.1016/0014-5793(95)00538-K; POHLIG G, 1985, J BIOL CHEM, V260, P3818; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114; RITTENHOUSE J, 1986, J BIOL CHEM, V261, P3939; ROSE M, 1988, FEBS LETT, V241, P55, DOI 10.1016/0014-5793(88)81030-5; Sambrook J., 2002, MOL CLONING LAB MANU; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; SCHORK SM, 1994, NATURE, V369, P283, DOI 10.1038/369283a0; WITT I, 1966, BIOCHIM BIOPHYS ACTA, V128, P63, DOI 10.1016/0926-6593(66)90142-1; WOLFE RG, 1956, J BIOL CHEM, V221, P61; ZWEIMULLER M, 1990, THESIS J WOLFGANG GO	40	72	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25000	25005		10.1074/jbc.273.39.25000	http://dx.doi.org/10.1074/jbc.273.39.25000			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737955	hybrid			2022-12-25	WOS:000076085400005
J	Hoke, DE; Regisford, EGC; Julian, J; Amin, A; Begue-Kirn, C; Carson, DD				Hoke, DE; Regisford, EGC; Julian, J; Amin, A; Begue-Kirn, C; Carson, DD			Murine HIP/L29 is a heparin-binding protein with a restricted pattern of expression in adult tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UTERINE EPITHELIAL-CELLS; RIBOSOMAL-PROTEIN; SYNTHETIC PEPTIDE; SULFATE; SURFACE; ATTACHMENT; ELECTROPHORESIS; PURIFICATION; RESOLUTION; CLEAVAGE	Heparin/heparan sulfate (Hp/HS)-binding proteins are implicated in a variety of cell biological processes including cell adhesion, modulation of blood coagulation, and cytokine/growth factor action. Hp/HS-interacting protein (HIP) has been identified in various adult tissues in humans. HIP supports high affinity, selective binding to Hp/HS, promotes cell adhesion, and modulates blood coagulation activities via Hp/HS-dependent mechanisms. Herein, a murine ortholog of human HIP is described that is 78.8% identical to human HIP and 99.8% identical at the cDNA level and identical at the aminoacid level to a previously described murine ribosomal protein, L29, Western blot analyses and immunohistological staining with affinity-purified antibodies generated against two distinct peptide sequences of murine HIP/L29 indicate that HIP/L29 is differentially expressed in adult murine tissues and cell types. In the normal murine mammary epithelial cell line, NMuMG, HIP/L29 is enriched in the 100,000 x g particulate fraction. HIP/L29 can be solubilized from the 100,000 x g particulate fraction with 0.8 M NaCl, suggesting that it is a peripheral membrane protein. HIP/L29 directly binds I-125-Hp in gel overlay assays and requires 0.75 M NaCl for elution from Hp-agarose. In addition, recombinant murine HIP expressed in Escherichia coli binds Hp in a saturable and highly selective manner, compared with other glycosaminoglycans including dermatan sulfate, chondroitin sulfate, keratan sulfate, and hyaluronic acid. Collectively, these data indicate that murine HIP/L29, Like its human ortholog, is a Hp-binding protein expressed in a restricted manner in adult tissues.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Biol Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Carson, DD (corresponding author), Univ Delaware, Dept Biol Sci, 117 Wolf Hall, Newark, DE 19716 USA.		Kirn-Safran, Catherine/AAB-9089-2022		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025235, R37HD025235] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; CARSON DD, 1994, INT J BIOCHEM, V26, P1269, DOI 10.1016/0020-711X(94)90096-5; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FOX MG, 1997, DNA SEQUENCE, V7, P1235; GAYNOR JJ, 1997, INSECT BIOCHEM MOLEC, V27, P233; GIOVANNA P, 1991, MOL CELL BIOL, V11, P4796; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Jacobs AL, 1997, CANCER RES, V57, P5148; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law PTW, 1996, BBA-GENE STRUCT EXPR, V1305, P105, DOI 10.1016/0167-4781(95)00224-3; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; Liu SC, 1996, J BIOL CHEM, V271, P11817, DOI 10.1074/jbc.271.20.11817; Liu SC, 1998, J BIOL CHEM, V273, P9718, DOI 10.1074/jbc.273.16.9718; Liu SC, 1997, P NATL ACAD SCI USA, V94, P1739, DOI 10.1073/pnas.94.5.1739; Liu SC, 1997, J BIOL CHEM, V272, P25856, DOI 10.1074/jbc.272.41.25856; Marchetti D, 1997, J BIOL CHEM, V272, P15891, DOI 10.1074/jbc.272.25.15891; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; NOMUR M, 1992, TRENDS BIOCHEM SCI, V7, P92; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OSTVOLD AC, 1992, FEBS LETT, V298, P219, DOI 10.1016/0014-5793(92)80061-K; OTAKA E, 1983, MOL GEN GENET, V191, P519, DOI 10.1007/BF00425772; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; Rohde LH, 1996, J BIOL CHEM, V271, P11824, DOI 10.1074/jbc.271.20.11824; Rohde LH, 1998, BIOL REPROD, V58, P1075, DOI 10.1095/biolreprod58.4.1075; RUDERT F, 1993, GENE, V133, P249, DOI 10.1016/0378-1119(93)90647-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SVOBODA M, 1992, EUR J BIOCHEM, V203, P341, DOI 10.1111/j.1432-1033.1992.tb16555.x; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YUENLING C, 1993, BIOCHEM BIOPH RES CO, V192, P583	36	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25148	25157		10.1074/jbc.273.39.25148	http://dx.doi.org/10.1074/jbc.273.39.25148			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737974	hybrid			2022-12-25	WOS:000076085400024
J	Ruvolo, PP; Deng, XM; Carr, BH; May, WS				Ruvolo, PP; Deng, XM; Carr, BH; May, WS			A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; PROGRAMMED CELL-DEATH; ACTIVATES RAF-1; MEMBRANE; OVEREXPRESSION; SEQUENCE	Phosphorylation of Bc12 at serine 70 may result from activation of a classic protein kinase C (PKC) isoform and is required for functional suppression of apoptosis by Bcl2 in murine growth factor-dependent cell lines (Ito, T., Deng, X, Carr, B,, and May, W. S, (1997) J. Biol, Chem. 272, 11671-11673), Human pre-B REH cells ex press high levels of Bcl2 yet remain sensitive to the chemotherapeutic agents etoposide, cytosine arabinoside, and Adriamycin. In contrast, myeloid leukemia-derived HL60 cells express less than half the level of Bcl-2 but are >10-fold more resistant to apoptosis induced by these drugs, The mechanism responsible for this apparent dichotomy appears to involve a deficiency of mitochondrial PKC alpha since 1) HL60 but not REH cells contain highly phosphorylated Bcl2; 2) PKC alpha is the only classical isoform co-localized with Bcl2 in HL60 but not REH mitochondrial membranes; 3) the natural product and potent PKC activator bryostatin-1 induces mitochondrial localization of PKC alpha in association with Bcl2 phosphorylation and increased REH cell resistance to drug-induced apoptosis; 4) PKC alpha can directly phosphorylate wild-type but not phosphorylation-negative and loss of function S70A Bcl2 in vitro; 5) stable, forced expression of exogenous PKC alpha induces mitochondrial localization of PKC alpha, increased Bcl2 phosphorylation and a >10-fold increase in resistance to drug-induced cell death; and (6) PKC alpha-transduced cells remain highly sensitive to staurosporine, a potent PKC inhibitor. Furthermore, treatment of the PKC alpha transformants with bryostatin-1 leads to even higher levels of mitochondrial PKC alpha, Bcl2 phosphorylation, and REH cell survival following chemotherapy, While these findings strongly support a role for PKC alpha as a functional Bcl2 kinase that can enhance cell resistance to antileukemic chemotherapy, they do not exclude the possibility that another Bcl2 kinase(s) may also exist. Collectively, these findings identify a functional role for PKC alpha in Bcl2 phosphorylation and in resistance to chemotherapy and suggest a novel target for antileukemic strategies.	Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	May, WS (corresponding author), Univ Texas, Med Branch, Grad Sch Biomed Sci, Sch Med, 301 Univ Blvd, Galveston, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA047993, R01CA044649] Funding Source: NIH RePORTER; NCI NIH HHS [CA47993, CA44649] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAMPANA D, 1993, BLOOD, V81, P1025; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CoustanSmith E, 1996, BLOOD, V87, P1140, DOI 10.1182/blood.V87.3.1140.bloodjournal8731140; EARL DCN, 1965, BIOCHEM J, V94, P721, DOI 10.1042/bj0940721; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Ito T, 1996, NAT MED, V2, P403, DOI 10.1038/nm0496-403; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Legdeur MCJC, 1996, EXP HEMATOL, V24, P1530; LEWIN NE, 1992, BIOCHEM PHARMACOL, V43, P2007, DOI 10.1016/0006-2952(92)90644-X; MAY WS, 1994, J BIOL CHEM, V269, P26865; MURAKAMI T, 1995, CANCER RES, V55, P3093; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SOZERI O, 1992, ONCOGENE, V7, P2259; Volm M, 1997, MED PEDIATR ONCOL, V28, P117; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	25	395	405	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25436	25442		10.1074/jbc.273.39.25436	http://dx.doi.org/10.1074/jbc.273.39.25436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738012	hybrid			2022-12-25	WOS:000076085400062
J	Stayner, CK; Cunliffe, HE; Ward, TA; Eccles, MR				Stayner, CK; Cunliffe, HE; Ward, TA; Eccles, MR			Cloning and characterization of the human PAX2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-COLOBOMA SYNDROME; HUMAN FETAL KIDNEY; WILMS-TUMOR; TRANSCRIPTION FACTOR; GENOMIC STRUCTURE; GENE-PRODUCT; EXPRESSION; MUTATION; WT1; SEQUENCE	PAX2, a member of the PAX gene family of developmental transcription factors, is expressed at high levels in the developing eyes, ears, central nervous and urogenital systems, as well as in Wilms' tumor and renal cell carcinoma. Expression of PAX2 in the urogenital system is associated with proliferating cells of the ureteric bud and the differentiating nephrogenic mesenchyme. To date, little is known about the molecular mechanisms controlling the regulation of PAX2 expression. This report describes the cloning and characterization of the human PAX2 gene promoter and localization of the transcription start sites in fetal kidney and Wilms' tumor. We identified two transcription start sites in a Wilms' tumor sample, which were found to be different from that in fetal kidney. The activity of a deletion series of the PAX2 promoter was assessed in NIH-3T3, COS-7, 293, and Madin-Darby canine kidney cells. Although some differences were observed in the activity of each promoter construct, the profile of activity for the promoter fragment series was similar in each experiment, regardless of cell type. The WT1 tumor suppressor protein, which has previously been shown to repress murine Pax2 expression in vitro, was shown to also repress expression from the human PAX2 promoter.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand	University of Otago	Eccles, MR (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, New Zealand.							ANSUBEL FM, 1989, CURRENT PROTOCOLS MO; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHEN Z, 1996, TRENDS GENET, V12, P3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; ECCLES MR, 1995, AM J PATHOL, V146, P40; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; Feather SA, 1997, NEPHROL DIAL TRANSPL, V12, P1354, DOI 10.1093/ndt/12.7.1354; Fu WM, 1997, GENE DEV, V11, P2066, DOI 10.1101/gad.11.16.2066; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GNARRA JR, 1995, CANCER RES, V55, P4092; Groene Hermann-Josef, 1993, Journal of the American Society of Nephrology, V4, P465; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEPAGE P, 1993, CANCER RES, V53, P1657; Mahmoud MS, 1996, BIOCHEM BIOPH RES CO, V228, P159, DOI 10.1006/bbrc.1996.1632; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Narahara K, 1997, J MED GENET, V34, P213, DOI 10.1136/jmg.34.3.213; Natoli TA, 1997, DEVELOPMENT, V124, P617; NORNES HO, 1990, DEVELOPMENT, V109, P797; Okladnova O, 1997, GENOMICS, V42, P452, DOI 10.1006/geno.1997.4735; PILZ AJ, 1993, MAMM GENOME, V4, P78, DOI 10.1007/BF00290430; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; RYAN G, 1995, DEVELOPMENT, V121, P867; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sanyanusin P, 1996, GENOMICS, V35, P258, DOI 10.1006/geno.1996.0350; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SANYANUSIN P, 1995, HUM MOL GENET, V4, P2183, DOI 10.1093/hmg/4.11.2183; Schimmenti LA, 1997, AM J HUM GENET, V60, P869; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STUART ET, 1995, HUM MOL GENET, V4, P1717, DOI 10.1093/hmg/4.suppl_1.1717; STUART ET, 1993, ANNU REV GENET, V27, P219; Torres M, 1995, DEVELOPMENT, V121, P4057; Torres MA, 1996, DEVELOPMENT, V122, P3381; WARD TA, 1994, CELL GROWTH DIFFER, V5, P1015; Winyard PJD, 1996, J CLIN INVEST, V98, P451, DOI 10.1172/JCI118811	46	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25472	25479		10.1074/jbc.273.39.25472	http://dx.doi.org/10.1074/jbc.273.39.25472			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738017	hybrid			2022-12-25	WOS:000076085400067
J	Vasudevan, S; Tsuruo, T; Rose, DR				Vasudevan, S; Tsuruo, T; Rose, DR			Mode of binding of anti-P-glycoprotein antibody MRK-16 to its antigen - A Crystallographic and molecular modeling study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CRYSTAL-STRUCTURE; X-RAY; MULTIDRUG-RESISTANCE; 3-DIMENSIONAL STRUCTURES; MONOCLONAL-ANTIBODIES; CANONICAL STRUCTURES; PEPTIDE COMPLEX; PROTEIN; FAB	Monoclonal antibody MRK-16 recognizes a discontinuous extracellular epitope on the multidrug resistance-associated ATP-binding cassette transporter, P-glycoprotein. The atomic basis for specificity of this antibody is of interest because of its potential as a modulator of P-glycoprotein activity. The crystal structure of Fab MRK-16 is reported to a resolution of 2.8 Angstrom. A structure for a portion of the epitope was derived by comparison to regions of solved structures with similar primary sequence, This has permitted a proposal for the mode of binding of the peptide epitope to the antibody, in which the peptide makes specific contacts with complementarity-determining regions H1, H2, and H3 from the heavy chain and L3 from the light chain. These interactions are consistent with epitope mapping studies and with the observation that MRK-16 is specific for human class I P-glycoprotein, This result identifies side chains in MRK-16 that would be amenable to alteration in antibody engineering experiments to derive improved multidrug resistance inhibitors for clinical use during chemotherapy. In particular, Arg-H97 contacts both Glu-746 and Asp-744 of the peptide, Arg-L96 contacts Asp-743, and Thr-H33 interacts with Thr-747. All of these epitope residues were implicated in mediating specificity by epitope mapping studies.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 113, Japan	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tokyo	Rose, DR (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	drose@oci.utoronto.ca						AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOSCH I, 1996, BIOCHIM BIOPHYS ACTA, V1288, P37; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, XPLOR VERSION 3 1; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; Chan HSL, 1996, EUR J CANCER, V32A, P1051, DOI 10.1016/0959-8049(96)00085-8; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHURCHILL MEA, 1994, J MOL BIOL, V241, P534, DOI 10.1006/jmbi.1994.1530; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KABAT EA, 1979, NIH PUBLICATION; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI HY, 1995, ACTA CRYSTALLOGR D, V51, P21, DOI 10.1107/S0907444994009194; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OH BH, 1993, J BIOL CHEM, V268, P11348; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; ROQUET F, 1992, J MOL BIOL, V223, P705, DOI 10.1016/0022-2836(92)90985-S; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; STEHLE T, 1993, EUR J BIOCHEM, V211, P221, DOI 10.1111/j.1432-1033.1993.tb19889.x; SWAIN AL, 1989, J BIOL CHEM, V264, P16620; TSURUO T, 1989, JPN J CANCER RES, V80, P627, DOI 10.1111/j.1349-7006.1989.tb01688.x; vandenElsen JMH, 1997, PROTEINS, V29, P113; VASUDEVAN S, 1994, J MOL BIOL, V241, P736, DOI 10.1006/jmbi.1994.1548; VASUDEVAN S, 1996, CONFORMATIONAL FLEXI, P109; Watanabe T, 1997, J NATL CANCER I, V89, P512, DOI 10.1093/jnci/89.7.512; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709	57	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25413	25419		10.1074/jbc.273.39.25413	http://dx.doi.org/10.1074/jbc.273.39.25413			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738009	hybrid			2022-12-25	WOS:000076085400059
J	Chen, J; Ruley, HE				Chen, J; Ruley, HE			An enhancer element in the EphA2 (Eck) gene sufficient for rhombomere-specific expression is activated by HOXA1 and HOXB1 homeobox proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; NEURAL CREST MIGRATION; EMBRYONIC EXPRESSION; IN-VITRO; HINDBRAIN; LIGANDS; SEGMENTATION; GUIDANCE; PATTERN; FAMILY	In the hindbrain of the mouse embryo, there is often coincident rhombomere-restricted expression of Eph receptor tyrosine kinases and Hox homeobox genes, raising the possibility of regulatory interactions. In this paper, we have identified cis-acting regulatory sequences of the EphA2 (Ech) gene, which direct node and hindbrain-specific expression in transgenic embryos. An 8-kilobase region of mouse genomic DNA element was sufficient to drive rhombomere 4 (r4)-specific expression while conferring patchy expression in the node. Further analysis localized the rhombomere-specific enhancer to a 0.9-kilobase sequence. This element contains multiple Hox-Pbx consensus binding sites that bind to both HOXA1/Pbx1 and HOXB1/Pbx1 proteins in vitro. Go-expression of either HOXA1 or HOXB1 with Pbx1 transactivated EphA2 enhancer-dependent reporter gene expression. These results, together with observations of reduced EphA2 expression in hoxa1 and hoxb1 double mutant mice, suggest that expression of EphA2 gene in rhombomere 4 is directly regulated by Hoxa1 and Hoxb1 homeobox transcription factors.	Vanderbilt Univ, Sch Med, Dept Med Rheumatol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Immunol Microbiol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Med Rheumatol, A4323 Med Ctr N, Nashville, TN 37232 USA.	Jin.Chen@mcmail.vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	NCI NIH HHS [P30 CA68485] Funding Source: Medline; NHGRI NIH HHS [R01 HG00684] Funding Source: Medline; NIGMS NIH HHS [F32 GM17003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; Chen J, 1996, ONCOGENE, V12, P979; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FROHMAN MA, 1992, MECH DEVELOP, V38, P55, DOI 10.1016/0925-4773(92)90038-L; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GANJU P, 1994, ONCOGENE, V9, P1613; Gavalas A, 1998, DEVELOPMENT, V125, P1123; Goddard JM, 1996, DEVELOPMENT, V122, P3217; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Hogan B, 1994, MANIPULATING MOUSE E; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NIETO MA, 1992, DEVELOPMENT, V116, P1137; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; ROCCO DG, 1997, EMBO J, V16, P3644; RUIZ JC, 1994, MECH DEVELOP, V46, P87; Sasaki H, 1996, GENES CELLS, V1, P59, DOI 10.1046/j.1365-2443.1996.04004.x; Scherer CA, 1996, CELL GROWTH DIFFER, V7, P1393; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; Studer M, 1998, DEVELOPMENT, V125, P1025; Taneja R, 1996, DEV BIOL, V177, P397, DOI 10.1006/dbio.1996.0173; Theil T, 1998, DEVELOPMENT, V125, P443; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Xu QL, 1995, DEVELOPMENT, V121, P4005	39	87	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24670	24675		10.1074/jbc.273.38.24670	http://dx.doi.org/10.1074/jbc.273.38.24670			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733765	hybrid			2022-12-25	WOS:000076007300057
J	Lin, SW; Kochendoerfer, GG; Carroll, KS; Wang, D; Mathies, RA; Sakmar, TP				Lin, SW; Kochendoerfer, GG; Carroll, KS; Wang, D; Mathies, RA; Sakmar, TP			Mechanisms of spectral tuning in blue cone visual pigments - Visible and raman spectroscopy of blue-shifted rhodopsin mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE COUNTERION; CONGENITAL NIGHT BLINDNESS; HUMAN COLOR-VISION; BOVINE RHODOPSIN; RESONANCE RAMAN; WAVELENGTH REGULATION; RETINAL CHROMOPHORE; AMINO-ACIDS; WATER MOLECULE; GREEN	Spectral tuning by visual pigments involves the modulation of the physical properties of the chromophore (Il-cis-retinal) by amino acid side chains that compose the chromophore-binding pocket, We identified 12 amino acid residues in the human blue cone pigment that might induce the required green-to blue opsin shift. The simultaneous substitution of nine of these sites in rhodopsin (M86L, G90S, A117G, E122L, A124T, W265Y, A292S, A295S, and A299C) shifted the absorption maximum from 500 to 438 nn, accounting for 2,830 cm(-1), or 80%, of the opsin shift between rhodopsin and the blue cone pigment. Raman spectroscopy of mutant pigments shows that the dielectric character and architecture of the chromophore-binding pocket are specifically altered, An increase in the number of dipolar side chains near the protonated Schiff base of retinal increases the ground-excited state energy gap via long range dipole-dipole Coulomb interaction. In addition, the W265Y substitution causes a decrease in solvent polarizability near the chromophore ring structure. Finally, two substitutions on transmembrane helix 3 (A117G and E122L) act in combination with the other substitutions to alter the binding-pocket structure, resulting in stronger interaction of the protonated Schiff base group with the surrounding dipolar groups and the counterion, Taken together, these results identify the amino acid side chains and the underlying physical mechanisms responsible for a majority of the opsin shift in blue visual pigments.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Biol & Biochem, New York, NY 10021 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; Rockefeller University; University of California System; University of California Berkeley	Sakmar, TP (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Biol & Biochem, 1230 York Ave, New York, NY 10021 USA.	sakmar@rockvax.rockefeller.edu	Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953; Carroll, Kate/0000-0002-7624-9617				ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; ATON B, 1977, BIOCHEMISTRY-US, V16, P2995, DOI 10.1021/bi00632a029; BEPPU Y, 1994, PHOTOCHEM PHOTOBIOL, V59, P660; BIRGE RR, 1980, J AM CHEM SOC, V102, P2195, DOI 10.1021/ja00527a008; BIRGE RR, 1985, P NATL ACAD SCI USA, V82, P4117, DOI 10.1073/pnas.82.12.4117; BLATZ PE, 1972, BIOCHEMISTRY-US, V11, P848, DOI 10.1021/bi00755a026; BRUNGER AT, 1992, X PLOR; CHAN T, 1992, J BIOL CHEM, V267, P9478; Chang BSW, 1995, MOL PHYLOGENET EVOL, V4, P31, DOI 10.1006/mpev.1995.1004; CHIU MI, 1994, GENOMICS, V21, P440, DOI 10.1006/geno.1994.1292; DENG H, 1994, BIOPHYS J, V66, P1129, DOI 10.1016/S0006-3495(94)80893-8; Fahmy K, 1996, BIOCHEMISTRY-US, V35, P15065, DOI 10.1021/bi961486s; Fasick JI, 1998, BIOCHEMISTRY-US, V37, P433, DOI 10.1021/bi972500j; HAN M, 1993, BIOPHYS J, V65, P899, DOI 10.1016/S0006-3495(93)81117-2; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HONIG B, 1979, J AM CHEM SOC, V101, P7084, DOI 10.1021/ja00517a060; Hope AJ, 1997, P ROY SOC B-BIOL SCI, V264, P155, DOI 10.1098/rspb.1997.0023; IRVING CS, 1970, BIOCHEMISTRY-US, V9, P858, DOI 10.1021/bi00806a020; KAKITANI H, 1985, PHOTOCHEM PHOTOBIOL, V41, P471, DOI 10.1111/j.1751-1097.1985.tb03514.x; KLEINSCHMIDT J, 1992, P NATL ACAD SCI USA, V89, P9181, DOI 10.1073/pnas.89.19.9181; Kochendoerfer GG, 1997, BIOCHEMISTRY-US, V36, P6577, DOI 10.1021/bi970322o; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; LIN SW, 1994, BIOCHEMISTRY-US, V33, P2151, DOI 10.1021/bi00174a023; LIVNAH N, 1993, J AM CHEM SOC, V115, P351, DOI 10.1021/ja00054a054; LOPPNOW GR, 1989, P NATL ACAD SCI USA, V86, P1515, DOI 10.1073/pnas.86.5.1515; Lythgoe J.N., 1972, HDB SENSORY PHYSL, VVII/1, P604; Mathies R. A., 1987, BIOL APPLICATIONS RA, P59; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; MOTTO MG, 1980, J AM CHEM SOC, V102, P7947, DOI 10.1021/ja00547a029; Nagata T, 1997, BIOCHEMISTRY-US, V36, P6164, DOI 10.1021/bi962920t; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1011; PALINGS I, 1987, BIOCHEMISTRY-US, V26, P2544, DOI 10.1021/bi00383a021; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; Sun H, 1997, P NATL ACAD SCI USA, V94, P8860, DOI 10.1073/pnas.94.16.8860; THOMAS DD, 1982, J MOL BIOL, V154, P145, DOI 10.1016/0022-2836(82)90422-3; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; WANG ZY, 1993, BIOCHEMISTRY-US, V32, P2125, DOI 10.1021/bi00060a001; YOKOYAMA R, 1990, P NATL ACAD SCI USA, V87, P9315, DOI 10.1073/pnas.87.23.9315; YOSHIZAWA T, 1992, PHOTOCHEM PHOTOBIOL, V56, P859, DOI 10.1111/j.1751-1097.1992.tb09707.x; ZHANG HZ, 1994, J AM CHEM SOC, V116, P10165, DOI 10.1021/ja00101a040; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	51	114	114	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24583	24591		10.1074/jbc.273.38.24583	http://dx.doi.org/10.1074/jbc.273.38.24583			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733753	hybrid			2022-12-25	WOS:000076007300045
J	Nagano, F; Sasaki, T; Fukui, K; Asakura, T; Imazumi, K; Takai, Y				Nagano, F; Sasaki, T; Fukui, K; Asakura, T; Imazumi, K; Takai, Y			Molecular cloning and characterization of the noncatalytic subunit of the Rab3 subfamily-specific GTPase-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; CA2+-DEPENDENT EXOCYTOSIS; TARGET PROTEIN; PC12 CELLS; SMG P25A; PURIFICATION; RABPHILIN-3A; REGULATORS; EXPRESSION; TRANSPORT	We recently purified and characterized from rat brain a GTPase-activating protein (GAP) specific for the Rab3 small G protein subfamily implicated in Ca2+-dependent exocytosis. Rab3 GAP showed two bands with M-r of about 130,000 (p130) and 150,000 (p150) on SDS-polyacrylamide gel electrophoresis. p130, but not p150, showed the catalytic activity. Because p150 was likely the subunit of Rab3 GAP, here we cloned the cDNA of p150, determined its primary structure, and characterized it. The tissue and subcellular distribution patterns of p150 and p130 were similar, and both the proteins were enriched in the synaptic soluble fraction. p150 was co-immunoprecipitated with p130 from this fraction. Recombinant p150 formed a heterodimer with recombinant p130 as estimated by sucrose density gradient ultracentrifugation. Recombinant p150 neither showed the Rab3A GAP activity nor affected the activity of recombinant p130. When p150 and p130 were co-expressed in the cells, the subcellular localization of each protein did not change. These results indicate that p150 is the noncatalytic subunit of Rab3 GAP.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; STAHL B, 1994, J BIOL CHEM, V269, P24770; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1993, CIBA F SYMP, V176, P128; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; TOMBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; VOLLMER P, 1995, METHOD ENZYMOL, V257, P118; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875	32	52	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24781	24785		10.1074/jbc.273.38.24781	http://dx.doi.org/10.1074/jbc.273.38.24781			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733780	hybrid			2022-12-25	WOS:000076007300072
J	Pomerance, M; Multon, MC; Parker, F; Venot, C; Blondeau, JP; Tocque, B; Schweighoffer, F				Pomerance, M; Multon, MC; Parker, F; Venot, C; Blondeau, JP; Tocque, B; Schweighoffer, F			Grb2 interaction with MEK-kinase 1 is involved in regulation of Jun-kinase activities in response to epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASES; MAP KINASE; SIGNAL-TRANSDUCTION; SH3 DOMAIN; RAS; PATHWAY; STRESS; BINDS; PHOSPHORYLATION	Epidermal growth factor (EGF) receptor was shown to be involved in the activation pathway of the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) cascade not only by EGF, but also by UV radiation or osmotic stress. This paper describes a specific interaction between the COOH-terminal SH3 domain of Grb2 and the NH2-terminal regulatory domain of MEKK1 in ER22 cells overexpressing the EGF receptor. This interaction results in the formation of a constitutive complex between Grb2 and MEKK1 in both proliferating and resting cells. EGF stimulation causes this complex to be rapidly and transiently recruited by Shc proteins. The subsequent release of the Grb2-MEKK1 complex from Shc proteins correlates with JNK activation. Transfection of the NH2-terminal regulatory domain of MEKK1 specifically inhibits EGF-dependent JNK activation indicating that Grb2 is involved in MEKK1 activation. Thus, adaptor proteins have a new role in the regulation of the SAPK/JNK cascade after EGF stimulation.	Fac Pharm Chatenay Malabry, INSERM, U486, F-92296 Chatenay Malabry, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, F-94403 Vitry Sur Seine, France; Exonhit Therapeut, F-75013 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis; Sanofi France	Pomerance, M (corresponding author), Fac Pharm Chatenay Malabry, INSERM, U486, Tour D1,5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.		Blondeau, Jean-Paul/AAH-6395-2019	Blondeau, Jean-Paul/0000-0003-4520-6822				ANALFI M, 1997, J BIOL CHEM, V272, P27804; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SARDET C, 1991, J BIOL CHEM, V266, P19166; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798	37	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24301	24304		10.1074/jbc.273.38.24301	http://dx.doi.org/10.1074/jbc.273.38.24301			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733714	hybrid			2022-12-25	WOS:000076007300006
J	Wang, F; Gao, JX; Mimura, J; Kobayashi, A; Sogawa, K; Fujii-Kuriyama, Y				Wang, F; Gao, JX; Mimura, J; Kobayashi, A; Sogawa, K; Fujii-Kuriyama, Y			Structure and expression of the mouse AhR nuclear translocator (mArnt) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; GAMMA-SUBUNIT; CDNA CLONING; DNA-BINDING; RECEPTOR; SEQUENCE; ARNT; PROTEINS; MUSCLE; DROSOPHILA	Aryl hydrocarbon receptor (AhR) nuclear translocator (Amt) gene has been isolated and characterized from a mouse genomic DNA library. The gene is about 60 kilobases long and split into 22 exons, An unusual exon/intron junctional sequence was found in the 11th intron of the gene that begins with GC at its 5'-end, The exon/intron arrangement of mArnt gene differs greatly from those of the other members of the same basic-helix-loop-helix/PAS family. The gene is TATA-less and has several transcription start sites. The promoter region of the mArnt gene is GC-rich and contains a number of putative regulatory DNA sequences such as two GC-boxes, a cAMP-responsive element, E-box, AP-1 site, and CAAT-box. Deletion experiments revealed that all these DNA elements made substantial contributions to a high level of expression of the gene, except for the cAMP-responsive element. Of all, two GC-boxes displayed the most dominant enhancing effects. It was demonstrated that there exist specific factors binding to these DNA elements in the nuclear extracts of HeLa cells. Among them, Sp1 and Sp3, and CAAT-box binding factor-A were identified to bind the GC-boxes and CAAT-box, respectively. Expression of MyoD in HeLa cells stimulated the Amt promoter activity by binding to the E-box.	Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808578, Japan	Tohoku University	Fujii-Kuriyama, Y (corresponding author), Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808578, Japan.	ykfujii@mail.cc.tohoku.ac.jp	Kobayashi, Akira/AAN-8003-2020; Mimura, Junsei/E-7893-2013	Kobayashi, Akira/0000-0001-9727-1218				BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DODGSON JB, 1983, J BIOL CHEM, V258, P4623; Ema M, 1996, MOL CELL BIOL, V16, P5865; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; EMIN M, 1997, NATURE, V386, P403; FYRBERG EA, 1981, CELL, V24, P107, DOI 10.1016/0092-8674(81)90506-7; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOTOH O, 1993, COMPUT APPL BIOSCI, V9, P361; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; JUNSEI M, 1994, PHARMACOGENETICS, V4, P349; Kim IS, 1996, MOL CELL BIOL, V16, P4003; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; Luo G, 1997, GENE EXPRESSION, V6, P287; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; Motohashi H, 1996, GENES CELLS, V1, P223, DOI 10.1046/j.1365-2443.1996.d01-230.x; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NUMBERGER M, 1991, EMBO J, V10, P2957, DOI 10.1002/j.1460-2075.1991.tb07846.x; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; SHIBAHARA S, 1985, EUR J BIOCHEM, V146, P15, DOI 10.1111/j.1432-1033.1985.tb08614.x; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Sogawa K, 1997, J BIOCHEM, V122, P1075; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WATANABE N, 1993, EUR J BIOCHEM, V214, P521, DOI 10.1111/j.1432-1033.1993.tb17950.x	36	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24867	24873		10.1074/jbc.273.38.24867	http://dx.doi.org/10.1074/jbc.273.38.24867			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733792	hybrid			2022-12-25	WOS:000076007300084
J	Akhmedov, AT; Frei, C; Tsai-Pflugfelder, M; Kemper, B; Gasser, SM; Jessberger, R				Akhmedov, AT; Frei, C; Tsai-Pflugfelder, M; Kemper, B; Gasser, SM; Jessberger, R			Structural maintenance of chromosomes protein C-terminal domains bind preferentially to DNA with secondary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOME; SMC FAMILY; DROSOPHILA-MELANOGASTER; DOSAGE COMPENSATION; NUCLEAR SCAFFOLD; IN-VITRO; CONDENSATION; COMPLEX; GENE	Structural maintenance of chromosomes (SMC) proteins interact with DNA in chromosome condensation, sister chromatid cohesion, DNA recombination, and gene dosage compensation. How individual SMC proteins and their functional domains bind DNA has not been described. We demonstrate the ability of the C-terminal domains of Saccharomyces cerevisiae snarl and SMC2 proteins, representing two major subfamilies with different functions, to bind DNA in an ATP-independent manner. Three levels of DNA binding specificity were observed: I) a >100-fold preference for double-stranded vel-sus single-stranded DNA; 2) a high affinity for DNA fragments able to form secondary structures and for synthetic cruciform DNA molecules; and 3) a strong preference for AT-rich DNA fragments of particular types, These include fragments from the scaffold-associated regions, and an alternating poly(dT-dA)poly(dT-dA) synthetic polymer, as opposed to a variety of other polymers. Reannealing of complementary DNA strands is also promoted primarily by the C-terminal domains. Consistent with their in vitro DNA binding activity, we show that overexpression of the SMC C termini increases plasmid loss without altering viability or cell cycle progression.	Basel Inst Immunol, CH-4005 Basel, Switzerland; ISREC, CH-1066 Epalinges, Switzerland; Univ Cologne, Inst Genet, D-50674 Cologne, Germany	Swiss Institute Experimental Cancer Research; University of Cologne	Jessberger, R (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.	jessberger@bii.ch		Gasser, Susan/0000-0003-3610-9123				AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BASTIA D, 1996, MONOGRAPH, V31, P177; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; Golz S, 1997, EUR J BIOCHEM, V245, P573, DOI 10.1111/j.1432-1033.1997.00573.x; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Heck MMS, 1997, CELL, V91, P5, DOI 10.1016/S0092-8674(01)80002-7; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; KNIGHT KL, 1985, J BIOL CHEM, V260, P867; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Kupfer C, 1996, EUR J BIOCHEM, V238, P77, DOI 10.1111/j.1432-1033.1996.0077q.x; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Mussmann R, 1997, EUR J IMMUNOL, V27, P2610, DOI 10.1002/eji.1830271021; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; ROCQUES PJ, 1995, HUM MOL GENET, V4, P243, DOI 10.1093/hmg/4.2.243; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	44	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24088	24094		10.1074/jbc.273.37.24088	http://dx.doi.org/10.1074/jbc.273.37.24088			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727028	hybrid			2022-12-25	WOS:000075893100069
J	Chang, XB; Hou, YX; Riordan, JR				Chang, XB; Hou, YX; Riordan, JR			Stimulation of ATPase activity of purified multidrug resistance-associated protein by nucleoside diphosphates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER P-GLYCOPROTEIN; CONJUGATE EXPORT PUMP; MRP GENE; LEUKOTRIENE C-4; PHARMACOLOGICAL CHARACTERIZATION; ADENOSINE-TRIPHOSPHATASE; TRANSPORT; GLUTATHIONE; BINDING; OVEREXPRESSION	Membrane vesicles prepared from cells expressing the multidrug resistance-associated protein (MRP) transport glutathione S-conjugates of hydrophobic substrates in an ATP dependent manner. Purified MRP possesses ATPase activity which can be further stimulated by anticancer drugs or leukotriene C4. However, the detailed relationship between ATP hydrolysis and drug transport has not been established. How the ATPase activity of MRP is regulated in the cell is also not known, In this report, we have examined the effects of different nucleotides on the ATPase activity of purified MRP. We have found that pyrimidine nucleoside triphosphates have little effect on enzymatic activity. In contrast, purine nucleotides dATP, dGTP, and adenosine 5'-(beta,gamma-imido)triphosphate function as competitive inhibitors. Somewhat unexpectedly, low concentrations of all the nucleoside diphosphates (NDPs) tested, except UDP, stimulate the ATPase activity severalfold. ADP or GDP at higher concentrations was inhibitory, reflecting NDP binding to the substrate site. On the other hand, the enhancement of hydrolysis at low NDP concentrations must reflect interactions with a separate site. Therefore, we postulate the presence of at least two types of nucleotide binding sites on the MRP, a catalytic site(s) to which ATP preferentially binds and is hydrolyzed and a regulatory site to which NDPs preferentially bind and stimulate hydrolysis, Interestingly, the stimulatory effects of drugs transported by MRP and NDPs are not additive, i.e. drugs are not able to further stimulate the NDP-activated enzyme. Hence, the two activation pathways intersect at some point. Since both nucleotide binding domains of MRP are likely to be required for drug stimulation of ATPase activity, the two sites that we postulate may also involve both domains.	Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Chang, XB (corresponding author), Mayo Clin Scottsdale, SC Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.							ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GRANT CE, 1994, CANCER RES, V54, P357; Heijn M, 1997, BBA-BIOMEMBRANES, V1326, P12, DOI 10.1016/S0005-2736(97)00003-5; Hooijberg JH, 1997, FEBS LETT, V413, P344, DOI 10.1016/S0014-5793(97)00940-X; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; Jedlitschky G, 1996, CANCER RES, V56, P988; Keppler D, 1996, ADV ENZYME REGUL, V36, P17, DOI 10.1016/0065-2571(95)00011-9; KRUH GD, 1994, CANCER RES, V54, P1649; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Stride BD, 1996, MOL PHARMACOL, V49, P962; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1; Zhu QC, 1997, ONCOL RES, V9, P229	34	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23844	23848		10.1074/jbc.273.37.23844	http://dx.doi.org/10.1074/jbc.273.37.23844			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726996	hybrid			2022-12-25	WOS:000075893100037
J	Peterson, CL; Zhao, YM; Chait, BT				Peterson, CL; Zhao, YM; Chait, BT			Subunits of the yeast SWI/SNF complex are members of the actin-related protein (ARP) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MULTISUBUNIT COMPLEX; NUCLEOSOMAL DNA; GENE-PRODUCTS; BINDING; TRANSCRIPTION; ACTIVATOR; ENHANCEMENT; EXPRESSION; SWI2/SNF2	The yeast SWI/SNF chromatin remodeling complex is comprised of 11 tightly associated polypeptides (SWI1, SWI2, SWI3, SNF5, SNF6, SNF11, SWP82, SWP73, SWP59, SWP61, and SWP29), We have used matrix-assisted laser desorption ionization time-of-flight mass spectrometry to identify the genes that encode the SWP59 and SWP61 subunits. Surprisingly, we find that SWP59 and SWP61 are encoded by the ARP9 and ARP7 genes, respectively, which encode members of the actin-related protein (ARP) family. Sequence analyses have shown that ARP9 and ARP7 are 24-26% identical (48-51% similar) to yeast actin and that they are likely to maintain the overall actin fold. Deletion of either the ARP9 or ARP7 gene causes typical swi/snf phenotypes, including growth defects on media containing galactose, glycerol, or sucrose as sole carbon sources. ARP9 and ARP7 are also required for expression of an HO-lacZ fusion gene and for full transcriptional enhancement by the GAL4 activator. The identification of two ARP family members as crucial subunits of the SWI/SNF complex suggests that the complex may contain a total of three different ATPase subunits; furthermore, the similarity of ARP7 and ARP9 to the HSP and HSC family of ATPases suggests the possibility that chromatin remodeling by SWI/SNF may involve chaperone-like activities.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Rockefeller University	Peterson, CL (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, 373 Plantat st,Biotech 2,Suite 301, Worcester, MA 01605 USA.	craig.peterson@ummed.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049650, R37GM049650] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [R01 GM049650, GM49650-05, R37 GM049650] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Fenyo D, 1996, ANAL CHEM, V68, pA721, DOI 10.1021/ac9621579; Fenyo D, 1998, ELECTROPHORESIS, V19, P998, DOI 10.1002/elps.1150190615; Frankel S, 1996, CURR OPIN CELL BIOL, V8, P30, DOI 10.1016/S0955-0674(96)80045-7; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Jiang YW, 1996, GENE DEV, V10, P604, DOI 10.1101/gad.10.5.604; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Poch O, 1997, YEAST, V13, P1053, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1053::AID-YEA164>3.0.CO;2-4; Qin J, 1997, ANAL CHEM, V69, P3995, DOI 10.1021/ac970488v; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STILLMAN DJ, 1994, GENETICS, V136, P781; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TREICH I, 1995, MOL CELL BIOL, V15, P4240; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WEBER V, 1995, MOL BIOL CELL, V6, P1263, DOI 10.1091/mbc.6.10.1263	35	119	124	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23641	23644		10.1074/jbc.273.37.23641	http://dx.doi.org/10.1074/jbc.273.37.23641			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726966	Green Published, hybrid			2022-12-25	WOS:000075893100007
J	Schafer, C; Ross, SE; Bragado, MJ; Groblewski, GE; Ernst, SA; Williams, JA				Schafer, C; Ross, SE; Bragado, MJ; Groblewski, GE; Ernst, SA; Williams, JA			A role for the p38 mitogen-activated protein kinase Hsp 27 pathway in cholecystokinin-induced changes in the actin cytoskeleton in rat pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; TYROSINE PHOSPHORYLATION; IN-VITRO; C-FOS; CELLS; CASCADE; STRESS; CERULEIN	Cholecystokinin (CCK) and other pancreatic secretagogues have recently been shown to activate signaling kinase cascades in pancreatic acinar cells, leading to the activation of extracellular signal-regulated kinases and Jun N-terminal kinases. We now show the presence of a third kinase cascade activating p38 mitogen-activated protein (MAP) kinase in isolated rat pancreatic acini, CCK and osmotic stress induced by sorbitol activated p38 MAP kinase within minutes; their effects were dose-dependent, with maximal activation of 2.8- and 4.4-fold, respectively. The effects of carbachol and bombesin on p38 MAP kinase activity were similar to those of CCK, whereas phorbol eater, epidermal growth factor, and vasoactive intestinal polypeptide stimulated p38 MAP kinase by 8-fold or less. Both CCK and sorbitol also increased the tyrosyl phosphorylation of p38 MAP kinase. Using the specific inhibitor of p38 MAP kinase, SE 203580, we found that p38 MAP kinase activity was required for MAP kinase-activated protein kinase-a activation in pancreatic acini. SE 203580 reduced the level of basal phosphorylation and blocked the increased phosphorylation of Hsp 27 after stimulation with either CCK or sorbitol. CCK treatment induced an initial rapid decrease in total F-actin content of acini, followed by an increase after 40 min. Preincubation with SE 203580 significantly inhibited these changes in F-actin content. Staining of the actin cytoskeleton with rhodamine-conjugated phalloidin and analysis by confocal fluorescence microscopy showed disruption of the actin cytoskeleton after 10 and 40 min of CCK stimulation. Pretreatment with SE 203580 reduced these changes. These findings demonstrate that the activation of p38 MAP kinase is involved not only in response to stress, but also in physiological signaling by gastrointestinal hormones such as CCK, where activation of G(q)-coupled receptors stimulates a cascade in which pas MAP kinase activates MAP kinase-activated protein kinase-2, resulting in Hsp 27 phosphorylation. Activation of p38 MAP kinase, most likely through phosphorylation of Hsp 27, plays a role in the organization of the actin cytoskeleton in pancreatic acini.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Anat & Cell Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schafer, C (corresponding author), Univ Michigan, Dept Physiol, 7737 Med Sci 2, Ann Arbor, MI 48109 USA.	claussch@umich.edu	Bragado, M Julia/L-6988-2014	Bragado, M Julia/0000-0001-7770-0775; Williams, John/0000-0002-6063-7615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041122, R37DK041122, R01DK052860, P30DK034933] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 52860, DK 41122, DK 34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLERS A, 1994, BLOOD, V83, P1791; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bragado MJ, 1997, AM J PHYSIOL-CELL PH, V273, pC101, DOI 10.1152/ajpcell.1997.273.1.C101; Bragado MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG401, DOI 10.1152/ajpgi.1997.272.3.G401; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CONDEELIS J, 1991, METHOD ENZYMOL, V196, P486; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dabrowski A, 1997, AM J PHYSIOL-CELL PH, V273, pC1472, DOI 10.1152/ajpcell.1997.273.5.C1472; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DING G, 1991, AM J PHYSIOL, V260, pC9, DOI 10.1152/ajpcell.1991.260.1.C9; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Garcia LJ, 1997, BBA-MOL CELL RES, V1358, P189, DOI 10.1016/S0167-4889(97)00056-6; Groblewski GE, 1997, GASTROENTEROLOGY, V112, P1354, DOI 10.1016/S0016-5085(97)70149-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LOGSDON CD, 1986, AM J PHYSIOL, V250, pG440, DOI 10.1152/ajpgi.1986.250.4.G440; LU L, 1992, AM J PHYSIOL, V263, pG327, DOI 10.1152/ajpgi.1992.263.3.G327; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; OKONSKI MS, 1990, J CLIN INVEST, V86, P1649, DOI 10.1172/JCI114887; OKONSKI MS, 1993, PANCREAS, V8, P638, DOI 10.1097/00006676-199309000-00018; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Piotrowicz RS, 1997, J BIOL CHEM, V272, P25920, DOI 10.1074/jbc.272.41.25920; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHICK J, 1984, J CELL BIOL, V99, P1559; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SOLOMON TE, 1983, AM J PHYSIOL, V245, pG99, DOI 10.1152/ajpgi.1983.245.1.G99; SOLOMON TE, 1994, PHYSL GASTROINTESTIN, V2, P1499; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WILLIAMS JA, 1978, AM J PHYSIOL, V253, pE517; WILLIAMS JA, 1993, EXOCRINE PANCREAS, P167; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	57	136	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24173	24180		10.1074/jbc.273.37.24173	http://dx.doi.org/10.1074/jbc.273.37.24173			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727040	hybrid			2022-12-25	WOS:000075893100081
J	Smith, MF; Carl, VS; Lodie, T; Fenton, MJ				Smith, MF; Carl, VS; Lodie, T; Fenton, MJ			Secretory interleukin-1 receptor antagonist gene expression requires both a PU.1 and a novel composite NF-kappa B/PU.1/GA-binding protein binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; NF-KAPPA-B; NEUTROPHIL ELASTASE PROMOTER; FAMILY MEMBER PU.1; DOMAIN-DNA COMPLEX; IL-1 RECEPTOR; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; REGULATORY REGIONS; ETS ONCOGENE	The human secretory interleukin-1 receptor antagonist (secretory IL-1Ra) gene is controlled through three lipopolysaccharide (LPS)-responsive promoter elements, one of which was identified as an NF-kappa B binding site. Sequence analysis of the secretory IL-1Ra promoter identified a potential PU.1 binding site located between positions -80 and -90 on the complementary strand overlapping the NF-kappa B site. Gel shift analysis using this potential binding site with nuclear extracts from RAW 264.7 macrophages demonstrated the formation of three complexes, one LPS-inducible and two constitutive. The inducible factor was identified as NF-KB, and the constitutive factors were identified as PU.1 and GA-binding protein. Site-directed mutagenesis of the -93 to -79 promoter region demonstrated that mutation of either the NF-kappa B 5'-half site or the PU.1/GA-binding protein half-site alone did not significantly decrease LPS responsiveness. However, a mutation that disrupted the binding of all three factors resulted in a 50% decrease in LPS responsiveness. A second PU.1 binding site centered at -230 was identified by gel shift and supershift assays. Mutation of the core GGAA region resulted ill a 50% decrease in LPS-responsive promoter activity. Mutation of both the distal and proximal LPS response elements led to an almost complete loss of responsiveness. These data therefore suggest that the regulation of IL-1Ra gene expression is a complex event involving the interactions of three different transcription factors with a single cis-acting element and that the two PU.1 binding sites are the major response elements for LPS-induced IL-1Ra gene expression.	Univ Virginia, Hlth Sci Ctr, Dept Med, Div Gastroenterol, Charlottesville, VA 22908 USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA	University of Virginia; Boston University	Smith, MF (corresponding author), Div Gastroenterol & Hepatol, Lane Rd,Bldg MR4,Rm 1031, Charlottesville, VA 22908 USA.	mfs3k@virginia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034358, R01AI034358] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34358] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AREND WP, 1994, J IMMUNOL, V153, P4766; AREND WP, 1989, J IMMUNOL, V143, P1851; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURAS JA, 1995, MOL IMMUNOL, V32, P541, DOI 10.1016/0161-5890(95)00018-A; BUTCHER C, 1994, J IMMUNOL, V153, P701; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARELLO CA, 1991, BLOOD, V77, P1627; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; Gabay C, 1997, J CLIN INVEST, V99, P2930, DOI 10.1172/JCI119488; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; Guthridge CJ, 1997, MOL CELL BIOL, V17, P1118, DOI 10.1128/MCB.17.3.1118; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HROMAS R, 1993, BLOOD, V82, P2998; HUNNINGHAKE GW, 1992, MOL CELL BIOL, V12, P3439, DOI 10.1128/MCB.12.8.3439; Jenkins JK, 1997, J IMMUNOL, V158, P748; Kamura T, 1997, J BIOL CHEM, V272, P11361; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LENNARD AC, 1995, CRIT REV IMMUNOL, V15, P77, DOI 10.1615/CritRevImmunol.v15.i1.30; Lodie TA, 1997, J IMMUNOL, V158, P1848; Lodie TA, 1998, J IMMUNOL, V161, P268; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1990, CELL, V61, P1166, DOI 10.1016/0092-8674(90)90677-7; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHACKELFORD R, 1995, J IMMUNOL, V154, P1374; SMITH MF, 1994, J IMMUNOL, V153, P3584; SMITH MF, 1992, J IMMUNOL, V149, P2000; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WATANABE M, 1993, ONCOGENE, V8, P2949; ZAHEDI KA, 1994, CYTOKINE, V6, P1, DOI 10.1016/1043-4666(94)90001-9; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	53	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24272	24279		10.1074/jbc.273.37.24272	http://dx.doi.org/10.1074/jbc.273.37.24272			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727052	hybrid			2022-12-25	WOS:000075893100093
J	Hellqvist, M; Mahlapuu, M; Blixt, A; Enerback, S; Carlsson, P				Hellqvist, M; Mahlapuu, M; Blixt, A; Enerback, S; Carlsson, P			The human forkhead protein FREAC-2 contains two functionally redundant activation domains and interacts with TBP and TFIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-TFIIB; CO-CRYSTAL STRUCTURE; DNA-BINDING; ALVEOLAR RHABDOMYOSARCOMA; NUCLEAR-PROTEIN; FUSION PROTEIN; TATA-ELEMENT; MOUSE EMBRYO; HELIX; HEAD	Forkhead-related activator 2 (FREAC-2) is a human transcription factor expressed in lung and placenta that binds to cia-elements in several lung-specific genes. We have identified the parts of FREAC-2 responsible for trans-activation and found two functionally redundant activation domains on the C-terminal side of the DNA binding forkhead domain. Activation domain 1 consists of the most C-terminal 23 amino acids of FREAC-2 and contains a sequence motif conserved in an activation domain of another forkhead protein, FREAC-1. Activation domain 2 is built up by three synergistic subdomains in the central part of the FREAC-2 protein. FREAC-2 was shown to interact in vitro with TBP and TFIIB. The target site for FREAC-2 on TBP was localized to the N-terminal repeat in the core domain of TBP. TFIIB binds FREAC-2 close to the cleft between its two globular domains, The part of FREAC-2 that binds TBP was mapped to 21 amino acids in the C-terminal end of the forkhead domain. This sequence is well conserved among forkhead proteins, raising the possibility that interaction with TBP may be a general characteristic of this family of transcription factors. Overexpression of TFIIB potentiates activation by FREAC-2 in a manner dependent on the FREAC-2 activation domains, Nuclear localization of FREAC-2 was found to depend on sequences from both ends of the forkhead domain.	Univ Goteborg, Dept Mol Biol, S-40530 Goteborg, Sweden	University of Gothenburg	Carlsson, P (corresponding author), Univ Goteborg, Dept Mol Biol, Medicinaregatan 9C,Box 462, S-40530 Goteborg, Sweden.		Carlsson, Peter/B-5551-2008	Carlsson, Peter/0000-0001-6535-5927; Mahlapuu, Margit/0000-0001-8740-8874				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; [Anonymous], 1997, NATURE, V387, pS; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CADIGAN KM, 1994, P NATL ACAD SCI USA, V91, P6324, DOI 10.1073/pnas.91.14.6324; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Chang HW, 1996, ONCOGENE, V13, P441; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dou CL, 1997, NEURON, V18, P539, DOI 10.1016/S0896-6273(00)80296-2; Ernstsson S, 1997, GENOMICS, V46, P78, DOI 10.1006/geno.1997.4986; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; HACKER U, 1995, EMBO J, V14, P5306, DOI 10.1002/j.1460-2075.1995.tb00215.x; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; KAUFMANN E, 1995, J MOL BIOL, V248, P239, DOI 10.1006/jmbi.1995.0218; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Labosky PA, 1997, DEVELOPMENT, V124, P1263; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OSBORNE MA, 1993, ANNU REV BIOCHEM, V62, P219; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PIERROU S, 1995, ANAL BIOCHEM, V229, P99, DOI 10.1006/abio.1995.1384; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Schlake T, 1997, P NATL ACAD SCI USA, V94, P3842, DOI 10.1073/pnas.94.8.3842; Schuddekopf K, 1996, P NATL ACAD SCI USA, V93, P9661, DOI 10.1073/pnas.93.18.9661; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUBLETT JE, 1995, ONCOGENE, V11, P545; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	59	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23335	23343		10.1074/jbc.273.36.23335	http://dx.doi.org/10.1074/jbc.273.36.23335			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722567	hybrid			2022-12-25	WOS:000075778100067
J	Jeziorski, MC; Greenberg, RM; Clark, KS; Anderson, PAV				Jeziorski, MC; Greenberg, RM; Clark, KS; Anderson, PAV			Cloning and functional expression of a voltage-gated calcium channel alpha(1) subunit from jellyfish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED IONIC CURRENTS; DEPENDENT CA2+ CHANNELS; AMINO-ACID-RESIDUES; BAG CELL NEURONS; BETA-SUBUNIT; SKELETAL-MUSCLE; SODIUM-CHANNEL; 1,4-DIHYDROPYRIDINE SENSITIVITY; MOLECULAR DETERMINANTS; APLYSIA-CALIFORNICA	Voltage-gated Ca2+ channels in vertebrates comprise at least seven molecular subtypes, each of which produces a current with distinct kinetics and pharmacology. Although several invertebrate Ca2+ channel cu, subunits have also been cloned, their functional characteristics remain unclear, as heterologous expression of a full-length invertebrate channel has not previously been reported. We have cloned a cDNA encoding the cu, subunit of a voltage-gated Ca2+ channel from the scyphozoan jellyfish Cyanea capillata, one of the earliest existing organisms to possess neural and muscle tissue. The deduced amino acid sequence of this subunit, named CyCa alpha(1), is more similar to vertebrate L-type channels (alpha(1S), alpha(1C), and alpha(1D)) than to non-1-type channels (alpha(1A), alpha(1B), and alpha(1E)) or low voltage-activated channels (alpha(1G)) Expression of CyCa alpha(1) in Xenopus oocytes produces a high voltage-activated Ca2+ current that, unlike vertebrate L-type currents, is only weakly sensitive to 1,4-dihydropyridine or phenylalkylamine Ca2+ channel blockers and is not potentiated by the agonist S(-)-BayK: 8644. In addition, the channel is less permeable to Ba2+ than to Ca2+ and is more permeable to Sr2+. CyCa alpha(1) thus represents an ancestral L-type alpha(1) subunit with significant functional differences from mammalian L-type channels.	Univ Florida, Whitney Lab, St Augustine, FL 32086 USA; Univ Florida, Dept Physiol, St Augustine, FL 32086 USA; Univ Florida, Dept Neurosci, St Augustine, FL 32086 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Anderson, PAV (corresponding author), Univ Florida, Whitney Lab, 9505 Ocean Shore Blvd, St Augustine, FL 32086 USA.	paa@whitney.ufl.edu			NIMH NIH HHS [MH 10625] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON PAV, 1987, J EXP BIOL, V133, P231; ANDERSON PAV, 1987, J EXP BIOL, V133, P215; ANDERSON PAV, 1993, P NATL ACAD SCI USA, V90, P7419, DOI 10.1073/pnas.90.15.7419; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BLAIR KL, 1993, J EXP BIOL, V185, P267; Bourinet E, 1996, J NEUROSCI, V16, P4983; BRUSCA RC, 1990, INTERVETRATES; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; EHRLICH BE, 1988, P NATL ACAD SCI USA, V85, P5718, DOI 10.1073/pnas.85.15.5718; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GRABNER M, 1994, FEBS LETT, V339, P189, DOI 10.1016/0014-5793(94)80413-3; GRABNER M, 1994, J BIOL CHEM, V269, P23668; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HILLE B, 1992, IONIC CURRENTS EXCIT; HOLMAN MA, 1991, J EXP BIOL, V161, P333; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; Ito H, 1997, MOL PHARMACOL, V52, P735, DOI 10.1124/mol.52.4.735; Kimura T, 1997, BIOCHEM BIOPH RES CO, V230, P147, DOI 10.1006/bbrc.1996.5732; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUNG C, 1989, NATO ADV SCI I A-LIF, V188, P203; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MACKIE GO, 1985, NATURE, V313, P791, DOI 10.1038/313791a0; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Naitoh Y., 1982, P1; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; NERBONNE JM, 1987, J NEUROSCI, V7, P882; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRZYSIEZNIAK J, 1992, J NEUROSCI, V12, P2065; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; SHUBA YM, 1991, J PHYSIOL-LONDON, V443, P25, DOI 10.1113/jphysiol.1991.sp018820; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; Skeer JM, 1996, BIOL REV, V71, P137, DOI 10.1111/j.1469-185X.1996.tb00744.x; Smith LA, 1996, J NEUROSCI, V16, P7868; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1995, HDB RECEPTORS CHANNE, P113; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THULEAU P, 1994, EMBO J, V13, P2970, DOI 10.1002/j.1460-2075.1994.tb06595.x; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943; White BH, 1997, J NEUROSCI, V17, P1582; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1996, PFLUG ARCH EUR J PHY, V431, P470; ZHENG W, 1995, J NEUROSCI, V15, P1132	65	52	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22792	22799		10.1074/jbc.273.35.22792	http://dx.doi.org/10.1074/jbc.273.35.22792			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712913	hybrid			2022-12-25	WOS:000075616600089
J	Levy, O; De la Vieja, A; Ginter, CS; Riedel, C; Dai, G; Carrasco, N				Levy, O; De la Vieja, A; Ginter, CS; Riedel, C; Dai, G; Carrasco, N			N-linked glycosylation of the thyroid Na+/I- symporter (NIS) - Implications for its secondary structure model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NOREPINEPHRINE TRANSPORTER; AMINOBUTYRIC-ACID TRANSPORTER; MEMBRANE TOPOLOGY; ANTIPEPTIDE ANTIBODIES; IODIDE TRANSPORTER; CELLS; EXPRESSION	The Na+/I- symporter (NIS), a 618-amino acid membrane glycoprotein that catalyzes the active accumulation of I- into thyroid cells, was identified and characterized at the molecular level in our laboratory (Dai, G., Levy, O., and Carrasco, N. (1996) Nature 379, 458-460), Because mature MS is highly glycosylated, it migrates in SDS-polyacrylamide gel electrophoresis as a broad polypeptide of higher molecular mass (similar to 90-110 kDa) than nonglycosylated NIS (similar to 50 kDa), Using site-directed mutagenesis, we substituted both separately and simultaneously the asparagine residues in all three putative N-linked glycosylation consensus sequences of NIS with glutamine and assessed the effects of the mutations on function and stability of NIS in COS cells. All mutants were active and displayed 50-90% of wild-type NIS activity, including the completely nonglycosylated triple mutant. This demonstrates that to a considerable extent, function and stability of NIS are preserved in the partial or even total absence of N-linked glycosylation. We also found that Asn(225) is glycosylated, thus proving that the hydrophilic loop that contains this amino acid residue faces the extracellular milieu rather than the cytosol as previously suggested. We demonstrated that the NH, terminus faces extracellularly as well, A new secondary structure model consistent with these findings is proposed,	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Carrasco, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave,F-209, Bronx, NY 10461 USA.	carrasco@aecom.yu.edu	Carrasco, Nancy/AAH-1053-2019; De la Vieja, Antonio/I-4774-2013	Carrasco, Nancy/0000-0003-4137-6162; De la Vieja, Antonio/0000-0002-1187-1907; Riedel, Claudia/0000-0001-6168-8601	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041544] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-07218] Funding Source: Medline; NIDDK NIH HHS [DK-41544] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BRUSS M, 1995, J BIOL CHEM, V270, P9197; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Dai G, 1996, HDB BIOL PHYS, VII, P343; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Fujiwara H, 1997, NAT GENET, V16, P124, DOI 10.1038/ng0697-124; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; Levy O, 1998, J BIOENERG BIOMEMBR, V30, P195, DOI 10.1023/A:1020577426732; Levy O., 1997, CURR OPIN ENDOCRINOL, V4, P364, DOI DOI 10.1097/00060793-199710000-00008; Matsuda A, 1997, J CLIN ENDOCR METAB, V82, P3966, DOI 10.1210/jc.82.12.3966; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; Paire A, 1997, J BIOL CHEM, V272, P18245, DOI 10.1074/jbc.272.29.18245; Pohlenz J, 1997, BIOCHEM BIOPH RES CO, V240, P488, DOI 10.1006/bbrc.1997.7594; Pohlenz J, 1998, J CLIN INVEST, V101, P1028, DOI 10.1172/JCI1504; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867; WU JSR, 1994, BBA-BIOMEMBRANES, V1192, P289, DOI 10.1016/0005-2736(94)90131-7	23	154	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22657	22663		10.1074/jbc.273.35.22657	http://dx.doi.org/10.1074/jbc.273.35.22657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712895	hybrid			2022-12-25	WOS:000075616600071
J	Redell, JB; Tempel, BL				Redell, JB; Tempel, BL			Multiple promoter elements interact to control the transcription of the potassium channel gene, KCNJ2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; RNA POLYMERASE-II; DNA-BINDING; NF-Y; FACTOR AP-2; K+ CHANNEL; FUNCTIONAL EXPRESSION; FAMILY MEMBERS; SUBUNIT GENE; CPG ISLANDS	Potassium channels play important roles in shaping the electrical properties of excitable cells. Toward understanding the transcriptional regulation of a member of the inwardly rectifying potassium channel family, we have characterized the genomic structure and 5'-proximal promoter of the murine Kcnj2 gene (also referred to as IRK1 and Kir2.1). The Kcnj2 transcription unit is composed of two exons separated by a 5.5-kilobase pair intron. Deletion analysis of 5'-flanking sequences identified a promiscuously active 172-base pair minimal promoter, whereas expression from a construct containing additional upstream sequences was cell type-restricted. The minimal promoter contained an E box, a Y box, and three GC box consensus elements but lacked both TATA and CCAAT box elements. The activity of the minimal promoter was found to be controlled by a combination of the activities of the transcription factors Sp1, Sp3, and NF-Y. The interplay between Sp1, Sp3, and NF-Y within the architecture of the Kcnj2 promoter, the ubiquitous nature of these trans-acting factors, and the action of tissue selective repressor element(s) may combine to enable a wide variety of cell types to differentially regulate Kcnj2 expression through transcriptional control.	Univ Washington, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Tempel, BL (corresponding author), Univ Washington, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Box 357923, Seattle, WA 98195 USA.	tempel@u.washington.edu			NHLBI NIH HHS [HL44948] Funding Source: Medline; NIDCD NIH HHS [DC/NS02739] Funding Source: Medline; NIGMS NIH HHS [T32GM07270] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002739] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; ARKETT SA, 1994, RECEPTOR CHANNEL, V2, P281; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Bock JH, 1997, GENE, V188, P9, DOI 10.1016/S0378-1119(96)00759-7; BORDONARO M, 1994, BIOTECHNIQUES, V16, P428; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; Gan L, 1996, J BIOL CHEM, V271, P5859, DOI 10.1074/jbc.271.10.5859; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII K, 1994, FEBS LETT, V338, P107, DOI 10.1016/0014-5793(94)80126-6; KAMP TJ, 1995, CELL MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02089942; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; Kim DS, 1997, J BIOL CHEM, V272, P5098, DOI 10.1074/jbc.272.8.5098; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUBO T, 1995, CANCER RES, V55, P3860; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LATCHMAN DS, 1993, PRACTICAL APPROACH S; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MCLARNON JG, 1993, GLIA, V9, P120, DOI 10.1002/glia.440090205; Mi HY, 1996, J NEUROSCI, V16, P2421; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MORI Y, 1995, J BIOL CHEM, V270, P27788, DOI 10.1074/jbc.270.46.27788; MORI Y, 1993, J BIOL CHEM, V268, P26482; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SAKURA H, 1995, FEBS LETT, V367, P193, DOI 10.1016/0014-5793(95)00498-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Schoots O, 1997, GENOMICS, V39, P279, DOI 10.1006/geno.1996.4495; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; SHENG ZH, 1994, DNA CELL BIOL, V13, P9, DOI 10.1089/dna.1994.13.9; SIMONCINI L, 1990, DEV BIOL, V138, P194, DOI 10.1016/0012-1606(90)90189-P; Spauschus A, 1996, J NEUROSCI, V16, P930; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TAKIMOTO K, 1994, CIRC RES, V75, P1006, DOI 10.1161/01.RES.75.6.1006; Tanizawa Y, 1996, DIABETOLOGIA, V39, P447, DOI 10.1007/BF00400676; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; Wickman K, 1997, GENOMICS, V40, P395, DOI 10.1006/geno.1997.4599; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Wymore RS, 1996, J BIOL CHEM, V271, P15629, DOI 10.1074/jbc.271.26.15629; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	96	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22807	22818		10.1074/jbc.273.35.22807	http://dx.doi.org/10.1074/jbc.273.35.22807			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712915	hybrid			2022-12-25	WOS:000075616600091
J	Yuasa, T; Ohno, S; Kehrl, JH; Kyriakis, JM				Yuasa, T; Ohno, S; Kehrl, JH; Kyriakis, JM			Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38 - Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase kinase kinase upstream of MKK6 and p38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; C-JUN; CELL-DEATH; TERMINAL KINASE; TNF RECEPTOR-1; TRANSDUCTION PATHWAYS; CYTOPLASMIC DOMAIN; FACTOR-ALPHA; EXPRESSION; APOPTOSIS	Tumor necrosis factor (TNF) elicits a diverse array of inflammatory responses through engagement of its type-1 receptor (TNFR1). Many of these responses require de novo gene expression mediated by the activator protein-1 (AP-1) transcription factor. We investigated the mechanism by which TNFR1 recruits the stress-activated protein kinases (SAPKs) and the p38s, two mitogen-activated protein kinase (MAPK) families that together regulate AP-1. We show that the human SPS1 homologue germinal center kinase (GCK) can interact in vivo with the TNFR1 signal transducer TNFR-associated factor-2 (TRAF2) and with MAPK/ERK kinase kinase 1 (MEKK1), a MAPK kinase kinase (MAPKKK) upstream of the SAPKs, thereby coupling TRAF2 to the SAPKs. Receptor interacting protein (RIP) is a second TNFR1 signal transducer which can bind TRAF2. We show that RIP activates both p38 and SAPK; and that TRAF2 activation of p38 requires RIP. We also demonstrate that the RIP noncatalytic intermediate domain associates in vivo with an endogenous MAPKKK that can activate the p38 pathway in vitro. Thus, TRAF2 initiates SAPK and p38 activation by binding two proximal protein kinases: GCK and RIP. GCK and RIP, in turn, signal by binding MAPKKKs upstream of the SAPKs and p38s.	Massachusetts Gen Hosp E, Diabet Res Lab, Med Res Lab, Charlestown, MA 02129 USA; Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; NIAID, Cell Mol Immunol Sect B, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	Yokohama City University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kyriakis, JM (corresponding author), Massachusetts Gen Hosp E, Diabet Res Lab, Med Res Lab, 149 13th St, Charlestown, MA 02129 USA.	kyriakis@helix.mgh.harvard.edu	Yuasa, Takashi/B-2595-2010; Ohno, Shigeo/B-1768-2010; Kehrl, John/AAE-6292-2019	Ohno, Shigeo/0000-0002-1294-5269; Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577, R29GM046577] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46577] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAZZONI F, 1996, TUMOR NECROSIS FACTO, P1717; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han WH, 1997, NATURE, V386, P563, DOI 10.1038/386563a0; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SAMBROOK J, 1989, MOL CLONING LAB MANA; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	58	240	246	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22681	22692		10.1074/jbc.273.35.22681	http://dx.doi.org/10.1074/jbc.273.35.22681			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712898	hybrid			2022-12-25	WOS:000075616600074
J	Hitomi, M; Shu, JY; Agarwal, M; Agarwal, A; Stacey, DW				Hitomi, M; Shu, JY; Agarwal, M; Agarwal, A; Stacey, DW			p21(Waf1) inhibits the activity of cyclin dependent kinase 2 by preventing its activating phosphorylation	ONCOGENE			English	Article						prostaglandin A2; cyclin; cyclin dependent kinase; gadd45; gadd153; p27(Kip1); p21(Waf1); p53	GROWTH ARREST; POTENTIAL MEDIATOR; PROSTAGLANDIN A(2); CDK2 ACTIVITY; DNA-DAMAGE; P53; P21; P27(KIP1); GENE; CLONING	Prostaglandin A2 (PGA2), a potent inhibitor of the growth of many cell types, inhibits G1 phase cyclin dependent kinases (cdk). Although PGA2 suppresses cyclin D1 and elevates p21(Waf1) levels, it was the failure of cdk2 to become activated by phosphorylation which correlated best with growth inhibition. In kinetic studies, cdk2 activation was inhibited efficiently only if p21(Waf1) levels increased prior to the activating phosphorylation; suggesting that p21(Waf1) had blocked this phosphorylation. This model was confirmed in cells from p21(Waf1) knockout mice where PGA2 was completely unable to block the activating phosphorylation of cdk2, or inhibit cdk2 activity. As expected, growth inhibition of p21(Waf1-/-) cells was not observed at PGA2 concentrations which inhibited cdk2 activity and growth of p21Waf1-/- cells.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hitomi, M (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NIGMS NIH HHS [GM52271] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN TM, 1992, ONCOGENE, V7, P1541; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOWE PH, 1993, J BIOL CHEM, V268, P21448; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Maniatis T., 1982, MOL CLONING; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; PRICE BD, 1993, ONCOGENE, V8, P3055; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sambrook J., 1989, MOL CLONING; Shu JY, 1996, ONCOGENE, V13, P2421; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	41	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					959	969		10.1038/sj.onc.1202005	http://dx.doi.org/10.1038/sj.onc.1202005			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747875	Bronze			2022-12-25	WOS:000075560900004
J	Santoro, MM; Penengo, L; Minetto, M; Orecchia, S; Cilli, M; Gaudino, G				Santoro, MM; Penengo, L; Minetto, M; Orecchia, S; Cilli, M; Gaudino, G			Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor	ONCOGENE			English	Article						metastasis; Ron; signal transduction; tumorigenesis; tyrosine kinase	MACROPHAGE-STIMULATING PROTEIN; LIGAND-INDEPENDENT ACTIVATION; NEOPLASIA TYPE 2B; NIH 3T3 CELLS; C-KIT; CONSERVED FEATURES; RET PROTOONCOGENE; TRANSFORMING GENE; CATALYTIC DOMAIN; GROWTH	Ron (the receptor for Macrophage Stimulating Protein) has never been implicated before in human malignancies or in cell transformation. In this report we show that Ron can acquire oncogenic potential by means of two amino acid substitutions-D1232V and M1254T-affecting highly conserved residues in the tyrosine kinase domain, The same mutations in Kit and Pet have been found associated with two human malignancies, mastocytosis and Multiple Endocrine Neoplasia type 2B (MEN2B), respectively. Both mutations caused Ron-mediated transformation of 3T3 fibroblasts and tumour formation in nude mice. Moreover, cells transformed by the oncogenic Ron mutants displayed high metastatic potential. The Ron mutant receptors were constitutively active and the catalytic efficiency of the mutated kinase was higher than that of wild-type Ron. Oncogenic Ron mutants enhanced activation of the Ras/MAPK cascade with respect to wild type Ron, without affecting the JNK/SAPK pathway. Expression of Ron mutants in 3T3 fibroblasts led to different patterns of tyrosine-phosphorylated proteins. These data show that point mutations altering catalytic properties and possibly substrate specificity of the Ron kinase may force cells toward tumorigenesis and metastasis.	Univ Torino, Dipartimento Sci & Tecnol Avanzate, I-15100 Alessandria, Italy; Ist Sci San Raffaele, DIBIT, I-20138 Milan, Italy; Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, I-16132 Genoa, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Turin; Vita-Salute San Raffaele University; University of Genoa; IRCCS AOU San Martino IST	Gaudino, G (corresponding author), Univ Torino, Dipartimento Sci Med, Sede Novara,Via Solaroli 17, I-28100 Novara, Italy.		Cilli, Michele/AAB-8529-2019	PENENGO, Lorenza/0000-0001-7888-4473; SANTORO, Massimo Mattia/0000-0003-4605-5085; Cilli, Michele/0000-0003-4083-8986				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Banu N, 1996, J IMMUNOL, V156, P2933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Correll Pamela H., 1997, Genes and Function, V1, P69; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; del Peso L, 1997, ONCOGENE, V15, P3047; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SAWYERS CL, 1994, CELL, V77, P1; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STACEY DW, 1991, ONCOGENE, V6, P2297; TSUJIMURA T, 1994, BLOOD, V83, P2619; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493	49	81	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	1998	17	6					741	749		10.1038/sj.onc.1201994	http://dx.doi.org/10.1038/sj.onc.1201994			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715276	Green Submitted			2022-12-25	WOS:000075337200009
J	Berninsone, P; Hirschberg, CB				Berninsone, P; Hirschberg, CB			Heparan sulfate/heparin N-deacetylase/N-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SULFATE SULFOTRANSFERASE; EXPRESSION; PROTEIN; GENE; BIOSYNTHESIS; MOUSE	Glycosaminoglycan N-acetylglucosaminyl N-deacetylases/N-sulfotransferases are structurally related enzymes that play an important role in the biosynthesis of heparan sulfate and heparin. They are dual catalytic, single membrane-spanning polypeptides of approximately 850-880 amino acids that catalyze the N-deacetylation of N-acetylglucosamine of glycosaminoglycans followed by N-sulfation of the same sugar. On the basis of homologies of these proteins with other N-acetylglucosaminyl N-deacetylases involved in the biosynthesis of chitin and putative deacetylases from bacteria, we have constructed two soluble chimeras between protein A and the amino- and carboxyl-terminal halves of the above mastocytoma holoenzyme. The carboxyl-terminal chimera half (amino acids 479-880) was able to catalyze the N-sulfation of glucosamine of heparan sulfate with a similar affinity for its two substrates, adenosine 3'-phosphate 5'-phosphosulfate and heparan sulfate, as the holoenzyme. However, the reaction only occurred at 30 degrees C and not at 37 degrees C, both temperatures at which the holoenzyme was active. The V-max of the chimera was 10-20-fold slower than that of the holoenzyme. Soluble chimeras between protein A and amino acids 43-521 and 43-680 of the holoenzyme were unable to catalyze the N-deacetylation of the bacterial N-acetylglucosaminyl-glucuronic acid polymer K5 under conditions where the holoenzyme was active. The recent appearance in genome data banks of homologs to the N-sulfotransferase domain and now the direct demonstration that this domain catalyzes this reaction raises the possibility that both N-deacetylation and N-sulfation activities of the holoenzyme might have emerged as gene fusions during evolution.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, 700 Albany St, Boston, MA 02118 USA.			Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM34396] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAME KJ, 1991, J BIOL CHEM, V266, P12461; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; Christodoulidou A, 1996, J BIOL CHEM, V271, P31420, DOI 10.1074/jbc.271.49.31420; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; deSouza SJ, 1996, GENES CELLS, V1, P493, DOI 10.1046/j.1365-2443.1996.d01-264.x; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Gladwin AJ, 1996, GENOMICS, V32, P471, DOI 10.1006/geno.1996.0145; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P8005, DOI 10.1073/pnas.90.17.8005; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; MANDON E, 1994, J BIOL CHEM, V269, P11729; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; POWERS PA, 1991, GENETICS, V129, P133; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	20	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25556	25559		10.1074/jbc.273.40.25556	http://dx.doi.org/10.1074/jbc.273.40.25556			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748218	hybrid, Green Submitted			2022-12-25	WOS:000076263100009
J	Chae, YK; Abildgaard, F; Chapmann, ER; Markley, JL				Chae, YK; Abildgaard, F; Chapmann, ER; Markley, JL			Lipid binding ridge on loops 2 and 3 of the C(2)A domain of synaptotagmin I as revealed by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPID-BINDING; BACKBONE ASSIGNMENT; CALCIUM-DEPENDENCE; C-2 DOMAIN; SENSITIVITY; DROSOPHILA; EXOCYTOSIS; C-2-DOMAIN; RELEASE	The C(2)A domain of synaptotagmin I, which binds Ca2+ and anionic phospholipids, serves as a Ca2+ sensor during excitation-secretion coupling. We have used multidimensional NMR to locate the region of C(2)A from rat synaptotagmin I that interacts, in the presence of Ca2+, with phosphatidylserine. Untagged, recombinant C(2)A was double-labeled with C-13 and N-15, and triple-resonance NMR data were collected from C(2)A samples containing either Ca2+ alone or Ca2+ plus 6:0 phosphatidylserine. Phospholipid binding led to changes in chemical shifts of backbone atoms in residues Arg(233) and Phe(234) of loop 3 (a loop that also binds Ca2+) and His(198), Val(205), and Phe(206) of loop 2. These residues lie along a straight line on a surface ridge of the C(2)A domain. The only other residue that exhibited appreciable chemical shift changes upon adding lipid was His(254); however, because His(254) is located on the other side of the molecule from the phospholipid docking site defined by the other residues, its shifts may result from nonspecific interactions. The results show that the "docking ridge" responsible for Ca2+-dependent membrane association is localized on the opposite side of the C(2)A domain from the transmembrane and C2B domains of synaptotagmin.	Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil, Madison, WI 53706 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Markley, JL (corresponding author), Univ Wisconsin, Dept Biochem, Natl Magnet Resonance Facil, 433 Babcock Dr, Madison, WI 53706 USA.			Chapman, Edwin/0000-0001-9787-8140	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002781, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035976, R01GM035976] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02301, RR02781] Funding Source: Medline; NIGMS NIH HHS [GM35976] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Katz B., 1969, SHERRINGTON LECT; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; Markley JL, 1998, PURE APPL CHEM, V70, P117, DOI 10.1351/pac199870010117; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Mennerick S, 1996, NEURON, V17, P1241, DOI 10.1016/S0896-6273(00)80254-8; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1997, J BIOMOL NMR, V10, P307, DOI 10.1023/A:1018349601965; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Uellner R, 1997, EMBO J, V16, P7287, DOI 10.1093/emboj/16.24.7287; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P6464, DOI 10.1021/ja00093a069	44	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25659	25663		10.1074/jbc.273.40.25659	http://dx.doi.org/10.1074/jbc.273.40.25659			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748232	hybrid			2022-12-25	WOS:000076263100023
J	Raussens, V; Fisher, CA; Goormaghtigh, E; Ryan, RO; Ruysschaert, JM				Raussens, V; Fisher, CA; Goormaghtigh, E; Ryan, RO; Ruysschaert, JM			The low density lipoprotein receptor active conformation of apolipoprotein E - Helix organization in N-terminal domain-phospholipid disc particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; ONSET ALZHEIMER-DISEASE; AMYLOID-BETA-PEPTIDE; SECONDARY STRUCTURE; APOLIPOPHORIN-III; AQUEOUS-SOLUTION; BINDING DOMAIN; HYPERCHOLESTEROLEMIA; DIMYRISTOYLPHOSPHATIDYLCHOLINE; RECOMBINATION	Lipid association is a prerequisite for receptor interactions of apolipoprotein E (apoE), Disc complexes of the N-terminal 22-kDa apoE3 receptor binding domain and dimyristoylphosphatidylcholine display full receptor binding activity. Studies have been performed to characterize conformational adaptations of the globular, lipid-free four-helix bundle structure that culminate in stable association of its amphipathic alpha-helices with a lipid surface. Helix-lipid interactions in bilayer disc complexes can conceivably adopt two orientations: parallel or perpendicular to the phospholipid acyl chains. Evidence based on infrared dichroism, geometrical arguments, and x-ray crystallography support the view that defined helical segments in the four-helix bundle realign upon lipid association, orienting perpendicular to the phospholipid fatty acyl chains, circumscribing the bilayer disc. Thus, it is likely that paired helical segments align in tandem, presenting a convex receptor-active surface.	Univ Alberta, Dept Biochem, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium	University of Alberta; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Raussens, V (corresponding author), Univ Alberta, Dept Biochem, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada.			Goormaghtigh, Erik/0000-0002-2071-2262				AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; DERGUNOV AD, 1994, BIOL CHEM H-S, V375, P485; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; FRINGELI UP, 1981, MEMBRANE SPECTROSCOP, P270; Goormaghtigh E, 1996, APPL SPECTROSC, V50, P1519, DOI 10.1366/0003702963904610; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, V1, P285; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JONAS A, 1986, METHOD ENZYMOL, V128, P553; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; NELSON CA, 1974, ANAL BIOCHEM, V59, P69, DOI 10.1016/0003-2697(74)90010-4; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RAUSSENS V, 1995, J BIOL CHEM, V270, P12542, DOI 10.1074/jbc.270.21.12542; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; RYAN RO, 1990, J LIPID RES, V31, P871; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	33	85	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25825	25830		10.1074/jbc.273.40.25825	http://dx.doi.org/10.1074/jbc.273.40.25825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748256	hybrid			2022-12-25	WOS:000076263100047
J	Gasparini, S; Danse, JM; Lecoq, A; Pinkasfeld, S; Zinn-Justin, S; Young, LC; de Medeiros, CCL; Rowan, EG; Harvey, AL; Menez, A				Gasparini, S; Danse, JM; Lecoq, A; Pinkasfeld, S; Zinn-Justin, S; Young, LC; de Medeiros, CCL; Rowan, EG; Harvey, AL; Menez, A			Delineation of the functional site of alpha-dendrotoxin - The functional topographies of dendrotoxins are different but share a conserved core with those of other Kv1 potassium channel-blocking toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; DENDROASPIS-POLYLEPIS-POLYLEPIS; GATED K+ CHANNEL; ALANINE-SCANNING MUTAGENESIS; RESONANCE SOLUTION STRUCTURE; AMINO-ACID-SEQUENCES; BLACK MAMBA VENOM; SCORPION TOXINS; HIGH-AFFINITY; SEA-ANEMONE	We identified the residues that are important for the binding of alpha-dendrotoxin (alpha DTX) to Kv1 potassium channels on rat brain synaptosomal membranes, using a mutational approach based on site-directed mutagenesis and chemical synthesis. Twenty-six of its 59 residues were individually substituted by alanine. Substitutions of Lys(5) and Leu(9) decreased affinity more than 1000-fold, and substitutions of Arg(3), Arg(4), Leu(6), and Ile(8) by 5-30-fold. Substitution of Lys(5) by norleucine or ornithine also greatly altered the binding properties of alpha DTX. All of these analogs displayed similar circular dichroism spectra as compared with the wild-type alpha DTX, indicating that none of these substitutions affect the overall conformation of the toxin. Substitutions of Ser(38) and Arg(46) also reduced the affinity of the toxin but, in addition, modified its dichroic properties, suggesting that these two residues play a structural role. The other residues were excluded from the recognition site because their substitutions caused no significant affinity change. Thus, the functional site of alpha DTX includes six major binding residues, all located in its N-terminal region, with Lys5 and Leu(9) being the most important. Comparison of the functional site of alpha DTX with that of DTX-K, another dendrotoxin (Smith, L. A., Reid, P. F., Wang, F. C., Parcej, D. N., Schmidt, J. J., Olson, M. A, and Dolly, J. O. (1997) Biochemistry 36, 7690-7696), reveals that they only share the predominant lysine and probably a leucine residue; the additional functional residues differ from one toxin to the other. Comparison of the functional site of alpha DTX with those of structurally unrelated potassium channel-blocking toxins from venomous invertebrates revealed the common presence of a protruding key lysine with a close important hydrophobic residue (Leu, Tyr, or Phe) and few additional residues. Therefore, irrespective of their phylogenetic origin, all of these toxins may have undergone a functional convergence. The functional site of alpha DTX is topographically unrelated to the "antiprotease site" of the structurally analogous bovine pancreatic trypsin inhibitor.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Univ Strathclyde, Strathclyde Inst Drug Res, Dept Physiol & Pharmacol, Glasgow G1 1XW, Lanark, Scotland	CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Strathclyde	Menez, A (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Aguglia, Umberto/AAB-9898-2019	Aguglia, Umberto/0000-0002-4574-2951; Rowan, Edward/0000-0002-9960-3308	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; BERNDT KD, 1992, J MOL BIOL, V227, P757, DOI 10.1016/0022-2836(92)90222-6; BERNDT KD, 1993, J MOL BIOL, V234, P735, DOI 10.1006/jmbi.1993.1623; BLACK AR, 1986, BIOCHEM J, V237, P397, DOI 10.1042/bj2370397; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BYRNES ME, 1995, PROTEIN PEPTIDE LETT, V1, P239; CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C; CHANG KJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P294, DOI 10.1016/0005-2736(75)90011-5; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DANSE JM, 1994, FEBS LETT, V356, P153, DOI 10.1016/0014-5793(94)01235-0; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; Drakopoulou E, 1996, J BIOL CHEM, V271, P11979, DOI 10.1074/jbc.271.20.11979; ENDO T, 1991, SNAKE TOXINS, P259; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; HALL A, 1994, BRIT J PHARMACOL, V113, P659; Harvey A.L., 1991, P131; HARVEY AL, 1989, BIOCHEM BIOPH RES CO, V163, P394, DOI 10.1016/0006-291X(89)92148-7; HARVEY AL, 1980, N-S ARCH PHARMACOL, V312, P1, DOI 10.1007/BF00502565; Harvey AL, 1997, GEN PHARMACOL-VASC S, V28, P7, DOI 10.1016/S0306-3623(96)00173-5; HARVEY AL, 1993, MED RES REV, V13, P81, DOI 10.1002/med.2610130104; Harvey AL, 1997, TOXICON, V35, P1263, DOI 10.1016/S0041-0101(97)00016-0; HOKAMA Y, 1976, J BIOCHEM, V79, P559, DOI 10.1093/oxfordjournals.jbchem.a131100; HOUSSET D, 1991, J MOL BIOL, V220, P757, DOI 10.1016/0022-2836(91)90115-M; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; HURST RS, 1991, MOL PHARMACOL, V40, P572; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; JOUBERT FJ, 1980, H-S Z PHYSIOL CHEM, V361, P661, DOI 10.1515/bchm2.1980.361.1.661; JOUBERT FJ, 1978, EUR J BIOCHEM, V87, P191, DOI 10.1111/j.1432-1033.1978.tb12366.x; KASSELL B, 1965, BIOCHEM BIOPH RES CO, V18, P255, DOI 10.1016/0006-291X(65)90749-7; Kim M, 1997, J NEUROSCI, V17, P8213; KWONG PD, 1995, STRUCTURE, V3, P1109, DOI 10.1016/S0969-2126(01)00246-5; LANCELIN JM, 1994, NAT STRUCT BIOL, V1, P246, DOI 10.1038/nsb0494-246; LAZARENO S, 1982, BRIT J PHARMACOL, V77, pP571; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MENEZ A, 1990, BIOCHIMIE, V72, P575, DOI 10.1016/0300-9084(90)90121-V; MENEZ A, 1992, P ROY SOC EDINB B, V99, P83, DOI 10.1017/S0269727000013075; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Naini AA, 1996, BIOCHEMISTRY-US, V35, P6181, DOI 10.1021/bi960067s; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; Owen DG, 1997, BRIT J PHARMACOL, V120, P1029, DOI 10.1038/sj.bjp.0701004; Pennington MW, 1996, BIOCHEMISTRY-US, V35, P16407, DOI 10.1021/bi962463g; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; RITONJA A, 1983, BIOCHIM BIOPHYS ACTA, V746, P138, DOI 10.1016/0167-4838(83)90067-5; Robertson B, 1996, FEBS LETT, V383, P26, DOI 10.1016/0014-5793(96)00211-6; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; SCHWEITZ H, 1994, P NATL ACAD SCI USA, V91, P878, DOI 10.1073/pnas.91.3.878; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; Shon KJ, 1998, J BIOL CHEM, V273, P33, DOI 10.1074/jbc.273.1.33; SKARZYNSKI T, 1992, J MOL BIOL, V224, P671, DOI 10.1016/0022-2836(92)90552-U; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; STRYDOM DJ, 1981, H-S Z PHYSIOL CHEM, V362, P1377, DOI 10.1515/bchm2.1981.362.2.1377; STRYDOM DJ, 1977, BIOCHIM BIOPHYS ACTA, V491, P361, DOI 10.1016/0005-2795(77)90279-3; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; TUCHSEN E, 1987, BIOCHEMISTRY-US, V26, P1918, DOI 10.1021/bi00381a020; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; VITA C, 1995, P NATL ACAD SCI USA, V92, P6404, DOI 10.1073/pnas.92.14.6404; YU MH, 1995, J MOL BIOL, V249, P388, DOI 10.1006/jmbi.1995.0304	71	69	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25393	25403		10.1074/jbc.273.39.25393	http://dx.doi.org/10.1074/jbc.273.39.25393			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738007	hybrid			2022-12-25	WOS:000076085400057
J	Mathes, C; Fleig, A; Penner, R				Mathes, C; Fleig, A; Penner, R			Calcium release-activated calcium current (I-CRAC) is a direct target for sphingosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; CA-2+-ACTIVATED K+ CHANNEL; INTRACELLULAR CA2+ STORES; PAROTID ACINAR-CELLS; SMOOTH-MUSCLE CELLS; MAST-CELLS; FATTY-ACIDS; CELLULAR PROLIFERATION; INOSITOL TRISPHOSPHATE	Whole cell patch-clamp recordings were made to study the regulation of the store-operated calcium release-activated calcium current (I-CRAC) by metabolites involved in the sphingomyelin pathway in RBL-2H3 cells. Sphingosine, a regulator of cell growth, inhibits I-CRAC completely within 200 s and independently from conversion to either sphingosine 1-phosphate or ceramide, Structural analogs of sphingosine, including N,N-dimethylsphingosine, DL-threo-dihydrosphingosine, and N-acetylsphingosine (C-2-ceramide) also block I-CRAC. This effect is always accompanied by an elevation of whole cell membrane capacitance. These sphingolipids appear, therefore, to accumulate in the plasma membrane and directly block I,, channels, Sphingosylphosphorylcholine also increases capacitance but does not inhibit I-CRAC, demonstrating structural specificity and that the elevation of capacitance is necessary but not sufficient for block. Nerve growth factor, which is known to break down sphingomyelin, inhibits I-CRAC and this inhibition can be antagonized by reducing sphingosine production with L-cycloserine, suggesting that I-CRAC is a physiologically relevant and direct target of sphingosine. We propose that sphingosine directly blocks I-CRAC suggesting that the sphingomyelin pathway is involved in I-CRAC regulation.	Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Max Planck Society	Penner, R (corresponding author), Univ Hawaii, Biomed Sci Bldg A-201,1960 East West Rd, Honolulu, HI 96822 USA.	rpenner@hawaii.edu		Fleig, Andrea/0000-0001-8396-7249; Penner, Reinhold/0000-0002-5366-1537				BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CHOI OH, 1993, J IMMUNOL, V151, P5586; Choi OH, 1996, NATURE, V380, P634; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Fatatis A, 1996, J BIOL CHEM, V271, P295, DOI 10.1074/jbc.271.1.295; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FLEIG A, 1995, J PHYSIOL-LONDON, V489, P41, DOI 10.1113/jphysiol.1995.sp021028; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; GRABBE J, 1994, ARCH DERMATOL RES, V287, P78, DOI 10.1007/BF00370723; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; HORIGOME K, 1994, J BIOL CHEM, V269, P2695; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HOTH M, 1993, ANN NY ACAD SCI, V70, P198; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; HUDSON PL, 1994, J BIOL CHEM, V269, P21885; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; MACKINNON R, 1989, BIOCHEMISTRY-US, V28, P8092, DOI 10.1021/bi00446a020; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MOCZYDLOWSKI E, 1985, J MEMBRANE BIOL, V83, P273, DOI 10.1007/BF01868701; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; Oral H, 1997, J BIOL CHEM, V272, P4836, DOI 10.1074/jbc.272.8.4836; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; Orlati S, 1996, CELL CALCIUM, V20, P399, DOI 10.1016/S0143-4160(96)90002-0; PANDOL SJ, 1994, BBA-BIOMEMBRANES, V1195, P45, DOI 10.1016/0005-2736(94)90007-8; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETROU S, 1994, J GEN PHYSIOL, V103, P471, DOI 10.1085/jgp.103.3.471; PITTET D, 1987, J BIOL CHEM, V262, P10072; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Sakano S, 1996, J BIOL CHEM, V271, P11148, DOI 10.1074/jbc.271.19.11148; SCHMITT H, 1995, J MEMBRANE BIOL, V145, P233; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Spiegel S, 1996, CHEM PHYS LIPIDS, V80, P27, DOI 10.1016/0009-3084(96)02543-1; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; SUGIYA H, 1990, CELL CALCIUM, V11, P469, DOI 10.1016/0143-4160(90)90079-A; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; WANG E, 1991, J BIOL CHEM, V266, P14486; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	56	102	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25020	25030		10.1074/jbc.273.39.25020	http://dx.doi.org/10.1074/jbc.273.39.25020			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737958	hybrid			2022-12-25	WOS:000076085400008
J	Cao, TT; Mays, RW; von Zastrow, M				Cao, TT; Mays, RW; von Zastrow, M			Regulated endocytosis of G-protein-coupled receptors by a biochemically and functionally distinct subpopulation of clathrin-coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; TRANSFERRIN RECEPTORS; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; INTERNALIZATION; MEMBRANE; DYNAMIN; RESENSITIZATION; SEQUESTRATION; BIOGENESIS	beta-2 Adrenergic receptors (B2ARs) are endocytosed by clathrin coated pits. This process serves specialized functions in signal transduction and receptor regulation, raising the question of whether B2ARs are associated with biochemically specialized membrane vesicles during their endocytic trafficking. Here we show that B2ARs are endocytosed by a distinct subpopulation of clathrin-coated pits, which represent a limited subset of coated pits present in the plasma membrane, even in cells overexpressing both B2ARs and p-arrestin. Coated pits mediating agonist-induced endocytosis of B2ARs differ from other coated pits mediating constitutive endocytosis of transferrin receptors in their temperature dependence for fission from the plasma membrane and in the association of their membrane coats with p-arrestin. Endocytosis of these coated pits generates endocytic vesicles selectively enriched in B2ARs, which fuse within similar to 10 min after their formation with a common population of endosomes containing both B2ARs and transferrin receptors. These observations demonstrate, for the first time, the existence of a functionally and biochemically distinct subpopulation of clathrin-coated pits that mediate the agonist-regulated endocytosis of G-protein-coupled receptors, and they suggest a new model for the formation of compositionally specialized membrane vesicles at the earliest stage of the endocytic pathway.	Univ Calif San Francisco, Nina Ireland Lab, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	von Zastrow, M (corresponding author), Univ Calif San Francisco, Nina Ireland Lab, Cell Biol Program, Rm LP-A104,401 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008120] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00218] Funding Source: Medline; NIGMS NIH HHS [T32GM08120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CARPENTIER JL, 1982, J CELL BIOL, V95, P73, DOI 10.1083/jcb.95.1.73; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; Krueger KM, 1997, J BIOL CHEM, V272, P5; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WHITE S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P28, DOI 10.1016/0167-4889(92)90081-L; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	28	117	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24592	24602		10.1074/jbc.273.38.24592	http://dx.doi.org/10.1074/jbc.273.38.24592			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733754	hybrid			2022-12-25	WOS:000076007300046
J	Cronin, CN				Cronin, CN			Redesign of choline acetyltransferase specificity by protein engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SUBSTRATE-SPECIFICITY; COENZYME SPECIFICITY; CONVERTING TRYPSIN; CARNITINE; DEHYDROGENASE; SEQUENCE; CHYMOTRYPSIN; EXPRESSION; BINDING	Since the development of site-directed mutagenesis techniques over 15 years ago (Zoller, M.J,, and Smith, M, (1982) Nucleic Acids Res. 10, 6487-6500), it has been a goal of protein engineering to utilize the procedure to redesign existing enzyme structures to produce proteins with altered or novel catalytic properties. To date, however, the more successful achievements have relied exclusively on the availability of three-dimensional protein structure maps to direct the redesign strategies. Presently, such maps are unavailable for choline acetyltransferase and carnitine acetyltransferase, enzymes that catalyze the reversible transfer of an acetyl group from acetyl-CoA to choline and L-carnitine, respectively. A more empirical approach, based on cross-referencing substrate structure comparisons with protein alignment data, was used to redesign choline acetyltransferase to accommodate L-carnitine as an acceptor of the acetyl group. A mutant choline acetyltransferase that incorporates four amino acid substitutions from wild type, shows a substantial increase in catalytic efficiency (k(cat)/K-m) toward L-carnitine (1,620-fold) and shifts the catalytic discrimination between choline and L-carnitine by >390,000 in favor of the latter substrate. These dramatic alterations in catalytic function demonstrate that significant success in protein redesign can be achieved in the absence of three-dimensional protein structure data.	Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Cronin, CN (corresponding author), Vet Affairs Med Ctr, Div Mol Biol, Mail Stop 151-S,4150 Clement St, San Francisco, CA 94121 USA.	ciaran@itsa.ucsf.edu			NHLBI NIH HHS [HL16251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bergman J., 1988, STUDIES NATURAL PR A, V1, P3; BLOISI W, 1990, EUR J BIOCHEM, V189, P539, DOI 10.1111/j.1432-1033.1990.tb15520.x; BRADLEY M, 1991, BIOCHEMISTRY-US, V30, P6124, DOI 10.1021/bi00239a006; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; BROWN NF, 1994, J BIOL CHEM, V269, P19157; CARBINI LA, 1993, J NEUROCHEM, V61, P247, DOI 10.1111/j.1471-4159.1993.tb03561.x; CHASE JFA, 1966, BIOCHEM J, V99, P32, DOI 10.1042/bj0990032; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Cronin CN, 1997, BIOCHEM BIOPH RES CO, V238, P784, DOI 10.1006/bbrc.1997.7390; Cronin CN, 1997, BIOCHEM BIOPH RES CO, V241, P803, DOI 10.1006/bbrc.1997.7865; Cronin CN, 1997, EUR J BIOCHEM, V247, P1029, DOI 10.1111/j.1432-1033.1997.01029.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIXON M, 1979, ENZYMES, P88; FEENEY R, 1990, BIOCHEM BIOPH RES CO, V166, P667, DOI 10.1016/0006-291X(90)90861-G; GANDOUR RD, 1985, BIOORG CHEM, V13, P197, DOI 10.1016/0045-2068(85)90022-7; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8764, DOI 10.1021/bi00195a018; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HERSH LB, 1982, J BIOL CHEM, V257, P2820; HERSH LB, 1977, J BIOL CHEM, V252, P4796; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Kawachi H, 1996, EUR J BIOCHEM, V238, P845, DOI 10.1111/j.1432-1033.1996.0845w.x; KLEANTHOUS C, 1984, BIOCHEM J, V223, P211, DOI 10.1042/bj2230211; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1750, DOI 10.1002/pro.5560040910; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	29	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24465	24469		10.1074/jbc.273.38.24465	http://dx.doi.org/10.1074/jbc.273.38.24465			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733738	hybrid			2022-12-25	WOS:000076007300030
J	Huber, I; Cukierman, E; Rotman, M; Aoe, T; Hsu, VW; Cassel, D				Huber, I; Cukierman, E; Rotman, M; Aoe, T; Hsu, VW; Cassel, D			Requirement for both the amino-terminal catalytic domain and a noncatalytic domain for in vivo activity of ADP-ribosylation factor GTPase-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE PROTEIN; GUANINE-NUCLEOTIDE; GOLGI MEMBRANES; BREFELDIN-A; ORGANELLE STRUCTURE; ARF PROTEIN; BETA-COP; BINDING; COATOMER; CONTAINS	The small GTP-binding protein ADP-ribosylation factor-1 (ARF1) regulates intracellular transport by modulating the interaction of coat proteins with the Golgi complex. Coat protein association with Golgi membranes requires activated, GTP-bound ARF1, whereas GTP hydrolysis catalyzed by an ARF1-directed GTPase-activating protein (GAP) deactivates ARF1 and results in coat protein dissociation. We have recently cloned a Golgi-associated ARF GAP. Overexpression of GAP was found to result in a phenotype that reflects ARF1 deactivation (Aoe, T, Cukierman, E, Lee, A., Cassel, D, Peters, P, J, and Hsu, V, W, (1997) EMBO J. 16, 7305-7316). In this study, we used this phenotype to define domains in GAP that are required for its function in vivo. As expected, mutations in the amino-terminal part of GAP that were previously found to abolish ARF GAP catalytic activity in vitro abrogated ARF1 deactivation in vivo. Significantly, truncations at the carboxyl-terminal part of GAP that did not affect GAP catalytic activity in vitro also diminished ARF1 deactivation. Thus, a noncatalytic domain is required for GAP activity in vivo. This domain may be involved in the targeting of GAP to the Golgi membrane.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Technion Israel Institute of Technology; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Cassel, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.		cukierman, edna/AAU-8932-2020; Cukierman, Edna/A-3951-2013	cukierman, edna/0000-0002-1452-9576; 				Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Aoe T, 1998, P NATL ACAD SCI USA, V95, P1624, DOI 10.1073/pnas.95.4.1624; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; WEISS O, 1989, J BIOL CHEM, V264, P21066	27	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24786	24791		10.1074/jbc.273.38.24786	http://dx.doi.org/10.1074/jbc.273.38.24786			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733781	hybrid			2022-12-25	WOS:000076007300073
J	Itoh, Y; Ito, A; Iwata, K; Tanzawa, K; Mori, Y; Nagase, H				Itoh, Y; Ito, A; Iwata, K; Tanzawa, K; Mori, Y; Nagase, H			Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (Gelatinase A) activated on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE; 4-AMINOPHENYLMERCURIC ACETATE; INTERSTITIAL COLLAGENASE; 72-KDA GELATINASE; PROGELATINASE-A; BINDING; COMPLEX; TIMP-2; FIBROBLASTS; DOMAIN	The cell-surface activation of pro-matrix metalloproteinase 2 (pro-MMP-2) is considered to be critical for cell. migration and invasion. Treatment of human uterine cervical fibroblasts with concanavalin A activates pro-MMP-2 on the cell surface by converting it to the 65-kDa form with a minor form of 45 kDa. However, the 65-kDa MMP-2 was inactivated by tissue inhibitor of metalloproteinases (TIMP)-2 that was bound to the plasma membrane upon concanavalin A treatment. TIMP-2 binds to the plasma membrane through its N-terminal domain by two different modes of interaction as follows: one is sensitive to a hydroxamate (HXM) inhibitor of MMPs and the other is HXM-insensitive. TIMP-2 bound to the membrane in a HXM-insensitive manner, comprising about 40-50% of TIMP-2 on the membrane, is the inhibitor of the cell surface-activated MMP-2. It, however, does not inhibit MMP-3, MMP-9, and the 45-kDa MMP-2 lacking the C-terminal domain. The inhibition of the 65-kDa MMP-2 by TIMP-2 is initiated by the interaction of their C-terminal domains. Subsequently, the MMP-2 .TIMP-2 complex is released from the membrane, and the activity of MMP-2 is blocked by TIMP-2. In the presence of collagen types I, II, III, V, or gelatin, the rate of inhibition of the 65-kDa MMP-2 by the membrane-bound TIMP-2 decreased considerably. These results suggest that the pericellular activity of MMP-2 is tightly regulated by membrane-bound TIMP-2 and surrounding extracellular matrix components.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan; Fuji Chem Ind Ltd, Dept Biopharmaceut, Toyama 9338511, Japan; Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan	University of Kansas; University of Kansas Medical Center; Tokyo University of Pharmacy & Life Sciences; Daiichi Sankyo Company Limited	Nagase, H (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.			Itoh, Yoshifumi/0000-0002-2128-2823	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189, R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 39189, AR 40994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302; Banyai L, 1996, J BIOL CHEM, V271, P12003, DOI 10.1074/jbc.271.20.12003; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; Benbow U, 1996, J BIOL CHEM, V271, P10715, DOI 10.1074/jbc.271.18.10715; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROWN PD, 1990, CANCER RES, V50, P6184; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUJIMOTO N, 1993, CLIN CHIM ACTA, V220, P31, DOI 10.1016/0009-8981(93)90004-N; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; Imai K, 1996, CANCER RES, V56, P2707; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LELIEVRE Y, 1990, MATRIX, V10, P292, DOI 10.1016/S0934-8832(11)80184-8; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MURPHY G, 1994, J BIOL CHEM, V269, P6632; NAGASE H, 1995, METHOD ENZYMOL, V248, P449; Nagase H, 1996, ZINC METALLOPROTEASE, P153; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OJIMA Y, 1989, BIOCHIM BIOPHYS ACTA, V1011, P61, DOI 10.1016/0167-4889(89)90079-7; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Rankin CA, 1996, KIDNEY INT, V50, P835, DOI 10.1038/ki.1996.383; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shipley JM, 1996, J BIOL CHEM, V271, P4335; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TANZAWA K, 1992, J ANTIBIOT, V45, P1733, DOI 10.7164/antibiotics.45.1733; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	47	123	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24360	24367		10.1074/jbc.273.38.24360	http://dx.doi.org/10.1074/jbc.273.38.24360			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733724	hybrid			2022-12-25	WOS:000076007300016
J	Wistedt, AC; Kotarsky, H; Marti, D; Ringdahl, U; Castellino, FJ; Schaller, J; Sjobring, U				Wistedt, AC; Kotarsky, H; Marti, D; Ringdahl, U; Castellino, FJ; Schaller, J; Sjobring, U			Kringle 2 mediates high affinity binding of plasminogen to an internal sequence in streptococcal surface protein PAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ASSOCIATED PLASMINOGEN; PROTON MAGNETIC-RESONANCE; RECOMBINANT KRINGLE-1; ACTIVATOR; IDENTIFICATION; DOMAIN; EXPRESSION; PYOGENES; RECEPTOR; PURIFICATION	Many cells express receptors for plasminogen (Pg), although the responsible molecules in most cases are poorly defined. In contrast, the group A streptococcal surface protein PAM contains a domain with two 13-amino acid residue long repeated sequences (a1 and a2) responsible for Pg binding. Here we identify the region in Pg that interacts with PAM. A radiolabeled proteolytic plasminogen fragment containing the first three kringles (K1-K3) interacted with streptococci expressing PAM or a chimeric surface protein harboring the a1a2 sequence. In contrast, plasminogen fragments containing kringle 4 or kringle 5 and the activable serine proteinase domain failed to bind to PAM expressing group A streptococci. A synthetic and a recombinant polypeptide containing the a1a2 sequence both bound to immobilized recombinant K2 (rK2) but not to rK1 or rK3. The interaction between the a repeat region and rK2 was reversible, and rK2 completely blocked the binding of Pg to the a1a2 region. The binding of the a repeat containing polypeptide to K2 occurred with an equilibrium association constant of 4.5 x 10(7) M-1, as determined by surface plasmon resonance, a value close to that (1.6 x 10(7) M-1) calculated for the a1a2-Pg interaction. Inhibition experiments suggested involvement of the lysine-binding site of K2 in the interaction. These data demonstrate that K2 contains the major Pg-binding site for PAM, providing the first well defined example of an interaction between an internal Pg-binding region in a protein and a single kringle domain.	Univ Lund, Dept Lab Med, S-22362 Lund, Sweden; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Lund University; University of Bern; Carnegie Mellon University; University of Notre Dame	Sjobring, U (corresponding author), Univ Lund, Dept Lab Med, Solvegatan 23, S-22362 Lund, Sweden.	ulf.sjobring@mmb.lu.se						BERGE A, 1993, J BIOL CHEM, V268, P25417; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CAPARON MG, 1992, J BACTERIOL, V174, P5693, DOI 10.1128/JB.174.17.5693-5701.1992; CASTELLINO FJ, 1984, SEMIN THROMB HEMOST, V10, P18, DOI 10.1055/s-2007-1004404; Cedervall T, 1997, BIOCHEMISTRY-US, V36, P4987, DOI 10.1021/bi962971q; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Coleman JL, 1997, CELL, V89, P1111, DOI 10.1016/S0092-8674(00)80298-6; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hembrough TA, 1996, J BIOL CHEM, V271, P25684, DOI 10.1074/jbc.271.41.25684; HUSMANN LK, 1995, INFECT IMMUN, V63, P345, DOI 10.1128/IAI.63.1.345-348.1995; JOHNSSON E, 1994, J IMMUNOL, V153, P3557; KASTERN W, 1992, J BIOL CHEM, V267, P12820; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; Marti DN, 1997, BIOCHEMISTRY-US, V36, P11591, DOI 10.1021/bi971316v; Mathews II, 1996, BIOCHEMISTRY-US, V35, P2567, DOI 10.1021/bi9521351; MEISSAUER A, 1992, EXP CELL RES, V199, P179, DOI 10.1016/0014-4827(92)90423-6; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MOSER TL, 1993, J BIOL CHEM, V268, P18917; MOTTA A, 1987, BIOCHEMISTRY-US, V26, P3827, DOI 10.1021/bi00387a014; NILSON BHK, 1995, BIOCHEMISTRY-US, V34, P13688, DOI 10.1021/bi00041a051; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PLOW EF, 1991, THROMB HAEMOSTASIS, V66, P32; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; RAMESH V, 1987, J MOL BIOL, V198, P481, DOI 10.1016/0022-2836(87)90295-6; REINARTZ J, 1995, J IMMUNOL, V154, P844; Ringdahl U, 1998, J BIOL CHEM, V273, P6424, DOI 10.1074/jbc.273.11.6424; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, P191; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; ULLBERG M, 1992, APMIS, V100, P21, DOI 10.1111/j.1699-0463.1992.tb00835.x; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x	37	64	66	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24420	24424		10.1074/jbc.273.38.24420	http://dx.doi.org/10.1074/jbc.273.38.24420			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733732	hybrid			2022-12-25	WOS:000076007300024
J	Chinchilla, D; Schwarz, FP; Eisenstein, E				Chinchilla, D; Schwarz, FP; Eisenstein, E			Amino acid substitutions in the C-terminal regulatory domain disrupt allosteric effector binding to biosynthetic threonine deaminase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE TRANSCARBAMOYLASE; LIGAND-BINDING; ISOLEUCINE; MECHANISM; VALINE; SITE	Shifts in the sigmoidal kinetics of allosteric threonine deaminase promoted by isoleucine and valine binding control branched chain amino acid biosynthesis in Escherichia coli. A highly conserved alpha-helix in the C-terminal regulatory domain of the tetrameric enzyme was previously implicated in effector binding and feedback inhibition. Double (447, 451) and triple (447, 451, 454) alanine replacements for the conserved amino acids leucine 447, leucine 451, and leucine 454 in this region yield enzyme variants that show increased sigmoidality in steady-state kinetics, and which are less sensitive to the allosteric modifiers isoleucine and valine, Equilibrium binding studies using fluorescence, enzyme kinetic, and calorimetric approaches indicate that the enzyme variants possess reduced affinity for isoleucine and valine, and suggest that heterotropic ligands can bind to the same site to promote their different effects. The increase in sigmoidal kinetics for the mutants relative to wildtype threonine deaminase may be attributable to the elimination of L-threonine binding to the effector sites, which activates the wild-type enzyme, Enzyme kinetic data and isotherms for active site ligand binding to the mutants can be analyzed in terms of a simple two-state model to yield values for allosteric parameters that are consistent with previous estimates based on an expanded two-state model for homotropic cooperativity for threonine deaminase.	Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21228 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore County	Eisenstein, E (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.							Adair GS, 1925, J BIOL CHEM, V63, P529; BURNS RO, 1979, J BIOL CHEM, V254, P1074; DAVIS L, 1965, ANAL BIOCHEM, V12, P36, DOI 10.1016/0003-2697(65)90139-9; DECEDUE CJ, 1975, J BIOL CHEM, V250, P1563; EISENSTEIN E, 1995, ARCH BIOCHEM BIOPHYS, V316, P311, DOI 10.1006/abbi.1995.1042; EISENSTEIN E, 1991, J BIOL CHEM, V266, P5801; EISENSTEIN E, 1990, BIOCHEMISTRY-US, V29, P3724, DOI 10.1021/bi00467a019; EISENSTEIN E, 1995, BIOCHEMISTRY-US, V34, P9403, DOI 10.1021/bi00029a016; EISENSTEIN E, 1994, J BIOL CHEM, V269, P29423; EISENSTEIN E, 1994, J BIOL CHEM, V269, P29416; FISHER KE, 1993, J BACTERIOL, V175, P6605, DOI 10.1128/jb.175.20.6605-6613.1993; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HOFLER JG, 1978, J BIOL CHEM, V253, P1245; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6570, DOI 10.1021/bi00143a029; Perutz M. F., 1990, MECH COOPERATIVITY; STEVENS RC, 1992, P NATL ACAD SCI USA, V89, P5281, DOI 10.1073/pnas.89.12.5281; UMBARGER HE, 1973, ADV ENZYMOL RAMB, V37, P349; Umbarger HE, 1987, ESCHERICHIA COLI SAL, P352; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46; ZHANG Y, 1992, BIOCHEMISTRY-US, V31, P792, DOI 10.1021/bi00118a022	23	13	14	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23219	23224		10.1074/jbc.273.36.23219	http://dx.doi.org/10.1074/jbc.273.36.23219			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722552	hybrid			2022-12-25	WOS:000075778100052
J	Deng, J; Szyf, M				Deng, J; Szyf, M			Multiple isoforms of DNA methyltransferase are encoded by the vertebrate cytosine DNA methyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE CELLS; METHYLATION; EXPRESSION; MECHANISM; SEQUENCE; ENZYMES; DOMAIN	This manuscript tests the hypothesis that multiple forms of cytosine-DNA methyltransferase (MeTase) are expressed in vertebrates in vivo. Vertebrate genomes are distinguished by tissue- tend gene-specific DNA methylation patterns. Specific methylation patterns are believed to encode epigenetic information. In distinction from the remarkable diversity of DNA methylation patterns, only one functional DNA MeTase cDNA has been identified to date in different vertebrate organisms. Using reverse transcription-polymerase chain reaction and RNase protection analyses, we show that the methyltransferase domain of the rat DNA MeTase is alternatively spliced in vivo, generating different in-frame variants of DNA MeTase in specific tissues. This process is developmentally regulated and is induced in PC12 cells by a known inducer of neuronal differentiation, nerve growth factor. The data presented here point toward a new mechanism for generating diversity of DNA MeTases and possibly diverse DNA methylation patterns.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; CHOI E, 1980, NATURE, V286, P776, DOI 10.1038/286776a0; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Mertineit C, 1998, DEVELOPMENT, V125, P889; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; NEBERT DW, 1979, MOL CELL BIOCHEM, V27, P27, DOI 10.1007/BF00849277; Ramchandani S, 1998, BIOL CHEM, V379, P535; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; ROBERTSON M, 1982, NATURE, V297, P184, DOI 10.1038/297184a0; SZYF M, 1992, J BIOL CHEM, V267, P12831; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	23	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22869	22872		10.1074/jbc.273.36.22869	http://dx.doi.org/10.1074/jbc.273.36.22869			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722504	hybrid			2022-12-25	WOS:000075778100004
J	Hocker, M; Rosenberg, I; Xavier, R; Henihan, RJ; Wiedenmann, B; Rosewicz, S; Podolsky, DK; Wang, TC				Hocker, M; Rosenberg, I; Xavier, R; Henihan, RJ; Wiedenmann, B; Rosewicz, S; Podolsky, DK; Wang, TC			Oxidative stress activates the human histidine decarboxylase promoter in AGS gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL 12-MYRISTATE 13-ACETATE; OXYGEN METABOLITE PRODUCTION; ISCHEMIA-REPERFUSION; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ORNITHINE DECARBOXYLASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PROTEIN-KINASE; OXIDANT STRESS	Oxidant stress is thought to play a role in the pathogenesis of many gastric disorders. We have recently reported that histidine decarboxylase (HDC) promoter activity is stimulated by gastrin through a protein kinase C- and extracellular signal-regulating kinase (ERK)-dependent pathway in gastric cancer (AGS-B) cells, and this transcriptional response is mediated by a downstream cis-acting element, the gastrin response element (GAS-RE). To study the mechanism through which oxidant stress affects gastric cells, we examined the effects of hydrogen peroxide (H2O2) on HDC promoter activity and intracellular signaling in AGS-B cells. H2O2 (10 mM) specifically activated the HDC promoter 10-12-fold, and this activation was blocked by both mannitol and N-acetylcysteine. Hydrogen peroxide treatment of AGS-B cells increased the phosphorylation and kinase activity of ERK-1 and ERK-2, but did not affect Jun kinase tyrosine phosphorylation or kinase activity. In addition, treatment of AGS-B cells with H2O2 resulted in increased c-fos/c-jun mRNA expression and AP-1 activity, and also led to increased phosphorylation of epidermal growth factor receptor (EGFR) and Shc. H2O2-dependent stimulation of HDC promoter activity was completely inhibited by kinase-deficient ERKs, dominant-negative (N17 and N15) Ras, and dominant-negative Raf, and partially blocked by a dominant-negative EGFR mutant. In contrast, protein kinase C blockade did not inhibit H2O2-dependent induction of the HDC promoter. Finally, deletion analysis demonstrated that the H2O2 response element could be mapped to the GAS-RE (nucleotides 2 to 24) of the basal HDC promoter. Overall, these studies suggest that oxidant stress activates the HDC promoter through the GAS-RE, and through an Ras-, Raf-, and ERK-dependent pathway at least partially involving the EGFR.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Free Univ Berlin, Klinikum Benjamin Franklin, Berlin, Germany; Humboldt Univ, Klinikum Charite, Med Klin, Schwerpunkt Hepatol & Gastroenterol, Berlin, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wang, TC (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, GRJ 724,32 Fruit St, Boston, MA 02114 USA.	Wang@Helix.MGH.Harvard.Edu		Wiedenmann, Bertram/0000-0002-7890-2552	NIDDK NIH HHS [DK41557, DK48077] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK041557, R01DK041557, R01DK048077] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMSTAD P, 1990, B CANCER, V77, P501; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Baeuerle PA, 1996, PATHOL BIOL, V44, P29; Baik SC, 1996, CANCER RES, V56, P1279; Bandyopadhyay U, 1997, BIOCHEM PHARMACOL, V54, P241, DOI 10.1016/S0006-2952(97)00156-1; BOUCLIER M, 1983, EUR J PHARMACOL, V90, P129, DOI 10.1016/0014-2999(83)90224-8; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CHING TL, 1995, INFLAMM RES, V44, P99, DOI 10.1007/BF01782018; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DAVIES GR, 1994, GUT, V35, P179, DOI 10.1136/gut.35.2.179; DAVIES GR, 1992, GUT, V33, P1467, DOI 10.1136/gut.33.11.1467; Drake IM, 1996, CARCINOGENESIS, V17, P559, DOI 10.1093/carcin/17.3.559; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJIMOTO K, 1992, J CLIN INVEST, V89, P126, DOI 10.1172/JCI115552; FUJIMOTO K, 1995, DIGEST DIS SCI, V40, P717, DOI 10.1007/BF02064967; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRAISHI H, 1994, GASTROENTEROLOGY, V106, P1199, DOI 10.1016/0016-5085(94)90010-8; HIRAISHI H, 1994, J CLIN INVEST, V93, P331, DOI 10.1172/JCI116964; Hocker M, 1997, AM J PHYSIOL-GASTR L, V272, pG822, DOI 10.1152/ajpgi.1997.272.4.G822; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; Hocker M, 1996, YALE J BIOL MED, V69, P21; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KOYAMA T, 1995, P SOC EXP BIOL MED, V209, P27, DOI 10.3181/00379727-209-43873; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; MIROSSAY L, 1994, AM J PHYSIOL, V267, pR602, DOI 10.1152/ajpregu.1994.267.2.R602; Nose K, 1996, BIOCHEM J, V316, P381, DOI 10.1042/bj3160381; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Pai R, 1998, GASTROENTEROLOGY, V114, P706, DOI 10.1016/S0016-5085(98)70584-0; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; Rao GN, 1996, ONCOGENE, V13, P713; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEN C, 1990, FASEB J, V10, P709; Smith GS, 1996, DIGEST DIS SCI, V41, P1157, DOI 10.1007/BF02088232; SZERBERENYI J, 1990, MOL CELL BIOL, V10, P5324; Taniguchi Y, 1996, NUCLEIC ACIDS RES, V24, P2746, DOI 10.1093/nar/24.14.2746; Wagner M, 1996, INT J CANCER, V68, P782, DOI 10.1002/(SICI)1097-0215(19961211)68:6<782::AID-IJC16>3.0.CO;2-2; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; YAJIMA N, 1995, DIGEST DIS SCI, V40, P879, DOI 10.1007/BF02064995; YOSHIKAWA T, 1993, GUT, V34, P732, DOI 10.1136/gut.34.6.732; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	46	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23046	23054		10.1074/jbc.273.36.23046	http://dx.doi.org/10.1074/jbc.273.36.23046			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722530	hybrid			2022-12-25	WOS:000075778100030
J	Konrat, R; Krautler, B; Weiskirchen, R; Bister, K				Konrat, R; Krautler, B; Weiskirchen, R; Bister, K			Structure of cysteine- and glycine-rich protein CRP2 - Backbone dynamics reveal motional freedom and independent spatial orientation of the LIM domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL-FREE APPROACH; MAGNETIC-RESONANCE RELAXATION; ZINC-FINGER MOTIF; NMR-SPECTROSCOPY; SENSITIVITY IMPROVEMENT; LARGER PROTEINS; CHEMICAL-SHIFTS; N-15 NMR; BINDING; SPECTRA	Members of the cysteine- and glycine-rich protein family (CRP1, CRP2, and CRP3) contain two zinc-binding LIM domains, LIM1 (amino-terminal) and LIM2 (carboxyl-terminal), and are implicated in diverse cellular processes linked to differentiation, growth control, and pathogenesis. Here we report the solution structure of full-length recombinant quail CRP2 as determined by multi-dimensional triple-resonance NMR spectroscopy. The structural analysis revealed that the global fold of the two LIM domains in the context of the full-length protein is identical to the recently determined solution structures of the isolated individual LIM domains of quail CRP2, There is no preference in relative spatial orientation of the two domains. This supports the view that the two LIM domains are independent structural and presumably functional modules of CRP proteins. This is also reflected by the dynamic properties of CRP2 probed by (15)N relaxation values (T(1), T(2), and nuclear Overhauser effect). A model-free analysis revealed local variations in mobility along the backbone of the two LIM domains in the native protein, similar to those observed for the isolated domains. Interestingly, fast and slow motions observed in the 58-amino acid linker region between the two LIM domains endow extensive motional freedom to CRP2, The dynamic analysis indicates independent backbone mobility of the two LIM domains and rules out correlated LIM domain motion in full-length CRP2, The finding that the LIM domains in a protein encompassing multiple LIM motifs are structurally and dynamically independent from each other supports the notion that these proteins may function as adaptor molecules arranging two or more protein constituents into a macromolecular complex.	Univ Innsbruck, Inst Organ Chem, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Konrat, R (corresponding author), Univ Innsbruck, Inst Organ Chem, Innrain 52A, A-6020 Innsbruck, Austria.	robert.konrat@uibk.ac.at	Bister, Klaus/AFA-9400-2022; Weiskirchen, Ralf/O-1734-2018	Weiskirchen, Ralf/0000-0003-3888-0931; Bister, Klaus/0000-0001-6545-5653				Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAVANAGH J, 1991, J MAGN RESON, V91, P429, DOI 10.1016/0022-2364(91)90209-C; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Dayie KT, 1996, ANNU REV PHYS CHEM, V47, P243, DOI 10.1146/annurev.physchem.47.1.243; DELAGLIO F, 1993, NMRPIPE SYSTEM SOFTW; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; Konrat R, 1997, J BIOL CHEM, V272, P12001, DOI 10.1074/jbc.272.18.12001; Kontaxis G, 1998, BIOCHEMISTRY-US, V37, P7127, DOI 10.1021/bi973055v; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KUPCE E, 1995, J MAGN RESON SER A, V115, P273, DOI 10.1006/jmra.1995.1179; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MCCOY MA, 1992, J AM CHEM SOC, V114, P2108, DOI 10.1021/ja00032a026; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; STONEHOUSE J, 1994, J MAGN RESON SER A, V107, P178, DOI 10.1006/jmra.1994.1066; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAIRA M, 1995, TRENDS GENET, V11, P431, DOI 10.1016/S0168-9525(00)89139-8; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Weiskirchen R, 1997, GENOMICS, V44, P83, DOI 10.1006/geno.1997.4855; WEISKIRCHEN R, 1995, J BIOL CHEM, V270, P28946, DOI 10.1074/jbc.270.48.28946; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	65	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23233	23240		10.1074/jbc.273.36.23233	http://dx.doi.org/10.1074/jbc.273.36.23233			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722554	hybrid			2022-12-25	WOS:000075778100054
J	Li, XY; McClure, WR				Li, XY; McClure, WR			Stimulation of open complex formation by nicks and apurinic sites suggests a role for nucleation of DNA melting in Escherichia coli promoter function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR INTERACTIONS; DEPENDENT RNA-POLYMERASE; LAMBDA-PR PROMOTER; LAC UV5 PROMOTER; TRANSCRIPTION INITIATION; GEL-ELECTROPHORESIS; MECHANISM; STABILITY; RECOGNITION; KINETICS	We report the effects of depurination and prenicking at various positions of the phage lambda prmup-1 Delta 265 promoter DNA on the rate of open complex formation. We have found that depurination and prenicking at positions around the -10 region strongly stimulated the rate of open complex formation. Since nicking and depurination are known to destabilize DNA helical structure, our observations indicate that the instability of the -10 region is important for open complex formation. We further infer that (i) the nucleation of DNA melting, which occurs during the isomerization from the closed complex into the open complex, contributes to the rate of open complex formation; (ii) the nucleation of melting occurs around the -10 region; and (iii) the propagation of DNA melting from the nucleation region is not rate-limiting. In addition, we have found that depurination at several positions inhibited open complex formation. We used dimethyl sulfate modification protection studies to show that most of the guanine bases that are among these positions are in contact with RNA polymerase in the open complex.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	McClure, WR (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.				NIGMS NIH HHS [GM 30375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; AUBLE DT, 1988, J MOL BIOL, V202, P471, DOI 10.1016/0022-2836(88)90279-3; AUSUBEL KFM, 1987, CURRENT PROTOCOLS MO; AYERS DG, 1989, J MOL BIOL, V207, P749, DOI 10.1016/0022-2836(89)90241-6; BOROWIEC JA, 1986, BIOCHEMISTRY-US, V25, P5051, DOI 10.1021/bi00366a012; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; COWING DW, 1989, J MOL BIOL, V210, P513, DOI 10.1016/0022-2836(89)90127-7; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; DUVALVALENTIN G, 1986, NUCLEIC ACIDS RES, V14, P1967, DOI 10.1093/nar/14.5.1967; ERIE DA, 1989, BIOCHEMISTRY-US, V28, P268, DOI 10.1021/bi00427a037; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOLJER I, 1992, BIOCHEMISTRY-US, V31, P11614, DOI 10.1021/bi00161a047; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; Li XY, 1998, J BIOL CHEM, V273, P23549, DOI 10.1074/jbc.273.36.23549; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MARGALIT H, 1988, BIOCHEMISTRY-US, V27, P5179, DOI 10.1021/bi00414a035; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MILLICAN TA, 1984, NUCLEIC ACIDS RES, V12, P7435, DOI 10.1093/nar/12.19.7435; MINCHIN S, 1993, BIOCHEM J, V289, P771, DOI 10.1042/bj2890771; PIETERS JML, 1989, NUCLEIC ACIDS RES, V17, P4551, DOI 10.1093/nar/17.12.4551; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; SIEBENLIST U, 1980, CELL, V20, P270; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; Zaychikov E, 1997, J BIOL CHEM, V272, P2259	44	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23558	23566		10.1074/jbc.273.36.23558	http://dx.doi.org/10.1074/jbc.273.36.23558			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722595	hybrid			2022-12-25	WOS:000075778100095
J	Nishikawa, K; Toker, A; Wong, K; Marignani, PA; Johannes, FJ; Cantley, LC				Nishikawa, K; Toker, A; Wong, K; Marignani, PA; Johannes, FJ; Cantley, LC			Association of protein kinase c mu with type II phosphatidylinositol 4-kinase and type I phosphatidylinositol-4-phosphate 5-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EPIDERMAL-CELLS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; 3-KINASE COMPLEX; YEAST; FAMILY; ACTIVATION; SUBSTRATE; ISOFORMS; POLYPHOSPHOINOSITIDES	Protein kinase C mu (PKC mu), also named protein kinase D, is an unusual member of the PKC family that has a putative transmembrane domain and pleckstrin homology domain. This enzyme has a substrate specificity distinct from other PKC isoforms (Nishikawa, K., Toker, A., Johannes, F. J., Songyang, Z., and Cantley, L. C. (1997) J. Biol. Chem. 272, 952-960), and its mechanism of regulation is not yet clear. Here we show that PKC mu forms a complex in vivo with a phosphatidylinositol 4-kinase and a phosphatidylinositol-4-phosphate 5-kinase. A region of PKC mu between the amino-terminal transmembrane domain and the pleckstrin homology domain is shown to be involved in the association with the lipid kinases. Interestingly, a kinase-dead point mutant of PKC mu. failed to associate with either lipid kinase activity, indicating that autophosphorylation may be required to expose the Lipid kinase interaction domain. Furthermore, the subcellular distribution of the PKC mu-associated lipid kinases to the particulate fraction depends on the presence of the amino-terminal. region of PKC mu including the predicted transmembrane region. These results suggest a novel model in which the noncatalytic region of PKC mu acts as a scaffold for assembly of enzymes involved in phosphoinositide synthesis at specific membrane locations.	Harvard Univ, Sch Med, Div Signal Transduct, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Boston Biomed Res Inst, Boston, MA 02114 USA; Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Boston Biomedical Research Institute; University of Stuttgart	Nishikawa, K (corresponding author), Harvard Univ, Inst Med, Div Signal Transduct, Beth Israel Deaconess Med Ctr, 10th Fl,330 Brookline Ave, Boston, MA 02215 USA.	knishika@ri.imcj.go.jp	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Marignani, Paola/0000-0001-8070-905X	NHLBI NIH HHS [P50-HL56993] Funding Source: Medline; NIGMS NIH HHS [R01-GM36624] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1991, METHODS INOSITIDE RE, P155; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FRUMAN D, 1998, IN PRESS ANN REV BIO; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; NISHIKAWA K, 1992, CELL SIGNAL, V4, P757, DOI 10.1016/0898-6568(92)90057-F; NISHIKAWA K, 1994, CELL SIGNAL, V6, P503, DOI 10.1016/0898-6568(94)90004-3; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; OGITA K, 1991, METHOD ENZYMOL, V200, P228; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; TOKER A, 1994, J BIOL CHEM, V269, P32358; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; WONG K, 1994, J BIOL CHEM, V269, P28878; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	39	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23126	23133		10.1074/jbc.273.36.23126	http://dx.doi.org/10.1074/jbc.273.36.23126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722541	hybrid			2022-12-25	WOS:000075778100041
J	Johanning, K; Juliano, MA; Juliano, L; Lazure, C; Lamango, NS; Steiner, DF; Lindberg, I				Johanning, K; Juliano, MA; Juliano, L; Lazure, C; Lamango, NS; Steiner, DF; Lindberg, I			Specificity of prohormone convertase 2 on proenkephalin and proenkephalin-related substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUENCHED FLUOROGENIC SUBSTRATE; HAMSTER OVARY CELLS; ENZYMATIC CHARACTERIZATION; PROCESSING ENZYME; HUMAN FURIN; AMINO-ACID; IN-VITRO; PROPROTEIN CONVERTASES; MOLECULAR-FORMS; RECOMBINANT PC1	In the central and peripheral nervous systems, the neuropeptide precursor proenkephalin must be endoproteolytically cleaved by enzymes known as prohormone convertases 1 and 2 (PC1 and PC2) to generate opioid-active enkephalins. In this study, we have investigated the specificity of recombinant mouse PC2 for proenkephalin-related internally quenched (IQ) peptides, for methylcoumarin amide-based fluorogenic peptides, and for recombinant rat proenkephalin. IQ peptides exhibited specificity constants (k(cat)/K-m) between 9.4 x 10(4) M-1 s(-1)(Abz-Val-Pro-Arg-Met-Glu-Lys-Arg-Tyr-Gly-Gly-Phe-Met-Gln-EDDnp; where Abz is ortho-aminobenzoic acid and EDDnp is N-(2,4-dinitrophenyl)ethylenediamine)) and 0.24 x 10(4) M-1 s(-1) (Abz-Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-EDDnp), with the peptide B to Met-enk-Arg-Phe cleavage preferred (Met-enk is met-enkephalin). Fluorogenic substrates with P1, P2, and P4 basic amino acids were hydrolyzed with specificity constants ranging between 2.0 x 10(3) M-1 s(-1) (Ac-Orn-Ser-Lys-Arg-MCA; where MCA is methylcoumarin amide) and 1.8 x 10(4) M-1 s(-1) (<Glu-Arg-Thr-Lys-Arg-MCA; where <Glu is pyroglutamic acid). Substrates containing only a single basic residue were not appreciably hydrolyzed, and substrates lacking a P4 Arg exhibited k(cat) of less than 0.05 s(-1). Substitution of ornithine for Lys at the P4 position did not significantly affect the k(cat) but increased the K-m 2-fold. Data from both sets of fluorogenic substrates supported the contribution of a P4 Arg to PC2 preference. Analysis of proenkephalin reaction products using immunoblotting and gel permeation chromatography demonstrated that PC2 can directly cleave proenkephalin and that the generation of small opioid peptides from intermediates is mediated almost entirely by PC2 rather than by PC1, These results are in accord with the analysis of PC2 knock-out brains, in which the amounts of three mature enkephalins were depleted by more than three-quarters.	Louisiana State Univ, Med Ctr, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Escola Paulista Med, Dept Biophys, BR-04044020 Sao Paulo, Brazil; Inst Rech Clin Montreal, Neuropeptide Struct & Metab Lab, Quebec City, PQ 2W 1R7, Canada; Univ Chicago, Sch Med, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Sch Med, Dept Biochem, Chicago, IL 60637 USA	Louisiana State University System; Universidade Federal de Sao Paulo (UNIFESP); Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Howard Hughes Medical Institute; University of Chicago; University of Chicago	Lindberg, I (corresponding author), Louisiana State Univ, Med Ctr, Sch Med, Dept Biochem, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@lsumc.edu	Lamango, Nazarius/W-8459-2019; Juliano, Luiz/D-7204-2012; Lindberg, Iris/Q-3825-2019	Juliano, Luiz/0000-0002-5589-2822; 	NIDA NIH HHS [R56 DA005084, DA00204, DA05084, R01 DA005084] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; BAILYES EM, 1995, BIOCHEM J, V309, P587, DOI 10.1042/bj3090587; BASAK A, 1995, INT J PEPT PROT RES, V46, P228; BIRCH NP, 1986, J BIOL CHEM, V261, P2213; Brakch N, 1997, BIOCHEMISTRY-US, V36, P16309, DOI 10.1021/bi9714767; BRAKCH N, 1993, BIOCHEMISTRY-US, V32, P4925, DOI 10.1021/bi00069a029; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CHRISTIE DL, 1984, BIOCHEM BIOPH RES CO, V120, P650, DOI 10.1016/0006-291X(84)91305-6; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DelNery E, 1997, BIOCHEM J, V323, P427, DOI 10.1042/bj3230427; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; FRIEDMAN TC, 1994, ENDOCRINOLOGY, V135, P854, DOI 10.1210/en.135.3.854; FRIEDMAN TC, 1995, ARCH BIOCHEM BIOPHYS, V316, P5, DOI 10.1006/abbi.1995.1002; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GIRAUD P, 1981, NEUROPEPTIDES, V1, P237, DOI 10.1016/0143-4179(81)90002-0; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; Hook VYH, 1996, ARCH BIOCHEM BIOPHYS, V328, P107, DOI 10.1006/abbi.1996.0149; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Johanning K, 1996, J NEUROCHEM, V66, P898; Johanning K, 1996, J BIOL CHEM, V271, P27871, DOI 10.1074/jbc.271.44.27871; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Ledgerwood EC, 1996, BIOCHEM MOL BIOL INT, V39, P1167; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LINDBERG I, 1984, BRAIN RES, V299, P73, DOI 10.1016/0006-8993(84)90789-3; LINDBERG I, 1990, ENDOCRINOLOGY, V126, P480, DOI 10.1210/endo-126-1-480; LINDBERG I, 1986, BIOCHEM BIOPH RES CO, V139, P1024, DOI 10.1016/S0006-291X(86)80280-7; LINDBERG I, 1992, J NEUROCHEM, V58, P448, DOI 10.1111/j.1471-4159.1992.tb09742.x; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MOCCHETTI I, 1984, EUR J PHARMACOL, V106, P427, DOI 10.1016/0014-2999(84)90734-9; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; ROEBROEK AJM, 1994, BIOCHIMIE, V76, P210, DOI 10.1016/0300-9084(94)90148-1; ROTHENBERG ME, 1995, J BIOL CHEM, V270, P10136, DOI 10.1074/jbc.270.17.10136; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; Wang WG, 1997, BIOCHEM BIOPH RES CO, V231, P149, DOI 10.1006/bbrc.1997.6065; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU Y, 1994, J BIOL CHEM, V269, P18408	55	91	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22672	22680		10.1074/jbc.273.35.22672	http://dx.doi.org/10.1074/jbc.273.35.22672			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712897	hybrid			2022-12-25	WOS:000075616600073
J	Chen, DW; Frey, PA				Chen, DW; Frey, PA			Phenylalanine hydroxylase from Chromobacterium violaceum - Uncoupled oxidation of tetrahydropterin and the role of iron in hyroxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID HYDROXYLASES; REDUCTIVE ACTIVATION; BINDING-SITES; EXPRESSION; COMPLEXES; MECHANISM; SEQUENCE; COFACTOR; CLONING; DNA	A gene encoding phenylalanine hydroxylase has been cloned from Chromobacterium violaceum and expressed in Escherichia coli. The purified phenylalanine hydroxylase contains copper, which does not support enzymatic activity, Upon removal of copper by dithiothreitol (DTT), the enzyme contains substoichiometric amounts of calcium and zinc but Little or no redox-active metal ions. The copper-depleted hydroxylase catalyzes the phenylalanine-dependent oxidation of 6,7-dimethyltetrahydropterin (DMPH4) by O-2 in a reaction in which phenylalanine is not hydroxylated and does not appear to undergo a chemical change, and hydrogen peroxide is produced. Analogs of phenylalanine also activate the oxidation of DMPH4. Both the copper-phenylalanine hydroxylase and the copper-depleted hydroxylase catalyze the hydroxylation of phenylalanine in the presence of DTT and FeSO4 in a reaction in which hydrogen peroxide is not produced. The apparent values of K-m for Fe2+ and DTT are 0.28 mu M and 1.1 mM, respectively, at 1.0 mM phenylalanine, 120 mu M DMPH4 and pH 7.4 and 23 degrees C. The apparent value of k(cat) is 14.3 s(-1) under these conditions. Glutathione, mercaptoethanol, and dihydrolipoate support the hydroxylation of phenylalanine essentially as well as DTT, Incubation of copper-depleted hydroxylase with FeSO4, phenylalanine, and DTT followed by gel permeation chromatography leads to an iron-hydroxylase containing approximately 1 molecule of iron per molecule of enzyme. The iron-hydroxylase displays an optical absorption band extending from 300 to 600 nm, and it catalyzes the hydroxylation of phenylalanine at the same maximum rate as the iron-activated hydroxylase but does not require added Fe2+. We conclude that iron participates in the hydroxylation of phenylalanine. Iron is not required for the oxidation of DMPH4, although it may exert a modest acceleration effect. A hypothetical mechanism is presented wherein the reaction of iron with the putative 4a-hydroperoxy-DMPH4 leads to 4a-hydroxy-DMPH4 and a high valent iron-oxy species. The iron-oxy species is postulated to react with phenylalanine in the hydroxylation process.	Univ Wisconsin, Grad Sch, Inst Enzyme Res, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Biol Sci, Dept Biochem, Inst Enzyme Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Frey, PA (corresponding author), Univ Wisconsin, Coll Agr & Biol Sci, Dept Biochem, Inst Enzyme Res, 1710 Univ Ave, Madison, WI 53706 USA.				NIDDK NIH HHS [DK 26807] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSCOUGH EW, 1980, INORG CHEM, V19, P3655, DOI 10.1021/ic50214a018; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AYLING J, 1973, ANAL BIOCHEM, V51, P80, DOI 10.1016/0003-2697(73)90454-5; BALASUBRAMANIAN S, 1994, BIOCHEMISTRY-US, V33, P8532, DOI 10.1021/bi00194a019; CARR RT, 1993, BIOCHEMISTRY-US, V32, P14132, DOI 10.1021/bi00214a009; CHEN DW, 1994, J BIOL CHEM, V269, P32120; DAVIS MD, 1993, ARCH BIOCHEM BIOPHYS, V304, P9, DOI 10.1006/abbi.1993.1315; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; DIX TA, 1985, BIOCHEMISTRY-US, V24, P5389; FISHER DB, 1972, J BIOL CHEM, V247, P2250; GIBBS BS, 1993, J BIOL CHEM, V268, P8046; GOODWIN BL, 1979, AROMATIC AMINO ACID, P5; GOTTSCHALL DW, 1982, J BIOL CHEM, V257, P845; GUIBAULT GG, 1964, ANAL CHEM, V36, P2495; Hillas PJ, 1996, BIOCHEMISTRY-US, V35, P6969, DOI 10.1021/bi9606861; JENNINGS IG, 1991, P NATL ACAD SCI USA, V88, P5734, DOI 10.1073/pnas.88.13.5734; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; Kaufmann S., 1962, OXYGENASES, P129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAELIA LE, 1992, INORG CHEM, V31, P4594, DOI 10.1021/ic00048a029; MAROTA JJA, 1984, BIOCHEMISTRY-US, V23, P1303, DOI 10.1021/bi00301a044; NAKATA H, 1979, J BIOL CHEM, V254, P1829; ONISHI A, 1991, J BIOL CHEM, V266, P18454; PEMBER SO, 1987, METHOD ENZYMOL, V142, P50; PEMBER SO, 1986, BIOCHEMISTRY-US, V25, P6611, DOI 10.1021/bi00369a042; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIF RF, 1981, PRACTICAL METHODS MO, P98; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; VOGT VM, 1970, J BIOL CHEM, V245, P4760; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; ZHAO GS, 1994, P NATL ACAD SCI USA, V91, P1366, DOI 10.1073/pnas.91.4.1366	33	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25594	25601		10.1074/jbc.273.40.25594	http://dx.doi.org/10.1074/jbc.273.40.25594			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748224	hybrid			2022-12-25	WOS:000076263100015
J	Muth, TR; Ahn, J; Caplan, MJ				Muth, TR; Ahn, J; Caplan, MJ			Identification of sorting determinants in the C-terminal cytoplasmic tails of the gamma-aminobutyric acid transporters GAT-2 and GAT-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; AMYLOID PRECURSOR PROTEIN; MDCK CELLS; RAT-BRAIN; HIPPOCAMPAL-NEURONS; GABA TRANSPORTERS; SECRETORY PATHWAY; FC-RECEPTORS; PDZ DOMAINS	In order to perform their physiologic functions, polarized epithelial cells must target ion transport proteins to the appropriate domains of their plasma membranes. Molecular signals responsible for polarized sorting have been identified for several membrane proteins which span the bilayer once. Most ion transport proteins are polytopic, however, and little is known of the signals responsible for the targeting of this class of polypeptides. Members of the gamma-aminobutyric acid (GABA) transporter family are polytopic membrane proteins found endogenously in both epithelial cells and neurons. We have identified narrowly defined sequences which are required for the proper accumulation of two members of this transporter family in Madin-Darby canine kidney cells. The highly homologous GABA transporter isoforms, GAT-2 and GAT-3, localize to the basolateral and apical surfaces, respectively, when expressed stably in Madin-Darby canine kidney cells. We have generated deletion constructs and chimeric transporters composed of complimentary portions of GAT-2 and GAT-3. We find that information which directs their differential sorting is present in the C-terminal cytoplasmic tails of these two polypeptides. A sequence of 22 amino acids at the C terminus of GAT-2 is required for the transporter's basolateral distribution and is capable of directing GAT-3 to the basolateral surface when appended to the C terminus of this normally apical polypeptide. The deletion of 32 amino acids from the C terminus of GAT-3 causes this transporter to become mislocalized to both surfaces. Moreover, removal of the final three amino acids of GAT-3 (THF) similarly disrupts its apical sorting. The GAT-3 C-terminal sequence resembles motifs which interact with PDZ domains, raising the possibility that the steady state distribution of GAT-3 at the apical plasmalemmal surface requires a protein-protein interaction mediated by its extreme C-terminal cytoplasmic tail. These data provide the first characterization of a protein-based signal required for the apical distribution of a membrane protein.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University; Yale University	Muth, TR (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.			Muth, Theodore/0000-0002-6882-1193; Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42136] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1996, J BIOL CHEM, V271, P6917, DOI 10.1074/jbc.271.12.6917; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DURKIN MM, 1995, MOL BRAIN RES, V33, P7, DOI 10.1016/0169-328X(95)00101-W; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FERREIRA A, 1993, J NEUROSCI, V13, P3112; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; Johnson J, 1996, J COMP NEUROL, V375, P212; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kwon HM, 1996, BIOCHEM SOC T, V24, P853, DOI 10.1042/bst0240853; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; RADIAN R, 1990, J NEUROSCI, V10, P1319; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SIMONS K, 1992, COLD SPRING HARB SYM, V57, P611, DOI 10.1101/SQB.1992.057.01.067; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	47	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25616	25627		10.1074/jbc.273.40.25616	http://dx.doi.org/10.1074/jbc.273.40.25616			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748227	hybrid			2022-12-25	WOS:000076263100018
J	Di Lisi, R; Millino, C; Calabria, E; Altruda, F; Schiaffino, S; Ausoni, S				Di Lisi, R; Millino, C; Calabria, E; Altruda, F; Schiaffino, S; Ausoni, S			Combinatorial cis-acting elements control tissue-specific activation of the cardiac troponin I gene in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-4; HEAVY-CHAIN GENE; ENHANCER-BINDING-FACTOR; SKELETAL-MUSCLE; MOLECULAR-CLONING; HEART DEVELOPMENT; RAT-HEART; EXPRESSION; PROMOTER; DISTINCT	The cardiac troponin I gene is one of the few sarcomeric protein genes exclusively expressed in cardiac muscle. We show here that this specificity is controlled by a proximal promoter (-230/+16) in transfected cardiac cells in culture, in the adult hearts, and in transgenic animals. Functional analysis indicates that MEF2/Oct-1, Spl, and GATA regulatory elements are required for optimal gene activation because selective mutations produce weak or inactive promoters. MEF2 and Oct-1 transcription factors bind to the same APT-rich element. A mutation that blocks this binding markedly reduces gene activation in vivo and in vitro, and overexpression of MEF2A, MEF2C, and MEF2D in noncardiac cells transactivates the cardiac troponin I promoter. Disruption of these elements inactivates the cardiac troponin I promoter in cultured cardiac cells but has a less important role in transfected adult heart. Moreover, nuclear extracts from an almost pure population of adult cardiac cells contain much lower levels of GATA binding activity compared with fetal cardiac cells. These findings point to a differential role of GATA factors in the maintenance of gene expression in the adult heart as compared with the activation of cardiac genes in fetal cardiomyocytes, Overexpression of GATA family members transactivates the cardiac troponin I promoter, and GATA-5 and GATA-6 are stronger transactivators than GATA-4, a property apparently unique to the cardiac troponin I promoter. Transgenic mice carrying the -230/+126 base pair promoter express beta-galactosidase reporter gene in the heart both at early stages of cardiogenesis and in the adult animals. These results indicate that the ability of the cardiac troponin I proximal promoter to target expression of a downstream gene in the heart is also maintained when the transgene is integrated into the genome.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Muscle Biol & Physiopathol, I-35121 Padua, Italy; Univ Turin, Dept Genet Biol & Med Chem, I-10126 Turin, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Turin	Ausoni, S (corresponding author), Univ Padua, Dept Biomed Sci, Via G Colombo 3, I-35121 Padua, Italy.	ausoni@civ.bio.unipd.it	Calabria, Elisa/K-3849-2014	Calabria, Elisa/0000-0001-6557-0379; Schiaffino, Stefano/0000-0002-5607-6421	Telethon [928] Funding Source: Medline	Telethon(Fondazione Telethon)		ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; AUSONI S, 1994, J BIOL CHEM, V269, P339; AUSONI S, 1991, DEVELOPMENT, V112, P1041; Bhavsar PK, 1996, GENOMICS, V35, P11, DOI 10.1006/geno.1996.0317; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTTRICK PM, 1993, CIRC RES, V72, P1211, DOI 10.1161/01.RES.72.6.1211; DAS HK, 1987, J BIOL CHEM, V262, P4787; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gove C, 1997, EMBO J, V16, P355, DOI 10.1093/emboj/16.2.355; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HINKLEY C, 1991, MOL CELL BIOL, V11, P641, DOI 10.1128/MCB.11.2.641; Hogan B, 1994, MANIPULATING MOUSE E; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KITSIS RN, 1993, METHODS MOL GENET, V1, P374; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; Murphy AM, 1997, BIOCHEM J, V322, P393, DOI 10.1042/bj3220393; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PRENTICE H, 1994, J MOL CELL CARDIOL, V26, P1393, DOI 10.1006/jmcc.1994.1157; Ritchie ME, 1996, J BIOL CHEM, V271, P25485; Ross RS, 1996, DEVELOPMENT, V122, P1799; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; Ventura C, 1997, J BIOL CHEM, V272, P6685, DOI 10.1074/jbc.272.10.6685; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; ZHU L, 1995, DEV BIOL, V169, P487, DOI 10.1006/dbio.1995.1163	53	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25371	25380		10.1074/jbc.273.39.25371	http://dx.doi.org/10.1074/jbc.273.39.25371			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738004	hybrid			2022-12-25	WOS:000076085400054
J	Germain, S; Bonnet, F; Philippe, J; Fuchs, S; Corvol, P; Pinet, F				Germain, S; Bonnet, F; Philippe, J; Fuchs, S; Corvol, P; Pinet, F			A novel distal enhancer confers chorionic expression on the human renin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; LEUCINE ZIPPER PROTEIN; TRANSGENIC MICE; NUCLEOTIDE-SEQUENCE; JUN ENCODES; PROMOTER; BINDING; CELLS; ONCOGENE; ELEMENTS	Renin catalyzes the rate-limiting step of the renin-angiotensin system, which regulates blood pressure and electrolyte homeostasis. To determine cell-specific human renin gene control elements, the transcriptional activity of promoter regions up to position -8876 was studied in renin-expressing cells. A positive regulatory region conferring similar to 57-fold higher transcriptional activity to the human renin gene promoter in chorionic cells was identified between nucleotides -5777 and -5552, It had the orientation-independent activity typical of classical enhancers. It also conferred similar to 59-fold higher transcriptional levels from the heterologous simian virus 40 (SV40) promoter in chorionic cells and similar to 6-fold higher transcriptional levels in Calu-6 and As4.1 cells, whereas no effect was measured in non-renin-expressing cells. DNase I footprinting showed that this enhancer contains three binding sites for chorionic cell nuclear extracts. Functional analysis suggested that the activity of the enhancer is regulated by differential mechanisms in the three renin-expressing cells involving a complex arrangement of AP-1 motifs binding cell-specific members of the basic leucine zipper family of transcription factors. Thus, our results demonstrate that this enhancer plays a key role in the expression of the human renin gene in the chorion and may also be involved in its regulated expression in other tissues.	Coll France, F-75005 Paris, France; INSERM, U36, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pinet, F (corresponding author), Coll France, 3 Rue Ulm, F-75005 Paris, France.	pinet@infobiogen.fr	Germain, Stephane/E-2301-2016; Pinet, Florence/F-2892-2013; Bonnet, Fabrice/G-4255-2017	Germain, Stephane/0000-0001-5992-1275; Pinet, Florence/0000-0002-5471-1487; Bonnet, Fabrice/0000-0001-9255-8228				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; BORENSZTEIN P, 1994, CIRC RES, V74, P764, DOI 10.1161/01.RES.74.5.764; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; DUNCAN KG, 1990, P NATL ACAD SCI USA, V87, P7588, DOI 10.1073/pnas.87.19.7588; FUKAMIZU A, 1989, BIOCHEM BIOPH RES CO, V165, P826, DOI 10.1016/S0006-291X(89)80040-3; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; Germain S, 1996, BIOCHEM J, V316, P107, DOI 10.1042/bj3160107; Germain S, 1997, FEBS LETT, V407, P177, DOI 10.1016/S0014-5793(97)00332-3; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Konoshita T, 1996, KIDNEY INT, V50, P1515, DOI 10.1038/ki.1996.466; Lang JA, 1996, AM J PHYSIOL-RENAL, V271, pF94, DOI 10.1152/ajprenal.1996.271.1.F94; LANG JA, 1995, HYPERTENSION, V25, P704, DOI 10.1161/01.HYP.25.4.704; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; PINET F, 1988, J CLIN ENDOCR METAB, V67, P1211, DOI 10.1210/jcem-67-6-1211; POISNER AM, 1981, ENDOCRINOLOGY, V109, P1150, DOI 10.1210/endo-109-4-1150; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; SKINNER SL, 1968, AM J OBSTET GYNECOL, V101, P529, DOI 10.1016/0002-9378(68)90564-4; SOUBRIER F, 1983, NUCLEIC ACIDS RES, V11, P7181, DOI 10.1093/nar/11.20.7181; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; Yan Y, 1997, CIRC RES, V81, P558, DOI 10.1161/01.RES.81.4.558	28	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25292	25300		10.1074/jbc.273.39.25292	http://dx.doi.org/10.1074/jbc.273.39.25292			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737995	hybrid			2022-12-25	WOS:000076085400045
J	Du, M; Sansores-Garcia, L; Zu, ZF; Wu, KKY				Du, M; Sansores-Garcia, L; Zu, ZF; Wu, KKY			Cloning and expression analysis of a novel salicylate suppressible gene, Hs-CUL-3, a member of cullin/Cdc53 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; KAPPA-B; F-BOX; INHIBITION; PROTEINS; COMPLEX; CYCLOOXYGENASE-2; INFLAMMATION; TRANSLATION; TRANSITION	By using a mRNA differential display technique to search for salicylate suppressible genes, we identified a cDNA in human foreskin fibroblasts, which by Gen-Bank(TM) DNA data base search shows sequence homology to the recently reported cullin/Cdc53 (CUL) family genes, especially CUL-3, We have cloned the full-length human CUL-3 (Hs-CUL-3) cDNA, It encodes a 768-amino acid polypeptide and has a predicted molecular weight of 88,939, The amino acid sequence of Hs-CUL-3 shows 46% homology to that of its Caenorhabditis elegans ortholog, Ce-CUL-3, and 27 and 23% to that of Hs-CUL-1 and Hs-CUL-2, respectively. Northern blot analysis showed that phorbol 12-myristate 13-acetate increased the expression of Hs-CUL-3 mRNA in a concentration- and time-dependent manner, and this increase was inhibited by sodium salicylate, Hs-CUL-3 widely expressed in human tissues and its expression in cultured COLO205 colon cancer cells was increased when compared with that in normal colon cells, It is Likely that Hs-CUL-3 is involved in cell proliferation control.	Univ Texas, Hlth Sci Ctr, Sch Med, Div Hematol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Acad Sinica, Inst Biomed Sci, Vasc Biol Res Program, Taipei 11529, Taiwan	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Academia Sinica - Taiwan	Wu, KKY (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Div Hematol, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.		Wu, Kenneth Kun-Yu/B-1070-2010	Sansores-Garcia, Leticia/0000-0003-2510-225X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50675] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pierce JW, 1996, J IMMUNOL, V156, P3961; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006	25	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24289	24292		10.1074/jbc.273.38.24289	http://dx.doi.org/10.1074/jbc.273.38.24289			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733711	hybrid			2022-12-25	WOS:000076007300003
J	Efimova, T; LaCelle, P; Welter, JF; Eckert, RL				Efimova, T; LaCelle, P; Welter, JF; Eckert, RL			Regulation of human involucrin promoter activity by a protein kinase C, Ras, MEKK1, MEK3, p38/RK, AP1 signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN ACTIVATION DOMAIN; NERVE GROWTH-FACTOR; NIH 3T3 CELLS; MAP KINASE; SUBSTRATE-SPECIFICITY; SUSTAINED ACTIVATION; CELLULAR STRESSES; GENE-EXPRESSION; PLASMA-MEMBRANE; PC12 CELLS	Involucrin is a marker of keratinocyte terminal differentiation. Our previous studies show that involucrin mRNA levels are increased by the keratinocyte differentiating agent, 12-O-tetradecanoylphorbol-13-acetate (TPA) (Welter, J.F., Crish, J. F., Agarwal, C., and Eckert, R. L. (1995) J. Biol. Chem, 270, 12614-12622). We now study the signaling cascade responsible for this regulation. Protein kinase C and tyrosine kinase inhibitors inhibit both the TPA-dependent mRNA increase and the TPA-dependent increase in hINV promoter activity. The relevant response element is located within the promoter proximal regulatory region and includes an AP1 site, AP1-1. Co-transfection of the hINV promoter with dominant negative forms of Ras, MEKK1, MEK1, MEK7, MEK3, p38/RK, and c-Jun inhibit the TPA-dependent increase. Wild type MEKK1 enhances promoter activity and the activity can be inhibited by dominant negative MEKK1, MEK1, MEK7, MEK3, p38/RK, and c-Jun. In contrast, wild type Raf-1, ERK1, ERK2, MEK4, or JNK1 produced no change in activity and the dominant negative forms of these kinases failed to suppress TPA-dependent transcription. Treatment with an S6 kinase (S6K) inhibitor, or transfection with constitutively active S6K produced relatively minor changes in promoter activity, ruling out a regulatory role for S6K. These results suggest that activation of involucrin transcription involves a pathway that includes protein kinase C, Pas, MEKK1, MEK3, and p38/RK. Additional pathways that transfer MEKK1 activation via MEK1 and MEK7 also may function, but the downstream targets of these kinases need to be identified. AP1 transcription factors appear to be the ultimate target of this regulation.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Orthoped, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm E532, Cleveland, OH 44106 USA.			Efimova, Tatiana/0000-0002-9869-1545	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39750] Funding Source: Medline; NIDDK NIH HHS [DK07678] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARROLL JM, 1992, J CELL SCI, V103, P925; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ECKERT RL, 1989, ENVIRON HEALTH PERSP, V80, P109, DOI 10.2307/3430736; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1996, CELL DEATH DIFFER, V3, P373; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GILFIX BM, 1985, J BIOL CHEM, V260, P4026; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; GRUDA MC, 1994, ONCOGENE, V9, P2537; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LaPres JJ, 1996, J BIOL CHEM, V271, P23154, DOI 10.1074/jbc.271.38.23154; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RICE RH, 1992, MONOGR NATL CANC I, P87; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; THOMAS G, 1993, BIOCHEM SOC T, V21, P901, DOI 10.1042/bst0210901; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WARHOL MJ, 1985, J HISTOCHEM CYTOCHEM, V33, P141, DOI 10.1177/33.2.2578499; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	82	143	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24387	24395		10.1074/jbc.273.38.24387	http://dx.doi.org/10.1074/jbc.273.38.24387			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733728	hybrid			2022-12-25	WOS:000076007300020
J	Merlos-Suarez, A; Fernandez-Larrea, J; Reddy, P; Baselga, J; Arribas, J				Merlos-Suarez, A; Fernandez-Larrea, J; Reddy, P; Baselga, J; Arribas, J			Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR-ALPHA; TNF RECEPTOR; L-SELECTIN; METALLOPROTEASE; MEMBRANE; INHIBITOR; DISINTEGRIN; CLEAVAGE; BETA	The extracellular domain of a heterogeneous group of transmembrane proteins can be proteolytically released from the cell surface, a process known as protein ectodomain shedding. Despite the biomedical importance of several substrates of the shedding system, such as the beta-amyloid precursor protein (beta APP), little is known about the regulation of protein ectodomain shedding, and the only protease known to be involved is the metalloprotease disintegrin, tumor necrosis factor-alpha converting enzyme (TACE). Here, we show that previously described pro-transforming growth factor-alpha shedding-defective cell mutants (M2 cells), known to be defective in ectodomain shedding of several molecules, that include beta APP, fail to shed the ectodomain of pro-TNF-alpha. The target of the mutation is a component required for TACE activity, since transfection of TACE into M2 cells has no effect on the shedding of pro-TNF-alpha and somatic cell fusions between M2 cells and TACE null cells recover the ability to shed pro-TNF-alpha, pro-transforming growth factor-alpha, and beta APP. Furthermore, we show that TACE is also necessary for the shedding of beta APP since TACE null cells show defective beta APP shedding. Biochemical evidence shows that the component that controls TACE is different from protein kinase C, the only known activator of protein ectodomain shedding, and that this component does not affect biosynthesis or processing of TACE or other metalloprotease disintegrins. The component mutated in M2 cells is likely to control only a subset of metalloprotease disintegrins involved in regulated ectodomain shedding, since Notch processing, a process known to be dependent on the activity of another metalloprotease disintegrin, Kuzbanian, is normal in M2 cells.	Hosp Gen Univ Vall Hebron, Med Oncol Serv, Lab Recerca Oncol, Barcelona 08035, Spain; Immunex Res & Dev Corp, Seattle, WA 98101 USA	Hospital Universitari Vall d'Hebron	Arribas, J (corresponding author), Hosp Gen Univ Vall Hebron, Med Oncol Serv, Lab Recerca Oncol, Psg Val Hebron 119-129, Barcelona 08035, Spain.	jarribas@hg.vhebron.es	Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664; Fernandez-Larrea, Juan Bautista/0000-0001-8007-8040				ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Couet J, 1996, J BIOL CHEM, V271, P4545; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	34	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24955	24962		10.1074/jbc.273.38.24955	http://dx.doi.org/10.1074/jbc.273.38.24955			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733803	hybrid			2022-12-25	WOS:000076007300095
J	Miyazawa, K; Mori, A; Miyata, H; Akahane, M; Ajisawa, Y; Okudaira, H				Miyazawa, K; Mori, A; Miyata, H; Akahane, M; Ajisawa, Y; Okudaira, H			Regulation of interleukin-beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; TERNARY COMPLEX FACTORS; NECROSIS-FACTOR-ALPHA; UA-RICH SEQUENCES; MAP KINASE; RHEUMATOID-ARTHRITIS; CELLULAR STRESSES; SUBSTRATE-SPECIFICITY; SYNOVIAL FIBROBLASTS; PYRIDINYL IMIDAZOLES	Involvement of p38 mitogen-activated protein (MAP) kinase in interleukin (IL)-6 gene expression of human fibroblast-like synoviocytes (FLSs) was assessed. p38 MAP kinase was constitutively expressed in human FLSs and activated in response to IL-1 beta. A pyridinylimidazole compound, SB203580, inhibited p38 MAP kinase activity in vivo, since the activity of MAPKAP kinase-2 (a substrate of p38 MAP kinase) in IL-1 beta-stimulated FLSs was totally suppressed by it. SB203580 concentration-dependently inhibited protein production and gene expression of IL-6 by human FLSs. The effect of SB203580 was dependent on de novo protein synthesis. SB203580 significantly reduced the stability of IL-6 mRNA without affecting the rate of IL-6 gene transcription. Here, we provide evidence that p38 MAP kinase is activated in response to IL-1 beta in human FLSs and is involved in IL-6 synthesis by stabilizing IL-6 mRNA.	Kissei Pharmaceut Co Ltd, Cent Res Labs, Matsumoto, Nagano 3998304, Japan; Natl Sagamihara Hosp, Clin Res Ctr Allergy & Rheumatol, Kanagawa 2888522, Japan; Univ Tokyo, Fac Med, Dept Med & Phys Therapy, Tokyo 1130033, Japan	Kissei Pharmaceutical Co Ltd; University of Tokyo	Miyazawa, K (corresponding author), Kissei Pharmaceut Co Ltd, Cent Res Labs, 4365-1 Kashiwabara, Matsumoto, Nagano 3998304, Japan.	keijimiya@aol.com						ADAMS JL, 1993, Patent No. 14081; AKIRA S, 1993, ADV IMMUNOL, V56, P1; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BAYAERT R, 1996, EMBO J, V15, P1914; Blanque R, 1997, DRUG EXP CLIN RES, V23, P63; BROZIK M, 1992, J RHEUMATOL, V19, P63; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIN JE, 1990, ARTHRITIS RHEUM, V33, P1776, DOI 10.1002/art.1780331204; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Griswold DE, 1996, PHARM COMMUN, V7, P323; GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUY GR, 1991, J BIOL CHEM, V266, P14343; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOUSSIAU FA, 1988, ARTHRITIS RHEUM, V31, P784, DOI 10.1002/art.1780310614; Ivashkiv LB, 1996, ADV IMMUNOL, V63, P337, DOI 10.1016/S0065-2776(08)60859-7; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600-065X.1995.tb00070.x; MANICOURT DH, 1995, ARTHRITIS RHEUM, V38, P1031, DOI 10.1002/art.1780380803; MIHARA M, 1995, BRIT J RHEUMATOL, V34, P321; Miyazawa K, 1996, BRIT J PHARMACOL, V118, P915, DOI 10.1111/j.1476-5381.1996.tb15486.x; Miyazawa K, 1998, AM J PATHOL, V152, P793; Miyazawa K, 1998, J BIOL CHEM, V273, P7620, DOI 10.1074/jbc.273.13.7620; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICHETT W, 1995, J INFLAMM, V45, P97; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; Ridley SH, 1997, J IMMUNOL, V158, P3165; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; SUTHERLAND GR, 1988, HUM GENET, V79, P335; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WENDLING D, 1993, J RHEUMATOL, V20, P259; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YOSHIZAKI K, 1996, JPN SOC IMMUNOL, V26, pI115; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	67	196	204	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24832	24838		10.1074/jbc.273.38.24832	http://dx.doi.org/10.1074/jbc.273.38.24832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733787	hybrid			2022-12-25	WOS:000076007300079
J	Casareno, RLB; Waggoner, D; Gitlin, JD				Casareno, RLB; Waggoner, D; Gitlin, JD			The copper chaperone CCS directly interacts with copper/zinc superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; P-TYPE ATPASES; HUMAN-CELLS; GENE; MUTATIONS; PROTEIN; DISEASE; MICE; DEGENERATION; HOMEOSTASIS	Dominantly inherited mutations in the gene encoding copper/zinc superoxide dismutase (SOD1) result in the fatal motor neuron disease familial amyotrophic lateral sclerosis (FALS), These mutations confer a gain-of-function to SOD1 with neuronal degeneration resulting from enhanced free radical generating activity of the copper present in the mutant enzyme. The delivery of copper to SOD1 is mediated through a soluble factor identified as the copper chaperone for SOD1 (CCS). Amino acid sequence alignment of SOD1 and CCS reveals a striking homology with conservation of the amino acids essential for mediating SOD1 homodimerization. Here we demonstrate that CCS and SOD1 directly interact in vitro and in vivo and that this interaction is mediated via the homologous domains in each protein. Importantly, CCS interacts not only with wild-type SOD1 but also with SOD1 containing the common missense mutations resulting in FALS. Our findings therefore reveal a common mechanism whereby different SOD1 FALS mutants may result in neuronal injury and suggest a novel therapeutic approach in patients affected by this fatal disease.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Gitlin, JD (corresponding author), St Louis Childrens Hosp, 1 Childrens Pl, St Louis, MO 63110 USA.	gitlin@kidsa1.wustl.edu			NIDDK NIH HHS [DK44464] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044464, R01DK044464] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; CARRI MT, 1994, FEBS LETT, V356, P314, DOI 10.1016/0014-5793(94)01295-4; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Elgersma Y, 1996, BBA-REV BIOMEMBRANES, V1286, P269, DOI 10.1016/S0304-4157(96)00012-3; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Moreno S, 1997, J HISTOCHEM CYTOCHEM, V45, P1611, DOI 10.1177/002215549704501204; PUFAHL R, 1997, SCIENCE, V238, P853; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SIDDIQUE T, 1996, HUM MOL GENET, V271, P1406; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	34	190	197	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23625	23628		10.1074/jbc.273.37.23625	http://dx.doi.org/10.1074/jbc.273.37.23625			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726962	hybrid			2022-12-25	WOS:000075893100003
J	Grasso, L; Huang, MX; Sullivan, CD; Messler, CJ; Kiser, MB; Dragwa, CR; Holroyd, KJ; Renauld, JC; Levitt, RC; Nicolaides, NC				Grasso, L; Huang, MX; Sullivan, CD; Messler, CJ; Kiser, MB; Dragwa, CR; Holroyd, KJ; Renauld, JC; Levitt, RC; Nicolaides, NC			Molecular analysis of human interleukin-9 receptor transcripts in peripheral blood mononuclear cells - Identification of a splice variant encoding for a nonfunctional cell surface receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-9 RECEPTOR; PSEUDOAUTOSOMAL REGION; GENOMIC ORGANIZATION; B-LYMPHOCYTES; ALPHA CHAIN; GENE; ASTHMA; MURINE; LOCALIZATION; ACTIVATION	Genetic studies on mouse models of asthma have identified interleukin-9 (IL9) as a determining factor in controlling bronchial hyperresponsiveness, a hallmark of the disease. Recently, the human IL9 receptor (hIL9R) gene locus has also been implicated in determining susceptibility to bronchial hyperresponsiveness and asthma. in order to evaluate the structure and function of the encoded product, we analyzed receptor transcripts derived from peripheral blood mononuclear cells of 50 unrelated donors. Sequence analysis of time entire coding region identified a splice variant that contains an in frame deletion of a single residue at codon 173 (Delta Q). This variant could be permanently expressed in a cytokine-dependent murine T-cell line but lacked the ability to induce proliferation in response to human IL9. In situ analyses of cells expressing the wild-type and Delta Q receptors found both forms to be expressed at the cell surface, but the Delta Q receptor was unable to bind hIL9 and could not be recognized by N-terminal specific antibodies. These findings demonstrate that hIL9R Delta Q presents an altered structure and function and suggests its potential role in down-regulating IL9 signaling in effector cells and associated biological processes.	Magainin Pharmaceut Inc, Magainin Inst Mol Med, Plymouth Meeting, PA 19462 USA; Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Expt Med Unit, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Nicolaides, NC (corresponding author), Magainin Pharmaceut Inc, Magainin Inst Mol Med, 5110 Campus Dr, Plymouth Meeting, PA 19462 USA.	nnicolaides@magainin.com	Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131; Holroyd, Kenneth/0000-0001-6050-3935				CHANG MS, 1994, BLOOD, V83, P3199; COFANO F, 1990, J BIOL CHEM, V265, P4064; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DESANCTIS G, 1997, NAT GENET, V11, P150; DONAHUE RE, 1990, BLOOD, V75, P2271; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; EWART S, 1995, J APPL PHYSIOL, V79, P560, DOI 10.1152/jappl.1995.79.2.560; GARRONE P, 1991, EUR J IMMUNOL, V21, P1365, DOI 10.1002/eji.1830210606; GESSNER A, 1994, INFECT IMMUN, V62, P4112, DOI 10.1128/IAI.62.10.4112-4117.1994; GODFRAIND C, 1998, IN PRESS J IMMUNOL; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HOLGATE ST, 1995, INT ARCH ALLERGY IMM, V107, P29, DOI 10.1159/000236921; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; Kammer W, 1996, J BIOL CHEM, V271, P23634, DOI 10.1074/jbc.271.39.23634; KERMOUNI A, 1995, GENOMICS, V29, P371, DOI 10.1006/geno.1995.9992; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; LEVITT RC, 1998, IN PRESS J ALLERG CL; Marsh DG, 1997, NAT GENET, V15, P389; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; RENAULD JC, 1990, J IMMUNOL, V144, P4235; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; ROBINSON DS, 1992, NEW ENGL J MED, V326, P289; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; SANGER JW, 1975, P NATL ACAD SCI USA, V72, P1913, DOI 10.1073/pnas.72.5.1913; STOECKERT CJ, 1990, EXP HEMATOL, V18, P1164; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; Vermeesch JR, 1997, HUM MOL GENET, V6, P1, DOI 10.1093/hmg/6.1.1; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; WILLIAMS DE, 1990, BLOOD, V76, P906; Yang YZ, 1996, J BIOL CHEM, V271, P28235, DOI 10.1074/jbc.271.45.28235; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zhu YX, 1997, J BIOL CHEM, V272, P21334, DOI 10.1074/jbc.272.34.21334	44	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24016	24024		10.1074/jbc.273.37.24016	http://dx.doi.org/10.1074/jbc.273.37.24016			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727018	hybrid			2022-12-25	WOS:000075893100059
J	Yan, J; Roy, S; Apolloni, A; Lane, A; Hancock, JF				Yan, J; Roy, S; Apolloni, A; Lane, A; Hancock, JF			Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT BINDING DOMAINS; PROTEIN-KINASE; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; N-RAS; CELLS; 14-3-3-PROTEINS; ASSOCIATION; SIGNAL	Ha-, N-, and Ki-Ras are ubiquitously expressed in mammalian cells and can all interact with the same set of effector proteins. We show here, however, that in vivo there are marked quantitative differences in the ability of Ki- and Ha-Ras to activate Raf-1 and phosphoinositide 3-kinase, Thus, Ki-Ras both recruits Raf-1 to the plasma membrane more efficiently than Ha-Res and is a more potent activator of membrane-recruited Raf-1 than Ha-Res. in contrast, Ha-Bas is a more potent activator of phosphoinositide 3-kinase than Ki-Ras. interestingly, the ability of Ha-Ras to recruit Rak-1 to the plasma membrane is significantly increased when the Ba-Ras hypervariable region is shortened so that the spacing of the Ha-Ras GTPase domains from the inner surface of the plasma membrane mimicks that of Ki-Ras, Importantly, these data show for the first time that the activation of different Ras isoforms can have distinct biochemical consequences for the cell, The mutation of specific Ras isoforms in different human tumors can, therefore, also be rationalized.	Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund Lab Expt Oncol, Brisbane, Qld 4006, Australia	University of Queensland	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund Lab Expt Oncol, Herston Rd, Brisbane, Qld 4006, Australia.		Yan, Jun/F-1224-2010	Yan, Jun/0000-0001-9617-0335; Hancock, John/0000-0003-0542-4710				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOS JL, 1989, CANCER RES, V49, P4682; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CLARK SF, 1988, J CELL BIOL, P1211; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LUO Z, 1996, J NATURE, V383, P181; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mineo C, 1997, J BIOL CHEM, V272, P10345; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PHILLIPS W, 1998, IN PRESS CANCER; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VICIANA PR, 1996, EMBO J, V15, P2442; VICIANA PR, 1994, NATURE, V370, P527; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	48	364	367	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24052	24056		10.1074/jbc.273.37.24052	http://dx.doi.org/10.1074/jbc.273.37.24052			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727023	hybrid			2022-12-25	WOS:000075893100064
J	Doring, F; Will, J; Amasheh, S; Clauss, W; Ahlbrecht, H; Daniel, H				Doring, F; Will, J; Amasheh, S; Clauss, W; Ahlbrecht, H; Daniel, H			Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM ANTIBIOTICS; EXPRESSION CLONING; FREE-ENERGIES; ZWITTERION; SOLVATION; OOCYTES; GLYCINE; MODEL	Proton-dependent electrogenic transporters for di- and tripeptides have been identified in bacteria, fungi, plants, and mammalian cells. They all show sequence-independent transport of all possible di- and tripeptides as well as of a variety of peptidomimetics, We used the mammalian intestinal peptide transporter PEPT1 as a model to define the molecular basis for its multisubstrate specificity. By employing computational analysis of possible substrate conformations in combination with transport assays using transgenic yeast cells and Xenopus laevis oocytes expressing PEPT1, the minimal structural requirements for substrate binding and transport were determined. Based on a series of medium chain fatty acids bearing an amino group as a head group (omega-amino fatty acids, omega-AFA), we show that electrogenic transport by PEPT1 requires as a minimum the two ionized head groups separated by at least four methylene groups. Consequently, a > 500 pm < 630 pm distance between the two charged centers (carboxylic carbon and amino nitrogen) is sufficient for substrate recognition and transport. Removal of either the amino group or the carboxyl group in omega-AFA maintained the affinity of the compound for interaction with the transporter but abolished the capability for electrogenic transport, Additional groups in the omega-AFA backbone that provide more hydrogen bonding sites appear to increase substrate affinity but are not essential. The information provided here does (a) explain the capability of the peptide carrier for sequence-independent transport of thousands of different substrates and (b) set the molecular basis for a rational drug design to increase the absorption of peptide-based drugs mediated by PEPT1.	Univ Giessen, Inst Nutr Sci, Mol Nutr Ctr, D-35392 Giessen, Germany; Univ Giessen, Inst Anim Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen	Daniel, H (corresponding author), Univ Giessen, Inst Nutr Sci, Mol Nutr Ctr, Wilhelmstr 20, D-35392 Giessen, Germany.	hannelore.daniel@ernaehrung.uni-giessen.de	Daniel, Hannelore/B-8982-2009; Döring, Frank/E-9483-2010; Amasheh, Salah/AAG-4035-2021					Amasheh S, 1997, J MEMBRANE BIOL, V155, P247, DOI 10.1007/s002329900177; BOLL M, 1994, PFLUG ARCH EUR J PHY, V429, P146, DOI 10.1007/BF02584043; Brandsch M, 1998, J BIOL CHEM, V273, P3861, DOI 10.1074/jbc.273.7.3861; CRAMER CJ, 1991, J AM CHEM SOC, V113, P8305, DOI 10.1021/ja00022a017; CRAMER CJ, 1992, SCIENCE, V256, P213, DOI 10.1126/science.256.5054.213; Daniel H, 1996, J MEMBRANE BIOL, V154, P197, DOI 10.1007/s002329900144; Daniel H, 1997, AM J PHYSIOL-RENAL, V273, pF1, DOI 10.1152/ajprenal.1997.273.1.F1; Doring F, 1997, BIOCHEM BIOPH RES CO, V232, P656, DOI 10.1006/bbrc.1997.6351; Doring F, 1996, J PHYSIOL-LONDON, V497, P773; Doring F, 1998, J CLIN INVEST, V101, P2761, DOI 10.1172/JCI1909; Enjoh M, 1996, BIOSCI BIOTECH BIOCH, V60, P1893, DOI 10.1271/bbb.60.1893; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FRISCH MJ, 1995, GAUSSIAN 94; Gordon MS, 1996, ACCOUNTS CHEM RES, V29, P536, DOI 10.1021/ar9600594; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; JENSEN JH, 1995, J AM CHEM SOC, V117, P8159, DOI 10.1021/ja00136a013; MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2; Price WD, 1997, J AM CHEM SOC, V119, P11988, DOI 10.1021/ja9711627; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Saito H, 1995, J PHARMACOL EXP THER, V275, P1631; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; Simon Craw JD, 1997, J CHEM SOC P1, V2, P869; STEINER HY, 1995, MOL MICROBIOL, V16, P825, DOI 10.1111/j.1365-2958.1995.tb02310.x; SUENRAM RD, 1978, J MOL SPECTROSC, V72, P372, DOI 10.1016/0022-2852(78)90137-6; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; Wenzel U, 1996, J PHARMACOL EXP THER, V277, P831; WENZEL U, 1995, BRIT J PHARMACOL, V116, P3021, DOI 10.1111/j.1476-5381.1995.tb15958.x	27	120	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23211	23218		10.1074/jbc.273.36.23211	http://dx.doi.org/10.1074/jbc.273.36.23211			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722551	hybrid			2022-12-25	WOS:000075778100051
J	Hassett, RF; Yuan, DS; Kosman, DJ				Hassett, RF; Yuan, DS; Kosman, DJ			Spectral and kinetic properties of the Fet3 protein from Saccharomyces cerevisiae, a multinuclear copper ferroxidase enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBATE OXIDASE; IRON UPTAKE; CERULOPLASMIN; YEAST; PURIFICATION; LACCASE; GENE; SITE; STELLACYANIN; MECHANISM	High affinity iron uptake in Saccharomyces cerevisiae requires Fet3p. Fet3p is proposed to facilitate iron uptake by catalyzing the oxidation of Fe(II) to Fe(III) by O-2; in this model, Fe(III) is the substrate for the iron permease, encoded by FTR1. Here, a recombinant Fet3p has been produced in yeast that, lacking the C-terminal membrane-spanning domain, is secreted directly into the growth medium. Solutions of this Fet3p at >1 mg/ml have the characteristic blue color of a type 1 Cu(II)-containing protein, consistent with the sequence homology that placed this protein in the class of multinuclear copper oxidases that includes ceruloplasmin. Fet3p has an intense absorption at 607 nm (epsilon = 5500 M-1 cm(-1)) due to this type 1 Cu(II) and a shoulder in the near UV at 330 nm (epsilon = 5000 M-1 cm(-1)) characteristic of a type 3 binuclear Cu(II) cluster. The EPR spectrum of this Fet3p showed the presence of one type 1 Cu(II) and one type 2. Cu(II) (A(parallel to) = 91 and 190 x 10(-4) cm(-1), respectively). Copper analysis showed this protein to have 3.85 g atom copper/mol, consistent with the presence of one each of the three types of Cu(II) sites found in multinuclear copper oxidases. N-terminal analysis demonstrated that cleavage of a signal peptide occurred after Ala-21 in the primary translation product. Mass spectral and carbohydrate analysis of the protein following Endo H treatment indicated that the preparation was still 15% (w/w) carbohydrate, probably O-linked. Kinetic analysis of the in vitro ferroxidase reaction catalyzed by this soluble Fet3p yielded precise kinetic constants. The K-m values for Fe(II) and O-2 were 4.8 and 1.3 mu M, respectively, while k(cat) values for Fe(II) and O-2 turnover were 9.5 and 2.3 min(-1), consistent with an Fe(II):O-2 reaction stoichiometry of 4:1.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kosman, DJ (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	camkos@acsu.buffalo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46787] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREASSON L-E, 1970, Biochimica et Biophysica Acta, V200, P247, DOI 10.1016/0005-2795(70)90168-6; ANDREASSON LE, 1979, BIOCHIM BIOPHYS ACTA, V568, P145, DOI 10.1016/0005-2744(79)90282-1; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Badsberg U, 1996, BIOCHEMISTRY-US, V35, P7021, DOI 10.1021/bi960621y; Bonomi F, 1996, J BIOL INORG CHEM, V1, P67, DOI 10.1007/s007750050024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CALABRESE L, 1981, BIOCHEM J, V199, P667, DOI 10.1042/bj1990667; CHIDAMBARAM MV, 1983, FEBS LETT, V159, P137, DOI 10.1016/0014-5793(83)80432-3; COLE JL, 1991, J AM CHEM SOC, V113, P9080, DOI 10.1021/ja00024a008; deSilva D, 1997, J BIOL CHEM, V272, P14208, DOI 10.1074/jbc.272.22.14208; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIBILIO AJ, 1992, INORG CHIM ACTA, V198, P145, DOI 10.1016/S0020-1693(00)92355-7; DISCHE Z, 1962, CARBOHYDR CHEM, V1, P479; EIDE D, 1992, J BIOL CHEM, V267, P20774; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; FRIEDEN E, 1965, J GEN PHYSIOL, V49, P213, DOI 10.1085/jgp.49.1.213; Frieden E., 1976, IRON COPPER PROTEINS, V74, P89; GREEN BN, 1991, BIOCHEM SOC T, V19, P929, DOI 10.1042/bst0190929; GUTTERIDGE JMC, 1989, CLIN HAEMATOL, V2, P195; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOSMAN DJ, 1985, BIOL APPL SPECTROSCO, P89; LEHLE L, 1984, BIOCHIM BIOPHYS ACTA, V799, P246, DOI 10.1016/0304-4165(84)90267-8; LERCH K, 1978, BIOCHIM BIOPHYS ACTA, V534, P7, DOI 10.1016/0005-2795(78)90470-1; Levi S, 1996, BIOCHEM J, V317, P467, DOI 10.1042/bj3170467; Lindley PF, 1997, J BIOL INORG CHEM, V2, P454, DOI 10.1007/s007750050156; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; MARCHESINI A, 1979, EUR J BIOCHEM, V101, P65, DOI 10.1111/j.1432-1033.1979.tb04217.x; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Miyajima H, 1996, FREE RADICAL BIO MED, V20, P757, DOI 10.1016/0891-5849(95)02178-7; NAKANO M, 1993, EUR NEUROL, V33, P44, DOI 10.1159/000118537; Okamoto N, 1996, HUM GENET, V97, P755; OSAKI S, 1966, J BIOL CHEM, V241, P5053; OSAKI S, 1966, J BIOL CHEM, V241, P2746; OSAKI S, 1967, J BIOL CHEM, V242, P2653; ROMERO A, 1993, J MOL BIOL, V229, P1007, DOI 10.1006/jmbi.1993.1101; SCHOSINSKY KH, 1974, CLIN CHEM, V20, P1556; Segel IH, 1975, ENZYME KINETICS, P54; SHIN W, 1996, J AM CHEM SOC, V118, P3203; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STRANGE RW, 1995, BIOCHEMISTRY-US, V34, P220, DOI 10.1021/bi00001a026; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TREFFRY A, 1993, BIOCHEM J, V296, P721, DOI 10.1042/bj2960721; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	58	87	88	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23274	23282		10.1074/jbc.273.36.23274	http://dx.doi.org/10.1074/jbc.273.36.23274			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722559	hybrid			2022-12-25	WOS:000075778100059
J	Ito, N; Wernstedt, C; Engstrom, U; Claesson-Welsh, L				Ito, N; Wernstedt, C; Engstrom, U; Claesson-Welsh, L			Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA; HIGH-AFFINITY BINDING; SIGNAL-TRANSDUCTION; TUMOR ANGIOGENESIS; KINASE RECEPTOR; PLC-GAMMA; PROTEIN; CELLS; RAS; FLT-1	Receptor tyrosine phosphorylation is crucial for sig nal transduction by creating high affinity binding sites for Src homology 2 domain-containing molecules. By expressing the intracellular domain of Flt-1/vascular endothelial growth factor receptor-1 in the baculosystem, we identified two major tyrosine phosphorylation sites at Tyr-1213 and Tyr-1242 and two minor tyrosine phosphorylation sites at Tyr-1327 and Tyr-1333 in this receptor. This pattern of phosphorylation of Flt-1 was also detected in vascular endothelial growth factor-stimulated cells expressing intact Flt-1. In vitro protein binding studies using synthetic peptides and immunoblotting showed that phospholipase C-gamma binds to both Y(p)1213 and Y(p)1333, whereas Grb2 and SHP2-containing tyrosine protein phosphatase (SHP-2) bind to Y(p)1213, and Nck and Crk bind to Y(p)1333 in a phosphotyrosine-dependent manner. In addition, unidentified proteins with molecular masses around 74 and 27 kDa bound to Y(p)1213 and another of 75 kDa bound to Y(p)1333 in a phosphotyrosine-dependent manner. SHP-2, phospholipase C-gamma, and Grb2 could also be shown to bind to the intact Flt-1 intracellular domain. These results indicate that a spectrum of already known as well as novel phosphotyrosine-binding molecules are involved in signal transduction by Flt-1.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Biomed Ctr, Ludwig Inst Canc Res, Uppsala Branch, S-75124 Uppsala, Sweden	Uppsala University; Ludwig Institute for Cancer Research	Claesson-Welsh, L (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.	lena.welsh.@medkem.uu.se		Claesson-Welsh, Lena/0000-0003-4275-2000				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HUYER G, 1995, BIOCHEMISTRY-US, V34, P1040, DOI 10.1021/bi00003a039; Joukov V, 1996, EMBO J, V15, P290; KOCH AE, 1994, J IMMUNOL, V152, P4149; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; MAGLIONE D, 1993, ONCOGENE, V8, P925; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SONYANG Z, 1993, CELL, V72, P767; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	48	90	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23410	23418		10.1074/jbc.273.36.23410	http://dx.doi.org/10.1074/jbc.273.36.23410			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722576	hybrid			2022-12-25	WOS:000075778100076
J	Pierce, HH; Schachat, F; Brandt, PW; Lombardo, CR; Kay, BK				Pierce, HH; Schachat, F; Brandt, PW; Lombardo, CR; Kay, BK			Identification of troponin C antagonists from a phage-displayed random peptide library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; EQUILIBRIUM BINDING CONSTANTS; INHIBITORY REGION; SKELETAL-MUSCLE; MACROMOLECULAR INTERACTIONS; BIOLOGICAL-ACTIVITY; SYNTHETIC PEPTIDES; KINETIC-ANALYSIS; SH3 LIGANDS; CALMODULIN	Affinity purification of a phage-displayed library, expressing random peptide 12-mers at the N terminus of protein III, has identified 10 distinct novel sequences which bind troponin C specifically. The troponin C-selected peptides yield a consensus binding sequence of (V/L)(D/E)XLKXXLXXLA. Sequence comparison revealed as much as a 62.5% similarity between phi T5, the peptide sequence of the phage clone with the highest level of binding to troponin C, and the N-terminal region of troponin I isoforms. Biotinylated peptides corresponding to library-derived sequences and similar sequences from various isoforms of troponin I were synthesized shown to bind troponin C specifically. Alkaline phosphatase fusion proteins of two of the phage clone sequences bound troponin C specifically, and were specifically competed by both library-derived and native troponin I peptides. Measurement of equilibrium dissociation constants of the peptides by surface plasmon resonance yielded dissociation constants for troponin C as low as 0.43 mu M for pT5; in contrast, dissociation constants for calmodulin were greater than 6 mu M for all peptides studied. Nondenaturing polyacrylamide gel electrophoresis demonstrated that pT5 formed a stable complex with troponin C in the presence of calcium. We also found that the pT5 peptide inhibited the maximal calcium-activated tension of rabbit psoas muscle fibers.	Duke Univ, Sch Med, Dept Cell Biol, Durham, NC 27710 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Macromol Interact Facil, Chapel Hill, NC 27599 USA; Columbia Univ, Sch Med, Dept Anat & Cell Biol, New York, NY 10032 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Columbia University	Schachat, F (corresponding author), Duke Univ, Sch Med, Dept Cell Biol, Durham, NC 27710 USA.				NEI NIH HHS [R01 EY11377] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011377] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adey NB, 1996, METHOD MOL CELL BIOL, V6, P34; ADEY NB, 1996, PHAGE DISPLAY PEPTID, P68; BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; Bevington PR., 2002, DATA REDUCTION ERROR; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; BRANDT PW, 1980, P NATL ACAD SCI-BIOL, V77, P4717, DOI 10.1073/pnas.77.8.4717; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEDMAN JR, 1993, J BIOL CHEM, V268, P23025; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; FOWLKES DM, 1992, BIOTECHNIQUES, V13, P422; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; KALININ NL, 1995, ANAL BIOCHEM, V228, P238, DOI 10.1006/abio.1995.1345; KATAYAMA E, 1982, J BIOCHEM-TOKYO, V91, P1449, DOI 10.1093/oxfordjournals.jbchem.a133835; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; Kay BK, 1995, PERSPECT DRUG DISCOV, V2, P251; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; MOTTI C, 1994, GENE, V146, P191, DOI 10.1016/0378-1119(94)90292-5; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Myszka DG, 1996, PROTEIN SCI, V5, P2468, DOI 10.1002/pro.5560051209; NGAI SM, 1992, J BIOL CHEM, V267, P15715; O'Shannessy D J, 1994, Curr Opin Biotechnol, V5, P65, DOI 10.1016/S0958-1669(05)80072-2; ONEIL KT, 1995, CURR OPIN STRUC BIOL, V5, P443, DOI 10.1016/0959-440X(95)80027-1; Pierce HH, 1996, MOL DIVERS, V1, P259, DOI 10.1007/BF01715530; PRADO A, 1995, MOL BIOL CELL, V6, P1433, DOI 10.1091/mbc.6.11.1433; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SPARKS AB, 1995, METHOD ENZYMOL, V255, P498; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; VANEYK JE, 1987, BIOCHEM CELL BIOL, V65, P982; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Yamabhai M, 1997, ANAL BIOCHEM, V247, P143, DOI 10.1006/abio.1997.2040	42	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23448	23453		10.1074/jbc.273.36.23448	http://dx.doi.org/10.1074/jbc.273.36.23448			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722581	hybrid, Green Published			2022-12-25	WOS:000075778100081
J	Slater, SJ; Taddeo, FJ; Mazurek, A; Stagliano, BA; Milano, SK; Kelly, MB; Ho, CJ; Stubbs, CD				Slater, SJ; Taddeo, FJ; Mazurek, A; Stagliano, BA; Milano, SK; Kelly, MB; Ho, CJ; Stubbs, CD			Inhibition of membrane lipid-independent protein kinase C alpha activity by phorbol esters, diacylglycerols, and bryostatin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; TRANSFERASE FUSION PROTEINS; CYSTEINE-RICH DOMAIN; BINDING DOMAIN; INDUCED DIFFERENTIATION; INDUCED TRANSLOCATION; REGULATORY DOMAIN; RAT-BRAIN; ACTIVATION; GAMMA	The activity of membrane-associated protein kinase C (PKC) has previously been shown to be regulated by two discrete high and low affinity binding regions for diacylglycerols and phorbol esters (Slater, S. J., Ho, C., Kelly, M. B., Larkin, J. D., Taddeo, F. J., Yeager, M. D., and Stubbs, C. D. (1996) J. Biol. Chem. 271, 4627-4631). PKC is also known to interact with both cytoskeletal and nuclear proteins; however, less is known concerning the mode of activation of this non-membrane form of PKC. By using the fluorescent phorbol ester, sapintoxin D (SAPD), PKC alpha, alone, was found to possess both low and high affinity phorbol ester-binding sites, showing that interaction with these sites does not require association with the membrane. Importantly, a fusion protein containing the isolated C1A/C1B (C1) domain of PKC alpha also bound SAPD with low and high affinity, indicating that the sites may be confined to this domain rather than residing elsewhere on the enzyme molecule. Both high and low affinity interactions with native PKC alpha were enhanced by protamine sulfate, which activates the enzyme without requiring Ca2+ or membrane lipids. However, this "non-membrane" PKC activity was inhibited by the phorbol ester 4 beta-12-O-tetradecanoylphorbol-13-acetate (TPA) and also by the fluorescent analog, SAPD, opposite to its effect on membrane-associated PKC alpha. Bryostatin-1 and the soluble diacylglycerol, 1-oleoyl-2-acetylglycerol, both potent activators of membrane-associated PKC, also competed for both low and high affinity SAPD binding and inhibited protamine sulfate-induced activity. Furthermore, the inactive phorbol ester analog 4 alpha-TPA (4 alpha-12-O-tetradecanoylphorbol-13-acetate) also inhibited non-membrane-associated PKC. In keeping with these observations, although TPA could displace high affinity SAPD binding from both forms of the enzyme, 4 alpha-TPA was only effective at displacing high affinity SAPD binding from nonmembrane-associated PHC. 4 alpha-TPA also displaced SAPD from the isolated C1 domain. These results show that although high and low affinity phorbol ester-binding sites are found on non-membrane-associated PKC, the phorbol ester binding properties change significantly upon association with membranes.	Thomas Jefferson Univ, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Stubbs, CD (corresponding author), Thomas Jefferson Univ, Dept Pathol & Cell Biol, Rm 271 JAH, Philadelphia, PA 19107 USA.				NIAAA NIH HHS [AA07215, AA07186, AA08022] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA008022, R01AA008022, P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P5002, DOI 10.1021/bi00390a018; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Bruins RH, 1995, ARCH BIOCHEM BIOPHYS, V324, P216, DOI 10.1006/abbi.1995.0033; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CARDELLINI E, 1993, BIOCHEM J, V291, P303, DOI 10.1042/bj2910303; CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI; DASILVA C, 1990, CANCER RES, V50, P2081; DELLAQUILA ML, 1987, CANCER RES, V47, P6006; DELLAQUILA ML, 1988, CANCER RES, V48, P3702; DIMITRIJEVIC SM, 1995, MOL PHARMACOL, V48, P259; FERRARI S, 1987, EUR J BIOCHEM, V163, P481, DOI 10.1111/j.1432-1033.1987.tb10894.x; GLYNN B, 1985, BIOCHEM J, V231, P489, DOI 10.1042/bj2310489; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Hunn M, 1997, FEBS LETT, V400, P226, DOI 10.1016/S0014-5793(96)01395-6; Hurley JH, 1997, PROTEIN SCI, V6, P477; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; ICHIKAWA S, 1995, J BIOCHEM-TOKYO, V117, P566, DOI 10.1093/oxfordjournals.jbchem.a124745; Irie K, 1997, BIOORGAN MED CHEM, V5, P1725, DOI 10.1016/S0968-0896(97)00116-8; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; ORR JW, 1992, J BIOL CHEM, V267, P15263; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; QUEST AFG, 1995, METHOD ENZYMOL, V252, P153; SAKO T, 1987, CANCER RES, V47, P5445; SHARKEY NA, 1985, BIOCHEM BIOPH RES CO, V133, P1051, DOI 10.1016/0006-291X(85)91242-2; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; Slater SJ, 1997, J BIOL CHEM, V272, P6167, DOI 10.1074/jbc.272.10.6167; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; STUBBS CD, 1981, BIOCHEMISTRY-US, V20, P4257, DOI 10.1021/bi00518a004; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WENDER PA, 1995, P NATL ACAD SCI USA, V92, P239, DOI 10.1073/pnas.92.1.239; Yanai Y, 1997, BIOORG MED CHEM LETT, V7, P117, DOI 10.1016/S0960-894X(96)00587-2; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	60	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23160	23168		10.1074/jbc.273.36.23160	http://dx.doi.org/10.1074/jbc.273.36.23160			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722545	hybrid			2022-12-25	WOS:000075778100045
J	Scaturro, M; Nastasi, T; Raimondi, L; Bellafiore, M; Cestelli, A; Di Liegro, I				Scaturro, M; Nastasi, T; Raimondi, L; Bellafiore, M; Cestelli, A; Di Liegro, I			H1(0) RNA-binding proteins specifically expressed in the rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN MESSENGER-RNA; CORTICAL-NEURONS; TRANSLATIONAL REGULATION; INTRACELLULAR-LOCALIZATION; TERMINAL DIFFERENTIATION; 3'-UNTRANSLATED REGION; ERYTHROLEUKEMIA-CELLS; HISTONE H1-DEGREES; FRIEND-CELLS; DROSOPHILA	During brain maturation, histone H1(0) accumulates in both nerve and glial cells. The expression of this "linker" histone, the role of which still remains unclear, is a complex process, having both transcriptional and post-transcriptional regulatory components. In particular, the expression of H1(0) in rat cortical neurons is regulated mainly at the post-transcriptional level, and unknown cellular proteins are likely to affect H1(0) mRNA stability and/or translation. In looking for such factors, we tested the ability of rat brain extracts to protect H1(0) RNA probe from degradation by T1 RNase. The results reported here demonstrate that rat brain contains at least one major (p40) and two minor (p110 and p70) binding factors, specific for H1(0) RNA, all of which are much more or exclusively expressed in adult rat brain, when compared with other tissues. The binding of the factors is confined to a portion of the 3'-untranslated region (3'-UTR), which is highly conserved among murine and human H1(0) mRNAs. These findings suggest that the proteins identified play a critical role in regulating the expression of H1(0) histone in the brain of mammals.	Dipartimento Biol Cellulare & Sviluppo Alberto Mo, I-90128 Palermo, Italy		Di Liegro, I (corresponding author), Dipartimento Biol Cellulare & Sviluppo Alberto Mo, Viale Sci,Parco Orleans, I-90128 Palermo, Italy.	diliegro@mbox.unipa.it	Bellafiore, Marianna/AAN-5526-2021; nastasi, tommaso/AAR-8730-2020; Raimondi, Lavinia/K-4085-2016; Scaturro, Maria/B-5005-2013	Bellafiore, Marianna/0000-0002-3092-1666; Raimondi, Lavinia/0000-0001-9394-2002; Scaturro, Maria/0000-0001-5614-8678				BANCHEV T, 1988, EXP CELL RES, V177, P1, DOI 10.1016/0014-4827(88)90019-5; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BOIX J, 1992, EXP CELL RES, V201, P531, DOI 10.1016/0014-4827(92)90306-S; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CASTIGLIA D, 1994, NEUROCHEM RES, V19, P1531, DOI 10.1007/BF00969002; Castiglia D, 1996, BIOCHEM BIOPH RES CO, V218, P390, DOI 10.1006/bbrc.1996.0068; CASTIGLIA D, 1993, NUCLEIC ACIDS RES, V21, P1674, DOI 10.1093/nar/21.7.1674; CASTIGLIA D, 1992, CELL MOL NEUROBIOL, V12, P259, DOI 10.1007/BF00712930; CESTELLI A, 1992, CELL MOL NEUROBIOL, V12, P33, DOI 10.1007/BF00711637; Cuezva JM, 1997, J BIOENERG BIOMEMBR, V29, P365, DOI 10.1023/A:1022450831360; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DILIEGRO I, 1990, CELL MOL NEUROBIOL, V10, P267, DOI 10.1007/BF00734579; DOMINGUEZ V, 1992, DEVELOPMENT, V115, P181; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GRUNWALD D, 1991, EXP CELL RES, V194, P174, DOI 10.1016/0014-4827(91)90350-4; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; KHOCHBIN S, 1991, FEBS LETT, V283, P65, DOI 10.1016/0014-5793(91)80554-G; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MOORMAN AFM, 1987, DIFFERENTIATION, V35, P100, DOI 10.1111/j.1432-0436.1987.tb00156.x; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; NAKAMURA M, 1994, NEURON, V13, P67, DOI 10.1016/0896-6273(94)90460-X; PEHRSON J, 1980, NATURE, V285, P43, DOI 10.1038/285043a0; Pennisi E, 1996, SCIENCE, V274, P503, DOI 10.1126/science.274.5287.503; PINA B, 1987, EUR J BIOCHEM, V164, P71, DOI 10.1111/j.1432-1033.1987.tb10994.x; PINA B, 1987, DEV BIOL, V123, P51, DOI 10.1016/0012-1606(87)90426-X; PINA B, 1984, BIOCHEM BIOPH RES CO, V123, P697, DOI 10.1016/0006-291X(84)90285-7; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; ROCHE J, 1985, NATURE, V314, P197, DOI 10.1038/314197a0; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SCATURRO M, 1995, NEUROCHEM RES, V20, P969, DOI 10.1007/BF00970744; Sossin WS, 1996, TRENDS NEUROSCI, V19, P215; Steward Oswald, 1995, Current Opinion in Neurobiology, V5, P55, DOI 10.1016/0959-4388(95)80087-5; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WOLFFE A, 1995, CHROMATIN STRUCTURE, P148; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007; ZLATANOVA JS, 1980, FEBS LETT, V112, P199, DOI 10.1016/0014-5793(80)80179-7	55	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22788	22791		10.1074/jbc.273.35.22788	http://dx.doi.org/10.1074/jbc.273.35.22788			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712912	hybrid			2022-12-25	WOS:000075616600088
J	ROISE, D; SCHATZ, G				ROISE, D; SCHATZ, G			MITOCHONDRIAL PRESEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review											ROISE, D (corresponding author), UNIV BASEL, BIOCTR, CH-4056 BASEL, SWITZERLAND.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM37803-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; AUSTEN BM, 1984, BIOCHEM J, V224, P317, DOI 10.1042/bj2240317; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; BRIGGS MS, 1984, BIOCHEMISTRY-US, V23, P3111, DOI 10.1021/bi00309a001; CHEN LB, 1981, COLD SPRING HARB SYM, V46, P141, DOI 10.1101/SQB.1982.046.01.018; DIERSTEIN R, 1985, J BIOL CHEM, V260, P5919; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; EILERS M, 1988, IN PRESS CELL; EPAND RM, 1986, J BIOL CHEM, V261, P17; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; HURT EC, 1987, NATURE, V325, P499, DOI 10.1038/325499a0; ITO A, 1985, J BIOCHEM-TOKYO, V98, P1571, DOI 10.1093/oxfordjournals.jbchem.a135426; KATAKAI R, 1984, J AM CHEM SOC, V106, P5715, DOI 10.1021/ja00331a049; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; Laxma Reddy G, 1986, FEBS Lett, V202, P349; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MAJZOUB JA, 1980, J BIOL CHEM, V255, P1478; MYERS M, 1987, BIOCHEMISTRY-US, V26, P4309, DOI 10.1021/bi00388a019; OHBA M, 1987, EMBO J, V6, P2109, DOI 10.1002/j.1460-2075.1987.tb02477.x; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, IN PRESS EMBO J, V7; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; SCHATZ G, 1987, EUR J BIOCHEM, V165, P1, DOI 10.1111/j.1432-1033.1987.tb11186.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SHINNAR AE, 1984, J AM CHEM SOC, V106, P5006, DOI 10.1021/ja00329a063; SKERJANC IS, 1987, EMBO J, V6, P3117, DOI 10.1002/j.1460-2075.1987.tb02621.x; TAMM LK, 1986, BIOCHEMISTRY-US, V25, P7470, DOI 10.1021/bi00371a032; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; YAFFE MP, 1985, EMBO J, V4, P2069, DOI 10.1002/j.1460-2075.1985.tb03893.x; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850; ZWIZINSKI C, 1983, J BIOL CHEM, V258, P4071	38	379	383	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1988	263	10					4509	4511						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M7886	9729103				2022-12-25	WOS:A1988M788600001
J	Kumar, S; Pandey, P; Bharti, A; Jin, SF; Weichselbaum, R; Weavers, D; Kufe, D; Kharbanda, S				Kumar, S; Pandey, P; Bharti, A; Jin, SF; Weichselbaum, R; Weavers, D; Kufe, D; Kharbanda, S			Regulation of DNA-dependent protein kinase by the Lyn tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; C-ABL; IONIZING-RADIATION; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; CELLULAR-RESPONSE; STRESS-RESPONSE; ACTIVATION; CELLS; PHOSPHORYLATION	The Src-like protein-tyrosine kinase Lyn is activated by ionizing radiation and certain other DNA-damaging agents, whereas the DNA-dependent protein kinase (DNA-PK), consisting of the catalytic subunits (DNA-PKcs) and Ku DNA-binding components, requires DNA double-stranded breaks for activation. Here me demonstrate that Lyn associates constitutively with DNA-PKcs. The SH3 domain of Lyn interacts directly with DNA-PKcs near a leucine zipper homology domain. We also show that Lyn phosphorylates DNA-PKcs but not Ku in vitro. The interaction between Lyn and DNA-PKcs inhibits DNA-PKcs activity and the ability of DNA-PKcs to form a complex with Ku/DNA. These results support the hypothesis that there are functional interactions between Lyn and DNA-PKcs in the response to DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Univ Chicago, Dept Radiat & Cellular Biol, Chicago, IL 60637 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago; Harvard University; Harvard Medical School	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA55241, CA75216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Kharbanda S, 1996, CANCER RES, V56, P3617; Kharbanda S, 1997, BIOCHIM BIOPHYS ACTA, V1333, pO1; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; Yuan ZM, 1996, ONCOGENE, V13, P939; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	34	33	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25654	25658		10.1074/jbc.273.40.25654	http://dx.doi.org/10.1074/jbc.273.40.25654			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748231	hybrid			2022-12-25	WOS:000076263100022
J	Abele, R; Lampinen, M; Keinanen, K; Madden, DR				Abele, R; Lampinen, M; Keinanen, K; Madden, DR			Disulfide bonding and cysteine accessibility in the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor subunit GluRD - Implications for redox modulation of glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR; BINDING-PROTEIN; ESCHERICHIA-COLI; LIGAND-BINDING; NITRIC-OXIDE; SITE; CHANNELS; RESIDUES; IDENTIFICATION; POTENTIATION	Redox agents elicit a wide variety of effects on the ligand affinity and channel properties of ionotropic glutamate receptors and have been proposed as potential therapeutic agents for neuropathological processes. One such effect is the dithiothreitol (DTT)-induced increase in agonist affinity of certain ionotropic glutamate receptors (GluRs), presumably due to reduction of a disulfide bridge formed between cysteine residues conserved among all GluRs. Using biochemical techniques, this disulfide is shown to exist in the ligand-binding domain of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor subunit GluRD, although GluRD homomeric receptors are not modulated by DTT. The disulfide is inaccessible to DTT, explaining the insensitivity of the intact receptor. Single mutants C260S and C315S show a 2-3-fold higher ligand affinity than wild-type, as observed for several intact GluRs, indicating that the affinity switch is completely contained within the ligand-binding domain. Also, mutants lacking the native disulfide show non-native oligomerization and dramatically reduced specific activity. These facts suggest that the disulfide bridge is required for the stability of the ligand-binding domain, explaining its conservation. A third cysteine residue in the ligand-binding domain exists as a free thiol, partially sequestered in a hydrophobic environment. These results provide a framework for interpreting a variety of GluR redox modulatory phenomena.	Max Planck Inst Med Res, ICSRG, D-69120 Heidelberg, Germany; Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; VTT Biotechnol & Food Res, FIN-02044 Espoo, Finland	Max Planck Society; University of Helsinki; University of Helsinki; VTT Technical Research Center Finland	Madden, DR (corresponding author), Max Planck Inst Med Res, ICSRG, Jahnstr 29, D-69120 Heidelberg, Germany.		Keinanen, Kari/E-9122-2010					AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FUCHS R, 1990, NUCLEIC ACIDS RES, V18, P4319, DOI 10.1093/nar/18.15.4319; GOZLAN H, 1994, EUR J PHARMACOL, V262, pR3, DOI 10.1016/0014-2999(94)90049-3; GOZLAN H, 1995, TRENDS PHARMACOL SCI, V16, P368, DOI 10.1016/S0165-6147(00)89077-X; Gozlan H, 1996, TRENDS PHARMACOL SCI, V17, P187, DOI 10.1016/0165-6147(96)81597-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hsiao CD, 1996, J MOL BIOL, V262, P225, DOI 10.1006/jmbi.1996.0509; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LAUBE B, 1993, FEBS LETT, V335, P331, DOI 10.1016/0014-5793(93)80412-N; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lipton SA, 1996, TRENDS PHARMACOL SCI, V17, P186, DOI 10.1016/0165-6147(96)20028-8; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OH BH, 1993, J BIOL CHEM, V268, P11348; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; TERRAMANI T, 1988, MOL PHARMACOL, V34, P117; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; Watase K, 1997, BIOCHEM J, V322, P385, DOI 10.1042/bj3220385; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; Wo ZG, 1996, MOL PHARMACOL, V50, P770	33	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25132	25138		10.1074/jbc.273.39.25132	http://dx.doi.org/10.1074/jbc.273.39.25132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737972	hybrid			2022-12-25	WOS:000076085400022
J	Genschik, P; Drabikowski, K; Filipowicz, W				Genschik, P; Drabikowski, K; Filipowicz, W			Characterization of the Escherichia coli RNA 3 '-terminal phosphate cyclase and its sigma(54)-regulated operon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ENHANCER-BINDING PROTEINS; HELA-CELL EXTRACT; WHEAT-GERM; TRANSCRIPTIONAL ACTIVATOR; MYXOCOCCUS-XANTHUS; 3',5'-PHOSPHODIESTER LINKAGE; POLYNUCLEOTIDE KINASE; PSEUDOMONAS-PUTIDA; FUNCTIONAL DOMAINS	The RNA 3'-terminal phosphate cyclase catalyzes the ATP-dependent conversion of the 3'-phosphate to the 2',3'-cyclic phosphodiester at the end of various RNA substrates, Recent cloning of a cDNA encoding the human cyclase indicated that genes encoding cyclase-like proteins are conserved among Eucarya, Bacteria, and Archaea, The protein encoded by the Escherichia coli gene was overexpressed and shown to have the RNA 3'-phosphate cyclase activity (Genschik, P,, Billy, E,, Swianiewicz, M,, and Filipowicz, W, (1997) EMBO J. 16, 2955-2967), Analysis of the requirements and substrate specificity of the E. coli protein, presented in this work, demonstrates that properties of the bacterial and human enzymes are similar, ATP is the best cofactor (K-m = 20 mu M), whereas GTP (K-m = 100 mu M) and other nucleoside triphosphates (NTPs) act less efficiently, The enzyme undergoes nucleotidylation in the presence of [alpha-P-32]ATP and, to a lesser extent, also in the presence of other NTPs. Comparison of 3'-phosphorylated oligoribonucleotides and oligodeoxyribonucleotides of identical sequence demonstrated that the latter are at least 300-fold poorer substrates for the enzyme. The E. coli cyclase gene, named rtcA, forms part of an uncharacterized operon containing two additional open reading frames (ORFs), The ORF positioned immediately upstream, named rtcB, encodes a protein that is also highly conserved between Eucarya, Bacteria, and Archaea. Another ORF, called rtcR, is positioned upstream of the rtcA/rtcB unit and is transcribed in the opposite direction, It encodes a protein having features of sigma(54)-dependent regulators. By overexpressing the N-terminally truncated form of RtcR, we demonstrate that this regulator indeed controls expression of rtcA and rtcB in a sigma(54)-dependent manner, Also consistent with the involvement of sigma(54) the region upstream of the transcription start site of the rtcA/rtcB mRNA contains the -12 and -24 elements, TTGCA and TGGCA, respectively, characteristic of sigma(54)-dependent promoters. The cyclase gene is nonessential as demonstrated by knockout experiments, Possible functions of the cyclase in RNA metabolism are discussed.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Filipowicz, W (corresponding author), Maulbeerstr 66, CH-4058 Basel, Switzerland.	Filipowi@fmi.ch		GENSCHIK, Pascal/0000-0002-4107-5071; Drabikowski, Krzysztof/0000-0002-1972-4493				ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; Arn EA, 1996, J BIOL CHEM, V271, P31145, DOI 10.1074/jbc.271.49.31145; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Blackburn P, 1982, ENZYMES, VXV, P317; BRANCH AD, 1982, SCIENCE, V217, P1147, DOI 10.1126/science.217.4565.1147; BRUN YV, 1992, GENE DEV, V6, P2395, DOI 10.1101/gad.6.12a.2395; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; FILIPOWICZ W, 1985, P NATL ACAD SCI USA, V82, P1316, DOI 10.1073/pnas.82.5.1316; FILIPOWICZ W, 1990, METHOD ENZYMOL, V181, P499; FILIPOWICZ W, 1984, TRENDS BIOCHEM SCI, V9, P68, DOI 10.1016/0968-0004(84)90186-5; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FILIPOWICZ W, 1983, NUCLEIC ACIDS RES, V11, P1405, DOI 10.1093/nar/11.5.1405; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FURNEAUX H, 1983, P NATL ACAD SCI-BIOL, V80, P3933, DOI 10.1073/pnas.80.13.3933; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; GEGENHEIMER P, 1983, J BIOL CHEM, V258, P8365; Genschik P, 1997, EMBO J, V16, P2955, DOI 10.1093/emboj/16.10.2955; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GRALLA JD, 1996, ESCHERICHIA COLI SAL, V1, P1232; GREER CL, 1983, CELL, V33, P899, DOI 10.1016/0092-8674(83)90032-6; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; Gu J, 1997, J BIOL CHEM, V272, P21989, DOI 10.1074/jbc.272.35.21989; GULATI P, 1995, J BACTERIOL, V177, P4645, DOI 10.1128/jb.177.16.4645-4651.1995; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; KESELER IM, 1995, J BACTERIOL, V177, P4638, DOI 10.1128/jb.177.16.4638-4644.1995; Keseler IM, 1997, P NATL ACAD SCI USA, V94, P1979, DOI 10.1073/pnas.94.5.1979; KIBERSTIS PA, 1985, EMBO J, V4, P817, DOI 10.1002/j.1460-2075.1985.tb03703.x; KIKUCHI Y, 1982, NUCLEIC ACIDS RES, V10, P7521, DOI 10.1093/nar/10.23.7521; KJEMS J, 1988, CELL, V54, P693, DOI 10.1016/S0092-8674(88)80014-X; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; LASKI FA, 1983, J BIOL CHEM, V258, P1974; LEE JH, 1994, J BIOL CHEM, V269, P20401; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Magasanik B., 1996, ESCHERICHIA COLI SAL, P1344; MARTINVERSTRAETE I, 1994, J MOL BIOL, V241, P178, DOI 10.1006/jmbi.1994.1487; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PERKINS KK, 1985, P NATL ACAD SCI USA, V82, P684, DOI 10.1073/pnas.82.3.684; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6694; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REINBERG D, 1985, J BIOL CHEM, V260, P6088; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ RC, 1983, J BIOL CHEM, V258, P8374; Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6; Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x; SHINGLER V, 1995, MOL MICROBIOL, V17, P505, DOI 10.1111/j.1365-2958.1995.mmi_17030505.x; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SIDRAUSKI C, 1997, CELL, V90, P1; SNYDER L, 1995, MOL MICROBIOL, V15, P415, DOI 10.1111/j.1365-2958.1995.tb02255.x; STRANGE N, 1987, EMBO J, V6, P2811; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; Takahashi K., 1982, ENZYMES, V15, p435 468; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TAZI J, 1993, MOL CELL BIOL, V13, P1641, DOI 10.1128/MCB.13.3.1641; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THONY B, 1989, FEMS MICROBIOL LETT, V63, P341; UHLENBECK OC, 1983, TRENDS BIOCHEM SCI, V8, P94, DOI 10.1016/0968-0004(83)90258-X; VICENTE O, 1988, EUR J BIOCHEM, V176, P431, DOI 10.1111/j.1432-1033.1988.tb14300.x; Westaway Shawn K., 1995, P79; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410	81	70	81	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25516	25526		10.1074/jbc.273.39.25516	http://dx.doi.org/10.1074/jbc.273.39.25516			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738023	hybrid			2022-12-25	WOS:000076085400073
J	Kiehn, J; Karle, C; Thomas, D; Yao, XZ; Brachmann, J; Kubler, W				Kiehn, J; Karle, C; Thomas, D; Yao, XZ; Brachmann, J; Kubler, W			HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; SELECTIVE INHIBITOR; INWARD RECTIFIER; K+-CHANNEL; CELLS; CURRENTS; POTENT; BLOCK; DIFFERENTIATION; MECHANISMS	We investigated the effects of the phorbol ester phorbol la-myristate 13-acetate (PMA) on the rapid component of the delayed rectifier potassium current, I-Kr, in guinea pig cardiomyocytes and found that the I-Kr current amplitude was reduced by 20% with 10 nM PMA and 44% with 100 nM PMA. The ether-a-go-go-related gene (HERG) encodes I-Kr in human heart. We expressed HERG heterologously in Xenopus oocytes and investigated the effects of PMA on the delayed rectifier potassium current. Upon application of PMA in a concentration of 100 nM, we found a similar reduction of HERG outward current amplitude by 59%. This reduction was due to a shift in the HERG activation curve by 37 mV. The ED50 for the PMA-induced shift was 9.0 nM. The inactive 4 alpha-phorbol 12-myristate 13-acetate (4 alpha-PMA) had no effect. PMA is known to act by stimulating distinct protein kinase cascades. Additional application of the specific protein kinase C inhibitors chelerythrine (10 mu M) or bisindolylmaleimide (1 mu M) could not attenuate the PMA-induced shift. In contrast, the shift by PMA was reduced significantly when the specific protein kinase A (PKA) inhibitors H89 (50 mu M) or KT5720 (2.5 mu M) were applied. Forskolin (400 mu M), an activator of the adenylate cyclase that results in PKA activation, shifted the HERG activation curve by 14 mV. Moreover the specific protein kinase C activator 1-stearoyl-2-arachidonylglycerol (10 mu M) showed no effect. Our data suggest that mainly PKA is mediating the shift of the HERG activation kinetics.	Med Univ Hosp Heidelberg, Dept Cardiol, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Kiehn, J (corresponding author), Med Univ Hosp Heidelberg, Dept Cardiol, Bergheimerstr 58, D-69115 Heidelberg, Germany.	johannkiehn@ukl.uni-heidelberg.de	Thomas, Dierk/ABA-4706-2021; Thomas, Dierk/V-3940-2017	Thomas, Dierk/0000-0002-5687-7843; 				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; Busch AE, 1996, PFLUG ARCH EUR J PHY, V432, P1094, DOI 10.1007/s004240050240; BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; CARMELIET E, 1993, EUR HEART J, V14, P3, DOI 10.1093/eurheartj/14.suppl_H.3; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GO M, 1987, BIOCHEM BIOPH RES CO, V144, P598; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOFFMAN R, 1991, CANCER CHEMOTH PHARM, V28, P102, DOI 10.1007/BF00689696; Hsu C, 1997, J SURG RES, V71, P161, DOI 10.1006/jsre.1997.5143; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KEATING MT, 1995, CIRCULATION, V92, P142, DOI 10.1161/01.CIR.92.1.142; KIEHN J, 1994, J CARDIOVASC PHARM, V24, P566, DOI 10.1097/00005344-199410000-00007; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; Liang BT, 1997, AM J PHYSIOL-HEART C, V273, pH847, DOI 10.1152/ajpheart.1997.273.2.H847; Liu YG, 1996, CIRC RES, V78, P443, DOI 10.1161/01.RES.78.3.443; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SANGUINETTI MC, 1995, CELL, V81, P1; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575	32	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25285	25291		10.1074/jbc.273.39.25285	http://dx.doi.org/10.1074/jbc.273.39.25285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737994	hybrid			2022-12-25	WOS:000076085400044
J	Minetti, CASA; Blake, MS; Remeta, DP				Minetti, CASA; Blake, MS; Remeta, DP			Characterization of the structure, function, and conformational stability of PorB class 3 protein front Neisseria meningitidis - A porin with unusual physicochemical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; BACTERIAL PORIN; OMPF PORIN; GONORRHOEAE; GENE; IDENTIFICATION; INSERTION; SEQUENCE	PorB proteins constitute the vast majority of channels in neisserial outer membranes and can be subdivided within meningococcal strains into two distinct and mutually exclusive families that are designated as class 2 and class 3 proteins. We recently characterized the functional activity and conformational stability of a PorB class 2 protein from Neisseria meningitidis (Minetti, C. A. S. A., Tai, J. Y., Blake, M. S., Pullen, J. K., Liang, S. M., and Remeta, D. P. (1997) J. Biol. Chem. 272, 10710-10720). To evaluate the structure-function relatedness among the PorB proteins, we have employed a combination of electrophoretic and spectroscopic techniques to assess the conformational stability of zwittergent-solubilized class 3 trimers, The functional, physicochemical, and structural properties of the meningococcal class 2 and class 3 proteins are comparable with the notable exception that the latter exhibits a significantly higher susceptibility to SDS. The SDS-induced dissociation and partial unfolding of PorB class 3 is characterized by a single two-state transition with a midpoint at 0.35% SDS. The native trimeric assembly dissociates reversibly, forming partially folded monomers that retain the characteristic P-sheet content of the transmembrane domain with a concomitant increase in random coil structure arising from unfolding the rigid surface loops. These results provide new insight into the elucidation of porin folding pathways and the factors that govern the overall structural stability of meningococcal proteins.	N Amer Vaccine Inc, Beltsville, MD 20705 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Ctr Biocalorimetry, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Minetti, CASA (corresponding author), N Amer Vaccine Inc, 12103 Indian Creek Court, Beltsville, MD 20705 USA.		Minetti, Conceicao/AGD-6419-2022; Minetti, Conceicao/B-5077-2009	Minetti, Conceicao/0000-0002-9682-2898; Minetti, Conceicao/0000-0002-9682-2898; Remeta, David/0000-0002-4142-0904				BARRERA O, 1984, INFECT IMMUN, V44, P565, DOI 10.1128/IAI.44.3.565-568.1984; BASH MC, 1995, INFECT IMMUN, V63, P1484, DOI 10.1128/IAI.63.4.1484-1490.1995; BLAKE MS, 1981, INFECT IMMUN, V33, P212, DOI 10.1128/IAI.33.1.212-222.1981; BOLLA JM, 1995, J BACTERIOL, V177, P4266, DOI 10.1128/jb.177.15.4266-4271.1995; BRAY MR, 1996, PROTEIN SCI, V5, P2312; BUTCHER S, 1991, GENE, V105, P125, DOI 10.1016/0378-1119(91)90523-E; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DELVIG AA, 1995, MICROBIOL-SGM, V141, P1593, DOI 10.1099/13500872-141-7-1593; EISELE JL, 1990, J BIOL CHEM, V265, P10217; EXNER MM, 1995, INFECT IMMUN, V63, P1567, DOI 10.1128/IAI.63.4.1567-1572.1995; FEAVERS IM, 1992, INFECT IMMUN, V60, P3620, DOI 10.1128/IAI.60.9.3620-3629.1992; FOUREL D, 1994, EUR J BIOCHEM, V222, P625, DOI 10.1111/j.1432-1033.1994.tb18905.x; FRASCH CE, 1985, REV INFECT DIS, V7, P504; FRASCH CE, 1978, J BACTERIOL, V136, P1127, DOI 10.1128/JB.136.3.1127-1134.1978; FRASCH CE, 1990, P 7 INT PATH NEISS C, P213; GUTTORMSEN HK, 1993, INFECT IMMUN, V61, P4734, DOI 10.1128/IAI.61.11.4734-4742.1993; HAINES KA, 1991, J CELL BIOL, V114, P433, DOI 10.1083/jcb.114.3.433; HAINES KA, 1988, J BIOL CHEM, V263, P945; HANCOCK REW, 1990, MOL MICROBIOL, V4, P1069, DOI 10.1111/j.1365-2958.1990.tb00680.x; HITCHCOCK PJ, 1989, CLIN MICROBIOL REV, V2, pS64, DOI 10.1128/CMR.2.Suppl.S64-S65.1989; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LYNCH EC, 1984, BIOPHYS J, V45, P104, DOI 10.1016/S0006-3495(84)84127-2; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MANDRELL RE, 1984, J IMMUNOL METHODS, V67, P1, DOI 10.1016/0022-1759(84)90080-2; MARCOVICHOUSLEY Z, 1986, BIOCHIM BIOPHYS ACTA, V869, P158; Minetti CASA, 1997, J BIOL CHEM, V272, P10710; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MURAKAMI K, 1989, INFECT IMMUN, V57, P2318, DOI 10.1128/IAI.57.8.2318-2323.1989; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; PARK K, 1992, PROTEIN SCI, V1, P1032, DOI 10.1002/pro.5560010809; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Popp B, 1997, BIOCHEMISTRY-US, V36, P2844, DOI 10.1021/bi961745d; PORAT N, 1995, INFECT IMMUN, V63, P2164, DOI 10.1128/IAI.63.6.2164-2172.1995; QI HL, 1994, INFECT IMMUN, V62, P2432, DOI 10.1128/IAI.62.6.2432-2439.1994; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; Saint N, 1996, J BIOL CHEM, V271, P20676, DOI 10.1074/jbc.271.34.20676; SCHIMID B, 1996, FEBS LETT, V381, P111; SCHINDLER M, 1984, FEBS LETT, V173, P85, DOI 10.1016/0014-5793(84)81022-4; SCHINDLER M, 1982, J CELL BIOL, V92, P742, DOI 10.1083/jcb.92.3.742; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Song JM, 1998, BBA-BIOMEMBRANES, V1370, P289, DOI 10.1016/S0005-2736(97)00279-4; Surrey T, 1996, BIOCHEMISTRY-US, V35, P2283, DOI 10.1021/bi951216u; TOKUNAGA M, 1979, EUR J BIOCHEM, V95, P441, DOI 10.1111/j.1432-1033.1979.tb12983.x; TOMASSEN J, 1990, INFECT IMMUN, V58, P1355; TSAI CM, 1981, J BACTERIOL, V146, P69, DOI 10.1128/JB.146.1.69-78.1981; VANDERLEY P, 1991, INFECT IMMUN, V59, P2963, DOI 10.1128/IAI.59.9.2963-2971.1991; WARD MJ, 1992, FEMS MICROBIOL LETT, V94, P283, DOI 10.1111/j.1574-6968.1992.tb05332.x; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; WETZLER LM, 1988, J EXP MED, V168, P1883, DOI 10.1084/jem.168.5.1883; WOLFF K, 1991, FEMS MICROBIOL LETT, V83, P179, DOI 10.1016/0378-1097(91)90351-A; ZAPATA GA, 1992, MOL MICROBIOL, V6, P3493, DOI 10.1111/j.1365-2958.1992.tb01784.x	58	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25329	25338		10.1074/jbc.273.39.25329	http://dx.doi.org/10.1074/jbc.273.39.25329			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737999	hybrid			2022-12-25	WOS:000076085400049
J	Solomon, V; Lecker, SH; Goldberg, AL				Solomon, V; Lecker, SH; Goldberg, AL			The N-end rule pathway catalyzes a major fraction of the protein degradation in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CARRIER PROTEIN; DEPENDENT PROTEOLYTIC SYSTEM; ACIDIC NH2 TERMINI; TRANSFER-RNA; AFFINITY PURIFICATION; CONJUGATING ENZYMES; PROTEASOME PATHWAY; MESSENGER-RNA; BINDING-SITES; LIGASE	In skeletal muscle, overall protein degradation involves the ubiquitin-proteasome system. One property of a protein that leads to rapid ubiquitin-dependent degradation is the presence of a basic, acidic, or bulky hydrophobic residue at its N terminus. However, in normal cells, substrates for this N-end rule pathway, which involves ubiquitin carrier protein (E2) E2(14k) and ubiquitin-protein ligase (E3) E3 alpha, have remained unclear. Surprisingly, in soluble extracts of rabbit muscle, we found that competitive inhibitors of E3 alpha markedly inhibited the I-125-ubiquitin conjugation and ATP-dependent degradation of endogenous proteins. These inhibitors appear to selectively inhibit E3 alpha; since they blocked degradation of I-125-lysozyme, a model N-end rule substrate, but did not affect the degradation of proteins whose ubiquitination involved other E3s. The addition of several E2s or E3 alpha to the muscle extracts stimulated overall proteolysis and ubiquitination, but only the stimulation by E3 alpha or E2(14k) was sensitive to these inhibitors. A similar general inhibition of ubiquitin conjugation to endogenous proteins was observed with a dominant negative inhibitor of E2(14k). Certain substrates of the N-end rule pathway are degraded after their tRNA-dependent arginylation. We found that adding RNase A to muscle extracts reduced the ATP-dependent proteolysis of endogenous proteins, and supplying tRNA partially restored this process. Finally, although in muscle extracts the N-end rule pathway catalyzes most ubiquitin conjugation, it makes only a minor contribution to overall protein ubiquitination in HeLa cell extracts.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1987, J CELL BIOCHEM, V34, P81, DOI 10.1002/jcb.240340203; CIECHANOVER A, 1988, J BIOL CHEM, V263, P11155; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; ELIAS S, 1990, J BIOL CHEM, V265, P15511; FAGAN JM, 1987, BIOCHEM J, V243, P335, DOI 10.1042/bj2430335; FERBER S, 1987, NATURE, V326, P808, DOI 10.1038/326808a0; FERBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; TAWA NE, 1994, MYOLOGY BASIC CLIN, P663; TEMPARIS S, 1994, CANCER RES, V54, P5568; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WING SS, 1992, J BIOL CHEM, V267, P6495; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639	47	103	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25216	25222		10.1074/jbc.273.39.25216	http://dx.doi.org/10.1074/jbc.273.39.25216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737984	hybrid			2022-12-25	WOS:000076085400034
J	Dadgostar, H; Cheng, GH				Dadgostar, H; Cheng, GH			An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappa B activation but is dispensable for c-Jun N-terminal kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAF-INTERACTING PROTEIN; CYTOPLASMIC DOMAIN; FAMILY; CD40; MEMBER; BINDS; DEATH	The diverse biological effects of the tumor necrosis factor (TNF) receptor superfamily are believed to be mediated in part through TNF receptor-associated factors (TRAFs), a family of cytoplasmic adaptor proteins which can activate intracellular signaling pathways, including the nuclear factor-kappa B (NF-kappa B) and c-Jun N-terminal kinase (JNK) pathways. TRAFs 2, 5, and 6 strongly activate both pathways when overexpressed; however, TRAF 3 (a close homologue of TRAF 5) does not significantly activate either pathway. The current study addresses the structural basis for this difference by substituting corresponding domains of TRAF 5 into TRAF 3 and testing activation of both pathways. A small region of TRAF 5 (the first zinc finger and 10 residues of the second zinc finger) is sufficient to convert TRAF 3 into an activator of both pathways. Also, an intact zinc ring finger is required for NF-kappa B activation but not JNK activation. In agreement with this finding, TRAF 2A, a TRAF 2 splice variant with an altered ring finger, is a specific activator of JNK. These findings suggest that different domains of TRAFs may be involved in NF-kappa B and JNK signaling. Also, alternative splicing of TRAFs may represent a novel mechanism whereby TNF family receptors can mediate distinct downstream effects in different tissues.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Cheng, GH (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.	genhongc@microbio.ucla.edu			NIGMS NIH HHS [GM 08042] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Brink R, 1998, J BIOL CHEM, V273, P4129, DOI 10.1074/jbc.273.7.4129; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	31	60	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24775	24780		10.1074/jbc.273.38.24775	http://dx.doi.org/10.1074/jbc.273.38.24775			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733779	hybrid			2022-12-25	WOS:000076007300071
J	Le Dantec, L; Castroviejo, M; Bove, JM; Saillard, C				Le Dantec, L; Castroviejo, M; Bove, JM; Saillard, C			Purification, cloning, and preliminary characterization of a Spiroplasma citri ribosomal protein with DNA binding capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM MYCOPLASMA-PNEUMONIAE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; PSEUDOMONAS-AERUGINOSA; HYDROXYLAMINE CLEAVAGE; PHYLOGENETIC ANALYSIS; POLYACRYLAMIDE GELS; SEQUENCE-ANALYSIS; GENE-CLUSTER; HISTONE H1	The rpsB-tsf-x operon of Spiroplasma citri encodes ribosomal protein S2 and elongation factor Ts, two components of the translational apparatus, and an unidentified X protein. A potential DNA-binding site (a 20-base pair (bp) inverted repeat sequence) is located at the 3' end of rpsB. Southwestern analysis of S. citri proteins, with a 30-bp double-stranded oligonucleotide probe (IRS), containing the 20-bp inverted repeat sequence and the genomic flanking sequences, detected an IRS-binding protein of 46 kDa (P46). P46 protein, which displays preferential affinity for the IRS, was purified from S. citri by a combination of affinity and gel filtration chromatographies. The native form of P46 seems to be homomultimeric as estimated by SDS-polyacrylamide gel electrophoresis analysis and gel filtration. A 3.5-kilobase pair S. citri DNA fragment comprising the P46 gene and flanking sequences was cloned and sequenced. Sequence analysis of this DNA fragment indicated that the P46 gene is located within the S10-spc operon of S. citri at the position of the gene coding for ribosomal protein L29 in the known S10-spc operons, The similarity between the N-terminal domain of P46 and the L29 ribosomal protein family and the presence of a 46-kDa IRS-binding protein in S. citri ribosomes indicated that P46 is the L29 ribosomal protein of S. citri, We suggest that P46 is a bifunctional protein with an L29 N-terminal domain and a C-terminal domain involved in IRS binding.	INRA, Biol Cellulaire & Mol Lab, F-33883 Villenave Dornon, France; Univ Victor Segalen Bordeaux 2, F-33883 Villenave Dornon, France; Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; CNRS, F-33077 Bordeaux, France	INRAE; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS)	Saillard, C (corresponding author), INRA, Biol Cellulaire & Mol Lab, BP 81, F-33883 Villenave Dornon, France.	saillard@bordeaux.inra.fr						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; ARNOLDSCHULZGAHMEN B, 1994, J BACTERIOL, V176, P50, DOI 10.1128/JB.176.1.50-60.1994; BENDIAK DS, 1981, MOL GEN GENET, V181, P356, DOI 10.1007/BF00425611; BORNSTEIN P, 1970, J BIOL CHEM, V245, P4854; Bornstein P, 1977, Methods Enzymol, V47, P132; Bove J.M., 1993, CLIN INFECT DIS, V17, P10; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKMAN TJ, 1993, J BACTERIOL, V175, P4274, DOI 10.1128/JB.175.14.4274-4281.1993; Buttner K, 1997, J BASIC MICROB, V37, P3; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; CHANGCHIEN LM, 1986, NUCLEIC ACIDS RES, V14, P1957, DOI 10.1093/nar/14.5.1957; Cordwell SJ, 1997, GENE, V195, P113, DOI 10.1016/S0378-1119(97)00063-2; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DERETIC V, 1990, J BACTERIOL, V172, P5544, DOI 10.1128/jb.172.10.5544-5554.1990; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Gouzy J, 1996, TRENDS BIOCHEM SCI, V21, P493, DOI 10.1016/S0968-0004(96)30040-6; Gryaznova OI, 1996, BIOCHIMIE, V78, P915, DOI 10.1016/S0300-9084(97)86713-2; GUDKOV AT, 1978, EUR J BIOCHEM, V90, P309, DOI 10.1111/j.1432-1033.1978.tb12605.x; GUDKOV AT, 1977, FEBS LETT, V82, P125, DOI 10.1016/0014-5793(77)80901-0; HARDY SJS, 1975, MOL GEN GENET, V140, P253, DOI 10.1007/BF00334270; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; Hilbert H, 1996, NUCLEIC ACIDS RES, V24, P628, DOI 10.1093/nar/24.4.628; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; KATO J, 1990, P NATL ACAD SCI USA, V87, P2887, DOI 10.1073/pnas.87.8.2887; KONYECSNI WM, 1990, J BACTERIOL, V172, P2511, DOI 10.1128/jb.172.5.2511-2520.1990; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDANTEC L, 1998, IN PRESS CURR MICROB; Li X, 1997, J BACTERIOL, V179, P7046, DOI 10.1128/jb.179.22.7046-7054.1997; LINDAHL L, 1990, BIOCHIM BIOPHYS ACTA, V1050, P337, DOI 10.1016/0167-4781(90)90191-4; MATTHAEI JH, 1961, P NATL ACAD SCI USA, V47, P1580, DOI 10.1073/pnas.47.10.1580; MICHAEL N, 1988, SCIENCE, V239, P1531, DOI 10.1126/science.2832940; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MOLLER W, 1972, EUR J BIOCHEM, V25, P5, DOI 10.1111/j.1432-1033.1972.tb01660.x; MYERS DA, 1988, J BIOL CHEM, V263, P17122; Oberto J, 1996, MOL MICROBIOL, V19, P1319, DOI 10.1111/j.1365-2958.1996.tb02476.x; OHKUBO S, 1987, MOL GEN GENET, V210, P314, DOI 10.1007/BF00325700; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; Pedersen LB, 1996, MOL MICROBIOL, V20, P295, DOI 10.1111/j.1365-2958.1996.tb02618.x; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; PERARA E, 1992, P NATL ACAD SCI USA, V89, P2125, DOI 10.1073/pnas.89.6.2125; POST LE, 1978, CELL, V15, P215, DOI 10.1016/0092-8674(78)90096-X; ROGERS MJ, 1985, P NATL ACAD SCI USA, V82, P1160, DOI 10.1073/pnas.82.4.1160; SAGLIO P, 1973, INT J SYST BACTERIOL, V23, P191, DOI 10.1099/00207713-23-3-191; SALTI V, 1989, BIOCHIM BIOPHYS ACTA, V1009, P161, DOI 10.1016/0167-4781(89)90096-1; Sambrook J., 2002, MOL CLONING LAB MANU; SARIS CJM, 1983, ANAL BIOCHEM, V132, P54, DOI 10.1016/0003-2697(83)90425-6; SCARLATO V, 1995, MOL MICROBIOL, V15, P871, DOI 10.1111/j.1365-2958.1995.tb02357.x; SONNHAMMER ELL, 1994, PROTEIN SCI, V3, P482; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; TISSIERES A, 1959, J MOL BIOL, V1, P221, DOI 10.1016/S0022-2836(59)80029-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULLY JG, 1977, SCIENCE, V195, P892, DOI 10.1126/science.841314; WAGAR EA, 1988, INFECT IMMUN, V56, P1678, DOI 10.1128/IAI.56.7.1678-1684.1988; WEISBURG WG, 1989, J BACTERIOL, V171, P6455, DOI 10.1128/jb.171.12.6455-6467.1989; WILSON CM, 1979, ANAL BIOCHEM, V96, P263, DOI 10.1016/0003-2697(79)90581-5; WOESE CR, 1980, P NATL ACAD SCI-BIOL, V77, P494, DOI 10.1073/pnas.77.1.494; WOOL IG, 1993, TRANSLATIONAL APPARATUS, P727; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; WOOL IG, 1996, RIBOSOMAL RNA GROUP, P153; YOSHIKAWA H, 1990, NUCLEIC ACIDS RES, V18, P1647, DOI 10.1093/nar/18.6.1647; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1; Zouine M, 1996, FEMS MICROBIOL LETT, V145, P41; ZURAWSKI G, 1985, NUCLEIC ACIDS RES, V13, P4521, DOI 10.1093/nar/13.12.4521	69	5	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24379	24386		10.1074/jbc.273.38.24379	http://dx.doi.org/10.1074/jbc.273.38.24379			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733727	Green Published, hybrid			2022-12-25	WOS:000076007300019
J	Luttik, MAH; Overkamp, KM; Kotter, P; de Vries, S; van Dijken, JP; Pronk, JT				Luttik, MAH; Overkamp, KM; Kotter, P; de Vries, S; van Dijken, JP; Pronk, JT			The Saccharomyces cerevisiae NDE1 and NDE2 genes encode separate mitochondrial NADH dehydrogenases catalyzing the oxidation of cytosolic NADH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITED CHEMOSTAT CULTURES; ROTENONE-INSENSITIVE NADH; UBIQUINONE OXIDOREDUCTASE; METABOLIC RESPONSES; RESPIRATORY-CHAIN; CANDIDA-UTILIS; GLUCOSE EXCESS; YEAST; PURIFICATION; CELLS	In Saccharomyces cerevisiae, the NDI1 gene encodes a mitochondrial NADH dehydrogenase, the catalytic side of which projects to the matrix side of the inner mitochondrial membrane, In addition to this NADH dehydrogenase, S. cerevisiae exhibits another mitochondrial NADH-dehydrogenase activity, which oxidizes NADH at the cytosolic side of the inner membrane. To investigate whether open reading frames YMR145c/NDE1 and YDL 085w/NDE2, which exhibit sequence similarity with NDI1, encode the latter enzyme, NADH-dependent mitochondrial respiration was assayed in wild-type S. cerevisiae and nde deletion mutants. Mitochondria were isolated from aerobic, glucose-limited chemostat cultures grown at a dilution rate (D) of 0.10 h(-1), in which reoxidation of cytosolic NADH by wild-type cells occurred exclusively by respiration. Compared with the wild type, rates of mitochondrial NADH oxidation were about 3-fold reduced in an nde1 Delta mutant and unaffected in an nde2 mutant. NADH-dependent mitochondrial respiration was completely abolished in an nde1 Delta nde2 Delta double mutant. Mitochondrial respiration of substrates other than NADH was not affected in nde mutants, In shake flasks, an nde1 Delta nde2 Delta mutant exhibited reduced specific growth rates on ethanol and galactose but not on glucose, Glucose metabolism in aerobic, glucose-limited chemostat cultures (D = 0.10 h(-1)) of an nde1 Delta nde2 Delta mutant was essentially respiratory. Apparently, under these conditions alternative systems for reoxidation of cytosolic NADH could replace the role of Nde1p and Nde2p in S. cerevisiae,	Delft Univ Technol, Kluyver Inst Biotechnol, Dept Microbiol & Enzymol, NL-2628 BC Delft, Netherlands; Goethe Univ Frankfurt, Inst Mikrobiol, Biozentrum N250, D-60439 Frankfurt, Germany	Delft University of Technology; Goethe University Frankfurt	Pronk, JT (corresponding author), Delft Univ Technol, Kluyver Inst Biotechnol, Dept Microbiol & Enzymol, Julianalaan 67, NL-2628 BC Delft, Netherlands.	j.t.pronk@stm.tudelft.nl		Pronk, Jack/0000-0002-5617-4611; Luttik, Marijke/0000-0002-9798-8072				AINSWORTH PJ, 1980, ARCH BIOCHEM BIOPHYS, V202, P172, DOI 10.1016/0003-9861(80)90420-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Beudecher R.F., 1990, YEAST BIOTECHNOLOGY, P103; Bjorkqvist S, 1997, APPL ENVIRON MICROB, V63, P128; BRUINENBERG PM, 1985, J GEN MICROBIOL, V131, P1043; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; DAWSON AG, 1979, TRENDS BIOCHEM SCI, V4, P171, DOI 10.1016/0968-0004(79)90417-1; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; DEVRIES S, 1992, EUR J BIOCHEM, V203, P587; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; DOUCE R, 1989, ANNU REV PLANT PHYS, V40, P371, DOI 10.1146/annurev.pp.40.060189.002103; Flikweert MT, 1997, APPL ENVIRON MICROB, V63, P3399, DOI 10.1128/AEM.63.9.3399-3404.1997; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HENSING MCM, 1995, ANTON LEEUW INT J G, V67, P261, DOI 10.1007/BF00873690; HOLLENBERG CP, 1970, BIOCHIM BIOPHYS ACTA, V201, P13, DOI 10.1016/0304-4165(70)90004-8; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; KAPPELI O, 1986, ADV MICROB PHYSIOL, V28, P181; LAGUNAS R, 1986, YEAST, V2, P221, DOI 10.1002/yea.320020403; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; LEHNINGER AL, 1955, HARVEY LECT, P176; MARRES CAM, 1991, EUR J BIOCHEM, V195, P857, DOI 10.1111/j.1432-1033.1991.tb15775.x; MOLLER IM, 1986, ANNU REV PLANT PHYS, V37, P309, DOI 10.1146/annurev.arplant.37.1.309; NOORMAN HJ, 1991, J GEN MICROBIOL, V137, P2171, DOI 10.1099/00221287-137-9-2171; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; OHNISHI T, 1973, BIOCHIM BIOPHYS ACTA, V301, P105, DOI 10.1016/0304-4173(73)90001-3; OHNISHI T, 1966, J BIOL CHEM, V241, P1797; PATCHETT RA, 1986, A VAN LEEUW J MICROB, V52, P387, DOI 10.1007/BF00393466; PETRIK M, 1983, J GEN MICROBIOL, V129, P43; PLUTHERO FG, 1993, NUCLEIC ACIDS RES, V21, P4850, DOI 10.1093/nar/21.20.4850; POSTMA E, 1989, APPL ENVIRON MICROB, V55, P468, DOI 10.1128/AEM.55.2.468-477.1989; Pronk JT, 1996, YEAST, V12, P1607, DOI 10.1002/(SICI)1097-0061(199612)12:16<1607::AID-YEA70>3.0.CO;2-4; RONNOW B, 1993, YEAST, V9, P1121, DOI 10.1002/yea.320091013; VANDIJKEN JP, 1986, FEMS MICROBIOL LETT, V32, P199, DOI 10.1016/0378-1097(86)90291-0; VANURK H, 1988, YEAST, V4, P283, DOI 10.1002/yea.320040406; VERDUYN C, 1991, ANTON LEEUW INT J G, V60, P325, DOI 10.1007/BF00430373; VERDUYN C, 1990, J GEN MICROBIOL, V136, P395, DOI 10.1099/00221287-136-3-395; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; von Jagow G, 1970, Eur J Biochem, V12, P583; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang XP, 1998, J BACTERIOL, V180, P822, DOI 10.1128/JB.180.4.822-830.1998; WEUSTHUIS RA, 1994, MICROBIOL-SGM, V140, P703, DOI 10.1099/00221287-140-4-703	46	217	227	6	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24529	24534		10.1074/jbc.273.38.24529	http://dx.doi.org/10.1074/jbc.273.38.24529			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733747	hybrid			2022-12-25	WOS:000076007300039
J	Park, K; Mukhopadhyay, S; Chattoraj, DK				Park, K; Mukhopadhyay, S; Chattoraj, DK			Requirements for and regulation of origin opening of plasmid P1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPY-NUMBER CONTROL; ESCHERICHIA-COLI; DNA-REPLICATION; INITIATOR PROTEIN; NEGATIVE CONTROL; REPA GENE; BINDING; INCOMPATIBILITY; SEQUESTRATION; MAINTENANCE	Origin opening is essential for the initiation of DNA replication in the theta mode and requires binding of initiator proteins. Using reactivity to KMnO4 in vivo as an assay, we find that, like initiation, origin opening of the Escherichia coli plasmid P1 requires the host initiators DnaA and HU and the plasmid-encoded initiator RepA. The ability to detect opening at the P1ori in vivo allowed us to study this activity at various copy numbers in chimeric replicons, The opening was prevented when the P1ori was cloned in high copy vectors or when excess RepA binding sites (iterons) mere provided in trans. However, when RepA supply was also increased, the opening was efficient. A further increase in RepA prevented opening. Replication of an incoming pi under these conditions correlated with opening. These results demonstrate that initiation is possible even at abnormally high origin concentrations and that oversupply of RepA, relative to iterons, can prevent replication by blocking origin opening. It appears that plasmid overreplication can be prevented either by limiting RepA or by accumulating RepA at a rate higher than that of the origin.	NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chattoraj, DK (corresponding author), NCI, Biochem Lab, NIH, 37-4D-18, Bethesda, MD 20892 USA.							ABELES AL, 1990, J BACTERIOL, V172, P4386, DOI 10.1128/jb.172.8.4386-4391.1990; ABELES AL, 1991, P NATL ACAD SCI USA, V88, P9011, DOI 10.1073/pnas.88.20.9011; Abeles AL, 1995, MOL MICROBIOL, V18, P903, DOI 10.1111/j.1365-2958.1995.18050903.x; AUSTIN SJ, 1985, J MOL BIOL, V183, P195, DOI 10.1016/0022-2836(85)90212-8; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHATTORAJ D, 1984, P NATL ACAD SCI-BIOL, V81, P6456, DOI 10.1073/pnas.81.20.6456; Chattoraj D K, 1995, Genet Eng (N Y), V17, P81; Chattoraj DK, 1997, PROG NUCLEIC ACID RE, V57, P145, DOI 10.1016/S0079-6603(08)60280-9; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; DURLAND RH, 1990, J BACTERIOL, V172, P3849, DOI 10.1128/jb.172.7.3849-3858.1990; FILUTOWICZ M, 1986, P NATL ACAD SCI USA, V83, P9645, DOI 10.1073/pnas.83.24.9645; HANSEN EB, 1986, P NATL ACAD SCI USA, V83, P4423, DOI 10.1073/pnas.83.12.4423; INGMER H, 1993, J BACTERIOL, V175, P7834, DOI 10.1128/JB.175.24.7834-7841.1993; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KIM K, 1985, J MOL BIOL, V185, P755, DOI 10.1016/0022-2836(85)90060-9; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; LIN LS, 1986, PLASMID, V15, P35, DOI 10.1016/0147-619X(86)90012-0; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; MURAISO K, 1990, J BACTERIOL, V172, P4441, DOI 10.1128/jb.172.8.4441-4447.1990; OGURA T, 1990, MOL GEN GENET, V220, P197; PAL SK, 1986, J MOL BIOL, V192, P275, DOI 10.1016/0022-2836(86)90364-5; PAL SK, 1988, J BACTERIOL, V170, P3554, DOI 10.1128/jb.170.8.3554-3560.1988; PAPP PP, 1994, J BIOL CHEM, V269, P23563; Sambrook J., 2002, MOL CLONING LAB MANU; SOM T, 1982, MOL GEN GENET, V187, P375, DOI 10.1007/BF00332615; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; SUTTON MD, 1995, J BACTERIOL, V177, P6657, DOI 10.1128/jb.177.22.6657-6665.1995; SWACK JA, 1987, J BACTERIOL, V169, P3737, DOI 10.1128/jb.169.8.3737-3742.1987; TERAWAKI Y, 1990, J BACTERIOL, V172, P786, DOI 10.1128/jb.172.2.786-792.1990; TSUTSUI H, 1983, J BACTERIOL, V155, P337, DOI 10.1128/JB.155.1.337-344.1983; WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9; WICKNER SH, 1987, P NATL ACAD SCI USA, V84, P3668, DOI 10.1073/pnas.84.11.3668	37	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24906	24911		10.1074/jbc.273.38.24906	http://dx.doi.org/10.1074/jbc.273.38.24906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733797	hybrid			2022-12-25	WOS:000076007300089
J	Schwartzbauer, G; Yu, JH; Cheng, H; Menon, RK				Schwartzbauer, G; Yu, JH; Cheng, H; Menon, RK			Transcription factor MSY-1 regulates expression of the murine growth hormone receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC PROMOTER; BOX-BINDING PROTEINS; NF-Y; MESSENGER-RNA; DNA-BINDING; IDENTIFICATION; INVITRO; CLONING; FAMILY; SEQUENCE	Previous studies identified and partially characterized a 42-base pair regulatory element in the 5'-flanking region of the L1 transcript of the murine growth hormone (GH) receptor gene that interacted with both double- and single-stranded DNA-binding proteins. We present evidence that the double-stranded DNA-binding protein is NF-Y, a CCAAT box-binding protein. Experiments with a dominant negative form of NF-Y indicate that NF-Y does not play a direct role in regulating the activity of the FP42 element. A cDNA clone that specifically interacts with the upper (coding) strand of the regulatory element was isolated by screening a cDNA expression library using the Southwestern technique, DNA sequencing, electrophoretic mobility shift assay, Southwestern blot analysis, and supershift EMSA confirm the identity of the single-stranded binding protein to be MSY-1, a DNA-binding protein that is evolutionary conserved from prokaryotes to eukaryote, Mapping of single-stranded DNA configurations reveals that MSY-1 can facilitate the formation of single-stranded DNA regions in the GH receptor 5'-flanking region, Transient transfection experiments support the role of MSY-1 as a repressor of GH receptor gene activation. Southwestern blot analysis indicates that the levels of nuclear MSY-1 are decreased in the livers of pregnant mice, suggesting a role for MSY-1 in the increased expression of the GH receptor during pregnancy.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Menon, RK (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.	menon@chplink.chp.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007729, R29DK049845] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK49845, 5T32DK07729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS TE, 1995, MOL CELL ENDOCRINOL, V108, P23, DOI 10.1016/0303-7207(95)92575-9; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Harvey S., 1995, GROWTH HORMONE; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LIM LC, 1993, J BIOL CHEM, V268, P18008; LIWEBER M, 1994, J IMMUNOL, V153, P4122; LLOBERAS J, 1995, MOL CELL BIOL, V15, P5092; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MENON RK, 1995, J BIOL CHEM, V270, P8851, DOI 10.1074/jbc.270.15.8851; Menon RK, 1997, MOL ENDOCRINOL, V11, P1291, DOI 10.1210/me.11.9.1291; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; OMAHONEY JV, 1994, MOL CELL ENDOCRINOL, V101, P129, DOI 10.1016/0303-7207(94)90227-5; Orita T, 1997, J BIOL CHEM, V272, P23216, DOI 10.1074/jbc.272.37.23216; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; SAMBROOK J, 1969, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHERRIE R, 1990, P NATL ACAD SCI USA, V87, P9028; SIMON M, 1995, J BIOL CHEM, V270, P21445; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SOUTHARD JN, 1995, ENDOCRINOLOGY, V136, P2913, DOI 10.1210/en.136.7.2913; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1992, NEW BIOL, V4, P349; TORCZYNSKI R, 1983, MOL GEN GENET, V191, P427, DOI 10.1007/BF00425758; WOLFFE AP, 1992, NEW BIOL, V4, P290; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; ZOU LL, 1995, ENDOCRINOLOGY, V136, P5236, DOI 10.1210/en.136.11.5236; Zou LL, 1997, ENDOCRINOLOGY, V138, P1771, DOI 10.1210/en.138.4.1771	39	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24760	24769		10.1074/jbc.273.38.24760	http://dx.doi.org/10.1074/jbc.273.38.24760			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733777	hybrid			2022-12-25	WOS:000076007300069
J	Riches, DWH; Chan, ED; Zahradka, EA; Winston, BW; Remigio, LK; Lake, FR				Riches, DWH; Chan, ED; Zahradka, EA; Winston, BW; Remigio, LK; Lake, FR			Cooperative signaling by tumor necrosis factor receptors CD120a (p55) and CD120b (p75) in the expression of nitric oxide and inducible nitric oxide synthase by mouse macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; TNF-ALPHA; MURINE MACROPHAGES; LISTERIA-MONOCYTOGENES; ACTIVATED MACROPHAGES; PROTEIN-KINASE; PATHWAY; CLONING; DOMAIN; IDENTIFICATION	Tumor necrosis factor-alpha (TNF alpha) is recognized by the cell-surface receptors CD120a (p55) and CD120b (p75). In the present study, we have investigated the role of these receptors in the expression of NO2- a stable metabolite of nitric oxide, and inducible nitric oxide synthase (iNOS) by mouse macrophages. Specific antibody-mediated aggregation of CD120a (p55) induced NO2- accumulation in culture supernatants and iNOS mRNA expression in macrophage lysates, whereas cross-linking of CD120b (p75) had a minimal effect. In contrast, simultaneous cross-linking of both receptors led to a marked augmentation in NO2- and iNOS mRNA expression. Antibody-mediated blockade of CD120a (p55) completely inhibited NO2- expression in response to TNF alpha, whereas blockade of CD120b (p75) reduced NO2- accumulation by similar to 50%. Specific Ligation of CD120a (p55) with either (i) human TNF alpha or (ii) by incubation with mouse TNF alpha following pretreatment of macrophages with blocking concentrations of anti-CD120b (p75) antibody resulted in a similar reduction in NO2- production in response to TNF alpha. Quantification of iNOS mRNA, protein, and NO2- expression during independent and coligation of CD120a (p55) and CD120b (p75) indicated that iNOS mRNA and protein expression was transient in nature when CD120a (p55) was cross-linked alone but was prolonged when both receptors were simultaneously cross-linked. In addition, cross-linking both receptors also led to a potentiation of NO2- accumulation in culture supernatants that was more pronounced at later time points. These findings suggest that while cross-linking of CD120a (p55) is necessary and sufficient for iNOS mRNA and NO(2)(-)expression, CD120b (p75) participates by (i) increasing the sensitivity of the cells to TNF alpha, probably by "passing" ligand to CD120a (p55), and (ii) initiating a signaling event that results in a more sustained induction of iNOS mRNA and protein and thereby augments the production of nitric oxide.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem Biophys & Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Calgary, Dept Med, Div Crit Care Med, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem, Div Crit Care Med, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Mol Biol, Div Crit Care Med, Calgary, AB T2N 4N1, Canada	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Calgary; University of Calgary; University of Calgary	Riches, DWH (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Neustadt Rm D405,1400 Jackson St, Denver, CO 80206 USA.				NHLBI NIH HHS [HL55549, HL56556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056556, R01HL055549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS LB, 1991, J IMMUNOL, V147, P1642; ADAMS LB, 1990, J IMMUNOL, V144, P2725; BAUMANN H, 1993, J IMMUNOL, V151, P4248; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BERMUDEZ LE, 1993, CLIN EXP IMMUNOL, V91, P277; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DING AH, 1988, J IMMUNOL, V141, P2407; GREEN SJ, 1990, J IMMUNOL, V144, P278; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAKE FR, 1994, J CLIN INVEST, V93, P1661, DOI 10.1172/JCI117148; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIEW FY, 1991, EUR J IMMUNOL, V21, P3009, DOI 10.1002/eji.1830211216; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Pinckard JK, 1997, J BIOL CHEM, V272, P10784; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; RICHES DWH, 1991, J BIOL CHEM, V266, P24785; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; Weiss T, 1997, J IMMUNOL, V158, P2398; Winston BW, 1997, J IMMUNOL, V159, P4491; WINSTON BW, 1995, J IMMUNOL, V155, P1525; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	39	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22800	22806		10.1074/jbc.273.35.22800	http://dx.doi.org/10.1074/jbc.273.35.22800			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712914	hybrid			2022-12-25	WOS:000075616600090
J	Xia, Y; Roman, LJ; Masters, BSS; Zweier, JL				Xia, Y; Roman, LJ; Masters, BSS; Zweier, JL			Inducible nitric-oxide synthase generates superoxide from the reductase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POSTISCHEMIC HEART; NADPH OXIDASE; PEROXYNITRITE; EXPRESSION; MECHANISM; INJURY; MACROPHAGES; CALMODULIN; INHIBITION	In the absence of L-arginine, the heme center of the oxygenase domain of neuronal nitric-oxide synthase reduces molecular oxygen to superoxide (OX). Our recent work has provided evidence that inducible NOS (iNOS) may also catalyze O-2(radical anion) formation in macrophages. However, there has been a lack of direct evidence of superoxide generation from the purified iNOS, and it was previously hypothesized that significant O-2(radical anion) production does not occur. Moreover, the mechanism and enzyme site responsible for OX generation is unknown. To determine whether iNOS produces O-2(radical anion) and to identify the mechanism of this process, we performed electron paramagnetic resonance measurements on purified iNOS using the spin trap 5,5-dimethyl-1-pyrroline N-oxide. In the presence of NADPH, prominent O-2(radical anion) adduct signals were detected from NOS. These signals were totally abolished by superoxide dismutase but not affected by catalase. High concentrations of L-arginine decreased this OX formation, whereas its enantiomer D-arginine did not. Pre-incubation of iNOS with the flavoprotein inhibitor diphenyleneiodonium totally blocked these O-2(radical anion) signals. Conversely, pretreatment of the enzyme with the heme blocker cyanide had no effect on OX generation. Furthermore, strong O-2(radical anion) generation was directly detected from the isolated iNOS reductase domain. Together, these data demonstrate that iNOS does generate O-2(radical anion), and this mainly occurs at the flavin-binding sites of the reductase domain.	Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med,Div Cardiol,Mol & Cellular Biophys Labs, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Health San Antonio	Zweier, JL (corresponding author), Johns Hopkins Asthma & Allergy Ctr, LA-14,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, R01HL038324, P50HL052315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52315, HL-38324] Funding Source: Medline; NIGMS NIH HHS [GM-52419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABU SH, 1993, P NATL ACAD SCI USA, V90, P10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BASTIAN NR, 1994, CURR OPIN IMMUNOL, V6, P131, DOI 10.1016/0952-7915(94)90044-2; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; Fossetta JD, 1996, FEBS LETT, V379, P135, DOI 10.1016/0014-5793(95)01496-9; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Giraldez RR, 1997, J BIOL CHEM, V272, P21420, DOI 10.1074/jbc.272.34.21420; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; MASTERS BSS, 1965, J BIOL CHEM, V240, P4081; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NISHIBAYASHI H, 1963, BIOCHIM BIOPHYS ACTA, V67, P520; POU S, 1992, J BIOL CHEM, V267, P24173; PROUGH RA, 1973, ANN NY ACAD SCI, V212, P89, DOI 10.1111/j.1749-6632.1973.tb47588.x; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Xia Y, 1996, J BIOL CHEM, V271, P10096, DOI 10.1074/jbc.271.17.10096; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954	29	311	320	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22635	22639		10.1074/jbc.273.35.22635	http://dx.doi.org/10.1074/jbc.273.35.22635			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712892	hybrid			2022-12-25	WOS:000075616600068
J	Zohar, M; Teramoto, H; Katz, BZ; Yamada, KM; Gutkind, JS				Zohar, M; Teramoto, H; Katz, BZ; Yamada, KM; Gutkind, JS			Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation	ONCOGENE			English	Article						Rho A GTPase; Ras; small G-proteins; transformation; stress fibers; signal transduction	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; SMALL GTPASE RHO; RAS TRANSFORMATION; FAMILY GTPASES; TRANSCRIPTIONAL ACTIVATION; SERINE/THREONINE KINASE; ACTIN POLYMERIZATION; INDEPENDENT PATHWAYS; CYCLE PROGRESSION	The small GTP-binding Rho proteins control a variety of biological activities, including organization of the actin cytoskeleton, regulation of gene expression and cellular transformation. In contrast, Ras proteins do not induce actin stress fibers, but potently transform cells which exhibit a morphology clearly distinct from that caused by activated forms of Rho. To investigate whether nuclear signaling and oncogenic potential of Rho are a consequence of its profound effect on cytoskeletal organization, we replaced each amino acid in the Rho effector loop with those of Ras, or replaced conserved residues with others known to result in differential signaling capability when introduced into Ras and Rad. These Rho mutants did not gain the ability to induce the MAPK, JNK or p38 pathways but, surprisingly, all Rho effector loop mutants still continued to induce actin stress fiber formation. However, three of these Rho mutants, with substitutions of leucine-39, glutamic acid-39, or cysteine-42, lost the ability to stimulate gene transcription via the serum response factor (SRF) and failed to induce neoplastic transformation. Thus, these results indicate that cytoskeletal changes are not sufficient to induce the transformed phenotype, and that Rho-effector molecules regulating the actin cytostructure are distinct from those signaling to the nucleus and subverting normal growth control.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Yamada, Kenneth/0000-0003-1512-6805				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1996, CANCER SURV, V27, P311; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SELF AJ, 1993, ONCOGENE, V8, P655; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	41	50	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					991	998		10.1038/sj.onc.1202022	http://dx.doi.org/10.1038/sj.onc.1202022			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747878				2022-12-25	WOS:000075560900007
J	Marie-Cardine, A; Hendricks-Taylor, LR; Boerth, NJ; Zhao, H; Schraven, B; Koretzky, GA				Marie-Cardine, A; Hendricks-Taylor, LR; Boerth, NJ; Zhao, H; Schraven, B; Koretzky, GA			Molecular interaction between the Fyn-associated protein SKAP55 and the SLP-78-associated phosphoprotein SLAP-130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE KINASE-ACTIVITY; MICE LACKING; T-CELLS; INTERLEUKIN-2 PRODUCTION; CLONING; ACTIVATION; P59(FYN); P56(LCK); COMPLEX	It has previously been reported that in resting T-lymphocytes the protein tyrosine kinase p59(fyn) constitutively co-precipitates with four phosphoproteins of 43, 55, 85, and 120 kDa, respectively. We have recently cloned the 55-kDa protein that was termed Src kinase-associated phosphoprotein of 55 kDa (SKAP55), Here we demonstrate that the recently characterized SH2-domain-containing leukocyte protein 76-associated phosphoprotein of 130 kDa (SLAP-130) is one of the components of the Fyn complex and that it also co-precipitates with SKAP55 in human T-cells, We establish that SKAP55 and SLAP-130 associate with each other when both molecules are co expressed in COS cells. By cotransfection of truncated mutants of SKAP55 and SLAP130 as well as by using the two-hybrid selection system, we further demonstrate that the association between SLAP-130 and SKAP55 is direct and involves the Src homology 3 domain of SKAP55 and the proline-rich sequence of SLAP-130.	Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program Mol Biol, Iowa City, IA 52242 USA	Ruprecht Karls University Heidelberg; University of Iowa; University of Iowa; University of Iowa	Marie-Cardine, A (corresponding author), Heidelberg Univ, Inst Immunol, Neuenheimer Feld 305, D-69120 Heidelberg, Germany.	m71@popix.urz.uni-heidelberg.de	Koretzky, Gary/AAU-5381-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053256] Funding Source: NIH RePORTER; NIAID NIH HHS [2T32 AI07260] Funding Source: Medline; NIGMS NIH HHS [R01 GM53256] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; daSilva AJ, 1997, J IMMUNOL, V158, P2007; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; LEE SK, 1994, INT IMMUNOL, V6, P1621, DOI 10.1093/intimm/6.10.1621; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; RIGLEY K, 1995, J IMMUNOL, V154, P1136; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Schraven B, 1997, IMMUNOL LETT, V57, P165, DOI 10.1016/S0165-2478(97)00053-9; SCHRAVEN B, 1997, KINASES PHOSPHATASES, P100; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	26	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25789	25795		10.1074/jbc.273.40.25789	http://dx.doi.org/10.1074/jbc.273.40.25789			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748251	hybrid			2022-12-25	WOS:000076263100042
J	Lee, YH; Yun, YD				Lee, YH; Yun, YD			HBx protein of hepatitis B virus activates Jak1-STAT signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; X-GENE; TYROSINE PHOSPHORYLATION; HEPATOCELLULAR-CARCINOMA; MAP-KINASE; TRANSCRIPTION; LIVER; CELLS; PATHWAY	The X-gene product (HBx) of the hepatitis B virus plays essential roles in viral replication and the generation of hepatocellular carcinoma. Although the mechanism for HBx action is unclear, HBx may exert its pleiotropic functions through the stimulation of signal transduction pathways including the Ras/mitogen-activated protein kinase cascade and/or inactivation of the p53 function. Here, we investigated whether HBx has the ability to activate the Jak-STAT signaling pathway. As a first step, we established stable cell lines constitutively expressing HBx, In these HBx-expressing stable cells, the tyrosine phosphorylation of various STATs, including STAT3 and -5, was constitutively enhanced by HBx, and the concomitant increase in STAT-dependent DNA binding and transcriptional activation was observed. Furthermore, HBx specifically elevated tyrosine phosphorylation and in vitro kinase activity of Jak1, but not Jak2 or Tyk2, through protein to protein interaction with Jak1. These results clearly establish HBx as the inducer of the Jak-STAT signaling pathway, and at the same time, HBx-mediated Jak-STAT activation may provide a novel mechanism for the pleiotropic functions of HBx, including transformation and promiscuous transcriptional activation.	Morgan Biotechnol Res Inst, Signal Transduct Lab, Kyunggido 449910, South Korea		Yun, YD (corresponding author), Morgan Biotechnol Res Inst, Signal Transduct Lab, 341 Pojungri, Kyunggido 449910, South Korea.		Lee, Young-Ho/G-2361-2014	Lee, Young-Ho/0000-0001-6415-4912				BARINAGA M, 1995, SCIENCE, V269, P1673, DOI 10.1126/science.7569891; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BRUNN GJ, 1995, J BIOL CHEM, V270, P11628, DOI 10.1074/jbc.270.19.11628; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVIERE J, 1989, CLIN EXP IMMUNOL, V77, P221; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	39	198	205	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25510	25515		10.1074/jbc.273.39.25510	http://dx.doi.org/10.1074/jbc.273.39.25510			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738022	hybrid			2022-12-25	WOS:000076085400072
J	Zakharova, N; Bass, I; Arsenieva, E; Nikiforov, V; Severinov, K				Zakharova, N; Bass, I; Arsenieva, E; Nikiforov, V; Severinov, K			Mutations in and monoclonal antibody binding to evolutionary hypervariable region of Escherichia coli RNA polymerase beta ' subunit inhibit transcript cleavage and transcript elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO CHARACTERIZATION; AMINO-ACID SUBSTITUTIONS; CONSERVED REGIONS; ACTIVE-CENTER; FACTOR TFIIS; TERMINATION; ARCHAEBACTERIAL; BETA'-SUBUNIT; PURIFICATION; LETHAL	A 190 amino acid-long region centered around position 1050 of the 1407-amino acid-long beta' subunit of Escherichia coli RNA polymerase (RNAP) is absent from homologues in eukaryotes, archaea and many bacteria. In chloroplasts, the corresponding region can be more than 900 amino acids long. The role of this hypervariable region was studied by deletion mutagenesis of the cloned E. coli rpoC, encoding beta', Long deletions mimicking beta' from Gram-positive bacteria failed to assemble into RNAP, Mutants with short, 40-60-amino acid-long deletions spanning beta' residues 941-1130 assembled into active RNAP in vitro. These mutant enzymes were defective in the transcript cleavage reaction and had dramatically reduced transcription elongation rates at subsaturating substrate concentrations due to prolonged pausing at sites of transcriptional arrest. Binding of a monoclonal antibody, Pyn1, to the hypervariable region inhibited transcription elongation and intrinsic transcript cleavage and, to a lesser degree, GreB-induced transcript cleavage, but did not interfere with GreB binding to RNAP, We propose that mutations in and antibody binding to the hypervariable, functionally dispensable region of beta' inhibit transcript cleavage and elongation by distorting the flanking conserved segment G in the active center.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Russian Academy of Sciences	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.	severik@waksman.rutgers.edu	Grivennikov, IGOR/ABA-6403-2020; Severinov, Konstantin/C-8545-2016					ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; ARCHAMBAULT J, 1992, MOL GEN GENET, V232, P408, DOI 10.1007/BF00266244; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; GRAGEROV AI, 1980, FEBS LETT, V122, P17, DOI 10.1016/0014-5793(80)80391-7; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HONORE N, 1993, MOL MICROBIOL, V7, P207, DOI 10.1111/j.1365-2958.1993.tb01112.x; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; Ito K, 1996, MOL GEN GENET, V251, P699, DOI 10.1007/BF02174119; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KEANA JFW, 1990, J ORG CHEM, V55, P3640, DOI 10.1021/jo00298a048; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Koulich D, 1997, J BIOL CHEM, V272, P7201, DOI 10.1074/jbc.272.11.7201; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDICK R, 1990, J BACTERIOL, V172, P2844, DOI 10.1128/jb.172.6.2844-2854.1990; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LUO JY, 1992, J BIOL CHEM, V267, P18175; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; Mollet C, 1998, GENE, V207, P97, DOI 10.1016/S0378-1119(97)00618-5; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; PETERSEN SK, 1991, J BACTERIOL, V173, P5200, DOI 10.1128/jb.173.16.5200-5206.1991; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; SEVERINOV K, 1994, J BIOL CHEM, V269, P14254; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; Severinov K, 1996, J BIOL CHEM, V271, P27969, DOI 10.1074/jbc.271.44.27969; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Tavormina PL, 1996, J BACTERIOL, V178, P5263, DOI 10.1128/jb.178.17.5263-5271.1996; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; Wu JS, 1996, P NATL ACAD SCI USA, V93, P11552, DOI 10.1073/pnas.93.21.11552; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; ZILLIG W, 1986, RNA POLYMERASE REGUL, P17	42	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24912	24920		10.1074/jbc.273.38.24912	http://dx.doi.org/10.1074/jbc.273.38.24912			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733798	hybrid			2022-12-25	WOS:000076007300090
J	Combadiere, C; Salzwedel, K; Smith, ED; Tiffany, HL; Berger, EA; Murphy, PM				Combadiere, C; Salzwedel, K; Smith, ED; Tiffany, HL; Berger, EA; Murphy, PM			Identification of CX(3)CR1 - A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; FUNCTIONAL EXPRESSION; HUMAN MONOCYTE; TROPIC HIV-1; CDNA CLONING; COFACTOR; ENTRY; GENE; 7-TRANSMEMBRANE; MIP-1-ALPHA	Fractalkine is a multimodular human leukocyte chemoattractant protein and a member of the chemokine superfamily. Unlike other human chemokines, the chemokine domain of fractalkine has three amino acids between two conserved cysteines, referred to as the CX3C motif. Both plasma membrane-associated and shed forms of fractalkine have been identified. Here, we show that the recombinant 76-amino acid chemokine domain of fractalkine is a potent and highly specific chemotactic agonist at a human orphan receptor previously named V28 or alternatively CMKBRL1 (chemokine beta receptor-like 1), which was shown previously to be expressed in neutrophils, monocytes, T lymphocytes, and several solid organs, including brain. CMKBRL1/V28 also functioned with CD4 as a coreceptor for the envelope protein from a primary isolate of HIV-1 in a cell-cell fusion assay, and fusion was potently and specifically inhibited by fractalkine. Thus CMKBRL1/V28 is a specific receptor for fractalkine, and we propose to rename it CX(3)CR1 (CX3C chemokine receptor 1), according to an accepted nomenclature system.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; CHU X Bichat, INSERM U479, F-75877 Paris, France	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Murphy, PM (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Rm 11N113, Bethesda, MD 20892 USA.		Combadiere, Christophe/I-5639-2013	Combadiere, Christophe/0000-0002-1755-4531				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; COMBADIERE C, 1995, J BIOL CHEM, V270, P30235; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HARRISON JK, 1994, NEUROSCI LETT, V169, P85, DOI 10.1016/0304-3940(94)90362-X; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Liao F, 1997, BIOCHEM BIOPH RES CO, V236, P212, DOI 10.1006/bbrc.1997.6936; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	28	238	262	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23799	23804		10.1074/jbc.273.37.23799	http://dx.doi.org/10.1074/jbc.273.37.23799			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726990	hybrid			2022-12-25	WOS:000075893100031
J	Okino, ST; Chichester, CH; Whitlock, JP				Okino, ST; Chichester, CH; Whitlock, JP			Hypoxia-inducible mammalian gene expression analyzed in vivo at a TATA-driven promoter and at an initiator-driven promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; DNA-BINDING; FACTOR-I; PHOSPHOGLYCERATE KINASE-1; CRYSTAL-STRUCTURE; PAS DOMAIN; TRANSCRIPTION; PROTEIN; DIOXIN; COMPLEX	We have analyzed protein-DNA interactions in vivo at transcriptional control elements for two hypoxia-inducible genes in mouse hepatoma cells. The promoter for the phosphoglycerate kinase 1 (PGK1) gene contains an initiator element, but no TATA sequence, whereas the promoter for the glucose transporter 1 (Glut1) gene contains a TATA element but no initiator sequence. Our findings reveal hypoxia-inducible, Arnt-dependent occupancy of DNA recognition sites for hypoxia-inducible factor 1 (HIF-1) upstream of both target genes. The conserved recognition motif among the five recognition sites is 5'-CGTG-3'. The PGK1 promoter exhibits constitutive occupancy of a binding site for an unknown protein(s); however, we detect no protein-DNA interaction at the initiator element, in either uninduced or induced cells. The Glut1 promoter also exhibits constitutive protein binding; in addition, the TATA element exhibits partial occupancy in uninduced cells and increased occupancy under hypoxic conditions. We find no evidence for hypoxia-induced changes in chromatin structure of either gene. Time-course analyses of the Glut1 gene reveal a temporal relationship between occupancy of HIF-1 sites and TATA element occupancy. Our findings suggest that the promoters for both hypoxia-responsive genes constitutively maintain an accessible chromatin configuration and that HIF-1 facilitates transcription by recruiting and/or stabilizing a transcription factor(s), such as TFIID, at both promoters.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Whitlock, JP (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005677, R01ES008655] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 05677, ES 08655] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ashok M, 1998, P NATL ACAD SCI USA, V95, P2761, DOI 10.1073/pnas.95.6.2761; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hahn ME, 1997, P NATL ACAD SCI USA, V94, P13743, DOI 10.1073/pnas.94.25.13743; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; ISSAC DD, 1997, GENE DEV, V10, P103; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kay SA, 1997, SCIENCE, V276, P753, DOI 10.1126/science.276.5313.753; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; MULLER PR, 1989, SCIENCE, V246, P780; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHEN ES, 1992, J BIOL CHEM, V267, P6815; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Wang G L, 1996, Curr Opin Hematol, V3, P156; WANG GL, 1993, J BIOL CHEM, V268, P21513; Wenger RH, 1997, BIOL CHEM, V378, P609; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; ZAWAL L, 1995, ANNU REV BIOCHEM, V64, P533; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	57	46	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23837	23843		10.1074/jbc.273.37.23837	http://dx.doi.org/10.1074/jbc.273.37.23837			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726995	hybrid			2022-12-25	WOS:000075893100036
J	Vanderstraeten, S; Van den Brule, S; Hu, JP; Foury, F				Vanderstraeten, S; Van den Brule, S; Hu, JP; Foury, F			The role of 3 '-5 ' exonucleolytic proofreading and mismatch repair in yeast mitochondrial DNA error avoidance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXONUCLEASE ACTIVE-SITE; LARGE RIBOSOMAL-RNA; ENCODING MIP1 GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; POLYMERASE-GAMMA; 3'->5' EXONUCLEASE; REPLICATION ERRORS; RIB2 LOCUS; MUTAGENESIS	In the D171G/D2SOA mutant generated at conserved aspartate residues in the Exo1 and Exo2 sites of the 3'-5' exonuclease domain of the yeast mitochondrial DNA (mtDNA) polymerase (pol-gamma), the mitochondrial genome is unstable and the frequency of mtDNA point mutations is 1500 times higher than in the wild-type strain and 10 times higher than in single substitution mutants. The 10(4)-fold decrease in the 3'-5' exonuclease activity of the purified mtDNA polymerase is associated with mismatch extension and high rates of base misincorporation. Processivity of the purified polymerase on primed single-stranded DNA is decreased and the K-m for dNTP is increased. The sequencing of mtDNA point mutations in the wild-type strain and in proofreading and mismatch-repair deficient mutants shows that mismatch repair contributes to elimination of the transitions while exonucleolytic proofreading preferentially repairs transversions, and more specifically A to T (or T to A) transversions. However, even in the wild-type strain, A to T (or T to A) transversions are the most frequent substitutions, suggesting that they are imperfectly repaired. The combination of both mismatch repair and proofreading deficiencies elicits a mitochondrial error catastrophe. These data show that the faithful replication of yeast mtDNA requires both exonucleolytic proofreading and mismatch repair.	Unite Biochim Physiol, B-1348 Louvain, Belgium		Foury, F (corresponding author), Unite Biochim Physiol, Pl Croix du Sud,2-20, B-1348 Louvain, Belgium.							AQUADRO CF, 1983, GENETICS, V103, P287; AVISE JC, 1991, ANNU REV GENET, V25, P45, DOI 10.1146/annurev.ge.25.120191.000401; BACKER J, 1985, CURR GENET, V10, P7, DOI 10.1007/BF00418487; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CHI NW, 1994, J BIOL CHEM, V269, P29984; CLARKWALKER GD, 1991, CURR GENET, V20, P195, DOI 10.1007/BF00326232; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P211, DOI 10.1007/BF00762583; CUI Z, 1989, CURR GENET, V16, P273, DOI 10.1007/BF00422114; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ERIKSSON S, 1995, J BIOL CHEM, V270, P18929, DOI 10.1074/jbc.270.32.18929; ESTEBAN JA, 1994, J BIOL CHEM, V269, P31946; Fijalkowska IJ, 1996, P NATL ACAD SCI USA, V93, P2856, DOI 10.1073/pnas.93.7.2856; FOURY F, 1979, P NATL ACAD SCI USA, V76, P6529, DOI 10.1073/pnas.76.12.6529; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FOURY F, 1989, J BIOL CHEM, V264, P20552; GRAY H, 1992, J BIOL CHEM, V267, P5835; HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; Kogelnik AM, 1996, NUCLEIC ACIDS RES, V24, P177, DOI 10.1093/nar/24.1.177; Kuhn FJP, 1996, J BIOL CHEM, V271, P29245; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4; LECRENIER N, 1995, MOL GEN GENET, V249, P1, DOI 10.1007/BF00290229; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MACINO G, 1979, P NATL ACAD SCI USA, V76, P131, DOI 10.1073/pnas.76.1.131; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; PONTKINGDON GA, 1995, NATURE, V375, P109, DOI 10.1038/375109b0; REENAN RAG, 1992, GENETICS, V132, P975; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; SOR F, 1983, NUCLEIC ACIDS RES, V11, P339, DOI 10.1093/nar/11.2.339; SOR F, 1984, NUCLEIC ACIDS RES, V12, P8313, DOI 10.1093/nar/12.22.8313	44	69	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23690	23697		10.1074/jbc.273.37.23690	http://dx.doi.org/10.1074/jbc.273.37.23690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726974	hybrid			2022-12-25	WOS:000075893100015
J	Kuhlbrodt, K; Schmidt, C; Sock, E; Pingault, V; Bondurand, N; Goossens, M; Wegner, M				Kuhlbrodt, K; Schmidt, C; Sock, E; Pingault, V; Bondurand, N; Goossens, M; Wegner, M			Functional analysis of Sox10 mutations found in human Waardenburg-Hirschsprung patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; ARCHITECTURAL TRANSCRIPTION FACTORS; CAMPOMELIC DYSPLASIA; NUCLEAR-LOCALIZATION; BETA-CATENIN; JC VIRUS; DNA; PROTEIN; DOMAIN	The Sry-related protein Sox10 is selectively expressed in neural crest cells during early stages of development and in glial cells of the peripheral and central nervous systems during late development and in the adult. Mutation of the Sox10 gene leads to neural crest defects in the Dominant megacolon mouse mutant and to combined Waardenburg-Hirschsprung syndrome in humans. Here, we have studied the four Sox10 mutations found to date in Waardenburg-Hirschsprung patients both in the context of the rat and the human cDNA. Unlike the rat Sox10 protein, which failed to show transcriptional activity on its own, human Sox10 displayed a weak, but reproducible, activity as a transcriptional activator, All mutant Sox10 proteins, including the one that only lacked the 106 last amino acids were deficient in this capacity, indicating that the carboxyl terminus of human Sox10 carries a transactivation domain. Whereas all four mutants failed to transactivate, only two failed to synergistically enhance the activity of other transcription factors. Synergy required both the ability to bind to DNA and a region in the amino-terminal part of Sox10, Those mutants that failed to synergize were unable to bind to DNA, Analysis of the naturally occurring Sox10 mutations not only helps to dissect Sox10 structure, but also allows limited predictions on the severity of the disease.	Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany; Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France	University of Hamburg; University Medical Center Hamburg-Eppendorf; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Wegner, M (corresponding author), ZMNH, Martinistr 52, D-20246 Hamburg, Germany.		Bondurand, Nadege/H-4737-2017	Bondurand, Nadege/0000-0002-1531-1544; Wegner, Michael/0000-0002-4586-3294; Sock, Elisabeth/0000-0001-9925-3136; Pingault, Veronique/0000-0001-7064-0765				BADNER JA, 1990, AM J HUM GENET, V46, P568; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kent J, 1996, DEVELOPMENT, V122, P2813; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Meyer J, 1997, HUM MOL GENET, V6, P91, DOI 10.1093/hmg/6.1.91; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nambu PA, 1996, DEVELOPMENT, V122, P3467; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; Roose J, 1998, NUCLEIC ACIDS RES, V26, P469, DOI 10.1093/nar/26.2.469; Russell SRH, 1996, DEVELOPMENT, V122, P3669; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Sock E, 1996, J VIROL, V70, P1512, DOI 10.1128/JVI.70.3.1512-1520.1996; Sock E, 1996, J BIOL CHEM, V271, P17512, DOI 10.1074/jbc.271.29.17512; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; TAKAMATSU N, 1995, MOL CELL BIOL, V15, P3759; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	42	104	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23033	23038		10.1074/jbc.273.36.23033	http://dx.doi.org/10.1074/jbc.273.36.23033			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722528	hybrid			2022-12-25	WOS:000075778100028
J	Stella, L; Caccuri, AM; Rosato, N; Nicotra, M; Lo Bello, M; De Matteis, F; Mazzetti, AP; Federici, G; Ricci, G				Stella, L; Caccuri, AM; Rosato, N; Nicotra, M; Lo Bello, M; De Matteis, F; Mazzetti, AP; Federici, G; Ricci, G			Flexibility of helix 2 in the human glutathione transferase P1-1 - Time-resolved fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL STRUCTURE; S-TRANSFERASE; LIFETIME DISTRIBUTIONS; HUMAN PLACENTA; RESOLUTION; PROTEINS; COMPLEX; RAT; MECHANISM	Time-resolved fluorescence spectroscopy and site-directed mutagenesis have been used to probe the flexibility of alpha-helix 2 (residues 35-46) in the apo structure of the human glutathione transferase P1-1 (EC 2.5.1.18) as well as in the binary complex with the natural substrate glutathione. Trp-38, which resides on helix 2, has been exploited as an intrinsic fluorescent probe of the dynamics of this region. A Trp-28 mutant enzyme was studied in which the second tryptophan of glutathione transferase P1-1 is replaced by histidine. Time-resolved fluorescence data indicate that, in the absence of glutathione, the apoenzyme exists in at least two different families of conformational states. The first one (38% of the total population) corresponds to a number of slightly different conformations of helix 2, in which Trp-38 resides in a polar environment showing an average emission wavelength of 350 nm. The second one (62% of the total population) displays an emission centered at 320 nm, thus suggesting a quite apolar environment near Trp-38. The interconversion between these two conformations is much slower than 1 ns. In the presence of saturating glutathione concentrations, the equilibrium is shifted toward the apolar component, which is now 83% of the total population. The polar conformers, on the other hand, do not change their average decay lifetime, but the distribution becomes wider, indicating a slightly increased rigidity. These data suggest a central role of conformational transitions in the binding mechanism, and are consistent with NMR data (Nicotra, M., Paci, M., Sette, M., Oakley, A. J., Parker, M. W., Lo Bello, M., Caccuri, A. M., Federici, G., and Ricci, G. (1998) Biochemistry 37, 3020-3027) and pre-steady state kinetic experiments (Caccuri, A. M., Lo Bello, M., Nuccetelli, M., Nicotra, M., Rossi, P., Antonini, G., Federici, G., and Ricci, G. (1998) Biochemistry 37, 3028-3034) indicating the existence of a pre-complex in which GSH is not firmly bound to the active site.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Phys, I-00133 Rome, Italy; Ist Nazl Fis Mat, I-00133 Rome, Italy; Osped Pediat IRCCS Bambin Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); IRCCS Bambino Gesu	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Viale Ric Sci, I-00133 Rome, Italy.	RICCIG@UNIROMA2.IT	CACCURI, ANNA MARIA/AFU-2643-2022; De Matteis, Fabio/ABG-1923-2020; Stella, Lorenzo/A-7996-2010	Stella, Lorenzo/0000-0002-5489-7381; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163; De Matteis, Fabio/0000-0001-7860-9754				ALCALA JR, 1987, BIOPHYS J, V51, P925, DOI 10.1016/S0006-3495(87)83420-3; ALCALA JR, 1987, BIOPHYS J, V51, P597, DOI 10.1016/S0006-3495(87)83384-2; ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; ARMSTRONG RN, 1994, ADV ENZYMOL RELAT A, V10, P1; BATTISTONI A, 1995, PROTEIN EXPRES PURIF, V6, P579, DOI 10.1006/prep.1995.1076; BEECHEM JM, 1988, P SPIE INT SOC OPT E, V909, P70; Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; BISMUTO E, 1989, PHOTOCHEM PHOTOBIOL, V50, P165, DOI 10.1111/j.1751-1097.1989.tb04143.x; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; Dietze EC, 1996, BIOCHEMISTRY-US, V35, P6745, DOI 10.1021/bi9530346; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; FERREIRA ST, 1994, BIOPHYS J, V66, P1185, DOI 10.1016/S0006-3495(94)80901-4; GRATTON E, 1989, FLUORESCENT BIOMOLEC, P17; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANDAW EM, 1984, AM J PHYSIOL, V246, pR665, DOI 10.1152/ajpregu.1984.246.5.R665; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; McMahon LP, 1997, J PHYS CHEM B, V101, P3269, DOI 10.1021/jp963273i; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Nicotra M, 1998, BIOCHEMISTRY-US, V37, P3020, DOI 10.1021/bi971902o; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RICCI G, 1991, J BIOL CHEM, V266, P21409; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Simons P C, 1981, Methods Enzymol, V77, P235; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; WANG RW, 1993, PROTEIN SCI, V2, P2085, DOI 10.1002/pro.5560021209; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	37	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23267	23273		10.1074/jbc.273.36.23267	http://dx.doi.org/10.1074/jbc.273.36.23267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722558	hybrid			2022-12-25	WOS:000075778100058
J	Guerrin, M; Simon, M; Montezin, M; Haftek, M; Vincent, C; Serre, G				Guerrin, M; Simon, M; Montezin, M; Haftek, M; Vincent, C; Serre, G			Expression cloning of human corneodesmosin proves its identity with the product of the S gene and allows improved characterization of its processing during keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEUM CHYMOTRYPTIC ENZYME; PROTEIN DESMOGLEIN-I; STRATUM-CORNEUM; ENDOGENOUS PROTEOLYSIS; CORNIFIED EPITHELIA; HUMAN-EPIDERMIS; PIG EPIDERMIS; DESQUAMATION; PSORIASIS; IDENTIFICATION	In human epidermis and other cornified squamous epithelia, corneodesmosin is located in the desmosomes of the upper living layers, and in related structures of the cornified layers, the corneodesmosomes. During maturation of the cornified layers, the protein undergoes a series of cleavages, thought to be a prerequisite of desquamation. Partial amino acid sequencing of corneodesmosin fragments suggested that it is related to the product of the S gene, previously identified in the human major histocompatibility complex. We report the expression cloning of corneodesmosin cDNA from a human epidermis library screened with monoclonal antibodies. Sequencing demonstrated that corneodesmosin is really the product of the S gene. However, analysis of 20 alleles of the gene revealed that its product is 27 amino acids longer than initially reported. Two additional polymorphic sites were described, and the position of the unique intron was ascertained. Corneodesmosin cDNA expression in COS-7 cells led to secretion of the protein. Precise epitope mapping allowed further characterization of the molecular forms of corneodesmosin present in the most superficial cornified layers, where fragments corresponding to the central region of the protein were detected. This indicated a cleavage of the N- and C-terminal domains of corneodesmosin before desquamation, These serine- and glycine-rich domains are proposed to mediate an adhesive function.	CHU Toulouse, UPS,Dept Biol & Pathol Cell, CNRS,Toulouse Purpan Sch Med, INSERM,IFR30,Univ Toulouse 3,CJF 96 02, F-31073 Toulouse, France; CNRS, INSERM U346, F-69437 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); VetAgro Sup	Serre, G (corresponding author), CHU Purpan, Lab Biol Cellulaire & Cytol, Pl Dr Baylac, F-31059 Toulouse, France.	serre@cict.fr	Simon, Michel/B-7308-2011	Simon, Michel/0000-0003-3655-6329				ALLEN TD, 1975, J ULTRA MOL STRUCT R, V51, P94, DOI 10.1016/S0022-5320(75)80011-6; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRYSK MM, 1989, EXP CELL BIOL, V57, P60; CHAPMAN SJ, 1990, ARCH DERMATOL RES, V282, P304, DOI 10.1007/BF00375724; CHAPMAN SJ, 1991, ARCH DERMATOL RES, V283, P167, DOI 10.1007/BF00372057; EGELRUD T, 1993, J INVEST DERMATOL, V101, P200, DOI 10.1111/1523-1747.ep12363804; EGELRUD T, 1990, J INVEST DERMATOL, V95, P456, DOI 10.1111/1523-1747.ep12555620; EGELRUD T, 1989, ACTA DERM-VENEREOL, V69, P470; Ghadially R, 1996, J INVEST DERMATOL, V107, P558, DOI 10.1111/1523-1747.ep12582813; GHADIALLY R, 1992, J INVEST DERMATOL, V99, P755, DOI 10.1111/1523-1747.ep12614489; HAFTEK M, 1991, J HISTOCHEM CYTOCHEM, V39, P1531, DOI 10.1177/39.11.1717544; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Holbrook K., 1994, KERATINOCYTE HDB, P3; Ishihara M, 1996, TISSUE ANTIGENS, V48, P182, DOI 10.1111/j.1399-0039.1996.tb02626.x; KING IA, 1987, J CELL BIOL, V105, P3053, DOI 10.1083/jcb.105.6.3053; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LUNDSTROM A, 1994, ARCH DERMATOL RES, V286, P369, DOI 10.1007/BF00371795; LUNDSTROM A, 1990, J INVEST DERMATOL, V94, P216, DOI 10.1111/1523-1747.ep12874531; Mallon E, 1997, J INVEST DERMATOL, V109, P183, DOI 10.1111/1523-1747.ep12319304; MENTON DN, 1971, J ULTRA MOL STRUCT R, V35, P247, DOI 10.1016/S0022-5320(71)80155-7; Montezin M, 1997, EXP CELL RES, V231, P132, DOI 10.1006/excr.1996.3452; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Reichert Uwe, 1993, P107; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; Simon M, 1997, J BIOL CHEM, V272, P31770, DOI 10.1074/jbc.272.50.31770; SIMON M, 1994, KERATINOCYTE HDB, P275; SKERROW CJ, 1989, J CELL SCI, V92, P667; SOMMER SS, 1992, BIOTECHNIQUES, V12, P82; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; SUZUKI Y, 1994, ARCH DERMATOL RES, V286, P249, DOI 10.1007/BF00387596; TIILIKAINEN A, 1980, BRIT J DERMATOL, V102, P179, DOI 10.1111/j.1365-2133.1980.tb05690.x; Trembath RC, 1997, HUM MOL GENET, V6, P813, DOI 10.1093/hmg/6.5.813; Velten F, 1998, TISSUE ANTIGENS, V51, P183, DOI 10.1111/j.1399-0039.1998.tb02963.x; Vicanova J, 1996, CELL TISSUE RES, V286, P115, DOI 10.1007/s004410050680; WALSH A, 1991, ARCH DERMATOL RES, V283, P174, DOI 10.1007/BF00372058; ZHOU YQ, 1993, P NATL ACAD SCI USA, V90, P9470, DOI 10.1073/pnas.90.20.9470	37	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22640	22647		10.1074/jbc.273.35.22640	http://dx.doi.org/10.1074/jbc.273.35.22640			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712893	hybrid			2022-12-25	WOS:000075616600069
J	Kim, JO; Nau, MM; Allikian, KA; Makela, TP; Alitalo, K; Johnson, BE; Kelley, MJ				Kim, JO; Nau, MM; Allikian, KA; Makela, TP; Alitalo, K; Johnson, BE; Kelley, MJ			Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines	ONCOGENE			English	Article						gene amplification; L-myc; cyclophilin; small cell lung cancer; tumor cell line; alternative splicing	NEURONAL CEROID-LIPOFUSCINOSIS; COMPLEX PATTERN; EXPRESSION; IDENTIFICATION; IMMUNOPHILINS; PROTEINS; ONCOGENE; BINDING; RLF	Specific genetic alterations affecting proto-oncogenes of the myc gene family are frequently detected in human lung cancer. Among 11 SCLC cell lines with L-myc gene amplification, four were found to have alteration of the RLF gene by Southern blot and RT-PCR analyses. One cell line, NCI-H378, contained aberrantly-sized L-myc-hybridizing bands by Southern and Northern blot hybridization but had no alteration of RLF: Some L-myc-hybridizing cDNAs from NCI-H378 contained a novel sequence with close homology to the cyclophilins joined to antisense L-myc exon 2 sequence. Full length cDNAs isolated from human skeletal muscle containing only the novel sequence identify open reading frames of 301 and 296 amino acids and differ in the C-terminal region by 22 and 17 amino acids. This gene, tentatively named PPIE (peptidyl-prolyl cis-trans isomerase E), has 83% amino acid identity with the central conserved region of cyclophilin A, is evolutionarily conserved by Southern blot, and exhibits differential tissue expression with highest levels found in muscle and brain. Coamplification of PPIE was observed in seven of eleven L-myc amplified cell lines. Analysis of radiation hybrids suggests that the gene order is RLF-PPIE-L-myc on chromosome Ip and pulse-field gel electrophoresis localizes all three genes to an 800 megabase Mlu I fragment. The prognostic and functional consequences of PPIE gene amplification in SCLC can now be determined.	NCI, Lung Canc Biol Sect, Med Branch, Div Clin Sci, Bethesda, MD 20889 USA; Univ Helsinki, Canc Biol Lab, Dept Virol & Pathol, FIN-00290 Helsinki, Finland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Helsinki	Kelley, MJ (corresponding author), NCI, Lung Canc Biol Sect, Med Branch, Div Clin Sci, Bethesda, MD 20889 USA.		Alitalo, Kari K/J-5013-2014; Kelley, Michael/AAC-8939-2019; makela, tomi/B-3734-2009	Alitalo, Kari K/0000-0002-7331-0902; Kelley, Michael/0000-0001-9523-6080; makela, tomi/0000-0002-4869-8044				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; CARNEY DN, 1985, CANCER RES, V45, P2913; CELANO P, 1992, J BIOL CHEM, V267, P15092; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; GAZDAR AF, 1985, CANCER RES, V45, P2924; HAENDLER B, 1990, EUR J BIOCHEM, V190, P477, DOI 10.1111/j.1432-1033.1990.tb15598.x; HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Johnson BE, 1996, J CELL BIOCHEM, P210; JOHNSON BE, 1996, LUNG CANC PRINCIPLES, P83; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MACLEANHUNTER S, 1994, ONCOGENE, V9, P3509; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; Phelps RM, 1996, J CELL BIOCHEM, P32; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SPICER DB, 1992, MOL CELL BIOL, V12, P1324, DOI 10.1128/MCB.12.3.1324; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	27	19	21	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	1998	17	8					1019	1026		10.1038/sj.onc.1202006	http://dx.doi.org/10.1038/sj.onc.1202006			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747881				2022-12-25	WOS:000075560900010
J	Fukushima, A; Okuda, A; Nishimoto, M; Seki, N; Hori, TA; Muramatsu, M				Fukushima, A; Okuda, A; Nishimoto, M; Seki, N; Hori, TA; Muramatsu, M			Characterization of functional domains of an embryonic stem cell coactivator UTF1 which are conserved and essential for potentiation of ATF-2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR DEVELOPMENTAL TRANSITION; EARLY XENOPUS-EMBRYOS; EARLY MOUSE EMBRYOS; TRANSCRIPTION FACTOR; CARCINOMA-CELLS; DNA-BINDING; POU-DOMAIN; GLUCOCORTICOID RECEPTOR; TERATOCARCINOMA CELLS; NEGATIVE REGULATION	We have recently cloned a cDNA encoding an embryonic stem cell transcriptional coactivator termed UTF1 from the mouse F9 teratocarcinoma cell line (Okuda, A, Fukushima, A., Nishimoto, M, Orimo, A., Yamagishi, T., Nabeshima, Y., Kuro-o, M., Nabeshima, Y., Boon, a, Keaveney, M., Stunnenberg, H.G., and Muramatsu, M. (1998) EMBO J. 17, 2019-2032). Here we have cloned a cDNA for human UTF1 and identified two highly conserved domains termed conserved domain (CD)1 and CD2. Human UTF1, like that of mouse, binds to ATF-2 and the mutagenesis analyses reveal that the leucine zipper motif within the CD2 of the UTF1 and metal binding motif of ATF-2 are involved in this interaction. The factor also binds to TATA-binding protein containing complex. By means of immunoprecipitation analysis, we mapped two domains which are independently able to bind to the complex. Importantly, both domains are located within the conserved domains (one in CD1 and the other in CD2). Furthermore, transient transfection analyses point out the importance of these domains for activating ATF-2. Thus, these results suggest that these two conserved domains identified here play important roles in activating specific transcription at least in part by supporting physical interaction between the upstream factor, ATF-2, and basal transcription machinery.	Saitama Med Sch, Dept Biochem, Moroyama, Saitama 3500495, Japan; Kazusa DNA Res Inst, Lab Gene Struct 1, Chiba 292, Japan; Natl Inst Radiol Sci, Div Genet, Inage Ku, Chiba 263, Japan	Saitama Medical University; Kazusa DNA Research Institute; National Institutes for Quantum Science & Technology	Muramatsu, M (corresponding author), Saitama Med Sch, Dept Biochem, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	muramasa@saitama-med.ac.jp						BRINSTER RL, 1974, J EXP MED, V140, P1049, DOI 10.1084/jem.140.4.1049; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; COLBERGPOLEY AM, 1985, NATURE, V314, P713, DOI 10.1038/314713a0; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Gilbert SF, 1991, DEV BIOL; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HASEGAWA T, 1990, DIFFERENTIATION, V42, P191, DOI 10.1111/j.1432-0436.1990.tb00761.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hogan B, 1994, MANIPULATING MOUSE E; HORI T, 1990, HUM GENET, V85, P576; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN GR, 1975, CELL, V6, P467, DOI 10.1016/0092-8674(75)90035-5; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEIJER D, 1990, NUCLEIC ACIDS RES, V9, P2241; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; MURPHY SP, 1988, P NATL ACAD SCI USA, V85, P5587, DOI 10.1073/pnas.85.15.5587; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PAPAIOANNOU VE, 1975, NATURE, V258, P70, DOI 10.1038/258070a0; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang XH, 1997, BIOCHEM BIOPH RES CO, V232, P336, DOI 10.1006/bbrc.1997.6284; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	45	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25840	25849		10.1074/jbc.273.40.25840	http://dx.doi.org/10.1074/jbc.273.40.25840			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748258	hybrid			2022-12-25	WOS:000076263100049
J	Horowitz, A; Simons, M				Horowitz, A; Simons, M			Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; IDENTIFICATION; SEQUENCE; BINDING; DOMAINS	Syndecans are transmembrane proteoglycans capable of carrying both heparan and chondroitin sulfate chains. The cytoplasmic tail of syndecan-4 was recently reported to undergo in vivo phosphorylation on Ser(183) in the membrane-proximal part of the tail (Horowitz, A., and Simons, M. (1998) J. Biol. Chem. 273, 10914-10918). However, the functional consequences of this event remain unknown. The cytoplasmic tail of syndecan-4 is known to undergo multimerization and to activate protein kinase C alpha (PKC alpha), with both events depending on the presence of the commonly occurring phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2). In the present investigation we found that phosphorylation of Ser(183) produced a 10-fold reduction in the ability of syndecan-4 to activate PKC alpha, without affecting its ability to bind the PKC. Because Ser(183) is adjacent to positively charged lysine groups that resemble PIP2-binding regions in several other proteins, phosphorylation of this serine may affect the binding affinity of the syndecan-4 cytoplasmic tail to PIP2. We found that the Ser(183)-phosphorylated cytoplasmic tail of syndecan-4 has indeed a significantly lower affinity to PIP2 compared with the nonphosphorylated tail. Furthermore, Ser(183) phosphorylation abolished PIP2-dependent oligomerization of syndecan-4 cytoplasmic tails. We conclude that Ser(183) phosphorylation regulates syndecan-4-dependent activation of PKC alpha by reducing the affinity to PIP2 and inhibiting the oligomerization of syndecan-4 cytoplasmic tails. These results further support the role of syndecan-4 in signal transduction in endothelial cells.	Harvard Univ, Sch Med, Dept Med,Beth Israel Deaconess Med Ctr, Cardiovasc Div,Angiogenesis Res Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Simons, M (corresponding author), Harvard Univ, Sch Med, Depr Med,Beth Israel Deaconess Med Ctr, Cardiovasc Div,Angiogenesis Res Ctr, 330 Brookline Ave, Boston, MA 02215 USA.		Simons, Michael/G-8553-2014; Horowitz, Arie/AAT-9482-2021; Horowitz, Arie/F-4628-2015	Simons, Michael/0000-0003-0348-7734; Horowitz, Arie/0000-0001-6239-1287	NHLBI NIH HHS [P50 HL56993, HL07374, R01 HL53793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053793, P50HL056993, T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Lee D, 1998, J BIOL CHEM, V273, P13022, DOI 10.1074/jbc.273.21.13022; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; YU FX, 1992, J BIOL CHEM, V267, P14616	16	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25548	25551		10.1074/jbc.273.40.25548	http://dx.doi.org/10.1074/jbc.273.40.25548			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748216	hybrid			2022-12-25	WOS:000076263100007
J	Dumin, J; Wilcox, BD; Otterness, I; Melendez, JA; Huang, CC; Jeffrey, JJ				Dumin, J; Wilcox, BD; Otterness, I; Melendez, JA; Huang, CC; Jeffrey, JJ			Serotonin-mediated production of interstitial collagenase by uterine smooth muscle cells requires inerleukin-1 alpha, but not interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; EPITHELIAL-CELLS; CLONING; CULTURES; PURIFICATION; ENDOMETRIUM; PARACRINE; STEROIDS; SEQUENCE; ENZYME	The activation of the gene for interstitial collagenase in myometrial smooth muscle cells is absolutely dependent upon the presence of serotonin. Our previous studies investigating the mechanisms of this induction demonstrated that the mRNAs of both interleukin-1 (IL-1) isoforms, IL-1 alpha and IL-1 beta, are induced by serotonin and that the induction of IL-1 is required for the subsequent induction of collagenase. These data provided compelling evidence that serotonin-induced IL-1 acts via an autocrine loop in activating the collagenase gene. The experiments described here were designed to examine the potential role of each IL-1 isoform in collagenase production by using neutralizing antisera specific to each isoform of the cytokine, The antisera were examined for their ability to inhibit the serotonin-dependent production of the mRNA for collagenase and of the cytokines themselves. Neutralizing antiserum against IL-1 alpha, but not against IL-1 beta, inhibited the induction of the mRNA for collagenase and of the mRNAs for both IL-1 alpha and IL-1 beta, Western analysis indicated that detectable levels of IL-1 alpha protein, but not that of IL-1 beta, are produced at the time of serotonin-dependent collagenase induction. In contrast, significant levels of IL-1 beta protein are detected only when bacterial lipopolysaccharide is added to the cells. Taken together, the results of our study indicate that IL-1 alpha, but not IL-1 beta, plays an obligatory role in multiple serotonin-mediated gene regulations in the myometrial smooth muscle cell. In addition, the data suggest that IL-1 beta production has the potential for modifying myometrial function in pathological settings, particularly that of uterine infection.	Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA	Albany Medical College; Pfizer	Jeffrey, JJ (corresponding author), Albany Med Coll, Dept Biochem & Mol Biol, 47 New Scotland Rd, Albany, NY 12208 USA.			Melendez, Juan/0000-0001-8021-3097	NCI NIH HHS [CA77068] Funding Source: Medline; NICHD NIH HHS [HD32585, HD05291] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005291, R01HD032585, R37HD005291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLAIR HC, 1986, J CELL PHYSIOL, V129, P111, DOI 10.1002/jcp.1041290116; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FINI ME, 1994, J BIOL CHEM, V269, P11291; GRAY PW, 1986, J IMMUNOL, V137, P3644; HALME J, 1980, ARCH BIOCHEM BIOPHYS, V199, P51, DOI 10.1016/0003-9861(80)90255-6; HARKNESS RD, 1956, J PHYSIOL-LONDON, V132, P502, DOI 10.1113/jphysiol.1956.sp005543; JEFFREY JJ, 1990, J CELL PHYSIOL, V143, P396, DOI 10.1002/jcp.1041430226; JEFFREY JJ, 1991, J CELL PHYSIOL, V146, P399, DOI 10.1002/jcp.1041460310; LISAK RP, 1994, J NEUROIMMUNOL, V55, P171, DOI 10.1016/0165-5728(94)90007-8; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; LONG NC, 1990, AM J PHYSIOL, V259, pR74; LONG NC, 1989, THERMOREGULATION RES, P78; LOPPNOW H, 1992, EXP CELL RES, V198, P283, DOI 10.1016/0014-4827(92)90381-H; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; NAGAI Y, 1966, BIOCHEMISTRY-US, V10, P988; PATEL JA, 1995, AM J RESP CELL MOL, V13, P602, DOI 10.1165/ajrcmb.13.5.7576697; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSWIT WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P285, DOI 10.1016/0003-9861(83)90032-2; RYDELEKFITZGERALD L, 1993, MOL CELL ENDOCRINOL, V91, P67, DOI 10.1016/0303-7207(93)90256-J; SCHATZ F, 1983, ENDOCRINOLOGY, V113, P1274, DOI 10.1210/endo-113-4-1274; Singer CF, 1997, P NATL ACAD SCI USA, V94, P10341, DOI 10.1073/pnas.94.19.10341; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARNER SJC, 1987, J EXP MED, V165, P1316, DOI 10.1084/jem.165.5.1316; WARNER SJC, 1987, J IMMUNOL, V139, P1911; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; WILCOX BD, 1994, J BIOL CHEM, V269, P29658; WILCOX BD, 1992, J BIOL CHEM, V267, P20752	33	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25488	25494		10.1074/jbc.273.39.25488	http://dx.doi.org/10.1074/jbc.273.39.25488			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738019	hybrid			2022-12-25	WOS:000076085400069
J	Lu, AL; Fawcett, WP				Lu, AL; Fawcett, WP			Characterization of the recombinant MutY homolog, an adenine DNA glycosylase, from yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTY; ENZYME ENDONUCLEASE-III; CATALYTIC MECHANISM; MISMATCH REPAIR; BASE-PAIR; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; MUTAGENIC SUBSTRATE; IONIZING-RADIATION; OXIDATIVE DAMAGE; EXCISION-REPAIR	The mutY homolog (SpMYH) gene from a cDNA library of Schizosaccharomyces pombe encodes a protein of 461 amino acids that displays 28 and 31% identity to Escherichia coli MutY and human MutY homolog (MYH), respectively. Expressed SpMYH is able to complement an E. coli mutY mutant to reduce the mutation rate. Similar to E. coli MutY protein, purified recombinant SpMYH expressed in E. coli has adenine DNA glycosylase and apurinic/apyrimidinic lyase activities on A/G- and A/7,8-dihydro-8-oxoguanine (8-oxoG)-containing DNA. However, both enzymes have different salt requirements and slightly different substrate specificities. SpMYH has greater glycosylase activity on 2-aminopurine/G and A/2-aminopurine but weaker activity on A/C than E. coli MutY. Both enzymes also have different substrate binding affinity and catalytic parameters. Although SpMYH has great affinity to A/8-oxoG-containing DNA as MutY, the binding affinity to A/G-containing DNA is substantially lower for SpMYH than MutY, SpMYH has similar reactivity to both A/G- and A/8-oxoG-containing DNA; however, MutY cleaves A/G-containing DNA about 3-fold more efficiently than it does A/8-oxoG-containing DNA. Thus, SpMYH is the functional eukaryotic MutY homolog responsible for reduction of 8-oxoG mutational effect.	Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	aluchang@umaryland.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aburatani H, 1997, CANCER RES, V57, P2151; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BOITEUX S, 1984, NUCLEIC ACIDS RES, V12, P549; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN T, 1990, J MOL BIOL, V212, P437, DOI 10.1016/0022-2836(90)90320-L; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CARBONNAUX C, 1991, BIOCHEMISTRY-US, V30, P5449, DOI 10.1021/bi00236a018; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; HALLIWELL B, 1989, FREE RADICLAS BIOL M; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Lu AL, 1996, J BIOL CHEM, V271, P24138, DOI 10.1074/jbc.271.39.24138; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LU AL, 1988, GENETICS, V118, P593; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MARGISON GP, 1981, P NATL ACAD SCI-BIOL, V78, P861, DOI 10.1073/pnas.78.2.861; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; NOELLING J, 1992, NUCLEIC ACIDS RES, V20, P6501, DOI 10.1093/NAR/20.24.6501; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; SU SS, 1988, J BIOL CHEM, V263, P6829; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; YEH YC, 1991, J BIOL CHEM, V266, P6480	57	69	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25098	25105		10.1074/jbc.273.39.25098	http://dx.doi.org/10.1074/jbc.273.39.25098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737967	hybrid			2022-12-25	WOS:000076085400017
J	Cho, YK; Northrop, DB				Cho, YK; Northrop, DB			Transpeptidation by porcine pepsin catalyzed by a noncovalent intermediate unique to its iso-mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITION; SUBSTRATE; ENZYMES	Porcine pepsin proteolysis of the hexapeptide Leu-Ser-p-nitro-Phe-Me-Ala Leu-OMe (where OMe = methoxy and Nle = norleucine) in the presence of dipeptide Leu-Leu synthesizes a new hexapeptide Leu-Ser-p-nitro-Phe-Leu-Leu. Contrary to transpeptidation kinetics of other proteases, which depend upon an acyl-enzyme intermediate, the time course for pepsin-catalyzed transpeptidation displays a distinct lag before reaching a steady-state reaction velocity. Moreover, this lag is coupled to burst kinetics for the formation of proteolytic products, Leu-Ser-p-nitro-Phe and Nle-Ala-Leu-OMe. The lag requires that free Leu-Ser-p-nitro-Phe accumulate in the reaction medium during the lag phase and subsequently rebind for transpeptidation, Consistent with this dissociative kinetic mechanism are normal solvent isotope effects on formation of the proteolytic products Leu-Ser-p-nitro-Phe (v(H)/v(D), = 2.2 +/- 0.2) and Nle-Ala-Leu-OMe (v(H)/v(D) = 1.8 +/- 0.1) as opposed to an inverse effect on the formation of the transpeptidation product Leu-Ser-p-nitro-Phe-Leu-Leu (v(H)/v(D) = 0.40 +/- 0.09), Because proteolysis is slower in D2O but transpeptidation is faster, the isotopically sensitive step must occur after release of both products of proteolysis, which precludes putative acyl-enzyme covalent intermediates. Isotopically enhanced transpeptidation is a new type of isotope effect but one that is consistent with the Uni Bi iso-mechanism previously postulated on the basis of solvent isotope effects on V-max but not on V-max/K-m (Rebholz, K. L., and Northrop, D, B, (1991) Biochem. Biophys Res. Commun, 179, 65-69) and confirmed by solvent isotope effects on the onset of inhibition by pepstatin (Cho, Y, a, Rebholz, a, L,, and Northrop, D, B, (1994) Biochemistry 33, 9637-9642). As a new biochemical mechanism for peptide bond synthesis that has a potential for applications in biotechnology, it is here proposed that the energy necessary to drive peptide synthesis from free peptides comes from the sizable free energy drop associated with rehydration of the active site of pepsin in 55 M water.	Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53706 USA; Changwon Natl Univ, Dept Biochem, Chang Won 641773, Kyungnam, South Korea	University of Wisconsin System; University of Wisconsin Madison; Changwon National University	Northrop, DB (corresponding author), Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, 425 N Charter St, Madison, WI 53706 USA.	dbn@pharmacy.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONOV VK, 1981, EUR J BIOCHEM, V117, P195; BRITTON HG, 1973, BIOCHEM J, V133, P255, DOI 10.1042/bj1330255; CHO YK, 1994, BIOCHEMISTRY-US, V33, P9637, DOI 10.1021/bi00198a032; CLEMENT GE, 1973, PROG BIOORG CHEM, V2, P676; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; DUNN BM, 1984, BIOCHEMISTRY-US, V23, P5241, DOI 10.1021/bi00317a023; FISHER LM, 1986, BIOCHEMISTRY-US, V25, P2529, DOI 10.1021/bi00357a037; FRIEDEN C, 1979, ANNU REV BIOCHEM, V48, P471, DOI 10.1146/annurev.bi.48.070179.002351; FRUTON JS, 1980, MOL CELL BIOCHEM, V32, P105; HUNKAPILLER MW, 1972, BIOCHEMISTRY-US, V11, P2829, DOI 10.1021/bi00765a015; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; JAMES MNG, 1983, J MOL BIOL, V163, P299, DOI 10.1016/0022-2836(83)90008-6; KASCHE V, 1989, PROTEOLYTIC ENZYMES, P125; KNOWLES JR, 1970, PHILOS T R SOC B, V257, P135, DOI 10.1098/rstb.1970.0016; KRESGE AJ, 1973, J AM CHEM SOC, V95, P3065, DOI 10.1021/ja00790a082; Northrop DB, 1998, ARCH BIOCHEM BIOPHYS, V352, P288, DOI 10.1006/abbi.1997.0589; REBHOLZ KL, 1991, BIOCHEM BIOPH RES CO, V176, P65, DOI 10.1016/0006-291X(91)90890-J	17	6	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24305	24308		10.1074/jbc.273.38.24305	http://dx.doi.org/10.1074/jbc.273.38.24305			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733715	hybrid			2022-12-25	WOS:000076007300007
J	Keilhack, H; Tenev, T; Nyakatura, E; Godovac-Zimmermann, J; Nielsen, L; Seedorf, K; Bohmer, FD				Keilhack, H; Tenev, T; Nyakatura, E; Godovac-Zimmermann, J; Nielsen, L; Seedorf, K; Bohmer, FD			Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; ADHESION MOLECULE-1 PECAM-1; SRC HOMOLOGY-2 DOMAINS; SH2 DOMAIN; DIFFERENTIAL REGULATION; INTACT-CELLS; C-KIT; KINASE; DEPHOSPHORYLATION; ASSOCIATION	The protein-tyrosine phosphatase SHP-1 binds to and dephosphorylates the epidermal growth factor receptor (EGFR), and both SH2 domains of SHP-1 are important for this interaction (Tenev, T., Keilhack, H., Tomic, S., Stoyanov, B., Stein-Gerlach, M., Lammers, R., Krivtsov, A. V., Ullrich, A., and Bohmer, F. D. (1997) J. Biol, Chem. 272, 5966-5973). We mapped the EGFR phosphotyrosine 1173 as the major binding site for SHP-1 by a combination of phosphopeptide activation, phosphopeptide competition, and receptor YF mutant analysis. Mutational conversion of the EGFR sequence 1171-1176 AEY-LRV into the high affinity SHP-1 binding sequence LEY-LYL of the erythropoietin receptor (EpoR) led to a highly elevated SHP-1 binding to the mutant EGFR (EGFR(1171-1176EpoR)) and in torn to an enhanced dephosphorylation of the receptor. SHP-1 expression interfered with EGF-dependent mitogen-activated protein kinase stimulation, and this effect was more pronounced in case of EGFR(1171-1176EpoR). Reduced SHP-1 binding to the EGFR Y1173F mutant resulted in a reduced receptor dephosphorylation by coexpressed SHP-1 and less interference with EGF-dependent mitogen-activated protein kinase stimulation. The effects of receptor mutations on SHP-1 binding were, however, stronger than those on receptor dephosphorylation by SHP-1. Therefore, receptor dephosphorylation may be the result of the combined activity of receptor-bound SHP-1 and SHP-1 bound to an auxiliary docking protein.	Univ Jena, Fac Med, Res Unit Mol Cell Biol, D-07747 Jena, Germany; Inst Mol Biotechnol eV, D-07745 Jena, Germany; Hagedorn Res Lab, DK-2820 Gentofte, Denmark	Friedrich Schiller University of Jena; Novo Nordisk; Hagedorn Research Institute	Bohmer, FD (corresponding author), Univ Jena, Fac Med, Res Unit Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5frbo@rz.uni-jena.de	Zimmermann, Jasminka Godovac/E-6863-2010	Tenev, Tencho/0000-0001-8762-1069				Adachi M, 1996, CELL, V85, P15; Atherton E., 1990, SOLID PHASE PEPTIDE; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; BOHMER FD, 1995, ANAL BIOCHEM, V228, P267, DOI 10.1006/abio.1995.1349; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; CANTLEY LC, 1994, J CELL SCI, P121; CASE RD, 1994, J BIOL CHEM, V269, P10467; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FAURE R, 1992, J BIOL CHEM, V267, P11215; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; SEEDORF K, 1995, PROTEIN TYROSINE KIN, V2, P123; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SOLER C, 1994, J BIOL CHEM, V269, P12320; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stewart JM, 1984, SOLID PHASE PEPTIDE; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	59	120	121	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24839	24846		10.1074/jbc.273.38.24839	http://dx.doi.org/10.1074/jbc.273.38.24839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733788	hybrid			2022-12-25	WOS:000076007300080
J	Seger, D; Gechtman, Z; Shaltiel, S				Seger, D; Gechtman, Z; Shaltiel, S			Phosphorylation of vitronectin by casein kinase II - Identification of the sites and their promotion of cell adhesion and spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; HEPARIN-BINDING DOMAIN; ARG-GLY-ASP; ENDOTHELIAL-CELLS; INTEGRIN ALPHA(V)BETA(3); EXTRACELLULAR-MATRIX; INVITRO PHOSPHORYLATION; FIBRINOGEN BEHAVIOR; FACTOR-VA	The cell adhesion protein vitronectin (Vn) was previously shown to be the major target in human blood for an extracellular protein kinase A, which is released from platelets upon their physiological stimulation with thrombin and also prevails as an ectoenzyme in several other types of blood cells. Because plasma Vn was shown to have only one protein kinase A phosphorylation site (Ser(378)) but to contain similar to 3 mol of covalently bound phosphate, and because human serum and blood cells were shown to contain also a casein kinase II (CKII) on their surface, we studied the phosphorylation of Vn by CKII attempting to find out whether such phosphorylation modulates Vn function, an acid test for its having a physiological, relevance. Here we show (i) that the CKII phosphorylation of Vn has a K-m of 0.5-2 mu M (lower than the Vn concentration in blood, 3-6 mu M), (ii) that it is targeted to Thr(50) and Thr(57), which are vicinal to the RGD site of Vn, and (iii) that the phosphorylation of Thr(57) facilitates the phosphorylation of Thr(50). The maximal stoichiometry of the CKII phosphorylation of plasma Vn was found to be low, which, in principle, could be due to its partial prephosphorylation in vivo. However, for the detection of a functional modulation, we needed a comparison between a fully phosphorylated Vn (at Thr(57) and Thr(50)) and a nonphosphorylated Vn, Therefore, we expressed Vn in a baculovirus system and show (i) that the CKII phosphorylation of wt-Vn enhances the adhesion of bovine aorta endothelial cells; (ii) that the double mutant T50E/T57E (in which the neutral Thr residues are replaced by the negatively charged Glu residues considered analogs of Thr-P) has a significantly enhanced capacity to promote cell adhesion and to accelerate cell spreading when compared with either wild-type Vn or to the neutral T50A/T57A mutant; and (iii) that, at least in the case of bovine aorta endothelial cells, the T50E/T57E mutant exhibits an enhanced adhesion, which seems to be due to an increased affinity toward the alpha(v)beta(3) Vn receptors.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaltiel, S (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	lishalt@wiccmail.weizmann.ac.il						AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V3; Beavo J A, 1974, Methods Enzymol, V38, P299; BHAKDI S, 1988, CLIN EXP IMMUNOL, V74, P459; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN C, 1991, J INVEST DERMATOL, V96, P724, DOI 10.1111/1523-1747.ep12470960; CHAIN D, 1990, FEBS LETT, V269, P221, DOI 10.1016/0014-5793(90)81159-L; CHAIN D, 1991, BIOCHEM J, V274, P387, DOI 10.1042/bj2740387; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DANO K, 1985, ADV CANC RES; DUSENBERY KE, 1988, BIOCHEM BIOPH RES CO, V153, P7, DOI 10.1016/S0006-291X(88)81182-3; EL MC, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31; ERIKSSON S, 1993, THROMB RES, V72, P315, DOI 10.1016/0049-3848(93)90140-J; FELDING HB, 1998, CURR OPIN CELL BIOL, V5, P864; Gechtman Z, 1997, BIOCHEM J, V325, P339, DOI 10.1042/bj3250339; Gechtman Z, 1997, EUR J BIOCHEM, V243, P493, DOI 10.1111/j.1432-1033.1997.0493a.x; HARTMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1136, P189, DOI 10.1016/0167-4889(92)90256-B; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; Horwitz AF, 1997, SCI AM, V276, P68, DOI 10.1038/scientificamerican0597-68; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; KALAFATIS M, 1993, BLOOD, V81, P704; KORCGRODZICKI B, 1988, BIOCHEM BIOPH RES CO, V157, P1131; KORCGRODZICKI B, 1988, P NATL ACAD SCI USA, V85, P7541, DOI 10.1073/pnas.85.20.7541; KORCGRODZICKI B, 1990, ANAL BIOCHEM, V188, P288, DOI 10.1016/0003-2697(90)90608-C; KORCGRODZICKI B, 1990, THESIS WEIZMANN I SC; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MARTIN SC, 1991, THROMB RES, V61, P243, DOI 10.1016/0049-3848(91)90100-B; MARTIN SC, 1992, THROMB RES, V68, P467, DOI 10.1016/0049-3848(92)90059-J; MARTIN SC, 1990, FEBS LETT, V272, P103, DOI 10.1016/0014-5793(90)80458-U; MCGUIRE EA, 1988, J BIOL CHEM, V263, P1942; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MEHRINGER JH, 1991, BIOCHEM BIOPH RES CO, V179, P655, DOI 10.1016/0006-291X(91)91422-9; MIMURO J, 1989, J BIOL CHEM, V264, P5058; OWENSBY DA, 1991, J BIOL CHEM, V266, P4334; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PODACK ER, 1984, ACTA PATH MICRO IM C, V92, P89; PREISSNER KP, 1989, EUR J IMMUNOL, V19, P69, DOI 10.1002/eji.1830190112; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1990, BIOCHEM BIOPH RES CO, V168, P966, DOI 10.1016/0006-291X(90)91123-A; PREISSNER KT, 1988, BLOOD, V71, P1581; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RAND MD, 1994, BLOOD, V83, P2180; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEIFFERT D, 1990, CELL DIFFER DEV, V32, P287, DOI 10.1016/0922-3371(90)90041-T; SHALTIEL S, 1993, MOL CELL BIOCHEM, V128, P283, DOI 10.1007/BF01076778; SHALTIEL S, 1993, INT CONGR SER, V1042, P311; SIGURDARDOTTIR O, 1990, BIOCHIM BIOPHYS ACTA, V1035, P56, DOI 10.1016/0304-4165(90)90173-T; SKUBITZ KM, 1992, CELL MOL BIOL, V38, P543; SKUBITZ KM, 1991, J IMMUNOL, V147, P638; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020	71	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24805	24813		10.1074/jbc.273.38.24805	http://dx.doi.org/10.1074/jbc.273.38.24805			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733784	hybrid			2022-12-25	WOS:000076007300076
J	Tsuda, T; Kaya, S; Yokoyama, T; Hayashi, Y; Taniguchi, K				Tsuda, T; Kaya, S; Yokoyama, T; Hayashi, Y; Taniguchi, K			ATP and acetyl phosphate induces molecular events near the ATP binding site and the membrane domain of Na+,K+-ATPase - The tetrameric nature of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-SENSITIVE PHOSPHOENZYME; ADENOSINE-TRIPHOSPHATASE; TRYPTOPHAN FLUORESCENCE; CONFORMATIONAL CHANGE; PHOSPHORYLATION; N-<PARA-(2-BENZIMIDAZOLYL)PHENYL>MALEIMIDE; NA,K-ATPASE; MECHANISM; PROBES; SODIUM	The addition of ATP to Mg2+-Na+-bound-probe labeled Na+,K+-ATPase preparations containing similar to 0.5 mol of pyridoxal 5'-diphospho-5'-adenosine (AP(2)PL) probe at Lys-480 and similar to 0.9 mol of fluorescein 5'-isothiocyanate (FITC) probe at Lys-501 showed a decrease and an increase in the AP(2)PL fluorescence intensity with neither significant ATP-dependent phosphorylation nor FITC fluorescence change. The rate constants for the fluorescence change increased nearly linearly with increasing ATP concentrations, The substitution of AcP for ATP decreased the FITC fluorescence rather monophasically, 8.5/s, which was followed by the half-site phosphorylation with same amount of components with different rate constant, 7.2 and 4.6/s, followed by a much slower increase in the two components of AP(2)PL fluorescence, 1.4 and 0.2/s. The addition of Na+ with increasing concentrations of ATP to the K+-bound AP(2)PL-FITC enzymes induced accelerations in the decrease and an increase in the AP(2)PL fluorescence intensity with two different increases in the FITC fluorescence intensity, showing that the same concentration of ATP is capable of inducing four different fluorescence changes. The addition of ATP to the Mg2+-Na+-bound enzymes modified with N-[p-(2-benzimidazolyl)phenyl] -maleimide (BIPM) at Cys-964 and retaining full Na+,K+-ATPase activity induced two different increases in BIPM fluorescence intensity. Each rate constant for the BIPM fluorescence change versus concentrations of ATP gave two intersecting straight lines. These data and the stoichiometries of fluorescence probe bindings and ATP- and AcP-dependent phosphorylation provide strong support for the conclusion that the functional membrane-bound Na+,K+ -ATPase is a tetramer.	Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 060, Japan; Kyorin Univ, Sch Med, Dept Biochem, Tokyo 181, Japan	Hokkaido University; Kyorin University	Taniguchi, K (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 060, Japan.							ALBERS RW, 1976, ENZYMES BIOLOGICAL M, V3, P283; EGUCHI H, 1993, BIOCHEM BIOPH RES CO, V196, P294, DOI 10.1006/bbrc.1993.2248; Gatto C, 1997, ARCH BIOCHEM BIOPHYS, V340, P90, DOI 10.1006/abbi.1997.9879; GLYNN IM, 1985, SODIUM PUMP, P589; JORGENSEN PL, 1991, SOC GEN PHY, V46, P189; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V525, P252, DOI 10.1016/0005-2744(78)90219-X; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KAYA SJ, 1994, J BIOL CHEM, V269, P7419; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; NAKAMURA Y, 1989, J BIOCHEM-TOKYO, V115, P454; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; POST RL, 1972, J BIOL CHEM, V247, P6530; REPKE KRH, 1986, BIOCHIM BIOPHYS ACTA, V864, P195, DOI 10.1016/0304-4157(86)90011-0; ROBINSON JD, 1993, BIOCHIM BIOPHYS ACTA, V1154, P83, DOI 10.1016/0304-4157(93)90018-J; TANIGUCHI K, 1986, J BIOL CHEM, V261, P3272; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; TANIGUCHI K, 1984, J BIOL CHEM, V259, P5228; TANIGUCHI K, 1986, J BIOCHEM-TOKYO, V100, P1231, DOI 10.1093/oxfordjournals.jbchem.a121828; TANIGUCHI K, 1982, J BIOL CHEM, V257, P659; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; TANIGUCHI K, 1994, SODIUM PUMP, P581; Taniguchi K, 1988, Prog Clin Biol Res, V268A, P369; Tsuda T, 1998, J BIOCHEM, V123, P169; Tsuda T, 1997, ANN NY ACAD SCI, V834, P186, DOI 10.1111/j.1749-6632.1997.tb52250.x; Tsuda T, 1998, J BIOL CHEM, V273, P24334, DOI 10.1074/jbc.273.38.24334; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688	26	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24339	24345		10.1074/jbc.273.38.24339	http://dx.doi.org/10.1074/jbc.273.38.24339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733721	hybrid			2022-12-25	WOS:000076007300013
J	Drmota, T; Gould, GW; Milligan, G				Drmota, T; Gould, GW; Milligan, G			Real time visualization of agonist-mediated redistribution and internalization of a green fluorescent protein-tagged form of the thyrotropin-releasing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHOLIPASE-C; STIMULATED INTERNALIZATION; CHOLECYSTOKININ RECEPTOR; THROMBIN RECEPTORS; ENDOCYTIC PATHWAY; FUSION PROTEIN; DESENSITIZATION	The long isoform of the rat thyrotropin-releasing hormone receptor (TRHR) was modified by the addition of a vesicular stomatitis virus (VSV) epitope tag and green fluorescent protein (GFP), VSV-TPHR-GFP hound TRH with affinity similar to that of the unmodified receptor and stimulated [H-3]inositol phosphate production. A clone stably expressing VSV-TRHR-GFP at some 120,000 copies/cell was selected to visualize this receptor during cellular exposure to TRH. internalization was detected within 3-5 mile after treatment with 1 x 10(-7) M TRH, with dramatic reductions in plasma membrane localization achieved within 10-15 min. The TRHR antagonist/inverse agonist chlordiazepoxide competitively inhibited internalization Hyperosmotic sucrose inhibited internalization of VSV-TRHR-GFP, measured both by intact cell [H-3]TRH binding studies and by confocal microscopy. Now TRH caused a redistribution of VSV-TRHR-GFP to highly punctate but plasma membrane-delineated foci. Pretreatment with the microtubule-disrupting agent nocodazole allowed internalization of the VSV-TRHR-GFP construct but only into vesicles that remained in close apposition to the plasma membrane, Covisualization of VSV-TRHR-GFP and Texas Red transferrin initially indicated entirely separate localizations. After exposure to TRH substantial amounts of VSV-TRHR-GFP were present in vesicles overlapping those containing Texas Red transferrin. Such results demonstrate the G protein-coupling capacity and provide real time visualization of the processes of internalization of a TRH-receptor-GFP construct in response to agonist.	Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Milligan, G (corresponding author), Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.		Gould, Gwyn/AAF-6721-2019; Milligan, Graeme/F-9426-2011	Gould, Gwyn/0000-0001-6571-2875; Milligan, Graeme/0000-0002-6946-3519				ANDERSON L, 1995, BIOCHEM J, V311, P385, DOI 10.1042/bj3110385; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; Drmota T, 1998, J BIOL CHEM, V273, P21699, DOI 10.1074/jbc.273.34.21699; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; GHOSH RN, 1994, J CELL SCI, V107, P2177; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HEIN L, 1994, J BIOL CHEM, V269, P27719; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HINKLE PM, 1989, MOL ENDOCRINOL, V3, P1337, DOI 10.1210/mend-3-9-1337; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; JAHRAUS A, 1994, J CELL SCI, V107, P145; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; KIM GD, 1994, J BIOL CHEM, V269, P19933; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Milligan G, 1998, TRENDS ENDOCRIN MET, V9, P13, DOI 10.1016/S1043-2760(98)00004-6; Molino M, 1997, J BIOL CHEM, V272, P6011, DOI 10.1074/jbc.272.9.6011; MOORE RH, 1995, J CELL SCI, V108, P2983; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; Petrou C, 1997, J BIOL CHEM, V272, P2326; Roettger BF, 1997, MOL PHARMACOL, V51, P357; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Svoboda P, 1996, MOL PHARMACOL, V49, P646; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Wise A, 1997, BIOCHEM J, V325, P17, DOI 10.1042/bj3250017; Yu R, 1997, J BIOL CHEM, V272, P28301, DOI 10.1074/jbc.272.45.28301; Yu R, 1997, MOL PHARMACOL, V51, P785, DOI 10.1124/mol.51.5.785; ZernickaGoetz M, 1997, DEVELOPMENT, V124, P1133; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	48	55	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24000	24008		10.1074/jbc.273.37.24000	http://dx.doi.org/10.1074/jbc.273.37.24000			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727016	hybrid			2022-12-25	WOS:000075893100057
J	Jeannin, E; Robyr, D; Desvergne, B				Jeannin, E; Robyr, D; Desvergne, B			Transcriptional regulatory patterns of the myelin basic protein and malic enzyme genes by the thyroid hormone receptors alpha 1 and beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; PROLIFERATOR-ACTIVATED RECEPTOR; LIGAND-BINDING DOMAIN; RESPONSE ELEMENT; DNA-BINDING; NUCLEAR RECEPTORS; DIFFERENTIAL EXPRESSION; FUNCTIONAL-ANALYSIS; BRAIN-DEVELOPMENT; ORPHAN RECEPTORS	While there is evidence that the two ubiquitously expressed thyroid hormone (T3) receptors, TR alpha 1 and TR beta 1, have distinct functional specificities, the mechanism by which they discriminate potential target genes remains largely unexplained. In this study, we demonstrate that the thyroid hormone response elements (TRE) from the malic enzyme and myelin basic protein genes (METRE and MBPTRE) respectively, are not functionally equivalent. The METRE which is a direct repeat motif with a 4-base pair gap between the two half-site hexamers binds thyroid hormone receptor as a heterodimer with 9-cis-retinoic acid receptor (RXR) and mediates a high T3-dependent activation in response to TR alpha 1 or TR beta 1 in NIH3T3 cells. In contrast, the MBPTRE, which consists of an inverted palindrome formed by two hexamers spaced by 6 base pairs, confers an efficient transactivation by TR beta 1 but a poor transactivation by TR alpha 1, While both receptors form heterodimers with RXR on MBPTRE the poor transactivation by TR alpha 1 correlates also with its ability to bind efficiently as a monomer, This monomer, which is only observed with TR alpha 1 bound to MBPTRE, interacts neither with N-CoR nor with SEC-I, explaining its functional inefficacy, However, in Xenopus oocytes, in which RXR proteins are not detectable, the transactivation mediated by TR alpha 1 and TR beta 1 is equivalent and independent of a RXR supply, raising the question of the identity of the thyroid hormone receptor partner in these cells. Thus, in mammalian cells, the binding characteristics of TR alpha 1 to MBPTRE (i.e. high monomer binding efficiency and low transactivation activity) might explain the particular pattern of T3 responsiveness of MBP gene expression during central nervous system development.	Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland	University of Lausanne	Desvergne, B (corresponding author), Univ Lausanne, Inst Biol Anim, Batiment Biol, CH-1015 Lausanne, Switzerland.	beatrice.desvergne@iba.unil.ch	Desvergne, Beatrice/C-8892-2016	Desvergne, Beatrice/0000-0001-5483-288X				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORREST D, 1991, EMBO J, V10, P269, DOI 10.1002/j.1460-2075.1991.tb07947.x; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Higuchi R., 1989, PCR TECHNOLOGY, P61; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HSU JH, 1995, ENDOCRINOLOGY, V136, P421, DOI 10.1210/en.136.2.421; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; KAMEI Y, 1996, CELL, V85, P1; KATZ D, 1995, MOL CELL BIOL, V15, P2341; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEE IJ, 1994, P NATL ACAD SCI USA, V91, P1647, DOI 10.1073/pnas.91.5.1647; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LeRicousse S, 1996, P NATL ACAD SCI USA, V93, P5072, DOI 10.1073/pnas.93.10.5072; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEDIN JA, 1994, MOL CELL ENDOCRINOL, V105, P27, DOI 10.1016/0303-7207(94)90032-9; MELLSTROM B, 1991, MOL ENDOCRINOL, V5, P1339, DOI 10.1210/mend-5-9-1339; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MODAK SP, 1993, ONCOGENE, V8, P645; MORIOKA H, 1988, MOL CELL BIOL, V8, P3542, DOI 10.1128/MCB.8.8.3542; NAWAZ Z, 1995, P NATL ACAD SCI USA, V92, P11691, DOI 10.1073/pnas.92.25.11691; ONATE SA, 1995, SCIENCE, V270, P1354; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; Strait KA, 1997, ENDOCRINOLOGY, V138, P635, DOI 10.1210/en.138.2.635; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; Tong GX, 1996, MOL CELL BIOL, V16, P1909; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WONG J, 1995, GENE DEV, P2696; YARWOOD NJ, 1993, J BIOL CHEM, V268, P21984; YEN PM, 1994, J BIOL CHEM, V269, P12704; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZHANG XK, 1992, NATURE, V355, P442	72	44	44	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24239	24248		10.1074/jbc.273.37.24239	http://dx.doi.org/10.1074/jbc.273.37.24239			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727048	hybrid			2022-12-25	WOS:000075893100089
J	Thannickal, VJ; Aldweib, KDL; Fanburg, BL				Thannickal, VJ; Aldweib, KDL; Fanburg, BL			Tyrosine phosphorylation regulates H2O2 production in lung fibroblasts stimulated by transforming growth factor beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERATING NADPH OXIDASE; SIGNAL-TRANSDUCTION; ACTIVATION; OXYGEN; CELLS; PROLIFERATION; NEUTROPHILS; RECEPTORS; PROTEINS; KINASE	Transforming growth factor beta 1 (TGF-beta 1) is a multifunctional, profibrotic cytokine involved in cellular growth and differentiation. We have previously described a cell surface-associated H2O2-generating NADH:flavin:O-2 oxidoreductase (referred to as NADIR oxidase) activity in human lung fibroblasts induced by TGF-beta 1 (Thannickal, V. J., and Fanburg, B. L. (1995) J. Biol. Chem. 270, 30334-30338). In this study, the potential for regulation of this novel TGF-beta 1-activated oxidase in fibroblasts by protein tyrosine phosphorylation was examined. Immunoblots using anti-phosphotyrosine antibody demonstrated a time-dependent but delayed phosphorylation of two proteins of 115 and 103 kDa in cells stimulated with TGF-beta 1 (2 ng/ml), Similar to the effect on TGF-beta 1-induced H2O2 production, phosphorylation of these proteins was blocked by the addition of actinomycin D. The protein-tyrosine kinase inhibitors genistein and herbimycin A inhibited TGF-beta 1-induced protein tyrosine phosphorylation, NADH oxidase activation, and H2O2 production in a dose-dependent manner. Catalase, diphenyliodonium (an inhibitor of flavoenzymes), and suramin (an inhibitor of receptor activation, added 4 h after TGF-beta 1) had no effect on the induction of protein tyrosine phosphorylation, Phosphorylation of the 115- and 103-kDa proteins preceded the generation of H2O2 production and returned to control levels when H2O2 was undetectable at 48 h after TGF-beta 1 exposure, These results suggest that protein tyrosine phosphorylation by a nonreceptor protein-tyrosine kinase(s) regulates the activity of the TGF-beta 1-responsive H2O2-generating NADH oxidase in human lung fibroblasts, Additionally, this study demonstrates that TGF-beta 1, which binds to a serine-threonine kinase receptor, is able to induce protein tyrosine phosphorylation in a delayed manner via a signaling pathway that requires transcriptional activation.	New England Med Ctr, Tupper Res Inst, Dept Med, Div Pulm & Crit Care, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Thannickal, VJ (corresponding author), New England Med Ctr, Tupper Res Inst, Dept Med, Div Pulm & Crit Care, 750 Washington St,NEMC 369, Boston, MA 02111 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003552, R01HL042376] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL-03552, HL-42376] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; KUSUNOKI T, 1992, BIOCHEM BIOPH RES CO, V183, P789, DOI 10.1016/0006-291X(92)90552-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LIBBY J, 1986, J CELL PHYSIOL, V129, P159, DOI 10.1002/jcp.1041290206; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; OBHA M, 1994, J CELL BIOL, V126, P1079; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Reimann T, 1997, FEBS LETT, V403, P57, DOI 10.1016/S0014-5793(97)00024-0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STOUFFER GA, 1994, J CLIN INVEST, V93, P2048, DOI 10.1172/JCI117199; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WEI HC, 1995, P SOC EXP BIOL MED, V208, P124	34	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23611	23615		10.1074/jbc.273.36.23611	http://dx.doi.org/10.1074/jbc.273.36.23611			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722602	hybrid			2022-12-25	WOS:000075778100102
J	Zhang, JH; Ding, XX				Zhang, JH; Ding, XX			Identification and characterization of a novel tissue-specific transcriptional activating element in the 5 '-flanking region of the CYP2A3 gene predominantly expressed in rat olfactory mucosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; RABBIT NASAL MICROSOMES; DNA-BINDING PROTEIN; MOLECULAR-CLONING; CYTOCHROMES P450; CDNA CLONING; STEROID 15-ALPHA-HYDROXYLASE; HETEROLOGOUS EXPRESSION; MARKER PROTEIN; PROMOTER	CYP2A3 is expressed preferentially in rat olfactory mucosa and is believed to play important roles in maintaining cellular homeostasis in the chemosensory tissue. DNase I footprinting analysis revealed a single protected region in the proximal promoter of the CYP2A3 gene with nuclear extracts from olfactory mucosa, but not from liver, lung, kidney, or brain. The core sequence of the binding site, named the nasal predominant transcriptional activating (NPTA) element, is similar to that of nuclear factor 1, but it interacted with unique proteins detected only in the olfactory mucosa in electrophoretic mobility shift assays or on Southwestern blots. The NPTA element is conserved in rat CYP2A3, mouse Cyp2a5, and human CYP2A6 genes and was found to be essential for transcriptional activity of the CYP2A3 promoter in in vitro transcription assays. NPTA-binding proteins were detectable at day 1 and were much more abundant at day 8 than at day 60 after birth. Furthermore, their levels decreased dramatically during chemically induced degeneration of the olfactory epithelium, paralleling the disappearance of CYP2A3 protein, and rebounded to higher than pretreatment levels during recovery. Thus, we have identified a novel transcriptional activation element potentially responsible for the olfactory mucosa-predominant expression of the CYP2A3 gene in rats and orthologous genes in mice and humans.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Environm Hlth & Toxicol, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Ding, XX (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza,Box 509, Albany, NY 12201 USA.	xding@wadsworth.org			NIDCD NIH HHS [DC-02640] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002640] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BUIAKOVA OI, 1994, GENOMICS, V20, P452, DOI 10.1006/geno.1994.1200; CHEN Y, 1992, NEUROREPORT, V3, P749, DOI 10.1097/00001756-199209000-00007; DAHL AR, 1991, CRIT REV TOXICOL, V21, P345, DOI 10.3109/10408449109019571; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; Davis JA, 1996, J NEUROSCI, V16, P5082; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING X, 1988, BIOCHEMISTRY-US, V27, P8330, DOI 10.1021/bi00422a007; DING X, 1993, CYTOCHROME P450 HDB, V105, P351; DING XX, 1990, MOL PHARMACOL, V37, P489; DING XX, 1994, ARCH BIOCHEM BIOPHYS, V315, P454, DOI 10.1006/abbi.1994.1524; DING XX, 1992, MOL PHARMACOL, V42, P1027; FERNANDEZSALGUERO P, 1995, AM J HUM GENET, V57, P651; Gao B, 1996, MOL CELL BIOL, V16, P5997; GETCHELL ML, 1993, ANN OTO RHINOL LARYN, V102, P368, DOI 10.1177/000348949310200509; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; Gonzalez FJ, 1996, FASEB J, V10, P1112, DOI 10.1096/fasebj.10.10.8751713; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gu J, 1997, TOXICOL APPL PHARM, V146, P134, DOI 10.1006/taap.1997.8238; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; IBEANU GC, 1995, BIOCHEMISTRY-US, V34, P8028, DOI 10.1021/bi00025a008; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; Kim J, 1997, J BIOL CHEM, V272, P29423, DOI 10.1074/jbc.272.47.29423; KIMURA S, 1989, BIOCHEMISTRY-US, V28, P3798, DOI 10.1021/bi00435a026; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; Liu C, 1996, MOL PHARMACOL, V50, P781; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; Longo V, 1997, BIOCHEM J, V323, P65, DOI 10.1042/bj3230065; Maxam A M, 1980, Methods Enzymol, V65, P499; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; NEF P, 1989, J BIOL CHEM, V264, P6780, DOI 10.1016/S0021-9258(18)83497-4; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PENG HM, 1993, J BIOL CHEM, V268, P17253; PEVSNER J, 1988, P NATL ACAD SCI USA, V85, P2383, DOI 10.1073/pnas.85.7.2383; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; ROUSSEL F, 1995, DNA CELL BIOL, V14, P777, DOI 10.1089/dna.1995.14.777; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHWOB JE, 1995, J COMP NEUROL, V359, P15, DOI 10.1002/cne.903590103; Su T, 1996, DRUG METAB DISPOS, V24, P884; Sumner C, 1996, J NEUROVIROL, V2, P87, DOI 10.3109/13550289609146542; SZABO P, 1995, J BIOL CHEM, V270, P10212, DOI 10.1074/jbc.270.17.10212; Tamura Taka-Aki, 1996, Methods (Orlando), V10, P312, DOI 10.1006/meth.1996.0108; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; UENO T, 1990, NUCLEIC ACIDS RES, V18, P4623, DOI 10.1093/nar/18.15.4623; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WALTERS E, 1992, J NEUROSCI RES, V33, P103, DOI 10.1002/jnr.490330113; WALTERS E, 1993, TOXICOLOGY, V81, P113, DOI 10.1016/0300-483X(93)90003-B; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang SS, 1997, J NEUROSCI, V17, P4149; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YOKOE H, 1993, P NATL ACAD SCI USA, V90, P4655, DOI 10.1073/pnas.90.10.4655; Yokomori N, 1997, J STEROID BIOCHEM, V62, P307, DOI 10.1016/S0960-0760(97)00048-4; Zhang QY, 1997, ARCH BIOCHEM BIOPHYS, V340, P270, DOI 10.1006/abbi.1997.9922	68	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23454	23462		10.1074/jbc.273.36.23454	http://dx.doi.org/10.1074/jbc.273.36.23454			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722582	hybrid			2022-12-25	WOS:000075778100082
J	Beck, MA; Esworthy, RS; Ho, YS; Chu, FF				Beck, MA; Esworthy, RS; Ho, YS; Chu, FF			Glutathione peroxidase protects mice from viral-induced myocarditis	FASEB JOURNAL			English	Article						selenium; GPX-1; malondialdehyde; virus titer; cardiac pathology	SELENIUM-DEFICIENT MICE; COXSACKIEVIRUS B3; HUMAN ENTEROVIRUS; KESHAN DISEASE; RNA; CATALASE; MALONDIALDEHYDE; EVOLUTION; INFECTION; VIRULENT	Glutathione peroxidase 1 (GPX-1) is a selenium-dependent enzyme with antioxidant properties, Previous investigations determined that mice deficient in selenium developed myocarditis when infected with a benign strain of coxsackievirus B3 (CVB3/0), To determine whether this effect was mediated by GPX-1, mice with a disrupted Gpx1 gene (Glbx1(-/-)) were infected with CVB3/0, Gpx1(-/-) mice developed myocarditis after CVB3/0 infection, whereas infected wild-type mice (Gpx1(+/+)) were resistant. Sequencing of viruses recovered from Gpx1(-/-)-infected mice demonstrated seven nucleotide changes in the viral genome, of which three occurred at the G residue, the most easily oxidized base, No changes were found in virus isolated from Gpx1(+/+) mice. These results demonstrate that GPX-1 provides protection against viral-induced damage in vivo due to mutations in the viral genome of a benign virus.	Univ N Carolina, Dept Pediat, FPG Child Dev Ctr, Chapel Hill, NC 27599 USA; City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA 91010 USA; Wayne State Univ, Inst Chem Toxicol, Detroit, MI 48201 USA	University of North Carolina; University of North Carolina Chapel Hill; City of Hope; Wayne State University	Beck, MA (corresponding author), Univ N Carolina, Dept Pediat, FPG Child Dev Ctr, 105 Smith Level Rd,CB 8180, Chapel Hill, NC 27599 USA.	melinda_beck@unc.edu		Esworthy, Steve/0000-0002-4111-3349	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046921] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54123] Funding Source: Medline; NIDDK NIH HHS [DK46921] Funding Source: Medline; NIEHS NIH HHS [P30 ESO6693] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; AKMAN SA, 1989, BIOCHIM BIOPHYS ACTA, V1009, P70, DOI 10.1016/0167-4781(89)90080-8; ALBRO PW, 1987, LIPIDS, V22, P751, DOI 10.1007/BF02533976; BECK MA, 1994, J INFECT DIS, V170, P351, DOI 10.1093/infdis/170.2.351; BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; Beck MA, 1996, J NUTR BIOCHEM, V7, P683, DOI 10.1016/S0955-2863(96)00132-5; BECK MA, 1994, J MED VIROL, V43, P166, DOI 10.1002/jmv.1890430213; BECK MA, 1994, J NUTR, V124, P345, DOI 10.1093/jn/124.3.345; Beutler E, 1982, GLUTATHIONE RED CELL, V3 rd; BURK RF, 1991, FASEB J, V5, P2274, DOI 10.1096/fasebj.5.9.1830557; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Chapman NM, 1997, J MED VIROL, V52, P258; CHAPMAN NM, 1994, ARCH VIROL, V135, P115, DOI 10.1007/BF01309769; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHU FF, 1993, J BIOL CHEM, V268, P2571; COMBS GF, 1984, ANNU REV NUTR, V4, P257, DOI 10.1146/annurev.nu.04.070184.001353; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Domingo E, 1997, BIOL TRACE ELEM RES, V56, P23, DOI 10.1007/BF02778981; Domingo E, 1995, MOL EVOLUTION VIRUSE, P181; Domingo Esteban, 1994, P161; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; GE KY, 1983, VIRCHOWS ARCH A, V401, P1, DOI 10.1007/BF00644785; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; GU BQ, 1983, CHINESE MED J-PEKING, V96, P251; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; JANERO DR, 1988, LIPIDS, V23, P452, DOI 10.1007/BF02535519; Jentzsch AM, 1996, FREE RADICAL BIO MED, V20, P251, DOI 10.1016/0891-5849(95)02043-8; Kang YJ, 1996, J BIOL CHEM, V271, P12610, DOI 10.1074/jbc.271.21.12610; LIN FB, 1993, ARCH BIOCHEM BIOPHYS, V305, P176, DOI 10.1006/abbi.1993.1408; MARTINO TA, 1977, HUMAN ENTEROVIRUS IN, P291; RAES M, 1987, FREE RADICAL BIO MED, V3, P3, DOI 10.1016/0891-5849(87)90032-3; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SCHWARZ K, 1957, J AM CHEM SOC, V79, P3292, DOI 10.1021/ja01569a087; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SPALLHOLZ JE, 1990, ANN NY ACAD SCI, V587, P123, DOI 10.1111/j.1749-6632.1990.tb00140.x; STEINHAUER DA, 1992, GENE, V122, P281, DOI 10.1016/0378-1119(92)90216-C; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TU ZG, 1995, J VIROL, V69, P4607, DOI 10.1128/JVI.69.8.4607-4618.1995; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; YANAGAWA H, 1992, J BIOL CHEM, V267, P13320; ZHANG LP, 1989, BIOCHIM BIOPHYS ACTA, V1006, P140, DOI 10.1016/0005-2760(89)90336-6	43	156	166	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1143	1149		10.1096/fasebj.12.12.1143	http://dx.doi.org/10.1096/fasebj.12.12.1143			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737717				2022-12-25	WOS:000075738500009
J	Hu, YH; Bock, G; Wick, G; Xu, QB				Hu, YH; Bock, G; Wick, G; Xu, QB			Activation of PDGF receptor alpha in vascular smooth muscle cells by mechanical stress	FASEB JOURNAL			English	Article						phosphorylation; MAP kinases; shear stress; AP-1 binding; platelet-derived growth factor receptor	ENDOTHELIAL-CELLS; PROTEIN-KINASES; SHEAR-STRESS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HYPERTENSION RESEARCH; B-CHAIN; GROWTH; STRAIN; ARTERIES	Hypertension increases mechanical force on the arterial wall by as much as 30%, resulting in marked alterations in signal transductions and gene expression in vascular smooth muscle cells (VSMCs) that contribute to matrix protein synthesis, cell proliferation, and differentiation. How the mechanical stimuli are converted into a biological signal in cells has yet to be studied. We investigated the role of both cyclic strain and shear stresses in initiating the cellular signaling on cultured VSMCs and found that mechanical forces evoked activation of mitogen-activated protein kinases, followed by enhanced DNA binding activity of transcription factor AP-1, Physical forces rapidly induced phosphorylation of platelet-derived growth factor receptor (PDGFR) alpha, an activated state. When GRB2, an adapter protein, was immunoprecipitated from treated VSMCs followed by Western blot analysis with anti-phosphotprosine, -PDGFR alpha, and -GRB2 antibodies, respectively, phosphotyrosine positive staining was observed on PDGFR alpha bands of the same blot in stretch-stressed VSMCs, supporting the mechanical stress-induced activation of PDGFR alpha, Conditioned medium from stretch-stressed VSMCs did not result in PDGFR alpha phosphorylation, and antibodies binding to all forms of PDGFs did not block stress-induced PDGFR alpha activation. Thus, mechanical stresses may directly perturb the cell surface or alter receptor conformation, thereby initiating signaling pathways normally used by growth factors.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Univ Innsbruck, Sch Med, Inst Gen & Expt Pathol, A-6020 Innsbruck, Austria	Austrian Academy of Sciences; University of Innsbruck	Xu, QB (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Rennweg 10, A-6020 Innsbruck, Austria.	qingbo.xu@oeaw.ac.at						ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANTONIADES HN, 1981, P NATL ACAD SCI-BIOL, V78, P7314, DOI 10.1073/pnas.78.12.7314; BANES AJ, 1990, AM BIOTECHNOL LAB, V8, P12; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BENES AJ, 1985, J CELL SCI, V75, P35; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DWORKIN B, 1988, BEHAVIOURAL MED CARD, P27; DZAU VJ, 1994, HYPERTENSION, V23, P1132, DOI 10.1161/01.HYP.23.6.1132; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FOLKOW B, 1995, J HYPERTENS, V13, P5; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FRANGOS JA, 1993, PHYSICAL FORCES MAMM; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Griendling KK, 1996, FASEB J, V10, P283, DOI 10.1096/fasebj.10.2.8641561; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HENRY JP, 1990, J HYPERTENS, V8, P783, DOI 10.1097/00004872-199009000-00001; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Hu YH, 1997, J BIOL CHEM, V272, P9113; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; LIU MY, 1995, AM J PHYSIOL-LUNG C, V269, pL178, DOI 10.1152/ajplung.1995.269.2.L178; Liu YS, 1996, J BIOL CHEM, V271, P3604; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MITSUMATA M, 1993, AM J PHYSIOL, V265, pH3, DOI 10.1152/ajpheart.1993.265.1.H3; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PATRICK CW, 1995, BLOOD PURIFICAT, V13, P112; PICKERING TG, 1988, BEHAVIOURAL MED CARD, P71; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RESNICK N, 1995, FASEB J, V9, P874, DOI 10.1096/fasebj.9.10.7615157; Reusch HP, 1997, BIOCHEM BIOPH RES CO, V237, P239, DOI 10.1006/bbrc.1997.7121; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ross R., 1980, HDB PHYSL CARDIOVA 2, P69; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; Xu QB, 1996, LAB INVEST, V74, P178; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zou YP, 1998, INT J MOL MED, V1, P827	49	169	182	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1135	1142		10.1096/fasebj.12.12.1135	http://dx.doi.org/10.1096/fasebj.12.12.1135			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737716				2022-12-25	WOS:000075738500008
J	Suzuki, A; Tsutomi, Y; Akahane, K; Araki, T; Miura, M				Suzuki, A; Tsutomi, Y; Akahane, K; Araki, T; Miura, M			Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21(WAF1) and IAP gene family ILP	ONCOGENE			English	Article						caspase 3; p21(WAF1); ILP; Fas-mediated apoptosis; HepG2 cell	TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; DEATH FACTOR; ICE-LIKE; B-CELLS; INVOLVEMENT; ANTIGEN; BCL-2; EXPRESSION; PROTEASES	The death receptor Fas transduces apoptotic death signaling mediated by caspases. In the present study, human hepatoma HepG2 cells showed the Fas-mediated apoptosis mediated by caspase, especially caspase 3, only in the presence of actinomycin D. Interestingly, cytosolic proteins extracted from intact HepG2. cells induced caspase 3 inactivation, Our results reveal that this inactivation was triggered by the direct inhibition of activated caspase 3 by IAP gene family ILP. In addition, a 53 kDa protein was co-immunoprecipitated with anti-human caspase 3 antibody from intact HepG2 cells. This protein was a complex-protein of procaspase 3 and the cell cycle regulator p21(WAF1) (p21), P21 bound to only procaspase 3, but not to activated caspase 3. We also demonstrate that p21 protein-loaded HepG2 cells resist to Fas-mediated apoptosis even in the presence of actinomycin D, Here we report that caspase 3 inactivation for the resistance to Fas-mediated apoptosis is induced by a procaspase 3/p21 complex formation and direct inhibition of activated caspase 3 by ILP.	Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Lab 4, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan; Osaka Univ, Sch Med, Dept Neuroanat, Biomed Res Ctr, Suita, Osaka 565, Japan	Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Osaka University	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, 16-13 Kitakasai 1, Tokyo 134, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hasegawa J, 1996, CANCER RES, V56, P1713; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LI Y, 1994, ONCOGENE, V9, P2261; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SMITH PK, 1985, ANAL BIOCHEM, V170, P203; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; Suzuki A, 1996, REPROD TOXICOL, V10, P465, DOI 10.1016/S0890-6238(96)00133-5; Suzuki A, 1997, EXP CELL RES, V233, P48, DOI 10.1006/excr.1997.3546; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Suzuki A, 1996, ONCOGENE, V13, P31; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	37	318	332	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					931	939		10.1038/sj.onc.1202021	http://dx.doi.org/10.1038/sj.onc.1202021			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747872				2022-12-25	WOS:000075560900001
J	Chen, HC; Chan, PC; Tang, MJ; Cheng, CH; Chang, TJ				Chen, HC; Chan, PC; Tang, MJ; Cheng, CH; Chang, TJ			Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MATRIX INTERACTIONS; SRC FAMILY KINASES; SWISS 3T3 CELLS; FACTOR-RECEPTOR; SIGNAL-TRANSDUCTION; MAP KINASE; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; COMPLEX-FORMATION; ADAPTER PROTEIN	Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase involved in integrin-mediated signal transduction pathway. In this report, we describe that the treatment of hepatocyte growth factor (HGF) stimulates a significant increase in the tyrosine phosphorylation of FAK in human embryonic kidney 293 cells. This stimulation is independent of cell adhesion or the integrity of the actin cytoskeleton, suggesting potentially different mechanisms by which the HGF receptors and integrins regulate the tyrosine phosphorylation of FAK. Our results also suggest that the activation of Src upon HGF stimulation is likely to be one, if not the only, of the mechanisms responsible for the HGF-induced tyrosine phosphorylation of FAK. Furthermore, we showed that a mutation in the Grb2 binding site Tyr-925 of FAK partially abolishes its increase in HGF-induced phosphorylation. Finally, we demonstrated that HGF stimulates the association of FAK with Grb2 in vitro and in intact cells and provided evidence that FAK might contribute to the activation of mitogen-activated protein kinase through Ras in HGF signaling by functioning as an adapter molecule.	Natl Chung Hsing Univ, Dept Zool, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Coll Life Sci, Inst Biochem, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Coll Agr, Dept Vet Med, Taichung 40227, Taiwan; Natl Cheng Kung Univ, Dept Physiol, Tainan 70101, Taiwan; Taichung Vet Gen Hosp, Nephrol Sect, Taichung, Taiwan	National Chung Hsing University; National Chung Hsing University; National Chung Hsing University; National Cheng Kung University; Taichung Veterans General Hospital	Chen, HC (corresponding author), Natl Chung Hsing Univ, Dept Zool, Taichung 40227, Taiwan.			Tang, Ming-Jer/0000-0002-0883-4363				BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1989, ONCOGENE, V4, P1983; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HATAI M, 1994, FEBS LETT, V350, P113, DOI 10.1016/0014-5793(94)00745-4; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; OWENS LV, 1995, CANCER RES, V55, P2752; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RANKIN S, 1994, J BIOL CHEM, V269, P704; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	56	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25777	25782		10.1074/jbc.273.40.25777	http://dx.doi.org/10.1074/jbc.273.40.25777			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748249	hybrid			2022-12-25	WOS:000076263100040
J	Sprong, H; Kruithof, B; Leijendekker, R; Slot, JW; van Meer, G; van der Sluijs, P				Sprong, H; Kruithof, B; Leijendekker, R; Slot, JW; van Meer, G; van der Sluijs, P			UDP-galactose : ceramide galactosyltransferase is a class I integral membrane protein of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; GOLGI-APPARATUS; CELLS; EXPRESSION; TRANSPORT; TOPOLOGY; SURFACE; GLUCOSYLTRANSFERASE; GALACTOCEREBROSIDE; GLUCOSYLCERAMIDE	UDP-galactose:ceramide galactosyltransferase (CGalT) transfers UDP-galactose 60 ceramide to form the glycosphingolipid galactosylceramide. Galactosylceramide is the major constituent of myelin and is also highly enriched in many epithelial cells, where it is thought to play an important role in lipid and protein sorting. Although the biochemical pathways of glycosphingolipid biosynthesis are relatively well understood, the localization of the enzymes involved in these processes has remained controversial. We here have raised antibodies against CGalT and shown by immunocytochemistry on ultrathin cryosections that the enzyme is localized to the endoplasmic reticulum and nuclear envelope but not to the Golgi apparatus or the plasma membrane. In pulse-chase experiments, we have observed that newly synthesized CGalT remains sensitive to endoglycosidase H, confirming the results of the morphological localization experiments. In protease protection assays, we show that the largest part of the protein, including the amino terminus, is oriented toward the lumen of the endoplasmic reticulum. CGalT enzyme activity required import of UDP-galactose into the lumen of the endoplasmic reticulum by a UDP-galactose translocator that is present in the Golgi apparatus of CHO cells but absent in CHOlec8 cells. Finally, we show that CGalT activity previously observed in Golgi membrane fractions in vitro, in the absence of UDP-glucose, is caused by UDP-glucose:ceramide glucosyltransferase. Therefore all galactosylceramide synthesis occurs by CGalT in vivo in the lumen of the endoplasmic reticulum.	Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1100 DE Amsterdam, Netherlands	Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam	van der Sluijs, P (corresponding author), Univ Utrecht, Sch Med, Dept Cell Biol, AZU Rm H02-314,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	pvander@knoware.nl	Kruithof, Boudewijn/C-1718-2014; van Meer, Gerrit/AAH-1560-2021	Kruithof, Boudewijn/0000-0002-9604-4563; van Meer, Gerrit/0000-0002-5976-6436; Sprong, Hein/0000-0002-0218-4320				BANSAL R, 1987, J NEUROCHEM, V49, P1902, DOI 10.1111/j.1471-4159.1987.tb02453.x; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; Burger KNJ, 1996, J CELL BIOL, V133, P15, DOI 10.1083/jcb.133.1.15; Coetzee T, 1998, TRENDS NEUROSCI, V21, P126, DOI 10.1016/S0166-2236(97)01178-8; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; DESHMUKH DS, 1988, NEUROCHEM RES, V13, P571, DOI 10.1007/BF00973300; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FLEISCHER B, 1977, J SUPRAMOL STR CELL, V7, P79, DOI 10.1002/jss.400070108; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOUL O, 1988, J NEUROCHEM, V50, P580, DOI 10.1111/j.1471-4159.1988.tb02950.x; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; NESKOVIC NM, 1973, J NEUROCHEM, V20, P1419, DOI 10.1111/j.1471-4159.1973.tb00254.x; Paul P, 1996, J BIOL CHEM, V271, P2287, DOI 10.1074/jbc.271.4.2287; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; RADIN NS, 1983, METHOD ENZYMOL, V98, P613; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1989, METHOD ENZYMOL, V179, P559; SATO C, 1988, J NEUROCHEM, V50, P1887, DOI 10.1111/j.1471-4159.1988.tb02493.x; SCHAERENWIEMERS N, 1995, J NEUROCHEM, V65, P2267; SCHULTE S, 1995, EUR J BIOCHEM, V233, P947, DOI 10.1111/j.1432-1033.1995.947_3.x; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SIEGRIST HP, 1979, J NEUROCHEM, V33, P497, DOI 10.1111/j.1471-4159.1979.tb05180.x; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAHL N, 1994, J NEUROSCI RES, V38, P234, DOI 10.1002/jnr.490380214; van der Bijl P, 1996, J CELL BIOL, V132, P813, DOI 10.1083/jcb.132.5.813; van der Bijl P, 1996, BIOCHEM J, V317, P589, DOI 10.1042/bj3170589; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341	49	133	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25880	25888		10.1074/jbc.273.40.25880	http://dx.doi.org/10.1074/jbc.273.40.25880			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748263	hybrid			2022-12-25	WOS:000076263100054
J	Sherwood, AL; Nguyen, AT; Whitaker, JM; Macher, BA; Stroud, MR; Holmes, EH				Sherwood, AL; Nguyen, AT; Whitaker, JM; Macher, BA; Stroud, MR; Holmes, EH			Human alpha 1,3/4-fucosyltransferases - III. A Lys/Arg residue located within the alpha 1,3-FucT motif is required for activity but not substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MOLECULAR-CLONING; FUCOSYL-TRANSFERASE; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; ALPHA-1,3-FUCOSYL-TRANSFERASE GENE; HELICOBACTER-PYLORI; ENZYME-ACTIVITY; ELAM-1 LIGAND; FUT3 GENE	Amino acid sequence alignment of human alpha 1,3/4-fucosyltransferases (FucTs) demonstrates that three highly conserved Lys residues are present in the catalytic domain of FucTs III, TV, V, and VI. Two of these sites are conserved in FucT VII, with the third located within the alpha 1,3-FucT motif as a conservative change to Arg at position 223. Site-directed mutagenesis experiments were conducted to change Lys(255) Of FucT V (equivalent to Arg(223) of FucT VII) to either Arg(255) or Ala(255). Enzyme assays demonstrate that the FucT V K255R mutant has a 34-fold lower specific activity than native FucT V and that the K255A mutant is inactive. Site-directed mutagenesis of FucT VII was also conducted to change Arg(223) to Lys(223) for analysis of the effect on enzyme kinetic parameters. No differences in acceptor specificities or K-m values for either substrate were observed between native FucT VII and the R223K mutant; however, the purified R223K mutant enzyme had a 2-fold increased specific activity compared with purified native FucT VII. No change in GDP-fucose-protectable pyridoxal-P/NaBH4 inactivation was observed for native or mutant FucT V or VII, further supporting the absence of involvement of this residue in sugar nucleotide binding. The results indicate that a basic residue in this position is required for enzyme activity, with a Lys residue providing higher intrinsic activity. The lack of influence of this site on substrate binding parameters and its location within the alpha 1,3-FucT motif suggest that at least some of the residues within this motif are involved in catalysis rather than substrate binding.	NW Hosp, Pacific NW Canc Fdn, Div Cell Surface Biochem, Seattle, WA 98125 USA; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	California State University System; San Francisco State University	Holmes, EH (corresponding author), NW Hosp, Pacific NW Canc Fdn, Div Cell Surface Biochem, 120 Northgate Plaza,Suite 218, Seattle, WA 98125 USA.	eholmes@nwbio.org			NATIONAL CANCER INSTITUTE [R01CA070740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM052588] Funding Source: NIH RePORTER; NCI NIH HHS [CA70740] Funding Source: Medline; NCRR NIH HHS [RR11805] Funding Source: Medline; NIGMS NIH HHS [GM52588] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1977, Lipids, V12, P455; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BrinkmanVanderLinden ECM, 1996, J BIOL CHEM, V271, P14492, DOI 10.1074/jbc.271.24.14492; Britten CJ, 1997, BBA-GEN SUBJECTS, V1334, P57, DOI 10.1016/S0304-4165(96)00076-1; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; Elmgren A, 1997, J BIOL CHEM, V272, P21994, DOI 10.1074/jbc.272.35.21994; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HOLMES EH, 1992, ARCH BIOCHEM BIOPHYS, V296, P562, DOI 10.1016/0003-9861(92)90611-Y; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; SajdelSulkowska EM, 1997, GLYCOCONJUGATE J, V14, P249, DOI 10.1023/A:1018550023637; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; Stroud MR, 1997, BIOCHEM BIOPH RES CO, V238, P165, DOI 10.1006/bbrc.1997.7254; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	36	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25256	25260		10.1074/jbc.273.39.25256	http://dx.doi.org/10.1074/jbc.273.39.25256			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737990	hybrid			2022-12-25	WOS:000076085400040
J	Tu, GC; Cao, QN; Zhou, F; Israel, Y				Tu, GC; Cao, QN; Zhou, F; Israel, Y			Tetranucleotide GGGA motif in primary RNA transcripts - Novel target site for antisense design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; C-ALPHA EXPRESSION; MESSENGER-RNA; KUPFFER CELLS; MULTIDRUG RESISTANCE; MONOCLONAL-ANTIBODY; ALCOHOLIC HEPATITIS; ALLOGRAFT-REJECTION; ESCHERICHIA-COLI; CATIONIC LIPIDS	Selecting effective antisense target sites on a given mRNA molecule constitutes a major problem in antisense therapeutics. By trial-and-error, only 1 in 18 (6%) of antisense oligonucleotides designed to target the primary RNA transcript of tumor necrosis factor-alpha (TNF-alpha) strongly inhibited TNF-alpha synthesis. Subsequent studies showed that the area in RNA targeted by antisense oligonucleotides could be moved effectively 10-15 bases in either direction from the original area. We observed that only molecules that incorporated a tetranucleotide motif TCCC (complementary to GGGA on RNA) yielded potent antisense oligonucleotides against TNF-alpha. A comprehensive literature survey showed that this motif is unwittingly present in 48% of the most potent antisense oligonucleotides reported in the literature. This finding was prospectively used to predict the sequences of additional antisense oligonucleotides for the rat TNF-alpha primary RNA transcript. Over 50% of antisense constructs (13 of 22) containing the TCCC motif were found to effectively inhibit TNF-alpha synthesis. Marked reductions in mRNA were also observed. This motif was found to be most effective when targeting introns in the primary RNA transcript, suggesting a nuclear localization for the antisense action. Predicting target sites based on the presence of this motif in primary RNA transcripts should be of value in the development on new antisense pharmacotherapy.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Chile, Ctr Gene Pharmacotherapy, Santiago, Chile	Jefferson University; Universidad de Chile	Tu, GC (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St,Rm 275, Philadelphia, PA 19107 USA.	tul@jeflin.tju.edu		Israel, Yedy/0000-0003-3468-7966				Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Alahari SK, 1996, MOL PHARMACOL, V50, P808; BAUTISTA AP, 1992, J LEUKOCYTE BIOL, V51, P39, DOI 10.1002/jlb.51.1.39; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; Bishop MR, 1996, J CLIN ONCOL, V14, P1320, DOI 10.1200/JCO.1996.14.4.1320; CATSICAS M, 1996, ANTISENSE THERAPEUTI, P57; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; COTTER FE, 1994, ONCOGENE, V9, P3049; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; Dean NM, 1996, BIOCHEM SOC T, V24, P623, DOI 10.1042/bst0240623; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; dHellencourt CL, 1996, BBA-MOL BASIS DIS, V1317, P168, DOI 10.1016/S0925-4439(96)00051-8; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; FELVER ME, 1990, ALCOHOL CLIN EXP RES, V14, P255, DOI 10.1111/j.1530-0277.1990.tb00482.x; Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0; Gewirtz AM, 1996, P NATL ACAD SCI USA, V93, P3161, DOI 10.1073/pnas.93.8.3161; GILES RV, 1995, ANTISENSE RES DEV, V5, P23, DOI 10.1089/ard.1995.5.23; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; Hartmann G, 1996, ANTISENSE NUCLEIC A, V6, P291, DOI 10.1089/oli.1.1996.6.291; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; Ho SP, 1998, NAT BIOTECHNOL, V16, P59, DOI 10.1038/nbt0198-59; IMAGAWA DK, 1991, TRANSPLANTATION, V51, P57, DOI 10.1097/00007890-199101000-00008; JOHANSSON HE, 1994, NUCLEIC ACIDS RES, V22, P4591, DOI 10.1093/nar/22.22.4591; KAMIMURA S, 1995, HEPATOLOGY, V22, P1304, DOI 10.1002/hep.1840220441; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LEE CH, 1995, SHOCK, V4, P1, DOI 10.1097/00024382-199507000-00001; LI G, 1993, J VIROL, V67, P6882, DOI 10.1128/JVI.67.11.6882-6888.1993; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Lima WF, 1997, J BIOL CHEM, V272, P626; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; Matteucci MD, 1996, NATURE, V384, P20; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; PERLAKY L, 1993, ANTI-CANCER DRUG DES, V8, P3; Probst JC, 1996, TRENDS GENET, V12, P290, DOI 10.1016/0168-9525(96)20009-5; RAINE CS, 1995, NAT MED, V1, P211, DOI 10.1038/nm0395-211; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; SHIRAI T, 1989, AGR BIOL CHEM TOKYO, V53, P1733, DOI 10.1080/00021369.1989.10869529; STEPKOWSKI SM, 1994, J IMMUNOL, V153, P5336; Stull R A, 1993, Antisense Res Dev, V3, P295; Stull RA, 1996, ANTISENSE NUCLEIC A, V6, P221, DOI 10.1089/oli.1.1996.6.221; STULL RA, 1992, NUCLEIC ACIDS RES, V20, P3501, DOI 10.1093/nar/20.13.3501; Stutz A, 1997, MOL CELL BIOL, V17, P1759, DOI 10.1128/MCB.17.4.1759; THIERRY AR, 1993, BIOCHEM BIOPH RES CO, V190, P952, DOI 10.1006/bbrc.1993.1142; TU GC, 1995, J BIOL CHEM, V270, P28402; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; vanHensbroek MB, 1996, J INFECT DIS, V174, P1091, DOI 10.1093/infdis/174.5.1091; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	56	90	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25125	25131		10.1074/jbc.273.39.25125	http://dx.doi.org/10.1074/jbc.273.39.25125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737971	hybrid			2022-12-25	WOS:000076085400021
J	Yoshima, T; Yura, T; Yanagi, H				Yoshima, T; Yura, T; Yanagi, H			Heat shock factor 1 mediates hemin-induced hsp70 gene transcription in K562 erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; ERYTHROID-DIFFERENTIATION; LINE K562; ACTIVATION; EXPRESSION; STRESS; HSF1; PROTEIN; DOMAIN; OLIGOMERIZATION	Transcriptional induction of the hsp70 gene is mediated by heat shock factor 1 (HSF1) rapidly activated upon heat and other stresses. HSF2 has been thought to be responsible for accumulation of HSP70 during hemin-induced differentiation of human K562 erythroleukemia cells because of accompanying acquisition of HSF2 DNA binding activity. However, there has not been any direct evidence for such a functional role of HSF2. The purpose of this study is to clarify the roles of HSF1 and HSF2 in HSP70 induction in hemin-treated K562 cells. We show here that a chimeric polypeptide of HSF2 and GAL4 DNA binding domain (GAL4-BD-HSF2) was unable to induce a GAL4 binding site-containing luciferase reporter gene in response to hemin and that exogenously overproduced HSF2 also failed to increase expression of a heat shock element-containing reporter. On the contrary, expression of a GAL4-BD-HSF1 chimeric protein responded to hemin treatment as well as to heat shock, and transiently overexpressed HSF1 caused hemin-responsive induction of the reporter gene in a dose-dependent manner. These results indicate that HSF1, rather than HSF2, primarily mediates the hemin-induced transcription of the hsp70 gene.	HSP Res Inst, Shimogyo Ku, Kyoto 6008813, Japan		Yanagi, H (corresponding author), HSP Res Inst, Shimogyo Ku, Kyoto Res Pk, Kyoto 6008813, Japan.	hyanagi@hsp.co.jp						ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BENSAUDE O, 1983, NATURE, V305, P331, DOI 10.1038/305331a0; BRUCE JL, 1993, CANCER RES, V53, P12; Bush KT, 1997, J BIOL CHEM, V272, P9086; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DIMERY IW, 1983, EXP HEMATOL, V11, P601; ETLINGER JD, 1980, J BIOL CHEM, V255, P4563; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Leppa S, 1997, J BIOL CHEM, V272, P15293, DOI 10.1074/jbc.272.24.15293; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Newton EM, 1996, MOL CELL BIOL, V16, P839; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SINGH MK, 1984, NATURE, V309, P631, DOI 10.1038/309631a0; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Yoshima T, 1997, BIOCHEM BIOPH RES CO, V240, P228, DOI 10.1006/bbrc.1997.7662; Yoshima T, 1998, NUCLEIC ACIDS RES, V26, P2580, DOI 10.1093/nar/26.11.2580; ZAKERI ZF, 1987, MOL CELL BIOL, V7, P1791, DOI 10.1128/MCB.7.5.1791; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	45	29	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25466	25471		10.1074/jbc.273.39.25466	http://dx.doi.org/10.1074/jbc.273.39.25466			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738016	hybrid			2022-12-25	WOS:000076085400066
J	Hendzel, MJ; Nishioka, WK; Raymond, Y; Allis, CD; Bazett-Jones, DP; Th'ng, JPH				Hendzel, MJ; Nishioka, WK; Raymond, Y; Allis, CD; Bazett-Jones, DP; Th'ng, JPH			Chromatin condensation is not associated with apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; HISTONE ACETYLATION; IN-VITRO; PROTEIN-SYNTHESIS; NUCLEAR MATRIX; DNA-DAMAGE; ACTIVATION; TRANSCRIPTION; CYCLE; PHOSPHORYLATION	Apoptosis plays an important role in the survival of an organism, and substantial work has been done to understand the signaling pathways that regulate this process. Characteristic changes in chromatin organization accompany apoptosis and are routinely used as markers for cell death. We have examined the organization of chromatin in apoptotic PC12 and HeLa cells by indirect immunofluorescence and electron spectroscopic imaging. Our results indicate that de novo chromatin condensation normally seen during mitosis does not occur when cells undergo apoptosis. Instead, the condensed chromatin typically observed results from aggregation of the heterochromatin. We present evidence that, early in apoptosis, there is a rapid degradation of the nuclease-hypersensitive euchromatin that contains hyperacetylated histones. This occurs coincident with the loss of nuclear integrity due to degradation of lamins and reorganization of intranuclear protein matrix. These events lead to collapse of the nucleus and aggregation of heterochromatin to produce the appearance of condensed apoptotic chromatin. This heterochromatin aggregate is then digested by nucleases to produce the oligonucleosomal DNA ladder that is a hallmark of late apoptosis. Unlike mitosis, we have not seen any evidence for the requirement of phosphorylated histones H1 and H3 to maintain the chromatin in the condensed state.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; Univ Calgary, Dept Anat, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada; Vical Inc, San Diego, CA 92121 USA; Ctr Hosp Univ Montreal, Lab Rech Autoimmun, Montreal, PQ H2L 4M1, Canada; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	Lady Davis Institute; McGill University; University of Calgary; University of Calgary; Universite de Montreal; University of Rochester	Th'ng, JPH (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mdjt@musica.mcgill.ca	Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945				ABOLHASSANIDADRAS S, 1994, J MICROSC-OXFORD, V174, P233, DOI 10.1111/j.1365-2818.1994.tb03470.x; Allera C, 1997, J BIOL CHEM, V272, P10817; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BazettJones DP, 1996, NUCLEIC ACIDS RES, V24, P321, DOI 10.1093/nar/24.2.321; BAZETTJONES DP, 1992, ELECTRON MICROSC REV, V5, P37, DOI 10.1016/0892-0354(92)90004-A; Boggs BA, 1996, CHROMOSOMA, V105, P303, DOI 10.1007/BF02524648; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRENEMAN JW, 1993, EXP CELL RES, V206, P16, DOI 10.1006/excr.1993.1115; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHIANG JL, 1995, SCIENCE, V268, P429; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; Davie JR, 1996, J CELL BIOCHEM, V62, P149, DOI 10.1002/(SICI)1097-4644(199608)62:2<149::AID-JCB2>3.0.CO;2-S; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Geier A, 1996, CANCER INVEST, V14, P435, DOI 10.3109/07357909609018901; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; Hendzel MJ, 1996, J MICROSC-OXFORD, V182, P1, DOI 10.1046/j.1365-2818.1996.123403.x; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Kew JNC, 1996, NEUROSCIENCE, V70, P329, DOI 10.1016/0306-4522(95)00365-7; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LINDENBOIM L, 1995, CANCER RES, V55, P1242; LU MJ, 1994, CHROMOSOMA, V103, P111; MARTIN SJ, 1995, SCIENCE, V269, P106, DOI 10.1126/science.7604270; MARUSHIGE Y, 1995, ANTICANCER RES, V15, P267; Medina V, 1997, CANCER RES, V57, P3697; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NISHIOKA WK, 1993, NAT IMMUN, V12, P113; NORBURY C, 1994, BIOCHEM BIOPH RES CO, V202, P1400, DOI 10.1006/bbrc.1994.2086; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; ONGKEKO W, 1995, J CELL SCI, V108, P2897; PANDEY S, 1995, J CELL BIOCHEM, V56, P1; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; THNG JPH, 1994, J BIOL CHEM, V269, P9568; TURNER BM, 1991, J CELL SCI, V99, P13; UCKER DS, 1991, NEW BIOL, V3, P103; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WALKER PR, 1994, BIOCHEM CELL BIOL, V72, P615, DOI 10.1139/o94-081; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Weaver VM, 1996, J CELL SCI, V109, P45; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1	59	115	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24470	24478		10.1074/jbc.273.38.24470	http://dx.doi.org/10.1074/jbc.273.38.24470			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733739	hybrid			2022-12-25	WOS:000076007300031
J	Parkkila, AK; Scarim, AL; Parkkila, S; Waheed, A; Corbett, JA; Sly, WS				Parkkila, AK; Scarim, AL; Parkkila, S; Waheed, A; Corbett, JA; Sly, WS			Expression of carbonic anhydrase V in pancreatic beta cells suggests role for mitochondrial carbonic anhydrase in insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SUBCELLULAR-LOCALIZATION; LIPID-PEROXIDATION; NITRIC-OXIDE; CDNA CLONING; REDOX STATE; ISLETS; GLUCOSE; METABOLISM; PURIFICATION	Carbonic anhydrase V (CA-V) is a mitochondrial enzyme that provides bicarbonate for pyruvate carboxylase in liver and kidney. In the course of a survey of the tissue distribution of CA-V, we detected intense immunostaining in pancreatic islets when sections from rat and mouse pancreases were reacted with a polyclonal antibody to recombinant mouse CA-V, The distribution and large number of CA-V-positive cells in each islet suggested that they represented beta cells. Double immunofluorescence staining of tissue sections and isolated islet cells showed cellular colocalization of CA-V and insulin, confirming that beta cells contain CA-V, Western blotting of rat islets of Langerhans and primary beta cells showed 33- and 30-kDa polypeptides of precursor and mature CA-V, respectively. The CA-V expression was beta cell-specific since no CA-V immunoreaction was detected in the primary alpha cells. Immunohistochemical staining for CA-I, CA-II, CA-TV, CA-VI, and CA-M was negative in beta cells, and Western blotting of beta cells also failed to identify any CA in beta cells except CA-V, The specific localization of CA-V in beta cells led us to hypothesize that CA-V may be functionally linked to the regulation of insulin secretion. Consistent with this hypothesis, the CA inhibitor acetazolamide was found to be a strong inhibitor of glucose-stimulated insulin secretion by isolated rat pancreatic islets.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Sly, WS (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Wahhed, Abdul/AAA-3099-2020	Parkkila, Seppo/0000-0001-7323-8536	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163, R01DK052194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40163, DK52194] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCROFT SJ, 1970, BIOCHEM J, V119, P5, DOI 10.1042/bj1190005; ASHCROFT SJH, 1979, BIOCHEM J, V184, P697, DOI 10.1042/bj1840697; BALBONI E, 1986, J BIOL CHEM, V261, P3563; BROLIN SE, 1981, ACTA ENDOCRINOL-COP, V96, P93, DOI 10.1530/acta.0.0960093; CORBETT JA, 1995, DIABET ANN, V9, P265; DODGSON SJ, 1984, ANN NY ACAD SCI, V429, P516, DOI 10.1111/j.1749-6632.1984.tb12380.x; DODGSON SJ, 1991, CARBONIC ANHYDRASES, P297; ELDER JA, 1973, BIOCHEMISTRY-US, V12, P976, DOI 10.1021/bi00729a029; Hazen SA, 1996, FASEB J, V10, P481, DOI 10.1096/fasebj.10.4.8647347; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MACDONALD MJ, 1985, DIABETES, V34, P246, DOI 10.2337/diabetes.34.3.246; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; NAGAO Y, 1993, P NATL ACAD SCI USA, V90, P7623, DOI 10.1073/pnas.90.16.7623; NAGAO Y, 1994, P NATL ACAD SCI USA, V91, P10330, DOI 10.1073/pnas.91.22.10330; NIEMELA O, 1995, HEPATOLOGY, V22, P1208, DOI 10.1016/0270-9139(95)90630-4; NIEMELA O, 1994, LAB INVEST, V70, P537; PANTEN U, 1975, DIABETOLOGIA, V11, P569, DOI 10.1007/BF01222108; Parkkila AK, 1996, J HISTOCHEM CYTOCHEM, V44, P245, DOI 10.1177/44.3.8648084; Parkkila S, 1996, HEPATOLOGY, V24, P1104; Parkkila S, 1996, SCAND J GASTROENTERO, V31, P305, DOI 10.3109/00365529609006403; Saarnio J, 1998, J HISTOCHEM CYTOCHEM, V46, P497, DOI 10.1177/002215549804600409; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; WRIGHT PH, 1971, DIABETES, V20, P33, DOI 10.2337/diab.20.1.33; ZHU XL, 1990, J BIOL CHEM, V265, P8795	30	53	56	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24620	24623		10.1074/jbc.273.38.24620	http://dx.doi.org/10.1074/jbc.273.38.24620			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733757	hybrid			2022-12-25	WOS:000076007300049
J	Bennett, MK; Van Leeuwen, JEM; Kearse, KP				Bennett, MK; Van Leeuwen, JEM; Kearse, KP			Calnexin association is not sufficient to protect T cell receptor alpha proteins from rapid degradation in CD4(+)CD8(+) thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; TCR-BETA PROTEINS; ENDOPLASMIC-RETICULUM; ANTIGEN RECEPTOR; MOLECULAR CHAPERONE; DEVELOPMENTAL REGULATION; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; QUALITY-CONTROL; INITIAL STEP	During T cell development, assembly of the mutisubunit T cell receptor (TCR) complex is regulated by the differential stability of newly synthesized TCR alpha molecules, having a half-life of approximately 20 min in immature CD4(+)CD8(+) thymocytes compared with >75 min in mature T cells. The molecular basis for TCRa instability in CD4(+)CD8(+) thymocytes is unknown but has been postulated to involve abnormalities in N-glycan processing and calnexin assembly as perturbation of these pathways markedly destabilizes TCR alpha proteins in all other T cell types examined. Here, we compared the processing of TCR alpha glycoproteins and their assembly with calnexin and calreticulin chaperones in CD4(+)CD8(+) thymocytes and splenic T cells, These studies show that TCR alpha glycoproteins synthesized in CD4(+)CD8(+) thymocytes were processed in a similar manner as those made in splenic T cells and that TCR alpha proteins stably associated with calnexin in both cell types. Interestingly, however, TCR alpha association with the calnexin-related molecule calreticulin was decreased in CD4(+)CD8(+) thymocytes compared with splenic T cells. Finally, TCR alpha degradation in CD4(+)CD8(+) thymocytes was impaired by inhibitors of proteasome activity, which was correlated with stabilization of calnexin TCR alpha complexes. These data demonstrate that calnexin association is not sufficient to protect TCR alpha proteins from rapid degradation in CD4(+)CD8(+) thymocytes, suggesting that additional components of the quality control system of the endoplasmic reticulum operate to ensure the proper folding of nascent TCR alpha glycoproteins.	E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	University of North Carolina; East Carolina University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kearse, KP (corresponding author), E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	kearse@brody.med.ecu.edu	van Leeuwen, Jeroen/G-3555-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042104] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI42104] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; INOUE S, 1992, J BIOL CHEM, V267, P9080; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KEARSE KP, 1995, J EXP MED, V181, P193, DOI 10.1084/jem.181.1.193; KEARSE KP, 1995, BIOESSAYS, V17, P1049, DOI 10.1002/bies.950171209; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KEARSE KP, 1994, EMBO J, V13, P4504, DOI 10.1002/j.1460-2075.1994.tb06772.x; KEARSE KP, 1995, IMMUNITY, V2, P391; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBO RT, 1989, J IMMUNOL, V142, P2736; LE AQ, 1994, J BIOL CHEM, V269, P7514; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PIND S, 1994, J BIOL CHEM, V269, P12784; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1994, J BIOL CHEM, V269, P7464; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	42	14	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23674	23680		10.1074/jbc.273.37.23674	http://dx.doi.org/10.1074/jbc.273.37.23674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726972	hybrid			2022-12-25	WOS:000075893100013
J	Dey, BR; Spence, SL; Nissley, P; Furlanetto, RW				Dey, BR; Spence, SL; Nissley, P; Furlanetto, RW			Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED STAT INHIBITOR; PROTEIN; FAMILY; ACTIVATION; CIS; SUBSTRATE; KINASES; CLONING; DOMAIN; SHC	SOCS (suppressor of cytokine signaling) proteins have been shown to be negative regulators of cytokine receptor signaling via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. We have cloned a member of this family (hSOCS-2) by utilizing the insulin-like growth factor I receptor (IGF-IR) cytoplasmic domain as bait in a yeast two-hybrid screen of a human fetal brain library. The hSOCS-2 protein interacted strongly with the activated IGF-IR and not with a kinase negative mutant receptor in the two-hybrid assay. Mutation of receptor tyrosines 950, 1250, 1251, and 1316 to phenylalanine or deletion of the COOH-terminal 93 amino acids did not result in decreased interaction of the receptor with hSOCS-2 protein. hSOCS-1 protein also interacted strongly with IGF-IR in the two-hybrid assay. Glutathione S-transferase-hSOCS-2 associated with activated IGF-IR in lysates of mouse fibroblasts overexpressing IGF-IR, Human embryonic kidney cells (293) were transiently transfected with vectors containing IGF-IR and FLAG epitope-tagged hSOCS-2, After IGF-I stimulation, activated IGF-IR was found in anti-FLAG immunoprecipitates and, conversely, FLAG-hSOCS-2 was found in anti IGF-IR immunoprecipitates. Thus, hSOCS-2 interacted with IGF-IR both in vitro and in vivo. HSOCS-2 mRNA was expressed in many human fetal and adult tissues with particularly high abundance in fetal kidney and adult heart, skeletal muscle, pancreas, and liver, These results raise the possibility that SOCS proteins may also play a regulatory role in IGF-I receptor signaling.	NCI, Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Strong Childrens Res Ctr, Rochester, NY 14642 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Rochester	Nissley, P (corresponding author), NCI, Metab Branch, NIH, Bldg 10,Rm 4N115, Bethesda, MD 20892 USA.	spniss@box-s.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051657] Funding Source: NIH RePORTER; NIDDK NIH HHS [1RO1 DK51657] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Aman NJ, 1997, CURR BIOL, V7, pR784, DOI 10.1016/S0960-9822(06)00405-2; Ausbel FM, 1994, CURRENT PROTOCOLS MO; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dey BR, 1998, GENE, V209, P175, DOI 10.1016/S0378-1119(98)00045-6; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	26	167	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24095	24101		10.1074/jbc.273.37.24095	http://dx.doi.org/10.1074/jbc.273.37.24095			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727029	hybrid			2022-12-25	WOS:000075893100070
J	Saunders, C; Keefer, JR; Bonner, CA; Limbird, LE				Saunders, C; Keefer, JR; Bonner, CA; Limbird, LE			Targeting of G protein-coupled receptors to the basolateral surface of polarized renal epithelial cells involves multiple, non-contiguous structural signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; NEPHROGENIC DIABETES-INSIPIDUS; MDCK CELLS; ALPHA(2A)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTORS; CYTOPLASMIC DOMAIN; LIGAND-BINDING; MEMBRANE; LOCALIZATION; TYROSINE	Truncations and chimeras of the alpha(2A)-adrenergic receptor (alpha(2A)AR) were evaluated to identify membrane domains responsible for its direct basolateral targeting in Madin-Darby canine kidney cells. An alpha(2A)AR truncation, encoding transmembrane (TM) regions 1-5, was first delivered basolaterally, but within minutes appeared apically, and at steady-state was primarily lateral ire its immunocytochemical localization. A TM 1-5 truncation with the third intracellular loop revealed more intense lateral localization than for the TRI 1-5 structure, consistent with the role of the third intracellular loop in alpha(2A)AR stabilization Addition of TM 6-7 of A(1) adenosine receptor (A(1)AdoR) to alpha(2A)ARTM1-5 creates a chimera, alpha(2A)ARTM1-5/A(1)AdoRTM6-7, which was first delivered apically, resulting either from loss of alpha(2A)AR sorting information in TM 6-7 or acquisition of apical trafficking signals within A(1)AdoRTM6-7. Evidence that alpha(2A)ARTM6-7 imparts basolateral targeting information is revealed by the significant basolateral localization of the A(1)AdoRTM1-5/alpha(2A)ARTM6-7 and A(1)AdoRTM1-5/alpha(2A)ARTM6-7 + i3 chimeras, in contrast to the dominant apical localization of A(1)AdoR. These results reveal that sequences within TM 1-5 and within TM 6-7 of the alpha(2A)AR confer basolateral targeting, providing the first evidence that alpha(2A)AR basolateral localization is not conferred by a single region but by non-contiguous membrane-embedded or proximal sequences.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, MRB 464, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [TG HL07323] Funding Source: Medline; NIDDK NIH HHS [DK 43879] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; FISH EM, 1994, NEW ENGL J MED, V330, P1580; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Inukai K, 1997, MOL ENDOCRINOL, V11, P442, DOI 10.1210/me.11.4.442; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; Nasman J, 1997, J BIOL CHEM, V272, P9703; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; Oksche A, 1996, MOL PHARMACOL, V50, P820; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; ROBINSON SW, 1994, MOL PHARMACOL, V46, P352; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; WANG CD, 1991, MOL PHARMACOL, V40, P168; WONG SKF, 1990, J BIOL CHEM, V265, P6219; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yeaman C, 1996, AM J PHYSIOL-CELL PH, V270, pC753, DOI 10.1152/ajpcell.1996.270.3.C753	39	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24196	24206		10.1074/jbc.273.37.24196	http://dx.doi.org/10.1074/jbc.273.37.24196			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727043	hybrid			2022-12-25	WOS:000075893100084
J	Li, XY; McClure, WR				Li, XY; McClure, WR			Characterization of the closed complex intermediate formed during transcription initiation by Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNASE-I; PROMOTER RECOGNITION; BACTERIOPHAGE-LAMBDA; SIGMA-70 SUBUNIT; WILD-TYPE; HOLOENZYME; PROTEIN; ACTIVATION; REPRESSOR; MECHANISM	We have carried out detailed DNase I footprinting studies of the closed complex formed on the phage lambda prmup-1 Delta 265 promoter under reaction conditions such that the contribution of the open complex to the footprint was negligible. Detailed quantification shows that the closed complex detected has the same binding constant as that determined in kinetic studies. The footprinting pattern of the closed complex shows major differences from that of the open complex. Not only is it about 20 base pairs shorter, there are also many fewer positions being protected around and upstream of the -35 region. We have derived potential contact regions in the closed and open complexes based on the DNase I footprinting patterns, and confirmed the contact region for the open complex by hydroxyl radical footprinting. One important finding is that most of the essential contacts with the phosphate groups in the -35 region are formed during the isomerization step, a conclusion consistent with our kinetic data showing that this step is salt dependent on this promoter. In addition, we found that the derived contact regions for the closed and open complexes are offset by about three base pairs in the -35 region, which suggests a shift of the contact during isomerization. Finally, we found that the footprintimg pattern of the complex formed at 4 degrees C has some similarities to as well as differences from the closed complex formed under standard transcription conditions.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	McClure, WR (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.				NIGMS NIH HHS [GM 30375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; AUBLE DT, 1988, J MOL BIOL, V202, P471, DOI 10.1016/0022-2836(88)90279-3; BOROWIEC JA, 1986, BIOCHEMISTRY-US, V25, P5051, DOI 10.1021/bi00366a012; BRENOWITZ M, 1986, P NATL ACAD SCI USA, V83, P8462, DOI 10.1073/pnas.83.22.8462; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHOY HA, 1986, J MOL BIOL, V191, P59, DOI 10.1016/0022-2836(86)90422-5; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; COWING DW, 1989, J MOL BIOL, V210, P513, DOI 10.1016/0022-2836(89)90127-7; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; DUVALVALENTIN G, 1986, NUCLEIC ACIDS RES, V14, P1967, DOI 10.1093/nar/14.5.1967; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; HAWLEY DK, 1980, P NATL ACAD SCI-BIOL, V77, P6381, DOI 10.1073/pnas.77.11.6381; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HEUMANN H, 1988, J MOL BIOL, V201, P115, DOI 10.1016/0022-2836(88)90443-3; HOFER B, 1985, NUCLEIC ACIDS RES, V13, P5995, DOI 10.1093/nar/13.16.5995; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; Li M, 1997, P NATL ACAD SCI USA, V94, P3691, DOI 10.1073/pnas.94.8.3691; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LI XY, 1989, DNA PROTEIN INTERACT, P63; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; OZOLINE ON, 1995, NUCLEIC ACIDS RES, V23, P4533, DOI 10.1093/nar/23.22.4533; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, P NATL ACAD SCI USA, V76, P3233, DOI 10.1073/pnas.76.7.3233; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P3740, DOI 10.1073/pnas.74.9.3740; Zaychikov E, 1997, J BIOL CHEM, V272, P2259	43	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23549	23557		10.1074/jbc.273.36.23549	http://dx.doi.org/10.1074/jbc.273.36.23549			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722594	hybrid			2022-12-25	WOS:000075778100094
J	Yoo, SJ; Kim, HH; Shin, DH; Lee, CS; Seong, IS; Seol, JH; Shimbara, N; Tanaka, K; Chung, CH				Yoo, SJ; Kim, HH; Shin, DH; Lee, CS; Seong, IS; Seol, JH; Shimbara, N; Tanaka, K; Chung, CH			Effects of the Cys mutations on structure and function of the ATP-dependent HslVU protease in Escherichia coli - The Cys(287) to Val mutation in HslU uncouples the ATP-dependent proteolysis by HslVU from ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE BINDING; ACTIVATED ATPASE; 26S PROTEASOMES; HS1VU PROTEASE; CLP PROTEASE; PROTEINS; COMPONENT; DEGRADATION; SUBUNIT; UBIQUITIN	To define the role of the Cys residues in the ATP-dependent HslVU protease, mutagenesis was performed to replace either Cys(261) Or Cys(287) in HslU with Val and Cys(159) in HslV with Ser or Ala. Whereas HslU/C261V could hydrolyze ATP and support the ATP-dependent proteolytic activity of HslV as well as the wild-type HslU, HslU/C287V could not hydrolyze ATP, Nevertheless, HslU/C287V could support the HslV-mediated proteolysis by forming the HslVU complex in the presence of ATP but not its absence, indicating that ATP binding but not its hydrolysis is essential for proteolysis. Whereas treatment of N-ethylmaleimide (NEM) resulted in dissociation of the oligomeric HslU into monomers, the C261V mutation, but not C287V, prevented the NEM effect. These results suggest that Cys261 is involved in oligomerization and that Cys(287) is related to the ATPase function of HslU, NEM also dissociated the dodecameric HslV into monomers, and this effect could be prevented by either the C159S or C159A mutation, suggesting the involvement of Cys(159) in oligomerization of HslV. Moreover, either mutation abolished both the basal and HslU-activated proteolytic activity of HslV and its ability to activate the HslU ATPase and to form the HslVU complex, indicating that Cys(159) is essential for the proteolytic activity of HslV and its interaction with HslU. These results suggest that the Cys residues play an important role in maintaining the structure and function of the HslUV protease.	Seoul Natl Univ, Coll Nat Sci, Dept Mol Biol, Seoul 151742, South Korea; Seoul Natl Univ, Coll Nat Sci, Res Ctr Cell Differentiat, Seoul 151742, South Korea; Sumitomo Elect Ind Ltd, Dept Biomed R&D, Yokohama, Kanagawa 244, Japan; Japan Sci & Technol Corp, CREST, Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan	Seoul National University (SNU); Seoul National University (SNU); Sumitomo Electric Industries; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science	Chung, CH (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Mol Biol, Seoul 151742, South Korea.	chchung@plaza.snu.ac.kr	Shin, Donghun/A-2092-2012					Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARMON T, 1990, J BIOL CHEM, V265, P20723; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; Chung CH, 1996, BIOL CHEM, V377, P549; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; Chung CH, 1997, BIOCHEM BIOPH RES CO, V241, P613, DOI 10.1006/bbrc.1997.7735; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huang HC, 1997, J BIOL CHEM, V272, P21364, DOI 10.1074/jbc.272.34.21364; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; KIMS KI, 1995, J BIOL CHEM, V270, P29799; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENON AS, 1987, J BIOL CHEM, V262, P14929; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seol JH, 1997, EUR J BIOCHEM, V247, P1143, DOI 10.1111/j.1432-1033.1997.01143.x; Shin DH, 1996, FEBS LETT, V398, P151, DOI 10.1016/S0014-5793(96)01223-9; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Yoo SJ, 1997, FEBS LETT, V412, P57, DOI 10.1016/S0014-5793(97)00742-4; Yoo SJ, 1997, BIOCHEM BIOPH RES CO, V238, P581, DOI 10.1006/bbrc.1997.7341; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035	52	12	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22929	22935		10.1074/jbc.273.36.22929	http://dx.doi.org/10.1074/jbc.273.36.22929			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722513	hybrid			2022-12-25	WOS:000075778100013
J	Hammacher, A; Richardson, RT; Layton, JE; Smith, DK; Angus, LJL; Hilton, DJ; Nicola, NA; Wijdenes, J; Simpson, RJ				Hammacher, A; Richardson, RT; Layton, JE; Smith, DK; Angus, LJL; Hilton, DJ; Nicola, NA; Wijdenes, J; Simpson, RJ			The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; IL-6 RECEPTOR; HIGH-AFFINITY; MONOCLONAL-ANTIBODIES; HEXAMERIC COMPLEX; BINDING-SITES; 2 DISTINCT; TRANSDUCER; EXPRESSION; MURINE	The transmembrane protein gp130 is a shared component of the receptor complexes for the interleukin-6 (IL-6)-type cytokines, which include IL-6, leukemia inhibitory factor (LIF) and oncostatin M (OSM). In addition to its role in the generation of high affinity receptors, gp130 is required for signal transduction by these cytokines. In the present study we have examined the role of the N-terminal located, extracellular immunoglobulin (Ig)-like module of gp130 in signal transduction by IL-6 and LIF. We have expressed wild-type human gp130 or three mutants in murine myeloid M1-UR21 cells that lack functional endogenous gp130 but express the IL-6 receptor (IL-GR) and the LIF receptor (LIFR). By measuring cellular responses, such as morphological changes upon differentiation, soft agar colony formation, and induction of tyrosine phosphorylation of the signal transducer and activator of transcription, STAT3, we show that signaling by IL-6, but not LIF, is significantly reduced by mutations in the Ig-like module of gp130. However, the binding of I-125-labeled IL-6 or LIF is not affected by these mutations. We also present evidence that the Ig-like module forms part of the epitope of an anti-gp130 monoclonal antibody that neutralizes the bioactivity of IL-6, but not of LIF or OSM. The data suggest that gp130-activation by IL-6 and LIF requires different regions of gp130, that the Ig-like module of gp130 may be required for IL B-induced gp130 dimerization, and that the stoichiometry of the high affinity IL-6 receptor-complex differs from those of the receptor-complexes for LIF and OSM.	Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Joint Prot Struct Lab, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; DIACLONE, F-25020 Besancon, France	Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute	Hammacher, A (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.	annet.hammacher@udwig.edu.au	Nicola, Nicos/D-2989-2011; Hilton, Douglas J/C-7250-2013	Nicola, Nicos/0000-0003-1054-7889; Hilton, Douglas J/0000-0002-7698-2392; Simpson, Richard/0000-0002-9834-0796; Smith, David/0000-0003-3608-0586; Richardson, Rachael/0000-0002-2412-8354				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Grotzinger J, 1997, PROTEINS, V27, P96; Hammacher A, 1996, J BIOL CHEM, V271, P5464, DOI 10.1074/jbc.271.10.5464; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LAYTON JE, 1991, J BIOL CHEM, V266, P23815; Layton JE, 1997, GROWTH FACTORS, V14, P117, DOI 10.3109/08977199709021515; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; METCALF D, 1989, LEUKEMIA, V3, P349; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P307; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neddermann P, 1996, J BIOL CHEM, V271, P30986, DOI 10.1074/jbc.271.48.30986; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; SALVATI AL, 1995, J BIOL CHEM, V270, P12242, DOI 10.1074/jbc.270.20.12242; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Taga T, 1996, J NEUROCHEM, V67, P1; WARD LD, 1994, J BIOL CHEM, V269, P23286; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Zhang JG, 1997, BIOCHEM J, V325, P693, DOI 10.1042/bj3250693; ZHANG JG, 1992, EUR J BIOCHEM, V207, P903, DOI 10.1111/j.1432-1033.1992.tb17123.x	46	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22701	22707		10.1074/jbc.273.35.22701	http://dx.doi.org/10.1074/jbc.273.35.22701			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712900	hybrid			2022-12-25	WOS:000075616600076
J	Stevenson, JM; Perera, IY; Boss, WF				Stevenson, JM; Perera, IY; Boss, WF			A phosphatidylinositol 4-kinase pleckstrin homology domain that binds phosphatidylinositol 4-monophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SUSPENSION-CULTURE; PH DOMAIN; PHOSPHOLIPASE-C; MESSENGER-RNA; PROTEIN; KINASE; CELLS; ARABIDOPSIS; ASSOCIATION	Pleckstrin homology (PH) domains are found in many proteins involved in signal transduction, including the family of large molecular mass phosphatidylinositol (PI) 4-kinases. Although the exact function of these newly discovered domains is unknown, it is recognized that they may influence enzyme regulation by binding different ligands. In this study, the recombinant PI 4-kinase PH domain was explored for its ability to bind to different phospholipids. First, we isolated partial cDNAs of the >7-kilobase transcripts of PI 4-kinases from carrot (DcPI4K alpha) and Arabidopsis (AtPI4K alpha). The deduced primary sequences were 41% identical and 68% similar to rat and human PI 4-kinases and contained the telltale lipid kinase unique domain, PH domain, and catalytic domain. Antibodies raised against the expressed lipid kinase unique, PH, and catalytic domains identified a polypeptide of 205 kDa in Arabidopsis microsomes and an F-actin-enriched fraction from carrot cells. The 205-kDa immunoaffinity-purified Arabidopsis protein had PI 4-kinase activity. We have used the expressed PH domain to characterize lipid binding properties. The recombinant PH domain selectively bound to phosphatidylinositol 4-monophosphate (PI-4-P), phosphatidylinositol 4,5-bisphosphate (PI-4,5-P(2)), and phosphatidic acid and did not bind to the S-phosphoinositides. The PH domain had the highest affinity for PI-4-P, the product of the reaction. Consideration is given to the potential impact that this has on cytoskeletal organization and the PI signaling pathway in cells that have a high PI-4-P/PI-4,5-P(2), ratio.	N Carolina State Univ, Dept Bot, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Boss, WF (corresponding author), N Carolina State Univ, Dept Bot, Box 7612, Raleigh, NC 27695 USA.	wendy_boss@ncsu.edu		Perera, Imara/0000-0001-9421-1420				Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; BOSS WF, 1989, 2ND MESSENGERS PLANT, P29; CARRAWAY KL, 1992, CYTOSKELETON PRACTIC; CHEN QY, 1990, PLANT PHYSIOL, V94, P1820, DOI 10.1104/pp.94.4.1820; CHO MH, 1993, PLANT PHYSIOL, V103, P637, DOI 10.1104/pp.103.2.637; COTE GG, 1994, BIOESSAYS, V16, P39, DOI 10.1002/bies.950160106; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gehrmann T, 1996, BBA-MOL CELL RES, V1311, P53, DOI 10.1016/0167-4889(95)00180-8; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GROSS W, 1992, BIOCHIM BIOPHYS ACTA, V1134, P73, DOI 10.1016/0167-4889(92)90029-B; HALL TC, 1978, P NATL ACAD SCI USA, V75, P3196, DOI 10.1073/pnas.75.7.3196; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; MORSE MJ, 1987, P NATL ACAD SCI USA, V84, P7075, DOI 10.1073/pnas.84.20.7075; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OKPODU CM, 1995, PLANT PHYSIOL, V107, P491, DOI 10.1104/pp.107.2.491; PERERA IY, 1992, PLANT PHYSIOL, V100, P812, DOI 10.1104/pp.100.2.812; Perera IY, 1996, CUR TOP PL, V17, P114; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Sambrook J., 2002, MOL CLONING LAB MANU; SANDELIUS AS, 1990, PLANT BIOL, V9, P139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTERLEE JS, 1997, PLANT PHYSIOL, V115, P864; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SOMMARIN M, 1988, BIOCHIM BIOPHYS ACTA, V958, P268, DOI 10.1016/0005-2760(88)90185-3; TAN Z, 1992, PLANT PHYSIOL, V100, P2116, DOI 10.1104/pp.100.4.2116; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; WONG K, 1994, J BIOL CHEM, V269, P28878; XU P, 1992, PLANT CELL, V4, P941, DOI 10.1105/tpc.4.8.941; YAMAMOTO YT, 1995, PLANT PHYSIOL, V107, P1029, DOI 10.1104/pp.107.3.1029; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; YU FX, 1992, J BIOL CHEM, V267, P14616; ZIELINSKI RE, 1987, PLANT PHYSIOL, V84, P937, DOI 10.1104/pp.84.3.937	50	124	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22761	22767		10.1074/jbc.273.35.22761	http://dx.doi.org/10.1074/jbc.273.35.22761			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712908	hybrid			2022-12-25	WOS:000075616600084
J	Bai, RY; Jahn, T; Schrem, S; Munzert, G; Weidner, KM; Wang, JYJ; Duyster, J				Bai, RY; Jahn, T; Schrem, S; Munzert, G; Weidner, KM; Wang, JYJ; Duyster, J			The SH2-containing adapter protein GRB10 interacts with BCR-ABL	ONCOGENE			English	Article						SH2; CML; Grb10; Bcr-Abl; yeast two-hybrid; tyrosine kinase; signal transduction	ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; SH2 DOMAIN; C-ABL; HEMATOPOIETIC-CELLS; INSULIN-RECEPTOR; BINDING ACTIVITY; TRANSFORMATION; ONCOGENE	Bcr-Abl is an oncogenic tyrosine kinase expressed in tumor cells of CML and a subset of ALL which in its unregulated and activated state is thought to cause cell transformation and leukemia. Bcr-Abl contains several autophosphorylation sites which serve as potential docking sites for SH2-containing signaling molecules; Mutational analysis has indicated that these autophosphorylation sites play a critical role in the transforming capability of Bcr-Abl, It has been shown that the SH2-containing adapter protein Grb(2) binds to the autophosphorylation site Tyr(p)177 whereby it couples Bcr-Abl to the Ras pathway. The biological consequences of this interaction, however, are presently unclear, A Tyr177-mutated Bcr-Abl which lacks the ability to interact with the Grb2-SH2 domain still transforms myeloid cells and generates tumors in nude mice. We performed a yeast two-hybrid screen to identify signaling proteins which bind to distinct Bcr-Abl autophosphorylation sites. Autophosphorylation of Bcr-Abl in yeast was accomplished by using the DNA binding protein LexA which permits dimerization and crossphosphorylation of the fused bait. Using a LexA-Bcr-Abl full length fusion protein as bait, we identified several SH2-containing proteins. Among them we confirmed molecules already shown by others to interact with Bcr-Abl, irt vivo, including Grb2, PI-3-kinase and Crk indicating that dimerization in yeast leads to autophosphorylation of tyrosine residues crucial for Bcr-Abl signaling in vivo. More importantly, we identified the SH2-containing protein Grb10 as a new binding partner for Bcr-Abl. This binding occurs in a phosphotyrosine-dependent manner at Bcr sites of Bcr-Abl. Both Abl and Bcr alone, as well as a kinase-defective Bcr-Abl, failed to interact with Grb10 in yeast. Mutational analysis uncovered a new SH2 binding site in Bcr-Abl located between Bcr aa242-446, which is different from the Grb2 binding site. Binding could be demonstrated in vitro and also in vivo as shown by co-immunoprecipitation analysis in CML cells. Using a temperature sensitive Bcr-Abl stably overexpressed in hematopoetic cells, we demonstrated that complex formation of Grb10 with Bcr-Abl was kinase activation-dependent in vivo. Notably, a Bcr-Abl mutant protein (Bcr/1-242-Abl) which lacks the ability to interact with Grb10 partially alleviated IL-3 dependence of Ba/F3 cells, indicating that the Grb10/Bcr-Abl interaction is important for Bcr-Abl-induced IL-3 independence of Ba/F3 cells. In addition, the Bcr/1-242-Abl mutant has a reduced capacity to induce focus formation in fibroblasts.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany; Univ Ulm, Dept Hematol & Oncol, D-89069 Ulm, Germany; Boehringer Mannheim GmbH, Dept Therapeut Biotechnol, D-8122 Penzberg, Germany; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Technical University of Munich; University of Munich; Ulm University; University of California System; University of California San Diego; University of California System; University of California San Diego	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismaningerstr 22, D-81675 Munich, Germany.			schrem, stanley/0000-0003-2909-0794	NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043054, R01 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SM, 1996, BLOOD, V87, P238; Bedi Atul, 1995, Blood, V86, P1148; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOTOH A, 1995, EXP HEMATOL, V23, P1153; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUTO TG, 1990, SCIENCE, V247, P1079; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	48	47	48	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	1998	17	8					941	948		10.1038/sj.onc.1202024	http://dx.doi.org/10.1038/sj.onc.1202024			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747873				2022-12-25	WOS:000075560900002
J	Paramio, JM; Lain, S; Segrelles, C; Lane, EB; Jorcano, JL				Paramio, JM; Lain, S; Segrelles, C; Lane, EB; Jorcano, JL			Differential expression and functionally co-operative roles for the retinoblastoma family of proteins in epidermal differentiation	ONCOGENE			English	Article						cell cycle; epidermal differentiation; retinoblastoma family	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE CONTROL; HUMAN KERATINOCYTES; TRANSGENIC MICE; GROWTH SUPPRESSION; MUSCLE-CELLS; P107; E2F; RB	Terminal differentiation requires cell cycle withdrawal, suggesting the involvement of negative cell cycle controllers in the process, We have analysed the involvement of the retinoblastoma family of proteins (pRb, p107 and p130) in epidermal proliferation and differentiation. These proteins play key roles as inhibitors of cell cycle progression and are involved in muscle and neuron differentiation, We found that during in vitro differentiation of human HaCaT keratinocytes, pRb, p107 and p130 are sequentially expressed, in contrast to the co-expression observed during cell cycle progression in the same cells. Immunofluorescence studies on skin sections revealed the presence of pRb and p107 in basal and suprabasal cell layers, whilst p130 is restricted to cells already committed to differentiation in the suprabasal compartments, To explore the functional significance of the differential expression of these proteins, transfection experiments mere performed in HaCaT keratinocytes. We observed that the forced over-expression of pRb, p107 or p130 individually did not induce differentiation of the transfected cells, However, the co-transfection of pRb and p107 induced the expression of early differentiation markers (keratin k10) and triple transfectants pRb + p107 + p130 expressed markers representative of later stages of epidermal differentiation (involucrin). Finally, we observed that these three proteins repress keratinocyte proliferation, although to a different extent (p107 > pRb greater than or equal to p130). These results indicate that the members of the pRb family play specific, yet coordinated roles during epidermal differentiation, and that the ordered progression along the different stages of this process results from the effects of different combinations of these proteins.	CIEMAT, Cell & Mol Biol Program, E-28040 Madrid, Spain; Univ Dundee, Inst Med Sci, Dept Anat & Physiol, CRC,Cell Struct Grp, Dundee DD1 4HN, Scotland	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; University of Dundee	Paramio, JM (corresponding author), CIEMAT, Cell & Mol Biol Program, E-28040 Madrid, Spain.		Lain, Sonia/B-6980-2014; Paramio, Jesus M/M-8482-2014; Segrelles, Carmen/E-3655-2016	Lain, Sonia/0000-0001-9693-5246; Paramio, Jesus M/0000-0001-7520-3177; Segrelles, Carmen/0000-0001-9340-2102; Lane, Birgit/0000-0003-1457-2934				ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; BARRANDON Y, 1989, P NATL ACAD SCI USA, V86, P4102, DOI 10.1073/pnas.86.11.4102; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; Leigh I., 1994, KERATINOCYTE HDB; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NEVINS JR, 1992, SCIENCE, V258, P424; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PARAMIO JM, 1994, EXP CELL RES, V215, P319, DOI 10.1006/excr.1994.1348; Paramio JM, 1997, BRIT J DERMATOL, V137, P44, DOI 10.1111/j.1365-2133.1997.tb03699.x; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Richon VM, 1996, CELL GROWTH DIFFER, V7, P31; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	48	63	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	1998	17	8					949	957		10.1038/sj.onc.1202031	http://dx.doi.org/10.1038/sj.onc.1202031			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747874				2022-12-25	WOS:000075560900003
J	Frevert, EU; Bjorbaek, C; Venable, CL; Keller, SR; Kahn, BB				Frevert, EU; Bjorbaek, C; Venable, CL; Keller, SR; Kahn, BB			Targeting of constitutively active phosphoinositide 3-kinase to GLUT4-containing vesicles in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4 TRANSLOCATION; GLYCOGEN-SYNTHASE; SKELETAL-MUSCLE; PROTEIN-KINASE; DNA-SYNTHESIS; INSULIN; ACTIVATION; ASSOCIATION	Constitutive activation of phosphoinositide S-kinase (PI3K) stimulates glucose transport and GLUT4 glucose transporter translocation to the plasma membrane in adipocytes, To determine whether a direct interaction of PI3K with GLUT4-containing vesicles (hereafter called GLUT4 vesicles) is important for the effect of insulin on GLUT4 translocation, we targeted constitutively active PI3K to GLUT4 vesicles. We fused the inter-Src homology region 2 of the regulatory p85 alpha subunit of PI3K (iSH2) either to a C-terminal sequence of GLUT4 (G4(c), amino acids 406-509) or to this region and the N-terminal tail of GLUT4 (G4(n), amino acids 1-19), resulting in the fusion proteins iSH2-G4(c) and G4(n)-iSH2-G4(c), respectively. Coexpression of the fusion proteins or untargeted iSH2 with the catalytic p110 alpha subunit of PI3K (p110) in 3T3-L1 adipocytes by adenovirus-mediated gene transfer increased total PI3K activity in homogenates 5.0-6.7-fold over nontransduced cells or cells transduced with adenovirus encoding beta-galactosidase, In contrast, PI3K activity in GLUT4 vesicles increased 11-13-fold with expression of either targeted construct and p110 but only 2-fold with the untargeted iSH2 and p110, indicating successful targeting of PI3K to GLUT4 vesicles. Both targeted and nontargeted constructs stimulated DNA synthesis to levels greater than insulin, demonstrating that both types of constructs had biologic activity in intact cells. Despite this, untargeted iSH2/p110 coexpression was more effective in stimulating 2-deoxyglucose uptake (6-fold) than either iSH2-G4c/ p110 or G4n-iSH2-G4c/p110 coexpression (both 2-fold). Only iSH2/p110 coexpression led to a significant GLUT4 translocation to the plasma membrane. Insulin-stimulated glucose transport was unaffected by any construct. Thus, a direct interaction between PI3K and GLUT4 vesicles is either not required or not sufficient for GLUT4 translocation and stimulation of glucose transport.	Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Dartmouth College	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Boston, MA 02215 USA.		Bjorbaek, Christian/S-4727-2019		NIA NIH HHS [AG00924] Funding Source: Medline; NIDDK NIH HHS [R01 DK43051, R01 DK043051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043051] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1992, J BIOL CHEM, V267, P19636; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; FROST SC, 1985, J BIOL CHEM, V260, P2646; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KING PA, 1992, J CLIN INVEST, V90, P1568, DOI 10.1172/JCI116025; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kummer JL, 1998, BIOCHEM BIOPH RES CO, V246, P282, DOI 10.1006/bbrc.1998.8599; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; WALSH JP, 1991, P NATL ACAD SCI USA, V76, P4350; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Zierath JR, 1996, SEMIN CELL DEV BIOL, V7, P295, DOI 10.1006/scdb.1996.0038	39	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25480	25487		10.1074/jbc.273.39.25480	http://dx.doi.org/10.1074/jbc.273.39.25480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738018	hybrid			2022-12-25	WOS:000076085400068
J	Murray, SR; Evans, CJ; von Zastrow, M				Murray, SR; Evans, CJ; von Zastrow, M			Phosphorylation is not required for dynamin-dependent endocytosis of a truncated mutant opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; OPIATE-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; DOWN-REGULATION; INTERNALIZATION; AGONIST; DESENSITIZATION; SEQUESTRATION; MECHANISMS; TERMINUS	Opioid receptors are regulated within minutes after activation by G protein-coupled receptor kinase-mediated phosphorylation and dynamin-dependent endocytosis, We addressed the question of whether phosphorylation is required for opioid receptor endocytosis by examining a functional, truncated mutant delta opioid receptor (DOR344T), which is missing phosphorylation sites located in the carboxyl-terminal cytoplasmic domain, DOR344T receptors expressed in Chinese hamster ovary cells remained predominantly in the plasma membrane, even in the presence of saturating concentrations of agonist, consistent with previous studies demonstrating strongly inhibited endocytosis of truncated receptors in this cell type. In marked contrast, DOR344T receptors expressed at similar levels in human embryonal kidney (HEK) 293 cells exhibited rapid, Ligand-induced internalization either in the presence of peptide (DADLE) or alkaloid (etorphine) agonist, Quantitative assays using ELISA and flow cytometric techniques indicated that DOR344T receptors were endocytosed in HEK293 cells with similarly rapid kinetics as full-length DOR (t(1/2) < 10 min), and both full-length DOR and DOR344T mutant receptors were endocytosed by a dynamin-dependent mechanism involving clathrin-coated pits. Nevertheless, DOR344T receptors failed to undergo any detectable constitutive or agonist-induced phosphorylation in the same cells in which dynamin-dependent endocytosis was observed. These findings establish the first example of a G protein-coupled receptor that does not require phosphorylation to undergo dynamin-dependent endocytosis, and they suggest that significant cell type-specific differences exist in the biochemical requirements for ligand-induced concentration of opioid receptors in clathrin-coated pits.	Univ Calif San Francisco, Dept Psychiat, Nina Ireland Lab, LPPI, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles	von Zastrow, M (corresponding author), Univ Calif San Francisco, Dept Psychiat, Nina Ireland Lab, LPPI, Box 0984,401 Parnassus Ave, San Francisco, CA 94143 USA.	zastrow@itsa.ucsf.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R37DA010711, R29DA010711, R01DA010711, P50DA005010] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10711, DA00218, P50 DA005010] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1996, J BIOL CHEM, V271, P4073; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Evans CJ, 1993, BIOL BASIS SUBSTANCE, P31; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Goodman O B Jr, 1998, Adv Pharmacol, V42, P429; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; HEIN L, 1994, J BIOL CHEM, V269, P27719; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; NESTLER EJ, 1993, CRIT REV NEUROBIOL, V7, P23; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Okayama H, 1992, Biotechnology, V24, P270; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PEI G, 1995, MOL PHARMACOL, V48, P173; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; Reisine T, 1996, ANN NY ACAD SCI, V780, P168, DOI 10.1111/j.1749-6632.1996.tb15121.x; Segredo V, 1997, J NEUROCHEM, V68, P2395; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242	31	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					24987	24991		10.1074/jbc.273.39.24987	http://dx.doi.org/10.1074/jbc.273.39.24987			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737953	hybrid			2022-12-25	WOS:000076085400003
J	Tell, G; Scaloni, A; Pellizzari, L; Formisano, S; Pucillo, C; Damante, G				Tell, G; Scaloni, A; Pellizzari, L; Formisano, S; Pucillo, C; Damante, G			Redox potential controls the structure and DNA binding activity of the paired domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID FRTL-5 CELLS; TRANSCRIPTION FACTOR; PAX GENES; CONFORMATIONAL-CHANGES; IN-VITRO; KAPPA-B; PROTEIN; ACTIVATION; SEQUENCE; RECOGNITION	Pax proteins are transcriptional regulators controlling a variety of cell fates during animal development. This role depends on the intact function of the paired (Prd) domain that is able to recognize specific DNA sequences. The Prd domain is composed of two distinct helix-turn-helix subdomains, PAI and RED. Molecular functions of Pax proteins are subjected to different levels of regulation involving both pre-translational and post-translational mechanisms. By using Pax-5 and Pax-8 recombinant proteins, we demonstrate that the binding activity of the Prd domain is regulated through the oxidation/reduction of conserved cysteine residues. Mass spectrometry analysis and mutagenesis experiments demonstrate that the redox regulation is accomplished through the reversible formation of an intramolecular disulfide bridge involving the cysteines present in the PAI subdomain, whereas the RED subdomain appears quite insensitive to redox potential. Circular dichroism experiments indicate that only the reduced form of the Prd domain is able to undergo the proper conformational change necessary for sequence-specific DNA binding. Nuclear extracts from different cell lines contain an activity that is able to reduce the Paired domain and, therefore, to control the DNA binding activity of this protein. Immunodepletion of nuclear extracts demonstrate that the protein Ref-1 contributes to the redox regulation of the Prd DNA binding activity. Given the modular nature of the Prd domain and the independent DNA binding specificity of the PAI and RED subdomains, we propose that this control mechanism should be involved in "switching" among different DNA sequences and therefore different target genes.	Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Univ Naples, CNR, Ctr Int Serv Spettrometria Massa, I-80131 Naples, Italy; CNR, Ist Ric Adattamento Bovini & Bufali Ambiente Mezz, I-80147 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Damante, G (corresponding author), Univ Udine, Dipartimento Sci & Tecnol Biomed, Via Gervasutta 48, I-33100 Udine, Italy.	giuseppe.damante@dstb.uniud.it	Pucillo, Carlo/A-5515-2008; Damante, Giuseppe/AAC-5200-2022	Pucillo, Carlo/0000-0002-4872-6156; Tell, Gianluca/0000-0001-8845-6448; Scaloni, Andrea/0000-0001-9362-8515; Damante, Giuseppe/0000-0003-2312-4009				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; ALTOMONTE M, 1993, J IMMUNOL, V151, P5115; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Asai T, 1997, BIOCHEM BIOPH RES CO, V236, P71, DOI 10.1006/bbrc.1997.6906; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BJORKMAN U, 1992, ENDOCRINOLOGY, V130, P393, DOI 10.1210/en.130.1.393; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSLINGER M, 1995, CURR OPIN GENET DEV, V5, P595, DOI 10.1016/0959-437X(95)80028-X; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAINAUT P, 1993, CANCER RES, V53, P4469; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jun S, 1996, DEVELOPMENT, V122, P2639; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; KURUCZ I, 1993, P NATL ACAD SCI USA, V90, P3830, DOI 10.1073/pnas.90.9.3830; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; Mansouri A, 1996, DEVELOPMENT, V122, P831; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Pellizzari L, 1996, BIOCHEM J, V315, P363, DOI 10.1042/bj3150363; POLEEV A, 1992, DEVELOPMENT, V116, P611; Poleev A, 1997, EUR J BIOCHEM, V247, P860, DOI 10.1111/j.1432-1033.1997.00860.x; Scaloni A, 1998, J MOL BIOL, V277, P945, DOI 10.1006/jmbi.1998.1629; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STUART ET, 1995, CLIN CANCER RES, V1, P207; STUDIER FW, 1991, METHOD ENZYMOL, V185, P60; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VanRenterghem P, 1996, BBA-GENE STRUCT EXPR, V1307, P97, DOI 10.1016/0167-4781(96)00018-8; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; WALLIN J, 1993, MAMM GENOME, V4, P354, DOI 10.1007/BF00360584; WALLIN J, 1994, DEVELOPMENT, V120, P1109; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	66	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25062	25072		10.1074/jbc.273.39.25062	http://dx.doi.org/10.1074/jbc.273.39.25062			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737963	hybrid			2022-12-25	WOS:000076085400013
J	Yu, X; Wu, LJC; Bowcock, AM; Aronheim, A; Baer, R				Yu, X; Wu, LJC; Bowcock, AM; Aronheim, A; Baer, R			The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER SUSCEPTIBILITY GENE; CELL-CYCLE CONTROL; DNA-LIGASE-III; NEGATIVE MODULATION; BREAST-CANCER; E1A PROTEIN; DAMAGE; PHOSPHORYLATION; PHOSPHOPROTEIN; TRANSFORMATION	The BRCA1 tumor suppressor encodes a polypeptide with two recognizable protein motifs: a RING domain near the N terminus and two tandem BRCT domains at the C terminus. Studies of tumor-associated mutations indicate that the RING and BRCT sequences are required for BRCA1-mediated tumor suppression. In addition, recent work has shown that BRCA1 is a potent regulator of RNA transcription and that the BRCT domains are also essential for this activity. Therefore, we used the Sos recruitment system to screen for proteins that bind this critical region of BRCA1. Our results show that the BRCT domains interact in vivo with CtIP, a protein originally identified on the basis of its association with the CtBP transcriptional co-repressor, This finding suggests that BRCA1 regulates gene expression, at least in part, by modulating CtBP-mediated transcriptional repression. Moreover, the in vivo interaction between BRCA1 and CtIP is completely ablated by each of three independent tumor-associated mutations affecting the BRCT motifs of BRCA1. These results indicate that the BRCA1-CtIP interaction may be required for tumor suppression by BRCA1.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75235 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Mol Genet, IL-31096 Haifa, Israel	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Baer, R (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.			Bowcock, Anne/0000-0001-8691-9090; Aronheim, Ami/0000-0002-8575-4092	NCI NIH HHS [CA76334, CA60650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060650, R01CA076334] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Larson JS, 1997, CANCER RES, V57, P3351; Mackey ZB, 1997, MOL CELL BIOL, V17, P989, DOI 10.1128/MCB.17.2.989; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tsan JT, 1997, ADV MOLEC BIOL, P217; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	35	319	323	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25388	25392		10.1074/jbc.273.39.25388	http://dx.doi.org/10.1074/jbc.273.39.25388			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738006	hybrid			2022-12-25	WOS:000076085400056
J	Ferreira, PA; Cai, YF; Schick, D; Roepman, R				Ferreira, PA; Cai, YF; Schick, D; Roepman, R			The cyclophilin-like domain mediates the association of ran-binding protein 2 with subunits of the 19 S regulatory complex of the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; FUNCTIONAL-ANALYSIS; COUPLED RECEPTORS; VISUAL PIGMENTS; 26S PROTEASOME; HOMOLOG NINAA; CDNA CLONING; DROSOPHILA; TRANSPORT; RHODOPSIN	The combination of the Ran-binding domain 4 and cyclophilin domains of Ran-binding protein 2 selectively associate with a subset of G protein-coupled receptors, red/green opsins, upon cis-trans prolyl isomerase-dependent and direct modification of opsin followed by association of the modified opsin isoform to Ran-binding domain 4. This effect enhances in vivo the production of functional receptor and generates an opsin isoform with no propensity to self-aggregate in vitro. We now show that another domain of Ran-binding protein 2, cyclophilin-like domain, specifically associates with the 112-kDa subunit, P112, and other subunits of the 19 S regulatory complex of the 26 S proteasome in the neuroretina. This association possibly mediates Ran-binding protein 2 limited proteolysis into a smaller and stable isoform. Also, the interaction of Ran-binding protein 2 with P112 regulatory subunit of the 26 S proteasome involves still another protein, a putative kinesin-like protein. Our results indicate that Ran-binding protein 2 is a key component of a macro-assembly complex selectively linking protein biogenesis with the proteasome pathway and, thus, with potential implications for the presentation of misfolded and ubiquitin-like modified proteins to this proteolytic machinery.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Ferreira, PA (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ferreira@post.its.mcw.edu	Roepman, Ronald/B-1339-2014; Ferreira, Paulo A/S-4209-2016; Ferreira, Paulo/A-3893-2008	Roepman, Ronald/0000-0002-5178-8163; Ferreira, Paulo A/0000-0003-4585-1717; 	NEI NIH HHS [R01 EY011993] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011993] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBURY ML, 1994, SOC GEN PHY, V49, P235; Arbour NC, 1997, HUM MOL GENET, V6, P689, DOI 10.1093/hmg/6.5.689; Bargmann CI, 1997, CELL, V90, P585, DOI 10.1016/S0092-8674(00)80518-8; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; FERREIRA PA, 1995, J BIOL CHEM, V270, P23179, DOI 10.1074/jbc.270.39.23179; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Ferreira PA, 1997, P NATL ACAD SCI USA, V94, P1556, DOI 10.1073/pnas.94.4.1556; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; MANUTIS M, 1997, J CELL BIOL, V135, P1457; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Nothwang HG, 1998, GENOMICS, V47, P383, DOI 10.1006/geno.1997.5119; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; PAK WL, 1986, PHOTOBIOCH PHOTOBIOP, V13, P229; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; REN MD, 1995, MOL CELL BIOL, V15, P2117; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P447; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Tsurumi C, 1996, EUR J BIOCHEM, V239, P912, DOI 10.1111/j.1432-1033.1996.0912u.x; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; WILKEN N, 1995, EUR J CELL BIOL, V68, P211; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yamamoto S, 1997, NAT GENET, V15, P175, DOI 10.1038/ng0297-175; Yokota K, 1996, MOL BIOL CELL, V7, P853, DOI 10.1091/mbc.7.6.853; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; 1996, NATURE S, V384, P5	56	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24676	24682		10.1074/jbc.273.38.24676	http://dx.doi.org/10.1074/jbc.273.38.24676			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733766	Green Published, hybrid			2022-12-25	WOS:000076007300058
J	Wang, PY; Kitchens, RL; Munford, RS				Wang, PY; Kitchens, RL; Munford, RS			Phosphatidylinositides bind to plasma membrane CD14 and can prevent monocyte activation by bacterial lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-COMPOSITION; FATTY-ACID; PROTEIN; RECEPTOR; LPS; LIPOPROTEIN; MACROPHAGES; METABOLISM; LIPOSOMES	Although bacterial lipopolysaccharides (LPS) and several other microbial agonists can bind to mCD14 (membrane CD14), a cell-surface receptor found principally on monocytes and neutrophils, host-derived mCD14 ligands are poorly defined. We report here that phosphatidylinositol (PtdIns), phosphatidylinositol-4-phosphate, and other phosphatidylinositides can bind to mCD14. Phosphatidylserine (PS), another anionic glycerophospholipid, binds to mCD14 with lower apparent affinity than does PtdIns. LPS-binding protein, a lipid transfer protein found in serum, facilitates both PS- and PtdIns-mCD14 binding. PtdIns binding to mCD14 can be blocked by anti-CD14 monoclonal antibodies that inhibit LPS-mCD14 binding, and PtdIns can inhibit both LPS-mCD14 binding and LPS-induced responses in monocytes. Serum-equilibrated PtdIns also binds to mCD14-expressing cells, raising the possibility that endogenous PtdIns may modulate cellular responses to LPS and other mCD14 ligands in vivo.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Cell Regulat Grad Program, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Munford, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	rmunf1@mednet.swmed.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018188, R37AI018188, R56AI018188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18188] Funding Source: Medline; NIAMS NIH HHS [AR41940] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGDADE JD, 1995, ATHEROSCLEROSIS, V117, P209, DOI 10.1016/0021-9150(95)05573-F; BRADAMANTE S, 1990, ANAL BIOCHEM, V185, P299, DOI 10.1016/0003-2697(90)90297-M; BRECKENRIDGE WC, 1982, BIOCHIM BIOPHYS ACTA, V712, P707, DOI 10.1016/0005-2760(82)90302-2; CUNNANE SC, 1989, AM J CLIN NUTR, V50, P801, DOI 10.1093/ajcn/50.4.801; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; Kitchens RL, 1998, J IMMUNOL, V160, P1920; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KITCHENS RL, 1998, ENDOTOXIN HLTH DIS; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; OTTERLEI M, 1993, INFECT IMMUN, V61, P1917, DOI 10.1128/IAI.61.5.1917-1925.1993; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SATTA N, 1994, J IMMUNOL, V153, P3245; Savedra R, 1996, J IMMUNOL, V157, P2549; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SCHWENDENER RA, 1984, BIOCHIM BIOPHYS ACTA, V772, P93, DOI 10.1016/0005-2736(84)90521-2; Sellati TJ, 1998, J IMMUNOL, V160, P5455; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; Tobias PS, 1992, J CELL BIOCHEM, V16C, P151; WADEE AA, 1983, J IMMUNOL, V130, P2271; WASSEF NM, 1984, P NATL ACAD SCI-BIOL, V81, P2655, DOI 10.1073/pnas.81.9.2655; WATALA C, 1990, CLIN CHIM ACTA, V188, P211, DOI 10.1016/0009-8981(90)90202-4; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J EXP MED, V186, P2051, DOI 10.1084/jem.186.12.2051; Wurfel MM, 1997, J IMMUNOL, V158, P3925; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; Yu WG, 1998, AM J PATHOL, V152, P759; ZOELLER RA, 1987, J BIOL CHEM, V262, P17212	36	75	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24309	24313		10.1074/jbc.273.38.24309	http://dx.doi.org/10.1074/jbc.273.38.24309			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733716	hybrid			2022-12-25	WOS:000076007300008
J	Patrick, GN; Zhou, PB; Kwon, YT; Howley, PM; Tsai, LH				Patrick, GN; Zhou, PB; Kwon, YT; Howley, PM; Tsai, LH			p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN-SPECIFIC ACTIVATOR; PROTEIN-KINASE; REGULATORY SUBUNIT; MICROBIAL METABOLITE; NEUROBLASTOMA-CELLS; CRYSTAL-STRUCTURE; NERVOUS-SYSTEM; INHIBITION; EXPRESSION; DIFFERENTIATION	Cyclin-dependent kinase 5 (Cdk5) was originally isolated by its close homology to the human CDC2 gene, which is a key regulator of cell cycle progression. However, unlike other Cdks, the activity of Cdk5 is required in post-mitotic neurons. The neuronal-specific p35 protein, which shares no homology to cyclins, was identified by virtue of its association and activation of Cdk5, Gene targeting studies in mice have shown that the p35/Cdk5 kinase is required for the proper neuronal migration and development of the mammalian cortex, We have investigated the regulation of the p35/Cdk5 kinase, Here we show that p35, the activator of Cdk5, is a short-lived protein with a half-life (t(1/2)) of 20 to 30 min. Specific proteasome inhibitors such as lactacystin greatly stabilize p35 in vivo, Ubiquitination of p35 can be readily demonstrated in vitro and in vivo. Inhibition of Cdk5 activity by a specific Cdk inhibitor, roscovitine, or by overexpression of a dominant negative mutant of Cdk5 increases the stability of p35 by 2- to 3-fold. Furthermore, phosphorylation mutants of p35 also stabilize p35 2- to 3-fold. Together, these observations demonstrate that the p35/Cdk5 kinase can be subject to rapid turnover in vivo and suggest that phosphorylation of p35 upon Cdk5 kinase activation plays a autoregulatory role in p35 degradation mediated by ubiquitin-mediated proteolysis.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Patrick, GN (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.	gpatrick@fas.harvard.edu		Howley, Peter/0000-0002-8668-9579	NCI NIH HHS [R01-CA 64888-3] Funding Source: Medline; NIGMS NIH HHS [GM53049] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053049] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Delalle I, 1997, J NEUROCYTOL, V26, P283, DOI 10.1023/A:1018500617374; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Lee KY, 1997, INT J BIOCHEM CELL B, V29, P951, DOI 10.1016/S1357-2725(97)00048-4; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Sheaff RJ, 1996, CHEM BIOL, V3, P869, DOI 10.1016/S1074-5521(96)90174-X; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Tomizawa K, 1996, NEUROSCIENCE, V74, P519, DOI 10.1016/0306-4522(96)00136-4; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	45	253	262	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24057	24064		10.1074/jbc.273.37.24057	http://dx.doi.org/10.1074/jbc.273.37.24057			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727024	hybrid			2022-12-25	WOS:000075893100065
J	Greenberg, JR; Phan, L; Gu, ZY; deSilva, A; Apolito, C; Sherman, F; Hinnebusch, AG; Goldfarb, DS				Greenberg, JR; Phan, L; Gu, ZY; deSilva, A; Apolito, C; Sherman, F; Hinnebusch, AG; Goldfarb, DS			Nip1p associates with 40 S ribosomes and the Prt1p subunit of eukaryotic initiation factor 3 and is required for efficient translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; INTACT YEAST-CELLS; STEM-LOOP MUTATION; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; RNA-BINDING; AMINOGLYCOSIDE ANTIBIOTICS; INTERNAL INITIATION; COMPLEX-FORMATION; SHUTTLE VECTORS	Nip1p is an essential Saccharomyces cerevisiae protein that was identified in a screen for temperature conditional (ts) mutants exhibiting defects in nuclear transport. New results indicate that Nip1p has a primary role in translation initiation. Polysome profiles indicate that cells depleted of Nip1p and nip1-1 cells are defective in translation initiation, a conclusion that is supported by a reduced rate of protein synthesis in Nip1p-depleted cells. Nip1p cosediments with free 40 S ribosomal subunits and polysomal preinitiation complexes, but not with free or elongating 80 S ribosomes or 60 S subunits. Nip1p can be isolated in an about 670-kDa complex containing polyhistidine-tagged Prt1p, a subunit of translation initiation factor 3, by binding to Ni2+-NTA-agarose beads in a manner completely dependent on the tagged form of Prt1p. The nip1-1 ts growth defect was suppressed by the deletion of the ribosomal protein, RPL46. Also, nip1-1 mutant cells are hypersensitive to paromomycin. These results suggest that Nip1p is a subunit of eukaryotic initiation factor 3 required for efficient translation initiation.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; NICHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA; Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Rochester	Goldfarb, DS (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	dasg@uhura.cc.rochester.edu			NIGMS NIH HHS [R01 GM12702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLROBYN JA, 1990, MOL CELL BIOL, V10, P6544, DOI 10.1128/MCB.10.12.6544; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; BENNE R, 1978, J BIOL CHEM, V253, P3078; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GU Z, 1995, THESIS U ROCHESTER R; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; HERSHEY JWB, 1996, POSTTRANSCRIPTIONAL; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; KANG HA, 1994, J BIOL CHEM, V269, P3934; KASPERAITIS MAM, 1995, FEBS LETT, V365, P47, DOI 10.1016/0014-5793(95)00427-B; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LEER RJ, 1985, NUCLEIC ACIDS RES, V13, P701, DOI 10.1093/nar/13.3.701; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; PALMER E, 1979, NATURE, V277, P148, DOI 10.1038/277148a0; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; PHAN L, 1998, IN PRESS MOL CELL BI, V18; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SHERMAN F, 1987, METHODS YEAST GENETI; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; SIKORSKI RS, 1989, GENETICS, V122, P19; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAKEM LP, 1990, GENETICS, V124, P515; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; Zanchin NIT, 1997, MOL CELL BIOL, V17, P5001, DOI 10.1128/MCB.17.9.5001; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	67	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23485	23494		10.1074/jbc.273.36.23485	http://dx.doi.org/10.1074/jbc.273.36.23485			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722586	Green Submitted, hybrid			2022-12-25	WOS:000075778100086
J	Juckett, M; Zheng, YH; Yuan, H; Pastor, T; Antholine, W; Weber, M; Vercellotti, G				Juckett, M; Zheng, YH; Yuan, H; Pastor, T; Antholine, W; Weber, M; Vercellotti, G			Heme and the endothelium - Effects of nitric oxide on catalytic iron and heme degradation by heme oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DEPENDENT FORMATION; ELEMENT-BINDING PROTEIN; FERRITIN MESSENGER-RNA; HUMAN SKIN FIBROBLASTS; RESPONSIVE-ELEMENT; OXIDATIVE STRESS; ACTIVATED MACROPHAGES; HYDROXYL RADICALS; REGULATORY FACTOR; CYTO-TOXICITY	We studied the effects of nitric oxide (NO) on the control of excess cellular heme and release of catalytically active iron. Endothelial cells (ECs) exposed to hemin followed by a NO donor have a ferritin content that is 16% that of cells exposed to hemin alone. Hemin-treated ECs experience a 3.5-fold rise in non-heme, catalytic iron 2 h later, but a hemin rechallenge 20 h later results in only a 24% increase. The addition of a NO donor after the first hemin exposure prevents this adaptive response, presumably due to effects on ferritin synthesis. NO donors were found to reduce iron release from hemin, while hemin accumulated in cells. A NO donor, in a dose-dependent fashion, inhibited heme oxygenase activity, measured by bilirubin production. Using low temperature EPR spectroscopy, heme oxygenase inhibition correlated with nitrosylation of free heme in microsomes, Nitrosylation of cellular heme prevented iron release, for while there was heme oxygenase-dependent release of iron in cells incubated with hemin for 24 h, the addition of a NO donor blocked iron release. This indicates that NO readily nitrosylates intracellular free heme and prevents its degradation by heme oxygenase. Nitrosylation of heme was found to reduce sensitization of cells to oxidative injury.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	Medical College of Wisconsin; Medical College of Wisconsin; University of Minnesota System; University of Minnesota Twin Cities	Juckett, M (corresponding author), Froedtert E, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.				NATIONAL CANCER INSTITUTE [K08CA068102] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NCI NIH HHS [CA68102] Funding Source: Medline; NCRR NIH HHS [RR01008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; BALLA G, 1991, LAB INVEST, V64, P648; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1995, AM J PHYSIOL-LUNG C, V268, pL321, DOI 10.1152/ajplung.1995.268.2.L321; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BASTIAN NR, 1994, J BIOL CHEM, V269, P5127; Berger TM, 1997, J BIOL CHEM, V272, P15656, DOI 10.1074/jbc.272.25.15656; CANTONI L, 1981, INT J BIOCHEM, V13, P823, DOI 10.1016/0020-711X(81)90102-6; DOCHERTY JC, 1984, ARCH BIOCHEM BIOPHYS, V235, P657, DOI 10.1016/0003-9861(84)90241-8; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; GORBUNOV NV, 1995, BIOCHEMISTRY-US, V34, P6689, DOI 10.1021/bi00020a014; Gorbunov NV, 1997, J BIOL CHEM, V272, P12328, DOI 10.1074/jbc.272.19.12328; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; GUTTERIDGE JMC, 1982, BIOCHEM J, V206, P605, DOI 10.1042/bj2060605; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P263, DOI 10.1042/bj1990263; Gutteridge JMC, 1996, BIOCHEM BIOPH RES CO, V229, P806, DOI 10.1006/bbrc.1996.1884; HAILE DJ, 1990, J BIOL CHEM, V265, P12786; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIBBS JB, 1984, BIOCHEM BIOPH RES CO, V123, P716, DOI 10.1016/0006-291X(84)90288-2; JUCKETT MB, 1995, AM J PATHOL, V147, P782; Juckett MB, 1996, FREE RADICAL BIO MED, V20, P63, DOI 10.1016/0891-5849(95)02024-1; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; KENNEDY MC, 1993, BIOCHEM BIOPH RES CO, V196, P632, DOI 10.1006/bbrc.1993.2296; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; KHATSENKO OG, 1993, P NATL ACAD SCI USA, V90, P11147, DOI 10.1073/pnas.90.23.11147; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; Kurata S, 1996, J BIOCHEM-TOKYO, V120, P49; KUROSS SA, 1988, BLOOD, V71, P876; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P674, DOI 10.1097/00005344-199504000-00023; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107, DOI 10.1152/ajpheart.1996.270.1.H107; MULSCH A, 1993, BIOCHEM BIOPH RES CO, V196, P1303, DOI 10.1006/bbrc.1993.2394; Mumby S, 1997, INTENS CARE MED, V23, P635, DOI 10.1007/s001340050386; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; PALLER MS, 1994, P NATL ACAD SCI USA, V91, P7002, DOI 10.1073/pnas.91.15.7002; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; Ponka P, 1997, BLOOD, V89, P1; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; Sergent O, 1997, HEPATOLOGY, V25, P122, DOI 10.1002/hep.510250123; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; Takahashi K, 1996, J NEUROCHEM, V67, P482; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WHARTON M, 1988, J IMMUNOL, V141, P1311; WILLIS D, 1995, BIOCHEM BIOPH RES CO, V214, P1152, DOI 10.1006/bbrc.1995.2406; Yee EL, 1996, AM J PHYSIOL-LUNG C, V271, pL512, DOI 10.1152/ajplung.1996.271.4.L512	56	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23388	23397		10.1074/jbc.273.36.23388	http://dx.doi.org/10.1074/jbc.273.36.23388			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722574	hybrid			2022-12-25	WOS:000075778100074
J	Kachel, K; Ren, JH; Collier, RJ; London, E				Kachel, K; Ren, JH; Collier, RJ; London, E			Identifying transmembrane states and defining the membrane insertion boundaries of hydrophobic helices in membrane-inserted diphtheria toxin T domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER DISTANCE MEASUREMENTS; CRYSTAL-STRUCTURE; REFINED STRUCTURE; COLICIN-A; FLUORESCENCE; CHANNELS; VESICLES; RESOLUTION; DEPENDENCE; RESIDUE	The membrane topography of proteins that convert between soluble and membrane-inserted states has proven a challenging problem. In particular, it has been difficult to define both whether a transmembrane orientation is achieved and what are the boundaries of membrane-inserted segments. In this report the fluorescence of bimane-labeled Cys residues and the binding of antibodies antibodies to BODIPY-labeled Cys residues are combined to define these features for helices THS and TH9 of the T domain of diphtheria toxin, Using a series of labeled residues the topography of these helices was examined in both conformations of membrane-inserted T domain identified previously (Wang, Y., Malenbaum, S. E., Kachel, K., Zhan, H., Collier, R. J., and London, E. (1997) J. Biol Chem, 272, 25091-25098). In the shallowly inserted conformation these helices are found to be aligned close to the cis surface of the bilayer all along their sequences. In contrast, in the more deeply inserted conformation most TH8 and TH9 residues examined located in a non-polar environment, with the boundaries of the membrane-inserted sequences close to residues 324 and 372-374 on the cia (insertion) side of the bilayer, It was also found that residues 348 and 349, which are in the loop connecting TH8 and TH9, reached the opposite trans side of the bilayer, but did not protrude fully into the aqueous environment. These boundaries suggest the membrane-inserted segments of TH8 and TH9 form transmembrane helices about 25 residues in length, and suggest that they are connected by a tight turn. It is concluded that this combination of fluorescent techniques can be combined to obtain transmembrane helix topography.	SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Harvard Medical School	London, E (corresponding author), SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.				NIAID NIH HHS [AI22021] Funding Source: Medline; NIGMS NIH HHS [GM31986] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022021, R37AI022021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell CE, 1997, BIOCHEMISTRY-US, V36, P481, DOI 10.1021/bi962214s; BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; CABIAUX V, 1994, MOL MICROBIOL, V11, P43, DOI 10.1111/j.1365-2958.1994.tb00288.x; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHUNG LA, 1992, BIOCHEMISTRY-US, V31, P6608, DOI 10.1021/bi00143a035; COLLIER RJ, 1982, ADP RIBOSYLATION REA, P573; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; Huynh PD, 1997, J GEN PHYSIOL, V110, P229, DOI 10.1085/jgp.110.3.229; KAISER R, 1998, IN PRESS BIOCH BIOPH; LADOKHIN AS, 1993, BIOCHEMISTRY-US, V32, P6951, DOI 10.1021/bi00078a020; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; LONDON E, 1998, MEMBRANE PROTEIN TRA, P201; MALENBAUM SE, 1998, IN PRESS J NATURAL T; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P45; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P29; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; MINDELL JA, 1992, BIOPHYS J, V62, P41, DOI 10.1016/S0006-3495(92)81772-1; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; SILVERMAN JA, 1994, J MEMBRANE BIOL, V137, P17; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Taylor KMP, 1996, BBA-BIOMEMBRANES, V1278, P35, DOI 10.1016/0005-2736(95)00195-6; TORTORELLA D, 1995, J BIOL CHEM, V270, P27446, DOI 10.1074/jbc.270.46.27446; Wang Y, 1997, J BIOL CHEM, V272, P25091, DOI 10.1074/jbc.272.40.25091; WEINER M, 1992, BIOPHYS J, V61, P437; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	31	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22950	22956		10.1074/jbc.273.36.22950	http://dx.doi.org/10.1074/jbc.273.36.22950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722516	hybrid			2022-12-25	WOS:000075778100016
J	Pham, PT; Olson, MW; McHenry, CS; Schaaper, RM				Pham, PT; Olson, MW; McHenry, CS; Schaaper, RM			The base substitution and frameshift fidelity of Escherichia coli DNA polymerase III holoenzyme in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; SPONTANEOUS MUTATION; MISMATCH REPAIR; NUCLEOTIDE MISINCORPORATION; REPLICATION FORK; EPSILON-SUBUNIT; BETA-SUBUNIT; MUTAGENESIS; EXONUCLEASE; COMPLEX	We have investigated the in vitro fidelity of Escherichia coli DNA polymerase III holoenzyme from a wildtype and a proofreading-impaired mutD5 strain. Exonuclease assays showed the mutD5 holoenzyme to have a 30-50-fold reduced 3'-->5'-exonuclease activity. Fidelity was assayed during gap-filling synthesis across the lacI(d) forward mutational target. The error rate for both enzymes was lowest at low dNTP concentrations (10-50 mu M) and highest at high dNTP concentration (1000 mu M) The mutD5 proofreading defect increased the error rate by only 3-5-fold. Both enzymes produced a high level of (-1)-frameshift mutations in addition to base substitutions. The base substitutions were mainly C-->T, G-->T, and G-->C, but cNTP pool imbalances suggested that these may reflect misincorporations opposite damaged template bases and that, instead, T-->C, G-->A, and C-->T transitions represent the normal polymerase III-mediated base base mispairs. The frequent (-1)-frameshift mutations do not result from direct slippage but may be generated via a mechanism involving "misincorporation plus slippage." Measurements of the fidelity of wild-type and mutD5 holoenzyme during M13 in vivo replication revealed significant differences between the in vivo and in vitro fidelity with regard to both the frequency of frameshift errors and the extent of proofreading.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Schaaper, RM (corresponding author), NIEHS, Mol Genet Lab, NIH, E3-01,POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	schaaper@niehs.nih.gov	Schaaper, Roel M/E-6680-2019	Schaaper, Roel M/0000-0003-1344-3196				BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; COX EC, 1982, GENETICS, V100, P7; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; FERSHT AR, 1983, J MOL BIOL, V165, P633, DOI 10.1016/S0022-2836(83)80271-X; Fijalkowska IJ, 1996, P NATL ACAD SCI USA, V93, P2856, DOI 10.1073/pnas.93.7.2856; FOWLER RG, 1992, MUTAT RES, V284, P307, DOI 10.1016/0027-5107(92)90015-T; Jonczyk P, 1998, J BACTERIOL, V180, P1563, DOI 10.1128/JB.180.6.1563-1566.1998; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1981, J BIOL CHEM, V256, P9883; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; Malia SA, 1996, BIOCHEMISTRY-US, V35, P4568, DOI 10.1021/bi9525132; MARUYAMA M, 1983, J MOL BIOL, V167, P757, DOI 10.1016/S0022-2836(83)80109-0; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Mo JY, 1996, J BIOL CHEM, V271, P18947, DOI 10.1074/jbc.271.31.18947; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; OBERFELDER R, 1987, J BIOL CHEM, V262, P4190; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pavlov YI, 1996, MUTAT RES-FUND MOL M, V357, P1, DOI 10.1016/0027-5107(96)00060-7; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; QUE BG, 1978, BIOCHEMISTRY-US, V17, P1603, DOI 10.1021/bi00602a004; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAAPER RM, 1991, GENETICS, V129, P317; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1985, GENE, V39, P181, DOI 10.1016/0378-1119(85)90312-9; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; SCHAAPER RM, 1992, J BACTERIOL, V174, P1974, DOI 10.1128/jb.174.6.1974-1982.1992; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SHIBUTANI S, 1993, CHEM RES TOXICOL, V6, P625, DOI 10.1021/tx00035a006; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	59	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23575	23584		10.1074/jbc.273.36.23575	http://dx.doi.org/10.1074/jbc.273.36.23575			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722597	hybrid			2022-12-25	WOS:000075778100097
J	Rafiq, I; Kennedy, HJ; Rutter, GA				Rafiq, I; Kennedy, HJ; Rutter, GA			Glucose-dependent translocation of insulin promoter factor-1 (IPF-1) between the nuclear periphery and the nucleoplasm of single MIN6 beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; KINASE; TRANSCRIPTION; ACTIVATION; INVOLVEMENT; BINDING	Using laser-scanning confocal microscopy, we have monitored glucose-induced changes in the subcellular localization of insulin promoter factor-1 (IPF-1) labeled with a c-myc epitope tag. This construct trans-activated the insulin promoter in single living MIN6-beta-cells as assessed by luciferase-based promoter analysis. IPF-1.c-myc expression also enhanced the response of the insulin promoter to elevations in extracellular glucose concentration. In the majority (148/235, 63%) of cells maintained at low (3 mM) extracellular glucose concentration, IPF-1.c-myc immunoreactivity was confined to the nuclear periphery. Incubation of cells at stimulatory (30 mM) glucose concentrations caused a rapid redistribution of the chimera to the nucleoplasm (775/958, 81% of cells). By contrast, the irrelevant transcription factor c-Fos, tagged with either c-myc or as a chimera with luciferase, was localized exclusively to the nucleoplasm irrespective of the glucose concentration. Furthermore, IPF-1 extended with the bulky (27 kDa) enhanced green fluorescent protein (EGFP) group was confined largely to the nucleoplasm at all glucose concentrations tested and did not support trans-activation of the insulin promoter by glucose. Movement of endogenous IPF-1 from the nuclear periphery to the nucleoplasm may therefore increase the trans-activational capacity of this factor in native beta-cells exposed to high extracellular glucose concentrations.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Rutter, GA (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.			Rutter, Guy/0000-0001-6360-0343	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HELM R, 1995, NATURE, V373, P663; JENSEN EV, 1991, NUCLEAR HORMONE RECE, P1; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; KENNEDY HJ, 1998, DIABETIC MED, V15, pS21; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MARIE S, 1993, J BIOL CHEM, V268, P23881; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Sambrook J., 2002, MOL CLONING LAB MANU; Sherf BA, 1994, PROMEGA NOTES, V49, P14; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, BIOCHEM BIOPH RES CO, V229, P746, DOI 10.1006/bbrc.1996.1875; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478	28	82	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23241	23247		10.1074/jbc.273.36.23241	http://dx.doi.org/10.1074/jbc.273.36.23241			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722555	hybrid			2022-12-25	WOS:000075778100055
J	Fomitcheva, J; Baker, ME; Anderson, E; Lee, GY; Aziz, N				Fomitcheva, J; Baker, ME; Anderson, E; Lee, GY; Aziz, N			Characterization of Ke 6, a new 17 beta-hydroxysteroid dehydrogenase, and its expression in gonadal tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; CYSTIC-DISEASE; CELLS; SEQUENCE; ENZYME; MOUSE; GENE; OXIDOREDUCTASE; CLONING	The abnormal regulation of the Ke 6 gene has been linked to the development of recessive polycystic kidney disease in the mouse. In this report, we have shown that Ke 6 is a 17 beta-hydroxysteroid dehydrogenase and can regulate the concentration of biologically active estrogens and androgens. The Ke 6 enzyme is preferentially an oxidative enzyme and inactivates estradiol, testosterone, and dihydrotestosterone. However, the enzyme has some reductive activity and can synthesize estradiol from estrone. We find that the Ke 6 gene is expressed within the ovaries and testes. The presence of Ke 6 protein within the cumulus cells surrounding the oocyte places it in a strategic location to control the level of steroids to which the egg is exposed. Previously, it had been shown that glucocorticoids can induce renal cysts in the neonatal rodent, only when given at a narrow time window of postnatal kidney development. We propose that the reduction in the level of Ke 6 enzyme, which occurs in the cpk, jck, and pcy mice, may lead to abnormal elevations in local level of sex steroids, which either directly or indirectly via abnormal glucocorticoid metabolism result in recessive renal cystic disease, a developmental disorder of the kidney.	Childrens Hosp, Div Nephrol, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92093 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California San Diego	Aziz, N (corresponding author), Childrens Hosp, Div Nephrol, Dept Med, 300 Longwood Ave,Enders 1251, Boston, MA 02115 USA.	naziz@alum.mit.edu	Baker, Michael/ABB-8508-2020	Baker, Michael/0000-0003-4387-3269				Andersson S, 1997, STEROIDS, V62, P143, DOI 10.1016/S0039-128X(96)00173-0; AVNER ED, 1984, EXPERIENTIA, V40, P489, DOI 10.1007/BF01952400; AZIZ N, 1993, MOL CELL BIOL, V13, P1847, DOI 10.1128/MCB.13.3.1847; AZIZ N, 1994, AM J PHYSIOL-RENAL, V267, pF791, DOI 10.1152/ajprenal.1994.267.5.F791; AZIZ N, 1995, J AM SOC NEPHROL, V6, P690; Aziz N, 1996, ENDOCRINOLOGY, V137, P5581, DOI 10.1210/en.137.12.5581; AZIZ N, 1996, J AM SOC NEPHROL, V7, P1743; Baker ME, 1996, BIOESSAYS, V18, P63, DOI 10.1002/bies.950180112; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BLOMQUIST CH, 1987, J CLIN ENDOCR METAB, V65, P647, DOI 10.1210/jcem-65-4-647; CROCKER JFS, 1976, AM J PATHOL, V82, P373; EDWARDS C, 1988, LANCET, P986; ERICKSON GF, 1985, ENDOCR REV, V6, P371, DOI 10.1210/edrv-6-3-371; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FILMER RB, 1973, AM J PATHOL, V72, P461; FITCH WM, 1967, SCIENCE, V214, P149; GEISSLER WM, 1994, NAT GENET, V7, P34, DOI 10.1038/ng0594-34; Janaswami PM, 1997, GENOMICS, V40, P101, DOI 10.1006/geno.1996.4567; Kikuti YY, 1997, GENOMICS, V42, P422, DOI 10.1006/geno.1997.4745; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee GY, 1998, BIOL REPROD, V58, P330, DOI 10.1095/biolreprod58.2.330; Leenders F, 1996, J BIOL CHEM, V271, P5438, DOI 10.1074/jbc.271.10.5438; LEENDERS F, 1994, EUR J BIOCHEM, V222, P221, DOI 10.1111/j.1432-1033.1994.tb18860.x; Li JM, 1997, P NATL ACAD SCI USA, V94, P3554, DOI 10.1073/pnas.94.8.3554; LOW SC, 1993, J ENDOCRINOL, V139, P27, DOI 10.1677/joe.0.1390027; LuuThe V, 1995, J STEROID BIOCHEM, V55, P581, DOI 10.1016/0960-0760(95)00209-X; MAXWELL MM, 1995, J BIOL CHEM, V270, P25213, DOI 10.1074/jbc.270.42.25213; MCDONALD ATJ, 1990, KIDNEY INT, V37, P901, DOI 10.1038/ki.1990.64; MOORE JB, 1992, EMBO J, V11, P1973, DOI 10.1002/j.1460-2075.1992.tb05251.x; OJEDA JL, 1986, NEPHRON, V42, P240, DOI 10.1159/000183674; OJEDA JL, 1981, EXPERIENTIA, V37, P894, DOI 10.1007/BF01985700; PEREY DYE, 1967, SCIENCE, V158, P494, DOI 10.1126/science.158.3800.494; Poutanen M, 1995, J STEROID BIOCHEM, V55, P525, DOI 10.1016/0960-0760(95)00201-4; POUTANEN M, 1993, ENDOCRINOLOGY, V133, P2639, DOI 10.1210/en.133.6.2639; PREMINGER GM, 1982, J UROLOGY, V127, P556, DOI 10.1016/S0022-5347(17)53911-7; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; SAWETAWAN C, 1994, MOL CELL ENDOCRINOL, V99, P161, DOI 10.1016/0303-7207(94)90004-3; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P202, DOI 10.1210/jcem-63-1-202; WELLING L, 1991, KIDNEY, V2, P1657; WHITEHOUSE RW, 1980, EXPERIENTIA, V36, P244, DOI 10.1007/BF01953758; WOO D, 1997, J AM SOC NEPHROL, V8, P385; WU L, 1993, J BIOL CHEM, V268, P12964; ZERRES K, 1994, NAT GENET, V7, P429, DOI 10.1038/ng0794-429; Zhang Y, 1996, J CLIN ENDOCR METAB, V81, P3594, DOI 10.1210/jc.81.10.3594	45	68	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22664	22671		10.1074/jbc.273.35.22664	http://dx.doi.org/10.1074/jbc.273.35.22664			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712896	hybrid			2022-12-25	WOS:000075616600072
J	Kampranis, SC; Maxwell, A				Kampranis, SC; Maxwell, A			The DNA gyrase-quinolone complex - ATP hydrolysis and the mechanism of DNA cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-PROTEIN; TOPOISOMERASE-II; NALIDIXIC-ACID; BINDING; INHIBITION; DRUGS; FRAGMENTS; ANTIBACTERIALS; RESISTANCE; MUTATIONS	Quinolone binding to the gyrase-DNA complex induces a conformational change that results in the blocking of supercoiling, Under these conditions gyrase is still capable of ATP hydrolysis which now proceeds through an alternative pathway involving two different conformations of the enzyme (Kampranis, S. C., and Maxwell, A. (1998) J. Biol. Chem, 269, 22606-22614), The kinetics of ATP hydrolysis via this pathway have been studied and found to differ from those of the reaction of the drug-free enzyme. The quinolone-characteristic ATPase rate is DNA-dependent and can be induced in the presence of DNA fragments as small as 20 base pairs. By observing the conversion of the ATPase rate to the quinolone characteristic rate, the formation and dissociation of the gyrase-DNA-quinolone complex can be monitored. Comparison of the time dependence of the conversion of the gyrase ATPase with that of DNA cleavage reveals that formation of the gyrase-DNA-quinolone complex does not correspond to the formation of cleaved DNA. Quinolone-induced DNA cleavage proceeds via a mechanism consisting of two cleavage events that is modulated in the presence of a nucleotide cofactor. We demonstrate that quinolone binding and drug-induced DNA cleavage are separate processes constituting two sequential steps in the mechanism of action of quinolones on DNA gyrase.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Maxwell, A (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.		Kampranis, Sotirios C/G-8374-2016	Kampranis, Sotirios C/0000-0001-6208-1684; Maxwell, Anthony/0000-0002-5756-6430				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; CABRAL MJH, 1997, NATURE, V388, P903; Cove ME, 1997, NUCLEIC ACIDS RES, V25, P2716, DOI 10.1093/nar/25.14.2716; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; DOBBS ST, 1992, NUCLEIC ACIDS RES, V20, P3567, DOI 10.1093/nar/20.14.3567; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Gmunder H, 1997, NUCLEIC ACIDS RES, V25, P604, DOI 10.1093/nar/25.3.604; HALLETT P, 1991, ANTIMICROB AGENTS CH, V35, P335, DOI 10.1128/AAC.35.2.335; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MAXWELL A, 1999, PROTOCOLS DNA TOPOIS, V1, P135; MAXWELL A, 1986, BIOMOLECULAR STEREOD, P137; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MORRISON A, 1980, J BIOL CHEM, V255, P2211; ODea MH, 1996, J BIOL CHEM, V271, P9723, DOI 10.1074/jbc.271.16.9723; ORPHANIDES G, 1994, NUCLEIC ACIDS RES, V22, P1567, DOI 10.1093/nar/22.9.1567; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Scheirer KE, 1997, J BIOL CHEM, V272, P27202, DOI 10.1074/jbc.272.43.27202; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SHEN LL, 1985, P NATL ACAD SCI USA, V82, P307, DOI 10.1073/pnas.82.2.307; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039; SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3879, DOI 10.1021/bi00435a038; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; TORNALETTI S, 1988, BIOCHIM BIOPHYS ACTA, V949, P279, DOI 10.1016/0167-4781(88)90153-4; TSE YC, 1980, J BIOL CHEM, V255, P5560; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; YOSHIDA H, 1993, ANTIMICROB AGENTS CH, V37, P839, DOI 10.1128/AAC.37.4.839; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	35	90	92	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22615	22626		10.1074/jbc.273.35.22615	http://dx.doi.org/10.1074/jbc.273.35.22615			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712890	hybrid			2022-12-25	WOS:000075616600066
J	Olmsted, VK; Awrey, DE; Koth, C; Shan, X; Morin, PE; Kazanis, S; Edwards, AM; Arrowsmith, CH				Olmsted, VK; Awrey, DE; Koth, C; Shan, X; Morin, PE; Kazanis, S; Edwards, AM; Arrowsmith, CH			Yeast transcript elongation factor (TFIIS), structure and function - I: NMR structural analysis of the minimal transcriptionally active region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEAR MAGNETIC-RESONANCE; BACKBONE DYNAMICS; CORRELATION SPECTROSCOPY; C-13-ENRICHED PROTEINS; ZINC-FINGER; N-15 NMR; DOMAIN; CLEAVAGE; SPECTRA	TFIIS is a general transcription elongation factor that helps arrested RNA polymerase II elongation complexes resume transcription. We have previously shown that yeast TFIIS (yTFIIS) comprises three structural domains (I-III). The three-dimensional structures of domain II and part of domain III have been previously reported, but neither domain can autonomously stimulate transcription elongation. Here we report the NMR structural analysis of residues 131-309 of yTPIIS which retains full activity and contains all of domains II and III. We confirm that the structure of domain II in the context of fully active yTFIIS is the same as that determined previously for a shorter construct. We have determined the structure of the C-terminal zinc ribbon domain of active yTFIIS and shown that it is similar to that reported for a shorter construct of human TFIIS, The region linking domain II with the zinc ribbon of domain III appears to be conformationally flexible and does not adopt a single defined tertiary structure. NMR analysis of inactive mutants of yTFIIS support a role for the linker region in interactions with the transcription elongation complex.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Banting & Best Dept Med Res, CH Best Inst, Toronto, ON M5G 1L6, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Arrowsmith, CH (corresponding author), Univ Toronto, Ontario Canc Inst, 500 Sherbourne St, Toronto, ON M5G 2M9, Canada.	carrow@oci.utoronto.ca		Koth, Christopher/0000-0003-3939-8856; Edwards, Aled/0000-0002-4782-6016; Arrowsmith, Cheryl/0000-0002-4971-3250				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CIPRESPALACIN G, 1995, BIOCHEMISTRY-US, V34, P15375, DOI 10.1021/bi00046a046; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; IKURA M, 1990, J AM CHEM SOC, V112, P90020; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P133; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MONTELIONE GT, 1992, J AM CHEM SOC, V114, P10974, DOI 10.1021/ja00053a051; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; Palmer Arthur G. Iii, 1993, Current Opinion in Biotechnology, V4, P385, DOI 10.1016/0958-1669(93)90002-E; PASCAL S, 1994, J MAGN RESON, V101, P197; PETERSON MG, 1991, NATURE, V354, P369; PLEVANI P, 1988, BIOCHIM BIOPHYS ACTA, V951, P268, DOI 10.1016/0167-4781(88)90096-6; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; REINES D, 1994, RAV S MOL C, V3, P263; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122; ZUIDERWEG ERP, 1985, BIOPOLYMERS, V24, P601, DOI 10.1002/bip.360240402	40	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22589	22594		10.1074/jbc.273.35.22589	http://dx.doi.org/10.1074/jbc.273.35.22589			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712887	hybrid			2022-12-25	WOS:000075616600063
J	Xia, Y; Tsai, AL; Berka, V; Zweier, JL				Xia, Y; Tsai, AL; Berka, V; Zweier, JL			Superoxide generation from endothelial nitric-oxide synthase - A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; ARGININE; PROTEIN; BINDING; INJURY; HEME	It has been previously shown that besides synthesizing nitric oxide (NO), neuronal and inducible NO synthase (NOS) generates superoxide (O-2(radical anion)) under conditions of L-arginine depletion. However, there is controversy regarding whether endothelial NOS (eNOS) can also produce O-2(radical anion). Moreover, the mechanism and control of this process are not fully understood. Therefore, we performed electron paramagnetic resonance spin-trapping experiments to directly measure and characterize the O-2(radical anion) generation from purified eNOS. With the spin trap 5,5-dimethyl-1-pyrroline-N-oxide (DMPO), prominent signals of O-2(radical anion) adduct, DMPO-OOH, were detected from eNOS in the absence of added tetrahydrobiopterin (BH4), and these were quenched by superoxide dismutase. This O-2(radical anion) formation required Ca2+/calmodulin and was blocked by the specific NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME) but not its non-inhibitory enantiomer D-NAME. A parallel process of Ca2+/calmodulin-dependent NADPH oxidation was observed which was also inhibited by L-NAME but not n-NAME. Pretreatment of the enzyme with the heme blockers cyanide or imidazole also prevented O-2(radical anion) generation. BH4 exerted dose-dependent inhibition of the O-2(radical anion) signals generated by eNOS. Conversely, in the absence of BH, L-arginine did not decrease this OX generation. Thus, eNOS can also catalyze OX formation, and this appears to occur primarily at the heme center of its oxygenase domain. O-2(radical anion) synthesis from eNOS requires Ca2+/calmodulin and is primarily regulated by BH, rather than L-arginine.	Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med,Div Cardiol,Mol & Cellular Biophys Labs, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; Univ Texas, Sch Med, Dept Internal Med, Div Hematol, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System	Zweier, JL (corresponding author), Johns Hopkins Asthma & Allergy Ctr, LA-14,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, P50HL052315, R29HL038324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52315, HL-38324] Funding Source: Medline; NIGMS NIH HHS [GM44911] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; POU S, 1992, J BIOL CHEM, V267, P24173; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Xia Y, 1996, J BIOL CHEM, V271, P10096, DOI 10.1074/jbc.271.17.10096; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954	25	562	573	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25804	25808		10.1074/jbc.273.40.25804	http://dx.doi.org/10.1074/jbc.273.40.25804			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748253	hybrid			2022-12-25	WOS:000076263100044
J	Malek, S; Huxford, T; Ghosh, G				Malek, S; Huxford, T; Ghosh, G			I kappa B alpha functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC RETENTION; C-REL; V-REL; DROSOPHILA; PHOSPHORYLATION; PROTEINS; P50; DEGRADATION; ACTIVATION; INHIBITION	We have determined the binding energies of complexes formed between I kappa B alpha and the wild type and mutational variants of three different Rel/NF-kappa B dimers, namely, the p50/p65 heterodimer and homodimers of p50 and p65. We show that although a common mode of interaction exists between the Rel/NF-kappa B dimers and I kappa B alpha, I kappa B alpha binds the NF-kappa B p50/p65 heterodimer with 60- and 27-fold higher affinity than the p50 and p65 homodimers, respectively. Each of the three flexibly linked segments of the rel homology region of Rel/NF-kappa B proteins (the nuclear localization sequence, the dimerization domain, and the amino-terminal DNA binding domain) is directly engaged in forming the protein/protein interface with the ankyrin repeats and the carboxyl-terminal acidic tail/PEST sequence of I kappa B alpha. In the cell, I kappa B alpha functions to retain NF-kappa B in the cytoplasm and inhibit its DNA binding activity. These properties are a result of the direct involvement of the nuclear localization sequences and of the DNA binding region of NF-kappa B in complex with I kappa B alpha. A model of the interactions in the complex is proposed based on our observations and the crystal structures of Rel/NF-kappa B dimers and the ankyrin domains of related proteins.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9600 Gilman Dr, La Jolla, CA 92093 USA.			Huxford, Tom/0000-0002-1939-7373; Malek, Shiva/0000-0002-9526-7968	NCI NIH HHS [I32 CA09523-13] Funding Source: Medline; NIGMS NIH HHS [2 T32 GM08326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008326] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bell S, 1996, MOL CELL BIOL, V16, P6477; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Govind S, 1996, MOL CELL BIOL, V16, P1103; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TATEI K, 1995, MOL CELL BIOL, V15, P3627; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	46	136	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25427	25435		10.1074/jbc.273.39.25427	http://dx.doi.org/10.1074/jbc.273.39.25427			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738011	hybrid			2022-12-25	WOS:000076085400061
J	Sanderson, RJ; Mosbaugh, DW				Sanderson, RJ; Mosbaugh, DW			Fidelity and mutational specificity of uracil-initiated base excision DNA repair synthesis in human glioblastoma cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLASE INHIBITOR PROTEIN; HUMAN APURINIC ENDONUCLEASE; POLYMERASE-BETA; ESCHERICHIA-COLI; HELA-CELLS; PURIFIED PROTEINS; MAMMALIAN-CELLS; BOVINE TESTIS; UNG GENE; NUCLEAR	The fidelity of DNA synthesis associated with uracil-initiated base excision repair was measured in human whole cell extracts. An M13mp2 lacZ alpha DNA-based reversion assay was developed to assess the error frequency of DNA repair synthesis at a site-specific uracil residue. All three possible base substitution errors were detected at the uracil target causing reversion of opal codon 14 in the Escherichia coli lacZ alpha gene. Using human glioblastoma U251 whole cell extracts, approximately 50% of the heteroduplex uracil-containing DNA substrate was completely repaired, as determined by the insensitivity of form I DNA reaction products to cleavage by a combined treatment of E. coli uracil-DNA glycosylase and endonuclease IV. The majority of repair occurred by the uracil-initiated base excision repair pathway, since the addition of the bacteriophage PBS2 uracil-DNA glycosylase inhibitor protein to extracts significantly blocked this process. In addition, the formation of repaired form I DNA molecules occurred concurrently with limited DNA synthesis, which was largely restricted to the HinfI DNA fragment initially containing the uracil residue and specific to the uracil-containing DNA strand. Based on the reversion frequency of repaired M13mp2 DNA, the fidelity of DNA repair synthesis at the target was determined to be about one misincorporated nucleotide per 1900 repaired uracil residues. The major class of base substitutions propagated transversion mutations, which were distributed almost equally between T to G and T to A changes in the template. A similar mutation frequency was also observed using whole cell extracts from human colon adenocarcinoma LoVo cells, suggesting that mismatch repair did not interfere with the fidelity measurements.	Oregon State Univ, Dept Agr Chem, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University	Mosbaugh, DW (corresponding author), Oregon State Univ, Dept Agr Chem, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BRANCH P, 1995, CANCER RES, V55, P2304; Caradonna S, 1996, EXP CELL RES, V222, P345, DOI 10.1006/excr.1996.0044; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; HUSAIN I, 1995, J BIOL CHEM, V270, P9683, DOI 10.1074/jbc.270.16.9683; IZUTA S, 1995, J BIOL CHEM, V270, P2595, DOI 10.1074/jbc.270.6.2595; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KOETSIER PA, 1993, BIOTECHNIQUES, V15, P260; Krokan HE, 1997, BIOCHEM J, V325, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; LONGLEY MJ, 1993, METHOD ENZYMOL, V218, P587; Lundquist AJ, 1997, J BIOL CHEM, V272, P21408, DOI 10.1074/jbc.272.34.21408; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P1743; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; MULLER SJ, 1993, J BIOL CHEM, V268, P1310; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, J BIOL CHEM, V269, P14367; WANG Z, 1989, J BIOL CHEM, V264, P1163; Wang ZG, 1997, J BIOL CHEM, V272, P24064, DOI 10.1074/jbc.272.38.24064; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022	60	34	35	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24822	24831		10.1074/jbc.273.38.24822	http://dx.doi.org/10.1074/jbc.273.38.24822			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733786	hybrid			2022-12-25	WOS:000076007300078
J	Tsuda, T; Kaya, S; Yokoyama, T; Hayashi, Y; Taniguchi, K				Tsuda, T; Kaya, S; Yokoyama, T; Hayashi, Y; Taniguchi, K			Half-site modification of Lys-480 of the Na+,K+-ATPase alpha-chain with pyridoxal 5 '-diphospho-5 '-adenosine reduces ATP-dependent phosphorylation stoichiometry from half to a quarter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; NA+/K+-ATPASE; CONFORMATIONAL-CHANGES; NA,K-ATPASE; BINDING; SODIUM; K+; IDENTIFICATION; ENZYME; ADP	Pig and dog kidney Na+,K+-ATPase preparations, irrespective of specific activity, showed similar to 0.5 mol of maximum phosphorylation/mol alpha-chain for ATP or acetyl phosphate (AcP) at steady state conditions. Pyridoxal 5'-diphospho-5'-adenosine (AP(2)PL)-treated pig kidney enzymes containing similar to 0.5 mol of AP(2)PL probe at Lys-480/ mol (Tsuda, T., Kaya, S., Funatsu, H., Hayashi, Y., and Taniguchi, K. (1998) J. Biochem. (Tokyo) 123, 169-174) showed a quarter-site phosphorylation by ATP and half-site phosphorylation from AcP. The addition of 10 mu M ATP to the Mg2+-Na+-bound AP(2)PL enzyme induced rapid quarter-site phosphorylation (47/s), followed by two different AP(2)PL fluorescence changes, a rapid decrease (29/s) and a slow increase (1.1/s). The addition of 1 mM AcP to the Mg2+-Na+-bound AP(2)PL enzyme induced a slow half-site phosphorylation (3/s), followed by a monophasic AP(2)PL fluorescence increase (1.2/s). After treatment of the AP(2)PL enzyme with fluorescein 5'-isothiocyanate to modify Lys-501 fully, the Mg2+-Na+-dependent phosphorylation capacity from ATP of the resulting AP(2)PL-fluorescein 5'-isothiocyanate enzyme was reduced to similar to 6% without significant changes in half-site phosphorylation capacity with respect to AcP, dynamic AP(2)PL fluorescence change by ATP and change by AcP. These data and others support the hypothesis that the functional membrane-bound Na+,K+-ATPase has tetrameric properties.	Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 060, Japan; Kyorin Univ, Sch Med, Dept Biochem, Mitaka, Tokyo 181, Japan	Hokkaido University; Kyorin University	Taniguchi, K (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 060, Japan.							ALBERS RW, 1976, ENZYMES BIOLOGICAL M, V3, P283; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; DZHANDZHUGAZYAN KN, 1985, SODIUM PUMP, P129; FROEHLICH JP, 1994, SODIUM PUMP, P441; Froehlich JP, 1997, ANN NY ACAD SCI, V834, P280, DOI 10.1111/j.1749-6632.1997.tb52259.x; GLYNN IM, 1985, SODIUM PUMP, P589; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hayashi Y, 1997, ANN NY ACAD SCI, V834, P19, DOI 10.1111/j.1749-6632.1997.tb52222.x; HINZ HR, 1990, J BIOL CHEM, V265, P10260; JENSEN J, 1992, BIOCHIM BIOPHYS ACTA, V1110, P81, DOI 10.1016/0005-2736(92)90297-Y; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KAYA SJ, 1994, J BIOL CHEM, V269, P7419; Liu GQ, 1996, FEBS LETT, V390, P323, DOI 10.1016/0014-5793(96)00687-4; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; MATSUI H, 1983, CURR TOP MEMBR TRANS, V19, P141; NAGAI M, 1986, J BIOL CHEM, V261, P3197; NAKAMURA Y, 1989, J BIOCHEM-TOKYO, V115, P454; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; NORBY JG, 1991, SOC GEN PHY, V46, P173; OTTOLENGHI P, 1985, SODIUM PUMP, P219; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PELUFFO RD, 1994, J BIOL CHEM, V269, P1051; Plesner IW, 1997, ANN NY ACAD SCI, V834, P412, DOI 10.1111/j.1749-6632.1997.tb52286.x; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; POST RL, 1972, J BIOL CHEM, V247, P6530; REPKE KRH, 1986, BIOCHIM BIOPHYS ACTA, V864, P195, DOI 10.1016/0304-4157(86)90011-0; ROBINSON JD, 1993, BIOCHIM BIOPHYS ACTA, V1154, P83, DOI 10.1016/0304-4157(93)90018-J; SARVAZYAN NA, 1995, J BIOL CHEM, V270, P26528, DOI 10.1074/jbc.270.44.26528; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHONER W, 1994, SODIUM PUMP, P332; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; TANIGUCHI K, 1984, J BIOL CHEM, V259, P5228; TANIGUCHI K, 1982, J BIOL CHEM, V257, P659; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; TANIMURA A, 1986, Journal of Experimental Pathology (New York), V2, P261; Thoenges D, 1997, J BIOL CHEM, V272, P16315, DOI 10.1074/jbc.272.26.16315; Tsuda T, 1998, J BIOCHEM, V123, P169; Tsuda T, 1998, J BIOL CHEM, V273, P24339, DOI 10.1074/jbc.273.38.24339; Tsuda T, 1997, ANN NY ACAD SCI, V834, P186, DOI 10.1111/j.1749-6632.1997.tb52250.x; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688	45	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24334	24338		10.1074/jbc.273.38.24334	http://dx.doi.org/10.1074/jbc.273.38.24334			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733720	hybrid			2022-12-25	WOS:000076007300012
J	Mandrup, S; Sorensen, RV; Helledie, T; Nohr, J; Baldursson, T; Gram, C; Knudsen, J; Kristiansen, K				Mandrup, S; Sorensen, RV; Helledie, T; Nohr, J; Baldursson, T; Gram, C; Knudsen, J; Kristiansen, K			Inhibition of 3T3-L1 adipocyte differentiation by expression of acyl-CoA-binding protein antisense RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; PEROXISOME PROLIFERATOR; FATTY-ACIDS; ADIPOSE CONVERSION; PPAR-GAMMA; CELLS; ADIPOGENESIS; METABOLISM; INDUCTION; INVOLVEMENT	Several lines of evidence have recently underscored the significance of fatty acids or fatty acid-derived metabolites as signaling molecules in adipocyte differentiation. The acyl-CoA-binding protein (ACBP), which functions as an intracellular acyl-CoA pool former and transporter, is induced during adipocyte differentiation. in this report we describe the effects of expression of high levels of ACBP antisense RNA on the differentiation of 3T3-L1 cells. Pools of 3T3-L1 cells transfected with vectors expressing ACBP antisense RNA showed significantly less Lipid accumulation as compared with cells transfected with the control vector. When individual clones were analyzed the degree of differentiation at day 10 was inversely correlated with the level of ACBP antisense RNA expression at day 0, Furthermore, in the clones with the highest levels of ACBP antisense expression, the induction of expression of the adipogenic transcription factors peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding protein alpha as well as several adipocyte-specific genes was significantly delayed and reduced. The adipogenic potential of antisense-expressing cells was partially restored by transfection with a vector expressing high levels of ACBP. Taken together, these results are strong evidence that inhibition of differentiation is causally related to the decreased expression of ACBP, indicating that ACBP plays an important role during adipocyte differentiation.	Odense Univ, Dept Mol Biol, DK-5230 Odense M, Denmark; Odense Univ, Inst Biochem, DK-5230 Odense, Denmark	University of Southern Denmark; University of Southern Denmark	Mandrup, S (corresponding author), Odense Univ, Dept Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.		Kristiansen, Karsten/J-5148-2014; Mandrup, Susanne/B-6693-2008	Kristiansen, Karsten/0000-0002-6024-0917; Mandrup, Susanne/0000-0002-0961-5787				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; AMRI EZ, 1994, J LIPID RES, V35, P930; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; BASS NM, 1993, MOL CELL BIOCHEM, V123, P191, DOI 10.1007/BF01076492; Brandes R, 1995, BIOCHEM PHARMACOL, V50, P1949, DOI 10.1016/0006-2952(95)02082-9; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; Faergeman NJ, 1997, BIOCHEM J, V323, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; HANSEN HO, 1991, BIOCHEM J, V277, P341, DOI 10.1042/bj2770341; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; JENSEN TG, 1992, BIOCHIM BIOPHYS ACTA, V1180, P65, DOI 10.1016/0925-4439(92)90028-L; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLYDE BJ, 1979, J LIPID RES, V20, P705; KNUDSEN J, 1994, BIOCHEM J, V302, P479, DOI 10.1042/bj3020479; KNUDSEN J, 1993, MOL CELL BIOCHEM, V123, P129, DOI 10.1007/BF01076484; KURIHARCUCH W, 1983, J CELL PHYSIOL, V114, P39, DOI 10.1002/jcp.1041140107; KURIHARCUCH W, 1978, P NATL ACAD SCI USA, V75, P6107, DOI 10.1073/pnas.75.12.6107; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; OWENS GP, 1989, MOL BRAIN RES, V6, P101, DOI 10.1016/0169-328X(89)90043-0; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; Schjerling CK, 1996, J BIOL CHEM, V271, P22514, DOI 10.1074/jbc.271.37.22514; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SHILLABEER G, 1994, J LIPID RES, V35, P592; SHILLABEER G, 1989, J CLIN INVEST, V84, P381, DOI 10.1172/JCI114177; TEBOUL L, 1995, J BIOL CHEM, V270, P28183, DOI 10.1074/jbc.270.47.28183; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; Xue JC, 1996, MOL CELL BIOL, V16, P1567	44	51	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23897	23903		10.1074/jbc.273.37.23897	http://dx.doi.org/10.1074/jbc.273.37.23897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727003	hybrid			2022-12-25	WOS:000075893100044
J	McCarthy, JV; Dixit, VM				McCarthy, JV; Dixit, VM			Apoptosis induced by Drosophila Reaper and Grim in a human system - Attenuation by inhibitor of apoptosis proteins (cIAPs)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; BACULOVIRUS IAP; MAMMALIAN-CELLS; GENE; PROTEASES; FAMILY; P35; EXPRESSION	Previous genetic studies have established Reaper and Grim as central regulators of apoptosis in Drosophila melanogaster. Reaper and Grim induce extensive apoptosis in Drosophila, yet share no homology to known vertebrate proteins. In this study, we show for the first time that ectopic expression of Reaper or Grim induced substantial apoptosis in mammalian cells. Reaper- or Grim-induced apoptosis was inhibited by a broad range of caspase inhibitors and by human inhibitor of apoptosis proteins cIAP1 and cIAP2. Additionally, in vivo binding studies demonstrated that both Reaper and Grim physically interacted with human IAPs through a homologous 15-amino acid N-terminal segment. Deletion of this segment from either Reaper or Grim abolished binding to cIAPs. In vitro binding experiments indicated that Reaper and Grim bound specifically to the BIR domain-containing region of cIAPs as deletion of this region resulted in loss of binding, The physical interaction was further confirmed by immunolocalization. When co-expressed, Reaper or Grim co-localized with cIAP1. However, deletion of the N-terminal 15 amino acids of Reaper or Grim abolished co-localization with cIAP1, suggesting that this homologous region can serve as a protein-protein interacting domain in regulating cell death, Moreover, by virtue of this interaction, we demonstrate that cIAPs can regulate Reaper and Grim by abrogating their ability to activate caspases and thereby inhibit apoptosis. This is the first function attributed to this 15-amino acid N-terminal domain that is the only region having significant homology between these Drosophila death inducers.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,Bldg 10,Room 290, S San Francisco, CA 94080 USA.		dixit, vishva m/A-4496-2012; mccarthy, justin/AAG-7550-2019	dixit, vishva m/0000-0001-6983-0326; mccarthy, justin/0000-0002-2667-7365				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEM RJ, 1994, APOPTOSIS, V2, P89; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VUICI D, 1997, P NATL ACAD SCI USA, V94, P10183; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wyllie A H, 1980, Int Rev Cytol, V68, P251	35	86	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24009	24015		10.1074/jbc.273.37.24009	http://dx.doi.org/10.1074/jbc.273.37.24009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727017	hybrid			2022-12-25	WOS:000075893100058
J	Bartkova, J; Lukas, J; Strauss, M; Bartek, J				Bartkova, J; Lukas, J; Strauss, M; Bartek, J			Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation	ONCOGENE			English	Article						cell cycle; cyclin D3; cell and tissue differentiation; G1/S transition	CELL-CYCLE; RETINOBLASTOMA-PROTEIN; DEPENDENT KINASES; D1 PROTEIN; PHASE PROGRESSION; EXPRESSION; G(1); GENE; FIBROBLASTS; LINES	The mammalian D-type cyclins DI, D2, and D3 activate the cyclin-dependent kinases CDK4 and CDK6 in G1 and thereby promote the cell's commitment to enter S phase. To elucidate the extent of functional overlap among the D-type cyclins, we have examined several aspects of the least characterized member of this subfamily of G1 cyclin proteins, cyclin D3. Microinjection of cyclin D3-neutralizing antibody inhibited G1/S transition in human (IMR-90) and rat (R12) diploid fibroblasts, indicating that analogous to cyclins D1 and D2, cyclin D3 is essential for timely progression through Gf. In contrast to cyclins D1 and D2, cyclin D3 was (i) ubiquitously expressed among a panel of 70 human cultured cell types; (ii) strongly upregulated upon induction of HL-60 leukaemia cells to differentiate; and (iii) accumulated to high levels in a wide range of quiescent cell types in mouse and human differentiated tissues. Complementary analyses of human biopsies and mouse tissues at different stages of foetal and postnatal development revealed lineage-dependent transient or long-term accumulation of the cyclin D3 protein, correlating with initiation/establishment or maintenance of the mature phenotypes, respectively. Our data support the notion that the biological roles of the individual D-type cyclins are not fully redundant, and suggest a possible dual role for cyclin D3 in cell proliferation and induction and/or maintenance of terminal differentiation.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Humboldt Univ, Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Danish Cancer Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; COLLINS SJ, 1987, BLOOD, V70, P1233; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KIESS M, 1995, ONCOGENE, V10, P159; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LOVEC H, 1994, ONCOGENE, V9, P322; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MURAO S, 1994, CELL BIOL LAB HDB, P207; PALMERO I, 1993, ONCOGENE, V8, P1049; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pokrovskaja K, 1996, CELL GROWTH DIFFER, V7, P1723; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Savatier P, 1996, ONCOGENE, V12, P309; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sun W, 1996, MOL REPROD DEV, V43, P414, DOI 10.1002/(SICI)1098-2795(199604)43:4<414::AID-MRD2>3.0.CO;2-S; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TAM SW, 1994, ONCOGENE, V9, P2663; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248	50	171	174	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1027	1037		10.1038/sj.onc.1202016	http://dx.doi.org/10.1038/sj.onc.1202016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747882				2022-12-25	WOS:000075560900011
J	Fu, YB; Ballicora, MA; Leykam, JF; Preiss, J				Fu, YB; Ballicora, MA; Leykam, JF; Preiss, J			Mechanism of reductive activation of potato tuber ADP-glucose pyrophosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADPGLUCOSE PYROPHOSPHORYLASE; CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; BACTERIAL GLYCOGEN; SUBUNIT STRUCTURE; BIOSYNTHESIS; EXPRESSION; MODULATION; PROTEINS; ENZYMES	The potato tuber (Solanum tuberosum L.) ADP-glucose pyrophosphorylase activity is activated by a incubation with ADP-glucose and dithiothreitol or by ATP, glucose-1-phosphate, Ca2+, and dithiothreitol. The activation was accompanied by the appearance of new sulfhydryl groups as determined with 5,5'-dithiobis(2-nitrobenzoic acid). By analyzing the activated and nonactivated enzymes on SDS-polyacrylamide gel electrophoresis under nonreducing conditions, it was found that an intermolecular disulfide bridge between the small subunits of the potato tuber enzyme was reduced during the activation. Further experiments showed that the activation was mediated via a slow reduction and subsequent rapid conformational change induced by ADP-glucose, The activation process could be reversed by oxidation with 5,5'-dithiobis(2-nitrobenzoic acid). Incubation with ADP-glucose and dithiothreitol could reactivate the oxidized enzyme. Chemical modification experiments with [C-14]iodoacetic acid and 4-vinylpyridine determined that the intermolecular disulfide bridge was located between Cys(12) of the small subunits of the potato tuber enzyme. Mutation of Cys(12) in the small subunit into either Ala or Ser eliminated the requirement of DTT on the activation and prevented the formation of the intermolecular disulfide of the potato tuber enzyme, The mutants had instantaneous activation rates as the wild-type in the reduced state. A two-step activation model is proposed.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Preiss, J (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	preiss@pilot.msu.edu		Ballicora, Miguel/0000-0002-5324-0724				AUSUBEL MF, 1997, CURRENT PROTOCOLS MO; BALLICORA MA, 1994, EUR J BIOCHEM, V222, P467, DOI 10.1111/j.1432-1033.1994.tb18887.x; BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; Fu YB, 1998, PLANT PHYSIOL, V117, P989, DOI 10.1104/pp.117.3.989; GHOSH HP, 1966, J BIOL CHEM, V241, P4491; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HAUGEN TH, 1979, J BIOL CHEM, V254, P127; HERTIG CM, 1983, J BIOL CHEM, V258, P984; IGLESIAS AA, 1993, J BIOL CHEM, V268, P1081; KLECZKOWSKI LA, 1993, J BIOL CHEM, V268, P6228; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE PROT, P77; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; NAKATA PA, 1994, J BIOL CHEM, V269, P30798; NAKATA PA, 1991, PLANT MOL BIOL, V17, P1089, DOI 10.1007/BF00037149; OKITA TW, 1990, PLANT PHYSIOL, V93, P785, DOI 10.1104/pp.93.2.785; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; PAULE MR, 1971, J BIOL CHEM, V246, P4602; PLAXTON WC, 1987, PLANT PHYSIOL, V83, P105, DOI 10.1104/pp.83.1.105; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; PREISS J, 1966, BIOCHEMISTRY-US, V5, P264; PREISS J, 1989, ADV MICROB PHYSIOL, V30, P183; Preiss J., 1996, PHOTOASSIMILATE DIST, V3, p63?96; Preiss J., 1988, BIOCH PLANTS, V14., P181; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; SCHEIBE R, 1991, PLANT PHYSIOL, V96, P1, DOI 10.1104/pp.96.1.1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; SOWOKINOS JR, 1982, PLANT PHYSIOL, V69, P1459, DOI 10.1104/pp.69.6.1459; SOWOKINOS JR, 1981, PLANT PHYSIOL, V68, P924, DOI 10.1104/pp.68.4.924; STONE KL, 1989, PRACTICAL GUIDE PROT, P423; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	33	108	114	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25045	25052		10.1074/jbc.273.39.25045	http://dx.doi.org/10.1074/jbc.273.39.25045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737961	hybrid			2022-12-25	WOS:000076085400011
J	Sato, M; Hresko, R; Mueckler, M				Sato, M; Hresko, R; Mueckler, M			Testing the charge difference hypothesis for the assembly of a eucaryotic multispanning membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER; SIGNAL SEQUENCE; ESCHERICHIA-COLI; ORIENTATION; INSERTION; RESIDUES; TOPOLOGY; GLUT-1	The Glut1 glucose transporter is a glycoprotein whose membrane topology has been verified by a number of experimental observations, all of which are consistent with a 12-transmembrane helix model originally based on hydrophobicity analysis. We used Glut1 as a model multispanning membrane protein to test the Charge Difference Hypothesis (Hartmann, E., Rapoport, T. A., and Lodish, H. F. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 5786-5790), which asserts that the topology of a eucaryotic multispanning membrane protein is determined solely by the amino acid charge difference across the first transmembrane segment. The charge difference across the first transmembrane segment of Glut1 was progressively inverted in two independent series of mutants, one series in which only the number of positively charged amino acid residues in the two flanking domains was altered and the other in which only the number of negatively charged residues in the two flanking domains was changed. The results indicate that the charge difference across the first transmembrane segment does affect the topology of the protein, but that contrary to the hypothesis, it only dictates the orientation of the first transmembrane segment and the disposition of the amino terminus and the first linker domain. Charge inversion resulted in the formation of aberrant molecules in which either the first or second transmembrane segment failed to insert into the membrane. The topology of downstream regions of Glut1 was unaffected by charge inversion across the first transmembrane segment, indicating that downstream sequences are important in determining the local topological disposition of the molecule.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012					ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; BELTZER JP, 1991, J BIOL CHEM, V266, P973; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; von Heijne G, 1994, Subcell Biochem, V22, P1; vonHeijne G, 1997, MOL MICROBIOL, V24, P249, DOI 10.1046/j.1365-2958.1997.3351702.x; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8	20	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25203	25208		10.1074/jbc.273.39.25203	http://dx.doi.org/10.1074/jbc.273.39.25203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737982	hybrid			2022-12-25	WOS:000076085400032
J	Vo, L; Lee, S; Marcinko, MC; Holmes, EH; Macher, BA				Vo, L; Lee, S; Marcinko, MC; Holmes, EH; Macher, BA			Human alpha 1,3/4-fucosyltransferases - II. A single amino acid at the COOH terminus of FucT III and V alters their kinetic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCOSYL-TRANSFERASE GENES; BLOOD-GROUP-B; MOLECULAR-CLONING; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; NEGATIVE INDIVIDUALS; DETERMINES EXPRESSION; ACCEPTOR SPECIFICITY; SELECTIN LIGAND	An analysis of the acceptor substrate specificity of domain swap mutants of human alpha 1,3/4-fucosyltransferases (FucTs) III and V has been carried out. The results demonstrate that changing Asp(336) of FucT III to Ala (as in FucT V) produced a protein (III/V-1) with a reduced activity with a variety of accepters. An analysis of the kinetic properties of FucT III and the III/V-1 mutant demonstrated that III/V-1 had a 40-fold reduction in its affinity for the H-type 1 acceptor substrate (Fuc alpha 1, 2Gal beta 1,3GlcNAc) and 4-fold reduction in its affinity for GDP-fucose when compared with FucT III. Further, the overall catalytic efficiency of III/V-1 was similar to 100-fold lower than that of FucT III with an H-type 1 acceptor substrate. The complementary domain swap resulting from the change of Ala(349) of FucT V to Asp (V/III1) produced a FucT that had higher enzyme activity with a range of acceptor substrates and had a higher affinity for an H-type 2 acceptor substrate (Fuc alpha 1,2Gal beta 1,4GlcNAc) with an 8-fold higher overall catalytic efficiency than that of FucT V. No significant change occurred in the K-m for GDP-fucose for this protein when compared with FucT V. Kinetic parameters of two other FucT domain swaps (III8/V and V-8/III), resulting in proteins that differed from FucT III and V at the NH, terminus of their catalytic domain, were not significantly different from those of the parental enzymes when H-type 1 and H-type 2 acceptor substrates were utilized. Thus, substitution of an acidic amino acid for a nonpolar amino acid (i.e. Asp versus Ala) at the COOH terminus of FucTs produces an enzyme with enhanced enzyme activities. These results, together with the results presented in the accompanying papers (Nguyen, A.T. Holmes, E. H., Whitaker, J. M., Ho, S., Shetterly, S., and Macher, B. A. (1998) J. Biol. Chem. 273, 25244-25249; Sherwood, A. L., Nguyen, A. T., Whitaker, J. M., Macher, B. A., and Holmes, E. H (1998) J. Biol. Chem. 273, 25256-25260), provide new insights into the structure/function relationships of human alpha 1,3/4-FucT enzymes.	NW Hosp, Pacific NW Canc Fdn, Seattle, WA 98125 USA; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	California State University System; San Francisco State University	Holmes, EH (corresponding author), NW Hosp, Pacific NW Canc Fdn, 120 Northgate Plaza,Suite 218, Seattle, WA 98125 USA.	eholmes@nwbio.org			NATIONAL CANCER INSTITUTE [R01CA070740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM052588] Funding Source: NIH RePORTER; NCI NIH HHS [CA70740] Funding Source: Medline; NCRR NIH HHS [P20 RR11805] Funding Source: Medline; NIGMS NIH HHS [GM52588] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8925, DOI 10.1021/bi952194e; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; Elmgren A, 1997, J BIOL CHEM, V272, P21994, DOI 10.1074/jbc.272.35.21994; KODA Y, 1993, BLOOD, V82, P2915; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nguyen AT, 1998, J BIOL CHEM, V273, P25244, DOI 10.1074/jbc.273.39.25244; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Seto NOL, 1997, J BIOL CHEM, V272, P14133, DOI 10.1074/jbc.272.22.14133; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; YADAV SP, 1991, J BIOL CHEM, V266, P698; Yamamoto F, 1996, J BIOL CHEM, V271, P10515, DOI 10.1074/jbc.271.18.10515; ZU HY, 1995, BIOCHEM BIOPH RES CO, V206, P362, DOI 10.1006/bbrc.1995.1050	31	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25250	25255		10.1074/jbc.273.39.25250	http://dx.doi.org/10.1074/jbc.273.39.25250			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737989	hybrid			2022-12-25	WOS:000076085400039
J	Nickel, V; Prehm, S; Lansing, M; Mausolf, A; Podbielski, A; Deutscher, J; Prehm, P				Nickel, V; Prehm, S; Lansing, M; Mausolf, A; Podbielski, A; Deutscher, J; Prehm, P			An ectoprotein kinase of group C streptococci binds hyaluronan and regulates capsule formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; EXTRACELLULAR ATP; ACID CAPSULE; M-PROTEIN; SYNTHASE; CELL; PYOGENES; SURFACE; PHOSPHORYLATION; GENE	A 56-kDa protein had been isolated and cloned from protoplast membranes of group C streptococci that had erroneously been identified as hyaluronan synthase, The function of this protein was reexamined. When streptococcal membranes were separated on an SDS-polyacrylamide,bel and renatured, a 56-kDa protein was detected that had kinase activity for a casein substrate. When this recombinant protein was expressed in Escherichia coli and incubated in the presence of [P-32]ATP, it was responsible for phosphorylation of two proteins with 30 and 56 kDa that were not present in the control lysate, The 56-kDa protein was specifically phosphorylated in an immunoprecipitate of a detergent extract of the recombinant E. coli lysate with antibodies against the 56-kDa protein, indicating that it was autophosphorylated. The E. coli lysate containing the recombinant protein could bind hyaluronan, and hyaluronan binding was abolished by the addition of ATP, Kinetic analysis of hyaluronan synthesis and release from isolated protoplast membranes indicated that phosphorylation by ATP stimulated hyaluronan release and synthesis. Incubation of membranes with antibodies to the 56-kDa protein increased hyaluronan release. The addition of [P-32]ATP to intact streptococci led to rapid phosphorylation of two proteins, 56 and 75 Ir;Da each at threonine residues. This phosphorylation was neither observed with [P-32]phosphate nor in the presence of trypsin, indicating that the kinase was localized extracellularly. The addition of ATP to growing group C streptococci led to increased hyaluronan synthesis and release,However marl;ed differences were found between group A and group C streptococci, Antibodies against the 56-kDa protein from group C streptococci did not recognize proteins from group A strains, and a homologous DNA sequence could not be detected by polymerase chain reaction or Southern blotting, in addition, Group A streptococci did not retain a large hyaluronan capsule like group C strains. These results indicated that the 56-kDa protein is an ectoprotein kinase specific for group C streptococci that regulates hyaluronan capsule shedding by phosphorylation.	Inst Physiol Chem & Pathobiochem, D-48129 Munster, Germany; Inst Med Mikrobiol & Immunol, D-89081 Ulm, Germany; Inst Biol & Chim Prot, CNRS, F-9367 Lyon, France	Centre National de la Recherche Scientifique (CNRS)	Prehm, P (corresponding author), Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48129 Munster, Germany.	prehm@uni-muenster.de		Prehm, Peter/0000-0002-8063-311X				Apasov SG, 1996, J BIOL CHEM, V271, P25677, DOI 10.1074/jbc.271.41.25677; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Dale JB, 1996, INFECT IMMUN, V64, P1495, DOI 10.1128/IAI.64.5.1495-1501.1996; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; EHRLICH YH, 1990, ANN NY ACAD SCI, V603, P401; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; FRIEDBERG I, 1995, J BIOL CHEM, V270, P20560, DOI 10.1074/jbc.270.35.20560; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KUBLER D, 1982, J BIOL CHEM, V257, P322; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; Lukomski S, 1997, J CLIN INVEST, V99, P2574, DOI 10.1172/JCI119445; MAUSOLF A, 1990, BIOCHEM J, V267, P191, DOI 10.1042/bj2670191; Moses AE, 1997, INFECT IMMUN, V65, P64, DOI 10.1128/IAI.65.1.64-71.1997; PREHM P, 1986, BIOCHEM J, V235, P887, DOI 10.1042/bj2350887; PREHM S, 1995, J ANAT, V187, P271; Prehm S, 1996, PROTEIN EXPRES PURIF, V7, P343, DOI 10.1006/prep.1996.0051; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; SKUBITZ KM, 1991, J IMMUNOL, V147, P638; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; VANDERIJN I, 1983, J BACTERIOL, V156, P1059, DOI 10.1128/JB.156.3.1059-1065.1983; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WESSELS MR, 1994, P NATL ACAD SCI USA, V91, P12238, DOI 10.1073/pnas.91.25.12238; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	33	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23668	23673		10.1074/jbc.273.37.23668	http://dx.doi.org/10.1074/jbc.273.37.23668			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726971	hybrid			2022-12-25	WOS:000075893100012
J	Opitz, OG; Jenkins, TD; Rustgi, AK				Opitz, OG; Jenkins, TD; Rustgi, AK			Transcriptional regulation of the differentiation-linked human K4 promoter is dependent upon esophageal-specific nuclear factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K3 KERATIN GENE; TRANSGENIC MICE; EPIDERMOLYTIC HYPERKERATOSIS; INTERMEDIATE FILAMENTS; EPITHELIAL-CELLS; EXPRESSION; ELEMENT; PROTEIN; AP-1; MUTAGENESIS	The stratified squamous epithelium comprises actively proliferating basal cells that undergo a program of differentiation accompanied by morphological, biochemical, and genetic changes. The transcriptional regulatory signals and the genes that orchestrate this snitch from proliferation to differentiation can he studied through the keratin gene family. Givers the localization of keratin 4 (K4) to the early differentiated suprabasal compartment sand leaving previously demonstrated that targeted disruption of this gene in murine embryonic stem cells results in impairment of the normal differentiation program in esophageal and corneal epithelial cells, we studied the transcriptional regulation of the human K4 promoter. A panel of K4 promoter deletions were found in transient transfection assays to be predominantly active in esophageal and corneal cell lines. A critical cis-regulatory element resides between -163 and -140 bp and contains an inverted CACACCT motif. A site-directed mutated version of this motif within the K4 promoter renders it inactive, whereas the wild-type version is active in a heterologous promoter system. It specifically binds esophageal-specific zinc-dependent transcriptional factors. Our studies demonstrate that regulation of the human K4 promoter is in part mediated through tissue-specific transcriptional factors.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hematol Oncol Unit, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Rustgi, AK (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Jackson 904,50 Blossom St, Boston, MA 02114 USA.	rustgi@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053377] Funding Source: NIH RePORTER; NIDCR NIH HHS [1P01 DE12467-01A1] Funding Source: Medline; NIDDK NIH HHS [R01-DK53377, 5P30DK43357-08] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHAN Y, 1994, GENE DEV, V8, P2563; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; CHUNG DC, 1995, J BIOL CHEM, V270, P8829, DOI 10.1074/jbc.270.15.8829; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FUCHS E, 1994, J CELL BIOL, V125, P511, DOI 10.1083/jcb.125.3.511; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jenkins TD, 1997, J BIOL CHEM, V272, P24433, DOI 10.1074/jbc.272.39.24433; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LU B, 1994, J BIOL CHEM, V269, P7443; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; Nakagawa H, 1997, J BIOL CHEM, V272, P16688, DOI 10.1074/jbc.272.26.16688; Ness SL, 1998, J BIOL CHEM, V273, P23904, DOI 10.1074/jbc.273.37.23904; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; RUGG EL, 1995, NAT GENET, V11, P450, DOI 10.1038/ng1295-450; RUGG EL, 1994, GENE DEV, V8, P1563; SNAPE AM, 1991, DEVELOPMENT, V113, P283; SNAPE AM, 1990, DEVELOPMENT, V109, P157; TAKAHASHI H, 1995, HISTOPATHOLOGY, V26, P45, DOI 10.1111/j.1365-2559.1995.tb00619.x; TSENG H, 1994, J CELL BIOL, V126, P495, DOI 10.1083/jcb.126.2.495; TSENG H, 1992, P NATL ACAD SCI USA, V89, P10311, DOI 10.1073/pnas.89.21.10311; VANMUIJEN GNP, 1986, EXP CELL RES, V162, P97, DOI 10.1016/0014-4827(86)90429-5; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Wanner R, 1997, ARCH DERMATOL RES, V289, P705, DOI 10.1007/s004030050265; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WU RL, 1994, J BIOL CHEM, V269, P28450; WU RL, 1993, J CELL SCI, V105, P303	47	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23912	23921		10.1074/jbc.273.37.23912	http://dx.doi.org/10.1074/jbc.273.37.23912			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727005	hybrid			2022-12-25	WOS:000075893100046
J	Rehm, BHA; Kruger, N; Steinbuchel, A				Rehm, BHA; Kruger, N; Steinbuchel, A			A new metabolic link between fatty acid de novo synthesis and polyhydroxyalkanoic acid synthesis - The phaG gene from Pseudomonas putida KT2440 encodes a 3-hydroxyacyl-acyl carrier protein coenzyme A transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLY(3-HYDROXYALKANOATE) SYNTHESIS; BIODEGRADABLE POLYESTERS; FLUORESCENT PSEUDOMONADS; AERUGINOSA; PLASMID; DNA; BACTERIA; CLONING; IDENTIFICATION	To investigate the metabolic link between fatty acid de novo synthesis and polyhydroxyalkanoic acid (PHA) synthesis, we isolated mutants of Pseudomonas putida KT2440 deficient in this metabolic route. The gene phaG was cloned by phenotypic complementation of these mutants; it encoded a protein of 295 amino acids with a molecular mass of 33,876 Da, and the amino acid sequence exhibited 44% amino acid identity to the primary structure of the rhlA gene product, which is involved in the rhamnolipid biosynthesis in Pseudomonas aeruginosa PG201. S-1 nuclease protection assay identified the transcriptional start site 239 base pairs upstream of the putative translational start codon, Transcriptional induction of phaG was observed when gluconate was provided, and PHA synthesis occurred from this carbon source. No complementation of the rhlA mutant P. aeruginosa UO299-harboring plasmid pBHR81, expressing phaG gene under lac promoter control, was obtained. Heterologous expression of phaG in Pseudomonas oleovorans, which is not capable of PHA synthesis from gluconate, enabled PHA synthesis on gluconate as the carbon source, Native recombinant PhaG was purified by native polyacrylamide gel electrophoresis from P. oleovorans-harborinag plasmid pBHR81. It catalyzes the transfer of the acyl moiety from in vitro synthesized 3-hydroxydecanoyl-CoA to acyl carrier protein, indicating that PhaG exhibits a 3-hydroxyacyl-CoA-acyl carrier protein transferase activity.	Univ Munster, Inst Mikrobiol, D-48149 Munster, Germany	University of Munster	Steinbuchel, A (corresponding author), Univ Munster, Inst Mikrobiol, Corrensstr 3, D-48149 Munster, Germany.		Rehm, Bernd HA/B-3675-2011	Rehm, Bernd/0000-0003-3908-8903				ALDEA M, 1988, GENE, V65, P101, DOI 10.1016/0378-1119(88)90421-0; ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Boulton C.A., 1987, BIOSURFACTANTS BIOTE, P47; BRANDL H, 1988, APPL ENVIRON MICROB, V54, P1977, DOI 10.1128/AEM.54.8.1977-1982.1988; Burger M, 1966, METHODS ENZYMOLOGY, V588, P441; BURGER MM, 1963, J BIOL CHEM, V238, P2595; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dotson GD, 1998, J BACTERIOL, V180, P330, DOI 10.1128/JB.180.2.330-337.1998; Eggink G.W., 1992, FEMS MICROBIOL REV, V105, P759; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Heath RJ, 1998, J BACTERIOL, V180, P1425, DOI 10.1128/JB.180.6.1425-1430.1998; HUIJBERTS GNM, 1992, APPL ENVIRON MICROB, V58, P536, DOI 10.1128/AEM.58.2.536-544.1992; HUIJBERTS GNM, 1994, J BACTERIOL, V176, P1661, DOI 10.1128/jb.176.6.1661-1666.1994; HUISMAN GW, 1989, APPL ENVIRON MICROB, V55, P1949, DOI 10.1128/AEM.55.8.1949-1954.1989; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Kraak MN, 1997, J BACTERIOL, V179, P4985, DOI 10.1128/jb.179.16.4985-4991.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langenbach S, 1997, FEMS MICROBIOL LETT, V150, P303, DOI 10.1016/S0378-1097(97)00142-0; LENZ RW, 1990, NATO ADV SCI I E-APP, V186, P23; MILLER JH, 1972, EXPT MOL GENETICS, P125; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; OCHSNER UA, 1994, J BIOL CHEM, V269, P19787; OELMULLER U, 1990, J MICROBIOL METH, V11, P73, DOI 10.1016/0167-7012(90)90050-G; Qi QS, 1997, FEMS MICROBIOL LETT, V157, P155, DOI 10.1111/j.1574-6968.1997.tb12767.x; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; Rock C O, 1981, Methods Enzymol, V71 Pt C, P163; ROTHMEL RK, 1991, METHOD ENZYMOL, V204, P485; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEGEL HG, 1961, ARCH MIKROBIOL, V38, P209, DOI 10.1007/BF00422356; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; STEINBUCHEL A, 1992, FEMS MICROBIOL LETT, V103, P217, DOI 10.1016/0378-1097(92)90313-D; STEINBUCHEL A, 1995, FEMS MICROBIOL LETT, V128, P219, DOI 10.1016/0378-1097(95)00125-O; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; TIMM A, 1990, APPL ENVIRON MICROB, V56, P3360, DOI 10.1128/AEM.56.11.3360-3367.1990; TIMM A, 1992, EUR J BIOCHEM, V209, P15, DOI 10.1111/j.1432-1033.1992.tb17256.x; VANDERLEIJ FR, 1995, CAN J MICROBIOL, V41, P222, DOI 10.1139/m95-191; VERWOERT IIGS, 1994, FEBS LETT, V348, P311, DOI 10.1016/0014-5793(94)00630-X; VUORIO R, 1994, FEBS LETT, V337, P289, DOI 10.1016/0014-5793(94)80211-4; WEBER K, 1969, J BIOL CHEM, V244, P4406; WORSEY MJ, 1975, J BACTERIOL, V124, P7, DOI 10.1128/JB.124.1.7-13.1975	48	204	221	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24044	24051		10.1074/jbc.273.37.24044	http://dx.doi.org/10.1074/jbc.273.37.24044			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727022	hybrid, Green Published			2022-12-25	WOS:000075893100063
J	Blackman, MJ; Fujioka, H; Stafford, WHL; Sajid, M; Clough, B; Fleck, SL; Aikawa, M; Grainger, M; Hackett, F				Blackman, MJ; Fujioka, H; Stafford, WHL; Sajid, M; Clough, B; Fleck, SL; Aikawa, M; Grainger, M; Hackett, F			A subtilisin-like protein in secretory organelles of Plasmodium falciparum merozoites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXOPLASMA-GONDII; SURFACE PROTEIN-1; DENSE GRANULES; ERYTHROCYTE INVASION; SERINE PROTEASES; PARASITOPHOROUS VACUOLE; PROHORMONE CONVERTASES; MALARIAL PARASITES; CELL INVASION; KNOWLESI	In the vertebrate host, the malaria parasite invades and replicates asexually within circulating erythrocytes. Parasite proteolytic enzymes play an essential but poorly understood role in erythrocyte invasion. We have identified a Plasmodium falciparum gene, denoted pf-sub-1, encoding a member of the subtilisin-like serine protease family (subtilases). The pfsub-1 gene is ex pressed in asexual blood stages of P. falciparum, and the primary gene product (PfSUB-1) undergoes post-translational processing during secretory transport in a manner consistent with its being converted to a mature, enzymatically active form, as documented for other subtilases. In the invasive merozoite, the putative mature protease (p47) is concentrated in dense granules, which are secretory organelles located toward the apical end of the merozoite. At some point following merozoite release and completion of erythrocyte invasion, p47 is secreted from the parasite in a truncated, soluble form. The subcellular location and timing of secretion of p47 suggest that it is likely to play a role in erythrocyte invasion. PfSUB-1 is a new potential target for antimalarial drug development.	Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Tokai Univ, Inst Med Sci, Isehara, Kanagawa 25911, Japan	MRC National Institute for Medical Research; Case Western Reserve University; Tokai University	Blackman, MJ (corresponding author), Natl Inst Med Res, Div Parasitol, Mill Hill, London NW7 1AA, England.	mblackm@nimr.mrc.ac.uk		Clough, Barbara/0000-0002-3235-6170				ACHBAROU A, 1991, MOL BIOCHEM PARASIT, V47, P223, DOI 10.1016/0166-6851(91)90182-6; AIKAWA M, 1990, ADV PARASIT, V29, P151, DOI 10.1016/S0065-308X(08)60106-2; AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; AIKAWA M, 1990, EXP PARASITOL, V71, P326, DOI 10.1016/0014-4894(90)90037-D; ALLEN G, 1981, LAB TECHNIQUES BIOCH; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BANNISTER LH, 1975, PARASITOLOGY, V71, P483, DOI 10.1017/S0031182000047247; BANNISTER LH, 1986, PARASITOLOGY, V92, P291, DOI 10.1017/S0031182000064064; BANYAL HS, 1981, J PARASITOL, V67, P623, DOI 10.2307/3280435; BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C; BLACKMAN MJ, 1993, MOL BIOCHEM PARASIT, V62, P103, DOI 10.1016/0166-6851(93)90182-W; BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P35, DOI 10.1016/0166-6851(91)90128-S; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; Blackman MJ, 1996, EXP PARASITOL, V83, P229, DOI 10.1006/expr.1996.0069; BONNIN A, 1995, J EUKARYOT MICROBIOL, V42, P395, DOI 10.1111/j.1550-7408.1995.tb01601.x; BRAUNBRETON C, 1988, NATURE, V332, P457, DOI 10.1038/332457a0; BRAUNBRETON C, 1992, P NATIONAL ACADEMY S, V89, P9647; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; COWAN DA, 1987, FEMS MICROBIOL LETT, V43, P155; CULVENOR JG, 1991, INFECT IMMUN, V59, P1183, DOI 10.1128/IAI.59.3.1183-1187.1991; DEJKRIENGKRAIKHUL PN, 1983, Z PARASITENKD, V69, P313, DOI 10.1007/BF00927873; DLUZEWSKI AR, 1986, EXP PARASITOL, V62, P416, DOI 10.1016/0014-4894(86)90050-0; DUBREMETZ JF, 1993, PARASITOL RES, V79, P402, DOI 10.1007/BF00931830; DUTTA GP, 1981, INDIAN J EXP BIOL, V19, P9; DVORAK JA, 1975, SCIENCE, V187, P748, DOI 10.1126/science.803712; ENTZEROTH R, 1986, EUR J CELL BIOL, V41, P182; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HADLEY T, 1983, EXP PARASITOL, V55, P306, DOI 10.1016/0014-4894(83)90027-9; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Howard RF, 1995, MOL BIOCHEM PARASIT, V74, P43, DOI 10.1016/0166-6851(95)02481-6; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; MCPHERSON RA, 1993, MOL BIOCHEM PARASIT, V62, P233, DOI 10.1016/0166-6851(93)90112-B; MEANS GE, 1979, ARCH BIOCHEM BIOPHYS, V194, P526, DOI 10.1016/0003-9861(79)90647-7; MILLER LH, 1979, J EXP MED, V149, P172, DOI 10.1084/jem.149.1.172; OGUN SA, 1994, EXP PARASITOL, V79, P270, DOI 10.1006/expr.1994.1090; Powner D, 1997, BIOCHEM SOC T, V25, pS230, DOI 10.1042/bst025230s; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; ROSENTHAL PJ, 1987, J EXP MED, V166, P816, DOI 10.1084/jem.166.3.816; SADAK A, 1988, MOL BIOCHEM PARASIT, V29, P203, DOI 10.1016/0166-6851(88)90075-8; SAKANARI JA, 1989, P NATL ACAD SCI USA, V86, P4863, DOI 10.1073/pnas.86.13.4863; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SamYellowe TY, 1996, PARASITOL TODAY, V12, P308, DOI 10.1016/0169-4758(96)10030-2; Sarath G., 1996, PROTEOLYTIC ENZYMES, P25; SCHREVEL J, 1990, BLOOD CELLS, V16, P563; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SIBLEY LD, 1994, EXP PARASITOL, V79, P301, DOI 10.1006/expr.1994.1093; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SNOUNOU G, 1988, MOL BIOCHEM PARASIT, V28, P153, DOI 10.1016/0166-6851(88)90063-1; TORII M, 1989, INFECT IMMUN, V57, P3230, DOI 10.1128/IAI.57.10.3230-3233.1989; TRAGER W, 1992, INFECT IMMUN, V60, P4656, DOI 10.1128/IAI.60.11.4656-4661.1992; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; Volkov A, 1996, J MOL BIOL, V262, P595, DOI 10.1006/jmbi.1996.0538; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; 1997, NATURE S, V387, P1	66	101	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23398	23409		10.1074/jbc.273.36.23398	http://dx.doi.org/10.1074/jbc.273.36.23398			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722575	hybrid			2022-12-25	WOS:000075778100075
J	Daniels, MJ; Turner-Cavet, JS; Selkirk, R; Sun, HZ; Parkinson, JA; Sadler, PJ; Robinson, NJ				Daniels, MJ; Turner-Cavet, JS; Selkirk, R; Sun, HZ; Parkinson, JA; Sadler, PJ; Robinson, NJ			Coordination of Zn2+ (and Cd2+) by prokaryotic metallothionein - Involvement of His-imidazole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-BINDING PROPERTIES; ESCHERICHIA-COLI; EXPRESSED PROTEIN; ZINC-FINGER; DNA-BINDING; RECEPTOR; METALLOPROTEINS; SENSITIVITY; CADMIUM; DOMAIN	In mammalian metallothionein Zn2+ is exclusively coordinated to Cys-thiolate to form clusters in which the metal is thermodynamically stable but also kinetically labile, By contrast, little is known about coordination to prokaryotic metallothionein, SmtA, 3 nmol of Zn2+ nmol(-1) SmtA were displaced by 8 nmol of p-(hydroxymercuri)phenylsulfonate implicating eight of the nine Cys in the coordination of three metal ions. None of the Zn2+ associated with SmtA was accessible to 4-(2-pyridylazo)resorcinol prior to the addition of p-(hydroxymercuri)phenylsulfonate. An unusual feature of SmtA is the presence of three His residues, and we have investigated whether these contribute to metal coordination. Less Zn2+ was associated with purified SmtA(H40R/H49R/H55R), in which all three His residues were substituted with Arg, and approximately one equivalent of Zn2+ was immediately accessible to 4-(2-pyridylazo)resorcinol. Following incubation of SmtA with Cd-111, three Cd-111 resonances were detected, two in a range expected for CdS4 and the third indicative of either CdNS3 or CdN2S2 coordination. Two-dimensional TOCSY H-1 NMR and Cd-111-edited H-1 NMR showed two His residues bound to Cd-111, confirming CdN2S2 coordination. The pH of half-dissociation of Zn2+ increased from 4.05 for SmtA to 5.37 for SmtA(H40R/H49R/H55R), Equivalent values for single His mutants SmtA(H40R), SmtA(H49R), and SmtA(H55R) were 4.62, 4.48, and 3.81, respectively, revealing that conversion of His(40) or His(49) to Arg impairs Zn2+ binding at the CdN2S2 and CdS4 sites. Only approximately two equivalents of Zn2+ were associated with purified SmtA(H49R), The appearance of a fourth Cd-111 resonance at lower pH suggests that an alternative CdN2S2 site also exists.	Newcastle Univ, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	Newcastle University - UK; University of Edinburgh	Robinson, NJ (corresponding author), Newcastle Univ, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.robinson@newcastle.ac.uk	Robinson, Nigel J/J-6363-2012	Robinson, Nigel J/0000-0001-5586-1092; Cavet, Jennifer/0000-0001-5913-7157; Parkinson, John Andrew/0000-0003-4270-6135				BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bird AJ, 1998, J BIOL CHEM, V273, P21246, DOI 10.1074/jbc.273.33.21246; BOBSEIN BR, 1980, J AM CHEM SOC, V102, P2454, DOI 10.1021/ja00527a053; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; COLEMAN JE, 1993, METHOD ENZYMOL, V227, P16; GAN T, 1995, J BIOL CHEM, V270, P5339, DOI 10.1074/jbc.270.10.5339; GIEDROC DP, 1989, BIOCHEMISTRY-US, V28, P2410, DOI 10.1021/bi00432a011; HIGHAM DP, 1984, SCIENCE, V225, P1043, DOI 10.1126/science.225.4666.1043; HUNT JB, 1984, J BIOL CHEM, V259, P4793; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; KAGI JHR, 1961, J BIOL CHEM, V236, P2535; Li H, 1996, BIOCHEMISTRY-US, V35, P13929, DOI 10.1021/bi961401n; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; OLAFSON RW, 1988, BIOCHEM J, V251, P691, DOI 10.1042/bj2510691; PAN T, 1990, BIOCHEMISTRY-US, V29, P9218, DOI 10.1021/bi00491a016; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SHI JG, 1992, FEBS LETT, V303, P159, DOI 10.1016/0014-5793(92)80509-F; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; STONEHOUSE J, 1994, J MAGN RESON SER A, V107, P178, DOI 10.1006/jmra.1994.1066; THIELE DJ, 1987, METALLOTHIONEIN, V2, P423; TOMMEY AM, 1991, FEBS LETT, V292, P48, DOI 10.1016/0014-5793(91)80831-M; TSUJIKAWA K, 1991, FEBS LETT, V283, P239, DOI 10.1016/0014-5793(91)80597-V; TURNER JS, 1993, J BIOL CHEM, V268, P4494; YU W, 1994, J BIOL CHEM, V269, P21010; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; ZERBE O, 1994, J AM CHEM SOC, V116, P377, DOI 10.1021/ja00080a046	31	61	62	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22957	22961		10.1074/jbc.273.36.22957	http://dx.doi.org/10.1074/jbc.273.36.22957			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722517	hybrid			2022-12-25	WOS:000075778100017
J	Kim, L; Wong, TW				Kim, L; Wong, TW			Growth factor-dependent phosphorylation of the actin-binding protein cortactin is mediated by the cytoplasmic tyrosine kinase FER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; PP60SRC SUBSTRATE; TRANSGENIC MICE; FOCAL ADHESIONS; FACTOR RECEPTOR; FPS/FES; IDENTIFICATION; CELLS; CATENIN; TRANSFORMATION	Previous characterization of the nonreceptor tyrosine kinase FER identified a tight physical association with the catenin pp120 and led to the suggestion that FER may be involved in cell-cell signaling. To further understand the function of FER, we have continued our analyses of the interaction of FER with pp120 and other proteins. The majority of FER is localized to the cytoplasmic fraction where it forms a complex with the actin-binding protein cortactin, The Src homology 2 sequence of FER. is required for directly binding cortactin, and phosphorylation of the FER-cortactin complex is up-regulated in cells treated with peptide growth factors. Using a dominant-negative mutant of FER, we provided evidence that FER kinase activity is required for the growth factor-dependent phosphorylation of cortactin. These data suggest that cortactin is likely to be a direct substrate of FER. Our observations provide additional support for a role of FER in mediating signaling from the cell surface, via growth factor receptors, to the cytoskeleton. The nature of the FER-cortactin interaction, and their putative enzyme-substrate relationship, support the previous proposal that one of the functions of the Src homology 2 sequences of nonreceptor tyrosine kinases is to provide a binding site for their preferred substrates.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wong, TW (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, POB 4000, Princeton, NJ 08543 USA.							ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; DOWNING JR, 1991, ONCOGENE, V6, P607; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2397; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KIM L, 1995, MOL CELL BIOL, V15, P4553; LETWIN K, 1988, ONCOGENE, V3, P621; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHECTER D, 1993, J OPER RES SOC, V44, P205; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	31	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23542	23548		10.1074/jbc.273.36.23542	http://dx.doi.org/10.1074/jbc.273.36.23542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722593	hybrid			2022-12-25	WOS:000075778100093
J	Nagao, M; Yamauchi, J; Kaziro, Y; Itoh, H				Nagao, M; Yamauchi, J; Kaziro, Y; Itoh, H			Involvement of protein kinase C and Src family tyrosine kinase in G alpha(q/11)-induced activation of c-jun N-terminal kinase and p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; FOCAL ADHESION KINASE; G-BETA-GAMMA; MAP KINASE; COUPLED RECEPTORS; ALPHA-SUBUNIT; DEPENDENT ACTIVATION; NH2-TERMINAL KINASE; SIGNALING PATHWAYS; REGULATED KINASE	Mitogen-activated protein kinases (MAPKs) are activated by various extracellular stimuli. The signaling pathways from G protein-coupled receptors to extracellular signal-regulated kinase have been partially elucidated, whereas the mechanisms by which G protein-coupled receptors stimulate c-Jun N-terminal kinase (JNK) and p38 MAPK activities remain largely unknown. We have recently demonstrated that the signal from G(q/11)-coupled mi muscarinic acetylcholine receptor to p38 MAPK is mediated by both G alpha(q/11) and G beta gamma in HEK-293 cells (Yamauchi, J., Nagao, M., Kaziro, Y., and Itoh, H. (1997) J. Biol. Chem. 272, 27771-27777). In the present study, we report that a constitutively activated mutant of G alpha(11) (G alpha(11) Q209L) activated not only p38 MAPK but also JNK, and the activation of JNK and p38 MAPK by Ga-11 Q209L was partially inhibited by prolonged treatment with phorbol 12-myristate 13-acetate and calphostin C. In addition, the G alpha(11) Q209L-stimulated activation of both kinases was blocked by a specific inhibitor of protein tyrosine kinases (PP2) and Csk ((C) under bar-terminal (S) under bar rc (k) under bar inase). Furthermore, we demonstrated that Gall Q209L stimulated Src family kinase activity and induced tyrosine phosphorylation of several proteins in HEK-293 cells. These results suggest that G alpha(q/11) stimulates JNK and p38 MAPK activities through protein kinase C- and Src family kinase-dependent signaling pathways.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Itoh, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.							Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EARP HS, 1995, J BIOL CHEM, V270, P28440; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; YAN MH, 1994, NATURE, V372, P798; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	50	113	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22892	22898		10.1074/jbc.273.36.22892	http://dx.doi.org/10.1074/jbc.273.36.22892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722508	hybrid			2022-12-25	WOS:000075778100008
J	Monsonego, A; Mizrahi, T; Eitan, S; Moalem, G; Bardos, H; Adany, R; Schwartz, M				Monsonego, A; Mizrahi, T; Eitan, S; Moalem, G; Bardos, H; Adany, R; Schwartz, M			Factor XIIIa as a nerve-associated transglutaminase	FASEB JOURNAL			English	Article						FXIIIa; thrombin; CNS; PNS; nerve regeneration	COAGULATION-FACTOR-XIII; PERIPHERAL-NERVE; BLOOD-COAGULATION; CELL-DEATH; PROTEASE NEXIN-1; CROSS-LINKING; INJURY; OLIGODENDROCYTES; SUBUNIT; NEURONS	Recent findings have led to changes in the traditional concept of nerve recovery, including the realization that injured nerves, like any other injured tissue, need the assistance of blood-derived cells and factors in order to heal. We show that factor XIIIa (FXIIIa, the potentially active a(2)-subunit of factor XIII), an enzyme that participates in blood coagulation by stabilizing the fibrin clot, is also active in the nervous system where it may play a key role in the healing of injured tissue. We demonstrate that the plasma, macrophages and nerves of fish contain a 55 kDa form of transglutaminase that cross-reacts immunologically with the a-subunit of FXIII in mammals (80 kDa). The fish enzyme in the plasma, unlike its mammalian counterpart, is active, pointing to a difference in control of the coagulation pathway in the two species. Analysis of FXIIIa expression in mammalian neural tissues and their response to injury revealed high levels of the enzyme in media conditioned by peripheral nerves as compared with medium conditioned by nerves of the central nervous system. Furthermore, similarity was observed in the postinjury behavior of FXIIIa in regenerating nerve tissues (peripheral nervous system of mammals and the central nervous system of fish). We suggest that the postinjury level of factor XIIIa in the nervous system may be related to the tissue's regenerative capacity, and that FXIIIa may therefore be a link underlying a possible association between the processes of blood coagulation and nerve healing.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Dept Hyg & Epidemiol, Debrecen, Hungary	Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnschwar@weizmann.weizmann.ac.il	Moalem-Taylor, Gila/C-3116-2008; Helga, Bárdos/AAH-4049-2021	Moalem-Taylor, Gila/0000-0003-3828-9527; 				Adany R, 1996, THROMB HAEMOSTASIS, V76, P74; Adany Roza, 1996, Seminars in Thrombosis and Hemostasis, V22, P399, DOI 10.1055/s-2007-999038; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; DEWITT DA, 1994, BRAIN RES, V656, P205, DOI 10.1016/0006-8993(94)91386-2; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUTTRIDGE DC, 1993, J BIOL CHEM, V268, P18966; KIESSELBACH TH, 1972, ANN NY ACAD SCI, V202, P318, DOI 10.1111/j.1749-6632.1972.tb16344.x; LAI TS, 1994, PROTEIN EXPRES PURIF, V5, P125, DOI 10.1006/prep.1994.1019; LIU DX, 1994, J NEUROCHEM, V62, P37; LORAND L, 1981, METHOD ENZYMOL, V80, P333; Mahoney SA, 1996, BIOCHEM BIOPH RES CO, V224, P147, DOI 10.1006/bbrc.1996.0998; MANN KG, 1993, METHOD ENZYMOL, V222, P1; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; MUSZBEK L, 1985, THROMB RES, V37, P401, DOI 10.1016/0049-3848(85)90069-6; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PERRY VH, 1992, BIOESSAYS, V14, P401, DOI 10.1002/bies.950140610; Pike CJ, 1996, J NEUROCHEM, V66, P1374; SAVIO T, 1989, J NEUROSCI, V9, P1126; SCHWARTZ M, 1995, MOL MED TODAY, V1, P60, DOI 10.1016/S1357-4310(95)92274-1; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; SO KF, 1985, BRAIN RES, V328, P349, DOI 10.1016/0006-8993(85)91047-9; SPIEGLER OL, 1996, FASEB J, V10, P1296; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; TOIDA M, 1995, HISTOCHEM J, V27, P440; TOIDA M, 1995, HISTOCHEM J, V27, P449; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; VAUGHAN PJ, 1993, J BIOL CHEM, V268, P3720	36	17	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1163	1171		10.1096/fasebj.12.12.1163	http://dx.doi.org/10.1096/fasebj.12.12.1163			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737719				2022-12-25	WOS:000075738500011
J	Dimon-Gadal, S; Gerbaud, P; Keryer, G; Anderson, W; Evain-Brion, D; Raynaud, F				Dimon-Gadal, S; Gerbaud, P; Keryer, G; Anderson, W; Evain-Brion, D; Raynaud, F			In vitro effects of oxygen-derived free radicals on type I and type II cAMP-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-5'-CYCLIC MONOPHOSPHATE; CULTURED HUMAN KERATINOCYTES; REGULATORY SUBUNIT; HYDROGEN-PEROXIDE; HUMAN-FIBROBLASTS; BINDING-SITES; MESSENGER-RNA; AMINO-ACIDS; OXIDATION; EXPRESSION	Oxygen free radicals may act as second messengers in signal transduction pathways and contribute to inflammatory diseases. We studied the action in vitro of radiolytically generated hydroxyl radicals ((OH)-O-.) and superoxide radicals (O(2)radical anion) on the cAMP-dependent protein kinases, I and II (PKAI and -II, respectively). The effects of the gasses O-2, and N2O used to produce O(2)radical anion or (OH)-O-. radicals by gamma-radiolysis of the water were also studied. PKAI is more sensitive than PKAII to oxygen gas (10 mM sodium formate) and to hydroxyl and superoxide radicals. Hydroxyl radicals decreased the kinase phosphotransferase activities stimulated either by cAMP or its site-specific analogs for both PKAI and PKAII; however, PKAI was more affected. The binding of [H-3]cAMP and of 8-N-3-[P-32]cAMP to RI regulatory subunits was decreased. (OH)-O-. caused a loss of tryptophan 260 fluorescence at site A of PKAI and of bityrosine production. Superoxide radicals affected only PKAI. O(2)radical anion modified both cAMP-binding sites A and B of the regulatory subunit but had a smaller effect on the catalytic subunit, The catalytic subunit was more sensitive to radicals when free than when part of the holoenzymes during exposure to the oxygen free radicals. These results suggest that oxygen free radicals alter the structure of PKA enzymes. Thus, oxidative modifications may alter key enzymes, including cAMP-dependent protein kinases, in certain pathological states.	Univ Paris 05, Fac Sci Pharmaceut & Biol Paris, INSERM, U427, F-75270 Paris 06, France; NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Raynaud, F (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol Paris, INSERM, U427, 4 Ave Observ, F-75270 Paris 06, France.			Gerbaud, Pascale/0000-0001-5579-1979				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BUBIS J, 1987, J BIOL CHEM, V262, P14961; CARMICHAEL DF, 1982, J BIOL CHEM, V257, P440; CHEVALIER M, 1990, J BIOL CHEM, V265, P42; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; Dean RT, 1997, BIOCHEM J, V324, P1; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DOSKELAND SO, 1978, BIOCHEM BIOPH RES CO, V83, P542, DOI 10.1016/0006-291X(78)91024-0; ERLICHMAN J, 1983, METHOD ENZYMOL, V99, P76; Evain-Brion D., 1986, P NATL ACAD SCI USA, V83, P5272, DOI [10.1073/pnas.83.14.5272, DOI 10.1073/PNAS.83.14.5272]; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fricke H., 1966, RADIATION DOSIMETRY, V2, P167; GARETT IR, 1990, J CLIN INVEST, V85, P632, DOI DOI 10.1172/JCI114485; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; GILL GN, 1970, BIOCHEM BIOPH RES CO, V39, P335, DOI 10.1016/0006-291X(70)90581-4; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Halliwell B., 1989, FREE RADICAL BIO MED, P86; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KERYER G, 1991, J CELL BIOL, V115, P284; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LOFFNER F, 1986, BRAIN RES, V363, P205, DOI 10.1016/0006-8993(86)91006-1; LONTZ W, 1995, FREE RADICAL BIO MED, V18, P349, DOI 10.1016/0891-5849(94)E0124-2; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; OGREID D, 1980, FEBS LETT, V121, P340, DOI 10.1016/0014-5793(80)80376-0; OHTA Y, 1991, ARCH DERMATOL RES, V283, P351, DOI 10.1007/BF00371814; PARISET C, 1989, J CELL BIOL, V109, P1195, DOI 10.1083/jcb.109.3.1195; Rao GN, 1996, ONCOGENE, V13, P713; RAYNAUD F, 1987, J INVEST DERMATOL, V89, P105, DOI 10.1111/1523-1747.ep12580448; Raynaud F, 1997, FREE RADICAL BIO MED, V22, P623, DOI 10.1016/S0891-5849(96)00353-X; RAYNAUD F, 1989, LANCET, P1158; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STEVENSON MA, 1994, CANCER RES, V54, P12; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TASKEN K, 1995, PROTEIN KINASE FACTS, P58; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; THOMAS G, 1986, BIOCHEM BIOPH RES CO, V139, P102, DOI 10.1016/S0006-291X(86)80085-7; UEDA M, 1984, J BIOL CHEM, V259, P9520; WALTER U, 1977, J BIOL CHEM, V252, P6494; ZOCCARATO F, 1989, EUR J BIOCHEM, V180, P473, DOI 10.1111/j.1432-1033.1989.tb14670.x	51	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22833	22840		10.1074/jbc.273.35.22833	http://dx.doi.org/10.1074/jbc.273.35.22833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712918	hybrid			2022-12-25	WOS:000075616600094
J	Kampranis, SC; Maxwell, A				Kampranis, SC; Maxwell, A			Conformational changes in DNA gyrase revealed by limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; BREAKAGE-REUNION DOMAIN; N-TERMINAL FRAGMENT; ESCHERICHIA-COLI; TOPOISOMERASE-II; NALIDIXIC-ACID; A-PROTEIN; CRYSTAL-STRUCTURE; B-PROTEIN; MECHANISM	We have used Limited proteolysis to identify conformational changes in DNA gyrase. Gyrase exhibits a proteolytic fingerprint dominated by two fragments, one of similar to 62 kDa, deriving hom the A protein, and another of similar to 25 kDa from the B protein. Quinolone binding to the enzyme-DNA complex induces a conformational change which is reflected in the protection of the C-terminal 47-kDa domain of the B protein. An active site mutant (Tyr(122) to Ser in the A protein) that binds quinolones but cannot cleave DNA still gives the quinolone proteolytic pattern, while stabilization of a cleaved-DNA intermediate by calcium ions does not reveal any protection, suggesting that the quinolone-induced conformational change is different from an "open-gate" state of the enzyme, A quinolone-resistant mutant of gyrase fails to give the characteristic quinolone-associated proteolytic signature. The ATP-induced dimerization of the B subunits is a key step of the gyrase mechanism. The proteolytic fingerprint of this conformation (stabilized by the non-hydrolyzable ATP analog 5'-adenylyl-beta,gamma-imidodiphosphate (ADPNP) shows a protection of the 43-kDa N-terminal domain of the B subunit, The presence of quinolones does not prevent dimerization since incubation of the enzyme-DNA complex with both ADPNP and quinolones gives rise to a complex whose proteolytic pattern retains the characteristic signature of dimerization but has lost the quinolone-induced protection. As a result, the quinolone-gyrase complex can still hydrolyze ATP, albeit with different kinetic characteristics. We interpret the proteolytic signatures observed in terms of four complexes of gyrase, each representing a particular conformational state.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Maxwell, A (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.		Kampranis, Sotirios C/G-8374-2016	Kampranis, Sotirios C/0000-0001-6208-1684; Maxwell, Anthony/0000-0002-5756-6430				ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, TRENDS MICROBIOL, V5, P102; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Caron P R, 1994, Adv Pharmacol, V29B, P271; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; DOBBS ST, 1992, NUCLEIC ACIDS RES, V20, P3567, DOI 10.1093/nar/20.14.3567; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; Kampranis SC, 1998, J BIOL CHEM, V273, P22615, DOI 10.1074/jbc.273.35.22615; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; MAXWELL A, 1998, PROTOCOLS DNA TOPOIS, V1; MORRISON A, 1980, J BIOL CHEM, V255, P2211; ORPHANIDES G, 1994, NUCLEIC ACIDS RES, V22, P1567, DOI 10.1093/nar/22.9.1567; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; REECE RJ, 1991, J BIOL CHEM, V266, P3540; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SHEN LL, 1989, J BIOL CHEM, V264, P2973; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; TSE YC, 1980, J BIOL CHEM, V255, P5560; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012; YOSHIDA H, 1993, ANTIMICROB AGENTS CH, V37, P839, DOI 10.1128/AAC.37.4.839	40	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22606	22614		10.1074/jbc.273.35.22606	http://dx.doi.org/10.1074/jbc.273.35.22606			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712889	hybrid			2022-12-25	WOS:000075616600065
J	Pawate, S; Schey, KL; Meier, GP; Ullian, ME; Mais, DE; Halushka, PV				Pawate, S; Schey, KL; Meier, GP; Ullian, ME; Mais, DE; Halushka, PV			Expression, characterization, and purification of C-terminally hexahistidine-tagged thromboxane A(2) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; LIGAND-BINDING; AFFINITY-CHROMATOGRAPHY; STEP PURIFICATION; HUMAN PLATELETS; PROTEINS; CLONING; ANTAGONIST; SUBTYPE; AGONIST	Thromboxane A(2) (TxA(2)) receptors belong to the class of G-protein-coupled receptors. Knowledge of the relationship of structure to function for TxA(2) receptors is limited because of their low levels of expression, lengthy purification procedures and poor recoveries. A C-terminal hexahistidine-tag (C-His) was ligated to the a-isoform of TxA(2), receptors and expressed in COS-7 and Chinese hamster ovary cells. The C-His-TxA(2), receptors bound the radioligands I-125-7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4-benzenesulfonylamino)bicyclo[3.1.1]hept-2-y]-5(Z)-heptenoic acid, an antagonist, and I-125-[1S-1 alpha,2 beta-(5Z),3 alpha(1E,3S*),4 alpha]-7-[3[(3-hydroxy-4-(4'-phenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-heptanoic acid, an agonist, with affinities not significantly different from those of the wild type (wt)-TxA(2), receptors. LipofectAMINE transfection of the cDNAs resulted in high levels of expression (B-max = 95 +/- 6 pmol/mg) of the C-His-TxA(2), receptors. In competition binding studies the IC50 values of five different ligands were not significantly different between C-His-TxA(2), and wt-TxA(2), receptors. Agonist-induced stimulation of cAMP and total inositol phosphate formation were not significantly different between the two receptors. Purification on a Ni2+-NTA column resulted in a rapid (within 4 h) purification with a 36 +/- 2% recovery and a 30 +/- 6-fold purification (n = 5). The partially purified receptors were resolved on SDS-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane, dissolved in acetone/trifluoroacetic acid/hexafluoroisopropanol/sinapinic acid, and successfully subjected to matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis. The results suggest that the combination of a high level of expression of C-His-TxA(2), receptors and a rapid purification procedure followed by SDS- polyacrylamide gel electrophoresis may provide a useful approach for mass-spectrometry based structure-function and other studies of TxA(2), receptors.	Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Ligand Pharmaceuticals	Halushka, PV (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, 171 Ashley Ave, Charleston, SC 29425 USA.				NHLBI NIH HHS [HL36838] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036838] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan CJ, 1996, J PHARMACOL EXP THER, V277, P1132; ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; Becker KP, 1998, BBA-MOL CELL RES, V1403, P109, DOI 10.1016/S0167-4889(98)00019-6; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; Courchesne PL, 1997, ELECTROPHORESIS, V18, P369, DOI 10.1002/elps.1150180311; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; DANGELO DD, 1994, J PHARMACOL EXP THER, V271, P1034; DOBELI H, 1990, MOL BIOCHEM PARASIT, V41, P259, DOI 10.1016/0166-6851(90)90189-S; Eckerskorn C, 1997, ANAL CHEM, V69, P2888, DOI 10.1021/ac970077e; Enguita FJ, 1996, FEMS MICROBIOL LETT, V137, P135; FONG TM, 1994, MED RES REV, V14, P387, DOI 10.1002/med.2610140402; Gao MH, 1998, P NATL ACAD SCI USA, V95, P1038, DOI 10.1073/pnas.95.3.1038; GRISSHAMMER R, 1995, Q REV BIOPHYS, V28, P315, DOI 10.1017/S0033583500003504; HALUSHKA PV, 1995, J LIPID MEDIAT CELL, V12, P361, DOI 10.1016/0929-7855(95)00023-J; Halushka PV, 1997, HANDB EXP PHARM, V126, P459; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Hayashi MK, 1996, J BIOCHEM, V120, P1232; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; HONDA A, 1993, J BIOL CHEM, V268, P7759; JANSSEN JJM, 1995, J BIOL CHEM, V270, P11222, DOI 10.1074/jbc.270.19.11222; JIN H, 1992, J BIOL CHEM, V267, P5735; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; Liang XL, 1996, ANAL CHEM, V68, P1012, DOI 10.1021/ac950685z; Lima JJ, 1996, J RECEPT SIGNAL TR R, V16, P357, DOI 10.3109/10799899609039956; MAYEUX PR, 1991, J BIOL CHEM, V266, P13752; MCALLISTER G, 1992, P NATL ACAD SCI USA, V89, P5517, DOI 10.1073/pnas.89.12.5517; MORINELLI TA, 1989, J PHARMACOL EXP THER, V251, P557; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKA M, 1992, J PHARMACOL EXP THER, V262, P632; PONG AS, 1994, ANAL BIOCHEM, V217, P165; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; QIAGEN, 1992, QIAEXPRESSIONIST; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; SAUDOU F, 1992, EMBO J, V11, P7, DOI 10.1002/j.1460-2075.1992.tb05021.x; Schey K L, 1996, Methods Mol Biol, V61, P227; SIMMONS TR, 1993, J LEUKOCYTE BIOL, V53, P173, DOI 10.1002/jlb.53.2.173; USHIKUBI F, 1989, J BIOL CHEM, V264, P16496; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	45	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22753	22760		10.1074/jbc.273.35.22753	http://dx.doi.org/10.1074/jbc.273.35.22753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712907	hybrid			2022-12-25	WOS:000075616600083
J	Aono, S; Ohkubo, K; Matsuo, T; Nakajima, H				Aono, S; Ohkubo, K; Matsuo, T; Nakajima, H			Redox-controlled ligand exchange of the heme in the CO-sensing transcriptional activator CooA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; CAMP RECEPTOR PROTEIN; OXYGEN SENSOR FIXL; ADENOSINE-MONOPHOSPHATE RECEPTOR; RESONANCE RAMAN-SCATTERING; CAP-DNA COMPLEX; RHODOSPIRILLUM-RUBRUM; CARBON-MONOXIDE; NITRIC-OXIDE; RHIZOBIUM-MELILOTI	The transcriptional activator CooA from Rhodospirillum rubrum contains a b-type heme that acts as a CO sensor in vivo, CooA is the first example of a transcriptional regulator containing a heme as a prosthetic group and of a hemeprotein in which CO plays a physiological role, In this study, we constructed an in vivo reporter system to measure the transcriptional activator activity of CooA and prepared some CooA mutants in which a mutation was introduced at Cys, His, Met, Lys, or Tyr, Only the mutations of Cys(75) and His(77) affected the electronic absorption spectra of the heme in CooA, The electronic absorption spectra, EPR spectra, and the transcriptional activator activity of the wild-type and mutant CooA proteins indicate that 1) the thiolate derived from Cys(75) is the axial ligand in the ferric heme, but it is not coordinated to the CO-bound ferrous heme; 2) Cys(75) is protonated or displaced in the ferrous heme; and 3) His(77) is the proximal ligand in the CO-bound ferrous heme and probably also in the ferrous heme, but it is not coordinated to the ferric heme, NMR spectra reveal that the conformational change around the heme, which will trigger the activation of CooA by CO, takes place upon the binding of CO to the heme,	Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan	Japan Advanced Institute of Science & Technology (JAIST)	Aono, S (corresponding author), Japan Adv Inst Sci & Technol, Sch Mat Sci, 1-1 Asahidai, Tatsunokuchi, Ishikawa 9231292, Japan.		Ohkubo, Kei/L-5002-2019; Aono, Shigetoshi/ABD-7618-2020; Ohkubo, Kei/E-5127-2012	Ohkubo, Kei/0000-0001-8328-9249; Aono, Shigetoshi/0000-0002-2870-3694; Ohkubo, Kei/0000-0001-8328-9249				AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ANDERSON WB, 1971, J BIOL CHEM, V246, P5928; Aono S, 1997, BIOCHEM BIOPH RES CO, V240, P783, DOI 10.1006/bbrc.1997.7746; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; CRAVEN PA, 1979, J BIOL CHEM, V254, P8213; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; DAWSON JH, 1987, CHEM REV, V87, P1257; EILEN E, 1978, BIOCHEMISTRY-US, V17, P2469, DOI 10.1021/bi00606a001; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GARGES S, 1985, CELL, V41, P745, DOI 10.1016/S0092-8674(85)80055-6; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; HAN S, 1990, P NATL ACAD SCI USA, V87, P205, DOI 10.1073/pnas.87.1.205; HASEGAWA T, 1984, J BIOCHEM-TOKYO, V96, P265, DOI 10.1093/oxfordjournals.jbchem.a134822; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; IGNARRO LJ, 1981, ARCH BIOCHEM BIOPHYS, V208, P75, DOI 10.1016/0003-9861(81)90125-9; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; KIM J, 1992, P NATL ACAD SCI USA, V89, P9700, DOI 10.1073/pnas.89.20.9700; KITAGAWA T, 1975, J BIOCHEM-TOKYO, V78, P719, DOI 10.1093/oxfordjournals.jbchem.a130960; KRAKOW JS, 1973, P NATL ACAD SCI USA, V70, P2529, DOI 10.1073/pnas.70.9.2529; LOIS AF, 1993, J BIOL CHEM, V268, P4370; Martinis SA, 1996, BIOCHEMISTRY-US, V35, P14530, DOI 10.1021/bi961511u; MILLER JH, 1992, SHORT COURSE BACTERI, P71; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; MONSON EK, 1995, J BIOL CHEM, V270, P5243, DOI 10.1074/jbc.270.10.5243; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Poulos TL, 1996, NAT STRUCT BIOL, V3, P401, DOI 10.1038/nsb0596-401; POWELL BS, 1994, NUCLEIC ACIDS RES, V22, P5765, DOI 10.1093/nar/22.25.5765; Rodgers KR, 1996, BIOCHEMISTRY-US, V35, P9539, DOI 10.1021/bi9530853; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; SVASTITS EW, 1989, BIOCHEM BIOPH RES CO, V165, P1170, DOI 10.1016/0006-291X(89)92725-3; Tahirov TH, 1996, NAT STRUCT BIOL, V3, P459, DOI 10.1038/nsb0596-459; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; YAMANAKA T, 1992, BIOCH BACTERIAL CYTO, P3	56	108	108	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25757	25764		10.1074/jbc.273.40.25757	http://dx.doi.org/10.1074/jbc.273.40.25757			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748246	hybrid			2022-12-25	WOS:000076263100037
J	Bass, RB; Falke, JJ				Bass, RB; Falke, JJ			Detection of a conserved alpha-helix in the kinase-docking region of the aspartate receptor by cysteine and disulfide scanning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED CROSS-LINKING; METHYL-ACCEPTING SITES; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; SERINE CHEMORECEPTOR; PROTEIN-STRUCTURE; TRANSMEMBRANE DOMAIN; CYTOPLASMIC FRAGMENT; INSULIN-RECEPTOR	The transmembrane aspartate receptor of Escherichia coli and Salmonella typhimurium propagates extracellular signals to the cytoplasm, where its cytoplasmic domain regulates the histidine kinase, CheA. Different signaling states of the cytoplasmic domain modulate the kinase autophosphorylation rate over at least a 100-fold range. Biochemical and genetic studies have implicated a specific region of the cytoplasmic domain, termed the signaling subdomain, as the region that transmits regulation from the receptor to the kinase. Here cysteine and disulfide scanning are applied to the N-terminal half of the signaling subdomain to probe its secondary structure, solvent exposure, and protein-protein interactions. The chemical reactivities of the scanned cysteines exhibit the characteristic periodicity of an alpha-helix with distinct solvent-exposed and buried faces. This helix, termed alpha 7, ranges approximately from residue 355 through 386. Activity measurements probing the effects of cysteine substitutions in vivo and in vitro reveal that both faces of helix alpha 7 are critical for kinase activation, while the buried face is especially critical for kinase down-regulation. Disulfide scanning of the region suggests that helix alpha 7 is not in direct contact with its symmetric partner (alpha 7') from the other subunit; presently, the structural element that packs against the buried face of the helix remains unidentified. Finally, a novel approach termed "protein interactions by cysteine modification" indicates that the exposed C-terminal face of helix alpha 7 provides an essential docking site for the kinase CheA or for the coupling protein CheW.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Falke, JJ (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	falke@colorado.edu			NIGMS NIH HHS [GM40731, R01 GM040731, R01 GM040731-12] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040731] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; Biemann HP, 1996, J BIOL CHEM, V271, P27927, DOI 10.1074/jbc.271.44.27927; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BOGONEZ E, 1985, P NATL ACAD SCI USA, V82, P4891, DOI 10.1073/pnas.82.15.4891; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; Chen XM, 1997, BIOCHEMISTRY-US, V36, P11858, DOI 10.1021/bi970911u; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; DANIELSON MA, 1997, THESIS U COLORADO BO; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FALKE JJ, 1986, BIOPHYS J, V49, pA20; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hughson AG, 1997, PROTEIN SCI, V6, P315; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; Iwama T, 1997, J BIOL CHEM, V272, P13810, DOI 10.1074/jbc.272.21.13810; KEHRY MR, 1985, J BACTERIOL, V163, P983, DOI 10.1128/JB.163.3.983-990.1985; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GF, 1994, J BIOL CHEM, V269, P29920; LEE GF, 1995, P NATL ACAD SCI USA, V92, P5416, DOI 10.1073/pnas.92.12.5416; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MOWBRAY SL, 1985, J BIOL CHEM, V260, P1711; Nara T, 1996, J BIOL CHEM, V271, P17932, DOI 10.1074/jbc.271.30.17932; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Nishiyama SI, 1997, J BACTERIOL, V179, P6573, DOI 10.1128/jb.179.21.6573-6580.1997; Okumura H, 1998, J BACTERIOL, V180, P1862, DOI 10.1128/JB.180.7.1862-1868.1998; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RUSSELL CB, 1989, J BACTERIOL, V171, P3609, DOI 10.1128/jb.171.7.3609-3618.1989; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Seeley SK, 1996, BIOCHEMISTRY-US, V35, P5199, DOI 10.1021/bi9524979; Stock AM, 1995, CURR OPIN STRUC BIOL, V5, P744, DOI 10.1016/0959-440X(95)80006-9; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; SUNDBERG SA, 1985, J BACTERIOL, V164, P282, DOI 10.1128/JB.164.1.282-287.1985; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; SWANSON RV, 1994, CURR BIOL, V4, P234, DOI 10.1016/S0960-9822(00)00052-X; TATSUNO I, 1994, MOL MICROBIOL, V14, P755, DOI 10.1111/j.1365-2958.1994.tb01312.x; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; Zhulin IB, 1997, BIOSCIENCE REP, V17, P335, DOI 10.1023/A:1027340813657	71	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25006	25014		10.1074/jbc.273.39.25006	http://dx.doi.org/10.1074/jbc.273.39.25006			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737956	Green Accepted, hybrid			2022-12-25	WOS:000076085400006
J	Croteau, W; Bodwell, JE; Richardson, JM; St Germain, DL				Croteau, W; Bodwell, JE; Richardson, JM; St Germain, DL			Conserved cysteines in the type 1 deiodinase selenoprotein are not essential for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE 5'-DEIODINASE; COLI RNASE-T; THYROID-HORMONE; CELLULAR UPTAKE; RAT-LIVER; 3,5,3'-TRIIODOTHYRONINE; TRANSPORT; HEPATOCYTES; THYROXINE; RESIDUES	The iodothyronine deiodinases are a family of oxidoreductases that catalyze the removal of iodide from thyroid hormones. Each of the three isoforms contain selenocysteine at its active site and several cysteine residues that may be important for catalytic activity. Of particular interest in the type I deiodinase (D1) is Cys(124) which is vicinal to the selenocysteine at position 126, and Cys(194), which has been conserved in all deiodinases identified to date. In the present studies, we have characterized the functional properties of C124A, C194A, and C124A/C194A. D1 mutants, which were prepared by site-directed mutagenesis and expressed in COS-7 cells. In broken cell preparations, the sensitivity of the mutants to the selective D1 inhibitors propylthiouracil and aurothioglucose were unaltered. Mutagenesis at the Cys(124) position was associated with a 7-11-fold increase in the K-m of dithiothreitol, whereas V-max values remained largely unchanged. However, both mutations resulted in marked decreases in V-max values when glutathione or a reconstituted thioredoxin cofactor system were used in the assay. In contrast to the results of these in vitro studies, no impairment in deiodinating capability was noted in intact cells expressing equivalent levels of the mutant constructs, These studies demonstrate that Cys(124) and Cys(194) influence the reactivity of the D1 with thiol cofactors in in vitro assay systems but are not determinants of the sensitivity of the enzyme to propylthiouracil and aurothioglucose. Furthermore, the observation that the cysteine mutants are fully active in intact cells demonstrates that the results of commonly used broken cell assays do not accurately predict the activity of the D1 in intact cells and suggests that glutathione and thioredoxin are not the major thiols utilized in vivo to support D1 activity.	Dartmouth Med Sch, Dept Med, Lebanon, NH 03756 USA; Dartmouth Med Sch, Dept Physiol, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College	St Germain, DL (corresponding author), Dartmouth Med Sch, Dept Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.				NIDDK NIH HHS [DK03535, DK42271, DK45337] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045337, R01DK042271, R01DK003535] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG SY, 1980, P NATL ACAD SCI-BIOL, V77, P3425, DOI 10.1073/pnas.77.6.3425; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; DEJONG M, 1993, J CLIN ENDOCR METAB, V77, P139, DOI 10.1210/jc.77.1.139; DIETRICHS D, 1991, J BACTERIOL, V173, P5983, DOI 10.1128/jb.173.19.5983-5991.1991; GALTON VA, 1986, ENDOCRINOLOGY, V118, P1918, DOI 10.1210/endo-118-5-1918; GOSWAMI A, 1983, ENDOCRINOLOGY, V112, P1180, DOI 10.1210/endo-112-4-1180; HENNEMANN G, 1986, ENDOCRINOLOGY, V119, P1870, DOI 10.1210/endo-119-4-1870; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; LEE H, 1971, BIOCHIM BIOPHYS ACTA, V242, P519, DOI 10.1016/0005-2744(71)90144-6; Leonard JL, 1986, THYROID HORMONE META, P189; Li ZW, 1996, J BIOL CHEM, V271, P1133, DOI 10.1074/jbc.271.2.1133; Li ZW, 1996, J BIOL CHEM, V271, P1127, DOI 10.1074/jbc.271.2.1127; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MENDEL CM, 1988, ENDOCRINOLOGY, V123, P1817, DOI 10.1210/endo-123-4-1817; MICHAL G, 1983, METHOD ENZYMAT AN, V1, P86; MOORADIAN AD, 1985, ENDOCRINOLOGY, V117, P2449, DOI 10.1210/endo-117-6-2449; Rudolph F B, 1979, Methods Enzymol, V63, P138; Sato K, 1984, Horm Metab Res Suppl, V14, P30; SHARIFI J, 1992, J BIOL CHEM, V267, P12539; STGERMAIN DL, 1988, J CLIN INVEST, V81, P1476, DOI 10.1172/JCI113479; STGERMAIN DL, 1994, TRENDS ENDOCRIN MET, V5, P36, DOI 10.1016/1043-2760(94)90119-8; StGermain DL, 1997, THYROID, V7, P655; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P11282; Sun BC, 1997, ENDOCRINOLOGY, V138, P5452, DOI 10.1210/en.138.12.5452; Winer BJ, 1971, STATISTICAL PRINCIPL, P201; YAN ZF, 1993, J BIOL CHEM, V268, P20179	32	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25230	25236		10.1074/jbc.273.39.25230	http://dx.doi.org/10.1074/jbc.273.39.25230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737986	hybrid			2022-12-25	WOS:000076085400036
J	Lalmanach, G; Lecaille, F; Chagas, JR; Authie, E; Scharfstein, J; Juliano, MA; Gauthier, F				Lalmanach, G; Lecaille, F; Chagas, JR; Authie, E; Scharfstein, J; Juliano, MA; Gauthier, F			Inhibition of trypanosomal cysteine proteinases by their propeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-B; SUBSTRATE-SPECIFICITY; PROCATHEPSIN-B; CRUZI; PROTEASE; CONGOLENSE; PEPTIDES; REGIONS; PAPAIN; MODEL	The ability of the prodomains of trypanosomal cysteine proteinases to inhibit their active form was studied using a set of 23 overlapping 15-mer peptides covering the whole prosequence of congopain, the major cysteine proteinase of Trypanosoma congolense. Three consecutive peptides with a common 5-mer sequence YHNGA were competitive inhibitors of congopain. A shorter synthetic peptide consisting of this 5-mer sequence flanked by two Ala residues (AYHNGAA) also inhibited purified congopain. No residue critical for inhibition was identified in this sequence, but a significant improvement in K-i value was obtained upon N-terminal elongation. Procongopain-derived peptides did not inhibit lysosomal cathepsins B and L but did inhibit native cruzipain (from Dm28c clone epimastigotes), the major cysteine proteinase of Trypanosoma cruzi, the proregion of which also contains the sequence YHNGA. The positioning of the YHNGA inhibitory sequence within the prosegment of trypanosomal proteinases is similar to that covering the active site in the prosegment of cysteine proteinases, the three-dimensional structure of which has been resolved. This strongly suggests that trypanosomal proteinases, despite their long C-terminal extension, have a prosegment that folds similarly to that in related mammal and plant cysteine proteinases, resulting in reverse binding within the active site, Such reverse binding could also occur for short procongopain-derived inhibitory peptides, based on their resistance to proteolysis and their ability to retain inhibitory activity after prolonged incubation. In contrast, homologous peptides in related cysteine proteinases did not inhibit trypanosomal proteinases and were rapidly cleaved by these enzymes.	Univ Tours, Fac Med, Enzymol & Prot Chem Lab, F-37032 Tours, France; Univ Fed Sao Paulo, Escola Paulista Med, BR-04044000 Sao Paulo, Brazil; Int Livestock Res Inst, Nairobi, Kenya; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21944 Rio De Janeiro, Brazil	Universite de Tours; Universidade Federal de Sao Paulo (UNIFESP); CGIAR; International Livestock Research Institute (ILRI); Universidade Federal do Rio de Janeiro	Lalmanach, G (corresponding author), Univ Tours, Fac Med, Enzymol & Prot Chem Lab, 2bis Bd Tonnelle, F-37032 Tours, France.		Chagas, Jair Ribeiro/AFV-6501-2022; Chagas, Jair R/A-1701-2012; Lecaille, Fabien/GRY-5313-2022	Chagas, Jair Ribeiro/0000-0002-0357-8276; Chagas, Jair R/0000-0002-0357-8276; Lecaille, Fabien/0000-0003-1060-4222; Lalmanach, Gilles/0000-0001-8562-4821				ASLUND L, 1991, MOL BIOCHEM PARASIT, V45, P345, DOI 10.1016/0166-6851(91)90103-D; Atherton E., 1990, SOLID PHASE PEPTIDE; AUTHIE E, 1992, MOL BIOCHEM PARASIT, V56, P103, DOI 10.1016/0166-6851(92)90158-G; AUTHIE E, 1994, PARASITOL TODAY, V10, P360, DOI 10.1016/0169-4758(94)90252-6; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; CAZZULO JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P186, DOI 10.1016/0167-4838(90)90166-D; Chagas JR, 1996, FEBS LETT, V392, P233, DOI 10.1016/0014-5793(96)00822-8; Chagas JR, 1997, MOL BIOCHEM PARASIT, V88, P85, DOI 10.1016/S0166-6851(97)00085-6; Chen YM, 1996, FEBS LETT, V393, P24, DOI 10.1016/0014-5793(96)00847-2; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; DelNery E, 1997, BIOCHEM J, V323, P427, DOI 10.1042/bj3230427; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; Groves MR, 1996, STRUCTURE, V4, P1193, DOI 10.1016/S0969-2126(96)00127-X; Kopitar G, 1996, EUR J BIOCHEM, V236, P558, DOI 10.1111/j.1432-1033.1996.00558.x; Lazo ND, 1997, BIOCHEMISTRY-US, V36, P2559, DOI 10.1021/bi963061b; LIMA APCA, 1992, MOL BIOCHEM PARASIT, V56, P335, DOI 10.1016/0166-6851(92)90183-K; MACH L, 1994, J BIOL CHEM, V269, P13036; MBAWA ZR, 1992, EUR J BIOCHEM, V204, P371, DOI 10.1111/j.1432-1033.1992.tb16646.x; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; MCKERROW JH, 1995, PARASITOL TODAY, V11, P279, DOI 10.1016/0169-4758(95)80039-5; MOREAU T, 1988, EUR J BIOCHEM, V173, P185, DOI 10.1111/j.1432-1033.1988.tb13983.x; NORTH MJ, 1990, PARASITOL TODAY, V6, P270, DOI 10.1016/0169-4758(90)90189-B; Plantier JC, 1998, J VIROL, V72, P677, DOI 10.1128/JVI.72.1.677-683.1998; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; SCHARFSTEIN J, 1986, J IMMUNOL, V137, P1336; Serveau C, 1996, BIOCHEM J, V313, P951, DOI 10.1042/bj3130951; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TAYLOR MAJ, 1995, PROTEIN ENG, V8, P59, DOI 10.1093/protein/8.1.59; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2	36	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25112	25116		10.1074/jbc.273.39.25112	http://dx.doi.org/10.1074/jbc.273.39.25112			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737969	hybrid			2022-12-25	WOS:000076085400019
J	Montano, MM; Jaiswal, AK; Katzenellenbogen, BS				Montano, MM; Jaiswal, AK; Katzenellenbogen, BS			Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSIVE ELEMENT; DNA-PROTEIN INTERACTION; HORMONE-BINDING DOMAIN; YA-SUBUNIT GENE; INDUCIBLE EXPRESSION; ER-BETA; IDENTIFICATION; ACTIVATION; ELECTROPHILE; INDUCTION	We have previously reported that antiestrogens stimulate quinone reductase (NAD (P)H: (quinone-acceptor) oxidoreductase (QR or NQO1); EC 1.6.99.2) enzymatic activity, an action that may provide protective effects against the toxicity and mutagenicity caused by quinones, We have now investigated the transcriptional regulation of the QR gene by antiestrogens. In transfection experiments employing the 5'-flanking (863-base pair) region of the human QR gene promoter with its electrophile/antioxidant response element (EpRE/ARE) or deleted or mutated constructs, we observe that antiestrogens induced an increase in QR gene promoter reporter activity in estrogen receptor (ER) negative breast cancer and endometrial cancer cells transfected with ER, and this induction by antiestrogens was repressed by estradiol, The stimulation of QR transcriptional activity required the 31-base pair electrophile-responsive region from the human QR gene promoter and a functional ER. Intriguingly, antiestrogens were stronger activators of the QR EpRE via the ER subtype ER beta than ER alpha. Oligonucleotide gel mobility and antibody shift assays reveal that the ER binds to the EpRE but is only a minor component of the proteins bound to the EpRE in ER-containing MCF-7 breast cancer cells. While binding of ER beta to the estrogen response element was weaker when compared with ER alpha, ER beta and ER alpha showed similar binding to the EpRE, Together these findings provide evidence that QR gene regulation by the antiestrogen-occupied ER is mediated by the EpRE-containing region of the human QR gene and indicate that the ER is one of the complex of proteins that binds to the EpRE. In addition, that ERP is a more potent activator at EpRE elements than is ERa: suggests that the different levels of these two receptors in various estrogen target cells could impact importantly on the antioxidant potency of antiestrogens in different target cells. These findings have broad implications regarding the potential beneficial effects of antiestrogens since EpREs mediate the transcriptional induction of numerous genes, including QR, which encode chemoprotective detoxification enzymes.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Baylor College of Medicine; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	katzenel@uiuc.edu			NATIONAL CANCER INSTITUTE [R37CA018119, R01CA018119] Funding Source: NIH RePORTER; NCI NIH HHS [CA18119, CA80959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; CHO HS, 1991, MOL ENDOCRINOL, V5, P1323, DOI 10.1210/mend-5-9-1323; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; Hellriegel ET, 1996, BIOCHEM PHARMACOL, V52, P1561, DOI 10.1016/S0006-2952(96)00560-6; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KRAUS WL, 1994, MOL ENDOCRINOL, V8, P952, DOI 10.1210/me.8.8.952; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; Montano MM, 1997, MOL ENDOCRINOL, V11, P330, DOI 10.1210/me.11.3.330; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; REESE JC, 1991, J BIOL CHEM, V266, P10880; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237, DOI 10.1016/0065-2571(89)90074-5; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WRENN CK, 1993, J BIOL CHEM, V268, P24089; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894	35	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25443	25449		10.1074/jbc.273.39.25443	http://dx.doi.org/10.1074/jbc.273.39.25443			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738013	hybrid			2022-12-25	WOS:000076085400063
J	Amino, R; Porto, RM; Chammas, R; Egami, MI; Schenkman, S				Amino, R; Porto, RM; Chammas, R; Egami, MI; Schenkman, S			Identification and characterization of a sialidase released by the salivary gland of the hematophagous insect Triatoma infestans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-CRUZI; TRANS-SIALIDASE; SALMONELLA-TYPHIMURIUM; MAST-CELLS; ACID; PROTEIN; NEURAMINIDASE; PURIFICATION; SELECTIN; REPEATS	Sialidases (EC 3.2.1.18) are commonly found in viruses, bacteria, fungi, protozoa, and vertebrates, but not in invertebrates. We have previously reported the presence of a new siaIidase activity in the gut of exclusively hematophagous insects of the Triatoma genus, which transmit Chagas' disease (Amino, R., Acosta, A, Morita, O. M., Chioccola, V. L. P., and Schenkman, S. (1995) Glycobiology 5, 625-631). Here we show that this sialidase is present in the salivary gland of Triatoma infestans, and it is released with the saliva during the insect bite. The sialidase was purified to homogeneity (>5000 times) to a specific activity of more than 20 units/mg. It elutes from a gel filtration column with a volume corresponding to the size of 33 kDa, and it migrates as a single 26-kDa band in SDS-polyacrylamide gel electrophoresis, which is unusually smaller when compared with other known sialidases. T. infestans sialidase hydrolyzes preferentially alpha 2-->3-linked sialic acids at pH 4-8, with maximaI activity between pH 5.5 and 6.5, which is compatible with the optimal pH of secreted sialidases. The sialidase is competitively inhibited by 2-deoxy-2,3-dehydro-N-acetyl-neuraminic acid (K-i = 0.075 mM) and differently from many sialidases, with exception of Salmonella typhimurium sialidase, it is inhibited competitively by HEPES (K-i = 15 mM). The fact that T. infestans sialidase is released with the saliva and can hydrolyze sialyl-Lewis(x) blood groups, which are the ligands for selectins, suggests that it might have a role in the blood feeding.	Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, BR-04023062 Sao Paulo, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Dept Histol, BR-04023062 Sao Paulo, Brazil; Ludwig Inst Canc Res, BR-01509010 Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Ludwig Institute for Cancer Research	Schenkman, S (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, R Botucatu 862-8, BR-04023062 Sao Paulo, Brazil.	Sergio.dmip@Epm.br	Marques-Porto, Rafael/H-3533-2016; Schenkman, Sergio/A-9227-2013; Chammas, Roger/A-8004-2011	Schenkman, Sergio/0000-0001-9353-8480; Chammas, Roger/0000-0003-0342-8726; Amino, Rogerio/0000-0002-8086-2932				AMINO R, 1995, GLYCOBIOLOGY, V5, P625, DOI 10.1093/glycob/5.6.625; ANSORGE W, 1983, ELECTROPHORESIS, V82, P235; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRIONES MRS, 1994, EXP PARASITOL, V79, P211, DOI 10.1006/expr.1994.1083; BRIONES MRS, 1995, J MOL EVOL, V41, P120, DOI 10.1007/BF00170663; BRIONES MRS, 1995, MOL BIOCHEM PARASIT, V70, P9, DOI 10.1016/0166-6851(95)00004-K; CHOU MY, 1994, J BIOL CHEM, V269, P18821; CHUANG NN, 1990, COMP BIOCHEM PHYS C, V97, P353, DOI 10.1016/0742-8413(90)90153-Z; Cocchiara R, 1997, J NEUROIMMUNOL, V75, P9, DOI 10.1016/S0165-5728(96)00229-9; CORFIELD T, 1992, GLYCOBIOLOGY, V2, P509, DOI 10.1093/glycob/2.6.509; COSTELLO M, 1979, NATURE, V281, P677, DOI 10.1038/281677a0; Crennell SJ, 1996, J MOL BIOL, V259, P264, DOI 10.1006/jmbi.1996.0318; CROSS GAM, 1993, ANNU REV MICROBIOL, V47, P385, DOI 10.1146/annurev.mi.47.100193.002125; DANG CV, 1989, J BIOL CHEM, V264, P15104; EMADIKHIAV B, 1995, EUR J PHARMACOL, V272, P97, DOI 10.1016/0014-2999(94)00628-K; ENGSTLER M, 1993, PARASITOL TODAY, V9, P222, DOI 10.1016/0169-4758(93)90018-B; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOSSRAU R, 1977, HISTOCHEMISTRY, V53, P189, DOI 10.1007/BF00498493; GUO XM, 1994, J AM CHEM SOC, V116, P5572, DOI 10.1021/ja00092a007; HARRIS JG, 1995, EUR J PHARMACOL, V279, P149, DOI 10.1016/0014-2999(95)00145-B; HOYER LL, 1991, J BIOCHEM-TOKYO, V110, P462, DOI 10.1093/oxfordjournals.jbchem.a123603; NOESKEJUNGBLUT C, 1995, J BIOL CHEM, V270, P28629, DOI 10.1074/jbc.270.48.28629; OConnell D, 1996, P NATL ACAD SCI USA, V93, P5883, DOI 10.1073/pnas.93.12.5883; Otsu K, 1995, EXP PARASITOL, V81, P529, DOI 10.1006/expr.1995.1146; PIRIESHEPHERD SR, 1995, J BIOL CHEM, V270, P5877, DOI 10.1074/jbc.270.11.5877; POWELL LD, 1986, ANAL BIOCHEM, V157, P179, DOI 10.1016/0003-2697(86)90211-3; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; ROGGENTIN P, 1993, MOL MICROBIOL, V9, P915, DOI 10.1111/j.1365-2958.1993.tb01221.x; Rosenberg A, 1976, BIOL ROLES SIALIC AC, P295; Saito M, 1995, BIOL SIALIC ACIDS, P261, DOI [10.1007/978-1-4757-9504-2_8, DOI 10.1007/978-1-4757-9504-2_8]; SCHAUB GA, 1992, ADV PARASIT, V31, P255, DOI 10.1016/S0065-308X(08)60023-8; SCHAUER R, 1989, BIOL CHEM H-S, V370, P183, DOI 10.1515/bchm3.1989.370.1.183; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SILVA CP, 1994, INSECT BIOCHEM MOLEC, V24, P493, DOI 10.1016/0965-1748(94)90044-2; STACK MS, 1992, BIOCHEM J, V284, P81, DOI 10.1042/bj2840081; TERRA WR, 1990, ANNU REV ENTOMOL, V35, P181, DOI 10.1146/annurev.en.35.010190.001145; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Vimr Eric R., 1994, Trends in Microbiology, V2, P271, DOI 10.1016/0966-842X(94)90003-5; WARE JA, 1995, HEMATOLOGY, P1161	40	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24575	24582		10.1074/jbc.273.38.24575	http://dx.doi.org/10.1074/jbc.273.38.24575			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733752	hybrid			2022-12-25	WOS:000076007300044
J	Skinner, KA; White, CR; Patel, R; Tan, S; Barnes, S; Kirk, M; Darley-Usmar, V; Parks, DA				Skinner, KA; White, CR; Patel, R; Tan, S; Barnes, S; Kirk, M; Darley-Usmar, V; Parks, DA			Nitrosation of uric acid by peroxynitrite - Formation of a vasoactive nitric oxide donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYL RADICAL PRODUCTION; HUMAN-BLOOD PLASMA; ORGANIC NITRATES; TYROSINE NITRATION; CARBON-DIOXIDE; PROTEIN MODIFICATIONS; S-NITROSOGLUTATHIONE; LIPID-PEROXIDATION; LUNG INJURY; SUPEROXIDE	Peroxynitrite (ONOO-), formed by the reaction between nitric oxide (. NO) and superoxide, has been implicated in the etiology of numerous disease processes. Low molecular weight antioxidants, including uric acid, may minimize ONOO--mediated damage to tissues. The tissue-sparing effects of uric acid are typically attributed to oxidant scavenging; however, little attention has been paid to the biology of the reaction products. In this study, a previously unidentified uric acid derivative was detected in ONOO--treated human plasma. The product of the uric acid/ONOO- reaction resulted in endothelium-independent vasorelaxation of rat thoracic aorta, with an EC50 value in the range of 0.03-0.3 mu M. Oxyhemoglobin, a . NO scavenger, completely attenuated detectable . NO release and vascular relaxation. Uric acid plus decomposed ONOO- neither released . NO nor altered vascular reactivity. Electrochemical quantification of . NO confirmed that the uric acid/ONOO- reaction resulted in spontaneous (thiol-independent) and protracted (t(1/2) similar to 125 min) release of . NO. Mass spectroscopic analysis indicated that the product was a nitrated uric acid derivative. The uric acid nitration/nitrosation product may play a pivotal role in human pathophysiology by releasing . NO, which could decrease vascular tone, increase tissue blood flow, and thereby constitute a role for uric acid not previously described.	Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35233 USA; Univ Alabama, Dept Med, Birmingham, AL 35233 USA; Univ Alabama, Dept Mol & Cellular Pathol, Birmingham, AL 35233 USA; Univ Alabama, Dept Pediat, Birmingham, AL 35233 USA; Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35233 USA; Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Parks, DA (corresponding author), Univ Alabama, Dept Anesthesiol, 619 S 19th St, Birmingham, AL 35233 USA.		Darley-Usmar, Victor/F-7656-2010	Darley-Usmar, Victor/0000-0001-8921-7086; Patel, Rakesh/0000-0002-1526-4303	NCRR NIH HHS [S10RR06487] Funding Source: Medline; NHLBI NIH HHS [HL 54815, HL 48676] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006487] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048676, R29HL054815] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; ANTONINI E, 1971, HAEMOGLOBIN MYOGLOBI, P12; BECKER BF, 1993, FREE RADICAL BIO MED, V14, P615, DOI 10.1016/0891-5849(93)90143-I; BECKER BF, 1991, CHEST, V100, pS176, DOI 10.1378/chest.100.3_Supplement.176S; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BENNETT BM, 1994, TRENDS PHARMACOL SCI, V15, P245, DOI 10.1016/0165-6147(94)90319-0; Berlett BS, 1996, P NATL ACAD SCI USA, V93, P1776, DOI 10.1073/pnas.93.5.1776; Caulfield JL, 1996, J BIOL CHEM, V271, P25859, DOI 10.1074/jbc.271.42.25859; Chang J, 1996, AM J PHYSIOL-LUNG C, V270, pL931, DOI 10.1152/ajplung.1996.270.6.L931; CholletMartin S, 1996, AM J RESP CRIT CARE, V153, P985, DOI 10.1164/ajrccm.153.3.8630584; CHONG S, 1991, BIOCHEM PHARMACOL, V42, P1433; Crow JP, 1996, ADV EXP MED BIOL, V387, P147; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; FUNG HL, 1993, AM J CARDIOL, V72, pC9, DOI 10.1016/0002-9149(93)90249-C; GIACOIA GP, 1995, SOUTH MED J, V88, P33, DOI 10.1097/00007611-199501000-00004; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; GROOTVELD M, 1987, BIOCHEM J, V243, P803, DOI 10.1042/bj2430803; GUTTERIDGE JMC, 1994, CHEM-BIOL INTERACT, V91, P133, DOI 10.1016/0009-2797(94)90033-7; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HADDAD IY, 1994, CHEST, V105, pS84, DOI 10.1378/chest.105.3_Supplement.84S; HADDAD IY, 1993, AM J PHYSIOL, V265, P555; HU P, 1994, AM J PHYSIOL, V266, pL628, DOI 10.1152/ajplung.1994.266.6.L628; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Ji YB, 1996, BIOCHEM J, V313, P377, DOI 10.1042/bj3130377; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kengatharan KM, 1996, BRIT J PHARMACOL, V119, P1411, DOI 10.1111/j.1476-5381.1996.tb16053.x; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; Konorev EA, 1996, BRIT J PHARMACOL, V119, P511, DOI 10.1111/j.1476-5381.1996.tb15701.x; KOWALUK EA, 1991, J PHARMACOL EXP THER, V259, P519; Langford EJ, 1996, ARTERIOSCL THROM VAS, V16, P51, DOI 10.1161/01.ATV.16.1.51; LIU S, 1994, J PHARMACOL EXP THER, V268, P1114; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; Mellander S, 1997, ACTA PHYSIOL SCAND, V160, P57, DOI 10.1046/j.1365-201X.1997.00117.x; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; MORO MA, 1995, BRIT J PHARMACOL, V116, P1999, DOI 10.1111/j.1476-5381.1995.tb16404.x; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182; RADOMSKI MW, 1993, CARDIOVASC RES, V27, P1380, DOI 10.1093/cvr/27.7.1380; Royall J A, 1995, New Horiz, V3, P113; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Shigenaga MK, 1997, P NATL ACAD SCI USA, V94, P3211, DOI 10.1073/pnas.94.7.3211; Skinner KA, 1997, ARCH BIOCHEM BIOPHYS, V342, P282, DOI 10.1006/abbi.1997.0114; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; Terada LS, 1996, J APPL PHYSIOL, V81, P2456, DOI 10.1152/jappl.1996.81.6.2456; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; VANDERVLIET A, 1994, BIOCHEM J, V303, P295, DOI 10.1042/bj3030295; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; WAYNER DDM, 1985, FEBS LETT, V187, P33, DOI 10.1016/0014-5793(85)81208-4; White CR, 1997, BIOCHEM J, V328, P517, DOI 10.1042/bj3280517; Whiteman M, 1996, FEBS LETT, V379, P74, DOI 10.1016/0014-5793(95)01489-6; WU MD, 1994, AM J PHYSIOL, V266, pH2108, DOI 10.1152/ajpheart.1994.266.5.H2108; WU XW, 1989, P NATL ACAD SCI USA, V86, P9412, DOI 10.1073/pnas.86.23.9412; Zapol W M, 1996, Acta Anaesthesiol Scand Suppl, V109, P81	68	111	116	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24491	24497		10.1074/jbc.273.38.24491	http://dx.doi.org/10.1074/jbc.273.38.24491			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733742	hybrid			2022-12-25	WOS:000076007300034
J	Katz, RA; Gravuer, K; Skalka, AM				Katz, RA; Gravuer, K; Skalka, AM			A preferred target DNA structure for retroviral integrase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-DNA; IN-VITRO; CRUCIFORM STRUCTURES; DIRECTS INTEGRATION; V(D)J RECOMBINATION; SUPERCOILED DNA; SITE SELECTION; HIV INTEGRASE; PROTEIN; INVITRO	The retroviral integrase protein catalyzes the insertion of linear viral DNA ends into the host cell DNA. Although integration in vivo is not site-specific, the detection of local and regional preferences within cellular DNA suggests that the integration reaction can be influenced by specific features of host DNA or chromatin. Here we describe highly preferred in vivo integration sites for avian sarcoma virus and human immunodeficiency virus-1 integrases within the stems of plasmid DNA cruciform structures, The preferred sites are adjacent to the loops ire the cruciform and are strand-specific. We suggest that the observed preference is due to the end-like character of the stem loop structure that allows DNA unpairing. From these results we propose that such unpairing may enhance both the processing and the joining steps in the integration reaction, and perhaps other cellular recombination reactions as men.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Katz, RA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	r_katz@fccc.edu	Gravuer, Kelly/AAJ-4802-2020	Gravuer, Kelly/0000-0002-2567-658X	NATIONAL CANCER INSTITUTE [R01CA071515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI040721, R01AI040385] Funding Source: NIH RePORTER; NCI NIH HHS [CA71515] Funding Source: Medline; NIAID NIH HHS [AI40721, AI40385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; BUSHMAN FD, 1994, P NATL ACAD SCI USA, V91, P9233, DOI 10.1073/pnas.91.20.9233; CAIN RJ, 1995, NUCLEIC ACIDS RES, V23, P2153, DOI 10.1093/nar/23.12.2153; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; Curcio MJ, 1996, TRENDS GENET, V12, P436; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FITZGERALD ML, 1994, J VIROL, V68, P4314, DOI 10.1128/JVI.68.7.4314-4321.1994; FURLONG JC, 1986, NUCLEIC ACIDS RES, V14, P3995, DOI 10.1093/nar/14.10.3995; Goulaouic H, 1996, J VIROL, V70, P37, DOI 10.1128/JVI.70.1.37-46.1996; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; MURCHIE AIH, 1992, METHOD ENZYMOL, V211, P158; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; Pearson CE, 1996, J CELL BIOCHEM, V63, P1; PRUSS D, 1994, J BIOL CHEM, V269, P25031; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3	37	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24190	24195		10.1074/jbc.273.37.24190	http://dx.doi.org/10.1074/jbc.273.37.24190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727042	hybrid			2022-12-25	WOS:000075893100083
J	Krause, A; Holtmann, H; Eickemeier, S; Winzen, R; Szamel, M; Resch, K; Saklatvala, J; Kracht, M				Krause, A; Holtmann, H; Eickemeier, S; Winzen, R; Szamel, M; Resch, K; Saklatvala, J; Kracht, M			Stress-activated protein kinase Jun N-terminal kinase is required for interleukin (IL)-1-induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; KAPPA-B KINASE; C-JUN; MAP KINASE; TRANSCRIPTION FACTOR; INFLAMMATORY CYTOKINES; NH2-TERMINAL KINASE; NUCLEAR FACTOR; MESSENGER-RNA	The cytokine interleukin-l (IL-1) is a major inflammatory hormone which activates a broad range of genes during inflammation. The signaling mechanisms triggered by IL-1 include activation of several distinct protein kinase systems. The stress-activated protein kinase (SAPK), also termed Jun N-terminal kinase (JNK), is activated particularly strongly by the cytokine. In an attempt to delineate its role in activation of gene expression by IL-1, we inhibited the IL-l-induced SAPK/JNK activity by stable overexpression of either a catalytically inactive mutant of SAPK beta (SAPK beta(K-R)) or antisense RNA to SAPK beta in human epidermal carcinoma cells. A detailed analysis of signal transduction in those cells showed that activation of neither NF kappa B nor p38 mitogen-activated protein kinase was affected, suggesting that we achieved specific blockade of the SAPK/JNK. In untransfected and vector-transfected KB cells, IL-1 induced a strong increase in expression of IL-6 and IL-8 mRNA, along with the synthesis of high amounts of the proteins. In two KB cell clones stably overexpressing the mutant SAPK beta(K-R), and three clones stably overexpressing antisense RNA to SAPK beta, expression of IL-6 and IL-8 in response to IL-1 was strongly reduced at both the mRNA and protein level. These data indicate that the SAPK/JNK pathway provides an indispensable signal for IL-l-induced expression of IL-6 and IL-8.	Hannover Med Sch, Inst Mol Pharmacol, D-30625 Hannover, Germany; Kennedy Inst Rheumatol, London W6 8LH, England	Hannover Medical School; University of Oxford	Kracht, M (corresponding author), Hannover Med Sch, Inst Mol Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.			Kracht, Michael/0000-0002-8501-043X				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRIGELIUSFLOHE R, 1996, BIOFACTORS, V9, P1; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAO Z, 1996, SCIENCE, V383, P443; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; ELIAS JA, 1990, J IMMUNOL, V145, P161; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUESDON F, 1993, J BIOL CHEM, V268, P14343; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAWLER S, 1997, FEBS LETT, V414, P153; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kannabiran C, 1997, MOL CELL BIOL, V17, P1, DOI 10.1128/MCB.17.1.1; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; KRACHT M, 1994, BIOCHEM J, V302, P897, DOI 10.1042/bj3020897; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; KUNSCH C, 1994, J IMMUNOL, V153, P153; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NG SB, 1994, J BIOL CHEM, V269, P19021; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ridley SH, 1997, J IMMUNOL, V158, P3165; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1994, J BIOL CHEM, V269, P25699; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; STOECKLE MY, 1991, NUCLEIC ACIDS RES, V19, P917, DOI 10.1093/nar/19.4.917; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Uciechowski P, 1996, FEBS LETT, V394, P273, DOI 10.1016/0014-5793(96)00967-2; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wu GD, 1997, J BIOL CHEM, V272, P2396; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	66	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23681	23689		10.1074/jbc.273.37.23681	http://dx.doi.org/10.1074/jbc.273.37.23681			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726973	hybrid			2022-12-25	WOS:000075893100014
J	McCartney, RG; Rice, JE; Sanderson, SJ; Bunik, V; Lindsay, H; Lindsay, JG				McCartney, RG; Rice, JE; Sanderson, SJ; Bunik, V; Lindsay, H; Lindsay, JG			Subunit interactions in the mammalian alpha-ketoglutarate dehydrogenase complex - Evidence for direct association of the alpha-ketoglutarate dehydrogenase and dihydrolipoamide dehydrogenase components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE; 2-OXOGLUTARATE DEHYDROGENASE; PROTEIN-X; SACCHAROMYCES-CEREVISIAE; MULTIENZYME COMPLEXES; MOLECULAR-CLONING; SUCCINYLTRANSFERASE COMPONENT; STRUCTURAL ORGANIZATION; BOVINE HEART; GENE	Selective tryptic proteolysis of the mammalian alpha-ketoglutarate dehydrogenase complex (OGDC) leads to its rapid inactivation as a result of a single cleavage within the N-terminal region of its alpha-ketoglutarate dehydrogenase (E1) component, which promotes the dissociation of the dihydrolipoamide dehydrogenase (E3) enzyme smd also a fully active E1' fragment. Similarities between the N-terminal region of E1 and the dihydrolipoamide acetyltransferase (E2) and E2-binding components (E3BP) of the pyruvate dehydrogenase complex are highlighted by the specific cross-reactivities of subunit-specific antisera. Analysis of the pattern of release of E1 and E1' polypeptides from the OGDC during tryptic inactivation suggests that both polypeptide chains of individual E1 homodimers must be cleaved to permit the dissociation of the E1 and E3 components. A new protocol has been devised that promotes E1 dissociation from the oligomeric dihydrolipoamide succinyltransferase (E2) core in an active state. Significant Bevels of overall OGDC reconstitution could also be achieved by re-mixing the constituent enzymes in stoichiometric amounts. Moreover, a high affinity interaction has been demonstrated between the homodimeric E1 and E3 components, which form a stable subcomplex comprising single copies of these two enzymes.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	University of Glasgow; Lomonosov Moscow State University	Lindsay, JG (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	G.Lindsay@bio.gla.ac.uk	Bunik, Victoria/E-3427-2012	Bunik, Victoria/0000-0002-2552-8560	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEHAL RH, 1993, ANNU REV NUTR, V13, P497, DOI 10.1146/annurev.nu.13.070193.002433; BROWN JP, 1976, BIOCHEM J, V155, P419, DOI 10.1042/bj1550419; DEMARCUCCI O, 1985, EUR J BIOCHEM, V149, P641, DOI 10.1111/j.1432-1033.1985.tb08972.x; DEMARCUCCI OL, 1985, BIOCHEM J, V226, P509, DOI 10.1042/bj2260509; JACKMAN SA, 1990, EUR J BIOCHEM, V193, P91, DOI 10.1111/j.1432-1033.1990.tb19308.x; JILKA JM, 1986, J BIOL CHEM, V261, P1858; Khailova L S, 1977, Biokhimiia, V42, P113; LAU KS, 1992, J BIOL CHEM, V267, P24090; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P11249, DOI 10.1021/bi00111a009; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; Mattevi A., 1992, CURR OPIN STRUC BIOL, V2, P877, DOI [10.1016/0959-440X(92)90114-M, DOI 10.1016/0959-440X(92)90114-M]; McCartney RG, 1997, BIOCHEMISTRY-US, V36, P6819, DOI 10.1021/bi9630016; NAKANO K, 1994, EUR J BIOCHEM, V224, P179, DOI 10.1111/j.1432-1033.1994.tb20010.x; NAKANO K, 1991, J BIOL CHEM, V266, P19013; NEAGLE JC, 1991, BIOCHEM J, V278, P423, DOI 10.1042/bj2780423; ODonohue J, 1996, QJM-MON J ASSOC PHYS, V89, P5, DOI 10.1093/oxfordjournals.qjmed.a030137; PATEL MS, 1995, FASEB J, V9, P1164, DOI 10.1096/fasebj.9.12.7672509; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; RICE JE, 1992, EMBO J, V11, P3229, DOI 10.1002/j.1460-2075.1992.tb05400.x; Sanderson SJ, 1996, BIOCHEM J, V319, P109, DOI 10.1042/bj3190109; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; SPENCER ME, 1984, EUR J BIOCHEM, V141, P361, DOI 10.1111/j.1432-1033.1984.tb08200.x; STANLEY C, 1980, BIOCHEM J, V257, P625; Stoops JK, 1997, J BIOL CHEM, V272, P5757, DOI 10.1074/jbc.272.9.5757; Usuda Y, 1996, MICROBIOL-UK, V142, P3347, DOI 10.1099/13500872-142-12-3347; WESTPHAL AH, 1990, EUR J BIOCHEM, V187, P235, DOI 10.1111/j.1432-1033.1990.tb15300.x	30	37	40	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24158	24164		10.1074/jbc.273.37.24158	http://dx.doi.org/10.1074/jbc.273.37.24158			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727038	hybrid			2022-12-25	WOS:000075893100079
J	Ness, SL; Edelmann, W; Jenkins, TD; Liedtke, W; Rustgi, AK; Kucherlapati, R				Ness, SL; Edelmann, W; Jenkins, TD; Liedtke, W; Rustgi, AK; Kucherlapati, R			Mouse keratin 4 is necessary for internal epithelial integrity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE SPONGE NEVUS; EPIDERMOLYSIS-BULLOSA SIMPLEX; INTERMEDIATE FILAMENTS; MESSENGER-RNAS; CELL TYPE; EXPRESSION; MUTATION; DIFFERENTIATION; HYPERKERATOSIS; GENES	Keratins are intermediate filaments ts of epithelial cells. Mutations in keratin genes expressed in skis lead to human disorders, including epidermolysis bullosa simplex and epidermolytic hyperkeratosis. We examined the role of keratin 4 (K4) in maintaining the integrity of internal epithelial linings by using gene targeting to generate mice containing a null mutation in the epithelial K4 gene. Homozygous mice that do not express K4 develop a spectrum of phenotypes that affect several organs which express K4 including the esophagus, tongue, and cornea. The cellular phenotypes include basal hyperplasia, Hack of maturation, hyperkeratosis, atypical nuclei, perinuclear clearing, and cell degeneration. These results are consistent with the notion that K4 is required for internal epithelial cell integrity. As mutations in K4 in humans lead to a disorder called white sponge nevus, the K4-deficient mice may serve as models Tor white sponge nevus and for understanding the role of K4 in cellular proliferation and differentiation.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hematol Oncol Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Div Neuropathol, Bronx, NY 10461 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10023 USA	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Rockefeller University	Kucherlapati, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	kucherla@aecom.yu.edu	Liedtke, Wolfgang B/G-4633-2011; Kucherlapati, Raju/ABC-8807-2021; Liedtke, Wolfgang/GNH-1878-2022		NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13330] Funding Source: Medline; NIDDK NIH HHS [DK40561] Funding Source: Medline; NIGMS NIH HHS [T32GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; CHAN YM, 1994, GENE DEV, V8, P2574, DOI 10.1101/gad.8.21.2574; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; COMPTON JG, 1991, ANN NY ACAD SCI, V642, P32; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; FRITHIOF L, 1976, ORAL SURG ORAL MED O, V41, P607, DOI 10.1016/0030-4220(76)90313-3; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; KLYMKOWSKY MW, 1983, J CELL BIOL, V96, P494, DOI 10.1083/jcb.96.2.494; KNAPP B, 1986, NUCLEIC ACIDS RES, V14, P751, DOI 10.1093/nar/14.2.751; KRAJEWSKA IA, 1992, PATHOLOGY, V24, P112, DOI 10.3109/00313029209063635; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LAUWERYNS B, 1993, INVEST OPHTH VIS SCI, V34, P1983; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; MCGINNIS JP, 1975, ORAL SURG ORAL MED O, V40, P644, DOI 10.1016/0030-4220(75)90374-6; MOLL R, 1982, DIFFERENTIATION, V23, P170, DOI 10.1111/j.1432-0436.1982.tb01280.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Moore K.L., 1988, DEV HUMAN, V4th ed.; MORRIS R, 1988, ACTA CYTOL, V32, P357; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; RICHARD G, 1995, NAT GENET, V11, P453, DOI 10.1038/ng1295-453; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; RUGG EL, 1995, NAT GENET, V11, P450, DOI 10.1038/ng1295-450; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAWAF MH, 1992, PATHOL BIOL, V40, P655; SAYAG J, 1985, ANN DERMATOL VENER, V112, P759; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; VANMUIJEN GNP, 1986, EXP CELL RES, V162, P97, DOI 10.1016/0014-4827(86)90429-5; VIAENE AI, 1995, ANAT REC, V241, P88, DOI 10.1002/ar.1092410112; WILEY L, 1991, INVEST OPHTH VIS SCI, V32, P594; WOLFE HG, 1966, BIOL LAB MOUSE; WURST W, 1995, GENE TARGETING PRACT, P234	37	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23904	23911		10.1074/jbc.273.37.23904	http://dx.doi.org/10.1074/jbc.273.37.23904			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727004	hybrid			2022-12-25	WOS:000075893100045
J	Belkner, J; Stender, H; Kuhn, H				Belkner, J; Stender, H; Kuhn, H			The rabbit 15-lipoxygenase preferentially oxygenates LDL cholesterol esters, and this reaction does not require vitamin E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TOCOPHEROL-MEDIATED PEROXIDATION; HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; ATHEROSCLEROTIC LESIONS; RETICULOCYTE LIPOXYGENASE; OXIDATIVE MODIFICATION; INITIATED OXIDATION; MESSENGER-RNA; PROTEIN; ATHEROGENESIS	The oxidation of low density lipoprotein (LDL) by mammalian 15-lipoxygenases (15-LOX) was implicated in early atherogenesis, We investigated the molecular mechanism of 15-LOX/LDL interaction and found that during short term incubations, LDL cholesterol esters are oxygenated preferentially by the enzyme. Even when the LDL particle was loaded with free linoleic acid, cholesteryl linoleate constituted the major LOX substrate. In contrast, only small amounts of free oxygenated fatty acid isomers were detected, and re-esterification of oxidized fatty acids into the LDL ester lipid fraction was ruled out. When LDL was depleted from alpha-tocopherol, specific oxygenation of the cholesterol esters was not prevented, and the product pattern was not altered. Similar results were obtained at low (LDL/LOX ratio of 1:1) and high LOX loading (LDL/LOX ratio of 1:10) of the LDL particle. During long term incubations (up to 24 h), a less specific product pattern was observed. However, when the hydroperoxy lipids formed by the 15-LOX were immediately reduced by the phospholipid hydroperoxide glutathione peroxidase, when the reaction was carried out with vitamin E-depleted LDL, or when the assay sample was diluted, the specific pattern of oxygenation products was retained over a long period of time. These data suggest that mammalian 15-LOX preferentially oxidize LDL cholesterol esters, forming a specific pattern of oxygenation products. During long term incubations, free radical-mediated secondary reactions, which lead to a more unspecific product pattern, may become increasingly important. These secondary reactions appear to be suppressed when the hydroperoxy lipids formed are immediately reduced, when alpha-tocopherol-depleted LDL was used, or when the incubation sample was diluted. It may be concluded that 15-LOX-initiated LDL oxidation constitutes a dual-type oxygenase reaction with an initial enzymatic and a subsequent nonenzymatic phase. The biological relevance of this dual-type reaction for atherogenesis will be discussed.	Humboldt Univ, Univ Clin Charite, Inst Biochem, D-10115 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kuhn, H (corresponding author), Humboldt Univ, Univ Clin Charite, Inst Biochem, Hess Str 3-4, D-10115 Berlin, Germany.	hartmut.kuehn@rz.hu-berlin.de						BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BELKNER J, 1991, FEBS LETT, V279, P110, DOI 10.1016/0014-5793(91)80263-3; BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; Harats D, 1997, ATHEROSCLEROSIS, V134, P279, DOI 10.1016/S0021-9150(97)89459-2; HARLAND WA, 1973, BIOCHIM BIOPHYS ACTA, V316, P378, DOI 10.1016/0005-2760(73)90076-3; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HILTUNEN T, 1995, CIRCULATION, V92, P3297, DOI 10.1161/01.CIR.92.11.3297; HOLVOET P, 1994, FASEB J, V8, P1279, DOI 10.1096/fasebj.8.15.8001740; KHOO JC, 1981, J BIOL CHEM, V256, P2659; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1992, EICOSANOIDS, V5, P17; KUHN H, 1994, J LIPID RES, V35, P1749; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; Kuhn H, 1997, J CLIN INVEST, V99, P888, DOI 10.1172/JCI119253; Kuhn H, 1997, CURR OPIN LIPIDOL, V8, P111; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P80, DOI 10.1016/0005-2760(93)90085-N; Lass A, 1996, BIOCHEM J, V314, P577, DOI 10.1042/bj3140577; MIDDLETON B, 1992, BIOCHEM BIOPH RES CO, V182, P830, DOI 10.1016/0006-291X(92)91807-3; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; OLEARY VJ, 1992, BIOCHEM J, V282, P631, DOI 10.1042/bj2820631; PORTER N, 1985, J CHEM SOC CHEM COMM, P1472, DOI 10.1039/c39850001472; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SATTLER W, 1994, ARCH BIOCHEM BIOPHYS, V309, P214, DOI 10.1006/abbi.1994.1105; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; Schnurr K, 1996, J BIOL CHEM, V271, P4653; Sendobry SM, 1997, BRIT J PHARMACOL, V120, P1199, DOI 10.1038/sj.bjp.0701007; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; Shen JH, 1995, FASEB J, V9, P1623, DOI 10.1096/fasebj.9.15.8529842; SPARROW CP, 1988, J LIPID RES, V29, P745; TAKANO T, 1990, J PHARMACOBIO-DYNAM, V13, P385, DOI 10.1248/bpb1978.13.385; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Upston JM, 1996, J LIPID RES, V37, P2650; Upston JM, 1997, J BIOL CHEM, V272, P30067, DOI 10.1074/jbc.272.48.30067; URSINI F, 1995, METHOD ENZYMOL, V252, P38; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971	43	98	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23225	23232		10.1074/jbc.273.36.23225	http://dx.doi.org/10.1074/jbc.273.36.23225			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722553	hybrid			2022-12-25	WOS:000075778100053
J	Loo, DT; Kanner, SB; Aruffo, A				Loo, DT; Kanner, SB; Aruffo, A			Filamin binds to the cytoplasmic domain of the beta(1)-integrin - Identification of amino acids responsible for this interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; LATE ACTIVATION ANTIGEN-4; BETA-1 INTEGRIN SUBUNIT; LYMPHOCYTE MIGRATION; TRANSENDOTHELIAL MIGRATION; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; PLASMA FIBRONECTIN; HUMAN-PLATELETS; VLA-4 INTEGRIN	Integrins play an important role in regulating cell adhesion, motility, and activation. In an effort to identify intracellular proteins expressed by activated T cells that interact with the cytoplasmic domain of beta(1)-integrin (CD29), we used the beta(1)-integrin cytoplasmic domain as bait in the yeast two-hybrid system. Here we report that the cytoplasmic domain of beta(1)-integrin specifically interacts with the cytoskeletal protein filamin. This interaction required all but the most carboxyl-terminal three residues of the cytoplasmic domain of beta(1), and the carboxyl-terminal 477 residues of filamin containing the terminal 4.5 similar to 96-residue tandem repeats of filamin. To verify this interaction in vivo, we showed that filamin specifically coprecipitated with beta(1) in mammalian cells. We also showed that recombinant filamin chimeric proteins were able to bind to the beta(1) cytoplasmic domain in vitro. We observed that a subset of single point mutations in the cytoplasmic domain of beta(1), which had been previously reported to impair its function, disrupt the interaction between beta(1) and filamin, Taken together, these findings suggest that the interaction between beta(1) and filamin, which in turn can bind actin, provides a mechanism for the interaction of this cell surface receptor with cytoskeletal proteins and that this interaction plays a role in normal receptor function.	Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA	Bristol-Myers Squibb	Loo, DT (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, POB 4000, Princeton, NJ 08543 USA.	lood@bms.com						ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BARON JL, 1994, J CLIN INVEST, V93, P1700, DOI 10.1172/JCI117153; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; CARLOS TM, 1990, BLOOD, V76, P965; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; CHAN PY, 1993, J BIOL CHEM, V268, P24655; CHISHOLM PL, 1993, EUR J IMMUNOL, V23, P682, DOI 10.1002/eji.1830230317; CHULUYAN HE, 1993, J CLIN INVEST, V92, P2768, DOI 10.1172/JCI116895; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FERGUSON TA, 1993, J IMMUNOL, V150, P1172; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HAUZENBERGER D, 1994, J IMMUNOL, V153, P960; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKUBOWSKI A, 1995, J IMMUNOL, V155, P938; KANNER SB, 1992, J IMMUNOL, V148, P2023; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KWEE L, 1995, DEVELOPMENT, V121, P489; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MASSIA SP, 1992, J BIOL CHEM, V267, P14019; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MOLOSSI S, 1995, J CELL PHYSIOL, V164, P620, DOI 10.1002/jcp.1041640321; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PRETOLANI M, 1994, J EXP MED, V180, P795, DOI 10.1084/jem.180.3.795; RATNER S, 1992, INVAS METAST, V12, P82; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SHIMIZU Y, 1992, J EXP MED, V175, P577, DOI 10.1084/jem.175.2.577; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; VanNhieu GT, 1996, J BIOL CHEM, V271, P7665, DOI 10.1074/jbc.271.13.7665; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	58	158	160	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23304	23312		10.1074/jbc.273.36.23304	http://dx.doi.org/10.1074/jbc.273.36.23304			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722563	hybrid			2022-12-25	WOS:000075778100063
J	Dubocovich, ML; Yun, K; Al-Ghoul, WM; Benloucif, S; Masana, MI				Dubocovich, ML; Yun, K; Al-Ghoul, WM; Benloucif, S; Masana, MI			Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms	FASEB JOURNAL			English	Article						melatonin receptors; suprachiasmatic nucleus; C3H/HeN mouse; luzindole; 4P-ADOT; 4P-PDOT; mt(1); Mel(1a); Mel(1b)	RAT SUPRACHIASMATIC NUCLEI; SUBTYPES; RETINA; CLOCK; LOCALIZATION; PHARMACOLOGY; INHIBITION; MODULATION; RESPONSES; BINDING	This study demonstrates the involvement of the MT2 (Mel(1b)) melatonin receptor in mediating phase advances of circadian activity rhythms by melatonin, In situ hybridization histochemistry with digoxigenin-labeled oligonucleotide probes revealed for the first time the expression of mt(1) and MT2 melatonin receptor mRNA within the suprachiasmatic nucleus of the C3H/HeN mouse. Melatonin (0.9 to 30 mu g/mouse, s.c.) administration during 3 days at the end of the subjective day (CT 10) to C3H/HeN mice kept in constant dark phase advanced circadian rhythms of wheel running activity in a dose-dependent manner [EC50=0.72 mu g/mouse; 0.98+/-0.08 h (n=15) maximal advance at 9 mu g/mouse], Neither the selective MT2 melatonin receptor antagonists 4P-ADOT and 4P-PDOT (90 mu/mouse, s.c.) nor luzindole (300 mu g/mouse, s.c.), which shows 25-fold higher affinity for the MTS than the mt(1) subtype, affected the phase of circadian activity rhythms when given alone at CT 10, All three antagonists, however, shifted to the right the dose-response curve to melatonin, as they significantly reduced the phase shifting effects of 0.9 and 3 mu g melatonin, This is the first study to demonstrate that melatonin phase advances circadian rhythms by activation of a membrane-bound melatonin receptor and strongly suggests that this effect is mediated through the MT2 melatonin receptor subtype within the circadian timing system. We conclude that the MT2 melatonin receptor subtype is a novel therapeutic target for the development of subtype-selective analogs for the treatment of circadian sleep and mood-related disorders.-Dubocovich, M. L., Yun, K., Al-Ghoul, W. M., Benloucif, S., Masana, M, I. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms.	Northwestern Univ, Dept Mol Pharmacol & Biol Chem S215, Sch Med, Drug Discovery Program, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Dubocovich, ML (corresponding author), Northwestern Univ, Dept Mol Pharmacol & Biol Chem S215, Sch Med, Drug Discovery Program, 303 E Chicago Ave, Chicago, IL 60611 USA.	dubo@nwu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052685, R01MH042922] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES 07124] Funding Source: Medline; NIMH NIH HHS [R01 MH052685-05, R01 MH042922-14, MH 52685, R01 MH052685, R01 MH042922, MH 42922] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMSTRONG SM, 1993, MELATONIN BIOSYNTHES, P187; Benloucif S, 1997, AM J PHYSIOL-REG I, V273, pR1855, DOI 10.1152/ajpregu.1997.273.6.R1855; Benloucif S, 1996, J BIOL RHYTHM, V11, P113, DOI 10.1177/074873049601100204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cassone V M, 1986, J Biol Rhythms, V1, P219, DOI 10.1177/074873048600100304; CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V; CASSONE VM, 1987, NEUROSCI LETT, V81, P29, DOI 10.1016/0304-3940(87)90335-1; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Conway S, 1997, FEBS LETT, V407, P121, DOI 10.1016/S0014-5793(97)00315-3; Doolen S, 1998, EUR J PHARMACOL, V345, P67, DOI 10.1016/S0014-2999(98)00064-8; DUBOCOVICH ML, 1983, NATURE, V306, P782, DOI 10.1038/306782a0; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; Dubocovich ML, 1996, BEHAV BRAIN RES, V73, P141; DUBOCOVICH ML, 1988, J PHARMACOL EXP THER, V246, P902; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; DUBOCOVICH ML, 1993, PHARM LIBR, V20, P285; DUBOCOVICH ML, 1998, MELATONIN RECEPTORS, P187; Foulkes NS, 1997, TRENDS NEUROSCI, V20, P487, DOI 10.1016/S0166-2236(97)01109-0; GOTO M, 1989, J PINEAL RES, V7, P195, DOI 10.1111/j.1600-079X.1989.tb00667.x; HAGAN RM, 1995, TRENDS PHARMACOL SCI, V16, P81, DOI 10.1016/S0165-6147(00)88985-3; Horn A. S., 1992, [No title captured], Patent No. [US5151446, 5151446]; KRAUSE DN, 1995, EUR J PHARMACOL, V276, P207, DOI 10.1016/0014-2999(95)00028-J; LAITINEN JT, 1990, ENDOCRINOLOGY, V126, P2110, DOI 10.1210/endo-126-4-2110; LEWY AJ, 1992, CHRONOBIOL INT, V9, P380, DOI 10.3109/07420529209064550; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; Masana MI, 1998, INT CONGR SER, V1152, P301; McArthur AJ, 1997, ENDOCRINOLOGY, V138, P627, DOI 10.1210/en.138.2.627; MILLER JA, 1987, NEUROSCI LETT, V81, P345, DOI 10.1016/0304-3940(87)90408-3; MIRANDA RC, 1992, CEREB CORTEX, V2, P1, DOI 10.1093/cercor/2.1.1; MORGAN PJ, 1994, NEUROCHEM INT, V24, P101, DOI 10.1016/0197-0186(94)90100-7; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SACK RL, 1992, J CLIN ENDOCR METAB, V75, P127, DOI 10.1210/jc.75.1.127; SIUCIAK JA, 1990, EUR J PHARMACOL, V180, P387, DOI 10.1016/0014-2999(90)90328-4; STARKEY SJ, 1995, NEUROREPORT, V6, P1947, DOI 10.1097/00001756-199510020-00029; Vanhoutte PM, 1996, PHARMACOL REV, V48, P1; Wirz-Justice Anna, 1995, P999; WittEnderby PA, 1996, MOL PHARMACOL, V50, P166; Ying SW, 1996, EUR J PHARMACOL, V296, P33, DOI 10.1016/0014-2999(95)00684-2; ZHDANOVA IV, 1995, CLIN PHARMACOL THER, V57, P552, DOI 10.1016/0009-9236(95)90040-3	41	316	341	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1211	1220		10.1096/fasebj.12.12.1211	http://dx.doi.org/10.1096/fasebj.12.12.1211			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737724				2022-12-25	WOS:000075738500016
J	Kothapalli, D; Hayashi, N; Grotendorst, GR				Kothapalli, D; Hayashi, N; Grotendorst, GR			Inhibition of TGF-beta-stimulated CTGF gene expression and anchorage-independent growth by cAMP identifies a CTGF-dependent restriction point in the cell cycle	FASEB JOURNAL			English	Article						signal transduction; promoter; wound repair; fibrosis; growth regulation	INDUCIBLE GENE; PROLIFERATION; FIBROBLASTS; PLATELETS; PATHWAYS; PROTEIN; FAMILY; ARREST; AMP	CTGF is a 38 kDa cysteine-rich peptide whose synthesis and secretion are selectively induced by transforming growth factor beta (TGF-beta) in connective tissue cells. We have investigated the sig naling pathways controlling the TGF-beta induction of connective tissue growth factor (CTGF) gene expression. Our studies indicate that inhibitors of tyrosine kinases and protein kinase C do not block the signaling pathway used by TGF-beta to induce CTGF gene expression. In contrast, elevation of cAMP levels within the target cells by a variety of methods blocked the induction of CTGF by TGF-beta, Furthermore, agents that elevate cAMP blocked the induction of anchorage-independent growth (AIG) by TGF-beta, Inhibition of AIG could be overcome by the addition of CTGF, indicating that it was not a general inhibition of growth but a selective inhibition of CTGF synthesis that is responsible for the inhibition of TGF-beta-induced AIG by cAMP, Kinetic studies of the induction of DNA synthesis by CTGF in cells arrested by cAMP indicate that the block occurs in very late G(1), These and other studies in monolayer cultures suggest that the CTGF restriction point in the cell cycle is distinct from the adhesion-dependent arrest point.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami	Grotendorst, GR (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, 1600 NW 10th Ave, Miami, FL 33136 USA.				NIGMS NIH HHS [GM37223] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037223] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; ASSOIAN RK, 1993, CELL BIOL BIOTECHNOL; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CHILDS CB, 1982, P NATL ACAD SCI-BIOL, V79, P5312, DOI 10.1073/pnas.79.17.5312; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; EDWARDS DR, 1991, HORMONAL CONTROL REG, V16; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; GROTENDORST GR, 1989, J CELL PHYSIOL, V140, P396, DOI 10.1002/jcp.1041400226; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HAMMES MS, 1995, KIDNEY INT, V48, P501, DOI 10.1038/ki.1995.320; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1989, CANCER RES, V49, P6024; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; THALACKER FW, 1992, BIOCHEM J, V287, P855, DOI 10.1042/bj2870855; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	34	96	100	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1151	1161		10.1096/fasebj.12.12.1151	http://dx.doi.org/10.1096/fasebj.12.12.1151			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737718				2022-12-25	WOS:000075738500010
J	Hui, R; Ball, JR; Macmillan, RD; Kenny, FS; Prall, OWJ; Campbell, DH; Cornish, AL; McClelland, RA; Daly, RJ; Forbes, JF; Blamey, RW; Musgrove, EA; Robertson, JFR; Nicholson, RI; Sutherland, RL				Hui, R; Ball, JR; Macmillan, RD; Kenny, FS; Prall, OWJ; Campbell, DH; Cornish, AL; McClelland, RA; Daly, RJ; Forbes, JF; Blamey, RW; Musgrove, EA; Robertson, JFR; Nicholson, RI; Sutherland, RL			EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival	ONCOGENE			English	Article						EMS1; cyclin D1; breast cancer; prognosis	CHROMOSOME 11Q13 REGION; ONCOGENE AMPLIFICATION; PROGNOSTIC VALUE; HUMAN CARCINOMAS; POOR PROGNOSIS; CONTACT SITES; CELL-LINES; OVEREXPRESSION; PHOSPHORYLATION; IDENTIFICATION	The EMS1 and CCND1 genes at chromosome 11q13 are amplified in about 15% of primary breast cancers but appear to confer different phenotypes in ER positive and ER negative tumours, Since there are no published data on EMS1 expression in large series of breast cancers we examined the relationship of EMS1 expression with EMSI gene copy number and expression of mRNAs for cyclin D1 and ER, In a subset of 129 patients, where matched tumour RNA and DNA was available, EMS1 mRNA overexpression was associated predominantly with gene amplification (P=0.0061), whereas cyclin DT mRNA overexpression was not (P=0.3142). In a more extensive series;of 351 breast cancers, there was no correlation between cyclin D1 and EMS1 expression in the EMS1 and cyclin D1 overexpressors (P=0.3503). Although an association between EMS1 mRNA expression and ER positivity was evident (P=0.0232), when the samples were divided into quartiles of EMSI or cyclin D1 mRNA expression, the increase in the proportion of ER positive tumours in the ascending EMS1 mRNA quartiles was not statistically significant (P=0.0951), In marked contrast there was a significant stepwise increase in ER positivity in ascending quartiles of cyclin D1 mRNA (P=0.030), A potential explanation for this difference was provided by the observation that in ER positive breast cancer cells oestradiol treatment resulted in increased cyclin D1 gene expression but was without effect on EMS1, The relationship between EMSI expression and clinical outcome was examined in a subset of 234 patients with median follow-up of 74 months, High EMSI expression was associated with age >50 years (P=0.0001), postmenopausal status (P=0.0008), lymph node negativity (P=0.019) and an apparent trend for worse prognosis in the ER negative subgroup, These data demonstrate that overexpression of EMS1 mRNA is largely due to EMSI gene amplification, is independent of cyclin DI and ER expression and, in contrast to cyclin D1, is not regulated by oestrogen, Independent overexpression of these genes may confer different phenotypes and disease outcomes in breast cancer as has been inferred from recent studies of EMSI and CCND1 gene amplification.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Mater Misericordiae Hosp, Dept Surg Oncol, Waratah, NSW 2298, Australia; City Hosp Nottingham, Dept Surg, Nottingham NG5 1PB, England; Univ Wales Coll Med, Breast Canc Unit, Tenovus Canc Res Ctr, Cardiff CF4 4XX, S Glam, Wales	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Cardiff University	Sutherland, RL (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.		Ball, Jonathon/K-1076-2015; Daly, Roger J/C-8179-2009; Sutherland, Robert L/A-8378-2008	Ball, Jonathon/0000-0003-0594-8063; Daly, Roger/0000-0002-5739-8027; Campbell, Douglas/0000-0001-9699-1854				ADNANE J, 1989, ONCOGENE, V4, P1389; Altucci L, 1996, ONCOGENE, V12, P2315; BARTKOVA J, 1995, ONCOGENE, V10, P775; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BERNS EMJJ, 1992, EUR J CANCER, V28A, P697, DOI 10.1016/S0959-8049(05)80129-7; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; Bringuier PP, 1996, ONCOGENE, V12, P1747; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FANTL V, 1993, CANCER SURV, V18, P77; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; GAFFEY MJ, 1993, MODERN PATHOL, V6, P654; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Hui R, 1996, CLIN CANCER RES, V2, P923; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Patel AM, 1996, ONCOGENE, V12, P31; Pelosio P, 1996, ANN ONCOL, V7, P695; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; vanDiest PJ, 1997, AM J PATHOL, V150, P705; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	36	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1053	1059		10.1038/sj.onc.1202023	http://dx.doi.org/10.1038/sj.onc.1202023			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747885				2022-12-25	WOS:000075560900014
J	Hallberg, B; Ashcroft, M; Loeb, DM; Kaplan, DR; Downward, J				Hallberg, B; Ashcroft, M; Loeb, DM; Kaplan, DR; Downward, J			Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase	ONCOGENE			English	Article						Ras; Trk; NGF; phosphatidylinositol 3-kinase; apoptosis; PKB	PHEOCHROMOCYTOMA PC12 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; TYROSINE KINASE; PROTEIN-KINASE; NEURONAL DIFFERENTIATION; ACTIVATION; RECEPTOR; NGF	The TrkA receptor protein tyrosine kinase is involved in signalling PC12 cell differentiation and cessation of cell division in response to nerve growth factor (NGF), To assess the importance of adaptor proteins and Pas in NGF control of phosphoinositide 3-OH kinase (PI 3-kinase), specific receptor mutations in Trk have been employed.. We show that phosphorylation of tyrosine 490, but not 785, of Trk is essential for activation of both Ras and PI 3-kinase in vivo, correlating with tyrosine phosphorylation of Shc and binding of Shc to the adaptor Grb2 and the Pas exchange factor Sos. A mutant receptor that lacks Y490 and Y785, but contains an introduced YxxM motif which binds the regulatory domain of PI 3-kinase, is unable to activate Pas despite causing increased PI 3-kinase activity. This indicates clearly that activation of PI 3-kinase by itself is not sufficient to cause activation of Pas, arguing against a model in which PI 3-kinase acts upstream of Pas, The Shc site of Trk is thus crucial for the activation of Pas and PI 3-kinase.	Imperial Canc Res Fund, London WC2A 3PX, England; Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Cancer Research UK; Umea University; McGill University; Columbia University	Downward, J (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BASU T, 1994, ONCOGENE, V9, P3483; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTER AN, 1992, J BIOL CHEM, V267, P14563; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jackson TR, 1996, J CELL SCI, V109, P289; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOZERI O, 1992, ONCOGENE, V7, P2259; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	41	44	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					691	697		10.1038/sj.onc.1201980	http://dx.doi.org/10.1038/sj.onc.1201980			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715270				2022-12-25	WOS:000075337200003
J	Fiermonte, G; Palmieri, L; Dolce, V; Lasorsa, FM; Palmieri, F; Runswick, MJ; Walker, JE				Fiermonte, G; Palmieri, L; Dolce, V; Lasorsa, FM; Palmieri, F; Runswick, MJ; Walker, JE			The sequence, bacterial expression, and functional reconstitution of the rat mitochondrial dicarboxylate transporter cloned via distant homologs in yeast and Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP TRANSLOCASE; TISSUE-SPECIFIC EXPRESSION; LIVER MITOCHONDRIA; CARRIER PROTEINS; SACCHAROMYCES-CEREVISIAE; UNCOUPLING PROTEIN-3; OXOGLUTARATE CARRIER; SUBSTRATE-BINDING; PHOSPHATE CARRIER; GENES ENCODE	The dicarboxylate carrier (DIC) belongs to a family of transport proteins found in the inner mitochondrial membranes. The. biochemical properties of the mammalian protein have been characterized, but the protein is not abundant. It is difficult to purify and had not been sequenced. We have used the sequence of the distantly related yeast DIC to identify a related protein encoded in the genome of Caenorhabditis elegans, Then, related murine expressed sequence tags were identified with the worm sequence, and the murine sequence was used to isolate the cDNA for the rat homolog, The sequences of the worm and rat proteins have features characteristic of the family of mitochondrial transport proteins. Both proteins were expressed in bacteria and reconstituted into phospholipid vesicles where their transport characteristics closely resembled those of whole rat mitochondria and of the rat DIC reconstituted into vesicles. As expected from the role of the DIC in gluconeogenesis and ureogenesis, its transcripts were detected in rat liver and kidney, but unexpectedly, they were also detected in rat heart and brain tissues where the protein may fulfill other roles, possibly in supplying substrates to the Krebs cycle.	Univ Bari, Dept Phamacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Universita degli Studi di Bari Aldo Moro; MRC Laboratory Molecular Biology	Walker, JE (corresponding author), Univ Bari, Dept Phamacobiol, Biochem & Mol Biol Lab, Via Orabona 4, I-70125 Bari, Italy.		Fiermonte, Giuseppe/D-3680-2018; lasorsa, francesco massimo m/B-7931-2008	Fiermonte, Giuseppe/0000-0002-6764-9395; lasorsa, francesco massimo m/0000-0001-8418-5222; Dolce, Vincenza/0000-0003-2966-4866; Walker, John/0000-0001-7929-2162				BATHGATE B, 1989, EUR J BIOCHEM, V183, P303, DOI 10.1111/j.1432-1033.1989.tb14929.x; BISACCIA F, 1988, BIOCHIM BIOPHYS ACTA, V933, P229, DOI 10.1016/0005-2728(88)90030-8; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Capobianco L, 1996, BIOCHEMISTRY-US, V35, P8974, DOI 10.1021/bi960258v; Chappell JB, 1967, BIOCH MITOCHONDRIA, P75; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; CROMPTON M, 1974, FEBS LETT, V46, P247, DOI 10.1016/0014-5793(74)80379-0; CROMPTON M, 1974, BIOCHEM J, V142, P127, DOI 10.1042/bj1420127; DOLCE V, 1994, J BIOL CHEM, V269, P10451; Dolce V, 1996, FEBS LETT, V399, P95, DOI 10.1016/S0014-5793(96)01294-X; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; IAOBAZZI V, 1996, PLANT PHYSIOL, V110, P1435; INDIVERI C, 1993, BIOCHIM BIOPHYS ACTA, V1143, P310, DOI 10.1016/0005-2728(93)90202-Q; INDIVERI C, 1989, BIOCHIM BIOPHYS ACTA, V977, P187, DOI 10.1016/S0005-2728(89)80070-2; INDIVERI C, 1989, BIOCHIM BIOPHYS ACTA, V977, P194, DOI 10.1016/S0005-2728(89)80071-4; JOHNSON RN, 1973, BIOCHEM J, V134, P769, DOI 10.1042/bj1340769; Kakhniashvili D, 1997, J BIOL CHEM, V272, P4516, DOI 10.1074/jbc.272.7.4516; KAPLAN RS, 1985, J BIOL CHEM, V260, P293; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LancarBenba J, 1996, BIOCHIMIE, V78, P195, DOI 10.1016/0300-9084(96)89505-8; LANCARBENBA J, 1994, BBA-BIOMEMBRANES, V1190, P213, DOI 10.1016/0005-2736(94)90076-0; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; MEIJER AJ, 1970, FEBS LETT, V8, P41, DOI 10.1016/0014-5793(70)80220-4; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; NESS GC, 1991, FEBS LETT, V288, P21, DOI 10.1016/0014-5793(91)80993-D; PALMIERI F, 1974, BIOCHIM BIOPHYS ACTA, V333, P195, DOI 10.1016/0005-2728(74)90004-8; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1971, EUR J BIOCHEM, V22, P66, DOI 10.1111/j.1432-1033.1971.tb01515.x; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PALMIERI F, 1998, IN PRESS FRONTIERS C; Palmieri L, 1996, FEBS LETT, V399, P299, DOI 10.1016/S0014-5793(96)01350-6; PASSARELLA S, 1973, FEBS LETT, V38, P91, DOI 10.1016/0014-5793(73)80521-6; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROBINSON BH, 1972, J MEMBRANE BIOL, V7, P391, DOI 10.1007/BF01867928; RUNSWICK MJ, 1994, DNA SEQUENCE, V4, P281, DOI 10.3109/10425179409020854; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; Solanes G, 1997, J BIOL CHEM, V272, P25433, DOI 10.1074/jbc.272.41.25433; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; WALKER JE, 1987, CHEM SCRIPTA, V27B, P97	47	110	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24754	24759		10.1074/jbc.273.38.24754	http://dx.doi.org/10.1074/jbc.273.38.24754			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733776	hybrid			2022-12-25	WOS:000076007300068
J	Jimenez-Garcia, E; Vaquero, A; Espinas, ML; Soliva, R; Orozco, M; Bernues, J; Azorin, F				Jimenez-Garcia, E; Vaquero, A; Espinas, ML; Soliva, R; Orozco, M; Bernues, J; Azorin, F			The GAGA factor of Drosophila binds triple-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN BINDING; HEAT-SHOCK PROMOTER; ASTERISK-H-DNA; TRANSCRIPTION FACTOR; NUCLEOSOME DISRUPTION; RAS PROMOTER; SP1 BINDING; HUMAN-CELLS; SEQUENCE; GENE	The Drosophila GAGA factor binds specifically to simple repeating d(GA.TC)(n) DNA sequences. These sequences are known to be capable of forming triple-stranded DNA as well as other non-B-DNA conformations. Here, it is shown that GAGA binds to a d[CT(GA.TC)](22) intermolecular tripler with similar specificity and affinity as to a regular double-stranded B form d[AG(GA.TC)](22) sequence. The interaction of GAGA with tripler DNA cannot, however, stimulate transcription in vitro. The affinity of GAGA for triplexes of the purine motif, such as a d[AG(GA.TC)](22) intermolecular tripler, is significantly lower. The DNA binding domain of GAGA is sufficient for efficient binding to tripler DNA. Eased on the reported solution structure of the complex of GAGA-DNA binding domain with double-stranded DNA, a model for its interaction with tripler DNA is proposed in which most of the protein-DNA contacts observed in duplex DNA are maintained, especially those occurring through the minor groove. The higher negative charge of the tripler is likely to have also an important contribution to both the specificity and affinity of the interaction.	CSIC, Ctr Invest Desenvolupament, Dept Mol & Cellular Biol, ES-08034 Barcelona, Spain; Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona	Azorin, F (corresponding author), CSIC, Ctr Invest Desenvolupament, Dept Mol & Cellular Biol, Jordi Girona Salgado 18-26, ES-08034 Barcelona, Spain.		Azorin, Fernando/N-4388-2014; Bernues, Jordi/ABE-8360-2021	Azorin, Fernando/0000-0002-8426-7858; Bernues, Jordi/0000-0001-6218-8254; Espinas, M Lluisa/0000-0003-3914-2228; Orozco Lopez, Modesto/0000-0002-8608-3278				BELTRAN R, 1993, J MOL BIOL, V230, P966, DOI 10.1006/jmbi.1993.1213; BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; Bernues J., 1995, NUCL ACIDS MOL BIOL, V9, P1; Bhat KM, 1996, DEVELOPMENT, V122, P1113; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; CASASNOVAS JM, 1987, EUR J BIOCHEM, V167, P489, DOI 10.1111/j.1432-1033.1987.tb13363.x; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; GEE JE, 1992, J BIOL CHEM, V267, P11163; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; Guieysse AL, 1997, J MOL BIOL, V267, P289, DOI 10.1006/jmbi.1997.0884; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KOWHI Y, 1993, GENE DEV, V7, P1766; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MARTINEZBALBAS A, 1993, NUCLEIC ACIDS RES, V21, P2557, DOI 10.1093/nar/21.11.2557; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MAYFIELD C, 1994, BIOCHEMISTRY-US, V33, P3358, DOI 10.1021/bi00177a029; OBRIEN T, 1995, GENE DEV, V9, P1098, DOI 10.1101/gad.9.9.1098; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Platero JS, 1998, J CELL BIOL, V140, P1297; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; REDDOCH JF, 1995, BIOCHEMISTRY-US, V34, P7659, DOI 10.1021/bi00023a012; Shields GC, 1997, J AM CHEM SOC, V119, P7463, DOI 10.1021/ja970601z; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; SOLIVA R, 1998, IN PRESS J AM CHEM S; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1996, METHOD ENZYMOL, V274, P291; WESTIN L, 1995, NUCLEIC ACIDS RES, V23, P2184, DOI 10.1093/nar/23.12.2184; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963	43	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24640	24648		10.1074/jbc.273.38.24640	http://dx.doi.org/10.1074/jbc.273.38.24640			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733760	hybrid			2022-12-25	WOS:000076007300052
J	Laser, M; Kasi, VS; Hamawaki, M; Cooper, G; Kerr, CM; Kuppuswamy, D				Laser, M; Kasi, VS; Hamawaki, M; Cooper, G; Kerr, CM; Kuppuswamy, D			Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; GENE-EXPRESSION; CYCLIC-AMP; PHAS-I; RAPAMYCIN	An adult feline right ventricular pressure overload (RVPO) model was used to examine the two S6 kinase (S6K) isoforms, p70(S6K) and p85(S6K), that are involved in translational and transcriptional activation. Biochemical and confocal microscopy analyses at the level of the cardiocyte revealed that p70(S6K) is present predominantly in the cytosol, substantially activated in 1-h RVPO (>12 fold), and phosphorylated in the pseudosubstrate domain at the Ser-411, Thr-421, and Ser-424 sites. p85(S6K), which was localized exclusively in the nucleus, showed activation subsequent to p70(S6K). With a sustained increase in phosphorylation for up to 48 h of RVPO at equivalent sites of p70(S6K), Thr-421 and Ser-424, but not at Ser-411. Neither isoform translocated between the cytosol and the nucleus. Further studies to determine potential upstream elements of S6K activation revealed: (i) similar time course of activation for protein kinase C isoforms (alpha, gamma, and epsilon) and c-Raf, (ii) absence of accompanying phosphatidylinositol S-kinase activation, (iii) activation of c-Src subsequent to p70(S6K), and (iv) similar changes in adult cardiocytes after treatment with 12-O-tetradecanoylphorbol-13-acetate. Thus, these studies suggest that a protein kinase C-mediated pathway couples pressure overload to growth induction via differential activation of S6K isoforms in cardiac hypertrophy.	Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA; Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Physiol, Charleston, SC 29425 USA; Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Cell Biol, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kuppuswamy, D (corresponding author), Med Univ S Carolina, Dept Med, Div Cardiol, 171 Ashley Ave, Charleston, SC 29425 USA.				NHLBI NIH HHS [HL-487788] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angst BD, 1997, CIRC RES, V80, P88, DOI 10.1161/01.RES.80.1.88; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Cooper G, 1997, ANNU REV MED, V48, P13, DOI 10.1146/annurev.med.48.1.13; COOPER G, 1974, J APPL PHYSIOL, V37, P762, DOI 10.1152/jappl.1974.37.5.762; COOPER G, 1986, CIRC RES, V58, P692, DOI 10.1161/01.RES.58.5.692; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; Fadden P, 1997, J BIOL CHEM, V272, P10240; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; GU X, 1994, CIRC RES, V75, P926, DOI 10.1161/01.RES.75.5.926; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HERSHEY JWB, 1990, ENZYME, V44, P17, DOI 10.1159/000468744; HOMMA T, 1992, J BIOL CHEM, V267, P23129; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Morgan HE, 1997, MOL CELL BIOCHEM, V176, P145, DOI 10.1023/A:1006855818855; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Paul K, 1997, CIRC RES, V81, P643; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; ROZICH JD, 1995, J MOL CELL CARDIOL, V27, P485, DOI 10.1016/S0022-2828(08)80044-2; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SafiejkoMroczka B, 1996, J HISTOCHEM CYTOCHEM, V44, P641, DOI 10.1177/44.6.8666749; Servillo G, 1997, ONCOGENE, V14, P1601, DOI 10.1038/sj.onc.1200996; Silvennoinen O, 1996, J IMMUNOL, V156, P100; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Takano H, 1996, FEBS LETT, V379, P255, DOI 10.1016/0014-5793(95)01523-X; TERADA N, 1993, J BIOL CHEM, V268, P12062; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	57	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24610	24619		10.1074/jbc.273.38.24610	http://dx.doi.org/10.1074/jbc.273.38.24610			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733756	hybrid			2022-12-25	WOS:000076007300048
J	Morooka, T; Nishida, E				Morooka, T; Nishida, E			Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MAP KINASE; PC-12 CELLS; RECEPTOR; TYROSINE; THREONINE; INSULIN	Nerve growth factor (NGF) induces sustained activation of classical MAP kinase (MAPK, also known as ERK) and neuronal differentiation in PC12 cells, whereas epidermal growth factor (EGF) induces transient activation of ERK/MAPK and stimulates proliferation of the cells, Although previous studies showed that sustained activation of ERK/MAPK is important for neuronal differentiation of the cells, a recent report revealed that inhibition of the sustained phase of ERK/MAPK activation alone does not block neurite outgrowth caused by NGF. These results suggest requirement for an additional signaling pathway(s) triggered by NGF in neuronal differentiation. Here we show that NGF induces sustained activation of p38, a subfamily member of the MAPK superfamily, and that inhibition of the p38 pathway blocks neurite outgrowth in PC12 cells. Surprisingly, expression of constitutively active MAPK/ERK kinase (MAPKK, also known as MEK) results in p38 activation as well as ERK/MAPK activation, and a p38 inhibitor blocks neurite outgrowth caused by the constitutively active MAPK/MEK, Moreover, constitutive activation of p38 is able to induce neurite outgrowth when combined with EGF treatment. These results reveal an essential role of p38 in neuronal differentiation in PC12 cells.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.							BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1998, NATURE, V392, P553, DOI 10.1038/33293; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	24	303	306	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24285	24288		10.1074/jbc.273.38.24285	http://dx.doi.org/10.1074/jbc.273.38.24285			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733710	hybrid			2022-12-25	WOS:000076007300002
J	Papadimou, E; Georgiou, S; Tsambaos, D; Drainas, D				Papadimou, E; Georgiou, S; Tsambaos, D; Drainas, D			Inhibition of ribonuclease P activity by retinoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNASE-P; DICTYOSTELIUM-DISCOIDEUM; DIFFERENTIATION; APOPTOSIS	The effect of two naturally occurring (retinol and all-trans retinoic acid) and two synthetic (isotretinoin and acitretin) analogs of vitamin A (retinoids) on tRNA biogenesis was investigated employing the RNase P of Dictyostelium discoideum as an in vitro experimental system. RNase P is an ubiquitous and essential enzyme that endonucleolytically cleaves all tRNA precursors to produce the mature 5' end. All retinoids tested revealed a dose-dependent inhibition of RNase P activity, indicating that these compounds may have a direct effect on tRNA biogenesis, Detailed kinetic analysis showed that all retinoids behave as classical competitive inhibitors. The K-i values determined were 1475 mu M for retinol, 15 mu M for ah-trans retinoic acid, 20 mu M for isotretinoin, and 8.0 mu M for acitretin, On the basis of these values acitretin is a 184, 2.5, and 1.9 times more potent inhibitor, as compared with retinol, isotretinoin, and all-trans retinoic acid, respectively. Taking into account that retinoids share no structural similarities to precursor tRNA, it is suggested that their kinetic behavior reflects allosteric interactions of these compounds with hydrophobic site(s) of D, discoideum RNase P.	Univ Patras, Sch Med, Dept Biochem, Patras 26500, Greece; Univ Patras, Sch Med, Dept Dermatol, Patras 26500, Greece	University of Patras; University of Patras	Drainas, D (corresponding author), Univ Patras, Sch Med, Dept Biochem, Patras 26500, Greece.	Drainas@med.upatras.gr						BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Botling J, 1997, J BIOL CHEM, V272, P9443; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DE LUCA LM, 1991, FASEB J, V5, P2924; Drainas D, 1996, MOL BIOL REP, V22, P135, DOI 10.1007/BF00988718; DRAINAS D, 1989, FEBS LETT, V251, P84, DOI 10.1016/0014-5793(89)81433-4; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Lacour M, 1996, BRIT J DERMATOL, V134, P1023, DOI 10.1111/j.1365-2133.1996.tb07936.x; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIPPMAN SM, 1995, J CELL BIOCHEM, P1; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; MUINDI JR, 1996, CANC TREAT RES, V870, P305; Plewig G, 1997, HAUTARZT, V48, P881, DOI 10.1007/s001050050679; ROSS AC, 1993, FASEB J, V7, P317, DOI 10.1096/fasebj.7.2.8440409; Sankaranarayanan R, 1996, IARC SCI PUBL, P47; SEGEL IH, 1975, ENZYME KINETICS, P110; STATHOPOULOS C, 1995, EUR J BIOCHEM, V228, P976, DOI 10.1111/j.1432-1033.1995.0976m.x; SYMONS RH, 1994, CURR OPIN STRUC BIOL, V4, P322, DOI 10.1016/S0959-440X(94)90099-X; TSAMBAOS D, 1991, EFFECTS SYNTHETIC RE, P659; vanderSaag PT, 1996, EUR J CLIN NUTR, V50, pS24; WIEDER JM, 1995, DERMATOL CLIN, V13, P891, DOI 10.1016/S0733-8635(18)30051-2	23	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24375	24378		10.1074/jbc.273.38.24375	http://dx.doi.org/10.1074/jbc.273.38.24375			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733726	hybrid			2022-12-25	WOS:000076007300018
J	San Agustin, JT; Leszyk, JD; Nuwaysir, LM; Witman, GB				San Agustin, JT; Leszyk, JD; Nuwaysir, LM; Witman, GB			The catalytic subunit of the cAMP-dependent protein kinase of ovine sperm flagella has a unique amino-terminal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; REGULATORY SUBUNIT; CYCLIC-AMP; C-GAMMA; SPERMATOZOA; MOTILITY; LOCALIZATION; ISOFORM; CALCIUM; CELLS	The basis for the unusual properties of the catalytic subunit (C) of ram sperm cAMP-dependent protein kinase was investigated. Ram sperm C was purified and found by mass spectrometry (MS) to be similar to 890 Da smaller than C alpha, the predominant somatic isoform. Partial internal amino acid sequence from ram sperm C was an exact match to that of bovine C alpha, but differed from the predicted sequences for the C beta and C gamma isoforms. MS analysis of 2-nitro-5-thiocyanatobenzoic acid fragments showed that the mass difference originated in the amino-terminal region. A unique blocked amino-terminal fragment was isolated from sperm C and sequenced by a combination of tandem mass spectrometry and Edman degradation of a subfragment, The results revealed that the amino-terminal myristate and the first 14 amino acids of C alpha are replaced by an amino-terminal acetate and six different amino acids in sperm C. The predicted mass difference due to these changes is 899 Da, The region of homology between sperm C and C alpha begins at the exon 1/exon 2 boundary in C alpha, suggesting that sperm C results from use of an alternate exon 1 in the C alpha gene. The different amino terminus of sperm C may be related to a unique requirement for localization of the "free" C subunit within the sperm flagellum.	Univ Massachusetts, Med Ctr, Dept Cell Biol, Shrewsbury, MA 01545 USA; Univ Massachusetts, Med Ctr, Prot Chem Facil, Shrewsbury, MA 01545 USA; Perkin Elmer Sciex, Appl Biosyst Div, Foster City, CA 94404 USA	University of Massachusetts System; University of Massachusetts System; Thermo Fisher Scientific; Applied Biosystems	San Agustin, JT (corresponding author), Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester Fdn Campus, Shrewsbury, MA 01545 USA.			Witman, George/0000-0002-9497-9218	NICHD NIH HHS [HD23858] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023858] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGUSTIN JTS, 1993, CELL MOTIL CYTOSKEL, V24, P264, DOI 10.1002/cm.970240407; BABCOCK DF, 1975, J BIOL CHEM, V250, P6488; BEEBE SJ, 1992, J BIOL CHEM, V267, P25505; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEEBE SJ, 1986, ENZYMES, V17, P43; BEUSHAUSEN S, 1992, P NATL ACAD SCI USA, V89, P1641, DOI 10.1073/pnas.89.5.1641; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; CUMMINGS DE, 1994, MAMM GENOME, V5, P701, DOI 10.1007/BF00426076; DACHEUX JL, 1983, BIOL REPROD, V29, P1033, DOI 10.1095/biolreprod29.4.1033; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DEY CS, 1991, J CELL SCI, V100, P815; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; Herberg FW, 1997, PROTEIN SCI, V6, P569; HOROWITZ JA, 1984, J BIOL CHEM, V259, P832; ISHIJIMA S, 1985, J EXP BIOL, V114, P463; JEKEL PA, 1983, ANAL BIOCHEM, V134, P347, DOI 10.1016/0003-2697(83)90308-1; Jones R, 1996, J CELL SCI, V109, P2561; LAKOSKI K, 1989, GAMETE RES, V23, P21, DOI 10.1002/mrd.1120230104; LIEBERMAN SJ, 1988, J CELL BIOL, V107, P1809, DOI 10.1083/jcb.107.5.1809; LINDEMANN CB, 1978, CELL, V13, P9, DOI 10.1016/0092-8674(78)90133-2; LOO JA, 1990, SCIENCE, V248, P201, DOI 10.1126/science.2326633; MACLEOD J, 1994, EUR J BIOCHEM, V225, P107, DOI 10.1111/j.1432-1033.1994.00107.x; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MOHRI H, 1980, EXP CELL RES, V127, P191, DOI 10.1016/0014-4827(80)90426-7; OKUNO S, 1990, BIOCHIM BIOPHYS ACTA, V1038, P204, DOI 10.1016/0167-4838(90)90206-U; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; OYEN O, 1990, BIOL REPROD, V43, P46, DOI 10.1095/biolreprod43.1.46; PARISET C, 1989, J CELL BIOL, V109, P1195, DOI 10.1083/jcb.109.3.1195; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; SANAGUSTIN JT, 1995, METHOD CELL BIOL, V47, P31, DOI 10.1016/S0091-679X(08)60787-6; SANAGUSTIN JT, 1994, CELL MOTIL CYTOSKEL, V27, P206, DOI 10.1002/cm.970270303; SANAGUSTIN JT, 1995, METHOD CELL BIOL, V47, P135, DOI 10.1016/S0091-679X(08)60801-8; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Scott JD, 1997, SOC GEN PHY, V52, P227; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TASH JS, 1982, BIOL REPROD, V26, P745, DOI 10.1095/biolreprod26.4.745; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THOMIS DC, 1992, J BIOL CHEM, V267, P10723; UHLER MD, 1986, J BIOL CHEM, V261, P5360; Vijayaraghavan S, 1997, BIOL REPROD, V56, P1450, DOI 10.1095/biolreprod56.6.1450; WIEMANN S, 1991, J BIOL CHEM, V266, P5140; Yanagimachi R., 1994, Zygote, V2, P371; YEUNG CH, 1984, GAMETE RES, V9, P99, DOI 10.1002/mrd.1120090109; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	55	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24874	24883		10.1074/jbc.273.38.24874	http://dx.doi.org/10.1074/jbc.273.38.24874			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733793	hybrid			2022-12-25	WOS:000076007300085
J	Luongo, CL; Contreras, CM; Farsetta, DL; Nibert, ML				Luongo, CL; Contreras, CM; Farsetta, DL; Nibert, ML			Binding site for S-adenosyl-L-methionine in a central region of mammalian reovirus lambda 2 protein - Evidence for activities in mRNA CAP methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING ENZYME; MESSENGER-RNA; VACCINIA VIRUS; TERMINAL REGION; GUANYLYLTRANSFERASE; PARTICLES; CORES; METHYLTRANSFERASE; IDENTIFICATION; LOCALIZATION	One or more proteins in mammalian reovirus core particles mediate two RNA methylation activities, (guanosine-7-N)-methyltransferase and (guanosine-2'-O)-methyltransferase, that contribute to forming the 5' cap 1 structure on viral mRNA, We used UV irradiation to identify core proteins that bind S-adenosyl-L-methionine (SAM), the methyl-group donor for both methyltransferases. A [methyl-H-3]SAM-binding site was observed among the reovirus lambda proteins; was shown to be specific by competition with low levels of S-adenosyl-L-homocysteine, the product of methyl-group transfer from SAM; and was subsequently localized to protein lambda 2, lambda 2 mediates the guanylyltransferase reaction in cap formation and was previously proposed to mediate one or both methylation reactions as well. SAM binding was demonstrated for both lambda 2 in cores and lambda 2 expressed in insect cells from a recombinant baculovirus. Using three different methods to cleave lambda 2, a binding site for SAM was tentatively localized to a central region of lambda 2, between residues 792 and 1100, which includes a smaller region with sequence similarity to the SAM-binding pocket of other methyltransferases. Alanine substitutions at positions 827 and 829 within this predicted binding region greatly reduced the capacity of baculovirus-expressed lambda 2 protein to undergo UV cross-linking to SARI but had no effects on either the guanylyltransferase activity of this protein or its conformation as judged by partial proteolysis, suggesting that one or both of these residues is essential for SAM binding. Based on these findings, we propose that the two methyltransferase activities involved in mRNA capping by reovirus cores utilize a single SAM-binding pocket within a central region of lambda 2.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA; Univ Wisconsin, Cell & Mol Biol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Nibert, ML (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53706 USA.	mlnibert@facstaff.wisc.edu	Contreras, Carlos M./AAZ-3345-2020		NCI NIH HHS [T32 CA09075] Funding Source: Medline; NIAID NIH HHS [R29 AI39533] Funding Source: Medline; NIGMS NIH HHS [T32 GM08349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahola T, 1997, J VIROL, V71, P392, DOI 10.1128/JVI.71.1.392-397.1997; ANDERS DG, 1983, J VIROL, V48, P197, DOI 10.1128/JVI.48.1.197-205.1983; BANERJEE AK, 1971, NATURE-NEW BIOL, V230, P169, DOI 10.1038/newbio230169a0; Bisaillon M, 1997, J BIOL CHEM, V272, P18298, DOI 10.1074/jbc.272.29.18298; Bisaillon M, 1997, J BIOL CHEM, V272, P29954, DOI 10.1074/jbc.272.47.29954; CASHDOLLAR LW, 1984, VIROLOGY, V133, P191, DOI 10.1016/0042-6822(84)90438-0; Centonze VE, 1995, J STRUCT BIOL, V115, P215, DOI 10.1006/jsbi.1995.1046; CLEVELAND DR, 1986, J VIROL, V60, P307, DOI 10.1128/JVI.60.1.307-311.1986; Dryden KA, 1998, VIROLOGY, V245, P33, DOI 10.1006/viro.1998.9146; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; FAUSNAUGH J, 1990, J BIOL CHEM, V265, P7669; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; FURUICHI Y, 1975, P NATL ACAD SCI USA, V72, P362, DOI 10.1073/pnas.72.1.362; FURUICHI Y, 1976, P NATL ACAD SCI USA, V73, P3448, DOI 10.1073/pnas.73.10.3448; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; LANGE C, 1991, NATURE, V352, P645, DOI 10.1038/352645a0; Liao HJ, 1997, VIROLOGY, V228, P19, DOI 10.1006/viro.1996.8365; Luongo CL, 1997, J VIROL, V71, P8035, DOI 10.1128/JVI.71.10.8035-8040.1997; MAO XD, 1995, MOL CELL BIOL, V15, P4167; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; Noble S, 1997, J VIROL, V71, P2182, DOI 10.1128/JVI.71.3.2182-2191.1997; Noble S, 1997, J VIROL, V71, P7728, DOI 10.1128/JVI.71.10.7728-7735.1997; RALPH SJ, 1980, J VIROL, V36, P894, DOI 10.1128/JVI.36.3.894-896.1980; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; SHATKIN AJ, 1974, P NATL ACAD SCI USA, V71, P3204, DOI 10.1073/pnas.71.8.3204; SHATKIN AJ, 1983, REOVIRIDAE, P79; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SHUMAN S, 1990, METHOD ENZYMOL, V181, P170; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; STARNES MC, 1993, VIROLOGY, V193, P356, DOI 10.1006/viro.1993.1132; VIRGIN HW, 1991, J VIROL, V65, P6772, DOI 10.1128/JVI.65.12.6772-6781.1991; WHITE CK, 1976, VIROLOGY, V70, P171, DOI 10.1016/0042-6822(76)90247-6; YAMAKAWA M, 1982, VIROLOGY, V118, P157, DOI 10.1016/0042-6822(82)90329-4	37	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23773	23780		10.1074/jbc.273.37.23773	http://dx.doi.org/10.1074/jbc.273.37.23773			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726986	hybrid			2022-12-25	WOS:000075893100027
J	Rameh, LE; Rhee, SG; Spokes, K; Kazlauskas, A; Cantley, LC; Cantley, LG				Rameh, LE; Rhee, SG; Spokes, K; Kazlauskas, A; Cantley, LC; Cantley, LG			Phosphoinositide 3-kinase regulates phospholipase C gamma-mediated calcium signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-BETA; PROTEIN-KINASE-B; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; LYSOPHOSPHATIDIC ACID; HOMOLOGY DOMAINS; LIPID PRODUCTS; CROSS-LINKING; ACTIVATION; WORTMANNIN	It has been demonstrated that the lipid products of the phosphoinositide a-kinase (PI3K) can associate with the Src homology 2 (SH2) domains of specific signaling molecules and modify their actions. In the current experiments, phosphatidylinositol 3,4,5-trisphosphate (Pt-dIns-3,4,5-P-3) was found to bind to the C-terminal SH2 domain of phospholipase C gamma (PLC gamma) with an apparent K-d of 2.4 pra and to displace the C-terminal SH2 domain from the activated platelet-derived growth factor receptor (PDGFR). To investigate the in vivo relevance of this observation, intracellular inositol trisphosphate (IP3) generation and calcium release were examined in HepGB cells expressing a series of PDGFR mutants that activate PLC gamma with or without receptor association with PI3K. Coactivation of PLC gamma and PI3K resulted in an similar to 40% increase in both intracellular IF, generation and intracellular calcium release as compared with selective activation of PLC gamma. Similarly, the addition of wortmannin or LY294002 to cells expressing the wild-type PDGFR inhibited the release of intracellular calcium. Thus, generation of PtdIns-3,4,5-P-3 by receptor-associated PI3K causes an increase in IP3 production and intracellular calcium release, potentially via enhanced PtdIns-4,5-P-2 substrate availability due to PtdIns-3,4,5-P-3-mediated recruitment of PLC gamma to the lipid bilayer.	Harvard Univ, Sch Med, Div Nephrol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Div Signal Transduct, Boston, MA 02215 USA; Schepens Eye Res Inst, Boston, MA 02114 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Schepens Eye Research Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Cantley, LG (corresponding author), Harvard Univ, Sch Med, Div Nephrol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R01GM048339, R37GM041890] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48871] Funding Source: Medline; NIGMS NIH HHS [GM48339, GM41890, R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Derman MP, 1996, J BIOL CHEM, V271, P4251; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; NAKANISHI S, 1994, J BIOL CHEM, V269, P6528; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Sambrook J., 2002, MOL CLONING LAB MANU; SECKL MJ, 1994, CANCER RES, V54, P6143; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Vossebeld PJM, 1997, BIOCHEM J, V323, P87, DOI 10.1042/bj3230087; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u	28	193	195	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23750	23757		10.1074/jbc.273.37.23750	http://dx.doi.org/10.1074/jbc.273.37.23750			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726983	hybrid			2022-12-25	WOS:000075893100024
J	Vasilyeva, E; Forgac, M				Vasilyeva, E; Forgac, M			Interaction of the clathrin-coated vesicle V-ATPase with ADP and sodium azide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; VACUOLAR H+-ATPASE; NUCLEOTIDE-BINDING-SITES; PROTON PUMP; SACCHAROMYCES-CEREVISIAE; NONCATALYTIC SITES; STRUCTURAL-CHANGES; NEUROSPORA-CRASSA; MEMBRANE ATPASES; CDNA SEQUENCE	The kinetics of adenosine triphosphate (ATP)-dependent proton transport into clathrin-coated vesicles from bovine brain have been studied. We observe that the vacuolar proton-translocating ATPase (V-ATPase) from clathrin-coated vesicles is subject to two different types of inhibition by ADP. The first is competitive inhibition with respect to ATP, with a K-i for ADP of 11 mu M. The second type of inhibition occurs after preincubation of the V-ATPase in the presence of ADP and Mg2+, which results in inhibition of the initial rate of proton transport followed by reactivation over the course of several minutes. The second effect is observed at ADP concentrations as low as 0.1-0.2 mu M, indicating that a high affinity inhibitory complex is formed between ADP and the V-ATPase and is only slowly dissociated after the addition of ATP. We have further investigated the effect of sodium azide, an inhibitor of the F-ATPases that has been shown to stabilize an inactive complex between ADP and the F-1-F-0-ATP synthase (F-ATPase), We observed that azide inhibited ATP-dependent proton transport by the purified, reconstituted V-ATPase with a K-0.5 of 0.2-0.4 mw but had no effect on ATP hydrolysis. Azide was shown not to increase the passive proton permeability of reconstituted vesicles and did not stimulate ATP hydrolysis by the reconstituted enzyme, in contrast with CCCP, which both abolished the proton gradient and stimulated hydrolysis, Thus, azide does not appear to act as a simple uncoupler of proton transport and ATP hydrolysis. Rather, azide may have some more direct effect on V-ATPase activity. Possible mechanisms by which azide could exert this effect on the V-ATPase and the contrasting effects of azide on the F- and V-ATPases are discussed.	Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	mforgac@opal.tufts.edu			NIGMS NIH HHS [GM 34478, R01 GM034478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1983, J BIOL CHEM, V258, P5238; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DAVID P, 1994, J BIOL CHEM, V269, P30158; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; Fillingame RH, 1997, J EXP BIOL, V200, P217; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FORGAC M, 1986, BIOCHEMISTRY-US, V25, P4275, DOI 10.1021/bi00363a015; FORGAC M, 1982, J BIOL CHEM, V257, P5652; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; HUANG CS, 1983, BIOCHIM BIOPHYS ACTA, V722, P107, DOI 10.1016/0005-2728(83)90163-9; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JAULT JM, 1994, J BIOL CHEM, V269, P319; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; KIBAK H, 1993, J BIOL CHEM, V268, P23325; KOBAYASHI H, 1977, J BIOCHEM-TOKYO, V81, P1071, DOI 10.1093/oxfordjournals.jbchem.a131530; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; MUNEYUKI E, 1993, BIOCHIM BIOPHYS ACTA, V1144, P62, DOI 10.1016/0005-2728(93)90031-A; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROBERTSON H. E., 1955, JOUR BIOL CHEM, V214, P295; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; STONE DK, 1982, J BIOL CHEM, V258, P4059; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1988, METHOD ENZYMOL, V157, P544; Vasilyeva E, 1996, J BIOL CHEM, V271, P12775, DOI 10.1074/jbc.271.22.12775; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P1; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBSTER LC, 1995, EUR J BIOCHEM, V232, P586; Webster LC, 1996, EUR J BIOCHEM, V240, P156, DOI 10.1111/j.1432-1033.1996.0156h.x; XIE XS, 1988, J BIOL CHEM, V263, P9859; XIE XS, 1988, METHOD ENZYMOL, V157, P634; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	55	28	31	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23823	23829		10.1074/jbc.273.37.23823	http://dx.doi.org/10.1074/jbc.273.37.23823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726993	hybrid			2022-12-25	WOS:000075893100034
J	Anders, RA; Dore, JE; Arline, SL; Garamszegi, N; Leof, EB				Anders, RA; Dore, JE; Arline, SL; Garamszegi, N; Leof, EB			Differential requirement for type I and type II transforming growth factor beta receptor kinase activity in ligand-mediated receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; HETEROOLIGOMERIC COMPLEXES; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; TYROSINE KINASE; INDUCED INTERNALIZATION; HOMOMERIC INTERACTIONS; SMAD PROTEINS; GS DOMAIN	Transforming growth factor beta (TGF beta) superfamily polypeptides regulate cell growth and differentiation by binding to single pass serine/threonine kinases referred to as TGF beta type I and type II receptors, Signal propagation is dependent upon heteromeric (type I-type II) complex formation and transphosphorylation of the type I receptor by the type II receptor. While many of the phosphorylation events necessary for receptor signaling have recently been characterized, the role of TGF beta receptor kinase activity in modulating receptor endocytosis has not been addressed. To that end, we have used chimeric receptors consisting of the extracellular domain of the granulocyte/macrophage colony-stimulating factor alpha and beta receptors spliced to the TGF beta type I and type II transmembrane and cytoplasmic domains to address the specific role of type I and/or type II receptor kinase activity in TGF beta receptor internalization, downregulation, and signaling. To inactivate chimeric receptor kinase activity, point mutations in the ATP binding site were made at amino acids 232 and 277 in the type I and type II receptor, respectively. Either of these mutations abolished plasminogen activator inhibitor 1 protein expression stimulated by granulocyte/macrophage colony-stimulating factor activation of chimeric heteromeric type I-type II TGF beta receptors, They did not, how ever, modulate TGF beta signaling stimulated through the endogenous TGF beta receptor. Although TGF beta receptor signaling was dependent upon the kinase activity of both chimeric receptors, the initial endocytic response was distinctly regulated by type I and/or type II receptor kinase activity. For instance, while heteromeric receptor complexes containing a kinase-inactive type I receptor were endocytosed similarly to wild type complexes, the kinase activity of the type II TGF beta receptor was necessary for optimal internalization and receptor down-regulation. Furthermore, these responses were shown to occur independently of type II receptor autophosphorylation but require a type II receptor capable of transphosphorylation.	Mayo Clin & Mayo Fdn, Thorac Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Leof, EB (corresponding author), Mayo Clin & Mayo Fdn, Thorac Res Unit, Guggenheim 642C, Rochester, MN 55905 USA.				NIGMS NIH HHS [GM 54200, GM 55816] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM055816, R01GM055816, R01GM054200] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BRAND T, 1993, J BIOL CHEM, V268, P11500; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOI ME, 1995, J BIOL CHEM, V270, P21144, DOI 10.1074/jbc.270.36.21144; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; FRANZEN P, 1995, BIOCHEM BIOPH RES CO, V207, P682, DOI 10.1006/bbrc.1995.1241; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MASSAGUE J, 1985, CANCER CELL, V3, P73; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Muramatsu M, 1997, MOL BIOL CELL, V8, P469, DOI 10.1091/mbc.8.3.469; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; RAJAGOPALAN M, 1995, BIOCHEM BIOPH RES CO, V211, P714, DOI 10.1006/bbrc.1995.1871; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; ZHAO J, 1995, CANCER RES, V55, P6181; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369	56	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23118	23125		10.1074/jbc.273.36.23118	http://dx.doi.org/10.1074/jbc.273.36.23118			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722540	hybrid			2022-12-25	WOS:000075778100040
J	Kolhekar, AS; Quon, ASW; Berard, CA; Mains, RE; Eipper, BA				Kolhekar, AS; Quon, ASW; Berard, CA; Mains, RE; Eipper, BA			Post-translational N-glycosylation of a truncated form of a peptide processing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; INTEGRAL MEMBRANE-PROTEIN; LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; HYDROXYLATING MONOOXYGENASE; SECRETORY GRANULES; CATALYTIC CORE; ATT-20 CELLS; ACTIVE-SITE; PROHORMONE	Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the carboxyl-terminal amidation of bioactive peptides through a two-step reaction involving the monooxygenase and lyase domains. PAM undergoes endoproteolytic cleavage in neuroendocrine cells in the lyase domain. To determine which of the two possible paired basic sites is utilized, truncated PAM proteins ending at these sites were stably expressed in Chinese hamster ovary cells. While characterizing the truncation mutants, it became apparent that N-glycosylation occurred post-translationally at the single site localized near the carboxyl terminus of the lyase domain. The post-translational N-glycosylation of this site does not require the newly synthesized protein to remain tightly bound to membranes. Both malfolded, secretion incompetent proteins and fully active, secreted proteins were subject to post-translational N-glycosylation.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Eipper, BA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 907 WBSB,725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032949, R56DK032949, R01DK032949] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32949] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BLOOMQUIST BT, 1993, CELL PHYSIOL BIOCHEM, V3, P197, DOI 10.1159/000154684; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GEETHAHABIB M, 1990, J BIOL CHEM, V265, P13655; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GLABE CG, 1980, J BIOL CHEM, V255, P9236; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; Hauser F, 1997, BIOCHEM BIOPH RES CO, V241, P509, DOI 10.1006/bbrc.1997.7854; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; JETHMALANI SM, 1994, J BIOL CHEM, V269, P23603; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Lindberg I., 1995, METH NEUROSCI, V23, P94; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILLER DA, 1992, ARCH BIOCHEM BIOPHYS, V298, P380, DOI 10.1016/0003-9861(92)90425-V; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NOGUCHI M, 1992, BIOCHEM J, V283, P883, DOI 10.1042/bj2830883; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; RONNETT GV, 1981, J BIOL CHEM, V256, P4704; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SCHULKE N, 1988, J BIOL CHEM, V263, P8832; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; TIKKANEN R, 1995, DNA CELL BIOL, V14, P305, DOI 10.1089/dna.1995.14.305; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117; YUN HY, 1995, J BIOL CHEM, V270, P15412, DOI 10.1074/jbc.270.25.15412; ZHOU A, 1994, J BIOL CHEM, V269, P17440	48	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23012	23018		10.1074/jbc.273.36.23012	http://dx.doi.org/10.1074/jbc.273.36.23012			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722525	hybrid			2022-12-25	WOS:000075778100025
J	May, JM; Cobb, CE; Mendiratta, S; Hill, KE; Burk, RF				May, JM; Cobb, CE; Mendiratta, S; Hill, KE; Burk, RF			Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DEHYDROASCORBATE REDUCTASE; RAT-LIVER; HUMAN-ERYTHROCYTES; OXIDATIVE STRESS; SELENIUM DEFICIENCY; LIPID-PEROXIDATION; SELENOPROTEIN-W; VITAMIN-C; PURIFICATION; GLUTATHIONE	Recycling of ascorbic acid from its oxidized forms is required to maintain intracellular stores of the vitamin in most cells. Since the ubiquitous selenoenzyme thioredoxin reductase can recycle dehydroascorbic acid to ascorbate, we investigated the possibility that the enzyme can also reduce the one-electron-oxidized ascorbyl free radical to ascorbate, Purified rat liver thioredoxin reductase catalyzed the disappearance of NADPH in the presence of low micromolar concentrations of the ascorbyl free radical that were generated from ascorbate by ascorbate oxidase, and this effect was markedly stimulated by selenocystine, Dehydroascorbic acid is generated by dismutation of the ascorbyl free radical, and thioredoxin reductase can reduce dehydroascorbic acid to ascorbate. However, control studies showed that the amounts of dehydroascorbic acid generated under the assay conditions used were too low to account for the observed loss of NADPH. Electron paramagnetic resonance spectroscopy directly confirmed that the reductase decreased steady-state ascorbyl free radical concentrations, as expected if thioredoxin reductase reduces the ascorbyl free radical, Dialyzed cytosol from rat liver homogenates also catalyzed NADPH-dependent reduction of the ascorbyl free radical. Specificity for thioredoxin reductase was indicated by loss of activity in dialyzed cytosol prepared from livers of selenium-deficient rats, by inhibition with aurothioglucose at concentrations selective for thioredoxin reductase, and by stimulation with selenocystine. Microsomal fractions prepared from rat liver showed substantial NADH-dependent ascorbyl free radical reduction that was not sensitive to selenium depletion. These results suggest that thioredoxin reductase can function as a cytosolic ascorbyl free radical reductase that may complement cellular ascorbate recycling by membrane-bound NADH-dependent reductases.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	May, JM (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 751 Med Res Bldg 2, Nashville, TN 37232 USA.				NIDDK NIH HHS [DK 50435, DK 26657] Funding Source: Medline; NIEHS NIH HHS [ES02497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, R01DK050435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497, R37ES002497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANDO M, 1994, JPN J OPHTHALMOL, V38, P1; BANDO M, 1988, JPN J OPHTHALMOL, V32, P176; BEHRENS WA, 1989, INT J VITAM NUTR RES, V59, P360; BIELSKI BHJ, 1975, ANN NY ACAD SCI, V258, P231, DOI 10.1111/j.1749-6632.1975.tb29283.x; BIELSKI BHJ, 1982, AM CHEM SOC ADV CHEM, V200, P81; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BUETTNER GR, 1993, FREE RADICAL BIO MED, V14, P49, DOI 10.1016/0891-5849(93)90508-R; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; BURK RF, 1975, ARCH BIOCHEM BIOPHYS, V170, P124, DOI 10.1016/0003-9861(75)90103-4; BURK RF, 1987, METHOD ENZYMOL, V143, P307; CLARK WM, 1960, OXIDATION REDUCTION, P467; DELBELLO B, 1994, BIOCHEM J, V304, P385, DOI 10.1042/bj3040385; ESAKI N, 1982, J BIOL CHEM, V257, P4386; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Glinn MA, 1997, BBA-BIOENERGETICS, V1318, P246, DOI 10.1016/S0005-2728(96)00142-9; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; HARA T, 1971, J BIOCHEM-TOKYO, V69, P825; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Hou WC, 1997, PLANT SCI, V128, P151, DOI 10.1016/S0168-9452(97)00153-2; ITO A, 1981, BIOCHEM BIOPH RES CO, V101, P591, DOI 10.1016/0006-291X(81)91300-0; IYANAGI T, 1969, BIOCHIM BIOPHYS ACTA, V172, P370, DOI 10.1016/0005-2728(69)90133-9; KOBAYASHI K, 1991, BIOCHEMISTRY-US, V30, P8310, DOI 10.1021/bi00098a005; LUMPER L, 1967, H-S Z PHYSIOL CHEM, V348, P323, DOI 10.1515/bchm2.1967.348.1.323; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; May JM, 1996, FREE RADICAL BIO MED, V20, P543, DOI 10.1016/0891-5849(95)02130-2; Morell S, 1997, FEBS LETT, V414, P567, DOI 10.1016/S0014-5793(97)01074-0; MUNDAY R, 1989, FREE RADICAL BIO MED, V7, P659, DOI 10.1016/0891-5849(89)90147-0; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227, DOI 10.1016/0009-3084(87)90052-1; NJUS D, 1991, FEBS LETT, V284, P147, DOI 10.1016/0014-5793(91)80672-P; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; OKAMURA M, 1979, J NUTR SCI VITAMINOL, V25, P269, DOI 10.3177/jnsv.25.269; PIETRI S, 1990, EUR J BIOCHEM, V193, P845, DOI 10.1111/j.1432-1033.1990.tb19408.x; ROGINSKY VA, 1994, FREE RADICAL BIO MED, V17, P93, DOI 10.1016/0891-5849(94)90107-4; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; SCHULER RH, 1977, RADIAT RES, V69, P417, DOI 10.2307/3574655; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; SCHULZE HU, 1970, H-S Z PHYSIOL CHEM, V351, P809, DOI 10.1515/bchm2.1970.351.2.809; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; VanDyke BR, 1996, FREE RADICAL BIO MED, V20, P985, DOI 10.1016/0891-5849(95)02186-8; VENDELAND SC, 1993, J BIOL CHEM, V268, P17103; WAGNER ES, 1987, BIOCHIM BIOPHYS ACTA, V902, P133, DOI 10.1016/0005-2736(87)90143-X; WELLS WW, 1995, METHOD ENZYMOL, V252, P30; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; Xu DP, 1996, BIOCHEM BIOPH RES CO, V221, P117, DOI 10.1006/bbrc.1996.0555; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5; YEH JY, 1995, FASEB J, V9, P392, DOI 10.1096/fasebj.9.5.7896009; YEW MS, 1983, HORM METAB RES, V15, P158, DOI 10.1055/s-2007-1018657; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581	52	137	142	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23039	23045		10.1074/jbc.273.36.23039	http://dx.doi.org/10.1074/jbc.273.36.23039			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722529	hybrid			2022-12-25	WOS:000075778100029
J	Hahn, T; Barth, S; Weiss, U; Mosgoeller, W; Desoye, G				Hahn, T; Barth, S; Weiss, U; Mosgoeller, W; Desoye, G			Sustained hyperglycemia in vitro down-regulates the GLUT1 glucose transport system of cultured human term placental trophoblast: a mechanism to protect fetal development?	FASEB JOURNAL			English	Article; Proceedings Paper	FASEB Summer Research Conference on Glucose Transporter Biology	JUN 08-13, 1997	COPPER MT, CO	FASEB		placenta; glucose; transport	CONGENITAL-MALFORMATIONS; GENE-EXPRESSION; SKELETAL-MUSCLE; MESSENGER-RNA; CELLS; INSULIN; INVITRO; LOCALIZATION; FAMILY; RAT	The trophoblast of human placenta is directly exposed to the maternal circulation. It forms the main barrier to maternal-fetal glucose transport. The present study investigated the effect of sustained hyperglycemia in vitro on the glucose transport system of these cells. Trophoblasts isolated from term placentas and immunopurified were cultured for 24, 48, and 96 h in DMEM containing either 5.5 (normoglycemia) or 25 mmol/l D-glucose (hyperglycemia), respectively. Initial uptake of glucose was measured using 3-O-[C-14]methyl-D-glucose. Kinetic parameters were calculated as K-M = 73 mmol/l and V-max = 29 fmol s(-1) per trophoblast cell. Uptake rates of cells cultured under hyperglycemic conditions did not differ at exogenous D-glucose concentrations in the physiological range (1, 5.5, 10, and 15 mmol/l), but were significantly decreased by 25% (P<0.05) at diabetes-like concentrations (20 and 25 mmol/l) as compared to normoglycemic conditions. This effect was due to a decrease in V-max (-50%), whereas K-M remained virtually unaffected. GLUT1 mRNA levels were lower by 50% (P<0.05; Northern blotting) and GLUT1 protein was reduced by 16% (P<0.05; Western blotting) in trophoblast cells cultured under hyperglycemic vs, normoglycemic conditions. We conclude that prolonged hyperglycemia in vitro reduces trophoblast glucose uptake at substrate concentrations corresponding to blood levels of poorly controlled diabetic gravidas. This effect is due to diminished GLUT1 mRNA and protein expression in the trophoblast.-Hahn, T., Earth, S., Weiss, U., Mosgoeller, W., Desoye, G. Sustained hyperglycemia in vitro down-regulates the GLUT1 glucose transport system of cultured human term placental trophoblast: a mechanism to protect fetal development?.	Graz Univ, Sch Med, Dept Obstet & Gynecol, A-8036 Graz, Austria; Univ Vienna, Inst Histol & Embryol, A-1090 Vienna, Austria	University of Graz; University of Vienna	Hahn, T (corresponding author), Graz Univ, Inst Histol & Embryol, Harrachgasse 21, A-8010 Graz, Austria.	tom.hahn@kfunigraz.ac.at		Mosgoller, Wilhelm/0000-0003-1436-1504				AGHAYAN M, 1992, DEVELOPMENT, V115, P305; BALDWIN SA, 1980, BIOCHEM BIOPH RES CO, V94, P1401, DOI 10.1016/0006-291X(80)90575-6; BARROS LF, 1995, PLACENTA, V16, P623, DOI 10.1016/0143-4004(95)90031-4; BEARD RW, 1979, PLACENTAL TRANSFER, P202; BEHAM A, 1988, PLACENTA, V9, P479, DOI 10.1016/0143-4004(88)90020-3; BIGORNIA L, 1986, BIOCHIM BIOPHYS ACTA, V885, P335, DOI 10.1016/0167-4889(86)90249-1; BISSONNETTE J M, 1979, Journal of Developmental Physiology (Eynsham), V1, P415; Bloxam DL, 1997, PLACENTA, V18, P99, DOI 10.1016/S0143-4004(97)90080-1; BOILEAU P, 1995, J CLIN INVEST, V96, P309, DOI 10.1172/JCI118036; BRUNETTE MG, 1990, MOL CELL ENDOCRINOL, V69, P59, DOI 10.1016/0303-7207(90)90089-Q; Buchanan T A, 1994, Curr Ther Endocrinol Metab, V5, P278; Cervar M, 1996, EUR J CLIN INVEST, V26, P30, DOI 10.1046/j.1365-2362.1996.87238.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarson LH, 1997, PLACENTA, V18, P333, DOI 10.1016/S0143-4004(97)80068-9; DEMOUZON SH, 1994, PLACENTA, V15, P35, DOI 10.1016/S0143-4004(05)80234-6; DESOYE G, 1994, MOL ASPECTS MED, V15, P505, DOI 10.1016/0098-2997(94)90004-3; DESOYE G, 1996, DIABETES REV, V4, P70; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; DEVASKAR SU, 1994, AM J OBSTET GYNECOL, V171, P1316, DOI 10.1016/0002-9378(94)90154-6; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P339, DOI 10.1016/0005-2736(78)90034-2; ERIKSSON UJ, 1991, DIABETOLOGIA, V34, P325, DOI 10.1007/BF00405004; FREINKEL N, 1980, DIABETES, V29, P1023, DOI 10.2337/diabetes.29.12.1023; GAITHER K, 1997, J SOC GYNECOL INVEST, V4, pA103; GARDNER HG, 1995, REPROD FERT DEVELOP, V7, P41, DOI 10.1071/RD9950041; GORDON MC, 1995, AM J OBSTET GYNECOL, V173, P1089, DOI 10.1016/0002-9378(95)91332-7; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HAHN T, 1995, CELL TISSUE RES, V280, P49, DOI 10.1007/s004410050329; Hahn T, 1996, Early Pregnancy, V2, P168; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HAUGUEL S, 1986, PEDIATR RES, V20, P269, DOI 10.1203/00006450-198603000-00015; HaugueldeMouzon S, 1997, J CLIN ENDOCR METAB, V82, P2689, DOI 10.1210/jc.82.8.2689; HAY WW, 1991, DIABETES, V40, P44, DOI 10.2337/diab.40.2.S44; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; Herrera E, 1985, Diabetes, V34 Suppl 2, P42; HOARE DG, 1972, J PHYSIOL-LONDON, V221, P311, DOI 10.1113/jphysiol.1972.sp009753; JANSSON T, 1993, J CLIN ENDOCR METAB, V77, P1554, DOI 10.1210/jc.77.6.1554; JOHNSON LW, 1980, AM J PHYSIOL, V238, pC160, DOI 10.1152/ajpcell.1980.238.5.C160; KAHN BB, 1986, ANN NY ACAD SCI, V488, P356; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KITAGAWA T, 1995, J CELL SCI, V108, P3735; Kitzmiller JL, 1996, DIABETES CARE, V19, P514, DOI 10.2337/diacare.19.5.514; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; LANG I, 1993, CELL TISSUE RES, V274, P211, DOI 10.1007/BF00318740; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCALL AL, 1982, P NATL ACAD SCI-BIOL, V79, P5406, DOI 10.1073/pnas.79.17.5406; MCGOWAN KM, 1995, PHARMACOL THERAPEUT, V66, P465, DOI 10.1016/0163-7258(95)00007-4; MCMAHON RJ, 1995, J BIOL CHEM, V270, P12094, DOI 10.1074/jbc.270.20.12094; McMahon RJ, 1996, AM J PHYSIOL-ENDOC M, V270, pE640, DOI 10.1152/ajpendo.1996.270.4.E640; MEDDINGS JB, 1990, J CLIN INVEST, V85, P1099, DOI 10.1172/JCI114541; MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292; Pedersen J, 1977, PREGNANT DIABETIC HE, P211; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; ROBINSON JWL, 1983, J PHYSIOL-LONDON, V344, P177, DOI 10.1113/jphysiol.1983.sp014932; RYBAKOWSKI C, 1991, Placenta, V12, P431; Sasson S, 1997, DIABETOLOGIA, V40, P30, DOI 10.1007/s001250050639; SCHMON B, 1991, J CLIN ENDOCR METAB, V73, P888, DOI 10.1210/jcem-73-4-888; SCHNEIDER H, 1981, PLACENTA S, V2, P129; SHAFRIR E, 1996, DIABETES REV, V4, P114; SHORTER SC, 1993, PLACENTA, V14, P571, DOI 10.1016/S0143-4004(05)80210-3; SIBLEY CP, 1988, OXFORD REV REPROD B, V10, P382; SIBLEY CP, 1992, FETAL NEONATAL PHYSL, V1, P62; STEINER M, 1994, HISTOCHEM J, V26, P934; TOWNER D, 1995, DIABETES CARE, V18, P1446, DOI 10.2337/diacare.18.11.1446; TOYODA N, 1987, J BIOL CHEM, V262, P2737; TUAN RS, 1991, J CELL SCI, V98, P333	69	79	85	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1221	1231		10.1096/fasebj.12.12.1221	http://dx.doi.org/10.1096/fasebj.12.12.1221			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737725				2022-12-25	WOS:000075738500017
J	Cheong, J; Coligan, JE; Shuman, JD				Cheong, J; Coligan, JE; Shuman, JD			Activating transcription factor-2 regulates phosphoenolpyruvate carboxykinase transcription through a stress-inducible mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; GROWTH-HORMONE GENE; TRANSGENIC MICE; C/EBP-ALPHA; GTP GENE; DIETARY-REGULATION; HEPATOMA-CELLS; RAT-LIVER; EXPRESSION; PHOSPHORYLATION	Several protein-nucleic acid complexes are observed when nuclear extracts from hepatoma cells are assayed for binding to the cAMP response element found in the phosphoenolpyruvate carboxykinase-cytosolic (PEPCK-C) promoter. Although cAMP response element-binding protein and CCAAT/enhancer binding proteins alpha and beta have been identified as Liver factors that bind this motif, an uncharacterized, slower migrating complex was also observed. We identify activating transcription factor-2 (ATF-2) as the factor in this complex and show that ATF-S stimulates expression from the PEPCK-C promoter. ATF-2 is a basic-leucine zipper transcription factor and a target for stress-activated protein kinases. We demonstrate that p38 beta mitogen-activated protein (MAP) kinase augments ATF-S transactivation activity on the PEPCK-C promoter, which is consistent with the interpretation that PEPCK-C promoter activity is maintained under stress through a p38 MAP kinase dependent pathway. In this regard, we show that treatment with sodium arsenite, a known activator of p38 MAP kinases, also stimulates expression from the PEPCK promoter. These results show that ATF-2 can stimulate transcription of the PEPCK-C promoter and support a role for stress inducible kinases in the maintenance of PEPCK-C expression.	NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Shuman, JD (corresponding author), NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.			Shuman, Jon/0000-0001-8412-9087				ALAM T, 1992, J BIOL CHEM, V267, P5021; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DIEHL AM, 1995, HEPATOLOGY, V22, P252, DOI 10.1016/0270-9139(95)90379-8; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GUNN JM, 1975, BIOCHEM J, V150, P195, DOI 10.1042/bj1500195; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KIOUSSIS D, 1978, J BIOL CHEM, V253, P4327; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; Nizielski SE, 1996, J NUTR, V126, P2697; Nizielski SE, 1996, AM J PHYSIOL-REG I, V270, pR1005, DOI 10.1152/ajpregu.1996.270.5.R1005; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 2002, MOL CLONING LAB MANU; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; TILGHMAN S M, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1304, DOI 10.1073/pnas.71.4.1304; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VIDNES J, 1976, ACTA PAEDIATR SCAND, V65, P297, DOI 10.1111/j.1651-2227.1976.tb04889.x; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557	39	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22714	22718		10.1074/jbc.273.35.22714	http://dx.doi.org/10.1074/jbc.273.35.22714			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712902	hybrid			2022-12-25	WOS:000075616600078
J	Liu, W; Litwack, ED; Stanley, MJ; Langford, JK; Lander, AD; Sanderson, RD				Liu, W; Litwack, ED; Stanley, MJ; Langford, JK; Lander, AD; Sanderson, RD			Heparan sulfate proteoglycans as adhesive and anti-invasive molecules - Syndecans and glypican have distinct functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; INTEGRAL MEMBRANE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; PROTEIN-KINASE-C; MESENCHYMAL INTERACTIONS; CHONDROITIN SULFATE; NERVOUS-SYSTEM; CORE PROTEINS; EXPRESSION	ARH-77 cells do not adhere to type I collagen and readily invade into collagen gels, but following expression of the transmembrane heparan sulfate proteoglycan syndecan-1, they bind collagen and fail to invade. We now show that cells transfected with syndecan-2 or syndecan-4 also bind collagen and are non-invasive. In contrast, cells transfected with the glycosylphosphatidylinositol-anchored proteoglycan glypican-1 do not bind to collagen and remain invasive, even though glypican- and syndecan-expressing cells have similar surface levels of heparan sulfate, and their proteoglycans have similar affinities for collagen. Analysis of cells expressing syndecan-1-glypican-1 chimeric proteoglycans reveals that inhibition of invasion requires the extracellular domain of syndecan but not its transmembrane or cytoplasmic domain. Surprisingly, cells bearing a chimera composed of the glypican extracellular domain fused to the syndecan transmembrane and cytoplasmic domains bind to collagen but remain invasive, implying that adhesion to collagen is not by itself sufficient to inhibit invasion. Apparently, the extracellular domain of syndecan-1, presumably by interacting with cell-surface signal transducing molecules, directly regulates complex cell behaviors such as motility and invasiveness. These results also show for the first time that syndecans and glypicans can have distinct functions, even when expressed by the same cell type.	Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Anat, Little Rock, AR 72205 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Massachusetts Institute of Technology (MIT); University of California System; University of California Irvine	Sanderson, RD (corresponding author), Univ Arkansas Med Sci, Dept Pathol, Slot 517,4301 W Markham, Little Rock, AR 72205 USA.		Lander, Arthur/L-2827-2019; Lander, Arthur D/C-9008-2011	Lander, Arthur/0000-0002-4380-5525; Lander, Arthur D/0000-0002-4380-5525	NATIONAL CANCER INSTITUTE [R29CA055879, R01CA068494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55879, CA 68494] Funding Source: Medline; NINDS NIH HHS [NS 26862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOUTIN EL, 1991, DEV BIOL, V148, P63, DOI 10.1016/0012-1606(91)90317-V; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; Carey DJ, 1997, BIOCHEM J, V327, P1; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Dhodapkar MV, 1998, BLOOD, V91, P2679, DOI 10.1182/blood.V91.8.2679.2679_2679_2688; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; Lander AD, 1996, PERSPECT DEV NEUROBI, V3, P347; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LIEBERSBACH BF, 1994, J BIOL CHEM, V269, P20013; LITWACK ED, 1994, J NEUROSCI, V14, P3713; Litwack ED, 1998, DEV DYNAM, V211, P72, DOI 10.1002/(SICI)1097-0177(199801)211:1<72::AID-AJA7>3.3.CO;2-8; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; McFall AJ, 1997, J BIOL CHEM, V272, P12901, DOI 10.1074/jbc.272.20.12901; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; PIERCE A, 1992, J BIOL CHEM, V267, P3894; Pulkkinen JO, 1997, ACTA OTO-LARYNGOL, V117, P312, DOI 10.3109/00016489709117794; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Saunders S, 1997, DEV BIOL, V190, P78, DOI 10.1006/dbio.1997.8690; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; STANLEY MJ, 1995, J BIOL CHEM, V270, P5077, DOI 10.1074/jbc.270.10.5077; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; TRAUTMAN MS, 1991, DEVELOPMENT, V111, P213; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; Wahl SM, 1996, J LEUKOCYTE BIOL, V59, P789, DOI 10.1002/jlb.59.6.789; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	57	144	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22825	22832		10.1074/jbc.273.35.22825	http://dx.doi.org/10.1074/jbc.273.35.22825			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712917	hybrid			2022-12-25	WOS:000075616600093
J	Valenti, G; Procino, G; Liebenhoff, U; Frigeri, A; Benedetti, PA; Ahnert-Hilger, G; Nurnberg, B; Svelto, M; Rosenthal, W				Valenti, G; Procino, G; Liebenhoff, U; Frigeri, A; Benedetti, PA; Ahnert-Hilger, G; Nurnberg, B; Svelto, M; Rosenthal, W			A heterotrimeric G protein of the G(i) family is required for cAMP-triggered trafficking of aquaporin 2 in kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLECTING DUCT; WATER CHANNEL; PLASMA-MEMBRANE; VASOPRESSIN; MICROSCOPY; TOXIN; PERMEABILITY; EXOCYTOSIS; EXPRESSION; TRANSPORT	Vasopressin is the key regulator of water homeostasis in vertebrates. Central to its antidiuretic action in mammals is the redistribution of the water channel aquaporin 2 (AQP2) from intracellular vesicles to the apical membrane of kidney epithelial cells, an event initiated by an increase in cAMP and activation of protein kinase A. The subsequent steps of the signaling cascade are not known. To identify proteins involved in the AQP2 shuttle we exploited a recently developed cell line (CD8) derived from the rabbit cortical collecting duct and stably transfected with rat AQP2 cDNA, Treatment of CD8 cells with pertussis toxin (PTX) inhibited both the vasopressin-induced increase in water permeability and the redistribution of AQP2 from an intracellular compartment to the apical membrane. ADP-ribosylation studies revealed the presence of at least two major PTX substrates, Correspondingly, two a: subunits of PTX-sensitive G proteins, G alpha(i2), and G alpha(i3), were identified by Western blotting. Introduction of a synthetic peptide corresponding to the C terminus of the G(i3) alpha subunit into permeabilized CD8 cells efficiently inhibited the cAMP-induced AQP2 translocation; a peptide corresponding to the a subunits of G(i1/2) was much less potent. Thus a member of the G(i) family, most likely G(i3), is involved in the cAMP-triggered targeting of AQP2-bearing vesicles to the apical membrane of kidney epithelial cells.	Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany; Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Justus Liebig Univ, Rudolf Buchheim Inst Pharmakol, D-35392 Giessen, Germany; CNR, Ist Biofis, I-56127 Pisa, Italy; Humboldt Universitat Berlin, Inst Anat, D-10115 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Universita degli Studi di Bari Aldo Moro; Justus Liebig University Giessen; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Humboldt University of Berlin; Free University of Berlin	Rosenthal, W (corresponding author), Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany.	rosenthal@fmp-berlin.de	frigeri, Antonio/AAC-6336-2022; Svelto, Maria/P-6186-2014	Nurnberg, Bernd/0000-0002-5995-6555; Procino, Giuseppe/0000-0002-0043-7523; Frigeri, Antonio/0000-0002-5284-2934; VALENTI, GIOVANNA/0000-0003-0233-0778; Svelto, Maria/0000-0002-5584-9541				AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; BENEDETTI PA, 1995, P SOC PHOTO-OPT INS, V2412, P56, DOI 10.1117/12.205348; BENEDETTI PA, 1995, ZOOL STUD, V34, P186; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FARINAS J, 1995, BIOPHYS J, V68, P1613, DOI 10.1016/S0006-3495(95)80335-8; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; Jena BP, 1997, P NATL ACAD SCI USA, V94, P13317, DOI 10.1073/pnas.94.24.13317; JO IH, 1995, P NATL ACAD SCI USA, V92, P1876, DOI 10.1073/pnas.92.6.1876; Katsura T, 1997, AM J PHYSIOL-RENAL, V272, pF816; Knepper MA, 1997, CURR OPIN CELL BIOL, V9, P560, DOI 10.1016/S0955-0674(97)80034-8; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Leopoldt D, 1997, N-S ARCH PHARMACOL, V356, P216, DOI 10.1007/PL00005044; LIEBENHOFF U, 1995, FEBS LETT, V365, P209, DOI 10.1016/0014-5793(95)00476-P; Mandon B, 1996, J CLIN INVEST, V98, P906, DOI 10.1172/JCI118873; NIELSEN S, 1993, AM J PHYSIOL, V265, pF225, DOI 10.1152/ajprenal.1993.265.2.F225; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Nurnberg B, 1996, FEBS LETT, V389, P61, DOI 10.1016/0014-5793(96)00584-4; RUDOLPH U, 1989, MOL CELL ENDOCRINOL, V63, P143, DOI 10.1016/0303-7207(89)90090-7; SABOLIC I, 1992, J CELL BIOL, V119, P111, DOI 10.1083/jcb.119.1.111; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; Valenti G, 1996, J BIOL CHEM, V271, P24365, DOI 10.1074/jbc.271.40.24365; VANDEWALLE A, 1989, J CELL PHYSIOL, V141, P203, DOI 10.1002/jcp.1041410128; WADE JB, 1994, SEMIN NEPHROL, V14, P322; WOLLHEIM CB, 1996, DIABETES REV, V4, P276	31	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22627	22634		10.1074/jbc.273.35.22627	http://dx.doi.org/10.1074/jbc.273.35.22627			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712891	hybrid, Green Published			2022-12-25	WOS:000075616600067
J	Ashrafi, K; Farazi, TA; Gordon, JI				Ashrafi, K; Farazi, TA; Gordon, JI			A role for Saccharomyces cerevisiae fatty acid activation protein 4 in regulating protein N-myristoylation during entry into stationary phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; MAMMALIAN G-PROTEIN; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; RESISTANT MUTANTS; GENETIC-ANALYSIS; YEAST PROTEIN; MYRISTOYLTRANSFERASE; EXPRESSION; ALPHA	Saccharomyces cerevisiae contains four known acyl-CoA synthetases (fatty acid activation proteins, Faaps), Faa1p and Faa4p activate exogenously derived fatty acids. Acyl-CoA metabolism plays a critical role in regulating protein N-myristoylation by the essential enzyme, myristoyl-CoA:protein N-myristoyltransferase (Nmt1p). In this report, we have examined whether Faa1p and Faa4p have distinct roles in affecting protein N-myristoylation as cells transition from growth in rich media to a growth-arrested state during nutrient deprivation (stationary phase). The colony-forming potential of 10 isogenic strains was defined as a function of time spent in stationary phase. These strains contained either a wild type or mutant NMTI allele, and wild type or null alleles of each FAA. Only the combination of the Nmt mutant (nmt451Dp; reduced affinity for myristoyl-CoA) and loss of Faa4p produced a dramatic loss of colony-forming units (CFU). The progressive millionfold reduction in CFU was associated with a deficiency in protein N-myristoylation that first appeared during log arithmic growth, worsened through the post-diauxic phase, and became extreme in stationary phase. Northern and Western blot analyses plus N-myristoyltransferase assays showed that Nmt is normally present only during the log and diauxic/post-diauxic periods, indicating that N-myristoylproteins present in stationary phase are "inherited" from these earlier phases. Moreover, FAA4 is the only FAA induced during the critical diauxic/early post-diauxic transition. Although substitution of nmt1-451D for NMT1 results in deficiencies in protein N-myristoylation, these deficiencies are modest and limited by compensatory responses that include augmented expression of nmt1-451D and precocious induction of FAA4 in log phase. Loss of Faa4p from nmt1-451D cells severely compromises their capacity to adequately myristoylate Nmt substrates prior to entry into stationary phase since none of the other Faaps are able to functionally compensate for its absence. To identify Nmt1p substrates that may affect maintenance of proliferative potential during stationary phase, we searched the yeast genome for known and putative N-myristoylproteins. Of the 64 genes found, 48 were successfully deleted in NMT1 cells. Removal of any one of the following nine substrates produced a loss of CFU similar to that observed in nmt1-451Dfaa4 Delta cells: Arf1p, Arf2p, Sip2p, Van1p, Ptc2p, YBL049W (homology to Snf7p), YJR114W, YKR007W, and YMR077C. These proteins provide opportunities to further define the molecular mechanisms that regulate survival during stationary phase.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	jgordon@pharmsun.wustl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038200] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; ABRAHAM PR, 1992, YEAST, V8, P227, DOI 10.1002/yea.320080309; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bhatnagar RS, 1997, BIOCHEMISTRY-US, V36, P6700, DOI 10.1021/bi970311v; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Boyum R, 1997, MICROBIOL-SGM, V143, P1901, DOI 10.1099/00221287-143-6-1901; Church C, 1996, J BIOL CHEM, V271, P18499, DOI 10.1074/jbc.271.31.18499; CYERT MS, 1993, ADV PROTEIN PHOSPHAT, V7, P429; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; EGNER R, 1993, J BIOL CHEM, V268, P27269; ERICKSON JR, 1993, GENETICS, V135, P655; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; JOHNSON DR, 1994, P NATL ACAD SCI USA, V91, P10158, DOI 10.1073/pnas.91.21.10158; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; JONES MH, 1995, P NATL ACAD SCI USA, V92, P9687, DOI 10.1073/pnas.92.21.9687; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KANIKENNULAT C, 1995, GENETICS, V140, P933; KANIKENNULAT C, 1990, MOL CELL BIOL, V10, P898, DOI 10.1128/MCB.10.3.898; KASSIR Y, 1978, GENETICS, V90, P49; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KNOLL LJ, 1995, J BIOL CHEM, V270, P20090, DOI 10.1074/jbc.270.34.20090; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; LEE KS, 1994, J BIOL CHEM, V269, P19725; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; LODGE JK, 1994, J BIOL CHEM, V269, P2996; Lodge JK, 1997, MICROBIOL-UK, V143, P357, DOI 10.1099/00221287-143-2-357; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; Rudnick D.A., 1992, LIPID MODIFICATION P, P37; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; SCHULLER HJ, 1992, EUR J BIOCHEM, V203, P607, DOI 10.1111/j.1432-1033.1992.tb16590.x; SCHWEIZER E, 1970, P NATL ACAD SCI USA, V67, P660, DOI 10.1073/pnas.67.2.660; Sherman F., 1986, METHODS YEAST GENETI; SHIOZAKI K, 1994, CELL MOL BIOL RES, V40, P241; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH N, 1985, BIOCHEMISTRY-US, V24, P6598, DOI 10.1021/bi00344a044; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TU JL, 1993, GENETICS, V135, P17; VALLIER LG, 1991, GENETICS, V129, P675; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x; Zhang LT, 1996, J BIOL CHEM, V271, P33131, DOI 10.1074/jbc.271.51.33131; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	66	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25864	25874		10.1074/jbc.273.40.25864	http://dx.doi.org/10.1074/jbc.273.40.25864			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748261	hybrid			2022-12-25	WOS:000076263100052
J	Kirsch, KH; Georgescu, MM; Hanafusa, H				Kirsch, KH; Georgescu, MM; Hanafusa, H			Direct binding of p130(Cas) to the guanine nucleotide exchange factor C3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; SRC HOMOLOGY-3 DOMAIN; C-TERMINAL REGION; TYROSINE PHOSPHORYLATION; ADAPTER PROTEINS; SH3 DOMAINS; V-CRK; PTP-PEST; ACTIVATION	p130(Cas) (Cas; crk-associated substrate) belongs to a new family of docking molecules. It contains one Src homology (SH) 3 domain in its amino terminal region followed by a region containing binding motifs for SH2 and SH3 domains. To gain further insight into Cas signaling we used the SH3 domain of Cas in a two-hybrid screen to search a human placenta library for binding partners. The screen confirmed a previous finding of its binding to the focal adhesion kinase (FAK) but also identified C3G, a guanine nucleotide exchange factor. We found direct interaction between Cas and C3G in vitro and in vivo. A series of analysis with C3G deletion mutants revealed a proline-rich Gas-binding site (Ala(0)-Pro(1)-Pro(2)-Lys(3)-Pro(4)-Pro(5)-Leu(6)-Pro(7)) located NH2-terminal to the previously characterized Crk binding motifs in C3G. Mutagenesis studies showed that Pro(1), Lys(3), and Pro(4) within the ligand-binding site are critical for high affinity interaction. These results, combined with sequence alignments of proline-rich binding elements from proteins known for Cas binding, define the consensus sequence XXPXKPX which is recognized by the CasSH3 domain. Cas shows structural characteristics of a docking molecule and may serve to bring C3G to specific compartments within the cell.	Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA	Rockefeller University	Hanafusa, H (corresponding author), Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA.	saburo@rockvax.rockefeller.edu	Georgescu, Maria-Magdalena/AAJ-6359-2020		NCI NIH HHS [CA44356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Astier A, 1997, J BIOL CHEM, V272, P228; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Ishino M, 1995, ONCOGENE, V11, P2331; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Law SF, 1996, MOL CELL BIOL, V16, P3327; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MAYRE BJ, 1998, CURR BIOL, V5, P296; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Nojima Y, 1996, Hum Cell, V9, P169; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Okada S, 1997, J BIOL CHEM, V272, P28179, DOI 10.1074/jbc.272.45.28179; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PATCH LA, 1995, J CELL SCI, V108, P1371; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	52	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25673	25679		10.1074/jbc.273.40.25673	http://dx.doi.org/10.1074/jbc.273.40.25673			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748234	hybrid			2022-12-25	WOS:000076263100025
J	Labesse, I; Ferrari, D; Chen, ZW; Rossi, GL; Kuusk, V; McIntire, WS; Mathews, FS				Labesse, I; Ferrari, D; Chen, ZW; Rossi, GL; Kuusk, V; McIntire, WS; Mathews, FS			Crystallographic and spectroscopic studies of native, aminoquinol, and monovalent cation-bound forms of methylamine dehydrogenase from Methylobacterium extorquens AM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY-AMINE DEHYDROGENASE; ELECTRON-TRANSFER COMPLEX; MAU GENE-CLUSTER; PARACOCCUS-DENITRIFICANS; TRYPTOPHAN TRYPTOPHYLQUINONE; THIOBACILLUS-VERSUTUS; CRYSTAL-STRUCTURE; KINETIC-PROPERTIES; PSEUDOMONAS AM1; BACTERIUM W3A1	Various monovalent cations influence the enzymatic activity and the spectroscopic properties of methylamine dehydrogenase (MADH). Here, we report the structure determination of this tryptophan tryptophylquinone-containing enzyme from Methylobacterium extorquens AM1 by high resolution x-ray crystallography (1.75 Angstrom). This first MADH crystal structure at low ionic strength is compared with the high resolution structure of the related MADH from Paracoccus denitrificans recently reported. We also describe the first structures (at 1.95 to 2.15 Angstrom resolution) of an MADH in the substrate-reduced form and in the presence of trimethylamine and of cesium, two competitive inhibitors. Polarized absorption microspectrophotometry was performed on single crystals under various redox, pH, and salt conditions. The results show that the enzyme is catalytically active in the crystal and that the cations cause the same spectral perturbations as are observed in solution. These studies lead us to propose a model for the entrance and binding of the substrate in the active site.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Dept Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Parma, Ist Sci Biochim, I-43100 Parma, Italy	Washington University (WUSTL); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Parma	Mathews, FS (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	mathews@biochem.wustl.edu		Labesse, Gilles/0000-0002-6861-3300	NHLBI NIH HHS [HL16251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anthony C., 1982, BIOCH METHYLOTROPHS; Bishop GR, 1996, BIOCHEMISTRY-US, V35, P8948, DOI 10.1021/bi960404x; Bishop GR, 1997, BIOCHEMISTRY-US, V36, P13586, DOI 10.1021/bi970586a; BOULTON CA, 1979, BIOCHIM BIOPHYS ACTA, V570, P22, DOI 10.1016/0005-2744(79)90197-9; BROOKS HB, 1993, BIOCHEMISTRY-US, V32, P2725, DOI 10.1021/bi00061a034; BRUNGER AT, 1992, XPLOR VERSION 3 1; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHEN L, 1988, J MOL BIOL, V203, P1137, DOI 10.1016/0022-2836(88)90134-9; CHEN LY, 1993, PROTEIN SCI, V2, P147; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; CHISTOSERDOV AY, 1994, J BACTERIOL, V176, P4052, DOI 10.1128/JB.176.13.4052-4065.1994; CHISTOSERDOV AY, 1994, J BACTERIOL, V176, P4073, DOI 10.1128/JB.176.13.4073-4080.1994; CHISTOSERDOV AY, 1992, BIOCHEM BIOPH RES CO, V184, P1181, DOI 10.1016/S0006-291X(05)80007-5; DAVIDSON VL, 1990, BIOCHIM BIOPHYS ACTA, V1016, P339, DOI 10.1016/0005-2728(90)90166-2; DAVIDSON VL, 1989, BIOCHEM J, V261, P107, DOI 10.1042/bj2610107; EADY RR, 1971, BIOCHEM J, V123, P757, DOI 10.1042/bj1230757; GORREN ACF, 1995, BIOCHEMISTRY-US, V34, P9748, DOI 10.1021/bi00030a012; GORREN ACF, 1994, BIOCHEMISTRY-US, V33, P12202, DOI 10.1021/bi00206a024; GORREN ACF, 1995, BIOCHEMISTRY-US, V34, P12926, DOI 10.1021/bi00040a002; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUIZINGA EG, 1992, BIOCHEMISTRY-US, V31, P9789, DOI 10.1021/bi00155a036; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIRIUKHIN MY, 1990, METHOD ENZYMOL, V188, P247; KOOYSTRA PJU, 1988, EUR J BIOCHEM, V177, P345; KUUSK V, 1994, J BIOL CHEM, V269, P26136; Labesse G, 1998, BIOINFORMATICS, V14, P206, DOI 10.1093/bioinformatics/14.2.206; MCINTIRE WS, 1995, METHOD ENZYMOL, V258, P149; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Merli A, 1996, J BIOL CHEM, V271, P9177, DOI 10.1074/jbc.271.16.9177; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; Scrutton NS, 1996, BIOCHEM J, V319, P1; UBBINK M, 1991, EUR J BIOCHEM, V202, P1003, DOI 10.1111/j.1432-1033.1991.tb16462.x; VELLIEUX FMD, 1986, EUR J BIOCHEM, V154, P383, DOI 10.1111/j.1432-1033.1986.tb09409.x; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Zhu ZY, 1998, BIOCHEM J, V329, P175, DOI 10.1042/bj3290175	43	31	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25703	25712		10.1074/jbc.273.40.25703	http://dx.doi.org/10.1074/jbc.273.40.25703			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748238	hybrid			2022-12-25	WOS:000076263100029
J	Blanchoin, L; Pollard, TD				Blanchoin, L; Pollard, TD			Interaction of actin monomers with Acanthamoeba actophorin (ADF/cofilin) and profilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPOLYMERIZING FACTOR; BINDING PROTEIN; F-ACTIN; NUCLEOTIDE-SEQUENCE; SKELETAL-MUSCLE; PORCINE BRAIN; ADP-ACTIN; COFILIN; PURIFICATION; FILAMENTS	Acanthamoeba actophorin is a member of ADF/cofilin family that binds both actin monomers and filaments. We used fluorescence anisotropy to study the interaction of actin monomers with recombinant actophorin labeled with rhodamine on a cysteine substituted for Serine-88. Labeled actophorin retains its affinity for actin and ability to reduce the low shear viscosity of actin filaments. At physiological ionic strength, actophorin binds Mg-ADP-actin monomers (K-d = 0.1 mu M) 40 times stronger than Mg-ATP-actin monomers. When bound to actin monomers, actophorin has no effect on elongation at either end of actin filaments by Mg-ATP-actin and slightly increases the rate of elongation at both ends by Mg-ADP-actin. Thus actophorin does not sequester actin monomers. Sedimentation equilibrium ultracentrifugation shows that actophorin and profilin compete for binding actin monomers. Actophorin and profilin have opposite effects on the rate of exchange of nucleotide bound to actin monomers. Despite the high affinity of actophorin for ADP-actin, physiological concentrations of profilin overcome the inhibition of ADP exchange by actophorin. Profilin rapidly recycles ADP-actin back to the profilin-ATP-actin pool ready for elongation of actin filaments.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Pollard, TD (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CARLIER MF, 1987, BIOCHEM BIOPH RES CO, V143, P1069, DOI 10.1016/0006-291X(87)90361-5; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COOPER JA, 1986, J BIOL CHEM, V261, P477; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; De La Cruz EM, 1996, BIOCHEMISTRY-US, V35, P14054, DOI 10.1021/bi961047t; DE LA CRUZ EM, 1995, BIOCHEMISTRY-US, V34, P5452, DOI 10.1021/bi00016a016; DRENCKHAHN D, 1986, J BIOL CHEM, V261, P2754; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IIDA K, 1993, GENE, V124, P115; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAHAM LE, 1993, J BIOL CHEM, V268, P14202; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; MABUCHI I, 1981, J BIOCHEM-TOKYO, V89, P1341; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MORIYAMA K, 1990, J BIOL CHEM, V265, P5768; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; MUNEYUKI F, 1985, J BIOCHEM-TOKYO, V97, P563, DOI 10.1093/oxfordjournals.jbchem.a135091; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; OHTA Y, 1989, J BIOL CHEM, V264, P16143; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; QUIRK S, 1993, BIOCHEMISTRY-US, V32, P8525, DOI 10.1021/bi00084a019; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; SUZUKI K, 1995, J BIOL CHEM, V270, P19551, DOI 10.1074/jbc.270.33.19551; TAKAGI T, 1988, J BIOL CHEM, V263, P3097; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x	47	144	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25106	25111		10.1074/jbc.273.39.25106	http://dx.doi.org/10.1074/jbc.273.39.25106			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737968	hybrid			2022-12-25	WOS:000076085400018
J	Halfter, W; Dong, SC; Schurer, B; Cole, GJ				Halfter, W; Dong, SC; Schurer, B; Cole, GJ			Collagen XVIII is a basement membrane heparan sulfate proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; DENSITY-LIPOPROTEIN-RECEPTOR; EXTRACELLULAR-MATRIX; MULTIPLE DOMAINS; CHICK-EMBRYO; BASAL LAMINA; AGRIN; EXPRESSION; PROTEIN; GENE	The present study shows that collagen XVIII is, next to perlecan and agrin, the third basal lamina heparan sulfate proteoglycan (HSPG) and the first collagen/proteoglycan with heparan sulfate side chains. By using monoclonal antibodies to an unidentified HSPG in chick, 14 cDNA clones were isolated from a chick yolk sac library. All clones had a common nucleotide sequence that was homologous to the mRNA sequences of mouse and human collagen XVIII. The deduced amino acid sequence of the chick fragment shows an 83% overall homology with the human and mouse collagen XVIII. Similar to the human and mouse homologue, the chick collagen XVIII mRNA has a size of 4.5 kilobase pairs. In Western blots, collagen XVIII appeared as a smear with a molecular mass of 300 kDa. After treatment with heparitinase, the protein was reduced in molecular mass by 120 kDa to a protein core of 180 kDa. Collagen XVIII has typical features of a collagen, such as its existence, under nondenaturing conditions, as a non-covalently linked oligomer, and a sensitivity of the core protein to collagenase digestion. It also has characteristics of an HSPG, such as long heparitinase-sensitive carbohydrate chains and a highly negative net charge. Collagen XVIII is abundant in basal laminae of the retina, epidermis, pia, cardiac and striated muscle, kidney, blood vessels, and lung. In situ hybridization showed that the main expression of collagen XVIII: HSPG in the chick embryo is in the kidney and the peripheral nervous system. As a substrate, collagen XVIII moderately promoted the adhesion of Schwann cells but had no such activity on peripheral nervous system neurons and axons.	Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15261 USA; Ohio State Univ, Neurobioltechnol Ctr, Columbus, OH 43210 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; Ohio State University	Halfter, W (corresponding author), Univ Pittsburgh, Dept Neurobiol, 1402 E Biol Sci Tower, Pittsburgh, PA 15261 USA.	whalfer@vms.cis.pitt.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033981] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33981-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BHATTACHARYYA A, 1991, NEURON, V7, P831, DOI 10.1016/0896-6273(91)90285-8; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; FITCH JM, 1989, DEVELOPMENT, V105, P85; FUKAI N, 1994, METHOD ENZYMOL, V245, P3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Halfter W, 1998, J COMP NEUROL, V397, P89, DOI 10.1002/(SICI)1096-9861(19980720)397:1<89::AID-CNE7>3.0.CO;2-E; Halfter W, 1998, J COMP NEUROL, V397, P105, DOI 10.1002/(SICI)1096-9861(19980720)397:1<105::AID-CNE8>3.0.CO;2-4; HALFTER W, 1987, J NEUROSCI, V7, P3712; HALFTER W, 1993, J NEUROSCI, V13, P2863; Halfter W, 1997, J COMP NEUROL, V383, P1; HALFTER W, 1994, EXP CELL RES, V214, P285, DOI 10.1006/excr.1994.1260; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KANWAR YS, 1984, P NATL ACAD SCI-BIOL, V81, P762, DOI 10.1073/pnas.81.3.762; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; MA E, 1994, J NEUROSCI, V14, P2943; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOLLER HJ, 1993, ANAL BIOCHEM, V209, P169, DOI 10.1006/abio.1993.1098; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSEN GS, 1995, J BIOL CHEM, V270, P15934, DOI 10.1074/jbc.270.27.15934; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WRIGHT TN, 1992, CURR OPIN CELL BIOL, V4, P793; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	47	262	270	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25404	25412		10.1074/jbc.273.39.25404	http://dx.doi.org/10.1074/jbc.273.39.25404			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738008	hybrid			2022-12-25	WOS:000076085400058
J	Nakai, J; Tanabe, T; Konno, T; Adams, B; Beam, KG				Nakai, J; Tanabe, T; Konno, T; Adams, B; Beam, KG			Localization in the II-III loop of the dihydropyridine receptor of a sequence critical for excitation-contraction coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL BLOCKERS; SKELETAL-MUSCLE; RELEASE CHANNEL; TRANSIENTS; MYOTUBES; REGIONS; CHARGE	Skeletal and cardiac muscles express distinct isoforms of the dihydropyridine receptor (DHPR), a type of voltage-gated Ca2+ channel that is important for excitation-contraction (EC) coupling. However, entry of Ca2+ through the channel is not required for skeletal muscle-type EC coupling. Previous work (Tanabe, T., Beam, K. G., Adams, B. A., Niidome, T., and Numa, S. (1990) Nature 346, 567-569) revealed that the loop between repeats II and III (II-III loop) is an important determinant of skeletal-type EC coupling. In the present study we have further dissected the regions of the II-III loop critical for skeletal-type EC coupling by expression of cDNA constructs in dysgenic myotubes. Because Ser(687) of the skeletal II-III loop has been reported to be rapidly phosphorylated in vitro, we substituted this serine with alanine, the corresponding cardiac residue. This alanine-substituted skeletal DHPR retained the ability to mediate skeletal-type EC coupling. Weak skeletal-type EC coupling was produced by a chimeric DHPR, which was entirely cardiac except for a small amount of skeletal sequence (residues 725-742) in the II-III loop. Skeletal-type coupling was stronger when both residues 725-742 and adjacent residues were skeletal (e.g. a chimera containing skeletal residues 711-765). However, residues 725-742 appeared to be critical because skeletal-type coupling was not produced either by a chimera with skeletal residues 711-732 or by one with skeletal residues 734-765.	Colorado State Univ, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 4448585, Japan; Tokyo Med & Dent Univ, Dept Pharmacol, Bunkyo Ku, Tokyo 113, Japan; Natl Inst Physiol Sci, Physiol Res Facil, Okazaki, Aichi 4448585, Japan; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	Colorado State University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Tokyo Medical & Dental University (TMDU); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University of Iowa	Beam, KG (corresponding author), Colorado State Univ, Dept Anat & Neurobiol, Ft Collins, CO 80523 USA.		Tuluc, Petronel/C-2527-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024444] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24444] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x	22	133	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					24983	24986		10.1074/jbc.273.39.24983	http://dx.doi.org/10.1074/jbc.273.39.24983			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737952	hybrid			2022-12-25	WOS:000076085400002
J	Nguyen, AT; Holmes, EH; Whitaker, JM; Ho, S; Shetterly, S; Macher, BA				Nguyen, AT; Holmes, EH; Whitaker, JM; Ho, S; Shetterly, S; Macher, BA			Human alpha 1,3/4-fucosyltransferases - I. Identification of amino acids involved in acceptor substrate binding by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; LEWIS-NEGATIVE INDIVIDUALS; L-SELECTIN; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; MOLECULAR-CLONING; P-SELECTIN; HUMAN ALPHA-1->3FUCOSYLTRANSFERASES; LEUKOCYTE TRAFFICKING; HELICOBACTER-PYLORI; ENZYME-ACTIVITY	In a previous study (Xu, Z., Vo, L., and Macher, B. A. (1996) J. Biol Chem. 271, 8818-8823), a domain swapping approach demonstrated that a region of amino acids found in human alpha 1,3/4-fucosyltransferase III (FucT III) conferred a significant increase in alpha 1,4-FucT acceptor substrate specificity into alpha 1,3-fucosyltransferase V (FucT V), which, under the same assay conditions, has extremely low alpha 1,4-FucT acceptor substrate specificity. In the current study, site-directed mutagenesis was utilized to identify which of the eight amino acids, associated with alpha 1,4-FucT acceptor substrate specificity, is/are responsible for conferring this new property. The results demonstrate that increased alpha 1,4-FucT activity with both disaccharide and glycolipid accepters can be conferred on FucT V by modifying as few as two (Asn(86) to His and Thr(87) to Ile) of the eight amino acids originally swapped from FucT III into the FucT V sequence. Neither single amino acid mutant had increased alpha 1,4-FucT activity relative to that of FucT V. Kinetic analyses of FucT V mutants demonstrated a reduced K-m for Gal beta 1,3GlcNAc (type 1) acceptor substrates compared with native FucT V. However, this was about 20-fold higher than that found for native FucT III, suggesting that other amino acids in FucT III must contribute to its overall binding site for type 1 substrates, These results demonstrate that amino acid residues near the amino terminus of the catalytic domain of FucT In: contribute to its acceptor substrate specificity.	NW Hosp, Pacific NW Canc Fdn, Seattle, WA 98125 USA; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	California State University System; San Francisco State University	Holmes, EH (corresponding author), NW Hosp, Pacific NW Canc Fdn, 120 Northgate Plaza,Suite 218, Seattle, WA 98125 USA.	eholmes@nwbio.org			NCI NIH HHS [CA70740] Funding Source: Medline; NCRR NIH HHS [P20 RR11805] Funding Source: Medline; NIGMS NIH HHS [GM52588] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM052588] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8925, DOI 10.1021/bi952194e; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; Elmgren A, 1997, J BIOL CHEM, V272, P21994, DOI 10.1074/jbc.272.35.21994; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMES EH, 1993, ARCH BIOCHEM BIOPHYS, V301, P190, DOI 10.1006/abbi.1993.1132; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; KODA Y, 1993, BLOOD, V82, P2915; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; Nagai K, 1997, GLYCOBIOLOGY, V7, P769, DOI 10.1093/glycob/7.6.769; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Sherwood AL, 1998, J BIOL CHEM, V273, P25256, DOI 10.1074/jbc.273.39.25256; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stroud MR, 1997, BIOCHEM BIOPH RES CO, V238, P165, DOI 10.1006/bbrc.1997.7254; Toki D, 1997, BIOCHEM J, V325, P63, DOI 10.1042/bj3250063; Vo L, 1998, J BIOL CHEM, V273, P25250, DOI 10.1074/jbc.273.39.25250; Watkins W M, 1980, Adv Hum Genet, V10, P1; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	35	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25244	25249		10.1074/jbc.273.39.25244	http://dx.doi.org/10.1074/jbc.273.39.25244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737988	hybrid			2022-12-25	WOS:000076085400038
J	Jansson, M; Andersson, G; Uhlen, M; Nilsson, B; Kordel, J				Jansson, M; Andersson, G; Uhlen, M; Nilsson, B; Kordel, J			The insulin-like growth factor (IGF)binding protein 1 binding epitope on IGF-I probed by heteronuclear NMB spectroscopy and mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTOPICALLY-ENRICHED PROTEINS; NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI; SIDE-CHAIN; LIGAND INTERACTIONS; RECEPTOR-BINDING; FUSION PROTEINS; ASSIGNMENT; SPECTRA; DOMAIN	NMR spectroscopy studies and biosensor interaction analysis of native and site-directed mutants of insulinlike growth factor I (IGF-I) was applied to identify the involvement of individual residues in IGF-I binding to IGF-binding protein 1 (IGFBP-1). Backbone NMR chemical shifts were found to be affected by IGFBP-1 binding in the following residues: Pro(2), Glu(3), Cys(6), Gly(7), Gly(19), Pro(28)-Gly(30), Gly(32), Arg(36), Arg(37), Gln(40)-Gly(42), Pro(63), Lys(65), Pro(66), and Lys(68)-Ala(70). Three IGF-I arginine side chains were identified by NMR to participate in IGFBP-1 binding. All IGF-I arginine residues were replaced by alanines, using site-directed mutagenesis, in four single substituted variants, IGF-I(R21A), IGF-I(R50A), IGF-I(R55A), and IGF-I(R56A), and one double replacement mutant, IGF-I(R36A/R37A), Biosensor interaction analysis binding studies demonstrate the involvement of Arg(36)-Arg(37) and Arg(50) in IGFBP-1 binding, while experiments with the IGF-I receptor implicate Arg(21), Arg(36)-Arg(37), and Arg(56) as part of the receptor binding epitope, These overlapping binding surfaces explain why IGF-I receptor and IGFBP-1 binding to IGF-I is competitive, The C terminus of free, but not IGFBP-1-bound, IGF-I is found to exist in two distinct, NMR-detectable conformations at 30 degrees C, One possible explanation for this structural heterogeneity could be cis-trans isomerization of the Cys(6)-Cys(48) disulfide bond.	Pharmacia & Upjohn Inc, Dept Struct Chem, SE-11237 Stockholm, Sweden; Royal Inst Technol, Dept Biochem & Biotechnol, SE-10044 Stockholm, Sweden	Pfizer; Pharmacia Corporation; Royal Institute of Technology	Kordel, J (corresponding author), Pharmacia & Upjohn Inc, Dept Struct Chem, SE-11237 Stockholm, Sweden.	johan.kordel@eu.pnu.com	Uhlen, Mathias/B-3262-2016; Uhlen, Mathias/AAV-8746-2021	Uhlen, Mathias/0000-0002-4858-8056; 				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; BACH LA, 1993, J BIOL CHEM, V268, P9246; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; BALLARD FJ, 1987, BIOCHEM BIOPH RES CO, V149, P398, DOI 10.1016/0006-291X(87)90380-9; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; Craven CJ, 1996, BIOCHEMISTRY-US, V35, P10287, DOI 10.1021/bi9605043; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FORSBERG G, 1990, BIOCHEM J, V271, P357, DOI 10.1042/bj2710357; Gargaro AR, 1996, EUR J BIOCHEM, V238, P435, DOI 10.1111/j.1432-1033.1996.0435z.x; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; HOBER S, 1994, BIOCHEMISTRY-US, V33, P6758, DOI 10.1021/bi00188a003; HUA QX, 1993, P NATL ACAD SCI USA, V90, P582, DOI 10.1073/pnas.90.2.582; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; Jansson M, 1997, J BIOL CHEM, V272, P8189, DOI 10.1074/jbc.272.13.8189; Jansson M, 1996, J BIOMOL NMR, V7, P131; Jansson M, 1997, FEBS LETT, V416, P259, DOI 10.1016/S0014-5793(97)01149-6; Jansson M, 1997, BIOCHEMISTRY-US, V36, P4108, DOI 10.1021/bi961553i; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KOBAYASHI Y, 1991, PEPTIDES 1990, P565; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; LOGAN TM, 1992, FEBS LETT, V314, P413, DOI 10.1016/0014-5793(92)81517-P; McAlister MSB, 1996, BIOCHEMISTRY-US, V35, P5982, DOI 10.1021/bi952756u; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; MONTELIONE GT, 1992, J AM CHEM SOC, V114, P10974, DOI 10.1021/ja00053a051; Moore DD, 1995, GLOB MOB SURV; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; NILSSON B, 1991, METHOD ENZYMOL, V198, P3; Olsen HB, 1996, BIOCHEMISTRY-US, V35, P8836, DOI 10.1021/bi960292+; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; OTTING G, 1993, BIOCHEMISTRY-US, V32, P3571, DOI 10.1021/bi00065a008; OTTING G, 1993, CURR OPIN STRUC BIOL, V3, P760, DOI 10.1016/0959-440X(93)90061-O; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; SANTORO J, 1992, J MAGN RESON, V97, P202, DOI 10.1016/0022-2364(92)90250-B; SATO A, 1992, J BIOCHEM-TOKYO, V111, P529, DOI 10.1093/oxfordjournals.jbchem.a123791; SATO A, 1993, INT J PEPT PROT RES, V41, P433; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YAMAZAKI T, 1995, J AM CHEM SOC, V117, P3556, DOI 10.1021/ja00117a025; ZHANG WG, 1994, J BIOL CHEM, V269, P10609	50	37	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24701	24707		10.1074/jbc.273.38.24701	http://dx.doi.org/10.1074/jbc.273.38.24701			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733769	hybrid			2022-12-25	WOS:000076007300061
J	Katan-Khaykovich, Y; Shaul, Y				Katan-Khaykovich, Y; Shaul, Y			RFX1, a single DNA-binding protein with a split dimerization domain, generates alternative complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B VIRUS ENHANCER; II GENE-REGULATION; FACTOR EF-C; NUCLEAR FACTOR; NF-X; TRANSCRIPTION; PROMOTER; ELEMENT; REGION; FAMILY	The transcription of various viral and cellular genes is regulated by palindromic and nonpalindromic DNA sites resembling the EP element of the hepatitis B virus enhancer, which generate similar DNA-protein complexes. The upper EP complex contains homodimers of the transcription regulator RFX1. We show that RFX1 possesses a split, extended dimerization domain composed of several evolutionarily conserved boxes, one of which was previously shown to mediate dimerization. Such an unusually long and complex dimerization domain could potentially serve for generating multiple complexes. In addition to the previously characterized complex, RFX1 generated a novel DNA-protein complex of extremely low mobility, formed only with palindromic DNA sites. Different deletions within the dimerization domain altered the relative abundance of the two complexes, suggesting an interplay between them. Formation of the low mobility complex correlated with transcriptional repression, in that both activities were mediated by several portions of the conserved region. Our results propose a mechanism by which the extended dimerization domain mediates the formation of alternative homodimeric complexes, which differ in the nature of the intersubunit interaction. By participating in different types of interactions, this domain may regulate the relative abundance of the different complexes, thus affecting transcriptional activity.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	lvshaul@weizmann.weizmann.ac.il						Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; Blake M, 1996, J VIROL, V70, P6060, DOI 10.1128/JVI.70.9.6060-6066.1996; BOLWIG GM, 1991, J VIROL, V65, P1884, DOI 10.1128/JVI.65.4.1884-1892.1991; Buckwold VE, 1997, VIROLOGY, V227, P515, DOI 10.1006/viro.1996.8360; DAVID E, 1995, J BIOL CHEM, V270, P8353, DOI 10.1074/jbc.270.14.8353; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; Emery P, 1996, MOL CELL BIOL, V16, P4486; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; GARCIA AD, 1991, VIROLOGY, V182, P857, DOI 10.1016/0042-6822(91)90629-P; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; KOUSKOFF V, 1991, J IMMUNOL, V146, P3197; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; SAFRANY G, 1993, GENE, V132, P279, DOI 10.1016/0378-1119(93)90208-K; SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SIEGRIST CA, 1993, EUR J IMMUNOL, V23, P2903, DOI 10.1002/eji.1830231126; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; SUPAKAR PC, 1989, NUCLEIC ACIDS RES, V17, P8611, DOI 10.1093/nar/17.21.8611; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; WU SY, 1995, MOL CELL BIOL, V15, P1479; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	39	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24504	24512		10.1074/jbc.273.38.24504	http://dx.doi.org/10.1074/jbc.273.38.24504			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733744	hybrid			2022-12-25	WOS:000076007300036
J	Orozco, BM; Hanley-Bowdoin, L				Orozco, BM; Hanley-Bowdoin, L			Conserved sequence and structural motifs contribute to the DNA binding and cleavage activities of a geminivirus replication protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLDEN MOSAIC-VIRUS; WHEAT DWARF VIRUS; REP PROTEIN; VIRAL-DNA; TRANSCRIPTIONAL REGULATION; INITIATOR PROTEINS; GENETIC-ANALYSIS; PLANT-CELLS; IDENTIFICATION; EXPRESSION	Tomato golden mosaic virus (TGMV), a member of the geminivirus family, has a single-stranded DNA genome that replicates through a rolling circle mechanism in nuclei of infected plant cells. TGMV encodes one essential replication protein, AL1, and recruits the rest of the DNA replication apparatus from its host. AL1 is a multifunctional protein that binds double-stranded DNA, catalyzes cleavage and ligation of single-stranded DNA, and forms oligomers, Earlier experiments showed that the region of TG:MV AL1 necessary for DNA binding maps to the N-terminal 181 amino acids of the protein and overlaps the DNA cleavage (amino acids 1-120) and oligomerization (amino acids 134-181) domains. In this study, we generated a series of site-directed mutations in conserved sequence and structural motifs in the overlapping DNA binding and cleavage domains and analyzed their impact on AL1 function in vivo and in vitro. Only two of the fifteen mutant proteins were capable of supporting viral DNA synthesis in tobacco protoplasts. In vitro experiments demonstrated that a pair of predicted alpha-helices with highly conserved charged residues are essential for DNA binding and cleavage. Three sequence motifs conserved among geminivirus AL1 proteins and initiator proteins from other rolling circle systems are also required for both activities. We used truncated AL1 proteins fused to a heterologous dimerization domain to show that the DNA binding domain is located between amino acids 1 and 130 and that binding is dependent on protein dimerization, In contrast, AL1 monomers were sufficient for DNA cleavage and ligation, Together, these results established that the conserved motifs in the AL1 N terminus contribute to DNA binding and cleavage with both activities displaying nearly identical amino acid requirements. However, DNA binding was readily distinguished from cleavage and ligation by its dependence on AL1/AL1 interactions.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Orozco, BM (corresponding author), N Carolina State Univ, Dept Biochem, Box 7622, Raleigh, NC 27695 USA.	orozco@bchserver.bch.ncsu.edu		Hanley-Bowdoin, Linda/0000-0001-7999-8595				Ach RA, 1997, MOL CELL BIOL, V17, P5077, DOI 10.1128/MCB.17.9.5077; ARGUELLOASTORGA GR, 1994, VIROLOGY, V203, P90, DOI 10.1006/viro.1994.1458; BISARO DM, 1982, NUCLEIC ACIDS RES, V10, P4913, DOI 10.1093/nar/10.16.4913; CHOI IR, 1995, VIROLOGY, V206, P904, DOI 10.1006/viro.1995.1013; Collin S, 1996, VIROLOGY, V219, P324, DOI 10.1006/viro.1996.0256; CORUZZI G, 1984, EMBO J, V3, P1671, DOI 10.1002/j.1460-2075.1984.tb02031.x; DELSOLAR G, 1993, MOL MICROBIOL, V8, P789; DESBIEZ C, 1995, P NATL ACAD SCI USA, V92, P5640, DOI 10.1073/pnas.92.12.5640; EAGLE PA, 1994, PLANT CELL, V6, P1157, DOI 10.1105/tpc.6.8.1157; Eagle PA, 1997, J VIROL, V71, P6947, DOI 10.1128/JVI.71.9.6947-6955.1997; ELMER JS, 1988, NUCLEIC ACIDS RES, V16, P7043, DOI 10.1093/nar/16.14.7043; FONTES EPB, 1992, PLANT CELL, V4, P597, DOI 10.1105/tpc.4.5.597; FONTES EPB, 1994, J BIOL CHEM, V269, P8459; FONTES EPB, 1994, PLANT CELL, V6, P405, DOI 10.1105/tpc.6.3.405; Gladfelter HJ, 1997, VIROLOGY, V239, P186, DOI 10.1006/viro.1997.8869; HAMILTON WDO, 1983, NUCLEIC ACIDS RES, V11, P7387, DOI 10.1093/nar/11.21.7387; HANLEYBOWDOIN L, 1998, IN PRESS CRIT REV PL; HEYRAUD F, 1993, EMBO J, V12, P4445, DOI 10.1002/j.1460-2075.1993.tb06130.x; HEYRAUDNITSCHKE F, 1995, NUCLEIC ACIDS RES, V23, P910, DOI 10.1093/nar/23.6.910; Hoogstraten RA, 1996, MOL PLANT MICROBE IN, V9, P594, DOI 10.1094/MPMI-9-0594; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; JUPIN I, 1995, FEBS LETT, V362, P116, DOI 10.1016/0014-5793(95)00221-T; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; KOONIN EV, 1992, J GEN VIROL, V73, P2763, DOI 10.1099/0022-1317-73-10-2763; KORNBERG A, 1992, DNA REPLICATION; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P482; LAUFS J, 1995, P NATL ACAD SCI USA, V92, P3879, DOI 10.1073/pnas.92.9.3879; Laufs J, 1995, FEBS LETT, V377, P258, DOI 10.1016/0014-5793(95)01355-5; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; NAGAR S, 1995, PLANT CELL, V7, P705, DOI 10.1105/tpc.7.6.705; NI TH, 1994, J VIROL, V68, P1128, DOI 10.1128/JVI.68.2.1128-1138.1994; NOIROTGROS MF, 1994, EMBO J, V13, P4412, DOI 10.1002/j.1460-2075.1994.tb06761.x; NUESCH JPF, 1995, VIROLOGY, V209, P122, DOI 10.1006/viro.1995.1236; Orozco BM, 1998, VIROLOGY, V242, P346, DOI 10.1006/viro.1997.9013; Orozco BM, 1996, J VIROL, V70, P148, DOI 10.1128/JVI.70.1.148-158.1996; Orozco BM, 1997, J BIOL CHEM, V272, P9840; SAUNDERS K, 1991, NUCLEIC ACIDS RES, V19, P2325, DOI 10.1093/nar/19.9.2325; Settlage SB, 1996, J VIROL, V70, P6790, DOI 10.1128/JVI.70.10.6790-6795.1996; SNYDER RO, 1990, CELL, V60, P105, DOI 10.1016/0092-8674(90)90720-Y; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; STANLEY J, 1995, VIROLOGY, V206, P707, DOI 10.1016/S0042-6822(95)80093-X; STENGER DC, 1991, P NATL ACAD SCI USA, V88, P8029, DOI 10.1073/pnas.88.18.8029; SUNTER G, 1990, VIROLOGY, V179, P69, DOI 10.1016/0042-6822(90)90275-V; SUNTER G, 1993, VIROLOGY, V195, P275, DOI 10.1006/viro.1993.1374; SUNTER G, 1989, VIROLOGY, V170, P243, DOI 10.1016/0042-6822(89)90372-3; TIMMERMANS MCP, 1994, ANNU REV PLANT PHYS, V45, P79, DOI 10.1146/annurev.pp.45.060194.000455; XIE Q, 1995, EMBO J, V14, P4073, DOI 10.1002/j.1460-2075.1995.tb00079.x; Xie Q, 1996, EMBO J, V15, P4900, DOI 10.1002/j.1460-2075.1996.tb00870.x	49	74	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24448	24456		10.1074/jbc.273.38.24448	http://dx.doi.org/10.1074/jbc.273.38.24448			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733736	hybrid			2022-12-25	WOS:000076007300028
J	Lam, LT; Bresnick, EH				Lam, LT; Bresnick, EH			Identity of the beta-globin locus control region binding protein HS2NF5 as the mammalian homolog of the notch-regulated transcription factor suppressor of hairless	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARR-VIRUS EBNA2; ERYTHROID-DIFFERENTIATION; HYPERSENSITIVE SITES; TRANSGENIC MICE; GAMMA-GLOBIN; FACTOR NF-E2; CHROMATIN STRUCTURE; DROSOPHILA HOMOLOG; ACTIVATION REGION; GENE-CLUSTER	Previously, we characterized a DNA-binding protein, HS2NF5, that bound tightly to a conserved region within hypersensitive site 2 (HS2) of the human beta-globin locus control region (LCR) (Lam, L, T., and Bresnick, E. H. (1996) J. Biol. Chem. 271, 32421-32429). The beta-globin LCR controls the chromatin structure, transcription, and replication of the beta-globin genes. We have now purified HS2NF5 to near-homogeneity from fetal bovine thymus, Two polypeptides of 56 and 61 kDa copurified with the DNA binding activity. The two proteins bound to the LCR recognition site with an affinity (3.1 nM) and specificity similar to mouse erythroleukemia cell HS2NF5. The amino acid sequences of tryptic peptides of purified HS2NF5 revealed it to be identical to the murine homolog of the suppressor of hairless transcription factor, also known as recombination signal binding protein J(K) or C promoter binding factor 1 (CBF1). The CBF1 site within HS2 resides near sites for hematopoietic regulators such as GATA-1, NF-ES, and TAL1. An additional conserved, high affinity CBF1 site was localized within HS4 of the LCR, As CBF1 is a downstream target of the Notch signaling pathway, we propose that Notch may modulate LCR activity during hematopoiesis.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 387 Med Sci Bldg,1300 Univ Ave, Madison, WI 53706 USA.	ehbresni@facstaff.wisc.edu			NIDDK NIH HHS [DK50107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050107, R37DK050107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; BRESNICK EH, 1997, CHEMTRACTS BIOCH MOL, V10, P1001; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; Christensen S, 1996, DEVELOPMENT, V122, P1373; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Elnitski L, 1997, J BIOL CHEM, V272, P369; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1994, DEV BIOL, V165, P574, DOI 10.1006/dbio.1994.1277; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; FURUKAWA T, 1994, BLOOD, V83, P1412; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; Gould KA, 1998, GENE EXPRESSION, V7, P87; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; Hanspal M, 1997, Curr Opin Hematol, V4, P142; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KAWAICHI M, 1992, J BIOL CHEM, V267, P4016; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Lam LT, 1996, J BIOL CHEM, V271, P32421, DOI 10.1074/jbc.271.50.32421; Lam LT, 1995, BIOCHEMISTRY-US, V34, P16347, DOI 10.1021/bi00050a015; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; MILNER LA, 1994, BLOOD, V83, P2057; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; OKA C, 1995, DEVELOPMENT, V121, P3291; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Ryan J A, 1989, Arch Psychiatr Nurs, V3, P323; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SORRENTINO B, 1990, NUCLEIC ACIDS RES, V18, P2721, DOI 10.1093/nar/18.9.2721; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wettstein DA, 1997, DEVELOPMENT, V124, P693; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353	71	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24223	24231		10.1074/jbc.273.37.24223	http://dx.doi.org/10.1074/jbc.273.37.24223			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727046	hybrid			2022-12-25	WOS:000075893100087
J	Mahmood, R; Ray, DS				Mahmood, R; Ray, DS			Nuclear extracts of Crithidia fasciculata contain a factor(s) that binds to the 5 '-untranslated regions of TOP2 and RPA1 mRNAs containing sequences required for their cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; RNA-POLYMERASE-II; TRYPANOSOMA-BRUCEI; KINETOPLAST DNA; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; MESSENGER-RNAS; TRANSCRIPTION; TOPOISOMERASE; LEISHMANIA	The Crithidia fasciculata replication protein A gene, RPA1, and topoisomerase II gene, TOP2, encode proteins involved in the replication of nuclear and mitochondrial DNA, respectively. Transcripts of both genes accumulate periodically during the cell cycle and attain their maximum levels just before S phase. Octamer consensus sequences within the 5'-untranslated region (UTR) of both genes have been shown to be necessary for cycling of these transcripts. Using a gel retardation assay, we show here that nuclear extracts of C. fasciculata contain a protein factor(s) that binds specifically to RNA from 5'-UTRs of TOP2 and RPA1 genes. In addition, mutations in the consensus octamer sequence abolish binding to the RNA in both cases. Ultraviolet cross-linking using a radiolabeled TOP2 5'-UTR probe identified proteins with apparent molecular masses of 74 and 37 kDa in the RNA-protein complex. Nuclear extracts prepared from synchronized cells show that the binding activity varies during the cell cycle in parallel with TOP2 and RPA1 mRNA levels. These results suggest that the cell cycle regulation of the mRNA levels of trypanosomatid DNA replication genes may be mediated by binding of specific proteins to conserved sequences in the 5'-UTR of their transcripts.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Ray, DS (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, 611 Circle Dr E, Los Angeles, CA 90095 USA.	danray@mbi.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053254, R56GM053254] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53254] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BROWN GW, 1994, MOL BIOCHEM PARASIT, V63, P135, DOI 10.1016/0166-6851(94)90016-7; BROWN GW, 1992, P NATL ACAD SCI USA, V89, P10227, DOI 10.1073/pnas.89.21.10227; Brown LM, 1997, NUCLEIC ACIDS RES, V25, P3281, DOI 10.1093/nar/25.16.3281; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Graham SV, 1996, NUCLEIC ACIDS RES, V24, P272, DOI 10.1093/nar/24.2.272; GUTTES EW, 1967, BIOCHIM BIOPHYS ACTA, V142, P181, DOI 10.1016/0005-2787(67)90526-6; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MGS, 1996, MOL CELL BIOL, V16, P1220; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PASION SG, 1992, MOL BIOCHEM PARASIT, V50, P57, DOI 10.1016/0166-6851(92)90244-E; PASION SG, 1994, J CELL SCI, V107, P3515; Pasion SG, 1996, MOL CELL BIOL, V16, P6724; Pays Etienne, 1993, Symposium of the Society for General Microbiology, V50, P127; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SIMPSON L, 1986, INT REV CYTOL, V99, P119; WOODWARD R, 1990, J CELL SCI, V95, P49	24	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23729	23734		10.1074/jbc.273.37.23729	http://dx.doi.org/10.1074/jbc.273.37.23729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726980	hybrid			2022-12-25	WOS:000075893100021
J	Feliciello, A; Rubin, CS; Avvedimento, EV; Gottesman, ME				Feliciello, A; Rubin, CS; Avvedimento, EV; Gottesman, ME			Expression of a kinase anchor protein 121 is regulated by hormones in thyroid and testicular germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-KINASE; II-BETA; CYCLIC-AMP; SUBUNITS; LOCALIZATION; CYTOSKELETON; CLONING; RAS; RII; BINDING	Distinct A Kinase Anchor Proteins (AKAPs) immobilize and concentrate protein kinase A II (PKAII) isoforms at specific intracellular locations. AKAP121 binds and targets PKAII alpha to the cytoplasmic surface of mitochondria. Mechanisms that control expression of this mitochondrial AKAP are unknown. We have cloned cDNA for rat AKAP-121 and show that AKAP121 protein expression is regulated by thyroid stimulating hormone (TSH) and cAMP. Differentiated thyroid cells (TL5) accumulate AKAP121 upon incubation with TSH or a cAMP analog. Levels of total and newly synthesized AKAP121 mRNA also increased after treatment. AKAP121 mRNA accumulated in the presence of cycloheximide, suggesting that transcription of the anchor protein gene is directly controlled by cAMP and PKA. AKAP121 is induced with similar kinetics when an unrelated, spermatocyte-derived cell line (GC-2) is incubated with 8-chlorophenylthio-cAMP. Thus, AKAP121 concentration may be controlled by hormones that activate adenylate cyclase. This mode of regulation could provide a general mechanism for (a) enhancing the sensitivity of distal organelles to cAMP and (b) shifting the focus of cAMP-mediated signaling from cytoplasm to organelles.	Columbia Univ, Inst Canc Res, New York, NY 10032 USA; Univ Naples Federico II, Fac Med, CNR,Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol & Cellulare, I-80131 Naples, Italy; Fac Med, Dipartimento Med Sperimentale & Clin, Catanzaro, Italy; Albert Einstein Coll Med, Atran Labs, Dept Mol Pharmacol, Bronx, NY 10461 USA	Columbia University; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Yeshiva University; Albert Einstein College of Medicine	Gottesman, ME (corresponding author), Columbia Univ, Inst Canc Res, HHSC Rm 914,701 W 168th, New York, NY 10031 USA.			Feliciello, Antonio/0000-0002-7932-2170	NIDDK NIH HHS [DK50702] Funding Source: Medline; NIGMS NIH HHS [GM 22792] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1993, J BIOL CHEM, V268, P20729; Cassano S, 1996, J BIOL CHEM, V271, P29870, DOI 10.1074/jbc.271.47.29870; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN MC, 1994, P NATL ACAD SCI USA, V91, P5533, DOI 10.1073/pnas.91.12.5533; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LEISER M, 1986, J BIOL CHEM, V261, P1904; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747	39	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23361	23366		10.1074/jbc.273.36.23361	http://dx.doi.org/10.1074/jbc.273.36.23361			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722570	hybrid			2022-12-25	WOS:000075778100070
J	Guilherme, A; Torres, K; Czeck, MP				Guilherme, A; Torres, K; Czeck, MP			Cross-talk between insulin receptor and integrin alpha(5)beta(1) signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MEDIATED CELL-ADHESION; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE DEPHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOTYROSINE PROTEIN; EXTRACELLULAR-MATRIX; SUBSTRATE FAMILY; TRANSDUCTION; ACTIVATION	The ligation and clustering of cell surface crp heterodimeric integrins enhances cell adhesion and initiates signaling pathways that regulate such processes as cell spreading, migration, differentiation, proliferation and apoptosis, Here we show that insulin treatment of Chinese hamster ovary cells expressing insulin receptors (CHO-T) markedly promotes cell adhesion onto a fibronectin matrix, but not onto bovine serum albumin or poly-lysine. Incubation of cells with a GRGDSP peptide that specifically binds integrins (but not the nonspecific GRADSP peptide) abolishes this insulin effect, as does the potent phosphoinositide 3-kinase (PI 3-kinase) inhibitor wortmannin. Moreover, a specific blocking monoclonal anti-alpha(5)beta(1) integrin antibody, PB-1, blocks insulin-stimulated cell adhesion onto fibronectin. Conversely, activating alpha(5)beta(1) integrins on CHO-T cells by adherence onto fibronectin markedly potentiates the action of insulin to enhance insulin receptor and insulin receptor substrate (IRS)-1 tyrosine phosphorylation, Activation of alpha(5)beta(1) integrin also markedly potentiates the recruitment of p85-associated PI 3-kinase activity to IRS-1 in response to submaximal levels of insulin in CHO-T cells. These data indicate that insulin potently activates integrin alpha(5)beta(1) mediated CHO-T cell adhesion, while integrin alpha(5)beta(1) signaling in turn enhances insulin receptor kinase activity and formation of complexes containing IRS-1 and PI 3-kinase, These findings raise the hypothesis that insulin receptor and alpha(5)beta(1) integrin signaling act synergistically to enhance cell adhesion.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czeck, MP (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.	Michael.Czech@ummed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN PJ, 1988, BIOCHEM BIOPH RES CO, V155, P603, DOI 10.1016/S0006-291X(88)80537-0; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CYBULSKY AV, 1994, J CLIN INVEST, V94, P68, DOI 10.1172/JCI117350; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Guilherme A, 1996, J BIOL CHEM, V271, P29533, DOI 10.1074/jbc.271.47.29533; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	40	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22899	22903		10.1074/jbc.273.36.22899	http://dx.doi.org/10.1074/jbc.273.36.22899			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722509	hybrid			2022-12-25	WOS:000075778100009
J	Mergler, S; Steinhausen, K; Wiederholt, M; Strauss, O				Mergler, S; Steinhausen, K; Wiederholt, M; Strauss, O			Altered regulation of L-type channels by protein kinase C and protein tyrosine kinases as a pathophysiologic effect in retinal degeneration	FASEB JOURNAL			English	Article						retinal pigment epithelium; bFGF; calcium channels; retinal pigment epithelium; RCS rats	PIGMENT EPITHELIAL-CELLS; SMOOTH-MUSCLE CELLS; FIBROBLAST GROWTH-FACTOR; ROD OUTER SEGMENTS; RCS RAT RPE; CALCIUM CHANNELS; CULTURED RAT; INOSITOL TRIPHOSPHATE; PHORBOL ESTERS; ROYAL-COLLEGE	The effect of protein tyrosine kinases (PTK) on L-type calcium channels in cultured retinal pigmented epithelium (RPE) from rats with retinal dystrophy was investigated. Barium currents through Bay K 8644 (10(-6) M) sensitive L-type channels were measured using the patch-clamp technique. The current density of L-type currents is twice as high and the inactivation time constants are much slower than in cells from nondystrophic control rats. Application of the PTK blockers genistein, lavendustin A, and herbimycin A (all 5X10(-6) M) led to an increase of Lr type currents. Intracellular application of pp60c-src (30 U/ml) via the patch pipette led to a transient decrease of L-type currents. The protein kinase A (PKA) and PKG blocker H9 (10(-6) M) showed no effect on L-type currents, However, the protein kinase C blocker chelerythrine (10(-5) M) reduced these currents. Up-regulation of PKC by 10(-6) M 4 beta-phorbol- 12 myristate-13-acetate (PMA) led to a decrease of C type currents. Additional application of genistein led to a further decrease of these currents. However, intracellular application of pp60(c-src) in PMA-treated cells led to a transient increase of L-type currents. Investigating the calcium response to bFGF application showed that RPE cells from RCS rats used different pathways than control RPE cells to increase cytosolic free calcium. This different pathway does not involve the activation of L-type channels. The present study with RPE cells from rats with retinal dystrophy shows a changed integration of PTK and PKC in channel regulation, Considering the altered response to bFGF in RCS-RPE cells, this disturbed regulation of L-type channels by tyrosine kinases is involved in the etiology of retinal degeneration in RCS rats.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Mergler, S (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, Hindenburgdamm 30, D-12200 Berlin, Germany.	wiederho@zedat.fu-berlin.de	Strauss, Olaf/AAA-6485-2019	Mergler, Stefan/0000-0001-8608-648X; Strauss, Olaf/0000-0002-6272-8596				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; Bechem M., 1997, Life Sciences, V60, P107; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; BOST LM, 1992, EXP EYE RES, V55, P727, DOI 10.1016/0014-4835(92)90177-T; BOST LM, 1994, EXP EYE RES, V58, P545, DOI 10.1006/exer.1994.1048; Cataldi M, 1996, J BIOL CHEM, V271, P9441, DOI 10.1074/jbc.271.16.9441; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; Chiang CE, 1996, BIOCHEM BIOPH RES CO, V223, P598, DOI 10.1006/bbrc.1996.0941; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; CONNOLLY SE, 1992, CURR EYE RES, V11, P1005, DOI 10.3109/02713689209033499; DETURCO EBR, 1992, EXP EYE RES, V55, P719, DOI 10.1016/0014-4835(92)90176-S; DOERNER D, 1992, BRAIN RES, V597, P30, DOI 10.1016/0006-8993(92)91502-6; DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73; EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718; EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301; ELHIFNAWI E, 1987, ADV BIOSCI, V62, P417; FACTOROVICH EG, 1990, NATURE, V347, P83; FACTOROVICH EG, 1992, J NEUROSCI, V12, P3554; GALIZZI JP, 1987, J BIOL CHEM, V262, P6947; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GOLDMAN AI, 1978, SCIENCE, V201, P1023, DOI 10.1126/science.567376; GREGORY CY, 1992, INVEST OPHTH VIS SCI, V33, P3121; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL MO, 1991, EXP EYE RES, V52, P591, DOI 10.1016/0014-4835(91)90061-I; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HERRON WL, 1969, INVEST OPHTH VISUAL, V8, P595; HETH CA, 1994, INVEST OPHTH VIS SCI, V35, P409; HETH CA, 1992, INVEST OPHTH VIS SCI, V33, P2839; HETH CA, 1992, INVEST OPHTH VIS SCI, V33, P1203; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; KOH SWM, 1992, CELL BIOL INT REP, V16, P1003, DOI 10.1016/S0309-1651(06)80053-6; LAVAIL MM, 1995, INVEST OPHTH VIS SCI, V36, pS211; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; McLaren MJ, 1997, FEBS LETT, V412, P21, DOI 10.1016/S0014-5793(97)00566-8; McLaren MJ, 1996, FEBS LETT, V387, P63, DOI 10.1016/0014-5793(96)00461-9; MCLAREN MJ, 1992, INVEST OPHTH VIS SCI, V33, P1027; MERGLER S, 1997, PFLUEGERS ARCH S, V433, pR168; MERGLER S, 1996, PFLUEGERS ARCH, V431, pR114; Miceli M. V., 1997, Investigative Ophthalmology and Visual Science, V38, pS329; NASH MS, 1995, NEUROCHEM INT, V27, P253, DOI 10.1016/0197-0186(95)00040-F; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; SATOH T, 1992, J BIOL CHEM, V267, P2537; Shuttleworth TJ, 1997, J EXP BIOL, V200, P303; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; STRAUSS O, 1993, PFLUG ARCH EUR J PHY, V425, P68, DOI 10.1007/BF00374505; Strauss O, 1997, FASEB J, V11, P859, DOI 10.1096/fasebj.11.11.9285484; STRAUSS O, 1994, J CELL PHYSIOL, V160, P89, DOI 10.1002/jcp.1041600111; Strauss O., 1997, Investigative Ophthalmology and Visual Science, V38, pS468; UEDA Y, 1993, INVEST OPHTH VIS SCI, V34, P3408; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WEN R, 1995, J NEUROSCI, V15, P7377; Wijetunge S, 1995, BIOCHEM BIOPH RES CO, V217, P1039, DOI 10.1006/bbrc.1995.2874; WIJETUNGE S, 1992, BIOCHEM BIOPH RES CO, V189, P1620, DOI 10.1016/0006-291X(92)90262-J	58	34	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1125	1134		10.1096/fasebj.12.12.1125	http://dx.doi.org/10.1096/fasebj.12.12.1125			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737715				2022-12-25	WOS:000075738500007
J	Pouliot, M; Gilbert, C; Borgeat, P; Poubelle, PE; Bourgoin, S; Creminon, C; Maclouf, J; McColl, SR; Naccache, PH				Pouliot, M; Gilbert, C; Borgeat, P; Poubelle, PE; Bourgoin, S; Creminon, C; Maclouf, J; McColl, SR; Naccache, PH			Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils	FASEB JOURNAL			English	Article						thromboxane; dexamethasone; lipopolysaccharide; cyclooxygenase	HUMAN AMNION CELLS; PHOSPHOLIPASE-D; H SYNTHASE-2; POLYMORPHONUCLEAR LEUKOCYTES; CYCLOOXYGENASE-2 EXPRESSION; GLUCOCORTICOIDS STIMULATE; INDUCIBLE CYCLOOXYGENASE; SUPEROXIDE GENERATION; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS	Proinflammatory agents were assessed for their capacity to stimulate the expression of the for their capacity to stimulate the expression of the inducible cyclooxygenase isoform (COX-2) in human neutrophils. A number of agents, including PMA, opsonized bacteria and zymosan, LPS, GM-CSF, TNF-alpha, and fMLP, induced COX-2 protein expression through signaling pathways involving transcription and protein synthesis events. Northern blots showed that freshly isolated neutrophils expressed low levels of COX-2 mRNA, which rapidly increased after incubation with inflammatory agents. A characterization of the signal transduction pathways leading to COX-2 protein expression was initiated. In LPS-treated neutrophils, efficient induction of COX-2 required the presence of serum and involved ligand binding to the CD14 surface antigen. The specific inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), SE 203580, had little effect on the induction of COX-2 expression in neutrophils, in contrast to what had been previously observed with other inflammatory cell types. Depending on the agonist present, ethanol differentially blocked the stimulated expression of COX-2, raising the possibility that phospholipase D activation might take part in the process of COX-2 induction. Major COX-2-derived prostanoids synthesized by inflammatory neutrophils were identified by liquid-chromatography and tandem mass-spectrometry as TXA(2) and PGE(2). The agonist-induced synthesis of TXA2 and PGE2 was effectively blocked by cycloheximide and by the specific COX-2 inhibitor NS-398. These results show that COX-2 can be induced in an active state by different classes of inflammatory mediators in the neutrophil. They support the concept that, in these cells, the COX-2 isoform is preeminent over COX-1 for the stimulated-production of prostanoids, and also suggest that neutrophil COX-2 displays a distinct profile of expression among circulatory cells.	CHU Laval, Ctr Rech, Ctr Rech Rhumatol & Immunol, Quebec City, PQ, Canada; Univ Laval, Quebec City, PQ G1K 7P4, Canada; CENS, CEA, SPI, DRM, F-91191 Gif Sur Yvette, France; Fac Med, Dept Med, F-91191 Gif Sur Yvette, France; Fac Med, Dept Physiol, F-91191 Gif Sur Yvette, France; Hop Lariboisiere, INSERM U348, F-7547 Paris 10, France; Univ Adelaide, Dept Microbiol & Immunol, Adelaide, SA, Australia	Laval University; Laval University; CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Adelaide	Pouliot, M (corresponding author), Brigham & Womens Hosp, Dept Anesthesia, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA.	pouliot@zeus.bwh.harvard.edu	Pouliot, Marc/G-4103-2016	Pouliot, Marc/0000-0002-2466-5424; Gilbert, Caroline/0000-0003-2722-1180; Bourgoin, Sylvain/0000-0001-9779-0368				Akarasereenont P, 1996, BIOCHEM BIOPH RES CO, V220, P181, DOI 10.1006/bbrc.1996.0377; ALBERT TJ, 1994, PROSTAGLANDINS, V48, P401, DOI 10.1016/0090-6980(94)90006-X; ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CHABOT MC, 1992, BIOCHEM J, V286, P693, DOI 10.1042/bj2860693; Crofford LJ, 1997, J RHEUMATOL, V24, P15; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Dayton ET, 1996, J NEUROIMMUNOL, V71, P11, DOI 10.1016/S0165-5728(96)00111-7; DELLABIANCA V, 1991, BIOCHEM BIOPH RES CO, V177, P948, DOI 10.1016/0006-291X(91)90630-P; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DVORAK AM, 1992, J HISTOCHEM CYTOCHEM, V40, P759, DOI 10.1177/40.6.1316915; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; GLASER KB, 1995, BIOCHEM PHARMACOL, V50, P913, DOI 10.1016/0006-2952(95)00211-H; Godessart N, 1996, J INVEST DERMATOL, V107, P726, DOI 10.1111/1523-1747.ep12365616; GOLDSTEIN IM, 1978, J EXP MED, V148, P787, DOI 10.1084/jem.148.3.787; HABIB A, 1993, J BIOL CHEM, V268, P23448; HERRMANN F, 1990, EUR J IMMUNOL, V20, P2513, DOI 10.1002/eji.1830201124; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; LYONSGIORDANO B, 1993, EXP CELL RES, V206, P58, DOI 10.1006/excr.1993.1120; Maloney CG, 1998, J IMMUNOL, V160, P1402; Margalit A, 1996, ANAL BIOCHEM, V235, P73, DOI 10.1006/abio.1996.0093; MASFERRER JL, 1994, RECEPTOR, V4, P25; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MOLLINEDO F, 1994, J IMMUNOL, V153, P2457; Niiro H, 1997, BLOOD, V89, P1621, DOI 10.1182/blood.V89.5.1621.1621_1621_1628; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; POTESTIO FA, 1988, J CLIN ENDOCR METAB, V67, P1205, DOI 10.1210/jcem-67-6-1205; POULIOT M, 1994, J IMMUNOL, V152, P851; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Pouliot M, 1997, J IMMUNOL, V158, P4930; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; Ridley SH, 1997, J IMMUNOL, V158, P3165; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; Sato T, 1996, J BONE MINER RES, V11, P392; Sciorra VA, 1996, J BIOL CHEM, V271, P14226, DOI 10.1074/jbc.271.24.14226; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SIMMONS PM, 1983, BIOCHEM PHARMACOL, V32, P1353, DOI 10.1016/0006-2952(83)90446-X; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith W.L.B.P., 1991, BIOCH LIPIDS LIPOPRO, P297, DOI [10.1016/S0167-7306(08)60338-5, DOI 10.1016/S0167-7306(08)60338-5]; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SURETTE ME, 1993, J EXP MED, V178, P1347, DOI 10.1084/jem.178.4.1347; TOMLINSON A, 1994, BRIT J PHARMACOL, V113, P693, DOI 10.1111/j.1476-5381.1994.tb17048.x; Vane JR, 1996, SCAND J RHEUMATOL, P9; Vigano T, 1997, AM J RESP CRIT CARE, V155, P864, DOI 10.1164/ajrccm.155.3.9117018; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YUCELLINDBERG T, 1995, INFLAMMATION, V19, P549, DOI 10.1007/BF01539135; ZAKAR T, 1989, J DEV PHYSIOL, V12, P269; ZAKAR T, 1995, ENDOCRINOLOGY, V136, P1610, DOI 10.1210/en.136.4.1610; Zurier R B, 1975, Inflammation, V1, P93, DOI 10.1007/BF00918062	65	102	102	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1109	1123		10.1096/fasebj.12.12.1109	http://dx.doi.org/10.1096/fasebj.12.12.1109			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737714				2022-12-25	WOS:000075738500006
J	Ge, NL; Elferink, CJ				Ge, NL; Elferink, CJ			A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein - Linking dioxin signaling to the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH-RECEPTOR; NUCLEAR TRANSLOCATOR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; TRANSCRIPTIONAL ACTIVATION; EXPRESSION; DROSOPHILA; CLONING; BINDING; DOMAINS; GENE	The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor in eukaryotic cells that alters gene expression in response to the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), In 5L hepatoma cells, TCDD induces a G(1), cell cycle arrest through a mechanism that involves the AhR. The retinoblastoma tumor suppressor protein (pRb) controls cell cycle progression through G(1), in addition to promoting differentiation, We examined whether the human AhR or its dimerization partner, the AhR nuclear translocator, interacts with pRb as a basis of the TCDD-induced cell cycle arrest. In vivo and in vitro assays reveal a direct interaction between pRb and the AhR but not the AhR nuclear translocator protein. Binding between the AhR and pRb occurs through two distinct regions in the AhR. A high affinity site lies within the N-terminal 364 amino acids of the AhR, whereas a lower affinity binding region colocalizes with the glutamine-rich transactivation domain of the receptor. AhR ligand binding is not required for the pRb interaction per se, although immunoprecipitation experiments in 5L cells reveal that pRb associates preferentially with the liganded AhR, consistent with a requirement for ligand-induced nuclear translocation. These observations provide a mechanistic insight into AhR-mediated cell cycle arrest and a new perspective on TCDD-induced toxicity.	Wayne State Univ, Inst Chem Toxicol, Detroit, MI 48201 USA	Wayne State University	Elferink, CJ (corresponding author), NCI, Genet Lab, NIH, Bethesda, MD 20892 USA.	Cornelis_Elferink@wayne.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639, R29ES007800] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06639, R29ES07800] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERTAZZI PA, 1993, EPIDEMIOLOGY, V4, P398, DOI 10.1097/00001648-199309000-00004; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHAN WK, 1994, J BIOL CHEM, V269, P26464; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; ELFERINK CJ, 1994, RECEPTOR, V4, P157; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANKINSON O, 1995, ARCH BIOCHEM BIOPHYS, V300, P1; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HENRY EC, 1994, MOL PHARMACOL, V46, P1022; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JAIN S, 1994, J BIOL CHEM, V269, P31518; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kobayashi A, 1997, J BIOCHEM, V122, P703; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Pollenz RS, 1996, J BIOL CHEM, V271, P30886, DOI 10.1074/jbc.271.48.30886; Reiners JJ, 1997, MOL CARCINOGEN, V19, P91, DOI 10.1002/(SICI)1098-2744(199707)19:2<91::AID-MC4>3.0.CO;2-O; Rininger JA, 1997, CHEMOSPHERE, V34, P1557, DOI 10.1016/S0045-6535(96)00451-1; SAFE SH, 1986, ANN REV PHARM TOXICO, V26, P517; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SCHOLLER A, 1994, MOL PHARMACOL, V45, P944; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; TIAN Y, 1997, TOXICOLOGIST, V37, P129; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xie Q, 1996, EMBO J, V15, P4900, DOI 10.1002/j.1460-2075.1996.tb00870.x	47	213	219	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22708	22713		10.1074/jbc.273.35.22708	http://dx.doi.org/10.1074/jbc.273.35.22708			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712901	hybrid			2022-12-25	WOS:000075616600077
J	Kundu, GC; Mandal, AK; Zhang, ZJ; Mantile-Selvaggi, G; Mukherjee, AB				Kundu, GC; Mandal, AK; Zhang, ZJ; Mantile-Selvaggi, G; Mukherjee, AB			Uteroglobin (UG) suppresses extracellular matrix invasion by normal and cancer cells that express the high affinity UG-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RECOMBINANT HUMAN UTEROGLOBIN; TISSUE-SPECIFIC EXPRESSION; RABBIT UTEROGLOBIN; PROGESTERONE-BINDING; GENE-EXPRESSION; 10-KDA PROTEIN; PHOSPHOLIPASE-A2 ACTIVITY; QUATERNARY STRUCTURE; POSSIBLE MECHANISM	Uteroglobin (UG) is a steroid-inducible, multifunctional, secreted protein with antiinflammatory and antichemotactic properties. Recently, we have reported a high affinity UG-binding protein (putative receptor), on several cell types, with an apparent molecular mass of 190 kDa (Kundu, G. C., Mantile, G., Miele, L., Cordella-Miele, E., and Mukherjee, A. B. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2915-2919). Since UG is a homodimer in which the 70 amino acid subunits are connected by two disulfide bonds, we sought to determine whether UG monomers also interact with the 190-kDa UG-binding protein and if so, whether it has the same biological activity as the dimer. Surprisingly, we discovered that in addition to the 190-kDa species, another protein, with an apparent molecular mass of 49 kDa, binds reduced UG with high affinity and specificity. Both 49- and 190-kDa proteins are readily detectable on nontransformed NIH 3T3 and some murine cancer cells (e.g. mastocytoma, sarcoma, and lymphoma), while lacking on others (e.g. fibrosarcoma). Most interestingly, pretreatment of the cells, which express the binding proteins, with reduced UG dramatically suppresses extracellular matrix (ECM) invasion, when such treatment had no effect on fibrosarcoma cells that lack the UG-binding proteins. Tissue-specific expression studies confirmed that while both 190- and 49-kDa UG-binding proteins are present in bovine heart, spleen, and the liver, only the 190-kDa protein is detectable in the trachea and in the lung. Neither the 190-kDa nor the 49-kDa protein was detectable in the aorta. Purification of these binding proteins from bovine spleen by UG-affinity chromatography and analysis by SDS-polyacrylamide gel electrophoresis followed by silver staining identified two protein bands with apparent molecular masses of 40 and 180 kDa, respectively. Treatment of the NIH 3T3 cells with specific cytokines (i.e. interleukin-6) and other agonists (i.e. lipopolysaccharide) caused a substantially increased level of I-125-UG binding but the same cells, when treated with platelet-derived growth factor, tumor necrosis factor-alpha, interferon-gamma, and phorbol 12-myristate 13-acetate, did not alter the UG binding. Taken together, these findings raise the possibility that UG, through its binding proteins, plays critical roles in the regulation of cellular motility and ECM invasion.	NICHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mukherjee, AB (corresponding author), NICHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.	mukherja@cc1.nichd.nih.gov	Kundu, Gopal C./ABA-9897-2020					Aoki A, 1996, MOL HUM REPROD, V2, P489, DOI 10.1093/molehr/2.7.489; ATGER M, 1979, BIOCHEM J, V177, P985, DOI 10.1042/bj1770985; BAKER ME, 1983, BIOCHEM BIOPH RES CO, V114, P325, DOI 10.1016/0006-291X(83)91631-5; BEATO M, 1976, J STEROID BIOCHEM, V7, P327, DOI 10.1016/0022-4731(76)90091-1; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BERNARD A, 1991, CLIN CHIM ACTA, V201, P231, DOI 10.1016/0009-8981(91)90374-L; BERNARD AM, 1989, CLIN CHEM, V35, P2141; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BUEHNER M, 1978, J MOL BIOL, V120, P337, DOI 10.1016/0022-2836(78)90072-4; BUEHNER M, 1982, J MOL BIOL, V159, P353, DOI 10.1016/0022-2836(82)90499-5; CABRE F, 1992, BIOCHEM PHARMACOL, V44, P519, DOI 10.1016/0006-2952(92)90444-N; Carlomagno T, 1997, J BIOMOL NMR, V9, P35, DOI 10.1023/A:1018619501038; CHILTON BS, 1987, J REPROD FERTIL, V79, P581, DOI 10.1530/jrf.0.0790581; CHILTON BS, 1988, MOL ENDOCRINOL, V2, P1169, DOI 10.1210/mend-2-12-1169; CHILTON BS, 1998, ENDOMETRIUM; DANIEL JC, 1984, J REPROD FERTIL, V72, P443, DOI 10.1530/jrf.0.0720443; DEHARO MSL, 1994, FEBS LETT, V349, P249, DOI 10.1016/0014-5793(94)00678-4; DelaCruz X, 1996, PROTEIN SCI, V5, P857; DOMINGUEZ P, 1995, FEBS LETT, V376, P257, DOI 10.1016/0014-5793(95)01294-4; FACCHIANO A, 1991, LIFE SCI, V48, P453, DOI 10.1016/0024-3205(91)90501-2; GILLNER M, 1988, J STEROID BIOCHEM, V31, P27, DOI 10.1016/0022-4731(88)90201-4; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HAY JG, 1995, AM J PHYSIOL-LUNG C, V268, pL565, DOI 10.1152/ajplung.1995.268.4.L565; HaywardLester A, 1996, MOL ENDOCRINOL, V10, P1335, DOI 10.1210/me.10.11.1335; Hewetson A, 1997, MOL CELL ENDOCRINOL, V136, P1, DOI 10.1016/S0303-7207(97)00203-7; Hynes RO, 1990, FIBRONECTINS; JACKSON PJ, 1988, J CHROMATOGR, V452, P359, DOI 10.1016/S0021-9673(01)81460-6; Kieber-Emmons T, 1998, DNA CELL BIOL, V17, P133, DOI 10.1089/dna.1998.17.133; KIKUKAWA T, 1989, MOL CELL ENDOCRINOL, V62, P177, DOI 10.1016/0303-7207(89)90004-X; KLEISSANFRANCISCO S, 1993, MOL ENDOCRINOL, V7, P214, DOI 10.1210/me.7.2.214; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; Magdaleno SM, 1997, AM J PHYSIOL-LUNG C, V272, pL1142, DOI 10.1152/ajplung.1997.272.6.L1142; MANTILE G, 1993, J BIOL CHEM, V268, P20343; MATTHEWS JH, 1994, PROTEINS, V20, P191, DOI 10.1002/prot.340200209; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; METAFORA S, 1987, GAMETE RES, V16, P229, DOI 10.1002/mrd.1120160305; MIELE L, 1987, ENDOCR REV, V8, P474, DOI 10.1210/edrv-8-4-474; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; MIELE L, 1990, J BIOL CHEM, V265, P6427; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; MORIZE I, 1987, J MOL BIOL, V194, P725, DOI 10.1016/0022-2836(87)90250-6; MORNON JP, 1978, J MOL BIOL, V122, P237, DOI 10.1016/0022-2836(78)90038-4; MORNON JP, 1979, J MOL BIOL, V127, P237, DOI 10.1016/0022-2836(79)90245-6; Mukherjee A B, 1988, Adv Exp Med Biol, V231, P135; MUKHERJEE AB, 1998, IN PRESS AM J KIDNEY; NIETO A, 1977, ARCH BIOCHEM BIOPHYS, V180, P82, DOI 10.1016/0003-9861(77)90011-X; OKUTANI R, 1992, J CHROMATOGR-BIOMED, V577, P25, DOI 10.1016/0378-4347(92)80595-H; PERI A, 1993, J CLIN INVEST, V92, P2099, DOI 10.1172/JCI116810; PONSTINGL H, 1978, BIOCHEMISTRY-US, V17, P3908, DOI 10.1021/bi00612a003; POPP RA, 1978, P NATL ACAD SCI USA, V75, P5516, DOI 10.1073/pnas.75.11.5516; RANDALL GW, 1991, J REPROD FERTIL, V91, P249, DOI 10.1530/jrf.0.0910249; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; Robinson CA, 1997, GENE, V198, P1, DOI 10.1016/S0378-1119(97)00305-3; ROBINSON DH, 1989, MOL CELL ENDOCRINOL, V63, P227, DOI 10.1016/0303-7207(89)90099-3; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; Russell RB, 1997, PROTEIN ENG, V10, P333, DOI 10.1093/protein/10.4.333; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; Singh G, 1997, AM J RESP CELL MOL, V17, P141, DOI 10.1165/ajrcmb.17.2.f138; SINGH G, 1993, EXP LUNG RES, V19, P67, DOI 10.3109/01902149309071081; Watson MA, 1996, CANCER RES, V56, P860; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YAO XL, 1998, AM J PHYSIOL, V18, pL864; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73; Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408	69	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22819	22824		10.1074/jbc.273.35.22819	http://dx.doi.org/10.1074/jbc.273.35.22819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712916	hybrid			2022-12-25	WOS:000075616600092
J	Stachelhaus, T; Mootz, HD; Bergendahl, V; Marahiel, MA				Stachelhaus, T; Mootz, HD; Bergendahl, V; Marahiel, MA			Peptide bond formation in nonribosomal peptide biosynthesis - Catalytic role of the condensation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE MULTIENZYME COMPLEX; COMPLETE NUCLEOTIDE-SEQUENCE; GRAMICIDIN-S SYNTHETASE-2; BACILLUS-BREVIS; CHLORAMPHENICOL ACETYLTRANSFERASE; TYROCIDINE BIOSYNTHESIS; MULTIFUNCTIONAL ENZYME; ESCHERICHIA-COLI; BIOCHEMICAL-CHARACTERIZATION; ACTIVATING DOMAIN	Recently, considerable insight has been gained into the modular organization and catalytic properties of nonribosomal peptide synthetases. However, molecular and biochemical aspects of the condensation of two aminoacyl substrates or a peptidyl and an aminoacyl substrate, leading to the formation of a peptide bond, have remained essentially impenetrable. To investigate this crucial part of nonribosomal peptide synthesis, an in vitro assay for a dipeptide formation was developed. Two recombinant holomodules, GrsA (PheATE), providing D-Phe, and a C-terminally truncated TycB, corresponding to the first, L-Pro-incorporating module (ProCAT), were investigated. Upon combination of the two aminoacylated modules, a fast reaction is observed, due to the formation of the linear dipeptide D-Phe-L-Pro-S-enzyme on ProCAT, followed by a noncatalyzed release of the dipeptide from the enzyme. The liberated product was identified by TLC, high pressure liquid chromatography-mass spectrometry, H-1 and C-13 NMR, and comparison with a chemically synthesized standard to be the expected D-Phe-L-Pro diketopiperazine. Further minimization of the two modules was not possible without a loss of transfer activity. Likewise, a mutation in a proposed active-site motif (HHXXXDG) of the condensation domain giving ProCAT(H147V), abolished the condensation reaction. These results strongly suggest the condensation domain to be involved in the catalysis of nonribosomal peptide bond formation with the histidine 147 playing a catalytic role.	Univ Marburg, Biochem Fachbereich Chem, D-35032 Marburg, Germany	Philipps University Marburg	Marahiel, MA (corresponding author), Univ Marburg, Biochem Fachbereich Chem, Hans Meerwein Str, D-35032 Marburg, Germany.	marahiel@ps1515.chemie.uni-marburg.de						BORCHERT S, 1994, J BACTERIOL, V176, P2458, DOI 10.1128/JB.176.8.2458-2462.1994; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Byford MF, 1997, CHEM REV, V97, P2631, DOI 10.1021/cr960018l; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; DECRECYLAGARD V, 1995, CR ACAD SCI III-VIE, V318, P927; deCrecyLagard V, 1997, ANTIMICROB AGENTS CH, V41, P1904, DOI 10.1128/AAC.41.9.1904; deFerra F, 1997, J BIOL CHEM, V272, P25304, DOI 10.1074/jbc.272.40.25304; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; FUJIKAWA K, 1971, J BIOCHEM, V69, P869, DOI 10.1093/oxfordjournals.jbchem.a129538; GAIDENKO TA, 1992, BIOTECHNOLOGIA, V3, P13; GEVERS W, 1968, P NATL ACAD SCI USA, V60, P269, DOI 10.1073/pnas.60.1.269; GEVERS W, 1969, P NATL ACAD SCI USA, V63, P1335, DOI 10.1073/pnas.63.4.1335; GOCHT M, 1994, J BACTERIOL, V176, P2654, DOI 10.1128/JB.176.9.2654-2662.1994; HAESE A, 1994, J MOL BIOL, V243, P116, DOI 10.1006/jmbi.1994.1634; HORI K, 1983, J BIOCHEM-TOKYO, V93, P177, DOI 10.1093/oxfordjournals.jbchem.a134152; HORI K, 1991, J BIOCHEM-TOKYO, V110, P111, DOI 10.1093/oxfordjournals.jbchem.a123528; Konz D, 1997, CHEM BIOL, V4, P927, DOI 10.1016/S1074-5521(97)90301-X; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; Ku J, 1997, CHEM BIOL, V4, P203, DOI 10.1016/S1074-5521(97)90289-1; KUROTSU T, 1991, J BIOCHEM-TOKYO, V109, P763, DOI 10.1093/oxfordjournals.jbchem.a123454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LEE SG, 1977, P NATL ACAD SCI USA, V74, P2343, DOI 10.1073/pnas.74.6.2343; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LEWENDON A, 1993, J BIOL CHEM, V268, P20997; LIPMANN F, 1971, ADV ENZYMOL RAMB, V35, P1; Marahiel MA, 1997, CHEM BIOL, V4, P561, DOI 10.1016/S1074-5521(97)90242-8; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Mootz HD, 1997, CURR OPIN CHEM BIOL, V1, P543, DOI 10.1016/S1367-5931(97)80051-8; PFEIFER E, 1995, BIOCHEMISTRY-US, V34, P7450, DOI 10.1021/bi00022a019; ROSKOSKI R, 1970, BIOCHEMISTRY-US, V9, P4839; ROSKOSKI R, 1970, BIOCHEMISTRY-US, V9, P4846; RUSSELL GC, 1992, BIOCHEM J, V287, P611, DOI 10.1042/bj2870611; RYDON HN, 1956, J CHEM SOC, P3642, DOI 10.1039/jr9560003642; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; Schneider A, 1998, MOL GEN GENET, V257, P308, DOI 10.1007/s004380050652; SHAW WV, 1983, CRC CR REV BIOCH MOL, V14, P1, DOI 10.3109/10409238309102789; SHAW WV, 1992, SCI PROGRESS-UK, V76, P565; Shiau CY, 1997, BIOCHEMISTRY-US, V36, P8798, DOI 10.1021/bi962932e; Stachelhaus T, 1996, BIOCHEM PHARMACOL, V52, P177, DOI 10.1016/0006-2952(96)00111-6; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VATER J, 1989, BIOL CHEM H-S, V370, P1013, DOI 10.1515/bchm3.1989.370.2.1013; Vater J, 1997, J PROTEIN CHEM, V16, P557, DOI 10.1023/A:1026386100259; VERCELLONE A, 1989, J BIOL CHEM, V264, P7447; VICAR J, 1973, COLLECT CZECH CHEM C, V38, P1940; VOLLENBROICH D, 1994, J BACTERIOL, V176, P395, DOI 10.1128/JB.176.2.395-400.1994; vonDohren H, 1997, CHEM REV, V97, P2675, DOI 10.1021/cr9600262; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841; Weinreb PH, 1998, BIOCHEMISTRY-US, V37, P1575, DOI 10.1021/bi9719859; YOUNG PE, 1976, J AM CHEM SOC, V98, P5365, DOI 10.1021/ja00433a051	60	258	276	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22773	22781		10.1074/jbc.273.35.22773	http://dx.doi.org/10.1074/jbc.273.35.22773			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712910	hybrid			2022-12-25	WOS:000075616600086
J	Landis, DM; Loeb, LA				Landis, DM; Loeb, LA			Random sequence mutagenesis and resistance to 5-fluorouridine in human thymidylate synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BONE-MARROW CELLS; ESCHERICHIA-COLI; GENE AMPLIFICATION; MEGAPRIMER METHOD; CRYSTAL-STRUCTURE; DRUG DESIGN; ACTIVE-SITE; SYNTHETASE; MECHANISM	Thymidylate synthase (TS) catalyzes the methylation of dUMP to dTMP and is the target for the widely used chemotherapeutic agent 5-fluorouracil. We used random sequence mutagenesis to replace 13 codons within the active site of TS and obtain variants that are resistant to 5-fluorodeoxyuridine (5-FdUR). The resulting random library was selected for its ability to complement a TS-deficient Escherichia coli strain, and sequence analysis of survivors found multiple substitutions to be tolerable within the targeted region. An independent selection of the library was carried out in the presence of 5-FdUR, resulting in a more limited spectrum of mutations. One specific mutation, C199L, was observed in more than 46% of 5-FdUR-resistant clones. A 5-FdUR-resistant triple mutant, A197V/L198I/C199F, was purified to apparent homogeneity. Kinetic studies with the substrate dUMP indicate that this mutant is similar to the wild type in regards to k(cat) and K-m values for dUMP and the cosubstrate CH2H4-folate. In contrast, equilibrium binding studies with the inhibitor, FdUMP, demonstrate that the dissociation constant (K-d) for FdUMP binding into the ternary complex was 20-fold higher than values obtained for the wild-type enzyme. This 5-FdUMP-resistant mutant, or others similarly selected, is a candidate for use in gene therapy to render susceptible normal cells resistant to the toxic effects of systemic 5-fluorouracil.	Univ Washington, Sch Med, Joseph Gottstein Mem Canc Res Lab, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Joseph Gottstein Mem Canc Res Lab, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Sch Med, Joseph Gottstein Mem Canc Res Lab, Dept Pathol, Box 357705, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NCI NIH HHS [R35-CA-39909] Funding Source: Medline; PHS HHS [5 T32 07266] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; BAPAT AR, 1983, J BIOL CHEM, V258, P4130; BARBOUR KW, 1992, MOL PHARMACOL, V42, P242; BELFORT M, 1984, J BACTERIOL, V160, P371, DOI 10.1128/JB.160.1.371-378.1984; BERGER SH, 1988, MOL PHARMACOL, V34, P480; BERGER SH, 1985, MOL PHARMACOL, V28, P461; CARR F, 1983, BLOOD, V62, P180; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; CLARK JL, 1987, CANCER TREAT REP, V71, P261; CLIMIE S, 1990, J BIOL CHEM, V265, P18776; COHEN SS, 1954, P NATL ACAD SCI USA, V40, P885, DOI 10.1073/pnas.40.10.885; DAVIS ST, 1993, MOL PHARMACOL, V43, P702; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; DEV IK, 1989, J BIOL CHEM, V264, P19132; ECKSTEIN JW, 1994, BIOCHEMISTRY-US, V33, P15086, DOI 10.1021/bi00254a018; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; GREM JL, 1990, CANC CHEMOTHERAPY PR, P180; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HARRAP KR, 1989, ADV ENZYME REGUL, V29, P161, DOI 10.1016/0065-2571(89)90099-X; HOUGHTON PJ, 1992, CANCER RES, V52, P558; HUGHEY CT, 1993, MOL PHARMACOL, V44, P316; JASTREBOFF MM, 1983, BIOCHEM PHARMACOL, V32, P2259, DOI 10.1016/0006-2952(83)90236-8; Marathi UK, 1997, CLIN CANCER RES, V3, P301; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MORAN RG, 1979, P NATL ACAD SCI USA, V76, P1456, DOI 10.1073/pnas.76.3.1456; MORITZ T, 1995, CANCER RES, V55, P2608; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; RODE W, 1980, J BIOL CHEM, V255, P1305; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8606, DOI 10.1021/bi00400a017; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P471, DOI 10.1021/bi00700a012; SANTI DV, 1984, FOLATES PTERINS, P345; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schiffer CA, 1995, BIOCHEMISTRY-US, V34, P16279, DOI 10.1021/bi00050a007; Seno T, 1985, Basic Life Sci, V31, P241; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; Suzuki M, 1996, MOL DIVERS, V2, P111, DOI 10.1007/BF01718708; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11; WASHTIEN WL, 1982, MOL PHARMACOL, V21, P723; WEBBER SE, 1993, J MED CHEM, V36, P733, DOI 10.1021/jm00058a010; WILLIAMS DA, 1987, J EXP MED, V166, P210, DOI 10.1084/jem.166.1.210; ZHANG HC, 1990, BIOCHEM BIOPH RES CO, V167, P869, DOI 10.1016/0006-291X(90)90604-L	47	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25809	25817		10.1074/jbc.273.40.25809	http://dx.doi.org/10.1074/jbc.273.40.25809			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748254	hybrid			2022-12-25	WOS:000076263100045
J	Imanaka, T; Hayashi, H; Kishi, K; Wang, LH; Ishii, K; Hazeki, O; Katada, T; Ebina, Y				Imanaka, T; Hayashi, H; Kishi, K; Wang, LH; Ishii, K; Hazeki, O; Katada, T; Ebina, Y			Reconstitution of insulin signaling pathways in rat 3Y1 cells lacking insulin receptor and insulin receptor substrate-1 - Evidence that activation of Akt is insufficient for insulin-stimulated glycogen synthesis or glucose uptake in rat 3Y1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; GROWTH-FACTOR-II; 3T3-L1 ADIPOCYTES; GLUT4 TRANSLOCATION; PHOSPHOINOSITIDE 3-KINASE; DNA-SYNTHESIS; SH2 DOMAIN; PHOSPHOTYROSINE PROTEIN; HEMATOPOIETIC-CELLS	Rat 3Y1 cells have endogenous insulin-like growth factor-1 receptors and insulin receptor substrate (IRS)-2, but lack both insulin receptor (IR) and IRS-1. To investigate the role of IR and IRS-1 in effects of insulin, we transfected IR and IRS-1 expression plasmids into cells and reconstituted the insulin signaling pathways. 3Y1 cells stably expressing the c-myc epitope-tagged glucose transporter type 4 (3Y1-GLUT4myc) exhibit no effects of insulin, at physiological concentrations. The 3Y1-GLUT4myc-IR cells expressing GLUT4myc and IR responded to phosphatidylinositol 3,4,5-trisphosphate (PI-3,4,5-P-3) accumulation, Akt activation, the stimulation of DNA synthesis, and membrane ruffling but not to glycogen synthesis, glucose uptake, or GLUT4myc translocation. The further expression of IRS-1 in 3Y1-GLUT4myc-IR cells led to stimulation of glycogen synthesis but not to glucose uptake or GLUT4myc translocation in response to insulin, although NaF or phorbol la-myristate 13-acetate did trigger GLUT4myc translocation in the cells. These results suggest that, in rat 3Y1 cells, (i) IRS-1 is essential for insulin-stimulated glycogen synthesis but not for DNA synthesis, PI-3,4,5-P-3 accumulation, Akt phosphorylation, or membrane ruffling, and (ii) the accumulation of PI-3,4,5-P-3 and activation of Akt are insufficient for glycogen synthesis, glucose uptake or for GLUT4 translocation.	Univ Tokushima, Inst Enzyme Res, Div Mol Genet, Tokushima 7708503, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1080071, Japan; Univ Tokyo, Fac Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan	Tokushima University; University of Tokyo; University of Tokyo	Ebina, Y (corresponding author), Univ Tokushima, Inst Enzyme Res, Div Mol Genet, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.		Ishii, Kazuo/M-3099-2016; Ishii, Kazuo/N-9946-2019; ishii, kazuo/K-7428-2014	Ishii, Kazuo/0000-0002-8363-8266; ishii, kazuo/0000-0001-7801-1891; Hayashi, Hideki/0000-0003-4585-6542				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HARE K, 1994, P NATL ACAD SCI USA, V91, P7415; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; ISHII K, 1995, BIOCHEM J, V309, P813, DOI 10.1042/bj3090813; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V148, P403, DOI 10.1016/0006-291X(87)91125-9; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	62	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25347	25355		10.1074/jbc.273.39.25347	http://dx.doi.org/10.1074/jbc.273.39.25347			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738001	hybrid			2022-12-25	WOS:000076085400051
J	Lee, C; Yim, MB; Chock, PB; Yim, HS; Kang, SO				Lee, C; Yim, MB; Chock, PB; Yim, HS; Kang, SO			Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; ASCORBIC-ACID; AUTOXIDATIVE GLYCOSYLATION; PHYSIOLOGICAL CONDITIONS; HYDROGEN-PEROXIDE; GLYOXALASE SYSTEM; DIABETES-MELLITUS; MAILLARD REACTION; OXIDANT STRESS; CROSS-LINKING	Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation were investigated. Glycation of bovine serum albumin by methylglyoxal generated the protein-bound free radical, probably the cation radical of the cross-linked Schiff base, as observed in the reaction of methylglyoxal with L-alanine (Yim, H.-S., Kang, S.-O., Bah, Y. C., Chock, P. B., and Yim, M. B. (1995) J. Biol. Chem. 270, 28228-28233) or with N-alpha-acetyl-L-lysine. The glycated bovine serum albumin showed increased electrophoretic mobility suggesting that the basic residues, such as lysine, were modified by methylglyoxal. The glycated protein reduced ferricytochrome c to ferrocytochrome c in the absence of oxygen or added metal ions. This reduction of cytochrome c was accompanied by a large increase in the amplitude of the electron paramagnetic resonance signal originated from the protein-bound free radical. In addition, the glycated protein catalyzed the oxidation of ascorbate in the presence of oxygen, whereas the protein free radical signal disappeared. These results indicate that glycation of protein generates active centers for catalyzing one-electron oxidation-reduction reactions. This active center, which exhibits enzyme-like characteristic, was suggested to be the cross-linked Schiff base/the cross-linked Schiff base radical cation of the protein. It mimics the characteristics of the metal-catalyzed oxidation system. The glycated bovine serum albumin cross-linked further to the cytochrome c in the absence of methylglyoxal. The cross-linked cytochrome c maintains its oxidation-reduction properties. These results together indicate that glycated proteins accumulated in vivo provide stable active sites for catalyzing the formation of free radicals.	Seoul Natl Univ, Coll Nat Sci, Dept Microbiol, Biophys Lab, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Mol Microbiol, Seoul 151742, South Korea; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kang, SO (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Microbiol, Biophys Lab, Seoul 151742, South Korea.	kangsaou@plaza.snu.ac.kr						AFANASEV IB, 1987, J CHEM SOC PERK T 2, P281, DOI 10.1039/p29870000281; Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; AMICI A, 1989, J BIOL CHEM, V264, P3341; BRINKMANN E, 1995, J CHEM SOC P2, P1; CABELLI DE, 1983, J PHYS CHEM-US, V87, P1809, DOI 10.1021/j100233a031; CHEUNG ST, 1979, BIOCHEM BIOPH RES CO, V90, P940, DOI 10.1016/0006-291X(79)91918-1; Elgawish A, 1996, J BIOL CHEM, V271, P12964, DOI 10.1074/jbc.271.22.12964; GASCOYNE PRC, 1980, INT J QUANTUM CHEM S, V7, P93; GORDILLO E, 1989, J BIOL CHEM, V264, P17024; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LO TWC, 1994, J BIOL CHEM, V269, P32299; MCLAUGHLIN JA, 1980, P NATL ACAD SCI USA, V77, P489; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NADEZHDIN AD, 1979, CAN J CHEM, V57, P3017, DOI 10.1139/v79-491; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; REYNOLDS T. M., 1963, ADVAN FOOD RES, V12, P1; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4; VLASSARA H, 1983, DIABETES, V32, P670, DOI 10.2337/diabetes.32.7.670; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WellsKnecht KJ, 1996, NEPHROL DIAL TRANSPL, V11, P41; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; YAN SD, 1994, J BIOL CHEM, V269, P9889; YIM HS, 1995, J BIOL CHEM, V270, P28228	33	129	133	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25272	25278		10.1074/jbc.273.39.25272	http://dx.doi.org/10.1074/jbc.273.39.25272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737992	hybrid			2022-12-25	WOS:000076085400042
J	Parman, T; Chen, GM; Wells, PG				Parman, T; Chen, GM; Wells, PG			Free radical intermediates of phenytoin and related teratogens - Prostaglandin H synthase-catalyzed bioactivation electron paramagnetic resonance spectrometry, and photochemical product analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DNA-DAMAGE; IN-VITRO; N-BROMOSUCCINIMIDE; CD-1 MICE; DRUG-METABOLISM; CHAIN CARRIERS; ACID; LIPOXYGENASE; EMBRYOTOXICITY; INHIBITION	Phenytoin and related xenobiotics can be bioactivated by embryonic prostaglandin H synthase (PHS) to a teratogenic free radical intermediate. The mechanism of free radical formation was evaluated using photolytic oxidation with sodium persulfate and by EPR spectrometry. Characterization of the products by mass spectrometry suggested that phenytoin photolyzes to a nitrogen-centered radical that rapidly undergoes ring opening to form a carbon-centered radical. PHS-1 was incubated with teratogen (phenytoin, mephenytoin, trimethadione, phenobarbital, and major metabolites) or its vehicle and the free radical spin trap alpha-phenyl-N-t-butylnitrone, and incubations were analyzed by EPR spectrometry. There was no alpha-phenyl-N-t-butylnitrone radical adduct in control incubations. For phenytoin, a putative unstable nitrogen-centered radical adduct and a stable carbon-centered radical adduct were detected. Free radical spin adducts also were detected for all other teratogens and metabolites except carbamazepine. The PHS inhibitor eicosatetraynoic acid abolished the free radical EPR signal. Incubation of 2'-deoxyguanosine with phenytoin and PHS-1 resulted in a 5-fold increase in its oxidation to 8-hydroxy-2'-deoxyguanosine. This is the first direct chemical evidence for PHS-catalyzed bioactivation of phenytoin and related teratogens to a free radical intermediate that initiates DNA oxidation, which may constitute a common molecular mechanism of teratologic initiation.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S2, Canada; Univ Guelph, Dept Clin Studies, Guelph, ON N1G 2W1, Canada	University of Toronto; University of Toronto; University of Guelph	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.	pg.wells@utoronto.ca						AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; ARLEN RR, 1990, FASEB J, V4, P608; BIRKETT DJ, 1993, TRENDS PHARMACOL SCI, V14, P292, DOI 10.1016/0165-6147(93)90043-J; CHOW YL, 1984, REV CHEM INTERMED, V5, P325, DOI 10.1007/BF03155672; CHOW YL, 1989, J ORG CHEM, V54, P530, DOI 10.1021/jo00264a005; CHOW YL, 1987, J ORG CHEM, V52, P1931, DOI 10.1021/jo00386a008; CLAYSON DB, 1994, MUTAT RES, V317, P25, DOI 10.1016/0165-1110(94)90010-8; COFFEY JW, 1982, FED PROC, V41, P1551; DOWNING DT, 1972, BIOCHIM BIOPHYS ACTA, V280, P343, DOI 10.1016/0005-2760(72)90102-6; Fantel AG, 1996, TERATOLOGY, V53, P196, DOI 10.1002/(SICI)1096-9926(199603)53:3<196::AID-TERA7>3.0.CO;2-2; Finnell RH, 1995, TERATOLOGY, V52, P324, DOI 10.1002/tera.1420520603; HAGEMAN WE, 1986, PROSTAGLANDINS, V32, P563, DOI 10.1016/0090-6980(86)90038-9; Halliwell B., 1989, FREE RADICAL BIO MED, P18; HAMMARSTROM S, 1977, BIOCHIM BIOPHYS ACTA, V487, P517, DOI 10.1016/0005-2760(77)90221-1; HANSEN DK, 1991, P SOC EXP BIOL MED, V197, P361; HANSEN DK, 1992, P SOC EXP BIOL MED, V199, P501; JUCHAU MR, 1992, DRUG METAB REV, V24, P195, DOI 10.3109/03602539208996293; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Kim PM, 1997, J PHARMACOL EXP THER, V280, P200; Kim PM, 1996, MOL PHARMACOL, V49, P172; KLEIN KL, 1984, PROSTAGLANDINS, V27, P659, DOI 10.1016/0090-6980(84)90005-4; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; KUPFER A, 1981, J PHARMACOL EXP THER, V218, P193; KUPFER A, 1979, CLIN RES, V27, P235; LAPOSA RR, 1995, TOXICOLOGIST, V15, P161; LAPOSA RR, 1996, FUNDAM APPL TOXIC S1, V30, P195; LIND J, 1993, J PHYS CHEM-US, V97, P1610, DOI 10.1021/j100110a023; LIU L, 1995, FREE RADICAL BIO MED, V19, P639, DOI 10.1016/0891-5849(95)00082-9; LUNING U, 1985, TETRAHEDRON, V41, P4289, DOI 10.1016/S0040-4020(01)97200-X; March J., 1992, ADV ORG CHEM, P897; MIRANDA AF, 1994, TOXICOL APPL PHARM, V124, P230, DOI 10.1006/taap.1994.1027; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Ozolins TRS, 1996, J PHARMACOL EXP THER, V277, P945; PARMAN T, 1996, FUNDAM APPL TOX 2 S1, V30, P1260; PEARSON PG, 1991, CHEM RES TOXICOL, V4, P436, DOI 10.1021/tx00022a007; RUDD NL, 1979, J PEDIATR-US, V94, P835, DOI 10.1016/S0022-3476(79)80173-0; SEIP M, 1976, ACTA PAEDIATR SCAND, V65, P617, DOI 10.1111/j.1651-2227.1976.tb04941.x; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; SHRINER RL, 1964, SYSTEMATIC IDENTIFIC, P289; SKELL PS, 1978, ACCOUNTS CHEM RES, V11, P381, DOI 10.1021/ar50130a003; SLATTER JG, 1991, CHEM RES TOXICOL, V4, P157, DOI 10.1021/tx00020a006; SPECTOR A, 1989, EXP EYE RES, V49, P685, DOI 10.1016/S0014-4835(89)80063-6; SPEIDEL BD, 1972, LANCET, V2, P839; SPITZ DR, 1987, J CELL PHYSIOL, V131, P364, DOI 10.1002/jcp.1041310308; SUN FF, 1981, PROSTAGLANDINS, V21, P333, DOI 10.1016/0090-6980(81)90151-9; VACA CE, 1988, MUTAT RES, V195, P137, DOI 10.1016/0165-1110(88)90022-X; VANWAUWE J, 1983, PROSTAGLANDINS, V26, P725, DOI 10.1016/0090-6980(83)90057-6; WELLS PG, 1982, J PHARMACOL EXP THER, V221, P228; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; WELLS PG, 1989, TOXICOL APPL PHARM, V97, P406, DOI 10.1016/0041-008X(89)90245-7; Wells PG, 1997, MUTAT RES-FUND MOL M, V396, P65, DOI 10.1016/S0027-5107(97)00175-9; WELLS PG, 1991, TOXICOLOGIST, V11, P1131; WELLS PG, 1997, HANDB EXP PHARM I, V124, P453; WELLS PG, 1997, COMPREHENSIVE TOXICO, V10, P489; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; Winn LM, 1995, EUR J NEUROL, V2, P5; YU WK, 1995, TOXICOL APPL PHARM, V131, P1, DOI 10.1006/taap.1995.1040; ZHANG YH, 1990, CAN J CHEM, V68, P1668, DOI 10.1139/v90-260	58	66	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25079	25088		10.1074/jbc.273.39.25079	http://dx.doi.org/10.1074/jbc.273.39.25079			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737965	hybrid			2022-12-25	WOS:000076085400015
J	Tang, SJ; Suen, TC; McInnes, RR; Buchwald, M				Tang, SJ; Suen, TC; McInnes, RR; Buchwald, M			Association of the TLX-2 homeodomain and 14-3-3 eta signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; T-CELL LEUKEMIA; IN-VIVO; 14-3-3-PROTEINS ASSOCIATE; SERINE PHOSPHORYLATION; HOMEOBOX GENE; HOX11 GENE; KINASE; EXPRESSION; RAF	Homeodomain proteins play important roles in various developmental processes, and their functions are modulated by polypeptide cofactors. Here we report that both in vitro and in vivo 14-3-3 eta is associated with the TLX-2 homeodomain transcription factor that is required for mouse embryogenesis. Expression of 14-3-3 eta shifts the predominant localization of TLX-2 in COS cells from the cytoplasm to the nucleus. Tlx-2 and 14-3-3 eta are expressed in the developing peripheral nervous system with spatially and temporally overlapping patterns, and they are also coexpressed in PC12 cells. Increased expression of either gene by transfection considerably inhibited nerve growth factor-induced neurite outgrowth of PC12 cells, and cotransfection of both genes led to a synergistic effect of suppression. These findings define 14-3-3 eta as a functional modulator of the TLX-2 homeodomain transcription factor and suggest that the in vivo function of TLX-2 in neural differentiation is likely regulated by signaling mediated by 14-3-3 eta.	Hosp Sick Children, Res Inst, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Buchwald, M (corresponding author), Hosp Sick Children, Res Inst, Dept Genet, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	buchwald@sickkids.on.ca						Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; DUBE ID, 1991, BLOOD, V78, P2996; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LICHTSTEINER S, 1995, EMBO J, V14, P3937, DOI 10.1002/j.1460-2075.1995.tb00065.x; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; Meller N, 1996, MOL CELL BIOL, V16, P5782; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Teng KK, 1994, CELL BIOL LAB HDB, P218; UM M, 1995, MOL CELL BIOL, V15, P5007; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; WATANABE M, 1991, MOL BRAIN RES, V10, P151, DOI 10.1016/0169-328X(91)90105-7; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YU U, 1997, NATURE, V358, P552; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhu AH, 1996, J BIOL CHEM, V271, P20993, DOI 10.1074/jbc.271.35.20993	51	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25356	25363		10.1074/jbc.273.39.25356	http://dx.doi.org/10.1074/jbc.273.39.25356			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738002	hybrid			2022-12-25	WOS:000076085400052
J	Voziyan, PA; Tieman, BC; Low, CM; Fisher, MT				Voziyan, PA; Tieman, BC; Low, CM; Fisher, MT			Changing the nature of the initial chaperonin capture complex influences the substrate folding efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DODECAMERIC GLUTAMINE-SYNTHETASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; NONNATIVE FORMS; ATPASE CYCLE; GROEL; PROTEIN; BINDING; RHODANESE; MECHANISM	For the chaperonin substrates, rhodanese, malate dehydrogenase (MDH), and glutamine synthetase (GS), the folding efficiencies, and the lifetimes of folding intermediates were measured with either the nucleotide-free GroEL or the activated ATP.GroEL.GroES chaperonin complex. With both nucleotide-free and activated complex, the folding efficiency of rhodanese and MDH remained high over a large range of GroEL to substrate concentration ratios (up to 1:1). In contrast, the folding efficiency of GS began to decline at ratios lower than 8:1. At ratios where the refolding yields were initially the same, only a relatively small increase (1.6-fold) in misfolding kinetics of MDR was observed with either the nucleotide-free or activated chaperonin complex. For rhodanese, no change was detected with either chaperonin complex. In contrast, GS lost its ability to interact with the chaperonin system at an accelerated rate (8-fold increase) when the activated complex instead of the nucleotide-free complex was used to rescue the protein from misfolding, Our data demonstrate that the differences in the refolding yields are related to the intrinsic folding kinetics of the protein substrates. We suggest that the early kinetic events at the substrate level ultimately govern successful chaperonin-substrate interactions and play a crucial role in dictating polypeptide flux through the chaperonin system. Our results also indicate that an accurate assessment of the transient properties of folding intermediates that dictate the initial chaperonin-substrate interactions requires the use of the activated complex as the interacting chaperonin species.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Fisher, MT (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	mfisher1@kumc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049309] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1988, BIOCHIM BIOPHYS ACTA, V956, P30, DOI 10.1016/0167-4838(88)90294-4; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Chan HS, 1996, PROTEINS, V24, P345; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Clark AC, 1997, J MOL BIOL, V268, P512, DOI 10.1006/jmbi.1997.0969; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; Eisenstein E, 1998, METHOD ENZYMOL, V290, P119, DOI 10.1016/S0076-6879(98)90011-8; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FISHER MT, 1992, J BIOL CHEM, V267, P1872; FISHER MT, 1994, J BIOL CHEM, V269, P13629; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FISHER MT, 1994, J BIOL CHEM, V269, P29598; FISHER MT, 1996, BIOCHEMISTRY MOSC, V63, P382; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; GOLUBINOFF P, 1989, NATURE, V342, P884; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Gross M, 1996, PROTEIN SCI, V5, P2506, DOI 10.1002/pro.5560051213; HOROWITZ PM, 1992, J BIOL CHEM, V267, P23596; Jaenicke R, 1996, CURR TOP CELL REGUL, V34, P209, DOI 10.1016/S0070-2137(96)80008-2; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P373; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; LIN S, 1995, J BIOL CHEM, V270, P1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Perrett S, 1997, J MOL BIOL, V269, P892, DOI 10.1006/jmbi.1997.1081; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; VITTANEN PV, 1992, PROTEIN SCI, V1, P363; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WOOLFOLK CA, 1966, ARCH BIOCHEM BIOPHYS, V116, P177, DOI 10.1016/0003-9861(66)90026-9; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567	47	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25073	25078		10.1074/jbc.273.39.25073	http://dx.doi.org/10.1074/jbc.273.39.25073			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737964	hybrid			2022-12-25	WOS:000076085400014
J	Wang, D; Sul, HS				Wang, D; Sul, HS			Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway - Involvement of protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RAT ADIPOSE-CELLS; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; 1-PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; OKADAIC ACID; ACTIVATION	Fatty acid synthase (FAS) is a critical enzyme in de novo lipogenesis. It catalyzes the seven steps in the conversion of malonyl-CoA and acetyl-CoA to palmitate, We have shown that the rate of FAS transcription is induced dramatically when fasted animals are refed with a high carbohydrate, fat-free diet or when streptozotocin-diabetic mice are given insulin. The FAS promoter was up-regulated by insulin through the proximal insulin response sequence containing an E-box motif at the -65-base pair position. Binding of upstream stimulatory factors to the -65 E-box is functionally required for insulin regulation of the FAS promoter. In the present study, we characterized signaling pathways in the insulin stimulation of FAS transcription using specific inhibitors for various signaling molecules and transfecting engineered phosphatidylinositol (PI) 3-kinase subunits and protein kinase B (PKB)/Akt, PD98059 and rapamycin, which inhibit MAP kinase and P70 S6 kinase, respectively, had little effect on the insulin-stimulated FAS promoter activity in 3T3-L1 adipocytes, On the other hand, wortmannin and LY294002, which specifically inactivate PI 3-kinase, strongly inhibited the insulin-stimulated FAS promoter activity. As shown in RNase protection assays, LY294002 also inhibited insulin stimulation of the endogenous FAS mRNA levels in 3T3-L1 adipocytes, Cotransfection of expression vectors for the constitutively active P110 subunit of PI 3-kinase resulted in an elevated FAS promoter activity in the absence of insulin and a loss of further insulin stimulation. Transfecting a dominant negative P85 subunit of PI 3-kinase decreased FAS promoter activity and blocked insulin stimulation. Furthermore, cotransfected wild-type PKB/Akt increased FAS promoter activity in the absence of insulin and a loss of insulin responsiveness of the FAS promoter. On the other hand, kinase-dead PKB/Akt acted in a dominant negative manner to decrease the FAS promoter activity and abolished its insulin responsiveness. These results demonstrate that insulin stimulation of fatty acid synthase promoter is mediated by the PI 3-kinase pathway and that PKB/Abt is involved as a downstream effector.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA.	hsul@nature.berkeley.edu	Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [DK-36264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; HAAVIK J, 1989, FEBS LETT, V251, P36, DOI 10.1016/0014-5793(89)81424-3; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PAULAUSKIS JD, 1989, BIOCHEM BIOPH RES CO, V158, P690, DOI 10.1016/0006-291X(89)92776-9; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367	52	114	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25420	25426		10.1074/jbc.273.39.25420	http://dx.doi.org/10.1074/jbc.273.39.25420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738010	hybrid			2022-12-25	WOS:000076085400060
J	Yeung, MC; Lau, AS				Yeung, MC; Lau, AS			Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; WILD-TYPE P53; LEUKEMIC-CELLS; FACTOR-ALPHA; EXPRESSION; DEATH; INDUCTION; CYCLE; INTERLEUKIN-6; INVOLVEMENT	Despite what is known about the early signaling events in tumor necrosis factor (TNF) alpha-induced apoptosis, characterization of the downstream events remains largely undefined. It is now known that a crosstalk exists between the interferon and TNF-alpha pathways. This linkage allows recruitment of the cell proliferation suppressor PKR (dsRNA-dependent protein kinase) from the interferon pathway to play a pivotal role in TNF-alpha-induced apoptosis. In this study, we took advantage of the differential TNF-alpha susceptibilities of human promonocytic U937 subclones, deficient in or overexpressing PKR, to further characterize the role of PKR in apoptosis. By reverse transcription-polymerase chain reaction, we demonstrated that TNF-alpha transiently induces the tumor suppressor p53 in U937 cells. This p53 induction lags behind the TNF-alpha induction of PKR by 1 h. By cell viability determination, ultrastructural studies, apoptotic DNA laddering, and antisense techniques, it was shown that inhibition of p53 expression in PKR-overexpressing U937 cells abrogates the TNF-alpha-induced apoptosis in these cells. Conversely, overexpressing wild type p53 in PKR-deficient U937 cells confers the susceptibility of these cells to TNF-alpha-induced apoptosis. This latter result indicates that p53 induction is an event downstream of TNF-alpha-induced up-regulation of PKR, thereby further establishing the critical role of p53 in TNF-alpha-induced apoptosis in U937 cells. PKR-overexpressing U937 cells were found to possess a constitutively higher level of p53, which partly explains why these cells spontaneously undergo apoptosis even without TNF-alpha treatment. Finally, a model is presented on the interplay between PKR and p53 in effecting TNF-alpha-induced apoptosis in U937 cells.	San Francisco Gen Hosp, Dept Pediat, Moses Grossman Infect Dis Lab, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Lau, AS (corresponding author), San Francisco Gen Hosp, Dept Pediat, Moses Grossman Infect Dis Lab, Rm 6E6,1001 Potrero Ave, San Francisco, CA 94110 USA.							Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DER SD, 1995, P NATL ACAD SCI USA, V92, P8841, DOI 10.1073/pnas.92.19.8841; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Kishi K, 1993, Gan To Kagaku Ryoho, V20, P1107; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lahdenpohja N, 1998, J IMMUNOL, V160, P1354; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; REIHSAUS E, 1990, ONCOGENE, V5, P137; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; Takizawa T, 1996, Nihon Rinsho, V54, P1836; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WU HY, 1994, J BIOL CHEM, V269, P20067; Yeung MC, 1998, AIDS, V12, P349, DOI 10.1097/00002030-199804000-00002; YEUNG MC, 1995, AIDS, V9, P137, DOI 10.1097/00002030-199509020-00004; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; YIN DL, 1995, NEUROSURGERY, V37, P758, DOI 10.1227/00006123-199510000-00021; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	34	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25198	25202		10.1074/jbc.273.39.25198	http://dx.doi.org/10.1074/jbc.273.39.25198			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737981	hybrid			2022-12-25	WOS:000076085400031
J	Govindan, MV; Warriar, N				Govindan, MV; Warriar, N			Reconstitution of the N-terminal transcription activation function of human mineralocorticoid receptor in a defective human glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANDROGEN RECEPTOR; HORMONE-BINDING DOMAIN; MAJOR TRANSACTIVATION DOMAIN; HUMAN ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; CHLORAMPHENICOL ACETYLTRANSFERASE; NUCLEAR RECEPTORS; GENE-EXPRESSION; STEROID-BINDING; DNA-BINDING	N-terminal sequences involved in transcription activation by the human mineralocorticoid receptor (hMR) have yet to be defined, We have addressed this issue and generated overlapping internal deletion mutants hMR Delta(59-162), hMR Delta(59-247), hMR Delta(59-328), hMR Delta(162-247), hMR Delta(247-328), hMR Delta(247-382), and hMR Delta(328-382), with intact DNA-binding and hormone-binding domains. A second set of mutant receptors with unique BglII sites was generated to facilitate the isolations of fragments. Immunodetection with anti-hMR peptide antibodies and hormone-binding assays showed that the mutations did not affect the expression of the receptors or ability to bind aldosterone, Distribution of aldosterone binding activity of wild type and deletion mutants expressed in HeLa cells was predominantly nuclear, Furthermore, deletion of sequences between 59 and 390 did not affect DNA binding activity. Transfection studies with HeLa cells revealed a region around residue 247 that was crucial for normal receptor function. Deletion of amino acids 59-162 did not affect the transcriptional activity of the hMR. However, deletion of sequences 247-382 and 328-382 markedly decreased the transcription activation function. The induction of the reporter gene by the chimera hGR Delta(71-262)/hMR(328-382) was 2-fold higher than with the wild type hGrR, but 200-fold when compared with hGR Delta(71-262), indicating that the AF-1 domain is located between positions 328 and 382 in the hMR.	Hop Hotel Dieu, Ctr Rech, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Quebec City, PQ G1R 2J6, Canada	Laval University	Govindan, MV (corresponding author), Hop Hotel Dieu, Ctr Rech, Cote Palais, Quebec City, PQ G1R 2J6, Canada.	manjapra.govindan@crhdq.ulaval.ca						ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; CIDLOWSKI JA, 1981, ENDOCRINOLOGY, V109, P1975; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GOVINDAN MV, 1991, J STEROID BIOCHEM, V39, P91, DOI 10.1016/0960-0760(91)90017-Y; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MCDONNELL DP, 1992, P NATL ACAD SCI USA, V89, P10563, DOI 10.1073/pnas.89.22.10563; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; PAGE N, 1994, AM J PHYSIOL-LUNG C, V267, pL464, DOI 10.1152/ajplung.1994.267.4.L464; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SCHWERK C, 1995, J BIOL CHEM, V270, P21331, DOI 10.1074/jbc.270.36.21331; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WARRIAR N, 1994, J BIOL CHEM, V269, P29016; WARRIAR N, 1994, BIOCHEMISTRY-US, V33, P12837, DOI 10.1021/bi00209a015; WARRIAR N, 1994, J BIOL CHEM, V269, P29010; WRIGHT APH, 1991, MOL ENDOCRINOL, V5, P1366, DOI 10.1210/mend-5-10-1366; YU CY, 1995, BIOCHEMISTRY-US, V34, P14163, DOI 10.1021/bi00043a022	39	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24439	24447		10.1074/jbc.273.38.24439	http://dx.doi.org/10.1074/jbc.273.38.24439			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733735	hybrid			2022-12-25	WOS:000076007300027
J	Syntichaki, P; Thireos, G				Syntichaki, P; Thireos, G			The Gcn5 Ada complex potentiates the histone acetyltransferase activity of Gcn5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PUTATIVE TRANSCRIPTIONAL ADAPTER; ACIDIC ACTIVATION DOMAINS; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; REMODELING FACTOR; NUCLEOSOMAL DNA; SWI/SNF COMPLEX; IN-VIVO	The Gcn5 histone acetyltransferase (HAT) is part of a large multimeric complex that is required for transcriptional activation in yeast. This complex can acetylate in vitro and in a Gcn5-dependent manner both nucleosomal and free core histones. For this reason it is believed that part of the function of the GcnF5.Ada complex is chromatin remodeling effected by histone acetylation. The roles of the other subunits of this complex are not yet known. We have generated mutated Gcn5 proteins with severely attenuated in vitro HAT activities. Despite their apparent loss in HAT activity, these GCN5 derivatives complemented all the defects of a gcn5 strain. We have shown that when these mutated proteins were produced in yeast cells in the absence of another component of the complex, Ada2, their activity was still compromised. By contrast, when produced in the wild type context, they were partially capable of acetylating free histones and were even more active when nucleosomal arrays were used as substrates. Kinetic enzymatic analyses showed that the rate of catalysis by Gcn5 was enhanced when the mutated proteins were produced in yeast in the presence of Ada2. Because Ada2 is required for the assembly of Gcn5, we conclude that one role for components of the Gcn5 Ada complex is the potentiation of its HAT activity.	Fdn Res & Technol, Inst Mol Biol & Biotechnol, Iraklion 71110, Greece; Univ Crete, Dept Biol, Iraklion 71110, Greece	University of Crete	Thireos, G (corresponding author), Fdn Res & Technol, Inst Mol Biol & Biotechnol, Iraklion 71110, Greece.	Thireos@imbb.forth.gr	Syntichaki, Popi/ABA-7218-2020	Syntichaki, Popi/0000-0001-9536-8905				BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE A, 1994, NATURE, V368, P4663; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	42	28	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24414	24419		10.1074/jbc.273.38.24414	http://dx.doi.org/10.1074/jbc.273.38.24414			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733731	hybrid			2022-12-25	WOS:000076007300023
J	Xu, J; Koudelka, GB				Xu, J; Koudelka, GB			DNA-based positive control mutants in the binding site sequence of 434 repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-PRM PROMOTER; COLI RNA-POLYMERASE; BACTERIOPHAGE-434 REPRESSOR; TRANSCRIPTION ACTIVATION; NONCONTACTED BASES; OPERATOR; RECOGNITION; AFFINITY; O(R)3; RESOLUTION	As detected by chemical nuclease treatments, the conformation of the 434 repressor-DNA complex depends on the sequence of the bound DNA (Bell, A. C., and Koudelka, G. B. (1993) J, Mel. Biol. 234, 542-553). We show here that these DNA sequence-dependent conformational changes alter the efficiency with which the repressor activates transcription from 434 P-RM. Several lines of evidence suggest that binding site sequence affects the repressor's ability to activate transcription by altering the accessibility of the activation surface on the repressor to RNA polymerase, The results presented here show that in addition to affecting transcription by altering the overall binding affinity of protein for DNA, DNA sequence may also modulate the activity of the DNA-bound protein.	SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Koudelka, GB (corresponding author), SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA.	koudelka@acsu.buffalo.edu	Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BELL AC, 1993, J MOL BIOL, V234, P542, DOI 10.1006/jmbi.1993.1610; BELL AC, 1995, J BIOL CHEM, V270, P1205, DOI 10.1074/jbc.270.3.1205; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; BUSHMAN FD, 1993, J MOL BIOL, V230, P28, DOI 10.1006/jmbi.1993.1123; BUSHMAN FD, 1986, P NATL ACAD SCI USA, V83, P9353, DOI 10.1073/pnas.83.24.9353; BUSHMAN FD, 1988, CELL, V54, P191, DOI 10.1016/0092-8674(88)90551-X; BUSHMAN FD, 1985, NATURE, V316, P651, DOI 10.1038/316651a0; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GUSSIN GN, 1992, J BACTERIOL, V174, P5156, DOI 10.1128/JB.174.15.5156-5160.1992; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HAWLEY DK, 1983, CELL, V32, P327, DOI 10.1016/0092-8674(83)90452-X; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1991, NUCLEIC ACIDS RES, V19, P4115, DOI 10.1093/nar/19.15.4115; KOUDELKA GB, 1993, J BIOL CHEM, V268, P23812; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; KULDELL N, 1994, J BACTERIOL, V176, P2291; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; LAUER G, 1981, Journal of Molecular and Applied Genetics, V1, P139; LAVIGNE M, 1992, BIOCHEMISTRY-US, V31, P9647, DOI 10.1021/bi00155a018; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Monsalve M, 1996, EMBO J, V15, P383, DOI 10.1002/j.1460-2075.1996.tb00368.x; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Ptashne M, 1986, GENETIC SWITCH; RODGERS DW, 1993, STRUCTURE, V1, P227, DOI 10.1016/0969-2126(93)90012-6; SHIMON LJW, 1993, J MOL BIOL, V232, P826, DOI 10.1006/jmbi.1993.1434; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Tang H, 1996, METHOD ENZYMOL, V273, P130; Tang Y, 1996, J BACTERIOL, V178, P6945, DOI 10.1128/jb.178.23.6945-6951.1996; WHARTON RR, 1986, THESIS HARVARD U CAM; WU L, 1993, J BIOL CHEM, V268, P18975; WU L, 1992, J BIOL CHEM, V267, P9134	40	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24165	24172		10.1074/jbc.273.37.24165	http://dx.doi.org/10.1074/jbc.273.37.24165			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727039	hybrid			2022-12-25	WOS:000075893100080
J	Zheng, XL; Guo, JH; Wang, H; Malbon, CC				Zheng, XL; Guo, JH; Wang, H; Malbon, CC			Expression of constitutively activated G(i alpha 2) in vivo ameliorates Streptozotocin-induced diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN ACTION; GLUCOSE-TRANSPORT; GLYCOGEN-SYNTHASE; MECHANISM	Streptozotocin treatment in vivo generates a model of insulin-dependent diabetes mellitus via destruction of the pancreatic beta-cells responsible for insulin secretion. Tissue-specific expression of the Q205L constitutively activated mutant form of the G-protein G(i alpha 2) in vivo ameliorates streptozotocin-induced insulin-dependent diabetes mellitus in transgenic mice. Conditional expression of Q205L G(i alpha 2) in vivo in liver, skeletal muscle, and adipose tissue markedly rectifies glucose tolerance, fasting glucose levels, and glycogen synthase activation in the mice with insulin-dependent diabetes mellitus, providing a novel therapeutic target for diabetes.	SUNY Stony Brook, Med Ctr, Dept Mol Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Med Ctr, Dept Physiol & Biophys, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Pharmacol, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020	Zheng, Xi-Long/0000-0002-0889-1827				Chen JF, 1997, J MOL MED, V75, P283, DOI 10.1007/s001090050113; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; KARNIELI E, 1981, J CLIN INVEST, V68, P811, DOI 10.1172/JCI110318; KOBAYASHI M, 1979, DIABETES, V28, P87, DOI 10.2337/diab.28.2.87; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LIKE AA, 1978, LAB INVEST, V38, P470; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; NISHIMURA H, 1989, AM J PHYSIOL, V256, pE624, DOI 10.1152/ajpendo.1989.256.5.E624; RAKIETEN N, 1976, P SOC EXP BIOL MED, V151, P632; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0	12	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23649	23651		10.1074/jbc.273.37.23649	http://dx.doi.org/10.1074/jbc.273.37.23649			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726968	hybrid			2022-12-25	WOS:000075893100009
J	Lorenzo, P; Bayliss, MT; Heinegard, D				Lorenzo, P; Bayliss, MT; Heinegard, D			A novel cartilage protein (CILP) present in the mid-zone of human articular cartilage increases with age	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN; IX	A novel, somewhat basic noncollagenous protein was purified from guanidine hydrochloride extracts of human articular cartilage using cesium chloride density gradient centrifugation, followed by ion-exchange chromatography at pH 5, and gel filtration on two serially coupled columns of Superose 6 and Superdex 200. The protein of 91.5 kDa contains a single polypeptide chain substituted with N-linked oligosaccharides. It appeared unique to cartilage as studied by enzyme-linked immunosorbent assay and immunoblots of various tissue extracts. Its concentration in articular cartilages showed some variability with age being lower in young individuals. It represents a chondrocyte product, since it is synthesized by articular chondrocytes in explant cultures. Interestingly, the distribution of the protein in the articular cartilage provides important information on the nature of chondrocytes at different compartments in the tissue. Thus, chondrocytes in the middle/ deeper layers of the tissue in particular, appeared to have produced the protein and deposited it in the interterritorial matrix. The protein was neither seen in the superficial nor in the deepest regions of the articular cartilage. Based on its immunolocalization we have named this protein CILP (cartilage intermediate layer protein).	Univ Lund, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Univ London Royal Vet Coll, London NW1 0TU, England	Lund University; University of London; University of London Royal Veterinary College	Heinegard, D (corresponding author), Univ Lund, Dept Cell & Mol Biol, POB 94, S-22100 Lund, Sweden.	Dick.Heinegard@medkem.lu.se						BANKER GA, 1972, J BIOL CHEM, V247, P5856; BAYLISS MT, 1983, BIOCHEM J, V209, P387, DOI 10.1042/bj2090387; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; HEINEGARD D, 1993, CONNECTIVE TISSUE IT, P103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON T, 1991, J BIOL CHEM, V266, P20428; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; PAULSSON M, 1983, BIOCHEM J, V212, P659, DOI 10.1042/bj2120659; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105	13	132	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23463	23468		10.1074/jbc.273.36.23463	http://dx.doi.org/10.1074/jbc.273.36.23463			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722583	hybrid			2022-12-25	WOS:000075778100083
J	Smith, KE; Walker, MW; Artymyshyn, R; Bard, J; Borowsky, B; Tamm, JA; Yao, WJ; Vaysse, PJJ; Branchek, TA; Gerald, C; Jones, KA				Smith, KE; Walker, MW; Artymyshyn, R; Bard, J; Borowsky, B; Tamm, JA; Yao, WJ; Vaysse, PJJ; Branchek, TA; Gerald, C; Jones, KA			Cloned human and rat galanin GALR3 receptors - Pharmacology and activation of G-protein inwardly rectifying K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GUINEA-PIG STOMACH; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; ALZHEIMERS-DISEASE; HORMONE SECRETION; NEUROPEPTIDE-Y; PEPTIDE; ANTAGONISTS; BINDING	The neuropeptide galanin has been implicated in the regulation of processes such as nociception, cognition, feeding behavior, and hormone secretion. Multiple galanin receptors are predicted to mediate its effects, but only two functionally coupled receptors have been reported. We now report the cloning of a third galanin receptor distinct from GALR1 and GALR2. The receptor, termed GALR3, was isolated from a rat hypothalamus cDNA library by both expression and homology cloning approaches. The rat GALR3 receptor cDNA can encode a protein of 370 amino acids with 35% and 52% identity to GALR1 and GALR2, respectively. Localization of mRNA, by solution hybridization/RNase protection demonstrates that the GALR3 transcript is widely distributed, but expressed at low abundance, with the highest levels in the hypothalamus and pituitary. We also isolated the gene encoding the human homologue of GALR3. The human GALR3 receptor is 90% identical to rat GALR3 and contains 368 amino acids. Binding of porcine I-125-galanin to stably expressed rat and human GALR3 receptors is saturable (rat K-D = 0.98 nM and human K-D = 2.23 nM) and displaceable by galanin peptides and analogues in the following rank, order: rat galanin, porcine galanin similar or equal to M32, M35 similar or equal to porcine galanin-(-7 to +29), galantide, human galanin > M40, galanin-(1-16) > [D-Trp(2)]galanin-(1-29), galanin-(3-29). This profile resembles that of the rat GALR1 and GALR2 receptors with the notable exception that human galanin, galanin-(1-16), and M40 show lower affinity at GALR3. In Xenopus oocytes, activation of rat and human GALR3 receptors co-expressed with potassium channel subunits GIRK1 and GIRK4 resulted in inward K+ currents characteristic of G(i)/G(o)-coupled receptors, These data confirm the functional efficacy of GALR3 receptors and further suggest that GALR3 signaling pathways resemble those of GALR1 in that both can activate potassium channels linked to the regulation of neurotransmitter release.	Synapt Pharmaceut Corp, Dept Mol Biol, Paramus, NJ 07652 USA; Synapt Pharmaceut Corp, Dept Pharmacol, Paramus, NJ 07652 USA		Smith, KE (corresponding author), Synapt Pharmaceut Corp, Dept Mol Biol, 215 Coll Rd, Paramus, NJ 07652 USA.							ARTYMYSHYN RP, 1992, NEUROCHEM INT, V20, pS189; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; BARTFAI T, 1992, TRENDS PHARMACOL SCI, V13, P312, DOI 10.1016/0165-6147(92)90098-Q; BARTFAI T, 1993, P NATL ACAD SCI USA, V90, P11287, DOI 10.1073/pnas.90.23.11287; BEDECS K, 1994, EUR J PHARMACOL, V259, P151, DOI 10.1016/0014-2999(94)90504-5; BERSANI M, 1991, ENDOCRINOLOGY, V129, P2693, DOI 10.1210/endo-129-5-2693; BOROWSKY B, 1997, SOC NEUR ABSTR, V22, P393; CHAKDER S, 1991, GASTROENTEROLOGY, V100, P711, DOI 10.1016/0016-5085(91)80015-2; Chan YY, 1996, ENDOCRINOLOGY, V137, P5303, DOI 10.1210/en.137.12.5303; Chan-Palay V, 1990, Adv Neurol, V51, P253; Cimini V, 1996, EXP CELL RES, V228, P212, DOI 10.1006/excr.1996.0319; CORWIN RL, 1993, EUR J NEUROSCI, V5, P1528, DOI 10.1111/j.1460-9568.1993.tb00221.x; Crawley JN, 1996, LIFE SCI, V58, P2185, DOI 10.1016/0024-3205(96)00093-8; CRAWLEY JN, 1993, BRAIN RES, V600, P268, DOI 10.1016/0006-8993(93)91382-3; CRAWLEY JN, 1990, J NEUROSCI, V10, P3695; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Diaz Z, 1996, BRAIN RES, V741, P32, DOI 10.1016/S0006-8993(96)00883-9; EVANS HF, 1991, ENDOCRINOLOGY, V129, P1682, DOI 10.1210/endo-129-3-1682; Fathi Z, 1997, MOL BRAIN RES, V51, P49, DOI 10.1016/S0169-328X(97)00210-6; Forray C., 1996, Society for Neuroscience Abstracts, V22, P1304; Grottoli S, 1996, J ENDOCRINOL INVEST, V19, P739, DOI 10.1007/BF03347877; GU ZF, 1994, AM J PHYSIOL, V266, pG839, DOI 10.1152/ajpgi.1994.266.5.G839; GU ZF, 1995, J PHARMACOL EXP THER, V272, P371; Gustafson EL, 1996, NEUROREPORT, V7, P953, DOI 10.1097/00001756-199603220-00025; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; HEDLUND PB, 1994, BRAIN RES, V634, P163, DOI 10.1016/0006-8993(94)90271-2; Howard AD, 1997, FEBS LETT, V405, P285, DOI 10.1016/S0014-5793(97)00196-8; JI RR, 1995, NEUROSCIENCE, V68, P563, DOI 10.1016/0306-4522(95)94333-T; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; Kask K, 1995, CELL MOL NEUROBIOL, V15, P653, DOI 10.1007/BF02071130; Kask K, 1997, LIFE SCI, V60, P1523, DOI 10.1016/S0024-3205(96)00624-8; Kinney GA, 1998, J NEUROSCI, V18, P3489; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; McCormick M, 1987, Methods Enzymol, V151, P445, DOI 10.1016/S0076-6879(87)51036-9; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; Parker EM, 1995, MOL BRAIN RES, V34, P179, DOI 10.1016/0169-328X(95)00159-P; REIMANN W, 1993, LIFE SCI, V52, P251; Renstrom E, 1996, NEURON, V17, P513, DOI 10.1016/S0896-6273(00)80183-X; SAHU A, 1994, ENDOCRINOLOGY, V134, P529, DOI 10.1210/en.134.2.529; SCHREIBER RC, 1994, NEUROSCIENCE, V60, P17, DOI 10.1016/0306-4522(94)90200-3; Shi TJS, 1997, NEUROSCI LETT, V237, P57, DOI 10.1016/S0304-3940(97)00805-7; Smith KE, 1997, J BIOL CHEM, V272, P24612, DOI 10.1074/jbc.272.39.24612; TSUDA K, 1989, HYPERTENSION, V14, P81, DOI 10.1161/01.HYP.14.1.81; Wang SK, 1997, J BIOL CHEM, V272, P31949, DOI 10.1074/jbc.272.51.31949; Wang ZL, 1997, J CLIN INVEST, V100, P189, DOI 10.1172/JCI119512; WYNICK D, 1993, P NATL ACAD SCI USA, V90, P4231, DOI 10.1073/pnas.90.9.4231; XU XJ, 1995, BRIT J PHARMACOL, V116, P2076, DOI 10.1111/j.1476-5381.1995.tb16414.x; Xu ZQ, 1996, NEUROREPORT, V8, P237, DOI 10.1097/00001756-199612200-00048; Xu ZQD, 1997, P NATL ACAD SCI USA, V94, P13262, DOI 10.1073/pnas.94.24.13262	51	222	232	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23321	23326		10.1074/jbc.273.36.23321	http://dx.doi.org/10.1074/jbc.273.36.23321			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722565	hybrid			2022-12-25	WOS:000075778100065
J	Awrey, DE; Shimasaki, N; Koth, C; Weilbaecher, R; Olmsted, V; Kazanis, S; Shan, X; Arellano, J; Arrowsmith, CH; Kane, CM; Edwards, AM				Awrey, DE; Shimasaki, N; Koth, C; Weilbaecher, R; Olmsted, V; Kazanis, S; Shan, X; Arellano, J; Arrowsmith, CH; Kane, CM; Edwards, AM			Yeast transcript elongation factor (TFIIS), structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BINDING DOMAIN; INTRINSIC BLOCKS; S-II; CLEAVAGE; DNA; STIMULATION; MUTAGENESIS; SITE; COMPLEXES	The transcriptionally active fragment of the yeast RNA polymerase II transcription elongation factor, TFIIS, comprises a three-helix bundle and a zinc ribbon motif joined by a linker region. We have probed the function of this fragment of TFIIS using structure-guided mutagenesis. The helix bundle domain binds RNA polymerase II with the same affinity as does the full-length TFIIS, and this interaction is mediated by a basic patch on the outer face of the third helix. TFIIS mutants that were unable to bind RNA polymerase II were inactive for transcription activity, confirming the central role of polymerase binding in the TFIIS mechanism of action. The linker and zinc ribbon regions play roles in promoting cleavage of the nascent transcript and read-through past the block to elongation. Mutation of three aromatic residues in the zinc ribbon domain (Phe(269), Phe(296), and Phe(308)) impaired both transcript cleavage and read-through. Mutations introduced in the linker region between residues 240 and 245 and between 250 and 255 also severely impaired both transcript cleavage and read-through activities. Our analysis suggests that the linker region of TFIIS probably adopts a critical structure in the context of the elongation complex.	Univ Toronto, Banting & Best Dept Med Res, CH Best Inst, Toronto, ON M5G 1L6, Canada; Univ Calif Berkeley, Div Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University of California System; University of California Berkeley; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Edwards, AM (corresponding author), Univ Toronto, Banting & Best Dept Med Res, CH Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	aled.edwards@utoronto.ca		Edwards, Aled/0000-0002-4782-6016; Arrowsmith, Cheryl/0000-0002-4971-3250; Koth, Christopher/0000-0003-3939-8856	NIGMS NIH HHS [GM54012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CIPRESPALACIN G, 1995, BIOCHEMISTRY-US, V34, P15375, DOI 10.1021/bi00046a046; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; HORIKOSHI N, 1990, J BIOL CHEM, V265, P11854; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Olmsted VK, 1998, J BIOL CHEM, V273, P22589, DOI 10.1074/jbc.273.35.22589; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Powell W, 1996, J BIOL CHEM, V271, P22301, DOI 10.1074/jbc.271.37.22301; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1994, RAV S MOL C, V3, P263; RIVA M, 1990, J BIOL CHEM, V265, P16498; RIVA M, 1987, J BIOL CHEM, V262, P14377; Rudd MD, 1996, J BIOL CHEM, V271, P21549, DOI 10.1074/jbc.271.35.21549; SOPTA M, 1985, J BIOL CHEM, V260, P353; Wu JS, 1996, P NATL ACAD SCI USA, V93, P11552, DOI 10.1073/pnas.93.21.11552	33	64	64	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22595	22605		10.1074/jbc.273.35.22595	http://dx.doi.org/10.1074/jbc.273.35.22595			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712888	hybrid			2022-12-25	WOS:000075616600064
J	Liu, CY; Shiraishi, A; Kao, CWC; Converse, RL; Funderburgh, JL; Corpuz, LM; Conrad, GW; Kao, WWY				Liu, CY; Shiraishi, A; Kao, CWC; Converse, RL; Funderburgh, JL; Corpuz, LM; Conrad, GW; Kao, WWY			The cloning of mouse keratocan cDNA and genomic DNA and the characterization of its expression during eye development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; LUMICAN; GENE; CORNEA; SEQUENCE; MATRIX; UNIQUE	Keratan sulfate proteoglycans (KSPGs) play a pivotal role in the development and maintenance of corneal transparency. Keratocan, lumican, and mimecan (osteoglycin) are the major KSPGs in vertebrate corneas. To provide a better understanding of the structure/function relationship of keratocan, we have cloned both the mouse keratocan gene and its cDNA. We have also examined its expression during embryonic development. The mouse keratocan gene spans approximately 6.5 kilobases of the mouse genome and contains three exons and two introns. Northern blotting and in situ hybridization were employed to examine keratocan gene expression during mouse development. Unlike lumican gene, which is expressed by many tissues other than cornea, keratocan mRNA is more selectively expressed in the corneal tissue of the adult mouse. During embryonic development, keratocan mRNA was first detected in periocular mesenchymal cells migrating toward developing corneas on embryonic day 13.5 (E13.5). Its expression was gradually restricted to corneal stromal cells on E14.5 similar to E18.5. Interestingly, keratocan mRNA can be detected in scleral cells of E15.5 embryos, but not in E18.5 embryos. In adult eyes, keratocan mRNA can be detected in corneal keratocytes, but not in scleral cells.	Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH 45267 USA; Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	University System of Ohio; University of Cincinnati; Kansas State University	Liu, CY (corresponding author), Univ Cincinnati, Dept Ophthalmol, Eden & Bethesda Ave,ML 0527, Cincinnati, OH 45267 USA.			Liu, Chia-yang/0000-0002-8398-5516	NEI NIH HHS [EY10556, EY09368, EY00952] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000952, R01EY009368, R01EY010556] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; AXELSSON I, 1984, ACTA OPHTHALMOL, V62, P25; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Doane KJ, 1996, EXP EYE RES, V62, P271; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; FUNDERBURGH JL, 1995, INVEST OPHTH VIS SCI, V36, P2296; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; LIU CY, 1994, J BIOL CHEM, V269, P24627; LIU CY, 1993, CURR EYE RES, V12, P963, DOI 10.3109/02713689309029222; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MAURICE DM, 1984, VEGETATIVE PHYSL BIO, P49; Meier S., 1982, Progress in Clinical and Biological Research, V82, P1; POOLE AR, 1986, BIOCHEM J, V236, P1; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; TASHEVA ES, 1998, IN PRESS GENE AMST; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	21	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22584	22588		10.1074/jbc.273.35.22584	http://dx.doi.org/10.1074/jbc.273.35.22584			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712886	hybrid			2022-12-25	WOS:000075616600062
J	Liu, MY; Xie, Z; Price, DH				Liu, MY; Xie, Z; Price, DH			A human RNA polymerase II transcription termination factor is a SWI2/SNF2 family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR COUPLING FACTOR; DNA-STIMULATED ATPASE; BINDING PROTEIN; RELEASE FACTOR; DROSOPHILA; ELONGATION; PURIFICATION; MECHANISMS; SEQUENCES; COMPLEXES	We obtained protein sequence information from Drosophila factor 2, an ATP-dependent RNA polymerase II transcription termination factor, and discovered that it was identical to a SWI2/SNF2 family member called lodestar. Portions of putative human and Caenorhabditis elegans homologues were found in the sequence data bases and a complete cDNA for the human factor was generated using polymerase chain reaction techniques. Recombinant human factor 2 was produced in a baculovirus expression system, purified, and characterized. Similar to the authentic Drosophila factor, the human factor displayed a strong double-stranded DNA-dependent ATPase activity that was inhibited by single-stranded DNA and exhibited RNA polymerase II termination activity. Both factors were able to work on elongation complexes from either species. We discuss the mechanism of termination by factor 2 and the implications for the role of factor 2 in cellular activities.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Howard Hughes Med Inst, Nashville, TN 37232 USA	University of Iowa; Howard Hughes Medical Institute; Vanderbilt University	Price, DH (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Price, David H/F-6173-2010	Liu, Mingyi/0000-0002-8101-8522; Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Collins AR, 1997, ENVIRON MOL MUTAGEN, V29, P152; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; LENNON GG, 1995, GENOMICS, V33, P151; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Mason SW, 1997, EMBO J, V16, P163, DOI 10.1093/emboj/16.1.163; Mason SW, 1997, J MOL BIOL, V268, P229, DOI 10.1006/jmbi.1997.0976; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PRICE DH, 1987, J BIOL CHEM, V262, P3244; Reeder RH, 1997, TRENDS BIOCHEM SCI, V22, P473, DOI 10.1016/S0968-0004(97)01133-X; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Xie Z, 1998, J BIOL CHEM, V273, P3771, DOI 10.1074/jbc.273.6.3771	36	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25541	25544		10.1074/jbc.273.40.25541	http://dx.doi.org/10.1074/jbc.273.40.25541			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748214	hybrid			2022-12-25	WOS:000076263100005
J	Gomez-Lorenzo, MG; Garcia-Bustos, JF				Gomez-Lorenzo, MG; Garcia-Bustos, JF			Ribosomal P-protein stalk function is targeted by sordarin antifungals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC PHOSPHOPROTEINS; CYCLOHEXIMIDE RESISTANCE; EUKARYOTIC RIBOSOMES; MOLECULAR-CLONING; RNA AUTOANTIBODY; YEAST GENE; DOMAIN; TRANSFORMATION; BINDING; MOIETY	Sordarin derivatives are remarkably selective inhibitors of fungal protein synthesis. Available evidence points to a binding site for these inhibitors on elongation factor 2, but high affinity binding requires the presence of ribosomes. The gene mutated in one of the two isolated complementation groups of Saccharomyces cerevisiae mutants resistant to the sordarin derivative GM193663 has now been identified. It is RPP0, encoding the essential protein of the large ribosomal subunit stalk rpP0. Resistant mutants are found to retain most of the binding capacity for the drug, indicating that mutations in rpP0 endow the ribosome with the capacity to perform translation elongation in the presence of the inhibitor. Other proteins of the ribosomal stalk influence the expression of resistance, pointing to a wealth of interactions between stalk components and elongation factors, The involvement of multiple elements of the translation machinery in the mode of action of sordarin antifungals may explain the large selectivity of these compounds, even though the individual target components are highly conserved proteins.	Glaxo Wellcome SA, Dept Res, Tres Cantos 28760, Spain	GlaxoSmithKline	Garcia-Bustos, JF (corresponding author), Glaxo Wellcome SA, Dept Res, Severo Ochoa 2, Tres Cantos 28760, Spain.	jfg32652@glaxowellcome.co.uk		Gomez Lorenzo, Maria de Gracia/0000-0003-2065-1145; Garcia-Bustos, Jose/0000-0002-6310-796X				Ballesta JPG, 1996, PROG NUCLEIC ACID RE, V55, P157, DOI 10.1016/S0079-6603(08)60193-2; CARRASCO L, 1973, BIOCHIM BIOPHYS ACTA, V319, P209, DOI 10.1016/0005-2787(73)90011-7; COVAL SJ, 1995, J ANTIBIOT, V48, P1171, DOI 10.7164/antibiotics.48.1171; FRIED HM, 1982, NUCLEIC ACIDS RES, V10, P3133, DOI 10.1093/nar/10.10.3133; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; Gudkov AT, 1997, FEBS LETT, V407, P253, DOI 10.1016/S0014-5793(97)00361-X; Guthrie C, 1991, GUIDE YEAST GENETICS; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Justice MC, 1998, J BIOL CHEM, V273, P3148, DOI 10.1074/jbc.273.6.3148; KAUFER NF, 1983, NUCLEIC ACIDS RES, V11, P3123; KAWAI S, 1992, J BACTERIOL, V174, P254, DOI 10.1128/jb.174.1.254-262.1992; Kinsman OS, 1998, J ANTIBIOT, V51, P41, DOI 10.7164/antibiotics.51.41; LARKIN JC, 1983, NUCLEIC ACIDS RES, V11, P403, DOI 10.1093/nar/11.2.403; LILJAS A, 1990, RIBOSOME, P309; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; REMACHA M, 1992, J BIOL CHEM, V267, P12061; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SANTOS C, 1995, J BIOL CHEM, V270, P20608, DOI 10.1074/jbc.270.35.20608; SANTOS C, 1994, J BIOL CHEM, V269, P15689; Schneider G, 1995, NAT PROD LETT, V7, P309, DOI 10.1080/10575639508043227; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; UCHIUMI T, 1994, EMBO J, V13, P3389, DOI 10.1002/j.1460-2075.1994.tb06641.x; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; Verschoor A, 1996, J CELL BIOL, V133, P495, DOI 10.1083/jcb.133.3.495; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8	31	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25041	25044		10.1074/jbc.273.39.25041	http://dx.doi.org/10.1074/jbc.273.39.25041			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737960	hybrid			2022-12-25	WOS:000076085400010
J	Burritt, JB; Busse, SC; Gizachew, D; Siemsen, DW; Quinn, MT; Bond, CW; Dratz, EA; Jesaitis, AJ				Burritt, JB; Busse, SC; Gizachew, D; Siemsen, DW; Quinn, MT; Bond, CW; Dratz, EA; Jesaitis, AJ			Antibody imprint of a membrane protein surface - Phagocyte flavocytochrome b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHAGE-DISPLAY LIBRARIES; SUPEROXIDE PRODUCTION; FILAMENTOUS PHAGE; TRANSFERRED NOESY; PLASMA-MEMBRANE; MOLECULAR-BASIS; MATRIX ANALYSIS; CYTOCHROME-B; EXCHANGE	Structural features of the integral membrane protein flavocytochrome b (Cyt b) were discovered using an antibody "imprint" of the Cyt b surface. Amino acid sequences were selected from a random nonapeptide phage-display library by their affinity for the monoclonal antibody 44.1 binding site, which recognizes the native conformation of the p22(phox) subunit of Cyt b, Transferred nuclear Overhauser effect spectroscopy and rotating frame Overhauser effect spectroscopy NMR were used to study the antibody-bound conformation of a synthetic peptide derived from phage-displayed sequences. The NMR data supported the phage-display analysis suggesting the existence of a complex epitope and allowed the modeling of the close spatial proximity of the epitope components (29)TAGRF(33) and (183)PQVNPI(188) from discontinuous regions of p22(phox). Although these regions are separated by two putative membrane-spanning domains and are 150 residues apart in the sequence, they appear to combine to form a complex epitope on the cytosolic surface of the transmembrane protein. NMR constraints, measured from the antibody-bound conformation of a composite peptide mimetic of the Cyt b epitope, and one constraint inferred from the phage-display results, were used to demonstrate the close proximity of these two regions. This information provides a low resolution view of the tertiary structure of the native discontinuous epitope on the Cyt b surface. Given additional antibodies, such imprint analysis has the potential for producing structural constraints to help support molecular modeling of this and other low abundance or noncrystallizable proteins.	Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Montana State Univ, Lab Vet Mol Biol, Bozeman, MT 59717 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman	Jesaitis, AJ (corresponding author), Montana State Univ, Dept Microbiol, 109 Lewis Hall, Bozeman, MT 59717 USA.			Quinn, Mark/0000-0001-8114-5073; Jesaitis, Algirdas/0000-0001-9001-5617	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI022735, R01AI026711, R01AI022735] Funding Source: NIH RePORTER; NCRR NIH HHS [2 P41 RR06009] Funding Source: Medline; NIAID NIH HHS [AI 22735, AI 26711] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AREPALLI SR, 1995, J MAGN RESON SER B, V106, P195, DOI 10.1006/jmrb.1995.1033; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; Burritt JB, 1996, ANAL BIOCHEM, V238, P1, DOI 10.1006/abio.1996.0241; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DAVIS DG, 1994, J MAGN RESON SER B, V104, P266, DOI 10.1006/jmrb.1994.1084; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DRATZ EA, 1993, NATURE, V363, P267; FEJZO J, 1989, J MAGN RESON, V82, P518, DOI 10.1016/0022-2364(89)90215-1; GIZACHEW D, 1998, BIOPHYS J, V74, pA74; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACKSON PL, 1995, J MAGN RESON SER B, V107, P289, DOI 10.1006/jmrb.1995.1092; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE, V5th edition; JESAITIS AJ, 1991, NEW BIOL, V3, P651; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; LANDY SB, 1989, J MAGN RESON, V81, P371, DOI 10.1016/0022-2364(89)90068-1; LONDON RE, 1992, J MAGN RESON, V97, P79, DOI 10.1016/0022-2364(92)90238-3; MEEKER AK, 1993, BIOTECHNIQUES, V15, P370; Moore DD, 1995, GLOB MOB SURV; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, BIOCHIM BIOPHYS ACTA, V932, P71, DOI 10.1016/0005-2728(88)90140-5; Roos D, 1996, BLOOD, V87, P1663; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH RM, 1991, BLOOD, V77, P673; ZHENG J, 1993, J MAGN RESON SER B, V101, P262, DOI 10.1006/jmrb.1993.1042; [No title captured]	31	48	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24847	24852		10.1074/jbc.273.38.24847	http://dx.doi.org/10.1074/jbc.273.38.24847			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733789	hybrid			2022-12-25	WOS:000076007300081
J	Grawunder, U; Zimmer, D; Kulesza, P; Lieber, MR				Grawunder, U; Zimmer, D; Kulesza, P; Lieber, MR			Requirement for an interaction of XRCC4 with DNA ligase IV for wild-type V(D)J recombination and DNA double-strand break repair in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SEVERE COMBINED IMMUNODEFICIENCY; ACTIVATING GENE; EXPRESSION; MUTATION; RAG-1; IDENTIFICATION; DIVERSITY; DEFECTS; SUBUNIT	The XRCC4 gene is required for the repair of DNA double-strand breaks in mammalian cells. Without XRCC4, cells are hypersensitive to ionizing radiation and deficient for V(D)J recombination. It has been demonstrated that XRCC4 binds and stimulates DNA ligase IV, which has led to the hypothesis that DNA ligase IV is essential for both of these processes. In this study deletion mutants of XRCC4 were tested for their ability to associate with DNA ligase IV in vitro and for their ability to reconstitute XRCC4-deficient cells in vivo. We find that a central region of XRCC4 from amino acids 100-250 is necessary for DNA ligase IV binding and that deletions within this region functionally inactivates XRCC4. Deletions within the C-terminal 84 amino acids neither affect DNA ligase IV binding nor the in vivo function of XRCC4. The correlation between the ability or inability of XRCC4 to bind DNA ligase IV and its ability or failure to reconstitute wild-type DNA repair in vivo, respectively, demonstrates for the first time that the physical interaction with DNA ligase IV is crucial for the in vivo function of XRCC4, Deletions within the N-terminal 100 amino acids inactivate XRCC4 in vivo but leave DNA ligase IV binding unaffected. This indicates further DNA ligase IV-independent functions of XRCC4.	Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90033 USA	University of Southern California	Lieber, MR (corresponding author), Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, 1441 Eastlake Ave,Mailstop 73, Los Angeles, CA 90033 USA.			Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Danska JS, 1996, MOL CELL BIOL, V16, P5507; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; Grawunder U, 1996, CURR TOP MICROBIOL, V217, P31; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR OPIN IMMUNOL, V10, P172, DOI 10.1016/S0952-7915(98)80246-X; Grawunder U, 1996, EUR J BIOCHEM, V241, P931, DOI 10.1111/j.1432-1033.1996.00931.x; Grawunder U, 1996, J EXP MED, V183, P1731, DOI 10.1084/jem.183.4.1731; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; REEVES WH, 1989, J BIOL CHEM, V264, P5047; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	34	128	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24708	24714		10.1074/jbc.273.38.24708	http://dx.doi.org/10.1074/jbc.273.38.24708			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733770	hybrid			2022-12-25	WOS:000076007300062
J	Saito, J; Kon, T; Nagasaki, A; Adachi, H; Sutoh, K				Saito, J; Kon, T; Nagasaki, A; Adachi, H; Sutoh, K			Dictyostelium TRFA homologous to yeast Ssn6 is required for normal growth and early development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; REPEAT MOTIF; SNAP HELIX; TPR MOTIFS; PROTEIN; DISCOIDEUM; GENE; TRANSCRIPTION; COMPLEX	The TPR (tetratricopeptide repeat) family became widespread during evolution, having been found from bacteria to mammals. By means of restriction enzyme-mediated integration, we have identified a Dictyostelium gene (trfA) highly homologous to a Saccharomyces cerevisiae gene encoding a TPR protein, Ssn6 (Cyc8), which functions as a global transcriptional repressor for diverse genes. The deduced amino acid sequence of the Dictyostelium gene product, TRFA, contains 10 consecutive TPR units as well as Gin repeats, Asn repeats, and a region rich in Glu, Lys, Ser, and Thr, The sequences of some of the 10 TPR units in TRFA are more than 70% identical to the corresponding units in Ssn6. The trfA(-) cells produced smooth plaques on a bacterial lawn and failed to aggregate normally when stirred on a plain agar plate, Individual trfA(-) cells also failed to correctly respond to cAMP, although the adenylyl cyclase of trfA(-) cells was expressed upon starvation and activated by stimulation with cAMP as in the wild-type cells. When cultured in a rich medium in suspension, they grew more slowly and stopped growing at a lower density than the wild-type cells. Furthermore, they divided into cells of various sizes and tended to be much smaller than the wild-type cells, These pleiotropic defects of the trfA(-) cells suggest the possibility that Dictyostelium TRFA may regulate the transcription of diverse genes required for normal growth and early development.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 153, Japan	University of Tokyo	Sutoh, K (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, 3-8-1 Komaba, Tokyo 153, Japan.		Nagasaki, Akira/M-4892-2018; Kon, Takahide/AAG-6975-2021	Nagasaki, Akira/0000-0002-1468-4592; Kon, Takahide/0000-0002-1231-7609				Adachi H, 1997, J CELL BIOL, V137, P891, DOI 10.1083/jcb.137.4.891; ADACHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1808, DOI 10.1006/bbrc.1994.2880; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIN G, 1991, J GEN MICROBIOL, V137, P501, DOI 10.1099/00221287-137-3-501; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Insall RH, 1996, CURR BIOL, V6, P719, DOI 10.1016/S0960-9822(09)00453-9; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIMMEL AR, 1985, MOL CELL BIOL, V5, P2123, DOI 10.1128/MCB.5.8.2123; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KONIJN TM, 1987, METHOD CELL BIOL, V28, P283; KUWAYAMA H, 1993, J CELL BIOL, V123, P1453, DOI 10.1083/jcb.123.6.1453; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Liu YZ, 1996, J BIOL CHEM, V271, P20853, DOI 10.1074/jbc.271.34.20853; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MORIO T, 1995, J PLANT RES, V108, P111, DOI 10.1007/BF02344314; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; Sambrook J., 1989, MOL CLONING, pA1; SCHNITZLER GR, 1994, GENE DEV, V8, P502, DOI 10.1101/gad.8.4.502; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SHAW DR, 1989, MOL GEN GENET, V218, P453, DOI 10.1007/BF00332409; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STROEHER VL, 1986, MOL CELL BIOL, V6, P4667, DOI 10.1128/MCB.6.12.4667; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; TRUMBLY RJ, 1988, GENE, V73, P97, DOI 10.1016/0378-1119(88)90316-2; TRUMBLY RJ, 1986, J BACTERIOL, V166, P1123, DOI 10.1128/jb.166.3.1123-1127.1986; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; Urushiyama S, 1997, GENETICS, V147, P101; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wang Lee-Ho, 1991, Gene Expression, V1, P207; Wang YW, 1998, J CELL SCI, V111, P373; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; Yip MLR, 1997, DEVELOPMENT, V124, P2129	45	4	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24654	24659		10.1074/jbc.273.38.24654	http://dx.doi.org/10.1074/jbc.273.38.24654			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733762	hybrid			2022-12-25	WOS:000076007300054
J	Souza, SC; de Vargas, LM; Yamamoto, MT; Lien, P; Franciosa, MD; Moss, LG; Greenberg, AS				Souza, SC; de Vargas, LM; Yamamoto, MT; Lien, P; Franciosa, MD; Moss, LG; Greenberg, AS			Overexpression of perilipin A and B blocks the ability of tumor necrosis factor alpha to increase lipolysis in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; HUMAN ADENOVIRUS TYPE-5; PROTEIN-KINASE; ADIPOSE-TISSUE; IN-VIVO; EXPRESSION; OBESITY; PHOSPHORYLATION; STIMULATION; INHIBITION	Perilipins, a family of phosphoproteins, are specifically located at the surface of intracellular lipid (triacylglycerol) droplets, the site of lipolysis. Stimulation of lipolysis in 3T3-L1 adipocytes by tumor necrosis factor alpha (TNF-alpha) is associated with a decrease in total cellular expression of perilipin A and B, consistent with the hypothesis that a decrease in perilipin protein expression is required for TNF-alpha-induced lipolysis. Adenovirus-mediated overexpression of perilipin A or B maintains perilipin protein levels on the lipid droplet and blocks TNF alpha-induced lipolysis. In contrast, overexpression of perilipin A or perilipin B does not inhibit isoproterenol-stimulated lipolysis and does not alter the isoproterenol-induced migration of perilipins from the lipid droplet. These results provide the first evidence of how perilipin functions and suggest that TNF-alpha regulates lipolysis, in part, by decreasing perilipin protein levels at the lipid droplet surface.	Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr, Boston, MA 02111 USA; New England Med Ctr, Tupper Res Inst, Div Endocrinol, Boston, MA 02111 USA; New England Med Ctr, Dept Med, Boston, MA 02111 USA; New England Med Ctr, Dept Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts University	Greenberg, AS (corresponding author), Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr, 711 Washington St, Boston, MA 02111 USA.							ARNER P, 1996, DIABETES REV, V4, P450; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Bruening W, 1998, NUCLEIC ACIDS RES, V26, P486, DOI 10.1093/nar/26.2.486; COPPACK SW, 1994, J LIPID RES, V35, P177; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FEINGOLD KR, 1992, ENDOCRINOLOGY, V130, P10, DOI 10.1210/en.130.1.10; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KOHANSKI RA, 1986, J BIOL CHEM, V261, P2272; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; OKUDA H, 1994, J LIPID RES, V35, P36; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; RAINES M, 1993, J BIOL CHEM, V278, P14572; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VIETOR I, 1993, J BIOL CHEM, V268, P18994	24	236	243	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24665	24669		10.1074/jbc.273.38.24665	http://dx.doi.org/10.1074/jbc.273.38.24665			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733764	hybrid			2022-12-25	WOS:000076007300056
J	Cheng, HC; Abdel-Ghany, M; Elble, RC; Pauli, BU				Cheng, HC; Abdel-Ghany, M; Elble, RC; Pauli, BU			Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FIBRONECTIN; BINDING; MOLECULE; MATRIX; CD26; HEPATOCYTES; EXPRESSION; INTEGRIN; DOMAIN; GLYCOPROTEIN	Endothelial cell adhesion molecules are partly responsible for the distinct organ distribution of cancer metastases. Dipeptidyl peptidase IV (DPP nr) expressed on rat lung capillary endothelia is shown here to be an adhesion receptor for rat breast cancer cells and to mediate lung colonization by these tumor cells. Fibronectin (FN) assembled on breast cancer cell surfaces into multiple, randomly dispersed globules from cellular and plasma FN is identified as the principal ligand for DPP IV. Ligand expression correlates quantitatively with the tumor cells' capabilities to bind to DPP IV and to metastasize to the lungs. DPP IV/FN-mediated adhesion and metastasis are blocked when tumor cells are incubated with soluble DPP TV prior to conducting adhesion and lung colony assays. Adhesion is also blocked by anti-DPP IV monoclonal antibody 6A3 and anti-FN antiserum. However, adhesion to immobilized FN is unaffected by soluble plasma FN and, thus, can happen during hematogenous spread of cancer cells at high plasma FN concentrations. The ability of many cancer cells to capture FN molecules on their surface and to augment such deposits by FN self-association during passage in the blood suggests that DPP IV/FN binding may be a relatively common mechanism for lung metastasis.	Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Pauli, BU (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.	bup1@cornell.edu			NATIONAL CANCER INSTITUTE [R01CA047668, R01CA071626] Funding Source: NIH RePORTER; NCI NIH HHS [CA47668, CA71626] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; ALBELDA SM, 1993, LAB INVEST, V68, P4; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; ELSABBAN ME, 1991, J CELL BIOL, V115, P1375, DOI 10.1083/jcb.115.5.1375; FELLIN FM, 1988, J BIOL CHEM, V263, P1791; Fidler Isaiah J., 1997, P135; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; GARDNER HA, 1988, CANCER INVEST, V6, P161, DOI 10.3109/07357908809077044; GOEBEL HW, 1992, VIRCHOWS ARCH B, V62, P9, DOI 10.1007/BF02899660; GUAN JL, 1990, J CELL BIOL, V110, P833, DOI 10.1083/jcb.110.3.833; HAREL S, 1988, HISTOCHEMISTRY, V89, P151; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOMANDBERG GA, 1987, THROMB RES, V48, P321, DOI 10.1016/0049-3848(87)90444-0; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HORMANN H, 1986, BIOPOLYMERS, V25, P947, DOI 10.1002/bip.360250513; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; Hynes RO, 1990, FIBRONECTIN; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; IwakiEgawa S, 1997, CELL IMMUNOL, V178, P180, DOI 10.1006/cimm.1997.1123; JOHNSON RC, 1991, CANCER RES, V51, P394; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; KORACH S, 1986, CANCER RES, V46, P3624; Lafrenie R M, 1993, Cell Biophys, V23, P3; LOSTER K, 1995, BIOCHEM BIOPH RES CO, V217, P341, DOI 10.1006/bbrc.1995.2782; MCCAUGHAN GW, 1990, HEPATOLOGY, V11, P534, DOI 10.1002/hep.1840110403; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MOORE KA, 1990, BLOOD, V75, P2085; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; NERI A, 1982, J NATL CANCER I, V68, P507; ODERMATT E, 1982, J MOL BIOL, V159, P109, DOI 10.1016/0022-2836(82)90034-1; PAULI BU, 1997, ENCY CANC, V1, P464; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RUOSLAHTI E, 1994, B I PASTEUR, V92, P242; Sakai K, 1996, J BIOCHEM-TOKYO, V119, P58; SCHARPE S, 1988, CLIN CHEM, V34, P2299; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SUGARBAKER EV, 1981, CANCER BIOL REV, V2, P235; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; WEISS L, 1986, J THEOR BIOL, V121, P307, DOI 10.1016/S0022-5193(86)80110-2; WU CY, 1993, J BIOL CHEM, V268, P21883; Yamaguchi N, 1996, TRANSPLANTATION, V62, P973, DOI 10.1097/00007890-199610150-00017; YEATMAN TJ, 1993, SEMIN SURG ONCOL, V9, P256; ZHU DZ, 1993, INT J CANCER, V53, P628; ZHU DZ, 1992, J CLIN INVEST, V89, P1718, DOI 10.1172/JCI115773; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	51	145	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24207	24215		10.1074/jbc.273.37.24207	http://dx.doi.org/10.1074/jbc.273.37.24207			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727044	hybrid			2022-12-25	WOS:000075893100085
J	Jensen, LT; Posewitz, MC; Srinivasan, C; Winge, DR				Jensen, LT; Posewitz, MC; Srinivasan, C; Winge, DR			Mapping of the DNA binding domain of the copper-responsive transcription factor Mac1 from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION DOMAIN; GAL4 DERIVATIVES; CANDIDA-GLABRATA; YEAST; TRANSPORT; PROTEIN; GENE; EXPRESSION; REPRESSION; SEQUENCE	Mad from Saccharomyces cerevisiae activates transcription of genes, including CTR1 in copper-deficient cells. N-terminal fusions of Mad with the herpes simplex VP16 activation domain were used to show that residues 1-159 in Mac1 constitute the minimal DNA binding domain. Mac1-(1-159) purified from Escherichia coli contains two bound Zn(II) ions. Electrophoretic mobility shift assays showed direct and specific binding by Mac1-(1-159) to a DNA duplex containing the copper-responsive element TTTGCTCA, The DNA binding affinity of Mac1-(1-159) for a duplex containing a single promoter element or an inverted repeat was 5 nM for the 1:1 complex. The N-terminal 40-residue segment of Mad is homologous to the DNA binding zinc module found in the copper-activated transcription factors Ace1 and Amt1. A MAC1 mutation yielding a Cys(11) --> Tyr substitution at the first candidate zinc ligand position relative to Ace1 resulted in a loss of in vivo function, Two TTTGCTCA promoter elements are necessary for efficient Mad-mediated transcriptional activation. The elements appear to function synergistically. Increasing the number of elements yields more than additive enhancements in CTR1 expression.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010	Jensen, Laran/0000-0003-3199-1743	NATIONAL CANCER INSTITUTE [R01CA061286] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHMAN C, 1990, MOL CELL BIOL, V10, P4778, DOI 10.1128/MCB.10.9.4778; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1994, CELL, V76, P893; DOBI A, 1995, J BIOL CHEM, V270, P10171, DOI 10.1074/jbc.270.17.10171; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Graden JA, 1996, BIOCHEMISTRY-US, V35, P14583, DOI 10.1021/bi961642v; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; JUNGMANN J, 1993, EMBO J, V12, P5061; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1996, MOL CELL BIOL, V16, P724; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; Linder Maria C., 1996, American Journal of Clinical Nutrition, V63, p797S; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TURNER RB, 1998, NAT STRUCT BIOL, V7, P9; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Wang D, 1997, J BIOL CHEM, V272, P19383, DOI 10.1074/jbc.272.31.19383; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112	41	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23805	23811		10.1074/jbc.273.37.23805	http://dx.doi.org/10.1074/jbc.273.37.23805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726991	hybrid			2022-12-25	WOS:000075893100032
J	Jiang, CJ; Imamoto, N; Matsuki, R; Yoneda, Y; Yamamoto, N				Jiang, CJ; Imamoto, N; Matsuki, R; Yoneda, Y; Yamamoto, N			Functional characterization of a plant importin alpha homologue - Nuclear localization signal (NLS)-selective binding and mediation of nuclear import of NLS proteins in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; PERMEABILIZED MAMMALIAN-CELLS; GUANINE-NUCLEOTIDE EXCHANGE; TRANSPORT SUBSTRATE; CYTOSOLIC FACTORS; RAN; GTP; IDENTIFICATION; ARABIDOPSIS; RANGAP1	Nuclear import of most nuclear proteins is initiated by recognition of the nuclear localization signal (NLS) by importin alpha. We recently isolated an importin alpha homologue from rice (rice importin alpha 1) and demonstrated that transcription of the gene is down-regulated by light in rice leaves. To address the function of rice importin alpha 1 in the process of nuclear import of proteins, we performed in vitro binding and nuclear import assays. The rice importin alpha 1 showed specific binding to fusion proteins containing either monopartite or bipartite NLSs, but not to a fusion protein containing a Mat alpha-2-type NLS, suggesting that there exists selective binding of rice importin alpha 1 to different plant NLSs. The rice importin alpha 1 is also capable of forming a complex with mouse importin beta and NLS protein in vitro. An in vitro nuclear import assay using permeabilized HeLa cells revealed that rice importin alpha 1, in conjunction with other vertebrate transport factors, mediates the nuclear envelope docking of NLS proteins and their subsequent translocation into the nucleus. These data provide strong, direct evidence suggesting that rice importin alpha 1 functions as a component of the NLS receptor in plant cells.	Natl Inst Agrobiol Resources, Dept Plant Physiol, Photosynthesis Lab, Tsuchiura, Ibaraki 3058602, Japan; Osaka Univ, Sch Med, Dept Anat & Cell Biol, Suita, Osaka 5650871, Japan; Cent Res Inst Elect Power Ind, Abiko, Chiba 2701194, Japan	National Institute of Agrobiological Sciences - Japan; Osaka University; Central Research Institute of Electric Power Industry - Japan	Yamamoto, N (corresponding author), Natl Inst Agrobiol Resources, Dept Plant Physiol, Photosynthesis Lab, 2-1-2 Kannondai, Tsuchiura, Ibaraki 3058602, Japan.	naoyam@abr.affrc.go.jp	Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022; Jiang, Chang-Jie/0000-0003-1845-541X				ACH RA, 1994, P NATL ACAD SCI USA, V91, P5863, DOI 10.1073/pnas.91.13.5863; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Ballas N, 1997, P NATL ACAD SCI USA, V94, P10723, DOI 10.1073/pnas.94.20.10723; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1995, METHOD ENZYMOL, V257, P135; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broder YC, 1997, FEBS LETT, V412, P535, DOI 10.1016/S0014-5793(97)00855-7; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Haizel T, 1997, PLANT J, V11, P93, DOI 10.1046/j.1365-313X.1997.11010093.x; Hicks GR, 1996, PLANT CELL, V8, P1337, DOI 10.1105/tpc.8.8.1337; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Imamoto N, 1998, EUR J HISTOCHEM, V42, P9; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Merkle T, 1996, PLANT J, V10, P1177, DOI 10.1046/j.1365-313X.1996.10061177.x; MERKLE T, 1994, PLANT J, V6, P555, DOI 10.1046/j.1365-313X.1994.6040555.x; Merkle T, 1997, TRENDS PLANT SCI, V2, P458, DOI 10.1016/S1360-1385(97)01140-0; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rosenblum JS, 1997, J CELL BIOL, V139, P1655, DOI 10.1083/jcb.139.7.1655; SAALBACH G, 1994, PLANT MOL BIOL, V24, P969, DOI 10.1007/BF00014451; SAFER D, 1989, ANAL BIOCHEM, V178, P32, DOI 10.1016/0003-2697(89)90351-5; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shoji K, 1998, GENE, V212, P279, DOI 10.1016/S0378-1119(98)00175-9; Smith HMS, 1997, PLANT PHYSIOL, V114, P411, DOI 10.1104/pp.114.2.411; Sweitzer TD, 1996, P NATL ACAD SCI USA, V93, P14574, DOI 10.1073/pnas.93.25.14574; Tsuji L, 1997, FEBS LETT, V416, P30, DOI 10.1016/S0014-5793(97)01092-2; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Yoneda Y, 1996, TRENDS MICROBIOL, V4, P1, DOI 10.1016/0966-842X(96)81494-6	53	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24083	24087		10.1074/jbc.273.37.24083	http://dx.doi.org/10.1074/jbc.273.37.24083			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727027	hybrid			2022-12-25	WOS:000075893100068
J	Kohama, T; Olivera, A; Edsall, L; Nagiec, MM; Dickson, R; Spiegel, S				Kohama, T; Olivera, A; Edsall, L; Nagiec, MM; Dickson, R; Spiegel, S			Molecular cloning and functional characterization of murine sphinogosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; RECEPTOR SUBSTRATE FAMILY; SPHINGOSINE KINASE; DIACYLGLYCEROL-KINASE; PHOSPHOTYROSINE PROTEIN; 3T3 FIBROBLASTS; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; SEQUENCE; CELLS	Sphingosine-l-phosphate (SPP) is a novel lipid messenger that has dual function. Intracellularly it regulates proliferation and survival, and extracellularly, it is a ligand for the G protein-coupled receptor Edp-1. Based on peptide sequences obtained from purified rat kidney sphingosine kinase, the enzyme that regulates SPP levels, we report here the cloning, identification, and characterization of the first mammalian sphingosine kinases (murine SPHK1a and SPHK1b), Sequence analysis indicates that these are novel kinases, which are not similar to other known kinases, and that they are evolutionarily conserved, Comparison with Saccharomyces cerevisiae and Caenorhabditis elegans sphingosine kinase sequences shows that several blocks are highly conserved in all of these sequences. One of these blocks contains an invariant, positively charged motif, GGHGK, which may be part of the ATP binding site. From Northern blot analysis of multiple mouse tissues, we observed that expression was highest in adult lung and spleen, with barely detectable levels in skeletal muscle and Liver. Human embryonic kidney cells and NIH 3T3 fibroblasts transiently transfected with either sphingosine kinase expression vectors had marked increases (more than 100-fold) in sphingosine kinase activity. The enzyme specifically phosphorylated D-erythro-sphingosine and did not catalyze the phosphorylation of phosphatidylinositol, diacylglycerol, ceramide, D,L-threo-dihydrosphingosine or N,N-dimethylsphingosine. The latter two sphingolipids were competitive inhibitors of sphingosine kinase in the transfected cells as was previously found with the purified rat kidney enzyme. Transfected cells also had a marked increase in mass levels of SPP with a concomitant decrease in levels of sphingosine and, to a lesser extent, in ceramide levels, Our data suggest that sphingosine kinase is a prototypical member of a new class of lipid kinases. Cloning of sphingosine kinase is an important step in corroborating the intracellular role of SPP as a second messenger.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA	Georgetown University; University of Kentucky; University of Kentucky	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 353 Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.	spiegel@biochem1.basic-sci.georgetown.edu		Kohama, Takafumi/0000-0002-6822-8170	NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; Edsall LC, 1997, J NEUROSCI, V17, P6952; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Rani CSS, 1997, J BIOL CHEM, V272, P10777; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1994, BIOCHEM J, V304, P661, DOI 10.1042/bj3040661; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	35	446	506	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23722	23728		10.1074/jbc.273.37.23722	http://dx.doi.org/10.1074/jbc.273.37.23722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726979	hybrid			2022-12-25	WOS:000075893100020
J	Lacour, T; Achstetter, T; Dumas, B				Lacour, T; Achstetter, T; Dumas, B			Characterization of recombinant adrenodoxin reductase homologue (Arh1p) from yeast - Implication in in vitro cytochrome P45011 beta monooxygenase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER FUNCTION; ESCHERICHIA-COLI; BOVINE ADRENODOXIN; SACCHAROMYCES-CEREVISIAE; DIRECT EXPRESSION; PROTEIN IMPORT; C REDUCTASE; GENE; MITOCHONDRIA; BINDING	The mammalian electron transfer chain of mitochondrial cytochrome P450 forms involved in steroidogenesis includes very specific proteins, namely adrenodoxin reductase and adrenodoxin. Adrenodoxin reductase transfers electrons from NADPH to adrenodoxin, which subsequently donates them to the cytochrome P450 forms. The Saccharomyces cerevisiae ARH1 gene product (Arh1p) presents homology to mammalian adreanodoxin reductase. We demonstrate the capacity of recombinant Arh1p, made in Escherichia coli, to substitute for its mammalian homologue in ferricyanide, cytochrome b: reduction, and, more importantly, in vitro 11 beta-hydroxylase assays. Electrons could be transfer-red from NADPH and NADH as measured in the cytochrome c reduction assay. Apparent K-m values were determined tea be 0.5, 0.6, and 0.1 mu M for NADPH, NADH, and bovine adrenodoxin, respectively, These values differ slightly from those of mammalian adrenodoxin reductase, except for NADH, which is a very poor electron donor to the mammalian protein. Subcellular fractionation studies have localized Arh1p to the inner membrane of yeast mitochondria. The biological function of Arh1p remains unknown, and to date, no mitochondrial cytochrome P450 has been identified. ARH1 is, however, essential for yeast viability because ale ARH1 gene disruption is lethal not only in aerobic growth conditions but also, surprisingly enough, during fermentation.	Hoechst Marion Roussel, Dept Biotechnol, F-93230 Romainville, France; Transgene SA, F-67000 Strasbourg, France	Sanofi-Aventis; Sanofi France; Transgene SA	Dumas, B (corresponding author), Hoechst Marion Roussel, Dept Biotechnol, 102 Route Noisy, F-93230 Romainville, France.							ACHSTETTER T, 1992, GENE, V110, P25, DOI 10.1016/0378-1119(92)90440-Z; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKERT V, 1994, J BIOL CHEM, V269, P2568; BLACKES WL, 1993, HDB EXPT PHARM, V105, P15; BRANDT ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P735, DOI 10.1016/0003-9861(92)90749-M; CHU JW, 1973, J BIOL CHEM, V248, P5183; DEGRYSE E, 1995, YEAST, V11, P629, DOI 10.1002/yea.320110704; DEGTYARENKO KN, 1995, PROTEIN ENG, V8, P737, DOI 10.1093/protein/8.8.737; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; Dumas B, 1996, EUR J BIOCHEM, V238, P495, DOI 10.1111/j.1432-1033.1996.0495z.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; Kagawa Norio, 1995, P419; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Lacour T, 1996, GENE, V174, P289, DOI 10.1016/0378-1119(96)00041-8; LAMBETH JD, 1977, J BIOL CHEM, V252, P2908; LAMBETH JD, 1979, J BIOL CHEM, V254, P2766; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; Manzella L, 1998, YEAST, V14, P839, DOI 10.1002/(SICI)1097-0061(19980630)14:9<839::AID-YEA283>3.0.CO;2-A; Moore DD, 1995, GLOB MOB SURV; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; SAGARA Y, 1993, BIOL PHARM BULL, V16, P627; SERRA EC, 1995, J BIOL CHEM, V270, P19930, DOI 10.1074/jbc.270.34.19930; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEMORI S, 1993, CYTOCHROME P450, P44; Thain A, 1996, TRENDS GENET, V12, P209, DOI 10.1016/S0168-9525(96)90022-0; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TULS J, 1987, J BIOL CHEM, V262, P10020; UHLMANN H, 1994, J BIOL CHEM, V269, P22557; UHLMANN H, 1995, J BIOL CHEM, V270, P29959; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; Vickery LE, 1997, STEROIDS, V62, P124, DOI 10.1016/S0039-128X(96)00170-5; WADA A, 1985, J BIOCHEM-TOKYO, V98, P245, DOI 10.1093/oxfordjournals.jbchem.a135264; WADA A, 1984, BIOCHEM BIOPH RES CO, V119, P365, DOI 10.1016/0006-291X(84)91660-7; WARBURTON RJ, 1995, BBA-PROTEIN STRUCT M, V1246, P39, DOI 10.1016/0167-4838(94)00178-J; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	48	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23984	23992		10.1074/jbc.273.37.23984	http://dx.doi.org/10.1074/jbc.273.37.23984			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727014	hybrid			2022-12-25	WOS:000075893100055
J	Pukatzki, S; Tordilla, N; Franke, J; Kessin, RH				Pukatzki, S; Tordilla, N; Franke, J; Kessin, RH			A novel component involved in ubiquitination is required for development of Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED PROTEOLYTIC PATHWAY; PROTEASOME PATHWAY; SIGNALING PATHWAYS; RIBOSOMAL-SUBUNIT; GENE; PROTEIN; DEGRADATION; SEQUENCE; ENZYME; DNA	A novel component of the ubiquitination system, called NOSA, is essential for cellular differentiation in Dictyostelium discoideum, Disruption of nosA does not affect the growth rate but causes an arrest in development after the cells have aggregated. nosA contains seven exons and codes for a developmentally regulated 3.5-kb mRNA, The 125-kDa NOSA protein is present in the cytosol at constant levels during growth and development. The C-terminal region of NOSA has homology with ubiquitin fusion degradation protein-2 (UFD2) of Saccharomyces cerevisiae and putative homologs in Caenorhabditis elegans and humans. UFD2 is involved in the ubiquitin-mediated degradation of model substrates in which ubiquitin forms part of the translation product, but ufd2 mutants have no detected phenotype, In accord with the homology to UFD2, we found differences in the ubiquitination patterns between nosA mutants and their parental cell line, While general in vivo and in vitro ubiquitination is minimally affected, ubiquitination of individual proteins is altered throughout growth and development in nosA mutants. These findings suggest that events involving ubiquitination are critical for progression through the aggregate stage of the Dictyostelium life cycle.	Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University	Kessin, RH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, 630 W 168th St, New York, NY 10032 USA.				NIGMS NIH HHS [GM33136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BOYMARCOTTE E, 1984, MOL GEN GENET, V193, P406, DOI 10.1007/BF00382076; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; CECCARELLI A, 1987, NUCLEIC ACIDS RES, V15, P7463, DOI 10.1093/nar/15.18.7463; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1994, BIOL CHEM H-S, V375, P565; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Clark A, 1997, MOL BIOL CELL, V8, P1989, DOI 10.1091/mbc.8.10.1989; EARLY A, 1988, DEV GENET, V9, P383, DOI 10.1002/dvg.1020090419; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; JACQUET M, 1988, MOL GEN GENET, V211, P441, DOI 10.1007/BF00425698; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; Kuspa A, 1996, P NATL ACAD SCI USA, V93, P5562, DOI 10.1073/pnas.93.11.5562; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; LOOMIS WF, 1997, DICTYOSTELIUM MODEL, P15; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MULLERTAUBENBERGER A, 1988, FEBS LETT, V229, P273, DOI 10.1016/0014-5793(88)81139-6; MULLERTAUBENBERGER A, 1988, J CELL SCI, V90, P51; MULLERTAUBENBERGER A, 1989, J BIOL CHEM, V264, P5319; OHMACHI T, 1989, BIOCHEMISTRY-US, V28, P5226, DOI 10.1021/bi00438a046; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PODGORSKI GJ, 1989, MOL CELL BIOL, V9, P3938, DOI 10.1128/MCB.9.9.3938; Ramos PCR, 1996, J EXP BOT, V47, P569, DOI 10.1093/jxb/47.4.569; REDMAN KL, 1994, INSECT BIOCHEM MOLEC, V24, P191, DOI 10.1016/0965-1748(94)90085-X; RICHARDSON DL, 1994, DEVELOPMENT, V120, P2891; Scheirton L S, 1993, Camb Q Healthc Ethics, V2, P495; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; SHAULSKY G, 1995, GENE DEV, V9, P1111, DOI 10.1101/gad.9.9.1111; SHAW DR, 1989, MOL GEN GENET, V218, P453, DOI 10.1007/BF00332409; SMITH DF, 1983, BIOCHEM BIOPH RES CO, V115, P360, DOI 10.1016/0006-291X(83)91012-4; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wang N, 1996, EMBO J, V15, P3890, DOI 10.1002/j.1460-2075.1996.tb00763.x; WESTPHAL M, 1986, FEBS LETT, V209, P92, DOI 10.1016/0014-5793(86)81090-0; WU L, 1995, DEV BIOL, V167, P1, DOI 10.1006/dbio.1995.1001; WU L, 1990, GENE, V91, P51, DOI 10.1016/0378-1119(90)90161-J	50	24	28	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24131	24138		10.1074/jbc.273.37.24131	http://dx.doi.org/10.1074/jbc.273.37.24131			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727034	hybrid			2022-12-25	WOS:000075893100075
J	Samari, HR; Seglen, PO				Samari, HR; Seglen, PO			Inhibition of hepatocytic autophagy by adenosine, aminoimidazole-4-carboxamide riboside, and N-6-mercaptopurine riboside - Evidence for involvement of AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; 5-AMINO-4-IMIDAZOLECARBOXAMIDE RIBOSIDE; ENERGY-DEPENDENCE; LYSOSOMAL PATHWAY; ATP DEPLETION; INTACT-CELLS; OKADAIC ACID; AMINO-ACIDS; DEGRADATION; LIVER	To examine the role of AMP-activated protein kinase (AMPK; EC 2.7.1.109) in the regulation of autophagy, rat hepatocytes were incubated with the AMPK proactivators, adenosine, 5-amino-4-imidazole carboxamide riboside (AICAR), or N-G-mercaptopurine riboside. Autophagic activity was inhibited by all three nucleosides, AICAR and N6-mercaptopurine riboside being more potent (IC50 = 0.3 mM) than adenosine (IC50 = 1 mM), 2'-Deoxycoformycin, an adenosine deaminase (EC 3.5.4.4) inhibitor, increased the potency of adenosine B-fold, suggesting that the effectiveness of adenosine as an autophagy inhibitor was curtailed by its intracellular deamination. 5-Iodotubercidin, an adenosine kinase (EC 2.7.1.20) inhibitor, abolished the effects of all three nucleosides, indicating that they needed to be phosphorylated to inhibit autophagy. A S-iodotubercidin-suppressible phosphorylation of AICAR to 4-aminoimidazole-4-carboxamide riboside monophosphate was confirmed by chromatographic analysis, AICAR, up to 0.4 mM, had no significant effect on intracellular ATP concentrations. Because activated AMPK phosphorylates and inactivates 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (EC 1.1,1.88), the rate-limiting enzyme in cholesterol synthesis, the strong inhibition of hepatocytic cholesterol synthesis by all three nucleosides confirmed their ability to activate AMPK under the conditions used. Lovastatin and simvastatin, inhibitors of HMG-CoA reductase, strongly suppressed cholesterol synthesis while having no effect on autophagic activity, suggesting that AMPK inhibits autophagy independently of its effects on HMG-CoA reductase and cholesterol metabolism.	Norwegian Radium Hosp, Dept Cell Biol, Canc Res Inst, N-0310 Oslo, Norway	University of Oslo	Seglen, PO (corresponding author), Norwegian Radium Hosp, Dept Cell Biol, Canc Res Inst, N-0310 Oslo, Norway.							ALBERTS AW, 1990, CARDIOLOGY, V77, P14, DOI 10.1159/000174688; ATKINSON DE, 1971, METABOLIC REGULATION, V5, P1; AW TY, 1989, AM J PHYSIOL, V257, pC435, DOI 10.1152/ajpcell.1989.257.3.C435; BONTEMPS F, 1983, P NATL ACAD SCI-BIOL, V80, P2829, DOI 10.1073/pnas.80.10.2829; BONTEMPS F, 1993, BIOCHEM J, V290, P671, DOI 10.1042/bj2900671; CARABAZA A, 1990, J BIOL CHEM, V265, P2724; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; GORDON PB, 1982, ARCH BIOCHEM BIOPHYS, V217, P282, DOI 10.1016/0003-9861(82)90504-5; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HELLAND S, 1982, CANCER RES, V42, P1130; HENDERSON JF, 1977, BIOCHEM PHARMACOL, V26, P1967, DOI 10.1016/0006-2952(77)90003-X; HENDERSON JF, 1972, CANCER CHEMOTH REP 2, V3, P71; HENIN N, 1995, FASEB J, V9, P541, DOI 10.1096/fasebj.9.7.7737463; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; HOLEN I, 1995, J BIOL CHEM, V270, P12823, DOI 10.1074/jbc.270.21.12823; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; Holen I, 1996, EUR J BIOCHEM, V236, P163, DOI 10.1111/j.1432-1033.1996.00163.x; Holtzman E, 1989, LYSOSOMES; HUE L, 1982, BIOCHEM J, V206, P359, DOI 10.1042/bj2060359; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; KOVACS AL, 1981, EXP CELL RES, V133, P431, DOI 10.1016/0014-4827(81)90336-0; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; MORTIMORE GE, 1990, INT J BIOCHEM, V22, P1075, DOI 10.1016/0020-711X(90)90104-B; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; PLOMP PJAM, 1987, EUR J BIOCHEM, V164, P197, DOI 10.1111/j.1432-1033.1987.tb11011.x; PLOMP PJAM, 1989, J BIOL CHEM, V264, P6699; RUSTAN AC, 1988, J BIOL CHEM, V263, P8126; SABINA RL, 1985, J BIOL CHEM, V260, P6107; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SCHELLENS JPM, 1988, EXP CELL RES, V177, P103, DOI 10.1016/0014-4827(88)90028-6; SCHWORER CM, 1979, P NATL ACAD SCI USA, V76, P3169, DOI 10.1073/pnas.76.7.3169; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Seglen PO, 1992, ENDOCYTOSIS, P247; Shevchuk I, 1996, INT J CANCER, V67, P791; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; VINCENT MF, 1992, BIOCHEM J, V281, P267, DOI 10.1042/bj2810267; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x	49	126	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23758	23763		10.1074/jbc.273.37.23758	http://dx.doi.org/10.1074/jbc.273.37.23758			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726984	hybrid			2022-12-25	WOS:000075893100025
J	Smalheiser, NR; Haslam, SM; Sutton-Smith, M; Morris, HR; Dell, A				Smalheiser, NR; Haslam, SM; Sutton-Smith, M; Morris, HR; Dell, A			Structural analysis of sequences O-linked to mannose reveals a novel Lewis X structure in cranin (Dystroglycan) purified from sheep brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ALPHA-DYSTROGLYCAN; CHONDROITIN SULFATE PROTEOGLYCAN; CENTRAL-NERVOUS-SYSTEM; EXTRACELLULAR-MATRIX; LE(X) CARBOHYDRATE; PERIPHERAL-NERVE; LAMININ; OLIGOSACCHARIDES; BINDING; CELLS	The Lewis X epitope, Gal beta 1-4(Fuc alpha 1-3)GlcNAc-R, has been implicated in cell-cell recognition events in a number of systems including the central nervous system and is expressed on diverse glycoconjugates including cell adhesion molecules, glycolipids, and the proteoglycan phosphacan, Although Lewis X sequences 3-Linked to mannose have been described within proteoglycan fractions of mammalian brain, these have not been reported in other contexts and have been widely believed to be peculiar constituents of brain proteoglycans. in the present paper, we confirm the existence of Lewis X structures O-linked to mannose within the mammalian br ain, demonstrate that these structures are present on a well defined mucin-like glycoprotein, cranin (dystroglycan), and report studies suggesting that the linkages involved may be predominantly 8-linked to mannose, Mannose-linked Lewis X is the latest in an increasing List of oligosaccharide recognition "tags" that have been shown to be expressed on cranin (dystroglycan) purified from brain.	Univ Illinois, Dept Psychiat & Anat Cell Biol, Chicago, IL 60612 USA; Univ Illinois, Inst Psychiat, Chicago, IL 60612 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Imperial College London	Smalheiser, NR (corresponding author), Univ Illinois, Dept Psychiat & Anat Cell Biol, 1601 W Taylor St, Chicago, IL 60612 USA.	smalheiser@psych.uic.edu		Smalheiser, Neil/0000-0003-1079-3406	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLENDOERFER KL, 1995, MOL CELL NEUROSCI, V6, P381, DOI 10.1006/mcne.1995.1029; Apperson ML, 1996, J NEUROSCI, V16, P6839; Belkin AM, 1996, CELL ADHES COMMUN, V4, P281, DOI 10.3109/15419069609010772; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; Brancaccio A, 1997, EUR J BIOCHEM, V246, P166, DOI 10.1111/j.1432-1033.1997.00166.x; Chiba A, 1997, J BIOL CHEM, V272, P2156; DELL A, 1994, METHOD ENZYMOL, V230, P108; DOWBENKO D, 1993, J BIOL CHEM, V268, P14399; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; EGGENS I, 1989, J BIOL CHEM, V264, P9476; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FINNE J, 1979, J BIOL CHEM, V254, P295; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gotz M, 1996, NEURON, V16, P551, DOI 10.1016/S0896-6273(00)80074-4; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KHOO KH, 1995, J BIOL CHEM, V270, P17114, DOI 10.1074/jbc.270.29.17114; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; Matsumura K, 1997, J BIOL CHEM, V272, P13904, DOI 10.1074/jbc.272.21.13904; Pall EA, 1996, J BIOL CHEM, V271, P3817; PENG HB, 1998, IN PRESS CELL ADHES; ROBERTS C, 1991, DEVELOPMENT, V112, P959; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; SMALHEISER NR, 1993, J NEUROSCI RES, V36, P528, DOI 10.1002/jnr.490360505; SMALHEISER NR, 1998, IN PRESS CELL ADHES; Streit A, 1996, J NEUROCHEM, V66, P834; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; TOLE S, 1995, J NEUROSCI, V15, P957; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Yamada H, 1996, J NEUROCHEM, V66, P1518; Yuen CT, 1997, J BIOL CHEM, V272, P8924	33	111	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23698	23703		10.1074/jbc.273.37.23698	http://dx.doi.org/10.1074/jbc.273.37.23698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726975	hybrid			2022-12-25	WOS:000075893100016
J	Ziogas, A; Lorenz, IC; Moelling, K; Radziwill, G				Ziogas, A; Lorenz, IC; Moelling, K; Radziwill, G			Mitotic Raf-1 is stimulated independently of Ras and is active in the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; CELL-CYCLE ARREST; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; AMINO-TERMINUS; IN-VIVO; C-JUN; ACTIVATION	Raf-1 is a Ser/Thr protein kinase that is involved in regulation of proliferation, differentiation, and apoptosis, Recently, we and others showed that Raf-1 is mot only activated in mitogenic pathways leading to cell cycle entry but also during mitosis, Transient expression studies in COS cells now demonstrate that, in contrast to growth factor-dependent activation of Raf-1, mitotic activation of Raf-1 is Ras-independent, Dominant negative RasS17N does not interfere with mitotic activation of Raf-1, whereas epidermal growth factor-dependent stimulation of Raf-1 is inhibited, In addition, the Raf-1 mutant RafR89L, which cannot bind to activated Ras, is still stimulated in mitotic cells, Mitotic activation of Raf-1 seems to be partially dependent on tyrosine phosphorylation since the kinase activity of the Raf mutant RafYY340/341FF, which can no longer be activated by Src, is reduced in mitotic cells. Surprisingly, cell fractionation experiments showed that mitotic-activated Raf-1 is predominantly located in the cytoplasm in contrast to the mitogen-activated Raf-1 that is hound to the plasma membrane, In addition, mitotic activation of Raf-1 does not lead to stimulation of the mitogen-activated protein kinase kinase (MAPKK or MEK) and the extracellular signal-regulated protein kinase (ERK). These data demonstrate that in mitotic cells a Ras-independent mechanism results in a cytoplasmic active Raf-1 kinase which does not signal via the MEW ERK pathway,These data demonstrate that in mitotic cells a Ras-independent mechanism results in a cytoplasmic active Raf-1 kinase which does not signal via the MEK/ERK pathway.	Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	University of Zurich	Radziwill, G (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30, CH-8028 Zurich, Switzerland.							Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JOHN J, 1988, J BIOL CHEM, V263, P11792; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lovric J, 1996, ONCOGENE, V12, P1109; MAMON H, 1991, COLD SPRING HARB SYM, V56, P251; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Pathan NI, 1996, J BIOL CHEM, V271, P30315, DOI 10.1074/jbc.271.48.30315; Popik W, 1996, MOL CELL BIOL, V16, P6532; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322	50	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24108	24114		10.1074/jbc.273.37.24108	http://dx.doi.org/10.1074/jbc.273.37.24108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727031	hybrid			2022-12-25	WOS:000075893100072
J	Soltoff, SP				Soltoff, SP			Related adhesion focal tyrosine kinase and the epidermal growth factor receptor mediate the stimulation of mitogen-activated protein kinase by the G-protein-coupled P-2Y2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MAP KINASE; EGF RECEPTOR; PC12 CELLS; PHOSPHOLIPASE-C; DEPENDENT PHOSPHORYLATION; MEMBRANE DEPOLARIZATION; SIGNAL-TRANSDUCTION; ATP; RAS	The activation of growth factor receptors and receptors coupled to heterotrimeric guanine nucleotide-binding proteins (G-proteins) can increase mitogen-activated protein (MAP) kinase activity in many cells. Previously, we demonstrated that the activation of G-protein-coupled P-2Y2 receptors by extracellular ATP and UTP stimulated MAP (p42 ERK2) kinase by a mechanism that was dependent on the elevation of [Ca2+](i) and the activation of related adhesion focal tyrosine kinase (RAFTK) (also called PYK2, CAK beta, and CADTK) and protein kinase C (PKC). Here, we examine further the signaling cascade between the P-2Y2 receptor and MAP kinase, MAP kinase was transiently activated by exposure of PC12 cells to UTP, UTP, ionomycin, and phorbol ester (phorbol 12-myristate 13-acetate) increased MAP kinase activity and also promoted the tyrosine phosphorylation of RAFTK, the epidermal growth factor (EGF) receptor, SHC, and p120(cbl). Down-regulation of PKC and inhibition of the elevation of [Ca2+](i), conditions that block the activation of MAP kinase, also blocked the increases in the tyrosine phosphorylation of RAFTK and the EGF receptor. AG1478, a tyrphostin selective for the EGF receptor, reduced the activation of MAP kinase, the tyrosine phosphorylation of SHC, the association of Grb2 with SRC, and the tyrosine phosphorylation of the EGF receptor and p120(cbl) but did not block the tyrosine phosphorylation of RAFTK. The similar effects of UTP, ionomycin, and phorbol 12-myristate 13-acetate (PMA) on these signaling proteins demonstrate that the two signaling molecules from phosphatidylinositol 4,5-bisphosphate hydrolysis ([Ca2+](i), from inositol 1,4,5-trisphosphate production, and diacylglycerol) can individually initiate the activation of MAP kinase in an EGF receptor-dependent manner. These results demonstrate that the P-2Y2 receptor-mediated transactivation of the EGF receptor occurs at a point downstream of RAFTK and indicate that the EGF receptor is required for P-2Y2 receptor-mediated MAP kinase activation. Although P-2Y2 and EGF receptors may both activate a similar multiprotein signaling cascade immediately upstream of MAP kinase, the P-2Y2 receptor appears to uniquely utilize [Ca2+](i), PKC, and, subsequently, RAFTK.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Soltoff, SP (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Signal Transduct, 330 Brookline Ave, Boston, MA 02215 USA.	ssoltoff@bidmc.harvard.edu			NIDCR NIH HHS [DE10877] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010877] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARRY VA, 1994, J CELL SCI, V107, P451; Burnstock G, 1996, CIBA F SYMP, V198, P1; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANGGUT W, 1995, FEBS LETT, V372, P173, DOI 10.1016/0014-5793(95)00971-B; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MORRISON P, 1993, J BIOL CHEM, V268, P15536; MURRIN RJA, 1992, MOL PHARMACOL, V41, P561; Neary JT, 1996, NEUROREPORT, V7, P2893, DOI 10.1097/00001756-199611250-00017; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	46	129	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23110	23117		10.1074/jbc.273.36.23110	http://dx.doi.org/10.1074/jbc.273.36.23110			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722539	hybrid			2022-12-25	WOS:000075778100039
J	Xiao, H; Jeang, KT				Xiao, H; Jeang, KT			Glutamine-rich domains activate transcription in yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; GENE-EXPRESSION; FUNCTIONAL DISSECTION; UPSTREAM ACTIVATOR; MAMMALIAN-CELLS; PHO5 PROMOTER; IN-VIVO; SP1; SEQUENCE; RECRUITMENT	Activation domains of eukaryotic transcription factors can be classified into at least three distinct types based on their amino acid composition: acidic, proline-rich, and glutamine-rich, Acidic activators, such as yeast GAL4 and GCN4 and herpes simplex virus VP16, have been shown to stimulate transcription in various higher and lower eukaryotic cells. Similarly, proline-rich activators also function in both mammalian and yeast cells. These activators are regarded to possess "universal" activating potentials. By contrast, several studies have suggested that glutamine-rich activators such as human Spl are active in higher (mammalian) but not lower (yeast) eukaryotic cells. One interpretation is that lower eukaryotic cells lack a critical cofactor necessary for a glutamine-rich domain. This reasoning is counter-intuitive because many native yeast activator proteins contain glutamine-rich domains. Here, we have investigated the activity of a glutamine-rich GAL4-Sp1 domain A (Sp1A) hybrid protein in yeast Saccharomyces cerevisiae. We show that GAL4-Sp1A activated a GAL1-lacZ reporter by more than 200-fold over basal when the reporter was carried on a 2 mu vector. The generality of the Sp1A results is supported by our finding that yeast glutamine-rich domains from HAP2 and MCM1 are also transcriptionally active in S. cerevisiae, Interestingly, we found that glutamine-rich domains are considerably less potent when responsive promoters (i.e. GAL1-lacZ) are integrated into yeast chromosome. Thus our results segregate the inherent transcriptional activity of a glutamine-rich domain in yeast S, cerevisiae from its apparent lack of activity when assayed on chromosomally embedded promoters.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Xiao, H (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	hxiao@atlas.niaid.nih.gov	Jeang, Kuan-Teh/A-2424-2008					Ausubel FM, 1994, CURRENT PROTOCOLS MO; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; Blau J, 1996, MOL CELL BIOL, V16, P2044; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KIM TK, 1993, J BIOL CHEM, V268, P20866; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; Majello B, 1998, J BIOL CHEM, V273, P16509, DOI 10.1074/jbc.273.26.16509; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NAKAO J, 1986, MOL CELL BIOL, V6, P2613, DOI 10.1128/MCB.6.7.2613; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PINKHAM JL, 1987, MOL CELL BIOL, V7, P578, DOI 10.1128/MCB.7.2.578; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUDOLPH H, 1987, P NATL ACAD SCI USA, V84, P1340, DOI 10.1073/pnas.84.5.1340; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; STRUHL K, 1981, J MOL BIOL, V152, P569, DOI 10.1016/0022-2836(81)90269-2; STRUHL K, 1982, COLD SPRING HARB SYM, V47, P901, DOI 10.1101/SQB.1983.047.01.104; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; XIAO H, 1989, NATURE HEAT SHOCK RE	45	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22873	22876		10.1074/jbc.273.36.22873	http://dx.doi.org/10.1074/jbc.273.36.22873			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722505	hybrid			2022-12-25	WOS:000075778100005
J	Muller, FU; Boknik, P; Knapp, J; Neumann, J; Vahlensieck, U; Oetjen, E; Scheld, HH; Schmitz, W				Muller, FU; Boknik, P; Knapp, J; Neumann, J; Vahlensieck, U; Oetjen, E; Scheld, HH; Schmitz, W			Identification and expression of a novel isoform of cAMP response element modulator in the human heart	FASEB JOURNAL			English	Article						cyclic AMP; transcription factor; DNA binding proteins; base sequence	TRANSCRIPTION FACTOR CREB; BINDING-PROTEIN CREB; GENE; SPERMATOGENESIS; CELLS; PHOSPHORYLATION; LOCALIZATION; INDUCIBILITY; ANTAGONIST; ACTIVATOR	In end-stage human heart failure, excessive beta-adrenergic stimulation of the cAMP-dependent signaling pathway due to enhanced endogenous catecholamines is hypothesized to contribute to expressional alterations of myocardial regulatory proteins. The cAMP response element modulator (CREM) regulates the transcription of cAMP-responsive genes and might be involved in the regulation of cardiac gem expression. Using the reverse transcription polymerase chain reaction, we identified a novel CREM mRNA, CREM-Ib Delta C-X, in the human heart. Overexpression of CREM-Ib Delta C-X decreased cAMP response element (CRE) -mediated gene transcription in HIT-T15 cells, and this activity was assigned to the part of the sequence encoding putative internally translated proteins. Two of three possible internally translated proteins were immunologically identified in cells overexpressing CREM-Ib Delta C-X tagged with the hemagglutinin epitope of the influenza virus. Both proteins were expressed in bacteria and showed CRE-specific DNA binding, formation of heterodimers with the cAMP response element binding protein (CREB), and inhibition of CREB's binding to the CRE. CREM expression was detected on the mRNA and protein levels in the human heart. We conclude that CREM-Ib Delta C-X generates internally translated repressors of CRE-mediated gem transcription, suggesting the first example for the existence and function of human cardiac CREM.-Muller, F. U., Boknik, P., Knapp, J., Neumann, J., Vahlensieck, U., Oetjen, E., Scheld, H. H., Schmitz, W. Identification and expression of a novel isoform of cAMP response element modulator in the human heart.	Univ Munster, Inst Pharmakol & Toxikol, D-48129 Munster, Germany; Univ Gottingen, Abt Mol Pharmakol, D-37070 Gottingen, Germany; Univ Munster, Klin & Poliklin Thorax Herz & Gefasschirug, D-48129 Munster, Germany	University of Munster; University of Gottingen; University of Munster	Muller, FU (corresponding author), Univ Munster, Inst Pharmakol & Toxikol, Domagkstr 12, D-48129 Munster, Germany.	mullerf@uni-muenster.de						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS J, 1992, METHOD ENZYMOL, V216, P469; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMOLLE D, 1990, MOL PHARMACOL, V37, P827; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; Girardet C, 1996, MOL ENDOCRINOL, V10, P879, DOI 10.1210/me.10.7.879; KATZ AM, 1994, ANN INTERN MED, V121, P363, DOI 10.7326/0003-4819-121-5-199409010-00009; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MASQUILIER D, 1993, CELL GROWTH DIFFER, V4, P931; MEYER TE, 1992, NUCLEIC ACIDS RES, V20, P6106, DOI 10.1093/nar/20.22.6106; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOTOMURA S, 1990, BRIT J PHARMACOL, V101, P363, DOI 10.1111/j.1476-5381.1990.tb12715.x; MULLER FU, 1995, CIRCULATION, V92, P2041, DOI 10.1161/01.CIR.92.8.2041; MULLER FU, 1993, CIRC RES, V72, P696, DOI 10.1161/01.RES.72.3.696; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Rockman HA, 1996, J CLIN INVEST, V97, P1618, DOI 10.1172/JCI118587; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; Sigmund M, 1996, EUR J CLIN PHARMACOL, V51, P127, DOI 10.1007/s002280050172; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WAEBER G, 1992, ENDOCRINOLOGY, V131, P2010, DOI 10.1210/en.131.4.2010; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423	28	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1191	1199						9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737722				2022-12-25	WOS:000075738500014
J	Yang, XL; Chernenko, G; Hao, YW; Ding, ZH; Pater, MM; Pater, A; Tang, SC				Yang, XL; Chernenko, G; Hao, YW; Ding, ZH; Pater, MM; Pater, A; Tang, SC			Human BAG-1/RAP46 protein is generated as four isoforms by alternative translation initiation and overexpressed in cancer cells	ONCOGENE			English	Article						four hBAG-1 isoforms; alternative translation initiation; subcellular localization; overexpression; cancer	BCL-2 PROTOONCOGENE EXPRESSION; SUBCELLULAR-DISTRIBUTION; CDNA CLONING; BAG-1; IDENTIFICATION; LOCALIZATION; CARCINOMA; RECEPTOR; APOPTOSIS; PRODUCTS	Previously, a Bcl-2-interacting protein, BAG-I, was cloned from mouse cells and was shown to interact with several other proteins and to be important for inhibition of apoptosis. Human BAG-1 (hBAG-1) cDNA, recently isolated by us and two other groups, has been shown to be identical to a hormone receptor-binding protein, RAP46. However, different molecular masses of hBAG-1 protein products were noted by these three groups. Here we demonstrated that hBAG-1 protein was expressed as four isoforms, designated p50, p46, p33 and p29, with apparent molecular masses of 50 kDa, 46 kDa, 33 kDa and 29 kDa, respectively. Deletion, site-directed mutagenesis and in vitro transcription/translation analysis showed that the four protein products of hBAG-1 were expressed by alternative initiation from four different start codons through a leaky scanning mechanism. Furthermore, we demonstrated that the distinct forms of hBAG-1. have different subcellular localizations, suggesting that they may have distinct functions in the cells. Characterization of hBAG-1 RNA and protein also showed that hBAG-1 was overexpressed in human cervical, breast and lung cancer cell lines. Taken together, these data clarify the conflicting observations reported in the literature and suggest that hBAG-1 is expressed as four forms of protein products, which may play a differential role in apoptosis and oncogenesis of human cells.	Mem Univ Newfoundland, Fac Med, St Johns, NF A1B 3V6, Canada; Newfoundland Canc Treatment & Res Fdn, Dr H Bliss Murphy Canc Ctr, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Tang, SC (corresponding author), Mem Univ Newfoundland, Fac Med, 300 Prince Philip Dr, St Johns, NF A1B 3V6, Canada.							AOKI M, 1993, J BIOL CHEM, V268, P22723; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; HALDAR S, 1994, CANCER RES, V54, P2095; IKEGAKI N, 1994, CANCER RES, V54, P6; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LIANG XH, 1995, J CELL BIOCHEM, V57, P509, DOI 10.1002/jcb.240570316; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; Lu QL, 1996, HUM PATHOL, V27, P102, DOI 10.1016/S0046-8177(96)90362-7; ORRENIUS S, 1995, J INTERN MED, V237, P529, DOI 10.1111/j.1365-2796.1995.tb00881.x; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Sambrook J., 2002, MOL CLONING LAB MANU; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	27	123	128	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					981	989		10.1038/sj.onc.1202032	http://dx.doi.org/10.1038/sj.onc.1202032			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747877				2022-12-25	WOS:000075560900006
J	Dessauer, CW; Tesmer, JJG; Sprang, SR; Gilman, AG				Dessauer, CW; Tesmer, JJG; Sprang, SR; Gilman, AG			Identification of a G(i alpha) binding site on type V adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP ACCUMULATION; PROTEIN ALPHA-SUBUNIT; BETA-GAMMA-SUBUNITS; CYTOSOLIC DOMAINS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; DISCRETE REGIONS; ESCHERICHIA-COLI; AMINO-TERMINUS; RAT-BRAIN	The stimulatory G protein alpha subunit G(s alpha) binds within a cleft in adenylyl cyclase formed by the alpha 1-alpha 2 and alpha 3-beta 4 loops of the C-2 domain. The pseudosymmetry of the C-1 and C-2 domains of adenylyl cyclase suggests that the homologous inhibitory alpha subunit G(i alpha) could bind to the analogous cleft within C-1. We demonstrate that myristoylated guanosine 5'-3-O-(thio)triphosphate-G(i alpha 1) forms a stable complex with the C-1 (but not the C-2) domain of type V adenylyl cyclase. Mutagenesis of the membrane-bound enzyme identified residues whose alteration either increased or substantially decreased the IC50 for inhibition by G(i alpha 1). These mutations suggest binding of G(i alpha) within the cleft formed by the alpha 2 and alpha 3 helices of C-1, analogous to the G(s alpha) binding site in C-2. Adenylyl cyclase activity reconstituted by mixture of the C-1 and C-2 domains of type V adenylyl cyclase was also inhibited by G(i alpha). The C-1b domain of the type V enzyme contributed to affinity for G(i alpha), but the source of C-2 had little effect. Mutations in this soluble system faithfully reflected the phenotypes observed with the membrane-bound enzyme. The pseudosymmetrical structure of adenylyl cyclase permits bidirectional regulation of activity by homologous G protein alpha subunits.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.		; Dessauer, Carmen/N-6933-2018	Tesmer, John/0000-0003-1125-3727; Dessauer, Carmen/0000-0003-1210-4280	NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371, R56DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antoni F A, 1998, Adv Second Messenger Phosphoprotein Res, V32, P153; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Dessauer CW, 1996, CLIN SCI, V91, P527, DOI 10.1042/cs0910527; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KATADA T, 1982, J BIOL CHEM, V257, P3739; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Summers MD, 1987, TEXAS AGR EXPT STATI; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Taussig Ronald, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P81; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WATSON PA, 1994, J BIOL CHEM, V269, P28893; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1993, J BIOL CHEM, V268, P23766; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	49	118	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25831	25839		10.1074/jbc.273.40.25831	http://dx.doi.org/10.1074/jbc.273.40.25831			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748257	hybrid			2022-12-25	WOS:000076263100048
J	Dierks, T; Miech, C; Hummerjohann, J; Schmidt, B; Kertesz, MA; von Figura, K				Dierks, T; Miech, C; Hummerjohann, J; Schmidt, B; Kertesz, MA; von Figura, K			Posttranslational formation of formylglycine in prokaryotic sulfatases by modification of either cysteine or serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; ENDOPLASMIC-RETICULUM; PROTEIN MODIFICATION; ESCHERICHIA-COLI; ARYLSULFATASE; GENE; CONVERSION; CLONING; BINDING; ATSA	Eukaryotic sulfatases carry an alpha-formylglycine residue that is essential for activity and is located within the catalytic site. This formylglycine is generated by posttranslational modification of a conserved cysteine residue. The arylsulfatase gene of Pseudomonas aeruginosa also encodes a cysteine at the critical position. This protein could be expressed in active form in a sulfatase-deficient strain of P. aeruginosa, thereby restoring growth on aromatic sulfates as sole sulfur source, and in Escherichia coli, Analysis of the mature protein expressed in E. coli revealed the presence of formylglycine at the expected position, showing that the cysteine is also converted to formylglycine in a prokaryotic sulfatase. Substituting the relevant cysteine by a serine codon in the P. aeruginosa gene led to expression of inactive sulfatase protein, lacking the formylglycine. The machinery catalyzing the modification of the Pseudomonas sulfatase in E. coli therefore resembles the eukaryotic machinery, accepting cysteine but not serine as a modification substrate, By contrast, in the arylsulfatase of Klebsiella pneumoniae a formylglycine is found generated by modification of a serine residue. The expression of both the Klebsiella and the Pseudomonas sulfatases as active enzymes in E. coli suggests that two modification systems are present, or that a common modification system is modulated by a cofactor.	Univ Gottingen, Inst Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; ETH Zentrum, Inst Microbiol, CH-8092 Zurich, Switzerland	University of Gottingen; Swiss Federal Institutes of Technology Domain; ETH Zurich	Dierks, T (corresponding author), Univ Gottingen, Inst Biochem & Mol Zellbiol, Biochem Abt 2, Gosslerstr 12D, D-37073 Gottingen, Germany.	dierks@ukb2-00.uni-bc.gwdg.de	Kertesz, Michael/A-6720-2011; Dierks, Thomas/A-3596-2012; KERTESZ, Michael/Q-7642-2019	Kertesz, Michael/0000-0003-2112-4451; Dierks, Thomas/0000-0001-6426-1339; KERTESZ, Michael/0000-0003-2112-4451				BEIL S, 1995, EUR J BIOCHEM, V229, P385, DOI 10.1111/j.1432-1033.1995.0385k.x; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; Dodgson K.S., 1982, SULFATASES MICROBIAL; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; HOLLOWAY BW, 1955, J GEN MICROBIOL, V13, P572, DOI 10.1099/00221287-13-3-572; HORN JM, 1988, J BACTERIOL, V170, P1637, DOI 10.1128/jb.170.4.1637-1650.1988; Hummerjohann J, 1998, MICROBIOL-SGM, V144, P1375, DOI 10.1099/00221287-144-5-1375; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Recksiek R, 1998, J BIOL CHEM, V273, P6096, DOI 10.1074/jbc.273.11.6096; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K	24	93	101	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25560	25564		10.1074/jbc.273.40.25560	http://dx.doi.org/10.1074/jbc.273.40.25560			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748219	hybrid			2022-12-25	WOS:000076263100010
J	Gutknecht, R; Manni, M; Mao, QC; Erni, B				Gutknecht, R; Manni, M; Mao, QC; Erni, B			The glucose transporter of Escherichia coli with circularly permuted domains is active in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; DEHYDROGENASE MULTIENZYME COMPLEX; FUNCTIONAL RECONSTITUTION; N-ACETYLGLUCOSAMINE; PROTEIN; PHOSPHOENOLPYRUVATE; PURIFICATION; GENE; PHOSPHORYLATION; CONSTRUCTION	The bacterial phosphotranaferase system (PTS) consists of two energy-coupling soluble proteins (enzyme I and HPr) and a large number of inner membrane transporters (enzymes II) that mediate concomitant phosphorylation and translocation of sugars and hexitols, The transporters consist of three functional units (IIA, IIB, IIC), which occur either as protein subunits or domains of a multidomain polypeptide, The membrane-spanning HC domain contains the substrate binding site; IIA and IIB are phosphorylation domains that transfer phosphate from HPr to the transported sugar. The transporter complexes of the PTS are good examples for variation of design by modular assembly of domains and subunits. The domain order is IIC-IIB in the membrane subunit of the Escherichia coli glucose transporter (IICBGlc) and IIB-IIC in Salmonella typhimurium sucrose transporter (IIBCSer). The phosphorylation domain of IICBGlc was translocated from the carboxyl-terminal to the amino-terminal end of the IIC domain, and the activity of the circularly permuted form was optimized by variation of the length and the composition of the interdomain linker. IIBapC(Glc) with an alanine-proline-rich interdomain linker has 70% of the control specific activity after purification and reconstitution into proteoliposomes. These results indicate that the aminoterminal end of IICBGlc must be on the cytoplasmic side of the inner membrane, that membrane insertion of the IIC domain is insensitive to the modification of its amino-terminal end, and that a domain swap as it could occur by a single DNA translocation event can rapidly lead to a functional protein, However, IIB could not be substituted for by glucokinase. Fusion proteins between the IIC domain and glucokinase do not transport and phosphorylate glucose in an ATP dependent mechanism, although the IIC moiety displays transport activity upon complementation with soluble subclonal IIB, and the glucokinase moiety retains ATP-dependent non-vectorial kinase activity. This indicates that IIC and IIB are two cooperative units and not only sequentially acting upon a common substrate, and that translocation of glucose must be conformationally coupled to the phosphorylation/dephosphorylation cycle of IIB.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern	Erni, B (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	erni@ibc.unibe.ch						BUHR A, 1993, J BIOL CHEM, V268, P11599; BUHR A, 1994, J BIOL CHEM, V269, P23437; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Eberstadt M, 1996, BIOCHEMISTRY-US, V35, P11286, DOI 10.1021/bi960492l; EBNER R, 1988, MOL MICROBIOL, V2, P9, DOI 10.1111/j.1365-2958.1988.tb00002.x; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1982, J BIOL CHEM, V257, P13726; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; GREEN JDF, 1992, J BIOL CHEM, V267, P23484; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; HUMMEL U, 1992, PROTEIN SCI, V1, P356; KUNDIG W, 1971, J BIOL CHEM, V246, P1393; Lanz R, 1998, J BIOL CHEM, V273, P12239, DOI 10.1074/jbc.273.20.12239; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; MAO QC, 1995, J BIOL CHEM, V270, P18295, DOI 10.1074/jbc.270.31.18295; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1993, J BIOL CHEM, V268, P11604; Meyer D, 1997, J BACTERIOL, V179, P1298, DOI 10.1128/jb.179.4.1298-1306.1997; Mukhija S, 1996, J BIOL CHEM, V271, P14819, DOI 10.1074/jbc.271.25.14819; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Ramirez BE, 1995, P NATL ACAD SCI USA, V92, P11949, DOI 10.1073/pnas.92.26.11949; REIZER A, 1991, J MOL EVOL, V33, P179, DOI 10.1007/BF02193633; REIZER J, 1994, PROTEIN SCI, V3, P440; Reizer J, 1996, RES MICROBIOL, V147, P458, DOI 10.1016/0923-2508(96)84000-9; REIZER J, 1996, MICROB COMP GENOMICS, V1, P53; ROBIEN MA, 1992, BIOCHEMISTRY-US, V31, P3463, DOI 10.1021/bi00128a021; Saier M H Jr, 1996, Microb Comp Genomics, V1, P129; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6	39	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25745	25750		10.1074/jbc.273.40.25745	http://dx.doi.org/10.1074/jbc.273.40.25745			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748244	hybrid			2022-12-25	WOS:000076263100035
J	Koudssi, F; Lopez, JE; Villegas, S; Long, CS				Koudssi, F; Lopez, JE; Villegas, S; Long, CS			Cardiac fibroblasts arrest at the G1/S restriction point in response to interleukin (IL)-1 beta - Evidence for IL-1 beta-induced hypophosphorylation of the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLLAGEN GENE-EXPRESSION; GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITOR; MESSENGER-RNA EXPRESSION; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; ANGIOTENSIN-II; IN-VITRO	Although responsible for only approximately one-third of the overall myocardial mass, the interstitial fibroblasts of the heart serve a fundamental role in establishing the functional integrity of myocardium and are the major source of myocardial extracellular matrix production. Their importance in clinical medicine is underscored by the observation that fibroblast numbers increase in response to several pathologic circumstances that are associated with an increase in extracellular matrix production such as long standing hypertension and myocardial injury/infarction. Up to the present time, however, there has been little information available on either the kinetics of the cardiac fibroblast cell cycle, or the fundamental mechanisms that regulate its entry into and exit from the cell cycle. Previous work from our laboratory examining the effects of interleukin (IL)-1 beta on myocardial growth and gene expression in culture indicated that cardiac fibroblasts have a diminished capacity to synthesize DNA in response to mitogen in the presence of this cytokine. The mechanism of IL-1 beta action was not clear, however, and could have resulted from action at several different points in the cell cycle, The investigations described in this report indicate that IL-1 beta exerts its effect on the fibroblast cell cycle at multiple levels through altering the expression of cardiac fibroblast cyclins, cyclin-dependent kinases, and their inhibitors, which ultimately affect the phosphorylation of the retinoblastoma gene product.	Vet Affairs Med Ctr, Div Cardiol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Res Serv, San Francisco, CA 94121 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Long, CS (corresponding author), Denver Hlth Med Ctr, Cardiol Sect, Box 0960,777 Bannock St, Denver, CO 80204 USA.	clong@dhha.org		Long, Carlin/0000-0001-7251-2847	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059428, R01HL058974] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59428, HL58974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BHAMBI B, 1991, AM J PATHOL, V139, P1131; Bick RJ, 1997, AM J PHYSIOL-HEART C, V272, pH1937, DOI 10.1152/ajpheart.1997.272.4.H1937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILLA CG, 1993, EUR HEART J, V14, P57; BUTT RP, 1995, ANN NY ACAD SCI, V752, P387, DOI 10.1111/j.1749-6632.1995.tb17446.x; CAMPBELL SE, 1995, J MOL CELL CARDIOL, V27, P1545, DOI 10.1016/S0022-2828(95)90359-3; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CARROLL EP, 1989, CARDIOVASC RES, V23, P655, DOI 10.1093/cvr/23.8.655; CASTRO A, 1994, BIOCHEM BIOPH RES CO, V201, P1072, DOI 10.1006/bbrc.1994.1814; Chandrasekar B, 1996, BIOCHEM BIOPH RES CO, V223, P365, DOI 10.1006/bbrc.1996.0900; CHAPMAN D, 1990, CIRC RES, V67, P787, DOI 10.1161/01.RES.67.4.787; CLEUTJENS JPM, 1995, J MOL CELL CARDIOL, V27, P1281, DOI 10.1016/S0022-2828(05)82390-9; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CONTARD F, 1991, LAB INVEST, V64, P65; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; Dostal DE, 1996, MOL CELL BIOCHEM, V157, P15; EGHBALI M, 1992, BASIC RES CARDIOL, V87, P183; EGHBALI M, 1991, CIRC RES, V69, P483, DOI 10.1161/01.RES.69.2.483; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FLANDERS KC, 1993, J CLIN INVEST, V92, P404, DOI 10.1172/JCI116581; Frimm CD, 1996, J MOL CELL CARDIOL, V28, P1279; Galea J, 1996, ARTERIOSCL THROM VAS, V16, P1000, DOI 10.1161/01.ATV.16.8.1000; GRANA X, 1995, ONCOGENE, V11, P211; GUARDA E, 1993, CARDIOVASC RES, V27, P2130, DOI 10.1093/cvr/27.12.2130; HARDING P, 1995, HYPERTENSION, V25, P421, DOI 10.1161/01.HYP.25.3.421; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; HOSENPUD JD, 1989, J HEART TRANSPLANT, V8, P460; HSUEH WA, 1995, ADV EXP MED BIOL, V377, P217; ISGAARD J, 1994, HYPERTENSION, V23, P884, DOI 10.1161/01.HYP.23.6.884; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Kacimi R, 1997, CIRCULATION, V96, P1937, DOI 10.1161/01.CIR.96.6.1937; KATSUURA G, 1989, ENDOCRINOLOGY, V124, P3125, DOI 10.1210/endo-124-6-3125; KATWA LC, 1993, CARDIOVASC RES, V27, P2125, DOI 10.1093/cvr/27.12.2125; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; Lagoo AS, 1996, J HEART LUNG TRANSPL, V15, P206; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAULEDERKIND SJF, 1995, J EXP MED, V182, P599, DOI 10.1084/jem.182.2.599; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; LONG CS, 1993, CLIN RES, V41, pA145; Long CS, 1996, TRENDS CARDIOVAS MED, V6, P217, DOI 10.1016/S1050-1738(96)00090-4; MARCZIN N, 1993, AM J PHYSIOL, V265, pH1014, DOI 10.1152/ajpheart.1993.265.3.H1014; Masamune A, 1996, J BIOL CHEM, V271, P9368, DOI 10.1074/jbc.271.16.9368; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Morgan DO, 1992, CURR OPIN GENET DEV, V2, P33, DOI 10.1016/S0959-437X(05)80318-1; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694; PALMER JN, 1995, J CLIN INVEST, V95, P2555, DOI 10.1172/JCI117956; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Patten M, 1996, J BIOL CHEM, V271, P21134, DOI 10.1074/jbc.271.35.21134; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1995, MOL CELL BIOL, V15, P742; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAKLATVALA J, 1995, BRIT MED BULL, V51, P402, DOI 10.1093/oxfordjournals.bmb.a072969; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SARZANI R, 1991, HYPERTENSION, V17, P888, DOI 10.1161/01.HYP.17.6.888; Schreur KD, 1997, AM J PHYSIOL-HEART C, V272, pH2591, DOI 10.1152/ajpheart.1997.272.6.H2591; SEN S, 1990, J BIOL CHEM, V265, P16635; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shioi T, 1997, CIRC RES, V81, P664; SHIOI T, 1996, CIRCULATION, V94, P658; TAKAHASHI N, 1994, J CLIN INVEST, V94, P1470, DOI 10.1172/JCI117485; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; Thompson NL, 1988, GROWTH FACTORS, V1, P91, DOI 10.3109/08977198809000251; TSUJINO M, 1994, CIRCULATION, V90, P375, DOI 10.1161/01.CIR.90.1.375; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; WAHLANDER H, 1992, HYPERTENSION, V19, P25, DOI 10.1161/01.HYP.19.1.25; WEBER KT, 1995, EUR HEART J, V16, P24, DOI 10.1093/eurheartj/16.suppl_C.24; Weber KT, 1995, EUR HEART J, V16, P12, DOI 10.1093/eurheartj/16.suppl_N.12; WEBER KT, 1989, J AM COLL CARDIOL, V13, P1637, DOI 10.1016/0735-1097(89)90360-4; Weber KT, 1996, CLIN CARDIOL, V19, P447, DOI 10.1002/clc.4960190602; YAO JL, 1992, CIRC RES, V71, P831, DOI 10.1161/01.RES.71.4.831; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250	99	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25796	25803		10.1074/jbc.273.40.25796	http://dx.doi.org/10.1074/jbc.273.40.25796			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748252	hybrid			2022-12-25	WOS:000076263100043
J	McKenzie, D; Bartz, J; Mirwald, J; Olander, D; Marsh, R; Aiken, J				McKenzie, D; Bartz, J; Mirwald, J; Olander, D; Marsh, R; Aiken, J			Reversibility of scrapie inactivation is enhanced by copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-RESISTANT STATE; AVIAN PRION PROTEIN; ALZHEIMERS-DISEASE; IN-VIVO; INFECTIVITY; CONVERSION; AGENT; PEPTIDES; EXPOSURE; REGIONS	The only known difference between the cellular (PrPC) and scrapie-specific (PrPSc) isoforms of the prion protein is conformational. Because disruption of PrPSc structure decreases scrapie infectivity, restoration of the disease-specific conformation should restore infectivity. In this study, disruption of PrPSc (as monitored by the loss of proteinase K resistance) by guanidine hydrochloride (GdnHCl) resulted in decreased infectivity. Upon dilution of the GdnHCl, protease resistance of PrP was restored and infectivity was regained. The addition of copper facilitated restoration of both infectivity and protease resistance of PrP in a subset of samples that did not renature by the simple dilution of the GdnHCl, These data demonstrate that loss of scrapie infectivity can be a reversible process and that copper can enhance this restoration of proteinase K resistance and infectivity.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53517 USA	University of Wisconsin System; University of Wisconsin Madison	McKenzie, D (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1655 Linden Dr, Madison, WI 53517 USA.		McKenzie, Debbie/G-4459-2015	McKenzie, Debbie/0000-0002-9291-6977; Bartz, Jason/0000-0003-4081-7886; Aiken, Judd/0000-0001-6119-4521				ANDRASI E, 1995, ARCH GERONTOL GERIAT, V21, P89, DOI 10.1016/0167-4943(95)00643-Y; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DICKINSO.AG, 1969, NATURE, V222, P892, DOI 10.1038/222892a0; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; MARSH RF, 1978, FED PROC, V37, P2076; MCKENZIE D, 1994, J VIROL, V68, P7534, DOI 10.1128/JVI.68.11.7534-7536.1994; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SAS INSTITUTE INC., 1989, SAS STAT US GUID VER, V2; SAS&REG; Procedures, 1990, VERSION 6; SHIN RW, 1994, J NEUROSCI, V14, P7221; Taylor DM, 1996, J GEN VIROL, V77, P811, DOI 10.1099/0022-1317-77-4-811; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0	31	117	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25545	25547		10.1074/jbc.273.40.25545	http://dx.doi.org/10.1074/jbc.273.40.25545			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748215	hybrid			2022-12-25	WOS:000076263100006
J	Zhang, BL; Zheng, Y				Zhang, BL; Zheng, Y			Negative regulation of rho family GTPases Cdc42 and Rac2 by homodimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; TRANSITION-STATE ANALOG; ACTIVATING PROTEINS; BINDING PROTEINS; MAST-CELLS; DROSOPHILA; COMPLEX; ORGANIZATION; ENDOCYTOSIS; OUTGROWTH	The Rho family GTPases are tightly regulated between the active GTP-bound state and the inactive GDP-bound state in a variety of signal transduction processes. Here the Rho family members Cdc42, Rac2, and RhoA were found to form reversible homodimers in both the GTP- and the GDP-bound states. The homophilic interaction of Cdc42 and Rac2, but not RhoA, in the GTP-bound state, caused a significant stimulation of the intrinsic GTPase activity, i.e. the activated form of Cdc42 and Rac2 acts as GTPase-activating proteins toward Cdc42-GTP or Rac2-GTP. The dimerization of the GTPases appeared to be mediated by the carboxyl-terminal polybasic domain, and the specific GTPase-activating effects of Cdc42 and Rac2 were also attributed to the structural determinant(s) in the same region of the molecules. Moreover, similar to the case of Cdc42 and Cdc42GAP interaction, Cdc42-GDP interacted with tetrafluoroaluminate and Cdc42-GTP gamma S (guanosine 5'-3-O-(thio)triphosphate) to form a transition state complex of the GTPase-activating reaction in which the carboxylterminal determinant(s) of the GTP gamma S-bound Cdc42 plays a critical role. These results provide a rationale for the fast rate of intrinsic GTP hydrolysis by Cdc42 and Rac and suggest that dimerization may play a role in the negative regulation of specific Rho family GTPases mediated by the carboxyl-terminal polybasic domain.	Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Zheng, Y (corresponding author), Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA.	yzheng@utmem1.utmem.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53943] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Davis CR, 1998, J BIOL CHEM, V273, P849, DOI 10.1074/jbc.273.2.849; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hoffman GR, 1998, J BIOL CHEM, V273, P4392, DOI 10.1074/jbc.273.8.4392; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Noel JP, 1997, NAT STRUCT BIOL, V4, P677, DOI 10.1038/nsb0997-677; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; PASTERIS NG, 1994, CELL, V79, P669; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Sprang SR, 1997, SCIENCE, V277, P329, DOI 10.1126/science.277.5324.329; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; Zhang BL, 1998, BIOCHEMISTRY-US, V37, P5249, DOI 10.1021/bi9718447; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	42	58	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25728	25733		10.1074/jbc.273.40.25728	http://dx.doi.org/10.1074/jbc.273.40.25728			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748241	hybrid			2022-12-25	WOS:000076263100032
J	Shimokata, K; Kitada, S; Ogishima, T; Ito, A				Shimokata, K; Kitada, S; Ogishima, T; Ito, A			Role of alpha-subunit of mitochondrial processing peptidase in substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-ORNITHINE TRANSCARBAMYLASE; RAT-LIVER; MALATE-DEHYDROGENASE; YEAST MITOCHONDRIA; BETA-SUBUNIT; PROTEOLYTIC CLEAVAGE; PRECURSOR PROTEINS; ARGININE RESIDUES; EXTENSION PEPTIDE; SYNTHETIC PEPTIDE	Mitochondrial processing peptidase is a heterodimer consisting of alpha-mitochondrial processing peptidase (alpha-MPP) and beta-MPP. We investigated the role of alpha-MPP in substrate recognition using a recombinant yeast MPP. Disruption of amino acid residues between 10 and 129 of the alpha-MPP did not essentially impair binding activity with beta-MPP and processing activity, whereas truncation of the C-terminal 41 amino acids led to a significant loss of binding and processing activity. Several acidic amino acids in the region conserved among the enzymes hom various species were mutated to asparagine or glutamine, and effects on processing of the precursors were analyzed. Glu(353) is required for processing of malate dehydrogenase, aspartate aminotransferase, and adrenodoxin precursors. Glu(377) and Asp(378) are needed only for the processing of aspartate aminotransferase and adrenodoxin precursors, both of which have a longer extension peptide than the others studied. However, processing of the yeast alpha-MPP precursor, which has a short extension peptide of nine amino acids, was not affected by these mutations. Thus, effects of substitution of acidic amino acids on the processing differed with the precursor protein and depended on length of the extension peptides. alpha-MPP may function as a substrate-recognizing subunit by interacting mainly with basic amino acids at a region distal to the cleavage site in precursors with a longer extension peptide.	Kyushu Univ, Fac Sci, Dept Chem, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Higashi Ku, Fukuoka 8128581, Japan.	a.itoscc@mbox.nc.kyushu-u.ac.jp						ARRETZ M, 1994, J BIOL CHEM, V269, P4959; ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P4; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; CHU TW, 1987, J BIOL CHEM, V262, P12806; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P7; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1985, P NATL ACAD SCI USA, V82, P4930, DOI 10.1073/pnas.82.15.4930; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; JOH T, 1987, BIOCHEMISTRY-US, V26, P2515, DOI 10.1021/bi00383a017; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; KITADA S, 1993, BIOCHEM BIOPH RES CO, V190, P289, DOI 10.1006/bbrc.1993.1044; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KUMAMOTO T, 1989, J BIOCHEM-TOKYO, V105, P72, DOI 10.1093/oxfordjournals.jbchem.a122622; Luciano P, 1997, J MOL BIOL, V272, P213, DOI 10.1006/jmbi.1997.1231; MCADA PC, 1982, J BIOL CHEM, V257, P3177; MORI M, 1980, P NATL ACAD SCI-BIOL, V77, P7044, DOI 10.1073/pnas.77.12.7044; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; OU WJ, 1994, J BIOL CHEM, V269, P24673; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PALMISANO A, 1995, INT J BIOCHEM CELL B, V27, P507, DOI 10.1016/1357-2725(95)00013-F; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; Shimokata K, 1997, J BIOCHEM-TOKYO, V122, P1019; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	40	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25158	25163		10.1074/jbc.273.39.25158	http://dx.doi.org/10.1074/jbc.273.39.25158			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737975	hybrid			2022-12-25	WOS:000076085400025
J	Bertram, JG; Bloom, LB; Turner, J; O'Donnell, M; Beechem, JM; Goodman, MF				Bertram, JG; Bloom, LB; Turner, J; O'Donnell, M; Beechem, JM; Goodman, MF			Pre-steady state analysis of the assembly of wild type and mutant circular clamps of Escherichia coli DNA polymerase III onto DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEINS; FLUORESCENCE ANISOTROPY; REPLICATION MACHINE; INITIATION COMPLEX; ATP ACTIVATION; HOLOENZYME; SUBUNIT; IDENTIFICATION; PURIFICATION; MECHANISM	The beta protein, a dimeric ring-shaped clamp essential for processive DNA replication by Escherichia coli DNA polymerase III holoenzyme, is assembled onto DNA by the gamma complex. This study examines the clamp loading pathway in real time, using pre-steady state fluorescent depolarization measurements to investigate the loading reaction and ATP requirements for the assembly of beta onto DNA. Two beta dimer interface mutants, L273A and L108A, and a nonhydrolyzable ATP analog, adenosine 5'-O-(3-thiotriphosphate) (ATP gamma S), have been used to show that ATP binding is required for gamma complex and beta to associate with DNA, but that a gamma complex-catalyzed ATP hydrolysis is required for gamma complex to release the beta DNA complex and complete the reaction. In the presence of ATP and gamma complex, the beta mutants associate with DNA as efficiently as wild type beta. However, completion of the reaction is much slower with the beta mutants because of decreased ATP hydrolysis by the gamma complex, resulting in a much slower release of the mutants onto DNA. The effects of mutations in the dimer interface were similar to the effects of replacing ATP with ATP gamma S in reactions using wild type beta. Thus, the assembly of beta around DNA is coupled tightly to the ATPase activity of the gamma complex, and completion of the assembly process requires ATP hydrolysis for turnover of the catalytic clamp loader.	Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Southern California; Arizona State University; Arizona State University-Tempe; Rockefeller University; Howard Hughes Medical Institute; Vanderbilt University	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA.		Bloom, Linda B/F-3684-2014		NIGMS NIH HHS [GM38839, GM21422, GM42554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM021422, R01GM021422, R37GM038839, R01GM042554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; XIAO H, 1993, J BIOL CHEM, V268, P11773	27	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24564	24574		10.1074/jbc.273.38.24564	http://dx.doi.org/10.1074/jbc.273.38.24564			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733751	hybrid			2022-12-25	WOS:000076007300043
J	Cheng, ZJ; Yu, QM; Wu, YL; Ma, L; Pei, G				Cheng, ZJ; Yu, QM; Wu, YL; Ma, L; Pei, G			Selective interference of beta-arrestin 1 with kappa and delta but not mu opioid receptor G protein coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; KINASE-C; HOMOLOGOUS DESENSITIZATION; BETA(2)-ADRENERGIC RECEPTOR; SYNERGISTIC REGULATION; CARBOXYL-TERMINUS; XENOPUS OOCYTES; PHOSPHORYLATION; INVOLVEMENT; MORPHINE	The role of beta-arrestin 1 (beta-arr1) in regulation of responsiveness of kappa, delta, and mu opioid receptors has been investigated in human embryonic kidney 293 cells cotransfected with opioid receptor and beta-arr1. Expression of human beta-arr1 attenuated kappa and delta opioid receptor subtype-mediated inhibition of cAMP production and resulted in a 100-fold increase of EC50 values for kappa-agonist U69593 and delta-agonist [D-Pen(2),D-Pen(5)]enkephalin and 30-40% reduction of their maximal responses. In contrast, coexpression of beta-arr1 with mu opioid receptor did not affect the concentration-effect relationship of mu-agonist [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]enkephalin. In parallel, kappa and delta receptor-mediated G protein activation was also remarkably attenuated by overexpression of beta-arr1, while the mu-agonist-stimulated response remained intact. These results indicate that beta-arr1 interferes receptor/G protein coupling and differentially regulates the responsiveness of opioid receptors, Truncation of kappa and delta opioid receptors at carboxyl termini abolished inhibition of beta-arr1 on the responsiveness of both receptors. Furthermore, mu opioid receptor became sensitive to beta-arr1 regulation following replacement of its carboxyl terminus with the corresponding portion of the delta receptor, Removal of potential phosphorylation sites on the carboxyl terminus of kappa opioid receptor led to reduced effect of beta-arr1 on the receptor-mediated response, These results suggest that receptor carboxyl terminus and its phosphorylation play an important role in the interaction of beta-arr1 and opioid receptors.	Chinese Acad Sci, Shanghai Inst Cell Biol, Shanghai 200031, Peoples R China; Shanghai Med Univ, Natl Lab Med Neurobiol, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Ma, L (corresponding author), Chinese Acad Sci, Shanghai Inst Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	gangpei@sunm.shcnc.ac.cn	Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472				Appleyard SM, 1997, J NEUROCHEM, V69, P2405; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Cai YC, 1996, BIOCHEM BIOPH RES CO, V219, P342, DOI 10.1006/bbrc.1996.0235; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; CHEN Y, 1994, J BIOL CHEM, V269, P7839; Cheng ZJ, 1997, NEUROREPORT, V8, P1913, DOI 10.1097/00001756-199705260-00024; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Diviani D, 1996, J BIOL CHEM, V271, P5049; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; FUKUSHIMA N, 1994, NEUROSCI LETT, V176, P55, DOI 10.1016/0304-3940(94)90870-2; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Noble F, 1996, BRIT J PHARMACOL, V117, P161, DOI 10.1111/j.1476-5381.1996.tb15169.x; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; Schulz S, 1998, NEUROSCIENCE, V82, P613; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; Sim LJ, 1996, NEUROREPORT, V7, P729, DOI 10.1097/00001756-199602290-00012; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; UEDA H, 1995, J NEUROSCI, V15, P7485; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242; Zhu X, 1997, BIOCHEM BIOPH RES CO, V232, P513, DOI 10.1006/bbrc.1997.6324	43	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24328	24333		10.1074/jbc.273.38.24328	http://dx.doi.org/10.1074/jbc.273.38.24328			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733719	hybrid			2022-12-25	WOS:000076007300011
J	Gratacap, MP; Payrastre, B; Viala, C; Mauco, G; Plantavid, M; Chap, H				Gratacap, MP; Payrastre, B; Viala, C; Mauco, G; Plantavid, M; Chap, H			Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C-gamma 2 is an early key event in Fc gamma RIIA-mediated activation of human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEINS; HUMAN BLOOD-PLATELETS; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; CROSS-LINKING; C ISOZYMES; RECEPTOR; KINASE; THROMBIN; TRANSLOCATION	Platelets express a single class of Fc gamma receptor (Fc gamma RIIA), which is involved in heparin-associated thrombocytopenia and possibly in inflammation. Fc gamma RIIA cross-linking induces platelet secretion and aggregation, together with a number of cellular events such as tyrosine phosphorylation, activation of phospholipase C-gamma 2 (PLC-gamma 2), and calcium signaling. Here, we show that in response to Fc gamma RIIA cross-linking, phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P-3) is rapidly produced, whereas phosphatidylinositol (3,4)bisphosphate accumulates more slowly, demonstrating a marked activation of phosphoinositide 3-kinase (PI 3-kinase). Inhibition of PI 3-kinase by wortmannin or LY294002 abolished platelet secretion and aggregation, as well as phospholipase C (PLC) activation, indicating a role of this lipid kinase in the early phase of platelet activation. Inhibition of PLC gamma 2 was not related to its tyrosine phosphorylation state, since wortmannin actually suppressed its dephosphorylation, which requires platelet aggregation and integrin alpha(IIb)/beta(3) engagement. In contrast, the stable association of PLC gamma 2 to the membrane/cytoskeleton interface observed at early stage of platelet activation was fully abolished upon inhibition of PI 3-kinase. In addition, PLC gamma 2 was able to preferentially interact in vitro with PtdIns(3,4,5)P-3. Finally, exogenous PtdIns(3,4,5)P-3 restored PLC activation in permeabilized platelets treated with wortmannin. We propose that PI 3-kinase and its product PtdIns(3,4,5)P-3 play a key role in the activation and adequate location of PLC gamma 2 induced by Fc gamma RIIA cross-linking.	Hop Purpan, Ctr Hosp Univ Toulouse, INSERM, U326, F-31059 Toulouse, France; Univ Toulouse 3, Inst Federat Rech Immunol Cellulaire & Mol, F-31059 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Payrastre, B (corresponding author), Hop Purpan, Ctr Hosp Univ Toulouse, INSERM, U326, F-31059 Toulouse, France.		Mauco, Gerard/A-3164-2016	Mauco, Gerard/0000-0003-2998-2397; , Bernard/0000-0002-8693-0190; Gratacap, Marie-Pierre/0000-0003-4362-6401				Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; ANDERSON CL, 1995, SEMIN THROMB HEMOST, V21, P1, DOI 10.1055/s-2007-1000374; ANDERSON GP, 1990, BLOOD, V76, P1165; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; Banno Y, 1996, J BIOL CHEM, V271, P14989, DOI 10.1074/jbc.271.25.14989; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; BLAKE RA, 1994, FEBS LETT, V342, P15, DOI 10.1016/0014-5793(94)80575-X; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRISTOL JA, 1994, TRENDS ENDOCRIN MET, V5, P402, DOI 10.1016/1043-2760(95)92522-K; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; CAZENAVE JP, 1983, ANN BIOL CLIN-PARIS, V41, P167; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COHEN P, 1971, J CLIN INVEST, V50, P762, DOI 10.1172/JCI106547; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; HOLMSEN H, 1970, J LAB CLIN MED, V75, P840; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUANG R, 1991, J BIOL CHEM, V266, P1652; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; LI RY, 1995, EMBO J, V14, P219; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Matsuo T, 1996, BIOCHEM J, V315, P505, DOI 10.1042/bj3150505; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; Polgar J, 1998, BLOOD, V91, P549, DOI 10.1182/blood.V91.2.549.549_549_554; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vossebeld PJM, 1997, BIOCHEM J, V323, P87, DOI 10.1042/bj3230087; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; YANO H, 1993, J BIOL CHEM, V268, P25846; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	63	148	150	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24314	24321		10.1074/jbc.273.38.24314	http://dx.doi.org/10.1074/jbc.273.38.24314			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733717	hybrid			2022-12-25	WOS:000076007300009
J	Ishisaki, A; Yamato, K; Nakao, A; Nonaka, K; Ohguchi, M; ten Dijke, P; Nishihara, T				Ishisaki, A; Yamato, K; Nakao, A; Nonaka, K; Ohguchi, M; ten Dijke, P; Nishihara, T			Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SERINE KINASE; TGF-BETA RECEPTOR; CYCLE CONTROL; I RECEPTORS; EXPRESSION; INDUCTION; PROTEINS; CLONING; IDENTIFICATION; ANTAGONIST	Members of the transforming growth factor-p (TGF-P) family, which includes the activins, relay signals from serine/threonine kinase receptors in membrane to nucleus via intracellular Sma- and Mad-related (Smad) proteins. Inhibitory Smad proteins were found to prevent the interaction between the serine/threonine kinase receptors and pathway-restricted Smad proteins. Smad7 was identified as a TGF-beta-inducible antagonist of TGF-beta signaling, and it may participate in a negative feedback loop to control TGF-beta signaling. Here we demonstrate that the mRNA expression of Smad7 is induced by activin A in mouse B cell hybridoma HS-72 cells, which undergo growth arrest and apoptosis upon exposure to activin A. The ectopic expression of mouse Smad7 in HS-72 cells suppressed the activin A-induced cell cycle arrest in the G(1) phase by abolishing the activin A-induced expression of p21(CIP1/WAF1) and hypophosphorylation of retinoblastoma protein. Furthermore, Smad7 expression suppressed activin A-induced apoptosis in HS-72 cells. Thus, our data indicate that Smad7 is an activin A-inducible antagonist of activin A-induced growth arrest and apoptosis of B lineage cells.	Natl Inst Infect Dis, Dept Oral Sci, Shinjuku Ku, Tokyo 1628640, Japan; Tokyo Med & Dent Univ, Fac Dent, Dept Mol Cellular Oncol Microbiol, Bunkyo Ku, Tokyo 1138549, Japan; Chiba Univ, Sch Med, Dept Med, Chuo Ku, Chiba 2600856, Japan; Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU); Chiba University; Ludwig Institute for Cancer Research	Nishihara, T (corresponding author), Natl Inst Infect Dis, Dept Oral Sci, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ishisaki, Akira/0000-0001-6704-4436				Akifusa S, 1998, EXP CELL RES, V238, P82, DOI 10.1006/excr.1997.3848; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; GONZALEZMANCHON C, 1989, ENDOCRINOLOGY, V125, P1666, DOI 10.1210/endo-125-3-1666; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HASHIMOTO O, 1998, IN PRESS CELL SIGNAL; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KOJIMA I, 1989, BIOCHEM BIOPH RES CO, V159, P1107, DOI 10.1016/0006-291X(89)92223-7; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LMACCARTHY S, 1993, J BIOL CHEM, V268, P23066; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOORE KJ, 1994, J IMMUNOL, V152, P2930; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NISHIHARA T, 1995, BIOCHEM BIOPH RES CO, V212, P255, DOI 10.1006/bbrc.1995.1964; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; NISHIHARA T, 1995, J INTERF CYTOK RES, V15, P509, DOI 10.1089/jir.1995.15.509; PERANDONES CE, 1993, J IMMUNOL, V151, P3521; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SPENCER SJ, 1990, J CLIN ENDOCR METAB, V71, P1678, DOI 10.1210/jcem-71-6-1678; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VALE W, 1986, NATURE, V321, P732; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Yamato K, 1997, MOL ENDOCRINOL, V11, P1044, DOI 10.1210/me.11.8.1044	43	111	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24293	24296		10.1074/jbc.273.38.24293	http://dx.doi.org/10.1074/jbc.273.38.24293			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733712	hybrid			2022-12-25	WOS:000076007300004
J	Kiyokawa, E; Hashimoto, Y; Kurata, T; Sugimura, H; Matsuda, M				Kiyokawa, E; Hashimoto, Y; Kurata, T; Sugimura, H; Matsuda, M			Evidence that DOCK180 up-regulates signals from the CrkII-p130(Cas) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; PHOSPHORYLATION-DEPENDENT MANNER; SRC HOMOLOGY-3 DOMAINS; MEDIATED CELL-ADHESION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SH3 DOMAINS; IN-VIVO; V-CRK; PROTEIN	DOCR180 is one of the two principal proteins bound to the SH3 domain of the adaptor protein CrkII. Here, we have studied the involvement of DOCR180 in integrin signaling. DOCR180 was neither phosphorylated nor bound to CrkII in quiescent NIH 3T3 cells and 3Y1 cells. We found that DOCR180 was phosphorylated and bound to CrkII in MH 3T3 cells stimulated with integrin and also in 3Y1 cells transformed by v-src or v-crk. The binding of DOCK180 to CrkII correlated with the binding of CrkII to p130(Cas), which is a major CrkII SH2 domain-binding protein at focal adhesions. In a reconstitution experiment, expression of DOCK180 induced hyperphosphorylation of p130(Cas) and a concomitant increase in the amount of CrkII bound to p130(Cas). Similarly, binding of DOCK180 to CrkII was also enhanced by the coexpression of p130(Cas). Finally, we found that coexpression of p130(Cas) and CrkII with DOCR180 induced local membrane spreading and accumulation of DOCK180-CrkII-p130(Cas) complexes at focal adhesions. These findings suggest that DOCK180 positively regulates signaling from integrins to CrkII-p130(Cas) complexes at focal adhesions.	Int Med Ctr Japan, Inst Res, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan; Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 1628840, Japan; Hamamatsu Univ Sch Med, Dept Pathol, Hamamatsu, Shizuoka 4313192, Japan	National Center for Global Health & Medicine - Japan; National Institute of Infectious Diseases (NIID); Hamamatsu University School of Medicine	Matsuda, M (corresponding author), Int Med Ctr Japan, Inst Res, Dept Pathol, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	mmatsuda@ri.imcj.go.jp		Matsuda, Michiyuki/0000-0002-5876-9969				BIRGE RB, 1992, J BIOL CHEM, V267, P10588; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nievers MG, 1997, J CELL SCI, V110, P389; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ota S, 1998, CELL SIGNAL, V10, P283, DOI 10.1016/S0898-6568(97)00130-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	43	171	173	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24479	24484		10.1074/jbc.273.38.24479	http://dx.doi.org/10.1074/jbc.273.38.24479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733740	hybrid			2022-12-25	WOS:000076007300032
J	Lowry, MB; Duchemin, AM; Coggeshall, KM; Robinson, JM; Anderson, CL				Lowry, MB; Duchemin, AM; Coggeshall, KM; Robinson, JM; Anderson, CL			Chimeric receptors composed of phosphoinositide 3-kinase domains and Fc gamma receptor ligand-binding domains mediate phagocytosis in COS fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NATURAL-KILLER-CELLS; SYK TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; HIGH-AFFINITY; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; LIPID PRODUCTS; MACROPHAGES; ASSOCIATION	Receptors for the Fc portion of IgG (Fc gamma R) initiate phagocytosis of IgG-opsonized particles by a process involving the assembly of a multi-molecular signaling complex. Several members of this complex have been identified, including Src family kinases, Syk/ZAP 70 family kinases, and phosphoinositide S-kinase (PIS-K). To test directly the role of PB-K in mediating phagocytosis, we assessed the phagocytic ability of chimeric receptors composed of Fc gamma R extracellular and transmembrane domains fused to regions of the p85 subunit of PI3-K. We found that chimeric receptors with cytoplasmic tails composed of the entire p85 subunit of PI3-K or the inter-Src homology 2 portion of p85 triggered phagocytosis in transfected COS fibroblasts, These two chimeras also showed phosphoinositide kinase activity in vitro when immunoadsorbed. In contrast, a chimera containing only the carboxyl-terminal Src homology 2 domain of p85 that does not interact with the catalytic p110 subunit of PI3-K did not trigger phagocytosis, nor did it show kinase activity in vitro. These data suggest that localization and direct activation of PI3-K at the site of particle attachment is sufficient to trigger the process of phagocytosis.	Ohio State Univ, Coll Med, Davis Res Ctr 1054, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Psychiat, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Cell Biol Neurobiol & Anat, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University; Ohio State University	Anderson, CL (corresponding author), Ohio State Univ, Coll Med, Davis Res Ctr 1054, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.				NCI NIH HHS [R01-CA44983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Duchemin AM, 1997, J IMMUNOL, V158, P865; DURDEN DL, 1995, J IMMUNOL, V154, P4039; ERNST LK, 1992, J BIOL CHEM, V267, P15692; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GRIFFIN FM, 1976, J EXP MED, V144, P788, DOI 10.1084/jem.144.3.788; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUTCHINSON MJ, 1995, EUR J IMMUNOL, V25, P481, DOI 10.1002/eji.1830250226; INDIK Z, 1991, J CLIN INVEST, V88, P1766, DOI 10.1172/JCI115496; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Lowry MB, 1998, J EXP MED, V187, P161, DOI 10.1084/jem.187.2.161; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; TOKER A, 1994, J BIOL CHEM, V269, P32358; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042; ZIGMOND SH, 1972, EXP CELL RES, V73, P383, DOI 10.1016/0014-4827(72)90062-6	46	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24513	24520		10.1074/jbc.273.38.24513	http://dx.doi.org/10.1074/jbc.273.38.24513			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733745	hybrid			2022-12-25	WOS:000076007300037
J	Schulz, JR; Sasaki, JD; Vacquier, VD				Schulz, JR; Sasaki, JD; Vacquier, VD			Increased association of synaptosome-associated protein of 25 kDa with syntaxin and vesicle-associated membrane protein following acrosomal exocytosis of sea urchin sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; FUSION COMPLEX; CDNA CLONES; IN-VITRO; SNAP-25; EGG; IDENTIFICATION; SPERMATOZOA; ACTIVATION; TRANSPORT	Synaptosomal-associated protein of 25 kDa (SNAP-25) is a palmitoylated integral membrane protein expressed almost exclusively in neuronal and neuroendocrine tissues. This protein forms a ternary complex with vesicle-associated membrane protein (VAMP) and syntaxin, which is thought to regulate the fusion of plasma and vesicle membranes during exocytosis, We report the identification of SNAP-25 expressed in sea urchin sperm. Sea urchin SNAP-25 shares greater identity with mammalian SNAP-25 than with mammalian SNAP-23, a ubiquitously expressed homologue believed to regulate membrane fusion in non-neuronal tissues. Sea urchin sperm contain a single exocytotic vesicle, the acrosomal vesicle, whose contents are exposed during the acrosome reaction. Fusion of the plasma membrane with the acrosomal vesicle membrane at multiple points (vesiculation) results in the release of SNAP-25 with the shed acrosome reaction vesicles. A complex containing SNAP-25, syntaxin, and VAMP is present in sperm, as detected by affinity chromatography and immunoprecipitation. Although this complex is present prior to the acrosome reaction, the amount of complex increases over 4-fold following acrosomal exocytosis, These findings support the involvement of SNAP-25 in the invertebrate sperm acrosome reaction, possibly through increased association with VAMP and syntaxin driving the fusion of plasma and acrosomal membranes.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Schulz, JR (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012986, R01HD012986] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-12986] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BARK IC, 1993, J MOL BIOL, V233, P67, DOI 10.1006/jmbi.1993.1485; BARROS C, 1967, J CELL BIOL, V34, P1; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bruns D, 1997, J NEUROSCI, V17, P1898; CASTELLANO LE, 1995, EUR J CELL BIOL, V67, P23; Conner S, 1997, MOL REPROD DEV, V48, P106; Darszon A, 1996, CURR TOP DEV BIOL, V34, P117, DOI 10.1016/S0070-2153(08)60710-3; EPEL D, 1978, MEMBRANE FUSION, P1; FOLTZ KR, 1993, DEV BIOL, V158, P46, DOI 10.1006/dbio.1993.1167; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; KUMAR S, 1993, MEGA; LOEWY A, 1991, J NEUROSCI, V11, P3412; Nicholas HBJ, 1997, GENEDOC; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PODELL SB, 1984, J CELL BIOL, V99, P1598, DOI 10.1083/jcb.99.5.1598; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; RISINGER C, 1993, J BIOL CHEM, V268, P24408; Rothman JE, 1996, PROTEIN SCI, V5, P185; Schulz JR, 1997, DEV BIOL, V191, P80, DOI 10.1006/dbio.1997.8712; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Vacquier VD, 1997, DEV BIOL, V192, P125, DOI 10.1006/dbio.1997.8729; VACQUIER VD, 1986, METHOD CELL BIOL, V27, P15, DOI 10.1016/S0091-679X(08)60340-4; Wang GY, 1997, J CELL SCI, V110, P505; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165	33	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24355	24359		10.1074/jbc.273.38.24355	http://dx.doi.org/10.1074/jbc.273.38.24355			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733723	hybrid			2022-12-25	WOS:000076007300015
J	Simonsson, S; Samuelsson, T; Elias, P				Simonsson, S; Samuelsson, T; Elias, P			The herpes simplex virus type 1 origin binding protein - Specific recognition of phosphates and methyl groups defines the interacting surface for a monomeric DNA binding domain in the major groove of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; UL9 GENE; VIRAL ORIGIN; REPLICATION; HELICASE; ORIS; COMPLEX; ORI(S); ICP8	The UL9 gene of herpes simplex virus type I (HSV-1) encodes an origin binding protein (OBP), It is an ATP-dependent DNA helicase and a sequence-specific DNA-binding protein, The latter function is carried out by the C-terminal domain of OBP (Delta OBP). We have now performed a quantitative analysis of the interaction between Delta OBP and its recognition sequence, GTTCGCAC, in oris, Initially optimal conditions for binding were carefully determined. We observed that complexes with different electrophoretic mobilities were formed, A cross-linking experiment demonstrated that nonspecific complexes containing 2 or more protein monomers per DNA molecule were formed at high protein concentrations. The specific complex formed at low concentrations of Delta OBP had an electrophoretic mobility corresponding to a 1:1 complex. We then demonstrated that the methyl groups of thymine in the major groove were essential for high affinity binding. Changes in the minor groove had considerably smaller effects. Ethylation interference experiments indicated that specific contacts were made between OBP and three phosphates in the recognition sequence. Finally, these observations were used to present a model of the surface of DNA that interacts with Delta OBP in a sequence-specific manner.	Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden	University of Gothenburg	Elias, P (corresponding author), Univ Gothenburg, Dept Biochem Med, Box 440, SE-40530 Gothenburg, Sweden.	per.elias@medkem.gu.se	Samuelsson, Tore/B-3548-2008; Simonsson, Stina/R-2699-2016; Samuelsson, Tore/X-7335-2019	Simonsson, Stina/0000-0001-9020-3714; 				ABBOTTS AP, 1995, J GEN VIROL, V76, P3125, DOI 10.1099/0022-1317-76-12-3125; Ausubel FM, CURRENT PROTOCOLS MO; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FIERER DS, 1995, J BIOL CHEM, V270, P7330, DOI 10.1074/jbc.270.13.7330; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; Hammarsten O, 1996, J GEN VIROL, V77, P969, DOI 10.1099/0022-1317-77-5-969; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; KOFF A, 1988, J VIROL, V62, P4096, DOI 10.1128/JVI.62.11.4096-4103.1988; Kornberg A., 1992, DNA REPLICATION; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; Lundback T, 1996, P NATL ACAD SCI USA, V93, P4754, DOI 10.1073/pnas.93.10.4754; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STABELL EC, 1993, NUCLEIC ACIDS RES, V21, P5203, DOI 10.1093/nar/21.22.5203; Stow ND, 1998, VIROLOGY, V240, P183, DOI 10.1006/viro.1997.8910; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365	30	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24633	24639		10.1074/jbc.273.38.24633	http://dx.doi.org/10.1074/jbc.273.38.24633			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733759	hybrid			2022-12-25	WOS:000076007300051
J	Bagrodia, S; Taylor, SJ; Jordon, KA; Van Aelst, L; Cerione, RA				Bagrodia, S; Taylor, SJ; Jordon, KA; Van Aelst, L; Cerione, RA			A novel regulator of p21-activated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACTIN STRESS FIBERS; RAS TRANSFORMATION; DEPENDENT ACTIVATION; FOCAL COMPLEXES; CDC42 GTPASES; RHO; RAC1; MEMBRANE; FAMILY	Proteins of the pal-activated kinase (Pak) family have been implicated in the regulation of gene expression, cytoskeletal architecture, and apoptosis, Although the ability of Cdc42 and Pac GTPases to activate Pak is well established, relatively little else is known about Pak regulation or the identity of Pak cellular targets. Here we report the identification of two closely related Pak3-binding proteins, possibly arising from alternative splicing, designated p50 and p85(Cool-1) (cloned out of library), Both isoforms of Cool contain a Src homology 3 domain that directly mediates interaction with Pak3 and tandem Dbl homology and pleckstrin homology domains. Despite the presence of the Dbl homology-pleckstrin homology motif, a characteristic of Rho family activators, activation of Cdc42 or Rac by Cool is not detectable. Instead binding of p50(Cool-1), but not p85(Cool-1), to Pak3 represses its activation by upstream activators such as the Dbl oncoprotein, indicating a novel mechanism of regulation of Pak signaling.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cornell University; Cornell University; Cold Spring Harbor Laboratory	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM40654, GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	32	262	268	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23633	23636		10.1074/jbc.273.37.23633	http://dx.doi.org/10.1074/jbc.273.37.23633			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726964	hybrid			2022-12-25	WOS:000075893100005
J	DeLange, F; Klaassen, CHW; Wallace-Williams, SE; Bovee-Geurts, PHM; Liu, XM; DeGrip, WJ; Rothschild, KJ				DeLange, F; Klaassen, CHW; Wallace-Williams, SE; Bovee-Geurts, PHM; Liu, XM; DeGrip, WJ; Rothschild, KJ			Tyrosine structural changes detected during the photoactivation of rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED DIFFERENCE SPECTROSCOPY; DRIVEN PROTON TRANSPORT; AMINO-ACID-SEQUENCE; BOVINE RHODOPSIN; METARHODOPSIN-II; RESONANCE RAMAN; FTIR SPECTROSCOPY; LOW-TEMPERATURE; F-HELIX; BACTERIORHODOPSIN PHOTOCYCLE	We present the first Fourier transform infrared (FTIR) analysis of an isotope-labeled eukaryotic membrane protein. A combination of isotope labeling and FTIR difference spectroscopy was used to investigate the possible involvement of tyrosines in the photoactivation of rhodopsin (Rho), Rho --> MII difference spectra were obtained at 10 degrees C for unlabeled recombinant Rho and isotope-labeled L-[ring-(2)H(4)]Tyr-Rho expressed in Spodoptera frugiperda cells grown on a stringent culture medium containing enriched L-[ring-(2)H(4)]Tyr and isolated using a His, tag, A comparison of these difference spectra revealed reproducible changes in bands that correspond to tyrosine and tyrosinate vibrational modes. A similar pattern of tyrosine/tyrosinate bands has also been observed in the bR --> M transition in bacteriorhodopsin, although the sign of the bands is reversed. In bacteriorhodopsin, these bands were assigned to Tyr-185, which along with Pro-186 in the F-helix, may form a hinge that facilitates alpha-helix movement.	Boston Univ, Dept Phys, Boston, MA 02215 USA; Boston Univ, Lab Mol Biophys, Boston, MA 02215 USA; Univ Nijmegen, Dept Biochem, Inst Cellular Signalling, NL-6500 HB Nijmegen, Netherlands	Boston University; Boston University; Radboud University Nijmegen	Rothschild, KJ (corresponding author), Boston Univ, Dept Phys, 590 Commonwealth Ave, Boston, MA 02215 USA.	kjr@bu.edu	de Grip, W.J./L-4335-2015; Rothschild, Kenneth/P-6177-2018	Rothschild, Kenneth/0000-0002-2847-6671	NEI NIH HHS [EY05499] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005499] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHL PL, 1989, BIOCHEMISTRY-US, V28, P10028, DOI 10.1021/bi00452a022; AHL PL, 1988, J BIOL CHEM, V263, P13594; BAENZIGER JE, 1992, BIOPHYS J, V62, P64, DOI 10.1016/S0006-3495(92)81780-0; BAGLEY KA, 1985, BIOCHEMISTRY-US, V24, P6055, DOI 10.1021/bi00343a006; BENDIT EG, 1967, BIOPOLYMERS, V5, P525, DOI 10.1002/bip.1967.360050607; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; BRAIMAN MS, 1988, PROTEINS, V3, P219, DOI 10.1002/prot.340030403; BREER H, 1993, CIBA F SYMP, V179, P97; CHANG SH, 1981, P NATL ACAD SCI-BIOL, V78, P3398, DOI 10.1073/pnas.78.6.3398; CLARK NA, 1980, BIOPHYS J, V31, P65, DOI 10.1016/S0006-3495(80)85041-7; DECALUWE GLJ, 1995, BIOPHYS CHEM, V56, P79, DOI 10.1016/0301-4622(95)00018-S; DEGRIP WJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P497, DOI 10.1111/j.1751-1097.1988.tb02852.x; DeLange F, 1997, EUR J BIOCHEM, V243, P174, DOI 10.1111/j.1432-1033.1997.0174a.x; DOHLMAN HG, 1987, KIDNEY INT, V32, pS2; DOUKAS AG, 1978, BIOCHEMISTRY-US, V17, P2430, DOI 10.1021/bi00605a028; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GREEN BH, 1977, NATURE, V269, P179, DOI 10.1038/269179a0; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Han M, 1996, J BIOL CHEM, V271, P32337, DOI 10.1074/jbc.271.50.32337; Han M, 1997, J BIOL CHEM, V272, P23081, DOI 10.1074/jbc.272.37.23081; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Hienerwadel R, 1997, BIOCHEMISTRY-US, V36, P14712, DOI 10.1021/bi971521a; JANSSEN JJM, 1995, J BIOL CHEM, V270, P11222, DOI 10.1074/jbc.270.19.11222; KANDORI H, 1995, BIOCHEMISTRY-US, V34, P14220, DOI 10.1021/bi00043a029; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KLINGER AL, 1992, BIOPHYS J, V63, P1244, DOI 10.1016/S0006-3495(92)81700-9; LEFKOWITZ RJ, 1986, TRENDS PHARMACOL SCI, V7, P444, DOI 10.1016/0165-6147(86)90417-7; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; LIU XM, 1995, BIOPHYS CHEM, V56, P63, DOI 10.1016/0301-4622(95)00016-Q; LUDLAM CFC, 1995, BIOCHEMISTRY-US, V34, P2, DOI 10.1021/bi00001a001; Ludlam GJ, 1997, FEBS LETT, V407, P285, DOI 10.1016/S0014-5793(97)00351-7; MAEDA A, 1993, BIOCHEMISTRY-US, V32, P12033, DOI 10.1021/bi00096a013; MATHIES R, 1977, J MOL BIOL, V109, P367, DOI 10.1016/S0022-2836(77)80040-5; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; Nishimura S, 1996, BIOCHEMISTRY-US, V35, P13267, DOI 10.1021/bi960911e; OSEROFF AR, 1974, BIOCHEMISTRY-US, V13, P4243, DOI 10.1021/bi00717a027; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1424; PALINGS I, 1987, BIOCHEMISTRY-US, V26, P2544, DOI 10.1021/bi00383a021; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; RAFFERTY CN, 1979, PHOTOCHEM PHOTOBIOL, V29, P109, DOI 10.1111/j.1751-1097.1979.tb09268.x; Rath P, 1998, BIOCHEM J, V329, P713, DOI 10.1042/bj3290713; RATH P, 1993, BIOCHEMISTRY-US, V32, P10277, DOI 10.1021/bi00090a001; RATH P, 1994, BIOPHYS J, V66, P2085, DOI 10.1016/S0006-3495(94)81003-3; RIDGE KD, 1992, J BIOL CHEM, V267, P6770; ROEPE P, 1987, BIOCHEMISTRY-US, V26, P6696, DOI 10.1021/bi00395a020; ROTHSCHILD KJ, 1986, PHOTOBIOCH PHOTOBIOP, V13, P245; ROTHSCHILD KJ, 1987, BIOPHYS J, V51, P345, DOI 10.1016/S0006-3495(87)83341-6; ROTHSCHILD KJ, 1980, BIOPHYS J, V31, P53, DOI 10.1016/S0006-3495(80)85040-5; ROTHSCHILD KJ, 1981, BIOCHEM BIOPH RES CO, V103, P483, DOI 10.1016/0006-291X(81)90478-2; ROTHSCHILD KJ, 1986, P NATL ACAD SCI USA, V83, P347, DOI 10.1073/pnas.83.2.347; ROTHSCHILD KJ, 1989, FEBS LETT, V250, P448, DOI 10.1016/0014-5793(89)80774-4; ROTHSCHILD KJ, 1976, SCIENCE, V191, P1176, DOI 10.1126/science.1257742; ROTHSCHILD KJ, 1983, SCIENCE, V219, P1333, DOI 10.1126/science.6828860; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; SIEBERT F, 1983, EUR J BIOCHEM, V136, P119, DOI 10.1111/j.1432-1033.1983.tb07714.x; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Tang L, 1995, ISRAEL J CHEM, V35, P193; Vonck J, 1996, BIOCHEMISTRY-US, V35, P5870, DOI 10.1021/bi952663c; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	68	34	34	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23735	23739		10.1074/jbc.273.37.23735	http://dx.doi.org/10.1074/jbc.273.37.23735			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726981	Green Published, hybrid			2022-12-25	WOS:000075893100022
J	Wenzel-Seifert, K; Hurt, CM; Seifert, R				Wenzel-Seifert, K; Hurt, CM; Seifert, R			High constitutive activity of the human formyl peptide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BINDING REGULATORY PROTEINS; INFECTED INSECT CELLS; LEUKEMIA HL-60 CELLS; PERTUSSIS-TOXIN; SIGNAL-TRANSDUCTION; HUMAN-NEUTROPHILS; ADENYLYL-CYCLASE; INVERSE AGONISM; CYCLOSPORINE-H	The formyl peptide receptor (FPR) couples to pertussis toxin (PTX)-sensitive Gi-proteins to activate chemotaxis and exocytosis in neutrophils. PTX reduces not only formyl peptide-stimulated but also agonist-independent ("basal") G(i)-protein activity, suggesting that the FPR is constitutively active. We aimed at identifying an inverse FPR agonist, i.e. a compound that suppresses constitutive FPR activity. In Sf9 insect cell membranes, the G-protein heterotrimer G(i)alpha(2)beta(1)gamma(2) reconstituted N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)stimulated guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) binding and GTP gamma S-sensitive high affinity [H-3]FMLP binding. The FPR "antagonist" cyclosporin H (CsH) potently and efficiently reduced basal GTP gamma S binding in Sf9 membranes. Another FPR antagonist, N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L-phenylalanine did not inhibit basal GTP gamma S binding but blocked the inhibitory effect of CsH on GTP gamma S binding. Na+ reduced basal GTP gamma S binding and eliminated the inhibitory effect of CsH. Similar effects of FMLP, CsH, and Na+ as in Sf9 membranes were observed with FPR expressed in the mammalian cell line HEK293. Our data show that the human FPR possesses high constitutive activity. CsH is an inverse FPR agonist and stabilizes the FPR in an inactive state. Na+ also stabilizes the FPR in an inactive state and, thereby, diminishes inverse agonist efficacy.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Wenzel-Seifert, K (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, 5064 Malott Hall, Lawrence, KS 66045 USA.		Seifert, Roland/G-3189-2013		NIGMS NIH HHS [GM 07365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; BARKER EL, 1994, J BIOL CHEM, V269, P11687; Barr AJ, 1997, J BIOL CHEM, V272, P32979, DOI 10.1074/jbc.272.52.32979; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; Burstein ES, 1997, MOL PHARMACOL, V51, P312, DOI 10.1124/mol.51.2.312; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CERESA BP, 1994, J BIOL CHEM, V269, P29557; Cetani F, 1996, FEBS LETT, V378, P27, DOI 10.1016/0014-5793(95)01384-9; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1990, MOL PHARMACOL, V37, P383; CUPO JF, 1989, BIOCHIM BIOPHYS ACTA, V982, P31, DOI 10.1016/0005-2736(89)90170-3; dePaulis A, 1996, J ALLERGY CLIN IMMUN, V98, P152, DOI 10.1016/S0091-6749(96)70237-3; DIETRICH A, 1992, FEBS LETT, V313, P220, DOI 10.1016/0014-5793(92)81195-R; DILLON SB, 1988, VIRCHOWS ARCH B, V55, P65; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GETHER U, 1995, J BIOL CHEM, V270, P28268; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GIERSCHIK P, 1989, EUR J PHARM-MOLEC PH, V172, P481, DOI 10.1016/0922-4106(89)90031-X; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; Gimpl G, 1996, EUR J BIOCHEM, V237, P768, DOI 10.1111/j.1432-1033.1996.0768p.x; GOTZE K, 1994, EUR J PHARM-MOLEC PH, V268, P151, DOI 10.1016/0922-4106(94)90184-8; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15162, DOI 10.1021/bi960757w; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HANF R, 1993, J PHYSIOL-LONDON, V461, P743, DOI 10.1113/jphysiol.1993.sp019539; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HINSCH KD, 1989, BIOCHIM BIOPHYS ACTA, V1013, P60, DOI 10.1016/0167-4889(89)90128-6; JACOBS AA, 1995, J LEUKOCYTE BIOL, V57, P679, DOI 10.1002/jlb.57.4.679; Jakubik J, 1995, FEBS LETT, V377, P275, DOI 10.1016/0014-5793(95)01360-1; KANAHO Y, 1990, J LEUKOCYTE BIOL, V47, P420, DOI 10.1002/jlb.47.5.420; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; KLEIN JB, 1992, J IMMUNOL, V148, P2483; KLINKER JF, 1994, BIOCHEM PHARMACOL, V48, P1857, DOI 10.1016/0006-2952(94)90583-5; KLINKER JF, 1994, BIOCHEM J, V304, P377, DOI 10.1042/bj3040377; Klinker JF, 1996, GEN PHARMACOL, V27, P33, DOI 10.1016/0306-3623(95)00107-7; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Leopoldt D, 1997, N-S ARCH PHARMACOL, V356, P216, DOI 10.1007/PL00005044; MCLEISH KR, 1991, BIOCHEM J, V279, P455, DOI 10.1042/bj2790455; MEWES T, 1993, CIRCULATION, V88, P2916, DOI 10.1161/01.CIR.88.6.2916; MUKAI H, 1992, J BIOL CHEM, V267, P16237; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NACCACHE PH, 1991, BLOOD, V78, P2534; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; NEVE KA, 1991, MOL PHARMACOL, V39, P733; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; Noguera MA, 1996, BRIT J PHARMACOL, V119, P158, DOI 10.1111/j.1476-5381.1996.tb15689.x; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; Smit MJ, 1996, P NATL ACAD SCI USA, V93, P6802, DOI 10.1073/pnas.93.13.6802; SOKOLOSKI JA, 1991, BIOCHEM J, V280, P515, DOI 10.1042/bj2800515; TIAN WN, 1994, MOL PHARMACOL, V45, P524; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRABER R, 1982, HELV CHIM ACTA, V65, P1655, DOI 10.1002/hlca.19820650538; vanKoppen CJ, 1996, MOL PHARMACOL, V49, P956; VOLPI M, 1985, P NATL ACAD SCI USA, V82, P2708, DOI 10.1073/pnas.82.9.2708; VONWARTBURG A, 1986, PROG ALLERGY, V38, P28; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Weill C, 1997, EUR J PHARMACOL, V333, P269, DOI 10.1016/S0014-2999(97)01139-4; WENZELSEIFERT K, 1993, J IMMUNOL, V150, P4591; WenzelSeifert K, 1996, BIOCHEM J, V314, P679, DOI 10.1042/bj3140679; WENZELSEIFERT K, 1991, J IMMUNOL, V147, P1940; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	83	91	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24181	24189		10.1074/jbc.273.37.24181	http://dx.doi.org/10.1074/jbc.273.37.24181			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727041	hybrid			2022-12-25	WOS:000075893100082
J	Glover, BP; McHenry, CS				Glover, BP; McHenry, CS			The chi psi subunits of DNA polymerase III holoenzyme bind to single-stranded DNA-binding protein (SSB) and facilitate replication of an SSB-coated template	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GAMMA-SUBUNIT; SLIDING CLAMPS; SIZE CLASSES; TAU-SUBUNIT; GENE 32; COMPLEX; MACHINE; BACTERIOPHAGE-T7; IDENTIFICATION	A complex of the chi and psi proteins is required to confer resistance to high levels of glutamate on the DNA polymerase III holoenzyme-catalyzed reaction (Olson, M., Dallmann, H. G., and McHenry, C. (1995) J. Biol Chem. 270, 29570-29577), We demonstrate that this salt resistance also requires templates to be coated with the Escherichia coli single-stranded DNA-binding protein (SSB). We show that this is the result of a direct chi psi-SSB interaction that is strengthened approximately 1000-fold when SSB is bound to DNA. On model oligonucleotide templates, DNA polymerase III core is inhibited by SSB. We show that the minimal polymerase assembly that will synthesize DNA on SSB-coated templates is polymerase III-tau-psi chi. gamma, the alternative product of the dnaX gene, will not replace tau in this reaction, indicating that tau's unique ability to bind to DNA polymerase III holding chi psi in the same complex is essential. All of our findings are consistent with chi psi strengthening DNA polymerase III holoenzyme interactions with the SSB-coated lagging strand at the replication fork, facilitating complex assembly and elongation.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet B121, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet B121, 4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM035695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CHA TA, 1988, CANCER CELL, V6, P1; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; FRADKIN LG, 1992, J BIOL CHEM, V267, P10318; GRIEP MA, 1990, BIOCHEMISTRY-US, V29, P9006, DOI 10.1021/bi00490a018; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1990, UCLA SYM BI, V127, P115; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MOK M, 1987, J BIOL CHEM, V262, P16644; MOLINEUX IJ, 1974, P NATL ACAD SCI USA, V71, P3858, DOI 10.1073/pnas.71.10.3858; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; REEMS JA, 1994, J BIOL CHEM, V269, P33091; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIAO H, 1993, J BIOL CHEM, V268, P11779	38	126	127	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23476	23484		10.1074/jbc.273.36.23476	http://dx.doi.org/10.1074/jbc.273.36.23476			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722585	hybrid			2022-12-25	WOS:000075778100085
J	Hood, J; Granger, HJ				Hood, J; Granger, HJ			Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; GENE-EXPRESSION; TYROSINE KINASE; PHORBOL ESTER; ANGIOGENESIS; RECEPTOR; RAS	Vascular endothelial growth factor (VEGF) is an endothelium-specific, secreted protein that acts as a vasodilator, angiogenic peptide, and hyperpermeability factor. Recent reports have shown that nitric oxide synthase inhibitors block proliferation and microvascular hyperpermeability induced by VEGF. This study examined the mechanisms by which nitric oxide and its downstream signals mediate the VEGF-induced proliferative response in human umbilical vein endothelial cells (HUVECs), Nitric oxide synthase blockade by N-G-nitro-L-arginine methyl ester prevented both the proliferative effect of VEGF and Raf-1 activation by VEGF as measured by cell counting and the capacity of immunoprecipitated Raf-1 to phosphorylate syntide 2, a Raf-1-specific synthetic substrate. VEGF-induced proliferation and Raf-1 kinase activity were also inhibited by Rp-8-pCPT-cGMPs and KT5823, inhibitors of the regulatory and catalytic subunits of cGMP-dependent protein kinase (PKG), respectively. The ability of PKG to stimulate proliferation was verified by the observation that the PKG activator, 8-pCPT-cGMPs, stimulated both Raf-1 kinase activity and endothelial proliferation in a dose-dependent manner. Furthermore, recombinant catalytically active PKG phosphorylated and activated Raf-1 in a reconstituted system. Finally, Raf-1 immunoprecipitated from VEGF-stimulated endothelial cells coprecipitated with PKG, indicating a direct protein-protein interaction in activated cells. We conclude that VEGF induces increases in both proliferation and Raf-1 kinase activity in HUVECs and these activities are dependent on NO and its downstream effector, PKG.	Texas A&M Univ Syst, Hlth Sci Ctr, Microcirculat Res Inst, College Stn, TX 77843 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Physiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Granger, HJ (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Microcirculat Res Inst, College Stn, TX 77843 USA.	granger@tamu.edu						BANAI S, 1994, CARDIOVASC RES, V28, P1176, DOI 10.1093/cvr/28.8.1176; Beasley D, 1997, J CARDIOVASC PHARM, V29, P323, DOI 10.1097/00005344-199703000-00004; BROCK TA, 1991, AM J PATHOL, V138, P213; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DEJONGE HW, 1995, J MOL CELL CARDIOL, V27, P93, DOI 10.1016/S0022-2828(08)80010-7; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Gudi T, 1996, J BIOL CHEM, V271, P4597; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lincoln TM, 1996, METHOD ENZYMOL, V269, P149; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OBRIAN CA, 1989, CANCER METAST REV, V8, P199, DOI 10.1007/BF00047337; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; SEETHARAM L, 1995, ONCOGENE, V10, P135; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIMA DT, 1995, MOL MED, V2, P64; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanderZee R, 1997, CIRCULATION, V95, P1030; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yamazaki T, 1997, J MOL CELL CARDIOL, V29, P2491, DOI 10.1006/jmcc.1997.0488; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	45	133	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23504	23508		10.1074/jbc.273.36.23504	http://dx.doi.org/10.1074/jbc.273.36.23504			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722588	hybrid			2022-12-25	WOS:000075778100088
J	Smyth, EM; Li, WH; Fitzgerald, GA				Smyth, EM; Li, WH; Fitzgerald, GA			Phosphorylation of the prostacyclin receptor during homologous desensitization - A critical role for protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT PHOSPHORYLATION; ANGIOTENSIN-II RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; EXPRESSION; CDNA; INVOLVEMENT; SUBTYPE; CLONING; 1A	Agonist-induced phosphorylation of an epitope-tagged prostacyclin receptor (HAhIP) is mediated primarily by PRC (Smyth, E. M., Nestor, P. V., and FitzGerald G. A. (1996) J. Biol. Chem. 271, 33698-33704). Based on the two consensus sites for protein kinase C (PKC) phosphorylation in the C-terminal region mutant HAhIPs were generated: S328A and S374A, in which an alanine replaced Ser-328 or Ser-374, respectively, S328A/S374A and C-DEL, in which the C-terminal portion was truncated at amino acid 313. Mutant receptors, stably expressed in HEK293 cells, coupled normally to cAMP production. Substantially less coupling to inositol phosphate was apparent with S328A, S328A/S374A, and C-DEL compared with HAhIP or S374A. Point mutants resolved by SDS-polyacrylamide gel electrophoresis as a broad band with a molecular mass of 44-62, indicating that the receptors are glycosylated, and immunofluoresence staining demonstrated their membrane localization. C-DEL demonstrated a substantial reduction in glycosylation; bands with molecular masses of 38-54 (glycosylated), 30, and 27 kDa (unglycosylated) were apparent. Although membrane localization was evident, cellular localization was more diffuse. HAhIP and S374A underwent iloprost- and PMA-induced phosphorylation (1 and 5 mu M, respectively, for 10 min). S328A and S328A/S374A showed a markedly less iloprost- and no PMA-induced phosphorylation. Phosphorylation of C-DEL was completely absent with either agonist. Electrospray mass spectrometry indicated that a peptide, including Ser-328, was phosphorylated in vitro by PKC, whereas one including Ser-374 was not. Iloprost (1 mu M, 10 min) desensitized HAhIP- and S374A-mediated adenylyl cyclase activation. A less impressive desensitization was evident with S328A and S328A/S374A, and no desensitization of C-DEL coupling was apparent. Exposure of transfected cells to iloprost (1 mu M) for increasing times induced a rapid desensitization of subsequent iloprost-induced (1 mu M) HAhIP and S374A adenylyl cyclase coupling. In contrast, no significant time-dependent desensitization of S328A, S328A/S374A, or C-DEL coupling was evident. These results indicate that PKC-dependent phosphorylation is of critical importance to homologous regulation of hIP. Ser-328 is a primary site for PKC phosphorylation of hIP.	Univ Penn, Ctr Expt Therapeut, Stellar Chance Labs 905, Philadelphia, PA 19104 USA	University of Pennsylvania	Fitzgerald, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, Stellar Chance Labs 905, 422 Curie Blvd, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	FitzGerald, Garret A/A-4222-2010		NHLBI NIH HHS [HL-57847, HL-0945502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057847] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bastepe M, 1997, MOL PHARMACOL, V51, P343, DOI 10.1124/mol.51.2.343; BOIE Y, 1994, J BIOL CHEM, V269, P12173; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; FISCH A, 1997, CIRCULATION, V96, P765; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Giovanazzi S, 1997, BIOCHEM J, V325, P71, DOI 10.1042/bj3250071; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HAUSDORFF WP, 1990, SYM SOC EXP BIOL, V44, P225; ISHII K, 1994, J BIOL CHEM, V269, P1125; KATOH H, 1995, BBA-GEN SUBJECTS, V1244, P41, DOI 10.1016/0304-4165(94)00182-W; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, NEUROSCI RES, V15, P3, DOI 10.1016/0168-0102(92)90013-3; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; SOLOMON T, 1994, ANAL BIOCHEM, V58, P541; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; Vezza R, 1996, J BIOL CHEM, V271, P30028, DOI 10.1074/jbc.271.47.30028	28	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23258	23266		10.1074/jbc.273.36.23258	http://dx.doi.org/10.1074/jbc.273.36.23258			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722557	hybrid			2022-12-25	WOS:000075778100057
J	Briggs, LJ; Stein, D; Goltz, J; Corrigan, VC; Efthymiadis, A; Hubner, S; Jans, DA				Briggs, LJ; Stein, D; Goltz, J; Corrigan, VC; Efthymiadis, A; Hubner, S; Jans, DA			The cAMP-dependent protein kinase site (Ser(312)) enhances dorsal nuclear import through facilitating nuclear localization sequence/importin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LARGE T-ANTIGEN; DROSOPHILA MORPHOGEN DORSAL; II SITE; TYROSINE PHOSPHORYLATION; DEGRADATION ESTABLISHES; DORSOVENTRAL PATTERN; TRANSCRIPTION FACTOR; TRANSPORT; EMBRYO	Control over the nuclear import of transcription factors (TFs) represents a level of gene regulation integral to cellular processes such as differentiation and transformation. The Drosophila TF Dorsal shares with other rel TF family members the fact that it contains a phosphorylation site for the cAMP-dependent protein kinase (PKA) 22 amino acids N-terminal to the nuclear localization signal (NLS) at amino acids 335-340. This study examines for the first time the nuclear import kinetics of Dorsal fusion proteins in rat hepatoma cells in vivo and in vitro. Nuclear uptake was found to be not only NLS-dependent, but also strongly dependent on the PKA site, whereby substitution of Ser(312) by either Ala or Glu using site-directed mutagenesis severely reduced nuclear accumulation. Exogenous cAMP or PKA catalytic subunit significantly enhanced the nuclear import of wild-type proteins both in vivo and in vitro. Using a direct binding assay, the molecular basis of PKA site enhancement of Dorsal fusion protein nuclear import was determined to be PKA site-mediated modulation of NLS recognition by the importin 58/97 complex. The physiological relevance of these results is supported by the observation that Drosophila embryos expressing PKA site Dorsal mutant variants were impaired in development. We conclude that the Dorsal NLS and PKA site constitute a phosphorylation-regulated NLS essential to Dorsal function and able to function in heterologous mammalian cell systems, where phosphorylation modulates the affinity of NLS recognition by importin.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signaling Lab, Canberra, ACT 2601, Australia; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Australian National University; John Curtin School of Medical Research; Yeshiva University; Albert Einstein College of Medicine	Jans, DA (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signaling Lab, POB 334, Canberra, ACT 2601, Australia.	David.Jans@anu.edu.au	Briggs, Lyndall J/A-7549-2011					BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRIEVER W, 1990, DEVELOPMENT, V109, P811; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; Govind S, 1996, MOL CELL BIOL, V16, P1103; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; ISODA K, 1994, P NATL ACAD SCI USA, V91, P5350, DOI 10.1073/pnas.91.12.5350; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KUBOTA K, 1993, BIOCHEM J, V296, P497, DOI 10.1042/bj2960497; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MELENDEZ A, 1995, GENETICS, V141, P1507; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; NORRIS JL, 1995, GENE DEV, V9, P358, DOI 10.1101/gad.9.3.358; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STJOHNSTON D, 1992, CELL, V68, P201; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANCUROVA I, 1995, J CELL SCI, V108, P779; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	47	86	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22745	22752		10.1074/jbc.273.35.22745	http://dx.doi.org/10.1074/jbc.273.35.22745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712906	hybrid			2022-12-25	WOS:000075616600082
J	Groblewski, GE; Yoshida, M; Bragado, MJ; Ernst, SA; Leykam, J; Williams, JA				Groblewski, GE; Yoshida, M; Bragado, MJ; Ernst, SA; Leykam, J; Williams, JA			Purification and characterization of a novel physiological substrate for calcineurin in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; REGULATED PHOSPHOPROTEIN; PROTEIN PHOSPHATASES; SIGNAL TRANSDUCTION; PHOSPHORYLATION; KINASE; DEPHOSPHORYLATION; IDENTIFICATION; TRANSCRIPTION; ACTIVATION	Although the calcium/calmodulin-regulated protein phosphatase calcineurin has been shown to play a role in a number of intracellular processes, relatively few of the downstream phosphoproteins that are dephosphorylated by this enzyme in cells have been described. Calcineurin was previously shown to play a role in amylase secretion by rat pancreatic acinar cells and to specifically dephosphorylate a 24-kDa cytosolic protein. The present study describes the purification and characterization of this novel phosphoprotein, termed CRHSP-24 (calcium-regulated heat-stable protein with a molecular mass of 24 kDa), Microgram quantities of CRHSP-24 were purified from a large-scale rat pancreas preparation in a procedure involving heat and acid precipitation, anion exchange chromatography, preparative electrophoresis, electroelution, and two-dimensional electrophoresis. Internal amino acid sequence was obtained from two peptides following trypsin digestion and high pressure liquid chromatography, Both sequences matched with 100% identity nucleotide sequences of expressed sequence tags from human placenta and rat PC-12 cells. Two CRHSP-24 transcripts of 0.7 and 2.9 kilobases were detected in multiple rat tissues by Northern analysis, whereas a single 24-kDa protein was observed by Western blotting. The CRHSP-24 protein is 147 amino acids in length, is composed of nearly 14% proline, and is phosphorylated entirely on serine residues. Western analysis and P-32 metabolic labeling of acini revealed CRHSP-24 to be maximally phosphorylated in control cells and to undergo a rapid sustained dephosphorylation on at least 3 serine residues in response to calcium-mobilizing stimuli. Dephosphorylation of CRHSP-24 was completely inhibited by pretreatment of acini with cyclosporin A or FK506. Furthermore, the inhibitory effects of FK506 were blocked by excess rapamycin. The ubiquitous expression of CRHSP-24 in rat tissues suggests that this novel calcineurin substrate plays a common role in calcium-mediated signal transduction.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Anat & Cell Biol, Ann Arbor, MI 48109 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan State University	Williams, JA (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 7737 Med Sci II, Ann Arbor, MI 48109 USA.	jawillms@umich.edu	Bragado, M Julia/L-6988-2014	Bragado, M Julia/0000-0001-7770-0775; Williams, John/0000-0002-6063-7615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933, R37DK041122, F32DK008819, R01DK041122] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34933, DK41122, DK08819] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bragado MJ, 1997, AM J PHYSIOL-CELL PH, V273, pC101, DOI 10.1152/ajpcell.1997.273.1.C101; BRAUN W, 1995, FASEB J, V9, P63, DOI 10.1096/fasebj.9.1.7529736; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Castiglia D, 1996, BIOCHEM BIOPH RES CO, V218, P390, DOI 10.1006/bbrc.1996.0068; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DESDOUITS F, 1995, P NATL ACAD SCI USA, V92, P2682, DOI 10.1073/pnas.92.7.2682; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; Groblewski GE, 1996, J BIOL CHEM, V271, P31502, DOI 10.1074/jbc.271.49.31502; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; JONES PG, 1994, MOL MICROBIOL, V11, P811, DOI 10.1111/j.1365-2958.1994.tb00359.x; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; MOMAYEZI M, 1987, J CELL BIOL, V105, P181, DOI 10.1083/jcb.105.1.181; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ONISHI H, 1996, AM J PHYSIOL, V271, pG531; Quinlan EM, 1996, J NEUROSCI, V16, P7627; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Williams John A., 1993, P167; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8	39	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22738	22744		10.1074/jbc.273.35.22738	http://dx.doi.org/10.1074/jbc.273.35.22738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712905	hybrid			2022-12-25	WOS:000075616600081
J	Veillette, A; Thibaudeau, E; Latour, S				Veillette, A; Thibaudeau, E; Latour, S			High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE P50(CSK); CELLS; GLYCOPROTEIN; ADHESION; PRODUCT; CLONING; FAMILY; ZAP-70	SHPS-1 (or SIRP) is a member of the immunoglobulin (Ig) superfamily abundantly expressed in neurons and other cell types, Within its cytoplasmic domain, it possesses at least two immunoreceptor tyrosine-based inhibitory motifs, which are targets for tyrosine phosphorylation and mediate the recruitment of SHP-2, an Src homology 2 (SH2) domain-containing protein-tyrosine phosphatase. Since other immunoreceptor tyrosine based inhibitory motifs-containing receptors have critical roles in the negative regulation of hemopoietic cell functions, we wanted to examine the expression of SHPS-1 in cells of hematological lineages. By analyzing a panel of hemopoietic cell lines, evidence was provided that SHPS-1 is abundantly expressed in macrophages and, to a lesser extent, in myeloid cells. No expression was detected in T-cell or B-cell lines. Expression of SHPS-1 could also be documented in normal ex vivo peritoneal macrophages. Further studies showed that SHPS-1 was an efficient tyrosine phosphorylation substrate in macrophages. However, unlike in non-hemopoietic cells, tyrosine-phosphorylated SHPS-1 in macrophages associated primarily with SHP-1 and not SHP-2, Finally, our analyses allowed us to identify several isoforms of SHPS-1 in mouse cells. In part, this heterogeneity was due to differential glycosylation of SHPS-1, Additionally, it was caused by the production of at least two distinct shps-1 transcripts, coding for SHPS-1 polypeptides having different numbers of Ig-like domains in the extracellular region, Taken together, these findings indicate that SHPS-1 is likely to play a significant role in macrophages, at least partially as a consequence of its capacity to recruit SHP-1.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Montreal Gen Hosp, Dept Med, Montreal, PQ H3G 1A4, Canada; Montreal Gen Hosp, Dept Oncol, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University	Veillette, A (corresponding author), McGill Univ, Dept Biochem, Rm 715,McIntyre Med Sci Bldg,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Latour, Sylvain/H-3652-2017	Latour, Sylvain/0000-0001-8238-4391				Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; Brooke GP, 1998, EUR J IMMUNOL, V28, P1, DOI 10.1002/(SICI)1521-4141(199801)28:01&lt;1::AID-IMMU1&gt;3.0.CO;2-V; Cao MY, 1998, J BIOL CHEM, V273, P15765, DOI 10.1074/jbc.273.25.15765; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; CHOW LML, 1994, ONCOGENE, V9, P3437; CHUANG W, 1990, DEV BIOL, V137, P219, DOI 10.1016/0012-1606(90)90249-I; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Comu S, 1997, J NEUROSCI, V17, P8702; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; SHARENBERG AM, 1996, CELL, V87, P961; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047	24	185	206	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22719	22728		10.1074/jbc.273.35.22719	http://dx.doi.org/10.1074/jbc.273.35.22719			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712903	hybrid			2022-12-25	WOS:000075616600079
J	Macias-Silva, M; Hoodless, PA; Tang, SJ; Buchwald, M; Wrana, JL				Macias-Silva, M; Hoodless, PA; Tang, SJ; Buchwald, M; Wrana, JL			Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; TGF-BETA RECEPTOR; MAD-RELATED PROTEIN; MESODERM-INDUCING SIGNALS; DIFFERENTIAL EXPRESSION; DROSOPHILA-MELANOGASTER; NEURAL DIFFERENTIATION; OSTEOGENIC PROTEIN-1; EPIDERMAL INDUCTION; ACTIVIN RECEPTORS	BMP7 and activin are members of the transforming growth factor beta superfamily. Here we characterize endogenous activin and BMP7 signaling pathways in P19 embryonic carcinoma cells. We show that BMP7 and activin bind to the same type II receptors, ActRII and IIB, but recruit distinct type I receptors into heteromeric receptor complexes. The major BMP7 type I receptor observed was ALK2, while activin bound exclusively to ALK4 (ActRIB). BMP7 and activin elicited distinct biological responses and activated different Smad pathways. BMP7 stimulated phosphorylation of endogenous Smad1 and 5, formation of complexes with Smad4 and induced the promoter for the homeobox gene, Tlx2. In contrast, activin induced phosphorylation of Smad2, association with Smad4, and induction of the activin response element from the Xenopus Mix.2 gene. Biochemical analysis revealed that constitutively active ALK2 associated with and phosphorylated Smad1 on the COOH-terminal SSXS motif, and also regulated Smad5 and Smad8 phosphorylation. Activated ALK2 also induced the Tlx2 promoter in the absence of BMP7. Furthermore, we show that ALK1 (TSRI), an orphan receptor that is closely related to ALK2 also mediates Smad1 signaling. Thus, ALK1 and ALK2 induce Smad1-dependent pathways and ALK2 functions to mediate BMP7 but not activin signaling.	Hosp Sick Children, Program Dev Biol, Div Gastroenterol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Wrana, JL (corresponding author), Hosp Sick Children, Program Dev Biol, Div Gastroenterol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jwrana@sickkids.on.ca	Wrana, Jeffrey/F-8857-2013	Macias-Silva, Marina/0000-0002-3972-0983; Hoodless, Pamela/0000-0003-1371-0725				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Arkell R, 1997, DEVELOPMENT, V124, P1; Armes NA, 1997, DEVELOPMENT, V124, P3797; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chang CB, 1997, DEVELOPMENT, V124, P827; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Frisch A, 1998, DEVELOPMENT, V125, P431; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; Hoodless PA, 1997, DEV GENES EVOL, V207, P19, DOI 10.1007/s004270050088; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Ladher R, 1996, DEVELOPMENT, V122, P2385; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIU F, 1995, MOL CELL BIOL, V15, P3479; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Roelen BAJ, 1997, INT J DEV BIOL, V41, P541; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Suzuki A, 1997, DEV BIOL, V189, P112, DOI 10.1006/dbio.1997.8652; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; Tang SJ, 1998, DEVELOPMENT, V125, P1877; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VANDENEIJNDENVANRAAIJ AJM, 1992, DEV BIOL, V154, P356, DOI 10.1016/0012-1606(92)90074-Q; VIDRICAIRE G, 1994, DEVELOPMENT, V120, P115; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940	74	386	420	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25628	25636		10.1074/jbc.273.40.25628	http://dx.doi.org/10.1074/jbc.273.40.25628			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748228	hybrid			2022-12-25	WOS:000076263100019
J	Begum, N; Ragolia, L; Rienzie, J; McCarthy, M; Duddy, N				Begum, N; Ragolia, L; Rienzie, J; McCarthy, M; Duddy, N			Regulation of mitogen-activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells - Evaluation of the role of the nitric oxide signaling pathway and potential defects in hypertension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE-PHOSPHATASE; DNA-SYNTHESIS; RAT; EXPRESSION; STRESS; MKP-1; STIMULATION; CASCADE; PHOSPHORYLATION	In this study, we examined the regulation of mitogen-activated protein kinase phosphatase (MKP-1) expression by insulin in primary vascular smooth muscle cell cultures. Insulin caused a rapid time- and dose-dependent induction of MKP-1 mRNA and protein expression. Blockade of nitric-oxide synthase (NOS) with N-G-monomethyl-L-arginine acetate, and cGMP with RpcGMP, completely inhibited MKP-1 expression. Insulin-mediated MKP-1 expression was preceded by inducible NOS (iNOS) induction and cGMP production. Blockade of phosphatidylinositol 3-kinase (PI3-kinase) signaling with wortmannin inhibited insulin-mediated iNOS protein induction, cGMP production, and MKP-1 expression To evaluate potential interactions between NOS and the mitogen-activated protein kinase (MAPK) signaling pathways, we employed PD98059 and SB203580, two specific inhibitors of ERKs and p38 MAPK. These inhibitors abolished the effect of insulin on MKP-1 expression. Only PD98059 inhibited insulin-mediated iNOS protein induction. Vascular smooth muscle cells from spontaneous hypertensive rats exhibited a marked decrease in MKP-1 induction due to defects in insulin-induced iNOS expression because of reductions in PI3-kinase activity. Treatment with sodium nitroprusside and 8-bromo-cGMP restored MKP-1 mRNA expression to levels comparable with controls. We conclude that insulin-induced MKP-1 expression is mediated by PI3-kinase-initiated signals, leading to the induction of iNOS and elevated cGMP levels that stimulates MKP-1 expression.	Winthrop Univ Hosp, Diabet Res Lab, Mineola, NY 11501 USA; SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Begum, N (corresponding author), Winthrop Univ Hosp, Diabet Res Lab, 259 1st St, Mineola, NY 11501 USA.		Ragolia, Louis/AAW-2383-2021	Ragolia, Louis/0000-0002-8292-5159				Bakris GL, 1996, ENDOCRINOL VASCULATU, P341; BARON AD, 1995, J CLIN INVEST, V96, P786, DOI 10.1172/JCI118124; Begum N, 1998, AM J PHYSIOL-CELL PH, V275, pC42, DOI 10.1152/ajpcell.1998.275.1.C42; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Begum N, 1996, EUR J BIOCHEM, V238, P214, DOI 10.1111/j.1432-1033.1996.0214q.x; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DUFF JL, 1993, J BIOL CHEM, V268, P26037; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAUFMAN PB, 1995, HDB MOL CELLULAR MET, P65; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kusari AB, 1997, MOL ENDOCRINOL, V11, P1532, DOI 10.1210/me.11.10.1532; Lai KH, 1996, J CLIN INVEST, V98, P1560, DOI 10.1172/JCI118949; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Ragolia L, 1997, J BIOL CHEM, V272, P23653, DOI 10.1074/jbc.272.38.23653; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; STOUT RW, 1992, EUR J EPIDEMIOL, V8, P134, DOI 10.1007/BF00145365; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; VINTERS HV, 1987, DIABETES METAB, V13, P294; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	40	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25164	25170		10.1074/jbc.273.39.25164	http://dx.doi.org/10.1074/jbc.273.39.25164			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737976	hybrid			2022-12-25	WOS:000076085400026
J	Chen, M; She, HY; Davis, EM; Spicer, CM; Kim, L; Ren, RB; Le Beau, MM; Li, W				Chen, M; She, HY; Davis, EM; Spicer, CM; Kim, L; Ren, RB; Le Beau, MM; Li, W			Identification of Nck family genes, chromosomal localization, expression, and signaling specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ADAPTER PROTEIN NCK; ALDRICH SYNDROME PROTEIN; SH2 DOMAIN; FACTOR RECEPTOR; DOCKING PROTEIN; KINASE PAK1; TYROSINE; BINDING; CELLS	Already a dozen molecules share binding to the Src homology (SH) 3 domains of human Nck, an SH3-SH3-SH3-SH2 adapter protein. We reason that there may be multiple gene members of Nck to accommodate the large binding repertoires. Here we report identification of novel human and mouse Nck genes and rename them as the Nck alpha and Nck beta genes (including the human Nck alpha, human Nck beta, mouse Nck alpha, and mouse Nck beta genes). Nck alpha and Nck beta share 68% amino acid identity, whereas the two Nck alpha and two Nck beta across the species show 96% identity to each other. The human Nck beta gene is mapped to 2q12, whereas the human Nck alpha gene has previously been mapped at 3q21. Antibodies specifically against Nck alpha and Nck beta detect Nck alpha and Nck beta with an identical molecular mass in the same cells of various origins. Ectopically expressed Nck beta, but not its SH2 domain mutant, strongly inhibits epidermal growth factor- and platelet-derived growth factor-stimulated DNA synthesis. Consistently, epidermal growth factor receptor and platelet-derived growth factor receptor preferentially interact with Nck beta over Nck alpha in vitro. This study indicates that Nck is a multiple gene family and that each gene may have its own signaling specificity. Because previous anti-Nck (human Nck alpha) antibodies cross-react with Nck beta, reassessment of those studies with specific Nck genes would be necessary.	Univ Chicago, Dept Pharmacol & Physiol Sci, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Sect Hematol & Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Brandeis University; Brandeis University	Li, W (corresponding author), Univ Chicago, Dept Pharmacol & Physiol Sci, Ben May Inst Canc Res, 5841 S Maryland,MC6027, Chicago, IL 60637 USA.	wli@ben-may.bsd.uchicago.edu			NATIONAL CANCER INSTITUTE [R01CA065567, R01CA068008] Funding Source: NIH RePORTER; NCI NIH HHS [CA65567, CA40046, CA68008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Choudhury GG, 1996, AM J PHYSIOL-RENAL, V270, pF295, DOI 10.1152/ajprenal.1996.270.2.F295; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HUEBNER K, 1994, GENOMICS, V22, P281, DOI 10.1006/geno.1994.1385; Kitamura Y, 1997, BIOCHEM J, V322, P873, DOI 10.1042/bj3220873; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1991, CELL REGUL, V2, P641, DOI 10.1091/mbc.2.8.641; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Park D, 1997, MOL CELLS, V7, P231; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rockow S, 1996, ONCOGENE, V12, P2351; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	53	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25171	25178		10.1074/jbc.273.39.25171	http://dx.doi.org/10.1074/jbc.273.39.25171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737977	hybrid			2022-12-25	WOS:000076085400027
J	Lee, CH; Chinpaisal, C; Wei, LN				Lee, CH; Chinpaisal, C; Wei, LN			A novel nuclear receptor heterodimerization pathway mediated by orphan receptors TR2 and TR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; MAJOR LATE PROMOTER; RETINOIC ACID; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; RESPONSE ELEMENT; HORMONE-RECEPTOR; GENE-EXPRESSION; I GENE; SUPERFAMILY	A unique heterodimerization pathway involving orphan receptors TR2 and TR4 is demonstrated. TR2 and TR4 preferentially form heterodimers in solution as well as on DNA elements containing a direct repeat-5 (DR5), The in vitro interaction between TR2 and TR4 is demonstrated by the yeast and the mammalian two-hybrid interaction assays, the pull-down assay, and the gel mobility shift assay, The in vivo interaction is demonstrated by following the intracellular localization of fusion receptors tagged with a green fluorescent protein, The dimerization is mediated by the ligand binding domains, and the three leucine residues on helix 10 of TR2 are critical for this interaction. In addition, coexpression of these two receptors exerts a much stronger repressive activity on a DR5-containing reporter than expressing either receptor alone. In the developing testis, TR2 and TR4 are coexpressed in the same testicular cell populations and exhibit a parallel pattern of expression along development. The preferential heterodimerization between TR2 and TR4 and their coexistence in specific germ cell populations suggest a physiological role of TR2/TR4 heterodimers in germ cell development.	Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Dept Pharmacol, Sch Med, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.				NIDA NIH HHS [DA08131, DA11190] Funding Source: Medline; NIDDK NIH HHS [DK46866] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011190, P01DA008131] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chinpaisal C, 1998, J BIOL CHEM, V273, P18077, DOI 10.1074/jbc.273.29.18077; Chinpaisal C, 1997, BIOCHEMISTRY-US, V36, P14088, DOI 10.1021/bi971598z; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HIROSE T, 1995, BIOCHEM BIOPH RES CO, V211, P83, DOI 10.1006/bbrc.1995.1781; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUGLY S, 1988, ENDOCRINOLOGY, V122, P1390, DOI 10.1210/endo-122-4-1390; Lee CH, 1996, MOL REPROD DEV, V44, P305, DOI 10.1002/(SICI)1098-2795(199607)44:3&lt;305::AID-MRD4&gt;3.0.CO;2-Q; Lee CH, 1997, J ENDOCRINOL, V152, P245, DOI 10.1677/joe.0.1520245; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; LEE HJ, 1995, J BIOL CHEM, V270, P30129; LIN TM, 1995, J BIOL CHEM, V270, P30121; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019; PHILIPPE K, 1995, CELL, V83, P859; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SIITERI JE, 1992, BIOL REPROD, V46, P284, DOI 10.1095/biolreprod46.2.284; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wei LN, 1996, J BIOL CHEM, V271, P5073; WHITE R, 1993, TRANSCRIPTION FACTOR, P143; ZHAO LJ, 1995, RECOMBINANT DNA METH, V2, P323	30	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25209	25215		10.1074/jbc.273.39.25209	http://dx.doi.org/10.1074/jbc.273.39.25209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737983	hybrid			2022-12-25	WOS:000076085400033
J	Miyazawa, K; Backstrom, G; Leppanen, O; Persson, C; Wernstedt, C; Hellman, U; Heldin, CH; Ostman, A				Miyazawa, K; Backstrom, G; Leppanen, O; Persson, C; Wernstedt, C; Hellman, U; Heldin, CH; Ostman, A			Role of immunoglobulin-like domains 2-4 of the platelet-derived growth factor alpha-receptor in ligand-receptor complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PDGF RECEPTOR; BETA-RECEPTOR; BB BINDING; TYROSINE KINASE; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; AMINO-ACIDS; FACTOR-AA; DIMERIZATION; IDENTIFICATION	Platelet-derived growth factor (PDGF) is a dimeric protein that exerts its effects through tyrosine Kinase alpha- and beta-receptors. The extracellular part of each receptor is composed of five Ig-like domains. Recombinant forms of a-receptor domains 1-4 (alpha RD1-4), 1-3 (alpha RD1-3), and 1 and 2 (alpha RD1-2) were prepared after expression in Chinese hamster ovary cells and were used to study the assembly of soluble ligand-receptor complexes. When incubated with micromolar concentrations of PDGF, both alpha RD1-3 and alpha RD1-4 formed complexes of 1:2 molar composition, i.e. one dimeric PDGF molecule bound two soluble receptors, alpha RD1-3, in contrast to alpha RD1-4, formed detectable 1:1 complexes under conditions of ligand excess. alpha RD1-4 displayed an increased ability to form 1:2 complexes as compared with alpha RD1-3 under conditions of limiting concentrations of ligand. We thus conclude that Ig-like domain 4-mediated receptor-receptor interactions contribute to 1:2 PDGF.alpha RD1-4 complex formation. Since alpha RD1-4 and alpha RD1-3 were equipotent in blocking binding of subnanomolar concentrations of PDGF to cell-surface receptors, we also conclude that this effect is predominantly achieved through formation of Ig-like domain 4-independent 1:1 ligand-receptor complexes. Finally, since alpha RD1-2 bound PDGF-BB with high affinity, whereas PDGF-AA was bound only with low affinity, we conclude that Ig-like domain 3 of the PDGF alpha-receptor contains epitopes of particular importance for PDGF-AA binding and that most of the PDGF-BB-binding epitopes reside in Ig-like domains 1 and 2.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ostman, A (corresponding author), Ludwig Inst Canc Res, POB 595, S-75124 Uppsala, Sweden.		MIYAZAWA, KEIJI/I-9713-2014					ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; Barleon B, 1997, J BIOL CHEM, V272, P10382; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLECHMAN JM, 1995, CELL, V80, P105; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; GALLAND F, 1993, ONCOGENE, V8, P1233; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HERREN B, 1993, J BIOL CHEM, V268, P15088; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROONEY BC, 1994, FEBS LETT, V339, P181, DOI 10.1016/0014-5793(94)80411-7; Shulman T, 1997, J BIOL CHEM, V272, P17400, DOI 10.1074/jbc.272.28.17400; TERMAN BI, 1991, ONCOGENE, V6, P1677; VASSBOTN FS, 1992, J BIOL CHEM, V267, P15635; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YU JC, 1994, J BIOL CHEM, V269, P10668	40	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25495	25502		10.1074/jbc.273.39.25495	http://dx.doi.org/10.1074/jbc.273.39.25495			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738020	hybrid			2022-12-25	WOS:000076085400070
J	Sebastiao, MP; Saraiva, MJ; Damas, AM				Sebastiao, MP; Saraiva, MJ; Damas, AM			The crystal structure of amyloidogenic Leu(55) -> Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; REFINEMENT; MUTATION; COMPLEX	The x-ray crystal structure of the amyloidogenic Leu(55) --> Pro transthyretin (TTR) variant, implicated as the causative agent in early-onset familial amyloidotic polyneuropathy (Jacobson, D. R., McFarlin, D. E., Kane, I., and Buxbaum, J. N. (1992) Hum. Genet. 89, 353-356), has been solved by molecular replacement, refined at 2.7 Angstrom to a R-cryst value of 0.190 (F-obs > 2.0 sigma), and compared with wild-type transthyretin to understand the molecular mechanism(s) involved in amyloidogenesis. Leu(55) --> Pro TTR crystallizes in space group C2, with eight monomers in the asymmetric unit, and the observed packing contacts are considerably different from those described for the wild-type protein. Refinement of the crystal structure shows that the proline for leucine substitution disrupts the hydrogen bonds between strands D and A, resulting in different interface contacts. Based on the assumption that the observed packing contacts may be significant for amyloidogenesis, a model for the TTR amyloid is proposed. It consists of a tubular structure with inner and outer diameters approximately of 30 and 100 Angstrom and four monomers per cross-section.	Univ Porto, Inst Ciencias Biomed Abel Salazar, Dept Mol Biol, P-4050 Porto, Portugal; Inst Biol Mol & Celular, P-4150 Porto, Portugal	Universidade do Porto; Universidade do Porto	Damas, AM (corresponding author), Univ Porto, Inst Ciencias Biomed Abel Salazar, Dept Mol Biol, Largo Prof Abel Salazar 2, P-4050 Porto, Portugal.	amdamas@ncc.up.pt	Saraiva, Maria João/K-3907-2013	Saraiva, Maria João/0000-0002-3360-6899				ANDRADE C, 1952, BRAIN, V75, P408, DOI 10.1093/brain/75.3.408; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; Bonifacio MJ, 1996, BBA-MOL BASIS DIS, V1316, P35, DOI 10.1016/0925-4439(96)00014-2; Damas AM, 1996, ACTA CRYSTALLOGR D, V52, P966, DOI 10.1107/S0907444996003307; Goldsteins G, 1997, BIOCHEMISTRY-US, V36, P5346, DOI 10.1021/bi961649c; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; Hamilton JA, 1996, AMYLOID, V3, P1, DOI 10.3109/13506129609014349; JACOBSON DR, 1992, HUM GENET, V89, P353; Jenne DE, 1996, P NATL ACAD SCI USA, V93, P6302, DOI 10.1073/pnas.93.13.6302; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANDA Y, 1974, J BIOL CHEM, V249, P6796; KELLY JW, 1994, AMYLOID, V1, P186, DOI 10.3109/13506129409148451; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LANS MC, 1993, CHEM-BIOL INTERACT, V88, P7, DOI 10.1016/0009-2797(93)90081-9; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; RICHARDSON SJ, 1994, AM J PHYSIOL, V266, pR1359, DOI 10.1152/ajpregu.1994.266.4.R1359; SARAIVA MJM, 1995, HUM MUTAT, V5, P191; SARAIVA MJM, 1991, AMYLOID AND AMYLOIDOSIS 1990, P569; Saraiva MJM, 1996, CIBA F SYMP, V199, P47; Sebastiao P, 1996, ACTA CRYSTALLOGR D, V52, P566, DOI 10.1107/S0907444995013965; SERPELL LC, 1995, J MOL BIOL, V254, P113, DOI 10.1006/jmbi.1995.0604; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; VAHLQUIS.A, 1973, EUR J CLIN INVEST, V3, P352, DOI 10.1111/j.1365-2362.1973.tb00362.x	28	109	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24715	24722		10.1074/jbc.273.38.24715	http://dx.doi.org/10.1074/jbc.273.38.24715			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733771	hybrid			2022-12-25	WOS:000076007300063
J	Donato, GM; Kawula, TH				Donato, GM; Kawula, TH			Enhanced binding of altered H-NS protein to flagellar rotor protein FliG causes increased flagellar rotational speed and hypermotility in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOID-ASSOCIATED PROTEIN; SALMONELLA-TYPHIMURIUM; BACTERIAL CHEMOTAXIS; MUTATIONAL ANALYSIS; TORQUE GENERATION; GENE-EXPRESSION; DNA INVERSION; MOTA PROTEIN; MOTILITY; SWITCH	H-NS is an Escherichia coli nucleoid protein known only to function as a modulator of gene expression. In this study, we found that specific single amino acid substitutions in H-NS caused are approximately 50% increase in flagellum rotational speed. In fluorescence anisotropy and chemical cross-linking assays, H-NS interacted with the flagellar torque-generating rotor protein FliG to form a complex with a K-d of 2.15 mu M. Furthermore, one of the altered H-NS proteins that exhibited high speed flagellum rotation bound FliG 50% tighter than wild-type H-NS. These results demonstrate the first non-regulatory role for H-NS and provide a direct correlation between H-NS-FliG binding affinities, flagellar rotation, and motor torque generation.	Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Kawula, TH (corresponding author), Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.	kawula@med.unc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034176] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMSLER CD, 1993, J BACTERIOL, V175, P6238, DOI 10.1128/JB.175.19.6238-6244.1993; Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BERTIN P, 1990, BIOCHIMIE, V72, P889, DOI 10.1016/0300-9084(90)90008-5; BERTIN P, 1994, J BACTERIOL, V176, P5537, DOI 10.1128/JB.176.17.5537-5540.1994; BLAIR DF, 1991, J MOL BIOL, V221, P1433, DOI 10.1016/0022-2836(91)90943-Z; BLAIR DF, 1990, CELL, V60, P439, DOI 10.1016/0092-8674(90)90595-6; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; CONLEY MP, 1989, J BACTERIOL, V171, P5190, DOI 10.1128/jb.171.9.5190-5193.1989; Donato GM, 1997, J BACTERIOL, V179, P6618, DOI 10.1128/jb.179.21.6618-6625.1997; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; FRANCIS NR, 1992, P NATL ACAD SCI USA, V89, P6304, DOI 10.1073/pnas.89.14.6304; GARZA AG, 1995, P NATL ACAD SCI USA, V92, P1970, DOI 10.1073/pnas.92.6.1970; Harshey RM, 1996, TRENDS MICROBIOL, V4, P226, DOI 10.1016/0966-842X(96)10037-8; HINTON JCD, 1992, MOL MICROBIOL, V6, P2327, DOI 10.1111/j.1365-2958.1992.tb01408.x; IRIKURA VM, 1993, J BACTERIOL, V175, P802, DOI 10.1128/JB.175.3.802-810.1993; JONES CJ, 1991, ADV MICROB PHYSIOL, V32, P109, DOI 10.1016/S0065-2911(08)60007-7; KAJITANI M, 1991, NUCLEIC ACIDS RES, V19, P1063, DOI 10.1093/nar/19.5.1063; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; KAWULA TH, 1991, J BACTERIOL, V173, P4116, DOI 10.1128/jb.173.13.4116-4123.1991; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; KHAN S, 1988, J MOL BIOL, V202, P575, DOI 10.1016/0022-2836(88)90287-2; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kutsukake K, 1997, MOL GEN GENET, V254, P440, DOI 10.1007/s004380050437; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LARSEN SH, 1974, P NATL ACAD SCI USA, V71, P1239, DOI 10.1073/pnas.71.4.1239; LARSEN SH, 1974, NATURE, V249, P74, DOI 10.1038/249074a0; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LIU QY, 1993, P NATL ACAD SCI USA, V90, P1761, DOI 10.1073/pnas.90.5.1761; Lloyd SA, 1997, J MOL BIOL, V266, P733, DOI 10.1006/jmbi.1996.0836; Lloyd SA, 1996, J BACTERIOL, V178, P223, DOI 10.1128/jb.178.1.223-231.1996; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MACNAB RM, 1984, ANNU REV BIOPHYS BIO, V13, P51; MANSON MD, 1977, P NATL ACAD SCI USA, V74, P3060, DOI 10.1073/pnas.74.7.3060; Marykwas DL, 1996, J MOL BIOL, V256, P564, DOI 10.1006/jmbi.1996.0109; MAY G, 1990, MOL GEN GENET, V224, P81, DOI 10.1007/BF00259454; OOSAWA K, 1994, J BACTERIOL, V176, P3683, DOI 10.1128/JB.176.12.3683-3691.1994; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; SHINDO H, 1995, FEBS LETT, V360, P125, DOI 10.1016/0014-5793(95)00079-O; SILVERMAN M, 1974, NATURE, V249, P73, DOI 10.1038/249073a0; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; Tang H, 1996, J MOL BIOL, V261, P209, DOI 10.1006/jmbi.1996.0453; TANG H, 1995, J BACTERIOL, V177, P3496, DOI 10.1128/jb.177.12.3496-3503.1995; Togashi F, 1997, J BACTERIOL, V179, P2994, DOI 10.1128/jb.179.9.2994-3003.1997; Toker AS, 1997, J MOL BIOL, V273, P623, DOI 10.1006/jmbi.1997.1335; Ueguchi C, 1996, J MOL BIOL, V263, P149, DOI 10.1006/jmbi.1996.0566; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; USSERY DW, 1994, BIOCHIMIE, V76, P968, DOI 10.1016/0300-9084(94)90022-1; VOGLER AP, 1991, J BACTERIOL, V173, P3564, DOI 10.1128/jb.173.11.3564-3572.1991; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; YAMADA H, 1991, MOL GEN GENET, V230, P332, DOI 10.1007/BF00290685; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986; Zhao RB, 1996, J BACTERIOL, V178, P258, DOI 10.1128/jb.178.1.258-265.1996	57	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24030	24036		10.1074/jbc.273.37.24030	http://dx.doi.org/10.1074/jbc.273.37.24030			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727020	hybrid, Green Published			2022-12-25	WOS:000075893100061
J	McDearmon, EL; Burwell, AL; Combs, AC; Renley, BA; Sdano, MT; Ervasti, JM				McDearmon, EL; Burwell, AL; Combs, AC; Renley, BA; Sdano, MT; Ervasti, JM			Differential heparin sensitivity of alpha-dystroglycan binding to laminins expressed in normal and dy/dy mouse skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; GLYCOPROTEIN COMPLEX; EXTRACELLULAR-MATRIX; CELL-ADHESION; SHORT ARM; IN-VITRO; G-DOMAIN; CHAIN; MEROSIN; MEMBRANE	The alpha-dystroglycan binding properties of laminins extracted from fully differentiated skeletal muscle were characterized. We observed that the laminins expressed predominantly in normal adult rat or mouse skeletal muscle bound alpha-dystroglycan in a Ca2+-dependent, ionic strength-sensitive, but heparin-insensitive manner as we had observed previously with purified placental merosin (Pall, E. A., Bolton, K, M,, and Ervasti, J. M, 1996 J. Biol, Chem, 271, 3817-3821). Rat skeletal muscle laminins partially purified by heparin-agarose affinity chromatography also bound alpha-dystroglycan without sensitivity to heparin. We also confirm previous studies of dystrophic dy/dy mouse skeletal muscle showing that the alpha 2 chain of merosin is reduced markedly and that the laminin alpha 1 chain is not up-regulated detectably. However, we further observed a quantitative decrease in the expression of laminin beta/gamma chain immunoreactivity in alpha 2 chain-deficient dy/dy skeletal muscle and reduced alpha-dystroglycan binding activity in laminin extracts from dy/dy muscle. Most interestingly, the alpha-dystroglycan binding activity of residual laminins expressed in merosin-deficient dy/dy skeletal muscle was inhibited dramatically (69 +/- 19%) by heparin. These results identify a potentially important biochemical difference between the laminins expressed in normal and dy/dy skeletal muscle which may provide a molecular basis for the inability of other laminin variants to compensate fully for the deficiency of merosin in some forms of muscular dystrophy,	Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Grad Program Mol & Cellular Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ervasti, JM (corresponding author), Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.		Ervasti, James/AAZ-4786-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR01985] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEGGS AH, 1991, AM J HUM GENET, V49, P54; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; BRANDENBERGER R, 1995, J CELL SCI, V108, P3099; BROWN JC, 1994, J CELL SCI, V107, P329; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Crawley S, 1997, EXP CELL RES, V235, P274, DOI 10.1006/excr.1997.3671; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; GEE SH, 1993, J BIOL CHEM, V268, P14972; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; Herrmann R, 1996, EUR J PEDIATR, V155, P968, DOI 10.1007/BF02282889; Hodges BL, 1997, J CELL SCI, V110, P2873; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Mayer U, 1997, EUR J BIOCHEM, V245, P745, DOI 10.1111/j.1432-1033.1997.t01-1-00745.x; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; MENKE A, 1995, J CELL SCI, V108, P727; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miyagoe Y, 1997, FEBS LETT, V415, P33, DOI 10.1016/S0014-5793(97)01007-7; Mora M, 1996, NEUROMUSCULAR DISORD, V6, P377, DOI 10.1016/0960-8966(96)00359-8; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; Pall EA, 1996, J BIOL CHEM, V271, P3817; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Ryan MC, 1996, MATRIX BIOL, V15, P369, DOI 10.1016/S0945-053X(96)90157-2; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SCHULER F, 1995, J CELL SCI, V108, P3795; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; SUNADA Y, 1995, NEUROLOGY, V45, P2084, DOI 10.1212/WNL.45.11.2084; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Tiger CF, 1997, MUSCLE NERVE, V20, P1515, DOI 10.1002/(SICI)1097-4598(199712)20:12<1515::AID-MUS6>3.0.CO;2-B; Tiger CF, 1997, J BIOL CHEM, V272, P28590, DOI 10.1074/jbc.272.45.28590; UTANI A, 1995, J BIOL CHEM, V270, P3292, DOI 10.1074/jbc.270.7.3292; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; Yao CC, 1996, J CELL SCI, V109, P3139; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119	60	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24139	24144		10.1074/jbc.273.37.24139	http://dx.doi.org/10.1074/jbc.273.37.24139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727035	hybrid			2022-12-25	WOS:000075893100076
J	Tsumaki, N; Kimura, T; Tanaka, K; Kimura, JH; Ochi, T; Yamada, Y				Tsumaki, N; Kimura, T; Tanaka, K; Kimura, JH; Ochi, T; Yamada, Y			Modular arrangement of cartilage- and neural tissue-specific cis-elements in the mouse alpha 2(XI) collagen promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XI COLLAGEN; FIBRILLAR COLLAGEN; GENE; EXPRESSION; ORGANIZATION; CONTRIBUTE; CLONING; REVEALS; COL11A1; CHAINS	Type XI collagen, a heterotrimer specific to cartilage matrix, plays an important role in cartilage morphogenesis. We analyzed various alpha 2(XI) collagen promoter-lacZ reporter gene constructs in transgenic mice to understand tissue-specific transcriptional regulation. The -530 promoter sequence was sufficient to direct reporter gene expression specifically to cartilage. Further deletion to -500 abolished reporter gene expression iu cartilage but activated the expression specific to neural tissues such as brain and neural tube. An additional 47-base pair deletion resulted in random tissue expression patterns. A 24-base pair sequence from -530 to -507 of the alpha 2(XI) promoter was able to switch the activity of the heterologous neurofilament light gene promoter from neural tissues to cartilage. These results suggest that the alpha 2(XI) collagen gene is regulated by at least three modular elements: a basal promoter sequence distal to -453, a neural tissue-specific element (-454 to -500), and a cartilage-specific element (-501 to -530), which inhibits expression in neural tissues and induces expression in cartilage.	Osaka Univ, Sch Med, Dept Orthopaed Surg, Suita, Osaka 5650871, Japan; NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Henry Ford Hosp, Ctr Bone & Joint, Biochem Sect, Detroit, MI 48202 USA	Osaka University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Henry Ford Health System; Henry Ford Hospital	Tsumaki, N (corresponding author), Osaka Univ, Sch Med, Dept Orthopaed Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Tanaka, Kazuhiro/Q-7387-2019	Tanaka, Kazuhiro/0000-0002-5138-8952; Tsumaki, Noriyuki/0000-0002-0520-3654				Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BONNEROT C, 1993, APPL LACZ GENE FUSIO, P451; Charron G, 1995, J BIOL CHEM, V270, P30604, DOI 10.1074/jbc.270.51.30604; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; FURUTO DK, 1983, ARCH BIOCHEM BIOPHYS, V226, P604, DOI 10.1016/0003-9861(83)90329-6; Hogan B, 1994, MANIPULATING MOUSE E; KIMURA T, 1989, J BIOL CHEM, V264, P13910; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LUI VCH, 1995, BIOCHEM J, V311, P511, DOI 10.1042/bj3110511; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; Sugimoto M, 1998, CELL TISSUE RES, V292, P325, DOI 10.1007/s004410051063; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; YOSHIOKA H, 1995, DEV DYNAM, V204, P41, DOI 10.1002/aja.1002040106	21	26	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22861	22864		10.1074/jbc.273.36.22861	http://dx.doi.org/10.1074/jbc.273.36.22861			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722502	hybrid			2022-12-25	WOS:000075778100002
J	Yu, Q; Pecchia, DB; Kingsley, SL; Heckman, JE; Burke, JM				Yu, Q; Pecchia, DB; Kingsley, SL; Heckman, JE; Burke, JM			Cleavage of highly structured viral RNA molecules by combinatorial libraries of hairpin ribozymes - The mot effective ribozymes are not predicted by substrate selection rules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO RINGSPOT VIRUS; HAMMERHEAD RIBOZYME; NUCLEOTIDE-SEQUENCE; INVITRO SELECTION; ACCESSIBLE SITES; IN-VITRO; SATELLITE; OLIGORIBONUCLEOTIDES; OLIGONUCLEOTIDES; IDENTIFICATION	Combinatorial libraries of hairpin ribozymes representing all possible cleavage specificities (>10(5)) were used to evaluate all ribozyme cleavage sites within a large (4.2-kilobase) and highly structured viral mRNA, the 26 S subgenomic RNA of Sindbis virus, The combinatorial approach simultaneously accounts for target site structure and dynamics, together with ribozyme folding, and the sequences that result in a ribozyme-substrate complex with maximal activity. Primer extension was used to map and rank the relative activities of the ribozyme pool against individual sites and revealed two striking findings. First, only a small fraction of potential recognition sites are effectively cleaved (activity-selected sites). Second, nearly all of the most effectively cleaved sites deviated substantially from the established consensus selection rules for the hairpin ribozyme and were not predicted by examining the sequence, or through the use of computer-assisted predictions of RNA secondary structure. In vitro selection methods were used to isolate ribozymes with increased activity against substrates that deviate from the GUC consensus sequence. trans-Acting ribozymes targeting nine of the activity-selected sites were synthesized, together with ribozymes targeting four sites with a perfect match to the cleavage site consensus (sequence-selected sites). Activity-selected ribozymes have much higher cleavage activity against the long, structured RNA molecules than do sequence-selected ribozymes, although the latter are effective in cleaving oligoribonucleotides, as predicted. These results imply that, for Sindbis virus 26 S RNA, designing ribozymes based on matches to the consensus sequence may be an ineffective strategy.	Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont	Burke, JM (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, 306 Stafford Hall, Burlington, VT 05405 USA.	jburke@zoo.uvm.edu	, John/AAB-5945-2021		NIAID NIH HHS [AI30534, AI29892] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030534, R01AI029892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; Birikh KR, 1997, RNA, V3, P429; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; Burke JM, 1997, NAT BIOTECHNOL, V15, P414, DOI 10.1038/nbt0597-414; BUTCHER SE, 1994, J MOL BIOL, V244, P52, DOI 10.1006/jmbi.1994.1703; BUTCHER SE, 1995, J BIOL CHEM, V270, P29648; BUTCHER SE, 1994, BIOCHEMISTRY-US, V33, P922; Cai ZP, 1996, BIOCHEMISTRY-US, V35, P6026, DOI 10.1021/bi952985g; CAMPBELL TB, 1995, RNA, V1, P598; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; Couture LA, 1996, TRENDS GENET, V12, P510, DOI 10.1016/S0168-9525(97)81398-4; Esteban JA, 1997, J BIOL CHEM, V272, P13629, DOI 10.1074/jbc.272.21.13629; FELDEN B, 1994, J MOL BIOL, V235, P508, DOI 10.1006/jmbi.1994.1010; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; GOODCHILD J, 1992, NUCLEIC ACIDS RES, V20, P4607, DOI 10.1093/nar/20.17.4607; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; Hampel A, 1998, PROG NUCLEIC ACID RE, V58, P1; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; Hampel A, 1997, Methods Mol Biol, V74, P171; Hertel KJ, 1996, EMBO J, V15, P3751, DOI 10.1002/j.1460-2075.1996.tb00745.x; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Jarvis TC, 1996, J BIOL CHEM, V271, P29107, DOI 10.1074/jbc.271.46.29107; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; JOSEPH S, 1993, J BIOL CHEM, V268, P24515; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; LIEBER A, 1995, MOL CELL BIOL, V15, P540, DOI 10.1128/MCB.15.1.540; Lima WF, 1997, J BIOL CHEM, V272, P626; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; RUBINO L, 1990, J GEN VIROL, V71, P1897, DOI 10.1099/0022-1317-71-9-1897; SARGUEIL B, 1995, BIOCHEMISTRY-US, V34, P7739, DOI 10.1021/bi00023a021; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SIMPSON DA, 1996, VIROLOGY, V2, P484; SPROAT B, 1995, NUCLEOS NUCLEOT, V14, P255, DOI 10.1080/15257779508014668; STRAUSS EG, 1984, VIROLOGY, V133, P92, DOI 10.1016/0042-6822(84)90428-8; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; USMAN N, 1996, NUCL ACIDS MOL BIOL, V10, P243; VANTOL H, 1991, VIROLOGY, V180, P23, DOI 10.1016/0042-6822(91)90005-V; Yu Q, 1997, Methods Mol Biol, V74, P161; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	43	50	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23524	23533		10.1074/jbc.273.36.23524	http://dx.doi.org/10.1074/jbc.273.36.23524			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722591	hybrid			2022-12-25	WOS:000075778100091
J	Fiermonte, G; Dolce, V; Palmieri, F				Fiermonte, G; Dolce, V; Palmieri, F			Expression in Escherichia coli, functional characterization, and tissue distribution of isoforms A and B of the phosphate carrier from bovine mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART MITOCHONDRIA; RAT-LIVER MITOCHONDRIA; TRANSPORT PROTEIN; N-ETHYLMALEIMIDE; SACCHAROMYCES-CEREVISIAE; OXOGLUTARATE CARRIER; GENES; YEAST; CARDIOLIPIN; SUBUNIT	The two isoforms of the mammalian mitochondrial phosphate carrier (PiC), A and B, differing in the sequence near the N terminus, arise from alternative splicing of a primary transcript of the Pic gene (Dolce, V., Iacobazzi, V., Palmieri, F., and Walker, J. E. (1994) J. Biol. Chem. 269, 10451-10460). To date, the PiC isoforms A and B have not been studied at the protein level. To explore the tissue-distribution and the potential functional differences between the two isoforms, polyclonal site-directed antibodies specific for PiC-A and PiC-B were raised, and the two bovine isoforms were obtained by expression in Escherichia coli and reconstituted into phospholipid vesicles. Western blot analysis demonstrated that isoform A is present in high amounts in heart, skeletal muscle, and diaphragm mitochondria, whereas isoform B is present in the mitochondria of all tissues examined. Heart and liver bovine mitochondria contained 69 and 0 pmol of PiC-A/mg of protein, and 10 and 8 pmol of PiC-B/mg of protein, respectively. In the reconstituted system the pure recombinant isoforms A and B both catalyzed the two known modes of transport (P-i/P-i antiport and P-i/H+ symport) and exhibited similar properties of substrate specificity and inhibitor sensitivity. However, they strongly differed in their kinetic parameters. The transport affinities of isoform B for phosphate and arsenate were found to be 3-fold lower than those of isoform A Furthermore, the maximum transport rate of isoform B is about 3-fold higher than that of isoform A. These results support the hypothesis that the sequence divergence between PiC-A and PiC-B may have functional significance in determining the affinity and the translocation rate of the substrate through the PiC molecule.	Univ Bari, Dept Pharmaco Biol, Biochem & Mol Biol Lab, I-70125 Bari, Italy	Universita degli Studi di Bari Aldo Moro	Palmieri, F (corresponding author), Univ Bari, Dept Pharmaco Biol, Biochem & Mol Biol Lab, Via E Orabona 4, I-70125 Bari, Italy.	fpalm@farmbiol.uniba.it	Fiermonte, Giuseppe/D-3680-2018; Fiermonte, Giuseppe/F-3159-2010	Fiermonte, Giuseppe/0000-0002-6764-9395; Dolce, Vincenza/0000-0003-2966-4866				BATTINI R, 1987, J BIOL CHEM, V262, P4355; BISACCIA F, 1994, BIOCHEMISTRY-US, V33, P3705, DOI 10.1021/bi00178a030; BISACCIA F, 1984, BIOCHIM BIOPHYS ACTA, V766, P386, DOI 10.1016/0005-2728(84)90254-8; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Capobianco L, 1996, BIOCHEMISTRY-US, V35, P8974, DOI 10.1021/bi960258v; Chappell JB, 1967, BIOCH MITOCHONDRIA, P75; COTY WA, 1975, J BIOL CHEM, V250, P3515; DESANTIS A, 1976, PLANT CELL PHYSIOL, V17, P1221; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; DOLCE V, 1994, J BIOL CHEM, V269, P10451; Dolce V, 1996, FEBS LETT, V399, P95, DOI 10.1016/S0014-5793(96)01294-X; Dyer J, 1997, BIOCHEM BIOPH RES CO, V230, P624, DOI 10.1006/bbrc.1996.6018; FERREIRA GC, 1992, J BIOL CHEM, V267, P5460; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FONYO A, 1980, J BIOENERG BIOMEMBR, V12, P137, DOI 10.1007/BF00744679; Fonyo A, 1975, BIOMEMBRANES STRUCTU, P287; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; GENCHI G, 1988, BIOCHIM BIOPHYS ACTA, V936, P413, DOI 10.1016/0005-2728(88)90018-7; GUERIN B, 1990, J BIOL CHEM, V265, P19736; HADVARY P, 1976, EUR J BIOCHEM, V67, P573, DOI 10.1111/j.1432-1033.1976.tb10723.x; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LAVAT A, 1979, ARCH BIOCHEM BIOPHYS, V194, P405, DOI 10.1016/0003-9861(79)90634-9; MARSH S, 1995, GENOMICS, V29, P814, DOI 10.1006/geno.1995.9924; MATSUDA C, 1993, J BIOL CHEM, V268, P24950; MENDE P, 1983, FEBS LETT, V158, P331, DOI 10.1016/0014-5793(83)80607-3; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1990, BIOCHIM BIOPHYS ACTA, V1018, P147, DOI 10.1016/0005-2728(90)90236-W; PALMIERI F, 1993, J BIOENERG BIOMEMBR, V25, P493, DOI 10.1007/BF01108406; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PALMIERI F, 1998, FRONTIERS CELL BIOEN; Palmieri L, 1997, FEBS LETT, V417, P114, DOI 10.1016/S0014-5793(97)01269-6; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; Phelps A, 1996, BIOCHEMISTRY-US, V35, P10757, DOI 10.1021/bi961052x; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5163; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; Schroers A, 1997, J BIOL CHEM, V272, P10558; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; STAPPEN R, 1994, J BIOL CHEM, V269, P11240; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; WALKER JE, 1987, CHEM SCRIPTA, V27B, P97; WEHRLE JP, 1989, J MEMBRANE BIOL, V111, P199, DOI 10.1007/BF01871006; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8	54	114	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22782	22787		10.1074/jbc.273.35.22782	http://dx.doi.org/10.1074/jbc.273.35.22782			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712911	hybrid			2022-12-25	WOS:000075616600087
J	Ledda-Columbano, GM; Curto, M; Piga, R; Zedda, AI; Menegazzi, M; Sartori, C; Shinozuka, H; Bluethmann, H; Poli, V; Ciliberto, G; Columbano, A				Ledda-Columbano, GM; Curto, M; Piga, R; Zedda, AI; Menegazzi, M; Sartori, C; Shinozuka, H; Bluethmann, H; Poli, V; Ciliberto, G; Columbano, A			In vivo hepatocyte proliferation is inducible through a TNF and IL-6-independent pathway	ONCOGENE			English	Article						cell proliferation; TNF; IL-6; TCPOBOP; ciprofibrate; liver	TUMOR-NECROSIS-FACTOR; PEROXISOME PROLIFERATOR; LIVER-REGENERATION; MOUSE-LIVER; C-FOS; BINDING-PROTEINS; MICE LACKING; RECEPTOR; GROWTH; ALPHA	Recent studies in mice harboring a targeted disruption of genes encoding TNF receptor 1 (TNFR-1) or Interleukin 6 (IL-6) suggested a critical role for TNF and IL-6 in initiation of liver regeneration after 2/3 partial hepatectomy. However, hepatocyte proliferation can also occur following treatment with agents that do not induce tissue loss (primary mitogens). To determine whether the above cytokines could also be involved in mitogen-induced liver cell proliferation, we studied the hepatocyte proliferative response after treatment with primary mitogens in mice knock-out for TNFR-1 or IL-6. Our results showed no difference in the proliferative response of the liver between the wild type and the knock-out mice following treatment with the mitogens I,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), or the peroxisome proliferator, ciprofibrate, suggesting that TNF or IL-6 may not play a major role in this type of proliferation. Gel shift assay indicated that TCPOBOP-induced hepatocyte proliferation is not associated with activation of STAT3 transcription factor, a major target of IL-6 and other growth factors/cytokines. Our results thus indicate that hepatocyte proliferation can be induced by at least two different pathways; compensatory regeneration being TNF and IL-6-dependent, and mitogen-induced direct hyperplasia which does not require TNF or IL-6.	Univ Cagliari, Dipartimento Tossicol, Sez Oncol & Patol Mol, Cagliari, Italy; Univ Rome, Dipartimento Biol Cellulare & Sviluppo, Rome, Italy; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Verona, Ist Sci Biochim, I-37100 Verona, Italy; Hoffman LaRoche, Basel, Switzerland; IRBM, Rome, Italy	University of Cagliari; Sapienza University Rome; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Verona; Roche Holding; Merck & Company	Ledda-Columbano, GM (corresponding author), Univ Cagliari, Dipartimento Tossicol, Sez Oncol & Patol Mol, Cagliari, Italy.		Menegazzi, Marta/AAE-7079-2019; Columbano, Amedeo/C-7463-2011; Ciliberto, Gennaro/J-4131-2017; Poli, Valeria/A-9215-2012	Menegazzi, Marta/0000-0003-1310-9227; Columbano, Amedeo/0000-0002-6956-9030; Ciliberto, Gennaro/0000-0003-2851-8605; Poli, Valeria/0000-0002-3739-3966				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Beebe LE, 1996, BIOCHEM PHARMACOL, V52, P1507, DOI 10.1016/S0006-2952(96)00525-4; BENEDETTI L, 1994, ARCH BIOCHEM BIOPHYS, V309, P1, DOI 10.1006/abbi.1994.1075; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; Columbano A, 1997, ONCOGENE, V14, P857, DOI 10.1038/sj.onc.1200891; CONI P, 1993, HEPATOLOGY, V17, P1109, DOI 10.1002/hep.1840170626; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; Higgins GM, 1931, ARCH PATHOL, V12, P186; HONKAKOSKI P, 1992, BIOCHEM PHARMACOL, V43, P2121, DOI 10.1016/0006-2952(92)90170-N; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Kubo Y, 1996, HEPATOLOGY, V23, P104, DOI 10.1002/hep.510230115; LEVINE WG, 1977, BIOCHEM PHARMACOL, V26, P939, DOI 10.1016/0006-2952(77)90470-1; MANENTI G, 1987, CHEM-BIOL INTERACT, V64, P83, DOI 10.1016/0009-2797(87)90062-7; MENGAZZI M, 1997, HEPATOLOGY, V25, P585; Ohmura T, 1996, AM J PATHOL, V148, P815; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TRAUTWEIN C, 1994, GUT, V35, P1163, DOI 10.1136/gut.35.9.1163; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WHITE TEK, 1993, BIOCHEM BIOPH RES CO, V193, P956, DOI 10.1006/bbrc.1993.1718; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	33	81	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1039	1044		10.1038/sj.onc.1202018	http://dx.doi.org/10.1038/sj.onc.1202018			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747883				2022-12-25	WOS:000075560900012
J	Maerz, WJ; Baselga, J; Reuter, VE; Mellado, B; Myers, ML; Bosl, GJ; Spinella, MJ; Dmitrovsky, E				Maerz, WJ; Baselga, J; Reuter, VE; Mellado, B; Myers, ML; Bosl, GJ; Spinella, MJ; Dmitrovsky, E			FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas	ONCOGENE			English	Article						human embryonal carcinomas; fibroblast growth factor-4; all-trans-retinoic acid; differentiation; tumorigenicity	FIBROBLAST GROWTH-FACTOR; GERM-CELL TUMORS; HUMAN TERATOCARCINOMA CELL; K-FGF; FACTOR-IV; RECEPTOR EXPRESSION; TRANSFORMING GENE; F9 CELLS; LINE; FAMILY	A subset of male germ cell cancers presenting with advanced stage abundantly express the fibroblast growth factor-4 (FGF4), FGF4 expression is restricted in vitro to undifferentiated embryonal carcinomas (ECs), During induced differentiation, FGF4 expression is repressed in maturation sensitive but not resistant human ECs, suggesting FGF4 plays an important role in malignant growth or differentiation of ECs, To explore these FGF4 signals in male germ cell cancers, the multipotent human EC NTERA-2 clone D1 (NT2/D1) cell line was studied, All-trans-retinoic acid (RA)-treatment of these cells induces re neuronal phenotype and represses tumorigenicity and FGF4 expression, In contrast, RA-treatment of retinoid resistant lines derived from NT2/D1 cells failed to repress FGF4 expression, This implicated FGF4 directly in regulating human EC growth or differentiation, To evaluate further this FGF4 role, FGF4 was constitutively over-expressed in NT2/D1 cells using a CMV-driven expression vector containing the neomycin resistance gene, Three stable transfectants expressing exogenous FGF4 were studied as was a control transfectant only expressing the neomycin resistance gene, RA-treatment repressed endogenous but not exogenous FGF4 expression, RA-treatment of these transfectants induced morphologic and immunophenotypic maturation, changes in RA-regulated genes, and a G1 cell cycle arrest in a manner similar to parental NT2/D1 cells, This indicated FGF4 over-expression did not block RA-mediiated differentiation, As expected, RA-treatment repressed tumorigenicity of the control transfectant after subcutaneous injection into athymic mice. Despite RA-treatment, this repressed tumorigenicity was overcome in all the transfectants over-expressing FGF4, The histopathology and neovascularization did not appreciably differ between xenograft tumors derived from FGF4 over-expressing versus control transfectants. FGF4 expression studies were extended to patient-derived germ cell tumors using total cellular RNA Northern analysis and an immunohistochemical assay developed to detect FGF4 protein expression, Germ cell tumors with EC components were significantly more likely to express FGF4 mRNA (P less than or equal to 0.0179) than other examined germ cell tumors without EC components, Immunohistochemical results from 43 germ cell tumors demonstrated increased FGF4 expression especially in non-seminomas having EC components, Thus, FGF4 promotes directly malignant growth of cultured ECs, overcomes the antitumorigenic actions of RA, and is selectively expressed in specific histopathologic subsets of germ cell tumors. Taken together, these findings indicate how differentiation and anti-tumorigenic retinoic acid signals can be dissociated in germ cell cancer.	Mem Hosp, Mol Med Lab, New York, NY 10021 USA; Mem Hosp, Dept Med, New York, NY 10021 USA; Mem Hosp, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Dmitrovsky, E (corresponding author), Mem Hosp, Mol Med Lab, 1275 York Ave, New York, NY 10021 USA.		Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [R01CA054494, U01CA060126, R01CA060126] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA 54494-06, CA 60126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANKO T, 1994, DEV BIOL, V161, P141, DOI 10.1006/dbio.1994.1016; Alanko T, 1996, EXP CELL RES, V228, P306, DOI 10.1006/excr.1996.0330; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Baldassarre G, 1996, INT J CANCER, V66, P538, DOI 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3; BASELGA J, 1993, ONCOGENE, V8, P3257; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAMPBELL WJ, 1992, IN VITRO CELL DEV-AN, V28A, P61; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CROUCH GD, 1991, CANCER RES, V51, P4882; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JUNG M, 1994, CANCER RES, V54, P5194; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; Miller K, 1996, CELL GROWTH DIFFER, V7, P203; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; MUMMERY CL, 1993, BIOCHEM BIOPH RES CO, V191, P188, DOI 10.1006/bbrc.1993.1201; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; PERTOVAARA L, 1993, BIOCHEM BIOPH RES CO, V191, P149, DOI 10.1006/bbrc.1993.1196; Quito FL, 1996, BLOOD, V87, P1282, DOI 10.1182/blood.V87.4.1282.bloodjournal8741282; RUSCH V, 1995, CANCER RES, V55, P1365; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHOFIELD PN, 1991, FEBS LETT, V280, P8, DOI 10.1016/0014-5793(91)80192-6; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STROHMEYER T, 1991, CANCER RES, V51, P1811; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TALARICO D, 1993, MOL CELL BIOL, V13, P1998, DOI 10.1128/MCB.13.4.1998; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; VELCICH A, 1989, ONCOGENE RES, V5, P31; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	50	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	1998	17	6					761	767		10.1038/sj.onc.1201992	http://dx.doi.org/10.1038/sj.onc.1201992			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715278				2022-12-25	WOS:000075337200011
J	Kim, YH; Choi, CY; Lee, SJ; Conti, MA; Kim, Y				Kim, YH; Choi, CY; Lee, SJ; Conti, MA; Kim, Y			Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; HOMEOBOX GENES; EXTRADENTICLE; FTZ; EXPRESSION; SYSTEM; NK-2	A novel family of cofactors that differentially interact with homeoproteins have been identified via a yeast two-hybrid screen. The proteins contain a conserved protein kinase domain that is separated from a domain that interacts with homeoproteins and hence are termed homeodomain-interacting protein kinases (HIPKs): HIPK1, HIPK2, and HIPK3, We show that HIPKs are nuclear kinases using GFP-HIPK fusion constructs. The DNA binding activity of the NK-3 homeoprotein is greatly enhanced by HIPK2, but this effect is independent of its phosphorylation by HIPK2. In cultured cells, HIPKs localize to nuclear speckles and potentiate the repressor activities of NK homeoproteins. The co-repressor activity of HIPKs depends on both its homeodomain interaction domain and a co-repressor domain that maps to the N terminus. Thus, HIPKs represent a heretofore undescribed family of co-repressors for homeodomain transcription factors.	NHLBI, LMC, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kim, Y (corresponding author), NHLBI, LMC, NIH, Bldg 10,Rm 8N228,10 Ctr Dr MSC1762, Bethesda, MD 20892 USA.			Lee, Seung-Jae/0000-0002-5155-5335				Burglin T.R, 1994, EVOLUTION HOMEOBOX G, P27; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Hong SB, 1997, GENE, V198, P373, DOI 10.1016/S0378-1119(97)00340-5; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; KRAUSE HM, 1989, EMBO J, V8, P1197, DOI 10.1002/j.1460-2075.1989.tb03492.x; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SCHUBERT FR, 1995, MECH DEVELOP, V51, P99, DOI 10.1016/0925-4773(95)00358-8; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0	24	241	257	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25875	25879		10.1074/jbc.273.40.25875	http://dx.doi.org/10.1074/jbc.273.40.25875			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748262	hybrid			2022-12-25	WOS:000076263100053
J	Yang, YN; Turner, RS; Gaut, JR				Yang, YN; Turner, RS; Gaut, JR			The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases A beta 40 and A beta 42 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; ENDOPLASMIC-RETICULUM; IN-VIVO; INTRACELLULAR PRODUCTION; HUMAN NEURONS; NT2N CELLS; PRESENILIN-1; BIP; PEPTIDE	Recent studies of cellular amyloid precursor protein (APP) metabolism demonstrate a beta-/gamma-secretase pathway resident to the endoplasmic reticulum (ER)/Golgi resulting in intracellular generation of soluble APP (APPs beta) and A beta 42 peptide. Thus, these intracellular compartments may be key sites of amyloidogenic APP metabolism and Alzheimer's disease pathogenesis. We hypothesized that the ER chaperone immunoglobulin binding protein (BiP/GRP78) binds to and facilitates correct folding of nascent APP. Metabolic labeling and immunoprecipitation of transiently transfected human embryonic kidney 293 cells demonstrated co-precipitation of APP with GRP78, revealing their transient interaction in the ER. Maturation of cellular APP was impaired by this interaction. Furthermore, the levels of APPs, A beta 40, and A beta 42 recovered in conditioned medium were lower compared with cells transfected with APP alone. Coexpression with APP of GRP78 T37G, an ATPase mutant, almost completely blocked cellular APP maturation as well as recovery of APPs, A beta 40, and A beta 42 in conditioned medium. The inhibitory effects of GRP78 and GRP78 T37G on A beta 40 and A beta 42 secretion mere magnified by co-expression with the Swedish mutation of APP (K670N/M671L). Collectively, these data suggest a transient and direct interaction of GRP78 with APP in the ER that modulates intracellular APP maturation and processing and may facilitate its correct folding.	Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan	Gaut, JR (corresponding author), Univ Michigan, Inst Gerontol, 300 NIB 974-2007, Ann Arbor, MI 48109 USA.	jrgaut@umich.edu	Turner, Raymond Scott/G-2263-2011	Turner, Raymond Scott/0000-0001-7534-2935	NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG08671, P50 AG008671] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; He XY, 1998, J BIOL CHEM, V273, P10741, DOI 10.1074/jbc.273.17.10741; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Yan SD, 1997, NATURE, V389, P689	33	165	176	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25552	25555		10.1074/jbc.273.40.25552	http://dx.doi.org/10.1074/jbc.273.40.25552			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748217	hybrid			2022-12-25	WOS:000076263100008
J	Rao, AW; Ceresa, BP; Santeler, SR; Pessin, JE				Rao, AW; Ceresa, BP; Santeler, SR; Pessin, JE			Expression of a dominant interfering dynamin mutant in 3T3L1 adipocytes inhibits GLUT4 endocytosis without affecting insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE-TRANSPORTER; PLECKSTRIN HOMOLOGY DOMAIN; COATED VESICLE FORMATION; ISOLATED RAT ADIPOCYTES; SKELETAL-MUSCLE; MEDIATED ENDOCYTOSIS; INTRACELLULAR SEQUESTRATION; STIMULATED TRANSLOCATION; SUBCELLULAR TRAFFICKING; RECEPTOR SUBSTRATE-1	To examine the role of clathrin-coated vesicle endocytosis in insulin receptor signaling and GLUT4 trafficking, we used recombinant adenovirus to express a dominant interfering mutant of dynamin (K44A/dynamin) in 3T3L1 adipocytes, Functional expression of K44A/dynamin, as measured by inhibition of transferrin receptor internalization, did not affect insulin-stimulated insulin receptor autophosphorylation, Shc tyrosine phosphorylation, or mitogen-activated protein kinase activation. Although the tyrosine phosphorylation of insulin receptor substrate-1 was slightly reduced, correlating with a 25% decrease in insulin receptor substrate-1-associated phosphatidylinositol 3-kinase activity, insulin-stimulated Akt kinase activation was unaffected. In contrast, expression of K44A/dynamin resulted in the cell-surface accumulation of GLUT4 under basal conditions and an inhibition of GLUT4 endocytosis without affecting insulin-stimulated GLUT4 exocytosis. These data demonstrate that disruption of clathrin-mediated endocytosis does not significantly perturb insulin receptor signal transduction pathways. Furthermore, K44A/dynamin expression causes an accumulation of GLUT4 at the cell surface, suggesting that GLUT4 vesicles exist in at least two distinct intracellular compartments, one that undergoes continuous recycling and a second that is responsive to insulin.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823, P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33823, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; Araki S, 1996, BIOCHEM J, V315, P153, DOI 10.1042/bj3150153; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bevan AP, 1997, J BIOL CHEM, V272, P26833, DOI 10.1074/jbc.272.43.26833; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CODERRE L, 1995, J BIOL CHEM, V270, P27584, DOI 10.1074/jbc.270.46.27584; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Dobson SP, 1996, FEBS LETT, V393, P179, DOI 10.1016/0014-5793(96)00879-4; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Gnudi L, 1997, MOL ENDOCRINOL, V11, P67, DOI 10.1210/me.11.1.67; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAMB JE, 1983, J BIOL CHEM, V258, P8751; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MIKI H, 1994, J BIOL CHEM, V269, P5489; MOULE SK, 1997, AM J CARDIOL, V80, P41; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; MUNOZ P, 1995, BIOCHEM J, V307, P273, DOI 10.1042/bj3070273; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Omata W, 1997, BIOCHEM BIOPH RES CO, V241, P401, DOI 10.1006/bbrc.1997.7810; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; Turinsky J, 1996, BIOCHEM J, V313, P215, DOI 10.1042/bj3130215; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; YANG J, 1993, J BIOL CHEM, V268, P4600; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	66	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25450	25457		10.1074/jbc.273.39.25450	http://dx.doi.org/10.1074/jbc.273.39.25450			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738014	hybrid			2022-12-25	WOS:000076085400064
J	Zhou, JS; Cribbs, L; Yi, JX; Shirokov, R; Perez-Reyes, E; Rios, E				Zhou, JS; Cribbs, L; Yi, JX; Shirokov, R; Perez-Reyes, E; Rios, E			Molecular cloning and functional expression of a skeletal muscle dihydropyridine receptor from Rana catesbeiana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; DEPENDENT PROTEIN-KINASE; 2 SIZE FORMS; CA2+ CHANNELS; ALPHA-1 SUBUNIT; BETA-SUBUNIT; ACTIVATION; INACTIVATION; SEQUENCE; FIBERS	In skeletal muscle the dihydropyridine receptor is the voltage sensor for excitation-contraction coupling and an L-type Ca2+ channel. We cloned a dihydropyridine receptor (named Fg alpha 1S) from frog skeletal muscle, where excitation-contraction coupling has been studied most extensively. Fg alpha 1S contains 5600 base pairs coding for 1688 amino acids. It is highly homologous with, and of the same length as, the C-truncated form predominant in rabbit muscle. The primary sequence has every feature needed to be an L-type Ca2+ channel and a skeletal-type voltage sensor. Currents expressed in tsA201 cells had rapid activation (5-10 ms half-time) and Ca2+ dependent inactivation. Although functional expression of the full Fg alpha 1S was difficult, the chimera consisting of Fg alpha 1S domain I in the rabbit cardiac Ca channel had high expression and a rapidly activating current. The slow native activation is therefore not determined solely by the alpha 1 subunit sequence. Its Ca2+-dependent inactivation strengthens the notion that in rabbit skeletal muscle this capability is inhibited by a C-terminal stretch (Adams, B., and Tanabe, T, (1997) J. Gen. Physiol. 110, 379-389). This molecule constitutes a new tool for studies of excitation-contraction coupling, gating, modulation, and gene expression.	Rush Univ, Dept Mol Biophys & Physiol, Chicago, IL 60612 USA; Loyola Univ, Dept Physiol, Maywood, IL 60153 USA	Rush University; Loyola University Chicago	Rios, E (corresponding author), Rush Univ, Dept Mol Biophys & Physiol, 1750 W Harrison, Chicago, IL 60612 USA.	erios@rush.edu			NIAMS NIH HHS [AR43113] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043113] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams B, 1997, J GEN PHYSIOL, V110, P379, DOI 10.1085/jgp.110.4.379; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; AVILASAKAR AJ, 1986, J MUSCLE RES CELL M, V7, P291, DOI 10.1007/BF01753649; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; Berjukow S, 1996, BRIT J PHARMACOL, V118, P748, DOI 10.1111/j.1476-5381.1996.tb15463.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTA G, 1986, J PHYSIOL-LONDON, V370, P151, DOI 10.1113/jphysiol.1986.sp015927; COTA G, 1983, J PHYSIOL-LONDON, V338, P395, DOI 10.1113/jphysiol.1983.sp014679; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FELDMEYER D, 1990, J PHYSIOL-LONDON, V425, P347, DOI 10.1113/jphysiol.1990.sp018107; Ferreira G, 1997, J GEN PHYSIOL, V109, P449, DOI 10.1085/jgp.109.4.449; GARCIA J, 1990, PFLUG ARCH EUR J PHY, V417, P114, DOI 10.1007/BF00370779; GARCIA J, 1990, PFLUG ARCH EUR J PHY, V416, P210, DOI 10.1007/BF00370245; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HOGAN K, 1994, GENOMICS, V24, P608, DOI 10.1006/geno.1994.1677; Johnson BD, 1997, J NEUROSCI, V17, P1243; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LAI Y, 1990, J BIOL CHEM, V265, P20839; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; Ren DJ, 1997, J BIOL CHEM, V272, P22393, DOI 10.1074/jbc.272.36.22393; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; ROTMAN EI, 1995, J BIOL CHEM, V270, P16371, DOI 10.1074/jbc.270.27.16371; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TOMASELLI GF, 1993, CIRC RES, V72, P491, DOI 10.1161/01.RES.72.3.491; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WANG ZY, 1995, J PHYSIOL-LONDON, V486, P131, DOI 10.1113/jphysiol.1995.sp020797; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; ZONG ZQ, 1994, BIOCHEM BIOPH RES CO, V201, P1117, DOI 10.1006/bbrc.1994.1821	48	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25503	25509		10.1074/jbc.273.39.25503	http://dx.doi.org/10.1074/jbc.273.39.25503			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738021	hybrid			2022-12-25	WOS:000076085400071
J	Baneres, JL; Roquet, F; Green, M; LeCalvez, H; Parello, J				Baneres, JL; Roquet, F; Green, M; LeCalvez, H; Parello, J			The cation-binding domain from the alpha subunit of integrin alpha(5)beta(1) is a minimal domain for fibronectin recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; DEPENDENT ADHESION SITE; CRYSTAL-STRUCTURE; LIGAND-BINDING; I-DOMAIN; CELL-ADHESION; CRITICAL RESIDUES; DIVALENT-CATIONS	The cation-binding domain from the alpha subunit of human integrin alpha(5)beta(1) was produced as a recombinant protein, alpha(5)-(229-448). This protein displays a well defined fold with a content of 30-35% alpha-helix and 20-25% beta-strand, based on circular dichroism. The binding of Ca2+ or Mg2+ to alpha(5)-(229-448) results in a biphasic conformational rearrangement consistent with the occurrence of two classes of cation-binding sites differing by their affinities. The two classes of sites are located in two conformationally independent lobes, as established by a parallel study of two recombinant half-domains (Nand C-terminal) that also adopt stable folds. Upon saturation with divalent cations, alpha(5)-(229-448) binds an Arg-Gly-Asp (RGD)-containing fibronectin ligand to form a 1:1 complex. Complex formation is associated with a specific conformational adaptation of the Ligand, suggesting an induced fit mechanism. In contrast, neither of the half-domains is competent for ligand binding. The alpha(5)-(229-448)-fibronectin complex is dissociated in the presence of an RGD peptide, as well as of a simple carboxylic acid, suggesting that the RGD aspartyl carboxylate is an essential element that directly interacts with the alpha(5) cation-binding domain.	Fac Pharm Montpellier, CNRS, UMR 9921, F-34060 Montpellier 2, France; Burnham Inst, La Jolla, CA 92037 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Sanford Burnham Prebys Medical Discovery Institute	Parello, J (corresponding author), Fac Pharm Montpellier, CNRS, UMR 9921, 15 Ave Charles Flahault, F-34060 Montpellier 2, France.	joseph@pharma.univ-montpl.fr			NCI NIH HHS [5PO1CA28896-15] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alemany M, 1996, BLOOD, V87, P592, DOI 10.1182/blood.V87.2.592.bloodjournal872592; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; [Anonymous], 1996, CIRCULAR DICHROISM C; AOTA S, 1994, J BIOL CHEM, V269, P24756; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BENZONANA G, 1972, BIOCHIM BIOPHYS ACTA, V278, P110, DOI 10.1016/0005-2795(72)90111-0; BLANCUZZI Y, 1993, BIOCHEMISTRY-US, V32, P1302, DOI 10.1021/bi00056a015; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EDWARDS JG, 1988, J CELL SCI, V89, P507; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLUKHOVA MA, 1993, SEMIN CANCER BIOL, V4, P241; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GULINO D, 1992, J BIOL CHEM, V267, P1001; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; Lombardo A, 1996, PROTEIN SCI, V5, P1934, DOI 10.1002/pro.5560050922; LOSTER K, 1995, J CHROMATOGR A, V711, P187, DOI 10.1016/0021-9673(95)00208-5; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARTIN SR, 1986, BIOCHEM J, V238, P485, DOI 10.1042/bj2380485; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; PARELLO J, 1971, BIOCHIMIE, V53, P1079, DOI 10.1016/S0300-9084(71)80196-7; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROQUET F, 1992, J MOL BIOL, V223, P705, DOI 10.1016/0022-2836(92)90985-S; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINHA D, 1994, BIOTECHNIQUES, V17, P509; Smith J.W., 1994, INTEGRINS MOL BIOL R, P1; SPEICHER DW, 1989, TECHNIQUES PROTEIN C, V1, P24; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; Stempfer G, 1996, NAT BIOTECHNOL, V14, P329, DOI 10.1038/nbt0396-329; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tatsumi R, 1997, ANAL BIOCHEM, V254, P126, DOI 10.1006/abio.1997.2369; THOMAS JO, 1989, METHOD ENZYMOL, V170, P549; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; TUCKWELL DS, 1997, INTEGRIN LIGAND INTE, P199; VANDERWE.DR, 1971, FEBS LETT, V14, P333, DOI 10.1016/0014-5793(71)80294-6; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575	58	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24744	24753		10.1074/jbc.273.38.24744	http://dx.doi.org/10.1074/jbc.273.38.24744			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733775	hybrid			2022-12-25	WOS:000076007300067
J	Burstein, ES; Spalding, TA; Brann, MR				Burstein, ES; Spalding, TA; Brann, MR			The second intracellular loop of the m5 muscarinic receptor is the switch which enables G-protein coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RANDOM SATURATION MUTAGENESIS; BETA-ADRENERGIC RECEPTORS; INVERSE AGONIST ACTIVITY; HIGH-THROUGHPUT ASSAYS; 3RD CYTOPLASMIC LOOP; CONNECTING HELIX-C; ACETYLCHOLINE-RECEPTOR; CONSTITUTIVE ACTIVATION; AMINO-ACID	We have completed a systematic search of the intracellular loops of a muscarinic acetylcholine receptor for domains that govern G-protein coupling. A unique feature of the second intracellular (i2) loop was an ordered cluster of residues where diverse substitutions cause constitutive activation. A second group of residues in i2 was identified where mutations compromised receptor/ G-protein coupling. The residues of each group alternate and are spaced three to four positions apart, suggesting an cu-helical structure where these groups form opposing faces of the helix. We propose that the constitutively activating face normally constrains the receptor in the "off-state," while the other face couples G-proteins in the "on-state." Therefore, the i2 loop functions as the switch enabling G-protein activation.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA		Burstein, ES (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley, San Diego, CA 92121 USA.							ARDEN JR, 1992, BIOCHEM BIOPH RES CO, V188, P1111, DOI 10.1016/0006-291X(92)91346-R; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BLUML K, 1994, J BIOL CHEM, V269, P18870; BLUML K, 1994, P NATL ACAD SCI USA, V91, P7980, DOI 10.1073/pnas.91.17.7980; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Burstein ES, 1998, BIOCHEMISTRY-US, V37, P4052, DOI 10.1021/bi972132j; Burstein ES, 1996, BIOCHEM PHARMACOL, V51, P539, DOI 10.1016/0006-2952(95)02234-1; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1997, MOL PHARMACOL, V51, P312, DOI 10.1124/mol.51.2.312; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; Burstein ES, 1997, J NEUROCHEM, V68, P525; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; DUERSON K, 1993, FEBS LETT, V324, P103, DOI 10.1016/0014-5793(93)81541-7; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; HOGGER P, 1995, J BIOL CHEM, V270, P7405; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Jakubik J, 1995, FEBS LETT, V377, P275, DOI 10.1016/0014-5793(95)01360-1; JONES PG, 1995, EUR J PHARM-MOLEC PH, V288, P251, DOI 10.1016/0922-4106(95)90036-5; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; Lu ZL, 1997, MOL PHARMACOL, V51, P234, DOI 10.1124/mol.51.2.234; MATSUI H, 1995, MOL PHARMACOL, V47, P88; MESSIER TL, 1995, PHARMACOL TOXICOL, V76, P308, DOI 10.1111/j.1600-0773.1995.tb00152.x; MORO O, 1993, J BIOL CHEM, V268, P22273; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; TIAN WN, 1994, MOL PHARMACOL, V45, P524; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219	67	105	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24322	24327		10.1074/jbc.273.38.24322	http://dx.doi.org/10.1074/jbc.273.38.24322			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733718	hybrid			2022-12-25	WOS:000076007300010
J	Dukes, ID; Sreenan, S; Roe, MW; Levisetti, M; Zhou, YP; Ostrega, D; Bell, GI; Pontoglio, M; Yaniv, M; Philipson, L; Polonsky, KS				Dukes, ID; Sreenan, S; Roe, MW; Levisetti, M; Zhou, YP; Ostrega, D; Bell, GI; Pontoglio, M; Yaniv, M; Philipson, L; Polonsky, KS			Defective pancreatic beta-cell glycolytic signaling in hepatocyte nuclear factor-1 alpha-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; INSULIN-SECRETION; MOUSE ISLETS; B-CELLS; GLUCOSE; EXPRESSION; RELEASE; MODY3; ONSET; RAT	Mutations in the hepatocyte nuclear factor-1 alpha (HNF-1 alpha) gene cause maturity onset diabetes of the young type 3, a form of type 2 diabetes mellitus, In mice lacking the HNF-1 alpha gene, insulin secretion and intracellular calcium ([Ca2+](i)) responses were impaired following stimulation with nutrient secretagogues such as glucose and glyceraldehyde but normal with non-nutrient stimuli such as potassium chloride. Patch clamp recordings revealed ATP-sensitive K+ currents (KATP) in beta-cells that were insensitive to suppression by glucose but normally sensitive to ATP, Exposure to mitochondrial substrates suppressed KATP, elevated [Ca2+](i), and corrected the insulin secretion defect. NAD(P)H responses to glucose were substantially reduced, and inhibitors of glycolytic NADH generation reproduced the mutant phenotype in normal islets. Flux of glucose through glycolysis in islets from mutant mice was reduced, as a result of which ATP generation in response to glucose was impaired. We conclude that hepatocyte nuclear factor-1 alpha diabetes results from defective beta-cell glycolytic signaling, which is potentially correctable using substrates that bypass the defect.	Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Chicago, IL 60637 USA; Glaxo Wellcome Inc, Res Inst, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Inst Pasteur, CNRS, Unite Rech Associee 1644, Dept Biotechnol, F-75015 Paris, France	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; GlaxoSmithKline; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Polonsky, KS (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, 5841 S Maryland Ave,MC 1027, Chicago, IL 60637 USA.	polonsky@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031842, P60DK020595, P01DK044840, R01DK031842, P30DK020595] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31842, DK44840, DK20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BENZ R, 1983, BIOPHYS J, V41, P381, DOI 10.1016/S0006-3495(83)84449-X; Budinger GRS, 1998, J BIOL CHEM, V273, P3320, DOI 10.1074/jbc.273.6.3320; Byrne MM, 1996, DIABETES, V45, P1503, DOI 10.2337/diabetes.45.11.1503; Cockburn BN, 1997, DIABETES, V46, P1434, DOI 10.2337/diabetes.46.9.1434; COOK DL, 1984, NATURE, V312, P446; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; DUKES ID, 1994, J BIOL CHEM, V269, P10979; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Fajans SS, 1996, DIABETIC MED, V13, pS90; FINDLAY I, 1991, CIRC RES, V69, P623; Froguel P, 1996, DIABETIC MED, V13, pS96; Jijakli H, 1996, ARCH BIOCHEM BIOPHYS, V335, P245, DOI 10.1006/abbi.1996.0505; Lehto M, 1997, J CLIN INVEST, V99, P582, DOI 10.1172/JCI119199; Leyssens A, 1996, J PHYSIOL-LONDON, V496, P111, DOI 10.1113/jphysiol.1996.sp021669; LIU ZR, 1995, BIOCHEM J, V308, P105, DOI 10.1042/bj3080105; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MEGLASSON MD, 1986, DIABETES METAB REV, V2, P215; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MISLER S, 1992, PFLUG ARCH EUR J PHY, V421, P289, DOI 10.1007/BF00374842; Mukai E, 1998, AM J PHYSIOL-ENDOC M, V274, pE38, DOI 10.1152/ajpendo.1998.274.1.E38; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; ROE MW, 1993, J BIOL CHEM, V268, P9953; SENER A, 1987, DIABETES, V36, P187, DOI 10.2337/diabetes.36.2.187; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; STURIS J, 1994, AM J PHYSIOL, V267, pE250, DOI 10.1152/ajpendo.1994.267.2.E250; TRENTHAM DR, 1968, BIOCHEM J, V109, P603, DOI 10.1042/bj1090603; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Zhou YP, 1996, AM J PHYSIOL-ENDOC M, V270, pE988, DOI 10.1152/ajpendo.1996.270.6.E988	35	142	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24457	24464		10.1074/jbc.273.38.24457	http://dx.doi.org/10.1074/jbc.273.38.24457			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733737	hybrid			2022-12-25	WOS:000076007300029
J	Song, JM; Midson, C; Blachly-Dyson, E; Forte, M; Colombini, M				Song, JM; Midson, C; Blachly-Dyson, E; Forte, M; Colombini, M			The topology of VDAC as probed by biotin modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; PEPTIDE-SPECIFIC ANTIBODIES; ANION-SELECTIVE CHANNEL; VOLTAGE-GATED CHANNEL; MOLECULAR-STRUCTURE; ION CHANNEL; PROTEIN; TOPOGRAPHY; YEAST	The outer membrane of mitochondria contains channels called VDAC (mitochondrial porin), which are formed by a single 30-kDa protein. Cysteine residues introduced by site-directed mutagenesis at sites throughout Neurospora crassa VDAC (naturally devoid of cysteine) were specifically biotinylated prior to reconstitution into planar phospholipid membranes. From previous studies, binding of streptavidin to single biotinylated sites results in one of two effects: reduced single-channel conductance without blockage of voltage gating (type 1) or locking of the channels in a closed conformation (type 2). All sites react with streptavidin only from one side of the membrane, Here, me extend this approach to VDAC molecules containing two cysteines and determine the location of each biotinylated residue with respect to the other within the membrane. When a combination of a type 1 and a type 2 site was used, each site could be observed to react with streptavidin. Two sets of sites located on opposite surfaces of the membrane were identified, thereby establishing the transmembrane topology of VDAC. A revised folding pattern for VDAC, consisting of 1 alpha helix and 13 beta strands, is proposed by combining these results with previously obtained information on which sites are lining the aqueous pore.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	University System of Maryland; University of Maryland College Park; Oregon Health & Science University	Colombini, M (corresponding author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA.		Colombini, Marco/A-1540-2014		NIGMS NIH HHS [GM 35759] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; COLOMBINI M, 1992, METHOD ENZYMOL, V207, P432; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P297; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; GUO XW, 1995, J STRUCT BIOL, V114, P41, DOI 10.1006/jsbi.1995.1004; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; MANNELLA CA, 1989, FEBS LETT, V253, P231, DOI 10.1016/0014-5793(89)80965-2; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; PENG SZ, 1992, J BIOENERG BIOMEMBR, V24, P27, DOI 10.1007/BF00769527; QIU XQ, 1994, J BIOL CHEM, V269, P7483; RAUCH G, 1994, BIOCHEM BIOPH RES CO, V200, P908, DOI 10.1006/bbrc.1994.1536; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Song JM, 1996, J BIOENERG BIOMEMBR, V28, P153, DOI 10.1007/BF02110646; Song JM, 1998, BIOPHYS J, V74, P2926, DOI 10.1016/S0006-3495(98)78000-2; STANLEY S, 1995, J BIOL CHEM, V270, P16694, DOI 10.1074/jbc.270.28.16694; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; THOMAS L, 1991, J STRUCT BIOL, V106, P161, DOI 10.1016/1047-8477(91)90085-B	24	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24406	24413		10.1074/jbc.273.38.24406	http://dx.doi.org/10.1074/jbc.273.38.24406			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733730	hybrid			2022-12-25	WOS:000076007300022
J	Tsukaguchi, H; Shayakul, C; Berger, UV; Mackenzie, B; Devidas, S; Guggino, WB; van Hoek, AN; Hediger, MA				Tsukaguchi, H; Shayakul, C; Berger, UV; Mackenzie, B; Devidas, S; Guggino, WB; van Hoek, AN; Hediger, MA			Molecular characterization of a broad selectivity neutral solute channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; WATER CHANNELS; UREA TRANSPORTER; XENOPUS-OOCYTES; RAT-KIDNEY; FUNCTIONAL EXPRESSION; CLONING; MEMBRANE; GLYCEROL; CELLS	In all living cells, coordination of solute and water movement across cell membranes is of critical importance for osmotic balance. The current concept is that these processes are of distinct biophysical nature. Here we report the expression cloning of a Liver cDNA encoding a unique promiscuous solute channel (AQP9) that confers high permeability for both solutes and water. AQP9 mediates passage of a wide variety of non-charged solutes including carbamides, polyols, purines, and pyrimidines in a phloretin- and mercury-sensitive manner, whereas amino acids, cyclic sugars, Na+, K+, Cl-, and deprotonated monocarboxylates are excluded. The properties of AQP9 define a new evolutionary branch of the major intrinsic protein family of aquaporin proteins and describe a previously unknown mechanism by which a large variety of solutes and water can pass through a single pore, enabling rapid cellular uptake or exit of metabolites with minimal osmotic perturbation.	Brigham & Womens Hosp, Div Renal, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Massachusetts Gen Hosp, Renal Unit, Boston, MA 02129 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Hediger, MA (corresponding author), Brigham & Womens Hosp, Div Renal, Dept Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.			Mackenzie, Bryan/0000-0002-9661-8838; Hediger, Matthias/0000-0003-1946-027X; Van Hoek, Alfred/0000-0003-2724-6855	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046289, R37DK032753, P01DK038452, R01DK032753] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46289, DK32753, DK38452] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; Che MX, 1997, FASEB J, V11, P101, DOI 10.1096/fasebj.11.2.9039951; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; EFFROS RM, 1993, J CLIN INVEST, V91, P2822, DOI 10.1172/JCI116525; Erlinger Serge, 1994, P769; FAIRNESS J, 1995, BIOPSY J, V68, P1613; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; HASEGAWA H, 1993, AM J PHYSIOL, V265, pC514, DOI 10.1152/ajpcell.1993.265.2.C514; Ishibashi K, 1997, J BIOL CHEM, V272, P20782, DOI 10.1074/jbc.272.33.20782; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V244, P268, DOI 10.1006/bbrc.1998.8252; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; KEDEM O, 1958, BIOCHIM BIOPHYS ACTA, V27, P229, DOI 10.1016/0006-3002(58)90330-5; Knepper MA, 1996, KIDNEY INT, V49, P1712, DOI 10.1038/ki.1996.253; LIDE DR, 1997, HDB CHEM PHYSICS; MA TH, 1994, J BIOL CHEM, V269, P21845; MANNUZZU LM, 1993, J MEMBRANE BIOL, V133, P85; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; ROMERO MF, 1998, METHODS ENZYMOL, V296; SMITH CP, 1995, J CLIN INVEST, V96, P1556, DOI 10.1172/JCI118194; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; Tsukaguchi H, 1997, J CLIN INVEST, V99, P1506, DOI 10.1172/JCI119313; VERKMAN AS, 1985, AM J PHYSIOL, V248, pF650, DOI 10.1152/ajprenal.1985.248.5.F650; VERKMAN AS, 1995, KIDNEY INT, V48, P1069, DOI 10.1038/ki.1995.390; VomDahl S, 1996, BIOL CHEM H-S, V377, P25, DOI 10.1515/bchm3.1996.377.1.25; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	30	375	386	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24737	24743		10.1074/jbc.273.38.24737	http://dx.doi.org/10.1074/jbc.273.38.24737			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733774	hybrid			2022-12-25	WOS:000076007300066
J	Zhou, MY; Fisher, EA; Ginsberg, HN				Zhou, MY; Fisher, EA; Ginsberg, HN			Regulated co-translational ubiquitination of apolipoprotein - B100 a new paradigm for proteasomal, degradation of a secretory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; B-CONTAINING LIPOPROTEINS; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; QUALITY-CONTROL; TRANSLOCATION; PATHWAY; HEAT-SHOCK-PROTEIN-70; ABETALIPOPROTEINEMIA	Presentation of a wild-type secretory protein, apolipoprotein B100 (apoB), to the cytosol for ubiquitin-proteasome proteolysis has been observed in HepG2 cells. A currently accepted model for proteasomal degradation of secretory proteins is retrograde translocation of the substrate polypeptides from the lumen of endoplasmic reticulum (ER) back to the cytosol. In this report, we present evidence that newly synthesized apoB becomes exposed to the cytosol and targeted to the proteasomes in a co-translational manner. Thus, after protein translation was synchronized with puromycin, partially synthesized apoB polypeptides were found to be conjugated to ubiquitin. The magnitude of co-translational ubiquitination and subsequent degradation of apoB was increased when cells were pretreated with either herbimycin A to induce cytosolic Hsp70 or with an inhibitor of microsomal triglyceride transfer protein; both treatments impede translocation of nascent apoB across the ER membrane. These treatments also decreased secretion of apoB and increased its degradation via the ubiquitin-proteasome pathway. We suggest that translocation arrest with subsequent co-translational exposure to the cytosol provides an alternative model to explain how mammalian secretory proteins can overcome topological segregation by the ER membrane and undergo degradation by the ubiquitin-proteasome pathway.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10025 USA	Columbia University; Icahn School of Medicine at Mount Sinai	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, P&S 9-510,630 W 168th St, New York, NY 10032 USA.	ginsbhe@cudept.cis.columbia.edu		Fisher, Edward/0000-0001-9802-143X				Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BONIFACINO JS, 1994, CELLULAR PROTEOLYTIC, P135; BONIFACINO JS, 1996, NATURE, V384, P399; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; Davis R A, 1993, Subcell Biochem, V21, P169; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; Du EZ, 1996, J LIPID RES, V37, P1309; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; Haghpassand M, 1996, J LIPID RES, V37, P1468; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lord JM, 1996, CURR BIOL, V6, P1067, DOI 10.1016/S0960-9822(02)70666-0; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MCCRACKEN AA, 1996, J CELL BIOL, V132, P292; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WETTERAU JR, 1992, SCIENCE, V258, P999; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	37	135	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24649	24653		10.1074/jbc.273.38.24649	http://dx.doi.org/10.1074/jbc.273.38.24649			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733761	hybrid			2022-12-25	WOS:000076007300053
J	Subramaniam, N; Cairns, W; Okret, S				Subramaniam, N; Cairns, W; Okret, S			Glucocorticoids repress transcription from a negative glucocorticoid response element recognized by two homeodomain-containing proteins, Pbx and Oct-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN GENE-EXPRESSION; COOPERATIVE DNA-BINDING; POU-DOMAIN; HOX PROTEINS; COORDINATE REGULATION; MEDIATED REPRESSION; CELL-LINE; RECEPTOR; COMPLEX; PROMOTER	Several studies have established that the prolactin (PRL) gene is expressed not only in lactotrophs and somatotrophs of the anterior pituitary but, albeit to a lesser extent, in non-pituitary cells like human thymocytes, decidualized endometrium, mammary glands during lactation, and some human non-pituitary cell lines. Despite the requirement in the pituitary for the pituitary-specific transcription factor Pit-1/GHF-1 for PRL expression, the expression in non-pituitary cells occurs in the absence of Pit-1/GHF-1 and can be repressed by glucocorticoids. This prompted us to investigate the transcription factors in non-pituitary cells which are involved in controlling expression and glucocorticoid repression of a previously characterized negative glucocorticoid response element from the bovine prolactin gene (PRL3 nGRE). Here we have demonstrated that non-pituitary cells (COS-7 and mouse hepatoma Hepa1c1c7 cells) conferred increased expression via the PRL3 nGRE mainly because of the binding of the ubiquitously expressed POU-homeodomain-containing octamer transcription factor-1 (Oct-1), to an AT-rich sequence present in the PRL3 sequence. However, full transcriptional activity required the binding of a second ubiquitously expressed homeodomain-containing protein, Pbx, previously shown to bind cooperatively with several homeotic selector proteins. The Pbx binding site in the PRL3 nGRE, located just upstream of the Oct-1 binding site, showed a strong sequence similarity with known Pbx binding sites and bound Pbx with an affinity similar to that of other established Pbx target sequences. Interestingly, both Oct-1 and Pbx binding to the PRL3 nGRE were found to be required for glucocorticoid repression. Addition of in vitro translated glucocorticoid receptor DNA binding domain to the nuclear extract prevented Oct-1 and Pbx from binding to the PRL element. The involvement of the homeobox protein Pbx in glucocorticoid repression via an nGRE identifies a new role for this protein.	Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet	Okret, S (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, F60 Novum, S-14186 Huddinge, Sweden.	Sam.Okret@mednut.ki.se						ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AKERBLOM IW, 1991, REPRESSION GENE EXPR, P175; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; BERWAER M, 1991, MOL CELL ENDOCRINOL, V80, P53, DOI 10.1016/0303-7207(91)90142-F; CAIRNS C, 1993, DNA CELL BIOL, V12, P695, DOI 10.1089/dna.1993.12.695; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; DROUIN J, 1993, REPRESSION TRANSCRIP, P118; GELLERSEN B, 1989, ENDOCRINOLOGY, V125, P2853, DOI 10.1210/endo-125-6-2853; GELLERSEN B, 1995, MOL ENDOCRINOL, V9, P887, DOI 10.1210/me.9.7.887; Goodman PA, 1996, MOL CELL ENDOCRINOL, V120, P139, DOI 10.1016/0303-7207(96)03830-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HORSEMAN ND, 1995, ENDOCRINOLOGY, V136, P5249, DOI 10.1210/en.136.12.5249; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACOB KK, 1995, MOL CELL ENDOCRINOL, V109, P175, DOI 10.1016/0303-7207(95)03500-7; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAUSHANSKY K, 1994, J IMMUNOL, V152, P1812; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; Knoepfler PS, 1997, ONCOGENE, V14, P2521, DOI 10.1038/sj.onc.1201097; Knoepfler PS, 1997, MECH DEVELOP, V63, P5, DOI 10.1016/S0925-4773(97)00669-2; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Meyer T, 1997, J BIOL CHEM, V272, P21090, DOI 10.1074/jbc.272.34.21090; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIESFELD R, 1988, UCLA S MOL CELL BIOL, V75, P193; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; ONEAL KD, 1992, MOL CELL ENDOCRINOL, V87, pR19, DOI 10.1016/0303-7207(92)90251-Z; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Pei L, 1996, J BIOL CHEM, V271, P20879; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RENKAWITZ R, 1993, ANN NY ACAD SCI, V684, P1, DOI 10.1111/j.1749-6632.1993.tb32266.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Subramaniam N, 1997, DNA CELL BIOL, V16, P153, DOI 10.1089/dna.1997.16.153; TANAKA H, 1991, P NATL ACAD SCI USA, V88, P5393, DOI 10.1073/pnas.88.12.5393; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YAN GZ, 1994, MOL CELL ENDOCRINOL, V101, pR25, DOI 10.1016/0303-7207(94)90255-0	64	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23567	23574		10.1074/jbc.273.36.23567	http://dx.doi.org/10.1074/jbc.273.36.23567			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722596	hybrid			2022-12-25	WOS:000075778100096
J	Gu, CH; Castellino, A; Chan, JYH; Chao, MV				Gu, CH; Castellino, A; Chan, JYH; Chao, MV			BRE: a modulator of TNF-alpha action	FASEB JOURNAL			English	Article						brain; reproduction; PCR; maltese binding protein	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; FACTOR RECEPTOR; ACTIVATION; KINASE; IDENTIFICATION; DOMAIN; DEATH	A stress-responsive gene highly expressed in brain and reproductive organs (BRE) is down-regulated after UV irradiation, DNA damaging agents, or retinoic acid treatment. The human BRE gene encodes a mRNA of 1.9 kb, which gives rise to a protein of 383 amino acids with a molecular size of 44 kilodaltons, BRE is not homologous to any known gene and its function has not been defined. Here we report that BRE was identified multiple times in a yeast two-hybrid screen of a murine cerebellar cDNA library, using the juxtamembrane domain of the p55 tumor necrosis factor a (TNF) receptor, The interaction between the p55 receptor and BRE was verified by an in vitro biochemical assay by using recombinant fusion proteins and by co-immunoprecipitation of transfected mammalian cells. In the yeast two-hybrid assay, BRE specifically interacted with p55 TNF receptor but not with other TNF family members such as the Fas receptor, the p75 TNF receptor, and p75 neurotrophin receptor. Overexpression of BRE inhibited TNF-induced NF kappa B activation, indicating that the interaction of BRE protein with the cytoplasmic region of p55 TNF receptor may modulate signal transduction by TNF-alpha.	Cornell Univ, Coll Med, Dept Cell Biol & Anat, New York, NY 10021 USA; Chinese Univ Hong Kong, Dept Clin Oncol, Prince Wales Hosp, Shatin, Peoples R China	Cornell University; Chinese University of Hong Kong; Prince of Wales Hospital	Chao, MV (corresponding author), NYU, Med Ctr, Skirball Inst, 540 1st Ave, New York, NY 10016 USA.	chao@saturn.med.nyu.edu		Chao, Moses/0000-0002-6969-3744	NCI NIH HHS [CA45670] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HSU KC, 1993, J BIOL CHEM, V268, P16430; LI L, 1995, BIOCHEM BIOPH RES CO, V206, P764, DOI 10.1006/bbrc.1995.1108; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NIKOLAI L, 1997, NATURE, V385, P539; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Robinson J. P., 1991, MEASURES PERSONALITY, V1, P1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRIPP ML, 1989, MOL MICROBIOL, V3, P1319, DOI 10.1111/j.1365-2958.1989.tb00113.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	27	45	49	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1101	1108		10.1096/fasebj.12.12.1101	http://dx.doi.org/10.1096/fasebj.12.12.1101			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737713				2022-12-25	WOS:000075738500005
J	Blaydes, JP; Hupp, TR				Blaydes, JP; Hupp, TR			DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site	ONCOGENE			English	Article						p53; CK2; DRB; UV-irradiation; phosphorylation	CASEIN KINASE-II; C-TERMINAL DOMAIN; RNA-POLYMERASE-II; WILD-TYPE P53; TRANSCRIPTIONALLY ACTIVE P53; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; BINDING ACTIVITY; IN-VITRO; HEAT-SHOCK	The sequence-specific DNA binding activity of p53 is negatively regulated by a C-terminal domain whose phosphorylation in vitro can activate the latent DNA binding function of the protein. The DNA binding activity of p53 is a core component of its stress-activated transcription function, yet it is not yet clear whether phosphorylation within the C-terminal domain plays a role in the p53 damage response in vise. As the casein kinase 2 (CK2) site at serine 392 is the C-terminal phosphorylation motif that exhibits the most pronounced conservation at the primary amino acid level, we have focused on determining whether the CK2 site is modified in vivo and whether radiation effects the extent of that phosphorylation. Using antibodies that can detect serine 392-phosphorylation of p53, we demonstrate that UV radiation can trigger extensive phosphorylation at the CK2 site. The CK2 inhibitor, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), can partially inhibit the UV-induced phosphorylation at serine 392, suggesting that CK2 is one of the major serine 392-kinases. However, a striking increase in UV-induced serine 392 phosphorylation and p53 transactivation function at higher levels of DRB suggests that a DRB-resistant/stress-activated pathway may target serine 392 irt vivo. These data demonstrate that radiation-induced phosphorylation of p53 can occur in vivo at serine 392 and implicate a CK2-independent signal cascade that can function to modulate serine 392 phosphorylation in cells.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				ABARZUA P, 1995, CANCER RES, V55, P3490; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BARETTINO D, 1988, BIOCHEM CELL BIOL, V66, P1177, DOI 10.1139/o88-135; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL C, 1993, CANCER RES, V53, P2697; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1994, ONCOGENE, V9, P3249; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; FUCHS B, 1995, EUR J BIOCHEM, V228, P2866; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALL PA, 1993, ONCOGENE, V8, P203; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Harlow E., 1988, ANTIBODIES LAB MANUA; Hecker D, 1996, ONCOGENE, V12, P953; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1991, CANCER RES, V51, P6304; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MacCallum DE, 1996, ONCOGENE, V13, P2575; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SEHGAL PB, 1975, SCIENCE, V190, P282, DOI 10.1126/science.1179208; SEHGAL PB, 1976, SCIENCE, V194, P431, DOI 10.1126/science.982026; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SOUSSI T, 1990, ONCOGENE, V5, P945; STONEWOLFF DS, 1981, MUTAT RES, V82, P147, DOI 10.1016/0027-5107(81)90146-9; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TARUNINA M, 1993, ONCOGENE, V8, P3165; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TISHLER RB, 1995, CANCER RES, V55, P6021; TRIGON S, 1995, J BIOL CHEM, V270, P13091, DOI 10.1074/jbc.270.22.13091; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469	83	100	102	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1045	1052		10.1038/sj.onc.1202014	http://dx.doi.org/10.1038/sj.onc.1202014			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747884				2022-12-25	WOS:000075560900013
J	Gollahon, LS; Kraus, E; Wu, TA; Yim, SO; Strong, LC; Shay, JW; Tainsky, MA				Gollahon, LS; Kraus, E; Wu, TA; Yim, SO; Strong, LC; Shay, JW; Tainsky, MA			Telomerase activity during spontaneous immortalization of Li-Fraumeni syndrome skin fibroblasts	ONCOGENE			English	Article						p53; telomeres; ALT pathway; senescence; cell hybrids	MAMMARY EPITHELIAL-CELLS; HUMAN PAPILLOMAVIRUS TYPE-16; CELLULAR SENESCENCE; CANCER SYNDROME; TUMOR-ANTIGEN; MUTANT P53; TRANSFORMATION; E6; GROWTH; DNA	Li-Fraumeni Syndrome (LFS) is characterized by heterozygous germline mutations in the p53 gene. Accompanied by genomic instability and loss or mutation of the remaining wild type p53 allele, a low frequency of spontaneous immortalization in LFS fibroblasts occurs. It is believed that the loss of p53 wild type function contributes to immortalization of these LFS fibroblasts, but it is not clear if this is sufficient. Because stabilization of telomere length is also thought to be a necessary step in immortalization, telomerase activity, expression of the telomerase RNA component (hTR) and telomere length were ana:lysed at various passages during the spontaneous immortalization of LFS skin fibroblasts. One LFS strain which immortalized, MDAH087 (087), had no detectable telomerase activity whereas another LFS strain which immortalized, MDAH041 (041), had detectable telomerase activity. In preimmortal cells from both strains, hTR was not detected by in situ hybridization. Immortal 087 cells remained negative for hTR, while immortal 041 cells demonstrated strong hTR in situ hybridization signals. 087 cells had long and heterogenous telomeres whereas telomeres; of 041 cells had short, stable telomere lengths. Tumorigenicity studies in nude mice with ras-transformed 087 and 041 cells resulted in both cell lines giving rise to tumors and retaining telomerase status. Overall these results suggest that strain specificity may be important in telomerase re-activation and that both abrogation of p53 function and a mechanism to maintain telomeres are necessary for immortalization.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Expt Pediat, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gollahon, LS (corresponding author), Texas Tech Univ, Dept Biol Sci, POB 43131, Lubbock, TX 79409 USA.		Shay, Jerry W/F-7878-2011	Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [T32CA009299, P01CA034936, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-P01 34936, CA-16672, CA-09299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Avilion AA, 1996, CANCER RES, V56, P645; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; Barrett J. Carl, 1993, P61; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gao QS, 1996, CANCER RES, V56, P3129; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; Gollahon LS, 1996, ONCOGENE, V12, P715; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Greider CW, 1991, CURR OPIN CELL BIOL, V3, P444, DOI 10.1016/0955-0674(91)90072-7; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; Hsiao RS, 1997, ANTICANCER RES, V17, P827; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; JORDAN C, 1990, IN SITU HYBRIDIZATIO, P61; Karlsson C, 1996, CANCER RES, V56, P241; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PIATYSZEK MA, 1996, METHODS CELL SCI, V17, P1; RAINEY WH, 1994, J CLIN ENDOCR METAB, V78, P705, DOI 10.1210/jc.78.3.705; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROSS SR, 1978, PERSISTENT VIRUSES, V11, P469; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SASAKI M, 1994, CANCER RES, V54, P6090; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1994, METH MOL G, V5, P263; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25; Tsutsui T, 1997, MOL CARCINOGEN, V18, P7, DOI 10.1002/(SICI)1098-2744(199701)18:1<7::AID-MC2>3.0.CO;2-F; VANDERHAEGEN BA, 1993, IN VITRO CELL DEV-AN, V29A, P180, DOI 10.1007/BF02634177; WATANABE S, 1993, JPN J CANCER RES, V84, P1043, DOI 10.1111/j.1349-7006.1993.tb02799.x; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; Yashima K, 1998, CLIN CANCER RES, V4, P229	74	48	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					709	717		10.1038/sj.onc.1201987	http://dx.doi.org/10.1038/sj.onc.1201987			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715272				2022-12-25	WOS:000075337200005
J	Dick, TP; Nussbaum, AK; Deeg, M; Heinemeyer, W; Groll, M; Schirle, M; Keilholz, W; Stevanovic, S; Wolf, DH; Huber, R; Rammensee, HG; Schild, H				Dick, TP; Nussbaum, AK; Deeg, M; Heinemeyer, W; Groll, M; Schirle, M; Keilholz, W; Stevanovic, S; Wolf, DH; Huber, R; Rammensee, HG; Schild, H			Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; 20S PROTEASOME; ANTIGEN PRESENTATION; PROTEOLYTIC ACTIVITY; INTERFERON-GAMMA; BRANCHED-CHAIN; DEGRADATION; LACTACYSTIN; DESTRUCTION; ACIDOPHILUM	Proteasomes generate peptides that can be presented by major histocompatibility complex (MHC) class I molecules in vertebrate cells. Using yeast 20 S proteasomes carrying different inactivated beta-subunits, we investigated the specificities and contributions of the different beta-subunits to the degradation of polypeptide substrates containing MHC class I ligands and addressed the question of additional proteolytically active sites apart from the active beta-subunits, We found a clear correlation between the contribution of the different subunits to the cleavage of fluorogenic and long peptide substrates, with beta 5/Pre2 cleaving after hydrophobic, beta 2/Pup1 after basic, and beta 1/Pre3 after acidic residues, but with the exception that beta 2/Pup1 and beta 1/Pre3 can also cleave after some hydrophobic residues. All proteolytic activities including the "branched chain amino acid-preferring" component are associated with beta 5/Pre2, beta 1/Pre3, or beta 2/Pup1, arguing against additional proteolytic sites. Because of the high homology between yeast and mammalian 20 S proteasomes in sequence and subunit topology and the conservation of cleavage specificity between mammalian and yeast proteasomes, our results can be expected to also describe most of the proteolytic activity of mammalian 20 S proteasomes leading to the generation of MHC class I ligands.	Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany; Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Hosp, Med Res Ctr, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; University of Stuttgart; Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Schild, H (corresponding author), Univ Tubingen, Inst Cell Biol, Dept Immunol, Morgenstelle 15, D-72076 Tubingen, Germany.		Groll, Michael/C-1174-2010; Groll, Michael/F-5572-2015					Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; Cardozo C, 1996, ARCH BIOCHEM BIOPHYS, V334, P113, DOI 10.1006/abbi.1996.0436; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DEL VM, 1991, CELL, V66, P1145; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1995, ARCH BIOCHEM BIOPHYS, V317, P69, DOI 10.1006/abbi.1995.1137; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARPUR AG, 1993, IMMUNOL LETT, V35, P235, DOI 10.1016/0165-2478(93)90188-8; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hisamatsu H, 1996, J EXP MED, V183, P1807, DOI 10.1084/jem.183.4.1807; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; Reidlinger J, 1997, J BIOL CHEM, V272, P24899, DOI 10.1074/jbc.272.40.24899; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAVORY PJ, 1993, BIOCHEM J, V296, P601, DOI 10.1042/bj2960601; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	34	210	215	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25637	25646		10.1074/jbc.273.40.25637	http://dx.doi.org/10.1074/jbc.273.40.25637			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748229	hybrid			2022-12-25	WOS:000076263100020
J	Moussaoui, M; Nogues, MV; Guasch, A; Barman, T; Travers, F; Cuchillo, CM				Moussaoui, M; Nogues, MV; Guasch, A; Barman, T; Travers, F; Cuchillo, CM			The subsites structure of bovine pancreatic ribonuclease a accounts for the abnormal kinetic behavior with cytidine 2 ',3 '-cyclic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; BINDING SUBSITES; ALLOSTERIC MODEL; ENZYME; CLEAVAGE; ENERGETICS; EXISTENCE; CATALYSIS; COMPLEX	The kinetics of the hydrolysis of cytidine 2',3'-cyclic phosphate (C>p) to 3'-CMP by ribonuclease A are multiphasic at high substrate concentrations. We have investigated these kinetics by determining 3'-CMP formation both spectrophotometrically and by a highly specific and quantitative chemical sampling method. With the use of RNase A derivatives that lack a functional p(2) binding subsite, evidence is presented that the abnormal kinetics with the native enzyme are caused by the sequential binding of the substrate to the several subsites that make up the active site of ribonuclease, The evidence is based on the following points. 1) Some of the unusual features found with native RNase A and C>p as substrate disappear when the derivatives lacking a functional p(2) binding subsite are used. 2) The k(cat)/K-m values with oligocytidylic acids of increasing lengths tending in C>p) show a behavior that parallels the specific velocity with C>p at high concentrations: increase in going from the monomer to the trimer, a decrease from tetramer to hexamer, and then an increase in going to poly(C), 3) Adenosine increases the k(cat) obtained with a fixed concentration of C>p as substrate. 4) High concentrations of C>p protect the enzyme from digestion with subtilisin, which results in a more compact molecule, implying large substrate concentration-induced conformational changes. The data for the hydrolysis of C>p by RNase A can be fitted to a fifth order polynomial that has been derived from a kinetic scheme based on the sequential binding of several monomeric substrate molecules.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra 08193, Spain; Univ Autonoma Barcelona, Inst Biol Fonamental Vicent Villar Palasi, Bellaterra 08193, Spain; CNRS, INSERM, U128, F-34293 Montpellier 5, France	Autonomous University of Barcelona; Autonomous University of Barcelona; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Nogues, MV (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Bellaterra 08193, Spain.	ibbm1@cc.uab.es	Moussaoui, Mohammed/A-5172-2013; Guasch, Alicia/ABH-3427-2020; Moussaoui, Mohammed/Y-7259-2019; Nogues, M. Victoria/H-6100-2015	Moussaoui, Mohammed/0000-0001-6694-7692; Moussaoui, Mohammed/0000-0001-6694-7692; Nogues, M. Victoria/0000-0002-7104-0961				ALONSO J, 1986, ARCH BIOCHEM BIOPHYS, V246, P681, DOI 10.1016/0003-9861(86)90324-3; ARNOTT S, 1976, J MOL BIOL, V106, P735, DOI 10.1016/0022-2836(76)90262-X; ARUS C, 1982, BIOCHEMISTRY-US, V21, P4290, DOI 10.1021/bi00261a018; BARDSLEY WG, 1975, BIOCHEM J, V149, P313, DOI 10.1042/bj1490313; BOIX E, 1994, J BIOL CHEM, V269, P2529; BOQUE L, 1994, J BIOL CHEM, V269, P19707; BRUNGER AT, 1985, P NATL ACAD SCI USA, V82, P8458, DOI 10.1073/pnas.82.24.8458; CRESTFIELD AM, 1962, ARCH BIOCHEM BIOPHYS, P217; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; CUATRECASAS P, 1968, SCIENCE, V162, P1491, DOI 10.1126/science.162.3861.1491; Cuchillo C. M., 1997, RIBONUCLEASES STRUCT, P272; CUCHILLO CM, 1993, FEBS LETT, V333, P207, DOI 10.1016/0014-5793(93)80654-D; DELLORENS R, 1989, PROTEIN ENG, V2, P417, DOI 10.1093/protein/2.6.417; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P5123, DOI 10.1021/bi00291a011; FERSHT A, 1985, ENZYME STRUCTURE MEC, P147; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; GUASCH A, 1989, J CHROMATOGR, V473, P281, DOI 10.1016/S0021-9673(00)91311-6; GUASCH A, 1984, INT J BIOCHEM, V16, P1071, DOI 10.1016/0020-711X(84)90090-9; HAFFNER PH, 1973, BIOCHEMISTRY-US, V12, P1608, DOI 10.1021/bi00732a023; IRIE M, 1984, J BIOCHEM-TOKYO, V96, P89, DOI 10.1093/oxfordjournals.jbchem.a134833; JANER M, 1990, Protein Engineering, V3, P369; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; MARKUS G, 1968, J BIOL CHEM, V243, P4070; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; Moussaoui M, 1996, J BIOL CHEM, V271, P4687; NOGUES MV, 1995, BBA-PROTEIN STRUCT M, V1253, P16, DOI 10.1016/0167-4838(95)00138-K; PARES X, 1991, ESSAYS BIOCHEM, V26, P89; PARES X, 1980, EUR J BIOCHEM, V105, P571, DOI 10.1111/j.1432-1033.1980.tb04534.x; PICCOLI R, 1984, J BIOL CHEM, V259, P693; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; RICHARDS FM, 1971, ENZYMES, V4, P647; RICHARDSON RM, 1988, BIOCHIM BIOPHYS ACTA, V953, P70, DOI 10.1016/0167-4838(88)90010-6; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V24, P229, DOI 10.1016/0006-3002(57)90186-5; TEIPEL J, 1969, BIOCHEMISTRY-US, V8, P4656, DOI 10.1021/bi00839a064; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; WALKER EJ, 1976, BIOCHEM J, V153, P329, DOI 10.1042/bj1530329; WALKER EJ, 1975, BIOCHEM J, V147, P425, DOI 10.1042/bj1470425; WIEKER HJ, 1967, EUR J BIOCHEM, V1, P251, DOI 10.1111/j.1432-1033.1967.tb00069.x	40	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25565	25572		10.1074/jbc.273.40.25565	http://dx.doi.org/10.1074/jbc.273.40.25565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748220	hybrid			2022-12-25	WOS:000076263100011
J	Sechler, JL; Schwarzbauer, JE				Sechler, JL; Schwarzbauer, JE			Control of cell cycle progression by fibronectin matrix architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; FOCAL ADHESIONS; PROTEIN; EXPRESSION; ACTIVATION; INHIBITION; ANCHORAGE; INTEGRINS; RECEPTOR	Developmental patterning and differentiation, maintenance of parenchymal cell function, and the size, shape, and invasiveness of tumors are all orchestrated by cell interactions with the extracellular matrix. Here we show that the fibrillar structure of fibronectin (FN) matrix encodes essential regulatory cues and controls cell proliferation and signaling through changes in matrix architecture. A matrix assembled from native FN stimulated cell growth. In contrast, a mutant FN (FN Delta III1-7) that contains all known cell binding motifs but forms a structurally distinct matrix inhibited progression from G(0)/G(1) into S phase. Furthermore, FN Delta III1-7 suppressed the stimulatory capacity of native FN and induced different levels of tyrosine phosphorylation of pp125(FAK). The differential effects on cell growth were ablated by blocking formation of matrix fibrils. Thus, modification of matrix architecture provides a novel approach to control cell proliferation.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Schwarzbauer, JE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	jschwarzbauer@molbio.princeton.edu		Schwarzbauer, Jean/0000-0003-1012-7593	NCI NIH HHS [CA 44627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bohmer RM, 1996, MOL BIOL CELL, V7, P101; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; PATCH LA, 1995, J CELL SCI, V108, P1371; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHWARTZ CC, 1991, WILDLIFE MONOGR, P1; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Sechler JL, 1996, CELL ADHES COMMUN, V4, P413, DOI 10.3109/15419069709004458; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WU CY, 1993, J BIOL CHEM, V268, P21883; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	33	120	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25533	25536		10.1074/jbc.273.40.25533	http://dx.doi.org/10.1074/jbc.273.40.25533			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748212	hybrid			2022-12-25	WOS:000076263100003
J	Tong, JC; Margoliash, E				Tong, JC; Margoliash, E			Cytochrome c heme lyase activity of yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; APOCYTOCHROME-C; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; NEUROSPORA-CRASSA; HOLOCYTOCHROME-C; IMPORT; SYNTHETASE; PROTEINS; SPECIFICITY	A highly efficient in vitro system was established for measuring by high performance liquid chromatography the formation of holocytochrome c by yeast mitochondria. Holocytochrome c formation required reducing agents, of which dithiothreitol was the most effective. With biosynthetically made, pure Drosophila melanogaster apocytochrome c and Saccharomyces cerevisiae mitochondria, the activity of cytochrome c heme lyase amounted to about 800 fmol min(-1) mg(-1) mitochondrial protein. The kinetics were typical Michaelis-Menten (K-m similar to 1 nM), as were those of mitoplasts with broken outer membranes (K-m similar to 3 nM). As tested with mitoplasts, holocytochromes c from a range of species were found to be competitive inhibitors of heme lyase at physiological concentrations, providing a mechanism for controlling this concentration in vivo. Apocytochrome c associated with yeast mitochondria in two phases of K-d, similar to 2 x 10(-10) and 10(-8) M, respectively, whereas mitoplasts had lost the high affinity binding. A site-directed mutant of apocytochrome c (lysines 5, 7, and 8 replaced by glutamine, glutamic acid, and asparagine) was found to be converted to holocytochrome c (K-m similar to 3.3 nM; maximal activity unchanged), even though the mutations completely eliminated the high affinity binding. Thus, the high affinity binding of apocytochrome c to mitochondria is not directly related to holocytochrome c formation.	Univ Illinois, Dept Biol Sci, Mol Biol Lab, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Margoliash, E (corresponding author), Univ Illinois, Dept Biol Sci, Mol Biol Lab, M-C 066,845 W Taylor St, Chicago, IL 60607 USA.	maem@uic.edu						BASILE G, 1980, J BIOL CHEM, V255, P7181; DAUM G, 1982, J BIOL CHEM, V257, P3028; DRYGAS ME, 1989, J BIOL CHEM, V264, P17897; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; DUMONT ME, 1996, ADV MOL CEL, V17, P103; FISHER WR, 1973, J BIOL CHEM, V248, P3188; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; HENNIG B, 1983, P NATL ACAD SCI-BIOL, V80, P4963, DOI 10.1073/pnas.80.16.4963; HENNIG B, 1981, EUR J BIOCHEM, V121, P203, DOI 10.1111/j.1432-1033.1981.tb06450.x; KORB H, 1978, EUR J BIOCHEM, V91, P609, DOI 10.1111/j.1432-1033.1978.tb12714.x; KOSHY TI, 1992, PROTEIN EXPRES PURIF, V3, P441, DOI 10.1016/1046-5928(92)90061-Z; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MARGOLIASH E., 1966, ADVANCE PROTEIN CHEM, V21, P113, DOI 10.1016/S0065-3233(08)60128-X; MARGOLIASH E, 1959, BIOCHEM J, V71, P559, DOI 10.1042/bj0710559; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; Moore G. R., 1990, CYTOCHROMES C EVOLUT, P161; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; Osheroff N. O., 1978, FRONTIERS BIOL ENERG, V1, P439; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; Pettigrew G. W, 1987, CYTOCHROMES C BIOL A, P29; RACKER E, 1950, BIOCHIM BIOPHYS ACTA, V4, P211, DOI 10.1016/0006-3002(50)90026-6; SEGEL IH, 1975, ENZYME KINETICS, P18; SPRINKLE JR, 1990, P NATL ACAD SCI USA, V87, P5729, DOI 10.1073/pnas.87.15.5729; SPRINKLE JR, 1994, MODERN ENZYMOLOGY PR, P627; SPRINKLE JR, 1991, NEW TRENDS BIOL CHEM, P99; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; STUART RA, 1990, BIOCHEMIE PARIS, P115; SWANSON MS, 1985, P NATL ACAD SCI USA, V82, P1964, DOI 10.1073/pnas.82.7.1964; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; TANAKA Y, 1988, J BIOCHEM-TOKYO, V104, P477, DOI 10.1093/oxfordjournals.jbchem.a122493; TANIUCHI H, 1983, J BIOL CHEM, V258, P963; VELOSO D, 1981, J BIOL CHEM, V256, P8646; VISCO C, 1985, J BIOL CHEM, V260, P6133; Wang K.Z., 1991, CHEM J CHINESE U, V14, P150; ZIMMERMANN R, 1981, EUR J BIOCHEM, V116, P455, DOI 10.1111/j.1432-1033.1981.tb05357.x	47	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25695	25702		10.1074/jbc.273.40.25695	http://dx.doi.org/10.1074/jbc.273.40.25695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748237	hybrid			2022-12-25	WOS:000076263100028
J	Desaubry, L; Johnson, RA				Desaubry, L; Johnson, RA			Adenine nucleoside 3 '-tetraphosphates are novel and potent inhibitors of adenylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; ADENOSINE; ATP; PURIFICATION; 3'-POLYPHOSPHATES; 2',5'-DIDEOXYADENOSINE; REQUIREMENTS; KINETICS; BINDING; METAL	2'-Deoxyadenosine 3'-tetraphosphate (2'-deoxy-3'-A(4)P) and 2',5'-dideoxyadenosine 3'-tetraphosphate (2',5'-dideoxy-3'-A(4)P) were synthesized, and their effects were tested on crude and purified forms of native adenylyl cyclases isolated from brain. Syntheses combined the method of alkoxide activation with the use of tribromoethyl phosphoromorpholino-chloridate as an initial phosphorylating agent. Inhibition of adenylyl cyclase was rapid in onset. With 2'-d-3'-A(4)P or 2',5'-dd-3'-A(4)P inhibition of a purified native enzyme conformed to a linear noncompetitive behavior with respect to substrate, metal-5'ATP. Order of potency was 2',5'-dideoxy- > 2'-deoxyadenosine and 3'-tetraphosphate > 3'-triphosphate. Both mechanism of inhibition and rank order of potency were consistent with inhibition via the 3'-nucleotide-(P)-site on adenylyl cyclase. Neither 2',5'-dd-3'-ATP nor 2',5'-dd-3'-A(4)P had any effect on the activities of other adenosine nucleotide binding proteins such as Ca2+/calmodulin-sensitive cyclic nucleotide phosphodiesterase, Na+/K+-ATPase, or cAMP-dependent protein kinase. With purified adenylyl cyclase from bovine brain 2',5'-dd-3'-A(4)P and 2'-d-3'-A(4)P gave, respectively, IC50 values of 9.3 and 15 nM and K-i values of 23 and 53 nM. These 3'-nucleotides are the most potent regulators described for adenylyl cyclases.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Johnson, RA (corresponding author), Lab Chim Organ Subst Nat, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Desaubry, Laurent G/R-5446-2017	Desaubry, Laurent G/0000-0002-1192-2970	NIDDK NIH HHS [DK38828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PR, 1984, J MED CHEM, V27, P1648, DOI 10.1021/jm00378a021; Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; Bryant SH, 1997, NATURE, V388, P34, DOI 10.1038/40313; BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; COUTSOGEORGOPOU.C, 1966, BIOCHIM BIOPHYS ACTA, V119, P442; DESAUBRY L, 1995, TETRAHEDRON LETT, V36, P995, DOI 10.1016/0040-4039(94)02424-A; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; ENGLUND PT, 1969, J BIOL CHEM, V244, P3038; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; FLORIO VA, 1983, THESIS U VIRGINIA; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; GOTO Y, 1991, J BIOCHEM-TOKYO, V109, P746, DOI 10.1093/oxfordjournals.jbchem.a123451; Gualix J, 1996, FEBS LETT, V391, P195, DOI 10.1016/0014-5793(96)00732-6; Hempel C. M., 1996, Society for Neuroscience Abstracts, V22, P261; JOHNSON RA, 1977, ARCH BIOCHEM BIOPHYS, V183, P216, DOI 10.1016/0003-9861(77)90435-0; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; JOHNSON RA, 1990, J BIOL CHEM, V265, P19035; KERAVIS TM, 1987, J CYCLIC NUCLEOTIDE, V11, P365; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE JW, 1996, YONSEI MED J, V36, P487; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STENGEL D, 1986, EUR J BIOCHEM, V161, P241, DOI 10.1111/j.1432-1033.1986.tb10148.x; TANG WJ, 1991, J BIOL CHEM, V266, P8595; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VANBOOM JH, 1977, NUCLEIC ACIDS RES, V4, P1047, DOI 10.1093/nar/4.4.1047; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; WOLIN MS, 1981, THESIS YALE U; YEUNG SMH, 1990, J BIOL CHEM, V265, P16745; ZAMECNIK P, 1983, ANAL BIOCHEM, V134, P1, DOI 10.1016/0003-2697(83)90255-5; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	42	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24972	24977		10.1074/jbc.273.38.24972	http://dx.doi.org/10.1074/jbc.273.38.24972			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733805	hybrid			2022-12-25	WOS:000076007300097
J	Harley, CA; Holt, JA; Turner, R; Tipper, DJ				Harley, CA; Holt, JA; Turner, R; Tipper, DJ			Transmembrane protein insertion orientation in yeast depends on the charge difference across transmembrane segments, their total hydrophobicity, and its distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INNER MEMBRANE; SIGNAL-ANCHOR PROTEINS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; BETA-LACTAMASE; AMINO-ACIDS; TOPOLOGY; RESIDUES; DOMAIN; DETERMINANTS	The determinants of transmembrane protein insertion orientation at the endoplasmic reticulum have been investigated in Saccharomyces cerevisiae using variants of a Type III (naturally exofacial N terminus (N-exo)) transmembrane fusion protein derived from the N terminus of Ste2p, the alpha-factor receptor. Small positive and negative charges adjacent to the transmembrane segment had equal and opposite effects on orientation, and this effect was independent of N- or C-terminal location, consistent with a purely electrostatic interaction with response mechanisms. A 3:1 bias toward N-exo insertion, observed in the absence of a charge difference, was shown to reflect the N-exo bias conferred by longer transmembrane segments. Orientation correlated best with total hydrophobicity rather than length, but it was also strongly affected by the distribution of hydrophobicity within the transmembrane segment, The most hydrophobic terminus was preferentially translocated, Insertion orientation thus depends on integration of responses to at least three parameters: charge difference across a transmembrane segment, its total hydrophobicity, and its hydrophobicity gradient. Relative signal strengths were estimated, and consequences for topology prediction are discussed. Responses to transmembrane sequence may depend on protein-translocon interactions, but responses to charge difference may be mediated by the electrostatic field provided by anionic phospholipids.	Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Tipper, DJ (corresponding author), Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA.		Harley, Carol/J-5375-2013	Harley, Carol/0000-0003-3610-0604				ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BELTZER JP, 1991, J BIOL CHEM, V266, P973; CARTWRIGHT CP, 1991, MOL CELL BIOL, V11, P2620, DOI 10.1128/MCB.11.5.2620; CARTWRIGHT CP, 1994, YEAST, V10, P497, DOI 10.1002/yea.320100409; CHAUDHURI B, 1992, FEBS LETT, V304, P41, DOI 10.1016/0014-5793(92)80585-5; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; KULKARNI MS, 1994, J BIOL CHEM, V269, P13141; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; Nacken V, 1996, GENE, V175, P253, DOI 10.1016/0378-1119(96)00171-0; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Persson B, 1997, J PROTEIN CHEM, V16, P453, DOI 10.1023/A:1026353225758; Powers T, 1997, SCIENCE, V278, P2072, DOI 10.1126/science.278.5346.2072; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; Siegel V, 1997, CELL, V90, P5, DOI 10.1016/S0092-8674(00)80307-4; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WILSON C, 1990, MOL CELL BIOL, V10, P449, DOI 10.1128/MCB.10.2.449	38	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24963	24971		10.1074/jbc.273.38.24963	http://dx.doi.org/10.1074/jbc.273.38.24963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733804	Green Published, hybrid			2022-12-25	WOS:000076007300096
J	Balbin, M; Fueyo, A; Knauper, V; Pendas, AM; Lopez, JM; Jimenez, MG; Murphy, G; Lopez-Otin, C				Balbin, M; Fueyo, A; Knauper, V; Pendas, AM; Lopez, JM; Jimenez, MG; Murphy, G; Lopez-Otin, C			Collagenase 2 (MMP-8) expression in murine tissue-remodeling processes - Analysis of its potential role in postpartum involution of the uterus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; HUMAN MATRIX METALLOPROTEINASE; SMOOTH-MUSCLE CELLS; LEUKOCYTE COLLAGENASE; SUBSTRATE-SPECIFICITY; ALPHA-1-PROTEINASE INHIBITOR; POLYMORPHONUCLEAR LEUKOCYTES; BIOCHEMICAL-CHARACTERIZATION; FIBROBLAST COLLAGENASE; CHROMOSOMAL LOCATION	Neutrophil collagenase or collagenase 2 (MMP-8) is unique among the family of matrix metalloproteinases (MMPs) because of its exclusive pattern of expression in inflammatory conditions. At present, no evidence of the occurrence of this enzyme in tissues other than human has been reported. In this work, we have cloned the murine homologue of human collagenase 2. The isolated cDNA contains an open reading frame coding for a polypeptide of 465 amino acids, which is 74% identical to its human counterpart. The mouse collagenase 2 exhibits the domain structure characteristic of several MMPs, including a signal sequence, a prodomain with the cysteine residue essential for enzyme latency, an activation locus with the Zinc-binding site, and a COOH-terminal fragment with sequence similarity to hemopexin. It also contains the three conserved residues (Tyr-209, Asp-230, and Gly-232) located around the Zinc-binding site and are distinctive of the collagenase subfamily. Northern blot analysis of RNAs isolated from a variety of mouse tissues revealed that collagenase 2 is expressed at late stages during mouse embryogenesis, coinciding with the appearance of hematopoietic cells. In addition, collagenase 2 was highly expressed in the postpartum uterus starting at 1 day postpartum and extending up to 5 days. Enzymatic analysis revealed that matrilysin, another MMP overexpressed in uterine tissue, is able to activate murine procollagenase 2. These data suggest that both enzymes could form an activation cascade resulting in the generation of the collagenolytic activity required during the process of massive connective tissue resumption occurring in the involuting uterus.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ Oviedo, Fac Med, Dept Biol Func, E-33006 Oviedo, Spain; Univ Oviedo, Fac Med, Dept Morfol & Biol Celular, E-33006 Oviedo, Spain; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Oviedo; University of Oviedo; University of Oviedo; University of East Anglia	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	CLO@DWARF1.QUIMICA.UNIOVI.ES	Fueyo, Antonio/ABH-3243-2020; Balbín, Milagros/I-4206-2015; Pendas, Alberto M/L-1017-2014; López-Otín, Carlos/AAB-2106-2020	Fueyo, Antonio/0000-0002-7121-9398; Balbín, Milagros/0000-0001-5325-0407; López-Otín, Carlos/0000-0001-6964-1904; Pendas, Alberto M/0000-0001-9264-3721; Knauper, Vera/0000-0002-3965-9924; Lopez, Jose Manuel/0000-0003-0589-4763				ABRAMSON SR, 1995, J BIOL CHEM, V270, P16016, DOI 10.1074/jbc.270.27.16016; Balbin M, 1996, J ENDOCRINOL, V149, P405, DOI 10.1677/joe.0.1490405; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BERGMANN U, 1989, J CLIN CHEM CLIN BIO, V27, P351; Chubinskaya S, 1996, LAB INVEST, V74, P232; Cole AA, 1996, J BIOL CHEM, V271, P11023, DOI 10.1074/jbc.271.18.11023; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Hanemaaijer R, 1997, J BIOL CHEM, V272, P31504, DOI 10.1074/jbc.272.50.31504; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HASTY KA, 1986, J BIOL CHEM, V261, P5645; HASTY KA, 1990, J BIOL CHEM, V265, P11421; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; JEFFREY JJ, 1991, J CELL PHYSIOL, V146, P399, DOI 10.1002/jcp.1041460310; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNAUPER V, 1990, FEBS LETT, V263, P355, DOI 10.1016/0014-5793(90)81412-H; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; Krane SM, 1996, J BIOL CHEM, V271, P28509, DOI 10.1074/jbc.271.45.28509; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MOOKHTIAR KA, 1990, BIOCHEMISTRY-US, V29, P10620, DOI 10.1021/bi00499a007; MULLIGAN MS, 1993, P NATL ACAD SCI USA, V90, P11523, DOI 10.1073/pnas.90.24.11523; MURPHY G, 1992, J RHEUMATOL, V19, P61; Pak JH, 1997, FEBS LETT, V404, P283, DOI 10.1016/S0014-5793(97)00141-5; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; PENDAS AM, 1995, GENOMICS, V26, P615, DOI 10.1016/0888-7543(95)80186-P; Pendas AM, 1996, GENOMICS, V37, P266, DOI 10.1006/geno.1996.0557; QUINN CO, 1990, J BIOL CHEM, V265, P22342; RudolphOwen LA, 1997, ENDOCRINOLOGY, V138, P4902, DOI 10.1210/en.138.11.4902; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHETTLER A, 1991, EUR J BIOCHEM, V197, P197, DOI 10.1111/j.1432-1033.1991.tb15899.x; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; WEISS SJ, 1982, J CLIN INVEST, V69, P255, DOI 10.1172/JCI110447; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WILCOX BD, 1992, J BIOL CHEM, V267, P20752; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wolf K, 1996, ENDOCRINOLOGY, V137, P5429, DOI 10.1210/en.137.12.5429	57	112	120	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23959	23968		10.1074/jbc.273.37.23959	http://dx.doi.org/10.1074/jbc.273.37.23959			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727011	hybrid			2022-12-25	WOS:000075893100052
J	Goalstone, ML; Leitner, JW; Wall, K; Dolgonos, L; Rother, KI; Accili, D; Draznin, B				Goalstone, ML; Leitner, JW; Wall, K; Dolgonos, L; Rother, KI; Accili, D; Draznin, B			Effect of insulin on farnesyltransferase - Specificity of insulin action and potentiation of nuclear effects of insulin-like growth factor-1, epidermal growth factor, and platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; 3T3-L1 ADIPOCYTES; RAS; RECEPTOR; MEMBRANE	We have previously demonstrated that insulin activates, farnesyltransferase (FTase) and augments the amounts of farnesylated p21(ras) (Goalstone, NI, L., and Draznin, B. (1996) J. Biol, Chem. 271, 27585-27589). We postulated that this aspect of insulin action might explain the "priming effect" of insulin on the cellular response to other growth factors. In the present study, we show the specificity of the effect of insulin on FTase. Insulin, but not insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), or platelet-derived growth factor (PDGF), stimulated the phosphorylation of the alpha-subunit of FTase and the amounts of farnesylated p21(ras). Even though all four growth factors utilized the Ras pathway to stimulate DNA synthesis, only insulin used this pathway to influence FTase, Insulin failed to stimulate FTase in cells expressing the chimeric insulin/ IGF-I receptor and in cells derived from the insulin receptor knock-out animals. Insulin potentiated the effects of IGF-1, EGF, and PDGF on DNA synthesis in cells expressing the wild type insulin receptor, but this potentiation was inhibited in the presence of the FTase inhibitor, alpha-hydroxyfarnesylphosphonic acid. We conclude that the effect of insulin on FTase is specific, requires the presence of an intact insulin receptor and selves as a conduit for the "priming" influence of insulin on the nuclear effects of other growth factors.	Denver Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA; Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80220 USA; NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Draznin, B (corresponding author), VA Hosp 151, 1055 Clermont St, Denver, CO 80220 USA.							ANDRES DA, 1993, J BIOL CHEM, V268, P1383; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; FARIA TN, 1994, J BIOL CHEM, V269, P13922; Goalstone M, 1997, BIOCHEM BIOPH RES CO, V239, P42, DOI 10.1006/bbrc.1997.7413; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; GOALSTONE ML, 1998, IN PRESS ENDOCRINOLO; HANCOCK JF, 1989, CELL, V57, P1165; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; REISS Y, 1991, J BIOL CHEM, V266, P10672; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; STOUT RW, 1996, DIABETES, V45, P45; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	19	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23892	23896		10.1074/jbc.273.37.23892	http://dx.doi.org/10.1074/jbc.273.37.23892			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727002	hybrid			2022-12-25	WOS:000075893100043
J	Reddy, YVR; Rao, DN				Reddy, YVR; Rao, DN			Probing the role of cysteine residues in the EcoP15I DNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; ESCHERICHIA-COLI; CATALYTIC PROPERTIES; SEQUENCE MOTIFS; DEPENDENT METHYLTRANSFERASES; S-ADENOSYLMETHIONINE; MODIFICATION SYSTEMS; HOMOGENEOUS ENZYME; CRYSTAL-STRUCTURE; ECORI METHYLASE	Chemical modification using thiol-directed agents and site-directed mutagenesis has been used to investigate the role of cysteine residues of EcoP15I DNA methyltransferase, Irreversible inhibition of enzymatic activity was provoked by chemical modification of the enzyme by N-ethylmaleimide and iodoacetamide, 5,5'-Dithiobis(2-nitrobenzoic acid) titration of the enzyme under nondenaturing and denaturing conditions confirmed the presence of six cysteine residues without any disulfides in the protein. An are that relatively bulky reagents inactivate the methyltransferase by directly occluding the substrate-binding site or by locking the methyltransferase in an inactive conformation, we used site-directed mutagenesis to sequentially replace each of the six cysteines in the protein at positions 30, 213, 344, 434, 553, and 577. All the resultant mutant methylases except for the C344S and C344A enzymes retained significant activity as assessed by in vivo and in vitro assays. The effects of the substitutions on the function of EcoP15I DNA methyltransferase were investigated by substrate binding assays, activity measurements, and steady-state kinetic analysis of catalysis, Our results clearly indicate that the cysteines at positions other than 344 are not essential for activity. In contrast, the C344A enzyme showed a marked loss of enzymatic activity. More importantly, whereas the inactive C344A mutant enzyme bound S-adenosyl-L-Methionine, it failed to bind to DNA. Furthermore, in double and triple mutants where two or three cysteine residues were replaced by serine, all such mutants in which the cysteine at position 344 was changed, were inactive. Taken together, these results convincingly demonstrate that the Cys-344 is necessary for enzyme activity and indicate an essential role for it in DNA binding.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rao, DN (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.							Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; Ahmad I, 1996, J MOL BIOL, V259, P229, DOI 10.1006/jmbi.1996.0315; AHMAD I, 1994, GENE, V142, P67, DOI 10.1016/0378-1119(94)90356-5; AHMAD I, 1995, GENE, V157, P143, DOI 10.1016/0378-1119(95)00671-R; AIKEN CR, 1991, J BIOL CHEM, V266, P19063; Bickle TA, 1993, NUCLEASES, P89; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COMMUNI D, 1995, BIOCHEM J, V310, P109, DOI 10.1042/bj3100109; COWARD JK, 1971, J ORG CHEM, V36, P2337, DOI 10.1021/jo00815a032; CREIGHTON TE, 1997, PROTEIN STRUCTURE PR, P287; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EVERETT EA, 1990, J BIOL CHEM, V265, P17713; GABBARA S, 1995, BIOCHEMISTRY-US, V34, P8914, DOI 10.1021/bi00027a044; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; HADI SM, 1983, J MOL BIOL, V165, P19, DOI 10.1016/S0022-2836(83)80240-X; HATTMAN S, 1985, J BACTERIOL, V164, P932, DOI 10.1128/JB.164.2.932-937.1985; HERMAN GE, 1982, J BIOL CHEM, V257, P2605; HO DK, 1991, ARCH BIOCHEM BIOPHYS, V284, P264, DOI 10.1016/0003-9861(91)90294-S; HUMBELIN M, 1988, J MOL BIOL, V200, P23, DOI 10.1016/0022-2836(88)90330-0; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; KNIPE JO, 1979, J AM CHEM SOC, V101, P4339, DOI 10.1021/ja00509a049; KOSSYKH VG, 1995, J BIOL CHEM, V270, P14389, DOI 10.1074/jbc.270.24.14389; KUMAR S, 1994, NUCLEIC ACIDS RES, V91, P10957; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; MEISEL A, 1995, EMBO J, V14, P2958, DOI 10.1002/j.1460-2075.1995.tb07296.x; MEISEL A, 1991, NUCLEIC ACIDS RES, V9, P3997; MI S, 1993, NUCLEIC ACIDS RES, V21, P4811; POGOLOTTI AL, 1988, J BIOL CHEM, V263, P7461; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; PROFY AT, 1986, J BIOL CHEM, V261, P15474; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; REICH NO, 1990, J BIOL CHEM, V265, P8966; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; SAHA S, 1995, J MOL BIOL, V247, P559, DOI 10.1016/S0022-2836(05)80137-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SZILAK L, 1994, NUCLEIC ACIDS RES, V22, P2876, DOI 10.1093/nar/22.15.2876; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WYSZYNSKI MW, 1993, NUCLEIC ACIDS RES, V21, P295, DOI 10.1093/nar/21.2.295	49	13	13	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23866	23876		10.1074/jbc.273.37.23866	http://dx.doi.org/10.1074/jbc.273.37.23866			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726999	hybrid			2022-12-25	WOS:000075893100040
J	Tzeng, YL; Zhou, XZ; Hoch, JA				Tzeng, YL; Zhou, XZ; Hoch, JA			Phosphorylation of the Spo0B response regulator phosphotransferase of the phosphorelay initiating development in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SIGNAL-TRANSDUCTION SYSTEM; ESCHERICHIA-COLI; MULTISTEP PHOSPHORELAY; BACTERIAL CHEMOTAXIS; SPORULATION; KINASE; TRANSCRIPTION; OPERON; PHOSPHATASE	The initiation of sporulation in Bacillus subtilis is regulated by the phosphorelay, a complex signal transduction system consisting of kinases and response regulators. The key component of a phosphorelay is the phosphotransferase, which recognizes two response regulators and transfers a phosphoryl group between them. In this reaction, the phosphoryl of one response regulator is transferred to a histidine on the phosphotransferase before phosphorylating an aspartate of the second response regulator. The phosphorylated histidine on the Spo0B phosphotransferase was found to be His(30). Site-directed mutation of His(30) to alanine destroyed its phosphotransferase activity in vitro and strains constructed with this mutation were unable to sporulate, None of the other 10 histidines of Spo0B was implicated in the phosphotransferase reaction. A structurally vulnerable site, histidine 23, was also identified through the mutational study. The His(30) of Spo0B resides in a domain with little sequence homology to functionally equivalent domains in the phosphorelays of other bacterial and yeast systems, suggesting that the two types of phosphotransfer domains evolved convergently.	Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Hoch, JA (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM19416] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019416, R01GM019416] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1996, METHODS MOL BIOL IN; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HULTQUIST DE, 1966, BIOCHEMISTRY-US, V5, P322, DOI 10.1021/bi00865a041; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; Kato M, 1997, CELL, V88, P717, DOI 10.1016/S0092-8674(00)81914-5; KOK J, 1994, J BACTERIOL, V176, P7155, DOI 10.1128/JB.176.23.7155-7160.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Ogino T, 1998, MOL MICROBIOL, V27, P573, DOI 10.1046/j.1365-2958.1998.00703.x; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; Perego M, 1996, MOL MICROBIOL, V19, P1151, DOI 10.1111/j.1365-2958.1996.tb02460.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Perego Marta, 1993, P615; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; SANNA MG, 1995, MOL MICROBIOL, V15, P1069, DOI 10.1111/j.1365-2958.1995.tb02282.x; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P701; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Smith R A, 1978, Methods Cell Biol, V19, P153; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; TRACH KA, 1993, MOL MICROBIOL, V8, P69, DOI 10.1111/j.1365-2958.1993.tb01204.x; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WELSH KM, 1994, J BACTERIOL, V176, P7161, DOI 10.1128/JB.176.23.7161-7168.1994; Zapf JW, 1996, BIOCHEMISTRY-US, V35, P2926, DOI 10.1021/bi9519361; ZHOU HJ, 1995, BIOCHEMISTRY-US, V34, P13858, DOI 10.1021/bi00042a018; Zhou XZ, 1997, PROTEINS, V27, P597, DOI 10.1002/(SICI)1097-0134(199704)27:4<597::AID-PROT11>3.0.CO;2-F	36	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23849	23855		10.1074/jbc.273.37.23849	http://dx.doi.org/10.1074/jbc.273.37.23849			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726997	hybrid			2022-12-25	WOS:000075893100038
J	Pye, DA; Vives, RR; Turnbull, JE; Hyde, P; Gallagher, JT				Pye, DA; Vives, RR; Turnbull, JE; Hyde, P; Gallagher, JT			Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR DIMERIZATION; EXTRACELLULAR DOMAIN; CELL-PROLIFERATION; BINDING DOMAIN; FGF; IDENTIFICATION; SPECIFICITY; ACTIVATION; GLYCOSAMINOGLYCANS; DISACCHARIDES	The interaction of heparan sulfate (HS) with basic fibroblast growth factor (bFGF) is influential in enabling the growth factor to bind to its cell surface tyrosine kinase receptor. In this study, we have investigated further the structural properties of HS required to mediate the activity of bFGF in a mitogenic assay. We have prepared a library of heparinase m-generated HS oligosaccharides fractionated by both their size (dp6-dp12) and sulfate content. The ability of these oligosaccharides to activate bFGF in a mitogenic assay was then correlated with their length and disaccharide composition. All octa- and hexasaccharide fractions tested were unable to activate bFGF. Dodeca- and decasaccharide fractions were found to contain both activating and nonactivating oligosaccharides, and showed a clear correlation between total sulfate content and the level of activatory activity. Disaccharide analysis of a range of dodeca- and decasaccharide fractions showed that both activating and non-activating oligosaccharides were composed mainly of N-sulfated and IdoA(2S)-containing disaccharides. The only significant difference between activating and non-activating oligosaccharides was the content of 6-O-sulfated disaccharides, in particular the disaccharide IdoA(2S)alpha 1,4GlcNSO(3)(6S). These results show that there is a requirement for B-O-sulfation of N-sulfated glucosamine residues, in addition to the 2-0-sulfation of IdoA, for the promotion of bFGF mitogenic activity by naturally occurring HS oligosaccharides. Analysis of the structure-activity relationships in the dodecasaccharide fractions in particular, suggests that a minimum bFGF activation sequence exists which is dependent on the positioning of at least one 6-O-sulfate group.	Univ Manchester, Christie Hosp, Paterson Inst Canc Res, CRC,Dept Med Oncol, Manchester M20 4BX, Lancs, England; CRC, Dept Drug Dev, Manchester M20 4BX, Lancs, England; Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester; University of Birmingham	Pye, DA (corresponding author), Univ Manchester, Christie Hosp, Paterson Inst Canc Res, CRC,Dept Med Oncol, Wilmslow Rd, Manchester M20 4BX, Lancs, England.		Vives, Romain/I-9372-2012					BRICKMAN YG, 1995, J BIOL CHEM, V270, P24941, DOI 10.1074/jbc.270.42.24941; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Miao HQ, 1996, J BIOL CHEM, V271, P4879; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PYE DA, 1994, BBA-MOL CELL RES, V1220, P266, DOI 10.1016/0167-4889(94)90148-1; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUSNATI M, 1994, BIOCHEM BIOPH RES CO, V203, P450, DOI 10.1006/bbrc.1994.2203; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; WALKER A, 1994, J BIOL CHEM, V269, P931; Wang HM, 1997, BIOCHEM BIOPH RES CO, V235, P369, DOI 10.1006/bbrc.1997.6789; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	35	237	245	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22936	22942		10.1074/jbc.273.36.22936	http://dx.doi.org/10.1074/jbc.273.36.22936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722514	hybrid			2022-12-25	WOS:000075778100014
J	Lykkesfeldt, J; Hagen, TM; Vinarsky, V; Ames, BN				Lykkesfeldt, J; Hagen, TM; Vinarsky, V; Ames, BN			Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes - reversal with (R)-alpha-lipoic acid supplementation	FASEB JOURNAL			English	Article						biomarker; oxidative stress; aging	ALPHA-LIPOIC ACID; TERT-BUTYL HYDROPEROXIDE; DEHYDROASCORBIC ACID; OXIDATIVE STRESS; METABOLIC ANTIOXIDANT; MITOCHONDRIAL DECAY; LIPID-PEROXIDATION; DIHYDROLIPOIC ACID; LIVER-MITOCHONDRIA; VITAMIN-E	Ascorbic acid recycling from dehydroascorbic acid and biosynthesis from gulono-1,4 lactone were used as measures of cellular response capacity to increased oxidative stress induced by tertbutylhydroperoxide. The hepatic ascorbic acid concentration was 54% lower in cells from old rats when compared to cells isolated from young rats (P<0.0005). Freshly isolated hepatocytes from old rats exhibited a significantly decreased ascorbic acid recycling capacity in response to oxidative stress (P<0.005) compared to cells from young rats. Ascorbic acid synthesis in these cells from old animals was unaffected by various concentrations of tert-butylhydroperoxide, but amounted to only approximately half of the biosynthetic rate when compared to cells from young animals (P<0.001). Cells from young animals were not significantly affected by the tert-butyl-hydroperoxide treatments. The results demonstrate a declining ability with age to respond to increased oxidative stress. (R)-alpha-Lipoic acid, a mitochondrial coenzyme, is a powerful antioxidant. A two-week dietary supplementation of old animals with 0.5% (R)-alpha-lipoic acid prior to cell, isolation almost completely reversed the age-associated effects on ascorbic acid concentration (P<0.0001), recycling (P<0.05) and biosynthesis after oxidative stress. These results provide further evidence for the potential of a-lipoic acid in treatment of diseases related to oxidative stress. Furthermore, the study extends the value of ascorbic acid as a biomarker of oxidative stress. Lyk-kesfeldt, J., Hagen, T. M., Vinarsky, V., Ames, B. N. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes-reversal with (R)-alpha-lipoic acid supplementation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Ames, BN (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.		Lykkesfeldt, Jens/A-1072-2011	Lykkesfeldt, Jens/0000-0002-6514-8407	NATIONAL CANCER INSTITUTE [R35CA039910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NCI NIH HHS [CA39910] Funding Source: Medline; NIEHS NIH HHS [ESO1896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Banhegyi G, 1996, FEBS LETT, V381, P39, DOI 10.1016/0014-5793(96)00077-4; Banhegyi G, 1997, FREE RADICAL BIO MED, V23, P793, DOI 10.1016/S0891-5849(97)00062-2; Barja G, 1996, Subcell Biochem, V25, P157; BECKMAN KB, 1998, IN PRESS PHYSL REV, V71; BELLOMO G, 1984, FEBS LETT, V168, P38, DOI 10.1016/0014-5793(84)80202-1; BELLOMO G, 1982, P NATL ACAD SCI-BIOL, V79, P6842, DOI 10.1073/pnas.79.22.6842; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bluck LJC, 1996, J MASS SPECTROM, V31, P741; Braun L, 1996, FEBS LETT, V388, P173, DOI 10.1016/0014-5793(96)00548-0; DE AK, 1991, MECH AGEING DEV, V59, P123, DOI 10.1016/0047-6374(91)90078-E; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; DEVASAGAYAM TPA, 1986, FEBS LETT, V205, P246, DOI 10.1016/0014-5793(86)80906-1; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; Haramaki N, 1995, BIOCHEM MOL BIOL INT, V37, P591; Haramaki N, 1997, FREE RADICAL BIO MED, V22, P535, DOI 10.1016/S0891-5849(96)00400-5; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Kitazawa M, 1997, PHOTOCHEM PHOTOBIOL, V65, P355, DOI 10.1111/j.1751-1097.1997.tb08571.x; Lykkesfeldt J, 1997, AM J CLIN NUTR, V65, P959, DOI 10.1093/ajcn/65.4.959; Lykkesfeldt J, 1996, BMJ-BRIT MED J, V313, P91, DOI 10.1136/bmj.313.7049.91; LYKKESFELDT J, 1995, ANAL BIOCHEM, V229, P329, DOI 10.1006/abio.1995.1421; MAITRA I, 1995, FREE RADICAL BIO MED, V18, P823, DOI 10.1016/0891-5849(94)00195-P; MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J; Moldeus P, 1978, Methods Enzymol, V52, P60; MOORE GA, 1983, FEBS LETT, V153, P289, DOI 10.1016/0014-5793(83)80626-7; Nishikimi M, 1979, Methods Enzymol, V62, P24; PACKER L, 1994, ANN NY ACAD SCI, V738, P257; Packer L, 1997, Adv Pharmacol, V38, P79; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; RIKANS LE, 1988, BIOCHIM BIOPHYS ACTA, V966, P269, DOI 10.1016/0304-4165(88)90076-1; Rikans LE, 1996, MECH AGEING DEV, V91, P165, DOI 10.1016/S0047-6374(96)01784-8; Roy S, 1997, BIOCHEM PHARMACOL, V53, P393, DOI 10.1016/S0006-2952(96)00764-2; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; SATO P, 1976, BIOCHEM BIOPH RES CO, V71, P293, DOI 10.1016/0006-291X(76)90281-3; SCHOLICH H, 1989, BIOCHIM BIOPHYS ACTA, V1001, P256, DOI 10.1016/0005-2760(89)90108-2; SCOTT BC, 1994, FREE RADICAL RES, V20, P119, DOI 10.3109/10715769409147509; SEARLS RL, 1960, J BIOL CHEM, V235, P2485; Sen CK, 1997, FREE RADICAL BIO MED, V22, P1241, DOI 10.1016/S0891-5849(96)00552-7; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SUZUKI YJ, 1993, FREE RADICAL RES COM, V18, P115, DOI 10.3109/10715769309147348; TSAO CS, 1989, LIFE SCI, V45, P1553, DOI 10.1016/0024-3205(89)90421-9; Xu DP, 1996, J BIOENERG BIOMEMBR, V28, P77; YU BP, 1989, OXYGEN RADICALS BIOL, P1067	48	120	126	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1183	1189		10.1096/fasebj.12.12.1183	http://dx.doi.org/10.1096/fasebj.12.12.1183			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737721				2022-12-25	WOS:000075738500013
J	Susini, S; Roche, E; Prentki, M; Schlegel, W				Susini, S; Roche, E; Prentki, M; Schlegel, W			Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells	FASEB JOURNAL			English	Article						glucagon-like peptide-1; pituitary adenylate cyclase-activating polypeptide; immediate-early response genes; proto-oncogenes; intracellular Ca2+	CYCLASE-ACTIVATING POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE-1; NERVE GROWTH-FACTOR; INSULIN-SECRETION; BETA-CELLS; PROINSULIN BIOSYNTHESIS; RESPONSE GENES; RECEPTOR; LINE; NUR77	To link glucose signaling to its longterm pleiotropic effects in the pancreatic p-cen, we have investigated whether glucose regulates immediate-early response genes (IEGs) coding for transcription factors implicated in cell proliferation and differentiation. Glucose causes a coordinated transcriptional activation of the IEGs c-fos, c-jun,JunB, zif-268, and nur-77 in the pancreatic beta-cell line INS-1. This activation is entirely dependent on the presence of the cell-permeant cAMP analog chlorophenylthio-cAMP, which has only a modest effect by itself. The accumulation of c-fos, JunB, and nur-77 mRNA occurs at physiological concentrations of glucose (3 to 11 mM), requires a 1-2 h period, and is mimicked by other nutrient stimuli including mannose, leucine plus glutamine, and pyruvate. Glucose is synergistic with the glucoincretin peptides GLP-1 and PACAP-38, whereas these neurohormonal agents have no effect at low (3 mM) glucose. Mechanistically, the synergy between glucose and the glucoincretins is not based on cAMP alone as glucose does not further increase intracellular cAMP in response to GLP-1 and PACAP-38. A role for Ca2+ signaling is inferred, since the L-type Ca2+ channel blocker nifedipine markedly reduces the induction of c-fos and nur-77 by glucose and GLP-1. The induction of IEGs by glucose and chlorophenylthioc-cAMP or GLP-1 and the inhibitory effect of nifedipine are also observed in the beta HC9 cell Line. The results indicate that GLP-1 and PACAP-38 act as competence factors for the action of glucose on c-fos,JunB, and nur-77. It is suggested that the synergistic effect of glucose and glucoincretins on IEG expression plays an important role in the adaptive processes of the beta-cell to hyperglycemia.	Univ Montreal, Dept Nutr, Ctr Rech LC Simard, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc, Ctr Rech LC Simard, Montreal, PQ H2L 4M1, Canada; Univ Geneva, Fondat Rech Med, CH-1211 Geneva, Switzerland	Universite de Montreal; Universite de Montreal; University of Geneva	Prentki, M (corresponding author), Univ Montreal, Dept Nutr, Ctr Rech LC Simard, 1560 Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	PRENTKIM@ERE.UMONTREAL.CA	Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672				ALARCON C, 1993, J BIOL CHEM, V268, P4276; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BLANCHARD JM, 1992, M S-MED SCI, V8, P455, DOI 10.4267/10608/3162; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; Bruce WR, 1996, EUR J CANCER PREV, V5, P41, DOI 10.1097/00008469-199612002-00007; BRUN T, 1993, J BIOL CHEM, V268, P18905; COFFER P, 1994, ONCOGENE, V9, P911; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOKE R, 1988, J ENDOCRINOL, V116, P357, DOI 10.1677/joe.0.1160357; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MacDonald MJ, 1996, MOL CELL ENDOCRINOL, V123, P199, DOI 10.1016/S0303-7207(96)03918-4; MARIE S, 1993, J BIOL CHEM, V268, P23881; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; Roche E, 1997, J BIOL CHEM, V272, P3091, DOI 10.1074/jbc.272.5.3091; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; SCHUIT FC, 1991, BIOCHEM BIOPH RES CO, V178, P1182, DOI 10.1016/0006-291X(91)91017-7; SHUPPIN GT, 1996, BIOCHEM J, V313, P259; Sjoholm A, 1996, J INTERN MED, V239, P211, DOI 10.1046/j.1365-2796.1996.377740000.x; Thorens B, 1995, DIABETES METAB, V21, P311; WAEBER G, 1994, J BIOL CHEM, V269, P26912; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; YADA T, 1994, J BIOL CHEM, V269, P1290; YOON JK, 1993, J BIOL CHEM, V268, P9148	41	121	126	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1173	1182		10.1096/fasebj.12.12.1173	http://dx.doi.org/10.1096/fasebj.12.12.1173			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737720				2022-12-25	WOS:000075738500012
J	Arora, KK; Krsmanovic, LZ; Mores, N; O'Farrell, H; Catt, KJ				Arora, KK; Krsmanovic, LZ; Mores, N; O'Farrell, H; Catt, KJ			Mediation of cyclic AMP signaling by the first intracellular loop of the gonadotropin-releasing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; THYROTROPIN RECEPTOR; CYTOPLASMIC DOMAINS; ADENYLYL-CYCLASE; PHOSPHOLIPASE-C; TRANSDUCTION; ACTIVATION; EXPRESSION; MUTATIONS	The gonadotropin-releasing hormone (GnRH) receptor, which is a unique G protein-coupled receptor without a C-terminal cytoplasmic domain, activates both inositol phosphate (InsP) and cAMP signaling responses. The function of the highly basic first intracellular (1i) loop of the GnRH receptor in signal transduction was evaluated by mutating selected residues located in its N and C termini, Replacements of Leu(58), Lys(59), Gln(61), and Lys(62) at the N terminus, and Leu(73), Ser(74), and Leu(80) at the C terminus, caused no change in binding affinity. The agonist-induced InsP and cAMP responses of the Q61E and K59Q,K62Q receptors were also unaffected, but the L58A receptor showed a normal InsP response and an 80% decrease in cAMP production. At the C terminus, the InsP response of the L73R receptor was normal, but cAMP production was reduced by 80%, The EC50 for GnRH-induced InsP responses of the S74E and L80A receptors was increased by about one order of magnitude, and the cAMP responses were essentially abolished. These findings indicate that cAMP signaling from the GnRH receptor is dependent on specific residues in the 1i loop that are not essential for activation of the phosphoinositide signaling pathway.	NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Catt, KJ (corresponding author), NICHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.	catt@helix.nih.gov		MORES, Nadia/0000-0002-4197-0914				Antoni FA, 1997, TRENDS ENDOCRIN MET, V8, P7, DOI 10.1016/S1043-2760(96)00206-8; Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; BOURNE GA, 1987, AM J PHYSIOL, V253, pE290, DOI 10.1152/ajpendo.1987.253.3.E290; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GRASSO P, 1995, MOL CELL ENDOCRINOL, V108, P43, DOI 10.1016/0303-7207(94)03461-2; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1994, BBA-MOL CELL RES, V1223, P261, DOI 10.1016/0167-4889(94)90235-6; KOSUGI S, 1994, BIOCHEM BIOPH RES CO, V200, P401, DOI 10.1006/bbrc.1994.1463; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUPHAL D, 1994, ENDOCRINOLOGY, V135, P315, DOI 10.1210/en.135.1.315; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Mores N, 1996, ENDOCRINOLOGY, V137, P5731, DOI 10.1210/en.137.12.5731; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WEISS ER, 1988, J BIOL CHEM, V263, P6150; Wu V, 1997, J BIOL CHEM, V272, P9037	35	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25581	25586		10.1074/jbc.273.40.25581	http://dx.doi.org/10.1074/jbc.273.40.25581			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748222	hybrid			2022-12-25	WOS:000076263100013
J	Fontaine, E; Ichas, F; Bernardi, P				Fontaine, E; Ichas, F; Bernardi, P			A ubiquinone-binding site regulates the mitochondrial permeability transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SEPARATE SITES; CYCLOSPORINE-A; PYRIDINE-NUCLEOTIDES; INORGANIC-PHOSPHATE; HEART-MITOCHONDRIA; CELL-DEATH; MODULATION; REDUCTION; MEMBRANE; DEPOLARIZATION	We have investigated the regulation of the mitochondrial permeability transition pore (PTP) by ubiquinone analogues. We found that the Ca2+-dependent PTP opening was inhibited by ubiquinone 0 and decylubiquinone, whereas all other tested quinones (ubiquinone 5, 1,4-benzoquinone, 2-methoxy-1,4-benzoquinone, 2,3-dimethoxy-1,4-benzoquinone, and 2,3-dimethoxy-5,6-dimethyl-1,8-benzoquinone) were ineffective. Pore inhibition was observed irrespective of the method used to induce the permeability transition (addition of P-i or atractylate, membrane depolarization, or dithiol cross-linking). Inhibition of PTP opening by decylubiquinone was comparable with that exerted by cyclosporin A, whereas ubiquinone 0 was more potent. Ubiquinone 5, which did not inhibit the PTP per se, specifically counteracted the inhibitory effect of ubiquinone 0 or decylubiquinone but not that of cyclosporin A. These findings define a ubiquinone-binding site directly involved in PTP regulation and indicate that different quinone structural features are required for binding and for stabilizing the pore in the closed conformation. At variance from all other quinones tested, decylubiquinone did not inhibit respiration. Our results define a new structural class of pore inhibitors and may open new perspectives for the pharmacological modulation of the PTP in vivo.	Univ Padua, Sch Med, Dept Biomed Sci, Lab Biophys & Membrane Biol, I-35121 Padua, Italy; Univ Padua, Sch Med, Consiglio Nazl Ric, Unit Study Biomembranes, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Bernardi, P (corresponding author), Dipartimento Sci Biomed Sperimentale, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.		Bernardi, Paolo/C-3656-2008; Ichas, François/ABD-8277-2020; Fontaine, Eric/ABA-8853-2020	Bernardi, Paolo/0000-0001-9187-3736; Ichas, François/0000-0001-8184-5248; Fontaine, Eric/0000-0002-5204-9477	Telethon [847] Funding Source: Medline	Telethon(Fondazione Telethon)		Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; CROMPTON M, 1988, BIOCHEM J, V255, P357; DIVIRGILIO F, 1982, J BIOL CHEM, V257, P4106; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Esposti MD, 1996, BIOCHEM J, V313, P327, DOI 10.1042/bj3130327; EVTODIENKO YV, 1994, CELL CALCIUM, V15, P143, DOI 10.1016/0143-4160(94)90053-1; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Schinder AF, 1996, J NEUROSCI, V16, P6125; White RJ, 1996, J NEUROSCI, V16, P5688; Yamaguchi M, 1998, J BIOL CHEM, V273, P8094, DOI 10.1074/jbc.273.14.8094; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	38	216	220	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25734	25740		10.1074/jbc.273.40.25734	http://dx.doi.org/10.1074/jbc.273.40.25734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748242	hybrid			2022-12-25	WOS:000076263100033
J	Hori, H; Yamazaki, N; Matsumoto, T; Watanabe, Y; Ueda, T; Nishikawa, K; Kumagai, I; Watanabe, K				Hori, H; Yamazaki, N; Matsumoto, T; Watanabe, Y; Ueda, T; Nishikawa, K; Kumagai, I; Watanabe, K			Substrate recognition of tRNA (Guanosine-2 '-)-methyltransferase from Thermus thermophilus HB27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-GUANINE TRANSGLYCOSYLASE; ESCHERICHIA-COLI; STRUCTURAL REQUIREMENTS; ANTICODON LOOP; METHYLATION; STABILITY; NUCLEOSIDES; SPECIFICITY; POLYMERASE; SEQUENCES	Transfer RNA (guanosine-2'-)-methyltransferase (Gm-methylase, EC 2.1.1.32) from Thermus thermophilus HB27 is one of the tRNA ribose modification enzymes. The broad substrate specificity of Gm-methylase has so far been elucidated using various species of tRNAs from native sources, suggesting that the common structures in tRNAs are recognized by the enzyme. In this study, by using 28 yeast tRNA(Phe) variants obtained by transcription with T7 RNA polymerase, it was revealed that the nucleotide residues G18 and G19 and the D-stem structure are essentially required for Gm-methylase recognition, and that the key sequence for the substrate is pyrimidine (Py)17G18G19. The other conserved sequences were found not to be essential, but U8, G15, G26, G46, U54, U55, and C56 considerably affected the methylation efficiency. These residues are located within a limited space embedded in the L-shaped three-dimensional structure of tRNA Therefore, disruption of the three-dimensional structure of the substrate tRNA is necessary for the catalytic center of Gm methylase to be able to access the target site in the tRNA, suggesting that the interaction of Gm-methylase with tRNA consists of multiple steps. This postulation was confirmed by inhibition experiments using nonsubstrate tRNA variants which functioned as competitive inhibitors against usual substrate tRNAs.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo	Watanabe, K (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.		Ueda, Takuya/K-5217-2014	Ueda, Takuya/0000-0002-7760-8271				Bjork Glenn R., 1995, P165; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; CARBON P, 1983, EMBO J, V2, P1093, DOI 10.1002/j.1460-2075.1983.tb01551.x; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; DAVANLOO P, 1979, NUCLEIC ACIDS RES, V6, P1571, DOI 10.1093/nar/6.4.1571; Dirheimer G., 1995, P93; DROOGMANS L, 1986, EMBO J, V5, P1105, DOI 10.1002/j.1460-2075.1986.tb04329.x; EDQVIST J, 1993, NUCLEIC ACIDS RES, V21, P413, DOI 10.1093/nar/21.3.413; EDQVIST J, 1992, NUCLEIC ACIDS RES, V20, P6575, DOI 10.1093/nar/20.24.6575; GAMBARYAN AS, 1976, NUCLEIC ACIDS RES, V3, P2079, DOI 10.1093/nar/3.8.2079; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GROSJEAN H, 1982, BIOCHIMIE, V64, P387, DOI 10.1016/S0300-9084(82)80576-2; GU XG, 1991, BIOCHEMISTRY-US, V30, P2999, DOI 10.1021/bi00226a003; GU XG, 1994, BIOCHEMISTRY-US, V33, P2255, DOI 10.1021/bi00174a036; HOLMES WM, 1992, J BIOL CHEM, V267, P13440; HORI H, 1989, J BIOCHEM-TOKYO, V106, P798, DOI 10.1093/oxfordjournals.jbchem.a122933; JOHNSON PF, 1983, NATURE, V302, P681, DOI 10.1038/302681a0; KEALEY JT, 1995, BIOCHEMISTRY-US, V34, P2441, DOI 10.1021/bi00008a006; KEITH JM, 1980, J BIOL CHEM, V255, P4636; KIM SH, 1974, P NATL ACAD SCI USA, V71, P4970, DOI 10.1073/pnas.71.12.4970; KLINE LK, 1982, ENZYMES, V15, P567; KUMAGAI I, 1980, P NATL ACAD SCI-BIOL, V77, P1922, DOI 10.1073/pnas.77.4.1922; KUMAGAI I, 1982, J BIOL CHEM, V257, P7388; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2138; MARECHALDROUARD L, 1990, FEBS LETT, V262, P170, DOI 10.1016/0014-5793(90)80181-H; MATSUMOTO T, 1990, J BIOCHEM-TOKYO, V107, P331, DOI 10.1093/oxfordjournals.jbchem.a123047; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; NISHIMURA S, 1979, TRANSFER RNA STRUCTU, P59; Persson BC, 1997, NUCLEIC ACIDS RES, V25, P4093, DOI 10.1093/nar/25.20.4093; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SOLL D, 1982, ENZYMES, V15, P557; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZWEYKOWSKAKULINSKA Z, 1992, EMBO J, V11, P1907, DOI 10.1002/j.1460-2075.1992.tb05243.x; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1; YAMAZAKI N, 1994, BIOSCI BIOTECH BIOCH, V58, P1128, DOI 10.1271/bbb.58.1128	42	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25721	25727		10.1074/jbc.273.40.25721	http://dx.doi.org/10.1074/jbc.273.40.25721			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748240	hybrid			2022-12-25	WOS:000076263100031
J	Rowe-Magnus, DA; Spiegelman, GB				Rowe-Magnus, DA; Spiegelman, GB			Contributions of the domains of the Bacillus subtilis response regulator Spo0A to transcription stimulation of the spoIIG operon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; ACTIVATE TRANSCRIPTION; PROTEIN; BINDING; SPORULATION; PROMOTER; PHOSPHORYLATION; DNA; INITIATION; MECHANISM	Spo0A is a response regulator that controls entry into sporulation by specifically stimulating or repressing transcription of critical developmental genes. Response regulators have at least two domains: an output transcription regulation domain and a receiver domain that inhibits the output domain, Phosphorylation of the receiver domain relieves the inhibition. We examined the in vitro transcription activation mechanism for Spo0A, phosphorylated Spo0A (Spo0A-P), and a deletion mutant that consists solely of the C-terminal output domain (Spo0ABD). Both Spo0A-P and Spo0ABD stimulated transcription from the spoIIG promoter 10-fold more efficiently than Spo0A Spo0A-P and Spo0ABD induced DNA denaturation by RNA polymerase in the -10 recognition region, whereas Spo0A did not. DNase I footprint assays revealed that phosphorylation enhanced binding of intact Spo0A to the OA boxes, while the binding of Spo0ABD was similar to that of Spo0A Thus, activation of Spo0A by phosphorylation is not primarily due to enhanced DNA binding. The presence of a phosphorylated N terminus increased the stability of the ternary complex at the spoIIG promoter. We propose that the primary effect of phosphorylation is to expose an RNA polymerase interaction domain to promote transcription from PspoIIG.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Spiegelman, GB (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	spie@unixg.ubc.ca		Rowe-Magnus, Dean/0000-0001-5133-4463				AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; ARAKAWA T, 1984, BIOCHEMISTRY-US, V23, P5912, DOI 10.1021/bi00320a004; ASAYAMA M, 1995, J MOL BIOL, V250, P11, DOI 10.1006/jmbi.1995.0354; BALDUS JM, 1995, MOL MICROBIOL, V17, P281, DOI 10.1111/j.1365-2958.1995.mmi_17020281.x; BALDUS JM, 1994, J BACTERIOL, V176, P296, DOI 10.1128/JB.176.2.296-306.1994; BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; BUCK M, 1989, NUCLEIC ACIDS RES, V17, P2597, DOI 10.1093/nar/17.7.2597; DOBINSON KF, 1987, BIOCHEMISTRY-US, V26, P8206, DOI 10.1021/bi00399a028; GRIMSLEY JK, 1994, J BIOL CHEM, V269, P16977; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; Huang KJ, 1997, P NATL ACAD SCI USA, V94, P2828, DOI 10.1073/pnas.94.7.2828; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; North AK, 1997, J MOL BIOL, V267, P17, DOI 10.1006/jmbi.1996.0838; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1991, GENE, V100, P207, DOI 10.1016/0378-1119(91)90368-L; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SATOLA S, 1991, P NATL ACAD SCI USA, V88, P4533, DOI 10.1073/pnas.88.10.4533; SATOLA SW, 1992, J BACTERIOL, V174, P1448, DOI 10.1128/jb.174.5.1448-1453.1992; Schyns G, 1997, J BACTERIOL, V179, P5605, DOI 10.1128/jb.179.17.5605-5608.1997; SPIEGELMAN GB, 1995, 2 COMPONENT SIGNAL T, P159; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; TRACH K, 1991, RES MICROBIOL, V142, P815, DOI 10.1016/0923-2508(91)90060-N; Wang L, 1997, GENE DEV, V11, P2569, DOI 10.1101/gad.11.19.2569	32	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25818	25824		10.1074/jbc.273.40.25818	http://dx.doi.org/10.1074/jbc.273.40.25818			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748255	hybrid			2022-12-25	WOS:000076263100046
J	Worgall, TS; Sturley, SL; Seo, T; Osborne, TF; Deckelbaum, RJ				Worgall, TS; Sturley, SL; Seo, T; Osborne, TF; Deckelbaum, RJ			Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR ACTIVITY; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A SYNTHASE; CHOLESTEROL ACYLTRANSFERASE; TRANSCRIPTION FACTOR; CULTURED-CELLS; SPHINGOMYELIN; IDENTIFICATION; PROTEOLYSIS; HOMEOSTASIS; PATHWAY	Membrane physiology, plasma lipid levels, and intracellular sterol homeostasis are regulated by both fatty acids and cholesterol. Sterols regulate gene expression of key enzymes of cholesterol and fatty acid metabolism through proteolysis of the sterol regulatory element-binding protein (SREBP), which binds to sterol regulatory elements (SRE) contained in promoters of these genes. We investigated the effect of fatty acids on SRE-dependent gene expression and SREBP, Consistent results were obtained in three different cell lines (HepG2, Chinese hamster ovary, and CV-1) transfected with SRE-containing promoters linked to the luciferase expression vector. We show that micromolar concentrations of oleate and other polyunsaturated fatty acids (C18:2-C22:6) dose-dependently (0.075-0.6 mmol) decreased transcription of SRE-regulated genes by 20-75%. Few or no effects were seen with saturated free fatty acids. Fatty acid effects on SRE-dependent gene expression were independent and additive to those of exogenous sterols, Oleate decreased levels of the mature sterol regulatory element-binding proteins SREBP-1 and -2 and HMG-CoA synthase mRNA, Oleate had no effect in sterol regulation defective Chinese hamster ovary cells or in cells transfected with mutant SRE-containing promoters. We hypothesize that unsaturated fatty acids increase intracellular regulatory pools of cholesterol and thus affect mature SREBP levels and expression of SRE-dependent genes.	Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; University of California System; University of California Irvine	Deckelbaum, RJ (corresponding author), Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Pediat, PH-1512,630 W 168th St, New York, NY 10032 USA.				NHLBI NIH HHS [HL 40404, HL 48044] Funding Source: Medline; NIDDK NIH HHS [DK 07715] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044, R01HL040404] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; Clarke SD, 1997, ANN NY ACAD SCI, V827, P178, DOI 10.1111/j.1749-6632.1997.tb51833.x; DAUMERIE CM, 1992, P NATL ACAD SCI USA, V89, P10797, DOI 10.1073/pnas.89.22.10797; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JAVITT NB, 1989, BIOCHEM J, V262, P989, DOI 10.1042/bj2620989; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Klansek JJ, 1996, J BIOL CHEM, V271, P4923; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LOPEZ JM, 1996, P NATL ACAD SCI USA, V93, P3786; Magana MM, 1997, J LIPID RES, V38, P1630; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; ROBINSON BS, 1997, IMMUNOLOGY, V91, P271; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; RUSS AP, 1992, BIOCHIM BIOPHYS ACTA, V1132, P329, DOI 10.1016/0167-4781(92)90172-V; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SPECTOR AA, 1985, J LIPID RES, V26, P1015; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; YANG J, 1994, GENE DEV, V15, P1910	33	248	251	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25537	25540		10.1074/jbc.273.40.25537	http://dx.doi.org/10.1074/jbc.273.40.25537			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748213	hybrid			2022-12-25	WOS:000076263100004
J	Saarela, J; Laine, M; Tikkanen, R; Oinonen, C; Jalanko, A; Rouvinen, J; Peltonen, L				Saarela, J; Laine, M; Tikkanen, R; Oinonen, C; Jalanko, A; Rouvinen, J; Peltonen, L			Activation and oligomerization of aspartylglucosaminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; 20S PROTEASOME; CRYSTAL-STRUCTURE; BETA-SUBUNITS; ASSOCIATION; MUTATION; SITE; CALRETICULIN; BIOSYNTHESIS; MECHANISM	Secretory, membrane, and lysosomal proteins undergo covalent modifications and acquire their secondary and tertiary structure in the lumen of the endoplasmic reticulum (ER). In order to pass the ER quality control system and become transported to their final destinations, many of them are also assembled into oligomers, We have recently determined the three-dimensional structure of lysosomal aspartylglucosaminidase (AGA), which belongs to a newly discovered family of homologous amidohydrolases, the N-terminal nucleophile hydrolases. Members of this protein family are activated from an inactive precursor molecule by an autocatalytic proteolytic processing event whose exact mechanism has not been thoroughly determined. Here we have characterized in more detail the initial events in the ER required for the formation of active AGA enzyme using transient expression of polypeptides carrying targeted amino acid substitutions. We show that His(124) at an interface between two heterodimers of AGA is crucial for the thermodynamically stable oligomeric structure of AGA. Furthermore, the side chain of Thr(206) is essential both for the proteolytic activation and enzymatic activity of AGA. Finally, the proper geometry of the residues His(204)-Asp(205) seems to be crucial for the activation of AGA precursor polypeptides. We propose here a reaction mechanism for the activation of AGA which could be valid for homologous enzymes as well.	Univ Helsinki, Dept Med Genet, FIN-00300 Helsinki, Finland; Natl Publ Hlth Inst, Dept Mol Genet, FIN-00300 Helsinki, Finland; Univ Joensuu, Dept Chem, FIN-87101 Joensuu, Finland	University of Helsinki; Finland National Institute for Health & Welfare; University of Eastern Finland	Peltonen, L (corresponding author), Univ Helsinki, Dept Med Genet, Mannerheimintie 166, FIN-00300 Helsinki, Finland.		Saarela, Jani/AAK-5033-2020	Saarela, Jani/0000-0001-7306-7175; Tikkanen, Ritva/0000-0002-8393-1825; Rouvinen, Juha/0000-0003-1843-5718				BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HALILA R, 1991, BIOCHEM J, V276, P251, DOI 10.1042/bj2760251; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; IKONEN E, 1991, GENOMICS, V11, P206, DOI 10.1016/0888-7543(91)90120-4; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Peltola M, 1996, HUM MOL GENET, V5, P737, DOI 10.1093/hmg/5.6.737; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PROIA RL, 1984, J BIOL CHEM, V259, P3350; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; RIIKONEN A, 1995, J BIOL CHEM, V270, P4903, DOI 10.1074/jbc.270.9.4903; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Simons JF, 1998, EMBO J, V17, P396, DOI 10.1093/emboj/17.2.396; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; Tikkanen R, 1997, EMBO J, V16, P6684, DOI 10.1093/emboj/16.22.6684; TIKKANEN R, 1995, DNA CELL BIOL, V14, P305, DOI 10.1089/dna.1995.14.305; Xuan JC, 1998, PROTEIN SCI, V7, P774, DOI 10.1002/pro.5560070327; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	34	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25320	25328		10.1074/jbc.273.39.25320	http://dx.doi.org/10.1074/jbc.273.39.25320			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737998	hybrid			2022-12-25	WOS:000076085400048
J	Souchelnytskyi, S; Nakayama, T; Nakao, A; Moren, A; Heldin, CH; Christian, JL; ten Dijke, P				Souchelnytskyi, S; Nakayama, T; Nakao, A; Moren, A; Heldin, CH; Christian, JL; ten Dijke, P			Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD-RELATED PROTEIN; SIGNALING PATHWAYS; PHOSPHORYLATION; SUPERFAMILY; ANTAGONIST; ACTIVATION; SER(465); MEMBRANE; FAMILY; BMP	Members of the transforming growth factor-beta (TGF-beta) family transmit signals from membrane to nucleus via intracellular proteins known as Smads. A subclass of Smad proteins has recently been identified that antagonize, rather than transduce, TGF-beta family signals. Smad7, for example, binds to and inhibits signaling downstream of TGF-beta receptors. Here we report that the C-terminal MAD homology domain of murine Smad7 (mSmad7) is sufficient for both of these activities. In addition, we show that mSmad7 interacts with activated bone morphogenetic protein (BMP) type I receptors (BMPR-Is), inhibits BMPR-I-mediated Smad phosphorylation, and phenocopies the effect of known BMP antagonists when overexpressed in ventral cells of Xenopus embryos. Xenopus Smad7 (XSmad7, previously termed Smad8) and mSmad7 are nearly identical within their bioactive C-domain, but have quite distinct N-domains. We found that XSmad7, similar to mSmad7, interacted with BMP and TGF-beta type I receptors and inhibited receptor-mediated phosphorylation of downstream signal-transducing Smads. However, XSmad7 is a less efficient inhibitor of T beta R-I-mediated responses in mammalian cells than is mSmad7. Furthermore, overexpression of XSmad7 in Xenopus embryos produces patterning defects that are not observed following overexpression of mSmad7, suggesting that mSmad7 and XSmad7 may preferentially target distinct signaling pathways. Our results are consistent with the possibility that the C-domain of antagonistic Smads is an effector domain whereas the N-domain may confer specificity for distinct signaling pathways.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden; Oregon Hlth Sci Univ, Sch Med, Dept Cell & Dev Biol, Portland, OR 97201 USA	Ludwig Institute for Cancer Research; Oregon Health & Science University	ten Dijke, P (corresponding author), Chiba Univ, Sch Med, Dept Internal Med, 1-8-1 Inohana, Chiba 2600856, Japan.	Peter.ten_Dijke@LICR.uu.se	Souchelnytskyi, Serhiy/G-6491-2011; Nakayama, Takuya/J-5812-2015; Nakayama, Toshinori/E-1067-2017; Dijke, Peter ten/AAG-4660-2021; Souchelnytskyi, Serhiy/J-9446-2014	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Nakayama, Takuya/0000-0002-5531-6710; Nakayama, Toshinori/0000-0002-1434-2007; Dijke, Peter ten/0000-0002-7234-342X; 				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Moon R. T., 1989, TECHNIQUE, V1, P76; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Nakayama T, 1998, DEVELOPMENT, V125, P857; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VIZE PD, 1994, TRENDS GENET, V10, P371, DOI 10.1016/0168-9525(94)90134-1; Watanabe TK, 1997, GENOMICS, V42, P446, DOI 10.1006/geno.1997.4753; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	39	125	135	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25364	25370		10.1074/jbc.273.39.25364	http://dx.doi.org/10.1074/jbc.273.39.25364			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738003	hybrid			2022-12-25	WOS:000076085400053
J	Bogdanov, VY; Poon, M; Taubman, MB				Bogdanov, VY; Poon, M; Taubman, MB			Platelet-derived growth factor-specific regulation of the JE promoter in rat aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACROPHAGE INFLAMMATORY PROTEIN-2; HUMAN ENDOTHELIAL-CELLS; KINASE-C ACTIVATION; COMPETENCE GENE-JE; CHEMOTACTIC PROTEIN-1; MESSENGER-RNA; ATHEROSCLEROTIC LESIONS; FACTOR INDUCTION; TISSUE FACTOR	JE is a member of the family of "immediate early" genes induced by growth factors and cytokines, JE encodes a low molecular weight secretory glycoprotein analogous to the human monocyte chemoattractant protein, MCP-1, JE and MCP-1 proteins are thought to play an important role in inflammation and in the recruitment of monocyte/macrophages to the vessel wall during the development of atherosclerosis. We have previously reported that the induction of JE in rat aortic smooth muscle cells (SMC) was specific to platelet-derived growth factor (PDGF) and was not seen with other growth agonists, Using a luciferase reporter system and transient transfection assays of rat aortic SMC, we now report the identification of a region in the proximal rat JE promoter that is responsive to PDGF but not to other growth factors (angiotensin II and alpha-thrombin) or cytokines (interleukin 1-beta and tumor necrosis factor-alpha). The fall response to PDGF (similar to 6-fold) requires the cooperative activity of two potentially novel cis-acting elements, at positions -146 to -128 and -84 to -59. While each element produces a different pattern in electrophoretic mobility shift assays, they appear to bind the same PDGF-responsive species. Further analysis of these regions should provide important insights into PDGF-specific responses in vascular SMC.	CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Taubman, MB (corresponding author), CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA.	M_Taubman@smtplink.mssm.edu		Bogdanov, Vladimir/0000-0003-4968-1129	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043302] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL43302] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DZAU VJ, 1994, J HYPERTENS, V12, pS3; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GREEN RS, 1995, LAB INVEST, V73, P476; HALL DJ, 1989, J CELL PHYSIOL, V141, P154, DOI 10.1002/jcp.1041410123; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLYCROSS BJ, 1993, J VASC RES, V30, P80, DOI 10.1159/000158979; HUANG S, 1992, AM J PATHOL, V141, P981; INTRONA M, 1987, J IMMUNOL, V138, P3891; LI YS, 1994, MOL CELL BIOCHEM, V141, P121, DOI 10.1007/BF00926175; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; MARMUR JD, 1992, CIRCULATION, V86, P53; MARRA F, 1993, J CLIN INVEST, V92, P1674, DOI 10.1172/JCI116753; Naito S, 1998, AM J PHYSIOL-CELL PH, V274, pC472, DOI 10.1152/ajpcell.1998.274.2.C472; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PATTON WF, 1995, J BIOL CHEM, V270, P21404, DOI 10.1074/jbc.270.36.21404; Poon M, 1996, AM J PATHOL, V149, P307; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARTZ CJ, 1991, CLIN CARDIOL, V14, P1, DOI 10.1002/clc.4960141302; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SHYY YJ, 1990, BIOCHEM BIOPH RES CO, V169, P346, DOI 10.1016/0006-291X(90)90338-N; TAKESHITA A, 1995, J IMMUNOL, V155, P419; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; TIMMERS HT, 1990, NUCLEIC ACIDS RES, V18, P23, DOI 10.1093/nar/18.1.23; Wilcox J N, 1992, J Vasc Surg, V15, P913; XIONG YM, 1991, IN VITRO CELL DEV B, V27, P355; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YU SF, 1990, J LEUKOCYTE BIOL, V48, P412, DOI 10.1002/jlb.48.5.412; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953	50	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24932	24938		10.1074/jbc.273.38.24932	http://dx.doi.org/10.1074/jbc.273.38.24932			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733800	hybrid			2022-12-25	WOS:000076007300092
J	Nakamura, K; Krupnick, JC; Benovic, JL; Ascoli, M				Nakamura, K; Krupnick, JC; Benovic, JL; Ascoli, M			Signaling and phosphorylation-impaired mutants of the rat follitropin receptor reveal an activation- and phosphorylation-independent but arrestin-dependent pathway for internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FOLLICLE-STIMULATING-HORMONE; MUSCARINIC ACETYLCHOLINE-RECEPTOR; NEPHROGENIC DIABETES-INSIPIDUS; LEYDIG TUMOR-CELLS; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; MEDIATED ENDOCYTOSIS; ALPHA(2A)-ADRENERGIC RECEPTOR; INTRACELLULAR LOOP	We have previously shown that the rat follitropin receptor (rFSHR) expressed in transfected cells becomes phosphorylated upon stimulation of the cells with agonist or a phorbol ester, Peptide mapping and mutagenesis studies have also shown that the agonist- or phorbol ester-induced phosphorylation of the rFSHR maps to Ser/Thr residues present in the first and third intracellular loops. The experiments presented herein were initially designed to test for the presence of additional phosphorylation sites on the second intracellular loop of the rFSHR. Analysis of two new mutants in which the two threonines in the second intracellular loop (rFSHR-2L) or the two threonines in the second intracellular loop and the seven Ser/Thr residues in the third intracellular loop (rFSHR-2L + 3L) were mutated showed that one or more of the two threonines in the second intracellular loop are phosphorylated in response to phorbol ester, but not in response to agonist stimulation. Since rFSHR-2L and rFSHR-2L + 3L displayed a reduction in agonist-induced signaling, two additional mutants (rFSHR-D389N and rFSHR-Y530F) were constructed in an attempt to better understand the relationship between the agonist-induced activation, phosphorylation, and internalization of the rFSHR, These point mutations impaired agonist-stimulated signal transduction and abolished agonist-induced phosphorylation, Co-transfection studies revealed that the phosphorylation of these mutants can be rescued by overexpression of G protein-coupled receptor kinase 2, but this increased phosphorylation only rescues the internalization of rFSHR-D389N, The internalization of both mutants could be rescued by overexpression of arrestin-3, however, Taken together, these results argue that the agonist-induced activation and phosphorylation of the rFSHR are not essential for internalization. while the interaction of the rFSHR with a nonvisual arrestin is essential for internalization.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Iowa; Jefferson University	Ascoli, M (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-512 BSB, Iowa City, IA 52242 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047417, R37GM047417] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-28962] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NIGMS NIH HHS [GM-47417] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CERESA BP, 1994, J BIOL CHEM, V269, P29557; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Dhanwada KR, 1996, MOL ENDOCRINOL, V10, P544, DOI 10.1210/me.10.5.544; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Ferguson SSG, 1996, BIOCHEM SOC T, V24, P953, DOI 10.1042/bst0240953; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1997, NEWS PHYSIOL SCI, V12, P145; FLETCHER PW, 1984, MOL CELL ENDOCRINOL, V34, P39, DOI 10.1016/0303-7207(84)90157-6; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIPKIN RW, 1995, J BIOL CHEM, V270, P26683, DOI 10.1074/jbc.270.44.26683; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Nakamura K, 1998, MOL ENDOCRINOL, V12, P580, DOI 10.1210/me.12.4.580; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; QUINTANA J, 1993, ENDOCRINOLOGY, V133, P2098, DOI 10.1210/en.133.5.2098; QUINTANA J, 1993, MOL ENDOCRINOL, V7, P767, DOI 10.1210/me.7.6.767; QUINTANA J, 1994, J BIOL CHEM, V269, P8772; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; Sadeghi H, 1997, MOL ENDOCRINOL, V11, P1806, DOI 10.1210/me.11.12.1806; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	42	59	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24346	24354		10.1074/jbc.273.38.24346	http://dx.doi.org/10.1074/jbc.273.38.24346			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733722	hybrid			2022-12-25	WOS:000076007300014
J	Ritzi, M; Baack, M; Musahl, C; Romanowski, P; Laskey, RA; Knippers, R				Ritzi, M; Baack, M; Musahl, C; Romanowski, P; Laskey, RA; Knippers, R			Human minichromosome maintenance proteins and human origin recognition complex 2 protein oil chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION LICENSING SYSTEM; DNA-REPLICATION; MCM-PROTEINS; S-PHASE; YEAST; XENOPUS; BINDING; FAMILY; CELLS; INITIATION	Minichromosome maintenance (Mcm) proteins and the constituents of the origin recognition complex (Orc) are essential components of the eukaryotic replication initiation apparatus. Published evidence strongly suggests that the binding of Mcm proteins to chromatin is contingent upon the prior binding of Ore proteins. Here we use two different approaches to investigate the presence of the human ORC2 protein and of Mcm proteins on chromatin of HeLa cells in various cell cycle phases. First, we mobilized chromatin-bound proteins by micrococcal nuclease and analyzed the resulting digestion products by sucrose gradient centrifugations. Under digestion conditions when Mcm proteins were almost entirely released from chromatin, ORC2 protein was found to be associated with chromatin fragments containing several hundred base pairs of DNA. Second, we used an in vivo cross-linking procedure to covalently link Mcm proteins and ORC2 to DNA by short exposure of intact HeLa cells to formaldehyde. Specific immunoprecipitations revealed that cross-linked nucleoprotein fragments carried either Mcm proteins or ORC2 protein, but not both. Based on the lengths of the DNA fragments in immunoprecipitates, we estimate that the distance between chromatin-bound ORC2 protein and chromatin-bound Mcm proteins must be at least 500-1000 base pairs in HeLa cells.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Wellcome CRC Inst, Cambridge CB2 1QR, England	University of Konstanz	Knippers, R (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; HANCOCK R, 1974, J MOL BIOL, V86, P649, DOI 10.1016/0022-2836(74)90187-9; Holthoff HP, 1998, J BIOL CHEM, V273, P7320, DOI 10.1074/jbc.273.13.7320; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; OHYASHIKI JH, 1988, CANCER GENET CYTOGEN, V34, P159, DOI 10.1016/0165-4608(88)90255-5; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; van Holde K.E., 1988, CHROMATIN; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	46	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24543	24549		10.1074/jbc.273.38.24543	http://dx.doi.org/10.1074/jbc.273.38.24543			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733749	hybrid			2022-12-25	WOS:000076007300041
J	de Moissac, D; Mustapha, S; Greenberg, AH; Kirshenbaum, LA				de Moissac, D; Mustapha, S; Greenberg, AH; Kirshenbaum, LA			Bcl-2 activates the transcription factor NF kappa B through the degradation of the cytoplasmic inhibitor I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; CARDIAC GENE-TRANSCRIPTION; VENTRICULAR MYOCYTES; DNA-BINDING; CYCLE PROGRESSION; INDUCED APOPTOSIS; KINASE RAF-1; P65 SUBUNIT; T-CELLS	Nuclear factor kappa B (NF kappa B) is a ubiquitously expressed transcription factor that is regulated by the cytoplasmic inhibitor protein I kappa B alpha. Biological agents such as tumor necrosis factor alpha (TNF alpha), which activate NF kappa B, result in the rapid degradation of I kappa B alpha Adenoviral-mediated gene transfer of Bcl-2 prevents apoptosis of neonatal ventricular myocytes induced by TMF alpha, In view of the growing evidence that NF kappa B may play an important role in regulating apoptosis, we determined whether TNF alpha! and Bcl-2 could modulate the activity of NF kappa B in ventricular myocytes. Stimulation of myocytes with TNFa: resulted in a 2.1-fold increase (p < 0.001) in NF kappa B-dependent gene transcription and nuclear DNA binding Similarly, a 1.9-fold increase (p < 0.0002) ire NF kappa B-dependent gene transcription was observed in myocytes expressing Bcl-2. Nuclear DNA binding activity of NF kappa B was significantly increased in myocytes expressing Bcl-2, with a concomitant reduction in I kappa B alpha protein level. The BcI-2-mediated loss of I kappa B alpha could be prevented by the proteasome inhibitor lactacystin, consistent with the notion that the targeted degradation of I kappa B alpha consequent to overexpression of BcI-2 utilizes the ubiquitin-proteasome pathway. This was further tested in human 293 cells in which the N-terminal region of I kappa B alpha was identified to be an important regulatory site for Bcl-2. Deletion of this region or a serine to alanine substitution mutant at amino acids 32 and 36, which are defective for both phosphorylation and degradation were more resistant than wild type I kappa B alpha to the inhibitory effects of Bcl-2. To our knowledge, this provides the first evidence for the regulation of I kappa B alpha by Eel-2 and suggests a link between Eel-2 and the NF kappa B signaling pathway in the suppression of apoptosis.	St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Manitoba Inst Cell Biol, Winnipeg, MB R2H 2A6, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba	Kirshenbaum, LA (corresponding author), St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Rm 3042,351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	Lorrie@SBRC.umanitoba.ca	Kirshenbaum, Lorrie A./F-5742-2014					Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1984, J BIOL CHEM, V259, P3492; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bellas RE, 1997, AM J PATHOL, V151, P891; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Kirshenbaum LA, 1997, CIRCULATION, V96, P1580, DOI 10.1161/01.CIR.96.5.1580; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; URBAN MB, 1991, NEW BIOL, V3, P279; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILLIAMS RS, 1993, AM J MED SCI, V306, P129, DOI 10.1097/00000441-199308000-00013; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	47	111	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23946	23951		10.1074/jbc.273.37.23946	http://dx.doi.org/10.1074/jbc.273.37.23946			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727009	hybrid			2022-12-25	WOS:000075893100050
J	Mao, PL; Jiang, YL; Wee, BY; Porter, AG				Mao, PL; Jiang, YL; Wee, BY; Porter, AG			Activation of caspase-1 in the nucleus requires nuclear translocation of pro-caspase-1 mediated by its prodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; TROPHIC FACTOR WITHDRAWAL; FACTOR-INDUCED APOPTOSIS; CELL-DEATH; PROTEIN; EXPRESSION; ICE; LOCALIZATION; PRECURSOR; PATHWAY	The interleukin-1 beta-converting enzyme-like protease precursor, pro-caspase-1, has an N-terminal prodomain that is removed during cleavage activation of the protease. Here we show that tumor necrosis factor treatment of HeLa cells induced apoptosis without detectable proteolytic activation of caspase-1 in the cytosol. Instead, tumor necrosis factor induced the translocation of procaspase-1 to the nucleus where it was proteolytically activated, releasing the intact prodomain. We identified a nuclear localization signal in the prodomain, which was required for translocation of both pro-caspase-1 as well as its prodomain to the nucleus. Surprisingly, transfected MCF-7 carcinoma or embryonic kidney 293T cells expressing the prodomain alone underwent apoptosis. These results show that death signal-induced nuclear targeting is a novel activity of a caspase prodomain and indicate that caspase-1 and its prodomain may have hitherto unsuspected nuclear functions in apoptosis.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Porter, AG (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; MAO PL, 1993, J BIOL CHEM, V268, P8131; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Nakagawara A, 1997, CANCER RES, V57, P4578; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; VanCriekinge W, 1996, J BIOL CHEM, V271, P27245, DOI 10.1074/jbc.271.44.27245; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	26	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23621	23624		10.1074/jbc.273.37.23621	http://dx.doi.org/10.1074/jbc.273.37.23621			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726961	hybrid			2022-12-25	WOS:000075893100002
J	Scott, DK; O'Doherty, RM; Stafford, JM; Newgard, CB; Granner, DK				Scott, DK; O'Doherty, RM; Stafford, JM; Newgard, CB; Granner, DK			The repression of hormone-activated PEPCK gene expression by glucose is insulin-independent but requires glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE-CARBOXYKINASE GENE; PYRUVATE-KINASE GENE; UPSTREAM STIMULATORY FACTOR; ACID RESPONSE ELEMENT; CARBOHYDRATE REGULATION; MESSENGER-RNA; MAMMALIAN GLUCOKINASE; RAT HEPATOCYTES; TRANSGENIC MICE; PRIMARY CULTURE	Phosphoenolpyruvate carboxykinase (PEPCK) is a rate-controlling enzyme in hepatic gluconeogenesis, and it therefore plays a central role in glucose homeostasis, The rate of transcription of the PEPCK gene is increased by glucagon (via cAMP) and glucocorticoids and is inhibited by insulin. Under certain circumstances glucose also decreases PEPCK gene expression, but the mechanism of this effect is poorly understood. The glucose-mediated stimulation of a number of glycolytic and lipogenic genes requires the expression of glucokinase (GK) and increased glucose metabolism. HL1C rat hepatoma cells are a stably transfected line of H4IIE rat hepatoma cells that express a PEPCK promoter-chloramphenicol acetyltransferase fusion gene that is regulated in the same manner as the endogenous PEPCK gene. These cells do not express GK and do not normally exhibit a response of either the endogenous PEPCK gene, or of the trans-gene, to glucose. A recombinant adenovirus that directs the expression of glucokinase (AdCMV-GK) was used to increase glucose metabolism in HL1C cells to test whether increased glucose flux is also required for the repression of PEPCK gene expression. In AdCMV-GK-treated cells glucose strongly inhibits hormone-activated transcription of the endogenous PEPCK gene and of the expressed fusion gene. The glucose effect on PEPCK gene promoter activity is blocked by 5 mM mannoheptulose, a specific inhibitor of GR activity. The glucose analog, 8-deoxyglucose mimics the glucose response, but this effect does not require GK expression. 3-O-methylglucose is ineffective. Glucose exerts its effect on the PEPCK gene within 4 h, at physiologic concentrations, and with an EC50 of 6.5 mm, which approximates the K-m of glucokinase. The effects of glucose and insulin on PEPCK gene expression are additive, but only at suboptimal concentrations of both agents. The results of these studies demonstrate that, by inhibiting PEPCK gene transcription, glucose participates in a feedback control loop that governs its production from gluconeogenesis.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.		Stafford, John/K-7763-2017	Stafford, John/0000-0001-6527-959X	NIDDK NIH HHS [DK35107] Funding Source: Medline; PHS HHS [P50H2598801] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035107, R01DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEALE EG, 1985, J BIOL CHEM, V260, P748; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; COLOSIA AD, 1988, J BIOL CHEM, V263, P18669; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; DUPRIEX VJ, 1997, DNA CELL BIOL, V9, P1075; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRANNER DK, 1986, RECENT PROG HORM RES, V42, P111; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MEYER S, 1991, EUR J BIOCHEM, V202, P985, DOI 10.1111/j.1432-1033.1991.tb16460.x; Mitanchez D, 1997, ENDOCR REV, V18, P520, DOI 10.1210/er.18.4.520; MITCHELL RA, 1971, BIOCHEMISTRY-US, V10, P2049, DOI 10.1021/bi00787a013; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; ROSELLA G, 1995, MOL ENDOCRINOL, V9, P1396, DOI 10.1210/me.9.10.1396; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; XU LZ, 1994, J BIOL CHEM, V269, P27458	55	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24145	24151		10.1074/jbc.273.37.24145	http://dx.doi.org/10.1074/jbc.273.37.24145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727036	hybrid			2022-12-25	WOS:000075893100077
J	Sunder-Plassmann, R; Reinherz, EL				Sunder-Plassmann, R; Reinherz, EL			A p56(lck)-independent pathway of CD2 signaling involves Jun kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; PROTEIN-TYROSINE KINASES; NATURAL-KILLER-CELLS; LYMPHOCYTE-T; ANTIGEN RECEPTOR; CYTOPLASMIC DOMAIN; INTERLEUKIN-2 GENE; C-JUN; TRANSCRIPTION FACTORS; INOSITOL PHOSPHATES	The p56(lck) Src family non-receptor tyrosine kinase has been shown to be critical for T lymphocyte differentiation and activation. Hence in the absence of p56(lck), T cell receptor triggered activation does not occur. We now provide evidence for a CD2-based signaling pathway which, in contrast to that of the T cell receptor, is independent of p56(lck). CD2-mediated interleukin-a production occurs via activation of Jun kinase in cell lines lacking p56(lck). Jun kinase then facilitates the binding of c-Jun/c-Fos heterodimers to the AP-1 consensus site and the subsequent transcriptional activity of the interleukin-a promoter. These data elucidate differences between TCR and CD2 signaling pathways in the same T cells.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Reinherz, EL (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu		Sunder-Plassmann, Raute/0000-0002-8297-118X	NIAID NIH HHS [AI19807, AI21226] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019807, R56AI019807, R01AI021226, R01AI019807] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; ALCOVER A, 1986, P NATL ACAD SCI USA, V83, P2614, DOI 10.1073/pnas.83.8.2614; ANDERSON SJ, 1994, ADV IMMUNOL, V56, P151, DOI 10.1016/S0065-2776(08)60451-4; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARULANANDAM ARN, 1991, J EXP MED, V173, P859, DOI 10.1084/jem.173.4.859; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIERER BE, 1990, J IMMUNOL, V144, P785; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; BOUSSIOTIS VA, 1994, J EXP MED, V180, P1665, DOI 10.1084/jem.180.5.1665; BREITMEYER JB, 1987, J IMMUNOL, V139, P2899; BROTTIER P, 1985, J IMMUNOL, V135, P1624; BROWN MH, 1988, EUR J IMMUNOL, V18, P1223, DOI 10.1002/eji.1830180812; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHANG HC, 1989, J EXP MED, V169, P2073, DOI 10.1084/jem.169.6.2073; CHANG HC, 1990, J EXP MED, V172, P351, DOI 10.1084/jem.172.1.351; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLAYTON LK, 1988, J IMMUNOL, V140, P3617; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crespo P, 1996, ONCOGENE, V13, P455; DEGRAZIA U, 1994, J EXP MED, V180, P1485, DOI 10.1084/jem.180.4.1485; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; FISCHER S, 1994, CELL MOL BIOL, V40, P605; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GARDNER P, 1989, J BIOL CHEM, V264, P1068; GASSMANN M, 1994, EUR J IMMUNOL, V24, P139, DOI 10.1002/eji.1830240121; GELFAND EW, 1988, EUR J IMMUNOL, V18, P917, DOI 10.1002/eji.1830180613; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GOLLOB JA, 1995, J EXP MED, V182, P721, DOI 10.1084/jem.182.3.721; Gollob JA, 1996, J IMMUNOL, V157, P1886; GRANELLIPIPERNO A, 1991, J IMMUNOL, V147, P2734; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWARD FD, 1992, J EXP MED, V176, P139, DOI 10.1084/jem.176.1.139; HOWARD FD, 1981, J IMMUNOL, V126, P2117; Hubert P, 1996, J IMMUNOL, V157, P4322; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO PM, 1995, IMMUNOL TODAY, V16, P159; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JIN YJ, 1990, J IMMUNOL, V144, P647; KAMOUN M, 1981, J EXP MED, V153, P207, DOI 10.1084/jem.153.1.207; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; King PD, 1996, INT IMMUNOL, V8, P1707, DOI 10.1093/intimm/8.11.1707; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; KRENSKY AM, 1983, J IMMUNOL, V131, P611; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MOINGEON PE, 1991, EUR J IMMUNOL, V21, P605, DOI 10.1002/eji.1830210311; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PANTALEO G, 1987, EUR J IMMUNOL, V17, P55, DOI 10.1002/eji.1830170110; Parra E, 1997, MOL CELL BIOL, V17, P1314, DOI 10.1128/MCB.17.3.1314; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; QUIAN D, 1997, J EXP MED, V185, P1253; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; RODEWALD HR, 1993, J EXP MED, V177, P1079, DOI 10.1084/jem.177.4.1079; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SunderPlassmann R, 1997, EUR J IMMUNOL, V27, P2001, DOI 10.1002/eji.1830270826; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6836, DOI 10.1073/pnas.81.21.6836	91	23	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24249	24257		10.1074/jbc.273.37.24249	http://dx.doi.org/10.1074/jbc.273.37.24249			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727049	hybrid			2022-12-25	WOS:000075893100090
J	Khuchua, ZA; Qin, WN; Boero, J; Cheng, J; Payne, RM; Saks, VA; Strauss, AW				Khuchua, ZA; Qin, WN; Boero, J; Cheng, J; Payne, RM; Saks, VA; Strauss, AW			Octamer formation and coupling of cardiac sarcomeric mitochondrial creatine kinase are mediated by charged N-terminal residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE; INNER; CARDIOLIPIN; ASSOCIATION; EXPRESSION; ISOENZYMES; BINDING; TISSUE; GENES	Mitochondrial creatine kinases form octameric structures composed of four active and stable dimers. Octamer formation has been postulated to occur via interaction of the charged amino acids in the N-terminal peptide of the mature enzyme. We altered codons for charged amino acids in the N-terminal region of mature sarcomeric mitochondrial creatine kinase (sMtCK) to those encoding neutral amino acids. Transfection of normal sMtCK cDNA or those with the mutations R42G, E43G/H45G, and K46G into rat neonatal cardiomyocytes resulted in enzymatically active sMtCK expression in all. After hypoosmotic treatment of isolated mitochondria, mitochondrial inner membrane-associated and soluble sMtCK from the intermembranous space were measured. The R42G and E43G/H45G double mutation caused destabilization of the octameric structure of sMtCK and a profound reduction in binding of sMtCK to the inner mitochondrial membrane. The other mutant sMtCK proteins had modest reductions in binding. Creatine-stimulated respiration was markedly reduced in mitochondria isolated from cells transfected with the R42G mutant cDNA as compared with those transfected with normal sMtCK cDNA. We conclude that neutralization of charges in N-terminal peptide resulted in destabilization of octamer structure of sMtCK. Thus, charged amino acids at the N-terminal moiety of mature sMtCK are essential for octamer formation, binding of sMtCK with inner mitochondrial membrane, and coupling of sMtCK to oxidative phosphorylation.	St Louis Childrens Hosp, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Winston Salem, NC 27157 USA; Inst Chem & Biol Phys, Lab Bioenerget, EE-0026 Tallinn, Estonia	St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Wake Forest University; Wake Forest Baptist Medical Center; National Institute of Chemical Physics & Biophysics (NICPB)	Strauss, AW (corresponding author), St Louis Childrens Hosp, Dept Pediat, Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.	strauss@kids.wustl.edu	Khuchua, Zaza/J-6536-2016	Khuchua, Zaza/0000-0003-3582-5670	FIC NIH HHS [F05 TW05101] Funding Source: Medline; NHLBI NIH HHS [R01 HL52350] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW005101] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052350] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BESSMAN SP, 1966, BIOCHEM BIOPH RES CO, V22, P597, DOI 10.1016/0006-291X(66)90317-2; BIERMANS W, 1990, BIOCHIM BIOPHYS ACTA, V1018, P225, DOI 10.1016/0005-2728(90)90254-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; CHENEVAL D, 1988, EUR J BIOCHEM, V171, P1, DOI 10.1111/j.1432-1033.1988.tb13750.x; CHIEN KR, 1985, J CLIN INVEST, V75, P1770, DOI 10.1172/JCI111889; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; FURTER R, 1992, BIOCHEM J, V288, P771, DOI 10.1042/bj2880771; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HAAS RC, 1989, J BIOL CHEM, V264, P2890; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; KALDIS P, 1994, BIOCHEMISTRY-US, V33, P952, DOI 10.1021/bi00170a014; KOTKE M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P215; Maniatis T., 1982, MOL CLONING LAB MANU; MULLER M, 1985, J BIOL CHEM, V260, P3839; PAYNE RM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P352, DOI 10.1016/0167-4781(91)90176-M; QIN W, 1998, IN PRESS MOL CELL BI; ROE CR, 1977, ANN CLIN LAB SCI, V7, P201; ROJO M, 1991, J BIOL CHEM, V266, P20290; ROSALKI SB, 1967, J LAB CLIN MED, V69, P696; SAKS VA, 1974, CIRC RES, V35, P138; SAKS VA, 1987, BIOCHIM BIOPHYS ACTA, V891, P138, DOI 10.1016/0005-2728(87)90005-3; SAKS VA, 1986, BIOCHEM BIOPH RES CO, V139, P1262, DOI 10.1016/S0006-291X(86)80314-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEGEL J, 1990, J BIOL CHEM, V265, P9221; SCHNYDER T, 1991, J CELL BIOL, V112, P95, DOI 10.1083/jcb.112.1.95; SCHOLTE HR, 1973, BIOCHIM BIOPHYS ACTA, V291, P764, DOI 10.1016/0005-2736(73)90479-3; Seraydarian M W, 1986, Adv Exp Med Biol, V194, P41; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; UAUSBEL FM, 1994, CURRENT PROTOCOLS MO; VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5	32	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22990	22996		10.1074/jbc.273.36.22990	http://dx.doi.org/10.1074/jbc.273.36.22990			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722522	hybrid			2022-12-25	WOS:000075778100022
J	Kornfeld, R; Bao, M; Brewer, K; Noll, C; Canfield, WM				Kornfeld, R; Bao, M; Brewer, K; Noll, C; Canfield, WM			Purification and multimeric structure of bovine N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME	N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome, A partially purified preparation of phosphodiester alpha-GlcNAcase from bovine pancreas was used to generate a panel of murine monoclonal antibodies. The anti-phosphodiester alpha-GlcNAcase monoclonal antibody UC1 was coupled to a solid support and used to immunopurify the bovine liver enzyme 670,000-fold in two steps to apparent homogeneity with an overall yield of 14%. The purified phosphodiester alpha-GlcNAcase has a specific activity of 498 mu mol of [H-3]GlcNAc-alpha-phosphomannose-alpha-methyl cleaved per h per mg of protein using 0.5 mM [H-3]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate. The subunit structure of the enzyme was determined using a combination of analytical gel filtration chromatography, SDS-polyacrylamide gel electrophoresis, and amino-terminal sequencing. The data indicate that bovine phosphodiester alpha-GlcNAcase is a 272,000-Da complex of four identical 68,000-Da glycoprotein subunits arranged as two disulfide-linked homodimers. A soluble form of the enzyme, isolated from fetal bovine serum, showed the same subunit structure. Both forms of the enzyme reacted with a rabbit antibody raised to the amino-terminal peptide of the liver enzyme, suggesting that phosphodiester alpha-GlcNAcase is a type I membrane-spanning glycoprotein with its amino terminus in the lumen of the Golgi apparatus.	Washington Univ, Sch Med, Div Hematol, Dept Med, St Louis, MO 63110 USA; Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA	Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Kornfeld, R (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Med, 660 S Euclid Ave,Box 8125, St Louis, MO 63110 USA.				NCI NIH HHS [CA08759] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; BAZIN R, 1989, J IMMUNOL METHODS, V116, P245, DOI 10.1016/0022-1759(89)90210-X; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; Harlow E., 1988, ANTIBODIES LAB MANUA; KIORNFELD S, 1987, FASEB J, V1, P462; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAMMERS G, 1988, BIOCHEM J, V256, P623, DOI 10.1042/bj2560623; LEE JK, 1995, ARCH BIOCHEM BIOPHYS, V319, P413, DOI 10.1006/abbi.1995.1312; MULLIS KG, 1994, J BIOL CHEM, V269, P1718; MULLIS KG, 1992, ANAL BIOCHEM, V205, P200, DOI 10.1016/0003-2697(92)90424-6; MULLIS KG, 1994, J BIOL CHEM, V269, P1727; Page T, 1996, GLYCOBIOLOGY, V6, P619, DOI 10.1093/glycob/6.6.619; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7	15	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23203	23210		10.1074/jbc.273.36.23203	http://dx.doi.org/10.1074/jbc.273.36.23203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722550	hybrid			2022-12-25	WOS:000075778100050
J	Polakiewicz, RD; Schieferl, SM; Gingras, AC; Sonenberg, N; Comb, MJ				Polakiewicz, RD; Schieferl, SM; Gingras, AC; Sonenberg, N; Comb, MJ			mu-opioid receptor activates signaling pathways implicated in cell survival and translational control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; AVIAN CILIARY GANGLION; HAMSTER OVARY CELLS; P70 S6 KINASE; COUPLED RECEPTORS; PHOSPHOINOSITIDE-3 KINASE; RAT-1 FIBROBLASTS; NEURONAL SURVIVAL; PHOSPHORYLATION; RAPAMYCIN	The mu-opioid receptor mediates the analgesic and addictive properties of morphine. Despite the clinical importance of this G-protein-coupled receptor and many years of pharmacological research, few intracellular signaling mechanisms triggered by morphine and other mu-opioid agonists have been described. We report that mu-opioid agonists stimulate three different effecters of a phosphoinositide 3-kinase (PI3K)-dependent signaling cascade. By using a cell line stably transfected with the mu-opioid receptor cDNA, we show that the specific agonist [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]enkephalin (DAMGO) stimulates the activity of Akt, a serine/threonine protein kinase implicated in protecting neurons from apoptosis, Activation of Akt by DAMGO correlates with its phosphorylation at serine 473, The selective PI3K inhibitors wortmannin and LY294002 blocked phosphorylation of this site, previously shown to be necessary for Akt enzymatic activity. DAMGO also stimulates the phosphorylation of two other downstream effecters of PI3K the p70 S6 kinase and the repressors of mRNA translation, 4E-BP1 and 4E-BP2. Upon mu-opioid receptor stimulation, p70 S6 kinase is activated and phosphorylated at threonine 389 and at threonine 421/serine 424, Phosphorylation of p70 S6 kinase and 4E-BP1 is also repressed by PI3K inhibitors as well as by rapamycin, the selective inhibitor of FRAP/mTOR, Consistent with these findings, DAMGO-stimulated phosphorylation of 4E-BP1 impairs its ability to bind the translation initiation factor eIF-4E. These results demonstrate that the p-opioid receptor activates signaling pathways associated with neuronal survival and translational control, two processes implicated in neuronal development and synaptic plasticity.	New England Biolabs Inc, Cell Signaling Lab, Beverly, MA 01915 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Polakiewicz, RD (corresponding author), New England Biolabs Inc, Cell Signaling Lab, 32 Tozer Rd, Beverly, MA 01915 USA.		Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437	NIDA NIH HHS [DA05706] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALESSI D, 1997, CURR BIOL, V8, P69; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Burt AR, 1996, BIOCHEM J, V320, P227, DOI 10.1042/bj3200227; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; GINGRAS AC, 1998, GENE DEV, V18, P334; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hauser KF, 1996, BRAIN RES, V720, P191, DOI 10.1016/0006-8993(96)00103-5; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; KAUFMAN DL, 1995, J BIOL CHEM, V270, P15877, DOI 10.1074/jbc.270.26.15877; Li LY, 1996, MOL PHARMACOL, V50, P599; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MERINEY SD, 1985, SCIENCE, V228, P1451, DOI 10.1126/science.2990029; MERINEY SD, 1991, J NEUROSCI, V11, P3705; MORRIS BJ, 1995, TRENDS NEUROSCI, V18, P350, DOI 10.1016/0166-2236(95)93927-P; PASTERNAK GW, 1988, OPIATE RECEPTORS; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Schuman EM, 1997, NEURON, V18, P339, DOI 10.1016/S0896-6273(00)81234-9; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Wilson MA, 1997, BIOCHEM J, V325, P217, DOI 10.1042/bj3250217	54	160	179	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23534	23541		10.1074/jbc.273.36.23534	http://dx.doi.org/10.1074/jbc.273.36.23534			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722592	hybrid			2022-12-25	WOS:000075778100092
J	Palomino, T; Sanchez-Pacheco, A; Pena, P; Aranda, A				Palomino, T; Sanchez-Pacheco, A; Pena, P; Aranda, A			A direct protein-protein interaction is involved in the cooperation between thyroid hormone and retinoic acid receptors and the transcription factor GHF-1	FASEB JOURNAL			English	Article						growth hormone gene; transcriptional regulation; nuclear receptors	RAT GROWTH-HORMONE; GENE-EXPRESSION; NUCLEAR RECEPTOR; FACTOR GHF-1/PIT-1; FACTOR TFIIB; ACTIVATION; PIT-1; PROMOTER; ELEMENTS; TRANSACTIVATION	The nuclear receptors for thyroid hormone (TRs) and retinoic acid (RARs and RXRs) cooperate with the pituitary-specific transcription factor GHF-1 to activate the rat growth hormone (GH) gene, The GH promoter contains a hormone response element (HRE), which binds TR/RXR and RAR/RXR heterodimers, located close to two binding sites for GHF-1, GHF-1 inhibits binding of TR/RXR and RAR/RXR heterodimers to an isolated HRE, Similarly, the receptors inhibit binding of GHF-1 to its cognate site. These results suggest the existence of direct protein to protein interactions between the receptors and the pituitary transcription factor. This was confirmed by in vitro binding studies with GST fusion proteins, which demonstrated a strong association of GHF-1 with RXR and a weaker interaction with RAR and TR, GHF-1 and the receptor heterodimers form a ternary complex with a fragment of the rat GH promoter, which contains binding sites for both, and GHF-1 increases receptor binding to the promoter when present in limiting conditions. These results suggest that the synergistic activation of the rat GH gene involves protein-DNA interactions as well as a physical association between the nuclear receptors and the pituitary-specific transcription factor GHF-1.-Palomino, T., Sanchez-Pacheco, A. Pena, P., Aranda, A. A direct protein-to-protein interaction is involved in the cooperation between thyroid hormone and retinoic acid receptors and the transcription factor GHF-1.	CSIC, Inst Invest Biomed, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.		Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589; Sanchez Pacheco, Aurora/0000-0002-7776-2594				BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHAMBON P, 1996, FASEB J, V10, P950; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; DESAIYAJNIK V, 1995, J VIROL, V69, P5103, DOI 10.1128/JVI.69.8.5103-5112.1995; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GARCIAVILLALBA P, 1993, BIOCHEM BIOPH RES CO, V19, P580; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; LIRA SA, 1993, MOL ENDOCRINOL, V7, P694, DOI 10.1210/me.7.5.694; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Sanchez-Pacheco A, 1998, FEBS LETT, V422, P103, DOI 10.1016/S0014-5793(97)01609-8; SANCHEZPACHECO A, 1995, ENDOCRINOLOGY, V136, P5391, DOI 10.1210/en.136.12.5391; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; YE ZS, 1988, J BIOL CHEM, V263, P7821; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	31	29	30	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1201	1209		10.1096/fasebj.12.12.1201	http://dx.doi.org/10.1096/fasebj.12.12.1201			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737723				2022-12-25	WOS:000075738500015
J	Winters, ZE; Ongkeko, WM; Harris, AL; Norbury, CJ				Winters, ZE; Ongkeko, WM; Harris, AL; Norbury, CJ			p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells	ONCOGENE			English	Article						p53; cell cycle; checkpoint; G2; Cdc2; phosphorylation	CYCLIN-DEPENDENT KINASES; P34CDC2 PROTEIN-KINASE; HUMAN CANCER-CELLS; TYROSINE PHOSPHORYLATION; DNA-DAMAGE; CHECKPOINT CONTROL; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; TYR15 PHOSPHORYLATION; G(2) DELAY	We have investigated the influence of p53 on radiation-induced G2 cell cycle arrest using human H1299 cells expressing temperature-sensitive p53. Gamma-irradiated cells lacking p53 arrested transiently in G2 with Cdc2 extensively phosphorylated at the inhibitory sites Thr14 and Tyr15, and with both Cdc2 and cyclin B1 restricted to the cytoplasm. Activation of p53 by temperature shift resulted in a more protracted G2 arrest that could not be overridden by checkpoint-abrogating drugs. Surprisingly, this enhancement of G2 arrest was associated with a marked lack of inhibitory phosphorylation of Cdc2 and with the nuclear localization of both Cdc2 and cyclin B1. While transient expression of an A14F15 mutant form of Cdc2 that is not subject to inhibitory phosphorylation induced mitotic catastrophe in cells lacking p53, the p53-expressing cells were relatively refractory to this effect. Enforced expression of p21(WAF1/CIP1) was sufficient to confer nuclear localization on Cdc2 in the p53 null cells, though immunodepletion experiments demonstrated that only a small proportion of Cdc2 was stably associated with p21(WAF1/CIP1) in the p53-expressing cells. We conclude that a p53-dependent pathway can operate after exposure of human cells to ionising radiation to promote G2 arrest accompanied by nuclear translocation rather than inhibitory phosphorylation of Cdc2.	Univ Oxford, Inst Mol Med, Oncol Mol Lab, Imperial Canc Res Fund,John Radcliffe Hosp, Oxford OX3 9DS, England	University of Oxford	Norbury, CJ (corresponding author), Univ Oxford, Inst Mol Med, Oncol Mol Lab, Imperial Canc Res Fund,John Radcliffe Hosp, Oxford OX3 9DS, England.		Harris, Adrian L/ABA-3343-2020; Winters, Zoe Ellen/GYE-7947-2022	Harris, Adrian L/0000-0003-1376-8409; 				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CohenJonathan E, 1997, RADIAT RES, V147, P277, DOI 10.2307/3579333; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; FAN SJ, 1995, CANCER RES, V55, P1649; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HERZINGER T, 1995, ONCOGENE, V11, P2151; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kao GD, 1997, CANCER RES, V57, P753; KASTAN MB, 1991, CANCER RES, V51, P6304; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Lee TH, 1996, P NATL ACAD SCI USA, V93, P352, DOI 10.1073/pnas.93.1.352; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; McDonald E, 1996, CANCER RES, V56, P2250; Moore DD, 1995, GLOB MOB SURV; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MUSK SRR, 1990, INT J RADIAT BIOL, V57, P1105, DOI 10.1080/09553009014551221; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Skladanowski A, 1997, CANCER RES, V57, P818; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VOJTESEK B, 1993, BRIT J CANCER, V67, P1254, DOI 10.1038/bjc.1993.234; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YAMATO K, 1995, ONCOGENE, V11, P1; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x	59	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					673	684		10.1038/sj.onc.1201991	http://dx.doi.org/10.1038/sj.onc.1201991			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715268				2022-12-25	WOS:000075337200001
J	Blahos, J; Mary, S; Perroy, J; de Colle, C; Brabet, I; Bockaert, J; Pin, JP				Blahos, J; Mary, S; Perroy, J; de Colle, C; Brabet, I; Bockaert, J; Pin, JP			Extreme C terminus of G protein alpha-subunits contains a site that discriminates between G(i)-coupled metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; BETA-GAMMA; COUPLING SELECTIVITY; INOSITOL PHOSPHATES; ADRENERGIC-RECEPTOR; INTRACELLULAR LOOP; SYNTHETIC PEPTIDES; CARBOXYL-TERMINUS; AMINO-ACIDS; ACTIVATION	Metabotropic glutamate receptors (mGlu receptors), the Ca2+-sensing receptor, gamma-aminobutyric acid type B receptors, and one group of pheromone receptors constitute a unique family (also called family 3) of heptahelical receptors, This original family shares no sequence similarity with any other G protein coupled receptors, The identification and comparison of the molecular determinants of receptor/G protein coupling within the different receptor families may help identify general rules involved in this protein/protein interaction. In order to detect possible contact sites important for coupling selectivity between family 3 receptors and the G protein alpha-subunits, we examined the coupling of the cyclase-inhibiting mGlu2 and mGlu4 receptors to chimeric alpha(q)-subunits bearing the 5 extreme C-terminal amino acid residues of either G alpha(qi)(,) G alpha(qo) or G alpha(qz). Whereas mGlu4 receptor activated all three chimeric G proteins, mGlu2 receptor activated G alpha(qi) and G alpha(qo) but not G alpha(qz). The mutation of isoleucine -4 of G alpha(qo) into cysteine was sufficient to recover coupling of the mutant G protein to mGlu2 receptor. Moreover, the mutation of cysteine -4 of G alpha(qo) into isoleucine was sufficient to suppress the coupling to mGlu2 receptor, Mutations at positions -5 and -1 had an effect on coupling efficiency, but not selectivity. Our results emphasize the importance of the residue -4 of the alpha-subunits in their specific interaction to heptahelical receptors by extending this finding on the third family of G protein coupled receptors.	CCIPE, CNRS, UPR 9023, F-34094 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS)	Pin, JP (corresponding author), CCIPE, CNRS, UPR 9023, 141 Rue Cardonille, F-34094 Montpellier 5, France.	pin@ccipe.montp.inserm.fr	Pin, Jean-Philippe/Y-6668-2019; Blahos, Jaroslav/G-4397-2014; Blahos, Jaroslav/G-8325-2017	Pin, Jean-Philippe/0000-0002-1423-345X; Blahos, Jaroslav/0000-0001-9803-0061; Blahos, Jaroslav/0000-0003-3355-1469; perroy, julie/0000-0001-6199-0448				Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONE EA, 1984, BIOCHEM J, V221, P803, DOI 10.1042/bj2210803; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PARKER EM, 1991, J BIOL CHEM, V266, P9987; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Taylor JM, 1996, J BIOL CHEM, V271, P3336; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; Tsu RC, 1997, MOL PHARMACOL, V52, P38, DOI 10.1124/mol.52.1.38; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	44	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25765	25769		10.1074/jbc.273.40.25765	http://dx.doi.org/10.1074/jbc.273.40.25765			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748247	hybrid			2022-12-25	WOS:000076263100038
J	Chen, XY; Reitman, M; Bieker, JJ				Chen, XY; Reitman, M; Bieker, JJ			Chromatin structure and transcriptional control elements of the erythroid Kruppel-like factor (EKLF) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL LIVER HEMATOPOIESIS; LOCUS-CONTROL REGION; BINDING-FACTOR; DEFINITIVE HEMATOPOIESIS; ERYTHROPOIETIN RECEPTOR; HYPERSENSITIVE SITES; BETA-THALASSEMIA; MICE LACKING; IN-VITRO; C-MYB	Erythroid Kruppel-like factor (EKLF) is a red cell-specific transcription factor whose activity is critical for the switch in expression from fetal to adult beta-globin during erythroid ontogeny, We have examined its own regulation using a number of approaches. First, the EKLF transcription unit is in an open chromatin configuration in erythroid cells. Second, in vivo transfection assays demonstrate that the more distal of the two erythroid-specific DNase-hypersensitive sites behaves as an enhancer. Although this conserved element imparts high level transcription to a heterologous promoter in all lines examined, erythroid specificity is retained only when it is fused to the proximal EKLF promoter, which contains an important GATA site. Third, extensive mutagenesis of this enhancer element has delimited its in vivo activity to a core region of 49 base pairs. Finally, in vitro footprint and gel shift assays demonstrate that three distinct DNA binding activities in erythroid cell extracts individually interact with three short sequences within this core enhancer element. These analyses reveal that high level erythroid expression of EKLF relies on the interplay between conserved proximal and distal promoter elements that alter chromatin structure and likely provide a target for genetic control via extracellular induction pathways.	CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bieker, JJ (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, Box 1126,1 Gustave L Levy Pl, New York, NY 10029 USA.		Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048721, F32DK009391] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48721, DK09391] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; Bieker J J, 1998, Curr Opin Hematol, V5, P145; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; Bonifer C, 1997, J BIOL CHEM, V272, P26075, DOI 10.1074/jbc.272.42.26075; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; Coles LS, 1996, NUCLEIC ACIDS RES, V24, P2311, DOI 10.1093/nar/24.12.2311; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FENG WC, 1994, J BIOL CHEM, V269, P1493; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; Jenkins NA, 1998, MAMM GENOME, V9, P174, DOI 10.1007/s003359900716; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Reese TT, 1997, GROWTH FACTORS, V14, P161, DOI 10.3109/08977199709021518; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Silver L, 1997, BLOOD, V89, P1154, DOI 10.1182/blood.V89.4.1154; Southwood CM, 1996, DEV DYNAM, V206, P248, DOI 10.1002/(SICI)1097-0177(199607)206:3<248::AID-AJA3>3.0.CO;2-I; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776	62	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25031	25040		10.1074/jbc.273.39.25031	http://dx.doi.org/10.1074/jbc.273.39.25031			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737959	hybrid			2022-12-25	WOS:000076085400009
J	Dunn, AD; Corsi, CM; Myers, HE; Dunn, JT				Dunn, AD; Corsi, CM; Myers, HE; Dunn, JT			Tyrosine 130 is an important outer ring donor for thyroxine formation in thyroglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; THYROID-HORMONE FORMATION; BOVINE THYROGLOBULIN; HORMONOGENIC SITES; DEHYDROALANINE RESIDUES; PORCINE THYROGLOBULIN; IDENTIFICATION; IODINATION; CLEAVAGE; FRAGMENT	The thyroid couples two iodotyrosine molecules to produce thyroid hormone at the acceptor site in thyroglobulin, leaving dehydroalanine or pyruvate at the donor position. Previous work has located the accepters but not the principal iodotyrosine donors. We incorporated [C-14]tyrosine into beef thyroid slices, isolated and iodinated the [C-14]thyroglobulin (Tg I), separated its N-terminal similar to 22-kDa hormone-rich peptide, and digested the latter with trypsin and endoproteinase Glu-C (EC 3.4.21.19). Nonlabeled thyroglobulin (Tg II) was isolated from the same glands and processed similarly, without iodination in vitro. Tg I was used to initially recognize pyruvate in peptide fractions, and Tg II was used to then identify its location in the thyroglobulin polypeptide chain. Sequencing of a tryptic peptide by mass spectrometry and Edman degradation showed a cleavage after Val(129). An endoproteinase Glu-C-generated peptide had the predicted molecular mass of a fragment containing residues 130-146 with Tyr(130) replaced by pyruvate; the identification of this peptide was supported by obtaining the expected shortened fragment after tryptic digestion. C-14-labeled pyruvate was identified in the same fraction as this peptide. We conclude that Tyr(130) is, important donor of the outer iodothyronine ring. Its likely acceptor is Tyr(5), the most important hormonogenic site of thyroglobulin, because Tyr(5) and Tyr(130) are proximate, because they are the most prominent early iodination sites in this part of thyroglobulin, and because the N-terminal region was previously found capable of forming T-4 by itself.	Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Med,Div Endocrinol, Charlottesville, VA 22908 USA	University of Virginia	Dunn, AD (corresponding author), Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Med,Div Endocrinol, Box 511, Charlottesville, VA 22908 USA.	add7k@virginia.edu			NCI NIH HHS [P30 CA45579] Funding Source: Medline; NIDDK NIH HHS [R01 DK11043, T32 DK07320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007320, R01DK011043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DENHARTOG MT, 1995, EUR J ENDOCRINOL, V132, P611, DOI 10.1530/eje.0.1320611; Dunn AD, 1996, ENDOCRINOLOGY, V137, P3279, DOI 10.1210/en.137.8.3279; DUNN JT, 1993, THYROID, V3, P119, DOI 10.1089/thy.1993.3.119; DUNN JT, 1982, J BIOL CHEM, V257, P88; DUNN JT, 1987, J BIOL CHEM, V262, P16948; FASSLER CA, 1988, J BIOL CHEM, V263, P17366; GAVARET JM, 1979, J BIOL CHEM, V254, P1218; GAVARET JM, 1980, J BIOL CHEM, V255, P5281; Gentile F, 1997, J BIOL CHEM, V272, P639; GREGG JD, 1988, J BIOL CHEM, V263, P5190; IEIRI T, 1991, J CLIN INVEST, V88, P1901, DOI 10.1172/JCI115513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS L, 1989, J BIOL CHEM, V264, P13541; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRIQ C, 1991, MOL CELL ENDOCRINOL, V81, P155, DOI 10.1016/0303-7207(91)90214-D; MARRIQ C, 1989, FEBS LETT, V242, P414, DOI 10.1016/0014-5793(89)80513-7; MARRIQ C, 1982, EMBO J, V1, P397, DOI 10.1002/j.1460-2075.1982.tb01181.x; MARRIQ C, 1983, BIOCHEM BIOPH RES CO, V112, P206, DOI 10.1016/0006-291X(83)91817-X; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; OHMIYA Y, 1990, J BIOL CHEM, V265, P9066; PALUMBO G, 1987, J BIOL CHEM, V262, P17182; RAWITCH AB, 1984, BIOCHEM BIOPH RES CO, V118, P423, DOI 10.1016/0006-291X(84)91320-2; RAWITCH AB, 1983, J BIOL CHEM, V258, P2079; ROE MT, 1989, ENDOCRINOLOGY, V124, P1327, DOI 10.1210/endo-124-3-1327; Taurog Alvin, 1996, P47; VEENBOER GJM, 1993, ENDOCRINOLOGY, V132, P377, DOI 10.1210/en.132.1.377; Xiao S, 1996, ARCH BIOCHEM BIOPHYS, V334, P284, DOI 10.1006/abbi.1996.0457; XIAO S, 1995, ARCH BIOCHEM BIOPHYS, V320, P96, DOI 10.1006/abbi.1995.1346	28	48	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25223	25229		10.1074/jbc.273.39.25223	http://dx.doi.org/10.1074/jbc.273.39.25223			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737985	hybrid			2022-12-25	WOS:000076085400035
J	Gregori, C; Porteu, A; Lopez, S; Kahn, A; Pichard, AL				Gregori, C; Porteu, A; Lopez, S; Kahn, A; Pichard, AL			Characterization of the aldolase B intronic enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE-HYDROXYLASE GENE; HORMONE RECEPTOR SUPERFAMILY; LIVER-SPECIFIC TRANSCRIPTION; TISSUE-SPECIFIC EXPRESSION; PYRUVATE-KINASE GENE; ALBUMIN GENE; INVITRO TRANSCRIPTION; MAMMALIAN-CELLS; TRANSGENIC MICE; HEPATOMA-CELLS	The aldolase B gene is transcribed at a high level in the liver, kidney, and small intestine. This high level of gene expression results from cooperation between a weak but liver-specific promoter and an intronic activator. A deletional study of this activator present in the first intron allowed us to ascribe the maximal enhancer function to a 400-base pair (bp) fragment (+1916 to + 2329). This enhancer is highly liver-specific and enhances the activity of heterologous minimal promoters in a position and distance-independent fashion in transiently transfected Hep G2 hepatoma cells. The aldolase B enhancer is composed of two domains, a 200-bp module (Ba) inactive by itself but which synergizes with another 200-bp module (Bb) that alone retains 25% of the total enhancer activity. The Eb sequence is 76% homologous between human and rat genes and contains several binding sites for liver-enriched nuclear factors, By electrophoretic mobility shift assays, we demonstrated that elements 5 and 7 bind hepatic nuclear factor 1 (HNF1), whereas element 2 binds hepatic nuclear factor 4 (HNF4). A functional analysis of the enhancer whose elements have been mutated demonstrated that mutation of any of the HNF1 sites totally suppressed enhancer activity, whereas mutation of the HNF4-binding site reduced it by 80%.	Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Pichard, AL (corresponding author), Inst Cochin Genet Mol, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.							BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; CAMPOS JR, 1991, EMBO J, V10, P1445; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; COGNET M, 1991, J BIOL CHEM, V266, P7368; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Faust DM, 1996, MOL CELL BIOL, V16, P3125; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; GREGORI C, 1994, NUCLEIC ACIDS RES, V22, P1242, DOI 10.1093/nar/22.7.1242; GREGORI C, 1991, BIOCHEM BIOPH RES CO, V176, P722, DOI 10.1016/S0006-291X(05)80244-X; GUDER WG, 1984, KIDNEY INT, V26, P101, DOI 10.1038/ki.1984.143; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; Harnish DC, 1996, J BIOL CHEM, V271, P13621, DOI 10.1074/jbc.271.23.13621; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MILLONIG JH, 1995, MOL CELL BIOL, V15, P3848; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MUNNICH A, 1985, J CLIN INVEST, V75, P1045, DOI 10.1172/JCI111766; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1997, MOL CELL BIOL, V17, P4948, DOI 10.1128/MCB.17.9.4948; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; ROUET P, 1995, NUCLEIC ACIDS RES, V23, P395, DOI 10.1093/nar/23.3.395; Sabourin JC, 1996, J BIOL CHEM, V271, P3469, DOI 10.1074/jbc.271.7.3469; SCHAPIRA F, 1975, ISOZYMES, V3, P987; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TRONCHE F, 1990, MOL BIOL MED, V7, P173; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; Whitelaw C B, 1991, Transgenic Res, V1, P3, DOI 10.1007/BF02512991; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	46	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25237	25243		10.1074/jbc.273.39.25237	http://dx.doi.org/10.1074/jbc.273.39.25237			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737987	hybrid			2022-12-25	WOS:000076085400037
J	Yasuda, Y; Masuda, S; Chikuma, M; Inoue, K; Nagao, M; Sasaki, R				Yasuda, Y; Masuda, S; Chikuma, M; Inoue, K; Nagao, M; Sasaki, R			Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	4th International Lubeck Conference on the Pathophysiology and Pharmacology of Erythropoietin and Other Hematopoietic Growth Factors	JUN 27-29, 1997	LUBECK, GERMANY				ENDOTHELIAL GROWTH-FACTOR; RECOMBINANT-HUMAN-ERYTHROPOIETIN; RECEPTOR MESSENGER-RNA; RAT UTERUS; LIGAND-BINDING; IN-VITRO; CELLS; EXPRESSION; GENE; BRAIN	Although erythropoietin (Epo) has been shown to possess in vitro angiogenic activity, its physiological significance has not been demonstrated. Normally angiogenesis does not occur actively in adults but an exception is the female reproductive organ. In the uterine endometrium, angiogenesis takes place actively for supporting the endometrial growth that occurs during transition from the diestrus to estrous stage. This transition is under control of 17 beta-estradiol (E-2), an ovarian hormone, and can be mimicked by injection of E-2 to ovariectomized (OVX) mouse. Thus, the uterus is a pertinent site to examine the Epo function in angiogenesis. We found that Epo protein and its mRNA were produced in an E-2-dependent manner, when the uterus from OVX mouse was cultured in vitro. The de novo protein synthesis was not needed for E-2 induction of Epo mRNA. Administration of E-2 to OVX mouse induced a rapid and transient increase in Epo mRNA in the uterus. Injection of Epo into the OVX mouse uterine cavity promoted blood vessel formation in the endometrium. Furthermore, injection of the soluble Epo receptor capable of binding with Epo into the uterine cavity of non-OVX mouse in diestrus stale inhibited the endometrial transition to proestrus stage, whereas heat-inactivated soluble Epo receptor allowed the transition to occur. These results, combined with our finding that the endothelial cells in uterine endometrium express Epo receptor, strongly suggest that Epo is an important factor for the E-2-dependent cyclical angiogenesis in uterus.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan; Kinki Univ, Sch Med, Dept Anat, Osaka 5890014, Japan	Kyoto University; Kindai University (Kinki University)	Sasaki, R (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan.	rsasaki@kais.kyoto-u.ac.jp						ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; ANAGNOSTOU A, 1976, J LAB CLIN MED, V88, P700; AUGUSTIN HG, 1995, AM J PATHOL, V147, P339; AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208; BIKFALVI A, 1994, LEUKEMIA, V8, P523; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CARLINI RG, 1995, KIDNEY INT, V47, P740, DOI 10.1038/ki.1995.113; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; Clark J.H., 1988, P675; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GALSON DL, 1993, BLOOD, V82, P3321; GOTO M, 1989, BLOOD, V74, P1415; GOTO M, 1988, BIO-TECHNOL, V6, P67, DOI 10.1038/nbt0188-67; HAM KN, 1970, J ENDOCRINOL, V46, P71, DOI 10.1677/joe.0.0460071; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HECHTER O, 1941, ENDOCRINOLOGY, V23, P25; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KIRKLAND JL, 1979, BIOL REPROD, V21, P269, DOI 10.1095/biolreprod21.2.269; KRANTZ SB, 1991, BLOOD, V77, P419; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Liu C, 1997, J BIOL CHEM, V272, P32395, DOI 10.1074/jbc.272.51.32395; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Masuda S, 1997, BRAIN RES, V746, P63, DOI 10.1016/S0006-8993(96)01186-9; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; NAGAO M, 1992, BIOCHEM BIOPH RES CO, V188, P888, DOI 10.1016/0006-291X(92)91139-H; NAGAO M, 1993, BLOOD, V81, P2503; OKANO M, 1994, FEBS LETT, V349, P229, DOI 10.1016/0014-5793(94)00673-3; PESCHLE C, 1973, ENDOCRINOLOGY, V92, P358; RISAU W, 1988, DEVELOPMENT, V102, P471; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; SCHOTT RJ, 1993, CARDIOVASC RES, V27, P1155, DOI 10.1093/cvr/27.7.1155; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; STACK G, 1984, ENDOCRINOLOGY, V115, P1141, DOI 10.1210/endo-115-3-1141; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; YASUDA Y, 1993, DEV GROWTH DIFFER, V35, P711; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	46	223	235	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25381	25387		10.1074/jbc.273.39.25381	http://dx.doi.org/10.1074/jbc.273.39.25381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	122RN	9738005	hybrid			2022-12-25	WOS:000076085400055
J	Carpenter, PB; Dunphy, WG				Carpenter, PB; Dunphy, WG			Identification of a novel 81-kDa component of the Xenopus origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; DNA-REPLICATION; BUDDING YEAST; MCM PROTEINS; CDC6 PROTEIN; EGG EXTRACTS; CHROMATIN; HOMOLOG; KINASES; CDK	The Xenopus origin recognition complex is essential for chromosomal DNA replication in cell-free extracts. We have immunopurified the Xenopus origin recognition complex with anti-Xorc2 antibodies and analyzed its composition and properties. Xorc2 (p63) is specifically associated with Xorc1 (p115) and up to four additional polypeptides (p81, p78, p45, and p40). The cDNA encoding p81 is highly homologous to various expressed sequence tags from humans and mice encoding a protein of previously unknown function. Immunodepletion of p81 from Xenopus egg extracts, which also results in the removal of Xorc2, completely abolishes chromosomal DNA replication. Thus, p81 appears to play a crucial role at S phase in higher eukaryotes.	CALTECH, Div Biol, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Dunphy, WG (corresponding author), CALTECH, Div Biol, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	dunphy@cco.caltech.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1	30	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24891	24897		10.1074/jbc.273.38.24891	http://dx.doi.org/10.1074/jbc.273.38.24891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733795	Green Accepted, hybrid			2022-12-25	WOS:000076007300087
J	Damer, CK; Partridge, J; Pearson, WR; Haystead, TAJ				Damer, CK; Partridge, J; Pearson, WR; Haystead, TAJ			Rapid identification of protein phosphatase 1-binding proteins by mixed peptide sequencing and data base searching - Characterization of a novel holoenzymic form of protein phosphatase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; REGULATORY SUBUNITS; PURIFICATION; MYOSIN; TYROSINE; CDNA; GENE	Microcystin-affinity chromatography was used to purify 15 protein phosphatase 1 (PP1)-binding proteins from the myofibrillar fraction of rabbit skeletal muscle. To reduce the time and amount of material required to identify these proteins, proteome analysis by mixed pep tide sequencing was developed. Proteins are resolved by SDS-polyacrylamide gel electrophoresis, electroblotted to polyvinylidene fluoride membrane, and stained. Bands are sliced from the membrane, cleaved briefly with CnBr, and applied without further purification to an automated Edman sequencer. The mixed peptide sequences generated are sorted and matched against the GenBank using two new programs, FASTF and TFASTF. This technology offers a simple alternative to mass spectrometry for the subpicomolar identification of proteins in polyacrylamide gels. Using this technology, all 15 proteins recovered in PP-1C affinity chromatography were sequenced. One of the proteins, PP-1bp55, was homologous to human myosin phosphatase, MYPT2. A second, PP-1bp80, identified in the EST data bases, contained a putative PP-1C binding site and a nucleotide binding motif. Further affinity purification over ATP-Sepharose isolated PP-1bp80 in a quaternary complex with PP-1C and two other proteins, PP-1bp29 and human p20, Recombinant PP-1bp80 also bound PP-1C and suppressed its activity toward a variety of substrates, suggesting that the protein is a novel regulatory subunit of PP-1.	Univ Virginia, Markey Ctr Cell Signaling & Biochem, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Haystead, TAJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 448, Charlottesville, VA 22908 USA.		Pearson, William/K-4908-2019	Pearson, William/0000-0002-0727-3680	NHLBI NIH HHS [HL19242] Funding Source: Medline; NIDDK NIH HHS [DK52378A] Funding Source: Medline; NLM NIH HHS [LM04969] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM004969] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DENT P, 1992, EUR J BIOCHEM, V210, P1037, DOI 10.1111/j.1432-1033.1992.tb17509.x; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; Fujioka M, 1998, GENOMICS, V49, P59, DOI 10.1006/geno.1998.5222; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KAHN P, 1995, SCIENCE, V270, P369, DOI 10.1126/science.270.5235.369; KATO K, 1994, J BIOL CHEM, V269, P15302; LAI EY, 1994, J MOL BIOL, V235, P377, DOI 10.1016/S0022-2836(05)80045-2; MATTHEWS RJ, 1991, IMMUNOGENETICS, V33, P33; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P3; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; TUNG HYL, 1984, EUR J BIOCHEM, V138, P635, DOI 10.1111/j.1432-1033.1984.tb07962.x; 1996, Patent No. 5536822	23	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24396	24405		10.1074/jbc.273.38.24396	http://dx.doi.org/10.1074/jbc.273.38.24396			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733729	hybrid			2022-12-25	WOS:000076007300021
J	Posern, G; Weber, CK; Rapp, UR; Feller, SM				Posern, G; Weber, CK; Rapp, UR; Feller, SM			Activity of Rap1 is regulated by bombesin, cell adhesion, and cell density in NIH3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DEPENDENT ACTIVATION; GROWTH-FACTORS; B-RAF; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAYS; DNA-SYNTHESIS; CYCLIC-AMP	Rap1 and Ras are homologous GTPases that are implicated in cell proliferation and differentiation. At present, little is known about the regulation of Rap1 activity. Using a recently developed assay with activation-specific probes, we found increased activity of endogenous Rap1 in NIH3T3 cells after stimulation with the neuropeptide growth factor bombesin in a concentration- and time-dependent manner. The activity of endogenous Ras was unaffected. Analysis of putative effecters showed no activation of c-Raf-1 or B-Raf after bombesin stimulation. However, MAPH/Erk-phosphorylation and the proliferation rate was increased. In addition, Rap1 was activated during cell adhesion to coated and uncoated tissue culture plates, as well as in response to various mitogens. Surprisingly, the basal Rap1 activity was observed to be cell density-dependent, with low levels when cells were reaching confluency. The results suggest that Rap1 acts as an important mediator of mitogenic signals distinct to Ras activation.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Mol Oncol Lab, D-97078 Wurzburg, Germany	University of Wurzburg	Feller, SM (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Mol Oncol Lab, Versbacher Str 5, D-97078 Wurzburg, Germany.							ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FELLER SM, 1995, ONCOGENE, V10, P1465; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROZENGURT E, 1995, CANCER SURV, V24, P81; SETHI T, 1992, CANCER RES, V52, pS2737; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	26	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24297	24300		10.1074/jbc.273.38.24297	http://dx.doi.org/10.1074/jbc.273.38.24297			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733713	hybrid			2022-12-25	WOS:000076007300005
J	Sark, MWJ; Fischer, DF; de Meijer, E; van de Putte, P; Backendorf, C				Sark, MWJ; Fischer, DF; de Meijer, E; van de Putte, P; Backendorf, C			AP-1 and ets transcription factors regulate the expression of the human SPRR1A keratinocyte terminal differentiation marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; PROLINE-RICH PROTEINS; HUMAN EPIDERMAL-KERATINOCYTES; CROSS-LINKED ENVELOPE; HUMAN-CHROMOSOME 1Q21; GENE-EXPRESSION; PROXIMAL PROMOTER; C-JUN; CHLORAMPHENICOL ACETYLTRANSFERASE; MOUSE KERATINOCYTES	The 173-base pair proximal promoter of SPRR1A is necessary and sufficient for regulated expression in primary keratinocytes induced to differentiate either by increasing extracellular calcium or by 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment. Whereas calcium-induced expression depends both on an AP-1 and an Ets binding site in this region, responsiveness to TPA resides mainly (but not exclusively) on the Ets element, indicating that Ets factors are important targets for protein kinase C signaling during keratinocyte terminal differentiation. This conclusion is further substantiated by the finding that expression of ESE-1, an Ets transcription factor involved in SPRR regulation, is also induced by TPA, with kinetics similar to SPRR1A. The strict AP-1 requirement in SPRR1A for calcium-induced differentiation is not found for SPRR2A, despite the presence of an identical AP-I consensus binding site in this gene. Binding site swapping indicates that both the nucleotides flanking the TGAGTCA core sequence and the global promoter context are essential in determining the contribution of AP-1 factors in gene expression during keratinocyte terminal differentiation. In the distal SPRR1A promoter region, a complex arrangement of positive and negative regulatory elements, which are only conditionally needed for promoter activity, are likely involved in gene-specific fine-tuning of the expression of this member of the SPRR gene family.	Leiden Univ, Leiden Inst Chem, Mol Genet Lab, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Backendorf, C (corresponding author), Leiden Univ, Leiden Inst Chem, Mol Genet Lab, POB 9502, NL-2300 RA Leiden, Netherlands.	Backendo@chem.leidenuniv.nl		Fischer, David/0000-0002-6690-0197				AN G, 1993, J BIOL CHEM, V268, P10977; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; BAUKNECHT T, 1995, J VIROL, V69, P1; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; Byrne C, 1997, BIOESSAYS, V19, P691, DOI 10.1002/bies.950190809; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CARRASCO D, 1995, ONCOGENE, V10, P1069; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P1619; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; ELLER MS, 1995, J CELL SCI, V108, P2714; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Fujimoto W, 1997, J INVEST DERMATOL, V108, P200, DOI 10.1111/1523-1747.ep12334240; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GARMYN M, 1995, DERMATOLOGY, V190, P305, DOI 10.1159/000246722; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; Gibbs S, 1996, ARCH DERMATOL RES, V288, P729, DOI 10.1007/BF02505289; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gruda MC, 1996, ONCOGENE, V12, P2177; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1993, AM J DERMATOPATH, V15, P20, DOI 10.1097/00000372-199302000-00004; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; Holbrook K., 1994, KERATINOCYTE HDB, P3; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LaPres JJ, 1996, J BIOL CHEM, V271, P23154, DOI 10.1074/jbc.271.38.23154; Lee JH, 1996, J BIOL CHEM, V271, P4561; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; Lohman FP, 1997, EXP CELL RES, V231, P141, DOI 10.1006/excr.1996.3458; Lohman FP, 1997, ONCOGENE, V14, P1623, DOI 10.1038/sj.onc.1200974; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Missero C, 1996, MOL CELL DIFFER, V4, P1; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Parker JN, 1997, CELL GROWTH DIFFER, V8, P751; Ponec M, 1997, ARCH DERMATOL RES, V289, P317, DOI 10.1007/s004030050198; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Rice R.H., 1994, KERATINOCYTE HDB, P259; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; RYSECK RP, 1991, ONCOGENE, V6, P533; Saunders N, 1996, J DERMATOL SCI, V13, P98, DOI 10.1016/S0923-1811(96)00535-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Tesfaigzi J, 1996, AM J RESP CELL MOL, V14, P478, DOI 10.1165/ajrcmb.14.5.8624253; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614	68	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24683	24692		10.1074/jbc.273.38.24683	http://dx.doi.org/10.1074/jbc.273.38.24683			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733767	hybrid			2022-12-25	WOS:000076007300059
J	Tian, D; Huang, DL; Short, S; Short, ML; Jungmann, RA				Tian, D; Huang, DL; Short, S; Short, ML; Jungmann, RA			Protein kinase A-regulated instability site in the 3 '-untranslated region of lactate dehydrogenase-A subunit mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; CYCLIC-AMP REGULATION; C6 GLIOMA-CELLS; GENE-EXPRESSION; EUKARYOTIC CELLS; HALF-LIFE; TRANSCRIPTION; PROMOTER; GROWTH; DECAY	Expression of the lactate dehydrogenase A subunit (LDH-A) gene can be controlled by transcriptional as well as posttranscriptional mechanisms, In rat C6 glioma cells, LDH-A mRNA is stabilized by activation and synergistic interaction of protein kinases A and C, In the present study, we aimed to identify the sequence domain which determines and regulates mRNA stability/instability by protein kinase A and focused our attention on the 3'-untranslated region (3'-UTR) of LDH-A mRNA. We have constructed various chimeric globin/lactate dehydrogenase (ldh) genes linked to the c-fos promoter and stably transfected them into rat C6 glioma cells, After their transfection, we determined the half-life of transcribed chimeric globin/ldh mRNAs, The results showed that at least three sequence domains within the LDH-A 3'-UTR consisting of nucleotides 1286-1351, 1453-1471, and 1471-1502 are responsible for the relatively rapid rate of LDH-A mRNA turnover in the cytoplasm, Whereas chimeric globin/ldh mRNAs containing the base sequences 1286-1351 and 1453-1471 were not stabilized by (S-p)-cAMPS, an activator of protein kinase A, instability caused by the 1471-1502 domain was significantly reversed. Additional deletion and mutational analyses demonstrated that the 3'-UTR fragment consisting of the 22 bases 1478-1499 is a critical determinant for the (S-p)-cAMPS-mediated LDH-A mRNA stabilizing activity, Because of its functional characteristics, we named the 22-base region "cAMP-stabilizing region."	Northwestern Univ, Sch Med, Dept Cellular & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Ctr Canc, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Jungmann, RA (corresponding author), Northwestern Univ, Sch Med, Dept Cellular & Mol Biol, Chicago, IL 60611 USA.	rjungman@nwu.edu			NIGMS NIH HHS [GM53115] Funding Source: Medline; NINDS NIH HHS [T32NS07140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHERN SM, 1993, J BIOL CHEM, V268, P2154; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; BANDYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060, DOI 10.1128/MCB.10.5.2060; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN M, 1993, J BIOL CHEM, V268, P24138; CLEVELAND D W, 1989, New Biologist, V1, P121; DERDA DF, 1980, J BIOL CHEM, V255, P1112; DIAMOND DJ, 1985, J MOL BIOL, V181, P41, DOI 10.1016/0022-2836(85)90323-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOD Y, 1988, J BIOL CHEM, V263, P7747; HUANG D, 1995, MOL CELL ENDOCRINOL, V108, P87, DOI 10.1016/0303-7207(94)03459-7; HUANG DL, 1995, MOL ENDOCRINOL, V9, P994, DOI 10.1210/me.9.8.994; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; JUNGMANN RA, 1983, J BIOL CHEM, V258, P5312; KWASTWELFELD J, 1989, J BIOL CHEM, V264, P6941; LEE C, 1979, J NATL CANCER I, V62, P193; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LI SSL, 1989, CELL BIOL INT REP, V13, P619, DOI 10.1016/0309-1651(89)90112-4; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LOWENHAUPT K, 1978, CELL, V14, P337, DOI 10.1016/0092-8674(78)90119-8; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARKERT CL, 1962, DEV BIOL, V5, P363, DOI 10.1016/0012-1606(62)90019-2; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MURPHY D, 1992, MOL CELL BIOL, V12, P2624, DOI 10.1128/MCB.12.6.2624; PALMITER RD, 1974, P NATL ACAD SCI USA, V71, P2357, DOI 10.1073/pnas.71.6.2357; RICHARDS AH, 1972, ENDOCRINOLOGY, V91, P287, DOI 10.1210/endo-91-1-287; RODGERS JR, 1985, METHOD ENZYMOL, V109, P572; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROSS J, 1988, MOL BIOL MED, V5, P1; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; SCHUMPERLI D, 1986, CELL, V45, P471, DOI 10.1016/0092-8674(86)90277-1; Scott W A, 1975, Methods Enzymol, V40, P273; SHAPIRO DJ, 1989, RECENT PROG HORM RES, V45, P29; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SHORT ML, 1994, BIOCHEM J, V304, P391, DOI 10.1042/bj3040391; SHORT S, 1991, J BIOL CHEM, V266, P22164; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; TIAN D, 1998, J BIOL CHEM, V273; VANOOYEN A, 1979, SCIENCE, V206, P337, DOI 10.1126/science.482942; VOLLOCH V, 1981, ORG EXPRESSION GLOBI, P251	50	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24861	24866		10.1074/jbc.273.38.24861	http://dx.doi.org/10.1074/jbc.273.38.24861			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733791	hybrid			2022-12-25	WOS:000076007300083
J	Brandt, JM; Djouadi, F; Kelly, DP				Brandt, JM; Djouadi, F; Kelly, DP			Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ACYL-COA DEHYDROGENASE; BROWN ADIPOSE-TISSUE; OXIDATION ENZYME; RAT-LIVER; HYPERTROPHY; METABOLISM; CDNA; FAILURE; HEART	To explore the gene regulatory mechanisms involved in the metabolic control of cardiac fatty acid oxidative flux, the expression of muscle-type carnitine palmitoyltransferase I (RI-CPT I) was characterized in primary cardiac myocytes in culture following exposure to the long-chain mono-unsaturated fatty acid, oleate, Oleate induced steady-state levels of M-CPT I mRNA 4.5-fold. The transcription of a plasmid construct containing the human M-CPT I gene promoter region fused to a luciferase gene reporter transfected into cardiac myocytes, was induced over 20-fold by long-chain fatty acid in a concentration-dependent and fatty acyl-chain length-specific manner. The M-CPT I gene promoter fatty acid response element (FARE-1) was localized to a hexameric repeat sequence located between 775 and 763 base pairs upstream of the initiator codon. Cotransfection experiments with expression vectors for the peroxisome proliferator-activated receptor alpha (PPAR alpha) demonstrated that FARE-1 isa PPAR alpha response element capable of conferring oleate-mediated transcriptional activation to homologous or heterologous promoters. Electrophoretic mobility shift assays demonstrated that PPAR alpha bound FARE-1 with the retinoid X receptor alpha. The expression of M-CPT I in hearts of mice nub for PPAR alpha was approximately 50% lower than levels in wild-type controls. Moreover, a PPAR alpha activator did not induce cardiac expression of the M-CPT I gene in the PPAR alpha null mice. These results demonstrate that long-chain fatty acids regulate the transcription of a gene encoding a pivotal enzyme in the mitochondrial fatty acid uptake pathway in cardiac myocytes and define a role for PPAR alpha in the control of myocardial lipid metabolism.	Washington Univ, Sch Med, Ctr Cardiovasc Res, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Cardiovasc Res, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Cardiovasc Res, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Paris 07, INSERM U319, F-75251 Paris 05, France	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Kelly, DP (corresponding author), Washington Univ, Sch Med, Ctr Cardiovasc Res, Dept Pediat, 660 S Euclid Ave,Campus Box 8086, St Louis, MO 63110 USA.	dkelly@imgate.wustl.edu	DJOUADI, Fatima/C-6187-2019; Kelly, Daniel/ABG-2056-2021	Djouadi, Fatima/0000-0003-0350-0935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045416, R01DK045416] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58493] Funding Source: Medline; NIDDK NIH HHS [DK45416] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT NR, 1982, CIRC RES, V50, P491, DOI 10.1161/01.RES.50.4.491; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; BING RJ, 1955, HARVEY LECT, P27; BISHOP SP, 1970, AM J PHYSIOL, V218, P153, DOI 10.1152/ajplegacy.1970.218.1.153; BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; Chatelain F, 1996, EUR J BIOCHEM, V235, P789, DOI 10.1111/j.1432-1033.1996.00789.x; CHRISTE ME, 1994, J MOL CELL CARDIOL, V26, P1371, DOI 10.1006/jmcc.1994.1155; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; ESSER V, 1993, J BIOL CHEM, V268, P5817; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GEBEL T, 1992, FEBS LETT, V309, P37, DOI 10.1016/0014-5793(92)80734-X; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLY DP, 1989, J BIOL CHEM, V264, P18921; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LEONE TC, 1995, J BIOL CHEM, V270, P16308, DOI 10.1074/jbc.270.27.16308; LEVY FH, 1997, AM J PHYSIOL, V41, pC457; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; MASSIE BM, 1995, CIRCULATION, V91, P1814, DOI 10.1161/01.CIR.91.6.1814; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1995, BIOCHEM SOC T, V23, P321, DOI 10.1042/bst0230321; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MOALIC JM, 1993, CIRCULATION, V87, P21; NAGAO M, 1993, J BIOL CHEM, V268, P24114; NEELY J R, 1972, Progress in Cardiovascular Diseases, V15, P289, DOI 10.1016/0033-0620(72)90029-1; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; SCHEUER J, 1993, CIRCULATION, V87, P54; SINGH B, 1984, ANAL BIOCHEM, V138, P107, DOI 10.1016/0003-2697(84)90776-0; TAEGTMEYER H, 1988, HYPERTENSION, V11, P416, DOI 10.1161/01.HYP.11.5.416; TAEGTMEYER H, 1994, CURR PROB CARDIOLOGY, V19, P61, DOI 10.1016/0146-2806(94)90008-6; TAKEYAMA D, 1995, CARDIOVASC RES, V29, P763, DOI 10.1016/S0008-6363(96)88610-X; vanderLeij FR, 1997, BBA-GENE STRUCT EXPR, V1352, P123, DOI 10.1016/S0167-4781(97)00037-7; Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3	43	380	393	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23786	23792		10.1074/jbc.273.37.23786	http://dx.doi.org/10.1074/jbc.273.37.23786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726988	hybrid			2022-12-25	WOS:000075893100029
J	Klezovitch, O; Edelstein, C; Zhu, LY; Scanu, AM				Klezovitch, O; Edelstein, C; Zhu, LY; Scanu, AM			Apolipoprotein(a) binds via its C-terminal domain to the protein core of the proteoglycan decorin - Implications for the retention of lipoprotein(a) in atherosclerotic lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; CYCLIN-DEPENDENT KINASES; LOW-DENSITY-LIPOPROTEIN; RECOMBINANT APOLIPOPROTEIN(A); EXTRACELLULAR-MATRIX; APO-B; PROTEODERMATAN SULFATE; ARTICULAR-CARTILAGE; GROWTH SUPPRESSION; CORONARY-ARTERIES	Although it is known that lipoprotein(a) (Lp(a)) binds to proteoglycans, the mechanism for this binding has not been fully elucidated. In order to shed light on this subject, we examined the interactions of decorin, a proteoglycan with a well defined protein core and a single glycosaminoglycan (GAG) chain, with Lp(a) and derivatives, namely Lp(a) deprived of apo(a), or Lp(a-), free apo(a), and the two main proteolytic fragments, F1 and F2, By circular dichroism criteria, the decorin preparations used had the same secondary structure as that previously reported for native decorin. Authentic low density lipoprotein from the same human donor was used as a control. In a solid phase system, Lp(a-)and low density lipoprotein hound to decorin in a comparable manner. This binding required Ca2+/Mg2+ ions, was lysine-mediated, and was markedly decreased in the presence of GAG-depleted decorin, suggesting the ionic nature of the interaction likely involving apoB100 and the GAG component of decorin, Free apo(a) also bound to decorin; however, the binding was neither cation-dependent nor lysine-mediated, unaffected by sialic acid depletion of apo(a), and markedly decreased when either reduced and alkylated apo(a) or reduced and alkylated decorin was used in the assay. Of note, the binding of apo(a) was unaffected when it was incubated with a spectrally native decorin that had been renatured from either 4 M guanidine hydrochloride by extensive dialysis or cooled from 65 to 25 degrees C, On the other hand, the binding significantly increased when decorin was depleted of GAGs, which by themselves had no affinity for apo(a), The binding of apo(a) to the decorin protein core was also elicited by the C-terminal domain of apo(a), and it was favored by high NaCl concentrations, 1 to 2 M, No binding was exhibited by the N-terminal domain accounting for the lack of effect of apo(a) size polymorphism on the binding. In the case of whole Lp(a), the binding to immobilized decorin was mostly GAG-dependent and ionic in nature. A minor contribution by apo(a) was detected when GAG-depleted decorin was used in the assay. Our results indicate that the binding of Lp(a) to decorin involves interactions both electrostatic (apoB100-GAG) and hydrophobic (apo(a)-decorin protein core), and that the binding of apo(a) requires decorin protein core to be in its native state.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Klezovitch, O (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC5041, Chicago, IL 60637 USA.	oklezovi@medicine.bsd.uchicago.edu			NHLBI NIH HHS [HL-18577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler A J, 1973, Methods Enzymol, V27, P675; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; CHANG CT, 1978, ANAL BIOCHEM, V91, P12; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHRISTNER JE, 1990, ANAL BIOCHEM, V184, P388, DOI 10.1016/0003-2697(90)90698-9; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLEN C, 1978, CLIN GENET, V14, P36; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Edelstein C, 1996, J LIPID RES, V37, P1786; Edelstein C, 1995, BIOCHEMISTRY-US, V34, P16483, DOI 10.1021/bi00050a032; Edelstein C, 1997, J BIOL CHEM, V272, P11079; EDELSTEIN C, 1997, CIRCULATION S, V96, P111; ERNST A, 1995, J BIOL CHEM, V270, P6227, DOI 10.1074/jbc.270.11.6227; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; FRANK S, 1995, ARTERIOSCL THROM VAS, V15, P1774, DOI 10.1161/01.ATV.15.10.1774; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOFF HF, 1993, J LIPID RES, V34, P789; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Klezovitch O, 1996, J CLIN INVEST, V98, P185, DOI 10.1172/JCI118765; KLEZOVITCH O, 1997, CIRCULATION S, V96, P112; KRESSE H, 1994, EUR J CLIN CHEM CLIN, V32, P259; KREUZER J, 1994, CHEM PHYS LIPIDS, V67-8, P175, DOI 10.1016/0009-3084(94)90137-6; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAWN RM, 1996, ATHEROSCLEROSIS CORO, P151; Libby P, 1997, CIRCULATION, V96, P4095; LIBBY P, 1997, INT J CARDIOL S2, V62, P23; Lin H, 1996, J HEART LUNG TRANSPL, V15, P1223; MARCOVINA SM, 1993, BIOCHEM BIOPH RES CO, V191, P1192, DOI 10.1006/bbrc.1993.1343; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; PEPIN JM, 1991, J LIPID RES, V32, P317; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; PULKKINEN L, 1992, CYTOGENET CELL GENET, V60, P107, DOI 10.1159/000133314; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; REBLIN T, 1995, ATHEROSCLEROSIS, V113, P179, DOI 10.1016/0021-9150(94)05445-O; RENUGOPALAKRISHNAN V, 1989, BIOPOLYMERS, V28, P1923, DOI 10.1002/bip.360281109; RIESSEN R, 1994, AM J PATHOL, V144, P962; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; ROUGHLEY PJ, 1989, BIOCHEM J, V262, P823, DOI 10.1042/bj2620823; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; SALONEN EM, 1989, EMBO J, V8, P4035, DOI 10.1002/j.1460-2075.1989.tb08586.x; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SMITH EB, 1990, ATHEROSCLEROSIS, V84, P173, DOI 10.1016/0021-9150(90)90088-Z; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; VANDERHOEK YY, 1994, ARTERIOSCLER THROMB, V14, P1792, DOI 10.1161/01.ATV.14.11.1792; WIGHT TN, 1996, ATHEROSCLEROSIS CORO, P421	62	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23856	23865		10.1074/jbc.273.37.23856	http://dx.doi.org/10.1074/jbc.273.37.23856			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726998	hybrid			2022-12-25	WOS:000075893100039
J	Meijer, MMC; Boonstra, J; Verkleij, AJ; Verrips, CT				Meijer, MMC; Boonstra, J; Verkleij, AJ; Verrips, CT			Glucose repression in Saccharomyces cerevisiae is related to the glucose concentration rather than the glucose flux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL HEXOSE TRANSPORTERS; LIMITED CONTINUOUS CULTURES; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; GLYCOLYTIC-ENZYMES; SUC2 GENE; HXT GENES; YEAST; AFFINITY; PHOSPHORYLATION	Glucose plays an important regulatory role in the yeast Saccharomyces cerevisiae, which is mostly reflected at the transcriptional level by glucose regression. The signal that initiates glucose repression is unknown, but data indicate that it is located at or above the level of glucose 6-phosphate, suggesting the involvement of either the intracellular or extracellular glucose concentration or the glucose flux in triggering glucose repression. We have investigated the role of the glucose flux and the extracellular glucose concentration in glucose repression by growing the cells in continuous culture under nitrogen limitation. By a step-wise increase ire the glucose feed concentration, the glucose flux and extracellular glucose concentrations were modulated in an accurate way. Furthermore, the glucose flux and glucose concentrations were modulated undependently of each other by increasing the dilution rate or by the use of fructose as a substrate. Using these approaches we demonstrate that glucose repression is related to the extracellular (or intracellular) glucose concentration rather than the glucose flux, At external glucose concentrations Bower than 14 mM, glucose repression of SUC2 gene transcription was not triggered,, whereas glucose repression of this gene was activated when the glucose concentration exceeded 18 mM. A comparable effect was observed for the glucose-repressible carbon source fructose.	Univ Utrecht, Dept Mol Cell Biol, Biomembrane Inst, NL-3584 CH Utrecht, Netherlands; Unilever Res Labs Vlaardingen, NL-3133 AT Vlaardingen, Netherlands	Utrecht University; Unilever	Meijer, MMC (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Biomembrane Inst, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	M.M.C.Meijer@bio.uu.nl						BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; BISSON LF, 1983, P NATL ACAD SCI-BIOL, V80, P1730, DOI 10.1073/pnas.80.6.1730; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; CARLSON M, 1987, J BACTERIOL, V169, P4873, DOI 10.1128/jb.169.11.4873-4877.1987; COONS DM, 1995, J BACTERIOL, V177, P3251, DOI 10.1128/jb.177.11.3251-3258.1995; DEKONING W, 1992, ANAL BIOCHEM, V204, P118, DOI 10.1016/0003-2697(92)90149-2; ENTIAN KD, 1984, MOL GEN GENET, V198, P50, DOI 10.1007/BF00328699; FIECHTER A, 1981, ADV MICROB PHYSIOL, V22, P123, DOI 10.1016/S0065-2911(08)60327-6; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; HARDER W, 1976, CONTINUOUS CULTURE, V6; HAWKINS PT, 1993, J BIOL CHEM, V268, P3374; HERBERT D, 1956, J GEN MICROBIOL, V14, P601, DOI 10.1099/00221287-14-3-601; HU Z, 1995, CURR GENET, V28, P258, DOI 10.1007/BF00309785; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; MA H, 1989, MOL CELL BIOL, V9, P5643, DOI 10.1128/MCB.9.12.5643; NEEDLEMAN R, 1991, MOL MICROBIOL, V5, P2079, DOI 10.1111/j.1365-2958.1991.tb02136.x; NEIGEBORN L, 1984, GENETICS, V108, P845; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Ozcan S, 1997, YEAST, V13, P127; POSTMA E, 1989, APPL ENVIRON MICROB, V55, P468, DOI 10.1128/AEM.55.2.468-477.1989; REIFENBERGER E, 1995, MOL MICROBIOL, V16, P157, DOI 10.1111/j.1365-2958.1995.tb02400.x; Reifenberger E, 1997, EUR J BIOCHEM, V245, P324, DOI 10.1111/j.1432-1033.1997.00324.x; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; ROSE M, 1991, EUR J BIOCHEM, V199, P511, DOI 10.1111/j.1432-1033.1991.tb16149.x; SIERKSTRA LN, 1992, J GEN MICROBIOL, V138, P2559, DOI 10.1099/00221287-138-12-2559; SIERKSTRA LN, 1993, YEAST, V9, P787, DOI 10.1002/yea.320090713; Smits HP, 1996, YEAST, V12, P439, DOI 10.1002/(SICI)1097-0061(199604)12:5<439::AID-YEA925>3.3.CO;2-N; TERSCHURE EG, 1995, MICROBIOL-UK, V141, P1101, DOI 10.1099/13500872-141-5-1101; THEVELEIN JM, 1992, ANTON LEEUW INT J G, V62, P109, DOI 10.1007/BF00584466; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; Thevenod-Fosse P., 1991, J SOFTWARE TESTING V, V1, P5; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; VANDIJKEN JP, 1986, FEMS MICROBIOL LETT, V32, P199, DOI 10.1016/0378-1097(86)90291-0; WALSH MC, 1994, J BACTERIOL, V176, P953, DOI 10.1128/JB.176.4.953-958.1994; WENDELL DL, 1993, J BACTERIOL, V175, P7689, DOI 10.1128/JB.175.23.7689-7696.1993; WEUSTHUIS RA, 1994, MICROBIOL REV, V58, P616, DOI 10.1128/MMBR.58.4.616-630.1994	39	75	77	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24102	24107		10.1074/jbc.273.37.24102	http://dx.doi.org/10.1074/jbc.273.37.24102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727030	hybrid			2022-12-25	WOS:000075893100071
J	Reha-Krantz, LJ; Marquez, LA; Elisseeva, E; Baker, RP; Bloom, LB; Dunford, HB; Goodman, MF				Reha-Krantz, LJ; Marquez, LA; Elisseeva, E; Baker, RP; Bloom, LB; Dunford, HB; Goodman, MF			The proofreading pathway of bacteriophage T4 DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; 3'->5'-EXONUCLEASE ACTIVITY; REPLICATION FIDELITY; BIOCHEMICAL BASIS; MUTATOR; ANTIMUTATOR; DYNAMICS	The base analog, 2-aminopurine (2AP), was used as a fluorescent reporter of the biochemical steps in the proofreading pathway catalyzed by bacteriophage T4 DNA polymerase, "Mutator" DNA polymerases that are defective in different steps in the exonucleolytic proof-reading pathway were studied so that transient changes in fluorescence intensity could be equated with specific reaction steps. The G255S- and D131N-DNA polymerases can hydrolyze DNA, the final step in the proofreading pathway, but the mutator phenotype indicates a defect in one or more steps that prepare the primer-terminus for the cleavage reaction. The hydrolysis-defective D112A/E114A-DNA polymerase was also examined. Fluorescent enzyme-DNA complexes were preformed in the absence of Mg2+, and then rapid mixing, stopped-flow techniques were used to determine the fate of the fluorescent complexes upon the addition of Mg2+. Comparisons of fluorescence intensity changes between the wild type and mutant DNA polymerases were used to model the exonucleolytic proofreading pathway. These studies are consistent with a proofreading pathway in which the protein loop structure that contains residue Gly(255) functions in strand separation and transfer of the primer strand from the polymerase active center to form a preexonuclease complex. Residue Asp(131) acts at a later step in formation of the preexonuclease complex.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Univ Alberta, Dept Chem, Edmonton, AB, Canada; Univ So Calif, Dept Biol Sci, Mol Biol Sect, Los Angeles, CA 90089 USA	University of Alberta; Arizona State University; Arizona State University-Tempe; University of Alberta; University of Southern California	Reha-Krantz, LJ (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.		Bloom, Linda B/F-3684-2014; Marquez-Curtis, Leah A/M-7152-2015; Reha-Krantz, Linda/A-3748-2014	Marquez-Curtis, Leah A/0000-0002-4047-2227; Baker, Rosanna/0000-0002-9970-6278; Reha-Krantz, Linda/0000-0003-4497-423X				BAKER R, 1996, THESIS U ALBERTA; Baker RP, 1998, P NATL ACAD SCI USA, V95, P3507, DOI 10.1073/pnas.95.7.3507; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; Marquez LA, 1996, J BIOL CHEM, V271, P28903, DOI 10.1074/jbc.271.46.28903; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; REDDY MK, 1992, J BIOL CHEM, V267, P14157; Reha-Krantz Linda J., 1994, P307; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; RehaKrantz LJ, 1995, METHOD ENZYMOL, V262, P323; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r	21	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22969	22976		10.1074/jbc.273.36.22969	http://dx.doi.org/10.1074/jbc.273.36.22969			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722519	hybrid			2022-12-25	WOS:000075778100019
J	Zhao, J; Renner, O; Wightman, L; Sugden, PH; Stewart, L; Miller, AD; Latchman, DS; Marber, MS				Zhao, J; Renner, O; Wightman, L; Sugden, PH; Stewart, L; Miller, AD; Latchman, DS; Marber, MS			The expression of constitutively active isotypes of protein kinase C to investigate preconditioning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; ISCHEMIA; RAT; ACTIVATION; HEART; CARDIOPROTECTION; CARDIOMYOCYTES; PROMOTER; INJURY	The role of protein kinase C (PKC) in ischemic preconditioning remains controversial because of difficulties with both its measurement and pharmacological manipulation. We investigated preconditioning in isolated neonatal rat cardiocytes by expressing constitutively active isotypes of PKC. Observations at differing durations of simulated ischemia suggested beta-galactosidase (beta-gal) activity reflected viability within transfected myocytes, Preconditioning with 90 min of ischemia significantly increased beta-gal activity and myocyte survival after 6 h of ischemia; an effect abolished by PKC inhibitors. After co-transfection with plasmids encoding beta-gal and either constitutively active mutants of PKC-delta, PKC-alpha, wild type PKC-delta, or empty vector, cardiocytes were subjected to 6 h of ischemia, Only PKC-delta, rendered constitutively active by a limited deletion within the pseudosubstrate domain, consistently increased resistance to simulated ischemia (beta-gal activity was 85.6 +/- 11.9% versus 53.7 +/- 6.5% (p less than or equal to 0.01) and dead myocytes 46.8 +/- 3.4% versus 68.7 +/- 2.8% (p less than or equal to 0.01)). Since transfection was apparent in only 5-12% of cells, the results suggested a protective bystander effect that was confirmed by co-culture of transfected myocytes with untransfected myocytes, In neonatal cardiocytes expression of active PKC-delta increases resistance to simulated ischemia. This observation may provide further insight into the mechanism and possible avenues for therapeutic exploitation of preconditioning.	United Med & Dent Sch Guys & St Thomass Hosp, St Thomas Hosp, Dept Cardiol, London SE1 7EH, England; Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW3 6LY, England; UCL, Sch Med, Dept Mol Pathol, London W1P 6DB, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London; University of London; University College London; UCL Medical School	Marber, MS (corresponding author), United Med & Dent Sch Guys & St Thomass Hosp, St Thomas Hosp, Dept Cardiol, London SE1 7EH, England.	m.marber@rayne.umds.ac.uk	marber, michael/AAW-7916-2021; Miller, Andrew/G-8291-2019; Renner, Oliver/M-7002-2015	Miller, Andrew/0000-0003-0661-249X; Renner, Oliver/0000-0002-4046-0517; Zhao, Jing/0000-0002-8140-3658	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; ARMSTRONG S, 1994, CARDIOVASC RES, V28, P1700, DOI 10.1093/cvr/28.11.1700; ARSTALL MA, 1996, CIRCULATION S1, V94, P423; BROOKS G, 1991, CANCER RES, V51, P3281; Brooks G, 1996, CIRC RES, V79, P627; COHEN MV, 1994, CIRC RES, V74, P998, DOI 10.1161/01.RES.74.5.998; COHEN MV, 1993, LANCET, V341, P6; Cumming DVE, 1996, J MOL CELL CARDIOL, V28, P2343, DOI 10.1006/jmcc.1996.0227; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GHO BCG, 1996, CIRCULATION S1, V94, P392; GORMAN C, 1995, DNA CLONING, P143; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; IKONOMIDIS JS, 1996, ISCHAEMIA PRECONDITI, P131; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KAWAMURA S, 1996, CIRCULATION S1, V94, P392; Kitakaze M, 1996, CIRCULATION, V93, P781, DOI 10.1161/01.CIR.93.4.781; KONING MMG, 1994, ANN NY ACAD SCI, V723, P333, DOI 10.1111/j.1749-6632.1994.tb36739.x; LI YW, 1995, AM J PHYSIOL-HEART C, V268, pH426, DOI 10.1152/ajpheart.1995.268.1.H426; Light PE, 1996, CIRC RES, V79, P399, DOI 10.1161/01.RES.79.3.399; Liu YG, 1996, CIRC RES, V78, P443, DOI 10.1161/01.RES.78.3.443; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MITCHELL MB, 1995, CIRC RES, V76, P73, DOI 10.1161/01.RES.76.1.73; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRZYKLENK K, 1995, BRIT HEART J, V74, P575; SPEECHLYDICK ME, 1994, CIRC RES, V75, P586, DOI 10.1161/01.RES.75.3.586; SUGDEN PH, 1995, CARDIOVASC RES, V30, P478, DOI 10.1016/S0008-6363(95)00096-8; Vahlhaus C, 1996, CIRC RES, V79, P407, DOI 10.1161/01.RES.79.3.407; VANWINKLE DM, 1991, CORONARY ARTERY DIS, V2, P613; VANWYLEN DGL, 1994, CIRCULATION, V89, P2283, DOI 10.1161/01.CIR.89.5.2283; WALL TM, 1994, J PHARMACOL EXP THER, V270, P681; WEBSTER KA, 1995, J MOL CELL CARDIOL, V27, P453, DOI 10.1016/S0022-2828(08)80041-7; ZHAO J, 1997, CIRCULATION, V96, P450	36	87	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23072	23079		10.1074/jbc.273.36.23072	http://dx.doi.org/10.1074/jbc.273.36.23072			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722533	hybrid			2022-12-25	WOS:000075778100033
J	Muthusamy, N; Leiden, JM				Muthusamy, N; Leiden, JM			A protein kinase C-, Ras-, and RSK2-dependent signal transduction pathway activates the cAMP-responsive element-binding protein transcription factor following T cell receptor engagement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; ANTIGEN RECEPTOR; FACTOR CREB; FOS TRANSCRIPTION; NUCLEAR FACTOR; PHOSPHORYLATION; GENE; LYMPHOCYTES; INDUCTION; EXPRESSION	The cAMP-responsive element-binding protein (CREB) transcription factor is required for normal T cell activation following stimulation through the T cell antigen receptor (TCR), CREB is present in resting T cells in an unphosphorylated and inactive state, TCR engagement results in the rapid phosphorylation of CREB on Ser(133) and its concomitant activation. In the studies described in this report, we have investigated the signaling pathway(s) that are responsible for CREB activation in normal T cells. Using pharmacological agonists, we show that protein kinase C (PKC)-, calcium/calmodulin-, and protein kinase A-dependent pathways are each capable of independently eliciting CREB phosphorylation in T cells and thymocytes, Pharmacological inhibitor studies demonstrated that the PKC-mediated signaling pathway is required for TCR-mediated activation of CREB, In contrast, inhibitors of protein kinase A and calmodulin kinases had no effect on CREB phosphorylation following TCR cross-linking, T cells lacking the p56(lck) tyrosine kinase failed to phosphorylate CREB in response to TCR engagement. Overexpression of dominant-negative mutant Ras and Raf-1 proteins in Jurkat T cells abolished TCR-mediated CREB phosphorylation, whereas overexpression of the RSK2 serine/threonine kinase significantly potentiated TCR-mediated CREB phosphorylation. Taken together, these experiments are consistent with a model in which TCR engagement leads to the rapid phosphorylation and activation of CREB via a signaling pathway involving the activation of p56(lck), PKC, Ras, Raf-1, MEK, and RSK2, Given the importance of CREB phosphorylation in normal T cell activation, this pathway may be an attractive target for the development of novel immunosuppressive agents.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Leiden, JM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.		Muthusamy, Natarajan/A-6915-2009		NIAID NIH HHS [AI29673] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029673, R37AI029673] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIN AR, 1993, CELL IMMUNOL, V152, P422, DOI 10.1006/cimm.1993.1302; ANDREW DP, 1995, J IMMUNOL, V155, P1671; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BLEMIS J, 1993, P NATL ACAD SCI USA, V90, P5889; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHULAK C, 1995, BRIT J PHARMACOL, V115, P330, DOI 10.1111/j.1476-5381.1995.tb15881.x; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; ENSLEN H, 1995, J BIOL CHEM, V270, P1038; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; OFIR R, 1991, GENE EXPRESSION, V1, P55; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; TANG SH, 1995, MOL PHARMACOL, V47, P863; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOLLBERG P, 1994, J BIOL CHEM, V269, P19719; WOODROW MA, 1993, J IMMUNOL, V150, P3853; WOTTON D, 1993, J BIOL CHEM, V268, P17975; XIE HJ, 1993, J IMMUNOL, V151, P880; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	43	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22841	22847		10.1074/jbc.273.35.22841	http://dx.doi.org/10.1074/jbc.273.35.22841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712919	hybrid			2022-12-25	WOS:000075616600095
J	Cheung, B; Hocker, JE; Smith, SA; Norris, MD; Haber, M; Marshall, GM				Cheung, B; Hocker, JE; Smith, SA; Norris, MD; Haber, M; Marshall, GM			Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation	ONCOGENE			English	Article						retinoic acid receptor beta; neuroblastoma; cell cycle; p21; prognosis	HUMAN LUNG-CANCER; RESISTANCE-ASSOCIATED PROTEIN; BINDING-PROTEINS; RAR-ALPHA; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL PATTERN; UP-REGULATION; GENE; GROWTH; LINES	We have previously shown that ectopic overexpression of retinoic acid receptor (RAR) subtypes alpha, beta and gamma in human neuroblastoma cells had different effects on growth and retinoid sensitivity. Only overexpressed RAR beta induced profound growth inhibition in the absence of additional retinoid, and increased retinoid sensitivity. In this study, we measured mRNA expression levels of RAR alpha, beta, and gamma in 50 primary neuroblastoma tumor samples, and found a strong correlation between favorable patient prognosis and high-level RAR beta expression. Human neuroblastoma cells transfected with a vector expressing RARE demonstrated irreversible growth arrest following a 1 week exposure to all-trans-retinoic acid, whereas control cells continued to proliferate. In the absence of additional retinoid, RAR beta transfectants demonstrated a higher proportion of cells in the G(0)/G(1) phase of the cell cycle, increased p21(WAF1/CIP1) expression and specific binding to a retinoic acid response element. These were changes which we also observed in control neuroblastoma cells following retinoid treatment. Our data indicate that RAR beta is an important factor mediating the growth inhibitory effects of retinoids in neuroblastoma cells. The favorable effect of high-le vel RARE expression on prognosis in primary tumor tissue may occur through RAR beta effects on p21(WAF1/CIP1) expression and consequent G(0)/G(1) cell cycle arrest.	Sydney Childrens Hosp, Childrens Canc Inst Australia, Randwick, NSW 2031, Australia	Children's Cancer Institute	Marshall, GM (corresponding author), Sydney Childrens Hosp, Childrens Canc Inst Australia, High St, Randwick, NSW 2031, Australia.			Norris, Murray/0000-0002-0632-4589; Haber, Michelle/0000-0003-2036-8817; Cheung, Belamy/0000-0001-8784-860X				Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BORDOW SB, 1994, CANCER RES, V54, P5036; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; Brodeur Garrett M., 1997, P761; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheung B, 1996, BIOCHEM BIOPH RES CO, V229, P349, DOI 10.1006/bbrc.1996.1804; CLAGETTDAME M, 1993, ARCH BIOCHEM BIOPHYS, V300, P684, DOI 10.1006/abbi.1993.1095; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GEBERT JF, 1991, ONCOGENE, V6, P1859; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KIM YH, 1995, CANCER RES, V55, P5603; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LUI Y, 1996, MOL CELL BIOL, V16, P1138; MACMILLAN RW, 1976, J PEDIATR SURG, V11, P461, DOI 10.1016/S0022-3468(76)80204-7; Mangelsdorf David J., 1994, P319; Manshouri T, 1997, BLOOD, V89, P2507, DOI 10.1182/blood.V89.7.2507; MARSHALL GM, 1995, ONCOGENE, V11, P485; MARSHALL GM, 1994, ANTICANCER RES, V13, P437; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; MORRISSKAY G, 1991, SEMINARS DEV BIOL, V2, P211; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; ROUSSELOT P, 1994, ONCOGENE, V9, P545; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615; ZHANG XK, 1994, CANCER RES, V54, P5663	49	50	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					751	759		10.1038/sj.onc.1201982	http://dx.doi.org/10.1038/sj.onc.1201982			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715277				2022-12-25	WOS:000075337200010
J	Tanaka, Y; Fujii, M; Hayashi, K; Chiba, N; Akaishi, T; Shineha, R; Nishihira, T; Satomi, S; Ito, Y; Watanabe, T; Satake, M				Tanaka, Y; Fujii, M; Hayashi, K; Chiba, N; Akaishi, T; Shineha, R; Nishihira, T; Satomi, S; Ito, Y; Watanabe, T; Satake, M			The chimeric protein, PEBP2 beta/CBF beta-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation	ONCOGENE			English	Article						PEBP2 beta/CBF beta; chimeric gene; acute myeloid leukemia; stress fibers; immunocytochemistry; transcription factor	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; BINDING-FACTOR-BETA; DNA-BINDING; FUSION TRANSCRIPT; AML1 GENE; SUBCELLULAR-LOCALIZATION	The chromosomal inversion 16(p13;q22) associated with human acute myeloid leukemia generates the chimeric PEBP2 beta/CBF beta-SMMHC gene. The PEBP2 beta/CBF beta portion of the chimeric polypeptide harbors most of the amino acid sequence of the PEBP2 beta/CBF beta protein, the non-DNA. binding subunit of the heterodimeric transcription factor, PEBP2/CBF, whereas the SMMHC portion of the chimera consists of the rod domain of the smooth muscle myosin heavy chain molecule. In this study we examined the subcellular localization of the chimeric protein land its effect both on stress fibers and transcriptional activation by transfecting cDNA into tissue culture cells. The localization of the chimera was investigated by immunocytochemical staining of cells and was found to be both cytoplasmic and nuclear, One aspect of the effect of expression of the chimera was a drastic alteration of cell morphology, The cells appeared elongated and possessed long cytoplasmic processes. Double fluorescent labeling revealed disorganization of the stress fibers and an altered F-actin staining pattern in the transfected cells. Studies using a deletion mutant showed that both the PEBP2 beta/CBF beta and SMMHC domains are necessary for the induction of the morphological alteration, A significant proportion of the chimeric protein was retained in the cytoskeleton after detergent extraction of the cells and could be recuperated as a membrane fraction, suggesting that this is one of the probable sites of action of the PEBP2 beta/CBF beta-SMMHC protein. Another effect of the chimeric protein was inhibition of transcriptional activation dependent on the PEBP2/CBF binding DNA sequence. However, deregulation of PEBP2/CBF site dependent transcription by itself was not sufficient to induce cell morphological changes. Taken together, these results indicate that the PEBP2 beta/CBF beta-SMMHC chimeric protein acts at two levels, at the level of stress fiber organization and at the level of transcriptional activation. We suggest that the action of PEBP2 beta/CBF beta-SMMHC depends to a great extent on whether it is located in the cytoplasm or in the nucleus.	Tohoku Univ, Sch Med, Dept Surg 2, Aoba Ku, Sendai, Miyagi 98077, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 60601, Japan; Tohoku Univ, Dept Mol Immunol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 98077, Japan	Tohoku University; Kyoto University; Tohoku University	Satake, M (corresponding author), Tohoku Univ, Dept Mol Immunol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 98077, Japan.							Aelst L, 1997, GENE DEV, V11, P2295; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; CLAXTON DF, 1994, BLOOD, V83, P1750; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; LENNY N, 1995, ONCOGENE, V11, P1761; Leung T, 1996, MOL CELL BIOL, V16, P5313; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; LU J, 1995, MOL CELL BIOL, V15, P1651; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sacchi N, 1996, ONCOGENE, V12, P437; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SALGIA R, 1995, ONCOGENE, V11, P1149; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; YANAGISAWA K, 1991, BLOOD, V78, P451; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	55	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					699	708		10.1038/sj.onc.1201985	http://dx.doi.org/10.1038/sj.onc.1201985			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715271				2022-12-25	WOS:000075337200004
J	Tibbs, VC; Gray, PC; Catterall, WK; Murphy, BJ				Tibbs, VC; Gray, PC; Catterall, WK; Murphy, BJ			AKAP15 anchors cAMP-dependent protein kinase to brain sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; SOMATIC-CELL LINE; RAT-BRAIN; ALPHA-SUBUNIT; SELECTIVE PHOSPHORYLATION; HIPPOCAMPAL-NEURONS; XENOPUS-OOCYTES; IDENTIFICATION; MODULATION; EXPRESSION	The voltage-sensitive sodium channel is regulated by cAMP-dependent protein kinase (PKA) phosphorylation, Using purified preparations of rat brain sodium channels, we have shown that the cu subunit was phosphorylated by a co-purifying protein kinase, The copurifying kinase was stimulated by cAMP and phosphorylated PKA substrate peptides, Both the regulatory and catalytic subunits of PKA were detected by immunoblotting in purified sodium channel preparations. Bound PKA was immunoprecipitated with anti-SP19 antibodies directed against the sodium channel alpha subunit, PKA bound to sodium channels phosphorylated the sodium channel alpha subunit on the same four serine residues as observed with exogenously added PKA, indicating that association with the sodium channel does not restrict the sites of phosphorylation, Analysis of proteins with high affinity for the type II alpha regulatory subunit of PKA in a gel overlay assay identified a 15-kDa cAMP-dependent protein kinase-anchoring protein (AKAP) in these preparations. Determination of its amino acid sequence by mass spectrometry revealed two peptides identical to AKAP15, a recently described AKAP that targets PKA to skeletal muscle calcium channels. The co-purifying AKAP was also immunoreactive with antibodies generated against AKAP15, and antibodies directed against AKAP15 co-immunoprecipitated the sodium channel. Our results indicate that PKA is bound to brain sodium channels through interaction with AKAP15, Association of AKAP1B with both skeletal muscle calcium channels and brain sodium channels suggests that it may have broad specificity in targeting PKA to ion channels for regulation.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, WK (corresponding author), Univ Washington, Dept Pharmacol, Mailstop 357280, Seattle, WA 98195 USA.				NINDS NIH HHS [NS07332, NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; Cantrell AR, 1997, J NEUROSCI, V17, P7330; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; Murphy BJ, 1998, TRENDS CARDIOVAS MED, V8, P89, DOI 10.1016/S1050-1738(97)00131-X; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smith RD, 1996, J NEUROSCI, V16, P1965; Smith RD, 1997, J NEUROSCI, V17, P6086; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016	34	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25783	25788		10.1074/jbc.273.40.25783	http://dx.doi.org/10.1074/jbc.273.40.25783			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748250	hybrid			2022-12-25	WOS:000076263100041
J	Jones, AT; Wessling-Resnick, M				Jones, AT; Wessling-Resnick, M			Inhibition of in vitro endosomal vesicle fusion activity by aminoglycoside antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHOLIPASE-D ACTIVITY; GTP-BINDING PROTEIN; LYSOSOMAL PHOSPHOLIPASES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GOLGI MEMBRANES; ACIDIC PHOSPHOLIPIDS; DEPENDENT FORMATION; PHOSPHATIDIC-ACID; COATED VESICLES	The effects of two aminoglycoside antibiotics, neomycin and Geneticin, on the endocytic pathway were studied using a cell-free assay that reconstitutes endosome-endosome fusion, Both drugs inhibit the rate and extent of endosome fusion in a dose-dependent manner with IC50 values of similar to 45 mu M and similar to 1 mM, respectively. Because the IC50 for neomycin falls within the range of affinities reported for its binding to acidic phospholipids, notably phosphatidylinositol 4,5-bisphosphate (PIP2), these data suggest that negatively charged lipids are required for endosome fusion. A role for negatively charged lipids in membrane traffic has been postulated to involve the activity of a PIP2-dependent phospholipase D (PLD) stimulated by the GTP-binding protein ADP-ribosylation factor (ARF). Although neomycin blocks endosome fusion at a stage of the in vitro reaction that is temporally related to steps inhibited by cytosolic ARFs when they bind guanosine-5'-gamma-thiophosphate (GTP gamma S), these inhibitors appear to act in a synergistic manner. This idea is confirmed by the fact that addition of a PIP2-independent PLD does not suppress neomycin inhibition of endosome fusion; moreover, in vitro fusion activity is not affected by the pleckstrin homology domain of phosphoinositide-specific phospholipase C delta 1, which binds to acidic phospholipids, particularly PIP2, with high affinity. Thus, although aminoglycoside-sensitive elements of endosome fusion are required at mechanistic stages that are also blocked by GTP gamma S-bound ARF, these effects are unrelated to inhibition of the PIP2-dependent PLD activity stimulated by this GTP-binding protein. These results argue that there are additional mechanistic roles for acidic phospholipids in the endosomal pathway.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Wessling-Resnick, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	wessling@hsph.harvard.edu	Jones, Arwyn T/E-4787-2010; Jones, Arwyn/ABE-8709-2020	Jones, Arwyn T/0000-0003-2781-8905; Jones, Arwyn/0000-0003-2781-8905				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BENNETT WM, 1983, NEPHRON, V35, P73, DOI 10.1159/000183050; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DANIN M, 1993, LIPID METABOLISM SIG, P14; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; GIURGEAMARION L, 1986, TOXICOL APPL PHARM, V86, P271, DOI 10.1016/0041-008X(86)90058-X; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond TG, 1997, AM J PHYSIOL-RENAL, V272, pF117, DOI 10.1152/ajprenal.1997.272.1.F117; HOSTETLER KY, 1982, P NATL ACAD SCI-BIOL, V79, P1663, DOI 10.1073/pnas.79.5.1663; Hudson RT, 1997, MOL BIOL CELL, V8, P1901, DOI 10.1091/mbc.8.10.1901; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones AT, 1997, BIOCHEM BIOPH RES CO, V236, P285, DOI 10.1006/bbrc.1997.6962; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KISHORE BK, 1990, J PHARMACOL EXP THER, V255, P867; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MIGNEOTLECLERCQ MP, 1995, J TOXICOL ENV HLTH, V44, P263; MINGEOTLECLERCQ MP, 1990, BIOCHEM PHARMACOL, V40, P499, DOI 10.1016/0006-2952(90)90548-Y; MINGEOTLECLERCQ MP, 1988, BIOCHEM PHARMACOL, V37, P591, DOI 10.1016/0006-2952(88)90130-X; MINGEOTLECLERCQ MP, 1990, BIOCHEM PHARMACOL, V40, P489, DOI 10.1016/0006-2952(90)90547-X; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; MORITZ A, 1992, J BIOL CHEM, V267, P7207; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SCHACHT J, 1978, J LIPID RES, V19, P1063; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; SPIRO DJ, 1995, J BIOL CHEM, V270, P13693, DOI 10.1074/jbc.270.23.13693; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; WEINSTEIN L, 1965, PHARM BASIC THERAPEU, P1274; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; WHATMORE J, 1994, FEBS LETT, V352, P113, DOI 10.1016/0014-5793(94)00930-9; WHITNEY JA, 1995, CELL, V83, P703; WILLIAMS SE, 1986, J ANTIBIOT, V39, P457, DOI 10.7164/antibiotics.39.457; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001	56	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25301	25309		10.1074/jbc.273.39.25301	http://dx.doi.org/10.1074/jbc.273.39.25301			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737996	hybrid			2022-12-25	WOS:000076085400046
J	Echtay, KS; Bienengraeber, M; Winkler, E; Klingenberg, M				Echtay, KS; Bienengraeber, M; Winkler, E; Klingenberg, M			In the uncoupling protein (UCP-1) His-214 is involved in the regulation of purine nucleoside triphosphate but not diphosphate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; NUCLEOTIDE-BINDING; CHEMICAL MODIFICATION; FATTY-ACIDS; HISTIDINE-RESIDUES; MITOCHONDRIA; PH; KINETICS; MECHANISMS; CARRIER	The nucleotide binding to uncoupling protein (UCP-1) of brown adipose tissue is regulated by pH, The binding pocket of the nucleotide phosphate moiety has been pro posed to be controlled by the protonization of a carboxyl group (pK approximate to 4.5) for both nucleoside diphosphates (NDP) and nucleoside triphosphates (NTP) (identified as Glu-190) and of a histidine (pK approximate to 7.2) for NTP only. Here we identify His-214 as a pH sensor specific for NTP binding only. In reconstituted UCP-1 from hamster, DEPC diminishes binding of NTP but not of NDP, It also prevents inhibition of H+ transport by NTP but not by NDP, Hamster UCP-1 expressed in Saccharomyces cerevisiae was mutated to H214N resulting in only moderate change of the binding affinity for NTP (GTP) but a 10-fold affinity decrease with the bulkier substituent in H214W, whereas the affinity for NDP (ADP) was largely unchanged. The steep decrease with pH of the binding affinity for NTP in wild type (from pH 6.0 to 7.5) was much flatter in the mutants. Also, the pH dependence of binding and dissociation rates was diminished in these mutants. The transport of H+ and Cl- was not affected. Thus, His-214 is only involved in nucleotide binding, whereas, as previously shown, His-145 and His-147 are involved only in H+ transport. The results validate the earlier proposal of a histidine regulating the NTP binding in addition to a carboxyl group controlling both NTP and NDP binding. It is proposed that His-214 protrudes into the binding pocket for the gamma-phosphate thus inhibiting NTP binding and that His214H(+) is retracted by a background -CO2- group to give way for the gamma-phosphate.	Univ Munich, Inst Phys Biochem, D-80336 Munich, Germany	University of Munich	Klingenberg, M (corresponding author), Univ Munich, Inst Phys Biochem, Schillerstr 44, D-80336 Munich, Germany.	klingenberg@pbm.med.uni-muenchen.de						Bienengraeber M, 1998, BIOCHEMISTRY-US, V37, P3, DOI 10.1021/bi972463w; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bragg PD, 1996, EUR J BIOCHEM, V241, P611, DOI 10.1111/j.1432-1033.1996.00611.x; Brandsch M, 1997, BBA-BIOMEMBRANES, V1324, P251, DOI 10.1016/S0005-2736(96)00231-3; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; Echtay KS, 1997, BIOCHEMISTRY-US, V36, P8253, DOI 10.1021/bi970513r; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; HUANG SG, 1995, EUR J BIOCHEM, V229, P718, DOI 10.1111/j.1432-1033.1995.tb20519.x; HUANG SG, 1995, BIOCHEMISTRY-US, V34, P349, DOI 10.1021/bi00001a043; Huang SG, 1996, BIOCHEMISTRY-US, V35, P7846, DOI 10.1021/bi960244p; Huang SG, 1998, J BIOL CHEM, V273, P859, DOI 10.1074/jbc.273.2.859; Klingenberg M, 1995, METHOD ENZYMOL, V260, P369, DOI 10.1016/0076-6879(95)60151-1; KLINGENBERG M, 1984, BIOCHEM SOC T, V12, P390, DOI 10.1042/bst0120390; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V21, P2950; KOPECKY J, 1987, EUR J BIOCHEM, V164, P687, DOI 10.1111/j.1432-1033.1987.tb11181.x; LANOUE KF, 1986, J BIOL CHEM, V261, P298; LANOUE KF, 1982, J BIOL CHEM, V257, P13740; Lim JS, 1996, FEBS LETT, V381, P188, DOI 10.1016/0014-5793(96)00124-X; LIN CS, 1980, FEBS LETT, V113, P299, DOI 10.1016/0014-5793(80)80613-2; Miles E W, 1977, Methods Enzymol, V47, P431; Modriansky M, 1997, J BIOL CHEM, V272, P24759, DOI 10.1074/jbc.272.40.24759; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; RIAL E, 1986, EUR J BIOCHEM, V161, P689, DOI 10.1111/j.1432-1033.1986.tb10494.x; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; SOBOLL S, 1984, EUR J BIOCHEM, V141, P231, DOI 10.1111/j.1432-1033.1984.tb08180.x; VERKMAN AS, 1989, BIOCHEMISTRY-US, V28, P4240, DOI 10.1021/bi00436a018; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x	30	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24368	24374		10.1074/jbc.273.38.24368	http://dx.doi.org/10.1074/jbc.273.38.24368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733725	hybrid			2022-12-25	WOS:000076007300017
J	Ouyang, YB; Moore, KL				Ouyang, YB; Moore, KL			Molecular cloning and expression of human and mouse tyrosylprotein sulfotransferase-8 and a tyrosylprotein sulfotransferase homologue in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EFFICIENT THROMBIN CLEAVAGE; VON-WILLEBRAND-FACTOR; TYROSINE SULFATION; FACTOR-VIII; HUMAN-COMPLEMENT; 4TH COMPONENT; P-SELECTIN; FACTOR-V; RESIDUES; IDENTIFICATION	Tyrosine O-sulfation, a common post-translational modification in eukaryotes, is mediated by Gels enzymes that catalyze the transfer of the sulfuryl group from 3'-phosphoadenosine 5'-phosphosulfate to tyrosine residues in polypeptides. We recently isolated cDNAs encoding human and mouse tyrosylprotein sulfotransferase-l (Ouyang, Y. B., Lane, W. S., and Moore, K. L. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2896-2901). Here we report the isolation of cDNAs encoding a second tyrosylprotein sulfotransferase (TPST), designated TPST-2. The human and mouse TPST-2 cDNAs predict type II transmembrane proteins of 377 and 376 amino acid residues, respectively. The cDNAs encode functional N-glycosylated enzymes when expressed in mammalian cells. In addition, preliminary analysis indicates that TPST-1 and TPST-2 have distinct specificities toward peptide substrates. The human TPST-2 gene is on chromosome 22q12.1, and the mouse gene is in the central region of chromosome 5. We have also identified a cDNA that encodes a TPST in the nematode Caenorhabditis elegans that maps to the right arm of chromosome III. Thus, we have identified two new members of a class of membrane-bound sulfotransferases that catalyze tyrosine O-sulfation. These enzymes may catalyze tyrosine O-sulfation of a variety of protein substrates involved in diverse physiologic functions.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Moore, KL (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13Th St,Mailstop 45, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL053602] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53602] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Ferrari S, 1996, GENOMICS, V35, P367, DOI 10.1006/geno.1996.0369; FESSLER LI, 1986, EUR J BIOCHEM, V158, P511, DOI 10.1111/j.1432-1033.1986.tb09784.x; HORTIN G, 1986, J BIOL CHEM, V261, P1786; HORTIN G, 1987, J BIOL CHEM, V262, P3082; HORTIN G, 1986, J BIOL CHEM, V261, P5827; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; HORTIN GL, 1990, BLOOD, V76, P946; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JENNE D, 1989, EUR J BIOCHEM, V185, P391, DOI 10.1111/j.1432-1033.1989.tb15127.x; JUKKOLA A, 1990, BIOCHEM BIOPH RES CO, V170, P264, DOI 10.1016/0006-291X(90)91269-X; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIU MC, 1985, P NATL ACAD SCI USA, V82, P34, DOI 10.1073/pnas.82.1.34; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; NIEHRS C, 1994, CHEM-BIOL INTERACT, V92, P257, DOI 10.1016/0009-2797(94)90068-X; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; RENSDOMIANO S, 1989, J BIOL CHEM, V264, P899; ROSA P, 1992, J BIOL CHEM, V267, P12227; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUIKO M, 1988, BIOCHEM BIOPH RES CO, V154, P1094, DOI 10.1016/0006-291X(88)90253-7; WATERSTON R, 1993, COLD SPRING HARB SYM, V58, P367, DOI 10.1101/SQB.1993.058.01.043; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	38	102	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24770	24774		10.1074/jbc.273.38.24770	http://dx.doi.org/10.1074/jbc.273.38.24770			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733778	hybrid			2022-12-25	WOS:000076007300070
J	Takatsu, H; Sakurai, M; Shin, HW; Murakami, K; Nakayama, K				Takatsu, H; Sakurai, M; Shin, HW; Murakami, K; Nakayama, K			Identification and characterization of novel clathrin adaptor-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; BREFELDIN-A; COMPLEX; EXPRESSION; TRANSPORT; SIGNALS; AP-3; YEAST; ACTIVATORS; SUBUNIT	We have identified a human similar to 87-kDa protein, designated as gamma 2-adaptin, that is similar to gamma-adaptin (called gamma 1-adaptin in this paper), a large chain of the AP-1 clathrin-associated adaptor complex, not only in the primary structure (60% amino acid identity) but also in the domain organization. Northern blot analysis has shown that its mRNA is expressed in a variety of tissues. Analysis using a yeast two-hybrid system has revealed that, similarly to gamma 1-adaptin, gamma 2-adaptin is capable of interacting not only with the sigma 1 chain (called as sigma 1A in this paper), the small chain of the AP-1 complex, but also with a novel sigma 1-like protein, designated as sigma 1B, which shows an 87% amino acid identity to sigma 1A; and that, unlike gamma 1-adaptin, it is unable to interact with beta 1-adaptin, another large chain of the AP-1 complex. Immunofluorescence microscopy analysis has revealed that gamma 2-adaptin is localized to paranuclear vesicular structures that are not superimposed on structures containing gamma 1-adaptin. Furthermore, unlike gamma 1-adaptin, gamma 2-adaptin is recruited onto membranes in the presence of a fungal antibiotic, brefeldin A. These data suggest that gamma 2-adaptin constitute a novel adaptor-related complex that participates in a transport step different from that of AP-1.	Univ Tsukuba, Inst Biol Sci, Tsukuba Sci City, Ibaraki 3058572, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba Sci City, Ibaraki 3058572, Japan; Univ Tsukuba, Gene Expt Ctr, Tsukuba Sci City, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba	Nakayama, K (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba Sci City, Ibaraki 3058572, Japan.		Shin, Hye-Won/P-5398-2018; Nakayama, Kazuhisa/ABF-2924-2020	Shin, Hye-Won/0000-0002-9138-9554; Nakayama, Kazuhisa/0000-0001-7701-7183				AKASAKI K, 1995, EXP CELL RES, V220, P464, DOI 10.1006/excr.1995.1338; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Harter C, 1996, BBA-REV BIOMEMBRANES, V1286, P75, DOI 10.1016/0304-4157(96)00003-2; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HORN M, 1994, BIOCHEM J, V301, P69, DOI 10.1042/bj3010069; HOSAKA M, 1994, BIOMED RES-TOKYO, V15, P383, DOI 10.2220/biomedres.15.383; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; Keller P, 1997, J CELL SCI, V110, P3001; KIRCHHAUSEN T, 1991, J BIOL CHEM, V266, P11153; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Ooi CE, 1997, EMBO J, V16, P4508; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; Shin HW, 1997, J BIOCHEM-TOKYO, V122, P525; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574	31	63	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24693	24700		10.1074/jbc.273.38.24693	http://dx.doi.org/10.1074/jbc.273.38.24693			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733768	hybrid			2022-12-25	WOS:000076007300060
J	Derst, C; Wischmeyer, E; Preisig-Muller, R; Spauschus, A; Konrad, M; Hensen, P; Jeck, N; Seyberth, HW; Daut, J; Karschin, A				Derst, C; Wischmeyer, E; Preisig-Muller, R; Spauschus, A; Konrad, M; Hensen, P; Jeck, N; Seyberth, HW; Daut, J; Karschin, A			A hyperprostaglandin E syndrome mutation in Kir1.1 (renal outer medullary potassium) channels reveals a crucial residue for channel function in Kir1.3 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INWARD-RECTIFIER; K+-CHANNEL; BARTTERS-SYNDROME; CLONING; EXPRESSION; PROTEIN; BRAIN; HYPERCALCIURIA; CHROMOSOME-21; HETEROGENEITY	Loss of function mutations in kidney Kir1.1 (renal outer medullary potassium channel, KCNJ1) inwardly rectifying, potassium channels can be found in patients suffering from hyperprostaglandin E syndrome (HPS), the antenatal form of Bartter syndrome. A novel mutation found in a sporadic case substitutes an asparagine by a positively charged lysine residue at amino acid position 124 in the extracellular M1-H5 linker region, When heterologously expressed in Xenopus oocytes and mammalian cells, current amplitudes from mutant Kir1.1a[N124K] channels were reduced by a factor of similar to 12 as compared with wild type, A lysine at the equivalent position is present in only one of the known Kir subunits, the newly identified Kir1.3, which is also poorly expressed in the recombinant system, When the lysine residue in guinea pig Kir1.3 (gpKir1.3) isolated from a genomic library was changed to an asparagine (reverse HPS mutation), mutant channels yielded macroscopic currents with amplitudes increased B-fold, From single channel analysis it became apparent that the decrease in mutant Kir1.1 channels and the increase in mutant gpKir1.3 macroscopic currents were mainly due to the number of expressed functional channels. Coexpression experiments revealed a dominant-negative effect of Kir1.1a[N124K] and gpKir1.3 on macroscopic current amplitudes when coexpressed with wild type Kir1.1a and gpKir[K110N], respectively. Thus we postulate that in Kir1.3 channels the extracellular positively charged lysine is of crucial functional importance. The HPS phenotype in man call be explained by the lower expression of functional channels by the Kir1.1a[N124K] mutant.	Max Planck Inst Biophys Chem, D-37070 Gottingen, Germany; Philipps Univ Marburg, Inst Physiol, D-35033 Marburg, Germany; Philipps Univ Marburg, Dept Pediat, D-35033 Marburg, Germany	Max Planck Society; Philipps University Marburg; Philipps University Marburg	Karschin, A (corresponding author), Max Planck Inst Biophys Chem, Fassberg 11, D-37070 Gottingen, Germany.	akarsch@gwdg.de						BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; BREDT DS, 1995, P NATL ACAD SCI USA, V92, P6753, DOI 10.1073/pnas.92.15.6753; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Derst C, 1997, BIOCHEM BIOPH RES CO, V230, P641, DOI 10.1006/bbrc.1996.6024; Doi T, 1996, J BIOL CHEM, V271, P17261, DOI 10.1074/jbc.271.29.17261; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Gosset P, 1997, GENOMICS, V44, P237, DOI 10.1006/geno.1997.4865; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Karolyi L, 1997, HUM MOL GENET, V6, P17; Kockerling A, 1996, J PEDIATR-US, V129, P519, DOI 10.1016/S0022-3476(96)70116-6; Kubo Y, 1996, J BIOL CHEM, V271, P15729, DOI 10.1074/jbc.271.26.15729; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LANG F, 1992, PHYSIOL REV, V72, P1, DOI 10.1152/physrev.1992.72.1.1; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; NAVARATNAM DS, 1995, J BIOL CHEM, V270, P19238, DOI 10.1074/jbc.270.33.19238; Ohira M, 1997, GENOME RES, V7, P47, DOI 10.1101/gr.7.1.47; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SEYBERTH HW, 1985, J PEDIATR-US, V107, P694, DOI 10.1016/S0022-3476(85)80395-4; SEYBERTH HW, 1997, OXFORD TXB CLIN NEPH, P1085; Shuck ME, 1997, J BIOL CHEM, V272, P586; SHUCK ME, 1994, J BIOL CHEM, V269, P24261; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Spauschus A, 1996, J NEUROSCI, V16, P930; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; Wischmeyer E, 1997, J PHYSIOL-LONDON, V504, P591, DOI 10.1111/j.1469-7793.1997.591bd.x; WISCHMEYER E, 1994, PFLUEGERS ARCH EUR J, V429, P809	36	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23884	23891		10.1074/jbc.273.37.23884	http://dx.doi.org/10.1074/jbc.273.37.23884			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727001	hybrid			2022-12-25	WOS:000075893100042
J	Karavitis, M; Fronticelli, C; Brinigar, WS; Vasquez, GB; Militello, V; Leone, M; Cupane, A				Karavitis, M; Fronticelli, C; Brinigar, WS; Vasquez, GB; Militello, V; Leone, M; Cupane, A			Properties of human hemoglobins with increased polarity in the alpha- or beta-heme pocket - Carbonmonoxy derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; LIGAND-BINDING; INFRARED-SPECTROSCOPY; DISTAL HISTIDINE; FUNCTIONAL-PROPERTIES; RESONANCE RAMAN; BOUND CO; MUTANTS; PROTEINS; SITE	The spectroscopic, conformational, and functional properties of mutant carbonmonoxy hemoglobins in which either the beta-globin Val(67)(Ell) or the alpha-globin Val(62)(Ell) is replaced by threonine have been investigated. The thermal evolution of the Soret absorption band and the stretching frequency of the bound CO were used to probe the stereodynamic propel-ties of the heme pocket. The functional properties mere investigated by kinetic measurements. The spectroscopic and functional data were related to the conformational properties through molecular analysis. The effects of this nonpolar-to-polar isosteric mutation are: (i) increase of heme pocket anharmonic motions, (ii) stabilization of the A(o) conformer in the IR, spectrum, (iii) increased CO dissociation rates. The spectroscopic data indicate that for the carbonmonoxy derivatives, the Val --> Thr mutation has a larger conformational effect on the beta-subunits than on the alpha-subunits. This is at variance with the deoxy derivatives where the conformational modification was larger in the heme pocket of the alpha-subunit (Cupane, A., Leone, Ri., Militello, V,, Friedman, R. K., Koley, A. P,, Vasquez, G. P,, Brinigar, W, S., Kara; vitis, M., and Fronticelli, C. (1997) J. Biol. Chern. 272, 26271-26278), These effects are attributed to a different electrostatic interaction between O-gamma of Thr(E11) and the bound CO molecule. Molecular analysis indicates a more favorable interaction of the bound CO with Thr OY in the beta-subunit heme pocket.	Univ Palermo, Dipartimento Sci Fis & Astron, I-90123 Palermo, Italy; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Temple Univ, Dept Chem, Philadelphia, PA 19122 USA; Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Palermo, Ist Nazl Fis Mat, I-90123 Palermo, Italy	University of Palermo; University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Palermo	Cupane, A (corresponding author), Univ Palermo, Dipartimento Sci Fis & Astron, Via Archirafi 36, I-90123 Palermo, Italy.	cupane@fisica.unipa.it	MILITELLO, VALERIA/F-2664-2011; Leone, Maurizio/F-2353-2010	Leone, Maurizio/0000-0002-0292-7657	NHLBI NIH HHS [HBLBI-48517] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALASUBRAMANIAN S, 1993, P NATL ACAD SCI USA, V90, P4718, DOI 10.1073/pnas.90.10.4718; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BRAUNSTEIN DP, 1993, BIOPHYS J, V65, P2447, DOI 10.1016/S0006-3495(93)81310-9; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CHANEY RH, 1979, J MENT DEFIC RES, V23, P1; CUPANE A, 1995, EUR BIOPHYS J BIOPHY, V23, P385, DOI 10.1007/BF00196825; Cupane A, 1997, J BIOL CHEM, V272, P26271, DOI 10.1074/jbc.272.42.26271; CUPANE A, 1993, EUR BIOPHYS J BIOPHY, V21, P385, DOI 10.1007/BF00185865; DOYLE ML, 1992, BIOCHEMISTRY-US, V31, P8629, DOI 10.1021/bi00151a033; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kushkuley B, 1996, BIOPHYS J, V70, P1214, DOI 10.1016/S0006-3495(96)79680-7; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; MILITELLO V, 1995, PROTEINS, V22, P12, DOI 10.1002/prot.340220103; MOORE EG, 1976, J BIOL CHEM, V251, P2788; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; OLSON JS, 1981, METHOD ENZYMOL, V76, P625; Pechik I, 1996, BIOCHEMISTRY-US, V35, P1935, DOI 10.1021/bi9519967; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; POTTER WT, 1990, BIOCHEMISTRY-US, V29, P6283, DOI 10.1021/bi00478a025; POTTER WT, 1983, BIOCHEM BIOPH RES CO, V116, P719, DOI 10.1016/0006-291X(83)90584-3; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHIMADA H, 1982, J BIOL CHEM, V257, P1893; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Uchida T, 1997, J BIOL CHEM, V272, P30108, DOI 10.1074/jbc.272.48.30108; Vasquez GB, 1998, ACTA CRYSTALLOGR D, V54, P355, DOI 10.1107/S0907444997012250	31	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23740	23749		10.1074/jbc.273.37.23740	http://dx.doi.org/10.1074/jbc.273.37.23740			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726982	hybrid			2022-12-25	WOS:000075893100023
J	Laufs, U; Liao, JK				Laufs, U; Liao, JK			Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY DISEASE; HYPERCHOLESTEROLEMIC HUMANS; MESSENGER-RNA; REDUCTASE; PROTEINS; ATHEROSCLEROSIS; DYSFUNCTION; INHIBITION; EXPRESSION	The mechanism by which 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors increase endothelial nitric oxide synthase (eNOS) expression is unknown. To determine whether changes in isoprenoid synthesis affects eNOS expression, human endothelial cells were treated with the HMG-CoA reductase inhibitor, mevastatin (1-10 mu M), in the presence of L-mevalonate (200 mu M), geranylgeranylpyrophosphate (GGPP, 1-10 mu M), farnesylpyrophosphate (FPP, 5-10 mu M), or low density lipoprotein (LDL, 1 mg/ml). Mevastatin increased eNOS mRNA and protein levels by 305 +/- 15% and 180 +/- 11%, respectively, Go-treatment with L-mevalonate or GGPP, but not FPP or LDL, reversed mevastatin's effects. Because Rho GTPases undergo geranylgeranyl modification, we investigated whether Rho regulates eNOS expression. Immunoblot analyses and [S-35]GTP gamma S-binding assays revealed that mevastatin inhibited Rho membrane translocation and GTP binding activity by 60 +/- 5% and 78 +/- 6%, both of which were reversed by co-treatment with GGPP but not FPP. Furthermore, inhibition of Rho by Clostridium botulinum. C3 transferase (50 mu g/ml) or by overexpression of a dominant-negative N19RhoA mutant increased eNOS expression. In contrast, activation of Rho by Escherichia coli cytotoxic necrotizing factor-1 (200 ng/ml) decreased eNOS expression. These findings indicate that Rho negatively regulates eNOS expression and that HMG-CoA reductase inhibitors up-regulate eNOS expression by blocking Rho geranylgeranylation, which is necessary for its membrane-associated activity.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liao, JK (corresponding author), Dept Med, Div Cardiovasc, 221 Longwood Ave,LMRC-322, Boston, MA 02115 USA.	jliao@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aktories K, 1997, J CLIN INVEST, V100, pS11; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BLUM CB, 1994, AM J CARDIOL, V73, pD3, DOI 10.1016/0002-9149(94)90626-2; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOHL RJ, 1995, J BIOL CHEM, V270, P17508, DOI 10.1074/jbc.270.29.17508; Laufs U, 1997, J BIOL CHEM, V272, P31725, DOI 10.1074/jbc.272.50.31725; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LIAO JK, 1995, J CLIN INVEST, V95, P1457, DOI 10.1172/JCI117816; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1994, J BIOL CHEM, V269, P12987; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; MCLENACHAN JM, 1991, CIRCULATION, V84, P1273, DOI 10.1161/01.CIR.84.3.1273; Nasmyth K, 1997, CURR OPIN CELL BIOL, V9, P396, DOI 10.1016/S0955-0674(97)80013-0; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; PEDERSEN TR, 1994, LANCET, V344, P1383; REDDY KG, 1994, J AM COLL CARDIOL, V23, P833, DOI 10.1016/0735-1097(94)90627-0; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tamai O, 1997, CIRCULATION, V95, P76, DOI 10.1161/01.CIR.95.1.76; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WERNS SW, 1989, CIRCULATION, V79, P287, DOI 10.1161/01.CIR.79.2.287; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	35	891	945	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24266	24271		10.1074/jbc.273.37.24266	http://dx.doi.org/10.1074/jbc.273.37.24266			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727051	hybrid			2022-12-25	WOS:000075893100092
J	Bai, M; Trivedi, S; Brown, EM				Bai, M; Trivedi, S; Brown, EM			Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; M2 MUSCARINIC RECEPTORS; CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION; G-PROTEIN; DE-NOVO; MUTATIONS; GENE; HYPOCALCEMIA	The extracellular calcium (Ca-o(2+))-sensing receptor (CaR) is a G protein-coupled receptor that plays important roles in calcium homeostasis, In this study, we employed epitope tagging, cell-surface biotinylation, and immunoprecipitation techniques to demonstrate that the CaR is expressed mostly in the form of a dimer on the surface of transfected human embryonic kidney (HEK293) cells. Western analysis of cell-surface proteins under nonreducing conditions showed that the CaR exists in several forms with molecular masses greater than 200 kDa, Most of these high molecular mass forms of the receptor could be converted to a single monomeric species at 160 kDa under reducing conditions. This result suggests that the CaR forms dimers or even higher oligomers on the cell surface through intermolecular disulfide bonds that are sensitive to reducing agents. Consistent with this hypothesis, use of a cell-surface cross-linking agent substantially increases the proportion of the putative dimeric CaR at 280 kDa relative to the monomeric form of the receptor at 160 kDa under reducing conditions. Dimerization of the CaR in intact cells was further demonstrated when we co-transfected and co-immunoprecipitated the wild type, full-length receptor and a truncated form of the CaR lacking its cytoplasmic tail. Taken together, we conclude from these results that the functional CaR resides on the cell surface of transfected HEK293 cells in the form of a dimer.	Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bai, M (corresponding author), Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, 221 Longwood Ave, Boston, MA 02115 USA.		Centeno, Patricia Pacios/O-8368-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009436] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09436] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bai M, 1997, J CLIN INVEST, V99, P88, DOI 10.1172/JCI119137; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DeLuca F, 1997, J CLIN ENDOCR METAB, V82, P2710, DOI 10.1210/jc.82.8.2710; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; FAJTOVA VT, 1991, AM J PHYSIOL, V261, pE151, DOI 10.1152/ajpendo.1991.261.1.E151; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERBERG JT, 1984, J BIOL CHEM, V259, P9285; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; POTTER LT, 1991, MOL PHARMACOL, V39, P211; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SCHULZ GE, 1985, PRINCIPLES PROTEIN S, P53; VENTER JC, 1983, FED PROC, V42, P273; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371	29	334	365	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23605	23610		10.1074/jbc.273.36.23605	http://dx.doi.org/10.1074/jbc.273.36.23605			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722601	hybrid			2022-12-25	WOS:000075778100101
J	Hoppel, CL; Kerner, J; Turkaly, P; Turkaly, J; Tandler, B				Hoppel, CL; Kerner, J; Turkaly, P; Turkaly, J; Tandler, B			The malonyl-CoA-sensitive form of carnitine palmitoyltransferase is not localized exclusively in the outer membrane of rat liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; ENERGY-METABOLISM; PROTEINS; TRANSLOCATION; COMPARTMENT; HEART; SITE	The data used to support the idea that malonyl-coenzyme A (CoA)-sensitive carnitine palmitoyltransferase (CPT-I) is localized on the outer mitochondrial membrane are based on harsh techniques that disrupt mitochondrial physiology. We have turned to the use of the French press, which produces a shearing force that denudes mitochondria of their outer membrane without the physiologically disruptive effects characteristic of phosphate swelling. Our results indicate that the mitoplasts contain just 15-19% of the outer membrane marker enzyme activity while retaining 85% of the total CPT activity and 50% of both CPT-I, as well as long-chain acyl-CoA synthase activity, the latter two supposed outer membrane enzymes. These mitoplasts were shown by electron microscopy to have the configuration of mitochondria that merely have been divested of their outer membranes. Carnitine-dependent fatty acid oxidation was retained in the mitoplasts, showing that they were physiologically intact. Moreover, protein immuno blotting analysis showed that CPT-I, as well as the inner CPT-II, was localized in the mitoplast fraction. The outer membrane fraction, which consisted of membrane "ghosts," contained most (50-60%) of marker enzyme activity, monoamine oxidase-B and porin proteins, but only about 27-29% CPT-I activity. Because CPT-I and long-chain acyl-CoA synthetase appear to be associated with both inner and outer membranes, we postulate that these enzymes reside in contact sites, which represent a melding of both limiting membranes.	Case Western Reserve Univ, Sch Med, Dept Vet Affairs Med Ctr, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Vet Affairs Med Ctr, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Vet Affairs Med Ctr, Dept Med, Cleveland, OH 44106 USA; Kyushu Dent Coll, Dept Oral Anat 2, Kitakyushu, Fukuoka 803, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Kyushu Dental University	Hoppel, CL (corresponding author), VA Med Ctr, Med Res Serv 151W, 10701 East Blvd, Cleveland, OH 44106 USA.	CLH5@po.cwru.edu						BRDICZKA D, 1994, MOL CELL BIOCHEM, V133, P69, DOI 10.1007/BF01267948; BRDICZKA D, 1994, BBA-BIOENERGETICS, V1187, P264, DOI 10.1016/0005-2728(94)90124-4; BREMER J, 1967, J BIOL CHEM, V242, P1744; BRENDEL K, 1967, BIOCHIM BIOPHYS ACTA, V137, P98, DOI 10.1016/0005-2760(67)90012-4; BROSNAN JT, 1973, J BIOL CHEM, V248, P4075; DECKER GL, 1977, J ULTRA MOL STRUCT R, V59, P44, DOI 10.1016/S0022-5320(77)80027-0; DECLERCQ PE, 1987, J BIOL CHEM, V262, P9812; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; Fraser F, 1998, BIOCHEM J, V329, P225, DOI 10.1042/bj3290225; FRASER F, 1977, BIOCHEM J, V323, P711; FRITZ IB, 1963, J LIPID RES, V4, P279; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HOPPEL C, 1979, J BIOL CHEM, V254, P4164; HOPPEL CL, 1972, J BIOL CHEM, V247, P832; HOPPEL CL, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P153; INGALLS ST, 1982, J LABELLED COMPD RAD, V19, P535, DOI 10.1002/jlcr.2580190408; Karnovsky M.J., 1971, P 11 M AM SOC CELL B, P146; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KOPEC B, 1973, J BIOL CHEM, V248, P4069; KORNBERG A, 1953, J BIOL CHEM, V204, P329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; MILLONIG G, 1961, J BIOPHYS BIOCHEM CY, V11, P736, DOI 10.1083/jcb.11.3.736; MORTON DJ, 1968, BIOCHEM J, V107, P377, DOI 10.1042/bj1070377; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; SAGGERSON D, 1992, ADV ENZYME REGUL, V32, P285; SAGGERSON ED, 1981, FEBS LETT, V129, P225, DOI 10.1016/0014-5793(81)80170-6; SCHNAITMAN C, 1967, J CELL BIOL, V32, P719, DOI 10.1083/jcb.32.3.719; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; Srere P.A., 1969, METHOD ENZYMOL, V13, P7; TANDLER B, 1990, J ELECTRON MICR TECH, V16, P81, DOI 10.1002/jemt.1060160110; TANDLER B, 1977, STAIN TECHNOL, V52, P238, DOI 10.3109/10520297709116783; TOMEC RJ, 1975, ARCH BIOCHEM BIOPHYS, V170, P716, DOI 10.1016/0003-9861(75)90169-1; Wharton DC., 1967, METHOD ENZYMOL, P245; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G	39	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23495	23503		10.1074/jbc.273.36.23495	http://dx.doi.org/10.1074/jbc.273.36.23495			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722587	hybrid			2022-12-25	WOS:000075778100087
J	Ianelli, CJ; DeLellis, R; Thorley-Lawson, DA				Ianelli, CJ; DeLellis, R; Thorley-Lawson, DA			CD48 binds to heparan sulfate on the surface of epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; LOW-AFFINITY LIGAND; B-CELL; FLAVOBACTERIUM-HEPARINUM; DEXTRAN SULFATE; FINE-STRUCTURE; HUMAN CD2; RAT CD2; IN-VIVO; ADHESION	CD48 is a member of the immunoglobulin superfamily whose cell surface expression is strikingly up-regulated on the surface of Epstein-Barr virus-infected B cells. To date, no ligand for human CD48 has been characterized. In this study, we show that human recombinant CD48 binds to the glycosaminoglycan heparan sulfate on the surface of human epithelial cells. We have produced a monoclonal antibody (615) against epithelial cell surfaces that blocks this binding and show that it too recognizes heparan sulfate. The specific epitope on heparan sulfate that is recognized by the antibody and is involved in binding is also expressed in vivo on the basolateral surfaces of mucosal epithelium and lamina propria.	Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA	Tufts University	Thorley-Lawson, DA (corresponding author), Tufts Univ, Sch Med, Dept Pathol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL CANCER INSTITUTE [R01CA031893, R01CA065883, R37CA031893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018757] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31893, CA 65883] Funding Source: Medline; NIAID NIH HHS [AI 18757] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; Brown MH, 1995, EUR J IMMUNOL, V25, P3222, DOI 10.1002/eji.1830251204; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; ESKO JD, 1992, ADV EXP MED BIOL, V313, P97; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; GALLAGHER JT, 1995, ADV EXP MED BIOL, V376, P125; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Ianelli CJ, 1997, J IMMUNOL, V159, P3910; KAPLAN AJ, 1993, J IMMUNOL, V151, P4022; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KATO M, 1994, J BIOL CHEM, V269, P18881; KLAMAN LD, 1995, J VIROL, V69, P871, DOI 10.1128/JVI.69.2.871-881.1995; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LINHARDT RJ, 1991, CURRENT PROTOCOLS MO, V2; Miyashita EM, 1997, J VIROL, V71, P4882, DOI 10.1128/JVI.71.7.4882-4891.1997; MIYASHITA EM, 1995, CELL, V80, P593, DOI 10.1016/0092-8674(95)90513-8; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANDRIN MS, 1993, J IMMUNOL, V151, P4606; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1987, EMBO J, V6, P3695, DOI 10.1002/j.1460-2075.1987.tb02703.x; THORLEYLAWSON DA, 1993, BIOCHEM SOC T, V21, P976, DOI 10.1042/bst0210976; THORLEYLAWSON DA, 1982, CELL, V30, P415, DOI 10.1016/0092-8674(82)90239-2; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; WARREN HS, 1990, IMMUNOL CELL BIOL, V68, P199, DOI 10.1038/icb.1990.28; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YOKOYAMA S, 1991, J IMMUNOL, V146, P2192	37	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23367	23375		10.1074/jbc.273.36.23367	http://dx.doi.org/10.1074/jbc.273.36.23367			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722571	hybrid			2022-12-25	WOS:000075778100071
J	Zhao, JH; Inoue, T; Shoji, W; Nemoto, Y; Obinata, M				Zhao, JH; Inoue, T; Shoji, W; Nemoto, Y; Obinata, M			Direct association of YY-1 with c-Myc and the E-box binding protein in regulation of glycophorin gene expression	ONCOGENE			English	Article						c-Myc; YY-1; E-box binding protein; glycophorin; murine erythroleukemia cells	MURINE ERYTHROLEUKEMIA-CELLS; REGION-LIKE SEQUENCE; MOUSE GLYCOPHORIN; TRANSCRIPTIONAL REPRESSION; LEUCINE ZIPPER; DIFFERENTIATION; YY1; COMMITMENT; MAX; IDENTIFICATION	We previously reported that YY-1, a versatile transcription factor, regulates expression of glycophorin gene by binding to its locus control region-like region (Gp-LCR) in combination with E-box binding protein during murine erythroleukemia (MEL) cell differentiation. In the present work, we demonstrated that YY-I and c-Myc, a nuclear oncoprotein, were physically associated in vivo and that down regulation of c-Myc liberated free W-l from its complex, resulting in the functional binding of W-l to the Gp-LCR. We also showed that the E-box binding protein (EBP) which bound to E-box was physically associated with YY-1, facilitated binding of YY-I to the neighboring site and their combinatorial binding may stimulate the Gp-LCR mediated enhancement of erythroid-specific transcription of glycophorin gene in MEL cells.	Tohoku Univ, Dept Cell Biol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University	Obinata, M (corresponding author), Tohoku Univ, Dept Cell Biol, Inst Dev Aging & Canc, Aoba Ku, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.		Watanabe, Mamoru/AHE-0489-2022					AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FREITAG SO, 1988, MOL CELL BIOL, V8, P1614; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GUALBERTO A, 1992, MOL CELL BIOL, V12, P38; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARUYAMA K, 1987, ONCOGENE, V1, P261; MATSUI Y, 1989, GENE, V77, P325, DOI 10.1016/0378-1119(89)90080-2; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Nemoto Y, 1996, J BIOL CHEM, V271, P13542, DOI 10.1074/jbc.271.23.13542; OHMORI Y, 1993, ONCOGENE, V8, P379; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Shaw P E, 1994, Methods Mol Biol, V30, P79; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAKADA S, 1992, JPN J CANCER RES, V83, P61, DOI 10.1111/j.1349-7006.1992.tb02352.x; TERAJIMA M, 1995, J BIOCHEM-TOKYO, V118, P593, DOI 10.1093/oxfordjournals.jbchem.a124951; TERAJIMA M, 1994, J BIOCHEM-TOKYO, V116, P1105, DOI 10.1093/oxfordjournals.jbchem.a124634; USHVA A, 1994, CELL, V76, P1115; YAMAMOTO T, 1989, CELL DIFFER DEV, V28, P129, DOI 10.1016/0922-3371(89)90049-X	46	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1009	1017		10.1038/sj.onc.1202026	http://dx.doi.org/10.1038/sj.onc.1202026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747880				2022-12-25	WOS:000075560900009
J	Villard, E; Alonso, A; Agrapart, M; Challah, M; Soubrier, F				Villard, E; Alonso, A; Agrapart, M; Challah, M; Soubrier, F			Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; FIBROBLAST GROWTH-FACTOR; MESSENGER-RNA STABILITY; INTERCELLULAR-ADHESION MOLECULE-1; PHORBOL-MYRISTATE ACETATE; VASCULAR SMOOTH-MUSCLE; GENE-EXPRESSION; PROTEOLYTIC RELEASE; DIABETES-MELLITUS; ALPHA	Angiotensin I-converting enzyme (ACE) has been implicated in various cardiovascular diseases; however, little is known about the ACE gene regulation in endothelial cells. We have investigated the effect of the protein kinase C activator phorbol 12-myristate 13-acetate (PMA) on ACE activity and gene expression in human umbilical vein endothelial cells (HUVEC). Our results showed a 3- and 5-fold increase in ACE activity in the medium and in the cells, respectively, after 24-h stimulation by PMA. We also observed an increase in the cellular ACE mRNA content starting after 6 h and reaching a 10-fold increase at 24 h in response to 100 ng/ml PMA as measured by ribonuclease protection assay. This effect was mediated by an increased transcription of the ACE gene as demonstrated by nuclear run-on experiments and nearly abolished by the specific PHC inhibitor GF 109203X. Our results indicate that PMA-activated PRC strongly increases ACE mRNA level and ACE gene transcription in HUVEC, an effect associated with an increased ACE secretion. A role for early growth response factor-1 (Egr-1) as a factor regulating ACE gene expression is suggested by both the presence of an Egr-1-responsive element in the proximal portion of the ACE promoter and the kinetics of the Egr-1 mRNA increase in HUVEC treated with PMA.	Fac Med Xavier Bichat, INSERM, U460, Paris, France; Hop St Louis, INSERM, U358, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Challah, M (corresponding author), Fac Med Xavier Bichat, INSERM, U460, Paris, France.		villard, eric/AAH-2868-2021; Villard, Eric/AAI-2464-2021	Villard, Eric/0000-0001-9801-7297				ALHENCGELAS F, 1991, J LAB CLIN MED, V117, P33; ARNAL JF, 1994, AM J PHYSIOL-HEART C, V267, pH1777, DOI 10.1152/ajpheart.1994.267.5.H1777; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BHANDARI B, 1994, MOL CELL BIOCHEM, V140, P31, DOI 10.1007/BF00928363; BHANDARI B, 1994, MOL CELL ENDOCRINOL, V91, P185; BLUMBERG PM, 1995, AGENT ACTION SUPPL, V47, P87; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CHALLAH M, 1995, CARDIOVASC RES, V30, P231, DOI 10.1016/0008-6363(96)88516-6; CHEN FY, 1994, BIOCHEM J, V302, P125, DOI 10.1042/bj3020125; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; CRAVEN PA, 1989, J CLIN INVEST, V83, P1667, DOI 10.1172/JCI114066; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DANSER AHJ, 1995, CIRCULATION, V92, P1387, DOI 10.1161/01.CIR.92.6.1387; DASARATHY Y, 1992, AM J PHYSIOL, V263, pL645, DOI 10.1152/ajplung.1992.263.6.L645; DEISHER TA, 1993, FEBS LETT, V331, P285, DOI 10.1016/0014-5793(93)80354-W; DHUMIERES S, 1986, EUR J PHARMACOL, V131, P13, DOI 10.1016/0014-2999(86)90510-8; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1995, BIOCHEM BIOPH RES CO, V206, P541, DOI 10.1006/bbrc.1995.1077; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FISHEL RS, 1995, J CLIN INVEST, V95, P377, DOI 10.1172/JCI117666; FISHEL RS, 1995, HYPERTENSION, V25, P343, DOI 10.1161/01.HYP.25.3.343; GILMAN M, 1993, CURRENT PROTOCOLS MO; GonzalezEspinosa C, 1996, BBA-MOL CELL RES, V1310, P217, DOI 10.1016/0167-4889(95)00168-9; GRIGORIAN GY, 1987, CIRC RES, V61, P389, DOI 10.1161/01.RES.61.3.389; HELLER R, 1992, J IMMUNOL, V149, P3682; Hempel A, 1997, CIRC RES, V81, P363, DOI 10.1161/01.RES.81.3.363; HSIEH HJ, 1991, AM J PHYSIOL, V260, pH642, DOI 10.1152/ajpheart.1991.260.2.H642; HUANG DL, 1995, MOL ENDOCRINOL, V9, P994, DOI 10.1210/me.9.8.994; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; HUBERT C, 1991, J BIOL CHEM, V266, P15377; HUG H, 1993, BIOCHEM J, V291, P829; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JANDELEIT K, 1992, CLIN EXP PHARMACOL P, V19, P343, DOI 10.1111/j.1440-1681.1992.tb00468.x; KAWAGUCHI H, 1990, J HYPERTENS, V8, P173, DOI 10.1097/00004872-199002000-00012; KAWAGUCHI H, 1990, BIOCHIM BIOPHYS ACTA, V1052, P503, DOI 10.1016/0167-4889(90)90162-7; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KHAN J, 1994, J CELL BIOL, V125, P461; KING SJ, 1992, AM J PHYSIOL, V263, pC743, DOI 10.1152/ajpcell.1992.263.4.C743; KRULEWITZ AH, 1984, AM J PHYSIOL, V247, pC163, DOI 10.1152/ajpcell.1984.247.3.C163; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; LANE TA, 1989, BIOCHEM BIOPH RES CO, V161, P945, DOI 10.1016/0006-291X(89)91334-X; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LIBERMAN J, 1980, ANN INTERN MED, V93, P825; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; MITSUMATA M, 1993, AM J PHYSIOL, V265, pH3, DOI 10.1152/ajpheart.1993.265.1.H3; MORISHITA R, 1994, J CLIN INVEST, V94, P978, DOI 10.1172/JCI117464; OHH M, 1994, J BIOL CHEM, V269, P30117; OKABE T, 1987, BIOCHEM BIOPH RES CO, V145, P1211, DOI 10.1016/0006-291X(87)91566-X; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PIQUILLO.Y, 1970, BIOCHIM BIOPHYS ACTA, V206, P136, DOI 10.1016/0005-2744(70)90090-2; PORTEU F, 1991, J BIOL CHEM, V266, P18846; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; RYAN US, 1976, TISSUE CELL, V8, P125, DOI 10.1016/0040-8166(76)90025-2; SHAI SY, 1992, CIRC RES, V70, P1274, DOI 10.1161/01.RES.70.6.1274; SHIBA T, 1993, AM J PHYSIOL, V265, pE783, DOI 10.1152/ajpendo.1993.265.5.E783; SHIOTA N, 1992, HYPERTENSION, V20, P168, DOI 10.1161/01.HYP.20.2.168; Takemoto M, 1997, J CLIN INVEST, V99, P278, DOI 10.1172/JCI119156; Terry CM, 1996, J LAB CLIN MED, V127, P81, DOI 10.1016/S0022-2143(96)90169-9; VANDYK DJ, 1994, EUR J CLIN INVEST, V24, P463, DOI 10.1111/j.1365-2362.1994.tb02376.x; Villard E, 1996, AM J HUM GENET, V58, P1268; Villard E, 1996, CARDIOVASC RES, V32, P999, DOI 10.1016/S0008-6363(96)00170-8; VUKPAVLOVIC Z, 1989, J LEUKOCYTE BIOL, V45, P503, DOI 10.1002/jlb.45.6.503; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	77	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25191	25197		10.1074/jbc.273.39.25191	http://dx.doi.org/10.1074/jbc.273.39.25191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737980	hybrid			2022-12-25	WOS:000076085400030
J	Westphal, V; Spetzler, JC; Meldal, M; Christensen, U; Winther, JR				Westphal, V; Spetzler, JC; Meldal, M; Christensen, U; Winther, JR			Kinetic analysis of the mechanism and specificity of protein-disulfide isomerase using fluorescence-quenched peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN-LIKE DOMAINS; ACTIVE-SITE CYSTEINE; EFFICIENT CATALYSIS; RIBONUCLEASE-A; BOND FORMATION; HUMAN LYSOZYME; GLUTATHIONE; BINDING; ISOMERIZATION; ENDOPEPTIDASES	Protein-disulfide isomerase (PDI) is an abundant folding catalyst in the endoplasmic reticulum of eukaryotic cells. PDI introduces disulfide bonds into newly synthesized proteins and catalyzes disulfide bond isomerizations, We have synthesized a library of disulfide-linked fluorescence-quenched peptides, individually linked to resin beads, for two purposes: 1) to probe PDI specificity, and 2) to identify simple, sensitive peptide substrates of PDI, Using this library, beads that became rapidly fluorescent by reduction by human PDI were selected. Amino acid sequencing of the bead-linked peptides revealed substantial similarities. Several of the peptides were synthesized in solution, and a quantitative characterization of pre-steady state kinetics was carried out. Interestingly, a greater than 10-fold difference in affinity toward PDI was seen for various substrates of identical length. As opposed to conventional PDI assays involving larger polypeptides, the starting material for this assay is homogenous. It is furthermore simple and highly sensitive (requires less than 0.5 mu g of PDI/assay) and thus opens the possibility for quantitative determination of PDI activity and specificity.	Carlsberg Lab, Dept Yeast Genet, DK-2500 Copenhagen, Denmark; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark; Univ Copenhagen, Chem Lab 4, DK-2100 Copenhagen, Denmark	University of Copenhagen	Winther, JR (corresponding author), Carlsberg Lab, Dept Yeast Genet, Gamle Carlsberg Vej 10, DK-2500 Copenhagen, Denmark.	jrw@crc.dk	Meldal, Morten/B-7626-2016; Winther, Jakob R./K-4451-2014	Meldal, Morten/0000-0001-6114-9018; Winther, Jakob R./0000-0001-6995-9154				BREDDAM K, 1992, EUR J BIOCHEM, V206, P103, DOI 10.1111/j.1432-1033.1992.tb16906.x; Creighton TE, 1997, BIOL CHEM, V378, P731; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; DARBY NJ, 1995, J MOL BIOL, V249, P463, DOI 10.1006/jmbi.1995.0309; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GIVOL D, 1965, P NATL ACAD SCI USA, V53, P676, DOI 10.1073/pnas.53.3.676; GOLDBERGER RF, 1964, J BIOL CHEM, V239, P1406; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HAYANO T, 1993, FEBS LETT, V328, P203, DOI 10.1016/0014-5793(93)80993-5; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; KEMMINK J, 1995, PROTEIN SCI, V4, P2587, DOI 10.1002/pro.5560041216; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Meldal M, 1998, METH MOL B, V87, P51; MELDAL M, 1991, ANAL BIOCHEM, V195, P141, DOI 10.1016/0003-2697(91)90309-H; Meldal Morten, 1994, Methods (Orlando), V6, P417, DOI 10.1006/meth.1994.1044; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; Nakamura S, 1996, J BIOCHEM-TOKYO, V120, P525; NOIVA R, 1993, J BIOL CHEM, V268, P19210; OLSEN K, 1992, EUR J BIOCHEM, V209, P777, DOI 10.1111/j.1432-1033.1992.tb17348.x; OTSU M, 1994, J BIOL CHEM, V269, P6874; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; RENIL M, 1998, IN PRESS J PEPT SCI; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; Ruoppolo M, 1996, BIOCHEMISTRY-US, V35, P13636, DOI 10.1021/bi960755b; Spetzler JC, 1998, J PEPT SCI, V4, P128, DOI 10.1002/(SICI)1099-1387(199804)4:2<128::AID-PSC137>3.3.CO;2-5; Walker KW, 1997, J BIOL CHEM, V272, P8845; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119	46	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					24992	24999		10.1074/jbc.273.39.24992	http://dx.doi.org/10.1074/jbc.273.39.24992			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737954	hybrid			2022-12-25	WOS:000076085400004
J	Benkirane, M; Chun, RF; Xiao, H; Ogryzko, VV; Howard, BH; Nakatani, Y; Jeang, KT				Benkirane, M; Chun, RF; Xiao, H; Ogryzko, VV; Howard, BH; Nakatani, Y; Jeang, KT			Activation of integrated provirus requires histone acetyltransferase - p300 AND P/CAF are coactivators for HIV-1 Tat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; NF-KAPPA-B; PROTEINS SPECIFICALLY ASSOCIATE; CARBOXYL-TERMINAL DOMAIN; TRANSCRIPTIONAL ACTIVATION; CELLULAR PROTEIN; IN-VITRO; CHROMATIN STRUCTURE; HUMAN CHROMOSOME-12	A unique aspect of the retrovirus life cycle is the obligatory integration of the provirus into host cell chromosomes. Unlike viruses that do not integrate, retroviruses must conserve an ability to activate transcription from a chromatin context. Human immunodeficiency virus (HIV)-1 encodes an unusual and an unusually potent transcriptional transactivator, Tat, which binds to a nascent viral leader RNA, TAR. The action of Tat has been well studied in various reductive model systems; however, the physiological mechanism through which Tat gains access to chromatin-associated proviral long terminal repeats (LTRs) is not understood. We show here that a nuclear histone acetyltransferase activity associates with Tat. Intracellularly, we found that Tat forms a ternary complex with p300 and P/CAF, two histone acetyltransferases (HATs). A murine cell defect in Tat transactivation of the HIV-1 LTR was linked to the reduced abundance of p300 and P/CAF. Thus, overexpression of p300 and P/CAF reconstituted Tat transactivation of the HIV-1 LTR in NIH3T3 cells to a level similar to that observed for human cells. By using transdominant p300 or P/CAF mutants that lack enzymatic activity, we delineated a requirement for the HAT component from the latter but not the former in Tat function. Finally, we observed that Tat-associated HAT is preferentially important for transactivation of integrated, but not unintegrated, HIV-1 LTR.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; IGH, UPR 1142, Montpellier, France	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Universite de Montpellier	Jeang, KT (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Ogryzko, Vasily/M-6665-2015; Jeang, Kuan-Teh/A-2424-2008; Chun, Rene/A-9415-2010	Ogryzko, Vasily/0000-0002-8548-1389; Chun, Rene/0000-0002-0190-0807				ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; Broder CC, 1996, PATHOBIOLOGY, V64, P171, DOI 10.1159/000164032; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DESAI K, 1991, P NATL ACAD SCI USA, V88, P8875, DOI 10.1073/pnas.88.20.8875; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224; HART CE, 1989, SCIENCE, V246, P488, DOI 10.1126/science.2683071; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; HUANG LM, 1993, J VIROL, V67, P6937, DOI 10.1128/JVI.67.12.6937-6944.1993; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jeang K., 1996, HUMAN RETROVIRUSES A, P3; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mavankal G, 1996, P NATL ACAD SCI USA, V93, P2089, DOI 10.1073/pnas.93.5.2089; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NEWSTEIN M, 1990, J VIROL, V64, P4565, DOI 10.1128/JVI.64.9.4565-4567.1990; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PALUDAN K, 1989, J VIROL, V63, P5201, DOI 10.1128/JVI.63.12.5201-5207.1989; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pennisi E, 1997, SCIENCE, V275, P155, DOI 10.1126/science.275.5297.155; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; VanLint C, 1996, GENE EXPRESSION, V5, P245; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Widlak P, 1997, J BIOL CHEM, V272, P17654, DOI 10.1074/jbc.272.28.17654; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WUBAER F, 1995, P NATL ACAD SCI USA, V92, P7153, DOI 10.1073/pnas.92.16.7153; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605	89	241	243	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24898	24905		10.1074/jbc.273.38.24898	http://dx.doi.org/10.1074/jbc.273.38.24898			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733796	hybrid			2022-12-25	WOS:000076007300088
J	Jean, D; Harbison, M; McConkey, DJ; Ronai, Z; Bar-Eli, M				Jean, D; Harbison, M; McConkey, DJ; Ronai, Z; Bar-Eli, M			CREB and its associated proteins act as survival factors for human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MELANOCYTES; GROWTH-FACTOR; SOMATOSTATIN GENE; TUMOR-GROWTH; C-FOS; EXPRESSION; TRANSCRIPTION; BINDING; KINASE; PHOSPHORYLATION	cAMP response element-binding protein (CREB) and activating transcription factor 1 (ATF-1), members of the CREB/ATF family, have been implicated in cAMP- and calcium-induced transcriptional activation. We have previously demonstrated that quenching of CREB-associated proteins in metastatic melanoma cells by a dominant-negative CREB (KCREB) that is mutated within its DNA-binding domain decreased their radiation resistance, and their tumorigenic and metastatic potential in nude mice, As the induction of apoptosis by diverse exogenous signals is dependent on the elevation of intracellular Ca2+, the purpose of this study was to determine the role of CREB and its associated proteins in apoptosis using KCREB, We used thapsigargin (Tg), which inhibits endoplasmic reticulum-dependent Ca2+-ATPase and thereby increases cytosolic Ca2+, to induce apoptosis, MeWo human melanoma cells were transfected with the KCREB expression vector and subsequently analyzed for their susceptibility to Tg-induced apoptosis, Here we demonstrate that expression of KCREB in MeWo cells rendered them susceptible to Tg-induced apoptosis, Tg treatment induced phosphorylation of CREB and possibly ATF-1 transcription factors. Treatment with Tg induced CRE-dependent transcription in parental cells, whereas this activation was reduced in the KCREB-transfected cells. In addition, CAT activity driven by the CRE-dependent promoter was inhibited in parental MeWo cells cotransfected with increasing concentrations of KCREB in a dose-dependent manner. We did not observe any changes in Bcl-2 or Bcl-2-related proteins (Bcl-x, Bax, and Bad) in control or KCREB-transfected cells before or after treatment with Tg, Collectively, these data indicate that CREB and its associated proteins act as survival factors for human melanoma cells, and hence contribute to the acquisition of the malignant phenotype.	Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Houston, TX 77030 USA; CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Houston, TX 77030 USA.	mbareli@notes.mdacc.tmc.edu	Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA 64137, CA 69676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA064137, R29CA069676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; Bussfeld D, 1997, IMMUNOBIOLOGY, V198, P291, DOI 10.1016/S0171-2985(97)80049-6; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISHIKAWA M, 1988, CANCER RES, V48, P665; ISHIZAKI Y, 1995, MOL BIOL CELL, V6, P1443, DOI 10.1091/mbc.6.11.1443; KOPF AW, 1995, CANCER-AM CANCER SOC, V75, P684, DOI 10.1002/1097-0142(19950115)75:2+<684::AID-CNCR2820751411>3.0.CO;2-B; LANSCHULZ WH, 1988, SCIENCE, V240, P1759; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LIU F, 1993, J BIOL CHEM, V268, P6714; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MULLER HK, 1994, CELL IMMUNOL, V157, P263, DOI 10.1006/cimm.1994.1221; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANDA T, 1991, J VIROL, V65, P557; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xie SH, 1997, CANCER RES, V57, P2295; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Yang YM, 1996, ONCOGENE, V12, P2223	47	139	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24884	24890		10.1074/jbc.273.38.24884	http://dx.doi.org/10.1074/jbc.273.38.24884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733794	hybrid			2022-12-25	WOS:000076007300086
J	Ni, J; Fernandez, MA; Danielsson, L; Chillakuru, RA; Zhang, JL; Grubb, A; Su, J; Gentz, R; Abrahamson, M				Ni, J; Fernandez, MA; Danielsson, L; Chillakuru, RA; Zhang, JL; Grubb, A; Su, J; Gentz, R; Abrahamson, M			Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-B; CELL-LINE; ESCHERICHIA-COLI; GEL ELECTROPHORESIS; CHICKEN CYSTATIN; GAMMA-TRACE; IDENTIFICATION; GENE; EXPRESSION; SEQUENCE	A previously undescribed human member of the cystatin superfamily called cystatin F has been identified by expressed sequence tag sequencing in human cDNA libraries. A full-length cDNA clone was obtained from a library made from mRNA of CD34-depleted cord blood cells. The sequence of the cDNA contained an open reading frame encoding a putative 19-residue signal peptide and a mature protein of 126 amino acids with two disulfide bridges and enzyme-binding motifs homologous to those of Family 2 cystatins. Unlike other human cystatins, cystatin F has 2 additional Cys residues, indicating the presence of an extra disulfide bridge stabilizing the N-terminal region of the molecule. Recombinant cystatin F was produced in a baculovirus expression system and characterized. The mature recombinant protein processed by insect cells had an N-terminal segment 7 residues longer than that of cystatin C and displayed reversible inhibition of papain and cathepsin L (K-i = 1.1 and 0.31 nM, respectively), but not cathepsin B. Like cystatin E/M, cystatin F is a glycoprotein, carrying two N-linked carbohydrate chains at positions 36 and 88. An immunoassay for quantification of cystatin F showed that blood contains low levels of the inhibitor (0.9 ng/ml). Six B cell lines in culture secreted barely detectable amounts of cystatin F, but several T cell lines and especially one myeloid cell line secreted significant amounts of the inhibitor. Northern blot analysis revealed that the cystatin F gene is primarily expressed in peripheral blood cells and spleen. Tissue expression clearly different fi-om that of the ubiquitous inhibitor, cystatin C, was also indicated by a high incidence of cystatin F clones in cDNA libraries from dendritic and T cells, but no clones identified by expressed sequence tag sequencing in several B cell libraries and in >600 libraries from other human tissues and cells.	Human Genome Sci Inc, Rockville, MD 20850 USA; Univ Lund Hosp, Dept Clin Chem, Inst Lab Med, S-22185 Lund, Sweden; Univ Lund, Dept Immunotechnol, S-22007 Lund, Sweden	GlaxoSmithKline; Human Genome Sciences Inc; Lund University; Skane University Hospital; Lund University	Abrahamson, M (corresponding author), Univ Lund Hosp, Dept Clin Chem, Inst Lab Med, S-22185 Lund, Sweden.	Magnus.Abrahamson@klinkem.lu.se	Abrahamson, Magnus/CAG-9507-2022	Grubb, Anders/0000-0002-0125-3662				ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ADAMS MD, 1995, NATURE, V377, P3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASSFALGMACHLEIDT I, 1988, BIOL CHEM H-S, V369, P263; BALBIN M, 1994, J BIOL CHEM, V269, P23156; BJORCK L, 1990, J VIROL, V64, P941; BJORK I, 1994, BIOCHEM J, V299, P219, DOI 10.1042/bj2990219; Bjorklund HV, 1997, J VIROL, V71, P5658; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchholz B, 1996, EUR J CANCER, V32A, P2101, DOI 10.1016/S0959-8049(96)00230-4; BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165; COLLINS AR, 1998, IN PRESS ORAL MICROB, V12; COX SW, 1989, J PERIODONTAL RES, V24, P353, DOI 10.1111/j.1600-0765.1989.tb00882.x; Ekiel I, 1997, J MOL BIOL, V271, P266, DOI 10.1006/jmbi.1997.1150; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; GABRIJELCIC D, 1990, J CLIN CHEM CLIN BIO, V28, P149; GENTZ R, 1992, EUR J BIOCHEM, V210, P545, DOI 10.1111/j.1432-1033.1992.tb17453.x; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GRUBB A, 1982, P NATL ACAD SCI-BIOL, V79, P3024, DOI 10.1073/pnas.79.9.3024; GRUBB A, 1984, FEBS LETT, V170, P370, DOI 10.1016/0014-5793(84)81346-0; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; Hakansson K, 1996, COMP BIOCHEM PHYS B, V114, P303, DOI 10.1016/0305-0491(96)00025-9; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; ISEMURA S, 1991, J BIOCHEM, V110, P648, DOI 10.1093/oxfordjournals.jbchem.a123634; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KIMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P454, DOI 10.1073/pnas.78.1.454; KOPPEL P, 1984, EXP CELL BIOL, V52, P293; KORANT BD, 1985, BIOCHEM BIOPH RES CO, V127, P1072, DOI 10.1016/S0006-291X(85)80054-1; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; LINDAHL P, 1994, BIOCHEMISTRY-US, V33, P4384, DOI 10.1021/bi00180a036; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MENEZES J, 1975, BIOMEDICINE, V22, P276; Ni J, 1997, J BIOL CHEM, V272, P10853; OLAFSSON I, 1988, SCAND J CLIN LAB INV, V48, P573, DOI 10.3109/00365518809085775; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; SCHNITTGER S, 1993, GENOMICS, V16, P50, DOI 10.1006/geno.1993.1139; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; Stenman G, 1997, CYTOGENET CELL GENET, V76, P45, DOI 10.1159/000134512; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALLENOHMAN M, 1994, INT J CANCER, V57, P544, DOI 10.1002/ijc.2910570418	56	129	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24797	24804		10.1074/jbc.273.38.24797	http://dx.doi.org/10.1074/jbc.273.38.24797			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733783	hybrid			2022-12-25	WOS:000076007300075
J	Liu, LP; Deber, CM				Liu, LP; Deber, CM			Uncoupling hydrophobicity and helicity in transmembrane segments - alpha-helical propensities of the amino acids in non-polar environments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; BETA-SHEET; PEPTIDES; INSERTION; PROLINE; CONFORMATIONS; PARAMETERS; PREDICTION; CHANNEL; KINASE	Although the chains of amino acids in proteins that span the membrane are demonstrably helical and hydrophobic, little attention has been paid toward addressing the range of helical propensities of individual amino acids in the non-polar environment of membranes. Because it is inappropriate to apply soluble protein-based structure prediction algorithms to membrane proteins, we have used de novo designed peptides (KKAAAXAAAAAXAAWAAXAAAKKKK-amide, where X indicates one of the 20 commonly occurring amino acids) that mimic a protein membrane-spanning domain to determine the cu-helical proclivity of each residue in the isotropic non-polar environment of n-butanol, Peptide helicities measured by circular dichroism spectroscopy were found to range from theta(222) = -17,000 degrees (Pro) to -38,800 degrees (ne) in n-butanol, The relative helicity of each amino acid is shown to be well correlated with its occurrence frequency in natural transmembrane segments, indicating that the helical propensity of individual residues in concert with their hydrophobicity may be a key determinant of the conformations of protein segments in membranes.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Deber, CM (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							ALTMANN KH, 1990, BIOPOLYMERS, V30, P107, DOI 10.1002/bip.360300112; BENEFRAIM I, 1993, BIOCHEMISTRY-US, V32, P2371, DOI 10.1021/bi00060a031; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BRANDL CJ, 1988, BIOPOLYMERS, V27, P1171, DOI 10.1002/bip.360270710; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; Chang DK, 1997, BIOPHYS J, V72, P554, DOI 10.1016/S0006-3495(97)78695-8; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; Chung LA, 1997, ANAL BIOCHEM, V248, P195, DOI 10.1006/abio.1997.2137; DEBER CM, 1990, BIOPOLYMERS, V29, P149, DOI 10.1002/bip.360290120; DEBER CM, 1995, BIOPOLYMERS, V37, P295, DOI 10.1002/bip.360370503; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GARY TM, 1984, J MOL BIOL, V175, P75; Hirota N, 1998, J MOL BIOL, V275, P365, DOI 10.1006/jmbi.1997.1468; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kothekar V, 1996, J BIOMOL STRUCT DYN, V14, P303, DOI 10.1080/07391102.1996.10508126; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; Lee S, 1997, BIOCHEMISTRY-US, V36, P3782, DOI 10.1021/bi962451v; LI SC, 1994, NAT STRUCT BIOL, V1, P368, DOI 10.1038/nsb0694-368; Li SC, 1996, P NATL ACAD SCI USA, V93, P6676, DOI 10.1073/pnas.93.13.6676; LIDE DR, 1991, CRC HDB CHEM PHYSICS; Liu LP, 1996, BIOPOLYMERS, V39, P465, DOI 10.1002/(SICI)1097-0282(199609)39:3<465::AID-BIP17>3.0.CO;2-A; Liu LP, 1997, BIOCHEMISTRY-US, V36, P5476, DOI 10.1021/bi970030n; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUNOZ V, 1994, PROTEINS, V20, P301, DOI 10.1002/prot.340200403; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REITHMEIER RAF, 1995, CURR OPIN STRUC BIOL, V5, P491, DOI 10.1016/0959-440X(95)80034-4; TAYLOR WR, 1994, PROTEINS, V18, P281, DOI 10.1002/prot.340180309; Vinogradova O, 1997, BIOPHYS J, V72, P2688, DOI 10.1016/S0006-3495(97)78912-4; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512	38	85	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23645	23648		10.1074/jbc.273.37.23645	http://dx.doi.org/10.1074/jbc.273.37.23645			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726967	hybrid			2022-12-25	WOS:000075893100008
J	Spadaccini, A; Tilbrook, PA; Sarna, MK; Crossley, M; Bieker, JJ; Klinken, SP				Spadaccini, A; Tilbrook, PA; Sarna, MK; Crossley, M; Bieker, JJ; Klinken, SP			Transcription factor erythroid Kruppel-like factor (ELKF) is essential for the erythropoietin-induced hemoglobin production but not for proliferation, viability, or morphological maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; LEUCINE ZIPPER PROTEIN; DNA-BINDING PROTEIN; HUMAN GAMMA-GLOBIN; FACTOR GATA-1; FACTOR NF-E2; FACTOR EKLF; CELL-LINES; BETA-THALASSEMIA; MESSENGER-RNA	The erythroid Kruppel-like factor (EKLF) is essential for the transcription of beta(maj) globin in erythroid cells. We show here that RNA for this transcription factor did not alter during erythropoietin-induced differentiation of J2E cells; however, EKLF protein content decreased and was inversely related to globin production. This unexpected result was also observed during chemically induced maturation of two murine erythroleukemia cell lines. To explore the role of EKLF in erythroid terminal differentiation, an antisense EKLF construct was introduced into J2E cells. As a consequence EKLF RNA and protein levels fell by approximately 80%, and the cells were unable to manufacture hemoglobin in response to erythropoietin, The failure to produce hemoglobin was due to reduced transcription of not only globin genes but also key heme enzyme genes. However, numerous other genes, including several erythroid transcription factors, were unaffected by the decrease in EKLF. Although hemoglobin synthesis was severely impaired with depleted EKLF levels, morphological maturation in response to erythropoietin continued normally. Moreover, erythropoietin-induced proliferation and viability were unaffected by the decrease in EKLF levels. We conclude that EKLF affects a specific set of genes, which regulates hemoglobin production and has no obvious effect on morphological changes, cell division, or viability in response to erythropoietin.	Dept Biochem, Lab Canc Med, Perth, WA 6001, Australia; Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	University of Western Australia; University of Sydney; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Klinken, SP (corresponding author), Dept Biochem, Lab Canc Med, Level 6,MRF Bldg,Rear,50 Murray St, Perth, WA 6001, Australia.		Sarna, Mohinder/AAO-9343-2020; Sarna, Mohinder/Q-7834-2016; Crossley, Merlin/D-7888-2011; Sarna, Mohinder/GYR-3271-2022	Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Crossley, Merlin/0000-0003-2057-3642; 				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BUSFIELD SJ, 1992, BLOOD, V80, P412; BUSFIELD SJ, 1995, EUR J BIOCHEM, V230, P475; BUSFIELD SJ, 1993, GROWTH FACTORS, V9, P307, DOI 10.3109/08977199308991591; CALLUS BA, 1995, HEMOGLOBIN, V19, P7; Chappell D, 1997, CELL DEATH DIFFER, V4, P105, DOI 10.1038/sj.cdd.4400219; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DALYOT N, 1993, NUCLEIC ACIDS RES, V21, P4031, DOI 10.1093/nar/21.17.4031; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; FENG WC, 1994, J BIOL CHEM, V269, P1493; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GRANDCHAMP B, 1984, P NATL ACAD SCI-BIOL, V81, P5036, DOI 10.1073/pnas.81.16.5036; GREEN AR, 1991, EMBO J, V10, P4143; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KAIHO SI, 1985, ANAL BIOCHEM, V149, P117, DOI 10.1016/0003-2697(85)90483-X; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lim SK, 1997, BLOOD, V90, P1291, DOI 10.1182/blood.V90.3.1291.1291_1291_1299; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MORISSON GR, 1965, ANAL CHEM, V37, P1124; MURRELL AM, 1995, ONCOGENE, V11, P131; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; Ponka P, 1997, BLOOD, V89, P1; PORCHER C, 1991, J BIOL CHEM, V266, P10562; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; ROUGEON F, 1977, GENE, V1, P229, DOI 10.1016/0378-1119(77)90047-6; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; Southwood CM, 1996, DEV DYNAM, V206, P248, DOI 10.1002/(SICI)1097-0177(199607)206:3<248::AID-AJA3>3.0.CO;2-I; Surinya KH, 1997, J BIOL CHEM, V272, P26585, DOI 10.1074/jbc.272.42.26585; TAKETANI S, 1992, EUR J BIOCHEM, V205, P217, DOI 10.1111/j.1432-1033.1992.tb16771.x; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1996, CELL GROWTH DIFFER, V7, P511; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WETMUR JG, 1986, P NATL ACAD SCI USA, V83, P7703, DOI 10.1073/pnas.83.20.7703; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675	75	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23793	23798		10.1074/jbc.273.37.23793	http://dx.doi.org/10.1074/jbc.273.37.23793			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726989	hybrid			2022-12-25	WOS:000075893100030
J	Thevananther, S; Kolli, AH; Devarajan, P				Thevananther, S; Kolli, AH; Devarajan, P			Identification of a novel ankyrin isoform (Ank(G)190) in kidney and lung that associates with the plasma membrane and binds alpha-Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE ANKYRIN; ALTERNATIVELY SPLICED FORMS; ANION-EXCHANGER; ALPHA-SUBUNIT; DISTINCT SITES; MAJOR ANKYRIN; SPECTRIN; BRAIN; NA,K-ATPASE; PROTEINS	Ankyrins are a family of adapter molecules that mediate linkages between integral membrane and cytoskeletal proteins, Such interactions are crucial to the polarized distribution of membrane proteins in transporting epithelia. We have cloned and characterized a novel 190-kDa member of this family from a rat kidney cDNA library, which me term Ank(G)190 based on the predicted size and homology with the larger neuronal Ank(G) isoform, Ank(G)190 displays a unique 31-residue amino terminus, a repeats domain consisting of 24 repetitive 33-residue motifs, a spectrin binding domain, and a truncated regulatory domain. Probes derived from the unique amino terminus hybridize to an 8-kilobase message exclusively ire kidney and lung and specifically to the kidney outer medullary collecting duets by in situ hybridization. Transfections of Madin-Darby canine kidney and COS-7 epithelial cell limes with a full-length Ank(G)190 construct result in (a) expression at the lateral plasma membrane, (b) functional assembly with the cytoskeleton, and (c) interaction with at least one membrane protein, the Na,K-ATPase. Two independent Na,K-ATPase binding domains on Ank(G)190 are demonstrated as follows: one within the distal 12 ankyrin repeats, and a second site within the spectrin binding domain. Thus, ankyrins may interact with integral membrane proteins in a pleiotropic manner that may involve complex tertiary structural determinants.	Yale Univ, Sch Med, Dept Pediat, Div Pediat Nephrol, New Haven, CT 06520 USA	Yale University	Devarajan, P (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, 111 E 210th St, Bronx, NY 10467 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047072] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK47072] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS J, 1989, J BIOL CHEM, V264, P6417; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; Devarajan P, 1996, CURR TOP MEMBR, V43, P97; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DRENCKHAHN D, 1987, EUR J CELL BIOL, V43, P479; Hoock TC, 1997, J CELL BIOL, V136, P1059, DOI 10.1083/jcb.136.5.1059; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JORDAN C, 1995, J BIOL CHEM, V270, P29971; KASHGARIAN M, 1991, SODIUM PUMP RECENT D, P573; KOOB R, 1987, European Journal of Cell Biology, V45, P230; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KUNIMOTO M, 1991, J CELL BIOL, V115, P1319, DOI 10.1083/jcb.115.5.1319; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; MORROW JS, 1997, HDB PHYSIOL 14, P485; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; SABROOK J, 1989, MOL CLONING LAB MANU; SIEGEL NJ, 1994, PEDIATR RES, V36, P129, DOI 10.1203/00006450-199408000-00001; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621	34	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23952	23958		10.1074/jbc.273.37.23952	http://dx.doi.org/10.1074/jbc.273.37.23952			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727010	hybrid			2022-12-25	WOS:000075893100051
J	Martinez-Pomares, L; Mahoney, JA; Kaposzta, R; Linehan, SA; Stahl, PD; Gordon, S				Martinez-Pomares, L; Mahoney, JA; Kaposzta, R; Linehan, SA; Stahl, PD; Gordon, S			A functional soluble form of the murine mannose receptor is produced by macrophages in vitro and is present in mouse serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CARBOHYDRATE-RECOGNITION DOMAINS; MONOCLONAL-ANTIBODY NLDC-145; DENDRITIC CELLS; IN-VITRO; TISSUE DISTRIBUTION; MOLECULAR-CLONING; INTERFERON-GAMMA; DEC-205 PROTEIN; DOWN-REGULATION	A soluble form of the mannose receptor (sMR) has been found in conditioned medium of primary macrophages in vitro and in mouse serum, sMR was released as a single species, had a smaller size than the cell-associated form, and accumulated in macrophage-conditioned medium, in a cytokine-regulated manner, to levels comparable with those found for cell-associated mannose receptor. Pulse-chase experiments showed that sMR production in culture occurred by constitutive cleavage of pre-existing full-length protein. A binding assay was developed to determine the sugar specificity of sMR and its ability to interact with pathogens and particulate antigens (i.e. Candida albicans and zymosan). Protease inhibitor studies suggested that sMR was produced by cleavage of an intact mannose receptor by a matrix metalloprotease or ADAM metalloprotease. A role for sMR in the immune response is proposed based on its binding properties, regulation by cytokines, and the previous discovery of putative ligands for the cysteine-rich domain of the mannose receptor in lymph nodes and spleen.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Washington Univ, Sch Med, St Louis, MO 63110 USA	University of Oxford; Washington University (WUSTL)	Martinez-Pomares, L (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		Stahl, Philip/D-6315-2012	Martinez-Pomares, Luisa/0000-0002-2331-127X				ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; Avrameas A, 1996, EUR J IMMUNOL, V26, P394, DOI 10.1002/eji.1830260219; BAZIL V, 1991, J IMMUNOL, V147, P1567; BAZIL V, 1995, IMMUNOL TODAY, V16, P135, DOI 10.1016/0167-5699(95)80130-8; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLUM JS, 1991, CARBOHYD RES, V213, P145, DOI 10.1016/S0008-6215(00)90605-0; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DOYLE AG, 1994, EUR J IMMUNOL, V24, P1441, DOI 10.1002/eji.1830240630; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; HARRIS N, 1992, BLOOD, V80, P2363; INABA K, 1995, CELL IMMUNOL, V163, P148, DOI 10.1006/cimm.1995.1109; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KERY V, 1992, ARCH BIOCHEM BIOPHYS, V298, P49, DOI 10.1016/0003-9861(92)90092-B; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; MARODI L, 1991, J IMMUNOL, V146, P2783; MartinezPomares L, 1996, J EXP MED, V184, P1927, DOI 10.1084/jem.184.5.1927; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Noorman F, 1997, J LEUKOCYTE BIOL, V61, P63, DOI 10.1002/jlb.61.1.63; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; PONTOW SE, 1992, INT REV CYTOL, V137B, P221; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SOUSA CRE, 1993, J EXP MED, V178, P509, DOI 10.1084/jem.178.2.509; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; STERNLICHT M, 1998, GUIDEBOOK EXTRACELLU; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TURNER MW, 1994, BIOCHEM SOC T, V22, P88, DOI 10.1042/bst0220088; VANDENEERTWEGH AJM, 1992, EUR J IMMUNOL, V22, P719, DOI 10.1002/eji.1830220315; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; WITMERPACK MD, 1995, CELL IMMUNOL, V163, P157, DOI 10.1006/cimm.1995.1110; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; YOSHIDA K, 1993, IMMUNOLOGY, V80, P34	44	94	99	8	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23376	23380		10.1074/jbc.273.36.23376	http://dx.doi.org/10.1074/jbc.273.36.23376			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722572	hybrid			2022-12-25	WOS:000075778100072
J	Qiu, Y; Sutton, L; Riggs, AF				Qiu, Y; Sutton, L; Riggs, AF			Identification of myoglobin in human smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESOPHAGOGASTRIC JUNCTION; LUMBRICUS-TERRESTRIS; ESOPHAGEAL BODY; NITRIC-OXIDE; HEMOGLOBIN; OPOSSUM; SPHINCTER; OXIDATION; MECHANISM; DIFFUSION	Myoglobin (Mb) has been believed to be absent generally from mammalian smooth muscle tissue. Examination of human rectal, uterine, bladder, colon, small intestine, arterial, and venous smooth muscle by immunohistochemical techniques shows that each of these tissues is immunopositive for both smooth muscle myosin and human Mb, Rib-specific primers were used for the polymerase chain reaction to generate cDNA from smooth muscle tissues. Southern hybridization with a Mb-specific probe gave a very strong signal with the cDNA from rectum, weaker signals from small intestine and uterus, a faint signal from colon, and no signal from bladder tissue. High performance Liquid chromatography analysis coupled with sequence determination has shown that contaminating heme-binding serum albumin as well as hemoglobin in extracts of smooth muscle seriously compromise any heme-based or spectrophotometric assay of Mb. Combined affinity and size exclusion chromatography, however, provide the necessary resolution. The cDNA-derived amino acid sequence of human smooth muscle Rib was found to be identical to that of Mb from striated muscle.	Univ Texas, Dept Zool, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Riggs, AF (corresponding author), Univ Texas, Dept Zool, Austin, TX 78712 USA.	riggs@uts.cc.utexas.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN HT, 1966, PHYSIOL REV, V46, P212, DOI 10.1152/physrev.1966.46.2.212; ANTONINI E, 1965, PHYSIOL REV, V45, P123, DOI 10.1152/physrev.1965.45.1.123; BIORCK G, 1949, ACTA MED SCAND     S, V226, P1; BLESSING MH, 1972, COMP BIOCHEM PHYSIOL, V41, P475, DOI 10.1016/0300-9629(72)90005-9; BLOOM W, 1968, TXB HISTOLOGY, P574; Bollage DM, 1991, PROTEIN METHODS, P96; CHRISTENSEN J, 1983, GASTROENTEROLOGY, V85, P650; CHRISTENSEN J, 1982, P SOC EXP BIOL MED, V170, P194; CHRISTENSEN J, 1973, GASTROENTEROLOGY, V64, P1119; CHRISTENSEN J, 1973, AM J PHYSIOL, V225, P1265, DOI 10.1152/ajplegacy.1973.225.6.1265; Cornfield DN, 1996, P NATL ACAD SCI USA, V93, P8089, DOI 10.1073/pnas.93.15.8089; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; FASOLD H, 1970, EUR J BIOCHEM, V15, P122, DOI 10.1111/j.1432-1033.1970.tb00985.x; GALARIS D, 1989, ARCH BIOCHEM BIOPHYS, V273, P497, DOI 10.1016/0003-9861(89)90509-2; HORNIG D, 1975, ANN NY ACAD SCI, V258, P103, DOI 10.1111/j.1749-6632.1975.tb29271.x; JAISLE F, 1966, KLIN WOCHENSCHR, V44, P1182, DOI 10.1007/BF01742095; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KAGEN LJ, 1967, IMMUNOLOGY, V12, P667; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; Lankester E.R, 1872, P ROY SOC LONDON, V21, P70; LANKESTER ER, 1871, PFLUGERS ARCH GES PH, V4, P315; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; PERCY WH, 1991, DIGEST DIS SCI, V36, P1057, DOI 10.1007/BF01297447; PRASAD R, 1978, EXPERIENTIA, V34, P484, DOI 10.1007/BF01935942; QIU Y, 1995, FASEB J, V9, P1353; SCHUDER S, 1979, ANAL BIOCHEM, V92, P473, DOI 10.1016/0003-2697(79)90687-0; SCHULZEDELRIEU K, 1982, AM J PHYSIOL, V242, pG258, DOI 10.1152/ajpgi.1982.242.3.G258; WELLER P, 1984, EMBO J, V3, P439, DOI 10.1002/j.1460-2075.1984.tb01825.x; WITTENBERG JB, 1965, J GEN PHYSIOL, V49, P57; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WITTENBERG JB, 1970, PHYSIOL REV, V50, P559, DOI 10.1152/physrev.1970.50.4.559; Zhu H, 1996, J BIOL CHEM, V271, P30007, DOI 10.1074/jbc.271.47.30007	35	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23426	23432		10.1074/jbc.273.36.23426	http://dx.doi.org/10.1074/jbc.273.36.23426			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722578	hybrid			2022-12-25	WOS:000075778100078
J	Shimbara, N; Ogawa, K; Hidaka, Y; Nakajima, H; Yamasaki, N; Niwa, S; Tanahashi, N; Tanaka, K				Shimbara, N; Ogawa, K; Hidaka, Y; Nakajima, H; Yamasaki, N; Niwa, S; Tanahashi, N; Tanaka, K			Contribution of proline residue for efficient production of MHC class I ligands by proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR-HISTOCOMPATIBILITY-COMPLEX; CYTOTOXIC T-LYMPHOCYTES; ANTIGEN PRESENTATION; ORNITHINE DECARBOXYLASE; PROTEIN ACTIVATOR; PEPTIDE; PA28; SUBUNITS; 20S; DEGRADATION	Proteasomes are processing enzymes capable of generating major histocompatibility complex (MHC) class I ligands, but the mechanism of how they excise ligands without destroying them is largely unknown. Previously, we reported that most products of ornithine decarboxylase degraded in vitro by the 26 S ATP-dependent proteasome, which contained one or two Pro residues (Tokunaga, F., Goto, T., Koide, T., Murakami, Y., Hayashi, S., Tamura, T., Tanaka, a, and Ichihara, A. (1994) J. Biol. Chem. 269, 17382-17385), which implied that the Pro residue has a role in the escape from random cleavage by proteasomes. Here, we examine the role of the Pro residue in producing MHC class I ligands in vitro. Proteasomes generated two cytotoxic T lymphocyte-epitopic precursor peptides, SIIPGLPLSL and DMYPHFMPTNL, from the 29-mer and 25-mer peptides harboring these sequences, which are derived hom the c-akt proto-oncogene and the pp89 protein of mouse cytomagalovirus, respectively. Replacement of the first or second Pro residue within these epitopes by Ala resulted in a marked reduction of this epitope-derived production or their random cleavage by proteasomes, irrespective of the presence of PA28, which greatly accelerates the generation of unmodified ligands. Moreover, replacement of a single amino acid residue other than Pro in both epitopic and flanking regions by Ala or Leu had no or little appreciable effect on the SIIPGLPLSL or its derivative production. Thus, Pro residue(s) within these epitopic sequences presumably contributes to efficient production of MHC class I ligands through prevention of their random cleavage by proteasomes.	Sumitomo Elect Ind Ltd, Biomed R&D Dept, Sakae Ku, Yokohama, Kanagawa 2448588, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130021, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1130021, Japan	Sumitomo Electric Industries; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science	Shimbara, N (corresponding author), Sumitomo Elect Ind Ltd, Biomed R&D Dept, Sakae Ku, 1 Taya Cho, Yokohama, Kanagawa 2448588, Japan.	nshinb@opele.sei.co.jp						AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Androlewicz MJ, 1996, IMMUNITY, V5, P1, DOI 10.1016/S1074-7613(00)80304-0; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; Brusic V, 1998, NUCLEIC ACIDS RES, V26, P368, DOI 10.1093/nar/26.1.368; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DEL VM, 1991, CELL, V66, P1145; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EGGERS M, 1995, J EXP MED, V182, P1865, DOI 10.1084/jem.182.6.1865; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; KEIL GM, 1987, J VIROL, V61, P1901, DOI 10.1128/JVI.61.6.1901-1908.1987; MA CP, 1992, J BIOL CHEM, V267, P10515; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; Monaco JJ, 1995, ANNU REV GENET, V29, P729, DOI 10.1146/annurev.ge.29.120195.003501; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Shimbara N, 1997, GENES CELLS, V2, P785, DOI 10.1046/j.1365-2443.1997.1610359.x; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Tanaka K, 1997, ADV IMMUNOL, V64, P1, DOI 10.1016/S0065-2776(08)60885-8; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; UENAKA A, 1994, J EXP MED, V180, P1599, DOI 10.1084/jem.180.5.1599; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WADA H, 1995, CANCER RES, V55, P4780; Yang B, 1996, J EXP MED, V183, P1545, DOI 10.1084/jem.183.4.1545; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	39	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23062	23071		10.1074/jbc.273.36.23062	http://dx.doi.org/10.1074/jbc.273.36.23062			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722532	hybrid			2022-12-25	WOS:000075778100032
J	Wells, MJ; Blajchman, MA				Wells, MJ; Blajchman, MA			In vivo clearance of ternary complexes of vitronectin-thrombin-antithrombin is mediated by hepatic heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED-PROTEIN; LOW-DENSITY-LIPOPROTEIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; HAMSTER OVARY CELLS; S-PROTEIN; UROKINASE RECEPTOR; ALPHA(2)-MACROGLOBULIN RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; ENDOTHELIAL-CELLS; CELLULAR INTERNALIZATION	Thrombin is inhibited by its cognate plasma inhibitor antithrombin, through the formation of covalent thrombin-antithrombin (TAT) complexes that are found as ternary complexes with vitronectin (VN-TAT). To determine whether the metabolism of VN-TAT ternary complexes is different from that previously reported for binary TAT complexes, plasma clearance studies were done in rabbits using human VN-TAT. I-125-VN-TAT was shown to be cleared rapidly from the circulation (t(1/2 alpha) = 3.8 min) in a biphasic manner mainly by the liver. I-125-TAT had a similar initial clearance (t(1/2 alpha) = 5.3 min) but had a significantly faster beta-phase clearance (t(1/2 beta) = 42.8 min versus 85.4 min for VN-TAT; p = 0.005). Protamine sulfate and heparin abolished the rapid initial alpha-phase of I-125-VN-TAT clearance and reduced its liver-specific association and in vivo degradation. Heparin also reduced the alpha-phase clearance of I-125-TAT and was associated with the appearance of high molecular weight complexes, suggesting enhanced complex formation between VN and TAT. I-125-VN-TAT binding to HepG2 cells was reduced by competition with VN-TAT or heparin but to a much lesser extent in the presence of TAT. The binding of VN-TAT to HepG2 cells was not inhibited by competition with the low density lipoprotein receptor-related protein ligand, methylamine-alpha(2)-macroglobulin. I-125-VN-TAT binding was also inhibited by treating HepG2 cells with heparinase or by growing the cells in the presence of beta-D-xyloside. Finally, both heparin and chloroquine, but not methylamine-alpha(2)-macroglobulin, reduced the internalization and degradation of VN-TAT by HepG2 cells. Taken together, these data indicate the importance of VN in TAT metabolism and demonstrate that VN-TAT binds to liver-associated heparan sulfate proteoglycans, which mediate its internalization and subsequent intracellular degradation.	McMaster Univ, Med Ctr, Dept Pathol, Hamilton, ON L8N 3Z5, Canada	McMaster University	Blajchman, MA (corresponding author), McMaster Univ, Med Ctr, Dept Pathol, 1200 Main St W,HSC 2N34, Hamilton, ON L8N 3Z5, Canada.							BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPEL DA, 1993, J BIOL CHEM, V267, P25764; Chen H, 1996, J BIOL CHEM, V271, P15993, DOI 10.1074/jbc.271.27.15993; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Coutts JC, 1995, IMMUNOL CELL BIOL, V73, P584, DOI 10.1038/icb.1995.92; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; deBoer HC, 1995, J BIOL CHEM, V270, P30733, DOI 10.1074/jbc.270.51.30733; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; FLECK A, 1985, ANN CLIN BIOCHEM, V22, P33, DOI 10.1177/000456328502200103; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P1; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOUINTHIBAULT I, 1995, BRIT J HAEMATOL, V90, P669, DOI 10.1111/j.1365-2141.1995.tb05599.x; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; ILL CR, 1985, J BIOL CHEM, V260, P5610; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; Krapp A, 1996, J LIPID RES, V37, P926; LIU LB, 1995, THROMB HAEMOSTASIS, V73, P405; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MIMURO J, 1989, J BIOL CHEM, V264, P936; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; PEAKE PW, 1997, CLIN EXP IMMUNOL, V106, P416; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIZZO SV, 1990, AM J MED, V87, pS10; PODACK ER, 1977, J IMMUNOL, V119, P2024; PODACK ER, 1986, J BIOL CHEM, V261, P7387; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; Preissner KT, 1996, SEMIN THROMB HEMOST, V22, P165, DOI 10.1055/s-2007-999005; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1988, THROMB HAEMOSTASIS, V60, P399; ROVELLI G, 1990, EUR J BIOCHEM, V192, P797, DOI 10.1111/j.1432-1033.1990.tb19293.x; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHEFFIELD WP, 1994, THROMB RES, V75, P293, DOI 10.1016/0049-3848(94)90240-2; Sheffield WP, 1995, MOL BASIS THROMBOSIS, P355; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1986, BLOOD, V68, P737; TOMASINI BR, 1988, BLOOD, V72, P903; vanMeijer M, 1997, THROMB HAEMOSTASIS, V77, P516; Warshawsky I, 1996, J BIOL CHEM, V271, P25873, DOI 10.1074/jbc.271.42.25873; Wells MJ, 1997, J BIOL CHEM, V272, P28574, DOI 10.1074/jbc.272.45.28574; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; Wu SM, 1996, ARCH BIOCHEM BIOPHYS, V326, P39, DOI 10.1006/abbi.1996.0044; Zhuang P, 1997, J BIOL CHEM, V272, P6858, DOI 10.1074/jbc.272.11.6858	56	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23440	23447		10.1074/jbc.273.36.23440	http://dx.doi.org/10.1074/jbc.273.36.23440			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722580	hybrid			2022-12-25	WOS:000075778100080
J	Cheng, C; Prince, LS; Snyder, PM; Welsh, MJ				Cheng, C; Prince, LS; Snyder, PM; Welsh, MJ			Assembly of the epithelial Na+ channel evaluated using sucrose gradient sedimentation analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; CAENORHABDITIS-ELEGANS; ION CHANNELS; SUBUNITS; NEURODEGENERATION; EXPRESSION; STABILITY; CLONING; DOMAIN	Three subunits, alpha, beta, and gamma, contribute to the formation of the epithelial Naf channel. To investigate the oligomeric assembly of the channel complex, we used sucrose gradient sedimentation analysis to determine the sedimentation properties of individual subunits and heteromultimers comprised of multiple subunits. When the alpha subunit was expressed alone, it first formed an oligomeric complex with a sedimentation coefficient of 11 S, and then generated a higher order multimer of 25 S, In contrast, individual beta and gamma subunits predominately assembled into 11 S complexes. We obtained similar results with expression in cells and in vitro. When we co-expressed beta with alpha or with alpha plus gamma, the beta subunit assembled into a 25 S complex. Glycosylation of the alpha subunit was not required for assembly into a 25 S complex. We found that the cu subunit formed intra-chain disulfide bonds. Although such bonds were not required to generate an oligomeric complex, under nonreducing conditions the Lu subunit formed a complex that migrated more homogeneously at 25 S. This suggests that intra-chain disulfide bonds may stabilize the complex. These data suggest that the epithelial Na+ channel subunits form high order oligomeric complexes and that the ct subunit contains the information that facilitates such formation. Interestingly, the ability of the alpha, but not the beta or gamma, subunit to assemble into a 25 S homomeric complex correlates with the ability of these subunits to generate functional channels when expressed alone.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, 500 EMRB, Iowa City, IA 52242 USA.	mjwelsh@blue.weeg.uiowa.edu		Welsh, Michael/0000-0002-1646-6206	NHLBI NIH HHS [HL07121] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; Corey DP, 1996, SCIENCE, V273, P323, DOI 10.1126/science.273.5273.323; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; PFAFFINGER PJ, 1995, J BIOL CHEM, V270, P28595, DOI 10.1074/jbc.270.48.28595; Pontiggia L, 1997, BIOCHEM BIOPH RES CO, V231, P755, DOI 10.1006/bbrc.1997.6188; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Young BD, 1984, CENTRIFUGATION PRACT, P127	24	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22693	22700		10.1074/jbc.273.35.22693	http://dx.doi.org/10.1074/jbc.273.35.22693			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712899	hybrid			2022-12-25	WOS:000075616600075
J	Boot, RG; Renkema, GH; Verhoek, M; Strijland, A; Bliek, J; de Meulemeester, TMAMO; Mannens, MMAM; Aerts, JMFG				Boot, RG; Renkema, GH; Verhoek, M; Strijland, A; Bliek, J; de Meulemeester, TMAMO; Mannens, MMAM; Aerts, JMFG			The human chitotriosidase gene - Nature of inherited enzyme deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITINASE PROTEIN FAMILY; MOLECULAR CHARACTERIZATION; ANTIFUNGAL PROPERTIES; PLANT CHITINASES; EXON MUTATION; EXPRESSION; CLONING; PURIFICATION; RESOLUTION; INHIBITORS	The human chitinase, named chitotriosidase, is a member of family 18 of glycosylhydrolases. Following the cloning of the chitotriosidase cDNA (Boot, R. G., Renkema, G. H., Strijland, A., van Zonneveld, A. J., and Aerts, J. M. F. G. (1995) J. Biol. Chem. 270, 26252-26256), the gene and mRNA have been investigated. The chitotriosidase gene is assigned to chromosome 1q31-q32. The gene consists of 12 exons and spans about 20 kilobases, The nature of the common deficiency in chitotriosidase activity is reported. A 24-base pair duplication in exon 10 results in activation of a cryptic 3' splice site, generating a mRNA with an in-frame deletion of 87 nucleotides. All chitotriosidase-deficient individuals tested were homozygous for the duplication. The observed carrier frequency of about 35% indicates that the duplication is the predominant cause of chitotriosidase deficiency, The presence of the duplication in individuals from various ethnic groups suggests that this mutation is relatively old.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Inst Anthropogenet, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Aerts, JMFG (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Aerts, Johannes/A-1028-2009; Renkema, Herma/L-1489-2015	Aerts, Johannes/0000-0001-8168-2565; Renkema, Herma/0000-0002-8174-6538; Boot, Rolf/0000-0002-7031-3390				ARIAS EB, 1994, BIOL REPROD, V51, P685, DOI 10.1095/biolreprod51.4.685; Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BENHAMOU N, 1993, CAN J MICROBIOL, V39, P318, DOI 10.1139/m93-045; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROEKAERT WF, 1988, PHYSIOL MOL PLANT P, V33, P319, DOI 10.1016/0885-5765(88)90001-X; CAMARA VM, 1990, LAB INVEST, V63, P544; COLLINGE DB, 1993, PLANT J, V3, P31, DOI 10.1046/j.1365-313X.1993.t01-1-00999.x; COULSON AFW, 1994, FEBS LETT, V354, P41, DOI 10.1016/0014-5793(94)01084-6; Eiberg H, 1997, HUM GENET, V101, P205, DOI 10.1007/s004390050615; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; HASEGAWA Y, 1994, HUM GENET, V93, P415; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; HUYNH QK, 1992, J BIOL CHEM, V267, P6635; JONK LJC, 1992, MECH DEVELOP, V36, P165, DOI 10.1016/0925-4773(92)90067-T; LEHRACH H., 1990, GENOME ANAL, P39; LIGHTENBERG JL, 1991, NUCLEIC ACIDS RES, V19, P297; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; ROBERTS WK, 1988, J GEN MICROBIOL, V134, P169; SAHAI AS, 1993, FEMS MICROBIOL REV, V11, P317, DOI 10.1111/j.1574-6976.1993.tb00004.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLUMBAUM A, 1986, NATURE, V324, P365, DOI 10.1038/324365a0; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; WAKAMATSU N, 1992, J BIOL CHEM, V267, P2406; WIEGANT J, 1991, GENOMICS, V10, P345, DOI 10.1016/0888-7543(91)90318-9	34	327	351	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25680	25685		10.1074/jbc.273.40.25680	http://dx.doi.org/10.1074/jbc.273.40.25680			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748235	hybrid, Green Published			2022-12-25	WOS:000076263100026
J	Hussain, MM; Bakillah, A; Nayak, N; Shelness, GS				Hussain, MM; Bakillah, A; Nayak, N; Shelness, GS			Amino acids 430-570 in apolipoprotein B are critical for its binding to microsomal triglyceride transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HEPG2 CELLS; SECRETION; ABETALIPOPROTEINEMIA; DEGRADATION; EXPRESSION; INHIBITION; DOMAIN; B-100	Several studies have demonstrated protein-protein interactions between microsomal triglyceride transfer protein (MTP) and apolipoprotein B (apoB). However, the binding sites involved in these interactions have not been elucidated. To identify an MTP binding site in apoB, we have expressed several apoB sequences as fusion proteins with the eight-amino acid FLAG peptide. The chimeras were transiently expressed in COS cells, and conditioned media were used to study the binding of these sequences to either immobilized or soluble MTP. A polypeptide containing amino acids 270-570 (B:270-570), but not 1-300, bound to MTP. AGI-S17, an antagonist of apoB-MTP binding, inhibited the binding of B:270-570 to MTP but not to M2, a monoclonal antibody that recognizes the FLAG peptide. These data indicated that B:270-570 contains an MTP binding site. Next, sequences within 270-570 were subjected to C-terminal truncations at natural proline residues. B:270-509 bound less efficiently than B:270-570, whereas, B:270-430 and other shorter chimeras did not bind to MTP. Furthermore, truncations at amino acids 502 and 509 decreased MTP binding by 73 and 42%, respectively. These data indicate that B:430-570 in the alpha(1)-globular domain of apoB plays a crucial role in MTP binding and presumably in the initiation and maturation of apoB-containing lipoproteins.	Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Dept Pathol, Philadelphia, PA 19129 USA; Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Dept Biochem, Philadelphia, PA 19129 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA	Drexel University; Drexel University; Wake Forest University; Wake Forest Baptist Medical Center	Hussain, MM (corresponding author), Allegheny Univ Hlth Sci, MCP Hahnemann Sch Med, Dept Pathol, 2900 Queen Lane, Philadelphia, PA 19129 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, P01HL049373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046900, R01DK046900, R29DK046900] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-22633, HL-49373] Funding Source: Medline; NIDDK NIH HHS [DK-46900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; EBERT DL, 1988, J LIPID RES, V29, P1501; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Haghpassand M, 1996, J LIPID RES, V37, P1468; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Ingram MF, 1997, J BIOL CHEM, V272, P10279; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LINTON MF, 1993, J LIPID RES, V34, P521; Luchoomun J, 1997, ARTERIOSCL THROM VAS, V17, P2955, DOI 10.1161/01.ATV.17.11.2955; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Sambrook J., 2002, MOL CLONING LAB MANU; SCHONFELD G, 1995, ANNU REV NUTR, V15, P23, DOI 10.1146/annurev.nu.15.070195.000323; Segrest JP, 1998, J LIPID RES, V39, P85; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801	35	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25612	25615		10.1074/jbc.273.40.25612	http://dx.doi.org/10.1074/jbc.273.40.25612			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748226	hybrid			2022-12-25	WOS:000076263100017
J	Barbero, P; Rovere, C; De Bie, I; Seidah, N; Beaudet, A; Kitabgi, P				Barbero, P; Rovere, C; De Bie, I; Seidah, N; Beaudet, A; Kitabgi, P			PC5-A-mediated processing of pro-neurotensin in early compartments of the regulated secretory pathway of PC5-transfected PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMEDIN-N-PRECURSOR; PROHORMONE CONVERTASES PC1; SUBTILISIN FAMILY; BIOCHEMICAL-CHARACTERIZATION; ENZYMATIC-PROPERTIES; ADRENAL-MEDULLA; IDENTIFICATION; CDNA; RAT; SEQUENCE	Among the members of the proprotein convertase (PC) family, PC1 and PC2 have well established roles as prohormone convertases. Another good candidate for this role is PC5-A that has been shown to be present in the regulated secretory pathway of certain neuroendocrine tissues, but evidence that it can process prohormones is lacking. To determine whether PC5-A could function as a prohormone convertase and to compare its cleavage specificity with that of PC1 and PC2, we stably transfected the rat pheochromocytoma PC12 cell line with PC5-A and analyzed the biosynthesis and subcellular localization of the enzyme, as well as its ability to process pro-neurotensin/neuromedin N (pro-NT/NN) into active peptides, Our data showed that in transfected PC12 cells, PC5-A was converted from its 126-kDa precursor form into a 117-kDa mature form and, to a lesser extent, into a C-terminally truncated 65-kDa form of the 117-kDa product. Metabolic and immunochemical studies showed that PC5-A was sorted to early compartments of the regulated secretory pathway where it colocalized with immunoreactive NT. Furthermore, pro-NT/NN was processed in these compartments according to a pattern that differed from that previously described in PC1- and PC2-transfected PC12 cells. This pattern resembled that previously reported for pro-NT/NN processing in the adrenal medulla, a tissue known to express high levels of PC5-A. Altogether, these data demonstrate for the first time the ability of PC5-A to function as a prohormone convertase in the regulated secretory pathway and suggest a role for this enzyme in the physiological processing of pro-NT/NN.	Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Kitabgi, P (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	kitabgi@ipmc.cnrs.fr	Seidah, Nabil/I-3596-2013; Rovere-Jovene, Carole/O-4557-2016	Seidah, Nabil/0000-0001-6503-9342; Rovere-Jovene, Carole/0000-0001-9400-7972				BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BIDARD JN, 1993, BIOCHEM J, V291, P225, DOI 10.1042/bj2910225; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; Campan M, 1996, BIOCHEMISTRY-US, V35, P3797, DOI 10.1021/bi952552d; CARRAWAY RE, 1990, J BIOL CHEM, V265, P8627; CARRAWAY RE, 1993, REGUL PEPTIDES, V43, P97, DOI 10.1016/0167-0115(93)90412-2; CARRAWAY RE, 1993, PEPTIDES, V14, P991, DOI 10.1016/0196-9781(93)90076-S; CARRAWAY RE, 1992, ANN NY ACAD SCI, V668, P1, DOI 10.1111/j.1749-6632.1992.tb27335.x; CARRAWAY RE, 1991, BIOCHEM BIOPH RES CO, V179, P301, DOI 10.1016/0006-291X(91)91369-N; CORDER R, 1982, NEUROPEPTIDES, V3, P9, DOI 10.1016/0143-4179(82)90061-0; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; DENADAI F, 1994, NEUROSCIENCE, V60, P159, DOI 10.1016/0306-4522(94)90211-9; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; DOBNER PR, 1987, P NATL ACAD SCI USA, V84, P3516, DOI 10.1073/pnas.84.10.3516; FISCHERCOLBRIE R, 1992, J NEUROCHEM, V59, P780, DOI 10.1111/j.1471-4159.1992.tb09440.x; GOEDERT M, 1983, NEUROSCI LETT, V35, P155, DOI 10.1016/0304-3940(83)90543-8; GONATAS JO, 1995, J CELL SCI, V108, P457; HALBAN PA, 1994, BIOCHEM J, V299, P1; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; KISLAUSKIS E, 1988, J BIOL CHEM, V263, P4963; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P614, DOI 10.1006/mcne.1994.1075; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Nachtigal MW, 1996, P NATL ACAD SCI USA, V93, P7711, DOI 10.1073/pnas.93.15.7711; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; ROTHENBERG ME, 1995, J BIOL CHEM, V270, P10136, DOI 10.1074/jbc.270.17.10136; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Rovere C, 1998, BIOCHEM BIOPH RES CO, V246, P155, DOI 10.1006/bbrc.1998.8506; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; ROVERE C, 1993, PEPTIDES, V14, P983, DOI 10.1016/0196-9781(93)90075-R; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHAW C, 1990, PEPTIDES, V11, P227, DOI 10.1016/0196-9781(90)90075-G; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TERENGHI G, 1983, ENDOCRINOLOGY, V112, P226, DOI 10.1210/endo-112-1-226; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702	50	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25339	25346		10.1074/jbc.273.39.25339	http://dx.doi.org/10.1074/jbc.273.39.25339			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738000	hybrid			2022-12-25	WOS:000076085400050
J	Brown, JP; Gee, NS				Brown, JP; Gee, NS			Cloning and deletion mutagenesis of the alpha(2)delta calcium channel subunit from porcine cerebral cortex - Expression of a soluble form of the protein that retains [H-3]gabapentin binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; GABAPENTIN NEURONTIN; H-3 GABAPENTIN; CA2+ CHANNELS; BETA-SUBUNIT; ZINC FINGERS; RAT-BRAIN; ACID; ALPHA-2-SUBUNIT; GABA	The anti-epileptic, anti-hyperalgesic, and anxiolytic agent gabapentin (1-(aminomethyl)-cyclohexane acetic acid or Neurontin) has previously been shown to bind with high affinity to the alpha(2)delta subunit of voltage-dependent calcium channels (Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., and Woodruff, G.N. (1996) J. Biol. Chem. 271, 5768-5776). We report here the cloning, sequencing, and deletion mutagenesis of the alpha(2)delta subunit from porcine brain. The deduced protein sequence has a 95.9 and 98.2% identity to the rat and human neuronal alpha(2)delta sequences, respectively. [H-3]Gabapentin binds with a K-D of 37.5 +/- 10.4 nM to membranes prepared from COS-7 cells transfected with wild-type porcine alpha(2)delta cDNA. Six deletion mutants (B-G) that lack the delta polypeptide, together with varying amounts of the alpha(2) component, failed to bind [H-3]gabapentin. C-terminal deletion mutagenesis of the delta polypeptide identified a segment (residues 960-994) required for correct assembly of the [H-3]gabapentin binding pocket. Mutant L, which lacks the putative membrane anchor in the delta sequence, was found in both membrane-associated and soluble secreted forms. The soluble form was not proteolytically cleaved into separate alpha(2) and delta chains but still retained a high affinity (K-D = 30.7 +/- 8.1 nM) for [H-3]gabapentin. The production of a soluble alpha(2)delta mutant supports the single transmembrane model of the alpha(2)delta subunit and is an important step toward the large-scale recombinant expression of the protein.	Univ Cambridge, Parke Davis Neurosci Res Ctr, Cambridge CB2 2QB, England	University of Cambridge	Brown, JP (corresponding author), Univ Cambridge, Parke Davis Neurosci Res Ctr, Forvie Site,Robinson Way, Cambridge CB2 2QB, England.							BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; BRICKLEY K, 1995, FEBS LETT, V364, P129, DOI 10.1016/0014-5793(95)00371-F; Brown JP, 1998, ANAL BIOCHEM, V255, P236, DOI 10.1006/abio.1997.2447; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; BURGESS AJ, 1988, EUR J BIOCHEM, V178, P527, DOI 10.1111/j.1432-1033.1988.tb14479.x; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHAUHAN NS, 1993, EUR J PHARMACOL, V244, P293; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; Dissanayake VUK, 1997, BRIT J PHARMACOL, V120, P833, DOI 10.1038/sj.bjp.0700988; DOOLEY DJ, 1986, GOLD JUB C NO EUR EP; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GOTZ E, 1993, ARZNEIMITTEL-FORSCH, V43-1, P636; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONMOU O, 1995, EPILEPSY RES, V20, P193, DOI 10.1016/0920-1211(94)00076-9; HONMOU O, 1995, BRAIN RES, V692, P273, DOI 10.1016/0006-8993(95)00634-3; ITAGAKI K, 1992, FEBS LETT, V297, P221, DOI 10.1016/0014-5793(92)80542-O; JAY SD, 1991, J BIOL CHEM, V266, P3287; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOSCHER W, 1991, NEUROSCI LETT, V128, P150, DOI 10.1016/0304-3940(91)90249-S; MACDONALD RL, 1993, EPILIPSIA, V34, P1; MELLICK GA, 1995, J PAIN SYMPTOM MANAG, V10, P265, DOI 10.1016/0885-3924(95)00001-F; Mellick GA, 1996, SLEEP, V19, P224, DOI 10.1093/sleep/19.3.224; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Patel J, 1996, CLIN NEUROPHARMACOL, V19, P185, DOI 10.1097/00002826-199619020-00008; PEREZREYES E, 1994, DRUG DEVELOP RES, V33, P295, DOI 10.1002/ddr.430330311; Petroff OAC, 1996, ANN NEUROL, V39, P95, DOI 10.1002/ana.410390114; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; RAMSAY RE, 1994, NEUROLOGY, V44, P23; REIMANN W, 1983, EUR J PHARMACOL, V94, P341, DOI 10.1016/0014-2999(83)90425-9; ROCK DM, 1993, EPILEPSY RES, V16, P89, DOI 10.1016/0920-1211(93)90023-Z; SCOTLAND PB, 1993, J CELL BIOL, V123, P719, DOI 10.1083/jcb.123.3.719; Segal AZ, 1996, NEUROLOGY, V46, P1175, DOI 10.1212/WNL.46.4.1175; Shimoyama N, 1997, NEUROSCI LETT, V222, P65, DOI 10.1016/S0304-3940(97)13331-6; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Singh L, 1996, PSYCHOPHARMACOLOGY, V127, P1, DOI 10.1007/BF02805968; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; TAYLOR CP, 1993, EPILEPSY RES, V14, P11, DOI 10.1016/0920-1211(93)90070-N; TAYLOR CP, 1994, NEUROLOGY, V44, P10; THURLOW RJ, 1993, EUR J PHARM-MOLEC PH, V247, P341, DOI 10.1016/0922-4106(93)90204-M; WAMIL A W, 1991, Neurology, V41, P140; WATSON WP, 1995, BRIT J PHARMACOL, V116, pP33; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Wiser O, 1996, FEBS LETT, V379, P15, DOI 10.1016/0014-5793(95)01475-6; Xiao W.-H., 1995, Society for Neuroscience Abstracts, V21, P897; XU XF, 1994, GENE, V148, P357, DOI 10.1016/0378-1119(94)90713-7	54	58	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25458	25465		10.1074/jbc.273.39.25458	http://dx.doi.org/10.1074/jbc.273.39.25458			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9738015	hybrid			2022-12-25	WOS:000076085400065
J	Beguin, P; Hasler, U; Beggah, A; Horisberger, JD; Geering, K				Beguin, P; Hasler, U; Beggah, A; Horisberger, JD; Geering, K			Membrane integration of Na,K-ATPase alpha-subunits and beta-subunit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO TRANSLATION; NEWLY SYNTHESIZED POLYPEPTIDE; INTRACELLULAR-TRANSPORT; PROTEIN TRANSLOCATION; TRANSMEMBRANE HELICES; FUNCTIONAL EXPRESSION; HYDROPHOBIC SEGMENTS; PRIMARY SEQUENCE; TOPOLOGY; OLIGOMERIZATION	The control of membrane insertion of polytopic proteins is still poorly understood, We carried out in vivo translation/insertion experiments in Xenopus oocytes with combined wild type or mutant membrane segments of the alpha-subunit of the heterodimeric Na,K-ATPase linked to a glycosylation reporter sequence. We confirm that the four N-terminaI hydrophobic segments of the alpha-subunit behave as alternating signal anchor/stop transfer motifs necessary for two lipid-inserted membrane pairs, For the six C-terminal membrane segments, however, proper packing depends on specific sequence information and association with the beta-subunit, M5 is a very inefficient signal anchor sequence due to the presence of prolines and polar amino acids. Its correct membrane insertion is probably mediated by posttranslational hairpin formation with M6, which is favored by a proline pair in the connecting loop, M7 has partial signal anchor function, which may be mediated by the presence of glycine and glutamine residues, The formation of a transmembrane M7/M8 pair requires the association of the beta-subunit, which induces a conformational change in the connecting extracytoplasmic loop that favors M7/M8 packing, The formation of the M9/M10 pair appears to be predominantly mediated by the efficient stop transfer function of M10. Mutations that provide signal anchor function to M5, M7, and M9 abolish or impede the transport activity of the enzyme, These data illustrate the importance of specific amino acids near or within hydrophobic regions as well as of subunit oligomerization for correct topographical alignment that is necessary for proper folding and/or activity of oligomeric membrane proteins.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Geering, K (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	kaethi.geering@ipharm.unil.ch	Horisberger, Jean-Daniel/A-2538-2009					ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J RECEPT SIGNAL TR R, V17, P29, DOI 10.3109/10799899709036593; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; DEBER CM, 1997, MOL B INT U, P25; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GEERING K, 1997, MOL B INT U, P173; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; High S, 1997, TRENDS CELL BIOL, V7, P206; HOMAREDA H, 1989, MOL CELL BIOL, V9, P5742, DOI 10.1128/MCB.9.12.5742; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; Karlish SJD, 1997, ANN NY ACAD SCI, V834, P30, DOI 10.1111/j.1749-6632.1997.tb52223.x; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SAKAGUCHI M, 1997, MOL B INT U, P135; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; XIE YH, 1995, J BIOL CHEM, V270, P11985, DOI 10.1074/jbc.270.20.11985; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; [No title captured]	35	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24921	24931		10.1074/jbc.273.38.24921	http://dx.doi.org/10.1074/jbc.273.38.24921			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733799	hybrid			2022-12-25	WOS:000076007300091
J	Richardson, RM; Pridgen, BC; Haribabu, B; Ali, H; Snyderman, R				Richardson, RM; Pridgen, BC; Haribabu, B; Ali, H; Snyderman, R			Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2 - Evidence for time-dependent signal generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; PLATELET-ACTIVATING-FACTOR; MUSCARINIC CHOLINERGIC RECEPTORS; CHEMOATTRACTANT RECEPTORS; PHOSPHOLIPASE-C; PROTEIN-KINASE; IL-8 RECEPTOR; GRO-GAMMA; PHOSPHORYLATION; DESENSITIZATION	Neutrophils and transfected RBL-2H3 cells were used to investigate the mechanism of cross-regulation of the human interleukin-8 (IL-8) receptors CXCR1 and CXCR2 by chemoattractants. In neutrophils, Ca2+ mobilization by the CXCR2-specific chemokine, growth-related oncogene alpha (Gro alpha), was desensitized by prior exposure to the chemoattractants N-formylated peptides (fMLP) or a complement cleavage product (C5a). In contrast, growth-related oncogene alpha did not desensitize the latter receptors. To investigate this phenomenon, CXCR2 was stably expressed in RBL-2H3 cells and mediated phosphoinositide hydrolysis, Ca2+ mobilization, chemotaxis, and secretion. In cells co-expressing CXCR2 and receptors for either C5a (C5aR) or fMLP (FR), CXCR2 was cross-phosphorylated and cross-desensitized by C5a and fMLP. However, neither C5aR nor FR was cross-phosphorylated or cross-desensitized by CXCR2 activation, although CXCR1 did mediate this process. Receptor internalization induced by IL-8 was more rapid and occurred at lower doses with CXCR2 than CXCR1, although both receptors mediated equipotent chemotaxis and exocytosis in RBL. Truncation of the cytoplasmic tail of CXCR2 (331T) prolonged its signaling relative to CXCR2, increased its resistance to internalization, and induced phospholipase D activation. 331T was resistant to homologous phosphorylation and cross-phosphorylation but not cross-desensitization of its Ca2+ mobilization by fMLP or C5a, indicating an inhibitory site distal to receptor/G protein coupling. In contrast to CXCR2, stimulation of 331T cross-desensitized Ca2+ mobilization by both FR and C5aR. CXCR2 and the mutant 331T induced phospholipase C beta(3) phosphorylation to an extent equivalent to that of CXCR1. Taken together, these results suggest that CXCR1 and CXCR2 bind IL-8 to produce a group of equipotent responses, but their ability to generate other signals, including receptor internalization, cross-desensitization, and phospholipase D activation, are very different. The latter phenomena apparently require prolonged receptor activation, which in the case of CXCR2 is precluded by rapid receptor phosphorylation and internalization. Thus, receptors coupling to identical G; proteins may trigger different cellular responses dependent on the length of their signaling time, which can be regulated by receptor phosphorylation.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University	Richardson, RM (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3680, Durham, NC 27710 USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038910, R29AI038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54166] Funding Source: Medline; NIAID NIH HHS [AI-38910] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; Ali H, 1998, J BIOL CHEM, V273, P11012, DOI 10.1074/jbc.273.18.11012; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Blackwood RA, 1996, J LEUKOCYTE BIOL, V60, P88, DOI 10.1002/jlb.60.1.88; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; GEISER T, 1993, J BIOL CHEM, V268, P15419; Grimm MC, 1998, J EXP MED, V188, P317, DOI 10.1084/jem.188.2.317; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; SNYDERMAN R, 1984, ANNU REV IMMUNOL, V2, P257, DOI 10.1146/annurev.immunol.2.1.257; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; TOMHAVE E, 1994, J IMMUNOL, V154, P3267; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	34	126	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23830	23836		10.1074/jbc.273.37.23830	http://dx.doi.org/10.1074/jbc.273.37.23830			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726994	hybrid			2022-12-25	WOS:000075893100035
J	Buchet, K; Godinot, C				Buchet, K; Godinot, C			Functional F1-ATPase essential in maintaining growth and membrane potential of human mitochondrial DNA-depleted rho degrees cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ATP SYNTHASE; SACCHAROMYCES-CEREVISIAE; HEART-MITOCHONDRIA; ENZYME COMPLEX; H+-ATPASE; MONOCLONAL-ANTIBODIES; YEAST MITOCHONDRIA; MIT-MUTANTS; HELA-CELLS	F1-ATPase assembly has been studied in human rho degrees cells devoid of mitochondrial DNA (mtDNA), Since, in these cells, oxidative phosphorylation cannot provide ATP, their growth relies on glycolysis, Despite the absence of the mtDNA-coded F0 subunits 6 and 8, rho degrees cells possessed normal levels of F1-ATPase alpha and beta subunits, This F1-ATPase was functional and azide- or aurovertin-sensitive but oligomycin-insensitive. In addition, aurovertin decreased cell growth in rho degrees cells and also reduced their mitochondrial membrane potential, as measured by rhodamine 123 fluorescence. Therefore, a functional F1-ATPase was important to maintain the mitochondrial membrane potential and the growth of these rho degrees cells, Bongkrekic acid, a specific adenine nucleotide translocator (ANT) inhibitor, also reduced rho degrees cell growths and mitochondrial membrane potential. In conclusion, rho degrees cells need both a functional F1-ATPase and a functional ANT to maintain their mitochondrial membrane potential, which is necessary for their growth. ATP hydrolysis catalyzed by F1 must provide ADP(3-) at a sufficient rate to maintain a rapid exchange with the glycolytic ATP(4-) by ANT, this electrogenic exchange inducing a mitochondrial membrane potential efficient enough to sustain cell growth. However, since the effects of bongkrekic acid and of aurovertin were additive, other electrogenic pumps should cooperate with this pathway.	Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Godinot, C (corresponding author), Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France.	godinot@univ-lyon1.fr						ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AVNER PR, 1973, EUR J BIOCHEM, V32, P312, DOI 10.1111/j.1432-1033.1973.tb02612.x; BERGMEYER HU, 1973, METHOD ENZYMAT AN, P1464; Bouzidi MF, 1996, BBA-MOL BASIS DIS, V1317, P199, DOI 10.1016/S0925-4439(96)00055-5; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CHANG T, 1973, J BIOL CHEM, V248, P2746; CHEN LB, 1989, METHOD CELL BIOL, V29, P103; CHOO WM, 1985, BIOCHIM BIOPHYS ACTA, V806, P290, DOI 10.1016/0005-2728(85)90108-2; COLLINSON IR, 1994, J MOL BIOL, V242, P408; Enjolras N, 1997, MOL CELL BIOCHEM, V167, P113, DOI 10.1023/B:MCBI.0000009692.67331.d3; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Giraud MF, 1997, EUR J BIOCHEM, V245, P813, DOI 10.1111/j.1432-1033.1997.00813.x; GRIFFITHS EJ, 1993, BIOCHEM J, V290, P489, DOI 10.1042/bj2900489; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; HERZBERG NH, 1993, EUR J CELL BIOL, V61, P400; HUNDAL T, 1984, J BIOENERG BIOMEMBR, V16, P535, DOI 10.1007/BF00743244; KOLAROV J, 1974, FEBS LETT, V45, P320, DOI 10.1016/0014-5793(74)80871-9; LARDY HA, 1969, ANNU REV BIOCHEM, V38, P991, DOI 10.1146/annurev.bi.38.070169.005015; LI K, 1995, AM J PHYSIOL-CELL PH, V269, pC1265, DOI 10.1152/ajpcell.1995.269.5.C1265; Linnett P E, 1979, Methods Enzymol, V55, P472; Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x; MARZUKI S, 1989, BIOCHIM BIOPHYS ACTA, V975, P222, DOI 10.1016/S0005-2728(89)80252-X; MORADIAMELI M, 1983, P NATL ACAD SCI-BIOL, V80, P6167, DOI 10.1073/pnas.80.20.6167; MORAIS R, 1994, CANCER RES, V54, P3889; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q; NORAIS N, 1991, J BIOL CHEM, V266, P16541; ORIAN JM, 1984, J BIOENERG BIOMEMBR, V16, P561, DOI 10.1007/BF00743246; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PEREIRADASILVA L, 1993, ARCH BIOCHEM BIOPHYS, V304, P310, DOI 10.1006/abbi.1993.1355; PETIT JM, 1994, EUR J BIOCHEM, V220, P871, DOI 10.1111/j.1432-1033.1994.tb18690.x; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; Saito K, 1997, BIOL PHARM BULL, V20, P345; SANDRI G, 1985, ARCH BIOCHEM BIOPHYS, V239, P595, DOI 10.1016/0003-9861(85)90729-5; SKOWRONEK P, 1992, BIOCHEM BIOPH RES CO, V187, P991, DOI 10.1016/0006-291X(92)91295-2; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1; TSUZUKI T, 1983, GENE, V25, P223, DOI 10.1016/0378-1119(83)90226-3; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341	41	194	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22983	22989		10.1074/jbc.273.36.22983	http://dx.doi.org/10.1074/jbc.273.36.22983			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722521	hybrid			2022-12-25	WOS:000075778100021
J	Matsumoto, K; Kataoka, H; Date, K; Nakamura, T				Matsumoto, K; Kataoka, H; Date, K; Nakamura, T			Cooperative interaction between alpha and beta chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MOTILITY; EPITHELIAL-CELLS; MAMMARY-GLAND; FACTOR GENE; HGF; IDENTIFICATION; PURIFICATION; ANTAGONIST; EXPRESSION; DIFFERENTIATION	Hepatocyte growth factor (HGF) is a heterodimeric molecule composed of the alpha-chain containing the N-terminal hairpin domain, four kringle domains, and the serine protease-like beta-chain, We prepared HGF/NK4 and HGF/beta from the entire HGF after single-cut digestion with elastase. HGF/NK4 contains the N-terminal hairpin and four kringle domains, while HGF/beta is composed of the C-terminal 16 amino acids of the alpha-chain and the entire beta-chain, linked by a disulfide bridge. HGF/NK4 competitively inhibited the binding of I-125-RGF to the receptor, and affinity cross-linking analysis indicated that HGF/NK4 alone can bind to the c-Met receptor. In contrast, HGF/beta alone did not competitively inhibit the binding of I-125-HGF to the receptor and did not bind to the c-Met/HGF receptor. Scatchard analysis and affinity cross-linking experiments indicated that HGF/beta specifically binds to c-Met in the presence of HGF/NK4 but not HGF/NK2, Neither HGF/NK4 nor HGF/beta alone induced mitogenic, motogenic (cell scattering), and morphogenic (induction of branching tubulogenesis) responses; however, HGF/beta did induce these biological responses in the presence of HGF/NK4. Consistent with these results, although neither HGF/NK4 alone nor HGF/beta alone induced tyrosine phosphorylation of the c-Met/HGF receptor, HGF/beta induced tyrosine phosphorylation of the receptor when c-Met/HGF receptor was occupied by HGF/NK4. These results indicate that HGF/beta binds to the c-Met/HGF receptor that is occupied by HGF/NK4 and induces receptor tyrosine phosphorylation and the subsequent biological activities of HGF. We propose that there exists a unique cooperative interaction between alpha- and beta-chains, this interaction leading to alpha-chain-dependent receptor tyrosine phosphorylation and subsequent biological responses.	Osaka Univ, Sch Med, Biomed Res Ctr, Div Biochem, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Div Biochem, Osaka 5650871, Japan.		MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482				BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; ITAKURA Y, 1994, CANCER LETT, V83, P235, DOI 10.1016/0304-3835(94)90325-5; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SILVAGNO F, 1995, ARTERIOSCL THROM VAS, V15, P1857, DOI 10.1161/01.ATV.15.11.1857; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; Takai K, 1997, BLOOD, V89, P1560, DOI 10.1182/blood.V89.5.1560.1560_1560_1565; TAKEBAYASHI T, 1995, J CELL BIOL, V129, P1411, DOI 10.1083/jcb.129.5.1411; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Yamada Akira, 1995, Biomedical Research (Tokyo), V16, P105; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHU H, 1994, J BIOL CHEM, V269, P29943	41	80	91	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					22913	22920		10.1074/jbc.273.36.22913	http://dx.doi.org/10.1074/jbc.273.36.22913			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722511	hybrid			2022-12-25	WOS:000075778100011
J	Collier, B; Goobar-Larsson, L; Sokolowski, M; Schwartz, S				Collier, B; Goobar-Larsson, L; Sokolowski, M; Schwartz, S			Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and Poly(rC)-binding proteins 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEGATIVE REGULATORY ELEMENT; 3' UNTRANSLATED REGION; LATE MESSENGER-RNAS; AU-RICH; POLIOVIRUS RNA; NUCLEAR; REPLICATION; POLYMERASE; EXPRESSION	Human papillomavirus (HPV) type 16 belongs to the group of "high risk" BPV types that are frequently detected in anogenital cancers. The expression of HPV-16 late genes encoding the virus capsid proteins L1 and L2 is restricted to terminally differentiated epithelial cells in the superficial layers of the squamous epithelium. We have previously identified negative elements in the 3' end of L2 RNA that act in cis to reduce mRNA utilization without substantially affecting mRNA levels. The experiments reported here demonstrate the interaction of cellular proteins with an inhibitory sequence present in the coding region of the L2 mRNA. Using RNA gel shift assays and UV cross-linking, we have detected three cellular proteins interacting specifically with the sense strand of the L2 mRNA, two of which were identified as heterogeneous ribonucleoprotein K (hnRNP K) and the poly(rC) binding- protein (PCBP). Recombinant hnRNP K, PCBP-1, and PCBP-2 that were over expressed in bacteria and partially purified bound to the HPV-16 L2 mRNA in a sequence-specific manner. Interestingly, PCBP-1, PCBP-2, and hnRNP K specifically and efficiently inhibited translation of the HPV-16 L2 mRNA in vitro. Therefore, these proteins may play an important role in the regulation of HPV-16 late gene expression and virus production in vivo.	Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Uppsala University	Schwartz, S (corresponding author), Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, Husargatan 3,Box 582, S-75123 Uppsala, Sweden.	Stefan.Schwartz@imim.uu.se		Sokolowski, Marcus/0000-0003-3931-1810				BILLAKANTI SR, 1996, HUMAN PAPILLOMAVIRUS; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; Dejgaard K, 1996, EUR J BIOCHEM, V241, P425, DOI 10.1111/j.1432-1033.1996.00425.x; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DietrichGoetz W, 1997, P NATL ACAD SCI USA, V94, P163, DOI 10.1073/pnas.94.1.163; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLNER L, 1991, J VIROL, V65, P6862, DOI 10.1128/JVI.65.12.6862-6871.1991; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FURTH PA, 1994, MOL CELL BIOL, V14, P5278, DOI 10.1128/MCB.14.8.5278; FURTH PA, 1991, J VIROL, V65, P5806, DOI 10.1128/JVI.65.11.5806-5812.1991; Gamarnik AV, 1997, RNA, V3, P882; HAGENSEE ME, 1996, PAPILLOMAVIRUS REV C, P85; Heino P, 1995, VIROLOGY, V214, P349, DOI 10.1006/viro.1995.0044; HOWLEY PM, 1996, VIROLOGY, V2, P2045; KENNEDY IM, 1991, J VIROL, V65, P2093, DOI 10.1128/JVI.65.4.2093-2097.1991; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MEYERS C, 1996, PAPILLOMAVIRUS REV C, P79; MYER VE, 1996, EMBO J, V15, P2130; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; ROSS J, 1995, MICROBIOL REV, V59, P15; SCHWARTZ S, 1997, SEMIN VIROL, V8, P1; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SHAH KV, 1996, FIELDS VIROLOGY, V2, P2077; Sokolowski M, 1997, ONCOGENE, V15, P2303, DOI 10.1038/sj.onc.1201415; Sokolowski M, 1998, J VIROL, V72, P1504, DOI 10.1128/JVI.72.2.1504-1515.1998; STANLEY MA, 1994, ANTIVIR RES, V24, P1, DOI 10.1016/0166-3542(94)90047-7; TAN W, 1995, J VIROL, V69, P2932, DOI 10.1128/JVI.69.5.2932-2945.1995; TAN W, 1995, J VIROL, V69, P5607, DOI 10.1128/JVI.69.9.5607-5620.1995; Zhao CP, 1996, J VIROL, V70, P3659, DOI 10.1128/JVI.70.6.3659-3667.1996; zur Hausen H, 1996, BIOCHIM BIOPHYS ACTA, V1288, P55	36	165	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22648	22656		10.1074/jbc.273.35.22648	http://dx.doi.org/10.1074/jbc.273.35.22648			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712894	hybrid			2022-12-25	WOS:000075616600070
J	Fischer, J; Palmedo, G; von Knobloch, R; Bugert, P; Prayer-Galetti, T; Pagano, F; Kovacs, G				Fischer, J; Palmedo, G; von Knobloch, R; Bugert, P; Prayer-Galetti, T; Pagano, F; Kovacs, G			Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours	ONCOGENE			English	Article						MET tyrosine kinase; germline mutation; allelic duplication; papillary renal cell tumours	HEPATOCYTE GROWTH-FACTOR; NORMAL KIDNEY TISSUE; SCATTER FACTOR; EPITHELIAL-CELLS; RECEPTOR; CARCINOMA; TUMORS; CYTOGENETICS; ABERRATIONS	Previous karyotyping showed a combined trisomy of chromosome 7 and 17 in sporadic and hereditary papillary renal cell rumours (RCT). A recent molecular analysis revealed a mutation in the MET tyrosine kinase (chromosome 7q31) in the germline of four out of seven families with hereditary papillary RCT (HPRCT), We have analysed germline cells as well as multiple tumours obtained from HPRCT families and sporadic cases for alteration of the MET tyrosine kinase and for allelic duplication at chromosome 7 and 17. We have detected a germ line mutation in the MET tyrosine kinase in one of the two families with HPRCTs and also found the same mutation in the germ line of one patient with clinically recognized multiple, bilateral papillary RCTs but without family history. The mutant MET allele is consequently duplicated and overexpressed in tumour cells indicating that duplication of the mutant MET allele is necessary before cells enter the tumorigenic pathway. The lack of germline mutation in two members of another HPRT family and duplication of the same parental allele of chromosome 7 in multiple tumours suggests that a germ Line event other than mutation of MET tyrosine kinase is involved in the development of these tumours, Duplication of different alleles of chromosome 7 in sporadic and of chromosome 17 in both types of tumours excludes a germline mutation at these chromosomal sites.	Ruprecht Karls Univ, Dept Urol, Mol Oncol Lab, D-69120 Heidelberg, Germany; Univ Padua, Dept Urol, I-35128 Padua, Italy	Ruprecht Karls University Heidelberg; University of Padua	Kovacs, G (corresponding author), Ruprecht Karls Univ, Dept Urol, Mol Oncol Lab, Neuenheimer Feld 365, D-69120 Heidelberg, Germany.		von Knobloch, Prof. Dr. Rolf/GRF-5837-2022	von Knobloch, Prof. Dr. Rolf/0000-0002-0358-203X				BENTZ M, 1996, CYTOGENET CELL GENET, V75, P177; Bernues M, 1995, CANCER GENET CYTOGEN, V84, P123, DOI 10.1016/0165-4608(95)00044-5; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; Bugert P, 1996, AM J PATHOL, V149, P2081; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; Duh FM, 1997, ONCOGENE, V15, P1583, DOI 10.1038/sj.onc.1201338; EMANUEL A, 1992, GENE CHROMOSOME CANC, V4, P75, DOI 10.1002/gcc.2870040110; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Kovacs A, 1993, J UROL PATHOL, V1, P301; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; KOVACS G, 1989, AM J PATHOL, V134, P27; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; KOVACS G, 1989, CANCER GENET CYTOGEN, V37, P289, DOI 10.1016/0165-4608(89)90063-0; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PLMEDO G, 1997, LAB INVEST, V77, P633; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; SACCONE S, 1992, GENOMICS, V13, P912, DOI 10.1016/0888-7543(92)90191-T; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZBAR B, 1995, J UROLOGY, V153, P907, DOI 10.1016/S0022-5347(01)67601-8	26	102	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					733	739		10.1038/sj.onc.1201983	http://dx.doi.org/10.1038/sj.onc.1201983			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715275	Bronze			2022-12-25	WOS:000075337200008
J	Zhang, JS; Nelson, M; McIver, B; Hay, ID; Goellner, JR; Grant, CS; Eberhardt, NL; Smith, DI				Zhang, JS; Nelson, M; McIver, B; Hay, ID; Goellner, JR; Grant, CS; Eberhardt, NL; Smith, DI			Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors	ONCOGENE			English	Article						7q31.2; LOH; thyroid cancer; FRA7G	SUPPRESSOR GENE; ONCOGENE ACTIVATION; BREAST-CANCER; FHIT GENE; CARCINOMAS; MUTATIONS; TUMORIGENESIS; NEOPLASMS; REGION; 3P14.2	We analysed 42 differentiated thyroid tumors including 15 follicular adenomas (FA), 13 papillary thyroid cancers (PTC) and 14 follicular thyroid carcinomas (FTC) with 13 microsatellite markers specific for the long arm of human chromosome 7 within 7q31; this region is deleted frequently in several other tumor types. Overall, 20 of the 42 samples analysed (48%) displayed LOH with one or more of the markers tested. LOH was detected most frequently (78%) in FTC, the most malignant of the thyroid tumors. A smallest common deleted region (SCDR) was defined in this tumor type flanked by markers D7S480 and D7S490, This SCDR is distinct fi:om D7S522, the most commonly deleted locus in many other tumors, which was deleted in only one FTC. D7S522 did show LOH in two of six informative PTCs, None of the PTC and only two of the FAs showed LOH in the FTC SCDR, Since FA is considered a premalignant stage of FTC, our results suggest that inactivation of a putative tumor suppressor at 7q31.2 may be acquired during adenoma to carcinoma progression. The absence of LOH at this locus amongst PTC suggests that inactivation of this tumor suppressor is specific for FTC, In conclusion, LOH at 7q31 is a frequent event in differentiated thyroid cancer, and we have defined a 2 cM SCDR specific for FTC.	Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, 200 1st St SW, Rochester, MN 55905 USA.		Hay, Ian/AAH-8508-2019	Hay, Ian/0000-0002-5527-3909	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achille A, 1996, CANCER RES, V56, P3808; Devilee P, 1997, GENE CHROMOSOME CANC, V18, P193; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; GREBE SK, 1997, W J MED, V165, P156; Grebe SKG, 1997, J CLIN ENDOCR METAB, V82, P3684, DOI 10.1210/jc.82.11.3684; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; HERRMANN MA, 1991, J CLIN INVEST, V88, P1596, DOI 10.1172/JCI115472; HERRMANN ME, 1992, CANCER GENET CYTOGEN, V62, P144, DOI 10.1016/0165-4608(92)90253-5; HICKS DG, 1990, AM J PATHOL, V137, P553; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; ITO T, 1992, CANCER RES, V52, P1369; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; LEMOINE NR, 1989, ONCOGENE, V4, P159; Lin JC, 1996, ONCOGENE, V13, P2001; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MCCONAHEY WM, 1986, MAYO CLIN PROC, V61, P978, DOI 10.1016/S0025-6196(12)62641-X; NAMBA H, 1990, J CLIN INVEST, V86, P120, DOI 10.1172/JCI114673; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; OAKAHASHI S, 1995, CANCER RES, V55, P4114; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SHRIDHAR V, 1997, IN PRESS ONCOGENE; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUAREZ HG, 1990, ONCOGENE, V5, P565; TEYSSIER JR, 1990, CANCER GENET CYTOGEN, V50, P249, DOI 10.1016/0165-4608(90)90184-C; Umbricht CB, 1997, CANCER RES, V57, P2144; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Williams GH, 1996, BRIT J CANCER, V74, P585, DOI 10.1038/bjc.1996.405; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; Zedenius J, 1996, HUM GENET, V97, P299, DOI 10.1007/BF02185758; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; ZENKLUSEN JC, 1994, ONCOGENE, V9, P28177	38	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					789	793		10.1038/sj.onc.1201996	http://dx.doi.org/10.1038/sj.onc.1201996			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715281				2022-12-25	WOS:000075337200014
J	Harhaj, EW; Sun, SC				Harhaj, EW; Sun, SC			I kappa B kinases serve as a target of CD28 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; C-REL; INTERLEUKIN-2 PRODUCTION; ACTIVATION PATHWAY; IL-2 PROMOTER; ALPHA; PHOSPHORYLATION; BETA; DEGRADATION; EXPRESSION	Optimal T cell. activation and interleukin-2 production requires a second signal in addition to antigen-mediated T cell receptor (TCR) signaling. The CD28 molecule has been demonstrated to act as an effective costimulatory molecule upon binding by B7.1 or B7.2 present on antigen-presenting cells, The CD28 signal acts in concert with the TCR signal to significantly augment activation of the NF-kappa B family of transcription factors. The interleukin-a gene is regulated by NF-kappa B among other transcription factors, in part, via a CD28 responsive element (CD28RE) present in the IL-2 promoter. Enhanced activation of NF-kappa B by CD28 is mediated by rapid phosphorylation and proteasome-mediated degradation of the NF-kappa B inhibitory proteins I kappa B alpha and I kappa B beta, which allows for accelerated nuclear expression of the liberated NF-kappa B, Herein, we provide evidence that the catalytic activities of two recently identified I kappa B kinases, IKK alpha and IKK beta, are significantly elevated when T cells are stimulated through CD28 in addition to mitogen treatment. Catalytically inactive forms of IKKs are able to block the in vivo phosphorylation of I kappa B alpha induced by mitogen and CD28, Furthermore, CD28-mediated reporter gene transactivation of the CD28RE/AP-1 composite element is consistently attenuated by the IKK mutants. These findings suggest that cellular signaling pathways initiated at the TCR and CD28 converge at or upstream of IKK, resulting in more robust kinase activity and enhanced and prolonged NF-kappa B activation.	Penn State Univ, Coll Med, Milton S Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Milton S Hershey Med Ctr, Dept Microbiol & Immunol, POB 850, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [1 R01 CA68471-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1054; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; Good L, 1996, BIOCHEM BIOPH RES CO, V223, P123, DOI 10.1006/bbrc.1996.0856; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Harhaj EW, 1996, ONCOGENE, V12, P2385; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Kaga S, 1998, J IMMUNOL, V160, P4182; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LAI JH, 1994, J BIOL CHEM, V269, P30077; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; McGuire KL, 1997, J IMMUNOL, V159, P1319; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25185	25190		10.1074/jbc.273.39.25185	http://dx.doi.org/10.1074/jbc.273.39.25185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737979	hybrid			2022-12-25	WOS:000076085400029
J	Murray, EW; Robbins, SM				Murray, EW; Robbins, SM			Antibody cross-linking of the glycosylphosphatidylinositol-linked protein CD59 on hematopoietic cells induces signaling pathways resembling activation by complement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; C-CBL PROTOONCOGENE; PHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; TYROSINE-PHOSPHORYLATED PROTEIN; ANTIGEN RECEPTOR; EGF STIMULATION; JURKAT CELLS; SH3 DOMAIN; T-CELLS; KINASE	CD59 is a glycosylphosphatidylinositol-anchored cell surface glycoprotein involved in protecting cells from host-mediated complement attack. Studies have shown that antibody cross-linking of CD59 induces a series of intracellular signaling events including the activation of protein-tyrosine kinases (PTK). To further characterize these events, antibodies and complement 8, one of the natural ligands of CD59, were used to activate CD59, Antibody-induced cross-linking of CD59 on the surface of THP-1 and U937 hematopoietic cell lines as well as exposure to complement 8 induces a rapid increase in the tyrosine phosphorylation of several proteins within the cell. Consistent with an early role for the Src family PTKs in these signaling events, we found that transient activation of Hck- and CD59-mediated signaling was abrogated in the presence of the Src family PTK-selective inhibitor PP1. Although the molecular mechanism by which CD59 communicates to lick is unknown, cellular fractionation studies indicated that both CD59 and Hck are compartmentalized in plasma membrane microdomains. We also detected tyrosine phosphorylation of the adaptor proteins p120(cbl) and Shc, and the cytoplasmic nonreceptor tyrosine kinase Syk. The identification of CD59-mediated signaling events may help explain why paroxysmal nocturnal hemoglobinuria patients, who are deficient in glycosylphosphatidylinositol-linked proteins including CD59, are susceptible to proliferative disorders.	Univ Calgary, Dept Oncol, Canc Biol Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Immunol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, Canc Biol Grp, Rm 393 HMRB,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Robbins, Stephen/0000-0001-7475-1665; Murray, Elizabeth/0000-0003-3087-7578				Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Brodsky RA, 1997, P NATL ACAD SCI USA, V94, P8756, DOI 10.1073/pnas.94.16.8756; BROOIMANS RA, 1992, EUR J IMMUNOL, V22, P791, DOI 10.1002/eji.1830220324; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; DECKERT M, 1995, EUR J IMMUNOL, V25, P1815, DOI 10.1002/eji.1830250704; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Horikawa K, 1997, BLOOD, V90, P2716, DOI 10.1182/blood.V90.7.2716.2716_2716_2722; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Killeen N, 1997, CURR BIOL, V7, pR774, DOI 10.1016/S0960-9822(06)00402-7; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Liu L, 1997, J BIOL CHEM, V272, P8983; LUBLIN DM, 1992, CURR TOP MICROBIOL, V178, P141; LUNDJOHANSEN F, 1993, EUR J IMMUNOL, V23, P2782, DOI 10.1002/eji.1830231110; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; MARCHBANK KJ, 1995, IMMUNOLOGY, V85, P146; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MERI S, 1991, LAB INVEST, V65, P532; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; MORGAN BP, 1985, BIOCHEM J, V231, P205, DOI 10.1042/bj2310205; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; MORGAN BP, 1989, BIOCHEM J, V164, P1; Murray EW, 1996, J BIOL CHEM, V271, P15330, DOI 10.1074/jbc.271.26.15330; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; VANDENBERG CW, 1994, IMMUNOLOGY, V81, P637	61	52	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25279	25284		10.1074/jbc.273.39.25279	http://dx.doi.org/10.1074/jbc.273.39.25279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737993	hybrid			2022-12-25	WOS:000076085400043
J	Staubs, PA; Nelson, JG; Reichart, DR; Olefsky, JM				Staubs, PA; Nelson, JG; Reichart, DR; Olefsky, JM			Platelet-derived growth factor inhibits insulin stimulation of insulin receptor substrate-1-associated phosphatidylinositol 3-kinase in 3T3-L1 adipocytes without affecting glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; RAT ADIPOCYTES; ACTIVATION; IRS-1; PHOSPHORYLATION; WORTMANNIN	Phosphatidylinositol 3-kinase (PI3K) activation is necessary for insulin-responsive glucose transporter (GLUT4) translocation and glucose transport. Insulin and platelet-derived growth factor (PDGF) stimulate PI3K activity in 3T3-L1 adipocytes, but only insulin is capable of stimulating GLUT4 translocation and glucose transport. We found that PDGF causes serine/threonine phosphorylation of insulin receptor substrate 1 (IRS-1) in 3T3-L1 cells, measured by altered mobility on SDS-polyacrylamide gel, and this leads to a decrease in insulin-stimulated tyrosine phosphorylation of IRS-1. The PI3K inhibitors wortmannin and LY294002 inhibit the PDGF-induced phosphorylation of IRS-1, whereas the MEK inhibitor PD98059 was without a major effect. PDGF pretreatment for 60-90 min led to a marked 80-90% reduction in insulin stimulatable phosphotyrosine and IRS-1-associated PI3K activity. We examined the functional consequences of this decrease in IRS-1-associated PI3K activity. Interestingly, insulin stimulation of GLUT4 translocation and glucose transport was unaffected by 60-90 min of PDGF preincubation. Furthermore, insulin activation of Akt and p70(s6kinase), kinases downstream of PI3K, was unaffected by PDGF pretreatment, Wortmannin was capable of blocking these insulin actions following PDGF pretreatment, suggesting that PI3K was still necessary for these effects. In conclusion, 1) PDGF causes serine/threonine phosphorylation of IRS-1, and PI3K, or a kinase downstream of PI3K, mediates this phosphorylation, 2) This PDGF-induced phosphorylation of IRS-1 leads to a significant decrease in insulin-stimulated PI3K activity. 3) PDGF has no effect on insulin stimulation of Akt, p70(s6kinase), GLUT4 translocation, or glucose transport. 4) This suggests the existence of an IRS-1-independent pathway leading to the activation of PI3K, Akt, and p70(s6kinase); GLUT4 translocation; and glucose transport.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA; Whittier Diabet Inst, La Jolla, CA 92093 USA; Vet Adm Res Serv, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu			NIDDK NIH HHS [DK 33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P570, DOI 10.1006/bbrc.1994.2703; BERNAL D, 1997, DIABETES S1, V46, pA5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; LAM K, 1994, J BIOL CHEM, V269, P20648; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; MARGALETSANCHEZ V, 1994, BIOCHEM BIOPH RES CO, V204, P446; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUON MJ, 1994, J BIOL CHEM, V269, P27920; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	42	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1998	273	39					25139	25147		10.1074/jbc.273.39.25139	http://dx.doi.org/10.1074/jbc.273.39.25139			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	122RN	9737973	hybrid			2022-12-25	WOS:000076085400023
J	Lanchy, JM; Keith, G; Le Grice, SFJ; Ehresmann, B; Ehresmann, C; Marquet, R				Lanchy, JM; Keith, G; Le Grice, SFJ; Ehresmann, B; Ehresmann, C; Marquet, R			Contacts between reverse transcriptase and the primer strand govern the transition from initiation to elongation of HIV-1 reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BINDING-SITE COMPLEMENTARY; DEPENDENT DNA-POLYMERASE; CRYSTAL-STRUCTURE; TRANSFER-RNAS; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; KINETIC-ANALYSIS; THUMB SUBDOMAIN; KLENOW FRAGMENT	HIV-1 reverse transcriptase (RT) utilizes RNA oligomers to prime DNA synthesis. The initiation of reverse transcription requires specific interactions between HIV-1 RNA, primer tRNA(3)(Lys) and RT, We have previously shown that extension of an oligodeoxyribonucleotide, a situation that mimicks elongation, is unspecific and differs from initiation by the polymerization rate and dissociation rate of RT from the primer-template complex, Here, we used replication intermediates to analyze the transition from the initiation to the elongation phases. We found that the 2'-hydroxyl group at the 3' end of tRNA had limited effects on the polymerization and dissociation rate constants. Instead, the polymerization rate increased 3400-fold between addition of the sixth and seventh nucleotide to tRNA(3)(Lys). The same increase in the polymerization rate was observed when an oligoribonucleotide, but not an oligodeoxyribonucleotide, was used as a primer. In parallel, the dissociation rate of RT from the primer-template complex decreased 30-fold between addition of the 17th and 19th nucleotide to tRNA(3)(Lys). The polymerization and dissociation rates are most likely governed by interactions of the primer strand with helix alpha H in the p66 thumb subdomain and the RNase H domain of RT, respectively.	CNRS, Inst Biol Mol & Cellulaire, Unite Propre Rech 9002, F-67084 Strasbourg, France; Case Western Reserve Univ, Sch Med, Div Infect Dis, Cleveland, OH 44106 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Case Western Reserve University	Marquet, R (corresponding author), CNRS, Inst Biol Mol & Cellulaire, Unite Propre Rech 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.			Marquet, Roland/0000-0002-4209-3976	PHS HHS [A131147] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BAMBARA RA, 1976, J BIOL CHEM, V251, P4090; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; Ding JP, 1997, BIOPOLYMERS, V44, P125, DOI 10.1002/(SICI)1097-0282(1997)44:2&lt;125::AID-BIP2&gt;3.0.CO;2-X; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; Friant S, 1996, NUCLEIC ACIDS RES, V24, P441, DOI 10.1093/nar/24.3.441; GANGLOFF J, 1984, J BIOCHEM BIOPH METH, V9, P201, DOI 10.1016/0165-022X(84)90025-3; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HERMANN T, 1994, NUCLEIC ACIDS RES, V22, P4625, DOI 10.1093/nar/22.22.4625; Horton NC, 1996, J MOL BIOL, V264, P521, DOI 10.1006/jmbi.1996.0658; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang Y, 1996, J VIROL, V70, P4700, DOI 10.1128/JVI.70.7.4700-4706.1996; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBER HE, 1989, J BIOL CHEM, V264, P4669; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Kang SM, 1997, J VIROL, V71, P207, DOI 10.1128/JVI.71.1.207-217.1997; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Levin HL, 1997, CELL, V88, P5, DOI 10.1016/S0092-8674(00)81851-6; LI XG, 1994, J VIROL, V68, P6198, DOI 10.1128/JVI.68.10.6198-6206.1994; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MASSIRE C, 1994, J MOL GRAPHICS, V12, P201, DOI 10.1016/0263-7855(94)80088-X; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; REARDON JE, 1991, J BIOL CHEM, V266, P14128; SKALKA A, 1993, REVERSE TRANSCRIPTAS; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; Zhang ZJ, 1996, VIROLOGY, V226, P306, DOI 10.1006/viro.1996.0658	61	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24425	24432		10.1074/jbc.273.38.24425	http://dx.doi.org/10.1074/jbc.273.38.24425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733733	hybrid			2022-12-25	WOS:000076007300025
J	Williams, NG; Zhong, HY; Minneman, KP				Williams, NG; Zhong, HY; Minneman, KP			Differential coupling of alpha(1)-, alpha(2)-, and beta-adrenergic receptors to mitogen-activated protein kinase pathways and differentiation in transfected PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RAS-DEPENDENT ACTIVATION; MAP KINASE; CYCLIC-AMP; SIGNALING PATHWAY; ALPHA-2-ADRENERGIC RECEPTOR; GAMMA-SUBUNITS; HYPERTROPHY; EXPRESSION; TRANSDUCTION	Three adrenergic receptor families that selectively activate three different G proteins (alpha(1)/G(q/11), alpha(2)/G(i), and beta/G(s)) were used to study mitogen-activated protein kinase (MAPK) activation and differentiation in PC12 cells. PC12 cells were stably transfected with alpha(1a)-, alpha(2A)-, or beta(1)-adrenerse receptors (ARs) in an inducible expression vector, and subclones were characterized. Norepinephrine stimulated inositol phosphate formation in alpha(1A)-transfected cells, inhibited cyclic adenosine 3'5'-monophosphate (cAMP) formation in alpha(1A)-transfected cells, and stimulated cAMP formation in beta(1)-transfected cells. Nerve growth factor activated extracellular signal-regulated kinases (ERKs) in all cell lines; however, norepinephrine activated ERKs only in alpha(1A)- and beta(1)-transfected cells but not in alpha(2A)-transfected cells. Norepinephrine also activated c-Jun NH2-terminal kinase and p38 MAPK in alpha(1A)-transfected cells but not in beta(1)- or alpha(2A)-transfected cells. Norepinephrine caused differentiation of PC12 cells expressing alpha(1A)-ARs but not those expressing beta(1)- or alpha(2A)-ARs. However, norepinephrine acted synergitically with nerve growth factor in promoting differentiation of cells expressing beta(1)-ARs. Whereas ERKs are activated by G(i)- but not G(s)-linked receptors in many fibroblastic cell lines, we observed the opposite in PC12 cells. The results show that activation of the different G protein signaling pathways has different effects on MAPKs and differentiation in PC12 cells, with G(q) signaling pathways activating all three major MAPK pathways.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Minneman, KP (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.				NINDS NIH HHS [NS32706, NS23756, NS09580] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032706] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ASANO T, 1992, J NEUROCHEM, V58, P2176, DOI 10.1111/j.1471-4159.1992.tb10961.x; BARIBAY JL, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BYLUND DB, 1994, PHARMACOL REV, V46, P121; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUZIC E, 1992, J BIOL CHEM, V267, P24045; ESBENSHADE TA, 1993, MOL PHARMACOL, V44, P76; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; GATTI G, 1988, BIOCHEM J, V255, P753, DOI 10.1042/bj2550753; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIRASAWA A, 1993, BIOCHEM BIOPH RES CO, V195, P902, DOI 10.1006/bbrc.1993.2130; HOWE LR, 1993, J BIOL CHEM, V268, P20717; Huang CM, 1996, J NEUROCHEM, V67, P530; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; KABIR AM, 1993, CELL SIGNAL, V5, P443, DOI 10.1016/0898-6568(93)90084-Y; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; Mark MD, 1997, J BIOL CHEM, V272, P17238, DOI 10.1074/jbc.272.27.17238; MINNEMAN KP, 1994, ANNU REV PHARMACOL, V34, P117; NASSERI A, 1987, MOL PHARMACOL, V32, P655; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; Tigyi G, 1996, J NEUROCHEM, V66, P549; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P133, DOI 10.1016/0304-419X(93)90002-T; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xin XH, 1997, MOL PHARMACOL, V51, P764, DOI 10.1124/mol.51.5.764; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; ZHONG HY, 1993, MOL PHARMACOL, V44, P1085	61	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 18	1998	273	38					24624	24632		10.1074/jbc.273.38.24624	http://dx.doi.org/10.1074/jbc.273.38.24624			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121HL	9733758	hybrid			2022-12-25	WOS:000076007300050
J	Deng, XZ; Sun, GR; Zheng, QH; Li, YX				Deng, XZ; Sun, GR; Zheng, QH; Li, YX			Characterization of human TCR V beta gene promoter - Role of the dodecamer motif in promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; VARIABLE-REGION GENE; CELL RECEPTOR GENE; NUCLEAR PROTEINS; DECAMER MOTIF; TRANSCRIPTIONAL ENHANCER; MONOCLONAL-ANTIBODY; EXPRESSION; REARRANGEMENT; BINDING	During T-lymphocyte development, the T-cell antigen receptor (TCR) gene expression is controlled by its promoter and enhancer elements and regulated in tissue and development stage-specific manner. To uncover the promoter function and to define positive and negative regulatory elements in TCR gene promoters, the promoter activities from 13 human TCR V beta genes were determined by the transient transfection system and luciferase reporter assay. Although most of the TCR V beta gene promoters that we tested are inactive by themselves, some promoters were found to be constitutively strong. Among them, V beta 6.7 is the strongest. 5'-Deletion and fragmentation experiments have narrowed the full promoter activity of V beta 6.7 to a fragment of 147 base pairs immediately 5' to the transcription initiation site. A decanucleotide motif with the consensus sequence AGTGAYRTCA has been found to be conserved in most TCR V beta gene promoters. There are three such decamer motifs in the promoter region of V beta 6.7, and the contribution of each such motif to the promoter activity has been examined. Further site-directed mutagenesis analyses showed that: 1) when two Ts in the decamer were mutated, the promoter activity was totally abolished; 2) when two additional nucleotides 3' to the end of decamer were mutated, the promoter activity was decreased to two-thirds of the full level; and 3) when the element with the sequence AGTGATGTCACT was inserted into other promoters, the original weak promoters become very strong. Taken together, our data suggest that the positive regulatory element in V beta 6.7 should be considered a dodecamer rather than a decamer and that it confers strong basal transcriptional activity on TCR VP genes.	Cornell Univ, Dept Med, Hosp Special Surg, Coll Med, New York, NY 10021 USA	Cornell University	Li, YX (corresponding author), Cornell Univ, Dept Med, Hosp Special Surg, Coll Med, 535 E 70th St, New York, NY 10021 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038035] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38035] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON SJ, 1989, MOL CELL BIOL, V9, P4835, DOI 10.1128/MCB.9.11.4835; ANDERSON SJ, 1988, P NATL ACAD SCI USA, V85, P3551, DOI 10.1073/pnas.85.10.3551; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; FONDELL JD, 1992, MOL CELL BIOL, V12, P1480, DOI 10.1128/MCB.12.4.1480; GAO MH, 1993, J IMMUNOL, V150, P4376; GOLDMAN JP, 1993, J EXP MED, V177, P729, DOI 10.1084/jem.177.3.729; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; LANIER ER, 1991, P NATL ACAD SCI USA, V88, P8131, DOI 10.1073/pnas.88.18.8131; LEE MR, 1992, J IMMUNOL, V148, P1906; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LI YX, 1991, J EXP MED, V174, P1537, DOI 10.1084/jem.174.6.1537; LI YX, 1990, J EXP MED, V171, P221, DOI 10.1084/jem.171.1.221; MCDOUGALL S, 1988, SCIENCE, V241, P205, DOI 10.1126/science.2968651; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; POSNETT DN, 1986, P NATL ACAD SCI USA, V83, P7888, DOI 10.1073/pnas.83.20.7888; PRASHAR Y, 1991, J IMMUNOL, V147, P3441; ROYER HD, 1987, P NATL ACAD SCI USA, V84, P232, DOI 10.1073/pnas.84.1.232; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SIU G, 1986, J EXP MED, V164, P1600, DOI 10.1084/jem.164.5.1600; VISSINGA CS, 1994, J IMMUNOL, V152, P1222; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	26	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23709	23715		10.1074/jbc.273.37.23709	http://dx.doi.org/10.1074/jbc.273.37.23709			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726977	hybrid			2022-12-25	WOS:000075893100018
J	Dietrich, J; Backstrom, T; Lauritsen, JPH; Kastrup, J; Christensen, MD; von Bulow, F; Palmer, E; Geisler, C				Dietrich, J; Backstrom, T; Lauritsen, JPH; Kastrup, J; Christensen, MD; von Bulow, F; Palmer, E; Geisler, C			The phosphorylation state of CD3 gamma influences T cell responsiveness and controls T cell receptor cycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; ACTIN-FILAMENTS; ALPHA-BETA; ACTIVATION; INTERNALIZATION; COMPLEXES; MOTIF; CD3	The T cell receptor (TCR) is internalized following activation of protein kinase C (PBC) via a leucine (Leu)based motif in CD3 gamma. Some studies have indicated that the TCR is recycled back to the cell surface following PKC-mediated internalization. The functional state of recycled TCR and the mechanisms involved in the sorting events following PKC-induced internalization are not known. In this study, we demonstrated that following PKC-induced internalization, the TCR is recycled back to the cell surface ins a functional state. TCR recycling was dependent on dephosphorylation of CD3 gamma, probably mediated by the serine/threonine protein phosphatase-ail but independent on microtubules or actin polymerization. Furthermore, in contrast to ligand-mediated TCR sorting recycling of the TCR was independent of the tyrosine phosphatase CD45 and the Src tyrosine kinases p56(Lck) and p59(Fyn). Studies of mutated TCR and chimeric CD4-CD3 gamma molecules demonstrated that CD3 gamma did not contain a recycling signal in itself. In contrast, the only sorting information in CD3 gamma was the Leu-based motif that mediated lysosomal sorting of chimeric CD4-CD3 gamma molecules. Finally, we found II correlation between the phosphorylation state of CD3 gamma and T cell responsiveness. Based on these observations a physiological role of CD3 gamma and TCR cycling is proposed.	Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Inst Med Anat, DK-2200 Copenhagen, Denmark; Malaghan Inst Med Res, Wellington, New Zealand; Basel Inst Immunol, CH-4005 Basel, Switzerland	University of Copenhagen; University of Copenhagen; Malaghan Institute; Victoria University Wellington	Dietrich, J (corresponding author), Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Bldg 18-3,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.	vader@biobase.dk	Geisler, Carsten/A-7056-2012; Bartels, Mette Damkjær/AAY-5809-2020	Geisler, Carsten/0000-0002-8472-0771; Bartels, Mette Damkjær/0000-0002-8187-3684				ALEXANDER D, 1989, EUR J BIOCHEM, V181, P55, DOI 10.1111/j.1432-1033.1989.tb14693.x; ALEXANDER DR, 1992, BIOCHEM J, V288, P69, DOI 10.1042/bj2880069; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; Durrbach A, 1996, J CELL SCI, V109, P457; GANZ MB, 1996, AM J PHYSIOL, V271, P108; Garland AM, 1996, MOL PHARMACOL, V49, P438; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEISLER C, 1988, SCAND J IMMUNOL, V27, P685, DOI 10.1111/j.1365-3083.1988.tb02402.x; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; GIANNINI E, 1995, J IMMUNOL, V154, P4055; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014-5793(91)80745-O; HOU XH, 1994, EUR J IMMUNOL, V24, P1228, DOI 10.1002/eji.1830240534; Hou XH, 1996, J BIOL CHEM, V271, P22815, DOI 10.1074/jbc.271.37.22815; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; KUHLMANN J, 1993, SCAND J IMMUNOL, V37, P271, DOI 10.1111/j.1365-3083.1993.tb01766.x; Lauritsen JPH, 1998, J IMMUNOL, V161, P260; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; LU Y, 1994, J IMMUNOL, V153, P1495; LUTON F, 1994, J IMMUNOL, V153, P63; Luton F, 1997, J IMMUNOL, V158, P3140; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; Maples CJ, 1997, J BIOL CHEM, V272, P6741, DOI 10.1074/jbc.272.10.6741; Margulies DH, 1997, CURR OPIN IMMUNOL, V9, P390, DOI 10.1016/S0952-7915(97)80086-6; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RUEGG CL, 1992, J BIOL CHEM, V267, P18837; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	49	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24232	24238		10.1074/jbc.273.37.24232	http://dx.doi.org/10.1074/jbc.273.37.24232			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727047	hybrid			2022-12-25	WOS:000075893100088
J	Kanai, Y; Segawa, H; Miyamoto, K; Uchino, H; Takeda, E; Endou, H				Kanai, Y; Segawa, H; Miyamoto, K; Uchino, H; Takeda, E; Endou, H			Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; MONOCLONAL-ANTIBODY 4F2; CELL-SURFACE ANTIGEN; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; PROTEIN; SYSTEM; FAMILY; LYMPHOCYTES; OOCYTES	A cDNA was isolated from rat C6 glioma cells by expression cloning which encodes a novel Na+-independent neutral amino acid transporter designated LAT1. For functional expression in Xenopus oocytes, LAT1 required the heavy chain of 4F2 cell surface antigen (CD98), a type II membrane glycoprotein. When co-expressed with 4F2 heavy chain, LAT1 transported neutral amino acids with branched or aromatic side chains and did not accept basic amino acids or acidic amino acids. The transport via LAT1 was Na+-independent and sensitive to a system L-specific inhibitor 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid. These functional properties correspond to those of the classically characterized amino acid transport system L, a major nutrient transporter. In in vitro translation, LAT1 was shown to be a nonglycosylated membrane protein consistent with the property of 4F2 light chain, suggesting LAT1 is at least one of the proteins formerly referred to as 4F2 light chain. LAT1 exhibits relatively low but significant amino acid sequence similarity to mammalian cationic amino acid transporters and amino acid permeases of bacteria and yeasts, indicating LAT1 is a new member of the APC superfamily, Because of highly regulated nature and high level of expression in tumor cell lines, LAT1 is thought to be up-regulated to support the high protein synthesis for cell growth and cell activation. The cloning of LAT1 is expected to facilitate the research on the protein-protein interaction in the transporter field and to provide a clue to the search for still unidentified transporters.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 181, Japan; Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 770, Japan; Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 920, Japan	Kyorin University; Tokushima University; Kanazawa University	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 181, Japan.							BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Broer S, 1997, BIOCHEM J, V324, P535, DOI 10.1042/bj3240535; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1975, CURRENT TOPICS MEMBR, V6, P227; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Gallardo MA, 1996, J MEMBRANE BIOL, V152, P57, DOI 10.1007/s002329900085; GAUGITSCH HW, 1992, J BIOL CHEM, V267, P11267; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HEDIGER MA, 1994, J EXP BIOL, V196, P15; HEMLER ME, 1982, J IMMUNOL, V129, P623; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACLEOD CL, 1994, J EXP BIOL, V196, P109; OXENDER DL, 1963, NATURE, V197, P765, DOI 10.1038/197765a0; PALACIN M, 1994, J EXP BIOL, V196, P123; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; SANG JS, 1995, CANCER RES, V55, P1152; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; WELLS RG, 1992, J BIOL CHEM, V267, P15285; Wolf DA, 1996, CANCER RES, V56, P5012; YAGITA H, 1986, CANCER RES, V46, P1478	36	841	880	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23629	23632		10.1074/jbc.273.37.23629	http://dx.doi.org/10.1074/jbc.273.37.23629			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726963	hybrid			2022-12-25	WOS:000075893100004
J	Ke, YH; Wu, JY; Leibold, EA; Walden, WE; Theil, EC				Ke, YH; Wu, JY; Leibold, EA; Walden, WE; Theil, EC			Loops and bulge/loops in iron-responsive element isoforms influence iron regulatory protein binding - Fine-tuning of mRNA regulation?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; ERYTHROID 5-AMINOLEVULINATE SYNTHASE; TRANSLATIONAL CONTROL; POSTTRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL ACONITASE; CYTOSOLIC ACONITASE; HIGH-AFFINITY; REGION	A family of noncoding mRNA sequences, iron-responsive elements (IREs), coordinately regulate several mRNAs through binding a family of mRNA-specific proteins, iron regulatory proteins (IRPs). IREs are hairpins with a constant terminal loop and base-paired stems interrupted by an internal loop/bulge tin ferritin mRNA) or a C-bulge tin m-aconitase, erythroid aminolevulinate synthase, and transferrin receptor mRNAs). IRP2 binding requires the conserved C-G base pair in the terminal loop, whereas IRP1 binding occurs with the C-G or engineered U-A. Here we show the contribution of the IRE internal loop/bulge to IRP2 binding by comparing natural and engineered IRE variants. Conversion of the internal loop/bulge in the ferritin-IRE to a C-bulge, by deletion of U, decreased IRP2 binding by >95%, whereas IRP1 binding changed only 13%. Moreover, IRP2 binding to natural IREs with the C-bulge was similar to the Delta U-6 ferritin-IRE: >90% lower than the ferritin-IRE. The results predict mRNA-specific variation in IRE-dependent regulation in vivo and may relate to previously observed differences in iron-induced ferritin and m-aconitase synthesis in liver and cultured cells. Variations in IRE structure and cellular IRP1/IRP2 ratios can provide a range of finely tuned, mRNA-specific responses to the same (iron) signal.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of North Carolina; North Carolina State University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Theil, EC (corresponding author), Childrens Hosp Oakland, Res Inst, 747 52nd St, Oakland, CA 94609 USA.	etheil@mail.cho.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK020251, R01DK047281, R37DK020251, R01DK020251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47281, DK20251] Funding Source: Medline; NIGMS NIH HHS [GM45201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addess KJ, 1997, J MOL BIOL, V274, P72, DOI 10.1006/jmbi.1997.1377; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DICKEY LF, 1988, J BIOL CHEM, V263, P3071; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; DIX DJ, 1993, J MOL BIOL, V231, P230, DOI 10.1006/jmbi.1993.1278; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3; Gdaniec Z, 1998, BIOCHEMISTRY-US, V37, P1505, DOI 10.1021/bi9719814; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; Henderson ER, 1996, J BIOL CHEM, V271, P4900; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Ke Y, 1998, FASEB J, V12, pA1474; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; LIANG LG, 1996, BIOCHEMISTRY-US, V35, P13585; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; Menotti E, 1998, J BIOL CHEM, V273, P1821, DOI 10.1074/jbc.273.3.1821; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PATINO MM, 1992, J BIOL CHEM, V267, P19011; Phillips JD, 1996, BIOCHEMISTRY-US, V35, P15704, DOI 10.1021/bi960653l; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; ROSE MD, 1990, METHODS YEAST GENETI, P179; Rouault TA, 1996, J BIOL INORG CHEM, V1, P494, DOI 10.1007/s007750050083; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; Schalinske KL, 1998, J BIOL CHEM, V273, P3740, DOI 10.1074/jbc.273.6.3740; SHULL GE, 1982, J BIOL CHEM, V257, P4187; SIERZPUTOWSKAGRACZ H, 1995, NUCLEIC ACIDS RES, V23, P146, DOI 10.1093/nar/23.1.146; Theil EC, 1998, MET IONS BIOL SYST, V35, P403; Theil EC, 1997, CH MICROBIOL SER, P131; THEIL EC, 1994, BIOCHEM J, V304, P1; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WANG YH, 1991, BIOL MET, V4, P56, DOI 10.1007/BF01135558; WANG YH, 1990, NUCLEIC ACIDS RES, V18, P4463, DOI 10.1093/nar/18.15.4463	57	114	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23637	23640		10.1074/jbc.273.37.23637	http://dx.doi.org/10.1074/jbc.273.37.23637			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726965	hybrid			2022-12-25	WOS:000075893100006
J	Martinez, E; Kundu, TK; Fu, J; Roeder, RG				Martinez, E; Kundu, TK; Fu, J; Roeder, RG			A human SPT3-TAF(II)31-GCN5-L acetylase complex distinct from transcription factor IID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING-PROTEIN; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; YEAST; SPT3; INITIATION; GCN5; GENE; INTERACTS; ADA2	In yeast, SPT3 is a component of the multiprotein SPT-ADA-GCN5 acetyltransferase (SAGA) complex that integrates proteins with transcription coactivator/adaptor functions (ADAs and GCN5), histone acetyltransferase activity (GCN5), and core promoter-selective functions (SPTs) involving interactions with the TATA-binding protein (TBP). In particular, yeast SPT3 has been shown to interact directly with TBP. Here we report the molecular cloning of a cDNA encoding a human homologue of yeast SPT3. Amino acid sequence comparisons between human SPT3 (hSPT3) and its counterparts in different yeast species reveal three highly conserved domains, with the most conserved ga-amino acid N-terminal domain being 25% identical with human TAF(II)18. Despite the significant sequence similarity with TAF(II)18, native hSPT3 is not a bona fide TAF(II) because it is not associated in vivo either with human TBP/TFIID or with a TFIID-related TBP-free TAF(II) complex. However, we present evidence that hSPT3 is associated in vivo with TAF(II)31 and the recently described longer form of human GCN5 (hGCN5-L) in a novel human complex that has histone acetyltransferase activity, We propose that the human SPT3-TAF(II)31-GCN5-L acetyltransferase (STAGA) complex is a likely homologue of the yeast SAGA complex.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Roeder, RG (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.			Kundu, Tapas/0000-0001-7790-214X	NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Candau R, 1996, MOL CELL BIOL, V16, P593; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; Collart MA, 1996, MOL CELL BIOL, V16, P6668; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HIRSCHHORN JN, 1988, MOL CELL BIOL, V8, P822, DOI 10.1128/MCB.8.2.822; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOFFMANN A, 1996, J BIOL CHEM, V271, P18184; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Winston, 1992, TRANSCRIPTIONAL REGU, P1271; WINSTON F, 1984, CELL, V39, P675, DOI 10.1016/0092-8674(84)90474-4; WINSTON F, 1987, GENETICS, V115, P649; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	27	161	170	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23781	23785		10.1074/jbc.273.37.23781	http://dx.doi.org/10.1074/jbc.273.37.23781			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726987	hybrid			2022-12-25	WOS:000075893100028
J	Mayne, GC; Murray, AW				Mayne, GC; Murray, AW			Evidence that protein kinase C epsilon mediates phorbol ester inhibition of calphostin C- and tumor necrosis factor-alpha-induced apoptosis in U937 histiocytic lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; DNA FRAGMENTATION; BINDING-PROTEIN; GENE-EXPRESSION; CERAMIDE; DEATH; TRANSLOCATION; ACTIVATION; INDUCTION; PHOSPHORYLATION	Protein kinase C (PKC) activators, such as the tumor-promoting phorbol esters, have been reported to protect several cell lines from apoptosis induced by a variety of agents. Recent evidence suggests that PKC epsilon is involved in protection of cardiac myocytes from hypoxia-induced cell death (Gray, M. O., Karliner, J. S., and Mochly-Rosen, D. (1997) J. Biol. Chem. 272, 30945-30951). We investigated the protective effects of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) on U937 histiocytic lymphoma cells induced to undergo apoptosis by tumor necrosis factor-alpha (TNF-alpha) or by the specific PKC inhibitor calphostin C. U937 cells were transiently permeabilized with a peptide (epsilon V1-2) derived from the V1 region of PKC epsilon that has been reported to specifically block translocation of PKC epsilon. The epsilon V1-2 peptide blocked the inhibitory effect of TPA on both TNF-alpha- and calphostin C-induced apoptosis, A scrambled version of epsilon V1-2 and a peptide reported to inhibit PKC beta translocation (beta C2-4) had no effect on the ability of TPA to inhibit apoptosis, These results suggest that PKC epsilon is required for the protective effect of TPA in TNF-alpha- and calphostin C-induced apoptosis, Furthermore, calphostin C reduced membrane-associated PKC epsilon activity and immunoreactivity, suggesting that PKC epsilon may play an important role in leukemic cell survival.	Flinders Univ S Australia, Fac Sci & Engn, Sch Biol Sci, Adelaide, SA 5001, Australia	Flinders University South Australia	Mayne, GC (corresponding author), Flinders Univ S Australia, Fac Sci & Engn, Sch Biol Sci, GPO Box 2100, Adelaide, SA 5001, Australia.	bigcm@flinders.edu.au						BASU A, 1995, INT J CANCER, V63, P597, DOI 10.1002/ijc.2910630422; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; Chmura SJ, 1996, CANCER RES, V56, P2711; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Durkin JP, 1996, J NEUROCHEM, V66, P951; GEIER A, 1994, IN VITRO CELL DEV-AN, V30A, P867; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HARRINGTON CR, 1990, ANAL BIOCHEM, V186, P285, DOI 10.1016/0003-2697(90)90081-J; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Jones BA, 1997, AM J PHYSIOL-GASTR L, V272, pG1109, DOI 10.1152/ajpgi.1997.272.5.G1109; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KILEY SC, 1995, J CELL SCI, V108, P1003; KIZAKI H, 1989, J BIOCHEM-TOKYO, V105, P673, DOI 10.1093/oxfordjournals.jbchem.a122724; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LEE HJJ, 1995, J BIOL CHEM, V270, P15979, DOI 10.1074/jbc.270.27.15979; LOTEM J, 1991, BLOOD, V78, P953; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McBain JA, 1996, INT J CANCER, V67, P715, DOI 10.1002/(SICI)1097-0215(19960904)67:5<715::AID-IJC21>3.0.CO;2-2; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; Mihalik R, 1996, INT J BIOCHEM CELL B, V28, P925, DOI 10.1016/1357-2725(96)00020-9; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ohizumi H, 1997, ANTICANCER RES, V17, P1051; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Pongracz J, 1996, LEUKEMIA RES, V20, P319, DOI 10.1016/0145-2126(95)00074-7; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Sawai H, 1997, J BIOL CHEM, V272, P2452; SOLARY E, 1993, BLOOD, V81, P1359; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; TAKANO Y, 1993, PATHOL RES PRACT, V189, P197, DOI 10.1016/S0344-0338(11)80092-0; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANDELOOSDRECHT AA, 1993, EXP HEMATOL, V21, P1628; VOZIYAN PA, 1995, BIOCHEM BIOPH RES CO, V212, P479, DOI 10.1006/bbrc.1995.1995; WAYS DK, 1992, CANCER RES, V52, P5604; WAYS DK, 1994, CELL GROWTH DIFFER, V5, P161; Wilson BE, 1996, MOL CELL BIOL, V16, P5546	50	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24115	24121		10.1074/jbc.273.37.24115	http://dx.doi.org/10.1074/jbc.273.37.24115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727032	hybrid			2022-12-25	WOS:000075893100073
J	Mounier, CM; Hackeng, TM; Schaeffer, F; Faure, G; Bon, C; Griffin, JH				Mounier, CM; Hackeng, TM; Schaeffer, F; Faure, G; Bon, C; Griffin, JH			Inhibition of prothrombinase by human secretory phospholipase A(2) involves binding to factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; ARTHRITIC SYNOVIAL-FLUID; COAGULATION FACTOR-XA; SNAKE-VENOM; HUMAN-PLASMA; PROTEIN-S; FACTOR-VA; PLATELET PHOSPHOLIPASE-A2; INFLAMMATORY DISEASES; ENZYMATIC-ACTIVITY	Human group II secretory phospholipase A(2) (hsPLA(2)) exhibits significant anticoagulant activity that does not require its enzymatic activity. We examined which coagulation factor was targeted by hsPLA(2) and analyzed which region of the protein may be involved in this inhibition. Prothrombin time coagulation assays indicated that hsPLA(2) did not inhibit activated factor V (FVa) activity, whereas activated factor X (FXa) one-stage coagulation assays suggested that FXa was inhibited. The inhibitory effect of hsPLA(2) on prothrombinase activity of FXa, FV, phospholipids, and Ca2+ complex was markedly enhanced upon preincubation of hsPLA(2) with FXa but not with FV, Prothrombinase activity was also strongly inhibited by hsPLA(2) in the absence of FL. High concentrations of FVa in the prothrombinase generation assay reversed the inhibitory effect of hsPLA(2). By using isothermal titration calorimetry, we demonstrated that hsPLA(2) binds to FXa in solution with a 1:1 stoichiometry and a K-d of 230 nM. By using surface plasmon resonance we determined the rate constants, k(on) and k(off) of the FXaksPLA(2) interaction and analyzed the Ca2+ effect on these constants. When preincubated with FXa, synthetic peptides comprising residues 51-74 and 51-62 of hsPLA(2) inhibited prothrombinase assays, providing evidence that this part of the molecule, which shares similarities with a region of FVa that binds to FXa, is likely involved in the anticoagulant interaction of hsPLA(2) with FXa. In conclusion, we propose that residues 51-62 of hsPLA(2) bind to FXa at a FVa-binding site and that hsPLA(2) decreases the prothrombinase generation by preventing FXa FVa complex formation.	Inst Pasteur, Unite Venins, F-75724 Paris 15, France; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Inst Pasteur, Lab Resonance Magnet Nucl, F-75724 Paris, France; Univ Cergy Pontoise, Dept Biol, F-95011 Cergy Pontoise, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Scripps Research Institute; Scripps Research Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CY Cergy Paris Universite	Bon, C (corresponding author), Inst Pasteur, Unite Venins, 25 Rue Dr Roux, F-75724 Paris 15, France.	cbon@pasteur.fr		Griffin, John/0000-0002-4302-2547; Hackeng, Tilman/0000-0003-0142-0843	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21544] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABU AS, 1994, TOXICON, V32, P749, DOI 10.1016/0041-0101(94)90344-1; BHATNAGAR RS, 1995, METHOD ENZYMOL, V250, P467; BUNDLE DR, 1994, METHOD ENZYMOL, V247, P288; CIRINO G, 1993, THROMB RES, V70, P337, DOI 10.1016/0049-3848(93)90106-X; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DEKRUIJFF B, 1975, BIOCHIM BIOPHYS ACTA, V406, P6, DOI 10.1016/0005-2736(75)90038-3; DENNIS EA, 1991, METHOD ENZYMOL, V197, P3; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FRANKEN PA, 1992, EUR J BIOCHEM, V203, P89, DOI 10.1111/j.1432-1033.1992.tb19832.x; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; Hackeng TM, 1997, P NATL ACAD SCI USA, V94, P7845, DOI 10.1073/pnas.94.15.7845; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; INADA M, 1994, J BIOL CHEM, V269, P26338; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KANE WH, 1981, J BIOL CHEM, V256, P1002; KINI RM, 1987, J BIOL CHEM, V262, P14402; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KOMATSUBARA T, 1995, CLIN CHIM ACTA, V236, P109, DOI 10.1016/0009-8981(95)06035-9; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KURIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1082, P285, DOI 10.1016/0005-2760(91)90204-U; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; MANN KG, 1990, BLOOD, V76, P1; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MOUNIER C, 1994, BBA-LIPID LIPID MET, V1214, P88, DOI 10.1016/0005-2760(94)90013-2; Mounier C, 1996, EUR J BIOCHEM, V237, P778, DOI 10.1111/j.1432-1033.1996.0778p.x; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; NEVALAINEN TJ, 1993, CLIN CHEM, V39, P2453; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Nyman KM, 1996, J SURG RES, V60, P7, DOI 10.1006/jsre.1996.0003; OUYANG C, 1992, TOXICON, V30, P945, DOI 10.1016/0041-0101(92)90040-C; OUYANG C, 1978, BIOCHIM BIOPHYS ACTA, V541, P394, DOI 10.1016/0304-4165(78)90198-8; PRUZANSKI W, 1993, J LIPID MEDIATOR, V8, P161; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; RINTALA E, 1995, SCAND J INFECT DIS, V27, P39; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; STEFANSSON S, 1990, BIOCHEMISTRY-US, V29, P7742, DOI 10.1021/bi00485a024; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; TRACY PB, 1982, BLOOD, V60, P59; VERHEIJ HM, 1980, EUR J BIOCHEM, V112, P25, DOI 10.1111/j.1432-1033.1980.tb04982.x; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHITE SR, 1993, J CLIN INVEST, V91, P2118, DOI 10.1172/JCI116436; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	52	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23764	23772		10.1074/jbc.273.37.23764	http://dx.doi.org/10.1074/jbc.273.37.23764			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726985	hybrid			2022-12-25	WOS:000075893100026
J	Rall, SC; Ye, P; Bu, GJ; Wardell, MR				Rall, SC; Ye, P; Bu, GJ; Wardell, MR			The domain structure of human receptor-associated protein - Protease sensitivity and guanidine HCl denaturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							39-KDA PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; MOLECULAR CHAPERONE; HEYMANN NEPHRITIS; AQUEOUS-SOLUTION; BINDING; LRP; CELLS; RAP	The 39-kDa receptor-associated protein (RAP), a specialized chaperone for endocytic receptors of the low density lipoprotein receptor gene family, is a triplicate repeat sequence (residues 1-100, 101-280, and 201-323, respectively), with the three repeats having different functional roles. The goal of the present study was tee use a combination of protease sensitivity and guanidine denaturation analyses to investigate whether human RAP correspondingly contained multiple structural domains, Protease sensitivity analysis using six proteolytic enzymes of varying specificity showed that RAP has two protease-resistant regions contained withins repeat 1 (residues 15-94) and repeat 3 (residues 223-323), Guanidine denaturation analysis showed that RAP has two phases in its denaturation, an early denaturation transition at 0.6 M guanidine HCl, and a broad second transition between 1.(3 and 3.0 M guanidine HCl. Analysis of the denaturation of the individual repeats showed that, despite the similarity in sequence and protease sensitivity between repeats 1 and 3, repeat 1 was a stable structure, with a sharp transition midpoint at 2.4 M guanidine NCl, while repeat 3 was relatively unstable, with a transition midpoint at 0.6 RI guanidine HCl. Repeat 2 had a denaturation profile almost identical to that of repeat 3, Denaturation analysis of the contiguous repeats 1 and 2 (residues 1-210) indicated that repeats 1 and 2 probably interact to form one structural domain represented by the broad transition, while repeat 3 constitutes a separate domain represented by the early transition, A two-domain model of RAP three-dimensional structure is proposed that integrates both structural and functional information, in which a helical segment from repeal 2 interacts with the known three-helix bundle of repeat 1 to form a four-helix bundle structural domain, while repeat 3 forms the other structural domain.	St Louis Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Cell Biol & Biophys, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University; Saint Louis University; Saint Louis University	Wardell, MR (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biophys, Campus Box 8231,660 S Euclid Ave, St Louis, MO 63110 USA.	mrw@patmos.wustl.edu			NHLBI NIH HHS [HL 59150] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059150] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; Kerjaschki D, 1996, J EXP MED, V183, P2007, DOI 10.1084/jem.183.5.2007; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; Nielsen PR, 1997, P NATL ACAD SCI USA, V94, P7521, DOI 10.1073/pnas.94.14.7521; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	26	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24152	24157		10.1074/jbc.273.37.24152	http://dx.doi.org/10.1074/jbc.273.37.24152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727037	hybrid			2022-12-25	WOS:000075893100078
J	Segall, AM				Segall, AM			Analysis of higher order intermediates and synapsis in the bent-L pathway of bacteriophage lambda site-specific recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATIVE RECOMBINATION; NUCLEASE ACTIVITY; ATTACHMENT SITES; DNA; COMPLEXES; HOMOLOGY; ATTL; INT	The integrase proteins of bacteriophage lambda mediates recombination via four distinct pathways. The recent in vitro reconstitution of the efficient bidirectional reaction between two attLtenP'1 target sites now allows comparisons of this pathway, known as the bent-L pathway, with the inefficient bidirectional straight-L pathway and with the efficient but unidirectional pathways of integration and excision. To this end, a series of higher order intermediates of the bent-L pathway was characterized using gel mobility shift assays, two-dimensional gel analysis, and footprinting. The analysis spans the initial binding of proteins to individual DNA target sites, synapsis of two partner DNA targets, and strand exchange. This study identifies a presynaptic "checkpoint" of recombination. IL shows that synapsis is a slow step in the recombination reaction, while subsequent strand exchange is comparatively fast. Synaptic complexes contain a preponderance of recombinant products, suggesting that an energetically favorable but somewhat subtle conformational change drives strand exchange. In addition, comparison of wild-type integrase with a catalytically defective mutant of integrase, IntF, showed that, ire addition to the catalysis defect, this mutant has different DNA-binding properties than the wild-type protein.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Segall, AM (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.			Segall, Anca/0000-0002-8454-5248	NIGMS NIH HHS [GM-52847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGIN AB, 1995, CURR BIOL, V5, P1312, DOI 10.1016/S0960-9822(95)00258-2; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; ECHOLS H, 1970, Journal of Molecular Biology, V47, P575, DOI 10.1016/0022-2836(70)90324-4; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; KIKUCHI A, 1985, J MOL BIOL, V52, P30; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LANDY A, 1983, LAMBDA, V2, P211; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUMDER A, 1993, FOOTPRINTING NUCLEIC, P45; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUMRYCH TE, 1990, NUCLEIC ACIDS RES, V18, P3953, DOI 10.1093/nar/18.13.3953; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGALL AM, 1993, EMBO J, V12, P4567, DOI 10.1002/j.1460-2075.1993.tb06145.x; Segall AM, 1996, GENES CELLS, V1, P453, DOI 10.1046/j.1365-2443.1996.d01-254.x; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; THEDERAHN T, 1990, BIOCHEM BIOPH RES CO, V168, P756, DOI 10.1016/0006-291X(90)92386-E; Tirumalai RS, 1997, P NATL ACAD SCI USA, V94, P6104, DOI 10.1073/pnas.94.12.6104	22	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					24258	24265		10.1074/jbc.273.37.24258	http://dx.doi.org/10.1074/jbc.273.37.24258			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9727050	hybrid			2022-12-25	WOS:000075893100091
J	Tao, WK; Kurschner, C; Morgan, JI				Tao, WK; Kurschner, C; Morgan, JI			Bcl-xS and Bad potentiate the death suppressing activities of Bcl-xL, Bcl-2, and A1 in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HUMAN FOLLICULAR LYMPHOMA; PROAPOPTOTIC PROTEIN BAX; C-ELEGANS CED-4; MOLECULAR REGULATION; APOPTOSIS; GENE; BCL-X(L); HOMOLOG; FAMILY	Members of the Bc1-2 family can be grouped into three classes based upon their effects on cell death. The first class suppresses death and includes Bcl-2. A second group which includes Bax, is lethal, whereas a third class, including Bcl-xS, potentiates killing although the members are not lethal by themselves. The proteins in the last class ape proposed to exert their activity by binding to anti-apoptotic family members, thereby making the cell more susceptible to killing by another agent. To test this hypothesis, an inducible yeast expression system is reported that permits the functional analysis of three Bcl-2 family members, in yeast. Bax is lethal, and this activity is suppressed by Bcl-xL, Bcl-2, and Al. Co-expression of Bcl-xS did not diminish the ability of any of the anti-apoptotic members to antagonize Bax. Rather, co-expression of Bcl-xS potentiated the anti-death activity of all three proteins. This effect was not the result of changes in either the levels or integrity of Bax or anti-apoptotic proteins. Thus, Bcl-xS can bind to anti-apoptotic family members, but this association does not result in loss of biological activity. Therefore, Bcl-xS may act downstream of Bax and in a pathway that is conserved in yeast.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Morgan, JI (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	jim.morgan@stjude.org	Morgan, James/GRO-2905-2022; Morgan, James/N-8104-2018; tao, wei/GXN-4445-2022	Morgan, James/0000-0002-8920-1065; 	NCI NIH HHS [P30 CA21756] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DALTON S, 1992, CELL, V68, P579; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Kurschner C, 1996, MOL BRAIN RES, V37, P249, DOI 10.1016/0169-328X(95)00323-K; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Miura M, 1996, CURR TOP DEV BIOL, V32, P139, DOI 10.1016/S0070-2153(08)60427-5; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WILLIAMS GT, 1994, J PATHOL, V173, P1, DOI 10.1002/path.1711730102; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 11	1998	273	37					23704	23708		10.1074/jbc.273.37.23704	http://dx.doi.org/10.1074/jbc.273.37.23704			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119JT	9726976	hybrid			2022-12-25	WOS:000075893100017
J	Gallois, C; Habib, A; Tao, JC; Moulin, S; Maclouf, J; Mallat, A; Lotersztajn, S				Gallois, C; Habib, A; Tao, JC; Moulin, S; Maclouf, J; Mallat, A; Lotersztajn, S			Role of NF-kappa B in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells - Involvement of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2; GROWTH-INHIBITORY PROPERTIES; SMOOTH-MUSCLE CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; INDUCIBLE CYCLOOXYGENASE; MEDIATED PATHWAY; ACTIVATION; KINASE; PROTEIN	During chronic liver diseases, hepatic stellate cells (HSC) acquire an activated myofibroblast-like phenotype and proliferate and synthesize fibrosis components. Endothelin-1 (ET-1), which inhibited the growth of human myofibroblastic HSC, increased the formation of two NF-kappa B DNA binding complexes; this effect was also observed with tumor necrosis factor-alpha (TNF-alpha). The complexes were identified as the p50/p50 and p50/p65 NP-kappa B dimers. Activation of NF-kappa B was associated with the degradation of the inhibitory protein I kappa B-alpha; no I kappa B-beta was detected. Activation of NF-kappa B and degradation of I kappa B-alpha were prevented by the NF-kappa B inhibitors sodium salicylate and MG-132. In addition to cyclooxygenase-1 (COX-1), COX-2 is also constitutively expressed in human HSC, and the use of dexamethasone and of SC-58125, a selective COX-2 inhibitor, revealed that COX-2 accounts for basal COX activity. Moreover, COX-2 mRNA and protein were up-regulated by ET-1 and TNF-alpha, whereas COX-1 was unaffected. Induction of COX-2 and stimulation of COX activity by ET-1 and TNF-alpha were prevented by sodium salicylate and MG-132, suggesting that activation of NF-kappa B by either factor is needed for stimulation of COX-2, Finally, SC-58125 and dexamethasone reduced the growth inhibitory effect of ET-1 and TNF-alpha, indicating that activation of COX-2 is required for inhibition of HSC proliferation. Taken together, our results suggest that NF-kappa B, by inducing COX-2 expression, may play an important role in the negative regulation of human myofibroblastic HSC proliferation.	Hop Henri Mondor, INSERM, Unite 99, F-94010 Creteil, France; Hop Lariboisiere, Inst Federat Rech Circulat Lariboisiere, INSERM, Unite 348, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, Unite 99, F-94010 Creteil, France.	loterszt@im3.inserm.fr	Habib, Aida/H-8647-2019; Lotersztajn, Sophie/K-9160-2017	Habib, Aida/0000-0001-6027-0043; lotersztajn, Sophie/0000-0002-0053-7807				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENO DWA, 1994, BBA-MOL CELL RES, V1222, P292, DOI 10.1016/0167-4889(94)90181-3; BENO DWA, 1993, HEPATOLOGY, V17, P707, DOI 10.1002/hep.1840170427; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; DEBOSSCHER K, 1997, P NATL ACAD SCI USA, V94, P13501; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DuBois RN, 1996, CANCER RES, V56, P733; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Frolich JC, 1997, TRENDS PHARMACOL SCI, V18, P30, DOI 10.1016/S0165-6147(96)01017-6; GEERTS A, 1991, HEPATOLOGY, V13, P1193, DOI 10.1002/hep.1840130628; HABIB A, 1993, J BIOL CHEM, V268, P23448; Hellerbrand C, 1996, HEPATOLOGY, V24, P670; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Israel A, 1997, NATURE, V388, P519, DOI 10.1038/41433; Kaplan MD, 1997, J BIOL CHEM, V272, P18534, DOI 10.1074/jbc.272.30.18534; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KESTER M, 1994, J BIOL CHEM, V269, P22574; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; MANCINI R, 1992, J HEPATOL, V15, P361, DOI 10.1016/0168-8278(92)90069-2; MARI B, 1994, J BIOL CHEM, V269, P8517; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Martinez J, 1997, AM J PHYSIOL-CELL PH, V273, pC1466, DOI 10.1152/ajpcell.1997.273.5.C1466; MATSUOKA M, 1989, LIVER, V9, P71; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; SCHMITTGRAFF A, 1991, AM J PATHOL, V138, P1233; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Stoltz RA, 1996, P NATL ACAD SCI USA, V93, P2832, DOI 10.1073/pnas.93.7.2832; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Weil R, 1997, J BIOL CHEM, V272, P9942; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; WU HY, 1994, J BIOL CHEM, V269, P20067; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	57	152	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 4	1998	273	36					23183	23190		10.1074/jbc.273.36.23183	http://dx.doi.org/10.1074/jbc.273.36.23183			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117JL	9722548	hybrid			2022-12-25	WOS:000075778100048
J	Wilson, JR; Ludowyke, RI; Biden, TJ				Wilson, JR; Ludowyke, RI; Biden, TJ			Nutrient stimulation results in a rapid Ca2+-dependent threonine phosphorylation of myosin heavy chain in rat pancreatic islets and RINm5F cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; INSULIN-SECRETION; BETA-CELLS; MOTOR PROTEINS; IN-VIVO; B-CELL; NONMUSCLE; CALCIUM; CALMODULIN; LOCALIZATION	Activation of protein kinases plays an important role in the Ca2+-dependent stimulation of insulin secretion by nutrients, The aim of the present study was to identify kinase substrates with the potential to regulate secretion because these have been poorly defined. Nutrient stimulation of the rat insulinoma RINm5F cell line and rat pancreatic islets resulted in an increase in the threonine phosphorylation of a 200-kDa protein. This was secondary to the gating of voltage-dependent Ca2+ channels because it was reproduced by depolarizing KCI concentrations and blocked by the Ca2+ channel antagonist, verapamil. The peak rises in [Ca2+](i) preceded or were coincident with the maximal threonine phosphorylation in response to both glyceraldehyde and KCl. In digitonin-permeabilized RINm5F cells a rise in Ca2+ from 0.1 to 0.15 mu M was sufficient to increase phosphorylation, Protein kinase C, protein kinase A, and Ca2+/calmodulin-dependent kinase II did not appear to be responsible for the phosphorylation, yet the Ca2+ dependence of the response suggests possible involvement of other members of the Ca2+/calmodulin-dependent kinase family. The 200-kDa protein was identified as myosin heavy chain by immunoprecipitation with a polyclonal nonmuscle myosin antibody. Phosphopeptide mapping indicated that the site of phosphorylation on myosin heavy chain was the same for both KCl- and glyceraldehyde-stimulated cells. Phosphoamino acid analysis confirmed a low basal phosphothreonine content of myosin heavy chain, which increased 6-fold in response to KCl. A lesser (a-fold) increase in serine phosphorylation was also detected using this technique. Although myosin IIA and IIB were shown to be present in RINm5F cells and rat islets, myosin IIA was the predominant threonine-phosphorylated species, suggesting that the two myosin species might be independently regulated. Our results identify myosin heavy chain as a novel kinase substrate in pancreatic beta-cells and suggest that it might play an important role in the regulation of insulin secretion.	Garvan Inst Med Res, Sydney, NSW 2010, Australia; Univ New S Wales, St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Biden, TJ (corresponding author), Garvan Inst Med Res, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	t.biden@garvan.unsw.edu.au	Biden, Trevor/AAW-2829-2021; Stehn, Justine/G-5115-2013	Stehn, Justine/0000-0002-2136-5450; Biden, Trevor/0000-0001-5211-0234				ADELSTEIN RS, 1987, AM J CARDIOL, V59, pB4, DOI 10.1016/0002-9149(87)90076-2; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT SJH, 1994, DIABETOLOGIA, V37, pS21, DOI 10.1007/BF00400822; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BIDEN TJ, 1993, J BIOL CHEM, V268, P11065; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; BYRON KL, 1997, AM J PHYSIOL, V273, pC394; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; COLCA JR, 1983, BIOCHEM J, V212, P819, DOI 10.1042/bj2120819; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; Easom RA, 1997, ENDOCRINOLOGY, V138, P2359, DOI 10.1210/en.138.6.2359; EASOM RA, 1990, J BIOL CHEM, V265, P14938; Ebihara K, 1996, ENDOCRINOLOGY, V137, P5255, DOI 10.1210/en.137.12.5255; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HARRISON DE, 1984, EXPERIENTIA, V40, P1075, DOI 10.1007/BF01971454; HASSON T, 1995, CURR OPIN CELL BIOL, V7, P587, DOI 10.1016/0955-0674(95)80017-4; HOWELL S L, 1986, Diabetes Metabolism Reviews, V2, P107; IIDA Y, 1997, AM J PHYSIOL-ENDOC M, V36, P782; IKEBE M, 1989, BIOCHEMISTRY-US, V28, P8750, DOI 10.1021/bi00448a011; JANJIC D, 1985, J ENDOCRINOL INVEST, V8, P423, DOI 10.1007/BF03348529; JONES PM, 1992, LIFE SCI, V50, P761, DOI 10.1016/0024-3205(92)90180-W; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; KELLEY CA, 1995, J BIOL CHEM, V270, P1395, DOI 10.1074/jbc.270.3.1395; KELLEY CA, 1994, CAN J PHYSIOL PHARM, V72, P1351, DOI 10.1139/y94-195; Krueger KA, 1997, J BIOL CHEM, V272, P27464, DOI 10.1074/jbc.272.43.27464; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LI GD, 1992, MOL PHARMACOL, V42, P489; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; Ludowyke RI, 1996, J IMMUNOL, V157, P5130; LUDOWYKE RI, 1994, EUR J CELL BIOL, V64, P357; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MAUPIN P, 1994, J CELL SCI, V107, P3077; MCKILLOP DFA, 1994, J MUSCLE RES CELL M, V15, P309; MOCHIDA S, 1995, J PHYSIOLOGY-PARIS, V89, P83, DOI 10.1016/0928-4257(96)80555-9; Mohlig M, 1997, ENDOCRINOLOGY, V138, P2577, DOI 10.1210/en.138.6.2577; MOUSSAVI RS, 1993, MOL CELL BIOCHEM, V128, P219, DOI 10.1007/BF01076773; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; NAGAI R, 1989, J BIOL CHEM, V264, P9734; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRAZ F, 1983, J IMMUNOL, V131, P1396; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Ruchhoeft ML, 1997, J NEUROBIOL, V32, P567, DOI 10.1002/(SICI)1097-4695(19970605)32:6<567::AID-NEU3>3.0.CO;2-Y; Ruppel KM, 1996, ANNU REV CELL DEV BI, V12, P543, DOI 10.1146/annurev.cellbio.12.1.543; Sabry JH, 1997, MOL BIOL CELL, V8, P2605, DOI 10.1091/mbc.8.12.2605; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1989, CELL REGUL, V1, P1; Titus MA, 1997, CURR BIOL, V7, pR301, DOI 10.1016/S0960-9822(06)00143-6; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WENHAM RM, 1992, BIOCHEM BIOPH RES CO, V189, P128, DOI 10.1016/0006-291X(92)91534-W; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X	63	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22729	22737		10.1074/jbc.273.35.22729	http://dx.doi.org/10.1074/jbc.273.35.22729			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712904	hybrid			2022-12-25	WOS:000075616600080
J	FitzGerald, MG; Marsh, DJ; Wahrer, D; Bell, D; Caron, S; Shannon, KE; Ishioka, C; Isselbacher, KJ; Garber, JE; Eng, C; Haber, DA				FitzGerald, MG; Marsh, DJ; Wahrer, D; Bell, D; Caron, S; Shannon, KE; Ishioka, C; Isselbacher, KJ; Garber, JE; Eng, C; Haber, DA			Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer	ONCOGENE			English	Article						PTEN/MMAC1; Cowden syndrome; breast cancer; genetic predisposition; yeast truncation assay		Heterozygous germline mutations in PTEN are responsible for most cases of Cowden Syndrome, a rare familial trait characterized by hamartomas and by predisposition to cancer of the breast and thyroid. The variable and often subtle clinical findings that characterize Cowden Syndrome are frequently unrecognized, raising the possibility that germline PTEN mutations may confer susceptibility to breast cancer in women who have not been diagnosed with this syndrome. To determine whether such mutations contribute to genetic predisposition to breast cancer within the general population, we analysed a cohort of women with early-onset breast cancer (<age 40), a subset of the population at increased risk for genetic susceptibility, Lymphoblast cell lines were analysed using either direct nucleotide sequencing (28 cases), denaturing gradient gel electrophoresis (DGGE) (34 cases) or a yeast-based truncation assay (110 cases). No definitive, truncating mutations were observed in 172 patients, Missense changes were noted in the germline of 2/60 patients analysed by direct nucleotide sequencing or DGGE, including a non-conservative amino acid substitution within the phosphatase domain, but neither showed loss of the wild-type allele in the corresponding breast tumor specimen, We conclude that germline mutations in PTEN are an uncommon cause of genetic predisposition to breast cancer within the general population.	Massachusetts Gen Hosp, Ctr Canc Risk Anal, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02114 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge, England; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 980, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Program Populat Sci, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Cambridge; Tohoku University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc Risk Anal, Charlestown, MA 02129 USA.		Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931; Ishioka, Chikashi/0000-0002-3023-1227; Eng, Charis/0000-0002-3693-5145				CLAUS EB, 1991, AM J HUM GENET, V48, P232; Dahia PLM, 1997, CANCER RES, V57, P4710; DAHIA PLM, 1998, IN PRESS ONCOGENE; DURR WM, 1998, IN PRESS ONCOGENE; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; FEILOTTER HE, 1998, IN PRESS ONCOGENE; FEILOTTER HE, 1998, IN PRESS BR J CANC; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; Guldberg P, 1997, CANCER RES, V57, P3660; Ishioka C, 1997, P NATL ACAD SCI USA, V94, P2449, DOI 10.1073/pnas.94.6.2449; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Longy M, 1996, ANN GENET-PARIS, V39, P35; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Wang SI, 1997, CANCER RES, V57, P4183	25	45	46	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					727	731		10.1038/sj.onc.1201984	http://dx.doi.org/10.1038/sj.onc.1201984			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715274				2022-12-25	WOS:000075337200007
J	West, MJ; Stoneley, M; Willis, AE				West, MJ; Stoneley, M; Willis, AE			Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway	ONCOGENE			English	Article						c-myc; eIF-4G; rapamycin; S6 kinase; TOR; translation	EPSTEIN-BARR-VIRUS; INITIATION-FACTOR 4E; 5' UNTRANSLATED REGION; MESSENGER-RNA; PROTEIN-KINASE; GROWTH-FACTOR; S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ORNITHINE DECARBOXYLASE; DEPENDENT TRANSLATION	Previous studies on the regulation of c-myc have focused on the transcriptional control of this proto-oncogene. We have investigated the signalling pathways involved under circumstances in which there is a translational upregulation in the levels of c-myc protein. We have demonstrated an up to tenfold serum-dependent increase of c-myc protein levels in Epstein-Barr virus immortalized B-cell lines 2-4 h after disruption of cellular aggregates, which is not accompanied by an equivalent increase in mRNA. Overall protein synthesis rates only increased threefold suggesting that the c-myc message was being selectively translated. We observed increases in the phosphorylation of p70 and p85 S6 kinases and of initiation factor eIF-4E binding protein 1 (4E-BP1) 1-2 h after stimulation, suggesting activation of the FRAP/TOR signalling pathway. The increased phosphorylation of 4E-BP1 led to a decrease in its association with eIF-4E and an increase in its association with the eIF-4G component of the eIF-4F initiation complex. The signalling; inhibitors rapamycin and wortmannin blocked the phosphorylation of 4E-BP1 and abolished the translational component of the c-myc response. Our data suggest that dissociation of eIF-4E from 4E-BP1, leading to an increase in the formation of the eIF-4F initiation complex, relieves the translation repression imposed ion the c-myc mRNA by its structured 5'UTR.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.			West, Michelle/0000-0002-9497-9365; Willis, Anne/0000-0002-1470-8531				ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; AMAN P, 1986, CURR TOP MICROBIOL, V132, P266; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHERNEY BW, 1994, P NATL ACAD SCI USA, V91, P12967, DOI 10.1073/pnas.91.26.12967; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DEAN M, 1986, J BIOL CHEM, V261, P9161; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Flynn A, 1996, EUR J BIOCHEM, V236, P40, DOI 10.1111/j.1432-1033.1996.00040.x; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JONES N, 1996, IMMUNOLOGY, V89, P26; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAZARUS P, 1992, ONCOGENE, V7, P1037; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LYONS RT, 1980, J BIOL CHEM, V255, P6330; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MAO XH, 1992, J BIOL CHEM, V267, P20444; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marshall CJ, 1996, FASEB J, V10, P7; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; NEPVEU A, 1987, ONCOGENE, V1, P243; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Paulin FEM, 1996, ONCOGENE, V13, P505; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REDPATH NT, 1992, ANAL BIOCHEM, V202, P340, DOI 10.1016/0003-2697(92)90115-N; Rosenwald IB, 1995, CANCER LETT, V98, P77, DOI 10.1016/0304-3835(95)90206-6; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WATERS CM, 1991, ONCOGENE, V6, P797; West MJ, 1995, ONCOGENE, V11, P2515; Young L S, 1992, Semin Cancer Biol, V3, P273	67	152	159	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					769	780		10.1038/sj.onc.1201990	http://dx.doi.org/10.1038/sj.onc.1201990			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715279				2022-12-25	WOS:000075337200012
